<SEC-DOCUMENT>0001437749-23-008847.txt : 20230331
<SEC-HEADER>0001437749-23-008847.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331162319
ACCESSION NUMBER:		0001437749-23-008847
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		23788096

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-537-7997

	MAIL ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gnpx20221231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:gnpx="http://www.genprex.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rr="http://xbrl.sec.gov/rr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>gnpx20221231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/31/2023 5:11:09 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001595248</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">Genprex, Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonFraction id="c96223893" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96223894" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96223895" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c96223896" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c96223897" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">48,105,962</ix:nonFraction>
<ix:nonFraction id="c96223899" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">48,105,962</ix:nonFraction>
<ix:nonFraction id="c96223898" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874,708</ix:nonFraction>
<ix:nonFraction id="c96223900" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874,708</ix:nonFraction>
<ix:nonFraction id="c96224243" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">78,017,853</ix:nonFraction>
<ix:nonFraction id="c96224244" contextRef="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,069,345</ix:nonFraction>
<ix:nonFraction id="c96224245" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">79,087,198</ix:nonFraction>
<ix:nonFraction id="c96224270" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">19,600,757</ix:nonFraction>
<ix:nonFraction id="c96224271" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,069,345</ix:nonFraction>
<ix:nonFraction id="c96224272" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,670,102</ix:nonFraction>
<ix:nonFraction id="c96224276" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">19,595,624</ix:nonFraction>
<ix:nonFraction id="c96224277" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,069,345</ix:nonFraction>
<ix:nonFraction id="c96224278" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,664,969</ix:nonFraction>
<ix:nonFraction id="c96224279" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.42</ix:nonFraction>
<ix:nonFraction id="c96224280" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.02</ix:nonFraction>
<ix:nonFraction id="c96224281" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.44</ix:nonFraction>
<ix:nonFraction id="c96224203" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96224189" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96224190" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c96224205" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96224328" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c96224383" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96224456" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224648" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224650" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224657" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224659" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c96224825" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,722,484</ix:nonFraction>
<ix:nonFraction id="c96224826" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">412,667</ix:nonFraction>
<ix:nonFraction id="c96224827" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,309,817</ix:nonFraction>
<ix:nonFraction id="c96224831" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.12</ix:nonFraction>
<ix:nonFraction id="c96224832" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c96224833" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.11</ix:nonFraction>
<ix:nonFraction id="c96224885" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,175,070</ix:nonFraction>
<ix:nonFraction id="c96224886" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">595,316</ix:nonFraction>
<ix:nonFraction id="c96224887" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,770,386</ix:nonFraction>
<ix:nonFraction id="c96224888" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,898,433</ix:nonFraction>
<ix:nonFraction id="c96224889" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">182,650</ix:nonFraction>
<ix:nonFraction id="c96224890" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">11,081,083</ix:nonFraction>
<ix:nonFraction id="c96224897" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,169,326</ix:nonFraction>
<ix:nonFraction id="c96224898" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">595,316</ix:nonFraction>
<ix:nonFraction id="c96224899" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,764,642</ix:nonFraction>
<ix:nonFraction id="c96224900" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,891,810</ix:nonFraction>
<ix:nonFraction id="c96224901" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">182,650</ix:nonFraction>
<ix:nonFraction id="c96224902" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">11,074,460</ix:nonFraction>
<ix:nonFraction id="c96224903" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.11</ix:nonFraction>
<ix:nonFraction id="c96224904" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.01</ix:nonFraction>
<ix:nonFraction id="c96224905" contextRef="d_2022-04-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.12</ix:nonFraction>
<ix:nonFraction id="c96224906" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.23</ix:nonFraction>
<ix:nonFraction id="c96224907" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0.00</ix:nonFraction>
<ix:nonFraction id="c96224908" contextRef="d_2022-01-01_2022-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.23</ix:nonFraction>
<ix:nonFraction id="c96224957" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,110,654</ix:nonFraction>
<ix:nonFraction id="c96224958" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">59,785</ix:nonFraction>
<ix:nonFraction id="c96224959" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,170,439</ix:nonFraction>
<ix:nonFraction id="c96224960" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">17,009,087</ix:nonFraction>
<ix:nonFraction id="c96224961" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">242,435</ix:nonFraction>
<ix:nonFraction id="c96224962" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">17,251,522</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="gnpx-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-03-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:InvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-10</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:InvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-01_2023-03-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-18_2022-11-18_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-18</xbrli:startDate><xbrli:endDate>2022-11-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-18</xbrli:startDate><xbrli:endDate>2022-11-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-04-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServiceProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServiceProvider2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServicesProvidedAtIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:VestingOfWarrantsForServiceProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-TimeBasedOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gnpx:TimeBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-01-01_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-01_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-ExcludingThe2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:ExcludingThe2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PerformancebasedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-01-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-07-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-01-01_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-01-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-17_2023-01-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:ConsultantWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-18</xbrli:startDate><xbrli:endDate>2023-02-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantsIssuedWithRegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-01_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-size: 10pt; margin: 0pt; font-family: Times New Roman;">&#xa0;</p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 14pt; margin: 0pt; text-align: center;"><b>UNITED STATES </b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:14pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549 </b></p>
<hr style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 18%; border: none; margin: 6 auto 6 auto;" />
<p style="font-family:'Times New Roman', Times, serif;font-size:14pt;margin:3pt;text-align:center;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2022-01-01_2022-12-31">10-K</ix:nonNumeric> </b></p>
<hr style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 18%; border: none; margin: 6 auto 6 auto;" />
<p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:0pt;text-align:left;"><b>(Mark&#xa0;One)</b></p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:top;width:4.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:95.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ANNUAL REPORT PURSUANT TO SECTION&#xa0;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#xa0;1934</b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:0pt;text-align:center;"><b>For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2022-01-01_2022-12-31">December 31, 2022</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:0pt;text-align:center;"><b>OR</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:top;width:4.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:95.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>TRANSITION REPORT PURSUANT TO SECTION&#xa0;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#xa0;1934</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>FOR THE TRANSITION PERIOD FROM&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; TO &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</b></p> </td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: center;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>Commission File Number&#xa0;<ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2022-01-01_2022-12-31">001-38244</ix:nonNumeric></b></p>
<hr style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 18%; border: none; margin: 6 auto 6 auto;" />
<p style="font-family: Times New Roman; font-size: 20pt; margin: 0pt; text-align: center;"><b>Genprex, Inc. </b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:0pt;text-align:center;"><b>(Exact Name of Registrant as Specified in Its Charter) </b></p>
<hr style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 18%; border: none; margin: 6 auto 6 auto;" />
<table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="0"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-12-31">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2022-01-01_2022-12-31">90-0772347</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>(State or other jurisdiction of incorporation or organization)</b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>(I.R.S. Employer Identification Number)</b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td></tr>
</tbody></table>
<table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="0"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2022-01-01_2022-12-31">3300 Bee Cave Road #650-227</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;">&#xa0;</p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2022-01-01_2022-12-31">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-12-31">Texas</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2022-01-01_2022-12-31">78746</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>(Address of principal executive offices)</b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>(Zip Code)</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:6pt;text-align:center;"><b>Registrant&#x2019;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2022-01-01_2022-12-31">877</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2022-01-01_2022-12-31">774-4679</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 0pt; text-align: center;"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p>
<p style="font-family: Times New Roman; font-size: 6pt; margin: 0pt; text-align: center;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:9pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>Title of each class</b></p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>&#xa0;</b></p> </td><td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>Trading</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>Symbol(s)</b></p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>&#xa0;</b></p> </td><td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><b>Name of each exchange on which registered</b></p> </td></tr>
<tr><td style="vertical-align:top;width:35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $0.001 per share</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;">&#xa0;</p> </td><td style="vertical-align:bottom;width:30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2022-01-01_2022-12-31">GNPX</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;">&#xa0;</p> </td><td style="vertical-align:bottom;width:35%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:9pt;margin:1pt;text-align:center;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2022-01-01_2022-12-31">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
</tbody></table>
<p style="font-size: 3pt; margin: 0; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif"><b>&#xa0;</b></p>
<p style="font-size: 3pt; margin: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif"><b>&#xa0;</b></p>
<p style="background-color: rgb(255, 255, 255); font-family: Times New Roman; font-size: 9pt; margin: 0pt; text-align: center;"><b>Securities registered pursuant to 12(g) of the Act: None</b></p>
<p style="font-size: 3pt; margin: 0; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif"><b>&#xa0;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#xa0;405 of the Securities Act.&#xa0;Yes&#xa0;&#x2610;&#xa0;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric>&#xa0;&#x2612;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#xa0;13 or 15(d) of the Act.&#xa0;Yes&#xa0;&#x2610;&#xa0;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric>&#xa0;&#x2612;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark whether the registrant&#xa0;(1)&#xa0;has filed all reports required to be filed by Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#xa0;months (or for such shorter period that the registrant was required to file such reports), and (2)&#xa0;has been subject to such filing requirements for the past 90&#xa0;days.&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2022-01-01_2022-12-31">Yes</ix:nonNumeric> &#x2612;&#xa0;No&#xa0;&#x2610;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule&#xa0;405 of Regulation&#xa0;S-T (&#xa7;232.405 of this chapter) during the preceding 12&#xa0;months (or for such shorter period that the registrant was required to submit such files).&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2022-01-01_2022-12-31">Yes</ix:nonNumeric> &#x2612;&#xa0;No&#xa0;&#x2610;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-size: 3pt; margin: 0; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&#xa0;</p>
<table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 9pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><td style="vertical-align: bottom; width: 39.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">Large&#xa0;accelerated&#xa0;filer:</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 6.4%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#x2610;</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 46.7%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">Accelerated filer</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 4.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#x2610;</p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><td style="vertical-align: bottom; width: 39.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2022-01-01_2022-12-31">Non-accelerated filer</ix:nonNumeric>:</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 6.4%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#x2612;&#xa0;&#xa0;</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 46.7%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">Smaller&#xa0;reporting&#xa0;company</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 4.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 9pt;"><td style="vertical-align: bottom; width: 39.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 6.4%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 46.7%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">Emerging&#xa0;growth&#xa0;company</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;">&#xa0;</p> </td><td style="vertical-align: bottom; width: 4.3%; font-family: &quot;Times New Roman&quot;; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin: 0pt; text-align: left;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-size: 3pt; margin: 0; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 31.5pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#xa0;13(a) of the Exchange Act.&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#xa0;12b-2 of the Act).&#xa0;Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric>&#xa0;No&#xa0;&#x2612;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30,&#xa0;2022&#xa0;was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="0" format="ixt:numdotdecimal" contextRef="i_2022-06-30">66</ix:nonFraction>&#xa0;million, computed by reference to the closing price of the registrant&#x2019;s common stock on June 30, 2022&#xa0;(the last business day of the registrant's most recently completed second fiscal quarter) of $1.39&#xa0;per share, as reported by The Nasdaq Capital Market.</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 6pt 0pt; text-indent: 31.5pt; text-align: justify;">As of March 15, 2023, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2023-03-15">51,974,078</ix:nonFraction>&#xa0;shares of the registrant&#x2019;s common stock outstanding.</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 6pt 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the registrant&#x2019;s 2023&#xa0;annual&#xa0;meeting of stockholders, are incorporated by reference into Part&#xa0;III of this Annual Report on Form 10-K. Such proxy statement will be filed with the SEC not later than 120 days after the conclusion of the registrant&#x2019;s fiscal year ended December 31, 2022.</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%">
  &#xa0;
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  &#xa0;
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="toc" title="toc" href="#"></a>TABLE OF CONTENTS </b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; ">Page</span></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#PART_I" style="-sec-extract:exhibit;"><b>PART I</b></a></p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_1">2</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_1" style="-sec-extract:exhibit;">Business</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_1">2</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1A.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_1A" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_1A">46</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 1B.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_1B" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align: bottom; width: 4%; text-align: right;"><a class="tocPGNUM" href="#Item_1B">76</a></td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_2" style="-sec-extract:exhibit;">Properties</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_2">76</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_3" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_3">76</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_4">76</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#PART_II" style="-sec-extract:exhibit;"><b>PART II</b></a></p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#PART_II">77</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 5.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_5" style="-sec-extract:exhibit;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_5">77</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 6.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[<a href="#Item_6" style="-sec-extract:exhibit;">Reserved</a>]</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_6">77</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 7.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_7" style="-sec-extract:exhibit;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_7">78</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 7A.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_7A" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_7A">85</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 8.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_8" style="-sec-extract:exhibit;">Financial Statements and Supplementary Data</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_8">85</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 9.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_9" style="-sec-extract:exhibit;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_9">85</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 9A.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_9A" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_9A">86</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 9B.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_9B" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_9B">87</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;">Item 9C.</td>
      <td style="vertical-align: top; width: 87%;"><a href="#Item_9C" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
      <td style="vertical-align: bottom; width: 4%; text-align: right;"><a class="tocPGNUM" href="#Item_9B">87</a></td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#PART_III" style="-sec-extract:exhibit;"><b>PART III</b></a></p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%; text-align: right;"><a class="tocPGNUM" href="#Item_10">88</a></td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 10.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_10" style="-sec-extract:exhibit;">Directors, Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_11">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 11.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_11" style="-sec-extract:exhibit;">Executive Compensation</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_11">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 12.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_12">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 13.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_13">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 14.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_14" style="-sec-extract:exhibit;">Principal Accountant&#xa0;Fees and Services</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_14">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#PART_IV" style="-sec-extract:exhibit;"><b>PART IV</b></a></p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#PART_IV">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 15.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_15" style="-sec-extract:exhibit;">Exhibits and&#xa0;Financial Statement Schedules</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_15">88</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Item 16.</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Item_16" style="-sec-extract:exhibit;">Form 10-K Summary</a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Item_16">92</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: top; width: 87%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Sig" style="-sec-extract:exhibit;"><b>SIGNATURES</b></a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Sig">93</a></p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align: top; width: 8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#Fin_State" style="-sec-extract:exhibit;"><b>FINANCIAL STATEMENTS</b></a></p> </td>
      <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Fin_State">F-1</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGNUM" style="text-align: center; width: 100%">
      &#xa0;
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">This Annual Report on Form&#xa0;10-K (this &#x201c;Annual Report on Form 10-K&#x201d; or this&#xa0;&#x201c;Annual Report&#x201d;) contains forward-looking statements that involve substantial risks and uncertainties.&#xa0;Unless the context requires otherwise, references to &#x201c;Genprex,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d; in this Annual Report refer to Genprex, Inc. Any statements in this Annual Report about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as &#x201c;believe,&#x201d; &#x201c;will,&#x201d; &#x201c;expect,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;estimate,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan&#x201d; and &#x201c;would.&#x201d; For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Annual Report. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 27.8pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Market conditions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our capital position;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to compete effectively and with larger and/or better-financed biotechnology and pharmaceutical companies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our uncertainty of developing marketable products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to develop and commercialize our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to obtain regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability and third parties&#x2019; ability to maintain and protect intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to raise additional future financing and possible lack of financial and other resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The effects and ultimate impact of public health crises such as&#xa0;the coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The success of our clinical trials through all phases of clinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to conduct and complete our clinical trials in accordance with projected timelines;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Any delays in regulatory review and approval of our current and future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our dependence on third-party manufacturers to supply or manufacture our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to control product development costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability&#xa0;to attract and retain key employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our ability to enter into new strategic collaborations, licensing or other arrangements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Changes in government regulation affecting product candidates that could increase our development costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Our involvement in patent, trademark,&#xa0;and other intellectual property litigation that could be expensive and divert management&#x2019;s attention;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">The possibility that there may be no market acceptance for our products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">Changes in third-party reimbursement policies which could adversely affect potential future sales of any of our products that are approved for marketing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements, which speak only as of the date of this Annual Report. Except as required by law, we assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements contained in this Annual Report. All forward-looking statements are expressly qualified in their entirety by the cautionary statements contained in this section.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="PART_I" title="PART_I" href="#"></a>PART I</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><a id="Item_1" title="Item_1" href="#"></a>Item 1. Business.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Overview </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.&#xa0;Our oncology platform utilizes our non-viral ONCOPREX&#xae; Nanoparticle Delivery System.&#xa0;Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating the beta cells&#xa0;that make insulin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Oncology Platform</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our lead oncology drug candidate, REQORSA&#xae; Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-001, is initially being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (&#x201c;NSCLC&#x201d;) and Small Cell Lung Cancer (&#x201c;SCLC&#x201d;).&#xa0;The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#xa0;We believe REQORSA&#x2019;s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, and that it can improve on current therapies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 1: We currently are enrolling and treating patients in the Phase 1 dose escalation portion of our Phase&#xa0;1/2&#xa0;Acclaim-1&#xa0;clinical trial.&#xa0;The Acclaim-1&#xa0;trial uses a combination of REQORSA and AstraZeneca PLC&#x2019;s Tagrisso&#xae; in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#x201c;EGFR&#x201d;) mutations and progression after treatment with Tagrisso. In&#xa0;August 2022,&#xa0;the Acclaim-1&#xa0;Safety Review Committee (&#x201c;Acclaim-1 SRC&#x201d;) approved escalating the dose from&#xa0;0.06&#xa0;mg/kg in the&#xa0;first&#xa0;cohort of patients to&#xa0;0.09&#xa0;mg/kg in the&#xa0;second&#xa0;cohort of patients and in December 2022,&#xa0;the SRC approved escalating the dose from 0.09 mg/kg in the second cohort to 0.12 mg/kg in the third and final cohort. We are thus enrolling and treating patients at the 0.12 mg/kg dose&#xa0;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle one of treatment for the remaining untreated patients, the Acclaim-1 SRC will meet and establish the maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D"). We will then proceed into the dose expansion portion of the study. The Food and Drug Administration (&#x201c;FDA&#x201d;) has granted Fast Track Designation for the Acclaim-1&#xa0;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 2: We&#xa0;currently are enrolling and treating patients in the Phase 1 dose escalation portion of our Phase&#xa0;1/2&#xa0;Acclaim-2&#xa0;clinical trial.&#xa0;The Acclaim-2&#xa0;trial uses a combination of REQORSA and Merck &amp; Co.&#x2019;s Keytruda&#xae; in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are currently being treated at the 0.06 mg/kg dose level in the first cohort of patients and, subject to Acclaim-2 Safety Review Committee ("Acclaim-2 SRC") approval, will be treated at successive dose levels of 0.09 mg/kg and 0.12 mg/kg. In March 2023, we amended the Acclaim-2 protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the dose escalation portion&#xa0;of the study to be completed by the end of 2023. We will then evaluate patients in the dose expansion portion of the study at the MTD or RP2D. The FDA has granted Fast Track Designation for the Acclaim-2&#xa0;treatment combination of REQORSA and Keytruda in NSCLC patients who have progressed after Keytruda treatment.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The dose expansion portion of Acclaim-2 is a Phase 2 study and the dose expansion portion of Acclaim-1 will be considered a Phase 2 study upon the filing with the FDA of an upcoming protocol amendment.&#xa0; The dose expansion provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the MTD or RP2D in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase 2 trial which will follow the dose expansion portion of each study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 3: In November 2022, we filed with the FDA our protocol for our Phase 1/2 Acclaim-3 clinical trial using&#xa0;a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq&#xae; as maintenance therapy in patients with extensive stage small cell lung cancer (&#x201c;ES-SCLC&#x201d;) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. We expect to dose the first patient in Acclaim-3 by the end of&#xa0;the third quarter of 2023. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The TUSC2 gene is one of a series of genes on the short arm of Chromosome 3 whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").&#xa0;We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates. In August 2022, we entered into a sponsored research agreement with MD Anderson to support further pre-clinical studies of TUSC2 and other tumor suppressor genes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Diabetes Gene Therapy</span></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d;) multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes.&#xa0;The same general novel approach is used in each of Type 1 and Type 2 whereby an adeno-associated virus (&#x201c;AAV&#x201d;) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-002 is being developed for the treatment of Type 1 diabetes and GPX-003 is being developed for the treatment of Type 2 diabetes. GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. GPX-003 is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of 2023 to obtain their guidance on the toxicology studies that we plan to conduct. In August 2022, we entered into a one-year sponsored research agreement with the University of Pittsburgh for the use of GPX-003 in a non-human primate (&#x201c;NHP&#x201d;) model in Type 2 diabetes and we expect data from this study to be reported by the end of 2023. In February 2023, the Company&#x2019;s research collaborators at the&#xa0;University of Pittsburgh&#xa0;presented preclinical data in a NHP model of Type 1 diabetes&#xa0;highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD 2023) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><b>Recent Developments - Financings</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">At-the-Market Offering Program</span></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On November 18, 2022, we entered into an Equity Distribution Agreement (the &#x201c;Equity Distribution Agreement&#x201d;) with JMP Securities LLC, serving as placement agent (&#x201c;JMP Securities&#x201d; or the &#x201c;Agent&#x201d;) with respect to an at-the-market offering program (our &#x201c;ATM&#x201d;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50.0 million through the Agent. We have agreed to pay the Agent a commission equal to three percent (3%) of the gross sales proceeds of any shares sold through the Agent under the Equity Distribution Agreement, and also have provided the Agent with customary indemnification and contribution rights. As of December 31, 2022 we have sold 3,886&#xa0;shares of our common stock for aggregate net proceeds to us totaling approximately $4,532.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Registered Direct Offering</span></i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On March 1, 2023,&#xa0;we completed a registered direct offering, in which we sold to an accredited healthcare-focused institutional investor an aggregate of 3,809,524 shares of our common stock and warrants to purchase up to 3,809,524 shares of our common stock, at a combined offering price of $1.05 per share of common stock and accompanying warrant. The warrants are exercisable immediately upon issuance, expire 5 years from the date of issuance and have an exercise price of $1.10 per share. We received net proceeds of approximately $3.6 million after commissions and estimated expenses, excluding any proceeds that may be received in the future from any exercise of the warrants.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"><b>Our Pipeline </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. We are developing our lead product candidate REQORSA to be administered with targeted therapies and with immunotherapies for NSCLC and SCLC. We continue&#xa0;to conduct preclinical research to explore how REQORSA may be administered with targeted therapies and immunotherapies in other solid tumors, and we are researching how other cancer fighting genes can enhance our portfolio using our non-viral gene therapy platform, the ONCOPREX Nanoparticle Delivery System. Using a different gene therapy delivery system, we are also developing our pre-clinical diabetes candidates, GPX-002 and GPX-003. The following table summarizes our product development pipeline.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="pipelinev20_850.jpg" src="pipelinev20_850.jpg" /></div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Introduction &#x2013; Cancer</b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Cancer and Genetic Mutations. </i>Cancer results from genetic mutations. Mutations that lead to cancer are usually present in two major classes of genes: oncogenes, which are involved in functions such as signal transduction and transcription; and tumor suppressor genes, which play a role in governing cell proliferation by regulating transcription. Transduction is the process by which chemical and physical signals are transmitted through cells. Transcription is the process by which a cell&#x2019;s DNA sequence is copied to make RNA molecules, which then can lead to protein expression. In cancer cells, the oncogene mutations may overwhelm the natural tumor suppression processes, or those tumor suppression processes may be impaired or absent. Functional alterations due to mutations in oncogenes or tumor suppressor genes may result in the abnormal and uncontrolled growth patterns characteristic of cancer. These genetic alterations facilitate such malignant growth by affecting signal transduction pathways and transcription, thus inhibiting normal growth signaling in the cell, circumventing the natural process of apoptosis, evading the immune system&#x2019;s response to cancer, and inducing angiogenesis, which is the formation of new blood vessels that supply cancer cells.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The most common genetic alterations present in lung cancer are in tumor suppressor genes.&#xa0; No targeted small molecule drugs have successfully been developed against tumor suppressor gene mutations in NSCLC or SCLC.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Another genetic condition often associated with lung cancer are mutations of tyrosine kinases. Tyrosine kinases are enzymes that play an important role in signal transduction through the modification of proteins by adding (phosphorylation)&#xa0;phosphate groups on the amino acid tyrosine, to change the proteins&#x2019; function. When an EGFR ligand binds to the EGFR, two EGFR transmembrane proteins are brought close together on the cell membrane surface, and the intracellular tyrosine kinase domains can autophosphorylate, and activate downstream processes, including cell signaling pathways that can lead to cell growth and proliferation. EGFRs can act similarly to a switch that turns &#x201c;on&#x201d; and &#x201c;off&#x201d; when phosphate groups are either added or taken away. Mutated kinases can have a malfunctioning on/off switch, causing the switch to be stuck in the &#x201c;on&#x201d; position leading to the loss of control of cell growth.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Cancer and the Immune System</i>. Cancer can also spread when the body&#x2019;s natural immune functions are impaired, including by the cancer cells themselves. PD-1, or Programmed Death-1, is a receptor expressed on the surface of activated T cells, which are part of the body&#x2019;s immune system. PD-L1 is a ligand for PD-1 which is expressed on the surface of cancer and other cells. The binding of PD-1 to PD-L1 has been speculated to contribute to cancer cells&#x2019; ability to evade the body&#x2019;s immune response. PD-1 and similar molecules&#xa0;are called immune checkpoint inhibitors&#xa0;because they can impede the normal immune response, for example by blocking the T cells from attacking the cancer cells. In many cancers, PD-L1 is up-regulated. Substantial research has been performed in the emerging field of immuno-oncology to discover drugs or antibodies that could block PD-L1 and similar receptors. It is believed that blocking the PD-1/PD-L1 interaction pathway and other similar checkpoints, such as cytotoxic T-lymphocyte-associated protein 4, or CTLA-4, with drugs called checkpoint inhibitors can prevent cancer cells from inactivating T cells, leading to an attack of the immune system on the cancer.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Current Treatment of NSCLC. </i>Chemotherapy is the standard treatment for the majority of NSCLC patients, as it is for many other cancer patients. Because it is a non-selective systemic treatment, rather than a targeted approach to treating cancer, chemotherapy also kills healthy cells and has a number of other undesirable side effects.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A subset of NSCLC patients carry&#xa0;one or both of two EGFR mutations, referred to as exon 19 deletion and exon 21 substitution, which make their tumors sensitive to EGFR tyrosine kinase inhibitors ("EGFR TKIs"). Several pharmacological and biological approaches, including EGFR TKIs, have been developed specifically to block activated EGFR for cancer therapy. EGFR TKI drugs are the most common targeted therapies used in lung cancer.&#xa0; Several EGFR TKI therapies are marketed commercially including, but not limited to, Tagrisso, Tarceva, Iressa and Gilotrif.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Approximately 17% of NSCLC patients of North American and European descent and approximately 30% to 50% of NSCLC patients of Asian descent have activating EGFR mutations. This means that the majority of NSCLC patients do not have activating EGFR mutations and are therefore &#x201c;EGFR negative&#x201d; and not optimal candidates for EGFR TKIs.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">However, while EGFR TKIs are most effective in patients who have an activating EGFR mutation and are therefore described as &#x201c;EGFR positive,&#x201d; they are significantly less effective in overall NSCLC populations and are&#xa0;generally not effective in patients without an activating EGFR mutation.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, even among those patients who are EGFR positive and benefit from EGFR TKI therapy, nearly all eventually become resistant to and ultimately no longer respond to EGFR TKI therapy, resulting in eventual disease progression. For example, according to the FLAURA study, sponsored by AstraZeneca, the median time to tumor progression for lung cancer patients on Tagrisso is approximately 18 months.&#xa0;Furthermore, clinical trials have shown that combining EGFR TKIs with conventional chemotherapy does not increase survival for lung cancer patients.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Current Treatment of SCLC</i>.&#xa0; SCLC is staged as limited stage, in which the cancer is only on one side of the chest and can be treated with a single radiation therapy field, or as extensive stage (ES), which includes all other patients. Since SCLC is an aggressive disease, the vast majority of patients have extensive stage SCLC. The standard treatment for ES-SCLC for many years was a combination chemotherapy with carboplatin and etoposide for 4 cycles of treatment, as treatment for longer duration or treatment including other agents was not shown to be beneficial.&#xa0; In the last several years the addition of immune checkpoint inhibitors has been shown to have improved efficacy when added to 4 cycles of chemotherapy.&#xa0; Thus, standard treatment now consists of either Tecentriq or Imfinzi added to 4 cycles of carboplatin and etoposide, and then Tecentriq or Imfinzi are continued as maintenance therapy until disease progression.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">However, treatment of ES-SCLC is not curative, and patients progress quickly.&#xa0; In patients receiving Tecentriq and chemotherapy, the PFS after starting maintenance Tecentriq is only 2.6 months.&#xa0; Further improvements in the treatment of ES-SCLC are needed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Epidemiology of Lung Cancer.</i>&#xa0;According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers and accounting for about one in five of all cancer deaths in the United States, making it the leading cause of cancer death in the U.S. with more people dying of lung cancer in the U.S. than of colon, breast and prostate cancers combined. In 2020, there were more than 2 million new lung cancer cases and approximately 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2023 there will be more than 238,000 new cases of lung cancer and more than 127,000 deaths from this disease. NSCLC represents about 82% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 14% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt;"><b>REQORSA</b><b>&#xae;</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">REQORSA&#xae; immunogene therapy (generic name: quaratusugene ozeplasmid) is designed to (i) interrupt cell signaling pathways that cause replication and proliferation of cancer cells, (ii) target and kill cancer cells, and (iii) stimulate the natural immune responses against cancer. REQORSA is an immunogene therapy in that it combines features of gene therapy and immunotherapy.&#xa0; It up-regulates TUSC2 expression in the cell, and also increases the anti-tumor immune cell population and down-regulates PD-L1, thereby potentially boosting the immune response to cancer.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">REQORSA consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles&#xa0;made from lipid molecules (our ONCOPREX Nanoparticle Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells. Cancer cells have elevated metabolism compared to healthy cells and as a result, are negatively charged compared to healthy cells, which are positively charged, or charge neutral. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. Tumor biopsy studies conducted at MD Anderson show that, in three patients, the uptake of TUSC2 in tumor cells after REQORSA treatment was&#xa0;10 to 33&#xa0;times the uptake in normal cells. We believe that REQORSA is the first systemic gene therapy to be used for cancer in humans. Since REQORSA, unlike many other gene therapies, is administered intravenously, it does not need to integrate into the patient's DNA.&#xa0; Many other&#xa0;gene therapies require complex procedures, such as removal of cells from a patient and modification&#xa0;of those cells which are then reinfused into the patient, and many lead to permanent changes in a patient's DNA.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Many approved cancer therapeutics target only single molecules or a single specific genetic abnormality related to driving the proliferation and survival of cancer cells. In contrast, REQORSA has been shown to have a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death (apoptosis)&#xa0;in cancer cells, and modulates the immune response against cancer cells. REQORSA also has been shown to be complementary with targeted drugs and immunotherapies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA&#x2019;s multimodal activity will block emerging bypass pathways, thereby potentially reducing the probability that drug resistance develops.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our preclinical and clinical data indicate that REQORSA is well tolerated and may be effective alone or in combination with targeted small molecule therapies.&#xa0;Preclinical data indicate that REQORSA may also be effective with immunotherapies, and in a three-drug combination with immunotherapy and chemotherapy. These data suggest that REQORSA, when combined with other therapies, may be effective in a large population&#xa0;of lung cancer patients.&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt;"><b>TUSC2, the Active Agent in REQORSA&#xae;</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">TUSC2&#xa0;is a multifunctional gene that plays a vital role in cancer suppression and normal cell regulation. Key TUSC2 anti-cancer mechanisms of action include the inactivation of multiple oncogenic kinases, the induction of apoptosis, the control of cell signaling and inflammation, and modulation of the immune system to fight cancer. REQORSA has been shown to be complementary with targeted drugs and immunotherapies. Our pre-clinical data indicate that REQORSA in combination with both EGFR TKIs and with immunotherapies can achieve results more favorable than results achieved with either REQORSA or such other therapies alone, and may make those drugs effective for patients with drug resistance who would not otherwise benefit from them.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Normal TUSC2 function is often inactivated at the early onset of cancer development, making TUSC2 a potential target for all stages of cancer, including metastatic disease. The TUSC2 protein is reduced or absent in approximately 82% of NSCLCs and in 100% of SCLCs. In patients with NSCLC, the loss of TUSC2 expression has been associated with significantly worse overall survival than when TUSC2 expression is not decreased.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Studies show TUSC2 protein functions as a key mediator in the Apaf1-mediated mitochondrial apoptosis pathway by recruiting and directing cytoplasmic Apaf1 protein to a critical cellular location and activating it <i>in situ,</i> thereby up-regulating activity of other proapoptotic effectors. TUSC2 functions to mediate apoptosis in cancer cells through interaction with Apaf1 and also down-regulates multiple tyrosine kinases that regulate cell growth, including EGFR, AKT,&#xa0;platelet-derived growth factor receptor ("PDGFR"), c-Kit, and c-Abl.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In normal cells, the proteins involved in the PI3K/AKT/mTOR pathway play an important role in cellular function and cellular trafficking. In this pathway, PI3K, a kinase, generates messenger molecules required to translocate AKT, another protein kinase, to the cell&#x2019;s plasma membrane where it is phosphorylated and activated.&#xa0;These proteins are often found to be aberrantly active in cancers, causing cells to lose their ability to control cell growth, proliferation, and differentiation. Thus, mutations in PI3K (overexpression) and its upstream activators, such as EGFR, have been associated with many forms of cancers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Similarly, proteins in the Ras/MAPK pathway, which is a signal transduction pathway that transduces signals to the cell nucleus where specific genes are activated for cell growth, division and differentiation, play a critical role in cellular responses to various stress stimuli, including osmotic stress, DNA damage, and inflammation. As shown in the figures below, the TUSC2 protein, a potent pan-kinase inhibitor, blocks multiple cell-signaling pathways downstream of the receptor (EGFR in the figures), leading to cell cycle interruption and thereby preventing cancer cell proliferation and survival.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Under stress conditions, such as oncogenic stress, cells go through a regulated process of programmed cell death, also known as apoptosis. As illustrated in the schematic below, the TUSC2 protein interacts via various apoptotic signaling pathways such as Apa1 to stimulate programmed cell death via the release of caspases, enzymes that play a significant role in apoptosis.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="gylze0pdymuz000002.jpg" src="gylze0pdymuz000002.jpg" /></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pan-Kinase Inhibition by TUSC2 </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="gylze0pdymuz000003.jpg" src="gylze0pdymuz000003.jpg" /></div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Stimulation of Apoptotic Signaling by TUSC2 </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&#xa0;&#xa0;</b></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our clinical and preclinical data indicate that the combination of REQORSA&#xa0;with EGFR TKIs, may increase anti-tumor activity in cancers with or without EGFR mutations and in cancers that have become resistant to EGFR TKI therapy, thus expanding the number of patients who could benefit from those drugs.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>TUSC2 and the Immune Response.</i> In addition to its pro-apoptotic cytotoxicity and tyrosine kinase inhibitory activity, TUSC2 enhances the immune response to cancer. Data from preclinical studies at MD Anderson has&#xa0;shown a therapeutic benefit from the combination of TUSC2 and anti-PD-1 antibody and a key role for TUSC2 in regulating immune cell subpopulations including cytokines, natural killer ("NK")&#xa0;cells, and T lymphocytes. In addition, TUSC2 has been found to down-regulate PD-L1 on the surface of cancer cells.&#xa0;As a result, lymphocytes expressing the PD-1 receptor are more likely to recognize the cancer cell as an altered cell that should be destroyed.&#xa0; In addition, by inducing tumor cell apoptosis TUSC2 increases antigen release and presentation, thus promoting an enhanced antitumor response in the presence of other immune regulators.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">NK cells, an important part of the innate immune system, have developed several mechanisms to distinguish healthy cells from target cells. These mechanisms allow NK cells to kill cells that are deemed dangerous to the host, including cancer cells. However, one of the consequences of malignant transformation is the ability of the cancer cell to evade the immune system. Cancer cells do so via the up-regulation and interplay of receptors, including checkpoint inhibitors such as PD-1 and PD-L1.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As shown in the illustration below, TUSC2 has been found to stimulate the release of interleukin-15, or IL-15, resulting in up-regulation of mature NK cells that circulate and target cancer cells.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="gylze0pdymuz000004.jpg" src="gylze0pdymuz000004.jpg" /></div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Modulation by TUSC2 of the Immune Response to Cancer </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>ONCOPREX&#xae;</b> <b> Nanoparticle Delivery System </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our&#xa0;oncology platform consists of anti-cancer genes expressing DNA plasmids contained in non-viral lipid nanoparticles delivered intravenously. REQORSA utilizes the ONCOPREX&#xae; Nanoparticle Delivery System to encapsulate the TUSC2 gene in positively charged nanoparticles that bind to negatively charged cancer cells, and then enter the cancer cell through selective endocytosis, a process by which cells take in substances from outside the cell by engulfing them in a vesicle. The nanoparticles in our system differ significantly from liposomes historically used for drug delivery in that they are true particles encapsulating the therapeutic payload within a bilamellar lipid coat.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><img alt="oncoprexlnp_850.jpg" src="oncoprexlnp_850.jpg" /></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Operation of the ONCOPREX Nanoparticle&#xa0;Delivery System</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The particle size is small enough to allow REQORSA to cross tight barriers in the lung, but large enough to avoid accumulation or clearance in the liver, spleen, and kidney. The cationic (positive) charge of the nanoparticles target cancer cells. A Phase 1&#xa0;clinical trial showed that intravenous REQORSA therapy selectively and preferentially targeted tumor cells, resulting in anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The ONCOPREX Nanoparticle Delivery System is a non-viral delivery system. Many gene&#xa0;therapies rely on viral based delivery systems. The benefit of the viral system is that viruses are skilled at penetrating cells. However, viruses can also affect more than one type of cell and it is possible that the virus may infect cells&#xa0;other than the targeted cells containing mutated genes. If this happens, healthy cells may be damaged causing other illness or diseases, such as cancer. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed and TUSC2 protein is capable of restoring certain defective functions in the cancer cell. REQORSA has been designed using the ONCOPREX Nanoparticle Delivery System to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. Studies in mice showed that the uptake of TUSC2 in tumor cells after REQORSA treatment was&#xa0;10 to 33 times the uptake in normal cells, and studies in three NSCLC patients showed a major increase in TUSC2 expression in tumor tissue one day after REQORSA administration.&#xa0; REQORSA is also delivered systemically as opposed to many other gene therapies.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>REQORSA Origins, Development Rationale, and Strategy </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">TUSC2 was discovered through a lung cancer research consortium from MD Anderson and The University of Texas Southwestern Medical Center along with the National Cancer Institute. The TUSC2 discovery teams included Jack A. Roth, MD, FACS, chairman of our Scientific Advisory Board.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our goal is to utilize our novel gene therapy platform to provide more effective treatments to large patient populations suffering from devastating illness.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">REQORSA, our lead product candidate, initially is being developed as a potential treatment for NSCLC.&#xa0; Clinical and preclinical data indicate that REQORSA, when combined with EGFR TKIs such as Tagrisso, Tarceva and Iressa, provides a synergistic effect that could also benefit the larger population of NSCLC patients who are EGFR negative (which is an indicator that they are not expected to benefit from EGFR TKI drugs alone). Further, our data shows that REQORSA may re-sensitize EGFR positive patients who become resistant to, and therefore no longer benefit from, EGFR TKIs alone. Thus, REQORSA may both significantly expand the benefit of EGFR TKIs to the majority of patients who do not have EGFR activating mutations, and also extend the usefulness and benefit of EGFR TKIs for the population of NSCLC patients who are EGFR positive, but whose tumors progress on EGFR TKIs. Preclinical and clinical data support&#xa0;our belief that REQORSA may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and also served as the basis for the receipt from the FDA in January 2020 of our first Fast Track Designation. In granting this Fast Track Designation, the FDA found that REQORSA has the potential to provide a benefit over existing therapies for patients whose tumors progress on Tagrisso. This FDA Fast Track Designation is for use of the combination of REQORSA with Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with&#xa0;Tagrisso.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pre-clinical data also have shown that REQORSA enhances the immune response to cancer. Data from preclinical studies at MD Anderson have&#xa0;shown a therapeutic benefit from the combination of TUSC2 and anti-PD-1 antibody and a key role for TUSC2 in regulating immune cell subpopulations including cytokines, NK&#xa0;cells, and T lymphocytes. In addition, TUSC2 has been found to down-regulate PD-L1 on the surface of cancer cells. These data, along with our previous pre-clinical and clinical data, provided the basis for the receipt from the FDA in December 2021 of our second Fast Track Designation.&#xa0;In granting this Fast Track Designation, the FDA found that REQORSA has the potential to provide a benefit over existing therapies for patients whose tumors progress on Keytruda. This FDA Fast Track Designation is for use of the combination of REQORSA with Keytruda for the treatment of NSCLC patients whose tumors progressed after treatment with&#xa0;Keytruda.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our study in SCLC builds on the pre-clinical data showing that REQORSA enhances the immune response to cancer, and that the combination of REQORSA and immune checkpoint inhibitors demonstrates a therapeutic benefit over immune checkpoint inhibitors alone.&#xa0; Immune checkpoint inhibitors, such as Tecentriq, have recently been approved for use in ES-SCLC.&#xa0; Tecentriq, for instance, is used in combination with the chemotherapy drugs carboplatin and etoposide for 4 cycles of therapy, and then Tecentriq is administered alone as maintenance therapy until disease progression.&#xa0; Unfortunately, this is a relatively short time since the median PFS after starting maintenance therapy is 2.6 months.&#xa0; Based on the immunologic activity of Reqorsa, we plan to combine REQORSA with Tecentriq and use this combination as maintenance therapy with the goal of prolonging PFS and survival of ES-SCLC patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Pre-clinical studies by MD Anderson researchers have included combining REQORSA with:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the EGFR TKI gefitinib (marketed as Iressa&#xae;&#xa0;by AstraZeneca Pharmaceuticals) in animals and in human NSCLC cells;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">third generation EGFR TKIs such as osimertinib (marketed as Tagrisso&#xae;&#xa0;by AstraZeneca Pharmaceuticals);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">MK2206 in animals (MK2206 is an inhibitor of AKT kinases, which affect cell signaling pathways downstream from tyrosine kinases);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the&#xa0;anti-PD-1 antibody pembrolizumab (the checkpoint inhibitor marketed as Keytruda&#xae;&#xa0;by Merck &amp; Co.) in animals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the anti-PD-1 antibody nivolumab (the checkpoint inhibitor marketed as Opdivo&#xae;&#xa0;by Bristol-Myers Squibb Company) in animals; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the anti-CTLA4 antibody ipilimumab (marketed as Yervoy&#xae;&#xa0;by Bristol-Myers Squibb Company) in animals.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The manufacturers of the marketed drugs were not involved in any of our clinical or preclinical studies. In clinical&#xa0;studies involving marketed drugs, the drugs were administered concurrently with REQORSA without being modified in any way, and the antibodies used in our preclinical studies that did not use the marketed drugs were the non-humanized equivalent to marketed drugs.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Data from these clinical and preclinical studies indicates that combining REQORSA with these other therapies yields results more favorable than either these therapies or REQORSA alone, with minimal side effects relative to other lung cancer drugs, thereby potentially making REQORSA a therapy complementary to these cancer treatments.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Acclaim-1 </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As described above, in January 2020, we received Fast Track Designation from the FDA for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC&#xa0;patients with EGFR mutations whose tumors progressed after treatment with Tagrisso.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We currently are enrolling patients in our Acclaim-1 trial, a Phase 1/2 open-label, dose-escalation and clinical response study of REQORSA in combination with Tagrisso in patients with advanced, EGFR-mutant, metastatic non-small-cell lung cancer who have progressed after treatment with Tagrisso. We anticipate enrolling patients at approximately 15-20 clinical sites and estimate that the dose escalation portion of the Acclaim-1 trial will enroll between 12 and 18 patients, the dose expansion portion of Acclaim-1 will enroll approximately 66 patients in 2 cohorts, and the&#xa0;randomized Phase 2 portion will enroll approximately 74 patients.&#xa0; Patients enrolled in the randomized Phase 2 portion of the study will be randomized 1:1 to either REQORSA and Tagrisso combination therapy or to Tagrisso monotherapy. Prior to entry into the trial, patients may receive local therapy such as radiation therapy, to progressing lesions.&#xa0;Patients will be treated until disease progression or unacceptable toxicity is experienced.&#xa0;Patients must have histologically confirmed unresectable stage III or IV EGFR-positive NSCLC (any histology) with:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">radiological progression on Tagrisso&#xa0;(third generation EGFR-TKI); and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an ECOG performance status of 0 to 1.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The primary endpoint of the dose escalation&#xa0;portion is dose limiting toxicity ("DLT"), defined as &#x2265;Grade 3 prolonged non-hematological or &#x2265;Grade 4 prolonged hematological toxicity occurring during the first cycle of therapy and considered to be possibly, probably, or definitely related to REQORSA and Tagrisso combination therapy.&#xa0;The primary endpoint of the expansion portion and of the Phase 2 randomized portion of the trial is progression-free survival which is defined as time from randomization to disease progression) or death.&#xa0;Patients will be followed for up to 12 months following administration of their last dose of Tagrisso. The expansion portion will be designated a Phase 2 trial in an upcoming protocol amendment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In February 2022, we dosed the first patient in the Acclaim-1 trial. In&#xa0;August 2022,&#xa0;the Acclaim-1 SRC approved escalating the dose from&#xa0;0.06&#xa0;mg/kg in the&#xa0;first&#xa0;cohort of patients to&#xa0;0.09&#xa0;mg/kg in the&#xa0;second&#xa0;cohort of patients and in December 2022, the SRC approved escalating the dose from 0.09 mg/kg in the second cohort to 0.12 mg/kg in the third and final cohort.&#xa0; We are thus enrolling and treating patients at the 0.12 mg/kg dose level in the dose escalation portion of the study. There have been no DLTs in the 0.06 or 0.09 mg/kg dose groups.&#xa0; After completion of enrollment and cycle one of treatment for the remaining untreated patients, the Acclaim-1 SRC will meet and establish the MTD&#xa0;or RP2D. We will then proceed into the dose expansion portion of the study which is a Phase 2 study. The principal advantage of adding the dose expansion portion to the study is to gain early evidence of drug effectiveness in defined distinct patient populations represented by the&#xa0;two&#xa0;expansion cohorts, in order to increase the likelihood of a successful randomized Phase&#xa0;2&#xa0;trial.&#xa0; We expect enrollment in the dose escalation portion of the Acclaim-1 trial will be completed in the next several days following the filing of this Annual Report. We expect to present dose escalation&#xa0;data at an upcoming scientific meeting and/or release data in the second quarter of 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">
   <div>
    <div>
     <img alt="a1new.jpg" src="a1new.jpg" /></div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Acclaim-2</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC&#xa0;patients whose tumors progressed after treatment with Keytruda.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In 2019, preclinical data were presented by MD Anderson collaborators relating to the combination of TUSC2, the active agent in REQORSA, with Keytruda showing that TUSC2 combined with the checkpoint blockade mechanism of action of Keytruda was more effective than Keytruda alone in increasing the survival of mice with a human immune system (humanized mice) that had metastatic lung cancer. MD Anderson also&#xa0;presented preclinical data in 2019 for the&#xa0;combination of TUSC2, Keytruda and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the addition of TUSC2 demonstrates synergy with Keytruda and with Keytruda combined with chemotherapy, and thus, may improve on the first-line standard of care for lung cancer. In May 2020, we entered into a worldwide, exclusive license agreement with&#xa0;The Board of Regents of the University of Texas System on behalf of MD Anderson&#xa0;for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and&#xa0;chemotherapy.&#xa0; For a further description and discussion of the exclusive license agreement with MD Anderson, please see the "Business - Licenses and Research Collaborations" section below in this Part I, Item 1 of this Annual Report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Acclaim-2 trial is a Phase 1/2 open-label, dose-escalation and clinical response study of REQORSA in combination with Keytruda in patients with advanced, metastatic non-small-cell lung cancer who have progressed after treatment with Keytruda. We expect to enroll&#xa0;patients at approximately 10-15 clinical sites and estimate that the dose escalation portion of the Acclaim-2 trial will enroll up to 18 patients, the dose expansion portion will enroll 36&#xa0; patients, and the Phase 2 randomized portion will enroll approximately 126 patients.&#xa0; Patients enrolled in the Phase 2 randomized portion of the study will be randomized 2:1 to either REQORSA and Keytruda combination therapy or to chemotherapy (docetaxel with or without ramucirumab). Patients will be treated until disease progression or unacceptable toxicity is experienced.&#xa0; Patients must have histologically confirmed unresectable stage III or IV NSCLC (any histology) with:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">radiological progression on Keytruda; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an ECOG performance status of 0 to 1.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The primary endpoint of the dose escalation&#xa0;portion is DLT, defined as &#x2265;Grade 3 prolonged non-hematological or &#x2265;Grade 4 prolonged hematological toxicity occurring during the first cycle of therapy and considered to be possibly, probably, or definitely related to REQORSA and Keytruda combination therapy.&#xa0;The primary endpoint of the dose expansion portion and the Phase 2 randomized portion of the trial is progression-free survival which is defined as time from randomization to disease progression&#xa0;or death.&#xa0;Patients will be followed for survival.&#xa0; The dose expansion portion is considered a Phase 2 study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In April 2022, we dosed the first patient in the Acclaim-2 trial at the 0.06 mg/kg dose level and, subject to Acclaim-2 SRC approval, will treat the two successive cohorts of patients at the&#xa0;0.09 mg/kg and 0.12 mg/kg dose levels. In March 2023, we amended the Acclaim-2 protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the&#xa0;dose escalation portion of the Acclaim-2 trial will be completed by the end of 2023.&#xa0;We will then evaluate&#xa0;patients in the dose expansion portion of the study&#xa0;at the MTD or RP2D to expand the safety and efficacy profile at that dose in order to better evaluate efficacy and to increase the likelihood of a successful randomized Phase 2 trial, which will follow the dose expansion portion.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <div style="text-align: center;">
   <div>
    <img alt="a2new.jpg" src="a2new.jpg" /></div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: center;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>Acclaim-3</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In November 2022, we filed with the FDA our protocol for our Phase 1/2 Acclaim-3 clinical trial using a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq as maintenance therapy in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Patients in the study will be enrolled after receiving initial treatment with 3-4 cycles of carboplatin, etoposide, and Tecentriq, and achieving complete response, partial response or stable disease.&#xa0;They will then receive treatment with REQORSA and Tecentriq as maintenance therapy every 21 days until disease progression.&#xa0;We expect to dose the first patient in Acclaim-3 by the end of the third quarter of 2023. We anticipate enrolling patients at approximately 10 U.S. clinical sites and estimate that the Phase 1 escalation portion of the Acclaim-3 trial will enroll up to 12 patients, and the Phase 2 portion will enroll approximately 50 patients.&#xa0;Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#xa0;The primary endpoint of the Phase 1 escalation portion is to determine the MTD or RP2D and the Phase 2 is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="acclaim3_850.jpg" src="acclaim3_850.jpg" /></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>ONC-001: REQORSA&#xae;</i><i> Phase 1 Monotherapy Trial (completed)</i>&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In 2012, MD Anderson researchers completed a Phase 1&#xa0;clinical trial of REQORSA as a monotherapy (the &#x201c;Phase 1 Monotherapy Trial&#x201d;) in patients with advanced NSCLC with disease progression at study entry.&#xa0;The primary objective of the REQORSA Monotherapy Trial was to assess the toxicity of REQORSA administered intravenously and to determine the MTD&#xa0;and RP2D of REQORSA alone. Secondary objectives were to assess the expression of TUSC2 following intravenous delivery of REQORSA in tumor biopsies and also to assess the anticancer activity of REQORSA. This trial showed that REQORSA was well tolerated and established the MTD and the therapeutic dosage for REQORSA at 0.06 mg/kg administered every 21 days. This MTD was established based on the occurrence of an asymptomatic, Grade 3 laboratory abnormality in 2 patients.&#xa0; Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients, and tumor regressions occurred in primary lung tumors and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients&#x2019; cancer cells&#xa0;and suggested that clinical anti-cancer activity was mediated by TUSC2.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In the Phase 1 Monotherapy Trial, REQORSA was injected intravenously in stage IV (metastatic) lung cancer patients who had received traditional platinum combination chemotherapy but still showed tumor progression at the time of entry into the study. Thirty-one subjects were treated at six dose levels. Seventy percent of subjects had received two or more prior chemotherapy regimens. The only serious adverse events&#xa0;were grade 3 fever (experienced by three patients) and grade 3 hypotension (experienced by 1 patient). The only dose-limiting toxicities were two episodes of transient grade 3 hypophosphatemia (abnormally low levels of phosphate in the blood) resulting in an MTD of 0.06 mg/kg. Five patients, or 22% of the 23 evaluable patients, achieved disease control for periods ranging from 2.6 months to 10.8 months. The median disease control period for these patients was 5.0 months (95% CI: 2.0-7.6). Median survival for all subjects in the Phase 1 Monotherapy Trial was 8.3 months (95% CI 6.0-10.5 months) and mean survival time was 13.2 months (95%CI 8.9-7.5 months) with a range of two to 23+ months.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Two subjects had reductions in primary tumor size of 14% and 26%. One subject with stable disease, a 54-year-old female with a large cell neuroendocrine carcinoma who received 12 cycles of REQORSA therapy, had evidence of a durable metabolic response, which is a lasting reduction of metabolic activity in the tumor, as shown by positron emission tomography ("PET")&#xa0;imaging. The response was documented with PET scans performed after the second, fourth and sixth doses, all showing markedly decreased metabolic activity in the tumor with no changes in size or number of metastases by computed tomography ("CT") imaging. The illustration below is of the PET scan of this subject performed at baseline (Illustration A) and after the fourth dose (Illustration B). This subject had received six prior chemotherapy regimens. Prior to entry in the Phase 1 Monotherapy Trial, two hepatic metastases were progressing on gemcitabine. The subject also had a metastasis in the head of the pancreas and a peripancreatic lymph node, shown by the arrows in the illustration below. Illustration A shows the pretreatment PET scan. Illustration B shows the post treatment PET scan performed 20 days following the fourth dose of REQORSA. All scans were performed within a 60 to 90 minute window after injection.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="gylze0pdymuz000006.jpg" src="gylze0pdymuz000006.jpg" /></div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Metabolic Tumor Response in a Metastatic Lung Cancer Subject </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     14
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>ONC-002: Phase 1/2 - Trial Combining REQORSA with Tarceva (Phase 1 portion completed; Phase 2 portion no longer enrolling in favor of conducting Acclaim-1)</i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Phase 1 Portion: </i>The Phase 1 Monotherapy Trial showed that REQORSA is well tolerated, that high levels of TUSC2 expression are detected in the tumor post-treatment, and that there was evidence of tumor growth suppression. Based on the results from the Phase 1 Monotherapy Trial and substantial preclinical evidence that REQORSA is complementary with EGFR TKIs, we&#xa0;began a Phase 1/2 trial (the &#x201c;Phase 1/2 Combination Tarceva Trial&#x201d;)&#xa0;at MD Anderson combining REQORSA with Tarceva in patients with Stage IV (metastatic) or recurrent NSCLC that is not potentially curable by radiotherapy or surgery.&#xa0; Patients were enrolled whether or not they had an activating EGFR mutation. Enrollment in the Phase 1 portion of the Phase 1/2 Combination Tarceva Trial commenced in 2014 at MD Anderson with Dr. Charles Lu as the Principal Investigator.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In the Phase 1&#xa0;portion of the Phase 1/2 Combination Tarceva Trial, 18 subjects were treated with the following dose levels:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 389px; margin-left: auto; margin-right: auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dose</b>&#xa0;<b>Level</b></p> </td>
     <td style="vertical-align: top; width: 20px;">&#xa0;</td>
     <td style="vertical-align: top; width: 296px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Drug Doses</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1</p> </td>
     <td style="vertical-align: top; width: 20px;">&#xa0;</td>
     <td style="vertical-align: top; width: 296px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: center;">Tarceva (100 mg/day) + REQORSA (0.045 mg/kg)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2</p> </td>
     <td style="vertical-align: top; width: 20px;">&#xa0;</td>
     <td style="vertical-align: top; width: 296px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tarceva (100 mg/day) + REQORSA (0.060 mg/kg)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3</p> </td>
     <td style="vertical-align: top; width: 20px;">&#xa0;</td>
     <td style="vertical-align: top; width: 296px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tarceva (150 mg/day) + REQORSA (0.045 mg/kg)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4</p> </td>
     <td style="vertical-align: top; width: 20px;">&#xa0;</td>
     <td style="vertical-align: top; width: 296px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tarceva (150 mg/day) + REQORSA (0.060 mg/kg)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As in the Phase 1 Monotherapy Trial, subjects received a pre-treatment regimen of oral and intravenous dexamethasone and diphenhydramine to prevent infusion reaction symptoms such as fever, along with an infusion of REQORSA every three weeks. Subjects received oral Tarceva daily during each three-week cycle during the treatment period.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Phase 1 portion of the Phase 1/2 Combination Tarceva Trial was also a dose escalation study with the primary purpose of determining the MTD. DLT were defined as grade 3, 4, or 5 events during the first cycle of treatment that were considered to be treatment related. At dose level 1, one subject had grade 3 adverse events of fatigue, muscle weakness, and hyponatremia (low sodium level) considered to be related to the study treatment (Tarceva). Therefore, three additional subjects were treated at this dose level (six subjects total), none of whom suffered a DLT. At dose level 2, there were no DLTs. At dose level 3, one subject had a grade 3 rash considered to be related to the study treatment (Tarceva); therefore, an additional three subjects were treated at this dose level (six subjects total). No additional subjects had a DLT. At dose level 4, there were no DLTs; thus, dose level 4, as the highest dose evaluated, was determined to be the dose to be used in the Phase 2 portion of the study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Since the eligibility criteria, drug administration details (other than dose) and evaluation details were identical for the Phase 1 portion and the Phase 2 portion, the three subjects in the Phase 1 portion of the Phase 1/2 Combination Tarceva Trial who were treated at the Phase 2 dose (0.06 mg/kg) were included in the analysis of the Phase 2 portion of the study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Phase 2 Portion</i>: The Phase 2 portion of the Phase 1/2 Combination Tarceva Trial was designed to include subjects treated with the combination of REQORSA and Tarceva at the Phase 2 dose with the primary goal of measuring the response rate, and secondary endpoints of stable disease, time to progression and overall survival. The response rate for cancer therapies was defined as Complete Response (CR) + Partial Response (PR); disease control rate was defined as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) &gt; 8 weeks.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Enrollment criteria for the Phase 2 portion were identical to those in the first phase. Subjects received three-week cycles of REQORSA in combination with Tarceva until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred&#xa0;first.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Of the 39 patients planned for the Phase 2 portion of the trial, 10 were enrolled (three of whom were also subjects of the Phase 1 portion of the Phase 1/2 Combination Tarceva Trial). None of the 10 subjects treated&#xa0;in the Phase 2 portion of the Phase 1/2 Combination Tarceva Trial suffered a DLT. Interim results from the Phase 2 portion for the 10 patients show that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">One patient had a response of CR for a study CR rate of 10% and the overall response rate (CR + PR) was also 10%;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align: top; text-align: justify;">Three patients had tumor regression; and</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Disease control rate was 70%.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The patient with the CR, a 58-year-old female, upon enrollment in the study had metastatic NSCLC following 6 cycles of pemetrexed and carboplatin and after two cycles of maintenance pemetrexed had cancer progression. The patient&#x2019;s tumor had EGFR exon 18 and 20 missense mutations, which are not sensitive to Tarceva alone. This patient had disappearance of lung lymph node metastases.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are no longer enrolling the Phase 2 portion of the Phase 1/2 Combination Tarceva Trial in favor of conducting the Acclaim-1 trial since Tagrisso has been shown to be more effective than Tarceva as initial therapy for patients with NSCLC with EGFR mutations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The response rate and disease control rate observed in the Phase 2 portion of the Phase 1/2 Combination Tarceva Trial substantially exceeds the response rate of 7% (with no CRs) and disease control rate of 58% reported for a clinical trial of the EGFR TKI afatinib (marketed as Gilotrif&#xae; by Boehringer Ingelheim Pharmaceuticals, Inc.) in a study referred to as the LUX-Lung 1 clinical trial. The LUX-Lung 1 clinical trial was a randomized, double blinded Phase 2b/3 clinical trial treating subjects with Stage IIIB or IV adenocarcinoma, a type of NSCLC.&#xa0; Patients in that trial had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with EGFR inhibitors erlotinib or gefitinib.&#xa0; A total of 585 patients were enrolled in that Phase 2b/3 clinical trial, whose primary endpoint was overall survival and whose secondary endpoints included progression-free survival and RECIST response. The Phase 2 portion of our Phase 1/2 trial was not blinded&#xa0;and was designed to treat NSCLC subjects regardless of EGFR status.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table provides&#xa0;data from the Phase 2 portion of the Phase 1/2 Combination Tarceva Trial for subjects with and without EGFR mutations.&#xa0; Note that two patients with disease progression on Tarceva received 10 and 12 cycles of Tarceva, respectively, before disease progression and entry into the trial.&#xa0;With the combination of REQORSA and Tarceva, both of these patients had stable disease, suggesting that the combination therapy may be an effective treatment for patients whose disease is progressing on Tarceva alone.</p>
  <div style="text-align: center;">
   <img alt="reqorsatarceva_850v1.jpg" src="reqorsatarceva_850v1.jpg" /></div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt;"><i>Preclinical Studies of REQORSA Supporting Our Conduct of Acclaim-1</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>REQORSA and Tyrosine Kinases.</i> Investigators at MD Anderson conducted preclinical research showing that REQORSA alone blocked the activation of the c-Abl tyrosine kinase. A number of other studies at MD Anderson have shown the complementary effects of REQORSA combined with a variety of targeted kinase inhibitory agents, both marketed and in various stages of clinical development, including Tarceva, Iressa, and Tagrisso.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>REQORSA and TUSC2 deficient and Tarceva or Iressa resistant cell lines. </i>MD Anderson researchers also tested REQORSA in TUSC2-deficient and Tarceva- or Iressa-resistant NSCLC cell lines. Treatment of the NSCLC EGFR mutation negative cell lines H1299, H322, H358 and H460 cancer cell line showed that the REQORSA combination significantly sensitized (p&lt;0.001) response of the cancer cell lines to both Tarceva or Iressa treatment and synergistically induced apoptosis <i>in vitro</i>. The findings were confirmed <i>in vivo </i>in an H322 orthotopic lung cancer mouse model. These studies included the Kras mutant cell line H460, which is significant because patients with Kras mutant tumors are generally unresponsive to Tarceva or Iressa. Synergistic induction of apoptosis was observed with the combination of REQORSA and concentrations of Tarceva or Iressa similar to steady-state serum concentrations achievable with oral dosing. The combination of REQORSA and either Tarceva or Iressa induced similar levels of tumor cell growth inhibition, apoptosis induction, and inactivation of oncogenic protein kinases.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Data from these and other studies suggest a combination of REQORSA with Iressa or Tarceva can promote synergistic tumor cell killing and overcome drug-induced resistance by simultaneously inactivating the EGFR and the AKT signaling pathways and by inducing apoptosis in resistant cells with nonmutated EGFR. These data suggest that NSCLC patients with an activating EGFR mutation, whose cancer progresses on Tarceva, may potentially benefit from REQORSA with Tarceva combination therapy. These data also suggest that NSCLC patients without an activating EGFR mutation (generally unresponsive to Tarceva) may potentially benefit from REQORSA with Tarceva combination therapy.&#xa0; These data provided strong support for the ONC-002 trial, which combined REQORSA with Tarceva.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>REQORSA in Tagrisso resistant cell lines</i>.&#xa0; Osimertinib, the only third-generation EGFR inhibitor, shows robust clinical activity, yet patients inevitably develop secondary resistance. An osimertinib resistant H1975-OsiR isogenic cell line was developed through continuous exposure to osimertinib, and an osimertinib resistant clone was selected which showed 100-fold higher resistance to osimertinib compared with its parental counterpart (H1975-parental). Xenograft tumors from both H1975-parental and H1975-OsiR cells were developed in NSG mice and were treated with osimertinib. H1975-OsiR tumors were significantly less sensitive than its parental counterpart. Synergistic antitumor activity of TUSC2+osimertinib was found in H1975-OsiR tumors where both TUSC2+osimertinib (5mg/kg) and TUSC2+osimertinib (10mg/kg) combinations showed a robust antitumor effect compared with single agent treatment groups. No synergistic effect was observed for H1975-parental tumors. In conclusion, TUSC2 therapy in combination with osimertinib showed synergistic antitumor efficacy in EGFR mutant osimertinib resistant NSCLC tumors.&#xa0;These data provide a strong biologic rationale for the Acclaim-1 clinical trial.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt;"><i>Preclinical Studies of TUSC2 in the Immune Response to Cancer Supporting Our Conduct of Acclaim-2 </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Preclinical studies indicate that REQORSA is selectively taken up by tumor cells with a 10 to 33 fold differential favoring uptake by tumor cells, thus imparting a passive targeting property without the need to attach targeting ligands.&#xa0; REQORSA targeting is partly due to the attraction of opposite charges (REQORSA has a positive charge, normal cells no charge, and most cancer cells have a negative charge), and partly due to enhanced endocytosis by tumor cells.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In experimental mouse xenograft models, the ONCOPREX delivery system was shown to efficiently deliver several therapeutic tumor suppressor genes (<i>TP53</i>, <i>FHIT</i>, <i>TUSC2</i>) to disseminated human cancer cells.&#xa0;Metastatic tumor growth was suppressed, and survival prolonged, after systemic administration of the genes via a nanovesicle vector. Human NSCLC A549 cells have no functional <i>TUSC2</i> gene expression.&#xa0; As shown in <span style="text-decoration: underline; ">Figure 1</span>, intratumoral administration of REQORSA (referred to as FUS1 in <span style="text-decoration: underline; ">Figure 1</span>) to subcutaneous NSCLC A549 tumor xenografts resulted in inhibition of tumor growth.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Figure 1.</b><b>&#xa0;Effect of REQORSA on the Growth of A549 Subcutaneous Tumor Xenografts in Nude Mice</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="figure1.jpg" src="figure1.jpg" /></div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Moreover, intravenous injections of REQORSA into mice bearing experimental A549 lung metastases resulted in a decrease in the number of metastatic tumor nodules.&#xa0;Lung tumor-bearing animals treated with REQORSA also had a significant increase (P=0.01) in survival time (median survival time: 80 days) compared with 48 to 51 days for control animals.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Analysis of <i>TUSC2</i> expression by IHC following REQORSA treatment showed distribution of <i>TUSC2</i> throughout the tumor in a high percentage of the tumor cells.&#xa0;These results demonstrate the potent tumor suppressing activity of the <i>TUSC2</i> gene, supporting the feasibility of using nanovesicles for systemic plasmid delivery to metastases as well as to primary tumors, and implicating REQORSA as a promising therapeutic agent for primary and disseminated human lung cancer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">REQORSA<i> Synergizes with Pembrolizumab</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">It was previously shown that the combination of REQORSA and an anti-PD1 antibody inhibited tumor growth synergistically in subcutaneous and metastatic NSCLC <i>KRAS</i> mutant syngeneic mouse models.&#xa0;To determine whether this synergy also applies to the <i>KRAS</i>/<i>LKB1</i> mutant subtype of human A549 NSCLC cells, humanized mice harboring <i>KRAS/LKB1</i> mutant A549 lung metastases were treated with REQORSA, pembrolizumab or the combination.&#xa0;These studies were performed with an improved humanized mouse model using fresh human umbilical cord blood derived CD34+ stem cells in NOD mice, which lack immune system cells.&#xa0;The reconstituted humanized mice have a fully competent human immune system with major functional immune populations&#xa0;and were&#xa0;used here to evaluate synergy between REQORSA and pembrolizumab.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The treatment strategy is shown in <span style="text-decoration: underline; ">Figure 2A</span>. REQORSA (referred to as TUSC2 in <span style="text-decoration: underline; ">Figure 2</span>) was administered intravenously every 48 hours for a total of three injections, and pembrolizumab was administered every 3-4 days a total of three times.&#xa0; Bioluminescence imaging was performed to visualize the intensity of tumor burden for mice in different treatment groups both in humanized and non-humanized mice.&#xa0;Both REQORSA and pembrolizumab monotherapies reduced the tumor burden significantly, although pembrolizumab was moderately more effective.&#xa0;Importantly, REQORSA plus pembrolizumab inhibited tumor growth synergistically (*P&lt; 0.05, **P&lt; 0.005, ***, P&lt; 0.0005). (<span style="text-decoration: underline; ">Figure 2B, C</span>).&#xa0;There was no antitumor effect of pembrolizumab and reduced change with REQORSA in non-humanized mice, which was expected since these mice have no immune cells.&#xa0; &#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To identify the immunological features associated with efficacy of this combination, in depth immune profiling of the tumor microenvironment was performed.&#xa0;An increased number of reconstituted human CD3+ T cells was found in all groups, compared with the untreated control.&#xa0;CD8+ T cells were significantly upregulated by pembrolizumab and its combination with REQORSA (<span style="text-decoration: underline; ">Figure 2D</span>).&#xa0;Levels of activated CD8+ T cells (CD8+CD69+) were also significantly increased in the combination group and were slightly higher than the pembrolizumab group (<span style="text-decoration: underline; ">Figure 2D</span>).&#xa0;There was no effect of pembrolizumab on NK/activated NK cells, whereas REQORSA alone enhanced their levels significantly, indicating REQORSA regulation of NK activation, which is consistent with the previous finding reported in syngeneic mice.&#xa0;The combination had a similar effect as REQORSA monotherapy (<span style="text-decoration: underline; ">Figure 2E</span>).&#xa0;REQORSA, pembrolizumab, and the combination, were all associated with significant decrease of reconstituted human MDSCs (CD33+ve), (<span style="text-decoration: underline; ">Figure 2F</span>).&#xa0;Pembrolizumab and the combination had a profound stimulatory effect on HLA-DR+ dendritic cells (DCs), (<span style="text-decoration: underline; ">Figure 2G</span>).&#xa0;REQORSA alone enhanced HLA-DR+DC levels moderately.&#xa0;Taken together, these results show that the combination of REQORSA and pembrolizumab enhanced the immune response and inhibited tumor growth synergistically (*P&lt; 0.05, **P&lt; 0.005, ***, P&lt; 0.0005).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">REQORSA also showed synergistic antitumor activity with nivolumab in the same mouse model, highlighting the role of REQORSA rendering <i>KRAS/LKB1</i> mutant tumors more sensitive to immune checkpoint blockade. Thus, these data suggest that the synergy of REQORSA with immune checkpoint inhibitors is not limited to pembrolizumab.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Figure 2. Synergistic Antitumor Effect of REQORSA Immunogene Therapy with Pembrolizumab on </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><i>KRAS/LKB1</i> Mutant Lung Metastases in the Humanized Mouse Model</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div style="text-align: center;">
   <div>
    <img alt="figure2.jpg" src="figure2.jpg" /></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>Preclinical Studies of TUSC2 Supporting Our Conduct of Acclaim-3</i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Transfection of SCLC cells in vitro with TUSC2 showed growth inhibition and a marked suppression of colony formation compared to cells transfected with a control vector &#xa0;&#xa0;These results demonstrate the potential tumor suppression function of TUSC2 in SCLC cells and suggest that TUSC2-mediated gene therapy could be a useful therapeutic strategy for the treatment of SCLC.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In studies in mice using xenografts of human NSCLC cell lines, the combination of quaratusugene ozeplasmid and immune checkpoint inhibitors has been shown to be synergistic.&#xa0; This is a class effect, having been documented with both pembrolizumab and nivolumab.&#xa0; Therefore, it would be expected that the combination of quaratusugene ozeplasmid and atezolizumab would also demonstrate synergy.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Introduction &#x2013; Diabetes</b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Diabetes Mellitus.</i> Diabetes mellitus refers to a group of metabolic diseases that affect how the body produces and uses blood sugar (glucose). Glucose is vital to health because it is an important source of energy for the cells that make up the body&#x2019;s muscles and tissues. It is also the brain's main source of fuel.&#xa0;Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage the eyes, kidneys, nerves, and the heart, and can also lead to coma and death.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Epidemiology of Diabetes.</i> According to the U.S. Center for Disease Control as of 2022, 37.3 million Americans, or&#xa0;approximately 11.3% of the population, have diabetes. It is also believed that more than 96 million Americans aged 18 years or older have prediabetes, which represents approximately 38% of the U.S. adult population.&#xa0;In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Also in 2021, diabetes caused more than 6.7 million deaths globally.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>The Role of Alpha Cells and Beta Cells</i>. The two most abundant endocrine cell types in the pancreas, the beta and the alpha cells, are essential for the maintenance of blood glucose homeostasis whereby levels of glucose are maintained by the body within a narrow range. While the beta cell produces insulin, the only blood glucose-lowering hormone of the body, the alpha cell releases glucagon, which elevates blood glucose. While the release products of the beta cell inhibit alpha cell function, the alpha cell releases factors that are stimulatory for beta cell function and increase glucose-stimulated insulin secretion.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In people with Type 1 diabetes, however, beta cells are destroyed by the immune system and no longer secrete insulin, leading to an absolute deficit of insulin. Type 2 diabetes is due to "insulin resistance," an initial resistance of the body's cells to obey the direction from insulin. To overcome this resistance, the beta cells secrete more insulin, and glucose is eventually forced into the cells. Glucose is maintained within normal limits, but at the expense of increased insulin secretion by the beta cells. After many years of such increased secretion, the beta cells become "tired" from working overtime, and the fatigue process begins. This fatigue tends to be progressive, and in time the compensation for insulin resistance disappears. At that point, blood glucose levels start going up.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Current Treatments for Diabetes.</i> Advances in new treatments have helped many people better manage the disease. However, despite patients' best attempts,&#xa0;managing diabetes remains a challenging, daily balancing act because exogenous insulin therapy simply cannot ideally mimic the body&#x2019;s biological function.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Type 1 diabetes patients are treated with insulin, with most of the progress in therapy relating to enhanced delivery of the drug and improved methods for measuring blood glucose levels. A variety of drug release technologies have allowed for rapid-acting, intermediate-acting and long-acting insulin injections that provide drug anywhere from one to 24 hours. In addition, improvements in needles, continuous delivery ports, and inhalation technologies all have helped patients better manage their disease and may impact quality of life, but none of these advances are disease modifying.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Type 2 diabetes patients are advised to use diet and exercise to manage their condition. When these lifestyle changes alone do not control the disease, Type 2 diabetes patients may be prescribed a variety of medications that help alter how the body manages blood sugar levels. For example, biguanides such as metformin, reduce the amount of glucose produced in the liver. DPP-4 inhibitors, such as Januvia&#xae;, Onglyza&#xae;, and Tradjenta&#xae;, improve blood sugar levels and prevent them from dropping too low. Glucagon-like peptides, such as Byetta&#xae;, Trulicity&#xae; and Victoza&#xae;, change the way the body produces insulin. Drugs in the SGLT2 inhibitor class, such as Farxiga and Invokana, release more glucose into the urine. Finally, insulin injections may be needed if these oral medications, along with diet and exercise, do not lower blood sugar levels enough. These medications, including insulin replacement therapy, while offering improvements for Type 2 diabetes patients, do not affect the underlying cause of the disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>GPX-002 and GPX-003</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As further described in the "Licenses and Research Collaborations" section below, we have exclusively licensed from the University of Pittsburgh&#xa0;multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes.&#xa0;The same general novel approach is used in each of Type 1 and Type 2 whereby an AAV vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct.&#xa0; In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized&#xa0;in preclinical studies at the University of Pittsburgh.&#xa0;GPX-002 is being developed for the treatment of Type 1 diabetes and GPX-003 is being developed for the treatment of Type 2 diabetes.&#xa0;GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells,&#xa0;which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system and GPX-003 is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of 2023 to obtain their guidance on the toxicology studies that we plan to conduct.&#xa0;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div style="text-align: center;">
   <div>
    <img alt="gpx002new.jpg" src="gpx002new.jpg" /></div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In August 2022, the Company entered into a one-year sponsored research agreement with the University of Pittsburgh for the use of GPX-003 in a NHP model in Type 2 diabetes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This gene therapy approach has been tested&#xa0;<i>in vivo</i>&#xa0;in mice and NHPs using an earlier construct&#xa0;as described below.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Preclinical Mouse Studies</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In studies in non-obese diabetic (&#x201c;NOD&#x201d;) mice and in mice treated to destroy insulin producing beta cells, both of which are models of Type 1 diabetes, our gene therapy approach restored normal blood glucose levels for an extended period of time, and markedly increased the mass of insulin producing beta cells.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The figures below show&#xa0;that starting approximately a week after injection of the engineered AAV construct (labeled AAV8-PM) into the pancreatic duct, the blood glucose level markedly improved in mice in which insulin producing cells had been destroyed by the drug alloxan (ALX).&#xa0; In addition, the mass of beta cells and beta-like cells producing insulin was significantly increased.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="diabetes3_850.jpg" src="diabetes3_850.jpg" /></div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Non-obese diabetic mice develop diabetes due to an immune attack that destroys the insulin producing beta cells in the pancreas.&#xa0;The figures below show&#xa0;that starting approximately a week after injection of the engineered AAV construct (labeled AAV8-PM) into the pancreatic duct the blood glucose level markedly improved in NOD mice.&#xa0;In addition, there is a significant increase in the mass of beta cells and beta-like cells that produce insulin.&#xa0;The improvement in glucose level normalization lasted approximately 4 months, which, according to the researchers could potentially translate to decades in humans.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: center;"><img alt="diabetes4_850.jpg" src="diabetes4_850.jpg" /></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The researchers also carried out an experiment to determine if the same AAV engineered construct could be used to convert human alpha cells to beta-like cells that would produce insulin as shown in the figures below. Human pancreatic islets were treated with streptozotocin (STZ) to destroy beta cells, and then were treated with the AAV engineered construct. They were then transplanted into NOD mice that had been treated with alloxan (ALX), and also modified so they would not reject human cells. The NOD mice that received the AAV engineered construct had significantly lower blood glucose levels and higher mass of beta and beta-like cells that secrete insulin than did control mice.&#xa0; These data suggest that the same AAV engineered construct can convert human alpha cells into insulin secreting beta-like cells.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="diabetes5_850.jpg" src="diabetes5_850.jpg" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Preclinical Non-Human Primate Studies</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In February 2023, the Company&#x2019;s research collaborators at the&#xa0;University of Pittsburgh&#xa0;presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD 2023) in Berlin, Germany. The statistically significant study results showed that after infusion of the AAV engineered construct all eight of the NHPs had:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Decreased insulin requirements (p&lt;0.001);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align: top; text-align: justify;">Increased c-peptide levels (p&lt;0.05);</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Improved glucose tolerance compared to baseline (p&lt;0.05) with one demonstrating reestablished normoglycemia; and</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Insulin and glucagon staining in the same cells, suggesting the formation of insulin-producing cells.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe these data in NHPs demonstrate the potential for this gene therapy treatment to eliminate the need for insulin replacement therapy for Type 1 and Type 2 diabetic patients.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="attd_graphs.jpg" src="attd_graphs.jpg" /></div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <div style="text-align: center;">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Discovery Programs</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Oncology</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i style="font-size: 10pt; text-indent: 36pt;">ONCOPREX</i>&#xae;&#xa0;<i style="font-size: 10pt; text-indent: 36pt;">Nanoparticle Delivery System as a platform</i>.&#xa0; We believe that the ONCOPREX Nanoparticle Delivery System may be applicable to delivery of a range of therapeutic and prophylactic plasmid DNA and RNA interference constructs and shows efficacy in cancers beyond lung cancer. We also believe that the manufacturing methods we have developed for REQORSA may be useful for a wide array of disease treatments. Clinical data from the use of REQORSA has&#xa0;shown that the ONCOPREX&#xa0;Nanoparticle Delivery System is well tolerated in humans and can be delivered at high therapeutic doses.</p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Rights to other Tumor Suppressor Genes.</i>&#xa0;We have licensed rights to the tumor suppressor gene, TUSC2, which is located in a sub-region of human Chromosome 3 known as 3p21.3, on which multiple tumor suppressor genes are located, including for example, 101F6, NPRL2, CACNA2D2, PL6, BLU, RASSF1, HYAL 1 and HYAL2. Using a number of techniques, MD Anderson researchers and their collaborators have identified these genes as potentially having cancer-fighting characteristics. MD Anderson researchers have subsequently conducted a number of preclinical studies on certain of these genes, particularly 101F6 and NPRL2, as well as TUSC2, both alone and in combination with other compounds, in order to assess their actual effects on lung cancer. Under past and current sponsored research agreements with MD Anderson, we support continuing research into the cancer-fighting properties of these and other genes in the 3p21.3 sub-region.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Researchers at MD Anderson have collaborated with other researchers to identify other genes, such as those in the 3p21.3 chromosomal region, which may act as tumor suppressors or have other cancer fighting functions. We hold rights to certain of these genes under license agreements with MD Anderson. Data from preclinical studies performed by MD Anderson researchers and others suggest that TUSC2, the active agent in REQORSA, could be effective against other types of cancer, including glioblastoma, head and neck, breast (including triple-negative breast cancer), renal cell (kidney), thyroid, and soft tissue sarcoma, as well as NSCLC and SCLC. Therefore, the ONCOPREX&#xa0;Nanoparticle Delivery System may allow delivery of a number of cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, we have identified internally other tumor suppressor genes on which we have filed for intellectual property protection.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><i>Diabetes</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In November 2022, we exclusively licensed from the University of Pittsburgh technology that transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company&#x2019;s existing diabetes technology.&#xa0;The technology modulates autoimmunity in Type 1 diabetes using gene therapy.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 36pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        25
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Process Development and Manufacturing</b></p>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have made substantial investment in manufacturing for our product candidates with the goal of mitigating the risks associated with the complex manufacturing of gene therapies. While we continue to use third-party contract development and manufacturing organizations ("CDMOs") in the manufacture&#xa0;of our product candidates, we believe we have a competitive advantage in our field based on core competencies we have developed that we are leveraging in the manufacture of our product candidates.&#xa0; These core competencies include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Extensive and diverse internal expertise;</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Customized chemistry, manufacturing and controls ("CMC") strategy for accelerated development;</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Risk assessment and remediation for FDA submissions;</p> </td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Novel and proprietary manufacturing processes;</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Integrated global Good Manufacturing Practices ("cGMP" or "GMP") manufacturing network; and</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Management of supply chain for business continuity.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In our oncology program, we are focused on preparing for commercial readiness for REQORSA.&#xa0; To date we have developed a robust manufacturing process for REQORSA through years of process development activities that we continue to improve with the dramatic development and expansion of advanced technologies in the nascent gene therapy sector. REQORSA is an immunogene therapy with two main components. The active agent in REQORSA is a DNA plasmid encoding the TUSC2 protein.&#xa0; The plasmid is encapsulated by non-viral DOTAP cholesterol lipid nanoparticles. This system of encapsulating DNA plasmid in non-viral lipid nanoparticles is referred to by us as our ONCOPREX Nanoparticle Delivery System. Each of these two components currently is manufactured by separate CDMOs and then transported to another CDMO for final drug formulation. REQORSA utilizes the ONCOPREX Nanoparticle Delivery System, a non-viral platform allowing for systemic delivery. REQORSA has been shown to be scalable at cGMP&#xa0;and can be stored for approximately 12 to 18 months for later use. Successful tech transfer of REQORSA from MD Anderson, where it was developed and previously manufactured, to CDMOs has been achieved as well as scale-up of our clinical grade manufacturing production in accordance with cGMP. The clinical grade material is being used to supply our Acclaim-1 and Acclaim-2 clinical trials and will be used to supply our Acclaim-3 clinical trials.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For our diabetes program, which is an earlier stage program than our oncology program, we are working with our academic collaborators at University of Pittsburgh to transfer the technologies associated with the manufacture of our GPX-002 and GPX-003 constructs to an appropriate integrated network of CDMOs and other vendors.&#xa0; This also involves the investigation of novel advanced technologies to incorporate in these processes.&#xa0; GPX-002 and GPX-003 involve the delivery of the Pdx1 and MafA genes into the pancreas via the pancreatic duct utilizing an AAV vector.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We manage our manufacturing arrangements with our CDMOs and other vendors through various agreements. &#xa0;&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt;"><b>Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Patents and other proprietary rights such as trademarks and trade secrets are critical to our business and to our ability to successfully develop and commercialize our product candidates.&#xa0; Our goal is to obtain, maintain, enhance and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the U.S. and in other countries. Our policy is to actively seek the broadest intellectual property protection possible for our product candidates, proprietary information, and proprietary technology through a combination of contractual arrangements, patents, trade secrets, trademarks, copyrights and regulatory exclusivity both in the U.S. and elsewhere in the world.&#xa0;Patents provide a period of exclusivity intended to make it more difficult for competitors to make, use or sell competing technologies. We additionally rely on regulatory protection afforded through data exclusivity, market exclusivity, orphan drug designation and/or patent term extensions, where available. We have developed and/or in-licensed numerous patents and pending patent applications that relate to compositions-of-matter, methods-of-use and other technologies and possess substantial know-how and trade secrets relating to the development of gene therapy technologies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As further described in the &#x201c;Licenses and Research Collaborations&#x201d; section below, we hold a worldwide, exclusive license from MD Anderson to patents covering the therapeutic use of TUSC2 and other genes that have been shown to have cancer fighting properties, including 14&#xa0;issued patents and 13 pending patent&#xa0;applications for technologies developed at MD Anderson and The University of Texas Southwestern Medical Center.&#xa0;These patents comprise various therapeutic, diagnostic, technical and processing claims relating to REQORSA and our ONCOPREX Nanoparticle Delivery System.&#xa0;We expect these patents and patent applications, if issued, to expire from 2024&#xa0;to 2038. The rights we have obtained pursuant to our license agreement with MD Anderson are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. As further described in the &#x201c;Licenses and Research Collaborations&#x201d; section below,&#xa0;we also hold worldwide, exclusive licenses to an issued patent and 7 pending patent applications for diabetes technologies developed at the University of Pittsburgh.&#xa0;We expect these patents and patent applications, if issued, to expire from 2035 to 2043.&#xa0;We also are prosecuting four patent applications relating to various oncology targets in our discovery program.&#xa0;In addition, for certain of our product candidates we also expect to have further exclusivity in the form of data and marketing exclusivity under pharmaceutical regulatory laws, including for example, potentially up to 12 years of exclusivity from the date of first BLA approval of our product candidates.&#xa0; For a further description and discussion of these laws, exclusivities and their regulatory background, please see the &#x201c;Business &#x2013; Government Regulation&#x201d; section below in this Part I, Item 1 of this Annual Report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We also have received trademark registrations for the trademarks GENPREX, REQORSA, and ONCOPREX.&#xa0;For a discussion of the challenges we face in obtaining or maintaining patent, trademark and/or trade secret protection, please see the risk factors under the heading &#x201c;Risks Related to Our Intellectual Property&#x201d; in Part I, Item 1A of this Annual Report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Licenses and Research Collaborations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Agreements with MD Anderson</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our ONCOPREX and REQORSA technologies are exclusively licensed pursuant to a Patent and Technology License Agreement dated July 20, 1994, with MD Anderson, as amended on September 1, 1996, August 11, 1997, July 31, 1994 and October 4, 2001 (collectively, the "1994 MD Anderson License Agreement"), between MD Anderson and Introgen Therapeutics, Inc. (f/k/a Intron Therapeutics, Inc.) (&#x201c;Introgen&#x201d;).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to the 1994 MD Anderson License Agreement, we have rights to patents covering use of various genes, including the TUSC2 gene, for treatment of cancer, as well as know-how and related intellectual property.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The exclusive licenses under the 1994 MD Anderson License Agreement&#xa0;will continue until the expiration of all patents covered by such agreement. Upon the expiration of the exclusive licenses, we will have a non-exclusive, fully paid-up right and license to use and otherwise exploit the technology rights licensed under the agreement. MD Anderson may terminate the agreement for, among other things, a breach of the agreement by us which remains uncured.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to a Technology Sublicense Agreement dated March 7, 2007 (&#x201c;Sublicense Agreement&#x201d;), Introgen sublicensed its rights under the 1994 MD Anderson License Agreement to Introgen Research Institute, Inc. (&#x201c;IRI&#x201d;).&#xa0;IRI&#xa0;is a Texas-based technology company formed by Rodney Varner, our President and Chairman of the Board and IRI's sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to an Assignment and Collaboration Agreement dated April 13, 2009 (&#x201c;IRI Collaboration Agreement&#x201d;)&#xa0;IRI assigned its rights under the Sublicense Agreement to us, and we granted to IRI a non-exclusive, royalty-free license to use and practice the licensed technology for non-commercial research purposes. As consideration for this assignment, we agreed to assume all of IRI&#x2019;s obligations to MD Anderson under the 1994 MD Anderson License Agreement, including ongoing patent related expenses and royalty obligations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The IRI Collaboration Agreement was amended by an Amended Collaboration and Assignment Agreement dated July 1, 2011 ("2011 IRI Collaboration Agreement"). The 2011 Collaboration Agreement provided that IRI would provide additional licensing opportunities and services to us, in return for monthly payments and our obligation to pay to IRI a royalty of 1%&#xa0;on sales of products licensed to us under the 1994 MD Anderson License Agreement. In 2012, IRI&#x2019;s obligation to provide those opportunities and services, and our obligation to make monthly payments to IRI, were terminated; however, we are required to pay a 1% royalty to IRI upon sales of products licensed to us under the 1994 MD Anderson License Agreement which royalty obligation continues for 21 years after the later of the termination of the 1994 MD Anderson License Agreement and the termination of the sublicense assigned by IRI to us.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to a Technology Sublicense Agreement dated June 1, 2011, we granted to IRI a non-exclusive sublicense, for non-commercial purposes, to the rights under the Sublicense Agreement.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">At the time that we entered into the 2011 IRI Collaboration Agreement, Mr. Varner was not an officer or director of Genprex, but he was deemed to be an &#x201c;affiliate&#x201d; of the Company due to his beneficial ownership of approximately 39% of our issued and outstanding shares. At the time we acquired the ONCOPREX and REQORSA technologies under the 2009 IRI Collaboration Agreement, they were the subject of the Phase 1 Monotherapy Trial. We completed the Phase 1 Monotherapy Trial and did substantial process development, manufacturing and regulatory work necessary to bring the technologies into a Phase 1/2 combination trial.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant&#xa0;to the 1994 MD Anderson License Agreement, the Sublicense Agreement and the 2009 IRI Collaboration Agreement, we are obligated to pay all fees, patent related expenses, royalties, and other amounts that become due with respect to the licensed patents, patent application and other technologies. We are also obligated to pay to MD Anderson royalties of 1.5% of net&#xa0;sales of the licensed products, as well as 1.5% of advance payments received by us (excluding amounts paid to us in reimbursement of development or other costs) from third parties pursuant to sublicense, marketing, distribution or franchise arrangements. Under the 2011 IRI Collaboration Agreement, we are obligated to pay to IRI a royalty of 1.0% of net sales of licensed products and 1.0% of certain other payments received by us. This royalty obligation continues for 21 years after the later of the termination of the 1994 MD Anderson License Agreement and the termination of the Sublicense Agreement. We have no other payment obligations to IRI under the 2009 IRI Collaboration Agreement or the 2011 IRI Collaboration Agreement. We were not required to make any up-front payments to MD Anderson or IRI when we entered into the 1994 MD Anderson License Agreement, the Sublicense Agreement or the 2009 IRI Collaboration Agreement.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On May 4, 2020 (the &#x201c;MD Effective Date&#x201d;), we entered into a Patent and Technology License Agreement with MD Anderson, as amended on March 3, 2021 (collectively, the &#x201c;2020 License Agreement&#x201d; and together with the 1994 MD Anderson License Agreement, collectively, the "MD Anderson License Agreements").&#xa0; Pursuant to the 2020 License Agreement, MD Anderson granted us a worldwide, exclusive, sublicensable, royalty-bearing license to certain licensed intellectual property and technology, including, without limitation, use of chemotherapy in combination with TUSC2 therapy and methods for treating cancer by administration of a TUSC2 in conjunction with EGFR inhibitors or other anti-cancer therapies in patients that are expected to be responsive to TUSC2 therapy (collectively, the &#x201c;Licensed IP&#x201d;), to manufacture, use, commercialize, seller, offer for sale and import licensed products related to the treatment of cancer using TUSC2 therapy in combination with certain immunotherapies (the &#x201c;Licensed Products&#x201d;). In consideration for our use of the Licensed IP, we are required to make certain payments to MD Anderson, including, without limitation, an upfront license fee as well as a fee paid to amend the agreement, annual maintenance fees ranging from the low five figures to low six figures, milestone payments aggregating up to a maximum of $6,150,000, low single digit royalty payments to low double digits royalty payments with lower net sales being subject to lower royalty payments, and minimum annual royalties after the first sale in a low six figure amount. In addition, we shall be required to reimburse MD Anderson for certain patent expenses. The 2020 License Agreement shall expire on the later to occur of (a) the expiration of all patents issued under the Licensed IP and the cancellation, withdrawal, or express abandonment of all patent applications under the Licensed IP, or (b) 30 years after the MD Effective Date, unless earlier terminated pursuant to the terms thereof.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>License Agreement with P53, Inc.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 26, 2010, IRI and P53, Inc., which subsequently changed its name to MultiVir Inc., (&#x201c;P53&#x201d;)&#xa0;entered into a Technology License Agreement ("P53 License Agreement")&#xa0;pursuant to which IRI granted to P53 a worldwide, exclusive license under certain patents related to the ONCOPREX Nanoparticle Delivery System that we are now using for the delivery of TUSC2, but only for P53&#x2019;s use in gene therapy products in which the sole active genes are P53 and MDA-7. As a result of the 2009 IRI Collaboration Agreement, we are the licensor under the P53 License Agreement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The P53 License Agreement authorizes P53 to develop, make and have made, use, offer for sale, sell, import and otherwise distribute the licensed products. As consideration for the P53 License Agreement, P53 agreed to pay IRI one-half of all amounts invoiced by MD Anderson to IRI, up to a maximum of $15,000 to be paid by P53, for patent prosecution expenses incurred prior to the effective date of the P53 License Agreement, as well as two-thirds of IRI&#x2019;s ongoing patent prosecution expenses, in each case with respect to the licensed patents. Additionally, P53 agreed to pay all amounts that become due to IRI as a result of the P53 License Agreement or the sales, licensing, or other activities of P53 under the P53 License Agreement. Pursuant to the P53 License Agreement, P53 has granted to IRI a fully paid license with respect to improvements made by P53 to the technology licensed to P53 under the P53 License Agreement. The P53 License Agreement remains in effect until the expiration of the last of the patents licensed under the agreement. The last licensed patent under the P53 License Agreement will expire in April 2025. We may terminate the agreement&#xa0;for, among other things, P53&#x2019;s breach of the agreement or if P53 challenges the validity or enforceability of any of the licensed patents. P53 may terminate the agreement upon 90 days&#x2019; written notice.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On February 11, 2020, we entered into an exclusive license agreement, as amended on August 8, 2022 and November 3, 2022 (collectively the &#x201c;2020 UP License Agreement&#x201d;), with the University of Pittsburgh - Of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d; or &#x201c;UP&#x201d;) pursuant to which UP granted us a worldwide, exclusive license to certain licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to diabetes gene therapy. The 2020 UP License Agreement permits us to make, have made, use and sell certain licensed technology and to practice the patent rights in the field of diabetes therapy. We have agreed to sell the licensed technology to UP upon its request on terms and conditions as such products and/or processes are made available to our most favored customer. As consideration for the 2020 UP License Agreement, we agreed to pay UP an initial license fee, annual maintenance fees, running royalties minimum annual royalties beginning with the first commercial sale of the licensed technology pursuant to such agreement, a share of non-royalty sublicense income, and milestone payments in the aggregate amount of up to $3,975,000, as well as patent prosecution expenses incurred prior to and after the effective date of the 2020 UP License Agreement. The 2020 UP License Agreement shall remain in effect until the later of 20 years after the first commercial sale of the licensed technology or the expiration of the last Valid Claim (as defined in the 2020 UP License Agreement). UP may terminate the agreement if, among other things, (i) we fail to cure a default, (ii) if we fail to achieve the specified milestones within the specified time periods or (iii) our intentional practice of the licensed patent rights or know-how outside the field of diabetes therapy. We may terminate the 2020 UP License Agreement upon six months&#x2019; prior written notice to UP and payment of all amounts accrued or due to UP through the effective date of termination.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On November 22, 2022&#xa0;and December 29, 2022, respectively,&#xa0;we entered into two separate exclusive license agreements with UP on generally the same terms as the 2020 UP License Agreement as described in the preceding paragraph. Both the exclusive license agreement dated November 22, 2022 (the "November 2022 UP License Agreement") and&#xa0;the exclusive license agreement dated December 29, 2022 (the "December 2022 UP License Agreement", and together with the 2020 UP License Agreement and the November 2022 UP License Agreement, collectively, the "UP License Agreements")&#xa0;relate to diabetes gene therapy. The November 2022 UP License Agreement related in particular to the transformation of macrophages enabling them to reduce autoimmunity activity in Type 1 diabetes while the December 2022 UP License Agreement related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Grants</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our technology discoveries and research and development programs have been the subject of numerous peer-reviewed&#xa0;publications and have been supported by Small Business Innovation Research ("SBIR")&#xa0;grants and grants from the National Institutes of Health ("NIH"), the United States Department of Treasury, and the State of Texas through its Texas Emerging Technology Fund. The rights we have obtained pursuant to our MD Anderson License Agreements are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. Our collaborators at University of Pittsburgh have also received grants from the NIH in connection with pre-clinical work on GPX-002.</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. There is also a strong emphasis on intellectual property and proprietary products.&#xa0; We have domestic and international competitors&#xa0;including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and other research institutions. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Currently, there are a number of drugs approved and under development for treatment of lung cancer. Treatments competitive with our primary product candidates generally fall into the following categories: chemotherapies such as cisplatin, carboplatin, docetaxel and pemetrexed; targeted therapies such as Tarceva, Iressa, Gilotrif, and Tagrisso, and immunotherapies such as checkpoint inhibitors and CAR and CAR T cells, and oncolytic virus-based technology. Any such competing therapy may be more effective and/or cost-effective than ours.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Type 1 diabetes is an autoimmune disease that permanently destroys beta cells of the pancreatic islet leading to the body no longer having the ability to produce insulin. Type 2 diabetes, also known as adult onset diabetes, is a condition associated with developed resistance to insulin. There are a number of approved treatments and therapies&#xa0;to manage diabetes including insulin, insulin analogs, continuous glucose monitoring, novel approaches to administration such as insulin pens and insulin pumps, and&#xa0;preventative therapeutics. Any of these therapies may be more effective, cost-effective, or considered less invasive than ours.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing drugs for the cancer indications that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target disease areas. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products that are more effective or less costly than any product candidates that we are currently developing or that we may develop, which could render our products obsolete or noncompetitive. Any product candidates that we successfully develop and commercialize may compete with existing and new therapies that may become available in the future. The availability of reimbursement from government and other third-party payers will also significantly affect the pricing and competitiveness of our products. For a further discussion of the challenges we face from competition, please see the "Risk Factors" section in Part I, Item 1A of this Annual Report.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Government Regulation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical drug product candidates that we develop must be approved by the FDA before they may be legally marketed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the United States, the FDA&#xa0;regulates pharmaceutical products under the Federal Food, Drug and Cosmetic Act (&#x201c;FDCA&#x201d;) and implementing regulations and other federal, state and local statutes and regulations.&#xa0; In the case of biologics, the section of the FDCA that governs the approval of drugs via New Drug Applications (&#x201c;NDAs&#x201d;) does not apply to the approval of biologics. Rather, biologics, such as gene therapy products, are approved for marketing under provisions of the Public Health Service Act ("PHSA") via a Biologics License Application (&#x201c;BLA&#x201d;). However, the application process and requirements for approval of BLAs are very similar to those for NDAs.&#xa0; The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement and&#xa0;civil and&#xa0;criminal penalties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>U.S. Biological Products Development Process</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The process required by the FDA before a biological product, including our REQORSA, GPX-002, GPX-003, and potential future product candidates, may be marketed in the United States generally involves the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices ("GLPs"), and applicable requirements for the humane use of laboratory animals or other applicable regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">submission to the FDA of an application for an IND, which must become effective before human clinical trials may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">performance of adequate and well-controlled human clinical trials according to the FDA&#x2019;s regulations, commonly referred to as Good Clinical Practices ("GCPs")&#xa0;and any additional requirements for the protection of human research patients and their health information, to establish the safety, purity, and potency of the proposed biological product for its intended use;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Compiling of information demonstrating that the product can be properly formulated, manufactured and stored;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product is produced and tested to assess compliance with GMP&#xa0;requirements to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">FDA review and approval, or licensure, of the BLA.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Within the FDA, the Center for Biologics Evaluation and Research (&#x201c;CBER&#x201d;)&#xa0;regulates gene therapy products. The FDA has published guidance documents related to, among other things, gene therapy products in general, their preclinical assessment, observing patients involved in gene therapy studies for delayed adverse events, potency testing, and chemistry, manufacturing and control information in gene therapy INDs.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Before testing any product candidate, including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of certain preclinical tests must comply with federal regulations and requirements, including GLPs.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Clinical trials involve the administration of the product candidate to volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the clinical trial sponsor&#x2019;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, patient selection and exclusion criteria, effectiveness criteria to be evaluated, and the parameters to be used to monitor patient safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#x2019;s regulations comprising the GCP requirements, including the requirement that all patients provide informed consent. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Further, each clinical trial must be reviewed and approved by an independent IRB&#xa0;at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of clinical trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent, which must be signed by each clinical trial patient or his or her legal representative, and must monitor the clinical trial until completed. Clinical trials involving biological product candidates also must be reviewed by an institutional biosafety committee ("IBC"), a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases that may overlap or be combined:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 1. The investigational product candidate is initially introduced into human patients and tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible. In the case of some products for severe or life-threatening diseases, especially when the product candidate may be inherently too toxic to be ethically administered to healthy volunteers, the initial human testing is often conducted in patients; gene therapy is usually administered to&#xa0;patients in Phase 1 trials. This is also true in situations where toxicity can only be judged in patients with disease. An evaluation for preliminary evidence of efficacy can be performed at this time.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 2. The investigational product candidate is evaluated in a limited patient population to identify possible common adverse effects and safety risks, to evaluate preliminarily the efficacy of the product candidate for specific targeted diseases, and to generate hypotheses for the dosage tolerance, optimal dosage, and dosing schedule.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 3. Clinical trials are undertaken to evaluate further dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial may be sufficient in rare instances, including (1) where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) when in conjunction with other confirmatory evidence. Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for non-oncology therapies. A single pivotal trial may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, the manufacturer of an investigational biologic in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational biologic.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The FDA recommends that sponsors observe patients for potential gene therapy-related delayed adverse events with agents such as those we are developing for a period of up to 15 years, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by questionnaire, of clinical trial patients.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA,&#xa0;and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or <i>in vitro </i>testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for expedited reporting. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the sponsor, or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the investigational product candidate has been associated with unexpected serious harm to patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Concurrently with clinical trials, companies usually complete additional animal studies and also develop additional information about the physical characteristics of the components of a product as well as finalize processes for manufacturing the components in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA, emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the components of a product candidate do not undergo unacceptable deterioration over their shelf life.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>U.S. Review and Approval Processes</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">After the completion of clinical trials of an investigational biologic product, a BLA is prepared and submitted to the FDA.&#xa0;FDA approval of a BLA must be obtained before commercial marketing and distribution of the product may begin in the United States. The BLA must include results of product development, laboratory, and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will file the BLA and, even if filed, that any approval will be granted on a timely basis, if at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Under the Prescription Drug User Fee Act, as amended (&#x201c;PDUFA&#x201d;), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes annual program fees on&#xa0;prescription drugs, including biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. No user fees are assessed on BLAs for products designated as orphan drugs, unless the application also includes a non-orphan indication.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Within 60 days following submission, the FDA reviews the BLA to determine if it is substantially complete before the agency files it. The FDA may request additional information or may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to an initial filing review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review of the BLA. &#xa0;Under PDUFA, FDA has agreed to performance goals to review 90% of original standard BLAs within 10 months of the 60-day filing date and 90% of original priority BLAs within six months of the 60-day filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the BLA submission. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP to assure and preserve the product&#x2019;s identity, safety, strength, quality, potency and purity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions. During the product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;)&#xa0;is necessary to assure that the benefits of the biologic outweigh the potential risks of the product to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#x2019;s safe use (&#x201c;ETASU&#x201d;). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. If the FDA concludes that a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Before approving a BLA, the FDA will typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in substantial compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites, to assure that the clinical trials were conducted in compliance with GCP requirements. To assure GMP, GLP and GCP compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently from how we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may resubmit the BLA, addressing all of the deficiencies identified in the letter, withdraw the application, or request a hearing.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If a product candidate receives regulatory approval, the FDA will issue an approval letter.&#xa0; The approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4&#xa0;clinical trials, designed to assess further a biological product&#x2019;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Expedited Development and Review Programs </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The FDA has four programs in place intended to facilitate and expedite development and review of new drugs and biologics intended to address unmet medical needs in the treatment of serious or life-threatening conditions. These are Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval Program, and Priority Review Designation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Fast Track program is intended to expedite or facilitate the process for reviewing a new product if it is intended for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Fast Track Designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A product can receive Breakthrough Therapy Designation if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A Breakthrough Therapy Designation conveys all of the features of Fast Track Designation in addition to more intensive FDA guidance on an efficient development program, organizational commitment involving senior managers, and eligibility for priority review. Specifically, the FDA intends to expedite the development and review of a Breakthrough Therapy by, where appropriate, intensively involving senior managers and experienced review staff in a proactive collaborative, cross-disciplinary review. Where appropriate, the FDA also intends to assign a cross-disciplinary project lead for the review team to facilitate an efficient review of the development program. The FDA notes that a compressed drug development program still must generate adequate data to demonstrate that the drug or biologic meets the statutory standard for approval. Omitting components of the development program that are necessary for such a determination can significantly delay, or even preclude, marketing approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Breakthrough Therapy Designation indicates that preliminary clinical evidence demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapy. Breakthrough Therapy Designation intensifies FDA involvement to ensure an efficient drug development program and is an organizational commitment from the FDA to involve its senior managers. A sponsor receiving Breakthrough Therapy Designation has up to six months after receiving the Breakthrough Therapy Designation to request an Initial Comprehensive Multidisciplinary meeting to discuss the drug development program. This initial meeting is a Type B meeting, used to discuss the overarching, high-level plan for drug development. These discussions include topics such as planned clinical trials and endpoints, any resizing or adaptations to the trials, plans for expediting the manufacturing development strategy and studies that potentially could be completed after approval. When Breakthrough Therapy Designation has been granted, the FDA is encouraged to meet regularly with the sponsor and subsequent meetings are considered Type B meetings and are established based on the needs of the program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The FDA may grant accelerated approval under its Accelerated Approval Program to a product candidate for a serious or life-threatening condition upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Accelerated approval is contingent on a sponsor&#x2019;s agreement to conduct at least one adequate and well-controlled additional post-approval trial&#xa0;to verify and describe the product&#x2019;s clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Fast Track Designation, Breakthrough Therapy Designation, RMAT, and Accelerated Approval do not change the standards for approval but may expedite the development process. Additionally, Fast Track Designation or Breakthrough Therapy Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process, including considering any new drug or biologic approvals that later the unmet medical need.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">An application for a product candidate may be eligible to obtain Priority Review Designation if it is intended to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. A Priority Review Designation means FDA&#x2019;s goal is to take action on the marketing application within six months (compared to ten&#xa0;months under standard review) of the 60-day filing date. Priority Review Designation does not change the standards for approval but may expedite the review process.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt;"><i>Orphan Designation and Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA or NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product marketing exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same use or indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA or NDA application user fee.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Post-Approval Requirements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Once a BLA is approved, maintaining post-approval compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register the establishments where the approved products are made with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP&#xa0;and other laws. Rigorous and extensive FDA regulation of products continues after approval, particularly with respect to GMP. We rely, and expect to continue to rely, on third parties for the production and distribution of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer.&#xa0;Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may&#xa0;result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We also must comply with the FDA&#x2019;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Failure to comply with the applicable U.S. requirements after approval&#xa0;may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>U.S. Patent Term Restoration</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Depending upon the timing, duration, and specifics of the FDA approval of the use of our current and potential product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 ("Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Biosimilars and Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA")&#xa0;created an abbreviated approval pathway for biological products shown to be highly similar to, or interchangeable with, an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The BPCIA includes, among other provisions:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A 12-year exclusivity period from the date of first licensure, or BLA approval, of the reference product, during which approval of a 351(k) application referencing that product may not be made effective;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A four-year exclusivity period from the date of first licensure of the reference product, during which a 351(k) application referencing that product may not be submitted; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">An exclusivity period for certain biological products that have been approved through the 351(k) pathway as interchangeable biosimilars.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The BPCIA also establishes procedures for identifying and resolving patent disputes involving applications submitted under section 351(k) of the PHSA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The BPCIA is complex and its interpretation and implementation by the FDA remains unpredictable. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate effect, implementation, and meaning of the BPCIA is subject to uncertainty.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Disclosure of Clinical Trial Information</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Pediatric Information </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Under the Pediatric Research Equity Act (&#x201c;PREA&#x201d;), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer that is subject to a BLA submitted on or after August 18, 2020.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Best Pharmaceuticals for Children Act (&#x201c;BPCA&#x201d;) provides a six-month extension of any non-patent exclusivity for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#x2019;s determination that information relating to the use of a new drug or biologic in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Additional U.S. Regulation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services ("CMS"),&#xa0;other divisions of the U.S. Department of Health and Human Services, for instance the Office of Inspector General, the U.S. Department of Justice ("DOJ"), and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the physician payment transparency laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH")&#xa0;and similar state laws, each as amended.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, may affect our business. These and other laws govern our use, handling and disposal of various biological, chemical, and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Federal and State Fraud and Abuse, Privacy and Transparency Laws</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Federal and state fraud and abuse laws, which generally will not be applicable to us or our current and potential product candidates unless and until we obtain FDA marketing approval for any of our current and potential product candidates, include, among others, anti-kickback statutes, the False Claims Act and related stated state and federal laws, the Stark Law and related state and federal laws, transparency laws, privacy and regulation regarding providing drug samples, sales and marketing activities and our relationships with customers and payors as follows.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The federal Anti-Kickback Statute prohibits, among other things, individuals and entities from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, recommending, ordering, or arranging for the purchase, lease, recommendation or order of any health care item or service reimbursable, in whole or in part, under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">HIPAA created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payers, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, or knowingly making, using, or causing to be made or used, a false statement to get a false claim paid. Several pharmaceutical and other health care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the company&#x2019;s marketing of the product for unapproved, and thus non-reimbursable, uses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The majority of states also have statutes or regulations similar to the federal Anti-Kickback Statute and false claims laws, which apply to items and services, reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and their respective implementing regulations, including the final Omnibus Rule published in 2013, imposes requirements on certain types of entities, including mandatory contractual terms, relating to the privacy, security, and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#x2019;s security standards and certain privacy standards directly applicable to business associates, which are independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other and from HIPAA in significant ways and may not have the same requirements, thus complicating compliance efforts.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Additionally, the federal Physician Payments Sunshine Act under the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with certain exceptions, annually report to CMS information related to certain payments or other transfers of value made or distributed to physicians, physician assistants, certain types of advanced practice nurses and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately, and completely the required information may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1 million per year for &#x201c;knowing failures.&#x201d;&#xa0;Certain states also mandate implementation of compliance programs, impose restrictions on pharmaceutical manufacturer marketing practices, and/or require the tracking and reporting of gifts, compensation, and other remuneration to healthcare providers and entities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Because of the breadth of these laws and the narrowness of the exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to, without limitation, significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, as part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved products to physicians. This practice is regulated by the FDA and other governmental authorities, including, in particular, requirements concerning record keeping and control procedures. Any failure to comply with the regulations may result in significant criminal and civil penalties as well as damage to our credibility in the marketplace.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Coverage and Reimbursement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In many of the markets where we may do business in the future, the prices of pharmaceutical products are subject to direct price controls (by law) and to reimbursement programs with varying price control mechanisms. In the United States, significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain product approval. Often private payers follow the coverage and reimbursement decisions of the Medicare program, and it is difficult to predict how CMS may decide to cover and reimburse approved products, especially novel products, and those determinations are subject to change.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Moreover, the process for determining whether a third-party payer will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payer will pay for the drug product. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payer not to cover our current and potential product candidates could reduce physician utilization of our products once approved. A payer&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#x2019;s determination to provide coverage for a drug product does not assure that other payers will also provide coverage for the drug product. Coverage and reimbursement for new products can differ significantly from payer to payer. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payer separately and will be a time-consuming process. Additionally, third-party reimbursement may not be available or may not be adequate to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Federal, state and local governments in the United States and foreign governments continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Future legislation could limit payments for pharmaceuticals such as the drug candidates that we are developing.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of drug products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate systems under which products may be marketed only after a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of studies or analyses of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to set their own prices for medicines, but exert cost controls in other ways, including but not limited to, placing revenue caps on product sales, providing reimbursement for only a subset of eligible patients, mandating price negotiations after a set period of time, or mandating that prices not exceed an average basket of prices in other countries. The downward pressure on health care costs in general, particularly treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, European governments may periodically review and decrease prices based on factors, including, but not limited to, years-on-market, price in other countries, competitive entry, new clinical data, lack of supporting clinical data, or other factors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, an emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Third-party payers are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drugs, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Legislative and Regulatory Changes, Including Health Care Reform</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The laws and regulation that affect our business are subject to change from time to time, and entirely new laws and regulations are sometimes adopted.&#xa0; In particular, healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices.&#xa0; In 2022, President Biden signed the Inflation Reduction Act, which, among other things, contains a provision that authorizes CMS to negotiate a "maximum fair price" for a limited number of high-cost, single-source drugs each year, and another provision that requires drug companies to pay rebates to Medicare if prices rise faster than inflation. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented in future years.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Environmental Regulation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, may affect our business. These and other laws govern our use, handling and disposal of various biological, chemical, and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith is unlikely to have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>U.S. Foreign Corrupt Practices Act</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to influence otherwise a person working in an official capacity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Other countries, including a number of EU member states, have laws of similar application, including anti-bribery or anti-corruption laws such as the UK Bribery Act. The UK Bribery Act prohibits giving, offering, or promising bribes to any person, as well as requesting, agreeing to receive, or accepting bribes from any person. Under the UK Bribery Act, a company that carries on a business or part of a business in the United Kingdom may be held liable for bribes given, offered or promised to any person in any country by employees or other persons associated with the company in order to obtain or retain business or a business advantage for the company. Liability under the UK Bribery Act is strict, but a defense of having in place adequate procedures designed to prevent bribery is available.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Government Regulation Outside of the United States</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be subjected to different types of restrictions in different countries.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Whether or not we obtain FDA approval for a product, we must obtain the required approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application equivalent to an IND prior to the commencement of human clinical trials. In the European Union, for example, a clinical trial authorization, or CTA, must be submitted to each country&#x2019;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#x2019;s requirements, clinical trials may start.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, the clinical trials are to be conducted in accordance with GCP, applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension, or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution in those countries.</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Employees and Human Capital</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of March 15, 2023, we had 28&#xa0;total employees, all&#xa0;of which were full-time.&#xa0;We are not a party to any collective bargaining agreements. We believe that we maintain good relations with our employees.&#xa0;Our employees are highly skilled, with many holding advanced degrees and having experience in drug development. We anticipate that the number of employees will continue to grow as we progress our product pipeline.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe that our success depends in large part on our ability to attract and retain experienced and skilled employees. We endeavor to provide competitive compensation and benefits packages&#xa0;that reflect the highly competitive nature of our industry, as well as opportunities for professional development which are&#xa0;designed to attract,&#xa0;engage,&#xa0;retain and reward talented individuals who possess the skills necessary to support our business objectives, assist in the achievement of our strategic goals and increase stockholder value. We employ a pay for performance philosophy. Annual salary increases,&#xa0;promotional opportunities,&#xa0;incentive bonuses and stock option grants are available to all employees and are based on merit and include individual and corporate performance factors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Much of our success is rooted in the diversity of our teams and our commitment to inclusion.&#xa0;We are committed to providing an environment of mutual respect and equal opportunity.&#xa0;We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives that a diverse workforce brings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Corporate Information and Available Information.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We were incorporated in Delaware in April 2009. Our principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746, and our telephone number is (877) 774-4679.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our website address is <i>www.genprex.com</i>. On our website, investors can obtain, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, our Code of Business Conduct and Ethics, including disclosure related to any amendments or waivers thereto, other reports&#xa0;and any amendments thereto filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act of 1934, as amended, as soon as reasonably practicable after we file such material electronically with, or furnish it to, the Securities and Exchange Commission ("SEC"). None of the information posted on our website is incorporated by reference into this Annual Report on Form 10-K. Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other information regarding us and other issuers that file electronically with the SEC. The address of the SEC&#x2019;s website is <i>www.sec.gov</i>. The information contained in the SEC&#x2019;s website is not intended to be a part of this filing.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have proprietary rights to a number of trademarks, including GENPREX, ONCOPREX and REQORSA, that are used in this Annual Report on Form 10-K. Solely for convenience, the trademarks and trade names in this Annual Report on Form 10-K are generally referred to without the &#xae; or &#x2122; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We qualify as an &#x201c;emerging growth company&#x201d; as the term is used in The Jumpstart Our Business Startups Act of 2012 ("JOBS Act"), and therefore, we may take advantage of certain exemptions from various public company reporting requirements, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a requirement to only have two years of audited financial statements and only two years of related selected financial data and management&#x2019;s discussion and analysis;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">exemption from the auditor attestation requirement on the effectiveness of our internal controls over financial reporting;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduced disclosure obligations regarding executive compensation; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We expect that our eligibility to qualify as an &#x201c;emerging growth company&#x201d; will end on December 31, 2023,&#xa0;the last day of our fiscal year following the fifth anniversary of the date of our initial public offering.&#xa0; As an emerging growth company, we may choose to take advantage of some, but not all, of the available benefits of the JOBS Act. We have taken advantage of some of the reduced reporting requirements in this Annual Report on Form 10-K. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     43
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>RISK FACTOR SUMMARY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled &#x201c;Risk Factors,&#x201d; together with the other information in this Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Operations&#xa0;and Need for Additional Capital</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.</p> </td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Our ability to utilize our net operating loss carryforwards may be limited, resulting in income taxes sooner than currently anticipated.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Development and Commercialization</b><b>&#xa0;of Our Current and Future Product Candidates</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our success depends greatly on the success of our development of REQORSA for the treatment of&#xa0;NSCLC and SCLC, and our&#xa0;other product candidates, including GPX-002 and GPX-003 for the treatment of diabetes.</p> </td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">If we are unable to secure contract manufacturers with capabilities to produce the products that we require, we could experience delays in conducting our planned clinical trials.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our current and potential product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our current and potential product candidates.&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for REQORSA and other current or future&#xa0;product candidates.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Fast track designation&#xa0;of our products by FDA and designation under any other FDA expedited development program may not actually lead to a faster development or regulatory review or approval process, nor will it assure FDA approval of our product candidates.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">A product candidate can fail at any stage of preclinical and clinical development.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">REQORSA&#xae;, GPX-002, GPX-003, and any other product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval. Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our&#xa0;product candidates, and the approval may be for a narrower indication than we seek.</p> </td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Even if we obtain regulatory approval of our current and future product candidates, the products may not gain market acceptance among physicians, patients, hospitals, treatment centers, third-party payors and others in the medical community.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">REQORSA&#xae;, GPX-002, GPX-003, and other current or future&#xa0;product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Our business has been adversely affected by the coronavirus pandemic which has delayed and may continue to delay our clinical trials and has disrupted and may continue to disrupt our supply chain and may have other adverse effects on our business and operations.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We face competition from other biotechnology and pharmaceutical companies, particularly those that are gene therapy companies, and our operating results will suffer if we fail to compete effectively.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Regulatory Approval and Marketing of Our Current and Future Product Candidates and Other Legal Compliance Matters</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We cannot provide assurance that REQORSA,&#xa0;GPX-002, GPX-003, or any of our other current or future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market them.</td>
    </tr>

    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Even if we obtain regulatory approval for our product candidates, our products will remain subject to regulatory oversight.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the FDA does not find the manufacturing facilities of our&#xa0;current or&#xa0;future contract manufacturers acceptable for commercial production, we may not be able to commercialize REQORSA, GPX-002, GPX-003,&#xa0;or any of our other current or future product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Coverage and reimbursement may be limited or unavailable in certain market segments for REQORSA, GPX-002, GPX-003, and our other current or future product candidates, if approved, which could make it difficult for us to sell REQORSA, GPX-002,&#xa0;GPX-003, and our other current or future product candidates profitably.</p> </td>
    </tr>

    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">Concerns about gene therapy, genetic testing, and genetic research could result in new and/or additional government regulations and requirements that restrict or prohibit the processes we use or delay or prevent the regulatory approval of our current and potential product candidates.</td>
    </tr>

    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</td>
    </tr>

    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">We are subject to a variety of risks associated with international operations which could materially adversely affect our business.</td>
    </tr>

    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x25cf;</td>
     <td style="vertical-align:top;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Dependence on Third Parties</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop our current and future product candidates and our financial condition and operating results could be adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We rely, in part, and expect to continue to rely, in part, on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We rely, and expect to continue to rely, on third parties to distribute, manufacture and perform release testing for our current and future&#xa0;product candidates and other key materials and if such third parties do not carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approvals for our product candidates.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align: top; width: 18pt; text-align: justify;">&#x25cf;</td>
     <td style="vertical-align: top; text-align: justify;">We have completed and may in the future complete related party transactions that were not and may not be conducted on an arm&#x2019;s length basis.</td>
    </tr>

    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Our Intellectual Property</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we fail to comply with obligations pursuant to our license agreements, we could lose intellectual property and other rights that are important to our business; if we fail to obtain licenses to advance our research and development that may be required we may be unable to develop the affected product exclusively, on acceptable terms or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The intellectual property rights we have licensed from MD Anderson and the UP&#xa0;are subject to the rights of the U.S. government.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Issued patents covering our&#xa0;product candidates could be found invalid or unenforceable if challenged in court.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have in the past and may again in the future have trademark applications in the United States and/or certain other countries, and failure to secure these registrations could adversely&#xa0;affect our business; additionally, we may need to enforce our trademark rights against third parties and expend significant resources to enforce such rights against infringement.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not be able to protect our intellectual property rights throughout the world.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Employee Matters and Managing Growth</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing arrangements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to our Securities</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The market price of our common stock may be highly volatile, and you may lose all or part of your investment.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">An active, liquid and orderly market for our common stock may not be sustained, and you may not be able to sell your common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&#x201c;Sarbanes-Oxley Act&#x201d;) could cause our financial reports to be inaccurate.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have no intention of declaring dividends in the foreseeable future.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are currently an emerging growth company&#xa0;and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Future sales&#xa0;and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Certain provisions in our organizational documents could enable our board of directors to prevent or delay a change of control.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our Amended and Restated Certificate of Incorporation and&#xa0;Amended and Restated Bylaws contain&#xa0;an exclusive forum provision with respect to certain actions which may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable and discourage lawsuits against us or our current or former directors or officers and/or stockholders in such capacity.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>General Risk Factors</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Obligations associated with being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to&#xa0;compliance matters.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 40pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be at risk of securities class action litigation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_1A" title="Item_1A" href="#"></a>Item 1A. Risk Factors.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>An investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and the other information in this Annual Report on Form 10-K before investing in our common stock. Our business and results of operations coul</i><i>d be seriously harmed by any of the following risks. The risks set out below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. If any of the following events occur, our business, financial condition and results of operations could be materially adversely affected. In such case, the value and trading price of our common stock could decline, and you may lose all or part of your investment</i>.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Risks Related to Our Operations and Need for Additional Capital </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are using the proceeds from our sales of securities to advance REQORSA through clinical development, and to advance our other pre-clinical development programs as well as for other corporate purposes. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional future capital to complete clinical development and commercialize REQORSA and for preclinical and clinical development and commercialization of our gene therapy for diabetes, GPX-002, GPX-003, and our other product candidates. If the FDA requires that we perform additional preclinical studies or clinical trials beyond what we currently anticipate, our expenses will further increase beyond what we currently expect and the anticipated timing of any potential approval of REQORSA, GPX-002, GPX-003, and our other current or future product candidates would likely be delayed. Furthermore, there can be no assurance that the costs to obtain regulatory approval of these product candidates will not increase.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We will continue to require substantial additional capital to continue our preclinical and clinical development and commercialization readiness activities. Because successful development of our current and potential product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize our current and future product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the progress, costs, results and timing of our preclinical development and clinical trials for REQORSA, GPX-002, GPX-003, and other current or future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the ability of third parties to deliver materials and provide services for us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the costs associated with securing and establishing commercialization and manufacturing capabilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">market acceptance of our current and future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to obtain, maintain, expand and enforce intellectual property rights for our products and product candidates, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our need and ability to hire additional management and scientific and medical personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the effect of competing drug candidates and new product approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Some of these factors are outside of our control. Although we expect that our existing cash will be sufficient to fund our current operations and planned clinical trial activities into the second quarter of 2024, this period could be shortened if there are any significant increases in planned spending on current or additional development programs or more rapid progress of these development programs than anticipated. Furthermore, we believe that our existing capital will not be sufficient to enable us to complete the development and commercialization of REQORSA, GPX-002, GPX-003,&#xa0;and our other current or future product candidates. Accordingly, we expect that we will need to raise additional funds in the future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 11pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><span style="font-size:10pt;">We have raised and may continue to raise capital through a variety of sources that may be available to us.&#xa0; On March 1, 2023,&#xa0;we completed a registered direct offering, in which we sold to an accredited healthcare-focused institutional investor an aggregate of 3,809,524 shares of our common stock and a like number of warrants, at a combined offering price of $1.05 per share of common stock and accompanying warrant, for net proceeds of approximately $3.6 million. On November 18, 2022, we entered into our Equity Distribution Agreement with JMP Securities as Agent, with respect to an at-the-market offering program (our &#x201c;ATM&#x201d;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50.0 million through the Agent.&#xa0;</span><span style="font-size:10pt;">We have agreed to pay the Agent a commission equal to three percent (3%) of the gross sales proceeds of any shares sold through the Agent under the Equity Distribution Agreement, and also have provided the Agent with customary indemnification and contribution rights. As of December 31, 2022 we have sold 3,886&#xa0;shares of our common stock for net proceeds to us totaling $4,532.&#xa0;&#xa0;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may seek additional funding through a combination of equity offerings, drawdowns on our ATM pursuant to our Equity Distribution Agreement with JMP Securities as Agent, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements, some of which may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. Additional funding may not be available to us on acceptable terms, if at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. Any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our existing capital stock. In addition, the issuance of additional shares by us may cause the market price of our shares to decline and result in dilution to our stockholders. Any debt financing secured by us in the future could involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our pre-clinical or clinical development programs, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, and we may be required to curtail or cease&#xa0;operations. Accordingly, our business may fail, in which case you would lose the entire amount of your investment in our securities.&#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have never been profitable and do not expect to be profitable in the foreseeable future. We have not yet submitted any drug candidates for approval by regulatory authorities in the United States or elsewhere. From our inception on April 1, 2009, to December 31, 2022, we incurred an accumulated deficit of approximately $100.4&#xa0;million. We incurred net losses of approximately $22.5&#xa0;million and approximately $19.6&#xa0;million for the years ended December 31, 2022&#xa0;and 2021, respectively.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, we have devoted most of our financial resources to our corporate overhead and research and development, including our preclinical development activities, manufacturing processes&#xa0;and clinical trials. We have not generated any revenues from product sales. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our current and potential product candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support our continuing product development efforts. We anticipate that any such losses could be significant for the next several years. If REQORSA, GPX-002, GPX-003, or any of our other current or future product candidates fail&#xa0;in clinical trials or does not gain regulatory approval, or if our drug candidates do not achieve market acceptance, we may never become profitable. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or if, or when, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are a clinical stage company with a limited operating history. Our operations to date have been limited to conducting clinical and preclinical research and development. We have not yet obtained any regulatory approvals for any of our drug candidates. Consequently, any predictions made about our future success or viability may not be accurate. Our operating results are expected to significantly fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">any delays in regulatory review and approval (assuming that our data support approval) of our current and future product candidates in clinical development, including our ability to receive approval from the FDA for REQORSA, GPX-002, or GPX-003;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">delays in the commencement, enrollment and timing of clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the success of our current and future product candidates through all phases of pre-clinical and clinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">potential side effects of our current and future product candidates that could delay or prevent approval or cause an approved drug to be taken off the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to obtain additional funding to develop our current and future&#xa0;product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our&#xa0;identification and development of&#xa0;additional drug candidates beyond REQORSA, GPX-002, GPX-003&#xa0;and our other current product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">competition from existing products or new products that continue to emerge;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to adhere to clinical trial requirements directly or with third parties such as contract research organizations ("CROs");</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our dependency on third-party manufacturers to manufacture our products and key ingredients;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to establish or maintain collaborations, licensing, sponsored research&#xa0;or other arrangements, particularly with MD Anderson and UP and otherwise relating to REQORSA, GPX-002, and GPX-003;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to defend against any challenges to our intellectual property including&#xa0;claims of patent infringement;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to enforce our intellectual property rights against potential competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to secure additional intellectual property protection for our product candidates and associated technologies as may be required or desirable as the development of the product candidates progresses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to attract and retain key personnel to manage our business effectively; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">potential product liability claims.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our ability to utilize&#xa0;our net operating loss carryforwards may be limited</i></b><b><i>, resulting in income taxes sooner than currently anticipated</i></b><b><i>.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of December 31, 2022, we had federal net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $68.9&#xa0;million&#xa0;for federal income tax purposes of which approximately $1.3&#xa0;million&#xa0;will begin to expire in 2030 and approximately $59.2 million&#xa0;can be carried forward indefinitely. These NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce or eliminate our future federal income taxes otherwise payable.&#xa0;Section&#xa0;382&#xa0;of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), imposes limitations on a corporation&#x2019;s ability to utilize NOLs if it experiences an ownership change as defined in&#xa0;Section&#xa0;382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under&#xa0;Section&#xa0;382&#xa0;determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate as defined in the Code. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under&#xa0;Section&#xa0;382&#xa0;as a result of events in the past or the issuance of shares of common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under&#xa0;Section&#xa0;382, which may result in expiration of a portion of our NOLs before utilization.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The utilization of our NOLs may also be limited under state laws.&#xa0; In addition, under the 2017 Tax Cuts and Jobs Act (the &#x201c;TCJA&#x201d;), tax losses generated in taxable years beginning after December 31, 2017 may be utilized to offset no more than 80% of taxable income annually. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.&#xa0; On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (the &#x201c;CARES Act&#x201d;), was signed into law. The CARES Act changed certain provisions of the TCJA. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021. It is uncertain if and to what extent various states will conform to the TCJA, as modified by the CARES Act.&#xa0; For these reasons, we may not be able to realize a tax benefit from the use of our NOLs, whether or not we attain profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Development and Commercialization of Our Current and Future Product Candidates </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our success depends greatly on the success of our development of REQORSA for the treatment of</i></b>&#xa0;<b><i>NSCLC and SCLC, and our</i></b>&#xa0;<b><i>other product candidates, including GPX-002 and GPX-003 for the treatment of diabetes.</i></b>&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">At this time, we are actively pursuing the development of REQORSA for NSCLC through our Acclaim-1 and Acclaim-2 clinical trials that are currently enrolling and for SCLC through our Acclaim-3 clinical trial expected to commence enrollment by the end of the third quarter of 2023.&#xa0; We are also pursuing the development of pre-clinical gene therapies GPX-002 and GPX-003 for Type 1 and Type 2 diabetes, respectively, as well as earlier discovery programs. In particular, we are dependent on the success of REQORSA, GPX-002 and GPX-003. We cannot provide you any assurance that we will be able to successfully advance REQORSA, GPX-002, GPX-003 or any of our other current or future product candidates through the development process, or that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in the development of a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, or developing or validating product release assays in a timely manner, which may prevent us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. Immunotherapy, gene therapy and biopharmaceutical product development are highly speculative undertakings and involve a substantial degree of uncertainty. Because REQORSA, GPX-002, GPX-003 and our other current product candidates are based upon novel technology, it is difficult to predict whether, either as stand-alone therapies or in combination with other drugs, they will show consistently favorable results and to predict the time and cost of their development and of subsequently obtaining regulatory approval. We believe only a few gene therapy products have been approved in the United States or Europe. We have found it difficult to enroll patients in our clinical studies in the past, have experienced certain difficulties in enrolling patients in our current trials and may continue to find it difficult in the future, which could delay or prevent clinical studies of REQORSA or other current or future product candidates.&#xa0;We may encounter other delays in our pre-clinical or clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of FDA and other regulatory authorities. We may not be successful in our efforts to identify or discover additional product candidates, or to develop product candidates that we have identified.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, the clinical trial requirements of the FDA, the European Commission, the European Medicines Agency (&#x201c;EMA&#x201d;), the competent authorities of the Member States of the European Union (&#x201c;EU&#x201d;) and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates. Even if we are successful in developing product candidates, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for these product candidates in either the United States or the EU, or how long it will take to commercialize any other products for which we receive marketing approval. In addition, any future marketing authorization granted by the European Commission may not be indicative of what the FDA may require for approval and vice versa.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to secure contract manufacturers with capabilities to produce the products that we require, we could experience delays in conducting our planned clinical trials.</i></b>&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Manufacturing REQORSA involves several manufacturing steps.&#xa0;Historically, part of our manufacturing process was conducted in manufacturing facilities at MD Anderson. We have transferred all of the steps of our manufacturing process to CDMOs and scaled-up clinical production in order to supply our Acclaim-1, Acclaim-2 and Acclaim-3 clinical trials. We also are preparing for commercial readiness for REQORSA through the development of an integrated supply chain network of manufacturing vendors and continue to work to identify cutting edge manufacturing technologies to optimize manufacturing processes and shelf life. With the advancement of the development of GPX-002 and GPX-003, we also are working to optimize the manufacture of these product candidates and to source high quality and integrated vendors capable of producing them in accordance with GMP.&#xa0; Although we have contracted with CDMOs to produce our products, no assurance can be given that such CDMOs will be able to continue to produce the products that we require. In addition, the tremendous growth in the gene therapy sector has created increasing demand for the services of CDMOs with gene therapy capabilities which may impact our ability to schedule production runs of our products or product components to meet our needs on a timely basis.&#xa0; Furthermore, manufacturing gene-based therapies is complex and highly regulated and a CDMO with which we have contracted may fail to produce our products or product components timely or in accordance with our specifications or applicable regulations. Although we have experienced a variety of these challenges to varying degrees in connection with performance by our CDMOs, to date they have not resulted in any measurable delay in our Acclaim-1 or Acclaim-2 clinical trials. Changing our current or future contract manufacturers may be difficult and could be costly, which could result in our inability to manufacture our clinical product candidates and a delay in the development of our clinical product candidate. Further, in order to maintain our development timelines, any changes to, or the addition of a new, third-party contract manufacturers may result in our incurring higher costs to manufacture our clinical product candidates.&#xa0;Any delay in the availability of product supply or product component supply could result in a delay in our clinical trials, including our Acclaim-1, Acclaim-2 and Acclaim-3 clinical trials as well as the commencement of clinical trials for GPX-002 and GPX-003.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our current and potential product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our current and potential product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our current and potential product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our current and potential product candidates, and the resulting publicity could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Concern about the environmental spread of our product, whether real or anticipated, could also hinder the commercialization of our products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Prior to receiving REQORSA in our Acclaim-1 clinical trial, patients are required to undergo genetic screening to detect EGFR mutations and in the Acclaim-2 clinical trial genetic screening to detect PD-L1 as well as other mutations relevant to cancer.&#xa0;&#xa0;Genetic testing has raised concerns regarding the appropriate utilization and the confidentiality of information provided by genetic testing.&#xa0;&#xa0;Genetic tests for assessing a person&#x2019;s likelihood of developing a chronic disease have focused public attention on the need to protect the privacy of genetic information. Genetic testing information is also subject to significant restrictions under both federal and state law.&#xa0;For example, concerns have been expressed that insurance carriers and employers may use these tests to discriminate on the basis of genetic information, resulting in barriers to the acceptance of genetic tests by consumers.&#xa0;This could lead to governmental authorities restricting genetic testing or calling for limits on or regulating the use of genetic testing, particularly for diseases for which there is no known cure. Any of the foregoing could decrease demand for REQORSA or our other product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; and proximity of patients to clinical sites; ability to comply with the eligibility and exclusion criteria for participation in the clinical trial; and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product candidates or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, our ability to successfully initiate, enroll and complete clinical trials in any foreign country is subject to numerous risks of conducting business in foreign countries, including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">difficulty in establishing or managing relationships with CROs and physicians;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">different standards for the conduct of clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our inability to locate qualified local consultants, physicians and partners; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for REQORSA and other current or future</i></b>&#xa0;<b><i>product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Clinical development is very expensive and can take many years.&#xa0;Delays in the commencement, enrollment and/or completion of our Acclaim-1, Acclaim-2 and Acclaim-3 clinical trials or any future clinical trials could increase our product development costs or delay or limit the regulatory approval of REQORSA or other product candidates. To date we have experienced delays in opening our clinical sites for our Acclaim-1 and Acclaim-2 trials.&#xa0; This has been due to a back-log in protocol review at the clinical trial sites due to the COVID-19 pandemic which has mostly resolved.&#xa0; We do not know and cannot predict whether future trials or studies of other current or future product candidates, including Acclaim-3, GPX-002 and GPX-003 will begin as planned, if at all, and we do not know and cannot predict whether our Acclaim-1 and Acclaim-2 clinical trials or any future trials or studies of other current or future product candidates will be completed on schedule, if at all. The start or end of a clinical study may be delayed or halted due to regulatory requirements, changes in the proposed regulatory approval pathway for a drug candidate, manufacturing challenges, including delays or shortages in available raw materials required to manufacture the drug product, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a&#xa0;comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria, such as mutation of the EGFR which is required for the Acclaim-1 trial and is present in a minority of NSCLC patients. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, which include the age and condition of the patients and the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments and/or availability of other investigational treatment options for the relevant disease.&#xa0; We have initiated our Acclaim-1 and Acclaim-2 clinical trials and plan to initiate our Acclaim-3 clinical trial pursuant to an existing IND.&#xa0;We have filed with the FDA amendments to our IND consisting of an updated chemistry, manufacturing and controls section, and the protocol for the respective clinical trial.&#xa0;We cannot be sure that issues will not arise in connection with the filing of these amendments or otherwise that will result in the FDA imposing a clinical hold which could result in the delay of either or both of these clinical trials. For GPX-002 and GPX-003 we have not yet filed an IND and cannot predict all of the challenges and issues that may arise in connection with the preparation and filing of these INDs, or whether these INDs will be filed at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fast track designation of our products by FDA and designation under any other FDA expedited development program may not actually lead to a faster development or regulatory review or approval process, nor will it assure FDA approval of our product candidates.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">REQORSA has received two fast track designations from FDA.&#xa0; We may in the future seek additional fast track designations for our products and/or request breakthrough therapy designation, accelerated approval or priority review of applications for approval. FDA has broad discretion whether or not to grant these designations and requests, so even if we believe a particular product candidate is eligible for these designations, we cannot assure you that the FDA will grant them. Even with fast track designation and other FDA expedited development programs, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation and other expedited program designations if it believes that the requirements of the program are no longer met.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 0pt;"><b><i>We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.&#xa0; </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may seek orphan drug designation in the United States and in the European Union for our product candidates. Upon receipt of regulatory approval, orphan drug status will provide us with seven years of market exclusivity in the United States under the Orphan Drug Act. However, there is no guarantee that the FDA will grant orphan drug designation for any of our drug candidates for any future indication, which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation. Moreover, there can be no assurance that another company also holding orphan drug designation for the same indication or which may receive orphan drug designation in the future will not receive approval prior to us, in which case our competitor would have the benefit of the seven years of market exclusivity, and we would be unable to commercialize our product for the same indication until the expiration of such seven-year period. Even if we are the first to obtain approval for the orphan drug indication, there are circumstances under which a competing product may be approved for the same indication during our seven-year period of exclusivity.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the Unites States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation makes a company eligible for grant funding of up to $400,000 per year for four years to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA application user fee.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&#x2019;s orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#x2019;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan drug designation for any of our drug candidates for any additional indications, if we elect to seek such designation. Even if orphan designation is granted it may be withdrawn by the FDA for non-compliance with regulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>A product candidate can fail at any stage of preclinical and clinical development. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including, but not limited to, a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. We may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to obtain sufficient funds required for clinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to reach agreements on acceptable terms with current or prospective vendors, CROs&#xa0;and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different vendors, CROs and trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">negative or inconclusive results from our clinical studies or the clinical studies of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">serious and unexpected side effects experienced by subjects in our clinical trials or by individuals using drugs similar to our current and future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;">unexpected results from pre-clinical testing and development;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">inability or delays in enrolling research subjects in clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">high drop-out rates and high fail rates of research subjects;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of pre-clinical or clinical testing;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">greater than anticipated clinical trial costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">poor effectiveness of our current and potential product candidates during clinical trials; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or vendor.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>REQORSA</i></b>&#xae;<b><i>, GPX-002, GPX-003,</i></b>&#xa0;<b><i>and any other product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval. Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our</i></b>&#xa0;<b><i>product candidates, and the approval may be for a narrower indication than we seek.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Clinical failure can occur at any stage of our clinical development. Clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Additionally, our partners, clients, other vendors, and/or other stakeholders may not agree with our interpretation(s) of data obtained from our clinical trials, which could potentially cause a variety of issues, including, but not limited to,&#xa0;delays, the necessity for additional studies and analyses, dependence on third-party validation, and/or other unforeseen challenges. Success in preclinical studies and early clinical trials does not ensure that subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Later-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. For example, the small number of patients in our completed Phase 1 Monotherapy clinical trial of REQORSA and the Phase 1/2 Combination Tarceva trial may make the results of these trials less predictive of the outcome of later clinical trials. In addition, although we observed encouraging clinical activity in the Phase 1 Monotherapy and Phase 1/2 Combination Tarceva trial, the primary objectives of the Phase 1 Monotherapy Trial and the Phase 1 portion of the Phase 1/2 Combination Tarceva trial were safety and MTD and not to demonstrate efficacy. The assessments of clinical activity from these clinical trials, some of which were not pre-specified, may not be predictive of the results of later clinical trials of REQORSA. Furthermore, safety events may be observed in later trials that alter the anticipated risk-benefit profiles of REQORSA or other product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We do not know whether any clinical trials we conduct will demonstrate the consistent or adequate efficacy and safety that would be required to obtain regulatory approval and market any products. If REQORSA, GPX-002 or GPX-003 or other current or future product candidates are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business would be harmed. If we are unable to bring REQORSA, GPX-002, GPX-003 or other product candidates to market, or acquire other products that are on the market or can be developed, our ability to create stockholder value will be limited.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Regulatory authorities also may approve a product candidate for more limited indications than requested, or they may impose significant limitations in the form of narrow indications.&#xa0;&#xa0;These regulatory authorities may require warnings or precautions with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials.&#xa0;&#xa0;In addition, regulatory authorities may not approve the labeling claims or allow the promotional claims that are necessary or desirable for the successful commercialization of our product candidates.&#xa0;&#xa0;Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely affect our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we obtain regulatory approval of our current and future product candidates, the products may not gain market acceptance among physicians, patients, hospitals, treatment centers, third-party payors and others in the medical community.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Ethical, social and legal concerns about gene therapy and genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. Even with the requisite approvals, the commercial success of REQORSA, GPX-002 and any of our other current or future product candidates will depend in part on the medical community, patients, and third-party payors accepting gene therapy products in general, and our current and future product candidates in particular, as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, hospitals, treatment centers, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors, including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the clinical indications for which our current and potential product candidates are approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">physicians, hospitals, treatment centers and patients considering our product candidates as a safe and effective treatment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the potential and perceived advantages of our&#xa0;product candidates over alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the prevalence and severity of any side effects;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">limitations or warnings contained in the labeling approved by the FDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the timing of market introduction of our product candidates as well as competitive products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the cost of treatment &#x2013;&#xa0;both in absolute terms and in relation to alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the availability of coverage, reimbursement and pricing by third-party payors and government authorities and the adequacy thereof;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors, including government authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the willingness, ability and availability of healthcare providers that can comply with the transportation, handling, and temperature-controlled storage requirements associated with our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the effectiveness of our sales and marketing efforts, which are subject to various limitations under applicable law.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our efforts to educate the medical community and third-party payors about the benefits of our product candidates may require significant resources and may never be successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>REQORSA</i></b>&#xae;<b><i>, GPX-002, GPX-003, and other current or future</i></b>&#xa0;<b><i>product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Undesirable side effects for REQORSA, GPX-002, GPX-003, or any of our other current or future product candidates could arise either during clinical development or, if approved, after the approved product has been marketed. A showing that REQORSA, GPX-002, GPX-003, or any of our other current or future product candidates cause undesirable or unacceptable side effects could interrupt, delay or halt clinical trials and result in the failure to obtain or suspension or termination of marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities only with restrictive label warnings.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If REQORSA, GPX-002, GPX-003, or any of our other current or future product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">we may be required to change instructions regarding the way the product is administered, conduct additional clinical trials or change the labeling of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">we may be subject to limitations on how we may promote the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">sales of the product may decrease significantly;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">regulatory authorities may require us to take our approved product off the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">we may be subject to litigation or product liability claims; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our reputation may suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Any of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of our products or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating revenues from the sale of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose us to significant product liability claims. We currently carry product liability insurance relating to our clinical trials only. Such insurance coverage may not protect us against any or all of the product liability claims that may be brought against us in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim brought successfully against us. In the event our product candidate is approved for sale by the FDA or other regulatory agency and commercialized, we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers and business partners,&#xa0;as well as personally identifiable information of clinical trial participants and employees. Similarly, our CROs, contractors and consultants possess certain of our sensitive data. The secure maintenance of this information is critical to our operations and business strategy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Despite the implementation of security measures, our internal computer systems and those of our CROs, CMOs, and other contractors and consultants are vulnerable to damage from cyberattacks, malicious intrusion, computer viruses, unauthorized access, loss of data privacy, natural disasters, terrorism, war and telecommunication, electrical failures or other significant disruption. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs and commercialization efforts. For example, the loss of clinical study data from completed or ongoing clinical studies for any of our drug candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development or commercialization of our drug candidates could be delayed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">While we have not experienced any such event to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our independent drug development programs. For example, the loss of clinical trial data from ongoing or future clinical trials for any of our product candidates could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. Our information security systems are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain information we gather and use in our business. For example, HIPAA and its implementing regulations impose, among other requirements, certain regulatory and contractual requirements regarding the privacy and security of personal health information. In addition to HIPAA, numerous other federal, state, and international laws, including, without limitation, state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and storage of personal information. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of confidential or proprietary information or personal health information, we could incur substantial liability, our reputation would be damaged, and the further development of our product candidates could be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business has been adversely affected by the coronavirus pandemic which has delayed and may continue to delay our clinical trials and has disrupted and may continue to disrupt our supply chain and may have other adverse effects on our business and operations</i></b><b><i>.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of the novel coronavirus ("COVID-19") evolved into a global pandemic as COVID-19 spread to many regions of the world. The extent to which COVID-19 and/or potential future outbreaks impact&#xa0;our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, including new variants and the actions to contain COVID-19&#xa0;or treat its impact, among others.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As a result of COVID-19, our business operations have been interrupted and delayed. Specifically, we have experienced delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring site review created by an accumulation of protocols while clinical trials and the clinical trial review process have been widely disrupted during the pandemic. Additionally, site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring, data analysis, and laboratory research activities may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the COVID-19 pandemic. If COVID-19 surges continue in the future, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, further delaying our clinical trials and potentially rendering us unable to conduct our trials at all. In addition, infections and deaths related to the COVID-19 pandemic or potential future outbreaks&#xa0;may disrupt the United States&#x2019; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA review and/or approval with respect to, our clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any lengthening of or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. Specifically, we may experience further delays in our Acclaim-1 trial or our Acclaim-2 trial and experience delays in our Acclaim-3 trial once that trial is open for enrollment, if a batch of REQORSA drug that is intended to be utilized expires and is no longer usable and there is a delay in producing a new batch. In this regard, to date certain batches and/or components of REQORSA have expired, and others may expire, without being used due to delay in our clinical trials. We also have been experiencing disruptions in our supply chain regarding our manufacturing and testing operations. This relates to general disruptions in the supply chain, and more specifically to the fact that certain raw materials used in the manufacture of REQORSA also are used in the manufacture of COVID-19 vaccines. Furthermore, supply chain delays could produce delays in clinical trial enrollment due to lack of adequate amounts of REQORSA.&#xa0;Moreover, if the COVID-19 pandemic continues or worsens or potential future outbreaks occur&#xa0;and our operations are further adversely impacted, we risk a delay, default and/or nonperformance under existing agreements which may increase our costs. These cost increases may not be fully recoverable or adequately covered by insurance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We currently utilize third parties to, among other things, manufacture raw materials and to manufacture clinical product. If any third-party parties in the supply chain for materials used in the production of our product candidates or the third-party manufacturers of our product candidates themselves are adversely impacted by COVID-19, variants of COVID-19, and/or potential future outbreaks or pandemics, our ability to manufacture our product candidates for our clinical trials and research and development activities related thereto may be disrupted.&#xa0; In general, we believe the supply chain overall in our industry has been disrupted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Work force shortages related to the COVID-19 pandemic have been experienced widely throughout our economy.&#xa0; Our growing nascent industry combined with these workforce shortages have resulted in staffing challenges experienced by us and by third parties that we utilize, including but not limited to manufacturing and testing organizations, CROs and clinical trial sites.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">COVID-19, which caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may continue to have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from COVID-19&#xa0;could materially and adversely affect our business and the value of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The ultimate impact of the&#xa0;COVID-19 pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face competition from other biotechnology and pharmaceutical companies</i></b><b><i>, particularly those that are gene therapy companies,&#xa0;</i></b><b><i>and our operating results will suffer if we fail to compete effectively.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. This is particularly so in the fast growing gene therapy space. We face competition from domestic and international competitors&#xa0;including major multinational pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research institutions.&#xa0; Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of these factors, our competitors may succeed in obtaining patent protection and/or FDA or other regulatory approval or in discovering, developing and commercializing drugs for the indications that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If our competitors market products that are more effective, safer or less expensive or reach the market sooner than our future products, if any, we may not achieve commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in all technologies that are or may become competitive with ours. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Regulatory Approval and Marketing of Our Current and Future Product Candidates and Other Legal Compliance Matters</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We cannot provide assurance that REQORSA,</i></b>&#xa0;<b><i>GPX-002, GPX-003,&#xa0;or any of our other current or future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market them. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our business currently depends largely on the successful development and commercialization of REQORSA, GPX-002, GPX-003, and our other current product candidates. Our ability to generate revenue related to product sales will depend on the successful development and regulatory approval of REQORSA for the treatment of cancer and/or GPX-002 and GPX-003 for diabetes. Even if we complete the necessary clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate. Further, even if we obtain regulatory approval, it may only apply to a narrower&#xa0;indication than we expect and&#xa0;our products will remain subject to regulatory scrutiny.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we receive approval of a BLA from the FDA. We have not submitted any marketing applications for any of our current and potential product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">BLAs must include extensive preclinical and clinical data and supporting information to establish the product candidate&#x2019;s safety and effectiveness for each desired indication. BLAs must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of a BLA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take years to complete, and approval is never guaranteed. If we submit a BLA to the FDA, the FDA must decide whether to file the BLA or refuse to file it. We cannot be certain that any submissions will be filed and reviewed by the FDA. In addition, regulators in other jurisdictions have their own procedures for approval of product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The FDA or regulators in other jurisdictions could delay, limit or deny approval of a product candidate for many reasons, including because they:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may not deem our product candidate to be safe and effective;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">determine that the product candidate does not have an acceptable benefit-risk profile;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">determine in the&#xa0;case&#xa0;of a BLA seeking&#xa0;accelerated approval that the BLA does not provide evidence that the product candidate represents a meaningful advantage over available therapies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">determine&#xa0;that&#xa0;the&#xa0;results on our primary endpoints are not&#xa0;clinically meaningful;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may not agree that the data collected from preclinical studies and clinical trials are acceptable or sufficient to support the approval of a BLA or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may&#xa0;determine&#xa0;that adverse events experienced by&#xa0;participants in&#xa0;our&#xa0;clinical trials represent an unacceptable level of risk;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may determine that population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may disagree regarding the formulation or the specifications of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may not approve the manufacturing processes associated with our product candidate or may determine that a manufacturing facility does not have an acceptable compliance status; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">may change approval policies or adopt new regulations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Even if a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States also have requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. Furthermore, regulatory approval for any of our future product candidates may be withdrawn after approval.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If we are unable to obtain approval from the FDA or other regulatory agencies for REQORSA, GPX-002, GPX-003,&#xa0;or our other current or future product candidates, or if, subsequent to approval, we are unable to successfully commercialize REQORSA,&#xa0;GPX-002, GPX-003,&#xa0;or our other current or future product candidates, we will not be able to generate sufficient revenue to become profitable or to continue our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. For example, in January 2017, the FDA Oncology Center of Excellence, or the Center of Excellence, was created to leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, and devices (including diagnostics). While the Center of Excellence is designed to help expedite the development of oncology and malignant hematology-related medical products and support an integrated approach in the clinical evaluation of drugs, biologics and devices for the treatment of cancer, the Center of Excellence may, at times, create confusion within the FDA and especially in the Center of Biologics and Research, which is the primary review division for REQORSA. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH, are also subject to review by NExTRAC. In August 2018, the NIH Director issued a statement describing a proposal intended to streamline the federal framework for oversight of gene therapy. The proposal, which the NIH developed in conjunction with the FDA, included amending the <i>NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules</i>, or <i>NIH Guidelines</i>, to eliminate duplicative review and reporting requirements for human gene transfer protocols. The statement also described NIH&#x2019;s effort to refocus the role of the RAC to be closer to its original mandate &#x2013; a transparent forum for science, safety, and ethics of emerging biotechnologies. Accordingly, the <i>NIH Guidelines</i> have been updated to reflect these changes. Additionally, before a clinical trial can begin at an NIH-funded institution, that institution&#x2019;s IRB, and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess the safety of the study. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for performing studies or for obtaining approval of any of our current and potential product candidates. The regulatory changes discussed herein as well as other existing and future regulatory developments may cause unexpected delays and challenges for companies seeking approval of gene therapy products, like REQORSA,&#xa0;GPX-002, GPX-003, and our other current or future product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">These regulatory review committees and advisory groups, and the new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current and potential product candidates or lead to significant post-approval limitations or restrictions. As we advance our current and potential product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. Any delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient revenue to maintain our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we obtain regulatory approval for our product candidates, our products will remain subject to regulatory oversight.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our product candidates for which we obtain regulatory approval&#xa0;will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates also may be subject to the specific obligations imposed as a condition for marketing authorization by equivalent authorities in a foreign jurisdiction, particularly by the European Commission, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4&#xa0;clinical trials, and surveillance to monitor the quality, safety and efficacy of the product.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For example, in the United States, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with the Federal Food, Drug, and Cosmetic Act ("FDCA")&#xa0;and implementing regulations and are subject to FDA oversight and post-marketing reporting obligations, in addition to other potentially applicable federal and state laws.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In the EU, any future advertising and promotion of our products will be subject to EU laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with health care professionals. These laws require that promotional materials and advertising for medicinal products are consistent with the product&#x2019;s Summary of Product Characteristics ("SmPC") as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comport with the SmPC is considered to constitute off-label promotion, which is prohibited in the EU. The applicable laws at EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, product manufacturers and their facilities may be subject to payment of application and program fees and are subject to continual review and periodic inspections by FDA and other regulatory authorities for compliance with cGMP, requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or disagree with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we fail to comply with applicable regulatory requirements for any product following approval, a regulatory authority may:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">issue a warning or untitled letter asserting that we are in violation of the law;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">suspend or withdraw regulatory approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">suspend any ongoing clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">restrict the marketing or manufacturing of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">seize or detain the product or otherwise demand or require the withdrawal or recall of the product from the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">refuse to permit the import or export of products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">request and publicize a voluntary recall of the product; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">refuse to allow us to enter into supply contracts, including government contracts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If the FDA does not find the manufacturing facilities of our</i></b>&#xa0;<b><i>current or</i></b>&#xa0;<b><i>future contract manufacturers acceptable for commercial production, we may not be able to commercialize REQORSA, GPX-002, GPX-003,</i></b>&#xa0;<b><i>or any of our other current or future product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We do not have the internal infrastructure or facilities to manufacture ourselves&#xa0;REQORSA, or earlier stage GPX-002 or&#xa0;GPX-003 which are in pre-clinical development, or any other current or future product candidate, and intend to rely on CDMOs for clinical trial needs and commercial supply. However, our strategy could change in the future and we could choose to develop such infrastructure. We do not have agreements for all of the steps relating to the ongoing supply of REQORSA or any of our other product candidates, and we may not be able to reach agreements with these or other contract manufacturers for sufficient supplies to complete clinical development and commercialize REQORSA or any of our other product candidates, if any of them are approved. The manufacture of gene therapy products is complex, and for CDMOs with whom&#xa0;we have agreements, there is no guarantee that they will be able to perform as required under the applicable governing agreement. Additionally, the facilities used by our contract manufacturers to manufacture product candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate manufactured at that facility. We are completely dependent on our third-party manufacturers for compliance with the requirements of U.S. and non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture materials that conform to our specifications and the FDA&#x2019;s cGMP&#xa0;standards and other requirements of any governmental agency to whose jurisdiction, we are subject, our product candidates will not be approved or, if already approved, may be subject to recalls. Reliance on third-party manufacturers entails risks including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility that we are unable to enter into manufacturing agreements with third parties to manufacture our product candidates on acceptable terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility that our contract manufacturers may breach the terms of their manufacturing agreements with us;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;">the possibility that our contract manufacturers may experience failures in product production; and</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility of termination or nonrenewal of any manufacturing agreement we may enter into.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if our product candidates are approved for commercialization and our contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis at commercially reasonable prices, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the government agencies that regulate our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">State and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and the United States Congress continues to strengthen the arsenal of enforcement tools.&#xa0;&#xa0;The Bipartisan Budget Act of 2018&#xa0;increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the Anti-Kickback Statute.&#xa0;&#xa0;Enforcement agencies also continue to pursue novel theories of liability under these laws.&#xa0;&#xa0;Government agencies have increased regulatory scrutiny and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay support, funding of independent charitable foundations and other programs that offer benefits for patients.&#xa0;&#xa0;Several investigations into these types of programs have resulted in significant civil and criminal settlements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws would increase significantly, and our costs associated with compliance with such laws would likely also increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs and interactions with physicians and other health care providers. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including off-label uses of our products, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of patient recruitment for clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of fines or other sanctions. The laws that may affect our ability to operate include, but are not limited to:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the Federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which impose criminal and civil penalties, through government, civil whistleblower or qui tam actions, on individuals and entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for&#xa0;purposes of the False Claims Act;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIPAA&#xa0;imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">HIPAA, as amended by HITECH&#xa0;and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the federal physician payment transparency requirements, sometimes referred to as the &#x201c;Physician Payments Sunshine Act,&#x201d;&#xa0;created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act&#xa0;(the Affordable Care Act)&#xa0;and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the U.S. FDCA, which prohibits, among other things, the adulteration or misbranding of drugs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the Foreign Corrupt Practices Act and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our current and potential product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Coverage and reimbursement may be limited or unavailable in certain market segments for REQORSA, GPX-002, GPX-003, and our other current or future product candidates, if approved, which could make it difficult for us to sell REQORSA, GPX-002, GPX-003, and our other current or future product candidates profitably.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, insurance companies and other third-party payors, and others in the medical community. Even if we obtain approval to commercialize our current and potential product candidates outside of the United States, a variety of risks associated with international operations could materially affect our business. Due to the novel nature of our technology, we face uncertainty related to pricing and reimbursement for our current and potential product candidates. The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. If market opportunities for our current and potential product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Successful sales of our products, if our current and potential product candidates are approved, depend on the availability of coverage and adequate reimbursement from third-party payors. In addition, because our current and potential product candidates represent new approaches to the treatment of cancer and diabetes, we cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our current and potential product candidates. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a covered benefit under its health plan;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">safe, effective and medically necessary;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">appropriate for the specific patient;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">cost-effective; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">neither experimental nor investigational.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors, and coverage and reimbursement for products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products and to justify the level of coverage and reimbursement relative to other therapies, with no assurance that coverage and adequate reimbursement will be obtained. Third party payors may also have difficulty in determining the appropriate coverage of REQORSA and our other current and future product candidates that are combination products, if approved, due to the fact that they are combination products that include another drug. To the extent there are any delays in determining such coverage or inadequate coverage and reimbursement for all aspects of our combination therapies, it would adversely affect the market acceptance, demand and use of our current and potential product candidates. Any denial in coverage or reduction in reimbursement from Medicare or other government programs may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our current and potential product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our current and potential product candidates will depend significantly on the availability of coverage and adequate reimbursement from third-party payors for our current and potential product candidates and may be affected by existing and future health care reform measures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concerns about gene therapy, genetic testing, and genetic research could result in new and/or additional government regulations and requirements that restrict or prohibit the processes we use or delay or prevent the regulatory approval of our current and potential product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Ethical, social, and legal concerns about gene therapy, genetic testing, and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive regulations or claims that our products are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our current and potential product candidates. It is impossible to predict whether legislative changes will be enacted, regulations, policies, or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could affect our ability to sell our products profitably. In particular the Affordable Care Act and its implementing regulations, among other things, subjected biological products to potential competition by lower-cost biosimilars, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our current and potential product candidates, under the Medicaid Drug Rebate Program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">More recently, other legislative changes that affect the pharmaceutical industry have been proposed and adopted in the United States since the Affordable Care Act was enacted.&#xa0;For example, the Inflation Reduction Act of 2022 included, among other things, a provision that authorizes CMS to negotiate a &#x201c;maximum fair price&#x201d; for a limited number of high-cost, single-source drugs every year, and another provision that requires drug companies to pay rebates to Medicare if prices rise faster than inflation.&#xa0; In addition, various states have adopted or are considering adopting laws that require pharmaceutical companies to provide notice prior to raising prices and to justify price increases. We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the demand for our current and potential product candidates, if we obtain regulatory approval;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to set a price that we believe is fair for our products;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to generate revenue and achieve or maintain profitability;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the level of taxes that we are required to pay; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the availability of capital.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We are subject to a variety of risks associated with international operations which could materially adversely affect our business.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We anticipate that we will be subject to additional risks in commercializing our product candidates outside the United States, including the following, any one or combination of which could have a material adverse effect on our business:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">different regulatory requirements for approval of product candidates&#xa0;in foreign countries;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">reduced protection for intellectual property rights;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#x37e;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#x37e;</p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">compliance with international data privacy laws, including GDPR;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country&#x37e;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">workforce uncertainty in countries where labor unrest is more common than in the United States&#x37e;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#x37e;&#xa0;and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, fires and medical epidemics.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may become subject to federal, state, local, and foreign&#xa0;laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and certain waste products, including numerous environmental, health and safety laws and regulations, such as those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may in the future involve the use of hazardous materials, including chemicals and biological materials. Our operations may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations may also&#xa0;result in substantial fines, penalties or other sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Dependence on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop our current and future product candidates and our financial condition and operating results could be adversely affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Because developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products are expensive, we have and may continue to enter into collaborations with companies that have the required expertise. Additionally, if any of our product candidates receive marketing approval, we may enter into sales and marketing arrangements with third parties. If we are unable to enter into arrangements on acceptable terms, or at all, we may be unable to effectively market and sell our products in our target markets. We expect to face competition in engaging collaborators. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements for the development of our current and potential product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">When we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the timing and future success of that product candidate to such third party.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">One or more of our collaboration partners may not devote sufficient resources to the development and commercialization of our product candidates or may otherwise fail in these efforts. The terms of any collaboration or other arrangement that we establish may contain provisions that are not favorable to us. In addition, any collaboration that we enter into may not be successful in the development and commercialization of our product candidates. In some cases, we may be responsible for continuing preclinical and initial clinical development of a product candidate or research program under a collaboration arrangement, and the payment we receive from our collaboration partner may be insufficient to cover the cost of such development. If we are unable to reach agreements with suitable collaborators for our product candidates, we may face increased costs, we may be forced to limit the number of our product candidates we can commercially develop or the territories in which we commercialize them. As a result, we may be unable to&#xa0;commercialize products or programs if we are unable to engage a suitable collaborator, which may have a material adverse effect on our operating results and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely, in part, and expect to continue to rely, in part, on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely in part on CROs and clinical trial sites to ensure our clinical trials are conducted properly and on time. While we have or will have agreements governing their activities, we may have limited influence over their actual performance because we control only certain aspects of our CROs&#x2019; activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.&#xa0; These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We and our CROs are required to comply with good clinical practices (GCPs) for conducting, recording and reporting the results of clinical trials to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA enforces these GCPs through periodic inspections of study sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving any marketing applications. In addition, our ongoing and future clinical trials will require a sufficient number of test subjects to evaluate the safety and effectiveness of our current and potential product candidates. Accordingly, if our CROs fail to comply with applicable regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects may be harmed, our costs could increase and our ability to generate revenues could be limited or delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely, and expect to continue to rely, on third parties to distribute, manufacture and perform release testing for our current and future</i></b>&#xa0;<b><i>product candidates and other key materials and if such third parties do not carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approvals for our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely, and expect to continue to rely on third-party CDMOs to produce REQORSA and expect to do so with GPX-002 and GPX-003 and other current and future product candidates and other key materials and on third-party contract testing organizations, or CTOs, for the establishment and performance of validated product release assays. Additionally, any CDMO may not have specific experience producing our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce our products at the quality, quantities, locations and timing needed to support commercialization. We do not have full control of these CDMOs, and they may prioritize other customers or be unable to provide us with enough manufacturing capacity to meet our objectives.&#xa0;We may change our manufacturing process, and there can be no guarantee that the regulatory authorities will approve any new process in a timely manner, or ever. Also, as a consequence of the manufacturing change, there may be a requirement to conduct additional preclinical safety or efficacy studies, develop new manufacturing and release assays and/or repeat all or part of the ascending dose safety study in animals or humans. Regulatory requirements ultimately imposed could adversely affect our ability to test, manufacture or market products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Historically, part of our manufacturing process was conducted in manufacturing facilities at MD Anderson.&#xa0;We have completed the technology transfer from MD Anderson to experienced commercial contract development and manufacturing organizations and have scaled-up clinical production of REQORSA appropriate for our Acclaim-1, Acclaim-2 and Acclaim-3 clinical trials. With the advancement of the development of GPX-002 and GPX-003, we also are working to optimize the manufacture of these product candidates and to source high quality and integrated vendors capable of producing them in accordance with GMP.&#xa0; No assurance can be given that such contract manufacturers will be able to, and will receive all approvals to, produce product sufficient for all of our clinical trial needs moving forward or for commercialization. In accordance with cGMPs, changing manufacturers may require the&#xa0;re-validation&#xa0;of manufacturing processes and procedures, and may require further preclinical studies or clinical trials to show comparability between the materials produced by different manufacturers. Changing our contract manufacturers may be difficult and could be costly if we do make such a change, which could result in our inability to manufacture our product candidates and a delay in the development of our product candidates and their commercial sale, should they be approved. Further, in order to maintain our development timelines in the event of a change in a third-party contract manufacturer, we may incur higher costs to manufacture our product candidates. There can be no guarantee that the regulatory authorities will approve any new process in a timely manner or ever. Regulatory requirements ultimately imposed could adversely affect our ability to test, manufacture or market products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In connection with our manufacturing activities, we may encounter technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. Further, we have not fully completed the characterization and validation activities necessary for commercial and regulatory approvals. If our manufacturing and testing partners do not enable such regulatory approvals, our commercialization efforts may be harmed. If such third-party manufacturers are unable to produce REQORSA, GPX-002, GPX-003, or other product candidates in the necessary quantities, or in compliance with cGMP&#xa0;or in compliance with pertinent regulatory requirements, and within our planned time frame and cost parameters, the development and sales of our products, if approved, would be materially harmed. The manufacturing processes used by our contract manufacturers to manufacture product candidates must be approved by the FDA as part of our BLA package and the facilities used by our contract manufacturers must maintain a compliance status acceptable to the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. Although we provide specifications, we do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs for the manufacture of our product candidates. If our CDMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory agencies, we will not be able to secure and/or maintain regulatory approval covering their manufacturing facilities. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly affect our ability to develop, obtain regulatory approval for or market our future product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our current and future product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, any significant disruption in our supplier relationships could harm our business. We source key materials, devices and equipment from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There is a small number of suppliers for certain key materials and components that are used to manufacture our current and future product candidates. Such suppliers may not sell these key materials to our manufacturers at the times or quantities we need them or on commercially reasonable terms. We may not have any control over the process or timing of the acquisition of these key materials by our manufacturers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We also expect to rely on other third parties to store and distribute our products for our clinical trials. Any performance failure on the part of these third parties&#xa0;could delay clinical development or marketing approval of our current and future product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have completed and may in the future complete related party transactions that were not and may not be conducted on an arm</i></b>&#x2019;<b><i>s length basis.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we are successful in commercializing REQORSA, our lead drug candidate, we will owe IRI a 1% royalty of our product sales. REQORSA&#xa0;is based upon patents and related technology covered by the 1994 MD Anderson License Agreement, under which we have rights to patents covering use of various genes, including the TUSC2 gene, for treatment of cancer, as well as know-how and related intellectual property. In 2007, the 1994 MD Anderson License Agreement was sublicensed by Introgen to IRI&#xa0;and in 2009 this sublicense was assigned by IRI to us, and we granted back to IRI a nonexclusive, royalty-free license to use and practice the licensed technology for non-commercial research purposes. As consideration for this assignment, we agreed to assume all of IRI&#x2019;s obligations to MD Anderson under the 1994 MD Anderson License Agreement, including ongoing patent related expenses and royalty obligations. IRI also agreed in 2011, pursuant to the 2011 IRI Collaboration Agreement,&#xa0;to provide additional technology licensing opportunities and services to us in return for monthly payments and our obligation to pay to IRI a royalty of 1%&#xa0;on sales of products licensed to us under the 1994 MD Anderson License Agreement. We also granted a non-exclusive, royalty-free sublicense to IRI in 2011 for non-commercial research purposes. IRI&#x2019;s obligations to provide additional technology licensing opportunities and services to us, and our obligation to make monthly payments to IRI, were terminated in 2012; however, our obligation to pay the 1%&#xa0;royalty to IRI upon sales of products licensed to us under the 1994 MD Anderson License Agreement is ongoing. This royalty obligation continues for 21 years after the later of the termination of the 1994 MD Anderson License Agreement and the termination of the sublicense assigned by IRI to us.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">IRI is controlled by Rodney Varner&#xa0;and IRI is owned by trusts for the benefit of Mr. Varner's descendants. Mr. Varner is currently Chairman of our board of directors, having joined our board of directors on August 15, 2012, and has been our Chief Executive Officer since August 29, 2012 and President since August 10, 2020; accordingly, in 2009 and 2011, when the above referenced agreements between IRI and Genprex were entered into, Mr. Varner was neither a member of our board of directors nor an executive officer of Genprex. When the 2011 IRI Collaboration&#xa0;Agreement was entered into, Mr. Varner was deemed to be an &#x201c;affiliate&#x201d; of the Company due to his beneficial ownership of approximately 39% of our issued and outstanding shares at that time. Although we believe that these transactions were conducted on an arm&#x2019;s length basis, it is possible that the terms were less favorable to us than they might have been in a transaction with an unrelated party.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The disruptions to the global economy since the COVID-19 global pandemic commenced in 2020 has impeded global supply chains, resulting in longer lead times and also increased critical component costs and freight expenses. We have experienced this impact most notably in our manufacturing operations due to the delay in our ability to acquire raw materials for our drug product. This delay has the potential to impact the timing of the conduct of our clinical trials. We have taken steps to minimize the impact of these increased costs by working closely with our suppliers. Despite the actions we have undertaken to minimize the impacts from disruptions to the global economy, there can be no assurances that unforeseen future events in the global supply chain, and inflationary pressures, will not have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to comply with obligations pursuant to our license agreements, we could lose intellectual property and other rights that are important to our business</i></b><b><i>; if we fail to obtain licenses to advance our research and development that may be required we may be unable to develop the affected product exclusively, on acceptable terms or at all</i></b><b><i>.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to&#xa0;the 1994 MD Anderson License Agreement and subsequent Amendments thereto, as well as&#xa0;the 2020 MD Anderson License Agreement, we hold worldwide, exclusive license rights to certain inventions covering the therapeutic use of TUSC2 and other genes and polypeptides that have been shown to have cancer fighting properties, as well as a number of related technologies. In addition, pursuant to the UP License Agreements, UP granted us a worldwide, exclusive license to certain licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to diabetes gene therapy.&#xa0;In addition,&#xa0;we expect to enter into additional license agreements in the future. Our existing and future license agreements may impose&#xa0;various payment&#xa0;and other obligations on us. If we fail to comply with our obligations under these agreements, our licensors&#xa0;may have the right to terminate our licenses, in which event we would not be able to market products covered by such licenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Moreover, in the event we need to obtain licenses from third parties to advance our research and development or allow commercialization of our product candidates, including additional technology that may be required or advisable to advance REQORSA,&#xa0;GPX-002, or GPX-003, we may fail to obtain any of such licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to develop or license replacement technology, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties or that we may be estopped from acquiring such rights due to prior art. Specifically, mice and NHP studies for which we have disclosed data relating to our diabetes program includes a technology to which we do not have exclusive rights, though we expect, but are not guaranteed, that we will have exclusive rights to the final product(s) developed under this program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In certain cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited to:&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the sublicensing of patent and other rights under our collaborative development relationships;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the priority of invention of patented technology.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The intellectual property rights we have licensed from MD Anderson and the UP</i></b>&#xa0;<b><i>are subject to the rights of the U.S. government.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The rights we have obtained pursuant to our license agreements with MD Anderson and the UP are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between such institution and the U.S. government. Additionally, to the extent there is any conflict between our license agreement&#xa0;and applicable laws or regulations, applicable laws and regulations will prevail. Similarly, to the extent there is any conflict between our license agreement with one of these institutions and the institution&#x2019;s funding agreement with the US government, the terms of the funding agreement will prevail. Some, and possibly all, of our licensed intellectual property rights&#xa0;have been developed in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or sublicensee to such inventions, to grant licenses to any of these inventions to a third party if the U.S. government determines that adequate steps have not been taken to commercialize the invention, that government action is necessary to meet public health or safety needs, that government action is necessary to meet requirements for public use under federal regulations, or the right to use or sell such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the U.S. government&#x2019;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing substantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if our licensors failed to disclose the invention to the government in a timely manner and/or failed to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title in any country in which a patent application is not filed within specified time limits. Furthermore, certain inventions are subject to transfer restrictions during the term of these agreements and for a period thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair the value of our intellectual property and could adversely affect our business.&#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our commercial success will depend in part on our ability and the ability of our licensors to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our novel technologies and products that are important to our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. The steps we or our licensors have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United States. Further, the examination process may require us or our licensors to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights already granted under any of our currently issued patents or those licensed to us and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we or our licensors are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected. It is also possible that we or our licensors will fail to identify patentable aspects of inventions made in the course of our development and commercialization. It is also possible that as research and development progresses, the direction of our intellectual property strategy and patent portfolio will change, resulting in strategic business decisions to allow certain patents or patent applications to be abandoned or lapse.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">With respect to patent rights, we do not know whether any of the pending patent applications relating to any of our current and future product candidates will result in the issuance of patents that effectively protect our technology or products, or if any of our licensors&#x2019; issued patents will effectively prevent others from commercializing competitive technologies and products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our or our licensor&#x2019;s patented technology, trademarks and other intellectual property rights is expensive, difficult and may in some cases not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and other post grant proceedings before the US Patent and Trademark Office ("USPTO")&#xa0;and corresponding foreign patent offices. Numerous US and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current and future product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Third parties may in the future assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, or any final product itself, the holders of any such patents may be able to block our ability to develop and commercialize such product candidate until such patents expire unless we obtained a license under the applicable patents, which license may not be available on acceptable terms, if at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Parties making claims against us may obtain injunctive or other equitable relief, which may hinder our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, may involve substantial litigation expense and diversion of our management&#x2019;s attention. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which licenses may not be on acceptable terms or require substantial time and monetary expenditure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Presently we believe that we have the necessary rights to the intellectual property, through licenses or other rights from third parties to develop our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties on reasonable terms, if at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If we are unable to successfully obtain rights to required third-party intellectual property, our business, financial condition and prospects for growth could suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Because we rely on and intend to continue to rely on third parties to manufacture our current and future product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions of such agreements, the need to share trade secrets and other confidential information increases the risk that such trade secrets may become known by our competitors, may be inadvertently incorporated into the technology of others, may be used inappropriately to create new inventions or may be disclosed or used in violation of such agreements.&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of research and development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of&#xa0;our trade secrets or other unauthorized use or disclosure may impair our competitive position and have a material adverse effect on our business.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent&#xa0;is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ an outside firm and rely on our outside counsel to pay these fees due to non-US patent agencies. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Although an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market which would have a material adverse effect on our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Issued patents covering our</i></b>&#xa0;<b><i>product candidates could be found invalid or unenforceable if challenged in court.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If we or one of our licensing partners, including MD Anderson or UP, initiate&#xa0;legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our current and potential product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current and potential product candidates. Such a loss of patent protection would have a material adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We currently and in the future may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#x2019;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and result in a diversion of management&#x2019;s attention.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may have potential ownership disputes arising, for example, from conflicting obligations of consultants, collaborators or others who are involved in developing our current and potential product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have in the past and may again in the future have trademark applications in the United States and/or certain other countries, and failure to secure these registrations could</i></b><b><i>&#xa0;adversely affect our business; additionally, we may need to enforce our trademark rights against third parties and expend significant resources to enforce such rights against infringement.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have obtained trademark registrations in the United States for GENPREX, ONCOPREX and REQORSA and we may in the future have pending trademark applications in the United States and/or certain other countries. During trademark registration proceedings, our application may be rejected. Although we would be given an opportunity to respond to the rejection of a trademark application, we may be unable to overcome such rejection. In addition, with respect to the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark, and our trademark may not survive such proceedings. Additionally, we may need to enforce our trademark rights against third parties and expend significant additional resources to enforce such rights against infringement. Moreover, any name we propose to use with our current and potential product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Filing, prosecuting and defending patents with respect to&#xa0;product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Employee Matters and Managing Growth</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing arrangements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have no sales, marketing or distribution experience. To develop sales, distribution and marketing capabilities, we will have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation that our product candidates will be approved by the FDA. For product candidates for which we decide to perform sales, marketing and distribution functions ourselves or through third parties, we could face a number of additional risks, including that we or our third-party sales collaborators may not be able to build and maintain an effective marketing or sales force, and we may experience difficulty in managing the growth of our organization. If we use third parties to market and sell our products, we may have limited or no control over their sales, marketing and distribution activities on which our future revenues may depend.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of March 15, 2023, we had 28&#xa0;total employees, all of which were full-time. As we advance our&#xa0;product candidates through preclinical studies and clinical trials, we will need to increase our clinical trial management, product development, manufacturing, regulatory, and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we may need to increase our general and administrative capabilities. We may not be able to attract or retain qualified personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are highly dependent on the development, manufacturing, regulatory, commercialization and business development expertise of our management team, key employees and consultants. Any of our executive officers or key employees or consultants may terminate their employment&#xa0;or engagement with us&#xa0;at any time. If we lose one or more of our executive officers or key employees or consultants, our ability to implement our business strategy successfully could be seriously harmed. Replacing executive officers, key employees and consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, we have scientific and clinical advisors and consultants who assist us in formulating our research, development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may evaluate and enter into various acquisitions and strategic partnerships, including licensing or acquiring additional products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">increased operating expenses and cash requirements;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the assumption of additional indebtedness or contingent liabilities;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the issuance of our equity securities;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">difficulties in achieving anticipated cost savings, synergies, business opportunities, and growth prospects from any business combination;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the diversion of our management&#x2019;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Moreover, we may not be able to locate suitable acquisition opportunities and such inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risks Related to our Securities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The market price of our common stock may be highly volatile, and you may lose all or part of your investment. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The market price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to obtain additional funding;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">adverse results or delays in preclinical or clinical trials;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">reports of adverse events in other gene therapy products or clinical trials of such products;</p> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">manufacturing and supply issues related to our existing or future products;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">any delay in filing an IND or BLA for our product candidates and any adverse development or perceived adverse development with respect to the FDA&#x2019;s review of that IND or BLA;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to develop successfully and commercialize our&#xa0;product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to maintain our existing strategic collaborations or enter into new collaborations;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in laws or regulations applicable to our products and product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to obtain adequate product supply for our product candidates or inability to do so at acceptable prices;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">adverse regulatory decisions;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">introduction of new products, services or technologies by our competitors;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to meet or exceed financial projections we may provide to the public;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to meet or exceed the financial projections of the investment community;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the perception of the pharmaceutical and biotechnology industries&#xa0;by the public, legislatures, regulators and the investment community;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">additions or departures of key scientific or management personnel;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">significant lawsuits, including patent or stockholder litigation;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">changes in the market valuations of similar companies;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">sales of our common stock by us or our stockholders;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">trading volume of our common stock;</p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">General economic conditions in the United States and abroad; and other events or factors, many of which may be out of our control, including, but not limited to, pandemics such as COVID-19, war, or other acts of God.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, companies trading in the stock market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>An active, liquid and orderly market for our common stock may not be sustained, and you may not be able to sell your common stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our common stock trades on the Nasdaq Capital Market. We cannot assure you that an active trading market for our common stock will be sustained. The lack of an active market may impair your ability to sell the common stock at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling common stock and may impair our ability to acquire other businesses, applications or technologies using our common shares as consideration, which, in turn, could materially adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Although our common stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange&#x2019;s minimum listing requirements, including the minimum bid price requirement and other applicable corporate governance requirements, or those of any other national exchange. If we are unable to maintain listing on Nasdaq, our common stock may remain thinly traded. The Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our stockholders: &#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the liquidity of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the market price of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to obtain financing for the continuation of our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number of investors that will consider investing in our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number of market makers in our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the availability of information concerning the trading prices and volume of our common stock; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the number of broker-dealers willing to execute trades in shares of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Global credit and financial markets have experienced volatility and disruptions in past years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, concerns about medical epidemics, and uncertainty about economic stability. We cannot assure you that further deterioration in credit and financial markets and confidence in economic conditions will not occur, particularly as a result of the ongoing COVID-19 pandemic. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Failure to maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (</i></b>&#x201c;<b><i>Sarbanes-Oxley Act</i></b>&#x201d;<b><i>) could cause our financial reports to be inaccurate.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are required pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to maintain internal control over financial reporting and to assess and report on the effectiveness of those controls. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Although we prepare our financial statements in accordance with accounting principles generally accepted in the United States, our internal accounting controls may not meet all standards applicable to companies with publicly traded securities. If we fail to implement any required improvements to our disclosure controls and procedures, we may be obligated to report control deficiencies, in which case we could become subject to regulatory sanction or investigation. Further, such an outcome could damage investor confidence in the accuracy and reliability of our financial statements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations.&#xa0;We have designed, implemented and tested the internal control over financial reporting required to comply with this obligation, which was and is time consuming, costly, and complicated. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our management has concluded that our internal controls over financial reporting were, and continue to be, ineffective, and as of the year ended December 31, 2022&#xa0;as a result of a material weakness in our internal controls due to the lack of segregation of duties. While management is working to remediate the material weakness, there is no assurance that such changes, when economically feasible and sustainable, will remediate the identified material weaknesses or that the controls will prevent or detect future material weaknesses. If we are not able to remediate this material weakness or maintain&#xa0;effective internal control over financial reporting,&#xa0;this could result in a material misstatement in our consolidated financial statements and a failure to meet our reporting and financial obligations,&#xa0;which could have a material adverse effect on our business.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have no intention of declaring dividends in the foreseeable future. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have never declared or paid cash dividends on our capital stock, and we do not currently anticipate declaring any dividends in the foreseeable future. We anticipate that we will retain all future earnings for the development, operation, and expansion of our business. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.&#xa0;Investors in our common stock should not expect to receive dividend income on their investment, and investors will be dependent on the appreciation of our common stock, if any,&#xa0;to earn a return on their investment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are currently an emerging growth company&#xa0;and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are currently an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.&#xa0;We expect that our eligibility to qualify as&#xa0;an &#x201c;emerging growth company&#x201d; will end on December 31, 2023, the last day of our fiscal year following the fifth anniversary of the date of our initial public offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies; however, we have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline. As of December 31, 2022, we had outstanding options to purchase an aggregate of 11,374,327&#xa0;shares of our common stock at a weighted average exercise price of $3.08&#xa0;per share and warrants to purchase an aggregate of 2,131,111&#xa0;shares of our common stock at a weighted average exercise price of $4.34&#xa0;per share. The exercise of such outstanding options and warrants will result in further dilution of your investment, even if there is no relationship between such sales and the performance of our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are unable to predict the effect that sales may have on the market price of our common stock. If any shares of our common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future sales</i></b>&#xa0;<b><i>and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We expect that significant additional capital will be needed in the future to continue our planned operations, including research and development, increased marketing, hiring new personnel, commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. We may sell a substantial number of shares of our common stock pursuant to our existing Equity Distribution Agreement with JMP Securities, pursuant to which we have the discretion to deliver placement notices to JMP Securities at any time throughout the term of the Equity Distribution Agreement covering shares of our common stock up to the aggregate offering price of $50 million; pursuant to such agreement, we have the discretion, subject to market demand, to vary the timing, prices, and quantity of shares sold, and there is no minimum or maximum sales price.&#xa0; Any sales of equity securities, whether pursuant to our Equity Distribution Agreement or otherwise,&#xa0;may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our industry and our market. If no analyst elects to cover us and publish research or reports about us, the market for our common stock could be severely limited and our stock price could be adversely affected. In addition, if one or more analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. If one or more analysts who elect to cover us issue negative reports or adversely change their recommendations regarding our common stock, our stock price could decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain provisions in our organizational documents could enable our board of directors to prevent or delay a change of control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We are authorized to issue up to 10,000,000 shares of preferred stock, none of which are outstanding as of March 15, 2023. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. The ability of our board of directors to issue preferred stock also could have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, our organizational documents contain provisions that may have the effect of discouraging, delaying or preventing a change of control of, or unsolicited acquisition proposals, that a stockholder might consider favorable. These include provisions:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">requiring at least 66-2/3% of the voting power of all of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class, to amend the Amended and Restated Bylaws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">providing that the authorized number of directors may be changed only by resolution of the board of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">providing that the directors may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding shares of capital stock entitled to vote generally at the election of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">providing that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">dividing our board of directors into three classes;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">requiring that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">providing that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#x2019;s notice;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">that do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">providing that special meetings of our stockholders may be called only by the Chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition, Delaware law makes it difficult for stockholders that recently have acquired a large interest in a corporation to cause the merger or acquisition of the corporation against the directors&#x2019; wishes. Under Section 203 of the Delaware General Corporation Law, a Delaware corporation may not engage in any merger or other business combination with an interested stockholder for a period of three years following the date that the stockholder became an interested stockholder except in limited circumstances, including by approval of the corporation&#x2019;s board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our Amended and Restated Certificate of Incorporation and</i></b>&#xa0;<b><i>Amended and Restated Bylaws contain&#xa0;an exclusive forum provision with respect to certain actions which may limit a stockholder</i></b>&#x2019;<b><i>s ability to bring a claim in a judicial forum that it finds favorable and discourage lawsuits against us or our current or former directors or officers and/or stockholders in such capacity</i></b><b>.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the following actions must be brought solely and exclusively in the Court of Chancery of the State of Delaware&#xa0;(i) any derivative action or proceeding brought on behalf of us&#x37e; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to us or our stockholders&#x37e; (iii) any action asserting a claim against us or any director or officer or other employee of the Company arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws&#x37e; or (iv) any action asserting a claim against us or any director or officer or other employee of the Company governed by the internal affairs doctrine.&#xa0;We believe that the exclusive forum provision may not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. We believe that to the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, we believe that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.&#xa0; This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers or other employees.&#xa0;Alternatively, if a court were to find the choice of forum provision contained in our Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, results of operations, and financial condition.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>General Risk Factors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obligations associated with being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to</i></b>&#xa0;<b><i>compliance matters.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As a publicly traded company we incur significant legal, accounting and other expenses. The obligations of being a public company in the United States require significant expenditures and places significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;) and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing requirements of The Nasdaq Capital Market. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly after we are no longer an &#x201c;emerging growth company&#x201d; or &#x201c;smaller reporting company.&#x201d; In addition, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential consequences.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our operations, and those of our CROs, contract manufacturers and other contractors, vendors and consultants, could be subject to power shortages, telecommunications failures, wildfires, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and pandemics and other natural or man-made disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our current and potential product candidates could be disrupted if the operations of our contract manufacturers are affected by a man-made or natural disaster or other business interruption.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, the global macroeconomic environment could be negatively affected by, among other things, new variants of the COVID-19 pandemic or other epidemics, instability in global economic markets, increased U.S. trade tariffs and trade disputes with other countries, supply chain weaknesses, instability in the global credit markets, severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates, uncertainty about economic stability,&#xa0;instability in the geopolitical environment, the Russian invasion of the Ukraine and other political tensions, and foreign governmental debt concerns. More recently, the closures of Silicon Valley Bank, or SVB, and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation, or&#xa0;the FDIC,&#xa0;created bank-specific and broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the&#xa0;FDIC&#xa0;jointly released a statement that depositors at SVB and Signature Bank would have access to their funds, even those in excess of the standard&#xa0;FDIC&#xa0;insurance limits, under a systemic risk exception, future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of market participants to access near-term working capital needs, and create additional market and economic uncertainty.&#xa0; There can be no assurance that any such continuing or future credit and financial market instability, liquidity shortages and a deterioration in confidence in economic conditions will not occur.&#xa0; Such challenges have caused, and may continue to cause, uncertainty and instability in local economies and in global financial markets, which could adversely affect our business, financial condition or results of operations.&#xa0; If these conditions continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and share price and could require us to delay or abandon development or commercialization plans.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We do not carry insurance for all categories of risk that our business may encounter. There can be no assurance that we will secure adequate insurance coverage or that any such insurance coverage will be sufficient to protect us from potential liability in the future. Any significant uninsured liability may require us to pay substantial amounts, which may adversely affect our financial position and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be at risk of securities class action litigation.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We may be at risk of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant stock price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business and results in a decline in the market price of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_1B" title="Item_1B" href="#"></a>Item 1B. Unresolved Staff Comments.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_2" title="Item_2" href="#"></a>Item 2. Properties.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our principal&#xa0;offices&#xa0;are located at 3300 Bee Cave Road, #650-227, Austin, Texas&#xa0;78746. We operate primarily as a virtual company and we believe our current facilities and those that we believe are available to us are sufficient to meet our current needs and that suitable space will be available as and when needed. We do not own any real property.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_3" title="Item_3" href="#"></a>Item 3. Legal Proceedings.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">From time to time, we may become involved in various lawsuits and legal proceedings. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_4" title="Item_4" href="#"></a>Item 4. Mine Safety Disclosures.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Not applicable.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     76
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="PART_II" title="PART_II" href="#"></a>PART II</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_5" title="Item_5" href="#"></a>Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Market Information</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock began trading on The Nasdaq&#xa0;Capital Market under the symbol &#x201c;GNPX&#x201d; on March 29, 2018. Prior to that date, there was no public trading market for our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Holders of Record</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As of March 15, 2023, there were approximately 145&#xa0;stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust or by other entities.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Dividend Policy</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Recent Sales of Unregistered Securities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div style="font-size: 10pt; text-indent: 36pt; text-align: justify;">
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended December 31, 2022, we issued and sold the following unregistered securities:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: top;">
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: 36pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1)</p> </td>
      <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">On October 1, 2022, we issued an aggregate of 5,000 shares of our common stock to a consultant&#xa0;in consideration of services during the three months ended December 31, 2022.</p> </td>
     </tr>

     <tr style="vertical-align: top;">
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: auto;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     </tr>

     <tr>
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2)</td>
      <td style="width: auto; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">On December 5, 2022, we issued an aggregate of 76,752 shares of our common stock to a consultant&#xa0;in consideration of services.</td>
     </tr>

     <tr>
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: auto;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: top;">
      <td style="width: 36pt;">&#xa0;</td>
      <td style="width: 36pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">3)</p> </td>
      <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">On December 20, 2022, we issued a warrant to purchase up to 3,000 shares of our common stock at an exercise price of $5.00&#xa0;per share&#xa0;to a consultant in consideration for services.</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The foregoing issuance of securities was not registered under the Securities Act or the securities laws of any state, and the securities were offered and issued in reliance on the exemption from registration under the Securities Act&#xa0;afforded by Section 4(a)(2).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px; text-align: justify;"><b><a id="Item_6" title="Item_6" href="#"></a>Item 6. [Reserved]</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     77
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_7" title="Item_7" href="#"></a>Item 7. Management&#x2019;s Discussion and Analysis of&#xa0;Financial Condition and Results of Operations.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>This Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations (&#x201c;MD&amp;A&#x201d;) contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated by forward- looking statements include, but are not limited to, those discussed in &#x201c;Risk Factors.&#x201d; We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Overview </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.&#xa0;Our oncology platform utilizes our non-viral ONCOPREX&#xae; Nanoparticle Delivery System.&#xa0;Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. In Type 2 diabetes, our technology&#xa0;is believed to work by replenishing and rejuvenating the beta cells&#xa0;that make insulin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Oncology Platform</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our lead oncology drug candidate, REQORSA&#xae; Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-001, is initially being developed in combination with top-selling cancer drugs to treat Non-Small Cell Lung Cancer (&#x201c;NSCLC&#x201d;) and Small Cell Lung Cancer (&#x201c;SCLC&#x201d;).&#xa0;The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#xa0;We believe REQORSA&#x2019;s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, and that it can improve on current therapies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 1: We currently are enrolling and treating patients in the Phase 1 dose escalation portion of our Phase&#xa0;1/2&#xa0;Acclaim-1&#xa0;clinical trial.&#xa0;The Acclaim-1&#xa0;trial uses a combination of REQORSA and AstraZeneca PLC&#x2019;s Tagrisso&#xae; in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#x201c;EGFR&#x201d;) mutations and progression after treatment with Tagrisso. In&#xa0;August 2022,&#xa0;the Acclaim-1&#xa0;Safety Review Committee (&#x201c;Acclaim-1 SRC&#x201d;) approved escalating the dose from&#xa0;0.06&#xa0;mg/kg in the&#xa0;first&#xa0;cohort of patients to&#xa0;0.09&#xa0;mg/kg in the&#xa0;second&#xa0;cohort of patients and in December 2022,&#xa0;the SRC approved escalating the dose from 0.09 mg/kg in the second cohort to 0.12 mg/kg in the third and final cohort. We are thus enrolling and treating patients at the 0.12 mg/kg dose&#xa0;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle one of treatment for the remaining untreated patients, the Acclaim-1 SRC will meet and establish the maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D"). We will then proceed into the dose expansion portion of the study. The Food and Drug Administration (&#x201c;FDA&#x201d;) has granted Fast Track Designation for the Acclaim-1&#xa0;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 2: We&#xa0;currently are enrolling and treating patients in the Phase 1 dose escalation portion of our Phase&#xa0;1/2&#xa0;Acclaim-2&#xa0;clinical trial.&#xa0;The Acclaim-2&#xa0;trial uses a combination of REQORSA and Merck &amp; Co.&#x2019;s Keytruda&#xae; in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are currently being treated at the 0.06 mg/kg dose level in the first cohort of patients&#xa0;and, subject to the Acclaim-2 Safety Review Committee approval, will be treated at successive dose levels of 0.09 mg/kg and 0.12 mg/kg. In March 2023, we amended the Acclaim-2 protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the dose escalation portion of&#xa0;the study to be completed by the end of 2023. We will then evaluate patients in the dose expansion portion of the study at the MTD or RP2D. The FDA has granted Fast Track Designation for the Acclaim-2&#xa0;treatment combination of REQORSA and Keytruda in NSCLC patients who have progressed after Keytruda treatment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The dose expansion portion of Acclaim-2 is a Phase 2 study and the dose expansion portion of Acclaim-1 will be considered a Phase 2 study upon the filing with the FDA of an upcoming protocol amendment.&#xa0;The dose expansion provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the MTD or RP2D in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase 2 trial which will follow the dose expansion portions of each study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Acclaim &#x2013; 3: In November 2022, we filed with the FDA our protocol for our Phase 1/2 Acclaim-3 clinical trial using a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq&#xae; as maintenance therapy in patients with extensive stage small cell lung cancer (&#x201c;ES-SCLC&#x201d;) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. We expect to dose the first patient in Acclaim-3 by the end of&#xa0;the third quarter of 2023. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The TUSC2 gene is one of a series of genes on the short arm of Chromosome 3 whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").&#xa0;We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates. In August 2022, we entered into a sponsored research agreement with MD Anderson to support further pre-clinical studies of TUSC2 and other tumor suppressor genes.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div style="font-size:10pt">
   <div style="font-family:'Times New Roman'">
    <div style="font-variant:normal">
     <i><span style="text-decoration: underline; ">Diabetes Gene Therapy</span></i>
    </div>
    <div style="font-variant:normal">
      &#xa0;
    </div>
    <div style="font-variant: normal; text-align: justify; text-indent: 36pt;">
      In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d;) multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes.&#xa0;The same general novel approach is used in each of Type 1 and Type 2 whereby an adeno-associated virus (&#x201c;AAV&#x201d;) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-002 is being developed for the treatment of Type 1 diabetes and GPX-003 is being developed for the treatment of Type 2 diabetes. GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. GPX-003 is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of 2023 to obtain their guidance on the toxicology studies that we plan to conduct. In August 2022, we entered into a one-year sponsored research agreement with the University of Pittsburgh for the use of GPX-003 in a non-human primate (&#x201c;NHP&#x201d;) model in Type 2 diabetes and we expect data from this study to be reported by the end of 2023. In February 2023, the Company&#x2019;s research collaborators at the&#xa0;University of Pittsburgh&#xa0;presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD 2023) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.
    </div>
    <div style="font-variant:normal">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>JOBS Act </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On April&#xa0;5, 2012, the JOBS Act&#xa0;was enacted. Section&#xa0;107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period provided in Section&#xa0;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &#x201c;emerging growth company&#x201d; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although we are currently an emerging growth company, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. We have implemented all new accounting pronouncements that are in effect and may affect our financial statements, and we do not believe that there are any other new accounting pronouncements that have been issued that would have a material impact on our financial position or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Notwithstanding the foregoing, subject to certain conditions set forth in the JOBS Act, as an &#x201c;emerging growth company,&#x201d; we intend to rely on certain exemptions, including, without limitation, the exemption from the requirements&#xa0;(i) to provide&#xa0;an auditor&#x2019;s attestation report on our system of internal controls&#xa0;over financial reporting pursuant to Section&#xa0;404(b) of the Sarbanes-Oxley Act,&#xa0;and (ii) to comply&#xa0;with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We expect that our eligibility to qualify as an &#x201c;emerging growth company&#x201d; will end on December 31, 2023, the last day of our fiscal year following the fifth anniversary of the date of our initial public offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recently Issued Accounting Pronouncements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our financial statements appearing in this Annual Report on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain<b>.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Research and Development Costs </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We record accrued expenses for costs invoiced from research and development activities conducted&#xa0;on our behalf&#xa0;by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract research, manufacturing, and testing activities. We record the costs of research and development activities based upon the amount of services provided, and we include these costs in accrued liabilities in the condensed balance sheets and within research and development expense in the condensed statements&#xa0;of operations. These costs are a significant component of our research and development expenses.&#xa0;Purchased materials to be used in future research are capitalized and included in research and development supplies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment in any of our clinical trials may vary from our estimates and could result in our reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from contract research organizations ("CROs") and other third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Income Taxes </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Deferred tax assets or liabilities are recorded for temporary differences between financial statement and tax basis of assets and liabilities, using applicable rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. We have provided a full valuation allowance on our deferred tax assets, which primarily consist of cumulative net operating losses from April 1, 2009 (inception)&#xa0;to December 31, 2022.&#xa0;Due to our history of operating losses since inception and losses expected to be incurred in the foreseeable future, a full valuation allowance was considered necessary.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Impairment of Long-Lived Assets </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#x2019;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Components of our Results of Operations and Financial Condition </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;"><b><i>Operating expenses </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">We classify our operating expenses into three categories: research and development, general and administrative, and depreciation.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Research and development</b>. Research and development expenses consist primarily of:</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27.8pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">costs incurred to conduct research, such as the discovery and development of our current and potential product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">costs related to the production and storage of supplies for engineering purposes and&#xa0;storage and usage of clinical supplies, including waste created in the process of producing clinical materials, spoilage, and testing of clinical materials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">costs related to the use of contract manufacturers, manufacturing consultants, testing organizations, cold-storage facilities, and logistics service providers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">fees paid to clinical consultants, clinical trial sites and vendors, including CROs in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical trial data, including all related fees, such as patient screening fees, laboratory work, and statistical compilation and analysis;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">costs related to compliance with drug development regulatory requirements; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b><b style="font-size: 3pt;">&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">costs related to staffing and personnel associated with research and development activities, including wages, taxes, benefits, leases, overheads, supplies, and share-based compensation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We recognize all research and development costs as they are incurred. Clinical trial costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We expect our research and development expenses to increase in the future as we continue to advance our current clinical trials, and advance additional current and future product candidates into and through clinical trials, as we pursue regulatory approval of our current and potential product candidates in the United States and Europe, and as we expand our research programs to include new therapies and new therapy combinations. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our current and potential product candidates may be affected by a variety of factors including the quality of our current and potential product candidates, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability, and limited contracted partners. We may never succeed in achieving regulatory approval for any of our current or future&#xa0;product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>General and administrative</b>.<i> </i>General and administrative expense consists of personnel related costs, which include salaries, as well as the costs of professional services, such as accounting and legal, travel, facilities, information technology and other administrative expenses. We expect our general and administrative expense to increase in future periods due to the anticipated growth of our business and related infrastructure as well as accounting, insurance, investor relations, legal, information technology, and other costs associated with being a public company.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Depreciation</b>. Depreciation expense consists of depreciation from our fixed assets consisting of our property, equipment, and furniture. We depreciate our assets over their estimated useful life. We estimate furniture and computer and office equipment to have a five-year life.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     81
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Results of Operations </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Comparison of the Years Ended&#xa0;December 31, 2022 and 2021</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The following summarizes our results of operations for the years ended December 31, 2022 and 2021.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Research and Development Expense. </b>Research and development ("R&amp;D") expense was $11,510,074&#xa0;for the year ended December 31, 2022&#xa0;as compared to $8,970,865 for the year ended December 31, 2021. This increase&#xa0;of $2,539,209, or 28%,&#xa0;is primarily due to (i) advancements and expansions in our manufacturing programs,&#xa0;including&#xa0;manufacturing and testing of our drug product, for our Acclaim-1 and Acclaim-2 clinical trials, (ii) increased&#xa0;usage of third-parties, including CROs, to manage and maintain our Acclaim-1 and Acclaim-2 clinical trials, and&#xa0;(iii) increase in R&amp;D personnel to support our manufacturing and pre-clinical and clinical programs.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>General and Administrative Expense. </b>General and administrative ("G&amp;A") expense for the year ended December 31, 2022&#xa0;was $12,295,070 as compared to $11,676,703 for the year ended December 31, 2021. The increase&#xa0;of $618,367, or 5%&#xa0;is primarily due to an increase in G&amp;A headcount and associated accruals from 7 full-time G&amp;A employees on&#xa0;December 31, 2021&#xa0;to 10&#xa0;full-time G&amp;A employees on December 31, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Interest Income. </b>Interest income was $90,098 and $5,133 for the years ended December 31, 2022 and 2021, respectively. This&#xa0;increase of $84,965&#xa0;was primarily due to changes in balances and a significant increase in interest rates of our money market instruments for the year ended&#xa0;December 31, 2022&#xa0;as compared to the prior year.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Interest Expense. </b>There was no interest expense for the years ended December 31, 2022 and 2021&#xa0;because we&#xa0;satisfied&#xa0;all debt obligations and repaid all short-term loans prior to 2019. As of&#xa0;December 31, 2022, we had no outstanding debt.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><b>Depreciation Expense. </b>Depreciation expense was $25,575 and $22,534 for the years ended December 31, 2022 and 2021, respectively. The&#xa0;increase of $3,041, or 13%, in depreciation&#xa0;was primarily due to the timing of purchases of computer equipment for new employees.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>Net Loss</b><b>.</b>&#xa0;<b> </b>We had a net loss of $23,740,621, for the fiscal year ended December 31, 2022 compared to a net loss of $20,664,969&#xa0;for the fiscal year ended December 31, 2021. The&#xa0;increase&#xa0;of&#xa0;3,075,652, or 15%, in net loss was primarily due to the expansion of our personnel and our clinical and manufacturing programs to support our Acclaim-1 and Acclaim-2 clinical trials.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     82
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Liquidity and Capital Resources </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">From inception through December 31, 2022, we have never generated revenue from product sales and have incurred net losses in each year. As of December 31, 2022, we had an accumulated deficit of $102,827,819. We have funded our operations primarily through the sale and issuance of capital stock. For the year ended&#xa0;December 31, 2021,&#xa0;we sold an&#xa0;aggregate of 4,000,000 shares of common stock for total net proceeds of $23,192,500 pursuant to registered direct offerings and issued 670,889&#xa0;shares of common stock with gross proceeds of $677,912 from warrant and option exercises.&#xa0;For the year ended&#xa0;December 31, 2022, we sold an&#xa0;aggregate of 3,886 shares of common stock for total net proceeds of $4,532 pursuant to our ATM facility as governed by the Equity Distribution Agreement (as further described below) and issued 116,973&#xa0;shares of common stock upon the exercise of&#xa0;options for&#xa0;gross proceeds of $1,755.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On November 18, 2022, we entered into our Equity Distribution Agreement with JMP Securities as Agent, with respect to an at-the-market offering program (our &#x201c;ATM&#x201d;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50.0 million through the Agent. We have agreed to pay the Agent a commission equal to three percent (3%) of the gross sales proceeds of any shares sold through the Agent under the Equity Distribution Agreement, and also have provided the Agent with customary indemnification and contribution rights. As of December 31, 2022 we had&#xa0;sold 3,886 shares of our common stock for net proceeds to us totaling $4,532.&#xa0;During January 2023, we issued an additional 53,592 shares of company stock for aggregate net proceeds of $78,355 under the 2022 ATM facility.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of&#xa0;December 31, 2022, we had $20,954,069&#xa0;in cash.&#xa0;Subsequent to year-end 2022, on March 1, 2023, we raised approximately $3.6 million in net proceeds in a registered direct offering pursuant to which we sold 3,809,524 shares of common stock and a like number of warrants.&#xa0; See &#x201c;Note 10&#xa0;&#x2013; Subsequent Events &#x2013; March 2023 Registered Direct Offering&#x201d; to the Financial Statements included in this Annual Report on Form 10-K.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We do not expect to generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of&#xa0;our current or potential product candidates, which we expect will take a number of years and which is subject to significant uncertainty.&#xa0;Accordingly, we anticipate that we will need to raise additional capital to fund our future operations, which include conducting our Acclaim-1, Acclaim-2,&#xa0;and Acclaim-3&#xa0;clinical trials (of which Acclaim-1 and Acclaim-2 are currently enrolling) and completing pre-clinical work and conducting clinical trials for our diabetes program. We expect enrollment in the Phase 1 dose escalation&#xa0;portion of the Acclaim-1 trial to be completed in the next several days following the filing of this Annual Report.&#xa0;After completion of enrollment and cycle one of treatment for the remaining untreated patients, the Acclaim-1 SRC will meet and establish the MTD&#xa0;or RP2D. We will then proceed into the dose expansion portion of the trial. We expect enrollment in the Phase 1 dose escalation portion of the Acclaim-2 trial to be completed by the end of&#xa0;2023 after which we will move into the dose expansion portion of the trial.&#xa0;Enrollment in the Acclaim-3 clinical trial is expected to commence by the end of the third quarter 2023.&#xa0; Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, drawdowns on our ATM pursuant to our Equity Distribution Agreement with JMP Securities as Agent,&#xa0;and debt financings and&#xa0;we may seek to raise additional capital through strategic collaborations. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all,&#xa0;which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant rights to others&#xa0;to&#xa0;develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to curtail or cease our operations.&#xa0;Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic considerations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Based on our current cash, we estimate that we will be able to fund our expenditure requirements for our current operations and planned clinical trial activities into the second quarter of&#xa0;2024.&#xa0;We have based these&#xa0;estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently plan due to incorrect assumptions or due to a decision to expand our&#xa0;activities beyond those currently planned. We previously have experienced delays&#xa0;in engaging clinical sites as a result of disruptions at these clinical sites caused by the COVID-19 pandemic.&#xa0;We also have experienced delays in clinical trial enrollment as a result of competition for patients. Delays in the conduct of our trials could result in utilizing our capital resources sooner without advancing our clinical trials as anticipated.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table sets forth the primary sources and uses of cash for the years ended December 31, 2022 and 2021:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Years Ended December 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2022</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2021</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17,778,964</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,284,924</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash provided (used) in investing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97,731</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(83,796</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash provided in financing activities</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,426</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,677,911</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17,674,807</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,309,191</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>Short Term Cash Requirements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We believe that our existing cash is sufficient to fund our expected short-term needs.&#xa0; We currently have certain fixed cash obligations with respect to development of materials used in our&#xa0;clinical studies&#xa0;and payment obligations associated with our ongoing conduct and monitoring of&#xa0;our Acclaim-1 and our Acclaim-2 clinical trials, and we expect that we have sufficient cash to cover these requirements. We do not expect our operations will require significant increases in our short-term cash needs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Long Term Cash Requirements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We regularly evaluate our business plans and strategy. These evaluations often result in changes to our business plans and strategy, some of which may be material and significantly change our cash requirements.&#xa0; Ongoing business development activity may require us to use some of our liquidity for an acquisition, or additional capital to fund newly acquired operations. If we raise additional funds by issuing equity securities, our existing security holders will likely experience dilution&#x37e; and the incurring of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that could restrict operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our future capital requirements depend on many factors, including, but not limited to:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the costs and timing of our development activities and preclinical and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the cost of manufacturing our existing and future products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the expenses needed to attract and retain skilled personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the costs associated with being a public company;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the costs associated with additional business development or mergers and acquisitions activity, including acquisition-related costs, earn-outs or other contingent payments and costs of developing and commercializing any technologies to which we obtain rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">third-party costs associated with the development and commercialization of our existing and future products and the ability of our development partners to satisfy our requirements on a timely basis;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the scope and terms of our business plans from time to time, and our ability to realize upon our business plans; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;width:93.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the&#xa0;costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Cash used in operating activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities was $17,778,964 and $14,284,924 for the years&#xa0;ended December 31, 2022 and 2021, respectively. The increase&#xa0;of $3,494,040, or 24%, in net cash used in operating activities&#xa0;in 2022&#xa0;was primarily due to us increasing our headcount from 15 full-time employees on&#xa0;December 31, 2021&#xa0;to 25 full-time employees on December 31, 2022, advancing our manufacturing programs, and the launch and continuing operations of our&#xa0;Acclaim-1 and Acclaim-2 clinical trials.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Cash used in investing activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash provided&#xa0;by&#xa0;investing activities was $97,731&#xa0;for the year ended&#xa0;on December 31, 2022 and net cash used in&#xa0;investment activities was&#xa0;$83,796 for the year&#xa0;ended&#xa0;December 31, 2021. The increase in net cash provided by&#xa0;investing activities of $181,527, or 217%,&#xa0;was primarily due to greater use of R&amp;D materials associated with testing and clinical use in our Acclaim clinical trials in the year ended December 31, 2022&#xa0;compared to the year ended&#xa0;December 31, 2021. Changes&#xa0;in intellectual property and research and development supplies during this period were negligible.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>Cash provided by financing activities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash provided by financing activities was $6,426 and $25,677,911 for the years ended December 31, 2022 and 2021, respectively. The&#xa0;decrease of $25,671,485, or 100%,&#xa0;in net cash provided by financing activities&#xa0;was primarily due to the $25,000,000 registered direct offering in February 2021 and there were no comparable capital raising activities throughout the year ended&#xa0;December 31, 2022.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_7A" title="Item_7A" href="#"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As a smaller reporting company, we are not required to provide the information called for by this item.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_8" title="Item_8" href="#"></a>Item 8. Financial Statements and Supplementary Data.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The financial statements and supplementary data required by this item are included after Part IV of this Annual Report on Form 10-K beginning on page F-1.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_9" title="Item_9" href="#"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">None.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_9A" title="Item_9A" href="#"></a>Item 9A. Controls and Procedures.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term &#x201c;disclosure controls and procedures&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to a company&#x2019;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in our internal control over financial reporting due to lack of segregation of duties.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><i>Management&#x2019;s Report on Internal Control over Financial Reporting</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Our principal executive officer and our principal accounting and financial officer are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management concluded that our internal controls over financial reporting were, and continue to be, ineffective as of December 31, 2022&#xa0;due to a material weakness in our internal controls due to the lack of segregation of duties.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">In light of the material weakness described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended December 31, 2022&#xa0;and as our operational activities increased, management determined and continues to determine that it does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to our size, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and has concluded that the control deficiency represents a material weakness.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Remediation Plans</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Management is actively engaged in remediation efforts to address the material weakness&#xa0;identified in the management&#x2019;s evaluation of internal&#xa0;controls and procedures. The remediation efforts, which have been or are in the process of being implemented, are intended to address the identified material weakness&#xa0;and include:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">new accounting software, processes, and workflows to further segregate duties among limited accounting staff;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">specific review procedures, including the added involvement of our General Counsel&#xa0;to review all accounting transactions following a given period in an effort to enhance accuracy of reporting;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">specific review procedures, including the added involvement of our manufacturing team,&#xa0;to enhance controls associated with the tracking and reporting of inventory&#xa0;values in our supply chain;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">a formal Disclosure Committee that has oversight responsibility for the accuracy and timeliness of disclosures made by the Company through controls and procedures and the monitoring of their integrity and effectiveness; and</td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">additional hiring of staff and development of accounting processes and policies to further segregate accounting responsibilities.&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">During the year ended December 31, 2022, we took&#xa0;actions to remediate the material weakness relating to our internal controls over financial reporting including:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the&#xa0;implementation of workflow approval processes in our accounting software to further segregate duties, enhance billing accuracy,&#xa0;and ensure transparency and oversight&#xa0;from department leaders, legal, and finance;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;"><b>&#xa0;</b></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the hiring of an IT consultant specialized in the evaluation and implementation of&#xa0;inventory management and quality systems software to ensure future implementation of systems with additional&#xa0;workflow and control functionality; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt; text-align: justify;">&#xa0;</td>
     <td style="width: 27pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">the hiring of an associate general counsel with SEC reporting experience to assist in the review and oversight of financial reporting and disclosure controls;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 3pt; margin: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As Management continues to evaluate and work to improve its&#xa0;internal&#xa0;control&#xa0;over financial reporting, we&#xa0;may take additional measures to address control deficiencies, or we&#xa0;may modify certain of the remediation measures described above. While remediation efforts are active, management requires additional time to demonstrate the operating effectiveness of our remediation efforts. The material weaknesses cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</p>
  <div style="font-size: 10pt;">
    &#xa0;
  </div>
  <div style="font-size: 10pt;">
   <b><i>Changes in Internal Control over Financial Reporting</i></b>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">There were no changes in our internal control over financial reporting&#xa0;during the year ended December 31, 2022&#xa0;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><i>Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_9B" title="Item_9B" href="#"></a>Item 9B. Other Information.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><a id="Item_9C" title="Item_9C" href="#"></a>Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">Not applicable.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     87
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="PART_III" title="PART_III" href="#"></a>PART&#xa0;III</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_10" title="Item_10" href="#"></a>Item 10. Directors, Executive Officers and Corporate Governance.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by this Item 10 is incorporated herein by reference&#xa0;to the information that will be contained in&#xa0;our definitive proxy statement (the &#x201c;Proxy Statement&#x201d;) for the 2023&#xa0;annual meeting of stockholders (the &#x201c;Annual Meeting&#x201d;),&#xa0;which is expected to be filed not later than 120&#xa0;days after the end of our fiscal year ended December 31, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">We have adopted a written Code of Business Conduct and Ethics, or Ethics Code, that applies to all of our officers, directors and employees. The Ethics Code is available on our website at&#xa0;www.genprex.com/investors/corporate-governance. We intend to satisfy the disclosure requirement under Item&#xa0;5.05 of Form&#xa0;8-K regarding an amendment to, or a waiver from, a provision of our Ethics Code that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and that relates to any element of the code of ethics definition enumerated in paragraph (b)&#xa0;of Item&#xa0;406 of the SEC&#x2019;s Regulation&#xa0;S-K, by posting such information on our website, www.genprex.com.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_11" title="Item_11" href="#"></a>Item 11. Executive Compensation.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by this Item 11 is incorporated herein by reference&#xa0;to the information that will be contained in&#xa0;our Proxy Statement for the Annual Meeting.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_12" title="Item_12" href="#"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by this Item 12&#xa0;is incorporated herein by reference&#xa0;to the information that will be contained in&#xa0;our Proxy Statement for the Annual Meeting.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_13" title="Item_13" href="#"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by this Item 13&#xa0;is incorporated herein by reference&#xa0;to the information that will be contained in&#xa0;our Proxy Statement for the Annual Meeting.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><a id="Item_14" title="Item_14" href="#"></a>Item 14. Principal Accountant&#xa0;Fees and Services.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by this Item 14&#xa0;is incorporated herein by reference&#xa0;to the information that will be contained in&#xa0;our Proxy Statement for the Annual Meeting.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="PART_IV" title="PART_IV" href="#"></a>PART IV</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><a id="Item_15" title="Item_15" href="#"></a>Item 15. Exhibits and&#xa0;Financial Statement Schedules.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(a)(1)</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 36pt;">The financial statements and supplementary data required by this item begin on page F-1.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(a)(2)</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Financial Statement Schedules.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 36pt;">All schedules are omitted because the required information is inapplicable or the information is presented in the financial statements and the related notes.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(a)(3)</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Exhibits.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     88
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><a id="Exhibits" href="#"></a>EXHIBIT INDEX</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Description of Exhibit</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000118518518000666/ex3-1.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on April 10, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">3.2</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000118518518000666/ex3-2.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of the Registrant, dated April 3, 2018, incorporated by reference to Exhibit 3.2 of the Registrant&#x2019;s Current Report on Form 8-K filed on April 10, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517286120/d415543dex41.htm" style="-sec-extract:exhibit;">Form of Common Stock Certificate of the Registrant, incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.2</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex46.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated November&#xa0;3, 2016, issued to Viet Ly, incorporated by reference to Exhibit 4.6 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.3</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517286120/d415543dex47.htm" style="-sec-extract:exhibit;">Form of Underwriter&#x2019;s Warrant Agreement, incorporated by reference to Exhibit 4.7 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.4</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018013042/gnpx-ex41_9.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on May 10, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.5</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018019446/gnpx-ex41_8.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated July 27, 2018, issued to Cancer Revolution, LLC, incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on August 6, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.6</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018019446/gnpx-ex42_7.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated July 27, 2018, issued to Inception Capital Management, LLC, incorporated by reference to Exhibit 4.2&#xa0;of the Registrant&#x2019;s Current Report on Form 8-K filed on August 6, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">4.7</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018019446/gnpx-ex43_6.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated July 27, 2018, issued to Cancer Biotech, LLC, incorporated by reference to Exhibit 4.3&#xa0;of the Registrant&#x2019;s Current Report on Form 8-K filed on August 6, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.8</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774919023451/ex_165668.htm" style="-sec-extract:exhibit;">Form of Warrant, incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Current Report on Form 8-K filed on November 22, 2019</a>.</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.9</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000143774920008700/ex_183249.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated April 24, 2020, issued to Cancer Revolution LLC, incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on April 28, 2020.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.10</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000143774921007317/ex_236861.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated August 10, 2020, issued to Capital City Technical Consulting, Inc., incorporated by reference to Exhibit 4.11 of the Registrant&#x2019;s Annual Report on Form 10-K filed on March 26, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.11</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000143774921007317/ex_237225.htm" style="-sec-extract:exhibit;">Amended and Restated Warrant&#xa0;Agreement, dated August&#xa0;10, 2020, issued to DABS Advanced Biotech Solutions, LLC., incorporated by reference to Exhibit 4.12 of the Registrant&#x2019;s Annual Report on Form 10-K filed on March 26, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.12</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000143774921007317/ex_237224.htm" style="-sec-extract:exhibit;">Amended and Restated Warrant&#xa0;Agreement, dated August&#xa0;10, 2020, issued to DABS Advanced Biotech Solutions, LLC., incorporated by reference to Exhibit 4.13 of the Registrant&#x2019;s Annual Report on Form 10-K filed on March 26, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.13</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000143774921002350/ex_225356.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated February 8, 2021, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on February 9, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.14</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921012395/ex_240206.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated February 10, 2021, issued to Bear Creek Capital LLC, incorporated by reference to Exhibit 4.1 of the Registrant&#x2019;s Quarterly Report on Form 10-Q filed on May 17, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.15</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921026629/ex_295742.htm" style="-sec-extract:exhibit;">Form of Warrant Agreement, dated as of July 1, 2021, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Quarterly Report on Form 10-Q filed on November 15, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.16</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774922020379/ex_407420.htm" style="-sec-extract:exhibit;">Warrant Agreement, dated as of July 1, 2022, issued to Bear Creek LLC, incorporated by reference to Exhibit 10.2 of the Registrant's Quarterly Report on Form 10-Q filed on August 12, 2022.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.17</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774923004771/ex_480883.htm" style="-sec-extract:exhibit;">Form of Warrant, dated March 1, 2023, incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K filed on February 27, 2023.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">4.18</td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="ex_451285.htm" style="-sec-extract:exhibit;">Description of Registrant's Securities.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">10.1</p> </td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774922020379/ex_407419.htm" style="-sec-extract:exhibit;">Form of Indemnity Agreement, by and between the Company and its directors and officers, dated as of May 17, 2022, incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q filed on August 12, 2022.</a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     89
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Description of Exhibit</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.2</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex102.htm" style="-sec-extract:exhibit;">Registrant&#x2019;s 2009 Equity Incentive Plan, including&#xa0;Form&#xa0;of Notice of Stock Option Grant, and Form of Stock Option Agreement thereunder, incorporated by reference to Exhibit 10.2 of the Registrant's Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.3</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000156459018008342/gnpx-ex103_159.htm" style="-sec-extract:exhibit;">Genprex, Inc. 2018 Equity Incentive Plan, dated April 3, 2018, including Form of Notice of Stock Option Grant, Form of Option Agreement, and Form of Notice of Exercise&#xa0;thereunder, incorporated by reference to Exhibit 10.3 of the Registrant&#x2019;s Annual Report on Form 10-K filed April 17, 2018.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">10.4</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">+</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000156459018008342/gnpx-ex104_158.htm" style="-sec-extract:exhibit;">Genprex, Inc. 2018 Employee Stock Purchase Plan, dated April 3, 2018, incorporated by reference to Exhibit 10.4 of the Registrant&#x2019;s Annual Report on Form 10-K filed April 17, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:top;width:91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">10.5</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">+</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018028631/gnpx-ex101_6.htm" style="-sec-extract:exhibit;">Genprex, Inc. Non-Employee Director Compensation Policy, dated November 2, 2018, incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on November 8, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:top;width:91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.6</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex106.htm" style="-sec-extract:exhibit;">Patent and Technology License Agreement, dated July 20, 1994, by and between the Board of Regents of the University of Texas System, The University of Texas M.D. Anderson Cancer Center and Intron Therapeutics, Inc., incorporated by reference to Exhibit 10.6 of the Registrant's Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.7</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex107.htm" style="-sec-extract:exhibit;">Amendment No. 3 to Patent and Technology License Agreement, dated October&#xa0;4, 2001, incorporated by reference to Exhibit 10.7 of the Registrant's Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.8</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex108.htm" style="-sec-extract:exhibit;">Technology Sublicense Agreement, dated&#xa0;March&#xa0;7, 2007, by and between Introgen Therapeutics, Inc., and Introgen Research Institute, Inc., incorporated by reference to Exhibit 10.8 of the Registrant's Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.9</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex109.htm" style="-sec-extract:exhibit;">Assignment and Collaboration Agreement, dated&#xa0;April&#xa0;13, 2009, by and between Gensolve, Inc. and the Registrant, incorporated by reference to Exhibit 10.9 of the Registrant's Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.10</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex1010.htm" style="-sec-extract:exhibit;">Technology License Agreement, dated February&#xa0;26, 2010, by and between Introgen Research Institute, Inc. and P53, Inc., incorporated by reference to Exhibit 10.10 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.11</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex1012.htm" style="-sec-extract:exhibit;">Technology Sublicense Agreement, dated&#xa0;June&#xa0;1, 2011, by and between the Registrant and Introgen Research Institute, Inc., incorporated by reference to Exhibit 10.12 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally&#xa0;filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.12</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517262354/d415543dex1013.htm" style="-sec-extract:exhibit;">Amended Collaboration and Assignment Agreement, dated July&#xa0;1, 2011, by and between Introgen Research Institute, Inc. and the Registrant, incorporated by reference to Exhibit 10.13 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.13</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517286120/d415543dex1014.htm" style="-sec-extract:exhibit;">Clinical Study Agreement, dated February&#xa0;10, 2014, by and between The University of Texas M.D. Anderson Cancer Center and the Registrant, incorporated by reference to Exhibit 10.14 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.14</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000119312517286120/d415543dex1015.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Clinical Study Agreement,&#xa0;dated June&#xa0;25, 2015, incorporated by reference to Exhibit 10.15 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.15</p> </td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000156459018008342/gnpx-ex1016_157.htm" style="-sec-extract:exhibit;">Executive Employment Agreement, dated April 13, 2018, by and between the Registrant and Rodney Varner, incorporated by reference to Exhibit 10.16 of the Registrant&#x2019;s Annual Report on Form 10-K filed on April 17, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.16</p> </td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/0001595248/000156459018008342/gnpx-ex1017_156.htm" style="-sec-extract:exhibit;">Executive Employment Agreement, dated April 13, 2018, by and between the Registrant and Ryan Confer, incorporated by reference to Exhibit 10.17 of the Registrant&#x2019;s Annual Report on Form 10-K filed on April 17. 2018.</a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     90
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Description of Exhibit</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.17</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:top;width:91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018013042/gnpx-ex102_6.htm" style="-sec-extract:exhibit;">Form of Registration Rights Agreement, dated May 6, 2018, incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 8-K filed on May 10, 2018.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:top;width:91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.18</p> </td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000156459018021749/gnpx-ex101_59.htm" style="-sec-extract:exhibit;">Consulting Agreement, dated August 13, 2018, by and between the Registrant and Viet Ly, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Quarterly Report on Form 10-Q filed on August 14, 2018.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: right;">10.19</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774919023451/ex_165667.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated November 20, 2019, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on November 22, 2019.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.20</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774920002863/ex_172373.htm" style="-sec-extract:exhibit;">Exclusive License Agreement, dated February 11, 2020, by and between the Registrant and the University of Pittsburgh &#x2013; Of the Commonwealth System of Higher Education, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on February 18, 2020.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.21</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774920003170/ex_173381.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated February 19, 2020, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on February 20, 2020.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.22</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774920005893/ex_177239.htm" style="-sec-extract:exhibit;">Executive Employment Agreement, dated March 12, 2020, by and between the Registrant and Catherine Vaczy, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on March 23, 2020.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.23</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774920005893/ex_177240.htm" style="-sec-extract:exhibit;">Executive Employment Agreement, dated March 12, 2020, by and between the Registrant and Michael Redman, incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Current Report on Form 8-K filed on March 23, 2020.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.24</td>
     <td style="vertical-align: top; width: 3%;">++</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921007317/ex_236118.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Patent and Technology License Agreement, dated March 3, 2021, by and between the Registrant and&#xa0;The University of Texas M.D. Anderson Cancer Center, incorporated by reference to Exhibit 10.29 of the Registrant&#x2019;s Annual Report on Form 10-K filed on March 26, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.25</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921007164/ex_236796.htm" style="-sec-extract:exhibit;">First Amendment to Executive Employment Agreement, dated March 24, 2021, by and between the Registrant and Catherine Vaczy, incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on March 25, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.26</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921007164/ex_236797.htm" style="-sec-extract:exhibit;">First Amendment to Executive Employment Agreement, dated March 24, 2021, by and between the Registrant and Michael Redman, incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Current Report on Form 8-K filed on March 25, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.27</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921022771/ex_287077.htm" style="-sec-extract:exhibit;">Offer Letter, dated September 27, 2021, by and between the Registrant and Mark S. Berger, M.D., incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Form 8-K filed on September 28, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.28</td>
     <td style="vertical-align: top; width: 3%;">+</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774921022771/ex_287079.htm" style="-sec-extract:exhibit;">Offer Letter dated September 27, 2021, by and between the Registrant and Hemant Kumar, PhD, incorporated by reference to Exhibit 10.3 of the Registrant&#x2019;s Current Report on Form 8-K filed on September 28, 2021.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.29</td>
     <td style="vertical-align: top; width: 3%;">++</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774922021064/ex_415027.htm" style="-sec-extract:exhibit;">First Amendment to Exclusive License Agreement, dated August 17, 2022, by and between Genprex, Inc. and the University of Pittsburgh - Of the Commonwealth System of Higher Education, incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on August 22, 2022.</a></td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       91
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Description of Exhibit</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.30</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774922027745/ex_449033.htm" style="-sec-extract:exhibit;">Equity Distribution Agreement, dated November 18, 2022, by and between Genprex, Inc. and JMP Securities LLC, incorporated by reference to Exhibit 1.1 of the Registrant's Current Report on Form 8-K filed on November 18, 2022.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.31</td>
     <td style="vertical-align: top; width: 3%;">++</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/ex_436276.htm" style="-sec-extract:exhibit;">Exclusive License Agreement, dated November 22, 2022, by and between Genprex, Inc. and the University of Pittsburgh - Of the Commonwealth System of Higher Education, incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on November 28, 2022.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.32</td>
     <td style="vertical-align: top; width: 3%;">++</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/ex_460640.htm" style="-sec-extract:exhibit;">Exclusive License Agreement, dated December 29, 2022, by and between Genprex, Inc. and the University of Pittsburgh - Of the Commonwealth System of Higher Education, incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on January 5, 2023.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">10.33</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1595248/000143774923004771/ex_480885.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated March 1, 2023, incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K filed on February 27, 2023.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">23.1</td>
     <td style="vertical-align: top; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="ex_451286.htm" style="-sec-extract:exhibit;">Consent of Daskzal Bolton LLP, Independent Registered Public Accounting Firm.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">31.1</td>
     <td style="vertical-align: top; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="ex_451287.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) of the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: right;">31.2</p> </td>
     <td style="vertical-align: top; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_451288.htm" style="-sec-extract:exhibit;">Certification of Chief&#xa0;Financial Officer Pursuant to Rules 13a-14(a) of the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: right;">32.1</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">**</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_451289.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.INS</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Instance Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.SCH</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Taxonomy Extension Schema Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.CAL</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.DEF</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.LAB</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: middle; width: 3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: middle; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101.PRE</p> </td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inline XBRL Taxonomy Extension Presentation Document.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%; text-align: right;">104</td>
     <td style="vertical-align: bottom; width: 3%;">*</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: Times New Roman; font-size: 10pt;">
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: justify;">*</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: justify;">Filed herewith.</p> </td>
    </tr>

    <tr>
     <td style="width: 27pt; font-family: Times New Roman; font-size: 10pt;">**</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">Furnished herewith.</td>
    </tr>

   </tbody>
  </table>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">+</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Indicates management contract or compensatory plan.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">++</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><a id="Item_16" title="Item_16" href="#"></a>Item 16. Form 10&#x2013;K Summary.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27.8pt;">None.</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     92
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Sig" title="Sig" href="#"></a>SIGNATURES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27.8pt;">Pursuant to the requirements of Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:59.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td colspan="2" style="vertical-align:top;width:40%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GENPREX, INC.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;">&#xa0;</td>
     <td colspan="2" style="vertical-align:top;width:40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;">&#xa0;</td>
     <td colspan="2" style="vertical-align:top;width:40%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 31, 2023</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p> </td>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:36.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ J. Rodney Varner</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p> </td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:36.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">J. Rodney Varner</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p> </td>
     <td style="vertical-align:top;width:36.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:59.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p> </td>
     <td style="vertical-align:top;width:36.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27.8pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Signature</b></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title</b></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:20%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">/s/ J. Rodney Varner</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Chief Executive Officer and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Chairman of the Board of Directors</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 20%; text-align: center;">March 31, 2023</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">J. Rodney Varner</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>(Principal Executive Officer)</i></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:20%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:20%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">/s/ Ryan M. Confer</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Chief Financial Officer</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 20%; text-align: center;">March 31, 2023</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Ryan M. Confer</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>(Principal Financial and Accounting Officer)</i></p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:20%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:20%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">/s/ Brent Longnecker</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 39%; text-align: center;">Member of the Board of Directors</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%; text-align: center;">March 31, 2023</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Brent Longnecker</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">/s/ Jose Antonio Moreno Toscano</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 39%; text-align: center;">Member of the Board of Directors</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%; text-align: center;">March 31, 2023</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Jose Antonio Moreno Toscano</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:20%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">/s/ Will R. Wilson, Jr.</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 39%; text-align: center;">Member of the Board of Directors</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 20%; text-align: center;">March 31, 2023</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;border-bottom: 1px #000000;;width:39%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Will R. Wilson, Jr.</p> </td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:20%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     93
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Fin_State" title="Fin_State" href="#"></a>GENPREX, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>INDEX TO&#xa0;FINANCIAL STATEMENTS</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#Report">Report of Independent Registered Public Accounting Firm</a>&#xa0;(PCAOB ID Number&#xa0;0<ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2022-01-01_2022-12-31">229</ix:nonNumeric>)</p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Report">F-2</a></p> </td></tr>
<tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#BS">Balance Sheets</a>&#xa0;- December 31, 2022 and December 31, 2021</p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#BS">F-3</a></p> </td></tr>
<tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#Ops">Statements of Operations</a>&#xa0;- December 31, 2022 and December 31, 2021</p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Ops">F-4</a></p> </td></tr>
<tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#Equity">Statements of Changes in Stockholders&#x2019; Equity</a>&#xa0;- December 31, 2022 and December 31, 2021</p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Equity">F-5</a></p> </td></tr>
<tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#Flows">Statements of Cash Flows</a>&#xa0;- December 31, 2022 and December 31, 2021</p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Flows">F-6</a></p> </td></tr>
<tr><td style="vertical-align:bottom;width:94%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-12pt;"><a style="-sec-extract:exhibit;" href="#Notes">Notes to Financial Statements</a></p> </td><td style="vertical-align:bottom;width:1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> </td><td style="vertical-align:bottom;width:5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><a class="tocPGNUM" href="#Notes">F-7</a></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&#xa0;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
  F-1
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  &#xa0;
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><span style="text-decoration: underline; "><a id="Report" title="Report" href="#"></a>Report of Independent Registered Public Accounting Firm</span></b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">To the Board of Directors and</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">Stockholders of Genprex, Inc.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">Austin, Texas</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; ">Opinion on the Financial Statements</span></i></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">We have audited the accompanying balance sheets of Genprex, Inc. (the &#x201c;Company&#x201d;) at December 31, 2022 and 2021, and the related statements of operations, changes in stockholders&#x2019; equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two- year period ended December 31, 2022 and 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; ">Emphasis of Matter</span></i></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">As discussed in Note 2, the accompanying financial statements at and for the year ended December 31, 2021 have been revised.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; ">Basis for Opinion</span></i></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; ">Critical Audit Matters</span></i></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as whole, and we are not, by communicating the critical matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; ">Valuation of equity transactions</span></i></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">As described in the Equity Note to the financial statements, the Company has complex equity transactions including the use of stock options and warrants. The estimates that management used in calculating the price value depend on assumptions specific to the nature of the management service activities with regard to the amount of the price model.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">The principal consideration for our determination surrounding equity transactions as a critical audit matter is the significant judgment by management when developing the valuation of options and warrants. This, in turn, led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#x2019;s significant assumptions related to the price model used to calculate equity transactions.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt; text-align: justify;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included evaluating the use of the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date, and recognizes the expense over the periods in which the related services are rendered based on the terms and conditions of the awards. Evaluation of management&#x2019;s assumptions related to the price model and evaluating whether assumptions used by management were reasonable considering the current and past performance of equity, the consistency, and whether these assumptions were consistent with evidence obtained in other areas of the audit.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2022-01-01_2022-12-31">Daszkal Bolton LLP</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">We have served as the Company&#x2019;s auditor since 2014.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2022-01-01_2022-12-31">Boca Raton, FL</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 0pt;">March 31, 2023</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
  F-2
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  &#xa0;
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="BS" title="BS" href="#"></a>Genprex, Inc. </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Balance Sheets </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td colspan="5" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td colspan="5" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021 (Revised)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><span style="text-decoration: underline; ">Assets</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223861" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:numdotdecimal" decimals="INF">20,954,069</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223862" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Cash" scale="0" format="ixt:numdotdecimal" decimals="INF">38,628,876</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223863" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">34,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223864" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223865" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">484,224</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223866" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">511,348</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223867" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">21,473,145</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223868" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">39,140,224</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223869" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">23,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223870" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">48,608</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;">Other assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 0pt;">Security deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223872" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">21,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223873" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">8,691</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0px; margin: 0px; text-indent: 9pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Supplies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c96223874" contextRef="i_2022-12-31" unitRef="USD" name="gnpx:ResearchAndDevelopmentAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,864,937</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"><ix:nonFraction id="c96223875" contextRef="i_2021-12-31" unitRef="USD" name="gnpx:ResearchAndDevelopmentAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,022,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 0pt;">Intellectual property, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223876" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" format="ixt:numdotdecimal" decimals="INF">702,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223877" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" format="ixt:numdotdecimal" decimals="INF">642,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223878" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,588,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223879" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,673,454</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223880" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">25,085,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223881" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">42,862,286</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><span style="text-decoration: underline; ">Liabilities and Stockholders' Equity</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223884" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">442,925</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223885" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">973,195</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223886" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,367,362</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223887" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">612,100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223888" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,810,287</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223889" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,585,295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Stockholders' equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock $<span style="-sec-ix-hidden:c96223893"><span style="-sec-ix-hidden:c96223894">0.001</span></span> par value: <span style="-sec-ix-hidden:c96223895"><span style="-sec-ix-hidden:c96223896">200,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c96223897"><span style="-sec-ix-hidden:c96223899">48,105,962</span></span> and <span style="-sec-ix-hidden:c96223898"><span style="-sec-ix-hidden:c96223900">47,874,708</span></span> shares issued and outstanding, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223891" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">48,106</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223892" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223901" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">125,054,453</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223902" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">120,316,315</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223903" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">102,827,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223904" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">79,087,198</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223905" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">22,274,740</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223906" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,276,991</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223907" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">25,085,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223908" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">42,862,286</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to the financial statements</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     F-3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Ops" title="Ops" href="#"></a>Genprex, Inc. </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Statements of Operations </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021 (Revised)</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Revenues</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223915" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223916" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cost and expenses:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223918" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">25,575</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223919" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,534</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223920" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">11,510,074</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223921" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,970,865</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223922" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">12,295,070</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223923" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">11,676,703</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Total costs and expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223924" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">23,830,719</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223925" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">20,670,102</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Operating loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96223926" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">23,830,719</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96223927" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,670,102</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223928" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">90,098</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223929" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">5,133</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96223930" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">23,740,621</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96223931" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,664,969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net loss per share &#x2014; basic and diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96223932" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.50</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96223933" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.44</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Weighted average number of common shares &#x2014; basic and diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223934" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,952,100</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223935" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,097,251</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     F-4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Equity" title="Equity" href="#"></a>Genprex, Inc.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Statements of Changes in Stockholders&#x2019; Equity </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Common Stock</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Shares</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Amount</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Total</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2020</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223946" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">43,117,681</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223947" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">43,118</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223948" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">89,295,601</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96223949" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,422,229</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223950" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">30,916,490</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issuance of stock for cash</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223951" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">4,670,889</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223952" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">4,670</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223953" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">25,673,241</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223954" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223955" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">25,677,911</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issuance of stock for services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223956" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">86,138</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223957" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">86</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223958" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">155,959</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223959" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223960" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">156,045</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Share based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223962" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223963" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">5,191,514</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223964" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223965" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">5,191,514</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223967" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223968" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223969" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,664,969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223970" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,664,969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2021</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223971" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874,708</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223972" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223973" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">120,316,315</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96223974" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">79,087,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223975" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,276,991</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issuance of stock for cash</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223976" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">120,859</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223977" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223978" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">6,305</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223979" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223980" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">6,426</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issuance of stock for services</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223981" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">110,395</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223982" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">111</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223983" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">163,121</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223984" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223985" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">163,232</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Share based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223987" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223988" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4,568,712</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223989" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96223990" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4,568,712</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223992" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96223993" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223994" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">23,740,621</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96223995" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">23,740,621</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Balance at December 31, 2022</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223996" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">48,105,962</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223997" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">48,106</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96223998" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">125,054,453</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96223999" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">102,827,819</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224000" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">22,274,740</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     F-5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Flows" title="Flows" href="#"></a>Genprex, Inc.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Statements of Cash Flows </b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td colspan="5" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended</em></em></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td colspan="5" rowspan="1" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2021</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash flows from operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224008" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">23,740,621</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224009" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">20,664,969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224011" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">25,575</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224012" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,534</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Share based compensation</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224013" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">4,731,944</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224014" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">5,347,559</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Accounts receivable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224016" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">34,852</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224017" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">127</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224018" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">27,125</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224019" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">126,795</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Deposits</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224020" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">13,127</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224021" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,050</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224022" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">530,269</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224023" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">780,226</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0px; margin: 0px; text-indent: 18pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Other current liabilities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224024" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,755,262</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224025" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">354,344</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224026" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">17,778,964</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224027" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,284,924</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash flows from investing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Additions to property and equipment</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224029" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224030" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">31,700</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Additions to intellectual property</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224031" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">59,735</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224032" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">40,735</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%; padding: 0px; margin: 0px; text-indent: 9pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Reductions (additions) to research and development supplies</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224033" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">157,465</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224034" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies" scale="0" format="ixt:numdotdecimal" decimals="INF">11,361</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash provided by (used in) investing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224035" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">97,731</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224036" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">83,796</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash flows from financing activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuances of common stock</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224038" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">6,426</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224039" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">25,677,911</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224040" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">6,426</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224041" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">25,677,911</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224042" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">17,674,807</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224043" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">11,309,191</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash, beginning of year</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224044" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">38,628,876</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224045" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">27,319,685</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Cash, end of year</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224046" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">20,954,069</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224047" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">38,628,876</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to the financial statements</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 10pt;">
     F-6
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="Notes" title="Notes" href="#"></a>Genprex, Inc. </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Notes to Financial Statements </b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2343482" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">1</em> &#x2013; Description of Business and Basis of Presentation</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <div style="font-variant: normal; text-align: justify;">
       We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.&#xa0;Our oncology platform utilizes our non-viral ONCOPREX&#xae; Nanoparticle Delivery System.&#xa0;Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type
      <em style="font: inherit;">1</em> diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. In Type
      <em style="font: inherit;">2</em> diabetes, our&#xa0;technology is believed to work by replenishing and rejuvenating the beta cells&#xa0;that make insulin.
     </div>
     <div style="font-variant: normal; text-align: justify;">
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Oncology Platform</span></i></p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Our lead oncology drug candidate, REQORSA&#xae; Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-<em style="font: inherit;">001,</em> is initially being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (&#x201c;NSCLC&#x201d;) and Small Cell Lung Cancer (&#x201c;SCLC&#x201d;).&#xa0;The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named <em style="font: inherit;">TUSC2.</em> REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#xa0;We believe REQORSA&#x2019;s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, and that it can improve on current therapies.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#x2013; <em style="font: inherit;">1:</em> We currently are enrolling and treating patients in the Phase <em style="font: inherit;">1</em> dose escalation portion of our Phase&#xa0;<em style="font: inherit;">1/2</em>&#xa0;Acclaim-<em style="font: inherit;">1</em>&#xa0;clinical trial.&#xa0;The Acclaim-<em style="font: inherit;">1</em>&#xa0;trial uses a combination of REQORSA and AstraZeneca PLC&#x2019;s Tagrisso&#xae; in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#x201c;EGFR&#x201d;) mutations and progression after treatment with Tagrisso. In&#xa0;<em style="font: inherit;"> August 2022,&#xa0;</em>the Acclaim-<em style="font: inherit;">1</em>&#xa0;Safety Review Committee (&#x201c;Acclaim-<em style="font: inherit;">1</em> SRC&#x201d;) approved escalating the dose from&#xa0;<em style="font: inherit;">0.06</em>&#xa0;mg/kg in the&#xa0;<em style="font: inherit;">first</em>&#xa0;cohort of patients to&#xa0;<em style="font: inherit;">0.09</em>&#xa0;mg/kg in the&#xa0;<em style="font: inherit;">second</em>&#xa0;cohort of patients and in <em style="font: inherit;"> December 2022,&#xa0;</em>the SRC approved escalating the dose from <em style="font: inherit;">0.09</em> mg/kg in the <em style="font: inherit;">second</em> cohort to <em style="font: inherit;">0.12</em> mg/kg in the <em style="font: inherit;">third</em> and final cohort. We are thus enrolling and treating patients at the <em style="font: inherit;">0.12</em> mg/kg dose&#xa0;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle <em style="font: inherit;">one</em> of treatment for the remaining untreated patients, the Acclaim-<em style="font: inherit;">1</em> SRC will meet and establish the maximum tolerated dose ("MTD") or recommended Phase <em style="font: inherit;">2</em> dose (<em style="font: inherit;">"RP2D"</em>). We will then proceed into the dose expansion portion of the study. The Food and Drug Administration (&#x201c;FDA&#x201d;) has granted Fast Track Designation for the Acclaim-<em style="font: inherit;">1</em>&#xa0;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#x2013; <em style="font: inherit;">2:</em> We&#xa0;currently are enrolling and treating patients in the Phase <em style="font: inherit;">1</em> dose escalation portion of our Phase&#xa0;<em style="font: inherit;">1/2</em>&#xa0;Acclaim-<em style="font: inherit;">2</em>&#xa0;clinical trial.&#xa0;The Acclaim-<em style="font: inherit;">2</em>&#xa0;trial uses a combination of REQORSA and Merck &amp; Co.&#x2019;s Keytruda&#xae; in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are currently being treated at the <em style="font: inherit;">0.06</em> mg/kg dose level in the <em style="font: inherit;">first</em> cohort of patients and, subject to the Acclaim-<em style="font: inherit;">2</em> Safety Review Committee approval, will be treated at successive dose levels of <em style="font: inherit;">0.09</em> mg/kg and <em style="font: inherit;">0.12</em> mg/kg. In <em style="font: inherit;"> March 2023, </em>we amended the Acclaim-<em style="font: inherit;">2</em> protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the dose escalation portion of&#xa0;the study to be completed by the end of <em style="font: inherit;">2023.</em> We will then evaluate patients in the dose expansion portion of the study at the MTD or <em style="font: inherit;">RP2D.</em> The FDA has granted Fast Track Designation for the Acclaim-<em style="font: inherit;">2</em>&#xa0;treatment combination of REQORSA and Keytruda in NSCLC patients who have progressed after Keytruda treatment.&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;">The dose expansion portion of Acclaim-<em style="font: inherit;">2</em> is a Phase <em style="font: inherit;">2</em> study and the dose expansion portion of Acclaim-<em style="font: inherit;">1</em> will be considered a Phase <em style="font: inherit;">2</em> study upon the filing with the FDA of an upcoming protocol amendment.&#xa0;The dose expansion provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the MTD or <em style="font: inherit;">RP2D</em> in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase <em style="font: inherit;">2</em> trial which will follow the dose expansion portions of each study.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#x2013; <em style="font: inherit;">3:</em> In <em style="font: inherit;"> November 2022, </em>we filed with the FDA our protocol for our Phase <em style="font: inherit;">1/2</em> Acclaim-<em style="font: inherit;">3</em> clinical trial using a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq&#xae; as maintenance therapy in patients with extensive stage small cell lung cancer (&#x201c;ES-SCLC&#x201d;) who did <em style="font: inherit;">not</em> develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. We expect to dose the <em style="font: inherit;">first</em> patient in Acclaim-<em style="font: inherit;">3</em> by the end of&#xa0;the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2023.</em> Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">TUSC2</em> gene is <em style="font: inherit;">one</em> of a series of genes on the short arm of Chromosome <em style="font: inherit;">3</em> whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").&#xa0;We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates. In <em style="font: inherit;"> August 2022, </em>we entered into a sponsored research agreement with MD Anderson to support further pre-clinical studies of <em style="font: inherit;">TUSC2</em> and other tumor suppressor genes.</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Diabetes Gene Therapy</span></i></p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#xa0;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d;) multiple technologies relating to the development of a gene therapy product for each of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> diabetes.&#xa0;The same general novel approach is used in each of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> whereby an adeno-associated virus (&#x201c;AAV&#x201d;) vector containing the <em style="font: inherit;">Pdx1</em> and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-<em style="font: inherit;">002</em> is being developed for the treatment of Type <em style="font: inherit;">1</em> diabetes and GPX-<em style="font: inherit;">003</em> is being developed for the treatment of Type <em style="font: inherit;">2</em> diabetes. GPX-<em style="font: inherit;">002</em> is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. GPX-<em style="font: inherit;">003</em> is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of <em style="font: inherit;">2023</em> to obtain their guidance on the toxicology studies that we plan to conduct. In <em style="font: inherit;"> August 2022, </em>we entered into a <em style="font: inherit;">one</em>-year sponsored research agreement with the University of Pittsburgh for the use of GPX-<em style="font: inherit;">003</em> in a non-human primate (&#x201c;NHP&#x201d;) model in Type <em style="font: inherit;">2</em> diabetes and we expect data from this study to be reported by the end of <em style="font: inherit;">2023.</em> In <em style="font: inherit;"> February 2023, </em>the Company&#x2019;s research collaborators at the&#xa0;University of Pittsburgh&#xa0;presented preclinical data in a NHP model of Type <em style="font: inherit;">1</em> diabetes highlighting the therapeutic potential of GPX-<em style="font: inherit;">002</em> at the <em style="font: inherit;">16th</em> International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD <em style="font: inherit;">2023</em>) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.</p>
     </div>
     <div style="font-variant:normal">
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
     </div>
    </div>
   </div>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Capital Requirements, Liquidity and Going Concern Considerations</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP") applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have <em style="font: inherit;">no</em> current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our patents.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property.&#xa0; To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, <em style="font: inherit;">no</em> assurances can be given that we will be successful in raising additional capital.&#xa0; If we are <em style="font: inherit;">not</em> able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations will continue to be materially affected. These financial statements do <em style="font: inherit;">not</em> include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2343483" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">2</em> &#x2013; Summary of Significant Accounting Policies</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our financial statements have been prepared in accordance with GAAP.&#xa0; Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion the financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the financial statements <em style="font: inherit;">not</em> misleading. The results of operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of results to be expected for the full year. A summary of our significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="gnpx:CorrectionOfErrorPolicyTextBlock" id="c96228147" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Correction of Immaterial Error</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Subsequent to the issuance of the Company's <em style="font: inherit;">2021</em> financial statements on <em style="font: inherit;"> March 30, 2022, </em>management discovered that it did <em style="font: inherit;">not</em> recognize share-based compensation expense over the service periods for awards with cliff-vesting provisions. The following table summarizes the impacts of this error correction on the Company's financial statements for <em style="font: inherit;">2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In accordance with Staff Accounting Bulletin (&#x201c;SAB&#x201d;) <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#x201c;Materiality,&#x201d; and SAB <em style="font: inherit;">No.</em> <em style="font: inherit;">108,</em> &#x201c;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,&#x201d; the Company evaluated the error and determined that the related impact did <em style="font: inherit;">not</em> materially misstate previously issued financial statements. Although the Company concluded that the misstatement was <em style="font: inherit;">not</em> material to its previously issued financial statements, the Company has determined it is appropriate to adjust its previously issued financial statements to correct for the error in the context of comparative financial statements. The following are the relevant line items from the Company&#x2019;s financial statements which illustrate the effect of the corrections to the period presented:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="gnpx:CorrectionOfErrorsTableTextBlock" id="c2343484" escape="true">
    <table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224231" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">42,862,286</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224233" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">42,862,286</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224234" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,585,295</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224236" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,585,295</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224237" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224239" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,874</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional paid-in capital</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224240" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">119,246,970</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224241" contextRef="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">1,069,345</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224242" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">120,316,315</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accumulated deficit</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224243">(78,017,853)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224244">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224245">(79,087,198)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224246" contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,276,991</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224248" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">41,276,991</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">For the Year ended December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statement of Operations</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;">&#xa0;</td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224258" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,534</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224260" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">22,534</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224261" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,607,751</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224262" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">363,114</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224263" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,970,865</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224264" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">10,970,472</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224265" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">706,231</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224266" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">11,676,703</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total costs and expenses</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224267" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">19,600,757</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224268" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">1,069,345</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224269" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">20,670,102</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Operating loss</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224270">(19,600,757)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224271">(1,069,345)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224272">(20,670,102)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224273" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">5,133</ix:nonFraction></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonFraction id="c96224275" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">5,133</ix:nonFraction></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net Loss</p> </td><td style="vertical-align: middle; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224276">(19,595,624)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224277">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224278">(20,664,969)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Loss per share</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224279">(0.42)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224280">(0.02)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224281">(0.44)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Weighted average common shares outstanding</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><ix:nonFraction id="c96224282" contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,097,251</ix:nonFraction></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#xa0;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><ix:nonFraction id="c96224284" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,097,251</ix:nonFraction></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:UseOfEstimates" id="c96228148" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c96228149" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Cash</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We consider all highly liquid short-term investments with an initial maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have <ix:nonFraction id="c96224172" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash equivalents, and had $<ix:nonFraction id="c96224174" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashUninsuredAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">20,679,538</ix:nonFraction> and $<ix:nonFraction id="c96224175" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashUninsuredAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">38,392,885</ix:nonFraction>&#xa0;in excess of FDIC insured limits of <em style="font: inherit;">$250,000</em> at <em style="font: inherit;"> December 31, 2022</em>&#xa0;and <em style="font: inherit;"> December 31, 2021</em>&#xa0;respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c96228150" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Fair Value of Financial Instruments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting Standards Codification ("ASC") <em style="font: inherit;">820,</em> Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC <em style="font: inherit;">820&#x2019;s</em> valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC <em style="font: inherit;">820</em> classifies these inputs into the following hierarchy:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <table style="width: 100%; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#xa0;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for identical instruments in active markets.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#xa0;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#xa0;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#xa0;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#xa0;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Instruments with primarily unobservable value drivers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c96228151" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Property and Equipment</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96224189">three</span> to <span style="-sec-ix-hidden:c96224190">five</span> years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c96228152" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Research and Development Materials Costs</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#xa0;for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#xa0;wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase <em style="font: inherit;">1/2</em>&#xa0;clinical trials and are expensed as incurred. Materials produced&#xa0;to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or&#xa0;clinical activities, or have spoiled.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development supplies purchased and capitalized for future use were&#xa0;$<ix:nonFraction id="c96224193" contextRef="i_2022-12-31" unitRef="USD" name="gnpx:ResearchAndDevelopmentAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,864,937</ix:nonFraction> and $<ix:nonFraction id="c96224194" contextRef="i_2021-12-31" unitRef="USD" name="gnpx:ResearchAndDevelopmentAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,022,403</ix:nonFraction> at <em style="font: inherit;"> December 31, 2022</em>&#xa0;and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c96228153" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Intellectual Property</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Intellectual property consists of&#xa0;legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c96228154" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Accounting for Stock-Based Compensation</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&#xa0;&#xa0;We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c96228155" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Long-Lived Assets</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows.&#xa0;During the years ended <em style="font: inherit;"> December 31, 2022</em>&#xa0;and <em style="font: inherit;"> December 31, 2021</em>, there were <ix:nonFraction id="c96224197" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> deemed impairments of our long-lived assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c96228156" escape="true"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Recent Accounting Developments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting pronouncements issued but <em style="font: inherit;">not</em> effective until after <em style="font: inherit;"> December 31, 2022</em>&#xa0;are <em style="font: inherit;">not</em> expected to have a significant effect on our financial condition, results of operations, or cash flows.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c2343485" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">3</em> &#x2013; Intellectual Property</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We own or have exclusive license agreements on <em style="font: inherit;">15</em>&#xa0;granted patents and <em style="font: inherit;">24</em>&#xa0;pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson,&#xa0;the University of Texas Southwestern Medical Center, and the University of Pittsburgh.&#xa0;These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>University of Pittsburgh</i></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 11, 2020, </em>we entered into an exclusive&#xa0;license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> diabetes. This license was <em style="font: inherit;">first</em> amended on <em style="font: inherit;"> August 17, 2022, </em>to extend the&#xa0;milestone related to the filing of a new investigational drug ("IND") application. This license was amended again on <em style="font: inherit;"> November 3, 2022, </em>to include a new licensed glucagon promoter technology&#xa0;related to Type <em style="font: inherit;">1</em> diabetes and set FDA and clinical milestones related to the glucagon technology.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> November 22, 2022, </em>we entered into an&#xa0;exclusive&#xa0;license agreement with the University of Pittsburgh relating to the transformation of macrophages enabling them to reduce autoimmunity activity in Type <em style="font: inherit;">1</em> diabetes.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> December 29, 2022, </em>we entered into an&#xa0;exclusive&#xa0;license agreement with the University of Pittsburgh&#xa0;relating to the use of an insulin promoter in combination with our existing gene therapy, including the <em style="font: inherit;">Pdx1</em> and MafA transcription factors, as a potential treatment for Type <em style="font: inherit;">2</em> diabetes.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>The University of Texas MD Anderson Cancer Center</i></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> May 4, 2020, </em>we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating&#xa0;to a portfolio of patent applications and related technology for the treatment of cancer using our&#xa0;lead drug candidate and immunotherapies.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2343486" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">4</em>&#xa0;&#x2013; Equity</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Registered Direct Offerings</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 10, 2021, </em>we completed a registered direct offering&#xa0;in which we sold to investors an aggregate of <ix:nonFraction id="c96224298" contextRef="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">4,000,000</ix:nonFraction> shares of our common stock at $<ix:nonFraction id="c96224299" contextRef="i_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">6.25</ix:nonFraction> per share.&#xa0;We received net proceeds of approximately $<ix:nonFraction id="c96224300" contextRef="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">23.2</ix:nonFraction> million after commissions and expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">See &#x201c;Note <em style="font: inherit;">10</em>&#xa0;&#x2013; Subsequent Events &#x2013; <em style="font: inherit;"> March 2023 </em>Registered Direct Offering&#x201d; for a description of the Company&#x2019;s registered direct offering of shares and warrants in <em style="font: inherit;"> March 2023 </em>resulting in net proceeds of approximately $<ix:nonFraction id="c96224302" contextRef="d_2023-03-01_2023-03-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">3.6</ix:nonFraction> million.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>At-The Market Offering</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> November 18, 2022, </em>we&#xa0;entered into an Equity Distribution Agreement with JMP Securities LLC&#xa0;("JMP Securities") pursuant to which we&#xa0;<em style="font: inherit;"> may </em>sell from time to time, at our option, shares of our common stock through JMP Securities, as sales agent (the <em style="font: inherit;">"2022</em> ATM Facility"), up to an aggregate offering price of&#xa0;$<ix:nonFraction id="c96224304" contextRef="d_2022-11-18_2022-11-18_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="USD" name="gnpx:CommonStockSharesAuthorizedValue" scale="6" format="ixt:numdotdecimal" decimals="-7">50</ix:nonFraction> million. Sales of the shares were, and if any future sales, will be made&#xa0;under the our previously filed and currently effective Registration Statement on Form S-<em style="font: inherit;">3</em> (Reg. <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">239134</em>), by means of ordinary brokers&#x2019; transactions on the NASDAQ Global Market or otherwise. Additionally, under the terms of the Sales Agreement, the shares <em style="font: inherit;"> may </em>be sold at market prices, at negotiated prices or at prices related to the prevailing market price. We&#xa0;will pay JMP Securities&#xa0;a commission of&#xa0;<ix:nonFraction id="c96224309" contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="Pure" name="gnpx:BrokerageCommissionsPercentageOfGrossProceeds" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>%&#xa0;of the gross proceeds from the sale of the shares. During the year ended <em style="font: inherit;"> December 31, 2022</em>, we sold <ix:nonFraction id="c96224310" contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">3,886</ix:nonFraction>&#xa0;shares for aggregate net proceeds of&#xa0;$<ix:nonFraction id="c96224311" contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">4,532</ix:nonFraction> under the <em style="font: inherit;">2022</em> ATM Facility.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Stock Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2022</em>, we&#xa0;issued (i) <ix:nonFraction id="c96224313" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">20,000</ix:nonFraction> shares of common stock for services provided to us&#xa0;valued at $<ix:nonFraction id="c96224314" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">42,400</ix:nonFraction>&#xa0;to the Chairman of our Scientific Advisory Board, (ii)&#xa0;<ix:nonFraction id="c96224315" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">13,643</ix:nonFraction> shares of common stock upon the exercise of warrants on a cashless basis, (iii) <ix:nonFraction id="c96224316" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">116,973</ix:nonFraction> shares of common stock upon the exercise of options by an executive, and (iv)&#xa0;<ix:nonFraction id="c96224317" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">76,752</ix:nonFraction> shares of common stock for services provided to us, valued at $<ix:nonFraction id="c96224318" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">99,010</ix:nonFraction>, to consultants.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2021</em>, we issued (i) <ix:nonFraction id="c96224319" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">670,889</ix:nonFraction> shares of common stock from the exercise of options for cash proceeds of $<ix:nonFraction id="c96224320" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">677,912</ix:nonFraction>, and (ii) <ix:nonFraction id="c96224321" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="gnpx:StockIssuedDuringPeriodSharesWarrantsIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">86,138</ix:nonFraction> shares of common stock for services provided to us,&#xa0;valued at $<ix:nonFraction id="c96224323" contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">154,648</ix:nonFraction>, to consultants.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Preferred Stock</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are&#xa0;authorized to issue <ix:nonFraction id="c96224325" contextRef="i_2018-04-03" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction> shares of preferred stock at a par value of $<ix:nonFraction id="c96224327" contextRef="i_2018-04-03" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share, <span style="-sec-ix-hidden:c96224328">none</span> of which are outstanding as of <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Common Stock</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are&#xa0;authorized to issue <ix:nonFraction id="c96224329" contextRef="i_2018-04-03" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000,000</ix:nonFraction> shares of common stock at a par value of $<ix:nonFraction id="c96224331" contextRef="i_2018-04-03" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share, all of which is voting common stock. There were <ix:nonFraction id="c96224332" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">48,105,962</ix:nonFraction>&#xa0;shares of common stock outstanding at <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><span style="text-decoration: underline; "><i>Common Stock Purchase Warrants</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Common stock purchase warrant activity for the years ended&#xa0;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> respectively are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2343487" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Warrants</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224435" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,154,747</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224436" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.37</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224437" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightIssuedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224438" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.29</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224439" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightCancelledDuringPeriod" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224440" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224441" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224442" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224443" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,204,747</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224444" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.39</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224445" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightIssuedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">103,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224446" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.54</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224447" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightCancelledDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">146,326</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224448" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.79</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224449" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">13,643</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224450" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.50</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224451" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,147,778</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224452" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.32</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><ix:nonFraction id="c96224453" contextRef="i_2022-12-31" unitRef="Share" name="gnpx:ClassOfWarrantOrRightExercisable" scale="0" format="ixt:numdotdecimal" decimals="INF">1,901,945</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><ix:nonFraction id="c96224454" contextRef="i_2022-12-31" unitRef="USDPerShare" name="gnpx:ClassOfWarrantOrRightExercisableExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.59</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2022</em>, we&#xa0;issued (i) a warrant&#xa0;to purchase up to <ix:nonFraction id="c96224334" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>&#xa0;shares of common stock to a service provider&#xa0;at an exercise price of $<ix:nonFraction id="c96224335" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.38</ix:nonFraction>&#xa0;per share, the fair market value of a share of common stock on the date of issuance, (ii) a warrant&#xa0;to purchase up to <ix:nonFraction id="c96224337" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>&#xa0;shares of common stock to a service provider&#xa0;at an exercise price of $<ix:nonFraction id="c96224338" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.49</ix:nonFraction>&#xa0;per share, the fair market value of a share of common stock on the date of issuance, (iii)&#xa0;a warrant, previously accounted&#xa0;as a warrant issuable to a consultant in consideration of services provided at our IPO, to purchase up to <ix:nonFraction id="c96224339" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction id="c96224341" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per share, the fair market value of a share of common stock at our IPO, and (iv) we issued <ix:nonFraction id="c96224342" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">13,643</ix:nonFraction> shares of common stock to a&#xa0;placement agent&#xa0;associated with a&#xa0;registered direct offering in <em style="font: inherit;"> November 2019&#xa0;</em>upon the&#xa0;exercise of&#xa0;warrants on a cashless basis. During the year ended&#xa0;<em style="font: inherit;"> December 31, 2022</em>, we recorded share-based compensation of $<ix:nonFraction id="c96224343" contextRef="d_2022-01-01_2022-12-31_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">55,612</ix:nonFraction> associated with the vesting of warrants.&#xa0;We&#xa0;expect&#xa0;to record $<ix:nonFraction id="c96224345" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-TimeBasedOptionsMember" unitRef="USD" name="gnpx:SharebasedPaymentArrangementExpenseFutureMilestone" scale="0" format="ixt:numdotdecimal" decimals="INF">90,689</ix:nonFraction>&#xa0;of share-based compensation for time-based vesting over the next year&#xa0;and another $<ix:nonFraction id="c96224346" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="USD" name="gnpx:SharebasedPaymentArrangementExpenseFutureMilestone" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction> of share-based compensation based on performance-based vesting.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#xa0;<em style="font: inherit;"> December 31, 2021</em>, we&#xa0;issued (i) a warrant&#xa0;to purchase up to <ix:nonFraction id="c96224347" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction> shares of common stock to a service provider&#xa0;at an exercise price of $<ix:nonFraction id="c96224348" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">7.22</ix:nonFraction> per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant&#xa0;to purchase up to <ix:nonFraction id="c96224349" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction> shares of common stock to a service provider&#xa0;at an exercise price of $<ix:nonFraction id="c96224350" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">3.36</ix:nonFraction>&#xa0;per share, the fair market value of a share of common stock on the date of issuance. During the year ended&#xa0;<em style="font: inherit;"> December 31, 2021</em>, we recorded share-based compensation of $<ix:nonFraction id="c96224352" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">200,282</ix:nonFraction> associated with the vesting of warrants.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Equity Incentive Plan</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our board of directors and stockholders have&#xa0;approved and adopted the Company&#x2019;s <em style="font: inherit;">2018</em> Equity Incentive Plan (<em style="font: inherit;">&#x201c;2018</em> Plan&#x201d;), which became effective on the completion of the IPO on <em style="font: inherit;"> April 3, 2018.&#xa0;</em>The <em style="font: inherit;">2018</em> Plan provides for the grant of incentive stock options that are intended to qualify under Section <em style="font: inherit;">422</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (&#x201c;ISOs&#x201d;), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs <em style="font: inherit;"> may </em>be granted only to employees. All other awards <em style="font: inherit;"> may </em>be granted to employees, including officers, and to non-employee directors and consultants.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan automatically increase on <em style="font: inherit;"> January 1 </em>of each year, beginning <em style="font: inherit;"> January 1, 2019 </em>by <ix:nonFraction id="c96224362" contextRef="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Pure" name="gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% of the total number of shares of the Company&#x2019;s common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the <em style="font: inherit;">2018</em> Plan. On <em style="font: inherit;"> January 1, 2021&#xa0;</em>and <em style="font: inherit;">2022,</em> the number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan was increased by an aggregate of <ix:nonFraction id="c96224366" contextRef="d_2021-01-01_2021-01-01_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">2,155,884</ix:nonFraction> and <ix:nonFraction id="c96224367" contextRef="d_2022-01-01_2022-01-01_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">2,393,735</ix:nonFraction> shares, respectively.&#xa0;As of <em style="font: inherit;"> December 31, 2022</em>, a total of <ix:nonFraction id="c96224368" contextRef="i_2022-12-31_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">481,772</ix:nonFraction> shares of common stock remain available for&#xa0;issuance for future awards under the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Employee Stock Purchase Plan</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our board of directors and stockholders approved and adopted the Company&#x2019;s <em style="font: inherit;">2018</em> Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on <em style="font: inherit;"> April 3, 2018.&#xa0;</em>The ESPP has <em style="font: inherit;">not</em> yet been utilized as a benefit available to our employees.&#xa0;The ESPP authorizes the issuance of <ix:nonFraction id="c96224373" contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">208,050</ix:nonFraction> shares of our common stock pursuant to purchase rights that <em style="font: inherit;"> may </em>be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on <em style="font: inherit;"> January 1 </em>of each calendar year, beginning on <em style="font: inherit;"> January 1, 2019, </em>by <ix:nonFraction id="c96224374" contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember" unitRef="Pure" name="gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" scale="-2" format="ixt:numdotdecimal" decimals="2">2</ix:nonFraction>% of the total number of shares of our&#xa0;common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined <em style="font: inherit;">not</em> to increase the number of shares reserved for issuance under the ESPP on&#xa0;<em style="font: inherit;"> January 1, 2022.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Stock Options</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022</em>,&#xa0;we had&#xa0;outstanding stock options to purchase <ix:nonFraction id="c96224377" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">11,374,327</ix:nonFraction>&#xa0;shares of common stock that have been granted to various executives, employees, directors, and independent contractors, including outstanding stock options to purchase <ix:nonFraction id="c96224378" contextRef="i_2022-12-31_PlanNameAxis-ExcludingThe2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">950,000</ix:nonFraction> shares of common stock issued as inducement grants, outside of the <em style="font: inherit;">2018</em> plan, associated with the hiring of new executives in <em style="font: inherit;">2021.</em>&#xa0;These options vest immediately or over periods ranging from <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224381" format="ixt-sec:durmonth">12</ix:nonNumeric>&#xa0;to <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c96224382" format="ixt-sec:durmonth">48</ix:nonNumeric>&#xa0;months, are exercisable for a period of up to <span style="-sec-ix-hidden:c96224383">ten</span> years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $<ix:nonFraction id="c96224384" contextRef="i_2022-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.298</ix:nonFraction>&#xa0;to&#xa0;$<ix:nonFraction id="c96224386" contextRef="i_2022-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">9.80</ix:nonFraction> per share. The per-share fair values of these options range from $<ix:nonFraction id="c96224387" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.24</ix:nonFraction>&#xa0;to $<ix:nonFraction id="c96224388" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">7.93</ix:nonFraction>, based on Black-Scholes-Merton pricing models with the following assumptions:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2343488" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expected term (in years):</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c96224456">10</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Risk-free rate:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><ix:nonFraction id="c96224458" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">0.07</ix:nonFraction>% &#x2013; <ix:nonFraction id="c96224460" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">4.77</ix:nonFraction>%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Volatility:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><ix:nonFraction id="c96224461" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="4">75.98</ix:nonFraction>% &#x2013; <ix:nonFraction id="c96224463" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="4">88.38</ix:nonFraction>%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Dividend yield:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><ix:nonFraction id="c96224465" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">In the year ended&#xa0;<em style="font: inherit;"> December 31, 2022</em>, we (i) granted stock options to purchase an aggregate of&#xa0;<ix:nonFraction id="c96224389" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">2,983,666</ix:nonFraction> shares of our&#xa0;common stock with exercise prices ranging from $<ix:nonFraction id="c96224391" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.27</ix:nonFraction>&#xa0;to $<ix:nonFraction id="c96224392" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.50</ix:nonFraction>&#xa0;per share to executives and&#xa0;employees,&#xa0;(ii) cancelled options to purchase <ix:nonFraction id="c96224393" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">66,667</ix:nonFraction> shares of common stock at exercise prices ranging from $<ix:nonFraction id="c96224395" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.00</ix:nonFraction> to $<ix:nonFraction id="c96224396" contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.66</ix:nonFraction> per share&#xa0;in connection with the termination of certain employees, and (iii) issued <ix:nonFraction id="c96224397" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">116,973</ix:nonFraction>&#xa0;shares of our common stock upon the exercise of options held by an executive with an exercise price of $<ix:nonFraction id="c96224399" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.02</ix:nonFraction>&#xa0;per share.</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#xa0;<em style="font: inherit;"> December 31, 2021</em>,&#xa0;we (i) granted stock options to purchase an aggregate of&#xa0;<ix:nonFraction id="c96224400" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">2,519,628</ix:nonFraction> shares of our common stock with exercise prices ranging from $<ix:nonFraction id="c96224401" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.72</ix:nonFraction>&#xa0;to $<ix:nonFraction id="c96224403" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.22</ix:nonFraction> per share to executives, employees, board members,&#xa0;and consultants, (ii) cancelled options to purchase <ix:nonFraction id="c96224404" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">118,507</ix:nonFraction> shares of common stock with&#xa0;exercise prices ranging from $<ix:nonFraction id="c96224405" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.45</ix:nonFraction>&#xa0;to&#xa0;$<ix:nonFraction id="c96224406" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.22</ix:nonFraction> per share due&#xa0;to the termination&#xa0;of former employees, and (iii) issued <ix:nonFraction id="c96224408" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">670,889</ix:nonFraction>&#xa0;shares of our&#xa0;common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from&#xa0;$<ix:nonFraction id="c96224409" contextRef="i_2021-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.015</ix:nonFraction>&#xa0;to $<ix:nonFraction id="c96224411" contextRef="i_2021-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.15</ix:nonFraction> per share.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The weighted average remaining contractual term for the outstanding options at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> is <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96224413" format="ixt-sec:duryear">7.08</ix:nonNumeric>&#xa0;and <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96224415" format="ixt-sec:duryear">7.24</ix:nonNumeric>&#xa0;years, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Stock option activity for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, is as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2343489" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Shares</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224469" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">6,844,069</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224470" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.81</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224471" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">2,519,628</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224472" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.26</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224473" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">670,889</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224474" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.01</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224475" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">118,507</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224476" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.00</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224477" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">8,574,301</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224478" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.35</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224479" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">2,983,666</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224480" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.16</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224481" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">116,973</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224482" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.02</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224483" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">66,667</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224484" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.55</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224485" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">11,374,327</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224486" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.08</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><ix:nonFraction id="c96224487" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">6,718,035</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><ix:nonFraction id="c96224488" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.23</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><i>Share-Based Compensation</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#xa0;<em style="font: inherit;"> December 31, 2022</em>,&#xa0;our total share-based compensation was approximately $<ix:nonFraction id="c96224418" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">4.7</ix:nonFraction>&#xa0;million, of which approximately $<ix:nonFraction id="c96224419" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">4.6</ix:nonFraction>&#xa0;million&#xa0;represents the vesting of options and warrants issued to service providers, executives, employees, and board members. As of&#xa0;<em style="font: inherit;"> December 31, 2022</em>, our&#xa0;total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board&#xa0;members, and service providers and <em style="font: inherit;">not</em> yet recognized was approximately $<ix:nonFraction id="c96224421" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">6.5</ix:nonFraction>&#xa0;million. We&#xa0;expect&#xa0;to record this stock-based compensation expense over the next <em style="font: inherit;">three</em>&#xa0;years using a graded vesting method. As of <em style="font: inherit;"> December 31, 2022</em>,&#xa0;the weighted average term over which these expenses are expected to be recognized is <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96224423" format="ixt-sec:duryear">1.76</ix:nonNumeric> years.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022</em>,&#xa0;there are&#xa0;<ix:nonFraction id="c96224424" contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;performance-based stock option awards outstanding and <ix:nonFraction id="c96224425" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> performance-based warrant outstanding issued to a service provider.&#xa0;Our total compensation cost related to the non-vested performance-based warrant&#xa0;<em style="font: inherit;">not</em> yet recognized was approximately $<ix:nonFraction id="c96224427" contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember" unitRef="USD" name="gnpx:WarrantNonvestedAwardCostNotYetRecognizedAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction>.&#xa0;The entirety of this warrant <em style="font: inherit;"> may </em>be recognized and recorded upon the achievement of certain milestones.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended <em style="font: inherit;"> December 31, 2021</em>, the Company's total share-based compensation was approximately $<ix:nonFraction id="c96224428" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">5.4</ix:nonFraction>&#xa0;million with approximately $<ix:nonFraction id="c96224429" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">5.2</ix:nonFraction>&#xa0;million representing the vesting of options issued to service providers, employees, and board members.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DefinedContributionPlanTextBlock" id="c2343490" escape="true">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">5</em>&#xa0;- <em style="font: inherit;">401</em>(k) Savings&#xa0;</span></b><b><span style="text-decoration: underline; ">Transactions</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2022,</em> we established a defined-contribution savings plan under Section&#xa0;<em style="font: inherit;">401</em>(k) of the Internal Revenue Code (<em style="font: inherit;">"401</em>(k) Plan") and established an employer matching program for participants in the <em style="font: inherit;">401</em>(k) Plan. The <em style="font: inherit;">401</em>(k) Plan covers all&#xa0;employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a&#xa0;pre-tax basis. We&#xa0;incurred&#xa0;$<ix:nonFraction id="c96224496" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">74,281</ix:nonFraction> of expense for matching contributions to the <em style="font: inherit;">401</em>(k) Plan during the year&#xa0;ended <em style="font: inherit;"> December 31, 2022</em>.&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c2343491" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">6</em>&#xa0;- Related Party Transactions</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Introgen Research Institute</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Introgen Research Institute (&#x201c;IRI&#x201d;) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board and IRI's sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In <em style="font: inherit;"> April 2009, </em>prior to Mr. Varner becoming an officer and director of our Company in <em style="font: inherit;"> August 2012, </em>we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in <em style="font: inherit;">2011</em> to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson (See Note <em style="font: inherit;">7</em> &#x2013; Commitments and Contingences &#x2013; Commitments &#x2013; MD Anderson Cancer Center).</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2343492" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">7</em>&#xa0;- Commitments and Contingencies</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Leases</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> April 16, 2018, </em>we executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On <em style="font: inherit;"> March 23, 2021, </em>we were&#xa0;informed&#xa0;by Dell Medical School that the University of Texas desired to use the space and&#xa0;<em style="font: inherit;">not</em> renew&#xa0;the space utilization agreement.&#xa0;The lease terminated&#xa0;on <em style="font: inherit;"> April 30, 2021, </em>and all our employees are currently working virtually while we evaluate future space needs post the COVID-<em style="font: inherit;">19</em> pandemic.&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Commitments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"><span style="text-decoration: underline; "><i>MD Anderson</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> July 2018, </em>we entered into a <em style="font: inherit;">two</em>-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy&#xa0;with a projected total cost of approximately $<ix:nonFraction id="c96224508" contextRef="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember" unitRef="USD" name="gnpx:LongTermContractEstimatedCost" scale="6" format="ixt:numdotdecimal" decimals="-6">2</ix:nonFraction> million. This agreement&#xa0;was extended beyond the original expiration date. This agreement expired in <em style="font: inherit;"> May 2022. </em>In <em style="font: inherit;"> August 2022, </em>we entered into a&#xa0;<em style="font: inherit;">three</em>-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on REQORSA and other potential product candidates in oncology&#xa0;to resensitize NSCLC and SCLC to targeted therapies and immunotherapies&#xa0;with a projected total cost of approximately $<ix:nonFraction id="c96224511" contextRef="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember" unitRef="USD" name="gnpx:LongTermContractEstimatedCost" scale="6" format="ixt:numdotdecimal" decimals="-5">2.9</ix:nonFraction>&#xa0;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2011,</em> we agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies&#xa0;and intellectual property originally licensed to another party under the <em style="font: inherit;">1994</em> License Agreement with MD Anderson (&#x201c;Original MD Anderson License Agreement&#x201d;). These technologies and intellectual property were later sublicensed to IRI (the &#x201c;IRI Sublicense&#x201d;). We&#xa0;also agreed to pay royalties of <ix:nonFraction id="c96224515" contextRef="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember" unitRef="Pure" name="gnpx:RoyaltyOnSalesPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">1</ix:nonFraction>% on sales of certain licensed products for a period of <ix:nonNumeric contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember" name="gnpx:RoyaltyTerms" id="c96224516" format="ixt-sec:duryear">21</ix:nonNumeric> years following the termination of the later of the Original MD Anderson License Agreement and the&#xa0;IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $<ix:nonFraction id="c96224517" contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember" unitRef="USD" name="gnpx:RoyaltyPaymentAnnualMinimum" scale="0" format="ixt:numdotdecimal" decimals="INF">20,000</ix:nonFraction>&#xa0;payable to the National Institutes of Health.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 3, 2021, </em>we entered into an amendment (the &#x201c;MD License Amendment&#x201d;) to the Patent and Technology License Agreement dated <em style="font: inherit;"> May 4, 2020, </em>with MD Anderson. The MD License&#xa0;Amendment grants us with&#xa0;a worldwide, exclusive, sublicensable license to an additional portfolio of <em style="font: inherit;">six</em> patents and <em style="font: inherit;">one</em> patent application and related technology for methods for treating&#xa0;cancer by administration of a <em style="font: inherit;">TUSC2</em> therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to <em style="font: inherit;">TUSC2</em> therapy. Pursuant to the MD License&#xa0;Amendment, we&#xa0;agreed to (i) pay annual maintenance fees ranging from the mid <em style="font: inherit;">five</em> figures to the low <em style="font: inherit;">six</em> figures, (ii) total milestone payments of $<ix:nonFraction id="c96224526" contextRef="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember" unitRef="USD" name="gnpx:LicenseAgreementMilestonePayment" scale="0" format="ixt:numdotdecimal" decimals="INF">6,150,000</ix:nonFraction>, (iii) a <em style="font: inherit;">one</em>-time fee in the mid <em style="font: inherit;">five</em>&#xa0;figures and (iv) certain patent related expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"><span style="text-decoration: underline; "><i>National Institutes of Health</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have a royalty obligation to the National Institutes of Health ("NIH") to be paid upon our receipt of FDA approval using NIH technology.&#xa0;The $<ix:nonFraction id="c96224531" contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember" unitRef="USD" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">240,000</ix:nonFraction> contingent obligation which increases annually by $<ix:nonFraction id="c96224532" contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember" unitRef="USD" name="gnpx:ContingentPaymentsAnnualIncrease" scale="0" format="ixt:numdotdecimal" decimals="INF">20,000</ix:nonFraction> and is $<ix:nonFraction id="c96224533" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherCommitment" scale="0" format="ixt:numdotdecimal" decimals="INF">340,000</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2022</em>, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify; text-indent: -9pt;"><i><span style="text-decoration: underline; ">University of Pittsburgh</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an exclusive license agreement dated <em style="font: inherit;"> February 11, 2020 </em>by and between us and the University of Pittsburgh, amended on <em style="font: inherit;"> August 17, 2022, </em>and amended again on&#xa0;<em style="font: inherit;"> November 3, 2022, </em>we agreed to pay (i) an initial licensing fee of $<ix:nonFraction id="c96224536" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:LicensingFeeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction>, (ii) annual maintenance fees of $<ix:nonFraction id="c96224537" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction> for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $<ix:nonFraction id="c96224541" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeAfterYearThreeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">40,000</ix:nonFraction> for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from <ix:nonFraction id="c96224544" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>% to <ix:nonFraction id="c96224545" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>%&#xa0;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $<ix:nonFraction id="c96224547" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualRoyaltyPaymentPerYearMinimum" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of <ix:nonFraction id="c96224549" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:ShareOfNonroyaltySublicenseIncomePercent" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>%, and (vi) an aggregate of $<ix:nonFraction id="c96224550" contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:MilestonePayment" scale="0" format="ixt:numdotdecimal" decimals="INF">3,975,000</ix:nonFraction> in milestone payments related to the usage of a glucagon promoter and&#xa0;gene therapy technologies to potentially treat Type <em style="font: inherit;">1</em> diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#xa0;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an&#xa0;exclusive license agreement dated <em style="font: inherit;"> November 22, 2022&#xa0;</em>by and between us and the University of Pittsburgh, we&#xa0;agreed to pay (i) an initial licensing fee of $<ix:nonFraction id="c96224554" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:LicensingFeeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction>, (ii) annual maintenance fees of $<ix:nonFraction id="c96224555" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction> for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $<ix:nonFraction id="c96224558" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeAfterYearThreeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">40,000</ix:nonFraction> for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from <ix:nonFraction id="c96224560" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>% to <ix:nonFraction id="c96224561" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>%&#xa0;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $<ix:nonFraction id="c96224562" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualRoyaltyPaymentPerYearMinimum" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of <ix:nonFraction id="c96224564" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:ShareOfNonroyaltySublicenseIncomePercent" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>%, and (vi) an aggregate of $<ix:nonFraction id="c96224565" contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:MilestonePayment" scale="0" format="ixt:numdotdecimal" decimals="INF">3,975,000</ix:nonFraction> in milestone payments related to the usage of a macrophage technology&#xa0;and&#xa0;gene therapy technologies to potentially treat Type <em style="font: inherit;">1</em> diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#xa0;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an&#xa0;exclusive license agreement dated <em style="font: inherit;"> December 29, 2022&#xa0;</em>by and between us&#xa0;and the University of Pittsburgh, we&#xa0;agreed to pay (i) an initial licensing fee of $<ix:nonFraction id="c96224570" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:LicensingFeeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction>, (ii) annual maintenance fees of $<ix:nonFraction id="c96224571" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">25,000</ix:nonFraction> for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $<ix:nonFraction id="c96224575" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualMaintenanceFeeAfterYearThreeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">40,000</ix:nonFraction> for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from <ix:nonFraction id="c96224578" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>% to <ix:nonFraction id="c96224579" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>%&#xa0;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $<ix:nonFraction id="c96224581" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:AnnualRoyaltyPaymentPerYearMinimum" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of <ix:nonFraction id="c96224583" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="Pure" name="gnpx:ShareOfNonroyaltySublicenseIncomePercent" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>%, and (vi) an aggregate of $<ix:nonFraction id="c96224585" contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember" unitRef="USD" name="gnpx:MilestonePayment" scale="0" format="ixt:numdotdecimal" decimals="INF">3,975,000</ix:nonFraction> in milestone payments related to the usage of an insulin&#xa0;promoter and&#xa0;gene therapy technologies to potentially treat Type <em style="font: inherit;">2</em>&#xa0;diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#xa0;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Contract Development and Manufacturing Organization</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We entered into a <em style="font: inherit;">three</em>-year&#xa0;development services agreement in <em style="font: inherit;"> July 2022&#xa0;</em>with a contract development and manufacturing organization to manufacture&#xa0;GMP grade materials for use in our clinical trials with a projected total cost of approximately $<ix:nonFraction id="c96224591" contextRef="i_2022-07-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember" unitRef="USD" name="gnpx:DevelopmentServicesAgreementExpectedTotalProjectCost" scale="6" format="ixt:numdotdecimal" decimals="-5">2.5</ix:nonFraction>&#xa0;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Contingencies</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">From time to time, we <em style="font: inherit;"> may </em>become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is <em style="font: inherit;">not</em> aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="gnpx:EffectOfCovid19PandemicTextBlock" id="c2343493" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">8</em>&#xa0;- Significant Events</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="color:#000000;">The COVID-<em style="font: inherit;">19</em>&#xa0;pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines <em style="font: inherit;"> may </em>result in continued impact from this pandemic in the future, which could adversely impact our operations.&#xa0;Through <em style="font: inherit;"> March 31, 2021,&#xa0;</em>we had&#xa0;<em style="font: inherit;">not</em> experienced any material impact on its financial results or operations&#xa0;as a result of the COVID-<em style="font: inherit;">19</em> pandemic. Beginning in <em style="font: inherit;"> June 2021, </em>we experienced&#xa0;delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. We also have&#xa0;experienced disruptions in our supply chain regarding our manufacturing and testing operations.&#xa0;We continue&#xa0;to closely monitor the impact of the COVID-<em style="font: inherit;">19</em> pandemic on its business and workforce.</span></p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2343494" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">9</em>&#xa0;&#x2013; Income Taxes </span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.&#xa0; The sources and tax effects of the differences are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2343495" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax provision at the federal statutory rate</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224624" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effect of operating losses</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224625" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="2" sign="-">21</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96224626" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <em style="font: inherit;"> December 31, 2022</em>, we&#xa0;have&#xa0;a net operating loss carryforward of approximately $<ix:nonFraction id="c96224620" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">68.9</ix:nonFraction><span style="font-size: 10pt;">&#xa0;million</span>&#xa0;for Federal and state purposes.&#xa0;This loss will be available to offset future taxable income.&#xa0;If <em style="font: inherit;">not</em> used, this carryforward will begin to expire in <em style="font: inherit;">2030.</em> The deferred tax asset relating to the operating loss carryforward has been fully reserved at&#xa0;<em style="font: inherit;"> December 31, 2022</em>&#xa0;and&#xa0;<em style="font: inherit;"> December 31, 2021</em>.&#xa0;The principal differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense.</p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2343496" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">10</em>&#xa0;&#x2013; Subsequent Events </span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><i><b>Reserves of <em style="font: inherit;">2018</em> Equity Incentive Plan and <em style="font: inherit;">2018</em> Employee Stock Purchase Plan</b></i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 1, 2023, </em>the total shares of common stock reserved under the <em style="font: inherit;">2018</em> Equity Incentive Plan increased by <ix:nonFraction id="c96224631" contextRef="d_2023-01-01_2023-01-01_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">2,405,298</ix:nonFraction> shares. On <em style="font: inherit;"> February 16, 2023,&#xa0;</em>the our Board of Directors determined that <em style="font: inherit;">no</em> additional shares would be reserved during the <em style="font: inherit;">2023</em>&#xa0;fiscal year for the <em style="font: inherit;">2018</em> Employee Stock Purchase Plan given that <em style="font: inherit;">no</em> shares have yet been issued under the plan.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Share Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 1, 2023, </em>we issued <ix:nonFraction id="c96224636" contextRef="d_2023-01-01_2023-01-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction> shares of common stock to&#xa0;the Chairman of our Scientific Advisory Board&#xa0;in consideration for services. During <em style="font: inherit;"> January 2023, </em>we issued <ix:nonFraction id="c96224637" contextRef="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">53,592</ix:nonFraction> shares of common stock for aggregate net proceeds of&#xa0;$<ix:nonFraction id="c96224638" contextRef="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">78,355</ix:nonFraction>&#xa0;under the&#xa0;<em style="font: inherit;">2022</em> ATM Facility.&#xa0;&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Option&#xa0;Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 17, 2023, </em><em style="font: inherit;"> January 23, 2023, </em>and <em style="font: inherit;"> January 30, 2023,&#xa0;</em>we&#xa0;issued grants of stock options&#xa0;under the <em style="font: inherit;">2018</em> Equity Incentive Plan&#xa0;to purchase a total of <ix:nonFraction id="c96224641" contextRef="d_2023-01-17_2023-01-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">82,500</ix:nonFraction> shares of common stock to new employees&#xa0;at the fair market value of the common stock on the date of issuance.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b><i>Warrant Issuance</i></b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 16, 2023, </em>we issued a warrant to purchase up to <ix:nonFraction id="c96224642" contextRef="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">30,000</ix:nonFraction> shares of its common stock at an exercise price of $<ix:nonFraction id="c96224643" contextRef="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.65</ix:nonFraction>&#xa0;per share to a consultant for services.&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Restricted Stock Units</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 18,&#xa0;</em><em style="font: inherit;">2023,</em> our Board of Directors approved the recommendations of the Company's Compensation Committee&#xa0;for the grant of restricted stock units (&#x201c;RSUs&#x201d;)&#xa0;pursuant to the <em style="font: inherit;">2018</em> Equity Incentive Plan&#xa0;in the aggregate of <ix:nonFraction id="c96224646" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:numdotdecimal" decimals="INF">353,195</ix:nonFraction> RSUs to non-executive employees.&#xa0;Each of these RSU grants vest in installments of <ix:nonFraction id="c96224647" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% on the <span style="-sec-ix-hidden:c96224648">first</span> anniversary of the date of grant and the remaining <ix:nonFraction id="c96224649" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% on the <span style="-sec-ix-hidden:c96224650">second</span> anniversary of the date of grant. Vested RSUs will be settled&#xa0;in shares of common stock on a <em style="font: inherit;">one</em>-to-<em style="font: inherit;">one</em> basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Executive Compensation</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 18, 2023, </em>our Board of Directors approved the recommendations of the Company's Compensation Committee for (i) annual incentive awards of an aggregate of $<ix:nonFraction id="c96224653" contextRef="d_2023-02-18_2023-02-18_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="USD" name="gnpx:AnnualIncentiveAwards" scale="0" format="ixt:numdotdecimal" decimals="INF">972,720</ix:nonFraction> and (ii) the grant of RSUs&#xa0;pursuant to the <em style="font: inherit;">2018</em> Equity Incentive Plan in the aggregate of <ix:nonFraction id="c96224655" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:numdotdecimal" decimals="INF">1,560,000</ix:nonFraction>&#xa0;RSUs to our executive officers.&#xa0;Each of these RSU grants vest in installments of <ix:nonFraction id="c96224656" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% on the <span style="-sec-ix-hidden:c96224657">first</span> anniversary of the date of grant and the remaining <ix:nonFraction id="c96224658" contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% on the <span style="-sec-ix-hidden:c96224659">second</span> anniversary of the date of grant. Vested RSUs will be settled in shares of common stock on a <em style="font: inherit;">one</em>-to-<em style="font: inherit;">one</em> basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; "><em style="font: inherit;"> March 2023 </em>Registered Direct Offering</span></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 1, 2023, </em>we&#xa0;completed a registered direct offering, in which we&#xa0;sold to an accredited healthcare-focused institutional investor an aggregate of <ix:nonFraction id="c96224662" contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">3,809,524</ix:nonFraction> shares of our common stock and warrants to purchase up to <ix:nonFraction id="c96224663" contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">3,809,524</ix:nonFraction> shares of our common stock, at a combined offering price of $<ix:nonFraction id="c96224664" contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USDPerShare" name="gnpx:EquityOfferingCombinedPurchasePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.05</ix:nonFraction> per share of common stock and accompanying warrant. The warrants are exercisable immediately upon issuance, expire <ix:nonNumeric contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c96224665" format="ixt-sec:duryear">5</ix:nonNumeric> years from the date of issuance and have an exercise price of $<ix:nonFraction id="c96224666" contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.10</ix:nonFraction> per share. We&#xa0;received net proceeds of approximately $<ix:nonFraction id="c96224667" contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">3.6</ix:nonFraction> million after commissions and estimated expenses, excluding any proceeds that <em style="font: inherit;"> may </em>be received in the future from any exercise of the warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ErrorCorrectionTextBlock" id="c2343497" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">11</em>&#xa0;&#x2013; Quarterly Data - Unaudited</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Revised Interim Financial Information</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The following tables represent amounts previously reported and revised as a result of the immaterial error associated with the accounting for share-based compensation. See Note <em style="font: inherit;">2</em> for additional information.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="c3F47E9C7-B553-47EA-B8DF-84A466C866B8" escape="true" continuedAt="FFB13516-11FC-4C05-BFC2-38DE3EC8F240">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224694" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">39,409,431</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224695" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224697" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">39,409,431</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224703" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,384,817</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224705" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224707" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,384,817</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224711" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,879</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224712" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224713" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,879</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224714" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">120,717,072</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224715" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">656,678</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224716" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">121,373,750</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224717" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">83,740,337</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224718" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">656,678</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224719" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">84,397,015</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224720" contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">37,024,614</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224721" contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224722" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">37,024,614</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224729" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">34,565,123</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224730" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224731" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">34,565,123</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224732" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,153,838</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224733" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224734" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,153,838</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224735" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,898</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224736" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224737" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">47,898</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224738" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">121,273,050</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224739" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">1,251,995</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224740" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">122,525,045</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224741" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">88,909,663</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224742" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,251,995</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224743" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">90,161,658</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224744" contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">32,411,285</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224745" contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224746" contextRef="i_2022-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">32,411,285</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224753" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">29,945,826</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224754" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224755" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">29,945,826</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224756" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,457,311</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224757" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224758" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,457,311</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224759" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">48,020</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224760" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224761" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">48,020</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224762" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">122,432,935</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224763" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">1,311,780</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224764" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">123,744,715</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224765" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">94,992,440</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224766" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,311,780</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224767" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">96,304,220</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224768" contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">27,488,515</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224769" contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224770" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">27,488,515</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:continuation id="FFB13516-11FC-4C05-BFC2-38DE3EC8F240">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224783" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224784" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224785" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224789" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,730</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224790" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224791" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,730</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224795" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,860,837</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224796" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">179,389</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224797" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,040,226</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224801" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,855,796</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224802" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">592,055</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224803" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,263,741</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224807" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">5,723,363</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224808" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">412,667</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224809" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">5,310,696</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating (loss) gain</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224813" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,723,363</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224814" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF">412,667</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224815" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">5,310,696</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224819" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">879</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224820" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224821" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">879</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224825">(5,722,484</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224826">412,667</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224827">(5,309,817</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224831">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224832">0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224833">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224837" contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,879,597</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224839" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,879,597</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Six Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224855" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224856" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224857" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224858" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224859" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224860" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224861" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,543</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224862" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224863" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,543</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224864" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">13,273</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224865" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224866" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">13,273</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224867" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,737,028</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224868" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">189,899</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224869" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,926,927</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224870" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">4,597,865</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224871" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">369,288</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224872" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">4,967,153</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224873" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,431,499</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224874" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">405,417</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224875" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,836,916</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224876" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">6,287,295</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224877" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">186,638</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224878" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">6,100,657</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224879" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">5,175,070</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224880" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">595,316</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224881" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">5,770,386</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224882" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">10,898,433</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224883" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">182,650</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224884" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">11,081,083</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224885">(5,175,070</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224886">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224887">(5,770,386</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224888">(10,898,433</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224889">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224890">(11,081,083</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224891" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">5,744</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224892" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224893" contextRef="d_2022-04-01_2022-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">5,744</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224894" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">6,623</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224895" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224896" contextRef="d_2022-01-01_2022-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">6,623</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224897">(5,169,326</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224898">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224899">(5,764,642</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224900">(10,891,810</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224901">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224902">(11,074,460</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224903">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224904">(0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224905">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224906">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224907">(0.00</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224908">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224909" contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,893,404</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224911" contextRef="d_2022-04-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,893,404</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224912" contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,892,919</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224914" contextRef="d_2022-01-01_2022-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,892,919</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Nine Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224927" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224928" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224929" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224930" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224931" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224932" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224933" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,224</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224934" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224935" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,224</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224936" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">19,497</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224937" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224938" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">19,497</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224939" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,593,309</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224940" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">435,578</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224941" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,157,731</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224942" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,191,174</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96224943" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">66,290</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224944" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,124,884</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224945" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,511,121</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224946" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">495,363</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224947" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,006,484</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224948" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,798,416</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224949" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">308,725</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224950" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">9,107,141</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224951" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">6,110,654</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224952" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">59,785</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224953" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">6,170,439</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224954" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">17,009,087</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224955" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">242,435</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96224956" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">17,251,522</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224957">(6,110,654</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224958">(59,785</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224959">(6,170,439</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224960">(17,009,087</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224961">(242,435</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224962">(17,251,522</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224963" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">27,877</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224964" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224965" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">27,877</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224966" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">34,500</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224967" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96224968" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">34,500</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224969" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,082,777</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224970" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">59,785</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224971" contextRef="d_2022-07-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,142,562</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224972" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">16,974,587</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224973" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">242,435</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96224974" contextRef="d_2022-01-01_2022-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">17,217,022</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224975" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.13</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224976" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0.00</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224977" contextRef="d_2022-07-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.13</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224978" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.35</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224979" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.01</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c96224980" contextRef="d_2022-01-01_2022-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.36</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224981" contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,984,724</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224983" contextRef="d_2022-07-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,984,724</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224984" contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,919,626</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#xa0;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96224986" contextRef="d_2022-01-01_2022-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">47,919,626</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:continuation>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-22
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>2
<FILENAME>ex_451285.htm
<DESCRIPTION>EXHIBIT 4.18
<TEXT>
<html><head>
	<title>ex_451285.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 4.18</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><b>DESCRIPTION OF THE REGISTRANT</b>&#8217;<b>S SECURITIES&nbsp;</b><b>REGISTERED PURSUANT TO SECTION 12 OF THE&nbsp;</b><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As of December 31, 2022, Genprex, Inc. (the &#8220;Company&#8221;) had one class of security registered under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Description of Common Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following description of the Company&#8217;s Common Stock is a summary and does not purport to be complete. It is&nbsp;subject to and qualified in its entirety by reference to the Company&#8217;s Amended and Restated Certificate of Incorporation &nbsp;(the &#8220;Certificate of Incorporation&#8221;) and the Company&#8217;s Amended and Restated Bylaws (the &#8220;Bylaws&#8221; and together with the Certificate of Incorporation, the &#8220;Charter Documents&#8221;), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.18&nbsp;is a part. The Company encourages you to&nbsp;read its Certificate of Incorporation, Bylaws, and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), for additional information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Authorized Capital Shares</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s authorized capital shares consist of 200,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, $0.001 par value per share (&#8220;Preferred Stock&#8221;). As of March 15, 2023, there were 51,974,078 shares of Common Stock issued and outstanding and no shares of Preferred Stock issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Voting Rights</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Holders of the Company&#8217;s Common Stock are entitled to one vote per share on each matter properly submitted to the stockholders of the Company for their vote; provided, however, that except as otherwise required by law, that holders of Common Stock are not entitled to vote on any amendments to the Certificate of Incorporation relating solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other series of Preferred Stock to vote thereon by law or pursuant to the Certificate of Incorporation. The Company&#8217;s Charter Documents do not provide for cumulative voting in the election of directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Dividend Rights</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Holders of the Company&#8217;s Common Stock are entitled, subject to the rights, privileges, restrictions and conditions attaching to any other class of shares ranking in priority to the Common Stock, to receive any dividend declared by the Company&#8217;s board of directors out of the Company&#8217;s assets which are legally available. Such dividends may be paid in cash, in property, or in shares of the Company&#8217;s capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has never declared or paid cash dividends on its capital stock.&nbsp; The Company currently intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any dividends on the Company's Common Stock in the foreseeable future.&nbsp; Any future determination to declare dividends will be made at the discretion of the Company's board of directors and will depend on, among other factors, the Company's financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that the Company's board of directors may deem relevant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Liquidation Rights</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Upon the Company&#8217;s liquidation, dissolution or winding-up, holders of the Company&#8217;s Common Stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of the Company&#8217;s outstanding shares of Preferred Stock.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Preemptive, Conversion and Subscription Rights</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Holders of the Company&#8217;s Common Stock have no preemptive, conversion or subscription rights.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Anti-takeover effects of our Charter Documents and Delaware law</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Set forth below is a summary of the provisions of the Company&#8217;s Certificate of Incorporation and Bylaws and the DGCL that could have the effect of delaying or preventing a change in control of the Company. The following description is only a summary, and it is qualified by reference to the Certificate of Incorporation, Bylaws and relevant provisions of the DGCL.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><u>Delaware Anti-Takeover Law</u></i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company is subject to Section 203 of the DGCL (&#8220;Section 203&#8221;) which generally prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; transaction with an &#8220;interested stockholder&#8221; for a period of three years following the time that such stockholder became an interested stockholder, unless:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">prior to &nbsp;the date of the transaction the board of directors of the corporation approved either the&nbsp;business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">upon consummation of the transaction which resulted in the stockholder becoming an&nbsp;interested stockholder, the interested stockholder owned at least 85% of the voting stock of the&nbsp;corporation outstanding at the time the transaction commenced, excluding for purposes of determining&nbsp;the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder)&nbsp;those shares owned (1) by persons who are directors and also officers and (2) employee stock&nbsp;plans in which employee participants do not have the right to determine confidentially whether&nbsp;shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at or subsequent to the date of the transaction, the business combination is approved by the board of&nbsp;directors and&nbsp;authorized at an annual or special meeting of stockholders, and not by written consent, by the&nbsp;affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the&nbsp;interested stockholder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Section 203 defines a "business combination" to include:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:3.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any merger or consolidation involving the corporation and the interested stockholder;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any sale, lease, exchange, mortgage, transfer, pledge or other disposition (in one transaction or a series of transactions)&nbsp;involving the&nbsp;interested stockholder of assets of the corporation or of any direct or indirect majority-owned subsidiary of the corporation which assets have an aggregate market value equal to 10% or more of either the aggregate market value of all the assets of the corporation determined on a consolidated basis or the aggregate market value of all the outstanding stock of the corporation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">subject to exceptions, any transaction that results in the issuance or transfer by the&nbsp;corporation of any stock of the corporation to the interested stockholder;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">subject to exceptions, any transaction involving the corporation that has the effect of&nbsp;increasing the proportionate share of the stock of any class or series of the corporation&nbsp;beneficially owned by the interested stockholder; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3.7%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the receipt by the interested stockholder of the benefit of any loans, advances,&nbsp;guarantees, pledges or other financial benefits provided by or through the corporation.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In general, Section 203 defines an &#8220;interested stockholder&#8221; a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, owned 15% or more of a corporation&#8217;s outstanding voting securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i><u>Certificate of Incorporation and Bylaws</u></i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Board of Directors Vacancies</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Charter Documents provide that, except as otherwise required by law, and subject to the rights of the holders of any series of Preferred Stock, all vacancies, and any newly created directorships, unless the Board of Directors determines that any such vacancies or newly created directorships shall be filled by the stockholders, shall, &nbsp;be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum. Further, the Company&#8217;s directors may only be removed with cause and by the affirmative vote of the holders of at least 66-2/3% of the voting power of all of the Company&#8217;s then outstanding capital stock. In addition, pursuant to the Company&#8217;s Certificate of Incorporation, the number of directors constituting the Company&#8217;s board of directors may be changed only by resolution of the Company&#8217;s board of directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Limits on Ability of Stockholders to Act by Written Consent or Call a Special Meeting</i>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Charter Documents require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent. In addition, pursuant to the Company&#8217;s Bylaws, special meetings of the Company&#8217;s stockholders may be called only by the chairman of the board, the Company&#8217;s Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Stockholder Proposals</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice.&nbsp; These advance notice procedures may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed and may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempt to obtain control of our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Staggered Board</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Charter Documents provide that the Company&#8217;s board of directors&nbsp;shall be divided into three classes and that directors shall be elected for a term of three years.&nbsp; Our classified board of directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us because it generally makes it more difficult for stockholders to replace a majority of the directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Issuance of Undesignated Preferred Stock</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As discussed above, our board of directors has the ability to designate and issue preferred stock with voting or other rights or preferences that could deter hostile takeovers or delay changes in our control or management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>No Cumulative Voting</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our Charter Documents do not expressly provide for cumulative voting. Without cumulative voting, a minority stockholder may not be able to gain as many seats on our board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board of directors&#8217; decision regarding a takeover.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Exclusive Forum</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Charter Documents provide that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of the Company,&nbsp;(ii) &nbsp;any action asserting a claim for breach of any fiduciary duty owed by any director, officer, or other employee of the Company to the Company or the Company&#8217;s stockholders, (iii) any action &nbsp;asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the DGCL or the Company&#8217;s Certificate of Incorporation or Bylaws or (iv)&nbsp;any action asserting a claim against the Company or any of the Company&#8217;s directors, officers or other employees governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Transfer Agent and Registrar</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s transfer agent and registrar is VStock Transfer, LLC whose address is 18 Lafayette Place, Woodmere, New York 11598.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Listing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;GNPX.&#8221;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_451286.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_451286.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 23.1</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Genprex, Inc.<br>
Austin, Texas</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File nos. 333-237543, 333-266896 and 333-269865) and the Registration Statement on Form S-3 (File no. 333-239134) of Genprex, Inc., of our report dated March 31, 2023 relating to the financial statements at and for the years ended December 31, 2022&nbsp;and 2021, which appear in this Annual Report on Form 10-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>/s/ Daszkal Bolton LLP</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Boca Raton, Florida</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">March 31, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_451287.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_451287.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit 31.1</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">I, J. Rodney Varner, certify that:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I have reviewed this annual report on Form 10-K of Genprex, Inc., a Delaware corporation (the &#8220;registrant&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Date: March 31, 2023</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>J. Rodney Varner</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">J. Rodney Varner</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Chief Executive Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(Principal Executive Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_451288.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_451288.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit 31.2</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">I, Ryan M. Confer, certify that:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I have reviewed this annual report on Form 10-K of Genprex, Inc., a Delaware corporation (the &#8220;registrant&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Date: March 31, 2023</p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Ryan M. Confer</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">Ryan M. Confer</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Chief Financial Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(Principal Financial and Accounting Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_451289.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_451289.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit 32.1</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In connection with the Annual Report on Form 10-K of Genprex, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, J. Rodney Varner, Chief Executive Officer of the Company, and Ryan M. Confer, Chief Financial Officer of the Company, hereby certifies, pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended and 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(1)</p>
			</td>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(2)</p>
			</td>
			<td style="vertical-align:top;width:92.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">Date: March 31, 2023</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>J. Rodney Varner</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">J. Rodney Varner</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Chief Executive Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(Principal Executive Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Ryan M. Confer</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">Ryan M. Confer</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Chief Financial Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(Principal Financial and Accounting Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">This certification accompanies the Report, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>gnpx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:20PM UTC 2023-03-31--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:gnpx="http://www.genprex.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.genprex.com/20221231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.genprex.com/20221231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-balance-sheets" roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-balance-sheets-parentheticals" roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-operations" roleURI="http://www.genprex.com/20221231/role/statement-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-changes-in-stockholders-equity" roleURI="http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-cash-flows" roleURI="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-business-and-basis-of-presentation" roleURI="http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-intellectual-property" roleURI="http://www.genprex.com/20221231/role/statement-note-3-intellectual-property">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Intellectual Property</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-401k-savings-transactions" roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - 401(k) Savings Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-related-party-transactions" roleURI="http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies" roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-significant-events-" roleURI="http://www.genprex.com/20221231/role/statement-note-8-significant-events-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Significant Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-subsequent-events" roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-tables" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 4 - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 4 - Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-common-stock-purchase-warrant-activity-details" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-assumptions-details" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 4 - Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-stock-option-activity-details" roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 4 - Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-401k-savings-transactions-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 5 - 401(k) Savings Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-income-tax-reconciliation-details" roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 9 - Income Taxes - Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-subsequent-events-details-textual" roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 10 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gnpx_AnnualIncentiveAwards" name="AnnualIncentiveAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" name="AnnualMaintenanceFeeAfterYearThreeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" name="AnnualMaintenanceFeeFirstThreeYearsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_AnnualRoyaltyPaymentPerYearMinimum" name="AnnualRoyaltyPaymentPerYearMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="gnpx_BearCreekCapitalWarrantOneMember" name="BearCreekCapitalWarrantOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_BearCreekCapitalWarrantTwoMember" name="BearCreekCapitalWarrantTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_BearCreekCapitalWarrantsMember" name="BearCreekCapitalWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_BrokerageCommissionsPercentageOfGrossProceeds" name="BrokerageCommissionsPercentageOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" name="ClassOfWarrantOrRightCancelledDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" name="ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightExercisable" name="ClassOfWarrantOrRightExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightExercisableExercisePrice" name="ClassOfWarrantOrRightExercisableExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ClassOfWarrantOrRightIssuedInPeriod" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_CommonStockSharesAuthorizedValue" name="CommonStockSharesAuthorizedValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_ConsultantMember" name="ConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_ConsultantWarrantsMember" name="ConsultantWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ContingentPaymentsAnnualIncrease" name="ContingentPaymentsAnnualIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_CorrectionOfErrorPolicyTextBlock" name="CorrectionOfErrorPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_CorrectionOfErrorsTableTextBlock" name="CorrectionOfErrorsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" name="DevelopmentAndManufacturingOfGMPGradeMaterialsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" name="DevelopmentServicesAgreementExpectedTotalProjectCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="gnpx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" name="DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_EffectOfCovid19PandemicTextBlock" name="EffectOfCovid19PandemicTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_EquityOfferingCombinedPurchasePrice" name="EquityOfferingCombinedPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_ExcludingThe2018EquityIncentivePlanMember" name="ExcludingThe2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_InvestorsMember" name="InvestorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_LicenseAgreementMilestonePayment" name="LicenseAgreementMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_LicensingFeeAmount" name="LicensingFeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_LongTermContractEstimatedCost" name="LongTermContractEstimatedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_MdAndersonMember" name="MdAndersonMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_MilestonePayment" name="MilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="gnpx_NationalInstituteOfHealthMember" name="NationalInstituteOfHealthMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_NonexecutiveEmployeesMember" name="NonexecutiveEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" name="PaymentsForProceedsFromResearchAndDevelopmentSupplies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_PerformancebasedWarrantMember" name="PerformancebasedWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_ResearchAgreementMember" name="ResearchAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ResearchAndDevelopmentAssetsCurrent" name="ResearchAndDevelopmentAssetsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_ResearchAndDevelopmentAssetsNoncurrent" name="ResearchAndDevelopmentAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_RoyaltyOnSalesPercentage" name="RoyaltyOnSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_RoyaltyPaymentAnnualMinimum" name="RoyaltyPaymentAnnualMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" name="RoyaltyPercentLicensedTechnologyCoveredByPatent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_RoyaltyTerms" name="RoyaltyTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_ScientificAdvisoryBoardChairmanMember" name="ScientificAdvisoryBoardChairmanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_ShareOfNonroyaltySublicenseIncomePercent" name="ShareOfNonroyaltySublicenseIncomePercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" name="SharebasedPaymentArrangementExpenseFutureMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" name="StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" name="StockIssuedDuringPeriodSharesWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_The2018EmployeeStockPurchasePlanMember" name="The2018EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_The2018EquityIncentivePlanMember" name="The2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_The2022AtmFacilityMember" name="The2022AtmFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_TimeBasedOptionsMember" name="TimeBasedOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_UniversityOfPittsburghMember" name="UniversityOfPittsburghMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" name="UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" name="UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_VestingOfWarrantsForServiceProviderMember" name="VestingOfWarrantsForServiceProviderMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_WarrantForServiceProvider2Member" name="WarrantForServiceProvider2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_WarrantForServiceProviderMember" name="WarrantForServiceProviderMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_WarrantForServicesProvidedAtIpoMember" name="WarrantForServicesProvidedAtIpoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" name="WarrantNonvestedAwardCostNotYetRecognizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" name="WarrantsIssuedWithRegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" name="statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" name="statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-4-equity-assumptions-details" name="statement-statement-note-4-equity-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" name="statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-4-equity-stock-option-activity-details" name="statement-statement-note-4-equity-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-4-equity-tables" name="statement-statement-note-4-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" name="statement-statement-note-9-income-taxes-income-tax-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="gnpx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>gnpx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:20PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:href="gnpx-20221231.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:href="gnpx-20221231.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:href="gnpx-20221231.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>gnpx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:20PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ErrorCorrectionTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-8-significant-events-" xlink:href="gnpx-20221231.xsd#statement-note-8-significant-events-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-8-significant-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EffectOfCovid19PandemicTextBlock" xlink:label="gnpx_EffectOfCovid19PandemicTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="gnpx_EffectOfCovid19PandemicTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions" xlink:href="gnpx-20221231.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-3-intellectual-property" xlink:href="gnpx-20221231.xsd#statement-note-3-intellectual-property" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-3-intellectual-property" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation" xlink:href="gnpx-20221231.xsd#statement-note-1-description-of-business-and-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-document-and-entity-information" xlink:href="gnpx-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals" xlink:href="gnpx-20221231.xsd#statement-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity" xlink:href="gnpx-20221231.xsd#statement-note-4-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantOneMember" xlink:label="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantTwoMember" xlink:label="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantsMember" xlink:label="gnpx_BearCreekCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantMember" xlink:label="gnpx_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_InvestorsMember" xlink:label="gnpx_InvestorsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PerformancebasedWarrantMember" xlink:label="gnpx_PerformancebasedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EmployeeStockPurchasePlanMember" xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_TimeBasedOptionsMember" xlink:label="gnpx_TimeBasedOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_VestingOfWarrantsForServiceProviderMember" xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProvider2Member" xlink:label="gnpx_WarrantForServiceProvider2Member" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProviderMember" xlink:label="gnpx_WarrantForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServicesProvidedAtIpoMember" xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_InvestorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServiceProviderMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServiceProvider2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gnpx_TimeBasedOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_PerformancebasedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions" xlink:href="gnpx-20221231.xsd#statement-note-5-401k-savings-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies" xlink:href="gnpx-20221231.xsd#statement-note-7-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMember" xlink:label="gnpx_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MdAndersonMember" xlink:label="gnpx_MdAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NationalInstituteOfHealthMember" xlink:label="gnpx_NationalInstituteOfHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAgreementMember" xlink:label="gnpx_ResearchAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UniversityOfPittsburghMember" xlink:label="gnpx_UniversityOfPittsburghMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_ResearchAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_MdAndersonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_NationalInstituteOfHealthMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_UniversityOfPittsburghMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events" xlink:href="gnpx-20221231.xsd#statement-note-10-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantWarrantsMember" xlink:label="gnpx_ConsultantWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NonexecutiveEmployeesMember" xlink:label="gnpx_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_ConsultantWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="gnpx-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorPolicyTextBlock" xlink:label="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorsTableTextBlock" xlink:label="gnpx_CorrectionOfErrorsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="gnpx_CorrectionOfErrorsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-tables" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantOneMember" xlink:label="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantTwoMember" xlink:label="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantsMember" xlink:label="gnpx_BearCreekCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CommonStockSharesAuthorizedValue" xlink:label="gnpx_CommonStockSharesAuthorizedValue" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantMember" xlink:label="gnpx_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_InvestorsMember" xlink:label="gnpx_InvestorsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PerformancebasedWarrantMember" xlink:label="gnpx_PerformancebasedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EmployeeStockPurchasePlanMember" xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_TimeBasedOptionsMember" xlink:label="gnpx_TimeBasedOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_VestingOfWarrantsForServiceProviderMember" xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProvider2Member" xlink:label="gnpx_WarrantForServiceProvider2Member" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProviderMember" xlink:label="gnpx_WarrantForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServicesProvidedAtIpoMember" xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_InvestorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServiceProviderMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServiceProvider2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gnpx_TimeBasedOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_BearCreekCapitalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_PerformancebasedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_CommonStockSharesAuthorizedValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-5-401k-savings-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-7-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ContingentPaymentsAnnualIncrease" xlink:label="gnpx_ContingentPaymentsAnnualIncrease" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMember" xlink:label="gnpx_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMilestonePayment" xlink:label="gnpx_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicensingFeeAmount" xlink:label="gnpx_LicensingFeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LongTermContractEstimatedCost" xlink:label="gnpx_LongTermContractEstimatedCost" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MdAndersonMember" xlink:label="gnpx_MdAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MilestonePayment" xlink:label="gnpx_MilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NationalInstituteOfHealthMember" xlink:label="gnpx_NationalInstituteOfHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAgreementMember" xlink:label="gnpx_ResearchAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyOnSalesPercentage" xlink:label="gnpx_RoyaltyOnSalesPercentage" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPaymentAnnualMinimum" xlink:label="gnpx_RoyaltyPaymentAnnualMinimum" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyTerms" xlink:label="gnpx_RoyaltyTerms" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UniversityOfPittsburghMember" xlink:label="gnpx_UniversityOfPittsburghMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_ResearchAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_MdAndersonMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_NationalInstituteOfHealthMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gnpx_UniversityOfPittsburghMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LongTermContractEstimatedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyOnSalesPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyTerms" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyPaymentAnnualMinimum" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LicenseAgreementMilestonePayment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ContingentPaymentsAnnualIncrease" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitment" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LicensingFeeAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_MilestonePayment" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-10-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualIncentiveAwards" xlink:label="gnpx_AnnualIncentiveAwards" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantWarrantsMember" xlink:label="gnpx_ConsultantWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EquityOfferingCombinedPurchasePrice" xlink:label="gnpx_EquityOfferingCombinedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NonexecutiveEmployeesMember" xlink:label="gnpx_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_ConsultantWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gnpx_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualIncentiveAwards" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_EquityOfferingCombinedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisable" xlink:label="gnpx_ClassOfWarrantOrRightExercisable" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisable" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity" xlink:href="gnpx-20221231.xsd#statement-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:href="gnpx-20221231.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:href="gnpx-20221231.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:href="gnpx-20221231.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>gnpx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:20PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DocumentAndEntityInformation" xlink:label="gnpx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="gnpx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_DocumentAndEntityInformation" xlink:to="gnpx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_The2022AtmFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2022 ATM Facility [Member]</link:label>
    <link:label xlink:label="gnpx_The2022AtmFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2022 ATM facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_The2022AtmFacilityMember" xlink:to="gnpx_The2022AtmFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CommonStockSharesAuthorizedValue" xlink:label="gnpx_CommonStockSharesAuthorizedValue" xlink:type="locator"/>
    <link:label xlink:label="gnpx_CommonStockSharesAuthorizedValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_CommonStockSharesAuthorizedValue</link:label>
    <link:label xlink:label="gnpx_CommonStockSharesAuthorizedValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Value</link:label>
    <link:label xlink:label="gnpx_CommonStockSharesAuthorizedValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the aggerate value for the shares authorized of common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_CommonStockSharesAuthorizedValue" xlink:to="gnpx_CommonStockSharesAuthorizedValue-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="gnpx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="gnpx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_BrokerageCommissionsPercentageOfGrossProceeds</link:label>
    <link:label xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brokerage Commissions, Percentage of Gross Proceeds</link:label>
    <link:label xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the commissions for brokerage services as a percentage of gross proceeds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:to="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-significant-accounting-policies-policies" xlink:label="gnpx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-significant-accounting-policies-policies" xlink:to="gnpx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]</link:label>
    <link:label xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-tables" xlink:label="gnpx_statement-statement-note-4-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-4-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-4-equity-tables" xlink:to="gnpx_statement-statement-note-4-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free rate:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-9-income-taxes-tables" xlink:label="gnpx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-9-income-taxes-tables" xlink:to="gnpx_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Restatement of Previously Issued Consolidated Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:to="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:to="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NonexecutiveEmployeesMember" xlink:label="gnpx_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_NonexecutiveEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-executive Employees [Member]</link:label>
    <link:label xlink:label="gnpx_NonexecutiveEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-executive employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_NonexecutiveEmployeesMember" xlink:to="gnpx_NonexecutiveEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:label="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:to="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EquityOfferingCombinedPurchasePrice" xlink:label="gnpx_EquityOfferingCombinedPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="gnpx_EquityOfferingCombinedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_EquityOfferingCombinedPurchasePrice</link:label>
    <link:label xlink:label="gnpx_EquityOfferingCombinedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Combined Purchase Price (in dollars per share)</link:label>
    <link:label xlink:label="gnpx_EquityOfferingCombinedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The combined purchase price of the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_EquityOfferingCombinedPurchasePrice" xlink:to="gnpx_EquityOfferingCombinedPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-assumptions-details" xlink:label="gnpx_statement-statement-note-4-equity-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-4-equity-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-4-equity-assumptions-details" xlink:to="gnpx_statement-statement-note-4-equity-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:label="gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-4-equity-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:to="gnpx_statement-statement-note-4-equity-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:label="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Income Tax Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:to="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]</link:label>
    <link:label xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="locator"/>
    <link:label xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:to="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatements" xlink:label="gnpx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="gnpx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_NotesToFinancialStatements" xlink:to="gnpx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServicesProvidedAtIpoMember" xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant for Services Provided at IPO [Member]</link:label>
    <link:label xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrant for service provided at IPO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:to="gnpx_WarrantForServicesProvidedAtIpoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="gnpx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="gnpx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualIncentiveAwards" xlink:label="gnpx_AnnualIncentiveAwards" xlink:type="locator"/>
    <link:label xlink:label="gnpx_AnnualIncentiveAwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_AnnualIncentiveAwards</link:label>
    <link:label xlink:label="gnpx_AnnualIncentiveAwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Incentive Awards</link:label>
    <link:label xlink:label="gnpx_AnnualIncentiveAwards-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of annual incentive awards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_AnnualIncentiveAwards" xlink:to="gnpx_AnnualIncentiveAwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in years): (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_VestingOfWarrantsForServiceProviderMember" xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of Warrants For Service Provider [Member]</link:label>
    <link:label xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">related to the share-based compensation associated with the vesting of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:to="gnpx_VestingOfWarrantsForServiceProviderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProviderMember" xlink:label="gnpx_WarrantForServiceProviderMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_WarrantForServiceProviderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant For Service Provider [Member]</link:label>
    <link:label xlink:label="gnpx_WarrantForServiceProviderMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the warrants for service providers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_WarrantForServiceProviderMember" xlink:to="gnpx_WarrantForServiceProviderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scientific Advisory Board Chairman [Member]</link:label>
    <link:label xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">related to the Chairman of the Scientific Advisory Board</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_TimeBasedOptionsMember" xlink:label="gnpx_TimeBasedOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_TimeBasedOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Options [Member]</link:label>
    <link:label xlink:label="gnpx_TimeBasedOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents time based options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_TimeBasedOptionsMember" xlink:to="gnpx_TimeBasedOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProvider2Member" xlink:label="gnpx_WarrantForServiceProvider2Member" xlink:type="locator"/>
    <link:label xlink:label="gnpx_WarrantForServiceProvider2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant For Service Provider 2 [Member]</link:label>
    <link:label xlink:label="gnpx_WarrantForServiceProvider2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">related to the 2nd warrant for service provider.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_WarrantForServiceProvider2Member" xlink:to="gnpx_WarrantForServiceProvider2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, number of shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_ResearchAndDevelopmentAssetsCurrent</link:label>
    <link:label xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Assets, Current</link:label>
    <link:label xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research and development assets classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:to="gnpx_ResearchAndDevelopmentAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock $0.001 par value: 200,000,000 shares authorized; 48,105,962 and 47,874,708 shares issued and outstanding, respectively</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantMember" xlink:label="gnpx_ConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label xlink:label="gnpx_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ConsultantMember" xlink:to="gnpx_ConsultantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ErrorCorrectionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Correction [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionTextBlock" xlink:to="us-gaap_ErrorCorrectionTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options expired or cancelled, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockParOrStatedValuePerShare</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to intellectual property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:to="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued, number of warrants (in shares)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="gnpx_ClassOfWarrantOrRightIssuedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, number of warrants (in shares)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancelled or expired, number of warrants (in shares)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights cancelled during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorPolicyTextBlock" xlink:label="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="gnpx_CorrectionOfErrorPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Correction of Error [Policy Text Block]</link:label>
    <link:label xlink:label="gnpx_CorrectionOfErrorPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of accounting policy for correction of errors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:to="gnpx_CorrectionOfErrorPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorsTableTextBlock" xlink:label="gnpx_CorrectionOfErrorsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="gnpx_CorrectionOfErrorsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Correction of Errors [Table Text Block]</link:label>
    <link:label xlink:label="gnpx_CorrectionOfErrorsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of correction of errors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_CorrectionOfErrorsTableTextBlock" xlink:to="gnpx_CorrectionOfErrorsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual property, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating (loss) gain</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:type="locator"/>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants</link:label>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)</link:label>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued in shares for exercise of cashless warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:to="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MdAndersonMember" xlink:label="gnpx_MdAndersonMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_MdAndersonMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MD Anderson [Member]</link:label>
    <link:label xlink:label="gnpx_MdAndersonMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MD Anderson.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_MdAndersonMember" xlink:to="gnpx_MdAndersonMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAgreementMember" xlink:label="gnpx_ResearchAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ResearchAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Agreement [Member]</link:label>
    <link:label xlink:label="gnpx_ResearchAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ResearchAgreementMember" xlink:to="gnpx_ResearchAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LongTermContractEstimatedCost" xlink:label="gnpx_LongTermContractEstimatedCost" xlink:type="locator"/>
    <link:label xlink:label="gnpx_LongTermContractEstimatedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_LongTermContractEstimatedCost</link:label>
    <link:label xlink:label="gnpx_LongTermContractEstimatedCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Contract, Estimated Cost</link:label>
    <link:label xlink:label="gnpx_LongTermContractEstimatedCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated total cost of of long term contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_LongTermContractEstimatedCost" xlink:to="gnpx_LongTermContractEstimatedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyOnSalesPercentage" xlink:label="gnpx_RoyaltyOnSalesPercentage" xlink:type="locator"/>
    <link:label xlink:label="gnpx_RoyaltyOnSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_RoyaltyOnSalesPercentage</link:label>
    <link:label xlink:label="gnpx_RoyaltyOnSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty on Sales, Percentage</link:label>
    <link:label xlink:label="gnpx_RoyaltyOnSalesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of sales of royalty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_RoyaltyOnSalesPercentage" xlink:to="gnpx_RoyaltyOnSalesPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NationalInstituteOfHealthMember" xlink:label="gnpx_NationalInstituteOfHealthMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_NationalInstituteOfHealthMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Health [Member]</link:label>
    <link:label xlink:label="gnpx_NationalInstituteOfHealthMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the national institute of health (NIH).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_NationalInstituteOfHealthMember" xlink:to="gnpx_NationalInstituteOfHealthMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ContingentPaymentsAnnualIncrease" xlink:label="gnpx_ContingentPaymentsAnnualIncrease" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ContingentPaymentsAnnualIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_ContingentPaymentsAnnualIncrease</link:label>
    <link:label xlink:label="gnpx_ContingentPaymentsAnnualIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Payments Annual Increase</link:label>
    <link:label xlink:label="gnpx_ContingentPaymentsAnnualIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual increase in contingent payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ContingentPaymentsAnnualIncrease" xlink:to="gnpx_ContingentPaymentsAnnualIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPaymentAnnualMinimum" xlink:label="gnpx_RoyaltyPaymentAnnualMinimum" xlink:type="locator"/>
    <link:label xlink:label="gnpx_RoyaltyPaymentAnnualMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_RoyaltyPaymentAnnualMinimum</link:label>
    <link:label xlink:label="gnpx_RoyaltyPaymentAnnualMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payment, Annual Minimum</link:label>
    <link:label xlink:label="gnpx_RoyaltyPaymentAnnualMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum of annual royalty payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_RoyaltyPaymentAnnualMinimum" xlink:to="gnpx_RoyaltyPaymentAnnualMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyTerms" xlink:label="gnpx_RoyaltyTerms" xlink:type="locator"/>
    <link:label xlink:label="gnpx_RoyaltyTerms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_RoyaltyTerms</link:label>
    <link:label xlink:label="gnpx_RoyaltyTerms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term (Year)</link:label>
    <link:label xlink:label="gnpx_RoyaltyTerms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Terms of the royalty agreement, as a percentage of net sales of licensed technologies .</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_RoyaltyTerms" xlink:to="gnpx_RoyaltyTerms-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="gnpx_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the 2018 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_The2018EquityIncentivePlanMember" xlink:to="gnpx_The2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EmployeeStockPurchasePlanMember" xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the 2018 employee stock purchase plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:to="gnpx_The2018EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear</link:label>
    <link:label xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year</link:label>
    <link:label xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award percentage applied on outstanding shares of common stock for automatically increase on each year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:to="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantsMember" xlink:label="gnpx_BearCreekCapitalWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bear Creek Capital Warrants [Member]</link:label>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Bear Creek Capital warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_BearCreekCapitalWarrantsMember" xlink:to="gnpx_BearCreekCapitalWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of warrants (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, number of warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanCostRecognized</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashEquivalentsAtCarryingValue</link:label>
    <link:label xlink:label="us-gaap_CashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantOneMember" xlink:label="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bear Creek Capital Warrant One [Member]</link:label>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Bear Creek Capital warrant one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_BearCreekCapitalWarrantOneMember" xlink:to="gnpx_BearCreekCapitalWarrantOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantTwoMember" xlink:label="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bear Creek Capital Warrant Two [Member]</link:label>
    <link:label xlink:label="gnpx_BearCreekCapitalWarrantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Bear Creek Capital warrant two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_BearCreekCapitalWarrantTwoMember" xlink:to="gnpx_BearCreekCapitalWarrantTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockSharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDepositOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMilestonePayment" xlink:label="gnpx_LicenseAgreementMilestonePayment" xlink:type="locator"/>
    <link:label xlink:label="gnpx_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_LicenseAgreementMilestonePayment</link:label>
    <link:label xlink:label="gnpx_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Payment</link:label>
    <link:label xlink:label="gnpx_LicenseAgreementMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of milestone payments made for License Agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_LicenseAgreementMilestonePayment" xlink:to="gnpx_LicenseAgreementMilestonePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:type="locator"/>
    <link:label xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount</link:label>
    <link:label xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cost not yet recognized for nonvested warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:to="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PerformancebasedWarrantMember" xlink:label="gnpx_PerformancebasedWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_PerformancebasedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance-based Warrant [Member]</link:label>
    <link:label xlink:label="gnpx_PerformancebasedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to performance-based warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_PerformancebasedWarrantMember" xlink:to="gnpx_PerformancebasedWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantWarrantsMember" xlink:label="gnpx_ConsultantWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ConsultantWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label xlink:label="gnpx_ConsultantWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to consultant warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ConsultantWarrantsMember" xlink:to="gnpx_ConsultantWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_ClassOfWarrantOrRightExercisableExercisePrice</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:to="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisable" xlink:label="gnpx_ClassOfWarrantOrRightExercisable" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, number of warrants (in shares)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightExercisable" xlink:to="gnpx_ClassOfWarrantOrRightExercisable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares &#8212; basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss per share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share &#8212; basic and diluted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:type="locator"/>
    <link:label xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_SharebasedPaymentArrangementExpenseFutureMilestone</link:label>
    <link:label xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Future Milestone</link:label>
    <link:label xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the share-based compensation expense based on future milestone.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:to="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:type="locator"/>
    <link:label xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies</link:label>
    <link:label xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions (additions) to research and development supplies</link:label>
    <link:label xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow or inflow for research and development supplies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:to="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Manufacturing of GMP Grade Materials [Member]</link:label>
    <link:label xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to development and manufacturing of GMP grade materials.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:to="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:type="locator"/>
    <link:label xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost</link:label>
    <link:label xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Services Agreement, Expected Total Project Cost</link:label>
    <link:label xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected total project cost under development services agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:to="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options exercised, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherCommitment</link:label>
    <link:label xlink:label="us-gaap_OtherCommitment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitment, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued with Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued in connection with Registered Direct Offering</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:to="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="gnpx_RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Registered Direct Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_RegisteredDirectOfferingMember" xlink:to="gnpx_RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax provision at the federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_InvestorsMember" xlink:label="gnpx_InvestorsMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_InvestorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investors [Member]</link:label>
    <link:label xlink:label="gnpx_InvestorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the investors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_InvestorsMember" xlink:to="gnpx_InvestorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock for cash (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock for services</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock for services (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseAgreementTermsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashUninsuredAmount</link:label>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock for cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EffectOfCovid19PandemicTextBlock" xlink:label="gnpx_EffectOfCovid19PandemicTextBlock" xlink:type="locator"/>
    <link:label xlink:label="gnpx_EffectOfCovid19PandemicTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Covid 19 Pandemic [Text Block]</link:label>
    <link:label xlink:label="gnpx_EffectOfCovid19PandemicTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for effects of COVID-19 pandemic.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_EffectOfCovid19PandemicTextBlock" xlink:to="gnpx_EffectOfCovid19PandemicTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancelled or expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights cancelled during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicensingFeeAmount" xlink:label="gnpx_LicensingFeeAmount" xlink:type="locator"/>
    <link:label xlink:label="gnpx_LicensingFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_LicensingFeeAmount</link:label>
    <link:label xlink:label="gnpx_LicensingFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Fee, Amount</link:label>
    <link:label xlink:label="gnpx_LicensingFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the agreed upon licensing fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_LicensingFeeAmount" xlink:to="gnpx_LicensingFeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMember" xlink:label="gnpx_LicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label xlink:label="gnpx_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An agreement where another party is permitted the right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_LicenseAgreementMember" xlink:to="gnpx_LicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excluding the 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">represents information excluding the 2018 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:to="gnpx_ExcludingThe2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:type="locator"/>
    <link:label xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent</link:label>
    <link:label xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Percent, Licensed Technology Covered by Patent</link:label>
    <link:label xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales of licensed technology covered by patents to be earned as royalty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:to="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplies</link:label>
    <link:label xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research and development assets classified as noncurrent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:to="gnpx_ResearchAndDevelopmentAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:type="locator"/>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_AnnualMaintenanceFeeAfterYearThreeAmount</link:label>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee, After Year Three, Amount</link:label>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The annual maintenance fee after the third year of an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:to="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_StockIssuedDuringPeriodSharesWarrantsIssued</link:label>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Issued (in shares)</link:label>
    <link:label xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:to="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:type="locator"/>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount</link:label>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee, First Three Years, Amount</link:label>
    <link:label xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of annual maintenance fees for the first three years of an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:to="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UniversityOfPittsburghMember" xlink:label="gnpx_UniversityOfPittsburghMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_UniversityOfPittsburghMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Pittsburgh [Member]</link:label>
    <link:label xlink:label="gnpx_UniversityOfPittsburghMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the University of Pittsburgh.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_UniversityOfPittsburghMember" xlink:to="gnpx_UniversityOfPittsburghMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:type="locator"/>
    <link:label xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_ShareOfNonroyaltySublicenseIncomePercent</link:label>
    <link:label xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of Non-Royalty Sublicense Income, Percent</link:label>
    <link:label xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:to="gnpx_ShareOfNonroyaltySublicenseIncomePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:type="locator"/>
    <link:label xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_AnnualRoyaltyPaymentPerYearMinimum</link:label>
    <link:label xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Royalty Payment Per Year, Minimum</link:label>
    <link:label xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum amount of royalty payment to be received each year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:to="gnpx_AnnualRoyaltyPaymentPerYearMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="locator"/>
    <link:label xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dosing of First Human Patient in a Phase I Clinical Trial [Member]</link:label>
    <link:label xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The scenario of a dosing of first human patient in a Phase I clinical trial.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:to="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember-label" xlink:type="arc"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MilestonePayment" xlink:label="gnpx_MilestonePayment" xlink:type="locator"/>
    <link:label xlink:label="gnpx_MilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">gnpx_MilestonePayment</link:label>
    <link:label xlink:label="gnpx_MilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment</link:label>
    <link:label xlink:label="gnpx_MilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of a payment to be received upon achievement of an agreed upon milestone.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gnpx_MilestonePayment" xlink:to="gnpx_MilestonePayment-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>gnpx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:20PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ErrorCorrectionTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-8-significant-events-" xlink:href="gnpx-20221231.xsd#statement-note-8-significant-events-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-8-significant-events-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EffectOfCovid19PandemicTextBlock" xlink:label="gnpx_EffectOfCovid19PandemicTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="gnpx_EffectOfCovid19PandemicTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions" xlink:href="gnpx-20221231.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-3-intellectual-property" xlink:href="gnpx-20221231.xsd#statement-note-3-intellectual-property" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-3-intellectual-property" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation" xlink:href="gnpx-20221231.xsd#statement-note-1-description-of-business-and-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-document-and-entity-information" xlink:href="gnpx-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals" xlink:href="gnpx-20221231.xsd#statement-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity" xlink:href="gnpx-20221231.xsd#statement-note-4-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantOneMember" xlink:label="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantTwoMember" xlink:label="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantsMember" xlink:label="gnpx_BearCreekCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantMember" xlink:label="gnpx_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_InvestorsMember" xlink:label="gnpx_InvestorsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PerformancebasedWarrantMember" xlink:label="gnpx_PerformancebasedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EmployeeStockPurchasePlanMember" xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_TimeBasedOptionsMember" xlink:label="gnpx_TimeBasedOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_VestingOfWarrantsForServiceProviderMember" xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProvider2Member" xlink:label="gnpx_WarrantForServiceProvider2Member" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProviderMember" xlink:label="gnpx_WarrantForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServicesProvidedAtIpoMember" xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_InvestorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServiceProviderMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServiceProvider2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="gnpx_TimeBasedOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_PerformancebasedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions" xlink:href="gnpx-20221231.xsd#statement-note-5-401k-savings-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies" xlink:href="gnpx-20221231.xsd#statement-note-7-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMember" xlink:label="gnpx_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MdAndersonMember" xlink:label="gnpx_MdAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NationalInstituteOfHealthMember" xlink:label="gnpx_NationalInstituteOfHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAgreementMember" xlink:label="gnpx_ResearchAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UniversityOfPittsburghMember" xlink:label="gnpx_UniversityOfPittsburghMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_ResearchAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_MdAndersonMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_NationalInstituteOfHealthMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_LicenseAgreementTermsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_UniversityOfPittsburghMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events" xlink:href="gnpx-20221231.xsd#statement-note-10-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantWarrantsMember" xlink:label="gnpx_ConsultantWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NonexecutiveEmployeesMember" xlink:label="gnpx_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NotesToFinancialStatementsAbstract" xlink:label="gnpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_ConsultantWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="gnpx-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorPolicyTextBlock" xlink:label="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-significant-accounting-policies-policies" xlink:label="gnpx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gnpx_CorrectionOfErrorPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CorrectionOfErrorsTableTextBlock" xlink:label="gnpx_CorrectionOfErrorsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="gnpx_CorrectionOfErrorsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-tables" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-tables" xlink:label="gnpx_statement-statement-note-4-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-4-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-9-income-taxes-tables" xlink:label="gnpx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsCurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ResearchAndDevelopmentAssetsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantOneMember" xlink:label="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantTwoMember" xlink:label="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BearCreekCapitalWarrantsMember" xlink:label="gnpx_BearCreekCapitalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_BrokerageCommissionsPercentageOfGrossProceeds" xlink:label="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_CommonStockSharesAuthorizedValue" xlink:label="gnpx_CommonStockSharesAuthorizedValue-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantMember" xlink:label="gnpx_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:label="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_InvestorsMember" xlink:label="gnpx_InvestorsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PerformancebasedWarrantMember" xlink:label="gnpx_PerformancebasedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear" xlink:label="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_SharebasedPaymentArrangementExpenseFutureMilestone" xlink:label="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants" xlink:label="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_StockIssuedDuringPeriodSharesWarrantsIssued" xlink:label="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EmployeeStockPurchasePlanMember" xlink:label="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_TimeBasedOptionsMember" xlink:label="gnpx_TimeBasedOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_VestingOfWarrantsForServiceProviderMember" xlink:label="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProvider2Member" xlink:label="gnpx_WarrantForServiceProvider2Member" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServiceProviderMember" xlink:label="gnpx_WarrantForServiceProviderMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantForServicesProvidedAtIpoMember" xlink:label="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount" xlink:label="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_InvestorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServiceProviderMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServiceProvider2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantForServicesProvidedAtIpoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_VestingOfWarrantsForServiceProviderMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="gnpx_TimeBasedOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantOneMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_BearCreekCapitalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_ExcludingThe2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_PerformancebasedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_CommonStockSharesAuthorizedValue-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_BrokerageCommissionsPercentageOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_StockIssuedDuringPeriodSharesWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_SharebasedPaymentArrangementExpenseFutureMilestone-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-5-401k-savings-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-7-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeAfterYearThreeAmount" xlink:label="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount" xlink:label="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualRoyaltyPaymentPerYearMinimum" xlink:label="gnpx_AnnualRoyaltyPaymentPerYearMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ContingentPaymentsAnnualIncrease" xlink:label="gnpx_ContingentPaymentsAnnualIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:label="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost" xlink:label="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:label="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMember" xlink:label="gnpx_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicenseAgreementMilestonePayment" xlink:label="gnpx_LicenseAgreementMilestonePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LicensingFeeAmount" xlink:label="gnpx_LicensingFeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_LongTermContractEstimatedCost" xlink:label="gnpx_LongTermContractEstimatedCost-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MdAndersonMember" xlink:label="gnpx_MdAndersonMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_MilestonePayment" xlink:label="gnpx_MilestonePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NationalInstituteOfHealthMember" xlink:label="gnpx_NationalInstituteOfHealthMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAgreementMember" xlink:label="gnpx_ResearchAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyOnSalesPercentage" xlink:label="gnpx_RoyaltyOnSalesPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPaymentAnnualMinimum" xlink:label="gnpx_RoyaltyPaymentAnnualMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent" xlink:label="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RoyaltyTerms" xlink:label="gnpx_RoyaltyTerms-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ShareOfNonroyaltySublicenseIncomePercent" xlink:label="gnpx_ShareOfNonroyaltySublicenseIncomePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UniversityOfPittsburghMember" xlink:label="gnpx_UniversityOfPittsburghMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:label="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_ResearchAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_MdAndersonMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_NationalInstituteOfHealthMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_LicenseAgreementTermsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="gnpx_UniversityOfPittsburghMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LongTermContractEstimatedCost-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyOnSalesPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyTerms-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyPaymentAnnualMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LicenseAgreementMilestonePayment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ContingentPaymentsAnnualIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitment-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_LicensingFeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualMaintenanceFeeAfterYearThreeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualRoyaltyPaymentPerYearMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ShareOfNonroyaltySublicenseIncomePercent-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_MilestonePayment-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual" xlink:href="gnpx-20221231.xsd#statement-note-10-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_AnnualIncentiveAwards" xlink:label="gnpx_AnnualIncentiveAwards-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ConsultantWarrantsMember" xlink:label="gnpx_ConsultantWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_EquityOfferingCombinedPurchasePrice" xlink:label="gnpx_EquityOfferingCombinedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NonexecutiveEmployeesMember" xlink:label="gnpx_NonexecutiveEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_NoteToFinancialStatementDetailsTextual" xlink:label="gnpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_RegisteredDirectOfferingMember" xlink:label="gnpx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ScientificAdvisoryBoardChairmanMember" xlink:label="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2018EquityIncentivePlanMember" xlink:label="gnpx_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_The2022AtmFacilityMember" xlink:label="gnpx_The2022AtmFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:label="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="gnpx_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_ScientificAdvisoryBoardChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_The2022AtmFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_ConsultantWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="gnpx_NonexecutiveEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="gnpx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_AnnualIncentiveAwards-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_EquityOfferingCombinedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-assumptions-details" xlink:label="gnpx_statement-statement-note-4-equity-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-4-equity-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:href="gnpx-20221231.xsd#statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:label="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisable" xlink:label="gnpx_ClassOfWarrantOrRightExercisable" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisableExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:label="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisable" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gnpx_ClassOfWarrantOrRightExercisableExercisePrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details" xlink:href="gnpx-20221231.xsd#statement-note-4-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:label="gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-4-equity-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity" xlink:href="gnpx-20221231.xsd#statement-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:href="gnpx-20221231.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies" xlink:label="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:href="gnpx-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:label="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses-1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest-1" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:href="gnpx-20221231.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:href="gnpx-20221231.xsd#statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:label="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpenses-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:href="gnpx-20221231.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.genprex.com/20221231/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="gnpx-20221231.xsd#gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:label="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="gnpx_ResearchAndDevelopmentAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a1new.jpg
<TEXT>
begin 644 a1new.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!.17AI9@  34T *@    @ ! ,"  (
M   (    /E$0  $    ! 0   %$1  0    !   6)5$2  0    !   6)0
M  !$:7-P;&%Y /_B$ A)0T-?4%)/1DE,10 ! 0  #_AA<'!L A   &UN=')2
M1T(@6%E:( ?G  $  0 ) #$ !&%C<W!!4%!,     $%04$P
M          #VU@ !     -,M87!P;
M                                $F1E<V,   %<    8F1S8VT   '
M   $G&-P<G0   9<    (W=T<'0   :     %')865H   :4    %&=865H
M  :H    %&)865H   :\    %')44D,   ;0   (#&%A<F<   [<    ('9C
M9W0   [\    ,&YD:6X   \L    /F-H860   ]L    +&UM;V0   ^8
M*'9C9W    _     .&)44D,   ;0   (#&=44D,   ;0   (#&%A8F<   [<
M    (&%A9V<   [<    (&1E<V,         "$1I<W!L87D
M
M                                  !M;'5C         "8    ,:')(
M4@   !0   '8:V]+4@    P   'L;F).3P   !(   'X:60      !(   (*
M:'5(50   !0   (<8W-#6@   !8   (P9&%$2P   !P   )&;FQ.3    !8
M  )B9FE&20   !    )X:71)5    !@   *(97-%4P   !8   *@<F]23P
M !(   *V9G)#00   !8   +(87(      !0   +>=6M500   !P   +R:&5)
M3    !8   ,.>FA45P    H   ,D=FE63@    X   ,N<VM32P   !8   ,\
M>FA#3@    H   ,D<G5250   "0   -296Y'0@   !0   -V9G)&4@   !8
M  .*;7,      !(   .@:&E)3@   !(   .R=&A42     P   /$8V%%4P
M !@   /096Y!50   !0   -V97-83    !(   *V9&5$10   !    /H96Y5
M4P   !(   /X<'1"4@   !@   0*<&Q03    !(   0B96Q'4@   "(   0T
M<W9310   !    16=')44@   !0   1F<'105    !8   1Z:F%*4     P
M  20 $P 0P!$ "  =0 @ &( ;P!J &G.[+?L "  3 !# $0 1@!A '( 9P!E
M "T 3 !# $0 3 !# $0 ( !7 &$ <@!N &$ 4P!Z .T ;@!E ', ( !, $,
M1 !" &$ <@!E '8 ;@#] "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K
M .8 <@!M $L ; !E '4 <@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0
M3 !# $0 ( !A "  8P!O &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R
M $P 0P!$ "  8P!O &P ;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P
M0P!$ " &109$!D@&1@8I!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" /
M $P 0P!$ " %Y@71!>(%U07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4
M1@!A '( 90!B &X _0 @ $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T
M!#@$000_!#L$-00Y $, ;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\
M=0!L &4 =0!R %< 80!R &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$
M $P 0P!$ " .*@XU $P 0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &(
M+0!, $, 1 !# &\ ; !O '( ( !, $, 1 !, $, 1  @ $, ;P!L &\ <@!I
M &0 ;P!+ &\ ; !O '( ( !, $, 1 .( [,#QP/! \D#O .W " #OP.X \P#
MO0.W "  3 !# $0 1@#D '( 9P M $P 0P!$ %( 90!N &L ; !I "  3 !#
M $0 3 !# $0 ( !A "  0P!O '( 90!S,*LPZ3#\ $P 0P!$=&5X=     !#
M;W!Y<FEG:'0@07!P;&4@26YC+BP@,C R,P  6%E:(        /,6  $    !
M%LI865H@        @O0  #UD____O%A96B        !,)   M(4   KF6%E:
M(        ">^   .%P  R(MC=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #8 .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M2_[<_VW__W!A<F$       ,    "9F8  /*G   -60  $]    I;=F-G=
M       !  $          0    $          0    $          0  ;F1I
M;@         V  "N    4@   $/   "PP   )H    U   !0    5$   C,S
M  (S,P ",S,          '-F,S(       $,<@  !?C___,=   'N@  _7+_
M__N=___]I    ]D  ,!Q;6UO9         80  "@0     #5&&2
M             '9C9W        ,    "9F8  P    )F9@ #     F9F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!4T#_D!67_7!/\ T$5;JIH'_("LO^N"?^@BK= !17*_
M&WXT>&_V=OA/KWC?Q?J4>D>&_#=HUY?W3@MY:+V '+,20H4<DD =:\=_9]_X
M*#77QW\?Z+I,_P %?C-X/TCQ/$\^D:]K>BQQV%PBQF4&8QRN]OO0942J,D@=
M:TC3DUS):&<JT(R4&]6?1E%?*7P3_P""HDW[0>OP)X5^!_Q<U+P[)KTV@2>(
MDM[(:= \-RUO-,Q-QO\ +1E8DA2< \$\5U/P1_X*5?#OX^>&_BU=:*^H+J7P
M9N]0MM?TF=46\*VGF'SXEW$-%+Y3[&R.00<&JEAZBW1G'%4I6L]]O/T/H2BO
MDW7?^"L6CA?A;!X:^&?Q&\;:M\6/"9\8Z9INCP6K7%K9 QAO.\R9%#*94S@D
M<]:N^/?^"FTGP_N_A[H]Q\&/BK<>-/B-;ZE=67A>*"R_M*TBLF42/,#<",!E
M<.N'/R]<'BCZO4[!];I=_P ^MO\ -'U+17CO[+/[:OAO]J/1/%CPZ7XB\'ZW
MX"O?[/\ $FB>([5;2]T>4Q"92^UF0QM&0RNK$$9JE^P[^WWX'_;\\'>(M9\%
MKJ<$?AK5I-+N8-0A$,SJ!NAN54$YAF3YD;N >!BI=*:NVMMRXUZ;:2>][?+<
M]OHKS']D/]J;1?VR/@E:>.O#]CJ>G:;>7MY8K!?HJSA[:XDMW)"LPP6C)'/0
MCI6'^U;^V[H_[+WB3PKX9B\->*O'GCGQL;AM%\-^';9)KRZBMU#3S,TCI''$
M@899FZD  ]CV<N;DMJ/VT%#VE]/\]CVJBOE_Q'_P4IOO#_P=7QA_PH?XVR)9
M7-Y;ZWI[Z3;P76A"VC25YI?,G"R0LK962)G!VMZ5S_AW_@K]H^I_!&W^(FI_
M"GXH>'?".J76D6ND:AJ%M:+'K/\ :5PL$+P;9V)5=RNVX#Y2,9/%5]7J/5(R
M^N4D[-^>S/L"BO,_B=^U)HOPL_:'^'7PWO;'4I]7^)4.IS:?<0JIM[<6, GE
M\TE@1N4X7 //7%?.OA+_ (+<^$=6\"Z?XVUKX7_%WPS\,M1NC:KXTNM(AGT>
MV(G,!DF:&5Y(XA(I4N4P,41H5)*Z7]?TASQ5*#M)_P!:?YK[S[6HKPW0_P#@
MH#X&?XU>.? WB!KKPAJ/@K1E\3I>:JT:6.N:,5W-J-I*K$20H?E<'#(<9'.:
MWOV:/VK])_:3_9]3XG1Z/K7A/PI=+/=V4VO1I;2W-A'DK>E Q*12*I==^&VX
M) R*F5*:5VOZ9<:T).R??\-SU2BOE?X/_P#!4_3OCGXGT&3PY\(_C)?> /%&
MH+IVE>-AH:?V3=,S^6L^WS//6V+ _OFC"XY.!7J'P*_:]T'X^^!?'VOZ7IVK
M6MK\/?$.J>'+Z.Y1 ]S/88\UXMK$%&S\N<'U HE1G'="AB*<_A9ZQ17S[_P\
M<\$P?\$_K;]HJZLM:M?"=[I2ZG;:<T2-J5PSR>5%;H@;:TKR855#?Q5?\3?M
M_P#@O0?V#9/VA+>#5-4\&QZ*FM&VMXU^V[6=4:$JS!1*CDHP+<%&&:/8S[=;
M?/L'UBGWZ7^7<]SHKYJ^$?\ P4ITWQS\8O"_@CQ5\-?B5\,=6\=132>&Y_$=
MC MGK#0Q>=)$DL,L@601_,%8#(S]*Z'6_P#@H/X!T#]N;2_@#/)J'_"8:II1
MU%;D1K]@AEVM(EF\F<BX>%'E5,<J/>G[&=[6Z7^0+$4VKWZV^?8]THKP7]I_
M]OO0_P!G;XF:/X"TOPIXQ^)/Q$URR?5(?#GA>T2>YM[)&V&YG>1TCAC+?*"S
M98C %>?_ !5_X*S)\(OA&/'&J_ OXW6_AVQMIYM;N+G2;>V.@/#+Y3I.))P2
M"<,KQ[E92"#3CAZDK-+<F6*I1;3>VY]=45\D^(?^"K0\'_#WP[K6L?!/XN:9
M?>,/$,'AW0-'GM;,7VLRS6SW"RP@7!7R]J$99@<]L<UI>./^"FLOPO\ A19^
M)/$WP7^*V@WVL>*;/PGI&A75O9_VCJUS<QN\;PA9RFS*%"68'<1QCFCZO4[?
MD+ZW2[_@SZDHKYI\#_\ !370==D\?:;XB\!_$+P%XL^'WA>;QC=:#KUC%'<Z
MAID8?,]L\<KQ2#>A0C<"&(S[96M_\%6M!NQX-L?!GPY^(WQ$\4>+O"EIXU?1
M-"M(&N-'TRY'[J2Y>25(U9FRH168D@]L9/J]3:P_K5*U[GU717R;\;O^"KEM
M\#_A'IWCS4/@O\9I/"-QIG]H:A?R:3!:_P!A-]H: P74<LRND@<#H&4AU()!
MK:\/?\%)[634?A_9^)_A?\1_ M]\2O% \+Z/;ZW;VR22.;5KG[2?+F?]SM4K
MG[V[MCFCZO4M>P?6J5[7_/KL?3%%?*OC7_@JMHMA\1O%&B^"_AA\5_BEIO@2
M];3O$FN>%M(CN;'3;E #+ A>5&N)(P?F6)6P>.36I\6?^"EFG>"_BK<>"?"/
MPS^)WQ.\2:/I5IK.NV?A[3HMV@P72EX%G\^2/]\Z@D1+EL"CZO4[!]:I=_Z\
MN_R/I:BN?^%'Q%M_BY\-]%\36NGZUI-OKEJEW'9ZM9M9WUL&'W)H6YC<=U/2
MN@K%Z:,W335T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'7A#X\:UXHU/XU>#-6U'Q]XDN=*TK2?$5SI-EJUJS;K>X6W3Y9!-DC?_ !@
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MG7A$$ $_/WMGR;]FW=MXW;L<5ZE117/*5VV=D(\L5'>P4445)04444 %%%%
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MDDFOZ*J_!?\ :VTBT\/_ /!QUX9L-/M;6QL;+Q9X:@M[:VB6&&"-;>W"JB*
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4450\5>)['P3X8U+6=4N8[/3-)M9+R[N)#A8(HU+NY]@H)_"@#
M\JO^#G;]L3^P? OA7X(:1=8NO$3KK_B!8VY6TB<BWA;'_/28%R#VA'K67_P;
M!_L@>1IOC#XX:M:_->,WAOP\SKTB0A[N9?\ ><)&"/\ GFXK\R_VT?VE[_\
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M^Q'^Q)X)_8)^"%KX(\%6TIA60W-_J-UM:]U:X;K-,P !;&%   50  *_&/\
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M++I_D74E[>7LFIQK%%*'@DFO[@R6GRDA(0'.#7J7Q2^-_P =O&7[9GCKX?\
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MT+Q;\3?&&N:]XEM-.TCPMHD<%P++2-0>UN)Y!/<"-8XB8HQ(T@,SNNQ 6VJ
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M8_ ']F&U_9]O=2GMO&GQ,\6'4HXXV3Q5XGN=82WV$G,0E)\LG=R1UP/2O,=
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MEG\7M%\7WGC!OB-X9U1AJNIZK(K6YU(^?$4C\^T*PR691X%C7RURJJ1]G44
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M&^J->OJ7@>SU2QL[977[+<1:A'#'.)D*DMA85VX(QELYS7?44 ?).D?\$>_
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MVH>*M+CT+1=/N8]4L!I$&IW$$XN'F9)7F7361X_+4*95*L<$'S/Q%^VE\5_
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M:^D** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(,K'9)Y; '% 'Z >!_BQX=^).K^)-/T/5K;4KSPAJ9T?68HL[M/NQ#%/Y+Y
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MYT/VJ> O9O*\>55Y5\MXO,="V$QG %?+W@?]GS5_$/QMC^$&J>//'7C#P_\
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M<YJ7Q4\5>*O[6\%_#/XP?$G4?A#>?&KP=X:\/>,[;5Y;Z_:WO+61M9L+;4I
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MK1UW]BOX6>)/CQ;_ !.N_!>E-X\M9(IAJ\9DAEFDB4I%)*J,$E=%.U6D5BH
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M7;:BP#S02)OCAN@0WD2JZ@$# !^L%1WEY#I]K)/<2QP00J7DDD8*J*.223P
M/4U\;?\ !.W]IK3_ /ACGXI:]#IOC#6%^&FHZB+HP>++CQG;:X]O91W#?V-J
M$^)+B!\[51@"DQ=#R":_/SQG\;->_:*^#/QZT'2/%GBO5O!_B#X%_P#";3Z7
M8>/M1\5S:=J":C"VR6[>&,07(MW=9[2WS'M0 J.,@'[F7E[#IUG+<7$T<%O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *F@?\@*R_ZX)_Z"*MU4T#_D!67_ %P3_P!!%6Z
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MA:[I6OZQ9_VQ'_:.FW]K<NAN=2-F9W,MDR-(BNH$;,@/VM_P2(\*6?@#P/\
M$S4M)\92>(/!U]JL%UI^B6?A#6=!TWPTZ6JK<1V<6IO)<2+*565U1BBR%P "
MQ% 'K_P$_;@^"OQ_^*4OAGP7KEK<>)5M);^WBFT:YT]M1MHW6*6:UDGAC6YC
M1V56:$L!N&>"":GQ\_X*)? O]G'XLS^&?'?BJWT?Q%I-C;ZE>/)HMY<0Z5;3
MLZPS7%U'"\5NC-')AI'4#82<#FOG[]C;]I_1_P!NG]O"U^(?B6S\9>%[[P_I
M^I:#\.O"&I^$=4L9;"TD9&O=4U"YEMU@6YNEMHA' ),10H 2TDC;>(_X*"_
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M!"&F,XEV*0^UU;H10!^I<VG6]Q>0W$EO#)<6X812L@+Q;N&VGJ,]\=:X_P"
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M8#&6 ,/A']N/X/Z_\=+KX5Z'J5U=>*=)U&72KFUL_#=^UC9W<:>=)"]VMO\
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M_P *=?\ Y'KN_LW$?R_BO\SS/[8PG\WX/_(_82BOQ[_XBL)/^B'O_P"%.O\
M\CT?\16$G_1#W_\ "G7_ .1Z/[-Q'\OXK_,7]L83^;\'_D?L)17X]_\ $5A)
M_P!$/?\ \*=?_D>C_B*PD_Z(>_\ X4Z__(]']FXC^7\5_F']L83^;\'_ )'[
M"45^/?\ Q%82?]$/?_PIU_\ D>C_ (BL)/\ HA[_ /A3K_\ (]']FXC^7\5_
MF']L83^;\'_D?L)1CG-?CW_Q%82?]$/?_P *=?\ Y'H_XBL)/^B'O_X4Z_\
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M?Q7^8?VQA/YOP?\ D?L)17X]_P#$5A)_T0]__"G7_P"1Z/\ B*PD_P"B'O\
M^%.O_P CT?V;B/Y?Q7^8?VQA/YOP?^1^PE%?CW_Q%82?]$/?_P *=?\ Y'H_
MXBL)/^B'O_X4Z_\ R/1_9N(_E_%?YA_;&$_F_!_Y'["45^/?_$5A)_T0]_\
MPIU_^1Z/^(K"3_HA[_\ A3K_ /(]']FXC^7\5_F']L83^;\'_D?L)17X]_\
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M>_\ X4Z__(]']FXC^7\5_F']L83^;\'_ )'["45^/?\ Q%82?]$/?_PIU_\
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M3M<U#PAXY^'MQX%;XC3^!O+74;B63P;.V^6W@OW:,LS"%0&:/>0WR\FHX_\
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MO;:TTJ""X-RKQW,<JW)9IB6<%\2# /NKXB[2_3^K_@5RX3E3?Z_U;\2AK?\
MP2>\6?"W1/$FN>./&GPY\+Z;X-\6MX3N(-1O;@2:U>K%#<1PVOEQDM]HCE4*
M3@KDEL8KNOB9_P $@]6\7?&CQ(VG>(OA;\*=";QU_P (%I&CW^KWMV)-4^RP
M3);6\IB,DHD\T89P-ISG@#/D?[4'_!2KQ=^U;H-UI^N>'O#>FQW?CE/'S/8F
M;<MVMI#:B ;V/[G9"K?WLD\XK7^(W_!5SQK\2_%>F:Q>>&/"MO<:7\34^*4:
M1-.4>_2WA@%L<MGR-L"G(^?)//2GRXC1]?\ AA<V$5TD[:?K_P  O_"__@D#
MXX\>3^'M/UGQM\.? OB3QEK6H:)X<T/6[V;[9KCV$SPW4L7EQLHC5T<+N(+[
M>!R!3?\ @E]^RAX=^/WQ]^*/AOQ9X3F\>7/@GPEJ>HZ9HMOJDFFKJ>I6MPD2
M1^>I4JKDL,D@#()Z5[K^R?\ \%7OAWH-OHOB_P"*EQ;ZAXL\)>(]9\1:3HX\
M$F^N-*^WS23-:Z;J/GJL4;O(=QGC9DR=IZ$?&'P6_:SUKX%^)OB?J6DZ5IET
MWQ2T+4_#U]'=L_\ H-O?2^8[Q%2,R)@ 9XZ\4E[:2E%_+[^GR'+ZO!PE'5=>
MO1;[];_Y'U-\:/\ @EKI/Q0UKP/I_@NQT'X*^/+[PSJ_B7QAX/UWQ4=8M/#E
MG92Q+'<M=H':/SDD9MCYVA">U>7^$/\ @DYXD\?Z5I<VC_$SX6WEYXQ:_;P+
M8?;9TN/'D-D"9I[,&/"(2K*GG;2Y4X&,5XQ^S/\ M(:K^RWJ/C"ZT73=-U*3
MQIX4O_"%X+TO^YM[Q55Y4VD$R*%&W=D>HKU#X$_\%.O%'P&^%_A'0[?P7X$\
M1:]\-;>^M?!/BC5+>9M2\+QW8;S5C".(Y<%F*>8IV$\4W&O%6B[_ -/];?+S
M)53#3=YJW]+M9:J[VM?R->T_X)*>,3X-N+F^\=?#G2?%UCX+F\?WO@NYO)CK
M=GI*1&59&58S'YCJ/N!LKN&>.:M6_P#P1]\:7OC#P[X=M_'GPYNO$&N:''XJ
MN=,@N+F6ZT/1FMA.;ZZ18B0H)$8C3=([L-H(.:]B\-_\%//AIHW[,6I7&N7S
M>,/BUJ7PTG\ &XD\%"SUAC+"8E6;4Q,T4EK%N)!6(2O@!O2OG/0O^"F7CGPY
M^TU9_%"UTGP_'J">$;;P1?Z4?.^PZKIL-NMN4D8.)5=U16W(P*L 14QEB'?^
MOZ14HX2-NM_/IY^9W'_#EGXC6+ZY>ZKXJ\&Z+X5TJTL+ZVU^Y@OV@U&*]5S
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M*P)5 [D#<0IP.IP:^>CFE?96^X^JED>%6KO]Y^$O_$-=^TE_SU^'/_@[E_\
MC%'_ !#7?M)?\]?AS_X.Y?\ XQ7[.?\ #POX#_\ 18OAI_X4=I_\71_P\+^
M_P#T6+X:?^%':?\ Q=7_ &ABNWX&7]DX'^;\4?C'_P 0UW[27_/7X<_^#N7_
M .,4?\0UW[27_/7X<_\ @[E_^,5^SG_#POX#_P#18OAI_P"%':?_ !==1\*O
MVG?AS\=-7NM/\%^.O"?BN^L81<7%OI.J0W<D$9.T.RQL2%)XR>,T/,L4E=K\
M!QR?!-V4OQ1^'?\ Q#7?M)?\]?AS_P"#N7_XQ1_Q#7?M)?\ /7X<_P#@[E_^
M,5^_U%9_VM7\ON-/[!PWG]Y^ /\ Q#7?M)?\]?AS_P"#N7_XQ1_Q#7?M)?\
M/7X<_P#@[E_^,5^_U%']K5_+[@_L'#>?WGX _P#$-=^TE_SU^'/_ (.Y?_C%
M'_$-=^TE_P ]?AS_ .#N7_XQ7[_44?VM7\ON#^P<-Y_>?@#_ ,0UW[27_/7X
M<_\ @[E_^,4?\0UW[27_ #U^'/\ X.Y?_C%?O]11_:U?R^X/[!PWG]Y^ /\
MQ#7?M)?\]?AS_P"#N7_XQ1_Q#7?M)?\ /7X<_P#@[E_^,5^_U%']K5_+[@_L
M'#>?WGX _P#$-=^TE_SU^'/_ (.Y?_C%'_$-=^TE_P ]?AS_ .#N7_XQ7[_4
M4?VM7\ON#^P<-Y_>?@#_ ,0UW[27_/7X<_\ @[E_^,4?\0UW[27_ #U^'/\
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M #U^'/\ X.Y?_C%'_$-=^TE_SU^'/_@[E_\ C%?O]11_:U?R^X/[!PWG]Y^
M/_$-=^TE_P ]?AS_ .#N7_XQ1_Q#7?M)?\]?AS_X.Y?_ (Q7[_44?VM7\ON#
M^P<-Y_>?@#_Q#7?M)?\ /7X<_P#@[E_^,4?\0UW[27_/7X<_^#N7_P",5^_U
M%']K5_+[@_L'#>?WGX _\0UW[27_ #U^'/\ X.Y?_C%'_$-=^TE_SU^'/_@[
ME_\ C%?O]11_:U?R^X/[!PWG]Y^ /_$-=^TE_P ]?AS_ .#N7_XQ1_Q#7?M)
M?\]?AS_X.Y?_ (Q7[_44?VM7\ON#^P<-Y_>?@#_Q#7?M)?\ /7X<_P#@[E_^
M,4?\0UW[27_/7X<_^#N7_P",5^_U%']K5_+[@_L'#>?WGX _\0UW[27_ #U^
M'/\ X.Y?_C%'_$-=^TE_SU^'/_@[E_\ C%?O]11_:U?R^X/[!PWG]Y^ /_$-
M=^TE_P ]?AS_ .#N7_XQ1_Q#7?M)?\]?AS_X.Y?_ (Q7[_44?VM7\ON#^P<-
MY_>?@#_Q#7?M)?\ /7X<_P#@[E_^,4?\0UW[27_/7X<_^#N7_P",5^_U%']K
M5_+[@_L'#>?WGX _\0UW[27_ #U^'/\ X.Y?_C%'_$-=^TE_SU^'/_@[E_\
MC%?O]11_:U?R^X/[!PWG]Y^ /_$-=^TE_P ]?AS_ .#N7_XQ1_Q#7?M)?\]?
MAS_X.Y?_ (Q7[_44?VM7\ON#^P<-Y_>?@#_Q#7?M)?\ /7X<_P#@[E_^,4?\
M0UW[27_/7X<_^#N7_P",5^_U%']K5_+[@_L'#>?WGX _\0UW[27_ #U^'/\
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MK_P<ZQK+_P $[M)#*K#_ (373N",_P#+*YK]"M _Y 5E_P!<$_\ 017Y[?\
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M%T[M._KIIUND?M]1117S!]J%%%% !1110 4444 %%%% !1110 4444 %%%%
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MS+M>TEMKO^S9'4R_VGLL?!-/:5VK>MGMY]/3;F?^&O;C_H Q?^!1_P#B:/\
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MEN/"VN^*&O/A+JZ^&?!>MV^@:UK<>MVS+9W$PAP1;G$LBJTZ E03U(!KS?\
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MN7^0?\07X3_Y\2_\#G_\D?I%_P /T?"O_1/_ !1_X%V_^-'_  _1\*_]$_\
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M (!UZ/4-/DVR+\LD;'Y)T[JP_KV-?3_P]^(5A\1]!6]LFVLORSP,?G@?T/\
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MM+?&VS\%:+<0PR7+3/+?.A>&W@BSF8@<D'Y0!GDN*]]_X+%QJWQ0^&F54_\
M%'1]O^FK5V'[!G[-GC'1/V*?'7C/PCID=UXX^(4#:/H9EN$M?LMB&*/.'<@#
M+%V&.3Y:5]!4RZC4S%X6C3M&%V[-MM))VZZMZ*W<_-,+Q3C\+PO'-\=BU*KB
M+0AS1A&,)N4H\S:2NDESRYM+1\SY,_:0^ FK?LR_&+5/!VL21W5QIXCEBNHT
M*QWD+KN210>G<$=BI%=O^SW^POK?QL^'ESXVUCQ!H7@/P/:R&(:QK#[5NF!P
M1$F1D \;B0"00,X->\?\% OV;_&.L?L8>!?''BO3([7QQX#MET77?)N$N?M-
MF3LBG+H2#A@C'/(\UJYG]O@L/V#/V=AI&?\ A&?L7[X)_JC=?9TV[\<;MWG8
MSWW=ZSJY53H5JLZD7RQBI1B[IM2:23Z^[=I]=#KP?&.*S' X+#X2M%5JM65*
MI424HITXRE)Q7PMU$DX7NDI;.QY;\=?V-;+X7_"JX\;>&?B5X-\>>'[.>.VN
M18R^5=PNYPO[O<V[)[9!P">0#77#_@G+I>B?#OPIXA\3?&#PCX3C\7:?'?V=
MOJ%JZL59%=E!WC<5W@$BJM_^RI\*/&/[)WC[XA>!_%GC+4+[P3;P_:[74+..
MWA>:3;\O"Y90&/(->Z?M*>$/A/XL_9W_ &?X_B=XK\0>%S_8$<=A)I]H)HG#
M0VX=I3L;:%^7GW/I6M'+J+4ZDJ<;<L6ESOEUE9OFOIVLWN<6,XHQT'0PM+$U
M6_:U(3:H+VJ4:2J1C[/E:>Z;DHJ\7MI<^9?CM^POKOP3MO"NJ0^(- \5>$_&
M%]%I]CKFE.7@261MH#KS[D8)!VD<&KGC#_@GQXLT?]J^'X1Z-?V.N:Q)8QZC
M+?%&M[:U@;)9WSD@+@#C)8L .:]E_;6-C^SOHGPC^"/AG2=2'A6#6K/Q!'KE
M[.DPU=C."1&5XX:4EN!P4P,')U_VN?VHIOV1_P#@J!>^*/[,_MC3[CPS:V&H
M6@?8[P-N8LC'@,K*#SP1D<9S3K9;@J<I>TO%1E!2U;M=-R2[K1:V]",!Q5Q!
MBJ5+ZJU4E4I8B5.ZC'GY)P5.4DG:,K-WBFE?1VZ>6-_P3=T?6]0NM%\.?&_X
M=ZUXMLPXDTIG\D.Z_>19-[9(P>W'?%<-^SM^Q+JWQT\)ZUXIU+Q'H/@KP5X?
MN&M+K6]2DW12S*0&2( @-C(^8D Y &37KGA7]FS]GG]M#Q'/I_PO\1>)/ OC
M2ZCEO;;1]4@,EL[ %G"=2%&>=LA('(':N5^!7[3/@_X:?"/Q!\#OC)X7U#5/
M#4.M32K=Z5+_ *19W*28? RN[:Z[E93D X((Q64L'A%4C*I&*@^:S4VXMJUD
MWK*/GM\CKIYYG,\+5I86K4G7BZ;E"=&$*L(-OGE"-U"I>UHJ[M9ZMV.3^.'[
M&5G\,_A7-XV\,_$KP;X\\.V=Q':W)LI?)NH'D.%_=Y;.3VR#@$X(!K4^&/\
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MPU\*+_X<>&;6+QU:ZQXL\&Z!\6K^^\:/]AEN%U!I+&,Q7DD"@M-:I=,> &
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MO[7VC_';QK>Z#I?AWX@V=SILSVFH3ZIHK6MKI\Z()##-(6(20JRD*1SD5?\
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M3COQ_A#_ (*'S7?PVTGPM\2/A_X9^*%EH*B/3;O4F,=Y;H  %9]K;L  9X)
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M# KU/_@VD?S/V\OCDVUE#:1(P5A@KG5'X(['V[5L_"KX]?#WXS_L\?$;P?\
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MBQ,^JPQ:4O[VY2Z5)&#PJPE$QW=*\>\>:IH?_!2S]C_P7H/P=^*WP^^$-_\
M#_XF^+-?UGP[XH\31^&,VVIWZW-AJT3N56;[/ /)*H3)'MPJX- 'P_\ !/\
MX)C_ !__ &BX_$#>"_A1XOUS_A%=3.C:PJ6HA?3KT#)MI5D*E90/X2,U#\+/
M^":OQ\^-7Q.\5>#/#/PG\:ZEXG\#N(O$&GG3V@DT9R<*DYDVK&S?PJ3EOX0:
M_4_]JK_@H'^S'\2/ ?QBU3Q9%'\5O!^K?&GPS#-;:5XCET+5M56S\."SO?$,
M,<8\R:-YHY" P"N9%)96(-0>,OBW=?'7]JG]HSPOK6M?LM_&+X2^,_$>B:K:
MZ1??$EO!]Y/9VNG)!INH6%_YG+P6NV*X25I'$RL2G<@'Y*>'/V,?BQXM_:$O
M/A/IWP]\577Q*TTSBZ\-BP==1MS#$99=\1 *[8P6YZC&,Y&?-)(VAD9'5E93
MAE(P0?0U^R'PY^)_[./_  3:\<_'CXF>$_C]XJOM5\;^*+7PEX \0Z+]G\2^
M)=-TRS^RWFI3R">2+=;SS(EE'.V#+%$Y4$,2/B__ (*C:!\%[#_@H+'\0/ ]
M\OB7X+?%A;?QNNE:)?0VVIZ.EVQ:\TR48D6UN8IQ, C*P56CP&% 'Q[7VA_P
M1B_X+.>.O^"1OQU^WV)NO$'PU\0S(OBCPNTN([I!Q]IM\\1W2+]UNC@;&XP5
MH?\ !53XE?L\_$"'X:CX,:'X@L=5LO!VAV^I7,VJVUQ:1HEB%:UECBMXV:^C
MDP)IBQ5V#':,YKX^H _NZ_97_:H\"_MI? K0?B-\.=>M?$/A7Q##YMO<1'#P
MN.'AE3K',C?*R-RI'T->A5_&G_P1B_X+.^.O^"1OQU%]8FZ\0_#3Q#,B^*/"
M[2XCND''VFWSQ'=(O1NC@;&XP5_KJ_98_:G\"_MH_ O0?B-\.=>M?$/A7Q##
MYMO<1'#PN.'AE3K'*C?*R-RI'T- 'H5?'W_!2'_DH_AO_L&R?^C:^P:^/O\
M@I#_ ,E'\-_]@V3_ -&TI;%0W/0?^"='_)&M3_["TG_HN.OH"OG_ /X)T?\
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M7XCWNA:U8WGC"[TV9O,T^6/5I6N)&BAAAV3(1%'YI4*6#$@'T5<_MA? >_\
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M%/PC_P"B;^#?_!7%_A1_J/B/^?D?Q#_B83*_^@6I]\?\S\0?.7^\OYT><O\
M>7\Z_;[_ (8I^$?_ $3?P;_X*XO\*/\ ABGX1_\ 1-_!O_@KB_PH_P!1\1_S
M\C^(?\3"97_T"U/OC_F?B#YR_P!Y?SH:>-5R74 =3FOV^_X8I^$?_1-_!O\
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M$4.L^$/#%OIL6J:_XAM[&$W<"R2JGE"&.-242XD;' V]!7QE\4_CQX/^/_\
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M /!N1#^R[9Z/\=OCMH\5Q\2KA%N_#7AJ[C#)X55AE;B=3P;P@Y"G_4_]=/N
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MJ]IISWR:E;Z==2R2Z7*J?,JS;@58Y4,.1P ?Z2-?_P"0%>_]<'_]!-?S.?L
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MBBO*/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;Z?\/OCI^TGX5\3>(OBQXZOC:^ O!&DZ'+JUUH4BV\ER;B:! 2;L0Q.X!X@
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M\LTWS+M%J4;2[7NGMH?I&61PDZW)C6U%]4UIZW3T_(=_PT9X0_Z"A_[\2?\
MQ-'_  T9X0_Z"A_[\2?_ !-?-6IZ9<:-J$UK=0R6]Q;L4DC<893_ )[]Z@K^
M:9^/'$<).$Z-)-:-.,TTUNFN?<_0(\%X!JZE+[U_\B?3@_:,\(G_ )BA_P#
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M&48<LY2E>R373=ZV5EZ^A]]_\-$>'_[FI?\ @/\ _7H_X:(\/_W-2_\  ?\
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MZ\_90_Y-S\(_]>"_S-*^I4HV5ST*BBBF2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5- _P"0%9?]<$_]!%?GM_P<X_\ *._2?^QUT[_T
M5<U^A.@?\@*R_P"N"?\ H(K\]O\ @YQ_Y1WZ3_V.NG?^BKFNK _[Q#U.',O]
MUGZ'X+UV'[.WAZ\\7_M#> =)T_56T&_U3Q)IUG;:FI ;3I)+F-5G!/&Y"=PS
MW KCZW?A;X%U'XH_%'PSX9T>18=7\1ZO::98RLY189YIDCC<L.1M9@<CGBOK
M);'P<?B1^M?PL\6?$!_B!KFE^./CM^T/IEKXO^*-W\+/AU%%-:PWJR6T;F74
M[Q7A E@60*,)@8/?J//_ /@V/LKC3/VW?C1:W5PMW=6N@^3/<+TN)%U%E>3_
M ($P+?C4.I?$SX?_ !D_;#\._#&+XY_M$7WQV\'W=WX1\,>/=42RDT2'52KP
M31K:!/,2.4JT9F.9.AW=#1_P:_:7<:%^V7\7K"[Q]LL/#:6UQAMP\V/4"C\]
M_F!Y[UY-2-J$_1=+=3WZ,KXJDM[-];]-MW_PUM6?I7_P4[_96^+'[9_[.UU\
M//AA\5K3X01^(-]OKVKKI+WU_<6;+@VT#+-'Y(?)#N"6*_*,9)K\>_\ B!SU
MS_HXO2O_  CI/_DNOZ$Z*^?/JS^>S_B!SUS_ *.+TK_PCI/_ )+H_P"('/7/
M^CB]*_\ ".D_^2Z_H3HH _GL_P"('/7/^CB]*_\ ".D_^2Z/^('/7/\ HXO2
MO_".D_\ DNOZ$Z* /Y[/^('/7/\ HXO2O_".D_\ DNC_ (@<]<_Z.+TK_P (
MZ3_Y+K^A.B@#^>S_ (@<]<_Z.+TK_P (Z3_Y+H_X@<]<_P"CB]*_\(Z3_P"2
MZ_H3HH _GL_X@<]<_P"CB]*_\(Z3_P"2Z/\ B!SUS_HXO2O_  CI/_DNOZ$Z
M* /RE_X)$?\ !K/X#_X)S?')_B3XZ\56_P 6O%>E%6\-K)I'V*QT23^*Y\II
M)/,G'1&) CY(!;#+]?\ _!0#]G'Q=^T)\7/@"WA?4_$?ART\,^*[Z_UC7M#E
MMDO-(MGT>]@5E\]74B221(SA&(#YP,9'TW10!\4R_P#!,7P[X?\ VN?@O&OA
M6?Q=X!\"^'_%.H76I>(KA=2>;Q!J-]87'VVZ60_O[F5A<R!RA5"#MV87'RIK
MO[-.N? WX$Z;<>,/AWK?PXU3X8>'?&"_%#XFP7EO&WC6._LKJ&$6]S$[W%V]
MS=3VUP#.B_9C#MX( K]@:IZ_X?L/%>AWFF:I8V>I:;J$+6]U:74*S07,;##(
MZ,"K*02""""#0!^./P>_94'Q/^'_ (K^&>M?#>71?C%XLMOAYJGB?PU9Z)I^
MBZ;_ ,([IVK1)<202VEU-O9L7!F\R1'D5$VH0M>O?M ?\$Y=9;]NG7I%\+^-
M+/P#K5WX8E\%7_@+0M$DC\)1Z>4:6W\VY9)],07*O,QM1MF2XD!!8%3^A'P=
M_9R\ _L]VEY!X%\&^&?",>H,K77]E:=%:FY*@A=Y0 MM!( ).,G&*[2@#\R/
M&/['&I7GQR^-&C6?PE^(&H_#/Q];>(;CQ3J$^F:5;>)H;FXG21%T#5%G\ZZ@
MN9-[?9KL!(T15W 8BIGP[_9/^-WC;3/",-GX-L_ /]CGQS8Z+K<&CV/AN\5;
M_0H;>PU+4;&RD:*&Z-V'CS#]Y($<HF<5^G5% 'Y%^+/V!O&OQ+^!NKZ+X/\
M@%JWPP6U^%%OX)\46#W5G;MXUU?^T].DWQM#,1<+!%!>R?;92LCBZP,DMC[@
M_98_9=_X9V_;5^,U[X=\(Z?X1^'?B;1?#ATV+38HK>QNKZ!;Z.Z=88\;9 C6
MRLY4%P$Y;''TI10!_(SX_P#^2B>)/^PQ>_\ I1)636MX_P#^2B>)/^PQ>_\
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MSWJ#:<9QQZU_(]2G*$G":LUHT]&GV:/TZ,DU=; .37B/A/\ :7\?>(?C_>>
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M !1110 4444 %%%% !1110 4444 ?R,^/_\ DHGB3_L,7O\ Z425DUK>/_\
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M<F16$TFU');<K-N..C&NMF^#_P .OB1H%GI;:#X7UO3?"Z3:-;6\:I-'I:E
MDMK\I^0; JM&>V,BO7Q_%>7J-7#U\'*,:D4M::BX+EG&Z3FTWS--/W%=<RBI
M15^##Y+BFX5*==-Q;?Q-J6L7JTDUHM5[SL[-M/3YB_9M_;2UGQGX\\3+K.O:
ME)!\1M$U'7/#MG<64UNOAB>V60Q64;NBJYDM0D^5+?.KU%^S3X5^+GQU\#^#
M[BQ\3_%;P]I^O>&'N-8U_6]6M[B":_9$:SFL(ES(%\T$NK85HR5(SBOI^_\
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MC'')"8I&G9"N'6[$I(:4G.<?*17VTW[+OA=S\RZDWUNC_A2']ESPJ3]W4O\
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M?^?M+[Y?_(!_K5A/Y9?<O\SP<7,B])'&>3\W6D,C''S-QR.>E>\_\*5\+_\
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M.-QVMP,_=;T.-CQI\9?"?PZ\+VNM:[XDT32=(OL?9;RYO(XX;K*%QY;$X?*
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M-%K4BAYGT*58=,A:]CLH[BYD^Y'"\\J*K MGYN/D?;BW7_!7'P=:_$"ZM_\
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M;DMTUOU_K\41W?[!&C^(;G2KBX\5:T+1;73K?4K73K:SL;/6TL;UKVV5DBB
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@"IH'_ " K+_K@G_H(JW530/\
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M 4444 %%%% !1110 4444 %%%% %30/^0%9?]<$_]!%6ZJZ$,:)9_P#7!/\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a2new.jpg
<TEXT>
begin 644 a2new.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!B17AI9@  34T *@    @ !0,!  4
M   !    2@,"  (    (    4E$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QCD1I<W!L87D _^(0"$E#0U]04D]&24Q%
M  $!   /^&%P<&P"$   ;6YT<E)'0B!865H@!^<  0 !  D ,0 $86-S<$%0
M4$P     05!03                        /;6  $     TRUA<'!L
M                                                           2
M9&5S8P   5P   !B9'-C;0   <    2<8W!R=   !EP    C=W1P=   !H
M   4<EA96@  !I0    49UA96@  !J@    48EA96@  !KP    4<E120P
M!M    @,86%R9P  #MP    @=F-G=   #OP    P;F1I;@  #RP    ^8VAA
M9   #VP    L;6UO9   #Y@    H=F-G<   #\     X8E120P  !M    @,
M9U120P  !M    @,86%B9P  #MP    @86%G9P  #MP    @9&5S8P
M   (1&ES<&QA>0
M
M &UL=6,         )@    QH<DA2    %    =AK;TM2    #    >QN8DY/
M    $@   ?AI9       $@   @IH=4A5    %    AQC<T-:    %@   C!D
M841+    '    D9N;$Y,    %@   F)F:49)    $    GAI=$E4    &
M HAE<T53    %@   J!R;U)/    $@   K9F<D-!    %@   LAA<@
M%    MYU:U5!    '    O)H94E,    %@   PYZ:%17    "@   R1V:59.
M    #@   RYS:U-+    %@   SQZ:$-.    "@   R1R=5)5    )    U)E
M;D="    %    W9F<D92    %@   XIM<P      $@   Z!H:4E.    $@
M [)T:%1(    #    \1C8453    &    ]!E;D%5    %    W9E<UA,
M$@   K9D941%    $    ^AE;E53    $@   _AP=$)2    &   ! IP;%!,
M    $@  !")E;$=2    (@  !#1S=E-%    $   !%9T<E12    %   !&9P
M=%!4    %@  !'IJ84I0    #   !)  3 !# $0 ( !U "  8@!O &H :<[L
MM^P ( !, $, 1 !& &$ <@!G &4 +0!, $, 1 !, $, 1  @ %< 80!R &X
M80!3 'H [0!N &4 <P @ $P 0P!$ $( 80!R &4 =@!N /T ( !, $, 1 !,
M $, 1  M &8 80!R '8 90!S &L Y@!R &T 2P!L &4 =0!R &4 ;@ M $P
M0P!$ %8 Y !R &D +0!, $, 1 !, $, 1  @ &$ ( !C &\ ; !O '( :0!,
M $, 1  @ &$ ( !C &\ ; !O '( 3 !# $0 ( !C &\ ; !O '( 00!# $P
M( !C &\ =0!L &4 =0!R( \ 3 !# $0 ( 9%!D0&2 9&!BD$&@0^!#L$3 0^
M!$ $/@0R!#@$.0 @ $P 0P!$( \ 3 !# $0 ( 7F!=$%X@75!> %V5]I@G(
M3 !# $0 3 !# $0 ( !- .  =0!& &$ <@!E &( ;@#] "  3 !# $0$)@0R
M!#4$0@0]!#X$.0 @!!8$&@ M!#0$. 1!!#\$.P0U!#D 0P!O &P ;P!U '(
M( !, $, 1 !, $, 1  @ &, ;P!U &P 90!U '( 5P!A '( ;@!A "  3 !#
M $0), D""1<)0 DH "  3 !# $0 3 !# $0 ( XJ#C4 3 !# $0 ( !E &X
M( !C &\ ; !O '( 1@!A '( 8@ M $P 0P!$ $, ;P!L &\ <@ @ $P 0P!$
M $P 0P!$ "  0P!O &P ;P!R &D 9 !O $L ;P!L &\ <@ @ $P 0P!$ X@#
MLP/' \$#R0.\ [< ( ._ [@#S .] [< ( !, $, 1 !& .0 <@!G "T 3 !#
M $0 4@!E &X :P!L &D ( !, $, 1 !, $, 1  @ &$ ( !# &\ <@!E ',P
MJS#I,/P 3 !# $1T97AT     $-O<'ER:6=H="!!<'!L92!);F,N+" R,#(S
M  !865H@        \Q8  0    $6REA96B        ""]   /63___^\6%E:
M(        $PD  "TA0  "N9865H@        )[X   X7  #(BV-U<G8
M   $      4 "@ / !0 &0 > ", *  M #( -@ [ $  10!* $\ 5 !9 %X
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MJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?__<&%R80       P    )F9@
M\J<   U9   3T   "EMV8V=T          $  0         !     0
M   !     0         !  !N9&EN         #8  *X   !2    0\   +#
M   F@   #4   %    !40  ",S,  C,S  (S,P          <V8S,@
M 0QR   %^/__\QT   >Z  #]<O__^YW___VD   #V0  P'%M;6]D
M!A   *!      -489(                      =F-G<        P    )F
M9@ #     F9F  ,    "9F8    ",S,T      (S,S0      C,S- #_VP!#
M  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'
M"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" '> U(# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%
M!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q
M%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ
M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?ZH^_J*^4]5_X*F^&?A;\8+S2_B+;V?A3P-K7A<>,?!/B_[69+'Q/8K$);B
M@J#%=QJRL(<L75@5YXKT[]D3]HGQ!\?_ -GV+XB>+O"+?#RQU8S:AIEA=W1E
MNTTL?-#<7(VJ(I)(QO,8SM!&3G.%*C.*YFM/Z_KR+AB*<I<L7K_7]+OT/7J*
M^-_A!_P4/^,'[2-I9>-OA[\ _P"V_@_J6HFTL-5O/%,%CK&IVHF\EK^*T9"O
MDY#,%:0,RJ2.HKUK]FS]L6/X[_%SXR>%[S3;30Q\*_$Z^'HIVO0[:FIMHY_.
MVD#9S)MQD].M.5"<;WZ>:)ABJ<K6Z[:/7KH>W45\L_#+_@IGI_B7_@GCKWQ[
MU_05T:WT:;4K:/2H;OSVO)K>\DM((D?:,M/(L8 P<&3OBH?#'_!3#_A(O^";
M7B[XY2>$9=.\1^ [*^77_"5S=;9M,U&S)$UF\FS(/W6#;?NN#BCZO4[=;?,/
MK5+OTO\ (^K**^/?AY_P46^(NC?%/X4Z+\5/A/I/A71?C/+]D\.ZKHWBA-49
M+DVIN42> Q1NJM&#\ZE@IZ]:W_VBO^"G&C_L_P#[:G@OX3S:#<:CINL"V3Q)
MXBCGVVWA6:^D>+38YAC&;B6-EY88!4\YH^KU+\J7F+ZW2Y>9OK;5-:L^HZ*^
M<_VJ/VW?$'PT^.WA_P"$?PQ\!_\ "QOB9KNERZ]-;7.IKIFFZ)IT;^7]HN9R
MKD;Y/D1%4DG]>;^)O[7W[0GPX^ -SXRNO@+X?M;SPU'J%QXCL[KQM$(X;:UC
M65;BTD2%O.61?,PK!&!3!'-$:$VD]-?-#EBJ:;6NF]DW^A]845\*ZI_P5%^+
M7A']DC2_BOKWP<\,V-CXQO-"M?"EM%XO\[^T?[3DVJUPWD#[/L#1DYW?>(XQ
M73?%[]OOXO\ [.7[-_BSQWXZ^%'@^SN=*OM+T_1['2O&/V]=1EO+I;=O-D$"
M^2$WH0<-NR>F*KZK4VTWMNB/KM*U]=K[/;[O(^Q**^1]$_X*&^/O 7QK;X>_
M%?X6:;X3\0:MX6U3Q/H$^D>)4U:TOTL$#S0R_NHWA;#+ABI4\CK7*V/_  5P
M\0?$3P7\#;'P1\.M+U+XC?&KPS+XIATW5O$2Z;IFEVL3*KJ;EHRTTA9@%1$S
MC).!1]5J=OQ7]=!_7*7?\'?IT^:/N*BODOXO_MF?'[X5_L\3>.KCX"Z':2>&
M[;4;OQ/8WOC2)?LD-H RS6KQPL)TE0.R@A&&T C)KFX_^"EWQ0\)? #PA\0_
M&7PCT#1](^(&O^'=*T!+'Q3]MDN(-5?!FE @7RVC1D.SG<21D8H6&FU=6[;H
M)8RFG9WVOL]ON/MBBOD?Q%_P4"^)WQ,^+OCK0/@?\&[;X@:+\,=2;1==UG5?
M$D>C17FH(H::SLE,;^8\>0&=RJ[B![D^*G_!0_QX/C]I/PG^'GPMTW5OB'_P
MBMKXKURQ\1>)XM*ATN.=BJVD;JDAN)PRL&*#8N,YYI?5Y_TU^/8/KE/?7>VS
MU?EIK\CZXHKE/@AXT\0?$+X6:/K'BKPG<>!_$%Y$QOM#GO8KQ["179=OG1_(
MX( 8$=F&0#D5U=8M6=CIC*ZN@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO#_ !%^W'HGAW]I*#X=
MR:1J$DDES%8OJ"NNR.>10579]XKR 6SWZ$"O.S+-L)@(PEC)J*G)15[ZR>RT
M_/9=3T,NRG%X^4XX2#DX1<G:VD5N]?RW['N%%5]7OSI>E75TL4D[6\3RB-/O
M2;03M'N<8KYC_9!_;C\2?'SXQWGA_5M&L8+.:VENH'M5</8A"!LE))#9SC/'
MS5S9CQ!@\%BJ&#Q#:G6;4;)M75MWTW2_X!U9?D.,QN%KXR@ER44G*[2=G?9=
M=G_PY]245Q?Q\^.6E?L]_#R;Q!JT=Q<1K(MO!;P8\RYE;.U!G@="23T -<W^
MS!^UMH_[3=KJ26MC=:3J>E[6GM)W$F8VSM=77@C((/ (-:5,\P%/'1RV=5*M
M)74=;M:_+H]+W,J>1XZI@99E"DW1B[.71/3Y]5K:VIZQ1117K'E!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >3_MS_ +,W_#8_[)'CSX9KJ*Z1
M/XLTQK:VO63>MK.K+)"[#J5$B)D#G&:^0KO]GKX]?'/X]? W6/%7P=T_P?XD
M^&VN::WB+QEI_CWSM/U?3+42;XH;%2"?-9@^)$R,8)QT_16BMZ>(E!67]7.:
MMA8U)<S;Z=M;.ZW7Y'YB_!S]@KQ5\,?CKXNUCQ1^RKHOQ"U'5/B/?>)-+\7'
MQO:6DEG92W@DMV^SD[MT0!?:>3TZUWFI_P#!+[Q?\0_ _P :+QYH?!?Q*_X6
MCK'C?X;>(K:X262".X@BC"RE<D07"K)')$W0$-C(%??U%7+&5&[_ .?ZLRCE
M])*S_3]$G\]S\L=9_P"";/Q,MO@E^R;IOB#X.:/\3H?A7H6L6/BOPP_B:VL8
MQ<7.SR"D[-M<*P+?+D<8KNIO^";-W\=_B+\!;?6?@G;_  Q^&?@O_A)EUOP[
M9>+EGDL7NHXC:SQSV[K(WFRJQ*H?EQ\W!K]%**IXVI^??K?SMU$LNI+\.W2W
ME?HKJ]C\X?#G["/QJ^!G[)'Q>^ O@?P_I*6/C'Q6MKI'CC^TX4OIO#]\P^V7
M%YEO-EN[:'?"I.3(&0C[IKJ_#_\ P3C^*G[+W[0GP;\?>$_'MY\2[7P9#'X(
MU+1KZPL='%IX9D3#&-H@@E:WD2*14?).&QR3G[SHJ?K<WVUWTWTM_5BE@*:M
MOI:VNUG?^KW/A3_@G+X6_: _9"\(V?PUUKX(VMYX?G\6:G>W'B>'QG8A;:TN
M[Z6<3?9<&1BB./D!R?:O4_\ @HY\*=8^,.@^'M+_ .%#>$OCMX6CDEEU"QU#
M6X]*U+39L*(I;221=HR-X8AT;[N,\U],45,L0W/VEE?Y_P"?Y%QPJ5+V5W;Y
M?Y?G<^,_V$OV3?B=\(?V2_BYX;\30SZ5#XNGU!_!OA"Z\0MK;^%;.6U,<=HU
M\_W]TF6P"53=C/6LFX_X)^>._&__  16\'?!>?\ LO0_B5X9T;2YHH;BX$UF
MNH6-Q'<+"\L>048Q["RYQNSVK[BHH^LSOS>:?W"6#I\O)K:S7R9\9^%/AM\;
MOVJ_VS/A/X\^)7PZT?X6^'?@]:ZG<""/Q%%J]UKNHWEN+<^7Y*@1VZ*"P+_,
M20,>GB?P@_9R_:J\(_L,:Q^SM8?"WPKX?A\2W.KV=UXUU+Q9;W%O965_=3.\
MB6<*M(\@BE("D@;L9K].**I8IK2RMIWZ7\_/J3+ Q>KD[ZW>FM[+MY+:Q\;_
M +</_!/V^^(?['7P7^&OA'1=.\4?\*U\4>&I)#J+Q1G^SK)E2YDS)P2T:\H/
MO XYKZV\6>&+?Q?X1U+1;C<MGJEG+92[."J2(4./P-:5%8RJR:2?2_XF\:,8
MR<EU27W'PO\ LD^'?VG/V+?A-X;^"=C\*/"7C/0_"-T--TOQLWBN.RM)-)\\
MLKSVA0SBX2)BNU,JS*#G&34GPF_X)-^%?B-^TQ\?/%WQF^'6AZ]#XL\7KJ'A
M>[GO#)(]A]DA1LK&X\O]ZK_*PSWZ5]R45H\5*[<=&]VK^O<Q6#A9*5VH[)VM
MM;L?F+\-_P#@F3\:=?\ V=_@K\&=1,/P]\*>$?$FL>,->U:TNK34GBN(K^67
M1[6.!B5E7#B5BP*KL4'+"MKXF?\ !.7XW^ ],_:(\-:'KA^*.C_'KP7/<SZE
M?_8M)FM/$T0$,2F%-J>7/;[0TB@8:(;O6OT@HJ_KE2]]/N\[^I']G4K6N^V_
M2UO3;RZGP#\+?^"8FH?LC_M/_!;XD> ?"-OK=G'H3:%XWTO4=8-U+H4[6ZD:
MEI[W,C!7\U6BD2(@,C#  S7,VO\ P22^+G[1/PL^*^K^//B?>>!?$_QKU.35
M=9\,V-A9:C:V?V:0C2X?MC R#R8XH3F)@%);'.2?TDHI?7*E[]>_SOU_K1#_
M +/HVMK;MLM5;I_6K/@C2_@Q^T9\.OBG\.?CY;^!]#\4?$";P*O@?XA^$'U^
M&VDN6AG,L5_9W9#1$LX+,C8XDQU!Q[OKMI\6/VC/V(?B9I?B_P #Z-X-\:>)
MM(U73='T.UUM+\".6V:.W$]QM6,2L['=MRJC'/6OH"BHE7;L[*Z_KN:0PJC=
M*3L^FGW[;_AY'P;^U%^Q%\1/B+_P22^$OPML?"ECX@\7>$G\,OK.A2:K#;PW
M,=EY?VJ$7#'9R%9<@\YR*XGXF?L&>*/B9^QC\1/ ?@W]FO2?@WJ'B#6- O'M
MXO&5MJ"Z_%;WRO/EU/[DQ0AR,D%M^!R*_2BBKCBYK;O?K_F9RP%.3NV]K=-K
M6[7ZGP?H'_!-+4OV7OVM?&&I?#/PO::Q\/OB5X$O-'GN-3U4W&H^$]22-_*2
M"6Y=I3:W.X!T4D*ZAC@5RB?L8>.-!_8A^!OPY\:?LV^#_C-!X/\ #*VFJPMX
MIATW5]!U$-C_ $:X(VM&5ZM'*K9 X(%?HW11];GU_7I\Q_4*>JCIOVMJT]FG
MV/B/X#?L=_%KPG_P2U^*OPW\2.UUXG\66VN1^%]!NM>.J-X?L[F%DM-->_EQ
MYNPYRY.T;^N!5OX__L??$+QO^P%^SWX&TG2;.X\5?#_7O!]_K5L]]$D=M%I_
ME_:BLA.V39M. O+=J^T:*GZS+FYO.Y?U.'+RZ[6^1\/^#/AQ\?\ ]A#XI_%B
MQ^'OPST'XL^"?B1XGN_&&C7#>)H=&N-"O+P*9[>Z6529(1(NY7CR=I(QFH_V
MY/@%XQ^/^M:%)XL_9=\&_%AH=#MQ#K&D^-5T75M"U)E)N(4G=4D^SK)@HZ/G
MJ2F3BON2BA8AJ7-97[Z_HR7@XN+AS.W;1V^]?G<\4_X)X?"#Q]\!_P!D#P?X
M6^)NO-XB\8Z9#(+NX:[:\:!&E=HK<SL TWE1E(_,/+;,U[7116,I.4G)]3JI
MP4(J"Z!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_C+J'AG1/%?AWQ%I=A']GDUJ% MWI\]K#%)&8)Y%)B?S%>+?]UE!K8^%O\
MP7JT'XK_ !!DL-'\#S:]I>L67B"Y\-P:%K"ZAKUY)I,4TOEW=@(E%H;M()#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX%;4?"NK?#Z+Q7I.HZAX=&BZ3H.JW,]HEI9K,MW-)>V+1W9D,Y6-\6S'Y1(
MOL_[*FC?$+PM_P %>/'&E_$?QEX?\<:Q:_"#1I8-0TK2?[*VQ/JVH%HY;?S9
M%#"0/L<-ED(R,@D^Z_#_ /X)P? _X6R^)?[!^'.AV-KXOT^XTG5;',LNGW%G
M.V^:W6U=V@CC=N2D:*#Z5-\"/V1?@E^Q[X]5?!/ASP]X5\5>*+$V:$WCR:CJ
MMK;$.8P9I&DECA\P' )$8<#@$"@#XCU[XS^*?V2_VU_VCOBQJ'B+6+SX-ZEX
MNM_!7C6PGEDF@\&[M$L7T_7+<9_=0B><V]R%P-LT<I_U;5P>E?#"?P5^S?\
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M^R]_P1]^"7[(/[0^K?$CP7H-S;:M?6_V>PM+JY-S:Z"&SYIM ^60R @$EF(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;/4XD'1?-7[ZCLL@8#TK'!XZ-.+I55>+.C,,ME5FJ]%VFOQ/A70O^#JK0?\
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MZ)#;6]G-:PE%8P3;Y':Z7 P  IR:S_AO_P %2/AYJGP1U#Q7X^%]\+]6\/\
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MX\.(YV1]I!VX(S[50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFUK1?!_Q'\6^&=+\'V'CW6M7TO3(?L^B:/=O/&)95DF21IHVMI@\"(T@$;D
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MR#1F^=KQ_.:&,Q(6<-/&2-K@T >;^&_V:/VCO@G\#_BQ\)?A['X)T>WUV_\
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M_B=^QA\1O%.O?M7WGACQ/I_A+4OC/H^DV7A75HI9#-I\]KISVTC3;5W1@NV
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M%WQ&\$_"6\BU'PGX?U#3;.U:*YMXFAM)KZZA427KVZ,2A;8"X5W#L :^JJ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !116+X*^(_AWXDVU[-X=U[1=?ATV[DT^[DTZ]CNEM;F,
MXDAD,;$+(N1E#AAGD4 ;5%%?F[^P3J_Q ^*_QS\=:Y<I\?M8U33O''B^PTG6
MM3\6AO ""VO+N&TMY+!+@2^4FU(\+ 2&7(/ ( /TBHK\Y=/_ ."T?Q \=? S
MXA>+O#?PW\,+??"S5=(\ ZYINHZV0MQXPN=4@LKRVMY8@P_L^!)E=;EES,9
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M]3^)WA>+P]JERULQT_R/M&EWAE7=Y@^U0;;B/"-\_P BX&0#Z2_9;_9=U?\
M9KM);&[^*?CSQ_I%O9PZ?I5EX@6QQID$7"_O+>WBDFD*[5,DK,2%'?)/GOPG
M_P"":]Y\&_VBO%'Q$TGXU_%&:Y\;>(%UW7M/O4TRYBU)4.(K$S-:>>EI%'^[
MCB210BEB#N9F/C?C3_@H!^T]X-\3^,]!F\#_  3;4O!_P\C^*<TXU743;R:>
MQN%.E!=F[[9NMI/](_U6TK^[R<"7QI_P5+^+VL1?%CQ5X&\!^ ;CP%\&_"VA
M>,M5AUG5;F+5]8M+[2AJ<]O;^6IBBFAA#!7DRKMM7 Y8 'UKX\_96\,_$KX\
MZ;X^UC[5>75AX6U+PA)ILA1M/OK&_EMY)UFC*DN3]F11SC#-D'/'SEJG_!$+
MP;<^$VT&Q^)GQ6TO2;[P7_PKO55BO;.6ZU+0(YKB2TL3<2V[R1"!;F2$/$5:
M2)45RQ7=7EGB'_@HEK/[-WQ#^+=UHXEU[4/B5\6-+T+PT-6AO[ZRT&WD\)V.
MI2S/;6B27#(L:N?)@4%I),DJ-S5TWPG_ &]?CU^T'^T1\"=/L='\+^"=)\16
M_BA/$VFZUI>HPOJ_]E7=E$+ZS$R1S1P307 E@$JJ<NZR;MJY /?=<_X)L>"=
M>^'GQ?\ #<VJ>)$L?C1I6GZ1K+I/&)+6*ST^.PB-N=F%8Q1*6W!@6)( '%<M
M\9_^"2GACXQ:YXP3_A8/Q(\.^$_B!JMCXA\0^&-*O+:/3M2U2T-MLN\O TL?
MF?9+<RQHX20Q@D9)SYS^Q#_P5T\7?M=?'KPG9Q^ 6/P]^(+ZJMA=V6D:LMUX
M82T,AMYM0NIH%LI4NEB8 6\A\MW1"7Y(\W_;P^('Q \0_MR_&SPOX-US]HZX
M\8:'X)T&Y^'VF^ IW_L.PU6X&H_O-25_]$6%YH[?>;C@Q))CD4 ?4.O?\$MO
M"NN?%74]4_X3#QU:^"=>\6P^.]6\"17<']AZCK<4L<XN')B-P(VGABG>!91&
M\J;BO)!Z/PO_ ,$]/"'A70/A_I\.J>(I8_ASXWU'QYI[R3QE[B]O7OWECEP@
MS$#J$VU1@C:G)P<_(NN_M9?'?]F/XR?M3>-(]/\ !OB;P[\,U\*:EXHLM2U.
M[269VT*S:^@TI%!B@P=\H:0$.[@8'+#U[XY_\%0-5^%G[8_AOP?I$W@/Q/X1
MU+Q?I'@S5+6S@U-]8T6YOPJ[Y[I8CI\;Q221DVS/YC(V<JWRT >BS?\ !,OP
MG#XE;6M.\3>,M'UB/Q'XG\4VM[:742S6-[KUJ]M</&3&<>4KEHLYVL 3NZ5R
M_@__ ()'Z-X3^ ?AOX?_ /"S?B!<6?P^O;35/!&I+%IUO?\ A.]MQ,IN(GCM
M@MPTRSRB87*RB42.3RQ->7-_P6#\:?#/P+\8O$GQ$\.>$=#U3X<:9<WL'PZ$
M>H6OBE&^WK9V<CRS)]GN[27S(G:YM ZIYJ@!CQ7MG_!/3]M+QK^T]XD\=:#X
MT\*QV$WA,6-Q9>(=-T75=+TC6H[E)"\,<>I0Q3":W>(J^,JPDC8;<E0 7O%7
M_!/2Y\7-X+URX^+WQ(A^)'@G[?!;>,K==.BO;JSO3&;BRE@%M]F:#]U"4'E;
MD:)6#9SG>_9=_89T_P#9(T+P7H?ACQOX[N/#/@VPU2T_LG4KV*XAUB:^OC>-
M>73>4'DGC=I%1E*C;*V03@UY_P#LUS^.O"__  5!^-'AOQ/\1M>\::/<>$M%
MU_3=-N(([73_  ^)KW4HA!;0Q_\ 3*&(/([,\C#)QP W]IG]KOXT:)^UCXD^
M&?PI\+?#G4(_"?P_@\=7=]XFU"ZA:[:2ZNH!8QK"IVLXMB1,Q*IGE6S0![Q\
M3/V>M'^*?Q=^'/C._NM0AU+X9WM[?:;%!(JPSO=6<EI()002P$<K$8(^8#J.
M*\;T'_@FM=>$/VIO%GQ6T?XU?%"QU3QMJMO?ZM8R1Z7=6\EM ?W6FQR2VC31
M6:+N41)(N"[MG>Q:O*6_X*L_$;XV>"-?\9_"7P/X.E\+_#OX?:/X_P#$]KXF
MU.>'4+\:A8R:A_9]DT*&-)([>)LSRY1I'4!0H9A5^+'_  4=^-'Q2TKXWWGP
MCT+P!HOA/X7> ['Q='KGB.6YEU"[^WZ&^I1116T0V+)%@$M(Q4Y4;3\Q ![1
M\*?^"7_A3X3_ !8\/:W;^+/&^H>%? ^JW^N^$O!EY=PMHOAJ]O!,LTL(6(3.
MJK<7 B261UA$SA1]W'#_ !R_X)_>+/VAO^"@7C[Q1_PF'CCX>^#_ !!\-]+\
M*/J/AR]M4;6%^V:@]W;.DT<C1NL<T12= KKYK;6ZXX'5/^"@'C+]G/0O#/C+
MXE6-KXF\16/P,OO&EQ'H.IW-GINIS&_TN"VB:UDS&LTC72[YR/W8+A1M)%;?
MQP_X*7_&+]D7PY\2-(^(7@GX>ZQX^\-^";7QSH">'-2NDTO489-2BT^:RG,Z
M^9'+'++&1*N4D5\[5*LM '5>/_\ @BA\._%TNO:?I?BSQYX1\'>*M.T/3M7\
M.:1<6JVUZNC1Q16'[Z6![A$5((@\:2!)"N2,EB>WU;_@FCX=U/XI^(->7QAX
MQM]'\0>-M+^(LOA])+<V-OKEC);.+B-C$95246L0DC+E3\Q7:3Q:_9@_:3^(
M_B']IKQQ\*/BEH_@NUU[P[H6F^*-/O\ PO<7,EI/9WDUU!Y$JW #B:*2U;YQ
M\KJX(5""*\IMO^"EGQ&NM7B\>+X/\'#X'7'Q+/PRC8W\_P#PDHE_M$Z2-3*[
M?(\G[<,?9Q^\$1W[L_)0!ZI\,?\ @GE:?!SQ#K-KX=^(OCK3_AWK,^J7;>!_
M]"DTNUFU#S6N/*E:W-TL0EFDE2+SMJN>/E^6M3PW_P $^_!OARP^#-J+W7;J
MW^"/AR\\,:1'-.F+^UNK*&SD-SA 6?RX5(*;<,2<=AX[_P $D_#'C'7_ !G\
M=_B)\1-0TC5/$-]\0-;\/QW=GJ.H2+;6]A?RP"V6&>0P1P1K'&(O+16QN+DD
MFO%?V'?^"K;?$C_@H+XLO-6\=:IKG@+XM1:U_P (MX=?3KF.'PN-!)$#PR/&
ML3G4[-;J[(C=\F%: /H+4O\ @DE'K'[-UG\'KKXT?$ZZ^&=MIK^'Y=%N;?29
M_M&D_*L5KYKV9=7BC78MPI$H!SG< P^M/#VA6WA;0+'3+-62STVWCM8%9R[+
M&BA5!8DDG ').37Q-H__  4/^-$?[*>@_%[4O!?PY^P?%ZXT73_AQX>MM3NO
MML-SJ]U'%9'5+EE\H1B&599/(3((*+N.&I/&WQA^('P>_;/\$ZE\5/$?@C1[
MO1_A3XOU?4VTZ]N[3PN@AO=*^SSSB8LZE0Q#-AB [;<YQ0!]S45^;WA?_@IW
MXK^,'BJT\+^(M/TFXO-#^(?@:&#5?#$NLZ#:W]IK-S<QX:&\CCGE6)K5MRD&
M&=77I@BM7P[_ ,%+OVAO'"^ =2TGP%\)H]%^*WC;6O 6@+=:K??:M/GL)K\+
MJ-UM3:\#QZ?,3!'B3<R?/@G: ?H917R[^SC_ ,%'--\3^"M/T_XI?8O"_CZY
M\8ZQX%$&B6E[J&G:C?:?>?96F@D6)C#%)NB8"X*E=Y!)VDUPO[/6C:QX?_X*
M43>'O 'Q*^)WC_PCX3T._C^*%UXGUHZII<.KS/ ^G6=KE5CAO8T\]Y8X J1P
MO$K@,RT ?;E%?G[\7_CU\9OA+^WU^TMJGP_L?"?B#P[X%\!^'/$>IV'B35;N
M$,L<6J2/;6*1!DBFF2)B9I 5W)&"",D=!X!_X*T:U\3;71]#TOPEI0\?^*?B
M!I6A:/I<MU)LD\.ZA8)K$>L/@;ODTSS]X7Y1<0E,@$4 ?<5%?$O_  4&_P""
MH7BK]F?]H23X<^ _"NGZ]K6C>#_^$SOQ>Z9JU^=45YY8;?3;5=/@E,,\IMY?
MW\^(E.P8;)V\U\5?^"I/QBTR+XN>)_#7PY\'6?@KX*:)H'B+6K+Q'>W5OKNH
M0ZAIL5_<6<:1KY<%Q CLNZ3<K-A=HY8 'W_17YK_ /!1[]L;XM_%3X"_'2;P
M/IOAO1/AK\-O%>D^#[[4VU2ZMO$MU=?:M,EN;FV\L"*.&/[6D>QSNE"R'*@J
MK?6G[9W[3'BCX-:[\-O!?@'1]#U7Q]\5];FTC29-<GDATO38K>SFO+FYG\H>
M9)MBA(6-,%V<?,H!- 'NE%?F!\8_CA\4OVXOCM\%_AKK5GX4T*'1?B/XA\+^
M.=*M=8U.&PUV[TO2Q>Q2PRVSQ3?9C!<13)&[ K.%5PRH<_3/_!4/3="\,_!E
M?$FK>/OBQX;OK.WDTGPQH'@C7)+"]\2ZS<#;9P11QJ9+FX\Q0$1F,2KO>1=J
MLR@'U-17Y;?$;5OC-XN\(?&S5/&7Q6\8^$_B!^S#\)_#NJVT'A[4Q::7?:^=
M*N-0O[N\A4;+R.6: 0;'_=B-9-J@MD>G?M&ZIKWB/XJ_!O5O /Q"^)W_  NG
MXF7NAZ_'X2@UMF\.:!H"&W;59[RQ"B-;,P^;&'ES*]S+&L;94A0#[[HK\^_B
M-JWBK]G[_@IS\+[&UUSXZ:3X:\7>*;NSU?7_ !=KJ7_A'Q")[&>6WT>QM(V;
MR)Q-M,,C1P[5M95+2%QG]!* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;;&ZBB<+) ?-DW# )#L-V"17%_#C]DG^QO\ @H9JGQV\;:+X)\":;X-\'?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+?"_]E3PM=?\(9XRU"^\2>'/$[^&=6TC4-0@O)[Q!"7%^HAC7[+\ZLI@D+,
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MYNQQ_P#Q$9_M0?\ 07\#_P#A.K_\<H_XB,_VH/\ H+^!_P#PG5_^.5J^!/\
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M$LT3(L;$?*11;"_R?@%\=_S\???T_P R'_B(S_:@_P"@OX'_ /"=7_XY0?\
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M,CJ*VIT\-)R2BM/(YZM7&046YOWO-_=^*_+H?4W_ !$9_M0?]!?P/_X3J_\
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M_.[6ON;W_$1G^U!_T%_ _P#X3J__ !RD7_@XW_:>9F UCP*2O!'_  CJ\?\
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MZC[[OLW^%F<A_P 1&?[4'_07\#_^$ZO_ ,<H_P"(C/\ :@_Z"_@?_P )U?\
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M@_Z"_@?_ ,)U?_CE?"]%'U.A_(ON#^T,3_._O/NC_B(S_:@_Z"_@?_PG5_\
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M_P#QZC^TL/\ S?@_\@_L?%_R?BO\S\=:*_8K_B%,TK_HN6M?^$U#_P#'J/\
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M^+O[;GQA^/W@&W\*^-OB5XN\3^&[9D==.OKW=#(R?<:3 !E*]BY;'UK].?\
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MOL90-OE[5VX QBJGC+X@ZY\1/'=_XHUS5+O5/$6J77VZ[U&9A]HN+C(/FL5
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M=J=AX-UJ72X+NYU&Y2:Y1 I#,JK@$YZ"OUQK^7__ (*H_P#*2GXY?]C;<_\
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MCN?0976J34U4DW9]5;IV"BBBO//5"BBB@ HHHH **** "BBB@ HHHH ****
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M@/\ Z)%XX_\ !C:?XT?\14O@/_HD7CC_ ,&-I_C7XL45?]F8?M^+,O[:Q?\
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M  .7^9]L?\/7=!_Z$_7?_ F'_&C_ (>NZ#_T)^N_^!,/^-?$]%'_ !%+B/\
MY_+_ , C_D'_ !"_AW_GR_\ P.7^9]L?\/7=!_Z$_7?_  )A_P :/^'KN@_]
M"?KO_@3#_C7Q/11_Q%+B/_G\O_ (_P"0?\0OX=_Y\O\ \#E_F?;'_#UW0?\
MH3]=_P# F'_&C_AZ[H/_ $)^N_\ @3#_ (U\3T4?\12XC_Y_+_P"/^0?\0OX
M=_Y\O_P.7^9]L?\ #UW0?^A/UW_P)A_QH_X>NZ#_ -"?KO\ X$P_XU\3T4?\
M12XC_P"?R_\  (_Y!_Q"_AW_ )\O_P #E_F?;'_#UW0?^A/UW_P)A_QH_P"'
MKN@_]"?KO_@3#_C7Q/11_P 12XC_ .?R_P# (_Y!_P 0OX=_Y\O_ ,#E_F?;
M'_#UW0?^A/UW_P "8?\ &C_AZ[H/_0GZ[_X$P_XU\3T4?\12XC_Y_+_P"/\
MD'_$+^'?^?+_ / Y?YGVQ_P]=T'_ *$_7?\ P)A_QH_X>NZ#_P!"?KO_ ($P
M_P"-?$]%'_$4N(_^?R_\ C_D'_$+^'?^?+_\#E_F?;'_  ]=T'_H3]=_\"8?
M\:/^'KN@_P#0GZ[_ .!,/^-?$]%'_$4N(_\ G\O_  "/^0?\0OX=_P"?+_\
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M26]];J_1?Y=C^BJBBBOG#[ **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\CCZ"<>OX"F03>?$K?WAFOI;_@G]H#^)?"?Q6LX+1+R\N-%6*VC*@LTC),%
M)Z9)%=V194\RQL,'&7*Y<VMK[1<MM-[6.'/,T66X*>,E'F4>72]MY*.]GM>Y
M\V%L?X 4$[3]U_\ ODU]*7SZ/^P3X'_LV%;'7/BYK5JIN9G036^@Q,,@*#P3
MZ?WB,GY0 >Z^'/B+QS8?L3>%]6\%Z/#X@\27NISF\:6S2XD>-I9B[G)'.[;S
M[U]!A.#U.K+#5JK56$'.<8PYW&SBE'22O/WKM+X=FV[V^?Q?&$H4XXBC23I3
MFH0E*?(I74FY:Q=H:63?Q;V2M?XPW<?=?_ODTN[ SVKZ<U+]J7XH_";QIH-W
M\1?"UG9Z#<221S6G]F1Q&]BPHD*G+99,A@.,YQWKH+7]D;P=X+^(UQ\3+K4K
M&;X3VMJNN6,*MO,LS'*V^WNBM@@=22JGH:FGP>\2W'!5&W%I5%4C[-PBU?G:
M<I>Y:]WNM--454XP6&2EC::2DFX.G/VBG).W(FHKW[VLM4[O71GR'G'\+_\
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ME@6!''X5Y_\ M8>"?#OBOX0>$/BKX;TN'05\2.;;4["$!84F^;YE X!#(X)
M (VG&<UOF?"U&@\33PN(]I/#WYXN#CHI*+<7S232;5[V=G<QRWBBM76'GBL/
M[.&(MR24U+5QYDI+EBTVD[;J^A\_EL?_ *JGTO5+K0]3M[ZQN)K.]LY!-!/"
MVV2%QR&4]C7UC^RC8>&_@+\'M$U#Q=9PS7GQ:U-=.@28#]Q9[657.1PI)R?^
MNB^E?.'QM^%UQ\%_BMK?AJ?=MTVX/V=V_P"6L#?-$WXJ0/J#7%F/#];!8*CC
MN>[E;F2T<&US0OYRC[RVM:QV9=Q#1QV-K8%0LHWY6]5-)\L[+M&7NO>][GW#
M^QG^V9:_'?3$T+79(;/Q?9QY('RQZF@ZR1C^\/XD[=1QT]^K\?M,U2ZT/4[>
M^L;B:SO;.0303PMMDA<<AE/K7Z$_L5?M=#]H70YM)U:(P^*='A5[EHXSY-Y'
MG:)01PK$]5/?D<=/VSP[\0OKZCEF8O\ ??9E_.ET?]Y?^3>N_P"*^(?A_P#4
M'+,\N7[G[4?Y&^J_NM_^ ^FTO_!0G_D@4?\ V%;?^3UX]_P3O_Y+=J'_ &"7
M_P#1D=>P_P#!0G_D@4?_ &%;?^3UX]_P3O\ ^2W:A_V"7_\ 1D=?KW4_)%\)
M]J44451 4444 %%%% !1110 5_+Y_P %59TA_P""E/QQWLJY\6W.,G&?E2OZ
M@Z_GY^,/[6WA?]E'_@I]^U5/XI^'?AOX@+X@U&[@T?\ M;2X-072M2C"F"4I
M+P86W$2!2&("XZ8KULIDU.32OI^J/"SZ*E3@I.ROO\F?"]EX:U+4O"]YKEO8
M7EQHNGW$=I=7\<1:VMII 3'$[CA7<*Q53R0I]*^P/V,OVW_BUX._9A\-_!WX
M!Z#JNL?$#_A*M1UO553PS;ZS;RV<\,*PA3,KB)E:-BS$*,?Q'MRWQR_X*5+^
MT+^QYX@^'.I?#GP%X-U;4?$NFZU;7'@W0X])LI8K>.59!<J&+229D&PXP!G-
M9O[(G_!1F^_9R^"^O_"O7_"\7BCX9^++AKG4X-,U.?0]<C=@H+0WT#!B!M&(
MY R=1P":]BHI3A[T=;[?UOZ'SM&4*=3W9M)K>UOEY>NOH?0NMWGQF7_@II^R
MS8_'+Q1\/]2\96GBRW<Z!X>M[2*\\-H\L9"WWV5%C\R4895RQ 4^O/[R5^#.
MMP>%OBU_P5#_ &9?CQX,NO$0T'XR^,+4#3=9L$M[C3)]--O9R()$=EF4E1\_
M!R#ZU^\U>'F&T/3TZZGT^4_\O-;Z[WO=65G?S045\0_M3?\ !PO^S'^Q9\;M
M9^'?Q*\1>+/#/BS0W GM9_">H.LB,,I+%(L122)ARKH2#SW!%>>_\18/[$O_
M $47Q#_X26I?_&:\T]@_2"BOS?\ ^(L']B7_ **+XA_\)+4O_C-'_$6#^Q+_
M -%%\0_^$EJ7_P 9H _2"BOS?_XBP?V)?^BB^(?_  DM2_\ C-'_ !%@_L2_
M]%%\0_\ A):E_P#&: /T@HK\W_\ B+!_8E_Z*+XA_P#"2U+_ .,T?\18/[$O
M_11?$/\ X26I?_&: /T@HK\W_P#B+!_8E_Z*+XA_\)+4O_C-'_$6#^Q+_P!%
M%\0_^$EJ7_QF@#](**_-_P#XBP?V)?\ HHOB'_PDM2_^,T?\18/[$O\ T47Q
M#_X26I?_ !F@#](**Y'X#_'GPA^TY\)-#\=> ]>L?$OA3Q';"ZL-0M'W1S(>
MH(ZJZG*LC ,K @@$$5UU !1110 4444 %%<C\7_C9H?P/T>UOM<:[6WO)_L\
M?V> RMNVEN0.V :YOX=_MA>#?BAXQM-#TN35&OKW=Y8FLVC3Y5+')SQP*!V9
MZE1110(*_.?_ (.=?^4?&A_]CKI__HFYK]&*_.?_ (.=V"?\$]M%9N OC2P)
M/I^YN:ZL#_'AZG#F7^ZS]#\&ZGTN&VN=5LX[R:6VLY+B-+B:)-\D,9<!W5?X
MF5<D#N0!7O.H?\$QOC!9?L]I\2(=&TG4M/\ [&3Q'-HECJ<<_B"UTMQE+Z2Q
M'[P0L/FR,G;SCKCB_B;\&]9_9%_:0T70M:CT_P 0:II,FC:[]GL6:2&^CG2"
M\B@&0"69'5",?>/&:^JC4C+2+/AI49QUDFE_F?I/X1^/=YXHTG5_!FB?'_X\
M:IKOA72!#JE_!\"HY?$^DV)3@RW>//0%#PY^<CD$]:^3/^")45G;_P#!7?X>
MQZ;=7%_IZ7>K+:W5Q'Y<UU$+2XV22+SM=EPS+DX)(KZS\1?&23P-\9M+UCP'
MIG[0EFGQ0^*]M\1?B'K%SX'U&UGTC3K:+$.AJJH3<1[MRG;E-I'!%?,O_!(_
M7H_%7_!;OP]JD6G/H\6J:]X@O$L'C\MK)9(;IQ$R_P +*#@CL017G1_A5/3R
M[/LD>O4=Z]*[U4EW[KNW\_/T/Z(Z*\7_ &@_V[_!/[,7BZ'1_%EMXFM9KJ(3
M6UQ#IC36URO<)(#@LO<=1]*X/_A\#\'/^>_B?_P4/_C7'0R#,:U-5:5&4HO9
MI-IGU,L52B^64E<^I**^6_\ A\#\'/\ GOXG_P#!0_\ C1_P^!^#G_/?Q/\
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M_/I?9=N[W.G"V]E=VW=KW[+;H:G_  :P?\G3_%#O_P 4E:\_]O=?N%7X>_\
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MU?2*_EC^KZ[+3?\ #>.N.JN=5?J^'O'#Q>BZR?\ -+]%T]3PS_@H3_R0*/\
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M_@G?\;K/7?A9J4OC3PNWC;PO!IL'B#XCPZIJ,.O:K:07SW$^FW%JJ_9]2MS
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MX9V5IK'A7XB+9^,-=\(WB36ZZ+JDQW:AI<KH(RZ&97;S(2 5G^4@CCU#6_\
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M:*** /G3_@I!_P DT\/_ /84_P#:3UX?^Q?_ ,G*>'?I<?\ HEJ]P_X*0?\
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MR_(^AR/_ '1>K_,****\\]8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M\(_#'X1?"G1]7T;0_$+:/KM]<:Q%>6!FN-'AD:,Q7%NQ^7>"-V.<[ #46O\
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MP0Q_95_:8^*VM>./'WPFL?%7BSQ!/]HO]2OM8U%I9VP% P+@*JJH "J H
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MODVUNH 6$$$$QC ^1LCCI5[XE?L^^!OC%H6GZ;XH\)Z'K5CI&/L$4]N%^PC
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MM_WZ7_"O:IYORQ4>79=_^ ?.U<@YYN?/NV]O^"?R)_V5>_\ 0/U'_P !)/\
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MN& [3^Z/_P D?.VQO0_E1L;T/Y5]$_\ #-/@?_H7[?\ [_2__%4?\,T^!_\
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M "(?ZX8#M/[H_P#R1\[;&]#^5&QO0_E7T3_PS3X'_P"A?M_^_P!+_P#%4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\
M/&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/
M^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C_P \;O\
M[Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (65
M8_\ /&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?
M_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C_P \
M;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_
M (658_\ /&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O
M_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C
M_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:
M*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_
M\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\
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M .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\
M/&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/
M^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C_P \;O\
M[Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (65
M8_\ /&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?
M_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C_P \
M;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_
M (658_\ /&[_ .^5_P#BJ/\ A95C_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O
M_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:*Y[_ (658_\ /&[_ .^5_P#BJ/\ A95C
M_P \;O\ [Y7_ .*H Z&BN>_X658_\\;O_OE?_BJ/^%E6/_/&[_[Y7_XJ@#H:
2*P1\1+(C_577_?*_XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>acclaim3_850.jpg
<TEXT>
begin 644 acclaim3_850.jpg
M_]C_X1(+17AI9@  34T *@    @ # $   ,    !"98   $!  ,    !!5@
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D
M,C R,SHP,SHP-R Q,#HP.#HT,P      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   #4J #  0    !   !J0         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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M![>YCAL;^=_A&_F)CUGZ[R8MZQ&D3TJB?Y7^:CPGN%O$.Q?0X*9>>MZU]>2
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M<" S+C  .$))300$       /' %:  ,;)4<< @   @   #A"24T$)0
M$,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      /T    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     T 0P!A &X ;P!N "  30!" #4 ,0 R #        ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!$0      !     "   "
M0    D      .$))300>       $     #A"24T$&@     #3P    8
M         :D   -2    #0!! &, 8P!L &$ :0!M %\ ,P!? #@ -0 P
M 0                         !              -2   !J0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !J0    !29VAT
M;&]N9P   U(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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MJP^FVOQ65$N>X!CW6O<(=;DFUIWO_J>G^Y_-?HT2OI_5-H+NHDD@;R**@"X
M!SFB';=T?G;U?8SN[Y!$4$I$DDFR=RQ69$F1LGNQK:YM;6N=O<T .>0!) ^E
MM;[?<I)))J5))))*?__9 #A"24T$(0      5P    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\
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M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M              #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M-@B#PU3_V@ , P$! A$#$0   -_@
M
M                                                          Z/
M7KR+UVE\O+5I@8/MI0
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MJ"Q V@C >304R*\E+"LA<088#(07%%#"3BW@JZ1!!D>3@>$6DF5<V(P
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MOVZ\C F   ."SHO +!BQ@N++""^T^RAY0$MJ,SYE&
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M>E-BP<K 7"%P!#%G1:@7W'67"%EA+A:V7AG63L6_&7XJL
M                           0)'&M@>"7?GR3H4X,DACY+0"_XIT6:EQ9
MV$IEW)E9                                            *1E7"W<I
MJ6E%22X H$7O'<8\BMQ845M*AE3"E94@O[(<B      0Y$ $.1  (<B#RSU
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MQ(N6*\%BA3TF@K853*$$X$64X+?2>#,B8CR++T2FI9N47*LDUFZ,
M #XKYDZ0@9)D]:Z/=KNI[Y\>NP*E>#FCBOCXK7J]6_CUY^@<@         K?
MJ_2P )%((]$MY+DR +;RC9D.*-$:2H5H(TQ8%?"8"K96$B#X(8F4Y*(E;3D
M '!R< Y.  <G .3D         \:_'R7(ZU">K';Y]_5*%0   .3Y.FYXA_=K
MHNVX>[;X>>0       "M^K]+  T_R /,+FBCY>N7MF&XGHM#)#+U"NI;(9>S
M$>2*2.52,@!BK,I)GW                   !T>K<HYFO>)D1?%0
M X(:]9@KMB'O6RG(      )3A=V            IT5#/H   4*T*@ #@Y
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M'-LUSXVI5NY8U,:O3>YYR_ZYNU7;%VUB0BYHL9-C\I!X.=NYA]
M    ZCD@ZTYI7FKFOGO\^H.KMH'W5S1\5\_3U]TI"U=E'>KUG2=E:=M*_9#5
M7F1<]9G)P/7ZHI7MK3[\U^JU^Z4A#D^:N5(FE?A3X5XJB:(2M/L*\$2=*G65
MNQ)&AN5@1:D-ZIWTKV4IR]<*0ZOS7S\J1%*\%3+&=3N]A=-:]%?/=1TUKVT=
M%411T*=M7?2O57S#4KVJU-QY#T:>:79." !P<@ X!R ?I,<7^I
M                  .#D Z?5N6,W7OCU:                'R>9E8?Q6@
M'!%UR(CQ? S8:)UL        "R^0B=$_JWSQ] RNZYN^Y#SSLP
M   &I3O_ !S60W;E &Z?S3N^?;5>ACI]6Y#D-6@+N&                 .
MGUY\G-PNOWYB5V+9?W7T *M:KO         &-J8US\Q#N/R7] SG:ETC]$3D
M?T>             !I8=*X3J>;_QX#?*Y5]#[)&E]0^*TD.0U7S;V"
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MD, !5K5=X         QM3&N:9'1>+46R<#T?>/?7"[1OD\P[V
M  !I8=*X3J>;_P >'!O<<N[UL%:[LBH       J4  AZ5DGQD3]<Q@    5Y
M4C[69-^#L7I6\L #YI2G6PZCYF5C "K6J[P        !C:F-<TV.B<5IED8>
M06'V?X-Y?F?<M'LUZ0      90S]$,]0  U$BZ8V1P :6'2N$Z^^V\ZOZA=O
MP@;9S/=RTGO]GGV!^GE(IV>      '-/60_E7']FOX[^)/FM !9;9S_S*HW;
M/UL)?1(:H   <GU2LSXD],N+,_5*@  >=?Q:;[%J'%:@5:U7>         ,;
M4QKFC!U#@DD7<>[>+V.^R+F]UCG7:*;'Y.9KN       V\C]/(]0 &A"7N&X
M$ #2PZ5PG6SW3F-0L.8L_E]3WJ.;]GRD3?T3HN_I+^H%))V?     ')P?!L3
M_*/R%M9_$OP9\U 68VL_\T.-VG]9.7T>&   !Z%K,G/ V2.\9(    DV7U^6
M)*&XK45:U7>         ,;4QKGYXW8/F;U/-W+9KF^399N[V7,N["FQ^3D:[
MH+M"^@E0EHJ <%.BD)9L>  ;>9^GB>H :$)>X;@0 -+#I7"<'&SZ)EZU/IVK
M_P!$X5O5<W[/L0ZKO%DW1>HZ+OZ3?J!26<GP+Z>8\UE#/S9HPL;P,K)[_-OV
M,>Q3Z8E[5]VW/U\>QY]ZZ/BK8H^4/D+:R^)O@SY!9C:S_P T.-VG]9.7T>&
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MKR4+)TQ \%6M5W@        #&U,:YI[[_P >M1DX++AK&_S.\[HG/.R #\^
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M]" R1\DXSO _G%^9$XX$:4LVLYNFQA;'O)2&K5?]V.#ZHF?$G9FQ9SZH
M    E63@Y1EH"K&K;V        !C:F-<T6.G\%J'X7"1FU768>7NL\Z[1P:
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M4<@W=OSG_,N<H^+PQX<W:]2_9WXNS=7S4&MJCU+U0J5]*SGYC*>\L@
M   /BOG[IZ         QM3&N:J6\\EQ$;+HUF<GKV='4NC_HB<C^D.#D
M  '!R  <'( !+N3$:7'2N'ZJV[<O WHN;=EV)]4WLH      !UU==:#[IZX4
MI5:R9,K6XOWC^YCRDVX>P_5*\@                   &-J8US\^?KOS3*%
MVQ:SGQ&<[4ND?HB<C^CP            !3Z2U#37Z#R?56W;EX&]!S?LVQ#J
MN\           3/AS<U8D\                     ,;4QKGYB'<?DOZ!G.
MU+I'Z(G(_H\            " N8E/9/4-.??.9:JV[<O WH.;]FV(=5W@
M      %?JB<,'8_?QY4                     #&U,:Y^8?W'Y+^P9SM2Z
M/^B)R/Z0             E/,@):RX73>WOF&JAO'+0-ZGFW:MB?5=W
M   ';YN3M'[/ZUK.                      %/;EC%;/Z?R"X##E,B<1L8
M            %.I/3H.YCTONV*59.*!7#$S)U\70        (CQ=GF/VOT+>
M2                                      (/WCTZE--*@
M"*MY,]QVTQGF^                                      !+F5#RCFZ
M\          !R1EO)GJ.VJ*\W@
M    !).?K/B9$8          !'6LB>X_;(CS=
M                 D"2U+S;N&          "LYX.Q^]C2H
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M+?H.P[9>UY<8#A1F.B[73*/NG;N45_0_K<ORMRJJJJG[>F<Z*K5V5ZWU1/\
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MZU,L<?%=O&VL&VOYJ\><4\P=CCV*_P"68V2)M+?+R:RLO&(=/YKK_*GRLO\
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MZ=(M)@"Z[R ACD)!%MD%9>:[D!#'(2"#IB%XETH\&(3]8\!N0$,<@(8Y"0\
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M[M%!<#'#:I2X2^JMP_\ %QC=L>S@Q 0&3^;N5F:-^/EQ/Y5>N&@GO0WYI_\
MR;T_+'_Q[=6G[H*R2<?=]6;A_P"+BC_CT?+B?RJ];,A/=04I<(^:?_R;T_+'
M_P >W5:*:[E1632"_5VX?^+FG_CT?+B?RJ];40CC7'S4XP*&<[FA9'-"R.:%
MD?+$B+ G7GU2S9NB+I:5V@%'U<ZS5M^^#;4?+^ZDZ*/]?[4G'^O]J3C&75#@
M)AXY_6Q]_O(V'+8]DGJM>1;!V/(M@['D6P=AOFT;5I$WU,*&O"[P$!9 V_L<
M/O\ =P<I<)=8!@[XZZ$!V@=K['J&_P!D/U?[H! ;@ZZ&#6@EG[(']V=P?U<
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M*E5SR K05WDDRWMSHN,O^&:Z1R!#0TY*5)VFIJ<4.W\!Y;]U^FG("]Y :?\
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M(YR, 3R+O)\ J<(FI$MXU"BI"@ 9#;MKY=^"Y2UU$[W4DYU))KMQZ%IZR>?
MM;%XNK0&BHRM0$U-:$D"I.??RRIA;V-:0W%20-SCTO6!##>3J&XXB@#?36Y*
MMRT)+*W@I4#]&F)KZ&'592L6) KH8BK5INKF"13.F[,*JDL=@&W$#WENR"05
M6NW(TS&X[#0YYC"6NKZ>!B._I)U*W@&:C>*<E,3<1MX6:RD.HTST-^=4#, G
M,$\M.2H502W>Q!+>6S1K*"5KM-.]N(J,CGCB=/\ %'\SXMLO^ /UFQ:!3]+%
MS&'(0>;XM-"=VW/%Q>11LUA*Y8,!DI)J5;DH2:$Y$4WU&%@M8&DE8T  ^<[
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M%A!/?1I.H:H+;*NVT;LL_P F.(2Q.&C:9R",P06.8/?Y?N : XCL^+6Z1,H
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M0#GS>_MQUES.(XZ@58D;<AL&_'I8YKAO >3(_+CTL'/9C:<;<;<*D?%H2Q-
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MAFLHBC&E>L9WH'4;6"0C6-]2"=P,CVW$#+;BXC4R!F+1QL.?64Q#+4!1PC%
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M$:7R1A/S=+Z P(I4U!(J3D :9DG'$G7B%R>,+U@$&GZ,*":%1H-0J@,&J-3
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M0QLJ<^[;NW;,9_W=[?E\^,SW=W<<9DUR\'D^?SXV\OC\->3=7+'.&7S>#^[
M-=G=WN_^/%=_=R?CQMR/=W_D\1P-U.2OG^;P8INQ4G/NY,O)X\!AM[N_W>'%
M:Y_)L[C7<<?-WOG^3'VF2 F35JH7<J6&QBFK03ER=_%:Y_/X=W=F<5U?-W?C
MQ2I [O(/!LP17+;W5RR\IP:[#OW_ #[<$@D_C\_?^3!SV[]X\OSY8-#EW=V0
MP034>/N\N*$FO=LVT\N-IKW5Y?-@&M3Y=_<*YY8IF!WO[_-BHJ#W=^GS]_%
M30]W>I^+97!RVGO=V>_.F-OA.\\GY<9<O+W4^3 !.6\9T)Y>7RXTUR[M^!0]
MWDS^<X%#E2GB\'Y/'@#=\G=W;<""Y0L@8,,R&!&PAMH/DRRP.7;3O]XU%,&I
MV]QQMSS[J':>7EP=5>[O[\  Y=WE^;%/S>[QXR.7S>#;Y^3%.ZO+N_%CE'CR
M_'@"N7D[O/GC(FF?=GR;MN :YY\OY-F[=B6UNDU0/D14J=HSJ,QF-V['B &S
MQ>0>#&WN\![N7 S\WDW]U,\;Z]W?\/FQ2N7=W;SF:8V[^[8?-7!"[#W>3O8
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M@F?K;81Q%:Z5D+'46 -%;-6U'<#G3+'$K9GE-HICT,VK-F4ERNLFM1H#;J[
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M6&ZFZN413W$%NR-$8HFJP21NL?31:/4"^"6' (K*">]0I_4C_4&6S$M66R9
MQ,G5:@-62$N* #'N?QOAW"1_4.(<9M>&W-L\C*UH]U'))%,O-+20RI&KPN0
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M1QC9]HG*$@1J<DBKJE<$<U%9A>\9XQ>O<\4N'+R2.:L['?L     4455 50
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M0#?]G'ZS?%22<<B_V?'/ Q65#4';0CRU\A\&/W__ +"=''[_ /\ 83HX_?\
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M8J@JJ\:CO0J<9M86<BH8#5&7C)(5$)!K55V +J-6!-E=R AY(PQV5S\ 45\
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MC HQ.5&+5),7 )IE=E5P7 I4/(SY5K0@-2N>8K3=BT;BLK2);P)%&$>2,<U
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M>(11,14*35B!M(45:G?I@1P\974=E4D \99 !XZ82XM9TD@;8R,&4^ @D'X
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M5I%9=1 R%6RK0 4\-<2<.F<FXM6TBNTHU2N= .::B@KI30*XFNVJ;2[4,NP
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ML2E]2\WT]75-S3S6%*[< @98N?XMOU%P+^P)FX/.0MU:L6T31[L\],B&ICD
M+(22=2LZ/9>\GNY>]?PJ;+,@21N!5H9E%0DJ@]\.M)$+(P/W6W%=V*[ONU=6
M(<$4(W9^.E*>+DSIB^]^_<6QIQ95:2\LXU ZX>D]Q;(*_2?GS0J/I*F2(:P\
M;Y_<'_=_73!\!^\D[L:E&B+>W+X,:(DIRG>?"?O8NT]$FC=X[C^(^7XOQO\
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MR\=K:VT-S):J[R!#([S21C0BJ-.JIJM:7T\W#FLN+65Y):7=NS!^IGAIJ"R
M!98V4@HX J*C.E3]PL5N$N/?2X2MO;G9$#LN9Q4$1J0>KCR:9@?1C#N+_BO$
M)!)?7,SRR-0+J>1B6)50%%22:* O^$ #X!,%YG-Y*>DC;:\@)V;B-N#X#C4Z
MD)RFE=VX$[QY/N-N-<E4AY=Y[P&[PX$<2:4'=X_B#(PJI%,30N<U/R;CX*4\
M8^*\;_AVPC<0N+=);:Z,LI?0)#$JII%3SC&5ZY2J582-&:"@8<#N[."".Z;K
M1(D93F@% E0G-],2!"!J,80NQHI-O<0W\*0.*@?:(JBO^R9%SWZ33D.6+&VM
MU0.MBG6%7#UE,7/.H$_G<E!O&7Q[@'U<WSQXMK6YOC;QL2-81WH:<U0B<\EC
M1<MYQ;H?>$QW5K;%%C>":-G8-)(%S1-.KK54')1D2,UT#%S_ !;?J+@'%AP'
M@-B]SQ6YD"(B"K$G/>0 H )8DJJJ&9F559@44I<^]ES'2ZN1F #2MO;D@$0@
M@=9)16N" 3IB6-%^'W*XRMXL:<'NYYF0J29NO@$("L" A2E22""*#(UQQWWI
ML+S@30WMZEP%N[![BXAT*BZ8I=:A3S-2L,PU""O.K+:^[?O?;P^ZCWQNA#-:
M=;<PB23K9[>&77U75R-J =U+H&KF:EKXK>\#DLIY;Q]9L9/MR+=]:"JW1;(Q
M]92NFK("#4:0/]-KV+B87C' ?LJS/I;J[Z*U(**4J&62/,0NU=*NP8&BT][/
M>8WBLG$^'06RQ:2#$8%9=;-6C!M50HH1O./<CB'!+BTBX_PU9(KR582J7]O+
M4.A"\]9E!'5S,200=58PJX]W+GW:]Y;1?>JPM)[622>V=[2[MIKF2Z1'0.)(
MWAD>BN#Y%R-]-QVTN(_>B]XE<SWQE"CK+AGTF2'3S1;% O4@ ?G'9I/PUW8Z
MB 1W/OA<QU@MSFL0-0+FX&1$8I]'&2&F/^&-687O&N-7KW/%+F0O)(YJS,=]
M:"@ H   J@!5"J /A"M4P'RKR^([U\8HP&.NU B@I0UI79LI6NZE*USI0TZR
M3(;AR><GER.P"@  ^ *HJQV# EN@"=R[AX?,:C%!N^))=*,UYK> [/(?BO&_
MX=L/+Q.XU\1#T2W9Q"CQG2">L-%9AGIC$D1)6A<5J(^'FQ6WX;$B]4JH%1B\
M:&5@0 9.>=.HLQ.DYUU8L[J?B, 9.&I"8])JL@EU&2@B8!PI"JXJ5J>::C'#
MX;&:.1(N'QH612H9EA%6 (!H=HKR_'N @;>JE^5H_GI\F+.[OKH0VZQRCK"I
M(1VB94;2H)J&.5!D=E,0.GO;'+Q*W673JBE+2 R221Q:BH(H&6,$F@H21F*8
MNAO^UM^HN+#@/ ;&2YXK<2*D:**L2<ZYD !0"Q)(55#,S*JLP9 4N?>NY0"Z
MN0*@ T)M[<FA$(('6/0-<, 3IB5$'WPG.OAK\(A@$=S[X7$9:WM]HC4U N+D
M"A$=1]'&2&F8?FQJ[B]XWQJ]>YXK<OJED<U9V/?H  !0*!S5 55 0 !F44'@
M)KM&5%.\$9\F&UQF@W]W=GA0R$%ME1MKR<N K0L&.P4/>\X\HPU4;2K$'D!)
MH0=VS+YZY5C.@T?T<CG793EKWL:Y%*\[>*'?GGE3+PU[V%A$)$IY:[.7P=_&
MLG5.=_)WEY!\IW_%'B;T6%,>B?3T?[WF^*<;_AVQ;\,XCP837DDG-G$TD;*&
M*KI"*0#IS:M:FM#S1465K9<.>VMK76 IGDF6K::Z!)_E@::$*<\C3;CAW$8^
M(11SVUD84BT RQW+.X:=5T4*Z':0\ZC$*M PH8989TGN191B:5::9)A"!(XH
M #4U!H*5^.L[&B@8X%,VUH9?%](*?)\%1M^"/@G"K?K>(7-^4055!J*+M9V5
M%%,R690!F2JYX 7B]A<>]5U%_P!3=?:(<@0#]G@U,&2($?2.55IF +!8U2,=
MK67\Q!^TQVM9?S$'[3':UE_,0?M,=K67\Q!^TQVM9?S$'[3':UE_,0?M,=K6
M7\Q!^TQVM9?S$'[3':UE_,0?M,=K67\Q!^TQVM9?S$'[3':UE_,0?M,=K67\
MQ!^TQVM9?S$'[3':UE_,0?M,:+"X@O?>ZY6MO"KK+'&*4$]P4-#&IRCBKJF<
M%:K&LC"]XUQN]>YXK<OKED<U9V.^NP "@"BBJH5%"JH PC,>:%S&^FI\MAJ:
M$$;!6E3GB)T"EY&4YTJ*T8G:2#4'2*T#&F>%YB4YN0S 8U5CWP ?&NK<#17D
MC4>$ 4JQV<M5/JJ":5I@O&D>PZ:TSU%@ !M&T5!(!)H2*MA7;2 016BG,@DU
MVBIVGEH*:@QI*5C&14AJ"E<ZZ*9;,MQJ-M37&F- /$!XS3*O+3\?Q;T1MKX^
M7P_%.-_P[8 /%[B".>^ZJ)(EB-'9H4+DNCELY$)2J@(DC DT&.HXQ?=?);,R
MHP15 K2I&@"M0HK78>3/X!09=4_S'XZL"'GN?D&WS8]WOJ9O^8/N+FF3"\;]
M1<Z]V>>/2./2/E./2/E./2/E./2/E./2/E./2/E./2/E./2/E./2/E./2/E.
M/2/E./2/E./2/E./2/E./2/E.*DYGP^3/YZY;:?#IKS:UINKRTV5_%EMPJLQ
M*C8-PKM[PKWAX:X!DD+IR$UW$&E:T.W=0US%,L%%8K&>_4[ ,SD".]3/?6@H
MR+,50[:$@'<<JTV9'(UW<N$FN)Y%13EF=1_&HW'948IN\O\ 9?&_X=L-:<+X
MFT-N6+:0B-SC0$DNI-:  "M!095Q W%KTSF($)544C535Z %:T&WQ;_@7ZI_
MF/QV9QZ .D>#>1X3GCW=^HF_Y@^XN?XMOU%^+T SP)KH>!>3P\O>&S%!L_LS
MC?\ #M]POU3_ #'XY+(/2V#PG(>?%,>[OU$W_,'W%U_%M^HOQ4'=@*HJQV ;
M<"6;G3G/O+X.4]_^SN-_P[?<+]4WZI^.0VX.SG'YAY,_D^#W?8CFB"45W5ZS
M9\A\AY,>F/+CTQY<>F/+BYJ/_BB?*BD>4'+XI3?@1Q)5SY!X<5/.F(S/XAR
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M "CQ/+C8<'<;56M:UMS<'U>4P^)F)NP5G,<X+58%JC*R"TL[*^=D>IE;BF4
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MO$?U7'U5W[$N7++ASQQK^NX1SFR3(BU3,9O0[+"VEY,9!9ZRE:;?G%SLM )
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MWQ>HUM:ZRE 3D4J'(VM6'9J6%]2DIAT]E251W+&64C@=+*K@T,GYAS'ZB/\
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MS,D50CVI">--,A3F*8QSG,4I"%$>_N 8*W5Y91S!V*,:RL8NLBHW7,U<D Q
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M!TBD0*425]9KG8ET3$9L4.\2E.LJ9)LBLLFXJ/$3C'D7%C+((C=L[8YY1H:
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MQGN\JU)M5M-7ZC;*X\N0H6&P5MW("0@)LY%RY0X3V7E'Q!Y@>HIQ.IWIP53
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MRY7L5\<H8[G-(N[)NQM-8RJNKLY^T6!TT;NGJ+;^4>Z>[E3_ &0%#,H%NH(
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M579T$A\1P3 PE+WCT#LBR4=MB/'!3G0:'72*Y7(F F4.B@8X*JE3*'4PE 0
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MS)_:]J\G-9+F<RG4+ROIU3)*T2K2!*QI3E^[EG&AUTKN*6+"7EQ*2#AR>7;
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MMT'<R0ZS8Q\2;MX/";'D6L)<7GRZ$CR=807+9O!\JK=6JE6K/ <4H_,K*LM
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M'/[SJDEE,<Z-)ZKAEAX_S5.E(++\GSNM#0HJG6=V]8-&K1L[)-JF=+.ER&%
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M0C<=S84\<6K:\XTJW<3Z7:7]AV@^G).J1<:"XY%NEH%Q'0BC5RXB0))(.47
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M/@[='"+9P'3O,4#I'_\ <^(G]KMT<HN&P^SJ  X)^FC]L'_>]@]V=(K&]@%
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MW&$PZ,XTPDS7*W'P1H/C_"2YIZ&QZ$91232-B:#$2QO.:QS=%-! P ! *4
M(OB-9,0SRQ<98:OTVJ1V'V"OMIO.4JWGTG"S=+A%J[)@Z:/8VN2U=8N&R2X*
M%*JU3,/42]M8XB\#:W@W&JG<KU+)1>5-ZNE5O&FW>1R;0*/*9_<Y>FN7EL3D
M;/J<;5'I6%=^Z237A(=#IX$!22*W/0<0HT UB\RS+.ZKE-.JZH>_,HZA4NML
M:C7H!4'?F^^-6=>C46X^;XO,*4?%UZCVT^K5+B9F434MC;5Z/T"G=+"_IDE$
M5*\L=,K$!#5"3G7M;IE:@;[&-I1K&0C6.8(NFZ0E1 $R &N_RL8I0-"#>\YJ
MF2["G;(-&81OV>4.7LEAH];G$'0F0,A3K!;Y"0BUTBI.F#]Q[P@J19-,Y+6W
MXX8W5<J/?!KI[U(P7RF\G;NXJ;608UU_<+%.R$K/6>5B64JNBF[?.5W7E' A
ME#%*4 L'+.E\<LTKO(>S/;)+26EQ\.H$@A8;HT;L+Q;8&&6<JUBJW:]LFWE3
MLW%L6<M-)JK ]<+@X7\R,S'':3 YWGT-)VJ9BJE6FHLH=A*7>VSE[MKUNV\1
M_ O/W&ROY%P/7[9R[4-W>+H'YI$'+E,AP#_!E'QJC_\ FTP,</T0#L)6+,1[
M^GFN3 4HA\8)$,8X_8$0[""SE0I!_P"*;B"!.GMZ#X! YOT1'M\8]_>/4PCU
M_P!T(]YOS.4WPA[/@'J/3^^Z]W8/)=*B4/\ BUS NG^D?J8/T!#L!7S3IUZ=
M56I_$'LZ"(HJ" _I&'M_AU?UOB_R9?\ [S];^O\ R7*;8.23#&''JLPH<IIW
M5M"FE:HTYWT7U,:]J5\;8G7ZC8(%9':Z3=8;6(ZJQ]%AXE9HR7KYF"22"D:[
M5!?(>0-OI7 52XPFH<"K5SBLF3)UYQZNJW*"JZ/DK=Y1^+4]&E5C(NTHF:0K
M$T2NZ3DG5/5G&C%$AW;<YLOL/);!L>Y3[A)V*SU/ACQST]/-5GVF:]981"/F
M4HAYK +43/J9"PADG%PN\JD,=4X 5%U#*+K-F+VK\>N>VFXKO^+9!Z&%S_DF
MOEPL#&U<?XJ]3/)7=9;F67B]-VEPX9Q\MD,*?/JW!.8Y1.W052BXEN4S<?&3
MMPDXN7:NX2S]3OD/P@X-6CE)S"W.1IT%K'"3&*E7,\F%=OLFAW>4B-"C^2LJ
M[>.4Z#4HAVSEWUL?*3$F#:'8/W)N*NT46)X#-,U)ZC?&2<T*T\?9:L)>J/HO
M)6<NS6D(U)K,*M7S&TYVK8)B.-HE?:KGL+K.V<NDF1ND0ZA/S=_;_L")U5")
MD*'4QU#%(4H?&)C"  '82-"F>J%#VD$$T [OA5, B<.O^Y 0["!G -TQ[A2:
M@9(.G</0RG453?\ ?!]CL(]1$1'J(_"(_&;N'Q&^N/YL[NX?C_\ 9[?KS?IA
M^I^2SR(I>D5>J<Z*IJ;FU8AR/SK+)G(MUFKWQQDGL;=JGFNZ:7D"-+WR"AH:
M!DH>QU=-U9HY2'2='%JF=FB[:9;Z@F4X!C<S:=<K<-HU%WV>P6G5_;G<8_C1
MC8>7<VN9K".@QKX88GD)^:Z*H5KT('[&(!VAVF[8=C^U-J\$F6OMM;S.EZ.A
M!EFOD\9@L,C<868)&!+?([7WGR0)Y_NJ7C\7E$\-$S9]Q7XX/,[RZ?>6O,J"
M[P[,G-*SJT2$@XE']EHM65JYH.HS[V3=JN5GD>@W<*+JG4,<3F$PW[D/RRX\
M\7;1%4RM.+3H.I[%AV;WN3C:W5(@$C/Y6;L%2G9UXC$P[0J*"9154*D0B21!
M^U+VT/:N+^:X6XY YP^A&>EW!?C1_(QR1JH7FKJ?<K)V=+2,RH.RLX"]T]JL
MG%R2R7R?*LFRR*"RI6ZR:>N<:Z!#:?9;!A1"QNIZ6RS:S$PBK:",33;,MCJF
MNNFK>L2>ML:AH,/+NH=F=R9LQ>E%50JQ%4B5I*V6B K2MRL["E5)*=EF,4K9
M[?*MG[V.J\ D^71/+S[YE%NETFB *+G1;*J 42IG$*7DCR4N[>Z7[8]6PBN,
MWF4Z7$M)#1<6Q>1WZ^M8Z0FJM&-[!76F;1*ZS*;BQ?PTF^(9BT<K.TU425ES
M3+,FXD;9F=0V",J,]&3--T1GF]\%ZG4[-9LTN4= W^FMI=W&.VI49>-9.4WC
M-RW43(NW63)U >H?&'?VZ]>[X_L^S]/ZEFWC99*5B,ZJ$I2(B;?PD!*6:21>
MZ'?JOFE9*C"PJ#J1=)N+7<&2:QR$$K=$YU3]$R'$.G4.OQ?#^?O[4Y:W&L1$
M[[H52R^NC7:5=+N<;?=GAV%?)-I4NOV!6KUP[E,0>3<H#.%C2=#O'2!! W8/
M@Z_H_P!L.[ZFD8127%V<RN9WR9R)_HDO2)JO8Y;-MJ<9*S=]Q'--&F4V<3HN
MJYU!0$B]G8J)*Y-'-HQZ<Y_^9//)Z]>[X_J.\ER?;V,_>D8>XV**82U*TJC0
MUV@,[ET(.^S677"^4VLT[6HNER3A,DFO6'\LFQ*H5142)&!0;I8L<V-W,4_/
M:&OJ-LO]NRO9LGS5AG;;J9Q<VFE:WG=&H<Y7T&P"X,YCY%T0&@"X$?(#S.TY
MQ60?RQMAKN)U/D'*Q8P,H2#;YI=;U<\YKS\ME,W"'4EG5HH,FF9@"GO2:2(*
MF(!#%'ZM9CI^?AX:1ND^:JT]C*2+5B\M-F) SMJ/7Z^W<*IK3$PG6:Q)2)FS
M<JBI&,>Y7$H)(*'+*S]/-8%(V&N-UH;X;'3;A1WH6+/K1*4ZRD:Q=V@:_)R,
M*6;AU_<91NBK&2K7P.F+APU526/V=Y\E98)6\Q];CKD_IZ<HR/9F-2EY23A8
MJS/(,JPR36"E)F$>M6SLZ8(KN&:Y"&,9)0"C];V^WM_;^IF,GJ$C*QS37MQR
MCCO23Q,#*3YWNG;19D*C0HY\G%-US142]FG)2.7Z_A:M"")U3%*'7LSUW*)"
M1E*2^MVH4=J]E8=_ OC6#'M0N6/7E!2,DTD'B2#&]4.1004,4"N44R+$ZIJ%
M$=1VS07;UC0<>SN[:E>'T;&/9F19U#/JU)VVRN6$/'(KR,L];0L2N=)J@0ZZ
MZA0(0HF, =J1I-47<.:MH52K=WK+EVS<1SMS7[9#,I^&6=1[LB;M@Y5C7Z9E
M$52E42,(E, " AVZ?#[?J7'8ZO9OD[.J!==LH=QLER:+TUE7)OCU?[?FFK.)
M=2P@Q)'PE:L]%DP.]5$C8S9OYX&\L0-VBI^"DF4Q"3D<QEX>7CG"3R.E(J3:
MI/8Z18.T#'0=,GS1<BJ2A#"4Y# 8!$!#MU^#X^@]._\ 0[6"Y7&?AJK4JG"R
MEDM%GL,DSAH&NUZ$9+24S.3<M(*MV,9$Q4>W47<.%E")(I$,<Y@* CV 0 >_
MH/> E$.H=>\#  @/UNUDW;8Y&5B<[JDK1H::D(2!E;-)(OM%O]6S.KD0A85L
MZD7*3BVW%BDL<A!(W1.=90033.(!U#H/PA[?S,*KA4B*9?:=0P$#[ =>G41^
M /:/8R4<AYA@[A<. $J9>G7]8D'113ZW42AV!1VX.L(=X$, %2*/^\2+T3#[
M/3KVZ>WXN[IT^M[?9_8.7TG:>(VM\+K;&Z7=J0TR;9I&%D[5+5RLN&:41H+1
M>$2;H$@[,5THFD4R?A\]HL9NJ[9&;/7/;B[IO)+7[A%8YQLY:\P>06"\-G.%
MQV7SE2U=;D7RKI=,OVJZI8GK_2]"BVE6TV:F8-BT8UB.=DFF:SD)!NW1%;T:
M.1F.8'R;L&]7/"N7!N6^?HRNHL9_9$*WQ"V/5\PP_486XJJT?."'VVJP$922
MR+&+;0SX6[1KT*NJDKRK;ISV^\*N-NV^FBRLNY7KC#@'J#.*UEO)MER?SIRY
MI%E9[M(6?6.1^TTZFV"3@K])U5G7%Y.F2;YL<R E!U'<8F\1B=5QG@/4.8/)
M^/Y+2]/Q7U ]%XG\@'K[$,^?<=.14EQB^Z6B\RZKQV=7Q>=K:D864DZA"Z+$
MLY-9:1CSM7Y*!I&BZCMG,.&R3-+C:6ETA<$V>%V_2:B-XLS[.:-5\2U5S);2
M]F*W6W\95H=6Q.A>R;./0DGSHJ2ZKD.3'*+1;%9AY<[U!9;]V6._R,\@Z%G'
M%GCSFCFY)X?QXJNA[-E6>0^OWRNRF@3TQ>;!%F]WD[5-.RL6;>':1XGY)<D*
M+C.T4*"H/_WB7+=!W"Q4.!VB4GYSA33J1F\E-7<:C&J2EEU+'X31K^\E)=:'
M92B2R2;Q0Q5D6!TDKQRAVC$^1=UX?5KUML)T(7EZQSD;%N(?B3)>F[4\HLFR
M5G,V4/&:+_(U9=R8QAD9",C%#IG5!TLDB4[PO: GIRJ;K*P5:]7KU)9FESD]
M Z,_C*MC4UZ/RU=S*1JLI)-EFU;S.4M+\(Z%.T40C59M91LAU?F5(/'ZN[76
M-PRSEMR<]";@A!\;>3DY%\EXZP4_U ,0K>SS-ZD[AHU:6*SJ6AYV1"D2<_%V
M5=DI*-$12 JBJ[PBV^^H_ML?.T]_KP9]QBR?)W;Y!:OY[5N*$;(U'?I>";QD
MM(QJPZ#S.E="*DY5\;Q2!@H@#G*(&2)1MQJG&S4..]WT>8]22 YAY55,[YF.
M9JC1:.$:TYQJI\K]PT>S.>/VCRUZT"J0\[28FA0K:/B5Q(2*>F:G*5YZ8_(3
M%L1Y,Z3LNO\ I/\ )R[<V* ^L^\S=JY*[51^)>':7EF4:S)V%2WJYUJ#C5G<
MM"U,YFC66C 5<QC%%0J?NH<UH_!,VM<CC5ZP/TWK^PJN,\=^<=8QR?Y&5#U$
MH!73W56AN7KRXZ=JFET_/$8\EPLK5"&3?,&J(R,:5=@NN74?3JMVA[+2N,'#
M>T\HO4UA-JS ]G?Z6&.\F:+?HKBADM'6J[VRV^R7?CSR4T#69>%B)%@_0D6F
M<5I))H\\/NY,LHO'NAW"<JU,]4#TN%++S#Q//N<..1G+>BIS^B1VC'V7&-[,
M_EJ7?,TBHMM):C(QTI)4N9-9F8.SMUVZK%MN-)H,7=.3+&0SG0IJW<^;]G/+
MS&=V:V!79HR5)A/,.M\@(YCD>J:[++S+A:OVNEA'./D6K.".(9@U=-UG-$T2
MC\?;OC.Q9]ZH&-XY='50SGF/:M0MW#2+A7M F]UTK;I*2:<0*?Q9VBOE;"VJ
MD3"R"YEG39PN]0ET7R[;.]SW/B??(W%J1ZW_ *B5=UZUDH_)*V/(K"9NF<C:
M[QSM+^KT]>8M+K-)G5Y"LI-;6SCU62BYF:CAX9LLL99],[ANMTQ'E'$\_P#<
M;='M?Z+W,B^6C?N%17MY0RC%HK=XK1)CA?&\1;#BKF*<( M L7]6MD.)G7EV
M$JZSC$]AN<!K*7)W=LMK,MR*N.[6#29O6YR3KDQ;#5>NV"+T207>U6*HL/,&
MCXF+;,F)&T>1(IB*'ZJ&::_ML1O>=M<8SKDWEO"7C3(\7.459T5>-NU,?Q^\
M<E-7O#_(&%#KNB:1F=$7C,^IWRRHX8P3XRJQ59R:181_+'AMPKO?.;F]PCI_
MIC:2$=4N2N%VZF2^0\E,0E<L;<5,AP:TR6(<?-)T6V2=&A9XTQ35F4T1@>!C
M%%%O>I 6;FT3>:Y'KDQP\J/HW0AN-K:-8<D,BK;+62\J.4\J],R),EIM_'8Z
M9*().HEA*'-*PH2'O39L3WI%8U#NM^G=O9;U(\6O3JD=2EHB5L5/Y%/[S-:#
MQC)J35!\96(M$;KMC=OI)JH@<4'JLLY,@8 .<2]N743Q*XY[+9O3&U>R<*<R
MN/\ +K3^=B.&99R+^[+=+/R,W^-RN'+'<H[-E\13:OG5<MS&$3B82<NLH@64
M= U2EUNW#6[<R,4UFU<9N,GK$<Q:W%.);&.5\(CEG$73L+U1EATS5\:</;1O
ME)X]S^RO*DY@33BLPO7DE6#9R\19BX:]L#/R!3T1EQ08<JO6&6U%QMN1\UMF
MSMAI,ES1?AP^F=&S[C5H^:;(UHX8(>:)G,XHL\JT2]51$B*3M>'<I71CR"NG
M)OEO%XQZ&?'R8P_9IICR*PY+2.1"%WYB/XO7RY@M-1MA8\IH.L1-623-->]7
M-D19-=T7SW_4W#?D/RKRW3#<C>0OI#\%W5(V6Y4'9U%)SEM3JQM#;DS!7":C
M6'W!Y_I;#-)Z"/*Q5B1C -YA#MTP>>\^/:2ZWN=PXW5>7JW%IOZ;^[1W&CFA
MR1>YK.,49!;89+C^MQ.OE<SRB;0GKK=(+7'WZ*D7-CJ[R+3*92%2=()<[N8K
M6A\BC\L,@];/+F'&.W(SN\%DZMQ]E-[X45;1$,QH+692JD]AMWH=HN9[$*<6
M[AI%BZ?BZ.=)BD+7U3^3-*JO*^?Y:6OGWRASQ"9@+/I7\N;/T^6G/RI3FK9C
MP_J]@EF<57HRU\=J].OZTI6VB<G*OWQE(IT=RLR*2+-P4RODFEZ?[#U"/1AL
MF9Q5GH7()I267(&M<B]3D>66AY'4M@8$OM6R6$RI6CDN$LNP8P'W4-W:I517
M3D%!XG0G(2/GL\X;LYSU77$NAHN$<U-)IM;Y-6_U(],F,KMU_P ]X@7K)];K
M=GD\.E))[F]IF5GL"T.Y>G:))2#Z.=]M]J/,Q7F%RRT=[Z1V)TKTJ=<J&4\P
M6;_5]D3X]ZZPW^]+9Y0FKY/,>25_TZ0KCZX1FBG"9<5HS-LZ%9B62;CAD \X
M_O-=C[Q4.)>0;)&+LME9U3#Z'/1=2)=]GTVHX.>*WB<SG+G$0F$M!5TS60<I
MKE1=&08 ]43XX8%I-)Y"!Q0=>L)RU1C*ZRK7*?!<YD.)!_3FE[_2V,!5M#NL
MOJM(XCZ%OKE9:,A[%-+L)%=X9F0J:3DK!/+LFY;TCE4[]*O"?4,]43-)&E-X
M#?;;4ZO$1J^62? )*[1](92NUW'C? "]O32HR*(25?:6!>&267\*3 4^7?'Y
M+&MK4L%VKOJAM\DR#98:[5[>Y[Y?W'D59^/,?=(^ZN8^Y/KU8D'%?<>9(N#J
M22JY#.%5BJG,?TZJ3 YALS/A3G7IM:C>GF=O6W(S)LO_ *7].Y-<?T)F&UBL
MV9Y67,Q<*C:7$](1L+.@N@=9!5XS36;M2J$G]BU:T:K:/4!R/+><URY6<-83
MCKS.A-5YPSR=>T1?/,XO7*>:MMOXANJ0UG4Z]*9+,T>!9@E$':1,0W 57;,?
M4]S7&\9L5HQS7/2LJNAP6:Y)BO.3-\FM/,>@ZI?95]'TPO+F>E=3V7D+3H-O
M%H2TJQ"(&QJILFCR(7=H*%"+<9MI-QXU\*9#CSD+'TN]71XM^I9I\KB6GDO^
MONM_M&/5'#;QG-BROD]#ZV2%>K-](AI9U8X)"/:LA&)0DFB_.]AN>5<G-!]1
M-[S8XTR_$>6JM&Y/V[+S<!*[I/$IY%/*HK2(U]QVBL?9M82YO+Q$/_'(-[6J
M[7>IG=%C'!.OP?F0RBAR)D('4YSF A"@'M$QC" %#[/8R4<F5<_>47"G4&Y>
MO=U3+T\:WV>XOV>WF.G!ES]1\'B$ *F4>_HF0O1,A>OP@'80*4X]0#]80P@'
M0/C#K[>W0$3].G7J/4.OUOMNG0>W^#Z?9.41_NCV'N('Q=3=>OZ0=N@B0H?&
M!C"/]H [?X4O_NNW<J4?T3=N_P L/_;_ *H=NXI#?84*/_ONG;_!F'_@F*/]
MPW8?$50._P!@^(1^R/0/#W=NHCT^R(=NX0'[ ]OA_2$/[OYJEVA-"HQW4#5R
M7:>;EML"9Q"TM0SU-.W2Z(2 JQU8.>-<E+(+ 1H)FZH>9U(;HRU"6U'.8K,Y
M-!FYCM$D;O665%?MGYP3CW#*W.9-* =(/CCT1,FX,541^U$1[1MHN]^I=-K4
MN]CHV)L5JM4'7H*4D9=)1:(81\O+OVD>^>RB*1CMDDU#'6*41( @ ]M@I%?>
M.*?=,AY$;)QR5J-ZD:S$6B^V'#2P![I<,^K[:>?RM@H:9+&B*;SRDU2%*85D
MD@\/60H#6W5AS?(J';6*4I+>?B5K='5]ZN#5I.OZVD[-,LX=VZ'RTW2B)45%
M/M2F$>@=K%'T2_TBZR%0E58.V,JE:X&R/*Q--SK)+P]A;0\@\7A)1!5$Y3MW
M)4E2F*8!+U >VA\):'99JS;=DV>R.A:":/JTW]P%<0B+!4*],U!307#5&NR=
M^A7%\B%GT4R5<J,47I/>#)J@9(M%RRCQ&U5<-KKNAW#C-I&H91.4'+^553RE
MVS1O]BP.R2RPOK)'P3"1:R9223*(</X9P209I.&?B6*]6/8H(J4=--:W(*&E
MX\$V%B>JL$64"].9QX6LTZ7E6I$FIQ*NH9RD!2B*A.ND4O2MIDL;J*Q(.$NM
M^I.TN,/N-*/)2,/)1+9MI\).04W0Y&Q%.W;D,FZ;.'31X*:8]%@$<?PVB$S[
M%<OK[2NY-C%(4G8^"CW:J+848&IUD\[(_*-KM$J1(ZQA%5Y*R;DRKA8ZRRBB
MIN5&+BC*526XDW3':+?;-;UH.(J4]-[;F--U&FEJ4F:85<.DS,KNRC5 =HLU
M3RHBBB14!(<]BH=>O](G;S4 1/;:;#6J!D[75P< F+<UCKK%^O+PH+@J02>]
M(I>(#!TZ]0[0] ?W*JL;Y8(YY-0%*=V&):VZ;B(T3_*$K$5M9XG,R<:P\HWG
M+HHJ))>$?$(=.W-K,.-M(TO0+%%WYD7ECS(T?<J?J4E;-IJU0ITG7<7*2VZO
M.[PK3,AS_0VT=$&:UUA181TG(QS589$C\5.2$A5XE:LX3QPO%GS26Y)W+0<:
M89I<+E0K=,4:^I0L9':-*7RMUB%L\&X08S5ABH>-GTTC.(U1PV\M53#ZM8X6
MVW0-\S_D=I5(L.?IUV9KH5SC5C"NX6E5Y).[!'%5-::FD"4*=J#A!RZ.7S3H
MHCYO;CCKQ+!'4-CRFSG/]&RBH:%-UVO76:;:)2X.\1M::PXS#@DO:8R)GT"O
M&L<J\!-7KX3&()3"*H6:O>62P!43*EFHWP$M1G)69:P)P<@4+ +M0J7N0_\
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M^%?;Z6W&3Y^LK_"OM]+;C)\_65_A7V^EOQD^?K*_PK[?2VXR?/UE?X5]@_\
MK;\9._V?_+UE??T]O3_TK[?2VXR?/UE?X5]OI;\8_GZRO\*^WTMN,GS]97^%
M?;Z6W&3Y^LK_  K[?2VXR?/UE?X5]OI;<9/GZRO\*^WTMN,GS]97^%?;Z6_&
M3Y^LK_"OZW;Z6W&3Y^LK_"OM]+;C)\_65_A7V^EMQD^?K*_PK[?2VXR?/UE?
MX5]OI;<9/GZRO\*^WTMN,GS]97^%?812Y:<8E5>@^%,V^Y60!$/A.;[JA\)
M^'NZCV\U;EUQ@,/7H4G\ON5^6D'7N!,GW4] #I\/ZX?A'M]+;B_\_P!E?X4]
MOI;<7_G^RO\ "GM]+;B_\_V5_A3V^EMQ?^?[*_PI[?2VXO\ S_97^%/;Z6O%
M_P"?W*_PI[?2VXO_ #^Y7^%/;Z6W%_Y_LK_"GM]+;B_\'_S^Y7\/L_\ XI^'
MM]+;B_\ /]E?X4]OI;<7_B_G]RO\*>WTMN+_ ,_V5_A3V^EMQ?\ G^RO\*>W
MTMN+_P _V5_A3V^EMQ?^?[*_PI[?2VXO_/\ 97^%/;Z6W%_Y_LK_  I[?2VX
MO_/[E?X4]OI;<7_G^ROZP_\ QI^OV^EMQ?\ G]RO[/\ \:?K=OI;<7_G^RO\
M*>WTMN+_ ,_V5_A3V ?Z6W%_N_\ I^RO\*>WVW+3B\ _[HN^Y64W7XQ$+3W_
M */7M]IRVXO*%^#_ .7[+"F /@#H-H[^G;Z67&#Y_LI_"OM]++C#\_V4?A7V
M^EEQA^?[*/PK[?2RXP_/]E'X5]OI9<8?G^RC\*^WTLN,/S_91^%?;Z67&'Y_
MLH_"OM]++C#\_P!E'X5]OI9<8?G^RC\*^WTLN,/S_91^%?;Z67&'Y_LH_"OM
M]++C#\_V4?A7V^EEQA^?[*/PK[?2RXP_/]E'X5]OW$B/WM9_M/;]Q(C][6?[
M3V_<2(_>UG^T]OW$B/WM9_M/;]Q(C][6?[3V_<2(_>UG^T]OW$B/WM9_M/;]
MQ(C][6?[3V_<2(_>UG^T]OW$B/WM9_M/;]Q(C][6?[3V_<2(_>UG^T]OW$B/
MWM9_M/;]Q(C][6?[3VFJ[Q_X^W+;9^MQK68L<+F=)3LLE Q#]RJQ82DLW;D(
M+-@]>H'124,/0QR&#OZ#VT5CH/&72Z&\QZ KEKUIM<<S>U]3-ZG<I%:'I]JM
M1I)FB1E6[5,MU6;!ZD99NNY2.F4XF3,  /R-$=_3I_FYEW]?9T_8?AZ]NGR+
M$=?B^3F?7NZ=>[R?@Z]NGR-$=0Z=0^36?=U]G_$?#VG],Q_BEK6IYO5CODK#
M?*'E$I8JM'+Q#<'4NT2E&D?Y4R]AFQ@.[;QY7:[4!Z*$*;[7L=V>+A"-2)BN
MHX.P9E230(45#J*"* >6"9 $3=0 0Z=![^SK5[SPJW:J98PAT+!(:)*XW*FJ
M4=7W:22[:?DI./8O C8)5NNFI[ZL1-N0AP,<Y0[^P*!$0PE,3S"G!BP\H4Q*
M @H!_*\ I>$?%XNO3IW]@0DZHG$N#MT7:;:7K9XETJR=D*JS?I-9)BU75CWJ
M7VR#@I117)]LF8P=_;K\BQ'3IU_<YG[/C_P/L[#_ )FA^X.H_P";F7<'7IU'
M]A]G4.SW<$<ID%,7CKVVRZ1U0E=9?<0STIY%-9UK0EY80\069>$?(.P0!,>B
M*Y#"8/&4!'_,L1W>W_-S+NZ=X]?V'NZ /81^1H@ Z"(F-',P(  '41$11  +
MT^'MG=[L^(W"MTK87$@SQ^TSF=2,;%:N[BW+1D_;YT+J,([MJK9[(()![HDH
M"YUTP1%3QE$:X^Y \7]-Q%A<3N$:E(Z=F;NKQU@=M&Y7;N-82#IJ=H$PT:&!
M51BL9)Z5/J<40*!A+^XL1\?[G,_9[.O^!^,>W[BQ'?\ _NYG\?3_ )'X^W7Y
M%B.GQ_)S+I^GY/:S:7%YH[DLWI,W7JS=;ZRK;=:IU&RV_P 7W)5^PRX)>1'2
M]G$A@8HFZBN(=W3M%YOC^2RVI:)/(R3F"HE%JZ,[:IAM#,5I28<1T6W3!5PC
M%1C91PX,'3P))B8>[IV@XSD%QPT+#WUG1=N*RAI^<NJJC8T8\4BOQ@G[IH:-
ME%8_SR"NBDL9=(IP,8@%$![!_F:'^V$0+_FYEWB'M /V'O$.W3Y%B.O3KT^3
MF77IUZ=?\#[.O=VZ?(L1U[^[Y.9?![?^)^#MU^1H?I\?R<SZ?%[?(^/LJNXB
MH5!!%(ZRRRK!F5-)%$HJ*JG'R1$$TTRB)A^(.O9A5M9RB0S:SRM8@+O&0%OK
MS&-E'],M:;A:L6ALW#SBGA9])FL+=3KXC"D<# 4Q3!V[X6(#[,<S_:?K]F6=
MXQCLWK.@R#&1DV%'H-41L%H>Q<.FFM,236,03*HHSBDEB&<*=0 @&#K[0[0$
M/R"X\7;$):U,9"2JL7IU(3K#VR1T.NU:RS^'0<$/[ZVC'$@W(X,'3RS+D 0Z
M&[PZ0L0/4.H?YN9=X?&'[#WAW=A_S+$=WM_S<S[OL_L/:>LN \5-6VJM59X,
M;8K#FN7/++#1DH1NF[4AOE!JT(WD9M)JL0ZC)F+ETF4Y?$F G* O(^0K+6.D
M8]VZCY*-DH)./DHR18N#M7\=)QSUH@\CI"/=)'27073(L@J0Q#E P"';H,+$
M!U]G6.9? '4?^)^+MHUNI>6/K54\>KK*WZU8X6OL743FU3DWCEA&V*W.3>4,
M?%OWC%=-(Y2J&$43_:@4AA#]Q8C][6GP=X_\1\7:Z2-*S-[;HW-:D[T#2']>
MKC>1:4&@L7*3)[=;8LFB!8FM-';@B2CH_4I5#@'?W]IV4X^<7M(W"+JT@VB;
M/)9EGY;,RKLL]9DD6<7,+H%3*S?.6"A5R)CWF2,!NO0>T[1-)S.5SJ]59X$?
M9:5>*>M5[57WIT4G*;>5A)=@U>M@<MEB*I'\(I+IG*=,QB" ]@D?N3($49R+
M LS]S9P@AD?+!P,4$V+'Y*&8*W'S1:>=[P"7V_E^'O[=T+$#]B.9#\/3_D?C
M[=/D:(Z^WI\FL^OZ7D=JCLMIQFR5C']!DGD-G^IV&D*PU%O4K'MWKMZRI\Z_
M:((V#W=I&N5!5; =N8C=02J&\(])74M-X4;M0LR@8XDQ/Z!8\>D&U5@897R_
M!,S<FU:NPBH8 5*)WBY4VR13 *AR]>RFM+\)MP0RA&H'T-;2E<K,6EI9ZE"C
M9%+RI-#^PEJI*X OQ=B'@!H'F?K>P\BX_B;L#[C^6+5GOY96F13*U /7$#*$
M6LZ,J2,%PYJB)TC>.521/'%*43"MX $W:P3G'SBWJ.X0537(SLL[E^8O+3"1
M$@HU(\)%J2K1I[@]FC,U"K>Y-5%W?EF PI_;%ZVA7">*>J:^G1IPU7O(4/,W
M$HK2[00IU#UJU-5V[1W!3Z21!$[1PFFX3Z"!P*(=.UKQ.D\2]@LVQT)N1[?<
MNC<DER7.BL5A1!J^N,;(1[).ML7YER T6=*)I/O&'NXJAU[-L-G\-N-?V]]8
MH>HL,<F\_>PVE/K38CHI5R 8U*18-I)X]GSN4_<13*9%TF8#IJ&3ZF[6*G6^
MCC5;A4)V4K%MJE@@$8RP5>S0;Q9A-5^=C'"!7,=+Q,@B=%=$X>(IR_"'0>QD
M@B(<52%*<Z8,&7C*0XB!#F)Y7B*4X@/01[AZ=D[]AG$#7MCH:DI)0B=TSK-!
ML5<4F(5?W29BB23<I"&>Q+D/*<$ !\"@"41ZAT[2>;[%DTME>BPK:,>3-$O5
M90@K3%-)IF61AG3^+6(91%"6CE 70,(_LB0@;N >G;I\C1/4>O0/DYGU[O;W
M>3\'3MU^1HGH'</^;F?</^)[%9Q53"9?'*J=./A*RI-22R;=,RSE1&-BV3M\
ML1H@05%3$3$J9"&.?H4!$*Q0:%1"W.\W::9UJF5*OQ#!Y-VFPR(G+'PL,W,"
M2;J0>"0WEE%0H=PB)@ .UAJ-JIR5<M=2G9FJVJMR\,T:3%<L]=DW,-8("7:&
M3-[I*PDNR5:N4A$?+62,7X.O:Z/:/E\I=&F;4V0T;17-8JI9A.AYU$+H-IB^
M6KW1LH:*JD2Y<ID<O#AX$?$!C?:]1"XZ)!YF_F,[SAY5XS1+[&UI%S4J-)W=
MVLPI4;:)DJ(-HM];7R)DF"0B8RY@]@%$!'[ALBRB1TVZC"3EF^Y2G5]C)S@U
MRL-2/+).>Z&!$OR?"-%"G<'\74H'* %,(@ IN4(V$4;K)%627*Q9 DH@8OC*
MN"AT0#RQ)T'J(] #M[O*5,D0Z%)!S[E,5M2(?>ZN4RK-'GN4FQ:.O<GB!@40
M5\'EK)B!DS&#O[?N-$_O<S_:>W08:) 1[@ZQS/\ :>W[C1/?[/\ -S/X@'_D
M?B'L(?(T3U .HA\G,^H!\8_L/<'=V2(6&BC'55201($<S$RSA=0C=NB3HEU,
MLNNH4A #J(F, =.H@':0FIGT_>1T3#Q#!U*RTJ_QU=!A&Q;%NH[?R#Q<WB!!
MJR:IG54$?UI"B/3NZ=GE'TW,GV>W:-90LE)5"X5M"&L4='V.)9V&NO7D:LD*
MJ#:=@9!N]:F$?V5LN0_3H8.@C\C1'0!Z"/R>S[A]G0?V'N'M^XT1[>G[GL_;
M\7^!]O=VZ?(T3U'V!\G,^H__ *'MU^1HGI\?R<S_ &GMT^18CK_YN9_M/;]Q
MXG][FG[1V_<6*_>]G^T=OW%BOWO9_M';]Q8K][V?[1V_<6*_>]G^T=OW%BOW
MO9_M';]Q8K][V?[1V_<6*_>]G^T=OW%BOWO9_M';]Q8K][V?[1V_<6*_>]G^
MT=OW%BOWO9_M';]Q8K][V?[1V_<6*_>]G^T?E_JT26P)Z4\SP.'.:A8HG&;W
M"YOK<NS)L3A0[3/K9/MG\;&39#^$QCG;N"BAXB"414+UY]3-<X]QMQR3AKP3
MXZ99EV2\S=&E-RM&UJ/.3<_< EMSM%>>T^:N,;79I-NLR@HUR1H@V;^[BHF@
MN").0+JI<<>*%PR$ZW!1]/8K-45QKT[DE?W[,H">VNTYFSL.^Y+3<@Q(C]^X
M5=V98;/*PLFW63CXQ0HHM3<V&F:\9<;JHXY:.>[J+Y5\@VT9L==N%6RW6+!7
M<2B,GW*B;O!WWCYM&=UML$?!U6P4Z08W)RU1>+ NBY%12P7; >/*:N<Q%&XM
M6'B]S'IL3G,:YOM@NKB(9Z\SV?4'7(F=T7>)FY"^>%>PB.>PIJ5(-$UB]6HF
M530YQU FJ[93>+EIT!EQ$X9T3:6-.CM/Y#VMHX@;E<KK%6.\U:JT3&:J\DP<
MSRYRGD)]VGXBI*I( D\PA[IO'_+L<L]QHV\RLE?,_M3&>N/(6S1^B.&=ZMNN
MUV,E9)G1+'2[@HYC(UBD!$E&JZGE'522(">*\Y)'1VV-^G;4N-> I;IJMUWF
MKL\:N-&K7'E]&:!EYLD+=)*1N=@G[$#5!NT"OG-[\F1RD?S"IBHUVK/^*,'M
MM6L>"<E-BT_38NM9VYT'%^0%5N,]9,WSC0-%M/)S.;)E5$J$ U9P/\GT=3)/
M[L(9PH5!PH[$GG<<]&U7CEQF>TVX^F)7;EPHDZ3$1E@JO*/E)6J12DYSCQ9J
MA8]MJ3#1H_C2Q?+*U"A3$E55%Q?+D>2"QDA.VYX[>SX#8^[U?-[)P5C:GB7(
MN)C25K*+_M-,L;+8)JM9?EFWZ.C!4R3<H(S"5'<VE^>"F%C@Y,5-!%,/4D"G
M^GYP:L+K@5)^G5,8BK-1ET>):9.<M&<%#:R?3D8G2VJ.@5BIH38JQ4.R%..:
M.T"NW97!P\9;GDK?-Z%(Y4CZUV7Y8TJ$I:GDC4T\-N7I[.MDFZ$:#&R_(BE.
MB]0= Y8K*(&<M5R$: N)400+QQUVZ\8^.&-:6_LWJ)Y)E> 9LTEE,MW^_8&[
MKJ''""TZHWG48-/2;NUBB2;Y%N_L< WMD@0X+.T$#HII1T!3,4FN.Q9? LTM
MVOY++QE,K41"ZI+$L;>YSU0SO/-4VIAD-9M;.-:O?N07L;Y_!NC+%$?*51.;
MT2-IY2VYS3KAQ\Y>7:Y\@]ZT^SY!:&>#T;2-<SN*XZV"XP,9;6D0O7;5!L6$
M8R(U(*4:#@B\@9KX#J]M*AM[SG;^#><:=ZG[C99RNR&\T?FAL'*."G:E<$B;
MIQSKDM?UF^:4JNOQ:/'$5XDHP\<Z.D#M51-% V^\?$KE.1T)EL_B/+B@\C]W
MI5<S79[?@F=3D3'<SN.LVPK%GEX).OO*FH1W7TVYSN!<2"[I<2)H]4^*L^\9
M4%]C7J?;1#[7C5=GI)*KFXQ8+G''=A.*X)87XRA3TDVS<MI)"NR:0KE1=11E
M8LC@AP,=&@5C5.)<!C6ZR'#CD+<Z5QSL.>Y/1L;Y"\D*1HU<ALDD:_Q>KG+B
M_0QYEA0I*1%*M3%\@65[49H2"9T2)JG3Y>XGN%,=<5<EM6_>FM;;/Q]M+^JY
M[4+%R-?4>].X_-Y@<_ON_EP'%=BT%E#H2L=\N/WM8%ZY:++-4E4SD9P.QY;3
MN.UFKD7RQC[9CF;N(ZN9_FA385;"QU8S>:/*R<8YKR\2HW6BYCWUP65!<K\3
M@*QBDQO@2SXZ:G<N*53_ *4',.Y(<YMVCM?T"W:=6..DO7Z54JI9JU'UF/S2
MHQGGKNC S$%UY%4' )%4!513C]N-6X!<'[O#;3R$OM0]2-A)S"]#AN G'FH5
MR*:YK*XO&6?6X2>SUK/T^,5LSRT)!).YBQ.%DS"F9XF5GQ^JF,\>>'O*7BI/
M<>.15SUGD_J]ZB/Z9I.4%(<ZC]RU,;YV&AQ%O6KK"JP;)9&/2KAX\\< R9EV
MYVK<[OTGN,ND<=>-<%6^17 '!^4>O;8\D9:-OVL\D'6>W8U0QFTV1:]1=2K%
M2TFUPOO-C9&%DZLTFHW9*K-DQ(FHE%RWIQ$B-2EN*]<?6>B/\;Q&4S'.-0D]
MMD:>RW\OI_0O-V>D)"M62D-E6DNWC[H=Q#-X]*828@B_!?MS@KJ/&WB(\LM.
MVGE"P4Y7ST(OI_#6JTG/*$U>UO+ZA;&_(J!W+AN>GV9P(Q\L\A+*C,S"#AL1
MRZ;" (Z%*<;^)N <S>5L)Q[],AW3^.G(.Y$F*JWR37<U?N>0^VP\#9-*J[>>
MM:=G S.1<)O?*JK9NDZ2;)E.*3RPN\DXY\8^3E-N?K<YQPEK\]LCB9N#/-\+
MT[$<KFM6KM"D&5QBRS,1F.C2T]'5R7D_?X^+5\1U1<G22-VY=9[!MW2N/9+3
M/4AI%7B$;LK R3O/ZS&2+""K,3?A45>L) \&BFS9229E720D*N'C.F(CS(VM
MOPP<S-3XU>G^?4Z)B/+CD]H?)=A,[,UTV$&)G(JYS"-,LL%$?(:A&4G"QY0^
M544Q*84_,Z"QWB$XN56R0.B\8-CVC<]QPNFY]'VGBYRR1F74M]RT7>KWR<KM
MGR[.<5 1BH+,6=)GONEA2$!)T[=% J]EM.!<<XR'H$%8>./]$[EOGL9G;"'U
M>IW2.;(:<PT33?Z1%MT+DU)6M15T[46^X&OJU&4;)$4,+,WFJ<3\AON :5*<
M>LGV'2K+EG-'AUS;I/'_ %CB2I<+U+2NAW#DSDTK:(QG.H5N9:GEXAY)MEY,
M\&@3W1$1="#G@-=H:!R?EADM6Y/>IE0_4(Y(V:R5V.-MI8R\7%MQ8NNNQ\W<
MD+#8[)>B*-Y:$+')O"+B?WHYCM3^:?TL,-V?B+QQE:OSBXNLAY&<I9!":<;9
MG6BW.VVO.\RO5:DPLR%5H[RN71Q'O)Q^X9K.7;58OB\E)B!3<O<99YSBG(C1
M_3UX/\>;QO-^E F31')KD_==_AKKJ]+E"1%JB4;E1:YE_N]:CF*K?S& R#DB
MA"+I] XTY3CZO&#0''J+<DWO)K%9G='-E4S/C_P8A,<;VNI<?9J/K]CKL\A;
M-+V66=QD?'HS*9Y-&+1C'"I1\P.W*VPTW+*9@%YV?T7>1A]CS6ITZO8]$GOM
M Y%T"#KSQ;'H/7MNB<ZNCZL2!R/XMI9I,RITR H!'":J1>7J_)EIO$EF+KGE
MQ=0EFO&;58W*M?C45\^,T7M<;(/6[M6>A(!JJHLYC4B)'?J$(4BR1R>,O("U
M6G,>*W(?,<GX]<%JWQC;Z-"R?)72-7XAS;V:@F&[1'W<[O@4))2Y&4A)I:7<
M++(/WM8"*2<LD'/4AG_(7AC7\>PAAQ@X[>L\SB^0,W&2CTNBX!Q!NU#J4BMR
MX3LDMH 2*5OKKVX*T-M:DD)%*+J"'E'9*.&2[P,^E<ZXKQO'^X&WC3J90K31
MJOG>=Y?M?'>/J9Y?.W:-?K/(O<+1I,Q%.DVBK;17D=6$YMN^<(+M4G100)&7
M O&KCE,<-$/3;=[U9_4.E;HF;D4'J(Q4>I)*82[72NS*7]U=V=$D(I0$H ".
M62QDBO 4 $!X5U9OE^-Y\VKGIX<6[H@&3-[&U"""]4Z8,ZQEJR?7&Q0$3F>9
MOF1QK\>BS0E&I7!Q<NW1#I@'J>PV&(ZG,<_8ST\X1E2ZS?>0A5.(&[4>Q\?<
MZB=489SD\'X62VK4*AK)N(V&DUW;29F 4=%.@0JRB>%Z=4>$O(7;:;4O2VXQ
M(2'*"C\[&F?933XBD92M*6:(M7%DTDV4O4C4X(JKB3;G JLTF](W\ &( C1?
M4CRW5XM'TF:OE-9NA]CCM;@VF Y]Q'J?'U%A>N/]CQAI9%W4%86]R!8ZT&I7
MQ.D^6*[.9)9LH1'T]$O3$LSV.KG'6R\@4=>S6C[/#8Q9N.^T6#=G]\S[=M8C
M)&T4YZ^JY<Y=IN6,L0LF1BU!1!-/Q+G3'U7=!NLGJ=_X^S/J!\(*Y9[-PUTV
M!R.Z671*SQ[K=,US6J9*$;.V=NJB5N8/U'*3,/!/.FHK(.NI@<#ROPNI<6&W
M-7B#H^0\*B9X? N:1<7Y;77#LOJ$NOAF\PFB6ZRUNT;"[6D)-\TN;>8\QJA,
MLR")ED5%EU>7?*W3N:EI<TCBSC% QS!MRVY8W*74\FYG<@LT<U"EYU8V>=KS
MW\N,OPXHKPRKCY(5!NT^56_54JC%R8,-YW8'K-?W:J\DZ.VS';]$84Z9RPLK
MS(P& CZ??[9+Y5.MFUISYML5:BFLPD@Y(H8YV*[@%3^\IF/DLCGTYRB5VY7<
MN0"=>6GZEQK;W.1NS?-\P.G";8XK]@5MK/C$RESJC5W30%9(SM5^/DE,!?%N
M4;]VMAA($G +FH\;PZ=SF(2N(SYZ)#@SD&44669Q*%@%R?QI.$4BO/, 5"GZ
ME$P0VD7W!T>:FX36Z3]#Y00MH1J^BZ]E^ L:*W-G<E5+'JW)S"%L%@'QE228
MZ"B:>,@]3.Q41*@0WN_%&8S?B_Q]U'A%?:#7YSG5ZBVA7J*C.4O'?01VH:SJ
M43$R:>DL'57M6345X@DP@XVNRK.9$%ET2KD:'4=<,\_L/#2D9Y0+;R\US/*[
M/1\!FU&P;?N*$;QFTZ[4DLVQA.2.M77:+%$VN B9>.T5['U<CYPY.Q<,TW!4
MT#^FAR9KO%WB!QZO?(:S^HUQ<GFU4&RPU4KR655V;;X7,0GW37UV>'U:_%CA
MK$I-22JYK RF7:29$U'+/R/29S_5/3ZXF97R YF<H-=H?+(L>C98^>X\1>7\
MI:_%M:%E#:OZM+M,_%W67J3%*8=/Y!<L#XV[54WGG6)QW@:UP@XN\DL)TSD1
MS:B^;VYZ+=PE]2P#1<ZV/383#<?J"3C1V,U&0 PD5'-V<;\G3OW4,% >K&3Z
MF?+>I#LDK38+0Z_F_";2W\MF<Z[09L+[2HSD+2F-GH;0'/B3=OI6C%>-&2!R
M*E.MY93D.41*;D3P@X9W:@WK#*IRV]/JWSW(':9*2JE2TFU\F>5#\'],T-XT
M?P]G1RW \:J58J<H\9F9ORF3>*^)LL114,0>S^$8]DMV"+]2'.K*RR>J*\?J
MG?JEEW'29N>*W@:C <@M<F7C4M@BB.Z]/R,K%REBAGI'+^,1]Y23#4LD9</>
M+R4QFOH:XCZA;+70:SZFJWCE!%P==D)2HV!^C<F<(%"NP(K-K!7&+-L_ERO'
M'C7\3A,"26QVSC#QNNTC.>GOBEVX"_<_3Z_I</RFNC2"JL?NL,^S*S\C,M@-
MHLG%.)58,:K4I*:KKABPFW"IQ?J^!1'F?H<7P6Q"T2U1Y\\(L:HN-\GU&=O)
MBU?W?*Z:^VV"BHS,M<M4,I7(^=F9!W$1JL])H5]Z[ KT#*1H-B<I:*^P3C7I
M7';^G;J>'N?E2J.KQKV$987*HJU5IB[UF9Y"9_'83GXVY\!::^A:]:K%)N':
M+)4Q4P%5M@/'AYQ2XY34[L'I!<B.3%PY(.BSI>0+/?,A-:6&;2M>L+.W-:U#
MSCM['$>RB9F)W,RZ43(IX6S86Y^'$'+<1.*Q_2XN\!Q4FK-ZD3C3&L5O=ZTW
M08%N[ME1MMG)K4?-)-K_ *VBSJEB@1@2)UR#DG+H%F8> ['CX]@.,1.+NG65
M]MT7>HBMTW.,MS30J74;-!)9;;J?EM"Y$<B7\&^AHR0.Q&PO7T<2W-@(_32\
MTBB3?%1-IU]7GW/J2;XSDC*:5;'%B>5XV$J$082)U+ >9>5P52& &ZPG9>,X
MCX.JGVWJ/5?:\HQ2D&XT5_TP[DGR^H2\LVWV;AM6F<EH^T*6"QHV*3KLQ4*O
MD(+,&C&-C"MXM!L=V<JSDZ9T^-%#LO#&ATW*YOD+LE.SVV1,1F](PC?N-$3Q
M+U2^59M8'\1R?U6^;9:8ZXUR,G(W17D762IOU3L'2"2@)IK.MDO_  QX,Q.6
MW_?CX9<LQH.<66=N.#YK6\P,2$G9J]7SDO2?Y%F-LFH]%VUM,7#66RVBRR )
M@@1%8I6G$-6]\.N- \5M&X>[E:N9_/>W6)O%[OC%SH<IHD1CN@0)E- B7+&7
MG)F&:&,[:0<@2QJBJD=1%%AY2H^H+0<]SMI-\Y\GQK#./G'5I"NV,)QCY+4M
MY:6'-S6J[ N'JXLDH".IK(]=4%VJ9I+2IA52$CDH'#XOAZ]>OYM2.<@&,@83
MHF$.IDU!^U$Y1_O3&*'P?H]D5#$*)T#"=$PAT%,QR^$XE'^]$P>WX>G8I5V+
M=4A 4  .D0_VJJH+*$Z#WF346*!Q*/VOB !Z=0 >P*E9MP/YB*HCY0 !EFX%
M!LNH7IX5'#<"E\"ANIB>$.G3IV!PFT;IK%465(H5(H&36<=?>%DPZ>%-5P B
M!S% #' 1\77KU[><X:HK'$ *)CE\1O" = +W>WIT_0Z=CF12*F90R8G$H=/$
M*9? 01^/P%#NZ=/K=B+"P:&535*NF<Z!%!36*/C*JF)P-Y:A3=X&#H8HC]@>
MQW"C1L==11%510Z)3'55;=/=E51$.BJC?PAY9C 8Q.G<(=W94IVB E66!T<@
MD#P>]>,RGO14_P!81UYAQ-YA0 _B'KU$0[R"@V22$IEC )" 4?,<=!74,/3[
M=5;H'C.;J8PAWC\((^!%,ON_G B(!WI X_PWE@'ZWS>OVW3V]O 5NF!?),W
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MY7*4RH,QE$//QV09(ELM>RRP+K.)S.*]NI:8&HQ-2E#.3E42+(G<@F82D6*
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MUR^469*I6KM$/FZI5RHR""Q$GJ"2P (E$#$(+-$2IMRLP$Y2F,9D7J)&2A@
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M H>'J/<!0#V   3]A+]HY%X'0O00<B(B9<.G0?-ZC[?B_2 P"S0\/GB[ @$
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MA91%"22:KB"GDJ#Y9Q* ' Q>I1*'](VB'$ Z"8>/63@)A#N$Q@+#$+U$?;T
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MT*4I1,8P]>G0I0 1,/V.Q5GP=1$ $K<!ZE*'0?\ #"'<H/\ O?8'P]>P  =
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MN'YP\/@]0W#[UQQNO$^.VN&J>S<=M83TVY;A!L]^XBUQ'-N+E)C,$8U&#JV
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M?.:YK[:'?- D[D:#5CD# \4051;K'513!+R"II)E!#J!O**4@%\KQ=>AA(4
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M#M?. 'ITP>I*-?.FZ1R5Y-5&FW!$QU6B[F&LN.8Y-(12:@$*LBLUG[&V, '
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M4I#:,V;P>:T28W8Z&A5/E9N^=N;E5KPVST!CH1Y(P3R.8EDTF**]1SW'][Y
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MU."I7#EN@8^=\@1("ZR:7B +5F'42^,Q1, >+OZ>SM^Z+'_X6W_;.W[HL?\
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H'J(F,/\ ?&,/PC_L2=?93_\ !$_,X_\ !+_=[?\ [2K_ .]#^P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>attd_graphs.jpg
<TEXT>
begin 644 attd_graphs.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!.17AI9@  34T *@    @ ! ,"  (
M   (    /E$0  $    ! 0   %$1  0    !   6)5$2  0    !   6)0
M  !$:7-P;&%Y /_B$ A)0T-?4%)/1DE,10 ! 0  #_AA<'!L A   &UN=')2
M1T(@6%E:( ?G  $  0 ) #$ !&%C<W!!4%!,     $%04$P
M          #VU@ !     -,M87!P;
M                                $F1E<V,   %<    8F1S8VT   '
M   $G&-P<G0   9<    (W=T<'0   :     %')865H   :4    %&=865H
M  :H    %&)865H   :\    %')44D,   ;0   (#&%A<F<   [<    ('9C
M9W0   [\    ,&YD:6X   \L    /F-H860   ]L    +&UM;V0   ^8
M*'9C9W    _     .&)44D,   ;0   (#&=44D,   ;0   (#&%A8F<   [<
M    (&%A9V<   [<    (&1E<V,         "$1I<W!L87D
M
M                                  !M;'5C         "8    ,:')(
M4@   !0   '8:V]+4@    P   'L;F).3P   !(   'X:60      !(   (*
M:'5(50   !0   (<8W-#6@   !8   (P9&%$2P   !P   )&;FQ.3    !8
M  )B9FE&20   !    )X:71)5    !@   *(97-%4P   !8   *@<F]23P
M !(   *V9G)#00   !8   +(87(      !0   +>=6M500   !P   +R:&5)
M3    !8   ,.>FA45P    H   ,D=FE63@    X   ,N<VM32P   !8   ,\
M>FA#3@    H   ,D<G5250   "0   -296Y'0@   !0   -V9G)&4@   !8
M  .*;7,      !(   .@:&E)3@   !(   .R=&A42     P   /$8V%%4P
M !@   /096Y!50   !0   -V97-83    !(   *V9&5$10   !    /H96Y5
M4P   !(   /X<'1"4@   !@   0*<&Q03    !(   0B96Q'4@   "(   0T
M<W9310   !    16=')44@   !0   1F<'105    !8   1Z:F%*4     P
M  20 $P 0P!$ "  =0 @ &( ;P!J &G.[+?L "  3 !# $0 1@!A '( 9P!E
M "T 3 !# $0 3 !# $0 ( !7 &$ <@!N &$ 4P!Z .T ;@!E ', ( !, $,
M1 !" &$ <@!E '8 ;@#] "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K
M .8 <@!M $L ; !E '4 <@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0
M3 !# $0 ( !A "  8P!O &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R
M $P 0P!$ "  8P!O &P ;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P
M0P!$ " &109$!D@&1@8I!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" /
M $P 0P!$ " %Y@71!>(%U07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4
M1@!A '( 90!B &X _0 @ $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T
M!#@$000_!#L$-00Y $, ;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\
M=0!L &4 =0!R %< 80!R &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$
M $P 0P!$ " .*@XU $P 0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &(
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M "@ +0 R #8 .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M2_[<_VW__W!A<F$       ,    "9F8  /*G   -60  $]    I;=F-G=
M       !  $          0    $          0    $          0  ;F1I
M;@         V  "N    4@   $/   "PP   )H    U   !0    5$   C,S
M  (S,P ",S,          '-F,S(       $,<@  !?C___,=   'N@  _7+_
M__N=___]I    ]D  ,!Q;6UO9         80  "@0     #5&&2
M             '9C9W        ,    "9F8  P    )F9@ #     F9F
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _?RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME#V5^65[-];.VUDUZ-?-GH93F$\5&7M+75M%TNN]VGZI_)!1117@GK!1110
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MH4M(K?FE)2D].B6_WFD,XG0J34WHYU-6]N6*:2];[?<?MQIW[7OPQU7X%?\
M"SH?'/AT_#_#$:\]VL=F=K%" [8R=P*X')(P*QO@!^WY\&?VI=7O-/\ A_\
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M<HH]K/:[_P"'W^\?LX]CB_'O[.'P]^*GB"#5O$W@7PAXAU2VP(KS4M'M[J=
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M=-W[WU^\7LX\O+96['):_P# /P+XK\'VOA[5/!GA74-!L1BVTZXTF"2UMO\
M<C*[5_ "KOPX^$WA;X/:(VF^$_#>A^&=/=O,:WTNQBM(W;^\5C4 GW/-=!10
MZU1QY6W;M<%3@GS)*YR/A[X!^!_"/C^Z\5Z3X/\ #.E^)KZ-HKG5;33(8;RX
M5B&8/(JAFR0"<GG KKJ**F524G>3N.,8QTBK!1114E!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSA\2O&&E?$K]HJ'6-&T+4=6M2?B9J1BCG2%Y5^3?C:& ^7ICB@#](**^<_\
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M0!Z=1110 4450\4>*=-\$>';S5]8O[32]+TZ)I[J[NI1%#;QKR7=FP%4>IH
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M^S;X)\0>,=,U=Y_B1\4-"M[^&5[9;=5TM%E'ER3/&Y=?-!(6,A"IR& /0O\
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M@_\ @C+Q_P $J?@'_P!B;8_^@5]-5\R_\$9?^457P#_[$VQ_] KZ:H ****
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M@T@*XQ7H.L_M)?M):U\%/VA?C99_%30[#3/@AXYU_3M%\)?\([!]BUC2]-N
MKPWDY/F^<\894="-I"D@Y->I1?\ !"?P9%IVF:'_ ,+4^,/_  @OA7Q!:^)/
M"?A,:S'_ &3X9N;>[%TBQIY>Z:,/N 68OM#G&#@UPO[,W_!(2\^(VN?%2_\
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M 2H!U/\ P19N?AIX9^+GQ_\  _P]^%7@'X=CPG=Z!<37WA.=YK;6K:^T[[5
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MV/\ Z!7TU7S+_P $9@5_X)5_ 0-U_P"$-L?_ $"OIJ@ HHHH **** "BBB@
MHHHH **H^(?$NG^$M*DOM4O+?3[.'&^>>0)&F>F2>*^3O^"AG_!4!?V4-$\*
MW7@F#PQXRDURYN(;I'O6/V58T5E/[L]R2.?2N/'9A0PE)UJ\K);]][;;GO\
M#O#&99YC(8'+J?-.;:7172<G>3T6BZL^OZ*^)?\ @GU_P5DG_:K\6^(M/\::
M?X7\&V^DVL<]M,EZX^TLS8*_O#C@<\5]D^&/%VE^-=,^VZ1J%KJ5GN*>=;R"
M1-PZC([BIR_,L/C*2K8>5T[^3TTV>IKQ-PGFF08R6!S.GRSC:]K..JNO>5T]
M/,T:*\[_ &O?%&H>"/V3?BAK6D74UCJVD>$M5O;*YB.)+>>.SE>-U/\ >5E!
M'N*_ O3/^"A/Q.^"W[*/P&^*W@K]M#QA\7/C5XPU33(]3^$6H-!J$-UYS$3V
MQ2-?-CV_*-S')W<<XKN/FS^CBBOAKXW_ /!9#6/"GQL^(?@KX:? _P 6?%Z;
MX+Z;;ZA\0-0TO5+:SM]%>2+SC:0"7YKFX6,,Q1<?<89R*Y[XH?\ !P#X3#_!
MVV^%_@JX\?7WQF\-7/BG2QJ.O6GAVWM;:W<I)#)+<G;]H+*ZK&.I7KR* /T&
MHK\M?^"F'_!7KXS_  P^$W[,.N> _A7XJ\-W'Q>\70V.M:-?26G]I%4D'_$N
MADW&-7G RLP^4IZ9KZ?_ ."GO[>WB#]B'_@F=XE^+UIX7DM?&2V-I:Z?HUY*
MDG]GZC>R1P1+,RG:XBDE!;:<-L(!YH ^JZ*_&OXJ_L[_ !<_8O\ !G@7Q]XC
M_;QGT?\ :#UJ.#6IO#OCG5H+?PEK";D^U6B0[<B) VT,.X'3(Q]2?M4_\%MK
M?]GWXKWW@3PO\.KCXI>(O"'@Z#QMXNGT_7[32['3K&2,2#[.]R1]ID=<NJ)R
M5QW- 'WA17PAXM_X+K>';WQ7\"]#^'?PT\7_ !&U;]H3PO-XE\+P6ES;V6SR
M\[H+DRG$6W:VYSE5QWK$TO\ X.#O!R_L?ZE\0=8^'_B+2?'6G^/I/ABG@,WT
M$EY=:\A&84N>(1&%W,96P $;KQD _0JBOEW]@K_@IC8_MC_%#Q]\.==\(W7P
M]^)OPW^SS:IH<FJ6^K03VDXS%=6]W;YBDC)RI'#*>H[U\E_\'$?@KXQ?LT_!
MWQ+\?/A]^TE\5/!\?]H:1I4'A#3G@32;82R);R2*2I?<V2_7[Q]* /U6HK\>
M?V[O$GQP_P""87AC]F"/2OC;\8/C)??$'XGV@U*TO);=+_5[5K=3_9J$*$\M
MVY^8\9)S7OUE_P '!W@WP/X2^/"_%'P#XA^'OCCX"SVEOJ7AC[=#J4VK/>,%
MM%MIXP(V,CLJ\D!<YSB@#]"**^$?A+_P6]L]>UGXA>'/'GPPU3P'XV\%^ Y_
MB-9:0NOV>K1>(-+AB,DGE7%N2D<R?*KQO@J6[@5D_ [_ (+?>+?VB?V<+[XI
M>%_V6_BI<>%ITL1H%Q=7]E:QZT\[%9GWR,%AMH&4[IVRK#! YH _02BOS_\
M W_!>;1]4_9G_:&\<>(/AOJ6E:W^S=/;0>(M&L-=M-4AOS.,HUK>1?NG7KGT
M(Q5SPE_P6XOKCXJ^%?"_BKX#^.O!LWQ2\,7/B/X=/=ZC:S2>*G@MOM!LG1"?
MLMPZ_<#D@@@\9H ^]**^']#_ ."Y7@;QE^SS\ ?''A_PGXBUC4OC]XH'A+3_
M  ]'+''>Z1>1NR7GGEA@K;,AWE1R"#Q75_\ !:[]K[Q'^QQ^PIJVK>"KA;/Q
MQXNU6P\(Z!=;0QL;J_G6#[0H/!:-"[@'C<HH ^M:*_*?_@MPG[0G[+'P.;X@
MZ7^T)XK\)^%_ _ABSTW0=,\,:.;S5?$_B$ "2?5964H+9MI)885=Q)'K^@G[
M+_Q/\0>*?V-O!/C#Q@VE7GB6\\+6VJ:LVDS++:37!MQ))Y3@E2"<\@XS[4 >
MJ45^7=E_P<OVLWPF^'_Q(F_9Y^)$/PV^(6O3>%-/UA=1LY)I=51W1((K<'=(
MCM&0),@9##!*FO5/!?\ P74\.Z'X3_: F^+7P]U_X6^(OV=[>VN]=TB2_@U,
MWL5TN;86\T>$9W+(NWL6ZX!H ^\**^'?@-_P63OO%GQP\'^ _BE\%O%?P?U+
MXH:#/X@\#SW^J6VH0:\D41F:U<P_ZBY$0W^6V>#UKR_PS_P<?66M_"GP)\4+
MSX$>/-'^#WB_Q2/"%SXJN-2M&_LZ],[0AA;KEY8=RG+C'(*X)% 'Z945^._Q
M*_X*E?'[Q3^UO^W!X)DT7Q#X/\._"OP#--X>O(+FV4>&ID@:2&]D(RTDET<-
M'MSL7AAUKTS_ ()K?\%C_&5_X$_9;\&_%CX:>-H_^%WZ3]BT;Q_?ZG:W UW4
M(86DD:6W3]Y$' RK-U!!QB@#]/**_/C]GC_@N^W[4?Q>LM/\%_!?Q!K7@>^\
M52^%?[9MO$6GMJMF\<C1M>3Z5N%Q';94G<22 ,X[5VO[(W[1OBKP3_P51^/'
M[/OB[7=3\2:>UC9_$+P9=7T@DEL;"ZQ%<V&0!^[BG&8QR0K$$T ?:5%%% !1
M110 4444 %%%% !7X\_\%D?B[X?_ &7?^"BUUXHTW]MZU_9K\6^*/"=A8ZCX
M>L/AO)XGN-0@@EG:&XN73<@;]XZQ[U#A0P!*FOV&K\F/^"Q.H_LW_ ?]J;QI
MK'C']HZW^$_Q0^(&A^']1TZR;PVVNOH.JZ->/-INK$11LZ1E#-"]NY"RJ[-S
MC% 'UA_P17^.-Y^T)^QBWB*[^-FI?M [O$%];0^,+SPA_P (O]JC3RQY4=K_
M !1QMN EQ\Q+#^&OG?\ X+Y_LO2_'']H3X'ZUK?P'^)?[27P_P!$L-:MM5\)
M>'M2DT^TTZXE^S&"_:6.1"9AM= C84J2=P*[6]M_X(-7GA/5_P!AZ]U3PG\6
M(_C,NN>,-7U75_$-MH,FA6/]I7$JS7$%K9.J^1"I<$*JA279@!G ^>_^#DSX
M4>-_BZ_@W3[3PQX]^)G@$>&M>$G@_P #ZF8=6CUYDB&FZK<6L;++=V-NVX,J
MY",P+#D @'KW_!#/X'>"?@KHWQ(C\&_LL_$/]F6/4;BQ>ZA\4ZM+?G7RJ3!7
MAWRR;1%DA@,9\P=:^^*^"_\ @B3HWQ0UK6/C1X^\9>#_ !_\.?!_CW4M'G\.
M>&?&4W_$S@N+?34M]1NQ 23;PSS)&4C)Z1D@ $5]B_'CX^>#?V8OA5J_C?Q]
MXBTOPMX7T.$S7FH7\PBC3T5<\L['"JBY9F( !) H Z^BOD^;_@L=\*_^&)/
M'QRM=.\:ZIH_Q4U)=&\)>';#2UN/$.OWKS31);PVRR8+GR)&Y< *,D@\5EZG
M_P %N?A*/@'X)\::+H7Q+\5:QX_UJ_\ #NE^"=(\.M-XJ&H6 =M0MY;-G41M
M:JA,F7P 5(+9% 'V)7QAK?\ RL)>'_\ LWZ^_P#4AMJ^C_V6OVF_"'[9'P"\
M-?$KP'J$FI>%_%5M]ILY)8C%-&0S))%(AY21)%9&4]&4CGK7SAK?_*PEX?\
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M,+<KINGV>GK>3M=7 MX5C\^5OO2-M W,>['DT 7J*** "BBB@ HHHH ****
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MENA?&;P?XH\2KHNF>+/#6HZP\)N5L;74X)KEH@2/,$:L6VY!&[&.*XS]MO\
M:JM_V+_V=-7^(%QH-]XG_LVYL[.'3+2>.WENYKJZBMHU$DGR*-\JDD] #7YN
M_ ;X>:#\._\ @GO^QAXST/1[73?%-Y\7;:&XU:"WVWD\-Q?ZDDT4DF-[1NH4
M%&.W@<5[M_P5A^)WQ$UK]@OQ])\0_ .B^ ]!TG7_  _-9ZC!XG75/M4:ZW:[
MGD001^2H0!B23C)';- 'OOAO]MSQ%X8^(/AW0_BQ\*]4^%]OXROETG0]4.N6
MFL65U?,"R6TKP<P/)@A"PP[< YKU'0?C9IZ^"=7U_P 37&A^%=-T>_GLYKFX
MUNVEM8TC?:'DF#!(RW=&(93P>:^6_P!M;XT>#_VW+'X8_#OX4>*_#_CCQ ?'
M^A:Y?2:)>I?1:)8V%TMS/<SR1$K%\L>U0Q!=FP,\U\QV_C'3="\%>%-/U1?#
M>C:+K7QQ\8RW'B'Q8\@\-:,T99E%W!E8IYILE8!.0BN"W)Q0!^AOQQ_;F\'_
M  8A^&-Y'<6OB+0_B=XEC\.6FKZ=J$#V-F7BEE-P\N[:8U$+ [3U->HZ!\1/
M#_BSPG_;VEZYH^I:'L:3^T;6]CFM-J_>;S5)3 P<G/&*_$_PWXG\(7>KS6/B
MS4+?7/AKH?[5-C+$QT@Z?IB6LFC22K+%;( J69EP^X#8P!8Y&:]:_:0TZ\\3
MV'QSU7X+IIJ_!6Y\8>$)K^6SM)I=!NC$<ZI,J6Y7S;+9]F$YMSM;:^<X:@#]
M#OCU^W7\,_V?OV:-:^+.H>*-'U;P;HK)$]YI5_!=1SRO(L:Q1NK[6?<PR,Y
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M%FM;N)9H9!T=& *D?4$&@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI>&H/BFJR>(KC4G8PS:I;*1EM,9QNC!) )4>M5]?_;:^,7_!+JW\9:<OQ/\
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M3Z39:I\/_C=XV\5Z7:>'] \6^(/#7C63P_HW@BQU2^,%CO !:6261V<QH "
MI)SG !]U?\$GO@GX@_9[_9'MO"_B/X0>!?@C>66JW3P^&_"FJ-J=CY+E6%PT
M[$LTKL6SN)("K[ ><_\ !43]K[X[_"G]H+X3_"OX(K\*?#5]\0K/4]0N?%?Q
M$FG72HS9^3_H,"Q$%KEUE+[3G*(2!P2-[_@B?!X#TG]D/6-'\!Z9X_T&/PWX
MSUG1=<TCQEJ[:KJFEZI;3"&>(SL3NC*I&Z@<8D]<U\R_\%5OAAXY_;,UZVM/
M%W[)WPF^+W_"%^)-6T_0UU3XO#0WATLK;^1>.D<\>))R'#1."T?DCINH ^PO
M^"=>L_M":O8>*_\ A?7C#X(^+)XY;8:,WP[%P$MD*OYHN?.)^8G9MQV#5]+5
M^?O_  0A_9HD_9ST7XE1R?LZ^!?V?_[5N;!A%X;^(+^+5UK8DPW2%II?(\O=
M@ ;=WF$X.,U^@5 %?5=8L]"LFN;ZZM[.W4@-+/*(T4G@9+$#FJT7C#29M&?4
MDU33GT^,[7NEN4,*G.,%\[1R0.O>OB3_ (+V_ &X_:V^!'PM^%MOXP^&/A7_
M (2SXB::[6WC:ZN8[7Q%]G2:5=/CCM\/.\C;28_,B)"'#@XKX)^ .@^!_CMX
MX_9G_9[\5?#_ ,'>&/A;HOQ5^('A_P 9Z%H%[=-X3\8:WI6FQR6]S%Y\K2>6
M3(SK"\C;7C.#Q@ '[PHXD0,I#*PR".A%?&.M_P#*PEX?_P"S?K[_ -2&VKQ[
M_@DM^T7\8O!__!(OX<W7@'X;ZA\=YK/Q)KN@V/VKQ9;:1+!HMKJ-W%9S?:+E
M2)U"1QQ*!SM"G.!5_P#9N^+'Q*^+G_!>2RO/B=\)V^$>J6OP)O(;/3SXEM=>
M^WPG7K8F;S+<!8\-\NQN3UZ4 ?I#7XU_\'J/_)B?PA_[*-%_Z;[ROV4K\:_^
M#U'_ ),3^$/_ &4:+_TWWE=6!_WFG_B7YHFI\+/Q8;K^ I*5NOX"DK_;(_G4
M*]*_X)J_\IEOV7?^QNM__0Z\UKTK_@FK_P IEOV7?^QNM_\ T.OPCZ2G_)OL
M;ZTO_3L#Z;A#_D:T_P#M[_TEG]>5>4_MV_\ )D'QD_[$;6__ $@GKU:O*?V[
M?^3(/C)_V(VM_P#I!/7^71^S'\T/[#:[_P!DGP6IY5K64$>H\^2N[T+X7^&?
M"VIK?:7X=T33KQ0RB>VLHXI #U&Y1GGO7 ?L2R-#^Q[X1=?O1V%PZ_42RD5X
MO^QM^V1\0/C/\>[7P_XAN+.32Y;:YE98[!(6+(A*_,!G@U^$XC+<3B*^,K49
M)1IRDY:M75Y=.NSW/]'LKXJRK+,NR' 8ZFY5<32I1IM14E&2A35VVTXZR6J3
MV\CZD\2_%SPKX*U3[#K'B31-*O=@D\BZO$BDVGH=I.<&N$_;ED67]DKQ@RD,
MK6L3*1T(,J8-><?M<_L'Z_\ M%?&!O$FFZUH]A:M906WE7(D\S* Y/R@C!S7
MH7[:UJ;']CKQ/;L0S6]A;Q$CH2KQK_2IPN&PM.O@YT*G-.4H\RM\+O'3\_N-
MLZS;.<3EV>8?,,+[*C3I5%2G>_M%R3N[7TLDNVY_3%^P-_R8Q\&?^Q&T7_T@
MAKUJO)?V!O\ DQCX,_\ 8C:+_P"D$->M5^[0^%'^;];^)+U844451F%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^6_P#P
M7._:4^#T_P 1]:\%_%#X&^&_BMH_PM^'MYXZO]2U2\^QS:9<2RK;V%I;LI$C
M?:)00^P_*%!Q7ZD5^5/_  7C\&?!7XL_M3_##0+[X&_$'X_?&RQL'U6'P]X0
MU$6,:Z3%.K ZFV"K0&9?D1L$G=@@'D [[_@WZ^)\VC^"O&'PFUKX+^!/@KXF
M\.6^F>*?[.\)2&:SU&PU.W\VWFF=F9A<!5VLKL2 !TZ5^B[NL:%F(55&22>
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MXNJH2]F[-*ZDTE:[MZGL%%%%>L?#A1110 4444 %%%% !1110 4444 %%%%
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MZ_&O_@]1_P"3$_A#_P!E&B_]-]Y7[*5^-?\ P>H_\F)_"'_LHT7_ *;[RNK
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M^'7BR\T__A'_  EJ&)M4\Z* K<W#2\N(78KMC)PI!V@ U^CU?G+_ ,&_VO\
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M7DO[=/\ R:=XR_Z]X_\ T<E>M5Y+^W3_ ,FG>,O^O>/_ -')1E'^_4?\<?\
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MBTG2+>S2^)R#YHC4!^I^]GJ: /S-_8>\9>"?BE_P6'^%>I?!&\\-ZGX9T?\
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M)?"GQ);Z1\3)-!GNM4OM3UO289EO]2NYY;BYN4A<.(MTDSA0"2%P,GFO2/\
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M\4K2\U;1.RT]#L\0O[#>>UI\.3Y\-+E<7J[MI.7Q)/XK[H****]P^)"BBB@
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M?)XQTVW;K'9Z_/ OI_"17T?17)_8&7)\RHQOZ'9&I5BK0J32\IR7Y,^:X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]K^U-^T!=?#G7O!E]K]_XE^P66+*_AG6.*V\P0^6-RG=M/S'MZB/]L[]D/\
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MU Z9?:1KMDZ:7_PL6Q@V26QUC36@#6.H6LD$4$SVK0K<I"@=5 92 9/[+?\
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M ."AVH?M)>-+[Q1XVU#1?V?_ (&:%KOPIO+O5KBRO()9K!KPZK<+$ZK+=&5
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M^L_"/A]O"WAC3=.DOKW59K"TBM9+^]96NKTQH%\V5E"@R-C<Q  R3@#I7-?
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M+-&LB%9;G[7(9 5X/Z/Z1I-KH&E6MA8VMO96-C$EO;V\$8CB@C0!51%& JJ
M  . !5BB@ HHHH *X/QE^TWX"\ _&SPW\-]:\4:;I?CCQE;2W6AZ3.Q6XU2.
M+_6&'(VN4ZE0<@<D8YJK^TS^U'X9_93\%V6L>(HM<U*XUB^33-)T?0M,EU/5
MM:NV1Y!!;6T0+R,(XY'/0*J,20!7YC_"W1OBM_P5'_:!TJ^\106.K> ]=O[[
M7/#_ (^T&*ZM-8^&T4!ECM'TN]>"-+&Z66.."YTZ87,LC>:TVR,** +6D_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>diabetes3_850.jpg
<TEXT>
begin 644 diabetes3_850.jpg
M_]C_X0PV17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    /  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHP-R Q,SHT.#HR.
M  22A@ '    $@   -Z@ 0 #     0 !  "@ @ $     0   U*@ P $
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MI[?'_]H # ,!  (1 Q$ /P#U5))4&W]:_:9J=BTCITZ9 M)L(V;I]#T_]/\
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M_P#59^5RJKD_^-/\]@_N2_Z3/@V+/'_I5?P=^1:*SL?^E5_!WY%HK4_XN_\
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M!1LK8R#&R=C/4W,]W^$3Y&!D77^JW.OI9I^AK]/:(!;^?4]_OWNW>_\ T?\
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! !+     $  0$L     0 !.$))300F       .             #^    X
M0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$         @  .$))300"       "   X0DE-
M!#        $! #A"24T$+0      !@ !    !#A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #>P    8              6D   -2
M(P!3 &, <@!E &4 ;@!S &@ ;P!T "  ,@ P #( ,P M #  ,P M #  -P @
M &$ =  @ #$ +@ T #( +@ Q #( ( !0 $T    !
M      $              U(   %I                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
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M &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #
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M(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/O_B#2!)0T-?4%)/1DE,10 ! 0
M#1!A<'!L A   &UN=')21T(@6%E:( ?G  , !P - !L .&%C<W!!4%!,
M $%04$P                       #VU@ !     -,M87!P;
M                                                    $61E<V,
M  %0    8F1S8VT   &T   !ZF-P<G0   .@    (W=T<'0   /$    %')8
M65H   /8    %&=865H   /L    %&)865H   0     %')44D,   04   (
M#&%A<F<   P@    ('9C9W0   Q     ,&YD:6X   QP    /FUM;V0   RP
M    *'9C9W    S8    .&)44D,   04   (#&=44D,   04   (#&%A8F<
M  P@    (&%A9V<   P@    (&1E<V,         "$1I<W!L87D
M
M                                      !M;'5C         "8    ,
M:')(4@   !(   '8:V]+4@   !(   '8;F).3P   !(   '8:60      !(
M  '8:'5(50   !(   '88W-#6@   !(   '89&%$2P   !(   '8;FQ.3
M !(   '89FE&20   !(   '8:71)5    !(   '897-%4P   !(   '8<F]2
M3P   !(   '89G)#00   !(   '887(      !(   '8=6M500   !(   '8
M:&5)3    !(   '8>FA45P   !(   '8=FE63@   !(   '8<VM32P   !(
M  '8>FA#3@   !(   '8<G5250   !(   '896Y'0@   !(   '89G)&4@
M !(   '8;7,      !(   '8:&E)3@   !(   '8=&A42    !(   '88V%%
M4P   !(   '896Y!50   !(   '897-83    !(   '89&5$10   !(   '8
M96Y54P   !(   '8<'1"4@   !(   '8<&Q03    !(   '896Q'4@   !(
M  '8<W9310   !(   '8=')44@   !(   '8<'105    !(   '8:F%*4
M !(   '8 $P 1P @ $@ 1 !2 "  - !+  !T97AT     $-O<'ER:6=H="!!
M<'!L92!);F,N+" R,#(S  !865H@        \U(  0    $6OEA96B
M  !OI   ./8   .16%E:(        &*4  "WA@  &-I865H@        ))X
M  ^$  "VPF-U<G8        $      4 "@ / !0 &0 > ", *  M #( -@ [
M $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"C *@
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M&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[
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M80       P    )F9@  \J<   U9   3T   "EMV8V=T          $  0
M       !     0         !     0         !  !N9&EN         #8
M */7  !4>P  3,T  )F:   F9@  #UP  % /  !4.P ",S,  C,S  (S,P
M        ;6UO9        !YM  !W!P  UWS6U*X
M '9C9W        ,    "9F8  P    )F9@ #     F9F     C,S-      "
M,S,T      (S,S0 _^X (4%D;V)E &1      0, $ ," P8
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MDW34%365."! 4($RDM(C<].4M'6U-G8(\)&AT4)B),'Q4G*"0Q87H,(S-"6
MD.&B4V.CLX3DEC?5)PG_V@ , P$! A$#$0   -_@
M
M
M
M
M
M                                _DUNS9&
M  !% A^>\64G>                          #UC31-J R$95
M             !K%%3!@$W&"4QW(S4                          12)6
M@                        $*":X                          (I$K
M0                        "%!-<                          $4B5
MH                    (BRBE*V>D  !"@FN
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M6LG[FP=Y1%NV,ZR6N3"G]*8[6]F*7UW<=\X;WB_W*]..OZ?=\"[%E>35RX1
M'0=!=G3M'<>;][QA'W8,NY U]HXDVG(.;][QA#6SN2$YKXXMQ(M/D%SWWVK$
M6TY"]+YZJ9MY<;,D;C9@  &K/7%^]$RA (I$K0  8UEU8SG
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MQ>   *=JHES$S0@!%(E:"KSR\YIRUU$WZ   (]]FMFVV^L?!8
M   Q=+5AJC;OHD  "%!-<KXSG];!\&?(   0CSYM<S<%[G[^GD
M       "A:N)T4S8# "*1*T%7GEYS3EKJ)OT   1[[-;-MM]8^"P
M     !T8UYJHV4J9   A037*^\\38)@>   !^'TBESG9;-U7 ^YP
M         -=6J+!HFR2 $4B5H*O/+SFG+743?H   CWV:V;;;ZQ\%@
M 8E/5,R     &(C4\^E.Y!\Z@  (4$J=Y^<6<EUS4PW(   %"O8K:5R?!NY<
MKV=J                 !KKRM5A-,&KZ7HF7#*I5YY><TY:ZB;]   $>^S6
MS;;?6/@L       =$-3XSB;18    !@8T+_I3]#_ .=7M   A0<;G?2S@P7J
M_9H@    0%Y&[1+_  GN7>[>^H                %%U<63TS*J KK,T$K
M5>>7G-.6NHF_0  !'OLULVVWUCX+       C48T.M'93^2:1R    !'DK7JB
MZZF0(R&#SER;)$,X3/VCGE@'6     "NCD[LL^N.>[\[MU8
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M3,. $4B5H*O/+SFG+743?H   CWV:V;;;ZQ\%@    #%.W5_%'][7%[Q>>G
M  &]#YE<R[MW3;D$       0H)K@                          BD2M!5
MYY><TY:ZB;]   $>^S6S;;?6/@L     8IVZOXH_O:XO>+STX   WH?,KF7=
MNZ;<@@      "%!-<                          $4B5H*O/+SFG+743?
MH   CWV:V;;;ZQ\%@    #%.W5_%'][7%[Q>>G   &]#YE<R[MW3;D$
M 4+%DQQ!-H  PD9M  , F?@ "/9(0  CN2(  (^$@P           12)6@J\
M\O.:<M=1-^@  "/?9K9MMOK'P6     ,4[=7\4?WM<7O%YZ<   ;T/F5S+NW
M=-N00     !1*60$>3WSL0 *FBS [J <:1N.SF? "+ACDEH=U (#F/"S$]H
MKR,?EIH!+,RX         "*1*T%7GEYS3EKJ)OT   1[[-;-MM]8^"P    !
MBG;J_BC^]KB]XO/3@  #>A\RN9=V[IMR"       -.(V$RPH %!A?:?L 1\-
M*,N?-D  H]*83:')L@&J,4:GT#3.P!I?&+C>2           !%(E:"KSR\YI
MRUU$WZ   (]]FMFVV^L?!8     Q3MU?Q1_>UQ>\7GIP  !O0^97,N[=TVY!
M       '!G.  '$G+  '$'DY8 ZH?R=D/9 .A'O';P < ?R=A
M*X#.1*T%7GEYS3EKJ)OT   1[[-;-MM]8^"Z/;#Y9:OG&;O$$,Z_AX.,B>3F
M.\1,E:?MX-X[F9YI,Q:?9_BC^]KB]XO/3@  #>A\RN9=V[IMR"       *AR
MS<R" "B<NE.Y@                     'X&@X;OQV R85@=:-X^EQ0WT
M <9R1V>U_M,LFI"TN0^OE@OM6    VY^371MF"-LT!^\[&GG=_F   -B/K?N
M_8)XA;^       /F:FP8;7P /E]FUV;)(                      (.$XP
M"#DO!F<CN2'AR9'"8DG$P\J654@                  !3X7!'D %51:J
M                       5151#$BP8",OG2S.DHO0L)ELD42,=%*TNR$F#
MFCJ*,NID]#)8 .JFK?5$>:EJU+BXG"4Q+R'>Y6Z4R
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MB1B<JJF.^RX2)RL?D98.WD>"SJ
M   %&=40N(82[F8IE<#2V#J9
M              '''Z C5*34/8
M
M
M
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MQ7,?5Q7,?5Q7,3U15*JW?5Q7,?5Q7,?5Q7,?5Q7,?9X&LV&@ XXQTA;..2*
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MDS8:&Q-L.]12V^6K M:9FY"Z,%AE.]RXN8?DI]09"IDW(J6JHA6X?(A5JR^
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MD"MDL+:XJAV94UM1SF8K;95%'II]:LMXI93 -JM@!:214+6-OQ9D^&F(M",
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M$<JL)=/5I60R! **0#0()]O03^B8+D#^9)HX_P#YA]7@I?8+)0 =;& RH/\
M:MVF%.)[W#;M-M>1: (SV2:M4B*Q9+B+62%)I0@#K(-.!%<;M@N'U'QGEA9^
M?@I$%%!X/%]4GC3'D&<UIXD,[_S:8S7TO1\'&YI[B:=(&2UTEK>X Y))7KB\
M7G_I 5YTK2O"]CG;0L? 945OM6(8?7' >-PR>B""/YQYLLT%JTTJBH12H9CZ
M +LJ@_ZS >GQ<1C!W,$,4CQN\C0:1)&0&4!)78\SR8+I/H_0BZR$_9P%@M:,
MW,UH**"?!Z'$GP1?K.%4$E0U*$D @E0#S!'(GS,3MZ]OE3+WP8PI1O&"@DU8
M#2M:$+J(UL"JU/+B]RV3G$5A;QEW8@FBCT *DD]0 !))  )/$.[9+[_P!UC8
M2A78!9&5%+*%++1F"M5:H:Z@*&EWDKV81V4$32.W,A412S&@J30 F@!)Z@">
M+7RG(2??;>.<Z89G[**4!HWGT1MV 8$&DNE@.9 '/B*XMY5>!U#*RD%65A4,
MI'(@@@@CD1S'!Q5Q/--E @=H;>&6XD13U-((D;0#4$!R"000"#7B_P!R6N0U
M8JU#]L=#AXC&*NKQ%1(KJ/[)6I!! (()M;>W-\7F=54FRNPI+D!26,(4*:CQ
MB0 .9-.,A9R75RTMK,\4I2UN9$22,T=2Z1,OBGKH>KGU<6^5Q%XD^/E!*NO4
M:$@CG0@@@@J0"""" 1T'@Z^D  Y\$$4(^H@KT6QK_)W BQF*N),K,YY*L6(@
MER;ZCX%9;0JQZZ-RYTXNLEDY5?)7$C2RL!0-+(Q>1@.= SDD"IZ_H\'@,EG9
M+'8V?LK_ !^790K*N/EL+DRW!5@P#V)47L,JCM(I( R'FRMN#9^=B"Y7'73P
MR4KH?0?%EC) U12IIEA>E'B='')APN87/P K$T03R4D=FTBO0MY0"6&D+JY#
MK.GS9<;C\&;N20H:EX552LB,0>U8&I4&FE2/ 2.!+)BO)):D:#V9-/1K$S+0
M^A6OHCAWTDT!-!S)IX /1]#C+W$F R,=O=BV5&>$!045PQ?QR5 +#F1ZE>--
MY9Q2K_?16]D#P'^!H8V]&*L)_P#A%. UIFLE HZE6Y=U'UINU'UC4<:K?=19
M/0FMHG_IB,!X),>,GB'H&>%CZ7,3@'P"I(\)XSHAVS&]<G<$_P"*04;4*@?>
MZD#T2!Z@X_9./\K3\5Q^R<?Y8GXKC]F(1_\ 5C_) >/V;MORS_[;C]G+;\L/
MO;C",_V9AY\ZT.IJBOA /('E4"M!U>9O7.V6"REQD?*85QEQ#:&:")<;(6#K
M,"*">?MNT%#I4C[(^*-@VUC97-U99"2.^N8;>+RB3R>V*N8FC!')KG1&S5 !
MC?K(H=]=WU_C[JUQ\K2SV\5Q#V$JVEZ7UA(C6BP3E]#UZW4\B*#:7=_=O7,S
MW[6-\ 6J(<:P:Y;6/[4L:P $\F[>G.O/O,EV*]K'92Z;6X%R"S27,4&A_)M(
MI&HB>-*S:T+U8*%K3:&*P^VLU+CI+6WCCF6W[6&,<HCVTX*K6)E/;,$"@ L!
M3EQO*^M;076Z/A>][>,NJ,\R2$1Q=HP(1.RT!*C0H)H.OCO;AR&SUQ6X#BDD
MG(N$N.V4QS)$24 52@1AR%37GX"<*<HN"^ S$FKLC=F?1V8TZ=8[/7U5J:==
M/!QOR+;NWK6[LSN._/:2W)A(<NH9>S$3U5: ZM0+5ZAUF2UR4\3Y*XNIKF7L
M@1"DDSZBD0/,1KR J!SJ:"OTA@ML=U_>_N' ;<DV;C+EK:POI[:%IY9KU9)C
M'$ZJ9'$:!G(J0H!- ./G+;T^5;O\9Q\Y;>GRK=_C./G+;T^5;O\ &<?.6WI\
MJW?XSCYRV]/E6[_&\?.6WI\JW?XSCYRV]/E6[_&<?.6WI\JW?XSC:FT.\;OI
MW)F]K2XC+2/:7M]/<0.\-A,\3-'*[*6C<!T-*A@"#UU^GA3KX)IR_P _1=_6
M\_)XY(H=N)BTU<R)LW>V]JVD>C\'ID23X%!\)'0376 VAMJ^R32.RSY+&PW\
ML:R0M!)$G;$H(9(G=7C9&!UL>1H1LWONM\38668@=,!EK:RACMK:*2SMP<+/
M#;(Q,<5QBH_(QRTF7$S/6LE.DE-BD;7=/%#DJA/]YE5B!ZBGU.+]<E'9>2SW
M,TU8I)2ZF0@A=+Q*"!SJVH>"B_0B!;Z>W.H'5"P5^7@JRL*'PBGU^/)[;)7<
MUL%"JDT@<( 2?%\534UYU)Y4XN+8RNG:(RZD-'74"-2GG1A6JFAH:'BPPN,C
M*V-M&$0'F:#F2QH*LQ)9C058DTXO\GBEF[>=2@#OJ2&-I&F,4"T'9QF1BQ6I
MY\^NI.,W*QD3*6L4D0*M19(Y*5244.M58:T%1I?QN?&3W9;PN,O=QA'.KQ
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MG&A)&?Q>+_$9:QFM<K:S/#-#*C1RPRQ,4DBEC<!TDC=2CHP#*P*L 01PN_\
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M SV[[&*PQ>9R&'R RMA-N#;26_DTES?($$DV5Q*6QG@*CQ;>=#K1@\G\0O\
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MK69:PR(5(](BA]3EP\%KK(9M1+,68F@',GT   /!Q=W\6H3SA0_/Q3H%%-/
M:<J\7*V46D2R%V\/,^ >@H\ \%3Q6LWDFO7V':-V.JNJO9]77STUTU\%.)87
MKH=2I]0BAX@M(:]C&@5:\S0"@J>+^=E):YC".">150P  \')C7C'6D:,(;60
M.G/^T-7,^C742?1)^D9O=4GK)T-Q^$C]F.E3U1Q=?A&]<]#?^Z![ ></KZ";
MW5)ZR=#<?A(_9CI4]4<77X1O7/0W_N@>P'G+F]U2>LG0W'X2/V8Z5/5'%U^$
M;UST-_[H'L!YRYO=4GK)T-Q^$C]F.E3U1Q=?A&]<]#?^Z![ ><N;W5)ZR=#<
M?A(_9CI4]4<77X1O7/0W_N@>P'G+F]U2>LG0W'X2/V8Z5/5'%U^$;UST-_[H
M'L!YRYO=4GK)T-Q^$C]F.E3U1Q=?A&]<]#?^Z![ ><N;W5)ZR=#<?A(_9CS-
MN=SN^+^^M=MWN(R5TTEFZ1W DLXX7B"O)'*H0EVUC14\J$<Z_MQO+\KM/>7%
M/^.-Y?E=I[RX_;K>WY=;^]./VZWM^76_O3A0-\[VU>'_ !]O]:G^#Y>GS-?2
MX_;K>WY=;^]. PWUO6OIWML1_,;,CC]N-Y?E=I[RXY[XWE3W7:>\N-Y8&V=F
MM<=FLA:1LWV31VEY/;QLU.6MDC4O2@U$T '+A/5'%U^$;UST-_[H'L!YRWLD
ML5E!D9ZEB/LJ"E*'JIQ\4I[8?N>/BE/;#]SQ\4I[8?N>/BE/;#]SQ\4I[8?N
M>/BE/;#]SQ\4I[8?N>/BE/;#]SQ)CVL%C#,IU!B?L37JH.NGF83OHL=LQYBZ
MLL;?6@M9)FMU;RU(T,AE6.4@QB/DN@AM76*<?-ZQWRM-[QX^;UCOE:;WCQ\W
MK'?*TWO'CYO6.^5IO>/'S>L=\K3>\>/F]8[Y6F]X\?-ZQWRM-[QX^;UCOE:;
MWCQ\WK'_ "M-[QXW-N&2%8Y,EE+R\* DB,W=U+<F,$\R(S+H#'FP6I )IPK>
M@>)93E7&IB?L!X37_2X^-G]K'W7'QL_M8^ZX^-G]K'W7'QL_M8^ZX^-G]K'W
M7'QL_M8^ZX^-G]K'W7'QL_M8^ZXGM4N3*'DU5(TTY4IUGSHGS*>>,?0G@GBG
M%?I'ZWG>/T)^HM/#QU_0'S>KZH>GP/0^ESYGI>>+ET%?_-&__]H " $! 08_
M /\ ZL$QO(P^DHF\B@)C#Y!Y^12A])C#_ '\/CF/%NT^.J-SCB/Q#6W6KGDB
MD*%T&&ZQQY'DULK/RB_5E8M:@UYNAH%30*O&'B6K1,YWC=4AC(#Y'^^$)IO0
MMJE8:.M]XKV8Y[5JE5+)H.CZ=I5K.L2NT+.<_IT;+V>W6>4*V5.1!JW,!$DC
M'4,0H>?C)^B3Z9>9^O[9>+]FF?9Q5,;U"P;S)7[)$7+C8*M(8FQK!M @GN3M
MV@J6!9XS19L4E6Y_;'([:&7Y]W>P;1+7&A]/TZQZ/CQ,IS?0-,M,SF](C@DM
M#OTY4:K7GU@IM9SE,3(SRDN@R6C72*Z"B8+-71$:-K676B+NV;Z55(&\46WP
MBIUHFR52SQC:8@IE@=1-)8&[^.=IJ 50A%2>KTG*4X"4/OJ[?. 5%!DV7=K@
M@@LZ7%%LD=90$6S<BKAPKZ"#Z4TRF.<?H* B(!XT7IOL;ASXA=0V[7BZ%B/'
M\YH7.M@J?*?&_)U5K,G?F47-6^S/(]\WV'7'E=6;3,J6-]B>4?>[-%2MY-5N
MAT58:E/RU5LL5CU\<PEF@')&<] 2 U]ZDWF(-Z=)<K&8CC*>U:K^@XH+E*<
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MF4-:Y4J=,KU)A=V;2P3@VEX4/?J[,,54CM$W2?K>I)F,4_K @B(@  'F(C]
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M &?DK:[=SU5<_AJS>D7=9HU9U.WT<92;<LT7#MDC)"FR$B;7V3KE+JBZ0T5
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MXCXWB*XVQ3'NC>IW7*O.V>.&FVMH]+3LLFF#"S+WW9Y%N\6CK<U/#J_5, E
MJIN40=K%4PJCM,;H_/;6K4&,AFV*9MHZFNT7-V[-5PFC6:SI:L9#*W..:)^1
M@>F;)"<YS (#Y>H?EZ7_ $-7K\2.?N]7\Q /_P"-;U](B!0#_P#2\I](B(@
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M&*8!*8!$! 0'P4B?-&/(I)E*FDBA2XE!!%(A0*FB@@BB1%!%(@ 4A"%*0A0
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MFE'9HMS&R"4L9)-%-$%0, "(@!?P^E3%$0,7'+P<I@'R$IR0KDQ#%$/I Q3
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MQN5<Z'Y5S34J[G-GT5OJ=3JT9F6EHQ5[G*UG>FH8_,UZ13-!RCY%0AK$60:
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MFY-*'B4&L5%E?2#@ZGL&R2:"7J]*92E  #9?T4Z'_P (S'@W]\?\/S/Q"/\
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MMHTA[[&R7U[&5C\EC>UCD?8+NO;AZ5B>D?/GWBN5H[A8^[8;N>X'U=>TQT7
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M#1*G8J+>*E.-BO(6T4^W0[R LU=F&A_(KJ+FX607;.$Q^@Z2IB_P^)UO'H]
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MG:[I*/4XU("PZ2KP_H:%*!"E507236063.DLBJ0JB2J2A1(HDJF<!(HFH01
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MY:WV5E:="-5JQ6G4GHI*M*3"K*+(N0%'IVY%3B5/U,L#X4Y2Q3,X[3.M>/\
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HV;<IU5"MVJ*;=$IUUCN%SE22*1,#K+JF.<?+S,<PB/TB(_\ TSO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>diabetes4_850.jpg
<TEXT>
begin 644 diabetes4_850.jpg
M_]C_X0N$17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    /  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHP-R Q,SHU,CHQ,0
M  22A@ '    $@   -Z@ 0 #     0 !  "@ @ $     0   U*@ P $
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M6N936QT;FM ,<2!VX24CQ>;_ /C3^1JL(&+S?_QI_(U&+FCDA)2Z\Q_QD_\
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9_^T3Z%!H;W1O<VAO<" S+C
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300        "  (X0DE-! (       @
M     #A"24T$,       ! $! 0$X0DE-!"T       8  0    <X0DE-! @
M     !     !   "0    D      .$))301$       0     @   D    )
M     #A"24T$'@      !      X0DE-!!H      WL    &
M  %I   #4@   ", 4P!C '( 90!E &X <P!H &\ =  @ #( ,  R #, +0 P
M #, +0 P #< ( !A '0 (  Q "X -  R "X ,0 R "  4 !-     0
M                   !              -2   !:0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !:0    !29VAT;&]N9P
M U(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   6D     4F=H=&QO;F<   -2     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3004       $    !SA"24T$#      *2@    $   "@    1
M >   '^    *+@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 1 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M_P#XT_D:K"!B\W_\:?R-1BYHY(24NO,?\9/_ (HJO_"=?_GS)7IR\Q_QD_\
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M9L?;L-9?8\N)!<ZU[B-&[WN=_P"!UJ?4.FU9[6-MLMK:S=I4\LG>/3?NV?\
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M &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ',
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M4%)/1DE,10 ! 0  #1!A<'!L A   &UN=')21T(@6%E:( ?G  , !P - !L
M.&%C<W!!4%!,     $%04$P                       #VU@ !     -,M
M87!P;
M        $61E<V,   %0    8F1S8VT   &T   !ZF-P<G0   .@    (W=T
M<'0   /$    %')865H   /8    %&=865H   /L    %&)865H   0
M%')44D,   04   (#&%A<F<   P@    ('9C9W0   Q     ,&YD:6X   QP
M    /FUM;V0   RP    *'9C9W    S8    .&)44D,   04   (#&=44D,
M  04   (#&%A8F<   P@    (&%A9V<   P@    (&1E<V,         "$1I
M<W!L87D
M                                                      !M;'5C
M         "8    ,:')(4@   !(   '8:V]+4@   !(   '8;F).3P   !(
M  '8:60      !(   '8:'5(50   !(   '88W-#6@   !(   '89&%$2P
M !(   '8;FQ.3    !(   '89FE&20   !(   '8:71)5    !(   '897-%
M4P   !(   '8<F]23P   !(   '89G)#00   !(   '887(      !(   '8
M=6M500   !(   '8:&5)3    !(   '8>FA45P   !(   '8=FE63@   !(
M  '8<VM32P   !(   '8>FA#3@   !(   '8<G5250   !(   '896Y'0@
M !(   '89G)&4@   !(   '8;7,      !(   '8:&E)3@   !(   '8=&A4
M2    !(   '88V%%4P   !(   '896Y!50   !(   '897-83    !(   '8
M9&5$10   !(   '896Y54P   !(   '8<'1"4@   !(   '8<&Q03    !(
M  '896Q'4@   !(   '8<W9310   !(   '8=')44@   !(   '8<'105
M !(   '8:F%*4    !(   '8 $P 1P @ $@ 1 !2 "  - !+  !T97AT
M $-O<'ER:6=H="!!<'!L92!);F,N+" R,#(S  !865H@        \U(  0
M  $6OEA96B        !OI   ./8   .16%E:(        &*4  "WA@  &-I8
M65H@        ))X   ^$  "VPF-U<G8        $      4 "@ / !0 &0 >
M ", *  M #( -@ [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L
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M,S,  C,S  (S,P          ;6UO9        !YM  !W!P  UWS6U*X
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M(3(S%!47-R(C-!89.8!!<) D)1$   <  0(" P<."@@"!PD! 0(#! 4&!P@
M$1(3(10)$"! ,16V=S!!87&!D;$B%M8WMWB84%'1,B/5%Y<X>6"A0I(S)-08
ME9: X5*T)29V\,%#-E8G1R@Y"A(  @$# 00$!0D2"@8&"04  0(#$00% "$Q
M$@9 02(346%Q% <0\(&1H=$RDK,@,%!@L4*R(S-STS1T%76U=@C!4G+2))2T
ME18VX6*"D]0X\:)#4X.6<("0PD0E-28W5$55A4;_V@ , P$! A$#$0   -_@
M
M
M
M                                     ^$<GW
M                                  "$CVDT
M                                $)'M)H
M      !!<)X @SSFD$72QD*:&(,L^9LT@                   A(]I-
M                          *#J-YB6GVI:U@*$J5UF'/0PWI7%^5>TK=,
M^#M0                 !"1[2:                             8@2U
M<49*EMM6V&/4LWHC#!R6M;?/0K!+/@                 :XA5F3";/QE0
M    1EC=WDW):0              ,6O7;#\E:'ME>$0[1B:F0WF=X
M *P2SX                 $0GS2'B:2:     1=C-ZZU:YN=L[Y4
M      (HW&WA7?+7SECE]XID0      .#P.8O.  "L$L^
M   !"1[2:    1UCMQZK:Y[\\M;DG;.^5             "L;K'!6(\RYGM&
M(J       #I)2'1N)[GA;I/0\P 5@EGP                  (2/:30  "$
ML+Z=-N:\Q@' ^M?JFH=9MLW^Z>UR,V+QL            ?*O)?@9&3'STNSR
MW\7R(       'B:Q-"\QO1W!:]EY@ K!+/@        #'V6?!"2M\F58Y6H3
M7&4      "$CVDT  '3[/8X=Q'HO"/U:MAZH3X]Z_P"OY);'XO.N<\K
M       '4\S3P*Z*Q%B/,N:^A;1        X-3^C>W,36UE%2GR "L$L^
M      *,*=SA[)4B"2K<-<V=M4:(    %9!9 ?7!"1[2:  >B6KAMI_2'<KS
M6^PW&'@K!^I_#H97)?9/$^2=L[Y4            .J9BG@/T9B+(^6\V
M    .H%'5.[L$FM\ZYI/: "L$L^        ! )7X1 =J.[%D!,    !#1JVF
MU@2."$CVDT  &#.D=21OC=S[K>ZU,.7\Y[)<X;PA-Y1EG7.>6
M #''U"R\H,C/,+T        ?/1JLIW&04U'-Z:3S !6"6?          P%)K
M,CP    #KAI?FY@=S!"1[2:  "G[R+Z)YS[QRU]VOBN$?U34.UW6 DG):6
M          !A-[UBYGT:ZG+SZZ        '!JFT;JQZ>6Y6>W  K!+/@
M   5^2W&.UO<$1AS%*Y-\'"*,,IKBSSEC2\@  #4/-CXRR!"1[2:  1=B]ZQ
M>UGW.5,IH?=KW62'YY:TX9OR\            ")-SMX ](LY]\YNY=TJY
M     '!JM4+RQJI2N,GH  5@EGP       /Y\',_W)J#Y!_14B  X0YGEV#N
MROS5;Q?1'QD\@  =6-58VA#P,?",3+HF@ %<OG?9,PY?SJ8<QYU+&5T =*LM
MF[K>ZR            !7ITOALS?"\GW[7*P         U7J-Y91&G;S5MP *
MP2SX       '\^+F;[E5"<@_HM1  !-)L&]E_FGWB>B?C'Y   &LP;+!0P87
MGX38L,J  8*Z/U/->9\SG_/^2               5B]8X*SKD[.@
M :UU&YL5GEL\GH414[BYVI0K5IU[:JEO6&6=G(      !_/CYG^Y50O(/Z+>
M   >4\NP7V5^:?>(Z)^,7D   :*QO4@$)'M)H ,%='ZG[S>ZMECM?@(
M          KPZ9PUA_,V9          U**%]>=6M;"8T]/BWR-X]6UJ)IW&U
MM7L*A2U [4       ?SXN9_N74)R!^BT  #FI)L&]E?FGWB.B?C%Y   &IB;
M9P!"1[2: "OC0.O,D=B\8G;.^5               1#NMM /H]IFYX'E
M     !THK*EN,TYJ62R2*)9N[QEZ,FEJ,M8)9\       #^?%S/]RZA.0/T6
M@  <U)-@WLK\T^\1T3\8O(   TT3<N (2/:30 89:=TEF;N/-H
M     Q0]CQ_VK";)7RN^         $-0CK'4,A=U6LK')J8 %8)9\
M#^?%S/\ <NH3D#]%H  '-238-[*_-/O$=$_&+R  !UXTJ3<V)!!"1[2: # [
M1>K,\=ZY3               QO\ 4;+KN3DF[0;J1-9K        <'(!J6VV
M2M K6UR4]L !6"6?        _GQ<S_<NH3D#]%H  '-238-[*_-/O$=$_&+R
M  !^<HB+/C*<$)'M)H!\"AEL=]>]ARGVCP@              #%7V#'_ +:$
MV3ODU\         !P:[\EQDQ"%Q-2@ !6"6?        _GQ<S_<NH3D#]%H
M '-238-[*_-/O$=$_&+R  !\8T0S?5 (2/:30"!,#ZQ-V;\P_;/;
M       5K]3X2R3EO-^R0          *N9:^227+2:D !6"6?        _GQ
M<S_<NH3D#]%H  '-238-[*_-/O$=$_&+R   -0DV]@"$CVDT QZU_P!?R%V#
MR"$L+Z=A]J'15?&@==]INL%C)K/M^?N^\E8PZS[A].K961^C<7V)>A<>
M      "N#J+"V/\ +N:        ' .0?E-:VA<9D5(W*3VP %8)9\
M#^?%S/\ <NH3D#]%H  '-238-[*_-/O$=$_&+R  !&IH^F^8 0D>TF@&/6O^
MOU#^2_0S,+;N=;!M_P"1/@4,M\2AD_QR7,H931L>->]@G[/^2]TO-:
M    ^-?2Q'NEM"._6N<?/^5        'B<G(/AHZ;-MD+X*UK;%/0  K!+/@
M       ?SXN9_N74)R!^BT  #FI)L&]E?FGWB.B?C%Y   AXHF-CHPH,%#UE
ML),H,!M#ZRB*[V&U3<>+?)              8M>NV'7LG)W+!U,E/*[X
M    >LY/,'4$=+JVR&PA6M+9)Z( %8)9\       #^?%S/\ <NH;D#]%B(
M)Y-@OLK\T^\3T3\8_(    J7,3CY!<*95G5;7-4S^Q>E96>B^ ]+SM.RSE;-
M_>QTX           Z3GJ7=L#5%??2>'S6\&RD?[)1F[0;H        ?F/T'(
M, 9*]$<MQ:7&WN/J4  *P2SX       '\^+F?[EU"<@?HM   YJ2;!O97YI]
MXCHGXQ>0    !"1[2:"L;=/3ZY?HYSQLE?+3=_QUX8.^_P"*SWYTRX
M    Q:]=L)KT.ZQ4]@Q^<O/V5^==2UC]88.TGD7/           #P.3Q0]B(
M %8)9\       #^?%S/]RZA.0/T6@  <U)-@WLK\T^\1T3\8O(     @^2K%
M.Z6&"'N>T6G\G9;7Y^M?B6QS\OMT[G@JN*_K]AUW)T\RO#<F    !U;+T_E7
MDO>M>K1IM="3]2KCK.5DQ.]DQW[J$WMD8[^F6>;7@F4P_P#;<;DOY3?8B^TX
MZP_F?,R-J]8             <$?0FD&,O)6"6? X.01/-+^2#F+Q@^^2+";A
M#E$ ?SXN9_N74)R!^BT  #FI)L&]E?FGWB.B?C%Y     &/LV=Q-D]1RMU^R
MR'V'QZLWJS!V9<IYP#%_UJPQ/]DQ\QZ/<^,7S+N7F#]-*/>]=K1CMMO-^@7<
M8;;;R!K=:%M[MOL6,TBZS6CG9Z,J:?<1)NEM-V@77[J$W<<'4E73[CHFPT>^
MZ[6$/;O;8Z^FV6=?/>6              A&$^LS0OMM.XQW)4H6DG8BL*SL-
M0;Y&?"I"IC32?/1_'&3]D(]TF3C/'HV]^F_T5_J7]E_LT:8'\\'GO[&TI\O?
M>#@  ',U/8]ZL_/WO5>[_)KS     (2/:305Z]+8?S@ZKEZ?0]BI=]URK%FW
MV^4GD>0RG\AO_J6<W9,7.         !^>K"#]_M9X\[NP             /F
M(T5T[F^6I:^1UL^H?0/E(1%7N_*$   /8371MN0"/IZ75(T.4   .WPN>^25
M     !"1[2:"I?LO7L2/9\=DUY3?05Z%:S[YQ=Q7M]O8SS#FLN/%\B
M                         /P')\--]I#\I]E#D   \#\@/AH^\^XA[CD
M     A(]I-                                   !P:H]#(2!4E^C)+
M6!+/:/-1V4JUO^Y   #UFE#;9+ILD+'ZM+L)*$TFP)5M@     !"1[2:
M                               #@KIEK8ZPFZ.C\6$O?8U+L)[3W
M'K0J(IW6/$LW:)W>I(Y%5+>Q6:GR      0D>TF@
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M+&$Q387O&1QK_$S%S9645O&RH>1K1&3A>"         #TG3D.I'<$?F(R&A
MD(_KBF%#JQWP  Z0=61[:A\=-)*7J)ZSYY]$[F     #'@B,SC!6L64@PD)Y
M)B!@89Y@Q>/I&1X*Q2SH$ F+19&=#*YBR\[,8XD5&<9'!@,6%'=C$@C(L$,(
MB"2R$[D5*$X&?97X=9+)#V%2A.AGP
M       "*XPT_*]'*&$V9TD< ZDO>)(X_P \,G*<UKL)K,Y)@
M                                     .KG!^@B",)4A'UGH.E1A-D(
M@
M
M
M              #_V@ ( 0(  04 _P#6*(@&@.0>T3% W_0'*/G+7^P)0 W8
M8 ]:<?X.0><I@ZM!2#J[!+S,(<P G+Z6Q60/DK;CD@SBC72%%D\_8"5"M>!?
M[&:O7]C-7K/)-O\ '8GS%L+^M=W2>_H.,12*OESD, W&%3F'6#XY]6(K@>7T
MO6R)*.2H5;P5!B?Z]/?T'&1AP'X4F>S^;5&8X$W+J+SY_2F?N;VSQVKSWBH>
M\=I=VUA72]8+C$\5CK"ZRN04::S2343NGIIPO!<B@;I$#<28X$ E4I]5*P%
M! >'R%X3'6.?JA7P>>H4JMU>>\1*M.CGD_;?GF33WUV'%)P %0V=G:XQZ;V\
MN\C><%]0#3,4W%52=9:5/H&M1$XE#I#A3 )BT;BZNT+F_=_-_P!1>9LMPI34
MKK/J+$_UZ>_H.*3QBDS\CJG]IY+@Q&H!@$>?TG9\@;_*9"_S&'S.(OJM:I;T
M+3-T/>/$_P!>GR7%.QXIEDUC58Z;VYBZ4#R<&-,!, <OI2B6IG4AG!$V S?]
M1>>\5#WCLL>:SN>+;6WIX)".U^ZG!B<W60PFX<]6C1#\10U^(H:_$4-!<6^C
M7%MK\10U^)M^87%OS+4HU0X+,W=2RQN.H_AFZS?N_EK6\N:]S:WE3.4 '^XN
M+4Z/*FL,N;BT2MVY&7PR@<#@S5!YD^HO#23YACP,;EU&UU&UU&UU&UU&UUGU
M2,8:D;1$4OP6.H%JWN$LB9%'WF(HWV/["8ZRIWW%XQ-V*JR:P4EVL55PG7_'
M3'GP\E!__/ /JY:Y:Y:Y:Y:Y:I_4>-ONOP25IUANDO3K4D_Q][7J)QB>%$>8
MTPZ2Z"IS'ZN0''GP4E _^ !'EU#KJ'74.NH==0ZZAU3'G4C;[K\"-Q3Q-ZCK
M0+'$_0#]TLDGD)PO73*<! >SZPHFY"0"%*;@I)^SP]'>I?>1M]U^!(0M\LL!
M0NZ%#CVX2P+5>/PHZBQN>%$Q.8  =@E*8>6@*!>#DG[/#T=ZE]Y&WW7X%/5B
M7"B^@&O*3"IYP1 4IP@\Q 2B&B<NGAI)^SP]'>I?>1M]U^!1O(]WQ^(M,*=G
MU,;^W6?SJOSJDQO"G&H42?6'#23]GAZ.]2^\C;[K\!=5RVMJE<53L,?QZ6Q]
MYEFJ>V_MJ[B\-R'JI@8.'DG[/#T=ZE]Y&WW7X!3U1HI^G3+2I\>P?J[)('.>
MJ?AA,4- //AY)^SP]'>I?>1M]U^ 49@&VUGU#ATQC5DICBC!5E^=&X54W-B7
M)55/5MLXKS9C%J>O33EIG,;?8S&H3%YW&GX:WL;U$1:X<W1S)P\D_9X>CO4O
MO(V^Z_ 94W7EE.]E+#+' H2O5R-?'6-S=AA,0&6NDW@;XN83">4%2[L;+(6E
MFADAC[*\QUCD!X7'XS)9:NV*1LU@J%$K;I=(7AS%IB>F)>7#23]GAZ.]2^\C
M;[K\!<60W2]MV$3Z5L0  #C&3R%]C%@J# WC<8C]F>'J<@-3 .GAI)_T >CO
M4_J/&T!!+^7OKRAC[3&H]/M5CL\^R&5"3=1HTZJ[S+8C+8#(\1E$LH\)C.R,
M6"MJRQ4:@RRLS^.4^$M&WX:J434P"H%2F42\/)/V>'H[U+[R-ONOY>ZL\JVB
MC@9"@9+M+7H5[6OC[ZYQ=^\&9O7KL.&3%'%5&>PJ25:DT[R/5:0;[5C97F3O
M;6]QJ5SWTC)/V>'H[U+[R-ONOY2I4IT2(U!*A>%2RY9R/%A94\AR@U(IZ4FQ
M:G4N:62DTQJNP"3<5;LYD*=]Y/.)_/)F_2224*Z4)R#3/AD7F,ZF^S#X7*YR
M[<6/J]2"R0T<W<72GI-X@TD3 NP7%M7F77<U0!565PAVU6K?6B=MU/BDVSJH
M22S4J$RG&\P\CTFUTFUTFUTFUTF#LY=V2?L\/1WJ7WD;?=?RA:MQ1UFZF05&
M/!*)T*FHZ.NBVY0/:S+PJ%E%6@4PSSNX*WC(Y6135Y%UW,6DE(RK9I'&KG 1
M:PV<1=]%7'*O)!'>[N4HV\>LVF*J?9NU&_HQ6LDD9?-S8%=.0-HJE<W4EUDB
M%;5D([XGP<H72Q::N'S<'(G4$D[_ "Z/R3W.MF#N2YF07ZS2J_5Z+S@CS&R5
MRFQJ<[$0O<TA;N4BHN5*]O&CZ.H/5]W)5;VAC/UPG\)/UOG[H7LG^.OUKG_K
M]:Y_:!ZY_P#,'MG\&OUOG]IKG=FMF'&N (6OVR!P>:S-E^GJWU^GJWU^GJWU
M^GJWU^GJWU^GJWU^GJWT5OUN4S X;+81.^7C_&K./[CFOC9FW.:&RBWD,PX3
MB1#,AV<;Y@VWS;7O=!]=LNC)+L/>1O=2T52BL$[5SF:KXCA:(41K.TIL(LW(
MXWESUZH.7= 1#7XJZZ?Q-QK\3<:_$W&OQ-QK\3<:_$W&OQ-QHUS<&+W"5:M,
M?75M>NK:]=6UZZMKUU;7KJVO75M>NK:/4J5. 0DM[]FVKRD^DZDG#M91I1--
M*KIKI+((JK-IT,4U[:S/P:*1[X.?8.OG?,#_ +\ZJO6:IU@82% P?]&(!=#Y
M$OU'I&$Q*I0(0H==4G\)O-CI_CZ &H!1+KI'ETB/D@)]1*0$*)1-HU,W64#
M'FM4J>K$Q@*4INHI1Z@+_$ U!YC4$"$J', G-HANH.X)^0!]>@-S$!Y@0W7H
MQQ PU>1>L.@ANL/-0P5#&,0:M*F-<!ZO5Z'F %Y%T;F8M(ARE+U])2 4.Y4
M_4 U>@H50$XB4*8=)1 PU:I#!2(4_32 0+YLB4#:   /_#H#RT( 8WJ@Y'(!
M=&IEZN@@E]60IND!T?SG$PF'LYCH1$?^0_\ _]H " $#  $% /\ UBTZ9ZIC
M4S$[0*82@ B)B'+YRV(@%?\ D=/93^NWI<_6%ZS#YR4:IZ!ZEU4J=H',  (E
M$]Q4.7Z57Z0M43F^.N,A1MKG\RI&U^)O=?B;[7XF^U2KW1ZGF*K$GC4[@GB]
M[.,N;DML2K>5*U2WQM*A<^9&.1EUDD3E<>G*;0N#[I/%[V<9FJO4-*E3H4^
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M?]^. 8K'DR+OWEW7O[SC\IS-<   '#$MJU0M:C4H'X;8_P#?+OU/N][?]^.
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M .$Q#GH>9"B<>13".BG'EUF W680Z^6B^<G(.T  H=G+0!R_Y#__V@ ( 0$
M 04 _P"6:H4F&1B93*CPZQ3?G3)?PXQO\._G3)?PXQO\._TU(J2[&1+;-A-S
MN!TFW![%$]#8)%R,CD+3%63!;AL*)2.!]$27\.,;_#O]-?,B#F2[<<@KV<UC
M,;L?:-39-5O0[P]Y>V.UY(9N&G9_,ZW-G(?5!-2BL3G\"E/H62_APC?X=_IJ
M<4*&GG\PS/[.,?VV>3L<:-3?N>^BCC*A5LL(G;.3 1/>#6Z#[%^A-YK&N.\4
MNW)>!'/I&U[\M=WRMAHIUTI8^>3:=P;YRTSQSIRO0#,/,$OT1FBG>:1IJGZR
M24U^LDE-(MS7RSRHX+=!]B_0CT1^8F1Z56<98XN,II-QU8&JFXW^'?R2!7V:
M5ZHCK[@\8[[NX9F<&MW^5R]535PV1#8.[Y<3 &O6!S Y1-W=T'V+]#27\.,;
M_#OY#,.18X5S,%EEA6D(TG[@1U]P>,W&5Q^9UD4B4@W"5X!Q,FL\0C5@Q[ZK
M%41(-*QNW,IF$Y>YN@^Q?H:2_AQC?X=^](-3K1'-OI9^(W >)!(JY,H/.17R
M]-0-)Q6=S>-36#0+A)!SD'%JC<+ZIP)BE$7C:!C&=W%(IP!==JG%I\NGN;H/
ML7@W<E Q++*3;ZW<F.F8RD[MX)F(GH=I9&L(_.5\O)?PXQO\._=<)9V;=(5_
M\H7.,2_V#Q>45:S\1MID\=A']CVFROJYL=Q,9!<4O1$J%RN6R2BB-B<3C,#B
MN!$>0R?<>+&"W']L+*1.S+'% 0[NZ#[%X/?(@IG)BQZVK-D,NWS,O<>V$\I.
MB;NS3%.O%F'?DU1O.[5B-<-/J# JS!]DE_#C&_P[]RZI5*]MB%$JE; ][O#R
M]_O L'QMU#)NOC%7("1S2?N!'7W!XI=TZE5#P#H YJ>X)=K=*-NE<JT6Z4TT
MN8^/A(-*IZ@834^YN@^Q>"DI<2?MVR#);\VI OQOA1Q8AMG*WTW1;;\RWZ T
MPU5^JS5^1D9C*>9CZ@-UJ7*)1#5,^UK&)#LDOX<8W^'?NHXQ"[>[J.(O7B9M
MZFA7>4S&13F 2+XX#Q(-)^X$>+-06"$XJ73A*!L(V0_2F-0T3N"RN+Q^;QRN
MV=XUW&0CKM[Q=C4H:93%+W-T'V+PFZG_ *U8<^$3R:PLE1DDE(5:QW9Q^&[<
M9 .ZA^R2_AQC?X=^[AK?(/U#M]*U6XC^]_O L_$;@/$@AV]KHU2<7(2_KK-Z
M8P>&K@AU-J;,J,_*K9E==;..W/=W0?8O 2AW2H!PP<?_ #_;/6O\_P!L]:_S
M_;/6MPW>\VJW:@A&7?6VED1&S_/]L]:_S_[/8:_S_P"ST&HJ[D\()N*,ANHO
M?<Q.N8Z#\PJC :(K%=DE_#C&_P ._<>A6Y!%MFW&&_MO;@>[P\NRE%HI\^ID
MFLLF^>!HU0D9Q;=.J=P58S5CE'+QC )=6(=C>"^OG..>4DKF2.S:ZZX6+;=W
M=!]B\!\PN0@[Q(TZ?/U=/7JZ>O5TPUZNGKU=/7JJ0Z"E2Y_+)$(6?1?L]Y<+
M5+-LC;^)>974BFA>EIW^13UO6U,<FI>/<4A7'Y=R5G5$^ID8W^'?N-Q@+7)K
M=CT79./#=:-#AETW?98MTBL:N^+43@9EM$ZU;?XMJ&TX2:TKYI5I6[0+E.UG
MV[[NZ#[%X#YA8#?YB1Y\_KU]>OKU]>OKU]>@Y@/RR?CY)]GOO=F=AC#2EQ6*
MQ>!Q>^I#^:LM6@D>R4OL&CWT8A_</;PU32Z3L?>Y$^PR]94Q8Q^;Q,?./Q%E
M17TT>%D[FE'*"6NU.PJTCNP/,.;A[UMXB5>K5XGD>WL%=QJ0,U[O6Y\4U3$<
MPY^7^86$0WB!,;GUFUUFUUFUUFUUFUUFT!S<_EE/'T3[/?FYE&W4$T^V2_AQ
MC?X=^TZBQ[2+>&23IH-HOH"$MPGUT]'"<N>GG7D>[;=5VX<NSN;9WZ]9Z53!
MM)LI/EEV?PNWJP20A6Q$BM;R#;)9X&?12.Q" 2?E_F%O]Q ^GO%]/RR?CZ)]
MGORL=*6F)E-VR7\.,;_#OVV5C;+R:# 8-7X' <>_SD"T+*PJ0-NU-APCB.$B
M6G16?W#ME=89"+CMQ0>)#\@U?,*QV4<2FD4K1SJ!8-C&JS&MT'V+P'S"W^X@
M?3WB^GY9/Q]$^SWYQ8-QFM7?;)?PXQO\._;'?,62BD?] 2-/55JZ8PI@<WA)
M"H]=K]DG+;F6+*NIMA8M>VL>^[N@^Q> ^86_W$#Z>\7T_+)^/HGV>\KCJNDE
M)5/@DKN1+4NNVCYMUV27\.,;_#OVPQ-3O5AQZHR:MHRJ;L@+R5:+:Q&-^H.!
M#GW)WMH\S*S9V9$"L"-9W=T'V+P'S"W^X@?3WB^GY9/Q]$^SWKN[M;"U<"!-
MHN%A#>,I8F,GV27\.,;_  []BKSU!*I>*#38Y -YQ[D9S%)>2\/L+D;-A>%$
M-*Q6*C;]W"-FMB'.:)J>[N@^Q> ^86_W$#Z>\7T_+)^/HGV>\HD[@%>GY*,#
M&-IWX[9+^'&-_AW[)29:IAX\XZPML5C^/FX-?,.I1HT;:CPTCMXF \57BA[,
M]EIS-WW=T'V+P'S"W^X@?3WB^GY9/Q]$^SWY0D3MTX/;)?PXQO\ #OV20N*=
M5,ZD#(IFXNMM-"3UV>%566J^O88LI*M2H6U<O*2@RB9?68E=Y6LE!G,=&](O
MHVB[;)MH$M4^[;7O#7V:P[P[DG!#W+V\LL=:.XQ6$=YT=H4+ZZK]W=!]B\!\
MPM_N('T]XOI^63\?1/L]YYU?2;YGE&[C5NU(;MDOX<8W^'?L=BX"^=R4.]_C
M&7F8P4"L]E7&SK<(13K C',^1W57&M@UU0>.+<=I"7ZO0B*<!(HR"4.F]12Q
M;I"N$?A<XHD^F+.13I95JFW037XUF7HX(W+0?7VJ-/89681XXM;?3137VE%.
MRM%LN[N@^Q> ^86_W$#Z>\7T_+)^/HGV>](=G<5(E@,CL32"4UAJ6TGWE8G*
M*W>X0]%#2*W1\1DLG'.G4HQ[[%"BJBIG^Q>U[MC(93E*4A>,E_@L,H6J;BF9
M^']57BTX(]0@"7Z^U>+9,-HCYF/O$R5RTV;,/':G$GN[H/L7@/F%O]Q ]'/^
M7K^7K^7K^7K^7K^7KF0-?+*" SZ)]GR.Z3&*;DM<8^>VA-I?VK_[<$B\!:PO
M:5L6HCMI<K1/-RC8[HR5+W2<14+WF;AS8U2D7C98M,*E,+; \0FW(0*P479N
M*K/(VC4H%"IELD3GVZ6&3D!P7\1:X!]79NG-FOWDV],X^$X<O/+9^23[6=EW
M=T'V+P'S"W^X@?3WB^GY9/Q]$^SY.2_AQC?X=]*_)IO<.=G>OW?B;>DG[*]L
M\E9YW#8]1X2*J2P\0LWPSBW:FMY6*YT&T;\(LNLV3IOGK,9C%)[$9'#J!RT5
MQ!B 8>G1*?2/=W0?8O ?,+?[B!]/>+Z?ED_'T3[/DY-U*5&-S>ONUK11RG.N
M'N=%.L$TEBRC8;RT"HC.;,YN6^2+3-_J9;6K=SV%9V5^"K8;R7HTCERBG$PK
MH.@A&80M&J6O25KN)1%N#V*I7II&XQA9SLDZ;3/-/B+;+MU<OL];HUEK&.HI
M)*I.,D=T,:V:>R>2030OEDUY?-RI7 E:W+HM*WKT)OC!$ UB7;:G/K@! 0UN
M@^Q>SJ+SY]F0?MB\3?\ Q$Q^T,B(_@'Q%1]YIEWVE6N5T(@&O3W/F%O]Q ^G
MO%]/RR?CZ)]GR<L\51S<7(?0 BDC&+)$V.5'):GO&5W7]>[MEI%1"2^;)[7&
ME9%I9WVXG'W .%BMQ^+JD=!OY>2&=)0,RMMR16HYW,-N79YLD^:>&,Q[F2 G
M6CW%MES++(EPEWN5Y9SZ;)/YFZD;(-9-M6N?K;T:9XFOMX+16+26.W#&Y2.%
M8PS8W!4D/M]X5+.HGX>QF2E&/T>,&R#2.4Q[6.ZC2E I<NUS=Y]>]CQ,DDGF
MQFVXW&/;V'W&R86N<;:..2AY'N/&W>   :W?E^AFK;!)JY+KM-ZWEE^K&MVQ
M#2DC<0Y941N(;+)+:?S^6_3S:*U2:W9_H7HMYM%"#?U]M)I5'\4L;=.;+ALL
M*@DY6N;A/=OS'BO22+W@1?%FA']<&:U^N#-:_7!FM?K@S6OUP9K7ZX,UH'Q9
MDNOE<%<EEC.\G/H\G)?PXQO\.^IQ[A*-A#GI';@J0CK*?,;D6#2K$L-NG4WC
ME@^<W) (^1T.]XUEY<.UMZ35Q6X!&K*-JA,TO;9')&R5'"W9KLMI&!NUBTL?
M^-S6*QN=P[1;-3@HM=E'F72K1J07F%Q>*Q>$QVLS@L(H\66,,:RA\,<;-?#'
M&S7PQQLU\,<;-?#'&S7PQQLU\,<;-4(TQRM;@   [5<TC5.!??#5'/7PU1SU
M\-4<]?#5'/7PU1SU\-4<]?#5'/01KCF I%K&R0%8 Y!Y.2_AQC?X=]/3M=82
M6,E4YLB+QSV)R.V\YCA2?:[:#=#!N]:[/D<5+(V0>T@LG?=6'$<LU&5%^8%7
M*8ZA<FR5E3N,ZND4EKJ]RV-QMOBE(G\Z/,.??-4 HVN2L;ZG;9*QO:.!72*5
M5QD%@E<37I7-&O3 0$/*R7\.,;_#OYCCZ-]IOY'N3N1HZ;:?FA-#;/V^HQ[C
M<1YAYM48* >YC Z.6W!&?'7OYC9=\P?S-H*0+E0(7L8%FKUA#W<[@5'+;2B8
MW4-HGSJW5]O$N<BMN@AZ/*R7\.,;_#OYCCZ'Y@_G'EW ;'9^1Z+W=$OMX[@D
M.KAW]D_(*K;\4.WE.*5F=(4P'[YN8&9O:9;O$[?K([(%^V^WBH=NN?<R;UQX
M.S_2DSX0P.O8O+ OH\K)?PXQO\._F*8>DNX-NP-1M\N4[COHQE&FA5N5A->)
M4.Y:HN8,38"S(HSPC4[6YPX-S(U-;Q23NHMLUN,3Q=R]L]WB1[DNO"&9:!G0
MP_<W(]PY/;=[/M8Z:.>9LX-;K+:SG?6!TXL%.%"17F9BI7+Z1>Y>\[;3$5V^
M<EVXC.GMQAKU#MQ;<TVL;N%12\HCGDE8X^ C]*K"8)C/B]1>OB]1>J<TLR+T
M?%ZB]?%ZB]./,LN+;S$S!3=;$_%ZB]?%ZB]8^9U>JYWQ>HO7Q>HO3J3.KX9M
M"R]1G3\7J+U\7J+U@9H9*X<[XO47KXO47IY9I9C!-D:7:**;XO47KXO47I,3
M1S%VY?Q>HO7Q>HO3R33S.";@TNT44WQ>HO7Q>HO22F?D;Q;?%ZB]?%ZB].1,
MZOBD\,O$6&OB]1>OB]1>D?,ZXOE#\7J+U\7J+TY4T+[%8OXO$7KXO47KXO47
MIM9I9G*5OB]1>OB]1>E)+!1YC/<*?ET4T%,3=,>9>R+D5-#;_8!>S)B-N_R5
M=-SH3JM2XF=\8,IMSOXVL<UT]$RY!O)'?;]AF[R-0&W*UTVW&?\ @S#E-PB9
M+N/BN9D3$W=&ID;(R"FV=D$1-[:;4\\I,%V@YILBQVX# #;UNTM,IS=YS=P@
M]>1-VOLAA,PE9;?+SWM/);;OE'&C;!UAY';;;]2*<EX^RA/290/QV3CR+]XA
MH-LM['QD/#SL87<V5<F-T/LW99@NU%EOMM1_E9(V*O9#W<SE:\&X_P!BEEC*
MY%;H$!9JS)6#HZW!W1DDS,29*R>F1B8),&I7/6;%:+*J3R?W5MOS<B<2:4W=
M;CSMR68R&\GMT>5UF1B5^1UV0U2F/,5,3?V7]P"4DKG"U.S+ONGVG0LX-QZ2
M*6AV^]Q*.)FDM(7<TP,WMNQ_I7K64FMS!PWZ:1NW?W<90)9NB')4)IP9\3[B
M2\NU%,)_GT<3A+BA2N:" ;A"-4E<!'MCDJXRH;M#+:]SK1->IER8@GIO7%:-
MDDK9-QHC\CFVQ6)L,)C4FV:!0=QW4FW"$0EUGV 9!4N(MF^1+EI99LXU3CE*
M E+:(!$V*U7S=H5TTP9IVU,X2$;U#-C@O*2"C&V4BT7">#& @TD>RGM91XI2
M.[)T04;V?;?L0TN39)N>Q.[9<(43*'LE9$Y RV1\5XNMW$9K.QE-J./K$NUV
M*.-S>*F2$4MKQAHBN1IU&ZP#P-@Z>TLT[CW2+3E='H[2LBPU*XD.SVW%#:/T
MEM/$UR;?%HG8VHF+<A-MFW"*9UN-.'"9B'8=R*6W.UL5G$U.*";?SS2+E[4#
M?NLG&Z;Y&-*WVF;VC4@Q6.@[M_):!:;U,W;O0LU7 =S:<AC(-!4*%&VHB B#
M&[/C.LEB8F;>C91.6WF<]S5D>YJ8X23?F,,>6SWGIZW"SV?=T.2VX'G&LW:I
MG-9&'_.%,O,N\L-YF;DD8YJ/>IDDA[?;2=5R%U3\XQ0Z*-:%0R)(?"I%*)J\
M9&,#,1[0]T@D->F!O$ %U4;-N*V68>/K:QQ2W_(;_]H " $" @8_ /\ V8M2
M=;&]4*3VCJNMAV_3+NZQJK*.&NRG\/JH?+]33:A*CP;?IEIKB9B=NSQ>JK5W
M:(UO^BTEQ):-"5FDCX2RL3W;LA:J$BA*D@5K3>!T_+<W\KK->Y"TRT%B;*&U
MN9&I<033K</=+'YG#$H@D5A-,DE0I"E3Q"=.:N:N6\)+&*F.[R=N\U/R>Q-Y
M< [Q1H@U012NE$WIPL^]IMX,7E&2O7PLT",P\91:^#7_ .<+;^ZLE^#U_P#G
M"V_NK)?@]7E[AO2M!D<FG#P6RX^^A,E6 :DLJ"-.%27[1%>&@VD?2-EK>6U$
M:VTPC#!^+CK&DG%3A'!L<"E3MKM\,WY7<_VB7IN5QV/REA:26F,NKYVNYNY1
MHK.(S3)&W"_'-W:LT<=*OPD UH#8<\^F"YGL\#<0B:QQD+*F4RRG[F\8=7%A
MCG();)7$;=XH(L;>[;B,<OHX7 8S'\C1Y&*[M+6V6=%LC%"\(2,]^5G,JR,]
MS<W:7%W<2TD>XHJ*OTD66,:WE,D\<CAP!P 1\/$&/$&!/&M**0:[]AUD('NZ
MV2VT++'P*.%G:4,>/X1J(Q0$4%3XM<R?E:_V:#4WY7<_VB7IOI-])=U';E\7
MR]D+?&QW+6JV]SEKFSF[I'2](MKI;6W6:Y-L>-I)Q:)W4@DX3D.8.8\K/?9N
MZDXYIYG:221J 59F))H %4;E4!5 4 #H)^W4/@KHU<'Z*FXL)D2<30K5T+CA
M>5(VV!DVT:H-=A&X^I@_R>Z^K;ZR?Y);_9W&N:;N\G6.VCNE+,QH /-K?W2=
M@ VDD  DZ\X$4B*]S<,%=2C@&XD(#*=JFF]3M&XT.SI=CB[&,/?7,R11J65
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MZKUALW]&8*E6&MHHW7ZAV47PZ!KLU0(:>'H?*/WV?[%-#;K?K?K?K?K?K?I
M=U=<R_E\?R Z%SMD(8:W%8.$;3QR-$JQK2OUTC ;*;ZG4UD'+&.\N06.]G,S
ML[?[3EF\5:?0']VKD&[NXI(++D]\@45.!X;C,Y2_O'BGKM:5+868-=JIP)U=
M&:K]HG=J@]0@BAK_  ZIXM(1Q%O7OZ'RC]]G^Q30^;3RZYE_2$?R Z%DK"E8
M[>2"ZDWTV0F.!33K[P/)0_\ =+J_%Y:F)VO9W4%E:J/(65JJ2!4'X)V@C;]
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M74$@$@E?&A(!*-5"0*@ZFL+ZTCFL9%X6C=0R,O@*D$$>#9LU>X^SY=M4L[D
M2KP ]X :A78U9E!%54F@.X#5H;VU24P3+-'Q"O!*@(5U\#*&(!ZJGHS6N*Q\
M]S<A"Y2*-Y&"K\)BJ GA7K-*#K.HX,U</!RE8027V2G7X4-A; -.4K4=],2E
MK;+0\=U/ E.UKTI<T75K';BXYCPJQ01T$=M;0V>5AM+2*@7[5:VZ1P1; >!
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MX[.\'; /J;];>3\]3]#M^ U_E//?W.WX#7^4L]_<[?\ #Z/_ -IY_P#N=O\
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M<PXS/W.>R=WE+*RR*39;CBAQDV.6:)Y;%;#'P"/O(Y$F:>YNG5E4H=>CB_\
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M/@86\:N\;%XF6&/FKE+$9ZYMN6LX+89"VC<K%=BSF\XM5G4?=%@G^VQJ=@D
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M>(#W$ &,@X5@UBX>%CV43$QC%$C=E'1D<V39L&#-NF!4T&K1JB1-,A0 I2%
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MX*=@]/7<*A[)P._81_\ F;ED/I[^+XPA@[_C>GK8=^MV?>RRFZMBN;V_3IZ
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MQ@ !'IS/VKDYP*M,U(E04>3=AL&434F^\A J+8[I_)).'CGR6Y"D)XSCX2
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M=;6::)(O-#&QW8&T!?+"JW=L(0)R3",.W<*>)(77E%^#9LHE!LWU;XOXOO\
M!0EV+(K"H\W#07^"IWJLQ+%+QQ[YC0,T<L4I-T)@5;R<^#,  Z+HI?@7WO\
M4/7W>X^G\'WO=<OY%VV8,6:"KAX]>KI-6C5LB03K+N7*YTT4$$B%$3',8"E
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M2+. 6<^$/"9,0.0Y@Z7- XGG9I4Y %O8+17&M]GVSE-$R+9T6;NXS\RH='N
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MS0E70D^%V"!'K3[]")2?"WT/9BK^HK/3(I//($>R@)F,)!$ 'H1_M3H/Q_\
MZJA_^JZ_2G0?_-4/_P!7U^E.@_\ FJ'_ .KZ_2G0?_-4/_U?7Z4Z#_YJA_\
MJ^OTIT'_ ,U0_P#U?7Z4Z#_YJA_^KZ[CJE!  ]/_ .:8@?\ 4#H1ZY2OJG88
MBR,F7$:IM7CN$>HR+9JZ/L7G$;KKMC'22742 3%*(@8Q0$0#L'1>X  B'?L
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ML6TI$R354H$5:R$:]279O&RA0_&34(8H_7#H"EX\X:4H   4N34(   #L
M0'8  .O\/>'_ -T]"_J#K_#WA_\ =/0OZ@Z_P]X?_=/0OZ@Z_P />'_W3T+^
MH.O\/>'_ -T]"_J#K_#WA_\ =/0OZ@Z_P]X?_=/0OZ@Z0=ML Q-NZ:K).6SE
M#*J*BX;N$#@H@N@LG E4261.4#$,40,40[@/0        !Z   ]   ?6 />-
MI.^YEGUWDF386;*0M],KEE?,V8J&5%HU=S,:]7;MA5.8WED,!/$81[=Q'K]
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M )@"Y<*)H]SA\7XWIZ6+"3<1,BW!,7 14FPD1;@KW\L5P9N%A2 X (@)NP"
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MH23A 7#!*"*5P4#)E WLR^1?(#,N*E XM\1RP/ G5;C@.AZM;;;,X)R%<P<
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MI<96][D7%;_M5>U%4;I/4BL-9F=:1TB0715'$BHKRXR70^0%:YH8]@KW,*Q
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MZUV:PK6M9YVYHUAG.+A1L&B8CB[.OXW)7/#7ES\IO$>8VK6B-A3N;Y!]B?)
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MI47E[LKZZ79W6H"-A'5PN,FD@W?VJT.(]L@M/V)X@T2(J]=&5<'32*43>$H
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@L$R\_P"8?.WDK*B@V)^*DRCFS9H@4C=ND0O_ *0W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>diabetes5_850.jpg
<TEXT>
begin 644 diabetes5_850.jpg
M_]C_X0O_17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    /  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHP-R Q,SHU-#HQ-@
M  22A@ '    $@   -Z@ 0 #     0 !  "@ @ $     0   U*@ P $
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MUH*CCTW#JV9>^K96^NEE=LM._9ZKG^T'>W9ZNWWI*:EMO4K&TLSJ*ZC9:QC
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M*<YSG8M3GNT<\M!<?ZSS[G(C.FX#+VY+,>MM[=VVP- <-Y+K/=_+<]ZEACC
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     T 0P!A &X
M;P!N "  30!" #4 ,0 R #        ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M<L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0 !
M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300        "  $X0DE-! (       0     .$))300P       "
M 0$X0DE-!"T       8  0    @X0DE-! @      !     !   "0    D
M    .$))301$       0     @   D    )      #A"24T$'@      !
M   X0DE-!!H      WL    &              %I   #4@   ", 4P!C '(
M90!E &X <P!H &\ =  @ #( ,  R #, +0 P #, +0 P #< ( !A '0 (  Q
M "X -  R "X ,0 R "  4 !-     0                         !
M          -2   !:0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !:0    !29VAT;&]N9P   U(    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   6D
M    4F=H=&QO;F<   -2     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3004       $
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MKI]S(_D;=GTE(,L%A]K2T- ;IM'+]W[_ /)329:5I].)BD9@T!6M&QQ+'.Q
M ?5;!XC7S1FN:]H>TRUP!!\BA@OW'=4-#[2(X($_2VJ;'EP)+2V"1!\D8DWJ
M1]E*B97J1](F+)))).7J5;J3++.GY+*V[K'5/%8_E;3L_P"DK*J]58ZSI>8Q
MK2]SJ+&AK6[B26.&UM?Y_P#424RZ?5Z.#16"YVVMHEYEW'YT)8/\P[_CKO\
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M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V0 X0DE-!"$      %<    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,P    $ .$))300&
M   '  @! 0 ! 0#_X0^@:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C M8S P,2 W.2XQ-&5C8C0R9C)C
M+" R,#(S+S Q+S$S+3$R.C(U.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO=&]S
M:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(B!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM<#I#<F5A=&5$871E
M/2(R,#(S+3 S+3 W5#$S.C0R.C$X+3 V.C P(B!X;7 Z365T861A=&%$871E
M/2(R,#(S+3 S+3 W5#$S.C4T.C$V+3 V.C P(B!X;7 Z36]D:69Y1&%T93TB
M,C R,RTP,RTP-U0Q,SHU-#HQ-BTP-CHP,"(@9&,Z9F]R;6%T/2)I;6%G92]J
M<&5G(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W Z24-#4')O
M9FEL93TB1&ES<&QA>2(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#IA.6(S
M.38U-"TV,#-E+31E8V4M8F-F-"UE-S1C.3)E-#,X8F8B('AM<$U-.D1O8W5M
M96YT240](F%D;V)E.F1O8VED.G!H;W1O<VAO<#HQ,#8W-64R,BTS,3)C+3,V
M-&8M.&$Q-BTP.3 T-F$P838S93$B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#TB>&UP+F1I9#HW,C8V,C9D-2TQ-S(R+31E8F$M8C=F-"TY,C!C.&$Q9#@X
M.3$B/B \>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HW,C8V
M,C9D-2TQ-S(R+31E8F$M8C=F-"TY,C!C.&$Q9#@X.3$B('-T179T.G=H96X]
M(C(P,C,M,#,M,#=4,3,Z-30Z,38M,#8Z,# B('-T179T.G-O9G1W87)E06=E
M;G0](D%D;V)E(%!H;W1O<VAO<" R-"XR("A-86-I;G1O<V@I(B!S=$5V=#IC
M:&%N9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B
M('-T179T.G!A<F%M971E<G,](F9R;VT@:6UA9V4O<&YG('1O(&EM86=E+VIP
M96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV960B('-T179T.G!A
M<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&EM86=E+W!N9R!T;R!I;6%G92]J
M<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS
M=&%N8V5)1#TB>&UP+FEI9#IA.6(S.38U-"TV,#-E+31E8V4M8F-F-"UE-S1C
M.3)E-#,X8F8B('-T179T.G=H96X](C(P,C,M,#,M,#=4,3,Z-30Z,38M,#8Z
M,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<" R-"XR
M("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@
M/"]X;7!-33I(:7-T;W)Y/B \>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS
M=&%N8V5)1#TB>&UP+FEI9#HW,C8V,C9D-2TQ-S(R+31E8F$M8C=F-"TY,C!C
M.&$Q9#@X.3$B('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z-S(V-C(V9#4M
M,3<R,BTT96)A+6(W9C0M.3(P8SAA,60X.#DQ(B!S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240](GAM<"YD:60Z-S(V-C(V9#4M,3<R,BTT96)A+6(W9C0M.3(P
M8SAA,60X.#DQ(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A8VME="!E
M;F0](G<B/S[_X@T@24-#7U!23T9)3$4  0$   T087!P; (0  !M;G1R4D="
M(%A96B 'YP #  < #0 ; #AA8W-P05!03     !!4%!,
M        ]M8  0    #3+6%P<&P
M                             !%D97-C   !4    &)D<V-M   !M
M >IC<')T   #H    "-W='!T   #Q    !1R6%E:   #V    !1G6%E:   #
M[    !1B6%E:   $     !1R5%)#   $%   " QA87)G   ,(    "!V8V=T
M   ,0    #!N9&EN   ,<    #YM;6]D   ,L    "AV8V=P   ,V    #AB
M5%)#   $%   " QG5%)#   $%   " QA86)G   ,(    "!A86=G   ,(
M "!D97-C          A$:7-P;&%Y
M
M                ;6QU8P         F    #&AR2%(    2   !V&MO2U(
M   2   !V&YB3D\    2   !V&ED       2   !V&AU2%4    2   !V&-S
M0UH    2   !V&1A1$L    2   !V&YL3DP    2   !V&9I1DD    2   !
MV&ET250    2   !V&5S15,    2   !V')O4D\    2   !V&9R0T$    2
M   !V&%R       2   !V'5K54$    2   !V&AE24P    2   !V'IH5%<
M   2   !V'9I5DX    2   !V'-K4TL    2   !V'IH0TX    2   !V')U
M4E4    2   !V&5N1T(    2   !V&9R1E(    2   !V&US       2   !
MV&AI24X    2   !V'1H5$@    2   !V&-A15,    2   !V&5N054    2
M   !V&5S6$P    2   !V&1E1$4    2   !V&5N55,    2   !V'!T0E(
M   2   !V'!L4$P    2   !V&5L1U(    2   !V'-V4T4    2   !V'1R
M5%(    2   !V'!T4%0    2   !V&IA2E     2   !V !, $< ( !( $0
M4@ @ #0 2P  =&5X=     !#;W!Y<FEG:'0@07!P;&4@26YC+BP@,C R,P
M6%E:(        /-2  $    !%KY865H@        ;Z0  #CV   #D5A96B
M      !BE   MX8  !C:6%E:(        "2>   /A   ML)C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #8 .P!  $4 2@!/ %0 60!> &,
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M   -60  $]    I;=F-G=          !  $          0    $
M 0    $          0  ;F1I;@         V  "CUP  5'L  $S-  "9F@
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M1,0E1F88_]H # ,! 0(1 Q$   #?X
M
M
M
M
M
M
M
M       !%[7)9VN::3)JC#:+Y?S2)FN66^V+D                     \.
M)U]\6SL%9M7V@                         "+"N6(G'L[8N;1X(&\>[*C
M;4UV<6[M=9]"#DG&                    !3R=?S#L; ^77]V8@YIGPBIE
M\XF4OKT1?'(F7$                      !\2,JF;.2V.ZTUM6G]J,1:Y9
M ;8HFB68                     X.08AQ;'"+?8SIMCP$)5P
M            "S43"K@VJ>RQL67U?H ")DEF
M!%.2L                       '1&G?J\A*_L:TV=L/( (F268
M             Z([I  $4Y*P=3JGJKB-UKVO+_LOBH
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M7DL_7G[Y           '4CYKDRDFMY)J !$R2S      'YP=3ZGU
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MSU7IUQ^U=Q           Z(TX,6_.K;7E-OA  B9)9@    "&#7[#_/?^?\
M_7>1^:+?28^J.)C^BU] ?X^99LVN          !3Q$ICR2<Y,=TP "*<E%A'
MSTC] R,]X_/P'1$=72?TG(MW;\VTYQG$?BP:E9<UV(#$O\__ );RL]]_4*V3
MR=+CZ"Z[T['/QKPJ\WJ7LGX-+2J#L/8OEQ?'V]ZAY[EO[E^C@          .
MAI<ZO(;/NUIYF,8 $3)+,     0H:?;=!;Y:?WF$ #K-?Z$OU._@6EUV-(
M        #JC25Q;VY;ETZ_0 !%.9*=9]<R-YKS2M]SC@!B_P/J=5Y^%OKR_1
M@ *>XSB?9W^3_1DN!:KI?0+I]T[]V2.D,<_+O$LC_4O;0          .AK\8
M-J9_8U[UQ4 ")DEF     (4-/MN@M\M/[S" !UFO]"7ZG?P+2Z[&D
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MO'O*U^>9<=0Y.-M=PW=Y+O0/R@          !P:AF#?FXRZTGEL( $3)+,
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MSFWO?JC]I;NWT-^K A3TNW:$GR[_ +O.$ #I-/Z"_P!2?X*)=,^@
M     !\SXD+=,DUU\8'4@,IGGROK]TC!NN3WE,QK0*:(V:Y//I,K>7$*6(EJ
MWN>F4.V,8EQ,+^/-+M?'F]:@          Z&O]AV9C\VM?4  B9)9A#4M^;?
MR,L-\@/@X !1/T%^H^\#]G_Z#Q"AI]MT%OEI_>80 .LU_H2_4[^!:778T@
M           !C3%J 3FK- .I 5CS3ZY,/8&&J^9*G(!$I7)^Q:5^V$6_B8BJ
MY\W9Q9L6H(H:YL<DR'SCS<F@          BKIFQYK>^=L<L]\0C.C-?53+R:
M1,DLPAJ6?-OY&6'^0'P<  HCZ"_4?>"^S_\ 0>(4-/MN@M\M/[S" !UFO]"7
MZG?P+2Z[&D              *)-9;!N;3N?3[ ZFK9K;VS)LZ58H       '
M!J&:G(;4FWH700          ,?XM$S79F,MK7:FH@HIGN@F8>^OK;&R2<&G+
M^&?FM@G\T/D  ![?[-^@^_9]2/M"(6=?L7\\OY[_ -@_$@!TFG]'#Z%?QR2W
M9-0              6^B=';2Y#?)WN.Y!Q#1+TN4W>][C*Z0       .#2JT
M=_<^WM#V             "FT>\GN?A/0.3\<STF0 $1^^('Q/SS7E  X/TQ?
MZ@              ZFIOJ;^V3MZ')P#5*P<AM9Y^.[)')P   <@ ZG(-9S6V
M]F'9U!V.0          #@BJIL>E52Q1,S)3?7L<OY2UUV/I*[*L8--B^D12L
M/S$J&7!B]%L8XRV>I:^R/,G'^^TR)3BP>9+QJ\3&'^/8MQ:,RXQ9-WK72
M        !&M&2":-G8D:D<T99][X(O:WB0K>[4YLY&K&^S9 TBN+S;>9_9%:
M'7O&I1*+/5MDI9X\)@;X<A9J(0<>;%J)N_::,K:M9QVQG)?F<4ZUL7(
M     .#6?Q;6<=\=C<=_;O3&^F;%^MO63?J];FQ6B3,*^..+'FOU-;U7B=6^
MK$W3+BI&6^BO68MO2<=)R8H4ODM>M)4F4?)KQDX]JR*EG*Y]L79X_+&<8
M        Q639*MJ&FV4LX\J48J+XBQ->0OXICU%O&3>*\8=UO7A]HI>^ZV6.
M>MGIRN89'3CN^"RJ;:E%UM[LSBW"_DQP9Z30          #@CCKES6MCL)#&
MFN;*>V*Z:/UGBGERO8178\V?U\/IRNBCZ%ITXGTR977QXC5RU!-<CU+8K7*F
MM,0R+F+1)^<+?IOW,54@                 <'(      .#D
M
M
M
M
M
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M,4#ZD$PA ";N]+,$ (0LH  O:'0W+Y5RA[:;[OUAQ[3D 2EZS0 #M+!B :
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M(M%,XZ*(MC44M_L5?4"/:;76,N*V[6EC)$DM/(XF$"%ZT3@:7//\69T(B 0
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M"\#ZZ3$^YLW)3ISCH#1L5NXX:K;'VYOW=VIY=C'RJ?1_R)_)R'E-[NPOY/\
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M75["6DTSW$K1O)(Q#AE+/&AHC*M5R J:FO*TCH4*%)+W<)$T&@T&-[ID*
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M'(L4JAXVV:SJ&%:UMT-2&&=>.8Q?Q[KRK83M=)&DSF%!),D+!H5DE4+(ZQ,
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MI)D2YC I,FJ-31_N:@<<4'"M/#4\,)R$=X3_ !>UJ;D6VE]9MP0#*#IT: 2
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M9(C1!"3IHZTIN9.W[1<P^]PBV"S3Q2&U84G><M$T8GC/M1QQZE= 59U:AQ+
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M Z/"TL\JI$O%F( 'I)R&)+;=+]3M':*6>.?LU#*:J&=6 XT-">(!X@8$:;I
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M5^Z.%KTC !X4^K$LI*^;C@Z4D )\^*>1;S_8;G\1)XP].+/^(3]POEJ,>&>
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M7CX0IXG'#.M,'"@BN=/DK@]GF?!GY261AZ,=&6!7K/SG :H\WQX=ADQ% >G
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MBYAW/:]WM;S;RD]C</;SZ9;^VMY4UH#5'BF=2IRJ0W$#$%NK,RQHJ@L2S$*
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M9#X\'K^L%?)@RFAP07-#C4Q)/D7=Q^L>U?WA;>,_WI^;',?Z4O?RN;RA6(J
M>&/HMQRSX88^%F+@ 8H?+ R@5PZN!102*"F=,$$FH6IQJU>QI!SXY]& .@_-
MB0_^FM/3GA@*Z H(Z./VL&.G#YL,1Q#4]/U84(!\_#"_P!.D9D#!#L&;K'#X
M?9X^1=W'ZQ[5_>%MXS_>GYL<Q_I6]_*YO+64?2J,$CAY:37/!SXBGQ8(-"*
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MAJR^;*N6*DY^13#4>!^;%?+/-XV1Q](X^D<?2./I''TCC,GQ/H#U8^@/5CZ
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ME84LJX!+U?41_;1\Q#>'9#<#UMJ;56N?KY6WN(O)/WU//W5A0M;BN>X^^?9
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M$IO4+HM[Y1_"I^('GG(C4K(]L-\5?X+R^GI+3+6\,8CI:'MV!:-:\ZMC,%C
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MHC@=H89/F6!1.=K1UHE[;GL\RE;/>HM2$1:'HKIG$U>OM0@)\C@%7RCY9T)
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MC]Q_4+U ,++7)(J7O<7(D.9$RK=9-RT=(JI'2<LWS)RD55!PB<BR"I0.0Q3
M ]23VEP#EO+S"2#>3L$W8+!;+&\9-5#J-(Q2?M$E*RI(ILHH)R-B*E0*H(F\
MOF$1&YT^6J#%[6=#GGEGND0HI(BWGYYZY8O'DD],DZ*N599S'('$$SD)W3#P
M]O14QHSI9MZ94Q:.KK?W;$Z "02MUF#JTK,U6Y03*'IG3$@%#MV[>'5BMT5
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MD>1+]Q"S;5VP5=QSTI5$#B03IJ  E$!ZS^D8)\+;X8,)Q?T_?^67$3/;1K>
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MAU&V\N/6(,<CN,DWFBFQ'L-3+!K7"3O4!>4X]&KA)#;A;D;Q1VAG M@2]Y,
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M1(AC^82@/5HT-*HU].Y7:LQ=-M]B*P2"2LU6A%'ZL3"3J@%\LFSCSRKD$O5
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MO  $>N;%^W/XJEFX4S_&#D)I.6Y'Q_Q>[\>ZS6<+SRA%26SW<-4DM#K%H=;
MYU:,<)6 7J;YI#)L5 9(JD$BQ$<<V;>/L.5OTZOH$&.B5>/2@:SM-6H^@6.E
MTO<8.KIB)ZG':Y68-O-IQI@)[M[T($*5(4RA\GB1^\.E_P MNE_DG,3_  7$
M/^(_(.OR_3\DWZDWZ0]<"O\ 8J3_ %MLWWQL^Q6W2+9D=?H=62EW-]H-0B=
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M3[A];RB'W.8@&.5,/<\3'N8#" B'(W(1 @>4!'N<? !]@=^O"3;]O_P'@?\
MY ]?Y4;_ /4//W#K_*C?_J'G[AU_E1O_ -0\_<.O\J-_^H>?N'2GEDVXF],_
ME#T7@=S>0>P=Q0[!W'K@6!3@H7^)-(?, & /,:V68Q@ #  _5$>WYWW[_P"L
M0Z,8A0*8_B8>X_6'N(]Q[C[>YAZ5*V$I5_36(F=0 %)-82""9U0\Q5!3*<0$
M?+XB =8]QLG^5/&[7HHD!-[KR,KM8XV3-$F,^P!.6=5J@MF]C<Z?8&RMSU&Y
M)K1\:F5$#I-H:0>J)^F1,I_R^'X/SON@ ?\ U@\?P!XCV_#VZP_G%?K9E(\0
M>0?+8./4=QTBL_=-[YG>77O69S#L?UM;833BSBQ79:V1+26GH<T2FP"-DC(M
ME"+M_,?ZX]S (@(]@ !["(=P ._8!^ZKK.1\E\@XT4')8&X7G<;/KF.O]<9/
M*9"PWOZ2L,V872G+1#V+]U74\I!=*OCG3133\X@!L]NO,)_4W&SWI!U=',74
M*@O2&M5J%D4+)4BK3D&O,3ADKC%5Q9 9?RKB1-^HHB4.R0&-]RRST#6G]SG(
M:!EI.&J$6[8,)&U2S)BLXC:ZQ?RBS>,8.IEXF1N1=P<B"(J>=0P$*(]<X]2Y
MM#F>%1_%;DAHM,L#>&GPEJEE^6U'+,RT1NWLEX,BT+<;%%-+DJ61>MFJ"*[W
MNBU1$I4_/S-;;!ES3&JSE]WQM;#<_>I&_C#C\AU;*&-_JTWJ[@CQRQ;7BXL'
M*4NI%HE(:%;/4F:WF734,/W+4_H<1%V"\,Z[,N:; SDJI!PDW:D8YR>O1$S,
MI-7RT3%2,L"*3AR1%8Z*1S' AA#RC4^//(/4\7Y/730.)FG<B+1D.*9FMF-F
MPZRT:>K<96XN/L\M;)V-L^;Z3-3[FN0KV="-D'$E&*.O% K@B/.S,.3- H64
MO\!M?'UM1<TI-A)>7-/KFKX^CH#B/N6B(-H^/M]N%VX[N3L6J,>V[ D@98O=
M4WW,PJ?%6]95D4/(S4T^VC7=#J+O2+!5ZS&L6GV!!YOG 2<!"3M@M4FZ5!=[
M)/DFL8V:";TESJE*&.7N[;YAF8Y_,\PM\XT:+\0V*R"PZ!G<S7,@)84<XMN<
M\>6,ZO-S+[:[+!.H1>3:/)&NPKF'=N"G.W=,SEQK=-?AZ]%W&^1UA=IR-2[M
MZW>JI&6Z?A*+J41"*OI-[4FVHTV-8SPPKM=1Y$'D#-5O*HD8H?>P=B^8/,'F
M[#V[%_MA]@^;P^;Y^N6.$\G_ (9NJ\^LXM>^Z,M0]6(]X?1U-T_C[+3QIO-:
M';,TT*\P#Q2-S-%RHQ9C*)/E'":9%Q%,QA*%#EYO!9WC$^"&-%$PBQKT=:2S
MF,@G:\/#0A0S:6G*,C'_ &4R25:)1SDZ"+50A.Q3 )2_)XDC],%I@_H[=I@_
MU_NG_P#EYY(/_P#D%MW_ #?*^%N/_P#L&H ?HXKO'W>8G^"XA_Q'Y!U^7Z?D
MF_4F_2'K@5_L5)_K;9OO_,=IU+/CVG2\:72<YM9!M]ZA2UM5"61G$C?8E<LT
M17ID"2B!%.T@T=@/;R#W)W+US9Y 7N5KMAN/*75Z/*5Y_"-GR;JN8AD^7UVA
M9EG\PL^23*:0AIH+#**E;>9MZLV<X"*AE/D (#V[" CX=_J@/<P=OI$O@'T#
MUF/%[1KQQOGOAJX+RBDN46:R<6A?R<J;-&0U\G]<QW KM$O&(YFE7,\TV?!2
M1G$%S.Y:'C62!$6ZHN5#^(=A\?T_TONUG$(Z5@8VB3NW8G8MQ93HR)#6S$\_
MOT5?KG2812/;N>TU:G%:9LP!P -3-5%BJ#V-V$P]O$1#\_L ?I?=_,ZYQ8IR
MDEGMER?E=S-_WGHF+RRV6FBST="Q=0R&-K-?M$RT%JLX?L+5F9GJZ*(J,52"
MA[3E, <R=U/M>O:=6N026/Q5%C-/V70-,L+2)HE'C8FPRFCFMG]P35Q"RM54
M(623.LLRKADV "0A!*/W-":XP^J$7KSFF65OE\IH#:3>T6+OZT.\3J,E<&4*
M R[RM,)TR"KU)M^WJMR'*00,(#U>'_*AWP?T&.UQ"0M^W<@<Q?\ ("P<JMEU
MM K%I4G-LE]&9QM(BLSJ<(HZCHBOQ;9K'0+!)!%@W3]1R=3G;R G;!6Y.J\J
M;!QXEJ/!1*4F6>K+?(,::YO/IVI1XBFP56E9=N+AH+0ZA0;B '['\/NYOE_$
M?2<)H^3.I.;=\FZCK4_K].E=PJ0H,6T3C[>[8XP7ME7S:T(KOB6G[/<Q\G(M
M?2:).4VZKHJG#W;*/ _#SKO+;A636\MS[!:FSVFO<)7G&_4H:K5QLUIYGD>_
MT3-=CIT?28U)I(M6JL>+$SUB9,470&(C0-'GJ;.Z=<M(U3;=/)ET2^KF-UW0
M]HO,QH%LJ>+UB4#[4KN85Z4F3(QJ#H1<K""CE8"JKG(7[VI]5QK2G>'V[D?R
MCXU<4GFXQ96_V_CM0WC38FGVZ_U59X(,V5L902ZS6-=J?WF\=IKD$%$R&#A/
MC5JM.W6OA]QOX_<AZ599E_R<TV VR6U.\2.<&S:Y6*TUN6B9O099DTC)Q8R[
MXYFC9<Z8"@=,?2ZR=UI]GD]"L68W';\!9:M+KG=/M<J.";'<\JI&CN'QR@:3
M=V"K5=L#IWW,+IXBJJ8PF./W8GB9PVXV5[D5N3;)2;UI\AH>L(8_EF8YL_M+
MZGU*.D+(E7+=,3&A:--Q$@2+C4&9$D&S%5VY5*CY0,OJ#"AVC)[;4]"T#&=>
MR2YK1[VRY;L>46)S5[_2)"6B%%(>?;QTF@55G(M!]!^Q717*4GJ"0O7$C]X=
M+_EMTO[I_P#Y>61_\0>W_*^%O_\ ,'H'\BV\?=YB?X+B'_$?D'7Y?I^2;]2;
M](>N!7^Q4G^MMF^_[;IND6B&I>?T&NS%ONMLL#H&4/7JQ ,E9&8EG[D0-Y$&
M;1$QA  ,<X]BE 3" #NF!;&I7:+GVP65Q-<"#O4$(9^M6ZRQ]Q=YM;WBB:/O
MMYO<%'IVB/(JIZGK+NV"8&%-NF("(=A$ $0]G;O^;X_=$P^P/S?G\ ]G?YQZ
MQO <K8PNB9?D4RF]YWN8I./FI=*.N$6=C!T*C/R.?2B[KF;-V%GETS'*94"(
M1YO3.9<.JEI6<VB&NM"O=?BK53K;7GB;^%L5=FV:3^*EHUVD(E5;.VBQ3![#
M%\0, & 0#[P,(>(@ B #W["(!X=^P"/6,X3QF<MI^K<9;?!WSF8Q8&B'HZFT
ML$2NW5X^0D@J5^C%/*Y4)9:8D'!0(Z;SWV:W[%!!T4^?[=D5GCKEFFH5:(N-
M-L<6NFNVD8:8:D<(^H*2BA6[YH<3(.4##ZC9RF=)0 .0P!][:!QUW:MJ6C--
M'C$6$PT9O5XJ<BWS!\VEZ_9ZM.-!!Y 6RJS[%M(1CU$?.V=MR&[& !**N(73
MXU>[3W%%S%FK<I$QO'G'Z[RPGZ6NG[FYJ\ERKCO^V6DDZBE#ME[ UB$YE0!]
M4%$U>Y^LZPC%ZFPHN5Y358RF46J1WO"C>*@8E $D2J.GBB[V1D':HF<.W;A1
M5R[=*J++'454.<?N;AHG+C2(+%LIY;\2\/4RO6;T9U$9T>Z\;[7IL?>LP=6@
M[9:-9W=U":"PF&;155(SUH4X(%45(8H\KN2*4)88"@<P^>_)7DEBK6TP\A7I
MF7QBRR-=J%"NJT%+(M)*+97]A23S+)-=!%4S!X@H)1\X"(=<2.'MBY$U*#Y-
M!-WO-38S*Q-O:7!.]RNSZ(NPJ[I!:MIM&LBLFZ3'S'5*CY3 ;S>40$>A[>WL
M/;\WJ%LVKV$:77K1P$S2&K4W(P\XXBIN5A]ZV)W+QS%_&QKULI(1C:0;J+("
M8%2IN"'[>4>_7_G9 _\ <MM_S!U_YV0/_<MM_P P=?\ G9 _]RVW_,'7_G9
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M[V;?XJW_ '/K^]FW^*M_W/K^]FW^*M_W/K^]FOY[5O\ N?7U0*4 *4A2D\"
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;@F0 $1'Q_J+W[!W^GMX_D_@ !^8';_T8W__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>figure1.jpg
<TEXT>
begin 644 figure1.jpg
M_]C_X  02D9)1@ ! 0  E@"6  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      "6     0   )8    !  .@ 0 #     0 !  "@ @ $     0   <:@
M P $     0   4(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ !W_V@ , P$
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M&@]"/6NYLYQ^U3\7/&\/QMM%U6+P=X,2[TN)P5%O<&,.;A>GS$\^E?I-XO\
MV"OA3XM\9ZCXF.J:KINEZU=1WNI:+:SA-.O9XNCRQ[>??FM[XK_L5_#CXF^(
M(?$UAJFI^$;[[$--NFT>80"[LUX$4PP=RX&*RC2?L.1:7C9+^27LN3G7FY>]
MIKUW.NM6B\2ZJVNV_P"\G4C-0?DHIQ[:VVN?DA\/?''B']HKQ#\ _@K\7?\
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M3Y_Z$WPM_P"!2_\ QZO1?^&&_P!E#_HG&G_]]3?_ !RC_AAO]E#_ *)QI_\
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M6^&__8+7_P!#:O;_ (F_\DW\5_\ 8)O_ /TG>O$/V)O^35OAO_V"U_\ 0VH
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M7H%%*W0=V<QX:\%>$/!L4L'A+1;/1HYSND6S@2 .1W(0#-=/113<F]R4@HI
M0>ASB@D 9/ %(8M%9YU?2@VPWL ;ICS%S_.K:SPNYC2168#. 03CZ4 2T5&L
MT3LR(ZLR]0""1]:BCO;.:4P13QO*O558%A]0#F@"S13'DCC7=(P4>I.!3P<\
MB@#B/B;_ ,DW\5_]@F__ /2=Z\0_8F_Y-6^&_P#V"U_]#:O;_B;_ ,DW\5_]
M@F__ /2=Z\0_8F_Y-6^&_P#V"U_]#:@#ZFHHHH **** "BBB@ HHHH ****
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M(48K"@U&C.G_ 'VUZ.,5^:9->+E6A4_N)/U4I/\ )HY+XF_\DW\5_P#8)O\
M_P!)WKQ#]B;_ )-6^&__ &"U_P#0VKV_XF_\DW\5_P#8)O\ _P!)WKQ#]B;_
M )-6^&__ &"U_P#0VJ2SZFHHHH **** "BBB@ HHHH **** "BBB@ KYU_:C
M^.X_9V^$FJ?$9=+EU6:V&R*- 2BR-PK2$=$'<U[YJ>IZ?HVGW&JZK<):6=JC
M22RR,%1$49))/05^3/Q,^)'CW]O'Q?=_!+X(9L_A-9S"#Q#XA*\7@!#-#;$C
MD<8R*&5!I.[5SX3^$_[;_P >/ 'C'7I?#6B6/B36OBQ?BZ6!2Q$%Y* @<;?X
M%7&<\<5^D_@_]AOQ9\4M5LO'W[8'BV?QCJ"?,NBQ,8]-A&=R#:"-Q4^M9/[#
M7[.OPN\ _%'XM#3=+6YN_!VN?V5I]Q/\[Q0+$K';GH2Q)S7ZGURX.G5A3Y:L
MN9ZZ['N\2XW XC%NKE]%TJ=H^ZWS:I)/6RW=WL8'ASPKX<\(:;%H_AC3H-,L
MX5"K%!&L:@*,#@5B_$3X=>%OBGX7G\'>,K=[K2[ET=XTE>)BT9ROS(5;K[UW
M-<#\2_".M^./"=QX>\/^([SPI>S.C+?V)43H$.2!N!&&Z&NH\ ^ ?^"?7P(^
M&_A_3_$?Q!TRPFBUK3?$>MZ=#(UQ*RK;)+L"E"VTG'&2,^]?IVWW3]*_+O\
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M7S)\'?VBYOB+K6I>%?&'A*^\&:UIL(N6CN\20/ W1UG4!#]*;X,_:G\"^/\
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M]*T2WM[NV.Z.15PRGVKT.OBS_ANSX1_] /Q/_P""::C_ (;L^$?_ $ _$_\
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MV&R_Y]X_^^!_A5JB@"K]ALO^?>/_ +X'^%'V&R_Y]X_^^!_A5JB@"K]ALO\
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M[9HI^^XJ.M[V\[:.WH] G[O-S:6M?ROJK^JU/H*N&^*'_)-/%O\ V"+_ /\
M2=Z\]\??M-_!/X9>)H?"'C+Q)#8ZI,%/E8+[ YPI<J"%R?6N@^*7B[PK'\,_
M$9FUBSB^VZ+>O"))XT,BO;OM*@D$@]L41]Z/.MMKA+27*]]SS;]BC_DU3X:?
M]@F/_P!#:OJ2OEO]BC_DU3X:>^DQ_P#H35]24 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%>6?&*\^)6G>"KC4/A8]A'J]LPD=M2SY
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M%VPO/%FLVNDPMG#7$JQ@X^IKI/%/*/VEK3[7\,KAF\#1_$%+>9)GTV5Q&NQ
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M_)JGPT_[!,?_ *&U?4E?+?[%'_)JGPT_[!,?_H;5]24AA1110 4444 %%%%
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MTGA'R/\ ";]CCX9_!G2KR]\*PB\\87D>YM:U ?:;@7)7!D!;.!GG KYS\'?
MO]LOX7_%_6_&>E^)--UW3_&-]!<ZN6B$3%;=/*0(.V$K]1)98H(FFF8)&@)9
MB<  =S6'I?BOPSK:-)I&J6UVJ,48QRJV&';KUH W(?,\E/.XDVC=CUQS4E-9
MT12[L%4<DDX%?&OQQ_;6^&7PHOCX/\/>9XQ\:3EHX-)TT>=)YP'"R%<A: /I
M7XC^.O#OPU\$ZOXV\4SQV^G:5;O,YD( 8J/E49[L< 5^&'[-?[<^K_#OQ-X_
MAU7PC/J/_"=ZG<:[H&G6:!YY)KEL2H2!D *H->W>/?A#^U'^TYX6G\;_ !U'
M]D^%+-UO+/PE:.4DN5_N7$@Y&,9KQ[]GKX;^ _@U\8[+Q/XJ\/O;6]G(;NVU
M6XOCLTU9_E%HJGAP@SD]\UY6,XQR? S>#QTVJTTN3MOZ:^B=SU,)PYC\5#ZQ
MAHWA'XON]=/5GU<OBG]OOX]S6UUX;TFS^%WAJ_!C=[D^=>(AX+;3T..E=)X9
M_P""<WA?5'&H_';Q?JGQ U!)/,3SYW2W7U CSC!KZ*\2?MC_ +-_ABSDNKKQ
MO87#1\>5;R>:Y/T6O%)?^"COP;NKJ2P\,:/K6O7 ^6,6MF[*[GH <=Z]4\LZ
MSXX?"/\ 9K\!?#AK?4O D4T/RV\,>FV8END=U(60*.3MQDFOEG_@FS%X(T:T
M'AO7/!-]I'C6TEOS%JMY:F,3V;2YC7S#_%@CY:N^/_VHO$_Q%N)(M6\#:CX(
MTRW4 ZE>,T$OEM]X*M8VG6/QJ^(_C*P\+?##Q@GA^P\I6EO9?WLF&'&U3W([
MU^89AXDO#YU')/9I\S^+FM%;:/3XO+S7<^[P?!<:V6O,N=Z+X>77KJO[OGZ]
MC]==8\1:#X?LI-1US4(+&VA&7DFD5%7ZDFOEKXB?MR_LY_#OR8[CQ+'K-Q.2
M%ATT&Y?.<8(2O&O#_P#P3QT[5)[JY^-7C[6?&HN.?)-P\$ ;.<[%./PKZC\
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MTNUTNTTVV*VBA$<PINP.G..M=5%:6D#;X84C;&,JH!Q^%9OASQ#H_BW0=/\
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M+\R0XSD^E7X]>^ 2_ME_M S?M&&VNH&MY8M+^V N%N-H^YZ$#I7AW[&GA_\
M98URYO?%?[2'C(BST:[9-,T:9V,)B4Y#,O/RD< 5R93%581JW2<X1FWO&SNN
M6W625OUT.G,*GLY.EJU&7*EUO92NGTC?\5W/Z-_V6'\!M\"/"8^&EO);^'%M
M$%H)1B1D'\;>[=:^A*X#X7ZEX$U;P)H][\-/)'AIX%^Q"W&V,1=MH]*[^O5Q
MT^:M.3OJ^N_S/,P,.6E%:?+8*PO$VC2>(M O]#BO9=.>]B:(7$!Q+%N&-RGU
M%;M%<<X*2L]CLC)Q::/P^^ 7P]LOAE^WS\5?!_AFZGO9X_#CND\[;IY)Y$R6
M)]2U?+#>4?V3#HD>W_A8?_"?9$>!_:._S>#_ ']N/PK^BZR^&?@/3?&EY\1+
M'1+>'Q)?QB&>^5?WTD8Z*Q]*Y;_AGWX,?\)K_P +$_X1*Q_X2$2>;]K\OY_,
M_O8SC/OBJPUX^RYW\,81?_;E7VBMZ_"RJLTY3G%:N3DD]G>E[-W^;YO^'/Q#
MNFCTU/VG;/XHF-/$=SIEH+(7N//?Y%"^1NY)W?W:^OM$_9<\*?&;]C3PKXC^
M*45Y;^*=%\,3[+E)7CF"112,B.,@$<#K7Z!^,O@)\'OB#K]OXH\9>%;+5-4M
M=HCGE3YP%.1G!&<'UK?^)%O!:?"WQ3;6T:Q11:-?*JJ,!0+=\ "M,-/DH>S>
M]H+RM!22?J^;7TZG/4IWG%IZ)R>N]Y**MZ+ET]?(\:_8G_Y-2^&2_P!S1X5'
MT4L/Z5\._MV?LX_&S6_C)8_&3X'^'SXDO+^QCL+V LH5$@^X1FON+]BC_DU3
MX:?]@F/_ -#:OJ2N6M1Y[:M6=_7R?D%>A3JTY4JT%*,E9IGX_?\ !/\ _91\
M<^&_$GB7XD_M$^%C:>);AT6S\\JR)&/[@7TZ<U^O,-I:VV?L\*19Z[%"_P J
ML44Z5+D35[_UM\AQI4X)1IP44DEHNP4445J6%,DBBF4I,@=3V89'Y&GT4 >)
M_$OX'^"?'>@:S"NF16^K7MI/%#=1#RW25T(1@5QT;%?SJ:S^SC\9_#FC:C\)
MKCX9S:OXIFDDC2\*[TN Y.)_,/?G/)K^I>HS%$9!*44N.C8&?SK.5*+/(QF1
MX:NTY1LTT]-+M=[;GP=^S_\ #O\ :=^$WP8\,>%+N]L+^YLK2%7@N ?,M_E'
M[K(X.WI7J47C;]HBPD"W_A&&]49R8&QGTQFOJ.BDZ?F5+*W>\*LE\[_FF?$7
MQF_:H\8?"?X;Z_XLU#P)>07>E6K2*7PT0DQ\NXC^'/6OSQTW_@H1^T)HFO>%
M-0UK^RM4M/%,L47]GP F8><,KY8'IGFOW.\3>&M$\8:#?^&?$5JE[IVI0O!/
M$XRKHXP0:^-_AS_P3[^ GPX\?6OQ"LK6XU&^TXEK..Z??%;'.047_9[4<DNY
MC/ XOF@E7]V[OHKM6T6QV%I\+/B3\50NK?%'6Y--TZZ59%TRR)7;W D/KCK7
MT%X4^'WA#P5:BU\.Z;%:]-SA078CN6/.:[.BG&FEJ=6%RJC2?.E>7=ZO^O0*
M***T/1"BBB@#R+XV_"6U^-?@2X\!WVKW6BVUU(CR36FWS"JYRGS<8.>:\7_9
ML_8[\/?LR7<H\'^*]4O]*E20&PNBAA\R0@F3(Y+#M7V+10 4444 9EYHFC:A
M,+B_L+>YE48#RQ([ >F6!-3V6GV&FQ&#3K:*UC)R5B147)[X4 9JY10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C?=/TI:1ONGZ4 ?
M'G[!_P#R;AIO_8<\3_\ I\O:^Q*^._V#_P#DW#3?^PYXG_\ 3Y>U]B4 ?__7
M_4OQG^Q-^SGX^\37_B[Q/X5@N]3U*3S)Y3U=\8R:Y<_\$]OV56_YDVW'TK[9
MHJ8044HQ5DBI2<G=G+>"_!OA[X?^&K'PCX5M5LM+TZ,1PQ+T51VKJ:**TG-R
M?-)ZF<(**M%604445)04A95&6./K2U^7'[3?B[Q;\0/VKO!O[.EKKM[X=\/7
M&FW&HW4NG2F&XEDC#;1O'\/'2LI5/?A32NY7_"+D_P $R^5*$ZDG916OS:2_
M%H_4<$'D5PWQ0_Y)IXM_[!%__P"D[U\7_P#!/+XL>+_B'X"\5>'/&%[)J<W@
MS6;C3(+N4[I988V.TN>[8[UZG^TOX2^/.LZ+KFI_#GQG8Z#H,&CW7VFTN+0S
M22E8G+E7!XRO KJK4U%JSNFDUZ-)K\&9)N\H25G%N+]4[/\ (TOV*/\ DU3X
M:?\ 8)C_ /0VKZDK\HOV5_AY^UGJG[//@2_\)?$S2M-T>;38VM;:73VD>*/<
M<*S9Y-?0'_"K?VU?^BLZ-_X+&_QK(H^W:*^(O^%6_MJ_]%9T;_P6-_C7SQ^T
MIXH_;7_9[\$6'BJW\>Z3XBO-4U.UTRWLX].9&>2Z) ;.?X<4 ?K)17PGI?PW
M_;=OM,M+VZ^*>C6TUQ#'(\7]F,?+9E!*YSV)Q5__ (5;^VK_ -%9T;_P6-_C
M0!]NT5\1?\*M_;5_Z*SHW_@L;_&O%?B;J'[:'PW\:_#OP=)\2=&O&\?ZE-IR
MR_V<R_9S%#YN_&><XQ0!^H]%?$7_  JW]M7_ **SHW_@L;_&C_A5O[:O_16=
M&_\ !8W^- 'V[17Q%_PJW]M7_HK.C?\ @L;_ !KQ7Q)J'[:'AWXW>#_@RWQ)
MT::3Q;87]Z+K^SF'DBQ )7;GG=F@#]1Z*^(O^%6_MJ_]%9T;_P %C?XT?\*M
M_;5_Z*SHW_@L;_&@#[=HKXB_X5;^VK_T5G1O_!8W^->+?"S4/VT/B=XG^('A
MJ/XDZ-9'P'K+:0TG]G,WV@K&K^9C/'7&* /U&HKXB_X5;^VK_P!%9T;_ ,%C
M?XT?\*M_;5_Z*SHW_@L;_&@#[=HKX5U+X>?MG:5I]UJ=U\6M&$-I$\KG^S&^
MZ@+'OZ"O"/V</$?[;O[0?@V^\;KX\TC0["#4+FQM@^G,SSI;-M,I&> W:@#]
M8:*^(O\ A5O[:O\ T5G1O_!8W^-'_"K?VU?^BLZ-_P""QO\ &@#[=HKX6U#X
M<?MJV%A<WQ^+&C,+>)Y,?V8W.Q2<=?:O+O@3)^VA\;?A;HOQ,A^)>C::NL"8
MBW_LYG*>3,\77/?9G\: /TZHKXB_X5;^VK_T5G1O_!8W^-'_  JW]M7_ **S
MHW_@L;_&@#[=HK\N?CQ?_MH?!#P5;>,9OB3HVIK<:E8Z=Y7]G,F#>RB(/G/\
M.<U[.OPO_;590W_"V=&Y&?\ D&-_C0!]OT5\1?\ "K?VU?\ HK.C?^"QO\:/
M^%6_MJ_]%9T;_P %C?XT ?;M%?ES\7+_ /;0^%6I^!M-E^).C7Q\:ZY!HJM_
M9S+Y!G5F\SKSC;TKVG_A5O[:O_16=&_\%C?XT ?;M%?$7_"K?VU?^BLZ-_X+
M&_QH_P"%6_MJ_P#16=&_\%C?XT ?;M%?EQHNH_MH:Q\=?$?P2'Q(T>.3P]I=
MGJ9N_P"SF(D%VQ&S;GC;CK7M7_"K?VU?^BLZ-_X+&_QH ^W:*^(O^%6_MJ_]
M%9T;_P %C?XT?\*M_;5_Z*SHW_@L;_&@#[=HK\N=6U#]M#2_COH?P0/Q)T9Y
M-:T:XU<7?]G,-@MY1%Y>W/.>N:]I_P"%6_MJ_P#16=&_\%C?XT ?;M%?$7_"
MK?VU?^BLZ-_X+&_QH_X5;^VK_P!%9T;_ ,%C?XT ?;M%?ES\'-0_;0^+C^,$
MB^).C6'_  B6NW>B'_B7,WG&UV_O>O&[=TKVG_A5O[:O_16=&_\ !8W^- 'V
M[2-]T_2OB/\ X5;^VK_T5G1O_!8W^-(?A;^VKC_DK.C?^"QO\: -K]@__DW#
M3O\ L.>)_P#T^7M?8E?%O_!/R'4+?]E[0X=5F6XO4U?Q()I57:LD@UJ]W,!V
M!/(K[2H _]#]_**** "BBB@ HHHH *^0OC[^R_>?%'QOH'Q5\!>(?^$3\9Z!
M%);1WAB\Y'MY<[D9._7K7U[16<Z:DTWNMON:?WIM/R949M)KH]SYZ_9N_9^T
M3]GGP1-X:T^Z.HZAJ5Q)>ZA>,-IN+F0Y9\=ASTKW^XMX+NWEM+J,2PS*R.C#
M*LK#!!'H14U%=%6JYN\OZMHON1G""6WF_F]6_O,[2-(TO0--M]'T6UCLK&T7
M9%#$H2-%'90. *T:*\_^)WC:X^'_ (/O/$MGI-SK=S#A8K6U0O(\C\+P.BYZ
MGL*PJU%"+DS6G!RDHH] K(U?0-%U]+>/6K&&^6UE6>(3('"2I]UUST([&OSQ
M_80_:.^+OQW\7?$ZR^**16@\/7RPVMDB!6ME).49A]XCWK]):WJ4G%1;^TE+
MY-77YF2DG*45T;7W!117S?\ M''X[R:!8VWP3O;'1BTN[4=2O<-]EME!+,D9
M^\:YZM505W_7F^R75FU.GS.W]>B[M]$?2%8^H^']$U>\L-0U2QBNKG2Y#+:R
M2(&:&1AM+(3T)'&17PW^PU\<_B/\7[7QIIGC>^AUZV\,:B;.UU>%!"+L <D1
MCH!7WY714I\JB^C2:]&KHPC.\I1ZQ;3]4[,***_/7]L7]IC7_AMXS\'?"#P9
MK5KX8U+Q2[O<ZQ>*'BLK>,9W;3P2U<\ZMI1AUD[+\7^2;-HPO&4ND5=^A^A5
M9%QH&B7>L6GB&YL8I=3L4>."X9 98DD^^JMU ;O7S+^RCXM^*'BGPWJK?$+Q
M%I/B^VMKIDL-6TMU(N8>WF1K]QAZ5]8UTU:7(TO)/[U<PIU.9/U:^X**Y/QQ
MXG;P;X7U#Q&EA/J;V<9=;>V3?+(PZ!1[U^9G[.O[8'Q=\;?$GXNM\3K)=+TC
MP;9F[MM," 30J%W .W4EAU':N55H\TX_RQE-^D5=_,W=.7+%I?%*,5ZR=D?J
M_61IN@:)HUS?7FE6,5I/J<OGW3QH%::7&-[D=6QW-?C-H/[7_P ?-'T/P+^T
M!XIUJWO?!OCG76TS^Q4MU5[6$N51Q*.6-?M1:W"W=K#=)PLR*X^C#-=7L9*G
MSONXM=FDFT_E);&'M8\_(M=+I]&KN/YQ:+%%><?%;QW=_#KP9?>)=/T>YUV[
MA7$-K:IO=Y#PN0.@SU-?G=^R]^T9^TO\<_#/Q95X+-/%FBWC6^E64P$45J2<
M;9'_ (MOO7/3GSRJ1@KN$>9_>E9>?O+R74VG'E4')V4I**^:;N_+1GZJ30Q7
M$3P3J'CD!5E(R"#P0:SM&T/1_#UD-.T.SBL+4,7\N%0B;FY)P.YK\KO _P =
M_P!H7P)^TYX7^!_CCQ-:>/IM<LS/JD-E L8TJ3&<%T^\![U^LU;<EZ<:J=T[
M_@[/\>JT?0R<[5)4FK-)/Y25U_PSU045\,?MN_M%?$/X'_#V^E^&/A^>_P!8
M-N\QOFCS:6B+U=ST+>@K6\$_M%WNB_LD:5\;OB#*M_JT^GB;9$NTW-PP^5$0
M=R>PKGC6BZ-6OT@TGYMWM9?)KUV-I4VJE.EUG=KY6O?MNOEN?9TD:2HT4BAD
M<$$'H0>HK-T70]'\.:;#H^@V<5A8P9\N&%0D:[B6.%' R237YY_\$[_VBOBI
M^T-HOCG5_B?(GF:9J@AM(5B$9AA9=P1L=2/>OTAKJJT7"W-U2?WI/]3&-1.4
MHK[+:^X**_-[]O+]J7XI_!'PT]G\+-"F6Y1H6N=7GBW6L$;N%PN>&8^E</\
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M/CYX,\ P_%SP[\0=0\2W4>J^7="WMD_L(1E^(TD(WG(X%?HAX9_8(EU?P_\
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M;;UYKZ^^*_[0'CO]F7X)?"'X7:3XLFN=0\=06\DNM740,FG6C*F5C100VP'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>figure2.jpg
<TEXT>
begin 644 figure2.jpg
M_]C_X  02D9)1@ ! 0  E@"6  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      "6     0   )8    !  .@ 0 #     0 !  "@ @ $     0   ].@
M P $     0   H$     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ #[_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/-M3_8^T37=%DM]6\;:]?:NU_I]_#JDTZ/- VF9-LD:%?+"KN.3MRW<U8O\
M]D;PM-X;N]-G\5ZW'?ZI=R7FJZF+A1-?>:GEO'.-OE^7L&  HV]017S%<?\
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ML 8ZGBO(O$?B?X\R?&C2X]"@U1?AUK5O#KLTPA(GLTM8R); H>0TS;3MZ]:
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MVK*//+/G+ $?*.PXH ^B/#W[4'P.\5:I;Z+H?BFWN+V[,@CCPZEFC3S"N2H
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MBO0_@SX33P?X2^&/C,V@FEN6:>R5W>69MSL?G  )Z <5ZE_PT-J'_1,?%O\
MX +_ /%T@/I*BOFW_AH;4/\ HF/BW_P7K_\ %T?\-#:A_P!$Q\6_^"]?_BZ
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M?=0L]-BU75-4C@N+TK<[=R2Q*L!W#>V24,G3'X5[S_PT!>#D?##Q;_X +_\
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MIVOFYM'U23]K%-=-K)_9T'A P"XVGRC,]Z&,>[INVKG'I7TC0 4444 %%%%
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M+C3;N+["^K3."JQQ0\*2<C/KCUK^@J')3FOQ7;X/_M7_ +57[1WP\^)_Q?\
M!5C\,]!^'TWVC]S,)+BY(=7* @ECDJ "> ,^M?M3%RN<YS3 DHHHI %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !32H(YIU% 'EO
MB3X*?"7QCXDA\8>*?".FZKK4"HJ7ES;)),HCY0;F&<+V]*ZG4/!WA;5;V#4]
M2T>UN;JTBD@ADDA5F2*8;9$4D<*PX(KJ:* .3\(>!O!_@+3#HO@K1;71+ R-
M*8;2%84+MU8A0.3ZUU3'!QTIU,=-^* /BGXK_&WQ-K_C/PM\/O@1XBL+'4M0
MU"_L]2N+^V>6.!K.V,X0 [>21C()KP75OVZO$>G>%?"ND3/IR>,9?$0TK5W#
M8M?L<5SY#SP@GGS">!GCFONOXH? +X:?&"#3X/&NF><=+F>XMW@D>W=9)5V.
M=T94G*\')K/N?V:?@K>>&=)\(W/A2Q;3=$EAFM5\H;T>%MZG?]X_-R<GD]:8
M'EOPL^)OQDUOX]Z[X(\33:9JGANUM);@R::K'^SY?,"P6\LI.)))$.Y@/NU]
ME5X)\/\ ]FSX6?"_Q7J/C3P782V6J:JTC7#&XD=)&E.YV*,Q7.1UQQ7O=( H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \H^+?P?\'?&?1+/0/&D5Q);6
M%REY UM.]M+'/&"%=7C(8$ GO7F5S^R%\#+OPG8^#[C09)+.PNWO1(;F;[3-
M/+CS&FGW;Y X #!B00,5]244 4-/LX=/MH;"UC$5O;QK'&B\!508 'T%7Z**
M "BBB@ HHHH \4U+]GOX,:IXY?XDZCX0L;OQ*TJ3F]ECWN94 "O@\;E X.,B
MO1='\,Z+X>FU&ZT>R2UEU2X:[NFC&#-.P"EW]20 /PKIJ* /F;0?V4/@[H'C
MIOB';:=<S:H+R748XI[N:6TBNYLEIHX&;RU?DX..*Z/Q1^SS\+O&>G>)--\0
M:4\T?BJ\AU"]*S.DGVJ!!'')&ZD%&"C'RD5[M47FCOWI@>*:W^S_ /"OQ)\.
M+#X3:OH2R^%]+>*2WM1))&4>$Y1PZ,'W G.<\FI=$^ GPK\.>!KOX<Z+X>BM
MM OY?/N8 SL\\N0=\DC,79L@<DYXKVH'/;%+2 \RN?A3X N_$>E>+YO#]I_;
M&B>8;6Z6,"5#*@1B2.6)4 9.:])B&$ Z5)10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?_U?W\HHKS'XB?&;X7_":TCO/B'XBM=$6;/E)._P"]EQ_<C&6;\!0!
MZ=3=BUX)X _:A^ _Q.U&/1O!OB^SO-2E.([5RT,\G^XDH4M^%>^*=P!]: &F
M-&^\,TJJ$&%Z4ZB@ HHHH **** "BBO-O&_Q3\,^ ?$'A+PUKGG?;/&E\^GV
M/E)N7SDC,IWG(P-JGF@#TFBO)M$^-/@;6O%_BGP4MT;.^\(W-K:7;7.V*-YK
MN/S(EB8GYB0>G7-=7>>/?!.G+*^H:]8VH@D:&0RW$:;95&60Y(PP')'6@#KJ
M*Y>P\;^#]5NDL=*UNRO+F6$7"10W$;NT)_Y:!5))7WZ54MOB)X#O8[R6T\0V
M$\>G?\?+1W,;+!SC]X0QV\\<T =G17EGB/XQ^!M"\/7?B2SOX]<M[*:*"9-.
MEBN'1Y6"J& ; Z\Y-;=G\2_A]J&I_P!B6?B/3YM2&0;5+F)IU*C+ QAMP('7
MCB@#N**Y;3_''@_5K:\O=+UJSN[?3R1<R17$;I"5Z^8RG"X]ZXCP7\<? 'Q
M\>^(/A[X4O/[0OO#EO;7-Q-"5DMF2ZSLV2*Q#$8.1VH ]@HKBF^)'@!;J:Q/
MB/3A<6P<RQ?:HM\8CX?<N[(V]\]*SI?BAX8&OZ#H5E+]O7Q%#//;W=NR26P2
M 98LX;\L T >C45RECXZ\&:I;7E[INNV-U;:?D7,L5S&Z0E>OF,&(7'O6EH_
MB+0_$-BFIZ#?P:E9R9"S6\BRQG'7YE)'% &S17SE8_M1_"_4/$MEX;MYKC.I
M2:I%;71C MIFT?\ X^MKYYQR!QS@UP^A?MQ?!3Q+X&L?'VBR7MS8ZAK$NB11
M" >?]IA4NQ*;ON;5+;O2BP'V+17@.E?M+_"?4_A>OQ8.J"WTEK%]1$$F/MGV
M>-BA;R%)8Y88&.IKA?"/[:7P@\7:7)J<4>I:9]EU&TTVYAOK1K>:WDOQFWDD
M1CQ')V;WHL!]<44Q'#C(I] !1110 4444 %%%% !1110 4444 %%%% !116-
MKWB'1/"^DW6O>(KR+3].L4,D]Q,P2.-!U9F/04 ;-%<II_CGPAJNI6VC:;JU
MM<WU[:B^@ACD#/+:DX$R@=4)/6NF,HW;=IS]* ):*S-3UG3M%T^YU;5YUL[*
MSC:6::4[4CC499F)Z #K63'XV\*RWVF:6FIP-=ZS";BRB#C?<0@!C)&/XEP0
M<T =3148D!&0":0R@?PGTZ4 2T5&9,?PFLR77=+AU.#199PM_<HTD<)^^R)]
MXCV% &O14>\]-IK$U[Q3H'A:Q_M/Q'>Q:;:>8D7FSL$3S)#M1<GNQX% &_14
M*SJZ[D!8=>*S=4U_2=%2&35K@6J7$BPQE\X:1ONJ/<T ;%%,W^@- <=P1]:
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MX[5ZYXU^ 'A;QE)KUU=W5U:WFM75I>+/ VU[>>S4I&\?!QP2#7$Z7^R/\/\
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M'_\ P62\5>,/&WA[P>_P^LK=-8OK:S:47,A9!.X3<!T)&<T ?OK134;>BO\
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MWC(&*^"/AYHOQ-OOC]XP\&:I\2=9O-)\))I]S#"YBQ/]H5F=)2$R5XQQ7WG
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ML-Y*=< 5^T@')K\COAGK3?%#XI^%O$NL#4=2TZ/5OMEI%+K-F\$%P"RAO*C
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M9XD\)>$]+O/#6H2Z=-+=%&>(X)7;G%?6BG(KXK_;5_Y$K1O^OP_^@U('Q/\
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M)^ /^1%\-?\ 8,L__1*5UC?>% '\)7Q=_P"2J^,?^PQ?_P#H]Z\[KT3XN_\
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M??J=*^+/VU?^1*T;_K\/_H-?::=*^+/VU?\ D2M&_P"OP_\ H-8"/S6HHHH
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ML5]C5^>WA&;XE2?MRRCXBQZ?&!X4G^P?8-^3;?:Q@R[_ ./Z<5^A-( HHHH
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M_P!AW4/_ $B:O1_C_P#M$?#[]FOP=!XW^([SQZ;<7*VJFWC\QO,<$C(R..*
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M;_K\/_H-8"/S6HHH[4 %?I]^QE_R32]_["$G\A7Y@U^GW[&/_)-+W_L(2?\
MH(H ^OG^[7AOQ#_Y#R?]<Q7N+]*\.^(?_(>7_KF*<0.$HHI*L!1UKZ5\.?\
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MF.7QG/3-?4?Q+ZV/T:OD_P#8@_X^/$W^[#_6OK#XE];'Z-30'E->[?#_ /Y
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M]5U)9'C,\2K&!$N]LD$]A0!^A5?''[4__'WH/^Y+_,5]CU\<?M3_ /'WH/\
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M/'5M>*-7U.WBM9Y-@PT4))08[8)-=5_PU+\8AUU1,>T:TP/UWJCJ?_(.N?\
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MO[#/@?2_!T_BHZ=XG\,>(VNTM][>'U;S$VDX\XN[';S\HK]&4^X* 'U\,?\
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MXW_:G_X_-!_W)?YBOLBOC?\ :G_X_-!_W)?YBKI[@?)-%%%:C-+1O^0S8?\
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MTWK\R/\ @DC_ ,F;Z1_V%M1_]&+7Z;T ?''[5/\ Q\:#])?Z5\D5];_M4_\
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MGKI7P&.FI+).MKK>KQB24[I&VW3C+'N3WK[2/2@#^&#X_?\ );O'?_8:OO\
MT<U>15Z[\?O^2W>._P#L-7W_ *.:O(J "O6/@1_R6OP)_P!AO3__ $>E>3UZ
MQ\"/^2U^!/\ L-Z?_P"CTH _N@A_U,?^Z/Y5POQ1_P"1 UO_ *]VKNH?]3'_
M +H_E7"_%'_D0-;_ .O=J: _+\4?6CTHK=#"O?\ ]FO_ )*"_P#U[/7S_7O_
M .S9_P E!?\ Z]GI2V!GW\G2OBS]M7_D2M&_Z_#_ .@U]IITKXL_;5_Y$K1O
M^OP_^@U@(_-:CM110 5^GW[&/_)-;[_L(2?^@BOS!K]/OV,?^2:7O_80D_\
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M>,'_ %S7^5:-9VE_\>,'_7-?Y5HU+ \5_:0_Y(%\0O\ L!W_ /Z):OX<9?\
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M%0_^3QO%W^Y;?^BQ7YZU^A7_  5#_P"3QO%W^Y;?^BQ7YZT %?H;_P $MO\
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M+#D9P: /.<]/J*_=+P,X_P"$.T$?].%M_P"BUK\EO^&!?VFO^BF:5_X+S_\
M%5]+Z;\+OVZ=*T^UTVU^)^@^3:1)$F=+R=J#:,_-Z"F!]_;A7SYXV_Y&.Y/K
MM_E7B7_"OOV\/^BGZ!_X*_\ [*N7U+X)?MN:I=O>W'Q/T+S'QG&F<<?\"H3
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M$I_C7Q_^V#\2_A]K/@[2(=+\26%W(EV25BG5B!MZX&:Q$?!^**P?^$I\-?\
M04M_^^Z;_P )7X9W;?[5ML^GF#.*0'05^GW[&7_)-+W_ +"$G_H(K\H_^$I\
M-?\ 04M_^^Z_2']D7XG_  [T;X<WEOJGB2PM96OI&"R3JIQ@<X-,#[Y?[M>&
M_$/_ )#R?]<Q73'XR_"<C_D;M,_\"4_QKQSQS\4_AM>:RLMOXITUU$8Y%RG7
M\Z: =17$_P#"ROAW_P!#-IW_ ($+31\2_AR>GBC3C_V\)5 =P.M?2OAS_D"6
MG^Y7QI_PLKX=C_F9M._\"%KZ"T+XP_"N#2+6*3Q;I@94&?\ 24Z_G2D!['17
MF7_"Y_A1_P!#=IG_ ($I_C7>:=JEEJ]I#J&F3I=6EPH:.6-MR.IZ$$=14 :.
M!28%+10 5^77QT\?^.]+_:,OH=-UV]L[O1[KP[#H^EQ,1;WEO?2E;YVCQB3"
M]3_#BOU%K"N_#.@7^JP:Y>Z?!/J%J,13O&K2QC_98C(H0'Q/\9H_CIXH^*'@
M77_#_P -VN=.\!:I=79D.H0H;R.: PC8I7Y.3GFO!_VW?AU^TA^U;\*+3X=:
M%\-?[#GMM0CO#/<ZE#(A5%8;<*H.3FOUMHH _DM_X=0_M??] 2R_\"T_PK]%
M_P!@K]GS]IK]CW_A+3X@\ )X@_X2/[-Y?V;4(H_+\C=G=N!SG=VK]NZ* /SG
M^+?_  T/\1[VPN[/X5/:"TC9"'U.%B=QSV6O)O\ A7'[27_1-A_X,H?_ (FO
MUP8X!/I7COQ#^-&@?#S5M*\.7%E=ZMK>LAW@LK&/S)O)B_UDK D *N:M2 ^/
M](^+WQ=_9X\$PMXQ^%<\L%]J5O9QO#J4!S/>.(XE(V]"W4]JX3XT^"/VC_BI
MXP'B>R^&GV*/R$B\M]2A8_+WR%KZ@_X:7^%'C77D\):[HEZ+5-2^QP7-W;C[
M,VIVZ^:D0.3B08^7/>NS\*?M-?#GQ'IGB35;V630X?"D\=O??;-JA6F^YM92
M0V>X!R.]2P/S1_X9^_::_P"B?I_X,8O_ (FOMOX:>+/C]X#\$Z5X4N/A'+<R
M:?'L:1=5@"MSG@%:^U+*\@O[=+JVD66*4!E=3E6!&0015JD!\(ZKK_[0&H:A
M/>I\)9$$S%L'5(./_':SQJ?[08()^$S\<_\ (4@_^)K[^HHN!\JV_P 5?CQ!
M;QPGX.3GRU"\:M;]O^ U/_PMKX[_ /1&Y_\ P;6__P 17U'10!\2?$WQ;\??
M'OP[\2^";?X1S6LNNZ?<6:2MJL#+&TR% Q 7) S7X%O_ ,$H_P!KYF)&AV(R
M3_R]I_A7]9]% '\S7[.G_!/;]K'X(?&CPM\4]2\+6NI6WA^Y^T/;Q7L:/(-I
M7 )& >:_9+Q[XT^/GC#PM>^'X/A%-;R70 #MJL! P<\@+7VG133 _(P?#?\
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MX_XN_P""-GP>TSPMJVH^'M<U>\U2VM99+6$NF))E4E%/RCJ<"D!_-S7Z&_\
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M!]-?\*B^%W_0J:;_ . L?^%.'PE^&*C"^%].4>UM&/Z5Z'10!Y]_PJ?X:?\
M0LZ?_P" Z?X4A^$WPS/7PQI__@,G^%>A5&\JH<&@#SUOA5\,%!(\,:<<?].R
M?X5PGP]_9V^''@RQU2RFTFTU(ZAJ-U?AYK=,QBY;<(EX/RIT%>"?'#]J:\T;
M4[?3?A;?6D5I']N6XU:Z@DN+22^LL?Z GE])'S][\!S7V%\-?$6H>+? VA>)
M]6L&TN]U6R@N9K9^L4DBY*\\\>] %?\ X5-\,O\ H6-._P# 9/\ "E_X5/\
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M\T?8C8XY^YG=FF!^E$D\*81W"E^%!.,GT%>#_$+X/W7BOQSHGQ*\,ZY)X?\
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M?[OG<92/.6-<)XH_:^U;QGH^LZ/\%_#MY<ZK-8/J.D70,;_:[."4).Z1\E)
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M"FJ^&M NO$GCB,K=>(9&N)].E13 9@YV7GEX(CFECVF0#C-?:\<21*%08 &
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]+]_**** "BBB@
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M WPHGO+_ ,/+<7-_?HD4MW>3O<3F&/[D8=R2$7L*]EHH :JJO2G444 %%%%
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M$D4US&DBGW4L"*[FOYK/'NH_LWP_MS?&=/VFS>S:.K1?V>EJ96VW'R;LB,C
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M/XZZ/\;_  <A\,ZUIT+PM:6++#;W:."#YL8^]P?2@#Z_HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F.Q4C S3Z\G^,=G\3=5\(R:+\*KNWTW5]
M0;R7O;@%OLL+ AI$4?><=@: .;^)WQ2U#2K#7=)^%\=IXC\9Z#%#=S:.\WES
M-;.<L5Z_,5!V^_6ORS/@K6O%VFWGBKX8:UKVLW?B:[O&@@L;5+>ZT[49&!>W
MU6Y8[S'$>BXP5%>T_#3X7ZEJNIV/PO\ $4M[X,^-'@-9+BV\10AIH-:LI)"3
M([MPZL3\T;?=/2OO#X)?!^/X3Z7K'VO4&U;6O$EZ^HZG=LHC$MRX"DHB\*H
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M_12T =U10"#R** "BBB@ KYD\5_LJ?#/X@_$_6/B;\0;;_A(+G4+"'3K>WN
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M]IK6[?2H/#D31V&AZ5*PA9SG!FQ@$ G.#G)Q7Z?D G)IH5%-%P)**0$'I2T
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M?@S^TE'\4]2T[1=0T=]&O-3LKF[@#,627['<&WEV$@90D;E;N*=@/J6BBBD
M4444 %%%% !1110 4R3[AJ"ZN([:-I97$:(I9F8X  ZDFL_1];TOQ#IT&JZ+
M=QWMG<C*2Q'<C#..#^% 'Q1\7_AS\0_B#\<=+#^&D;P5IB+<)>P2)'/-J)C>
M-)9R1N,< ;Y5!Y-8/P,_9T^)6B2>(G\07C^$GGT>PT.VGT^56FD:RE>1KP'&
M 9 P&"">M?H7Y2C..]+Y:YSWI@?)?[(.DW&C_#[7M(N;Z749K/Q#J<;7,_\
MK)BLI^9\=S7U-I>F66D6@LM/@2VA4L0D8"KECDG ]2<U\Z_LO?\ (M^*_P#L
M9=5_]'&OIND F 3G%&!Z4M% "  # XHP,YQS2T4 )@=<=::R K@#%/HH SI-
M.MY/,62)&292D@('S*>Q]15N&WA@ACMXD5(XP%50,  <  5-10 F!Z4;5]*6
MB@!  .@ZUPOQ"\%2>/?#\N@)J]YHGF,K"YL)/*G7:<X#>A[UW=% 'YS^*/@C
MK>C?%[P;X(M?B3XF_L_7;:^EN,WIW;K8*4VGMUYKZW^&GPFD^'$EZY\3ZKX@
M%Z%&-2G\[R]O=/3/>N&\?_\ )R'PS_Z\=6_]!2OIJF U1M4*><4ZBBD 4444
M %%%% !1110!%+_#]:_(SP18>!$_:2L?$EM$ZZW=^*M0M)M!,\A^RQQ&0Q7W
ME8VC+EG/;#\<U^MUY*(8'E()" G Z\#/'O7QC\&_CAX3^)OQL\9>&X?!D^F:
MCH4L<46HRV8CD=#$';SI.JL3]T=Q30'VI(-R@'GD5^.VI_M6_&>T\:^*](75
M$6P:>XM[*0PKLA2/4$MO-C ^8"-&^;S.IY'%?L65W+C.*\^/PG^'#76I7K>'
MK,SZNI2Z<Q+F56.2#]3R?>@#X)\>?&77M=_8_P#&K>*K6ZUF[D?4=,2^M808
MY(K:4*D\F,!01W'%?2'ACXSZ7X:TFR\+3Z/J%R=#\,V>IS7,,!>%E,:@1HW=
M\<XJU^TMH.C^&OV7O'6CZ%:1V5E;Z5((XHEVHOS#L*]'^&M]H<GA#PWHS7$/
M]I/I%I*T&X&4Q>6HW%>NW/% $2?&GP/I_A;1/$_BN\_X1Z/7D#V\5[^[EYQP
M5['D5UL_CSPM;ZQ9^'VOD;4KY/,CMT.Z3R\9WL!]U?<\5Y/\4O@)HGQ7\6Z+
MJ_B6YD_LO1K>2);*,865Y'5\L?3Y0,5WEWX!\$Z;XI@^(#A+#48;86+S&0(D
MD.,*CYX..U(# T+X^> /$.M:YH]C/*!H5O+=33LF(7B@<QRLC=]K @URFG?M
M2_#_ %75++0K*WO#J-]=O:I"\80@JB2;B6(&"LBD#.3GI3]'^ GPV\+IJ5I;
M7<D(\0+-"R23@%X9RSO&F3G;N8MQWJGIG[.?PQN5L1!>2:A'I]\E\Y68.TEU
M"04+LO(V[0,>@I@>KZY\7?AQX:DNH=>UZVLI+)MDR2/AD; .".O0BI]3^*?@
M'1I;&#5-9@MI-1@-S KM@M !N\P^BX[G%>:^*_V9_AOXN\2:]XKU6&4ZAXBA
MB@N#NRH2+^XIX#-@9/7BM'Q!^S[X&\1ZA/J%[YX-UI$>BR*'X-M$<ICT8$YR
M.M(#;A^/?PBG%IY7B:T8WSM'"N_YG=.HQU!^M;'ASXJ^#O%7@JX^(&C7+2Z-
M:QW$CRLA0[;;/F'#8X&TUXY;?LF_"?3KV.^:*62[+JY=WY=U)8D#W)YQZ5UF
MD_!BPL?"VN^ KG4IY] U6V6SBMU.TP08(<*P_B?)R:8#?"G[2_PJ\3VT,KZD
M-,FN91#%#=8220LH=2H!.05(.:LZA^TE\&K73]3O8/$EM=OI=O-<2PQMF39;
MKO? [G'-4KC]FSX8RZKIVL6M@+5]-LC8QH@&WRR,;L?WQ_>ZURVK?L??"/5[
M::W:VE@\]75FB;:2)$2,\_[J ?G2 ]#L_P!H7X076FV>H/XDM8%O(/M"H[X8
M*,!@1V()QCUKTWPWXFT/Q=I$&N^';M+ZPN1F.:,Y5L'!_(U\\O\ LF_"Q])N
M=+\F4R7)B8S[OWJO%+YH93VRW4=Z]S\"^"M#^'WARU\+>'HS'9V@;:&.268E
MF8^Y)S0!YMX]^*GC+PKXAET;1?A_J7B*V5%;[7;/$L9+#E<.0<CO7S;\(OC5
M9"QU77/A=\%M5M[>]O9DO)(F@0R74#F.0M\W)# \U^A&P;MU?)7[&Z[_ (8Z
MP"3_ ,C%K7_I7)3 ^I='NYK_ $VVO;BW:SEGC5VA<@M&S#)4XXR*TZ:JA1@4
MZD 50U&>:*PN9;6/S9DC=D0\!F4$@?B:OUP'C[1O%>NZ/]A\(:W_ &!>^8K?
M:!&)<H.J[3QS0!\TV7Q/_:8?PUHNI7?P_@34+K5FM[NW\_F&PW?+-TZ[2.*^
MS8)"85+C#8&1Z&O@?48_V@['XU:1\+!\1@T&IZ7<:@9_L:;E:%PH4#I@YKZT
M^'OA[QOX=LKB#QEXC_X2.>60-'*8EB\M>ZX7K38'IE%%%( HHHH **** /_5
M_:WXF_%#P]\,;&RO->:1WU*<6UM! ADGGE(W;8T'). 2:Y_2/CEX&U>UTZ:/
M4H;2;5$:2"WN3Y,Y"YW9C;!&,'KZ<5#\:_ABOQ"30-1LM2;2-:\-7GVVPNE4
M.$D*&-@RG@@J:^<M5_9+M=9UZUUW5O%5Q=RE;5KQG1=\LUH9#&48<QJ2_P P
M'4"NBG&ZV(D['OMW^TE\*;-[!'\1V+_VC<_9(C'*''F["^&(^[\H)R>*VO\
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MS 5L/4]EB(.,NS33UVT9$9J2O'4_JCC_ &\OV699A;Q^-;<N>@V/_A7=Z_\
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M20K%!:^;>3Z?HT$L/ :WO%M'F:3/(7<&8$#MBD!]D?M8LK?LX?$#'_0+D_\
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M$K30O"5Y:+HVW,*(^T>0@VC=G'S$YK\T?C5\-]:\/>*[;6DL#+IEZNZ!X?F
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M[862:9I*VLS%(QU;:<,?4U\A?L?:_-*FN>&OO0Q%+E0/4\'^5?W5PEE%;//
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M ,>D'^XO\J .:\;_ /(OW'X?SKY_]J^@/&W_ "+]Q^'\Z^?_ %JEL 44>]%
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MMT;H198]1M([5XSX._:5^-OCS3[S4_#GPI,T%C>7%C*6OE7$]L^R0#CH#WH
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M\#'/&*\U<18Y3J5%5E>>DM=_7N=^:91AL;0EAL534H/=/9]3]3_ O[,?P=\
MSW<EKXR>^>]E$[?:KN.0AP,97)JG/^R]\([C5Y=:N?'<DCRL6"FZBV+D] *_
MG*^(-SXDT+X@IH\FHW40MU="#.^,!3@]:X'^W?$;Z-$YU2ZR'!SYS],_6O+C
M7:QL\QY5[::47+E5VELM5I;R.*GPQ@(*:ITE%3WMI?1+6WDD?U&ZK^S5\#O$
M4VGRZGX@BN)=+8M&?M$>2",;6YY ZXJ73_V4O@?H&C/IHU)$2]W-*[S(#*'.
M>N>@[8K^:KX5+XU\7>/3X:T74;F:YO7*1AIWQ@@Y/7M7Z1?M%>&/$NA> ?#5
MM=7\[3Z-9&*9ED8;V*@>O.*\*MP]@*]>6(K4TY2O=V[GU.$Q^(H993R6C5E'
M#0:<8*3234N96UZ2U]3]'-6_96_9ZUKP^/#%WK, T]-XB1;F/,;..2ASP<\U
MXBO_  3F_9AC&U?%THVCO>1?KS7\^FG:[XD#*KZK=?+=S#'G/G&![U+J&O>(
MEOKI%U2Z'$9'[Y_0Y[U]MPEQ7F61866"RG$2I4F[N*;MYZ/OY'-BI>WQ$\55
MUJ2UE+JWW;ZOS/Z=?!7[(?P5\/>&YO"FA:\U[:R(3*&N$FR#WQD@8K*T/]DG
MX.>%[0V&A^.9[2W.[Y!=QX&XY(&3P*_)C]CGQ%KVA2:MKMW>S7$=_I4]ND;2
M,Q+!Q\W)X(R:^,-=\4>(X=2DTVXU*ZB<3S(H\UP>&)P>:TGQ?F<H2IRKRY9.
M[7=]SPLKX<P."K5<1A:2C.H[R:ZOS/Z_OAQX?T#PMX6LM \,W8O;"RW*L@D$
MF23DY8?6O0*_.'_@E]=7-W^S:TUW/)<2?VQ=#=(Q9L;(^YK]'J^<G)R;D^I[
M=PIC-MQ3ZCD&<8ZU('RI\8?CM\"_AYXN.@?$5 ^JF".0_N?,Q&QRF3^&0*]B
MT31? GBS1++7M/TRWEL]11;J)C$H)WCAOKCBORC_ &ZM"75?CI/-C[FG6PS[
M@'%?HE\$+G7--^'?@73;;3";2[M0+B7S-_E!$^5O^!'C':OELGX@>)Q^)P;2
M_=M?CW/U/B[@G"8#(,MS2A.3J5U)R3V5NQ[)'X"\(J[2+I-L&9=A/EKROITZ
M5NZ;HNG:0'33+>.V21MS"-0NYO4X[UHP_=ZYJ7I7U1^6!7*>-;#3M7\*:QHV
MKW*V=E?VLUO-,Q"B-)5*%B3P,9[UU.Y?6OG+]KAPG[-/Q'EC)##1YR"#@YXZ
M8I ?-7@O]F?X;>#O!FI>#-,^+;R6US@P2?:H-]KCGY"#T-9NM?L;_#2\\4:5
MXWUOXF2C5=.2+R)WGB0E8CD'KSGO7X'_  :TG5_%_C*/1K>>:1))(=V'=L*
M,]#7W=^T'X<U&^^&\TEK+(7T>W9B5+9")@8XZ<5ZV4YSBL#4=7"3<9-.+?D]
MUZ,BI24UROU/T9?]F[X=7PF@U;XLK?V]U<M<RQR3V[;W;G')[=JW-)_9]^#>
MA:O::K9_$2))+2990OVJ 9Q_"3GH?2OYI--N]1>ZL$^TS[E=V;]XW0J,'K4>
MMW6J"\:);B8L\D>T!WYP?K7E%G]6:_#3PWKEW?RV_CO[1#<3),L<$L1\C'&
M5/0FNRUA_"LJV%E<>.K6T%BA4(9X09"1@%LG)Q7Y2_LW^#M0\'> ++7K];B"
M[U:/S',FXDK_  C&<@5^?7[5?A?Q!X5^(>E/.+J*&YMTD#%V"MMX;!!P: /U
MS^)_[$7P;^+?BJ;QEXM^+C3W4O  N;?8BCHJ\\"O0_A#^S%\,OA-9:EH?ASX
ML//8:E&Z/;&Z@PCR#'F+@\-WK^<2PCUNZTI[:VFN))F9L*';.!R>_I7J_P
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MG_'K%_N+_*LYH#RKX]?\D?\ %/\ UZ'_ -"%?B\.E?M#\>O^2/\ BG_KT/\
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M1Q%+VF(CS1IN:C*R\GN>[C_$')L+C%@,3B8QJOH_ZLCQ_P#;2_9TM;'1]/\
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M/_!,/4H]4_9XN;F*'R3_ &U>*ZXQ\X6/-?H]7PDHM-IG[>G?4*0^M+36Z8I
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M<2%D)]\=17K6J?M6Z5=:;=VL7@3Q/OGAD1?^)<W5E('?WK[!5,'.32E<G.:
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MX8+&IS_>)KSW5?VH_AKHNB0>(-0EGCM;BYU"S&(\MYVF-LG4_1N : / M?\
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M (=M_L?@;CX)B '/,KT@.;_X)>W=K'^QUX1629%(DNN"P!_UIK]!VO;+:?\
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M (^(_P#OL?XU^9?[:-U;M\0-*VRHW^@CHP/\9KZA_P"&2/A)C&-2_P# ^?\
M^*K$U3]B;X!ZK(MSK&GW=T\:[0\MY*Q ],EJD#\L_M$/]]?^^A1]HASC>O\
MWT*_3A?V%/V:V4LFC2L!Z7<G^->:_"W]@+X4Z1X>FM?B+;-J>IM>73I.EU(%
M%N\K&&/KU5" :- /B;0IX3KNF?O%'^E0_P 0_OBOW=L[VR^R0_Z1']Q?XQZ?
M6ODJ/]A3]G#>LD6BS%D.01=R<$?C73+^R=\'2WEJVH9'&!J,W\MU(#VOQM>6
M9\/W $\9Z?Q#U^M> _:K7&?.3_OH5I/^R5\')5\J07[@\X.H3'C_ +ZJF?V/
M?@>P^6WO6.,C%_+S_P"/4P(?M5M@GS4X_P!H?XT?:K8C/G)_WT/\:\ZO/V*/
M!K_%.PU:">[3PFFGRQSV1OI?,>[+Y20?-T"\5Z>/V-_@F1_QZWW_ ('3?_%4
M >S_  _O+0:"N9XQB1OXQ_C7=?;K+_GXC_[['^-?,T7[(OP<AS#"FH)WVB_F
M'XXW5+_PR1\)/34O_!A/_P#%4@/IA9XW*["&#="#D5-7/^&O#6F^%-#L?#^D
M[_LFGQB*+S',C[1TRS<D_6N@H **** /_]/]W==+!8L'&37-F1\XS72ZYM\N
M,L,\US>Z//W:[Z'P&%5:AYC^IH\Q_P"\:=OC_N4>9'_=K4FP@D;N35.]U#^S
MK*ZU&4YCM(I)6&<9"+DC/:KF^/\ N_K56\_L_P"QW/\ :*@6GE/YV_[OE[3N
MS[8S2"Q^8UK^WOXUUC2-1U_2?#-NMCIUTJ.WF>:1%AVP53D,R  'H#7U'X#^
M.7BKQ)XTUS3-:T^VBT33M*_M1)+=S)- -F]8ISTWNN2 .G>O*K7XI_L67%E-
MI.CV=K<6UM=J[I;0%09$!4NQ&,HJKDY[<XKV'X?:O\"=2\9^*]&\"6@&HQPL
M=4E7(A=)$&>IP?E/X"N9+4L^7I_VT_%/AI-0T:V\-V4#C0K35-+AC)59+B\=
MF\DCVB!;CO5[Q)^W#XM\/7%Y8MH=N]Q%J>G6\ W'Y[.X5?M$I'JC, /J*Z72
M?%W[(^A:5)#JL']HW'A72K>]:YN(297L&=X8"O\ >(#%0/3FNEU?Q_\ LC12
MW5WJNFP^=8WMGISEH3N$]YLEA ]OE4D]L4-".)/[87Q+U#P[>ZCH/AVUFO)3
M#=6*&3A+&2:6*0S@D?O%$1;:*^F/@?\ %&/XB)K8%O#%+:/;3M+ I5)TNX1(
MKD'G/4'/I7D$OC3]DEM.U8KIJ/#)>1!D2)@]S,SNJ/!R-R;@_3CK7N/PDMOA
M]%=^);WP5N\RYN8?M,3+L\D+"HAC5>RA,8K2$==Q/8]?UN:WB\)ZY->SBWMT
MM9#)(4$@1=IR=AX;'I7QS^SX\5O\5-*L?"GF:KHZV%R9[B32/L"VNYE9/+DP
M-WF$G(KZX\6>'+CQCX#\2>%;";[+/JUG+:I*?X&D4J#^%<-\'_@5JGPTN-.N
M[_QIJFN&TLUMFMKF0-!N"@;@,=L<5SU_C9K#8Y+]N\9_98\>_P#7FN?^^Q7Y
MX?LJ)H,7PKL]1E=1-)"Q+8Y,O3GZ#@5^B7[=4;R_LN>.HHAEWM44#U)D4"OR
MZ^$WP(\<VGABTL+;Q+]CTB8*\L<8RZ.0"0K>]>=G'!\.(<MQ&35<=]5A4Y7*
M5KW47?DMYGYIXG\*8S-,-1C@5%SA.]I-J-FFKNW:]UYH^DH Q@19C^[\S+8/
M.W-?.7[7>FF^^%E[+HL)>WMKJ"0ENJIG!_"O:O$/[+JWL+:EH7BW4+::;[JO
M*653C!/]:^4/B'-XN^'.JZI\*?&FK#6[34].DFAE88SM!P/J*^_X+\!,NK8Z
MAC,ISF<ZE"C*$J;3CSQ46F^VE[G\RX'P-SKAVK2S.].K&G5C4E9/F23LTGVL
MSY)^'.M6N@>.M#UC4<-;1W">:&Z;#QS_ #K]H?#6H:S#X\L8+>VSX=FTOS)+
M@C]V?,Y..V?2OQ6^%WAI?&WB[0]"D?RDGD4R,> $4Y/Z"OV(TK4%N;>WTNSU
M$36,"^4%B<' 08"X[9Q7\M_21X9SC,<FH2P].4Z%)U.:UW&/,DN;3KH['] \
M1^*>7<+\1JI+"+$8G$8>5&*D[1ASR7+)MZ:NZ?D=+I$EM#J.J6-M<B!9^(7/
M3*MD?I7YM?MS^%;=/'^G^);;#VEU"821T\P')K[P\1W.B^'+@I?:A%#$%##>
MPW9(R0!U)%?#G[2?Q*\$>,?#_P#PC.BL\^H6%R)/-92 <#Y@,UXOT;O!7B/$
MXR6?X6C/ZI[*7-*2M>R6JZNSBM?4_$?#3CG-J&.PW#T\&N2C6J7E%7Y?::27
M-MRII6M<ZW]A4Z;J,.J>&KG;YT-TL^['S"-EQ@?7;7WWXVLM(&M1Q1QKY3QJ
MSH<80KT)]Z_)']G+XC:3\-]1U;5=5@FE;4(XUC,*L6 B8^GN:]3\1_&?Q]\8
M/$=KX(^&=C/Y^I$JO4.6']YCT&/6OZ<R7Z,W%F?\78#BR6+5'!4*:LY/9*]U
M;HI+5MGI^)'"F*S'&X_*,!@?>KU(3]N]DE!72^=V?<.M65A?6,S7 2Y=MRK&
M5##;C@@U^'_B2.2UU_78Y8O(>&ZERH[%6[5^AN@?$[Q5\)=)UOPA\3"#XB\/
MSK$(R"Q*LH8$$=1SUKX6\67L7C'QY-J$""&/6KU01TP7(!./UK[['^"F?9'A
ML77KXUXG#2KJ5-_RJ=[6\G=;:'1X!9#C,DS#'83%4>6$8J/,KVDX;NS[IWT[
M'[._"G2(-3\ 6#3W2VEZEC"L08<+E!\WU]*Z?0M)T+P#X)N_#DMT=1O;Z5I7
MD)W$DG(Y-?/-]\7O O@^[L_![F>26SMXXI)+=#(J%%'#;<XP*9?_ !HT*WM5
MN]$TN_UX.P$C06[D1 \<G'7VK^1^/?HB<?9MQ#)UYRGAZTG4C.3TBE=QB[NZ
M\EL?+\.^*O$>%X:Q'#63Y3:&*DY2GR.\TV]7+M;HSP_]L>ZN?^$6\/6_/DF[
M=F/HP4;:^6O@QK,7AWXL:!J\O"R.;=_I+\H_(FOJ/]H/Q=X/\??#O[/HMR7U
M"RN$F:&0;7CV\,"#SG-?$>A7LVGZWI^M&$N]K/'(D:C)9D8$ #WK][X,\-\^
MH8? 9-F5%TZ\TXI-W=KM<U_1W/T_P=P#J<&5\LK4G&2=2+BU9^]=[>=['[5_
M$GXLS_"MM%L;?1DO]+U"%3YQ&<N>N#[5V]S)HVM>$$UYK+^SY;O'E1D8+*1\
MV5]#7@6F_%F6#2K/_A9GA:XTJRE*O;O>0&2WWD!L(P'!YZ5-%XB\6_'*XU33
MOAG,MOINEA5OM4D&(X0P_P!7"O\ >Q7\LY3]#'BJCFRI8A+#4:,G*>*4^:$E
MS>[9)_$]$UW/J>,.,LJSCA7!\+8#AIT\T4>2I4DK0BEISJ75_B?>?[%OA+2?
M!?P^UG2M%8&VEUJZN-@.1&TJ1DK^!K[-KXH_8;^P?\*LU.VL)VNUL]:NH7F8
MY:21%0,Q^M?:]?U!F4:4:\XT)<T5HF]+VTO;SW/TWAC+L1@\OH87%5.>I"*3
MEW:6X4QQG%/IK=JXF>\CY9\<::E[XYUYWQ\JVV#_ -LC7H_PUT"[L?#6@3QZ
ME,\,,,ADB<[@Y<\#/8+V%><>-;W[/XX\0("/]7;'\XS7H_P[M]>/A?PU,MTA
MM5B<SJ5P64D[ /<&OYI\+N=\;9_S;7A^1UULSC6IQH)ZPZ'KT?3%)+Q&>,TJ
M'(HD^X:_I:YQGYX?M8>$+:_^(.B>,5_L07.CV+,HU/4#:.SH6,;>6#AO+)+1
MD]&K1UF[T>__ ."?VJ7.A:>VEV4GA^7; [%R&#X=MQY;<V6![YKI?B]\%O'W
MC_XSMXCT:'2FTB+1(+;=J=N+E?M F=F"+V^4C)KHOCUINJ:+^R1XTTS7'@:]
MM-$DCD-JGE0Y&/N)V&.U#$]C\5-;U_7=>^#GP_TZQ@D_LT6S JJDAYT<ISCJ
M<=*[[X0_ OQG?ZA;Z_JH71]/A.=TYVM(#V ZUJ_"/XQ>%/#7P[T3P_?6D\;V
ML*LJFU:52_7<AP>M>N:5/\<?C! ]Y\/-":PTZ,%A>ZIE%DYQA$[5^8XSZ-_%
MN.QF(7)2PF$G*4O;5)IIJ3;TBM6]=3Z;ASZ:^>Y5PW3X1X:R&7MZ?/%U*EHT
M]9-\WFVF>"_M(^&M0\$?##3O#TVHIJ%M/K+W($?/EJ5)49[9->1_LO7^K6?Q
M)-EIWS6<\+/.&Z+L.03^-=[^TKK/CWP]9+\,_B;HT5E?S-'<6EW <Q3;#_"?
MT->*_"SQ(_A.Q\6ZU <7CV0MH,?\])F"\5^U\,?1_P 9@L'@>',RJ1K1Q*FE
M.G\,E*4KM=K75_0_GCCOBO/N(LFS+%9WAHT\95DERK6-WR1A)?=?U1]R?$7]
MHS1K'5?[+L8Y?$&MHP1+:V0N 3Q_#FNABM?C]XOTM[&P^'5S8RWL$A$MU($B
M0,OWL>_:OKC]F7X'>!?A_I\7B"VL4FOM7M+62::X0-(LPC!8@MR,L<U]?WGV
M>6Z$!8A<8"#H>*]M9=P9P_2I99D64PG&C)24ZMW+G7VK)JUMNMSP<L^CKE%U
MB,UG.M7=G*3DU?;33I=;'\F_C7X?>(O!?BR3PAK5FUKJ=P5)A^\=\AQ@8ZY/
M2OO7X7^/]+^'_@K3/#'B[3;[19].=D#36S^7*RG/#8P:]1^.?P]LKW]OOP#I
ML\6^*^CCN'0C.3#DC/XU^ME]X6\/[(H]2LX+E%.%6:-7"GH2 17G5,?E>+H8
MW"9MA.>GB-U&3ARJ][+1Z'Z#Q_X<X3B'"4L)B)R@J<N:+BU=-:+?<_(FQ^.W
M@"]U=8VO)EEN7$8D:%DB#GHI8\9-?.O[9?BVYD.C^ DCS%<_Z8TG]X#@ 5^R
M'QZ^$OAWQ=\._$GARPT>VANKBS::"2&%4*3QC=&RD#[Q(Q7X+_&'Q)#XR\)^
M%-2NOW>JZ09+&Z1AB0,G!W=^HKW\LX"R2/#\J_#E&5&.'?O0<^;22^+9>?W'
MX-@_!+#9#Q7E^80E*K";DFY;J?*W%Z?,ZK]CJ%KWQ;XI\)+*+9-;THP-+_=8
M-\H)]#7T?H/[+WBS0[ZY<:];0&5"B!'Y;/3-?&GP"\1^(?"_BV63PQH,VO7^
MHQ>4((5+,$#?>X[9[U^H%A\%OVHM<TN+Q0MOIVE$<KI\K%G88S\S]C7XEQK]
M&_.,UJTLWIYC1PU&O32M-7DW%M+1:V:ZL_J_A[Z0/'W"U;%Y7PY@:=7#U'&?
M--VUY5=+S.(^$7PA^)/PM\8R7&K7L-QX>N$?[4OF95\C@X]<U^77Q4\^^^*'
MBJ.>,13S7\B!%.1EFPOYC%?J?KNE_M-:3I%W>?\ "&1WZ67WV@FW!^/X5/7%
M?E'X@O\ 4'^(-WJGB" V]W)>K+<1-P4(()4_3%;^'/@%F>0XF>-S'&4:TL1*
M%->R?9MWDKZ;I?+R/+S_ ,5>)>+<WGG&?97##3ITN5.+3<W>^MC[GTBP\9WA
M\"?L[^$;PV=[J,$?VJ=>3%%C=(WX \5]!_%?]A#P4ME"?!ET^CWL(5+B4DO]
MJ48+L<]&)YS6#^Q+H]]XX^*NN?&F6>-K"SC_ +,M4^\^1AF;'88_.OTB\72"
M[FRYP0O(/\Z_K7Q%XZQW#^/HY;D]3V?LHKGY>LY+7FOORZ)7V/AO"_@NE@LJ
MY\337MJ[<ZCMJVW?\#\ROV2O"T_A3]O&_P!.>3S8_P"PY2C$Y)4!5Y]^*^MO
MBE?FW\7>+HRVTB[4CC./E3!Q7DOP6T"^T[]N2/598R(+G1;V,/C@LCCC\C73
M_&'4#%\0_%L4;'<+V/[HR1D)T'K7\#^.T)XG!8=RU;KTV_6[-?%;-'@\'0J+
M2]6"^^Y]P7OAS7O&7AO2P-7^RN(CO>)"@D5U7:"#R,8KT[0-&M= TJTTFR01
MP6L810.F>I/XG)KC_"^@WJZA!XE?4KB2VN-/@A%I*,*KIR9,=F.<&O3!7[%'
MX4?J"V"F"13TI]?E-\>/VK/VD-%_:KD_9Q^!VA:=JUQ_9L5^GVLE3@J6?+>U
M,9^JV]13P<C-?$G[/OBK]L;6?&-W;?'WPSIFD:"MJS0S64FZ0W 884CT(S7V
MPF=@S0 ^BBB@ HHHH ^:/$G[.6FZ]'K-A'K%S::=JVI1:Q]G0*5BOXI%D60$
M]5+*"5/!KC_^&-O 1MWBDN[EWF:)Y'R-S-$TKDCT#&4Y XZ5]CT47 ^3G_91
M\+-90QIJ$RW]K)9R0W>U=R?8H6@1=N,$%'.0>_->G_"3X.Z%\(X-0MM"EEE3
M4/(W^:<D&"/RQCZ]37L5% !7D7C#X0^%_'/B[2?%OB.V%Y)H]O/;Q02#,1%P
M02Q'<C;Q7KM% 'Q_I/['O@/2D6)9Y94CENI$W!=V+F-XBK'^+:'.W/2L?6OV
M*?!&L7;W!U.[MTF#1R(FW!C>.*-U'ID1#D<YS7VQ10!\</\ L:^!!IVEZ5:W
MES!;6.%E52,W"+<BZ4,>H(=1R.2.*^PH(_*B6(# 08'X5+10 U@2.*\+\:_
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MV<2;0QN-^ WF@]>!QZ5RL'[%'P\MS.8[RY!G,I)R,CSKMKLX/LS;1[5]H44
M?(.@?L@>"-&OK?4+J\N+^:V@DMDW[0!%)$8@, 8W*&.&ZUZQ\,/A+IGPO&I/
M8W4M[<ZHUN)9),+A+6,11*%''"CD]S4OQU^-/A/X _#?5/B7XR<BQTY<+&OW
MYI6X2-?=C7YT6W[4?[>GBKP\?BIX4^$]G'X2>,W4%M/(1>2VOW@P7KDKR*=P
M/UW!!Z4M?.?[,/[0%A^T;\-+?QU;:;/HUW'(UM>6<Z,K13Q_> W 9![&OHRD
M 4444 %%%% '!_$W3?%&L> =?TSP9<"TUJYM)$M)2<;92..>V1QFODW5=/\
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M]KO79X+^[3PL&@T>Q%Q>.L^Y1/)<_98EC('*%\%GZ!<FOKF\\#>"=1B>&_\
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M$7VGQ;?7=Q<63I9F:8G:Z\LX^@Z5\K>)OVCOVA=,UUM*;QUJD;VRE7 G/44
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M\RJ%VCWKHOV9O$'C>P\(?%#5UU*7Q'K&GP"Y@OY)9)K268QO-Y4:/C:8\[6
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MN?,9CXPXBG06.PV5UJF&E+DC527+.7]WR?1]3\?-;\+R^%M:N-(OHUCDLV9
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M\2_M0^&K+7O$MC8:!+I.DPW-U&'>3S6A@5GP>VXJ*^NJ\W^+ZJ/A3XSP,?\
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ME T_5/$OPW\0>5$CZ;>H@#!AC<O7K7V+\,/V[OB9X2N6TWQ$HO-'E #*/]8
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MNJ_^CC7T5J4S6EE<WJC<8(GDQZ[%)Q^E?.O[+W_(M>+/^QEU7_T<:^A->_Y
MFH_]>TO_ * : /PBUS_@M+=:/K6H:1_PKU9/L5Q+!N^TXW>6Q7/3OBO#OC7_
M ,%99_B_X-B\)/X'6P$=_97OF"?=_P >DRR[<8_BVXK\D/'/_(ZZ_P#]?]U_
MZ-:N6H _?-?^"VMPBJH^'2\ #_CY]/PKZZ_8U_X*+S_M7_$^Z^';^$UT06]C
M)>><)O,SY9 VX]\U_*E7ZX?\$;/^3F]3_P"P)<?^AI0!_43&"%YI](OW12T
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M=_ 98U(7)W*.#70_L1W45[^S;X5NH.8YC>.N1@X:ZE(R.U 'UE1110 4444
M%%%% 'YK?&O_ )*5J_\ O+_Z#7E5>J_&S_DI6L?[R_\ H(KRKFN@8<]:]D^
M?_)3M._W)?\ T&O&J]E^ ?\ R4[3O]R7_P!!I2V _1D]12TAZBEK &%%>._$
M7XIZEX#U"WLK/PIJ/B!9T+F2R0,J8.-K9[UX[I/[6AUR[U*PTKX?ZY<7.CS_
M &:[01#,4NW=M/O@B@1]B45S?A+7I_$V@6FMW-A-IDETNXVUP,2Q^S#UKI*
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MK%XD_P"%KP#1-2T&.&[EL(X6:6*VN)&2)^,[@V.U(#KOV7O^1:\6?]C+JO\
MZ.-?0>O?\@34?^O:7_T U\S_ +(FL66O^!_$6L::Q>UO/$.J21EE*DJTN1D'
MD5],Z]_R!-1_Z]I?_0#0!_"%XY_Y'77_ /K_ +K_ -&M7+5U/CG_ )'37_\
MK_NO_1K5RU !7ZX?\$;/^3G-3_[ EQ_Z&E?D?7ZX?\$;/^3F]3_[ EQ_Z&E
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MO3+.&&:1]3T_[.?*; L6\M;D'_:+N I[9IW#4C3X,?M.3^!_%NAZ/'-87=S
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M6BZ+I\\]AJD,@_?-/P8I(SU*<G/TKT^]_:6^#=EK_AO[9K\,[Z_@0&'Y@JG
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M'3<,C=CD9%(#OU^*WPT*_P#(T:;_ .!,?^-?(O[3'Q!\#:C?:*;'Q!8SA(Y
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M7C'[./B3XEWOP_\ $L?A,3^)XA/;);OJDK(P>:V!N@'89(24D8[5U7P4T/\
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M;QPWB6YAGMY8)?*2)0A,!!'YXYK]/**Y:M64Y.<MWJ=\(**45TT(K>(001P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '__7_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gpx002new.jpg
<TEXT>
begin 644 gpx002new.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!.17AI9@  34T *@    @ ! ,"  (
M   (    /E$0  $    ! 0   %$1  0    !   6)5$2  0    !   6)0
M  !$:7-P;&%Y /_B$ A)0T-?4%)/1DE,10 ! 0  #_AA<'!L A   &UN=')2
M1T(@6%E:( ?G  $  0 ) #$ !&%C<W!!4%!,     $%04$P
M          #VU@ !     -,M87!P;
M                                $F1E<V,   %<    8F1S8VT   '
M   $G&-P<G0   9<    (W=T<'0   :     %')865H   :4    %&=865H
M  :H    %&)865H   :\    %')44D,   ;0   (#&%A<F<   [<    ('9C
M9W0   [\    ,&YD:6X   \L    /F-H860   ]L    +&UM;V0   ^8
M*'9C9W    _     .&)44D,   ;0   (#&=44D,   ;0   (#&%A8F<   [<
M    (&%A9V<   [<    (&1E<V,         "$1I<W!L87D
M
M                                  !M;'5C         "8    ,:')(
M4@   !0   '8:V]+4@    P   'L;F).3P   !(   'X:60      !(   (*
M:'5(50   !0   (<8W-#6@   !8   (P9&%$2P   !P   )&;FQ.3    !8
M  )B9FE&20   !    )X:71)5    !@   *(97-%4P   !8   *@<F]23P
M !(   *V9G)#00   !8   +(87(      !0   +>=6M500   !P   +R:&5)
M3    !8   ,.>FA45P    H   ,D=FE63@    X   ,N<VM32P   !8   ,\
M>FA#3@    H   ,D<G5250   "0   -296Y'0@   !0   -V9G)&4@   !8
M  .*;7,      !(   .@:&E)3@   !(   .R=&A42     P   /$8V%%4P
M !@   /096Y!50   !0   -V97-83    !(   *V9&5$10   !    /H96Y5
M4P   !(   /X<'1"4@   !@   0*<&Q03    !(   0B96Q'4@   "(   0T
M<W9310   !    16=')44@   !0   1F<'105    !8   1Z:F%*4     P
M  20 $P 0P!$ "  =0 @ &( ;P!J &G.[+?L "  3 !# $0 1@!A '( 9P!E
M "T 3 !# $0 3 !# $0 ( !7 &$ <@!N &$ 4P!Z .T ;@!E ', ( !, $,
M1 !" &$ <@!E '8 ;@#] "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K
M .8 <@!M $L ; !E '4 <@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0
M3 !# $0 ( !A "  8P!O &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R
M $P 0P!$ "  8P!O &P ;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P
M0P!$ " &109$!D@&1@8I!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" /
M $P 0P!$ " %Y@71!>(%U07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4
M1@!A '( 90!B &X _0 @ $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T
M!#@$000_!#L$-00Y $, ;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\
M=0!L &4 =0!R %< 80!R &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$
M $P 0P!$ " .*@XU $P 0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &(
M+0!, $, 1 !# &\ ; !O '( ( !, $, 1 !, $, 1  @ $, ;P!L &\ <@!I
M &0 ;P!+ &\ ; !O '( ( !, $, 1 .( [,#QP/! \D#O .W " #OP.X \P#
MO0.W "  3 !# $0 1@#D '( 9P M $P 0P!$ %( 90!N &L ; !I "  3 !#
M $0 3 !# $0 ( !A "  0P!O '( 90!S,*LPZ3#\ $P 0P!$=&5X=     !#
M;W!Y<FEG:'0@07!P;&4@26YC+BP@,C R,P  6%E:(        /,6  $    !
M%LI865H@        @O0  #UD____O%A96B        !,)   M(4   KF6%E:
M(        ">^   .%P  R(MC=7)V        !      %  H #P 4 !D '@ C
M "@ +0 R #8 .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )
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M2_[<_VW__W!A<F$       ,    "9F8  /*G   -60  $]    I;=F-G=
M       !  $          0    $          0    $          0  ;F1I
M;@         V  "N    4@   $/   "PP   )H    U   !0    5$   C,S
M  (S,P ",S,          '-F,S(       $,<@  !?C___,=   'N@  _7+_
M__N=___]I    ]D  ,!Q;6UO9         80  "@0     #5&&2
M             '9C9W        ,    "9F8  P    )F9@ #     F9F
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MX#$ 'L:DC\>Z'-XUD\-IK6DMXBAM!?R:4+N,WL=N6VB8PYWB,M\N\C&>,YH
MUJ**Y/1?CWX%\2?$F^\&Z=XT\)ZAXOTU&DO-#MM7MY=2M57 8R6ZN9% R,DJ
M,9'K0!UE%%9/C3Q[H?PWT-M4\1:UI.@Z:LB0F[U&[CM8 [L%1=\A"[F8@ 9R
M20!S0!K449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK/
ME\6:7#XGAT1]2T]=:N+9[R*P:X074D"LJM*L>=Q1695+ 8!8#.2* -"BBB@
MHHHH **** "BBB@ HJ'4M2M]&TZXO+RXAM;2UC::>>9Q''"B@EF9CPJ@ DD\
M "F:-K-GXCTBUU#3[JVOK"^A2XMKFWE66&XC<!E='4D,K*0002"#F@"S1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 449HSF@ HJGJ_B&P\/QJU]>
MVMFLAPIFE6/<?09/-2:7J]KK=HMQ9W-O=P,2!)#('4D=>1Q0!8HHHH ****
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M7_K<^LR# *C2=>4^:4[.][JRV2;WL%%%%?+'OA7R+_P7L=D_X(Y?M"E25/\
MPB4_(./XTKZZKB?VD/V>_#'[5_P+\3_#GQI:W%]X5\7V3:?J4$%P]O)+"Q!(
M61"&4Y Y!H _G,^,/Q5\2?L=?\$])?V1?B#JU[?6M]J?@SXB_"?5KA6']J:1
M>WD$UU9AN@:VF9R%'I)C "U]M_M;?\%2OVH=1\<?M9?$'X9^,_ '@[X<_LBZ
MW:Z1-X2U7P^+VZ\8_,%F>6Z9@\ 8AO+$>-W"\$%C]Z_M2_\ !(;X$?MD^#_A
MGHOCSPI<:E;_  CCBA\,SP:A-;75G%&D2+&TJ,&D0B&,E7)!*YZYKG/VD_\
M@A?^S7^UC^T!>_$GQEX(N[GQ!K3VTFN06>L75EI_B-[<CR6O;:*18YRNT#)'
MS8^;- 'P_P#'_P#X+R_%K]FF3XV:=KDEC)KGCKP-X9\;_ FR?2XQ.IUCRH7L
MG4*!<-;3S$Y?)(@;/#8KE?VB?^"LG[96F_M.>._A+X#N-=UKQA\!?#.BC5;?
MPW\+/^$FC\;:Y<6L<]U]L>)U_LVT+.Z1M$ISLSGG(_4K]H/_ ()D?!?]I_XW
M?"[XA>,/",-]XE^#LJR^&)(9WMX+0(Z21H\*$))&CQJRJP(4@XZD'E?VK_\
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MRRVK/I?B?XD>*)M66&)I?%OBR]UYK6*(,(XX?M#L(U&XYVC<W&XG H ^+_\
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MVE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\.%U98?&'AO1K?Q#?6,T3Q!+"=Y8X[A9& 1TWPR*Q5CM(&[&1GX]_P""?/\
MP37\;?LZ?MS>-M=\4K8-\+?A[%J>F_!V".X662UM-:OO[2U$L@.8S%($MDW
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MV-_CN_PC_9U_9_\ $/PXTG0/#7[/WC32M?OOB#'K]M/9Z_9Z3+)+;?8[1/\
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MWA/Q%H&I>+KNVOM1\.3ZKJ\^F7LJW#1HAB2-!.HF!CB=23A,B@#]5:*^+_\
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M9\;>/_#/B37/@TGB[P\OQ.\4Z5K]_I&J-J(MHK@RVD;)9K-$Y7RF#HCJ'52
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M=O,_.KX$_P#!N;\$8_@QX77X@:+KMQXV_LV$ZY):>()EMVO"H,NP*0NT-D#
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M>^(/#_Q+\0)KLG@G1M-D_P"$5\-^7#%$D=E%<%G#LT7G/*!'F1B55,<_8M%
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M43T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3K=61XW_ ,%=?"/B#6O!_@F\MH+V\\&Z=<3_ -KQ6ZLZQSG ADE5>JX# $\
MFN/_ ."1^EZ[!\3O%UUI\-Y;^ VTP+<%T9;:6]WCR_+SP7"[LD=L9K[Z\1Z=
M=>%-8N+>6+?;R'*D8=74\X(YZ="#5*>TOI?#=Y<6]BUO8Z=$96*P^7&.0,
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MP_4P,G5IINEI9Z75UL_+HG_3]$HHHKN/F0HHHH **** "BBB@ HHHH ****
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M5"H00C<C:V #Z^HK\N/^"G'_  <9^%_@K^QIX6\9? ^ZAU#Q5XV\6GPO;_\
M"4^&-4MX]&$&#>RS6QCCE9XM\0$8.6,A*A]I%>E^%/\ @O3\$_V?OAY\/]#^
M.7Q6\/W'Q*US1K75=:N?#GAG58]+T^.Z;-O+<(\3260:-X\I<;7&<E5!% 'W
MY17RS^U/_P %H?V<?V,_%T.@^/OB#%I^L7VAVGB+3[6UT^YOFU:SNIC# ]L8
M483,S G:A)"C<<+S7*_%C_@X&_93^"'Q)U3PEXF^(UQINN:#K T35H3H5^Z:
M3.0A#SR+"4CB)D"B0G:2&&?E; !]H45\B_"K_@NK^RW\9;WQ]%HOQ/M?+^&V
MD2>(-8N+O3;NU@?3HW"-=VSR1 7,6]D4&+=NWKMR&!/>?L1_\%,OA)_P4)?7
M(_AGJFO7TWAV*VN;V+4_#]]I3"&X#F"5/M$2"1) C$%">!GCB@#WZBOE7XR?
M\%H_V>_V?_VC)OA?XN\6:OHWB*SU"VTF\NIO#FH#2;&[N$5X89;[R?LZLZLI
M!W[>>2,''F7AK_@K?=_#_P#;T_:^\+_$^XT?1_A'^SKHFAZO;W]GIT\M^B7D
M DF,NQG,OS, H2,$#UH ^]Z*^'[S_@NQ\#OC9\-OBY:_!GQS8^(OB#X"\":G
MXPTVSOM+N[:VU*.VM7E$L+2I&+B-74!Q&V<9[ D<[_P2O_X+W_"?]MCPG\*?
M!7B3QEIL'QT\::$+R]TVUTB\L]-GO45GGMK>>13$TB*N2BR,1@C)(( !^@5%
M?*ND_P#!:/\ 9[U;]J.+X/GQ9JUCXONM;E\-6SW_ (=U"STV[U2)MKV<=Y+"
ML+RAN  V"2 "<C/IG[9W[=_PK_X)_?#.V\6?%;Q1#X<TO4+Q=/L(UMY;N\U*
MY8$B&""%6DD; ).U< <DB@#UZBOD7Q%_P7*_9O\ #'P,\%^/[GQ=K+:7\0KB
M\MO#^G0^&M1EUG4GLW*712Q6$S[(64AG*!!CJ:X#XG?\%>&\7?MG?L;:'\(-
M6\+^*OA+^T<VO-?ZJUK*UP5L;<.JPDLAA=9=RNLB%@5((4T ??-%?FQ^QI_P
M7N\.Q?LDWWCO]H35K'1]:U+XE:YX+\-Z;X;T.\O+K5XK)HMHCMH?-D=U60;W
M&%Y7H2 ?L"U_;-\+_%/]AK6/C;X!UFQD\-KX<U#7--U+7+"\M;6/[-',2]S#
MY8N%C22)@X5-Y"G:"<9 /9Z*^9?&?_!5WX0_!>WT#2?&'B::Z\9ZEX5L?%D^
MF>&_#^IZL[V$Z,3>QQ0P/*+4,DF7< H-N[!(!]*\<?M>^"O"G[(FI?&[3]0;
MQ-X$L_#K^)K:[TB&2[;4;00^:AB6-68[A@?=^7)+8 . #U"BO@G6/^"VGAV7
MQ#^S?XBAL]8T7P#\7M.UF35+2^\,ZE+K/VZWL;.XM;6RA6(27.YKAUWQ12)(
M%RK  FO>T_X*;?!6;]GJQ^)T/BZ2X\,ZIJ[>';2&'2KR35KG55=D;3ET\1?:
MC=JR.##Y6\!22 HS0![W17"?L_?M+>"_VH_ADOB[P1K U;15N)[.<O;RVUQ8
MW,#%9K>>"55EAFC88:.158<<<BO)O@O_ ,%=?V?_ -H'Q[X;\/>%?&\U]<>,
M)I;30[V;1;^TTS5[N(,TMG!>2PK;R7*!6)A#[_E(P2"* /I2BO#M,_X*+_"?
M4_VBH?A;_;6L6?BJ\U&XT>R:^\/ZA9Z;J-_;H9)K2WO985MIIE16;8DA)"G&
M<5S'A+_@KY\ /''Q'TOPQIGC*\N+K6-;;PS;WQT'4(]*&K"1X_[/>]:$6Z73
M,C!8F<,WRX^\,@'TQ17A\?\ P43^$][^TA/\*;'6]4U?Q=8WATV__LW0KZ\T
M[2[L0F8VUS?1PM;0S",;BCR C@'!(%<OX+_X+ ?L^_$+X?\ B+Q=I'C>>[\(
M^%[:WGOM=&B7ZZ<\D\HACM8)C"%N+LRD)]GA+RAB%*@\4 ?3%%>%^&/^"C_P
ME\7_  7\3>.K/6]8.E^#;Y-+URPD\/:A'K6E7CE/+MY=.,/VM9'\R,J/*^8,
M",C)K'C_ ."K7P3G^%\/BB+Q!K<PN-?E\*QZ)'X:U%O$!U6*+SY;+^S!!]K$
MJ0XE8&+ C(;."#0!]&45YUI7[16B_$/]F:\^)7A>[,>D-H]WJ5I/K6G7=B(3
M LF3<6\D:W"*K1G<NP-@' .1GQB3_@KE\)?AKX*\&P^-O%*7WC;Q!X+TWQI/
MI_A/P]JNJK-87418W\$4<#S"T#(YW2 ,B[=^"0" ?5E%?+M]_P %;/A>W[3G
MPW^'.CKXB\30_%#PJ/%FCZ]HVC7E]I\EM)/##;_-%"PVN96+2$A(=F)"I8"N
M@3_@J1\#Y/CM_P *['C)O[<_ML^&1=_V5>?V.=7'731J/E?9/M>>/)\W=N^7
M&[B@#Z"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLKQ?KCZ-
MI@6WVM>W3"&W4_WC_$?91DGZ4 <Q\6_BE'X6TRY$<C1QVY$<LD9_>22GI#'Z
M-CEF_A'OT^=[^35/$6I+J4CO'+"XDA6/(2$@Y&/ZD\GO74?'LR0>)-*MXV^T
M:;!;L875PRSW!),FXC^,G'O@U^2?BS]I_P"(^L>.M:\0W7C/7=&U73KZ9(K*
M&X,5O8"-R%B\G[I   .0<UTY1P]B,\K5*5&:BJ:3UOJWMMZ;GK9AQ/@N$\%0
MQ>(I.I.NWM;W8JUU=]==5UV;5C]1OC_X>O\ 5/!&L:EX:F6TN/%&G3I9S9VB
MROS&0R$_PG=R#[U^;OP _9,\>ZK\8/#?VKPUJ7AIO#^I17M_JEV/+">6VY]C
MYS(SX(&,YSS7Z$? 'XU76L?!'0/$7B+3X6CUO1EO]6TZ1=L4CK$S[P#]PG:#
MGL#BOFOP#_P5)^(.H:?!I]U\.? _CN\U-!=V&GZ?:S6MU81N?E1Q&&#*!CYV
M*YYS7G8?C&601K8)I7JW3=G*SCH[6W3OHK/7RW^L_P"(5U>,_J^94N9QPZBT
MN>,.:,_>BGSZ)Q4?>=UI;6^B]J_:2/B#Q!\ O%]GX/63_A)+RV=[3RFVRN.
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MAW4TAMK6X634[2X);R;B*611Y<JKY@9LAAU_8FHS=Q+=+ 9(_.92XCW#<5!
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MV6FZS9)<>')+O5;>[BO#YDBI/ L<3!A$S..,*:R(?V(?CH/V7X_V43\.K/\
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MI7A'G=*$IJ/\TDO=7S=CC/V=?VL_!?Q_OM6TGPIJ%S)<6B^=-8W]HT/VF,'
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M.P[FK?@7P%H?PP\)V>@^&]'TS0-#TY2EKI^GVR6UM;*6+$)&@"J"S$\#J2:
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M%$L;AE\P !F\M/F&.?K[X@_L-_"'XJ_#O6O"?B+X>^&=6\/>(-<E\37]G/:
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M?BQID.I?%KP3H.M79@%S;W4FK?8Q</9&9K0^29Y(HX1((L#S"^ ,X';>._\
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MO'$KQ7-FL*R-*'+-Y4F_(8 ?J1X:^#_A_P"'VA>(K/PSI.GZ+_PD]_=ZO?\
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MV$<Y!QD\U[/^Q[^SWJGA3]GGQKIGC:WFATSQ%'<30Z6[;GL81 Q+8_A8LH?
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M# _Q+BO _P#@H'\+->O-<TKQ5I^D7NL1V=JVGWUM;Q&2>V.\LK[.NTY(..A
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M7C+3EL[.^O@S6]HXFCDWN%!) V'@#DX''6I&<!I?_!6WPC86GC%?%W@+XH>
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MAXX\5?"<^(M)UFQUS6+_ ,F/1]7N(9(X+2^DCEN)VL8X(XD:X7,JCDI@5M?
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M"@^#M]%X+^#WPKF\"_%"?QOK&C^$+F[N;:_MFTBYL(V,TL*-+=[IER654"(
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M%?\ "">+?#-_K=^=&,4%Y)<V5]:7B6WFAU:6020O#AE< .&7)]!^ G_!.U/
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MX D4'E60Y^]M<9!]/K7C7QZ_X);6?Q"^+=]K\NI>(]"_M202ZC#86Z36U^V
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MQ1117&8A1110!S_Q4^%7ASXW_#W5?"?B[1['Q!X<UR$V]]I]VF^&Y3(.&'U
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MF:C+'Y-M(#E"0@+R;>P(Z@9S7V1\(/@9K&CZK<:C>W"V?VJ/RR-FZ3&<\ \
M\=3R/2N[-,5@Z.+I5>'E*E:-I2UZ_P")_?T?R/!RF.,JY=B*/&,H8ARDG""<
M7MYP5DNU]4KKK8\K_9E_9(L? 6@Z7H&CV,FFZ7:-]I6.<[YYF)R;B<GN3T!P
M6P. HKZQT71H-!T]+>W4A5R68G+2,>K,>Y)[TW1M#MM M3%;1[=QW.['<\K?
MWF8\D_6KE>;&+YG.;<I2=VWJV^[,\5BW6481BHP@K1BM%%=D%%%%4<8445C_
M !#U[4/"_@'7-2TG2YM<U33[">YL].B8+)?S)&S1PJ20 78!020!GK0!3O/C
M'X3L-/N[N3Q+H8MM/U--$NI%O8V6UOG=(UM9""=DQ>2-=C8;+KQR*T/%WC32
M? .C?VAK6HV>EV/GPVWGW,@CC\V618HDR?XGD=5 [E@*_-CX&_L)?&_X*^;H
M^N>&]"UBV^)%_P"%_&6OWFB3MMMM?M-;@GU&>Z\YANEFMI.6C!4_80.N,\E\
M'OA3\9/VN/@E<31CXMW6A^(8H%UR_P!8\0K,NJ7<?BR*2"[TG,K&W$%A#-N8
M+$0HC7:SC=0!^M%1W-S'9V[S321Q11C<[NVU5'J2>E?FW\9OAG^TEX?T?2?#
M?AO1_B1J(T#Q=J\V@^(%\22W%RE@NLVS6D-R&N462-K$W!$UR)V*CR]@8@U]
M/?MG? ?X@?'3]AKXU>"[W4-/U[6O$VEWT7A^#1(9='E$>S=!;M(T[DR%E"EP
MR*V[! &: /HH-N&1R#T-9>D>.-'U_P 2ZOH]EJ5G=:KH!A74K2*4-+9&5/,B
M$B]5WI\PSU'-?"7@KX>?&>7]HOPA<:?I/Q>TG3H=5T"?2KC4]<5M(TOPQ%8H
MFI6&HP&=_,OWG$W++(Y9H&6550@2?&'X&_%R#_@H[XL\0>"=&\?::_B36?#5
MSI_B"'5DC\+?8+6QEBU%+ZV$N9'.510T3,3L*,NUB0#[YGNH[4+YDD<?F,$7
M<P7<QZ >Y]*DK\K_  ?^RC\<_$OPDTZ_^(TGQ?\ %&K>&?&WA?6]6T**Y:UD
M,]M<3C4+S3[C[<QN%9)(R43R(PL:E$#9%>S?LK^&/VB[[]I/XB7UQ8ZMX!TG
M4[ ^0GB:XGU_2DO8]4DPT(-X'9I+$H=\8AB7(78Q3- 'W57,^)OC/X3\&>)(
M='U;Q%I.GZK.]K'':3W*I,[74S06P"DY_>RJR+_>92!7PC\3/AI^T#=Z#\4(
M=/M?BI_PG5QXJ6>]U6/5M^A:IX9_M!&6VTFW6Z0Q7 M!@JODR\2J9BSJ37\/
M?LF_%K4M6^'>H:K;^*O%DFG7?A&:XU37((K/4([>S\27EW)'-&9Y6S;VLD?S
M-([LNW)+9% 'Z.4444 %##<,'D'@@]Z** /*/BCX&FN--;28FDVPN;O3AN^6
M91]^ _[2YROMCT-?"G[=W[:NN? #Q3IG@WP3:Z?'KEY9#4+V_O8/.6TC+%41
M(^A<[226Z>E?IIX@T*+Q#IS6\C-&P(>*5/O0N.C#W'_UJ^-_VY_^"=NB_M1>
M([779K[4/#OB_1X##<3:?$LBZA;9R)!&W#8))(!R,FO6R.I@Z>,C+'J]/7SU
MZ775'BY_1QU3!2AESM4TZV=NMGT9Y%_P3R_:^U;]J&W\5>'?'-K9KJ&B"'S[
MZQB\F.Y@E)"2%,X62-QGC@@FO=]-^&FG_#CQSY?BF^6XMX$,D45FOFM/N!"N
M0/NCG//-<%^SG^S-X9_9>\*7>F:#)>:E?:Q*LNHZC=8-Q>,HP  O"JHSA1ZD
MFI/C[\8H?@M\)/$'CB^MY-2DL47R8"V#/(Q$<2$]EZ9/H*\?B+#8/&9E%X"G
M\4DH+;LMNU]5V_ ^CX.P')@'BL[E?V$7)RW<7J[I]6DNSU6FNIYI^V!^Q[#\
M?QI$>F^)+JR;1[AY(+J.UW221. &1XV(^;@$$$\UU?PL^'5A\#/@]?6NF6\T
MUOHEDWE(3F>^G;+,2?[[;3^E?,WPS_X*)_$*?XJZ+#XF@T2\T/7+V.T,%E:^
M3-8F1@J/&^26VDC(;J*_0+XO^%M6\1ZA:W%])INEZ>((VM2KKNN"4&Z3RU^9
MF)SR1^-<O$63YMEF'IY?BI7I1O*,$_=N[WUT>C;WOOIN<&38/(,UG5S;A]2]
MLE*/+-I>\U9-+6]TVTD].79:(_*9/B7\0OVH/'%L^EZIKT.NR78,<%L\D%OI
M2A^0P&%557KNY->__MV>,1IB>!O"[ZEJ;7UQYM]>66G2O%/=\+';<(02SR[V
M53Q@9Z5],VWQ*^%OPC\:0Z3K&J:'<>)+AE865[>168D8_=W1KDDGT<C/I6#X
M=_9/^'_A#XHS^.M/L];NO%&IW<SSS:QJ!OA9,V"!!D#:-I(!.2H&!@5Q\:8N
MMFU.A"EAXX>$59)7V;5W?E2EM9)::MMNY]QX&</T.&LUK9MF59U:D4TH1<6N
M=IZ3?->%M[\KUM8\V_9L^#'QJT_QOI.O>*O&^L:=I.ER1RIHR3Q7EU=JO/ES
M2;-J@C@D;F]^]?1'Q'\97O@CX.>+/$&BV1OM6TO3;B\L[8H7+R*I(!'5L=2.
M^*^$?VYOVFO%FI?'CQ%X5M?$&I>%M&\+LD,,%G,;>2Z8H&,[N.6!)X'0 5]0
M_P#!.WQ7XO\ B#\"?"MQXIN+FXU34KJ6VM[J9/WUW;!L13..,G&<GN!FO<PO
M"=3(\OHX^K-2A4<7RMMO577EJMTMO,X>(N/*'&&;8C+L-1]E5P\9VE&$8PM%
MVEHM;WUC*3;>SM='R5^R7^T9\2OB+^U'X3DL/%VO>(KC6+U?[:M)IC+:"T.3
M*7C^[&JCH0!@@"OT^\#>"="\6ZCJG]J0-Y-BJS"=93'@$X*L1USU ZU%IGP)
M;PCJ4_V/2=!T>34'(DFL+>-9KTYSPJ*&;UYP!WKU[X;_  FA\-6D<EVNZ16$
MJPDAL/\ WW/1G].R]O6O4X@S*AF-6,X45"*25M-?P7R/@^&,OQ644Y+V\I3;
M;O=JU^F]]>I:^'G@R'3HH;H6:V-O;J5L;0+M\E3UD8?WV]^0..I-=;117CI6
M5D>U*3D^:3NV%%%%!(4444 %%%% !1110 4444 %5]3TJUUNQDM;RVM[RVDQ
MOBFC$D;X((RIX." ?J*L44 8OA'X<>'OA_)?OH.@Z+HCZK.;F]:PLHK8WDIZ
MR2%%&]^3\S9/--\(?##PU\/KS4+C0?#NAZ'<:M+Y]]+I]A%;/>R<_/*44%VY
M/+9/-;E% '(7WP6T&PBUJ]\.Z)X9T#Q+JOF7"ZO'HT+RK>%&6.YD "F5E+$\
ML"1D9&37 ?L7?L=R_LMVOC/6/$'BRX^('Q&^)6L#6O%/B6;3X]/%])'"EO;P
M0VZ,RPV\$,:HB;F/+$L2QKVZB@#G+'X/>$=,\=S>*;;PMX<M_$]TI6;5XM-A
M2_E!&"&G"^801QR:U]1\/:?J]W!<7=C9W4]JLB0R30J[Q+(-KA21D!EX('4<
M&KE% &?!X2TJU731'IFGQC1U*6 6V0?805V$1<?(-OR_+CCCI38_!FCQ72SK
MI.FK,ETU\L@M4#+<,NUI@<9\QE."W4CC-:5% &;<>#-'NK._MY=)TV2WU63S
M;V)[5&2\? &Z08PYPJC+9/RCTJCK_P )?"OBOQ);ZQJGAGP_J6L6<+6T%]=:
M=#-<PQ,"&C61E+*I!.5!P<FN@HH HV?A?3=/FGDM].L8)+J)()GCMU5I8T!"
M(Q Y502 #P 3BLGQ/\'/"/C?PS::+K7A7PWJ^CV!4VUA>Z9#<6ML5&%V1NI5
M<#@8 Q7244 9]]X2TG4_#+Z+<Z7I]QHTD'V9["6V1[5HL8\LQD;2N.-N,8KQ
M+]J7]B:Z^,WP%D^&?P^\4Z?\&O!^NF:T\30:!X;MFFU/3YT\N>WMVW(EK(ZD
MJ9@CD!C@9P1[[10!Q7_#./@*?X:^'_!]YX/\.:IX9\*VL%EI.GZCI\5Y!8Q0
MQK%&$616 *HH&1S@5LZM\,O#>O7.BS7WA_0[R;PW()=)DGL(I&TMP  T!928
MB  ,I@X%;E% '.V'PC\)Z5XYN/$]KX8\.V_B6Z4K/JT6FPI?3 C!#3!=[ CU
M-:$'@S1[6PL;6/2=-CM=,E\^SA6U01VDGS?/&N,(WS-RN#\Q]36E10!DWG@+
M0M0U!;NXT729[I+M-06:2SC:1;E$\M)PQ&?,5"5#_>"G .*UJ** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,+5?A]8ZC.TL9DLY)#E_*V['/J58%<^X
M&:9%\/(8H]O]H:D/]R58P/P50*Z"B@#E;3X4VEIJ$UTMU<)<7'^MEB2..27_
M 'F"Y-:$7P_TM?\ 6PR71]9YGDS^!./TK:HHLEL5*3EK)W(;/3K?3DVV\$,"
M^D:!?Y5-1102%%%% !1110 4444 <3^T%^T1X2_9=^'$GBOQKJ4NEZ+'=6]B
MLD5I-=RS7$\BQ0Q)%"K.[O(RJH53DD5YS)_P4F^"OAS6-:TFZ\4?V/)X:T^[
MU"^%QIES!# MI&DMY"K>7M:>W25&EA3,B;N5R#CT;XZ_ O3?C[H.AZ?J=U?6
M<>@^(-.\10-:LH9Y[*X2XC1MP/R,R ,!SCH17SG\9_\ @E59ZMH?QEG\'ZW'
M;ZE\4+35IK>VOM/M,Z9J6HA!<7$=\(3=(A*EA&&*@L>"ORT >D6'_!2OX1ZG
M;Z3Y.M:P;[6M;?P_:Z8V@7RZC]K6!+DA[<Q"2./[,ZS^:ZJGE'=NP#3=*_X*
M9?!W7=*U&ZL_$.H7'V/[,UK NBWGVC6X[F=K>WEL(S%NO(Y9D=%> .I*]<8)
MSOAC_P $YM'\*>.++Q;XE\6^)/&WBS[;>7FIZAJ"V\(U7S],CTP0O'#&B)''
M;1*%V!26+,Q)/'B/[0G_  1MO->^$6EZ3H/C#6O%UUH$^CZ7IUOK-]%ILFG^
M';"Y:X&G6]Q!;G]\7,?^D3I(Q6%1QUH ]]\)?\%,_A)X_FL8=!U/Q'K5SJ&@
M#Q/'!8^&=1GECT]I)(HY9%6$^69)(I$1&PS,IP.]4_$W_!5GX&^#O"FDZUJ7
MBVZMM/U:TN+\O_8M](VGP6UT+.YDN@L1-LL-P1$_F[<,1USFN7^&O_!-R\OO
MV9-6\,^,O%$VF^*O%7AS2O#^H77AI([>TL(=-N9YK1(4\L!ALE$<P90DP#_*
MH<BI-#_X))>"](^$FI^$F\1^))K?6-'OM(N;A%MH&VW>JC4Y'2..,1QXF&U5
M5=JIQ@GF@#J/$/\ P5,^"OA3PA9ZUJ'B+5K6WO)]1MS;MX?U WEHVGK$]ZT\
M A\R%(8YHY6:15'EN&R11;?\%+OAGKUII^I:5K<#:$;V[M=3N=0M[JPN+*.#
M3)-2$T<$D.^5)+9!*K?*K1G<I8_*;'B7_@GEX5\3^,_$VN3:QKT=QXICUZ*Y
M1'CV1C5[.SM)]N5S\B6493.<%FSD8 Q_''_!+[P;X\EO7NM<\21M?0"!_+DB
M^4?V#)HF1E.OV>0O_P!= .W% &E'_P %1?@S<?#BZ\40^(-6FL;6Z6U-LN@7
M_P#:$NZS:^65+4PB9H3:*\XE";/+1CGBO;/A]X[TWXH^ ]%\2Z+,]SH_B"QA
MU&QF>)HFF@E021OM8!ERK X(!YKXD_;:_P""26H?%.70[WP7??VDT5S8MJEE
MJ6I"R\U;'2)].M&BD$$J[<S%YHW0B1<JI7)!^S?@QX=UOPA\(O"^D^)+S2]0
M\0:;I5M:ZE<Z;:?9+.>X2)5D:&+_ )9QE@=J]A@8'2@#IJ*** "BBB@ JCKG
MA^W\06ZI,&62,[HI8SMDA;U4]OY'O5ZB@#SN[\"P^&M0GNKK2X+AID9&U"UA
M^<!@02\8^Z?]I<CZ5\Z_&KX$6OBCP%JWAGQ!;G5/#&KQF$W=JW &<JVX<QR*
M0#SW%?9U96K>"]-UAVDDMQ',XP98CY;M]2.OXYK&I2<I1J0;C*+NFNC/4R_,
MOJT9T:D%.G45I1?5:K\F^Z9^97P3_P""=WA'X8?$/3]7_M?6O%5_:S#^R[>\
M5%B@E/"N0H^=AGC/ ZXKZ T_5I+[Q%-->2/)-')Y1WG)4*=H7V  Z5](P_!>
MWT75/MVFIIOVE3E7GM!O7Z.F.??%97B;X,0>(+MI[SP_:37+?>N+*[\EW]SD
M#/XUGF4L=CI^VQ=7GDM->WRV^X]C(\TR;*H/#X##>SIO5VU?,][W=VK)=>FQ
M^(_[27P7\5>'?C)XITW5/#.N:QJNN:E-<65U!:/<+J"2.3&R2 $< @<D;<=J
M_1C]FCP?K4?PT\*^%M=N!)XD72(HI69MW^E1ID*S?[N4)]:^CK;X#VD9VC2-
M:E7^Y+J**OZ&NB\-?"$:*^ZUL]*T;(P9(4-Q<$?[[<#]:]S.\ZQ.:X>CAZ\(
MQ5/JMWI;MHK=-?P/F.&LNR[A_%8G&8.I4J2K;*224=>;5W?,T^MEI?N?+7B7
M]FK1OB;XHM[WQ%X#TO4-6L2(EN]2M /+QT!<_> [#YO85]!_"CX,W&@1QW$<
M$<5R8Q&+N>+:ENG39!#U Q_$V,^F*],TGPA9Z3,)MLES=?\ />X;S)/P)X7\
M *U*\6G1:24Y.7+M=Z+T70]7'9PZ_-[*G&GS_%RJSE_B>[_J]S-T+PK:Z"6D
M7?/=2#$EQ,=TC^V>P]A@5I445T'BA1110 4444 %%%% !1110 44U)%D!VLK
M8)!P>A%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^$_AC_ ,%E
MK6?X\_$'1/&UGX9T?PGX,7Q)/-=V5Q<F^TV'1[V.V_TA)8UBF>X$@9%MG=DQ
MA@ =U=[X'_X*V>$?BK\4_!7AOPKX1\:ZTGB:YUFPU*XBM8BWAVYTZ&WG:*=5
M=E??'<1L#&[ !EZDD#2O/^"37PH\2ZQXDGUN;Q9XDTWQ!-K$\6D:AJYDT_19
MM5???26D:JIC=VR069RF3MQDUJ7'_!.'P/KV@:!I=[XD\;:A+X6DU%!<KJ<-
MO<7-OJ%LMO=6D_D11J8GC5#PJN&0,'SDD W?@Q_P4!^&OQETK6)_[7'A2ZT+
M4SI-W8>(98+.Y%QY"7 5,2,DF87#81F(P00""*X7Q+_P5W^&/@WX6:;XPU;2
M?'NEZ3X@DE;0EO='6UFU^TBMS<R7ULLDBAK=80'RQ5SN4!"6 /:?LZ?\$\?A
MO^S=X7U32K"RO/$4.L2PS3RZ^8KR1#%:)9IY>(U6/$$:H2B@GDDDDD\N/^"5
M?@,>"O#^B?\ "3?$25?!UPS^&KJYUB.ZN/#MLT'D-96WG0NGV<QA5*R([?(A
MWY4&@#,^&/\ P4)U'XJ?M1^&_"NDVFA7G@_Q/K&HVUCJ<0F$UQ90Z'8:G;S#
M<0 SM=L""OW0O .37U;7D?AG]BGP7X5^+VG^.+?^V'U[3;^ZU*)Y;O=&TUQ8
M6]A*2F ,&&VCX& &W'OBO7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **1W6-=S$*HZDGI2T ?'?QF_X*7:W\+O^"A6F
M_!ZWT/PQJ&GW5[H]DT+WL\6M7"7T5S+->0KY9@,-I';F217=6*!B.0 ='1O^
M"T7P5\2Z3J5UIMQXBU!K2[T^VM((;*/S-62^FE@M9X29 BQ/)#(,S-$PPN5&
MY<^I_$K]A[P+\5O%VN:[JT>K?VIKNI:-JTD\%V8VMKC2B_V9XN/DRLDB2#G>
MDC*>":XNR_X);> ]'^"_B#X>Z?KWC;3?"/B%%M7T^WO+8+:68\S-G&6MRS0D
M2$?O3(X"KM=2H- $&G_\%.-'7Q)XRTG4OA[\2+74?#OBM/"6D6<&F+<7/BBY
M-FEXWV90X \N(L[[V5510V[Y@*9??\%;_A/9:7<ZD(_&$VBZ?X;MO$^HZHNB
MNMGI<5S-);V]M.[$;+J2XADA$."0ZG.%^:M+5/\ @F5X#:ZNKG2]>\?>&YA?
M66JZ=+INN&-M"N[6P&G_ &BV+HY5IK15BF#[UD"@E0W-6[;_ ()J_"E?A9XC
M\'1V.J-H?B?1=-T2]0Z@SR!;"::XM[A7.3]H\^=YFD.=SX)&." >7?&__@L_
MX+T']FW7O%/@'1O$GBCQ3I^F:O=_V2-*:X717T^18)GU Q2;4@$TD:[XW?<&
M)7(#$?8WA[4'U?P_8W4BHLEU;QRL$^Z"R@G'MS7SE\1/^"5G@+XI^#K/2-8\
M2?$(M%IE[H=]>V>KQV-SK.G7<JS2V=SY$*(T0D1678B,.1G#,#])Z;81Z5IU
MO:PY\JVC6),GG:H '\J )J*** "BBB@ HHHH **** "ODK_@L/\ \%#[[_@G
MC^SGINM>'8=+O?&?B/5HK'2;6_1G@:-/WEQ(ZJ5)58QMX(P9%KZUK^>?_@OG
M^UB/VD?V\=4T6QNO.\._#&$Z!:[6_=O=9#W<GI_K,1Y](J^EX4RF..Q\8U%>
M$?>EY]E\W;Y7/#X@S!X3".4':4M%^K^2/IW_ (-N/CGJWQ7_ &A_C7<>(=5\
M8:IK6OJFNR(UPSZ):F6X<RL49_DN'=@%VK_JXVYK]>Z^#_\ @WL_9._X9\_8
M;MO%6HVIA\1?%"X_MN?>N'CLP-EI&?\ @&9/^VM?>%9<48BE5S.JZ/PJR_\
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M37QM)JVFA)-.TG2YBHLY;B0L"K73%_*106(BD8@*N:ROVK_V]+7]F[XD^'_
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MDDDFCN8XY?,>0.[.R#>S%AP:]DH **** "BBB@ HHHH **** "BBB@ HHHH
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MX0H>98+I1#&JX1L[')<[AY?X)_X*4?&#5OAG/K-QKFJ3Z/I_C+3H8F30(/\
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M_:9\<?!7^SOV=XO&&G?#X?%6WU46VHM9:3I@7<U@4W[I[@N5C$AVJ-K-R",
M'[%U6N]9L["]M[:>ZMH;B\)$$4DJJ\Q')V@G+8]J_(;X@?\ !>'XE>/OV,/@
M/XQ\(>+OA/X+^(7Q"\+:EK^L^&;OPEK?B;4KM[262%&M;>QW&"UD>WF+27!
M08PQ"L:Y$_MF:I_P4&_:A_X)4_&#6M,L]%UCQA?^+3?V5FS&WCGMXA;.T>XE
M@C&(L 22 V,G&2 ?M/=:S9V5];VLUU;0W5WGR(7E59)L<G:I.6QWQ1J.LV>C
MB'[9=6UK]HD$47G2K'YCGHJY/+'T'-?E)_P7*E\?)_P6$_857X7MX83Q[*_B
M>+1V\1^<=*BD:TA5I)UA(D94C+L%4@L0!D9KYU_:D_;M\=?MY? #X"VGQ,T_
M0=,^(WPE_;!TCP!KTNA+(NFZC+;[RMQ"'9F4'<05)_@!XW8 !^]U%?C?\:/^
M"[?[17AS1/BY\?/#?AGX6M^SA\%_B4WP^U'0KY;D>*-:CCN([>6\CF5_)C;=
M-&50KQN((;;D]E^UY_P5_P#VC-1^.?[17_"B=&^%MK\//V4M%L-9\3_\);%=
M2:EXH,]M]KDBMO*=5A"Q+(!N&2RCD[MH /U<FG2VA:21ECCC4LS,<*H'4D^E
M1Z=J=OK%C'=6=Q#=6TPW1RPN)(W'J&'!_"OQ]^-O_!6SXZ?\%![GQ/X-^!/A
M_P"&^B>#;/X$1_$'Q:/%[7;7M\FI6)9K*TDA($;HDA"R.I4LN6(7 /M'_!,'
MX[ZU^S%_P;/>"/B)X=\.R>+M=\%_#W4-7LM(3=_ITD,URX4[06VC&6VC.U3C
MF@#]'+N[BL+62>>2.&&%2[R2,%5%'4DG@ >M)97T.I6D=Q;S17%O,H>.2-@R
M.IZ$$<$>XK\'+#_@J[\?OV]O@=\</"NI>+/A#XR^&T7[/NJ>-?$6K>%O#=[;
M'1;^XLG5-":>2Y95NHF;+%E8LJ-P#DCZ,_X);?MR^,?AWKW[!/P#L;?0V\$_
M$'X'MK^IS36[M?I<6MNQB$4@<*J?(,@H2<GD4 ?JY17XZ^"_^"[7QZ^,_P +
M? /A7P?H_P -?^%O?%SXO^(? FAZEJ5M<IH>CZ7I@A8W$T22-)+,5F_A8 [2
M=I.!7L7[1/[<G[6'P>\?_ ']G*Q;X*WG[17Q<76-0U/Q*UG?#POI>G61=XVC
M@+B=YI(E^;/"L,!2#D 'Z445^+OCS_@O[^T*W[%EGXAL?!GA/1?$W@?XF:E\
M.?BGXLMM#O\ 7=#\-"S6-EOX[2&03>5+O8$LQ"F/ R74"W\?O^"_?Q2\,1?!
M;P/X3\5?!_5_%7C+P7=^--=\<Z+X3UWQ#H5RBSW$5K:6=A; WD;N80LSS#$3
ML00N* /V5FF2WA:21ECCC!9F8X50.I)J/3=3M]8L8[JSN(;JVF&Z.6%Q)&X]
M0PX/X5\;_ O]KWQ)^W+_ ,$6/$WQ(\8^#[WP'XLU;P3K]OJ^C7%M+;_9[B""
MYA9XTE'F".38)%#9(#@9.,G\Z?V?O^"MGC']B'_@FE^Q+\)_ /\ 86CZW\1_
M#.I:IJ'B76/#VH^(H-&L[>\N HCL-/!N)I'<$$@$(HR1@Y4 _>2BOR%_9J_X
M+^?%:'Q_\(M8^.GA'0? OPT\>Z1XBTO4+HZ1>V$T6NZ/&;E9HS<L&2VN[8Q[
M(WC+!V8;SM->?ZQ_P<&?M I\*_@38WUCX#\&^+_CAI^K>-O[5F\):MKMOH>@
M1S21:="MA8M)/-//Y+.\WW$1T.T<D '[8W6LV=C?6]K-=6T-S=Y$$+RJLDV.
M3M4G+8]JLU^(>D_M@>+?VZ/V]?\ @FA\0_'GA.;P1XRNM2\<:?JNE&UN+2)Y
M[:T1%GACG E6*9=K*'R5W$9.,U[9_P $L?\ @K9\<_VK_P!O75?AO\7;[X8?
M#?4K&74_M/PSO_#FJ:=XH@@A!^S36EW*QMKQ#@M(>#L4LJ[3D 'ZB:OXAT_P
M_P#9_M]]9V/VJ40P?:)EC\Z0]$7<1N8^@YJY7YP?M>>#M4\9_P#!:W1]2\8#
MP#XA^'?PO^$5UXUM](UCP]+J4UDL6I1BXGMMTXCCU M$FRXV'9&NW822U=+\
M%/\ @H!\=([#X ?$GXA:?\-V^%_[2&KVFD:=HVBV]TNL>$6U"UFN=,>6YDE:
M*\#)$$F"Q1;&?*[@IR ??5%?)?\ P2B_:-^-W[9GP7TOXL?$8?#[1?"7BJPE
M71=!T2RN3?Q2174D1NKBYDE*;95C)$*1_("N9&.0/*?VN_\ @JSXF^ /[3,M
MKX;\8?#?Q=X5T/QGHOA+6?"]AX7U>XU&R%]/#;3FXUA&-C;W43S!Q Z\J K8
M8B@#]"J*_-_XN?\ !1O]HK0/"/[17Q-T.U^%4/PY_9S\;7F@S:1>Z?>2:IXJ
ML[86LDY6X6<1VLB1W!"-Y<@=QRJ@<_HUIM\FJ:=;W4>X1W$:RJ&'.& (S^=
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M;Q5H6C>,O#]UINM6>FZII=VACN+6]B2:"9#U#HP*D?45\U?MC?\ !5/X)_\
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MCA^-O@>0VUC_ &@&%TWEW,0VY$#[=L\@+J#%$7D!."H/% '"_M"_\$&_@?\
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MTO3[>UCW>7;QK$FXY.%&!G\JFHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /F7]IW]KRS\)Z!JM[<:K_8/A72F,4]VF?/O7SMV
M)CGD\!5Y;V%>#_LH_P#!0;P?XZ^,2V'A^+6=/UJ.)Y5M-1A$2ZM /OA6!(W
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MXK*;598X)9V,DNX*BA(7&2?O8'>NGU'Q]H6D7,,-UK6E6\US;/>0QR7<:O-
MB[GE4$Y9%7DL. .:^5OC[_P3QU/4O@#\"/"?A'1_ 'BJ+X.:E%?76D>+?-73
M=<QI]Q;.6*QRXD::<RY=&&<Y&:\R^$__  1W\1>!_B?X'NO$VI:7XVT?1=,T
M6&2=M6FL9-"FL8KE)(+:$P2&>T?[1A8FEB#*")%88P ?;/P[_:*\!_%KPSH.
ML>&_&'AW6--\4HSZ1-;W\;#4@OWO*&<N1W &1WKI-;\5:7X9>T74M2L-/:_F
M%M;"YN$B-Q*>D:;B-S'LHR:_.K2/^"2WQ4TWPE\'O#%K_P *GT/0_AC+8,9=
M*B-M</-9ZL+IKP.+3S6:XME53$)(U20,6:4-Q[G\2_V$?$P_:!\%^+M/O-'^
M*>FZ3;7MC<6WQ&N3<S:&US>07 OK!HX"GFQK$T:J51@NS$HP<@'O/Q#_ &B/
M"OPVM8)+S4H[QIM=LO#LD5@RW$EI>7<JQ0I*JG,?S,"=W('.*N? WXSZ+^T+
M\*-&\9^'6NFT77HFFM3<P^3*55V0[ER<?,IKXK^ /_!)GQ5\*G0WM[I-QK&G
MZYI%Q)K[:U/,WB*TL]9?4'>>T^SHL=R5?&]I)FW%AO"5]7?L5_ [4OV;/V7O
M"'@?6+JROM2\/VTD,\]IN\F0M-)("NX ]' Y'6@#U*BBB@ HHHH **** "BB
MB@ K\=OVZ/\ @A[^T-^T+^V%\1/''ACQ'X;M?#WB;5C>6$,_B"[@DCC,:+AD
M6,JIRIX!-?L317J93G&(R^HZN'M=JVJOUN<&89;1QD%"M>R=]'8_!Z3_ (-U
MOVH)4*MXI\(LK#!#>)KT@_AY=9Z?\&T_[0\9;;??#;YCEC_:L_S'W_<<U^^-
M%>^N.\S6W+_X#_P3R/\ 5/ _WOO_ . ?@^O_  ;L?M0QHJKXI\((D:A55?$M
MZJH!T  BP /05]F?\$7/^"87Q>_8/^,'C;7/B/K&BZGI^OZ/!8V:66K7%ZR2
MI,78E9$4*-O<<U^BE%<F.XNQV+H2P]7EY9;V6O?OY'3A>'<)AZL:U.]UW844
M45\N>Z%?.?\ P5H_9J\4?M>_\$]/B5\/O!;K_P )-K=G;RV,)N5MA?-;W<-R
MUMYK JAF6%HPS J"X+#;FOHRB@#\J9/V>-:^)?@/XJZII_P;_:2\5_$?XC>%
MK#X<M'\8+G2?[(MH9[IY/._T-@S0V#-)/YRC).U8SN;*OLOV-/BS^SS^Q&OP
MT_X0/6O'FO?!+XNZ!X];Q'IS(U]\6-/2_CN[B]7SIBS:FB!HY8I9.3!'L=@P
M _5.B@#\F_VEOV6O%WC7]I+XT>)O$W@K]J35OAS^TEH6CO!IG@"728;BU6+3
M_L<^DZQ;W9+0.I)=9(Y#&!,XR&4Y]S\ ?L8:_P"%O&_[9<D?@^^-GX]\#:#X
M<\+W-^T,]SK4=KX;DM&MV<$[BL[;&W85G8GD<U]XT4 ?F'\#/A'\3_V-?$UK
MJFM?!'QA\3D^)/P,\(^"D32/L<\OAW5--LIH;K3+[SYD\JVF>X#F92Z91\@D
M#/EWP[_84^+W[/7A3]FWQ;KGAKXW6]CX=^#G_"O?$&E_#"\TYM?\/:@M^;K]
MY#=;DFM9D(C9H6W*T,9;*GC]C:* /S/^!W[/^N_\$_\ XT_#+QIX9^"?Q:\:
M?#VZ^$B^!+32))-.OO$WA&\&J37WEWJ^<D(BN%G"O)$S+&8%##;@CV?_ ()D
M?!WQ)^S/_P $C+'POX]\/P^ ==TVU\137>DS74)BTE;C4+Z>*,2JWE[!'*F&
M!Q@CI7V35/Q%X>L?%V@7NEZG:PWVG:E ]M=6\J[HYXW4JRL/0@D4I7M[NXU:
M^I^0/[!\_B+X\?LQ_L-_#>'X97W@>3X.:Y8>(M:\6ZA>:?'I:Q6MC=YM[%XY
MFEFNKQ9@SQ&-2B^:SY !-C]@;]F*/X7>)?A#X'^)B_'?5-0^%?BV37]*UJR\
M1:)-\.W,T]X;35(Y05NO+NEN&3RFS(TLCK\P&:_5#X7?L]^"?@OX"T/PQX8\
M,:3I6A^&X8X--MEA$GV54B\I<.^YRPC^3<S%BO!-;4?P[\/PQ+&NA:.L<:0Q
M*HLHP%2%MT2@;>B,=RC^$\C!K']]Y?C\C3]WYGYC^&/V=M4\&_\ !#[P3\.8
M=)TG3_'=EXVM?$6M:0M_:1W"QVGB^.[OKJ5O,VGR8 'D8L2H"@X.!5?XZ^"_
M&/A3P;^UU\#['X97'Q"U;]I#Q5>WWAGQ;9W^GMHT U&PMU2+4I9)EFMY=/2)
MI501N6C2-H^O'Z@2?#SP_-&Z/H>CLLB31NILHR&69MTP/R\B1@"P_B/)S4@\
M#Z*+KSO['TOSO.%QYGV2/=YHC\H/G&=WE_)GKMXZ<4?OO+\?F+]WYGY0?&[P
MCXL^%7P?_:W^%MG\/=0^,5[^T%IEMJ'A?QAINH:<^F7RSZ+;:9#'?337"/ T
M5S:NT/RL)3(H0[LX^E_VVOAI=?'#_@DC'\/-"U;PW<>+]-T'2+R71K[5X((M
M5.C7-E/?6$LA8HH/D- Y;Y$9P'P,U]AQ_#KP_%"L:Z#HRQQQQ1*HLHPJI$V^
M)0-O1&.Y1T4\C!I9/AYX?FC=7T/1V619D<&RC(99CNF!XY$A +#^(C)S2_?^
M7XE?NO/\#\Y_'K>)OVT?CM\2?B%8_#_7/AC:P_!#6_AE8Z5XEN+"UUCQ7K=\
M@O(;1((9Y!Y4$<1*,[#<;AB@V M7T1X<TRWUW_@DWI_PY;6O#UGXJOOA#::!
M]GN-4@58;JYTO[%"'<,5VM<9C# D,P(!-?2@\#Z*+KSO['TOSA,+CS/LD>[S
M1'Y8?.,[A'\F>NWCIQ44?PZ\/Q0K&N@Z,L<<<42J+*,*J1-OB4#;T1OF4=%/
M(P:?[[R_'Y"_=^9^</P>;Q%X\US]D_5M3\(:UX+3X/\ PY\5^%/%":]=64)L
MKN'2],M6D5HYW#P&:&11(#P5^8+4'[/_ .R_J'A3X&?\$\?#E]H&E6VI?!W7
M"_BNQ:ZM6D\/7,F@WSCS '/[QII(Y,+DDL'Z#=7Z32_#SP_,CJ^AZ.RR+,CA
MK*,AA,<S \<B0@%O[Q'.:D'@?15N?._L?2_.$RW D^R1[A*(_+#YQG<(_D!Z
MA>.G%'[[R_'YA^[\S\G/C[^S?XMUN_\ %7C#19-:;3?#W[1<GQ,@L?"6N:=;
MZSKFB7VB6^FQ:CIIG9H'E%UYA19,&4I*%(?:3]-_\$^A;_ KPE>:IX1^'WQZ
MUU_B[\2ID\377C6\TU]2TF9;-8Y=4N([9MD<&ZW2$H/WN_DJ,\_8:?#GP]%
ML:Z#HRQQQQ0J@LHPJI$^^)0-OW4?YE'13R,&M#2]&L]$ADCLK6VLXYI7GD6"
M)8U>1SN9R .68DDGJ33A[6_OV^5Q2Y+>[<LT445L9A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '*?$OX.Z/\ %)(&OEFANK;B.X@;;(%[J>""/8U/X#^%
M&B?#F(_V;:_Z0PP]S*?,F<?[QZ#V&!7245G[&'-SVU.OZ_B?8_5^=\G:^@44
M45H<@4444 %%%% !1110 4444 8.N_"_P[XFE\R_T33;J0]7>W7<?QQFK_AS
MPOI_A'319Z79V]C:ABWEPIM7)ZGZU?HK.-&"ESI*_>VI*IQ3YDM0HHHK0H**
M** "BBB@ HHHH R;_P "Z-J>MPZE<:78S7]N=T<[0@R*>QS[5K444E%+8J52
M4DE)WML%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gylze0pdymuz000002.jpg
<TEXT>
begin 644 gylze0pdymuz000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K 90# 2(  A$! Q$!_\0
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MCDNHU>.-G +9&>!1*U]!T*CE'WB]1114FX4444 %%%% !1110 4444 %%%%
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M1.'MY_-3&<8)P,&MRL>UT&&Q\0-J-FL4$,EMY,D,:;0S!LAN/;(K8H ****
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MUM;O!<38P/,D8C'T J4:/92ZBB1WC1Q'.7D4'/':@$H]B.#7;M?-A#$0L<D
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M8WC*ZW.N.F)/,^V=551QNXS5/^Q[LPS7"A65<@'<.:L2!U^=2=QXJNTL\:E
MQ.XY.>U=>&JMK4\G%T;/0SY["[MK1)9(' ?&&*U$?,CD50"'.<FM:35+SRHH
MV)?R?NYZ"GMJB7-_'/<6RNHX9 .!]*]!-'EM23,J.[G5FBCD.#@MGH:L)J]X
M(8PLA(A.5.<5;3^SIKBY+1E=X^01GCZ4U=)B?2I94N0K*Q'EXY-!.G5&A:>+
M;B+41,6D2)UPZ*>!Z5MV'CJ0I<+*Z,4^:/<,DCTXKDKG0[F&"W=GC,,C#:5;
M)-=%::?8VT=O^[^<,I?*@D$[20?R-#\RHI_99WVDWYU/3(+PQ-$9%SM/:BIK
M+'V&#;TV#'Y45D=BV,CQ!I^I7,L4U@ZLH4K)$QQGW%>?:BNI:-?RQ7,;!9/F
M5=V%.?2O7ZH:MI-OJ]H89AAARC@<J::DS*5*,G<\?5;A4*J1L?J"*E2U<$ D
ME3V).*WO['F@N3;3( P/5N<#U^E3QV ";B?E7@"F39&%'8%9&4# [D]/TJS%
M8X3<1U.!@9K<6SB0 @;@?O<5:2W$;8V#:>F:!F/'IVW:-N0?>KB::%D ( !Z
M5II$N#&6XZ\"I4CROW26% S/CL!DJ3Q4@LEV$ 98&M':2-P &.M! !SG(/I0
M,H?95V@A!QUS2M;C>#A0#5S:N2N"<]*84)0C;R*!%7R5!8%NOH*:(0R$8)Q5
MLY.UAC/M2!3O)!)!'.!0!7,>0KA*/)Q(.%Y%6/*_=DD-M)P#3_LY+HA #=<D
M\4!8IK']Y=RBC8-@.[D5;$2_.QVJPZ _Q4AC01KM?+'.Y<=*!6*Q +*=Q.:7
M"KN+' QGGM6=XAUV'1Y(H(6$DTP_=ACC:/4UEO!-=P1SW,OFF8$HK2 %L==J
MYK.51)V6XKZ\J-W^T=. VM>0;AV,@S5Q#'(%9 '!Z8.17F^H^'9KG)AB ; 8
M N!G(R /4X[5C6MIK>G3E[266$I$)RV_"A#TSV_"HC6ONCF6(FI6E$]-U5D:
M]MK<I@@/*<^PP*@\(RJVFS)M!\FY<'\>:\[U#Q=J%Q=VS2$)<QPE'*<;QG.<
M5W7P[M+N'13=7$9+7DY>,/\ Q#IDU<7=W1I"\JG,MC)DN!%;6FH!0<7;NWYD
M5IZ'HBWNF>?]MNX\R.-L<N%'-<)J']J66HW.C.L@*W)RH'8G/Y8KT2UOE>QC
MMK<);VZ<@1]6/<DU#@I--G9@Z\Z-.<8Z-M?A<G;P["O+:I?!?><4+X=B9L+J
ME\WTG%4KB&&0'G/U-8L]M)$^Z-R/3!I\D.QT?6\1_-^".G_X1M<$_P!HZA_W
M^I#X<7 _XF.H8/\ TUK$L]>OM/9#<-Y]NIRROUQ]:[:VN8[P&>"+?&\9<8/"
MCUIJG!]"7C,0OM?@C$_X1Q-^/[0U#@=/-IA\/)M;_B8W_P#W]K=WC[)OVL,O
M@2^O'2E/E^<B&.0*5&4[GWI^RAV%]=K_ ,WX?\ P&\/IM7_B97_O^]J-] 7>
M?^)E>]."9*Z$,A#Y8[E^YQP/K3"%*[@P);[V1TJ94HVV+AC:]_B_(YR+3!:E
MI!<S29&-LC9%8OB:%Q:Q7"#(B.'QV!KLYH0<J"I Y#>M9LT((8,H*G@J:\NM
M%PES(]3#XAR=V]3C]&\21:?)(TVYD,+J HR<D8%6HO&5G'964=P9D>V<MF)
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MKWPYJ%M;IOFE@947.,G'2L6S\0:Q;V-O"WA'4RT<2H2)8>H&/[] '6T5S/\
MPDVK_P#0H:I_W]A_^+H_X2;5_P#H4-4_[^P__%T =-17,_\ "3:O_P!"AJG_
M ']A_P#BZ/\ A)M7_P"A0U3_ +^P_P#Q= '345S/_"3:O_T*&J?]_8?_ (NC
M_A)M7_Z%#5/^_L/_ ,70!TU)BN:_X2;5_P#H4-4_[^P__%T?\)-J_P#T*&J?
M]_8?_BZ .D* TPQ#TKGO^$FU?_H4-4_[^P__ !=1S^)]76WE(\*:G&0A.\R0
MX7CK]^E9#NSI/)'I56ZO+>S8(QW2'HB]:XGX?^//$/B:3RM1\-S1P D#4(_E
MC;'?#'^1-7[\S1:G,92=Q8]?3M43T6AK2Y92]YFM<ZRT!"EK>)CT1G&[\JK/
MK=]&<@HR^A6N%U6SO+S4]5F0(4-M&J^9#N+XW9"G/!J)[W5C=%8C=I$49-K1
M[MN%^4CC^M85&W\+:.N"IKXE<]"A\2QLZ_;+53CHZCI6M%:V%] TL&,/_$IY
M!_I7G&DM<R6;_:#(S+(0K2#!8<>P/KU%=GX5251.>?)('7UJJ,IWM)W(Q-*D
MH<T=&7Y-&^[Y4Q']XMS4#V-\DCR;5D !&2<EA6[175<X.5'*S PQ#S;=D<GY
M6/<?2NAL(5@LT5=WS#<=W7FK!4-U /U%+1<2C8****104444 %%%% !115/5
M=1BTG2KK4)_]7;QEV]\4 699HH(S)-(L:#JS' K"O?&N@V)(DO"Q'7RXV8?F
M!7FW_"6)KCM=WUVA!)*1;L*@] *LO:"[6R!EB N7$; +S&6&5^N0<U@ZK?PG
M/*I-Q;A^)V.B^+_!T$7V2PO(K5"[/L="@W,<DY/'6NKAGBN(EE@D22-N0R'(
M-> WOAVVM=1M[._O/(NKAAB)(PQ0$X7=DCK3+#Q!<>"]4D>POWN+6%]LT#C:
M'P<$ 9/YU2J=S.G7J?\ +Q'T+15;3KZ'4M.MKZ YBN(UD3Z$9JS6IV!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4A 92K $'J#2T4 ( % "@ #H!56]TZWOTQ,OS#HPZBK=% ',S>%Y<GR;
MA2.P<8K+TK39]6@EF@>-4CF>!MV<[E.#^%=CJ"7$FGW"6DOE7)C/E/C.&QQQ
M]:\\^$%WK^H6.JSZNJ0Q)>21I"B8S+NS(Q_' %3R(U5::ZG6VWAB-2#<S%_]
ME1@5N111PQB.) J#H *?1322V(E)RW"BBBF2%%%% !1110 4444 %%%% !6=
MKNEKK6A7NFLVS[1$4#>A['\ZT:* /D_5=(U'PWJALM2@:*1&R,_=D&>H/<&M
MRV\<ZH+J6:54FC>5)8X6X6(J>-N/;BOH;4]&T[6K;[/J5E#<Q>DBYQ]#VKCK
MGX.^%+B4ND5W;@_PQ3G _/-0XOH0X]CQN;7[F;[$]S&LLUG/YL4K$[MN<[#Z
MC--T_2M3\8ZV]OI]N2T\A>1\?)$">237KN@_#/P9=P_;8(KRYC$CQ[;B8XRK
M%3P,=Q7>Z?I=CI-L+>PM(K>(?PQKC_\ 724.XE#N)I.GQZ3I%II\7,=O$L8/
MK@5<HHK0T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *K75]!:8$C?,>BCJ:LUQ-_),NIS&4G=OQSV'
M:HG)I:&M*,92]YF]<:O-&NY8%5?5VYK.76IK0$16T"HS%B$7&2>I^M<9KD%Q
MJ>MP#9;RK':28^T1EU!W+TY&#6<NIW\4%I!'+.H54C=&CSP>"V<9X]<BL*DI
M/X6SKA"DOB1Z;;^*868+<0E/]I3D5N0S1W$0DB<.AZ$5Y3H=O)!H=LKLS2%=
MSEQ@DGKGWKM?"OFCSUY\G Z^M.C.;=I:DXBC2C!3AIY'2T445TG"%%%% !11
M10 4444 %%%% !1110 4453U6YN+/2KJZM8!//#&9%B)QOQSCZF@#'\#?\BX
M?^ONX_\ 1K5TE>=_"7Q))X@T:[V6+P6L%Q)^\D/+NSEB /0 BO1* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "J-_I<&H %P5D'1UZU>HH!.QRLWAF[4GRI8G'OD&J5GI-Q?
MQO);2P2(DC1LP8\,IP1T[&NNU 71TZX^Q,JW0C)B+#(W8XR/2O//A!JNMZO8
MZI-J5O%;6\=W(JQHIRTI;+\GL.GXU'(C55IHZBW\,'(-S,,=U0?UK?@MXK:%
M8H4"H.PJ6BJ44MB)3E+<****9(4444 %%%% !1110 4444 %%%8OB7Q';>&]
M-^TSD&5SLACS]YO\*3=E=B;25V;54[C5=/M3BXO;>,^CR 5YU/J>IZDB27ER
M,RH9(X%D" K[#O\ C61J&EB2'>(XR2H<J7&[:>AQ63JNUTC&=6?+S01Z;X>A
MT/3+(V>CSVYB,KRE4D!^9CDUMU\X7^A7M@\LA!B6.4Q [\%F'7;Z@>M;_A[6
MO%6DVXN8;M;JT0,QMKB3)95^]MSR,4U474RIXIMVG&Q[A165X>U^R\2Z1'J-
MB^Z-OE9>Z,.H-:M:G8%%%% !1110 4444 %%1RSQ0C,CA:S9]8'(A3_@34U%
MLB4XQW-:HI+B&+[\BK]37/R7MS-]Z1L>@XJ @]ZKD75F+K]D;KZO:H<!F;Z"
MJ[Z[&#\L+GZG%9&*0K6D80,I5ZG0TV\0$=+?\VIA\1L/^78?]]5ELE1LE;*G
M#L8NO5[FO_PDI[VP_P"^J>OB6/\ BMV'T:L J:815>QIOH1]:K+J=5'X@LV^
M]YB_45<BU"TF^Y.G/8G%<10,YJ7AX]"XXV:W1WX((R"#2UPT-Y<0']W*Z_0U
MJ6WB"=#B95D'J.#6,J$EL=,,9![Z'2T52MM4M;K 63:_]UN#5VL6FMSJC)25
MT%%%%(84444 %%%% "$@#). *H2:M 'V0AIF_P!GI^=0>(6F&G@1Y"%L.1Z5
MY6NJZA"VK6J7,@>XF=;9LG,851NQZ8!S6<I-,WIP@U>1ZE/J]S%S]G51[G-9
ML.K/8(R06D$:.YD8(",L>2?J:X"#Q!>R2:?<R/=26T$,,<S]48LHWEO4C(-0
MPMJ,FGS7<;W";&G+RO<%@Z@L %7/';TZ5C4E)_"VCIA&E;5'IL?BH9Q-;$#U
M5JV++4K6_'[B3+#JIX->+R7E_P#V>[SNRZAF'RX@Y"&,D<Y[Y[FMWP]+=&5S
M([C4%EQ*@/"GMM']W%*G.HG:6H5*-%QO'0]6HI$W;%W?>QS]:6NL\\**** "
MBBB@ HHHH **** "O-OC#H%[JN@VU[9HTOV%F:2->NT@9(^F*])HZC!H!ZGS
M18^*;(7-C=7UO+*UM +:2$(K)*HZ'YN5(]O2ID\46RV#0^7<29C"K#(0R1,"
M#N5NHZ=/>O7M=^&'AO79FG-N]G<,<M+:MMW'W'2N1F^!S^8?L_B%EC["2W!/
MYYK-Q9FXLY/5O&*:K</<W-MYLT,Y>T\P?*(SUC<#J.]5H/$UK%%<D6LHN+E'
MC>"$?NY-WW>O*X]NN*['2/@[:WRBX;Q&]Q;;V0^3 %.5.",D^H/:N]T#X?>'
MO#LBSVMIYMTO2><[F'T[#\!24'>[%R.]V4/A9X>O/#WA()?+LGN93.8^Z @
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M\@B$43!2S%B,E<]34W_"/ZQ_T-FH?]^(?_B*Z*B@#G?^$?UC_H;-0_[\0_\
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M?3T%:-%5&"1$ZLI;A1115&84444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU !112;AV(Y]Z %HI 0>A!QUI: "BBD) &2<4 +1110 4444 %%%% !1110
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gylze0pdymuz000003.jpg
<TEXT>
begin 644 gylze0pdymuz000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A 7P# 2(  A$! Q$!_\0
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MSRD(3DJ-Q.!GFM,6MLH4"WB 12B@(.%/4#V]J /-(?'=]]IF\K[':?;+F/\
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MM#:W,S,Q&4]4]!D]JYZYT:[BL[=W:+Y_F"K)EAZ$U$EC=W.JE($,CLFX*".
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MN4CEN/M!P1< C<F#GY1C JWB(+1.YER2ZJUBCX?FN])M61]&U&=IG\W,,8(
M(X')'-=7;^)+]#N3PKK3$C'%NI'_ *%4=KX(NG()\2:TI]I4_P#B:V(? EV1
MQXP\0K])T_\ B:NA%-\QQXFHWH4_^$GU/RO+'A#7]F<X^RKU_P"^J7_A*M6,
MJN?"GB/<!@L+5<@?]]5I_P#"!7N/^1V\2C_MY3_XFD_X0*]_Z'?Q+_X$K_\
M$UW'GV1ECQ-J8C=3X2\1\G('V5<'Z_-3O^$EU O&3X4\3<#D_95S^'S5I?\
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M'_76X_\ 1ST =C115'5)I([0B"^MK2;((>< KCOQD4F[#23=F[%"/_D?)_\
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ME &Q6'XP_P"12U'_ *YC^8K<K#\8?\BEJ/\ US'\Q0!N4444 %%%% !1110
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M+2"=8Y+2ZC54=YBZ@&)0@8'&><@\8IY\7Z>MV+1TGBN=Q1HY% V-@$ \\Y#
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gylze0pdymuz000004.jpg
<TEXT>
begin 644 gylze0pdymuz000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "W :P# 2(  A$! Q$!_\0
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MS5HJO9W'VB')^^IVL/>K%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)(R*I7%N'!XJ^!04R*4X*2
M'3FXLY>XT\\X&0>HQ6!>^$M)O7+7&F0LYZLJ[2?Q%>A/;@]JA-D">E>?+"-.
M\78]".+35I*YYKIWA'P\Z&:WTM6 =D_>Y;E20>ON*Z6TTI8D$<,*1(/X47 J
M_P"';,'393C_ )>[@?\ D5JW([0#M2^JRD_>=Q_6XQ7NHH6ED(\<5K11[13T
MA"U*!7=2I*".&K5<V)13L48K8Q&T4[%)B@!E(13Z0B@0PTVI"*90 TTTT^FD
M4 ,-)3J::8A*::?330 PTE.--H =;2_9[U&/W)/D;^AK;KGY%WH5]16S9S&X
MM(Y#]XC#?4=:4BH]B>BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#-%+6:VIMSLB'XFH6U.Y[!!^%;*G
M)G*Z\$;0%. '4]JYXZO>#^)/^^!2#6[M>NP_\!JO82)^MTUW)?!]Y;7^C32V
MS[T%[<@G:1_RU8]_8BN@ KFK/5ULXC%%:1(A=G(3CYF.2?Q))K2AUZU?&]7C
MS^(J71FNA<<32EU-7%+BHH;F"X_U4JM[ \U/BLWH;IIZH;BEQ3\4;:0$>*3%
M/(I,4 ,(IM/(I#3 8::13Z:: &4AIQIM AAIIIYIM AM(:6D-,!AI*<:;0 E
M6M*?#30D]]X_&JM/LVV:E&>SJ5/\_P"E#V!;FU1114&@4444 %%%% !1110
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MD'H: $I%)%U;L.T@_7BEJ)I5\R,*V6$B]/K3 Z*BBBLS0**** "BBB@ HH/
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M>EM&R-!N5VW.&<G=P!SZ\ ?E6EGHJ_@!35R6T]A>!2%JLP:==7)&R(A3_$W
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M,=2YIM+0 ZES3*,T /S2YIF:,T /S1FFT4@'9HS3:3- #LTE)FDI@+FDHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gylze0pdymuz000006.jpg
<TEXT>
begin 644 gylze0pdymuz000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &/ DD# 2(  A$! Q$!_\0
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M&R,'O_DU8B<C.[\?:@#0$K8SG/\ ^JDDE=5./Y4P$>F1Z?T_E2/C;U&?\\T
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MS0!H C'3^E*3D^Y/I2=!N'';_/Z49S^/^?\ /UH 8S<<]<9Z?3T_S^E4Y6X
M_3_/^>:LR-TQ]1ST_P#KU2D;@D?7K_GT_6@"A.P+=>G/O]?K_C55L@[<]*DE
M8[SW&<?Y_2HLG.>_<^M !CY2?\FG0DAN?Y5#<R$1G:<$].:+?F,;B>E &G"V
M>G&.GM5VV7-RAQW].?\ /'^>]&W&!Z=<X%7K4XN4'3GG_/\ GK^- &M1110
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M./7BLV](MGWL/EX&#_*MH@$YXR>W^?\ /YUGWD*RQ-T.!D'TH KV\XD'!QU
MJXLC C X/7O6#;W'ESM&PQS^GO6PLX(R#QZ_Y_SS0!IPR.3SP,?Y_K5])-W!
MZGN.M9$$XV@G'3C JTLXS@=Z )W0#GVK"OX4$G(YZ5LM/N)"C-9]T TF2 3V
M_*@#!D4 \C;BHV<!>>._^?RJ_<JH#$8'!KG]3NF@A; Y]N: *.JZ@MGDJ<OV
M'6L?^UKJ13F,<^U95_*\D;%B.IX_"F6-QMAVL<<]S_G_ #]* -!=4O$E_>*!
M'ZX&/\]*W+.1'VN7'KZ5S$]Q%+%L=\$G@X]:U-*B?RUVX*CG- '5DNP'EK\M
M64B?&>?Z51MIVA558EN>_P#]>M^U0/'G'0=,8S0!;TJW(/S '/8#K77VJX0<
M].W<5A::B1GBMZ+E,>O'ZT 38Y7'MWJ.9RJ<9R ,^U*7V@DY]^?KQ_G_ !JE
M++YAP/\ /T_SV- #,&1LD<>_^?K^?TJ*YRJ?Y_S_ )YJ7.TY([_U/^?QJM-.
MN<%N?YT 9CE@>0!T_"LZ^G^78#DFKT\F6R&X'09Z"LB8&2XVAL\]<T 7;6(^
M6&'0C/%:-NA)^GZ55M5)4 _J*T(4V#)S0!9C'R\YZ<_E4UMD7D8]&]:8.F0
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M';E> ?UJ_"01D\^OY4 6%&!D=^W^?\\5+ /](B^N.GM_];^=19R>ON*GM_\
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M./W+9.<#I_GZ5B3$9*@G)ZY^O^?RK46]C:/AN?3_ #_GFL^:W5G)3C/3/\Z
M*42JC\C@<9-6)$>1LC..?PIK1E1G<.GK4T%P OS$9[$T $4(0%F7GKZTH?\
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M* $L"<8QP1TK5PS $'![\=\_XYK*M0ZSL/X2>1BMN%#QUYP!D4 6E3,8['&
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MEP1G/0Y_7_\ 56A:H60*V.."1_GVH E"A2/J#C'^?\FK22X3@#/8XJMY!/?
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M^[ Q@DU#(3_!Z_I4TJ1J#\_Y571C(W"]#QG_ #]: &A^-I&#Z?CT_E4B!1R
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M %__ %J9D'GH/7I29Z  <CL.O^<F@"*[ \OJ,'J361=[UA)CSD=.U:MYO\H
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MKG'3_(JI)OVMCT/Y4 5IW7JQ!Q^M5I,,NY>_;\_\:BEF;.),YSS[U)%,#%@
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M:,5RI3#M[C'2@!'A,@.,[AG%-2UE(SM^E.ENR20G ],?X5?LY Z!'.,]B.U
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M )_G]*M!6SR,'ZTH!^;(_3I0! ),*0<DG\*<48(S  N3Q[5)SR-O(]:8&(F
MR?ICC\Z  @S+M8;?:JC1R6TI&P;?4BM+RXVE!<'=TS@YJP+59'SR<'^M %>V
MB++N89Y_S_GWIPC1RR<#G\ZM"UV(/+# 8SFD?]VI!X/0\]Z +&GZ>BM@G?\
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MN1^M $0W$G)S[^O^<"H+T+Y++T/3CM5H[@<CK_/_ #C'X_C5.[QSSG P/TH
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M=W\HO\Q_SZ5I)'$JY8@8[X_S_D5Y_H-S=7=\O&X X)R<5Z(MG*T>6*].1^5
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M_)TX^57/3C_/^?TH 4@8YZ <_3_.:L0M\X]<XXJ$+MX)]/\ /\J?&>?E[^M
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M><C@8Z\4 :,&-O'KUQ_GTJ:H85^4>WK_ )^M34 %%%% !1110 4444 %%%%
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M9F^7:3^/^?\ /%0JNT\=^V/\_P"<T !7/)/!_P _X_E5>0@MMR ?\_I5LGC
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MQ_M/E1-Y;<]_6@!]UF1AMX+=JV=(LWB =\*O7)JMH=D]V!)(F#GGCI73^4H
M4'TY_P _Y_J 6K6/< 0,C':K>,GZ\_Y_7_)Y@M$PN,8'I5D,.<<Y]?2@"-U#
M?[WJ<_Y]?R]JGC)4 ;<=^:8 Q(Y).>?\_P">OM3\[<#'&.U %R)LIC.!Z]A4
MZX['\*IQ-@\=_P!>*N"@!:*** "BBB@ HHHH **** *T[A0!D@@=^U5"XSCG
M/M_G_/-23-EB-W<Y.:AVG[OZ_P"?I0 'YHLYY(X)/7BHG5P>/7OWYQ_GZU/@
M9SC&.?3%1.#GG@ <?E_^OCZ4 0GW&<],U7E52?\ /TJX1G/&?7'^?UJNYW-G
M&>X__70!5,"LV#RI]!V]O\__ %ZLND6[/NV*,G/3&*TB<>_U%074XBCR>.,<
M]?SH P-12.VC(0YV]*H:7-YH;< !CU_SZ4:BSW+L4?)[UFRW!L;;(R6/M0!T
MD+1)(,L=P/XUKI+YD7R_2O/[6^E8DONSGT[UUFC3,Y!;@4 :A1E!)[]LU@7$
M$:RNR<$=<&NANYDBC+.2.?\ /ZUSMSSN:-NO3F@#)EGF\W@\?6J\DTC2XW<]
MCG_.:MF&27G=D]N>M5VM91+G(//'>@"Y9>>7VO\ ,*TK?3HUNA.GW^HYXJI9
M_(P9@,<=JV[5HF(V]>W^?\]: +\:$J#G!]N._P#G\J?) CK\Z9;'?K_GI^=$
M 5>^>WZBK&#N!Q^)H JQ6Z)G$87MVX_SQ273JD+[N!W%6PISQ_D<?X5E:ADC
M9MQQ_2@#F-1"S.=ISS_6LB6WD9UP"1WP/\^M;-Q;C=DL%&1WS4^G6:RW"#@]
M* )M!@E5OF#<#O\ RKJH^OM_G_/XTR.%(4VH #QZ9_STJ6(#.<#'T_R: +!3
MCDCC]/\ ]5*@*\8&<_Y_6G8'0GZ'T_SQ2@\@[2!_G_/Y>E $HX4!1D>YJ12=
MPXZ'CCK42J.<#CITIP.&P1U]O\^U &BC;@"!UYYIU5[9P01C'UJQ0 4444 ,
ME_U+X_NFLQ%RN<]3FM.7_5/]/6LQ<A<>HH 3HN0/H/IG_/\ A3#C/?C_ .O3
M\\=/\Y_SZ_XUFFQ[]_\ /YF@";A>6P#C\O\ /^>U0S .O!Z]>:0[G[\TK#RH
M69CVS_A_GVH HJXB/.!WJ66='@)##I7-:UJXCW!6Y[8[5FV^J22Y4GGZ_P!:
M ,[Q9>.K,@./?K7*66M264K>8V5-=/XB@>6R,CX+>XKB8M/EGG;>K;0?S&:
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MM #"1@;1Q_\ 7/\ A_.JIZ_E_.K1''/)/7'/I_G\:IR83H!ZYQF@!0,#'/\
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M!!/^?\XH L8R3]>>?I1^)_WAZ=,_Y]*3G_/U_P#K_P#ZNQU/?KU/Y?T'^10
M\,5&/\C_  IPSCFHAU'N?3W_ ,G_ ":4N2 /_KX_Q_SZB@!RDD\'/K5^#A,G
M  [_ .?PK/CY/L/\/\_I6A ,+T_2@";H,"BBB@ HHHH **** "BBB@#*< 2-
MN]?\_P"?_KTA8_='!/YY_P _RHE7$IY')Y'Y"F[N -G../KU_G_*@ V$=./3
M]/\ /X4TN0!CZ#'X<5)D,"I^7V(Z?Y_J*B<<^GKCG/\ G_/L -+.P! ^F/\
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MDG'>@#H9MCPK".>G YI8[, JN,DG'&!3=.B%R3+G+>I_^M6Y%!$NUFR/?&:
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MC(SGD>H/XT*.1P<\?AS1O^7!&/Z4J_=)]O\ ZW^?_K4 -& 0.?IG_/O6MO\
M^FL?Y?\ UZRG.?PXS_G^M;- !1110 R7_5OCKM[5EGD GIC'^?UK4EYB<8_A
M/6LGMG/OG\!_AG\J #<#UP3@<9_S_D_6FG[O!S[^O^?\:4Y.0>,]>?KG^O\
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M4 8LL0M[48P3CGC)_P \U@R&2:3Y0>O'-=Q+X5OY4"FZ@QCN#5!O 5]ORMY
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M\'W=_*6CFA&?[S'C]*AL/!%[:ON-Q;G\\_RH SX+%8U"F/! Z =?2HI5*R8
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52MBJ)LY<[@XS[FKFP>K?]]&@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>oncoprexlnp_850.jpg
<TEXT>
begin 644 oncoprexlnp_850.jpg
M_]C_X0_K17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    /  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHP-R Q,SHT,SHS,0
M  22A@ '    $@   -Z@ 0 #     0 !  "@ @ $     0   U*@ P $
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 2P    !  $!+     $  3A"24T$)@      #@             _
M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-!         (  #A"24T$ @       @
M.$))300P       ! 0 X0DE-!"T       8  0    (X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      WL    &              &U   #
M4@   ", 4P!C '( 90!E &X <P!H &\ =  @ #( ,  R #, +0 P #, +0 P
M #< ( !A '0 (  Q "X -  R "X ,0 R "  4 !-     0
M           !              -2   !M0                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !M0    !29VAT;&]N9P   U(    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ;4     4F=H=&QO;F<   -2     W5R;%1%6%0    !
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M3004       $     SA"24T$#      .L0    $   "?    4@   >   )G
M   .E0 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M/Y519]7^FM?N+'/'9CG$M_U_K(>W*,K@1101&0J0MY&FBRLNON?ZN0]H8#
M:T?0IJ8V&M;N_<7=XN.S&QZZ&"&UM ^)_.=_:<ALZ;@5V"QF/6U[=6N#1H?$
M*RG0@03*1LE6@  % *2224BE))))*?_4]527RJDDI^JDE\JI)*?JI)?*J22G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI__9 #A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@
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M;
M    $61E<V,   %0    8F1S8VT   &T   !ZF-P<G0   .@    (W=T<'0
M  /$    %')865H   /8    %&=865H   /L    %&)865H   0     %')4
M4D,   04   (#&%A<F<   P@    ('9C9W0   Q     ,&YD:6X   QP
M/FUM;V0   RP    *'9C9W    S8    .&)44D,   04   (#&=44D,   04
M   (#&%A8F<   P@    (&%A9V<   P@    (&1E<V,         "$1I<W!L
M87D
M                                                  !M;'5C
M     "8    ,:')(4@   !(   '8:V]+4@   !(   '8;F).3P   !(   '8
M:60      !(   '8:'5(50   !(   '88W-#6@   !(   '89&%$2P   !(
M  '8;FQ.3    !(   '89FE&20   !(   '8:71)5    !(   '897-%4P
M !(   '8<F]23P   !(   '89G)#00   !(   '887(      !(   '8=6M5
M00   !(   '8:&5)3    !(   '8>FA45P   !(   '8=FE63@   !(   '8
M<VM32P   !(   '8>FA#3@   !(   '8<G5250   !(   '896Y'0@   !(
M  '89G)&4@   !(   '8;7,      !(   '8:&E)3@   !(   '8=&A42
M !(   '88V%%4P   !(   '896Y!50   !(   '897-83    !(   '89&5$
M10   !(   '896Y54P   !(   '8<'1"4@   !(   '8<&Q03    !(   '8
M96Q'4@   !(   '8<W9310   !(   '8=')44@   !(   '8<'105    !(
M  '8:F%*4    !(   '8 $P 1P @ $@ 1 !2 "  - !+  !T97AT     $-O
M<'ER:6=H="!!<'!L92!);F,N+" R,#(S  !865H@        \U(  0    $6
MOEA96B        !OI   ./8   .16%E:(        &*4  "WA@  &-I865H@
M        ))X   ^$  "VPF-U<G8        $      4 "@ / !0 &0 > ",
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M_MS_;?__<&%R80       P    )F9@  \J<   U9   3T   "EMV8V=T
M      $  0         !     0         !     0         !  !N9&EN
M         #8  */7  !4>P  3,T  )F:   F9@  #UP  % /  !4.P ",S,
M C,S  (S,P          ;6UO9        !YM  !W!P  UWS6U*X
M             '9C9W        ,    "9F8  P    )F9@ #     F9F
M C,S-      ",S,T      (S,S0 _^X (4%D;V)E &1      0, $ ," P8
M              #_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$!
M 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# __" !$( ;4#4@,!$0 "$0$#$0'_Q $M  $  @(" P$!
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M=;5V<(#2LU1DI.+3=!>$-67_V@ , P$! A$#$0   /W\
M
M
M
M                     '5W-E07N?E6F_7/.^%9C7-.5EZ-RK5^D39B,A^@
MKA_6+\:7LH   ]4.DKV.(WF%R^VS'>6N1
M       Z21'M",NW4       *?=9\^:L?37AW!,UJW<VF2L?SWL%:-2]$ZQM
MJC5#9<%AEW;;&M"W7]@?EKOF;VE<   "OVZ\JF;5NA]W9Y(
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M'GGK<!9FRKYLFHZH.DZS?+2\]VM"^B?+X7)K7(3EA,S^B;@O5^PIS@
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MO-M9&Y^4(@R&E>$,9K8KKI[7TC#AQH(NSIW4B6FSR-9[19?#]4V3Z=ZF]TP
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MXQ%:JS8Z:JL:^&XRM)UG)76A/!5&>5[N6VF8MY/J4LIJ0VH[))WLX   :_\
MNWE+4]ZB\(;9?+?O&_G"_58HTFUN)IU(;A'?/&EV!TUYCOS\>[OD_A.9UO\
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M>Z'!EJ813R4/TNL0=U_T'&&P6%U>#\RO[C.=9S)=3MC.@[A^?>W,_M=D
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MU,=X1^2-:-H]4U9Z)T"<.*:+LVPW'I#5+WZQZ&VIZ/Z_
M  ZJ5VLR%MQYOB=WC)CY[UNO5C-ZEM\I+[      'P,=C"K6_P#(H=W+FO17
M^)R3";//'+^[8[B=BQ@ETLZ@    !6WHO&;)<Z[, -:&Y>5->^U^:^FJ6.(;
MUJV>=OQFK7A'9?74^?Q/9;GE]7&XW2O^1-3QFED,<DOIGN]4P*AFN)">WF6Y
MG82&RZD.\>IL5U#6ML')^&VNGM[%XCIN[[FWOL                 #KZ]I
M5WIG#YHT_I$=;!I]C^>=C         QPKP1FCU)UD)N;-0ZV>UN;+<2O+6
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M;YKXII=NM9[.AE)Z]/VT=<LZU13BN:V0Y#2I8L=NW\<M^CG/DN0
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MN=>?-;^F>CW;,48BSMO&=66)+";*Z\)?NH2QC:O?:W=25>R_HZ]/:]W5>
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MF7LN&PA@FH[3#&JY>UEYK=TKK79YDO<SM\O<W7>[7VU'T[ET*H
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M.J4)LW) 0ZPQ&,<!@W.QDO(E      '4T8_G3\RY^',)6^56%?=[QT)XZ<
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M?FO]+YPLYO: >"3^V\3L3[#\A:E?F_\ 2;=!AKGI=9N?I%^G_P!8:WD5U*
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MZK#W(NN9CF\#9GT]Y9U^^>O3M%/''LK<CC:O;:=>>\6]3T#A+G;S:
M                        "C//[[1_P3,>3U@A/?\ '5ZL)@!">1A7W*PZ
M&JV+ZE-Q)@%GKV$J:'D/)[1?H']'8*SFV6V*Y/!95C,Z([QE30CYWS<&:_7[
M++4J6;#:8;;QX4T(XREO+_I3S3*O0^=X5C,K5'@7HSK>:;_L&DC8C2+_ .-"
M:T>VVWZ O1V"                                HMSZ]T@<$S/O$,5W
M*RIM)* !]H/G%Z@'L;!K>KU6L70L)LE#]#WI; >\0 %4M/NM 'G+.<B9U.Z6
M-'Z4/8^<74SPQVI#U,@IQG^YA:'5[S@8NJ-N'9<7LUZMC0
M                 ,,L9]"WGC-UVUFX'9YRA1G,6V/TH@   6KO99 T3(\B
M#[3-_OHS!6BVVV  &%V$_P"=3S/GXYQ=3CQ=9N-E6>O3CJTF^L7P@DN\EG&E
M/)6L7?#L9QZF]?T!A;H;W9@                               "),-5T
M ^<\[&>)J>IA&]6%1;0   )FO);,ZK>\/'5!/VQ4/T3^F<    -=/,LAJ"XM
ME>MI1\GWOZ?)RU+KIH=Y)'J\16^%E/X .ZKP_1OZ=U^5,O2
M                    TS<.R^O/FM^/K=R0[N-C66QF^D0 \%F[V68M5O.-
MC:H&QSIV/W$]MQ(   \%#.=WVIGCN4C+%5/8 ',J0R:ZEX\L>%39C>R[:^RX
MJ]G0;(                                 4_P!*N]%/GW-<"G$?*K#X
M;/:Q7>TNEJP^\K+[>>4+"KU>N7'(EB -L'8<7M%ZUC0   !@N/GHISV^H_H5
MY%F(JR5E*=P]WM+N[Y93!FZ7!IQZBA'*[V7D30
M            ^$K3SQ/+Z[>:7_QE >QY@\GSB  '9UH?H1](X&P.R4
M                                       .OI1UR\QR&KWD^2P7'S^0
M >AE-U+SZD.#)'C2LZOY-KW8,9>_H=B
M                 (LQ%6@G.KZD6@WD<XRISJD+-[7;WIZ!96DVVVSO(T\;
MM9NOIQS"]D^D0
M Q"RGR&YEYU2
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M6I\CKN&\<>/JU=J%UMC^O9ZP;$*5,@$#GZ<+&QY3C%ME7*K5LL"#9!N!3%,
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ME7D8[CVZ%0FURI5.47<#3Y[ZR4:[7BO8.>P>*Y7Y5#,Y!8CF<0BX[FB_^_\
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M&_T\LDWEHURBT>-WR'X_]>>P\ .>WF_7TMTT5I<=Q9$T&7T6CTN SRI\ WL
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MFCW&4))*=_R9.6E)I.3@7Z[6AUVIPL6RIV=VJD8G4Z!>HC1:S_1 #WY[#P.
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M-;_\$;;/9J/CF5ZTPT*IQ4Q$SK/SWBHQ][JE3T=!US):=<:=4:-I5?O7AJ&
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M3A%TSCQTE]5/PU5M17E6R9AH$=5-'LXTRAY[6@I5*;+%.7P.0B@"V]N?MUN
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MW.IPC$ X5$A \#.0X8HF$"E#GOS]>?3)[E56)Q-<B@\.4#%53%(_G;D^9RE
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M+)DM0"MDLPK3JK/T\CH69R>@Y)0J#7\Y@N'+\RJ13)<Q"$3+ZK$WY^"@^R9
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M?4)P5"!Q1XF7BCPYN&54/X <X<^HI_<@*'#@B(__ $F__]H " $!  $% /\
M[LYF;AJY%W#[B- 7>;/W&[G-(:&UO:$ZUWUW_P"Y;7^QU0[B]V,[K]+_ /\
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M5-&^V;VOD>XO4#C#[C6!S.TU?[F752T/LQ^XWUCU!YUZ[G8]V1L7CJE1)?\
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M]?MPM5IN\%V9TIHXN'83-SM#Y\ ^PPQ,%3B:WV+IF;3?4_K7E6?['SK=_P"
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M."&VN2BT\RT&/EYTIU5>1V>VSV]Q<0W1!+12PW\HF0]Z36S.%'^^2+)B0,=
M]4;9M\=OR]@W=K:'BD<=L;A+9&[],:1AR.)KPQOG_2:QM=;YME]<7"<38PI9
ML_PB4 S-V7)/A]S%"-)J&/RGW+IG;7O+"+:[>VDD2A6&:">0RK,:^Z"AE;5)
MI4J:@FF/F3O,4,-]T_<=3Q07$9 99[9K>195C<$:6#*'BE4Y,BL"5.?R;M[/
M>8I-L:#=_@[I\E5[DDVQEJ*++&\BQR"E$E&86F7S,N^N+.>UVJXVJ:"EP?\
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MC2EPDA54BB2.V4S1  <ZI<@$9]5;5LW4]K>3V5+O;+:*&XB:"VMHA%/;AID
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MS'\R4(RQ7$;=OD(/'LQGQQI'&N-4@] _3BH4U].,AC+CA9>![,>-?6,4"BF
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M.8BN0P!)(<5.+&XZ+WBTNKDVLEN]G.\=K,H9E>-Q%,5CE5'%&5'8(HU1ABU
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M-([F*2$_ZZ'3_M!< -[7;Z>W[_JH+2+][*X4>:II7U"I/F&+R6 _Y1"(H_\
MEQC0M/335Z_)ML>FJ+(';NTQ^,U]84>>OUEM9-9\IG3E"=ZB*E--?9S>F0%0
MI;MXC"0I(-"* "85U9"F;!E).(WHD@X5)='4'B5!9D8=XH#W'Z-[/9-;K!;Z
M>8TLJQ*NLD+XFR-2*8VS:I+5/B;TT@99$>&7^Q,I*$#@W:#Q&+2UCN;"6ZGG
M6%$CN8W;F-4#4%S5000S')3QQ#LMHBG<9)FB4%@%+KJ!!8Y >$T/;Z\6%W<H
MHM;E':-E8,#RW*2*U/9=&%"ISI0]N.85MHE%M'<,99DCT13,5B+ZO89R*A3G
M2A[1B[MX;BQ;D0K+(XN8^4J.V@5E]G5JR*\14'MQ%!%#!*TL,DD1CF219A%G
M(D+*2'E09F+)Z9@'%QO:HHVR.58M3,%+R,*\N)3G(RC-P/8'M$<,<,</*5M9
M)&!S\7+T+Y@S#5Z@#0=N)$EN*%E(J97-*BE0J*@R[B<-M=W;M\='#RM H8V\
M) ?4#DK>T5(#5RIV^3IK_P" ;;_[I']4ES:RE)EX$>?(CN(/:#EB"^WJ76JJ
M54D"B$^R0H%* ]PJ*UXC%E!M%ROQ#QLCRZ:BA\0H#36R $K7($TSQ#<7%S)/
M;3<Q?$ 9%D-&\ 4 -S" I!'ARSIB&6_L^1')(V@ZU<:V0(J.10(=*L0<Q4TK
MD<1NCMR7E4+(581L5B9-*N10DN:#L/8<)').H<20U.=%IS RLU-*G,9$CCB.
MI8NJQL0JEBFF2M7T@T!C9B.^G#,8B7;%Y\[0U.DA55=:O&Y<Y ZE8!?:()X8
M2QA#6\\:R&74H+HK47E@>RVNJL'S  ##/&V6N\W*R60#.KE0*L1I0RJ*@E"#
M1@*9U(RQ8W>T3(;R,'4Z :37( Y48TJ#YC3$;W;BB"BJHHHKQ-.\]I/U8\G'
MRC^03P@T+HR_:",222*1SHXW'J41L/2KQLI'93R0747[R)U<>E2"/R8G>'_U
M>:DR?V)1K'V$D>KZJ^W6M+A@8(._F./>./\ EQD@']9P, #AB@&>)MVG7WLP
MTI_8!J6]#MP_953V_6+M5I$?C9HA'H:@1:  MJ)H0M-2@#432@K@*9$-!34%
MD+&G::RTJ>W"Z)(F+#Q54K)I[U.IJCA6H \_T>M-MMFB-Y+\+H5Y$CU:9&+4
M,C*,AGCH/I^[OK=MPCWE[F3ER*\=M&\90(TH]V'<C4RJ2!VYXZ<OKKIS;+"U
M7=D)F@G5W8,SD:QSGHK>TQH #D2.&-EW3<#;I8-NCT87$+Y/S64D*Y*@CB30
M T!-<;CTWO5XD%K!>M>Q.Q'L*Y%W"I/$S1491VL,L?,&]>QMIYKM(.5;3N(X
MVC26D<=2Z911J" &%"//3'7 W/8;&%&VN$BUBGK%+2<?C21WUDBK*K:@ ,@#
MCI/<.F@EIMD+22)$C5EM[X$&4NQ)=]8"F-R I2JT)Q;6T3Q? 16L3HD041K+
M<*);AP%\.MY"=1XC)> ^B&M&D&K,DNN@=F2,K&IXU6@]>/%,^KL(F55'GTB+
M/$MIN>E;H*W-1UJ\DAKXP2/'KJ"K@T [13R=-?\ P#;?_=(_K$EB<K(IJ",B
M".T'%M=W-RTDT3 KJX"AKP%!F>/:<"T2T$:LP9S754C@!D*"IKVGLKWR6T2/
M\0\:J$I14(IF#PHM*K05X<,\"&X?WH1@\9!)D9JU->!U5S)-1ZAB2&]DD6?7
MJU %BXH  36M5 H*Y4[1C<9?@ZVD[Z@H(!7,D4R([34<.[#[I;-R9:!0!G10
M*:34>*O;4<?5@W%W,7E(I4]@'  #( =P_F-YXB$(8NK'A'(U-8?NAFH-9_PI
M0)3X6DI+!/$R3HQ5E/%6'$']/ BA%00?)$2:W5@W+;O,$AK&W^I)5#W!A]3'
M;0D!VKF<E51FSL>Q4&9/JXD8BBLZC:[9>7"#Q(K5Y3^U*U6/FTCL\EM:&O)K
M5B.Q0*OZ#2BCSN#V82*- L:@  9  9  =P'UD=I $:9HM(C K*9J4!&6K5KS
M#5I3S98C%W.AFTC4VJ5VU4%:#4B<:]X[L(%NXQ*Y]DQJ&8#,@-773M[5';]"
MIX8DN;K8)>3&FMOW;,J4KK**Q<+3,G3D,SEBS:YM=$%S")8JTI)&20'%*Y$@
MC.A\V-POK:P+V5JJF9PHTQJYHNKS$]@KWG+/$5W9[$7M94#!@T5"IX$U<$ _
MM 9XF$.RNZQ2F-O%$ )$I5:EP"5J/9J,\CB]M;7:'EFM7TR^P%C?]5I&8)J/
M8 Q)Q-LT.T2#=8@7:(A49  *L=1  H1X@:$'(D8LH;O:9$GNG$<1\#"1ZT"*
MZL5U5(R+"G'AA=HALW.Y&8Q"("C\VI!2G -4&M33MK3/$D4BTE1BK#N930CU
M$$?0:6R;0'S+<PZ6/:=&EUKV5%*X=HP[3!3I\4!4D#*JE5.9[!GW8>]NF5IF
MAU-*6K)S:>SQR\?A$=*4[.WR;''^IL>V#_\ <H3^?^9/-]$&X<F9@2J**N0.
M)I4!5':[%4':U2,,MHL07]D&4CSZR8XCZ!J [SC]])3_ )</Z?SXI)$A\[(0
M?]B1A]V/=V\)/]F3\Y7\N&$<A53V (E/0:2'[\5^+G'_ '[_ **?[.%2_*S0
M_MT1O5(H"_\ I$ /ZXPSVDAYBTU(V3I7AJ6IR/8P)5OPL?I%6%5.%NX5H4*"
MO_"<E0A[^6X'+/$1OHX(M,)<M'S+9E*2I^O$V3KZ>U>Y@#A!'+S+21=<4@X2
M1G@?,R^RZ\58<,Q]..WMXB\[FBJ.)_0!Q).0&9(Q+LVW3+)(^5S,O!J'*"(_
M[I3[;?XC?L@>6_W!E\1"HI\Q\;?^8/5]:9[A$:?6VMBU#&!PH01IRSU=I]%,
M0R23,T9U!6=V74@)",8T"L20 :L_BX\,&1[XQNU!4(E6)X  AG;T GS]^*'C
MY3B_W*WVNXDZB2V10[3*+<&2V5-1C5=;:4;V2^DMF<L=$76V;3/<6L6S*&=%
M!"D2.Q!S%#3.G=C8=GW3?(X"RM-N$!BED,JW<>A(RZ>!>3"05U5*.=1ICYI;
M3<9O#9PC5V.AN%,;@]H="K5'><;(=VVEKN [K<A569H=)Y:5-5#%JC*A&7'&
MT6?3=B\HM;VY:>V1M4B\T@PR,I(,JZ!H#T.DC.E<6.V;D_.W"SZ5N8KO0X+5
M]I8>;XAS(XR%)\6@Y9\,=$+T]:R)L,V]Q&X$LG,FBNEHJ(2 J+$\1+(R@%S4
M-F,6F^HZ?]67%\+)X:9(1.4DO1V>]MU6-1Q$A8XW4#@+J;_\UO*TLCA8U%23
MP [SAY+,Q1QL:T1F 8'\1!#1ZCWJ #QSXX>0LP.I5U,D91-3!=>M&!\-:C4M
M">.)MP6>4W2R ,7(/,+9$TH*-VY94KZ?));'_!V_;T_NV%M7[Z_R%F8@*!4D
MY #O).0'G.#RW>:G:@\'_I&*J?2I;! MA_Z9/S*?RXS@>O[+QM]U5Q4\X?\
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MH-2.97617(YYT/%:T-.P8A1V >1M*CM8T)('H J3P XG NU?5;D5! )J*TJ
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M[(/'!O5NI!>5_>:CJ/I)X@]JFJTRI3$NW=/;++)O:1M(_(3W!502SS$D):U
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M^I,HE7_:\0]3#!U0O93G\4=9(J^=#XU_U2P'=@7#*LMB302QG5&?,2,U/F8
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MTNX2EL?%1J,(PQS#',/"6)T2#)"=$@7(XEOH&/*C35D?&@[ K&JRQ'+W4E:
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M\7,R&$EA?3,C!E/<RFH/V\>_"WMNFFUO(Q,H'!6;*11_9<-EV"GDOMIE:O\
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MHR/&" S*4"HX!(UA""I J5K6F=<(9=0!NA'+&!"0BBE3,TE=,;!B $XT.>H
M8V2WB6(0RW,ZR55#JCYVE58L"0H4^','M!Q$-NC!LM,@G8!"P82$48M5P%CT
M\O30$$D5-<+''9N=O-Q;\F3W(B1=:UTLOO&YBU#B2I!J6I3%TI""*.61450
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M)"OWRG[/*1C:;\&O/M$J?VXZQO\ ]E?M^C&\LBHVAPC-[*2E2(V:H( #=I%
M:$\,7\=U<:MX81:6$ZJYC%=2+-XEU D,4J"R]N5,02R<J$_Q)G958%5'PVDL
M&% 59N+  :B0,*#W?0W7=*T<)R(O/),/$1YTBU'_ %A@#R!:\?Z?<,\60=:2
MS5E([N9FH]2:1Y+BYVF\>"YE@DA9UR;ERKID4-Q76A*DK0Z217/RZ2%YRA@I
M854AA1T<?BCD&3K7N8$,JD-HC869?31C5HF(J(V/X@1G%+PD0&M)%=1B&><5
MLG!CE'?%(-+>M?:'G Q-:R-J*')AP92*HX\S*0?61V>3+CBWO["\EM]PA;5'
M+$[1R(>]74AAYZ'/@13%KL_5,-IO>U0R!UYH-M<JV8J+FV"MF"0U4.JM6).>
M(]OF^7MY%<K,)1-'>1N^L"E"98Q50,E% 5<"6IDJQN-FV?Y?VI$DO,,][<22
MRAZ%5(6(1KDA*'/QAGUUU&D=KO\ O!.TQL6CLX5$%G&6I73!'134@5+ES4 U
MKB@.6)=WW!:V<+45/]]-Q6(?LCVI3V+X>)Q<7EW)JN97+,?.>[N X =@ 'DM
MXY4K;H=3]VE*&A\S,47T%A_H%2-26EMID'G=-$Z+Z6$3@=Y & 0<CY9H>,ME
M<:O^ZF\)]2R!2?[7TJ4R^B%527)  '$DY #SDY#%KLD+@QV@/,(X-</G(?.$
MRC'=I/?Y;>V*GX<'5(>Z-3XO[YI&/2Q_#@ "@'TC5*R2*T1\X8%DKYTE560]
MA)I[1JK=X\D6V2-_XO;K2$G_ !HLR8:_[Q#5HN\53NQY_P"F1[B.T=GER/ES
M.'O[^8P[6AH7XL[?[N$'VW/?[*#-CV8C;E"*SB73%$#41IZ?Q.W%W.;-Z@/)
M?WK+XR$4'S&KG\J_8/\ 0)[<R%)*AD<"I1U(9'%>U6 -.#"JG(G$]RMN$A+T
MD0<(9&J0%[X)<V@?LSA:CI0^1$NFI8W"F&7S+)EJ_P!1J-7S8FM9Q2:-BK>D
M=H\Q%".\$?5-O4@_S!)2V4_BDX-*1^I"#D>!D('9@LS$L34D\23Q)\@6M*]O
M<!F3ZA4XC>2.E[. []ZBG@C_ -13G^V7/;].X@C-)B*J?VU(9*^;4!7S5Q,J
M(5@EK(@/8K$ZD/<8G#QL.PKY_(KHQ#@U!!H01P(/?@+N<HM]UX<ZGNI>[G 9
MH_9S5%#^->W >> B$\'6C1MYU=:J1ZP?-BH-1Y,R!@M;VS&(<7/A0><NU%IZ
M\'FRB]O1PCC)$"G_ (DN1DI^K& #VMA9[R6I4450-*1KV*BC)1Z,SVU/E)P<
MJ'G-]RH/S?Z!M14^)"%1J%5=6]J*0#,QO05IFK .E&48Y:!OAW!*!LW4JQ5X
MG(R+Q."I89.NEQ[7DIA;NM=RM$"3#M>$91S=Y*>Q)^SI8Y _4RW]]*8]KB-'
M8>T[=D47ZTC=IX(/$W8,?$2*$B50D<8]F.,>RB_E)XEB2>/ELK9UK$9!J'>J
M^\<?8H'^M3M^IDNTHL)8OKIE#(0 SL!GR)@ )J"L;JL]".9B2VN8BEPG%3Y\
MP01DRL,U8$JPS!(\I-A>R1 \0#53Z5-5/K&";K;;*=N]H@K'UH5_)C+I^QKY
MQ(?_ #\5M;6TMSWQPK7[7U'%;^^EE\S,=(]"^R/4/HK&J%EJ*@"I-30*.]G8
MA%':3YCBSLWISPM7I^NQU-Z@30>8#_01Y@M DP/^I.@\7_I867TD>6&]M)-,
MZ'+M!!R*L.U6&1!R(P]]M">R*R6_%XN\H.+Q=U*LG BF>*@Y?1 _$> [3Y@.
M)/HP)M[<HW%;=2.=)W:O]RA[2WC/X5[<1M,%2WC%(XDR2->Y1VD_B8^)CF3]
M"XN"/8A8CS%G5?R*?M^IH>&-5C%6-:TC!"M'7,\ASX0I.9@D]R3FAB.9EJAD
MB3VB%*NG_-B/CC]/BC/$.1BH-1]'W$3/_9!('I(R'K(P?\J?[R?F;&=L?[R?
M_BQ00-7U#\II@10P,7/8@YC?8IT@>=W4#MQ'?;@B_%+FD8.H(2*:W;(/+3(4
M 2,$A 22Q_T$-RYTPZ#'*WZJ,04E/F@E"R'NCYAQ-;7,>BXC8JR]S#CZ1V@]
MH((R/E2XMI6CG4U#*:$>L8_\9L"9CQFAHCGSNA'+<]YHI\^*VN^Q#]F9'C(]
M+ ,OV98JNZ6!'_\ 4+^<#%9][L5'FD+G[%4X.O<9[EQV11Z!ZVDJ?6%PR;1:
M1VBD4UCQS$?\ULQ7]D+AI'8M(QJ234D]Y)S/T=QE_#H3_:9V'W4/K'U:&Z@K
M*OLN"5=?[+K1AYQ6A[0</+;%9&/;E%+ZV53%(3WO&I_:PU8Y H_7C:@'_,BY
MB'_9]&,C#_Z0?HK]V%T1$@\"J,5/^NXC4>DDX5[]U7S'WC>@CPQ#S&CX7_+<
MUP.,GB_V<D'J48"1Q*J#L  'V#'O;6-O2H/Y1BO\.@K_ ,M/T8"1H%0=@%!]
M@_T&:.10R,"""*@@\01V@]HPABI3)89&-%=>"VTS')9$]FVF8Z9$I#(0ZHS/
M%*C)*A(96!#*1Q# Y@CN/T> QP^GIS"#-B,R 33(=K,?"B\6<@#MQ%%,@6ZE
M/,<<=)( "5_80*O<2"1Q_P!')(+B)7@<$,K $$'B"#D0>XXYMJCRPJ*"A!N(
ME'!5+$"XB'9'(PE091RG),2.1S+=#0NH-%/=(K /"W>LBCS,W'%1P^B!VGAB
MHMV _:HGW.5/V X_=C^\/TXSM_\ :0_D;%.0?M4?E88$<$+NU>$8UMZVRB0?
MM,]/,<17NYJAN4.J.,'4L;4IK=B!S90#0&@2,5$:U\1_T>$T\16[ H)4.B0#
MNU#VE_9?4G>N'EM526M<TTPR>M:&!SWFD1.")*H/^*C1>H.-<3>IP,>& ,.\
M21$?]O 0"-6/87#'U"/62?5@&6&0)^U[E1Z=6J4C^RB^G :XEJ>U8QH!\S.2
MTK>G6OHPOPMC$C#MT@MZV-6/K/D)ELXF/G13^48!&W05_P"6GZ,!5 "CL'^D
M>N3;X&?O,:D_:1C1#$J+W* !]W_V3?_:  @! P(&/P#_ .]G<;GNU_#:[="N
MJ265UCC1>]W<A5'G) QN&V?*OIR\ZIW&V5>9+$T=I8(9"5B!N[DH)&DD!2-8
M4?F,"%;MQ?;IM^X;%M]A:1J]Y%90O/<62.51)99+T4D@+L(S<P0\L."?W='-
MONW6?SJZ@MKIQ9R3R136L5O;->R(+>P:,6CTF:)C)=25!M4!F57C1@VT&#?=
MQ>^^*N(9A=S&26-XY,M<H6(/$5J\3"('E NQ*C5A;VUZEGY$:C6S1)*D@! >
M1%D9G6,$,02P+#4R5,;()=HWO95G96H&@J&*FAC(1M6K6"*5Y0H5)"UH!#:W
M6B]X&*0:)*A58@*<F*AE+:"VG4 U#E]3QQJCOIXW'ZK CUJP8'!FN+/^(;>O
MM- NFX4=_))*RT[HV#]T;'+$6X[5>)/9O4!E/ @T96!HRNIR9& 934, 13_1
M>VV2*,;G\P;S0MMM\;A:&5@D<MW+1A:V^HCQLK2.*\J-Z,5C@^:74C;WO-S<
MR_"V%I<OMUG:K;E8ITV^VE#)?W,,A8R3W+NTD7(-O'()"<7<N];^(]IEW#XR
M/G 6M\Z6]L4CMU@:KO<FZ:.-Q;K/ 28W5D(<+:!_E;<W>W1UEM[F]F7;BHD0
MH;5VN$DENMN(=P+<P'E*\@A8*]!8V>_]0]-[3:"9KB:&V6\NN=<O&(N;*\IB
M&F**L4$*@QPHS ,U13:^G]SZJL]QW.V1D,[PR)S4U'E"2CM(QCCTQZ]>M@J@
ML5&G'\7"P75LJE1%%(%I$RLIB D6-5 #$+I!I6M"V9*7T=U:SZ-#,8&6>2-4
M3PQR%=" 9:I 2:HP&M"0PNTM5$I@F,>1>17@Y;QT85<C5EI+4-2Q3PJ,:.IK
M&:7:TC!$Q!YH&K26-<Y$4&K,V8"N=;$*ACN;64/ XJ&' ]GJ(-00<P000"/J
MKCK_ *.LWEN$\6XV,?"_@4>.2),@-P@0%H6%#<JIMI*ZHGCV[?-FO$N-INX4
MEAD3V7C=0RL*T(J#P(!!R(!!'^BMOT1T';QW?S.OX=:!M)AVZU+<MMPNPS(I
M56)6VMRP>ZF&A%8*RG^.6'4>]7G4)W2.5[Z407HN)XY-9EN%MW6Y@9I(J(E:
MVJ$QR(#;D-M]ET9*%Z;V^]OOCMUFATV\<TER&-M:T$9W"XBT$LT(2UA=ETS:
M7IBUW&VLI=TZL2,*=RW!S=7>79"\E5MHZU*QVZQ@5S+',_0DM;ZVCFMG%"KJ
M&4^D$$8FN>EO9!9_A7(TLY(.I)6#,C4! J:$E-;&.)8C=V4^TZ+B"*4R-*[&
M4E0QRU+DKJ2A544D,58@%AB"R:/5M4D<7-100%=T7- :*K#@ *)3W=>6L;Q1
M75K*'MW%01^@Y@@Y$$ @@@@$$>6NK[L::X%3GC,YX)!X>7J3Y<-X>GMRBDW?
M:QP6,M*%W6RCX +%<RQ7D<:#PI>NH 6(4_T3W7JR]@:XN4TQ6MLG[R[O)CHM
MK:,<2TLA 8BNB,/(?"AQU/OG7.W<W=-_AE6ZEY\)-O.C*]JW+CE9U@MI$6WC
MA"N%B9) ND<T=1[VET]I\OH)(CN4UK,X-Q?M#&UWMMO<(Y,@$GBO9EDD5#(T
M<;L[!DV_8MAVV&SV:TB6.&&)0D<:**!55:  ?>:DU))P233''MQ2F*4QF,L4
M -*TP1@WED1%O"+0-1:3)0@Q2A@RLK*S*I8-H+5H5+*7VT17,6YL^DQB&(GF
M#5D9'#,Y,F2ZEXT$@7106VPSRQ?P^\ED,1H05E#!-*DL5,+>%(@ A-5)C#<U
MS[(Q[(P!VUQJ[?ZL'.N7#!:M#B@/]?EZ-^8\?AEZ=WJWEE<"I^ O&^ OUIVJ
M(;@3GN:W5J^'R);;YNZ6\S $!E<Y&M,U4CL.5:XBW6]W:--O>M'HS#PL$:NE
M21I=@C5 HQ"G,TQ<;IMN[Q2;?$X1G\2@,0"%\04ECJ%  220!4Y8:39-TCN%
M J=-0: E:Z6 ;3J!&JE*BE<?P<[W!_$:5TU-*:^7[=-'M^"FJNOP\<L+8[OO
M,<%T30*5<YT5J552*T="16H#*3Q&$W:]W6)-O8$J]2U=/M4"@L2IR8 54Y-0
MX^.VV^CFM,JLIX54.-0-"I*,K@, =+*W @E+RSEUV[$T-"O D&H8!AF.T#OX
M$'$5M#NB%Y'T(U&$;OP"I*5$3L3DH5R6.0J<3[CN=RL-C& 6=JT4$@5- 32I
MS/ #,T )Q>V$%RK7EOHYB?B02 E"1W-I:A%02K#B"!=<Z^11"0')K1:ZLR:4
MH-#ZFKI0HX<J4:D3WDZQJ[Z%K^)J%J #,D*K,:<%5F-%4D7LEO=*T=O(Z2$5
MHKQU#@U&>D@@TJ*@BM0<0V\-XIGD!*KF":%U(S \0,<GA/BI&YI1&(W2S6^C
M^)LE1IP33E+(I=&<F@"LJEJUI0&M*'%Q8;9NT<MY$Y5D\2G4HJP&H#40,SIK
M09G+%MMVX[M''?3-I5/$Q+4!H=(;2:,IHU,F!X$8A7=M[BAYB*ZGQ,&1]6A@
M45@0VEJ&N8%>&((+'<$DEEA$J@5%8RSH&%0!FT<@ ]HZ'(%%)%W+>WZQQP$<
MPD,=-0YX!22*1R$D5 T-4C2:7*;!NJ7+0A2^D.-(:H6NI5XT/#NQ-;R[_&)H
MW",-,F3$T -$I4]G?BXAVZ]266)(G<"OA6=.9$34#VT\0\W&F)[V]W5([6*4
MQ.Q5SI=0K$$!21DZ$&FDAEH3J%7WJ/?(VVM9>69 LE ^DOI(T5]E2:TIEQPU
MQLFY1W$0XZ:@@5*UHP!I56%:4JI'8<7-M;7*//#36H.:U9U%?-JCD6HRU(Z^
MTI .SOOL2[C5AH8.M--=1+,H4 :22Q;30$UIGB\GAO$Y-NSK*3X0ACJ'U:J4
M"D$$\!0YY&BW-JY:$LPJ0RFJ,4848 BC*1F.S++^8L_Y#_TA;$W$/25D\]M"
M'*K<;L0KW3 JRZY[.P8K;1MJ7G/.S*ZHRXV+Y?=')M"G>I!)8WT5C$9(+)T(
MFG$@JJRV,2.)=":5N8U:#0)QJV/HSIBTY.RV$ CC'%F/%Y)&RURRN6DE<YO(
MS-V^0@<:X ;// %:>K!"\,L.>_''@:X)\D75L4(6XC4I*PJ&HR%(W%#[52J9
MJ23R06C1';%M.FXR0&$"*)&24H"&.8G2O@<'47 -6DU>$-06UQ<D?'Q^[FX?
MO% \1"E@O,4K(%#'2' )J/)7'#'KQ7L^AU;TR0";_;;F >9I871&]*L0P[B
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M]XP<N)P2._+S8.?DN4O25M+^&)RVA74,NJ,ZD--2Z8U;VLFH5H"]>G]WM(Q
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M^U0V;_"2O%*J,D3SK=6KQE)XGJO,U1H#X)'Y_4'3.RRVTLACCU[?;ZI)!I+
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M6^7\X02174T\MA;V=Q#(2LDD@=I)&M799'U-[WFK%)&\,M!CJ7YEW<,:MO\
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M6MBBR:Q445E51S&QN_3&\;C=6Q-TB-;V\!N/B;B-V6(:5DC!(+:H"Y929 P
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M5N63-N ;IS?.L-L:\ZSN)S;QQR$0N5(DD@FO %U0N]N@D*<L2255M*EF(O\
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M1*FN.WMXT=KB0"/_ "VAAH)&H +4[ON\.UW4,-Q<.Z1-N+PJ%KI77#'!57(
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M)@M\V-ACW.WAOW-G->0+SI8PB:I#5%9@'#1B4@&95&HOIU&&UM84CMHU"HB
M*JJHHJJHH%4 4    %!_+01QP/,2/O\ Z_)"?VOS?4@.H/I_IV]O?B@\DS>@
M?9Q\C>@_D^L;;I-]N#\P406[VT$@@BNY5!,5E)=20R0P7+:N6K!E8:A&?'I
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M+'&YU(33J2XZH:*&?<)8BMM%()%01*RF5V "&634!1*@(B:F)R7Z7#Z-?Y&
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M8R&'HO"F#W9??AO#3/ )X</7_P"3'HIB3P]N"!]>#Y\ #L)'Y_R'R,IX$4P
M?:&1](R^J2/\/$^@<!ZSY1$#D./I_J^LG^8_4FXQ_P#26V;C)?F[BYDMW<AG
M9U@Y*(662<N()Y))! L9=F?308DFCV^[4.S,('N+)((PQ)"((MO#%$KI6IX
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M5"F; T%C;](1WUI;JSF-[FY:.%5!+22R));VT! !I(T:$'PI4D*2Z>P22!W
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M(DTO=<-/O(J(M"2) Y(&5;X#ASY/^VWE@V^RMFGO9FT)&HJTC'@BCM)[!Q/
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MKR)6(FCN8I)+>]FMI :+=P2*DL+>**0,@*\N6N+;KC9KR.25I(Q)*JUC^(>
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M3+&W-=50JZ'5GB!]OV2699+,B*.J+-,;7<6GCDMH'=99T:VGGJ\2,I",H)-
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M0U#.&J.1M%I.N;S.\_I-/M\?S;.V&CG-A"O-[O[D&?QN3JF>UYIUWH+:2T0
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MKM3RWA7(^<Z5U,4AZAU_B,!G\S<NJCE&(IJU;&L)]A[FM<X7M541?I_1@O\
M5'QF5D$N,-7'Y!\EY&=+#K[FLQ/0*DO-N=_):N)*-"KB:G@-KHA@LC2R(P^4
MED^X0;*P*I!D1.T:/E!,.N;Y5PFHTG)>I6N"Q,C,37W59*INVYZPN(;FZ/42
M!ZE=2*![)<V[CJ2*$8/O>N>=-US8<7KV5FZ+C/?JB!(B2HM/W3D5L;&=&%&D
M5[B5Y:^YM*]MM"<![PK!L0JURI_1E>)YW/=RTTS=]7UW$<3TR@XKM[#B6KZ;
MS@.D/U+.4O5&0&9J2G,FXRY;<3'/9!86GG"CFD%B'8S2M;>;O/9FLY_TCJF&
MZ-KN:;'-\X[OS[CM86WZKJ. :ZQK!P.IP,-7#22=L%$-.@$;/KV3*_S+2]8"
MUWV HJ[AT[Y-YK:]>YCM>6XOIOQUIH%)9:3L_-KW85-:/08O)Q--6/M/NLBS
MX(K**4L9 G&1VAQF3A=*Q.YHLY4;^+ANR\SUO)=AJN3Z6;*K,MU_(9_8U]?/
MO.=Z&S@2(K)+6LEPI8OL3XT0I!,)_3T'$/:UW\V8S2Y\7N:COMR;6GEPXIVH
MOT^Y'DE81J_L<U%]<NU\DBEG7^#S$ZS>OX_J[JB*.X8OE57R.T&9O[_IZ[3&
M^'5SP>!U>)_IA<UNCU7R SNSO\OIH-?WSHPZ:AKY.'U66LLQ,FWLL;#6!UF@
M&%R?\,]4]R?Z5_4L;\ALS\?^FZW_ %'_ )C]$^2G2>Z8;+@QWQF^66LYGU0?
M=^<7_( :6AS>2H,GI2OIJ2M?:Q&N!*A6GWD62BK\)N[=H^5''O\ 4"^,?QO_
M -0VOUWRKZ1\>^>5];S;F&:E<FNZCCEYU/G>/V_5165'R/JVAKKFSL32'-BA
MGQCOB(P'W%Y!O?\ 3KVN7Z-HN4?"_P"7N0^2G?\ D\^+.P4:/U?)YN'\6^4:
MCJ%/[Z"WV4/K-<;15]4LD\NIAPI,I6"8]WDOP&?65"?,Q.*DX07X8NSDAWR=
M)\\5(ZK??ISO\F37NTQ>U?\ UQMUJ,6*D94G?FT;^'SOK?C1<?'_ %'R/POP
M"^ \OJ^9[GG]?JDZMT.@YITB.E5C-%D]=EXN<L+W1 GL?)LOS<.4>5&5[&#8
M4C?]+/LG-/\ 4#H_BSW'GD7Y7:_C_0ODIRG-V/+[/=]LVK+GY@<=ZGA2FS6"
MY9H\9T>>M16PJ[1U%I31HI1073P?>>O3^"\NYWS&Z^3GR]^66\^)/,NA_$1[
M,/C/E=@:;"YS8?)SY4<B=TM8,^&S*<='8YN=H;&PG5D'3CBN%9G"T34^7OP@
MK?BKL?A]S[YB\E+W'X<\#+N.=7YKG6\=SN&QOS'XORW0<QT^GJ8=WT[F%?77
MT&L+,!*;83;:5Y8PWW&=#Z=+#8;OXW=M[!\S^=<EX_S?6WMATC0TNXY]2YSX
M?X7;\#E=$,')<!JM:,A,T*MQ%%H.;;*CA2K,L2 TDD>VKNB6@[':U /A_7[:
MY=)0X['60_D!PV+HK#\VK1(=)MR,Q$?[6^_W>?">?'K_ %)OF+\/N=Z/O'6,
M-U?A?QYZI\=ZRT@0:OH_+.F_$;FEKS':"6<<8Z_0<3[J^#9V,AJ(0F-L+@;7
MC<U'+_J,_$_JF]ONFLUG^I'_ *8V>^0?2"2GP]-O-]\A(W!M%W?95;GHTE.:
MSV&XM"TP?PB1A1F(J^Q57B!?F5'U--DO]/3Y<_#SB?#=C(D1X]=\Q^F;'Y08
MS*,^55W&#92R-@TWQN-75HHAD(]NRO+U_O1H6C3_ %A>5_*OJM!Q#H>J^5_7
M>\X3([ALJKNNH\IZMQOGT7":7D<)X7%ZB:YMZ2;7+!I4F306$90%$Q[FHO\
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M5S J,2/-XS?+W$7Q[?<]&HWS^WQY7]Z^?]607Q9^1O.. MHQ_ UG08^\X/\
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MN<>883%5!^[PP7E51/*^?6)XQS#CV6WNEV'%M;W0DO>=;B\DIX66R6[HN?\
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M-=['.\+X_P"J(,5];'LYS_$P;97N>".B.4;/<%CF_><9$<GAR^$3]_IK+ND
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M_P"PL+BUEA@5=5"E65C.DO0<>' @@))ERCD7Z,#'CB<]R_L:B^NR\EYIM;?
MZF9SO1V-3IMI63<M1SJ*N0+K>UC6H"R94:G2$_Q,<0890(,AQ_M*UKO;V#14
MMSFZK8;/& H^>9'GNLRFXE7T_)75-K-7KG0:8UGG+&+C\*\\A*\K36%E629"
MI&^RQWJ5@=.W'4,"OL)=Q?0<5D:''UD6/;DACQ??*RMH(\9EC.YCI2,J]1&<
M]X2Y:W6=[&K%<]MMRS;5)UDU5GKID>C\/-('<1J*;G.P<Z<P?ATRKWN$B2#
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MK26D?E6JT^AKC6V#N&@&^15Y;8L&HJ:P\C!#?_PDDC0M8IK'H4G:[[):ROV
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MM^X&ZU$"AL)F;IS"1S%,*UNP CN9[F^]">WRGGSZI.C9+Y*=%U?1=N'X_O\
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MM=F]C?3[S-"K["BWR'N+"O#&TUG5V-.7G'$Z1EFZ-:$9-5K+"UB%:=P@N_,
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M(TBN&D[JV>I@V^-Z/A@?(CE&3(CW!=K-/?1Z;84LP4<(F$;Q'IQYQ[",OM&
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MZL4G3]5TX?'A8%$ PAN^DB7'\+Z=&Y_@DV\L:_P;KN<=LJO4K%_@EYSA^=L
M9.K$B_Q!)>3KF:U/'W6(J*GIT2ZZKM1UBHC&4.:MG87-1PM_PQX^<PH\W3-
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MS,'U'-Z"IO\ 1<OZS7P/R]I;T&TNJITROM8\<[H8ICPO^@1IZ*^NI-!0S]?
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M1RG'4=!3.F?J<)L,@)%>KWFD*HD:[4<BXUT.QV.WM9\F]NKS10Y,,VU;1B2
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M<1/J1]WS*PT--&*3\'UD<?E?#41O)1@D6IG3'4HJ^OBDFVP<AK9ZW..WU#"
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M>N<=1W6T^,F/[)VC'T.DP'1PYO,2^DZ?G>EA5>>S&G-LJ"AG::JP>@@RHU?
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MT^[^'I?N/<3ROU^X]Q/HG[U(JKZ\(J(GE?HGT3S_ +/P]?XE_P#=?^?GTO\
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MD]8;E4<<'M] N'TH]17+ N<]J\:<Z1HV]Y[JX256ZP<B0OAL8M_4HTD$Z_\
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MLZ RF2&]\GV&28X2M5$<X:>@V0D1!W'0NR6S?'GPK9G7=NYCD\_7P]C45/\
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M"''ZN0'2QYM5=R[^INBDBCBCM:^=*DRF^U\8;6/:Q6JCF^"-1Z*GK_Y2>/\
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MHOT5I@N<Q4_:CO'KJ-E)5RR+#J/29AO>JJY"2-Q?$5J^554]GN]OC]GCTO\
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M5/"O\^?/N5/IY_'^I&AU\*59V4^7$KJNK@C4TZTM;&4&#5U<$+?+C3K*?(&
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M2IT$ \BITM*Y_E5=4Z"M+&M83'/7W/$TOV#*B(1CV_3U+LL\2ON3E<4SI+2
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MK)F9JEE'5?JOE3'A/(J^5_?Z_+5=?!K8_E%^Q B1X8?*)X1?M1QC9Y1/[O\
$[4W_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>pipelinev20_850.jpg
<TEXT>
begin 644 pipelinev20_850.jpg
M_]C_X1 ]17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHP." Q-#HP,3HQ.
M  .@ 0 #     ?__  "@ @ $     0   U*@ P $     0   8D
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   / P        !(     0   $@
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MG._\DBI):J]']5%]GJ\_\YW_ ))/]GK_ )7^<[_R2(DEJKT>"+[/5Y_YSO\
MR2DVEC3N$SYDG_JBII):J'#TI__9_^T8G%!H;W1O<VAO<" S+C  .$))300$
M       /' %:  ,;)4<< @   @   #A"24T$)0      $,W/^GVHQ[X)!7!V
MKJ\%PTXX0DE-!#H      /T    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     T
M0P!A &X ;P!N "  30!" #4 ,0 R #        ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M     0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300        "   X0DE-! (       (  #A"24T$,
M     0$ .$))300M       &  $    ".$))300(       0     0   D
M  )      #A"24T$1       $     (   )    "0      X0DE-!!X
M  0     .$))300:      -3    !@             !B0   U(    / %
M:0!P &4 ; !I &X 90!V #( , !? #@ -0 P     0
M       !              -2   !B0                     !
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M;&]N9P   8D     4F=H=&QO;F<   -2     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      \?     0   *
M  !*   !X   BL    \# !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !* * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MK^]_W/9?RIL2^C4+.GPPGIICW;?T#?;^]_5W),;T\.&SIKFF#!]!H_-=I/\
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M\6-\$E/_TNR^O1(Z321H1DL@_P!BU<4<G)))-UA)B?<=8X[KM?KW_P D4_\
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M\DB)):J]'@B^SU>?^<[_ ,DI-I8T[A,^9)_ZHJ:26JAP]*?_V0 X0DE-!"$
M     %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,P
M  $ .$))300&       '  @! 0 ! 0#_X1%0:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C M8S P,2 W
M.2XQ-&5C8C0R9C)C+" R,#(S+S Q+S$S+3$R.C(U.C0T(" @(" @(" B/B \
M<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM
M<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S:&]P(#(T+C(@*$UA8VEN=&]S
M:"DB('AM<#I#<F5A=&5$871E/2(R,#(S+3 S+3 X5#$S.C4S.C$X+3 V.C P
M(B!X;7 Z36]D:69Y1&%T93TB,C R,RTP,RTP.%0Q-#HP,3HQ."TP-CHP,"(@
M>&UP.DUE=&%D871A1&%T93TB,C R,RTP,RTP.%0Q-#HP,3HQ."TP-CHP,"(@
M9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!P:&]T;W-H;W Z0V]L;W)-;V1E/2(S
M(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.F5E9#5E83<V+6-C8C,M-#$V
M,BUA9#<T+6,U.#,T,F(T,V5D-"(@>&UP34TZ1&]C=6UE;G1)1#TB861O8F4Z
M9&]C:60Z<&AO=&]S:&]P.C5C-C-C9#(S+3!F,C8M86$T,BTY-F0X+3!E.39B
M9F8T9F1E,2(@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)X;7 N9&ED.F)B
M,&-C9&(W+3$U86,M-&%A8BUB-F(V+68Y,35B,CEA,V$U82(^(#QX;7!-33I(
M:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-R96%T
M960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z8F(P8V-D8C<M,35A8RTT
M86%B+6(V8C8M9CDQ-6(R.6$S835A(B!S=$5V=#IW:&5N/2(R,#(S+3 S+3 X
M5#$S.C4S.C$X+3 V.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0
M:&]T;W-H;W @,C0N,B H36%C:6YT;W-H*2(O/B \<F1F.FQI('-T179T.F%C
M=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z8V1D8C0W
M-C8M,C0W,RTT8C<U+3DS.30M,C8S9F)C8F4V964S(B!S=$5V=#IW:&5N/2(R
M,#(S+3 S+3 X5#$S.C4Y.C$P+3 V.C P(B!S=$5V=#IS;V9T=V%R94%G96YT
M/2)!9&]B92!0:&]T;W-H;W @,C0N,B H36%C:6YT;W-H*2(@<W1%=G0Z8VAA
M;F=E9#TB+R(O/B \<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z-F8V,#DW,C M8F$V8BTT8C5F+6(P9C8M
M.3,T868S-C8Q.#(V(B!S=$5V=#IW:&5N/2(R,#(S+3 S+3 X5#$T.C Q.C$X
M+3 V.C P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W @
M,C0N,B H36%C:6YT;W-H*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B \<F1F.FQI
M('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S=$5V=#IP87)A;65T97)S/2)F
M<F]M(&EM86=E+W!N9R!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)D97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@
M9G)O;2!I;6%G92]P;F<@=&\@:6UA9V4O:G!E9R(O/B \<F1F.FQI('-T179T
M.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z965D
M-65A-S8M8V-B,RTT,38R+6%D-S0M8S4X,S0R8C0S960T(B!S=$5V=#IW:&5N
M/2(R,#(S+3 S+3 X5#$T.C Q.C$X+3 V.C P(B!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!0:&]T;W-H;W @,C0N,B H36%C:6YT;W-H*2(@<W1%=G0Z
M8VAA;F=E9#TB+R(O/B \+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM
M<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z-F8V
M,#DW,C M8F$V8BTT8C5F+6(P9C8M.3,T868S-C8Q.#(V(B!S=%)E9CID;V-U
M;65N=$E$/2)A9&]B93ID;V-I9#IP:&]T;W-H;W Z9F,Q-S1F-3DM8S U,RTW
M9C0U+3@W,&(M,CED,S<Y-&$V9CAC(B!S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240](GAM<"YD:60Z8F(P8V-D8C<M,35A8RTT86%B+6(V8C8M9CDQ-6(R.6$S
M835A(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M
M971A/B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B
M/S[_[@ A061O8F4 9$     ! P 0 P(#!@               /_; (0  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @("
M @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!B0-2
M P$1  (1 0,1 ?_$ 5D  0 ! P4! 0             '! 4& 0,("0H""P$!
M  $% 0$! 0            0! @,%!@<("0H0   $! (&!@H" 0,# P0#  ,$
M!08  0('( @1$A,6%PDP%!4U&!H00#$R,S0V-QD*(C@A4&!!)$0E<(!"(T4F
M)T<H.1$   <   ,!!P<2$ P#!0,- 0(#! 4&!P 1"!(@(3$3%)<X02+3U!4U
MUS!189$S=+1UE;75%C9VUA<WF!!Q@;'1,I(CLS26MG>W> E P4)RLM)SDR24
M)1AB)B=@H5)#*.%3AW" \(*B5&2DQ$7F1Z<2  (! @,#!08.# H&!0L"!P$"
M Q$$ "$2,1,%02(RDP8@47&1T10P8:&QLM(C,W/3-'24-A"!0G*20[,5-765
M-T!0P?%2PK34U0?PX6)C)!;B4X/#I&""HJ/C1&3$)447<(!4A%6%I28(_]H
M# ,! 0(1 Q$   #W\
M
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M3ALJ-=<=V3Q9G/?CMT       +?5<*   !L*;ZH   HBM  !'&30R/CWP
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M\&Y Z'H<4D69;'RQKL(.:1)%;CR4UU(.W?/UME]+=9;,EOZX_P"7GZ*9K$E
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MEQWL,%\P7XU(LR+!?274LV:S<I6W9;;]'ORN+FLV;&,!GX<TA9JRVF5Q<@
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M.SUMZC9+W&OPW8XI%U&61-/* XF2L6>6K1DLR&RZII=9:TOEMW%"19C%P
M       55,'91K[]Y*  %LNU]SMV   Y62N=[&-=U8 'AD^R/ESS8_07@P
M  %KS/T%/S!_0G)8DH           ;"N^H   -JE=VM   !BM:[  !H67/IK
MW@W(   MUVON-NP  %AD:/(8^_\ A8 !MUP952RKI)  %LNU]SMV   Y52^<
M[&M;U@ 'AD^R/ESS8_07@P    %KS/T%/S!_0G)8DH           ;"N^H
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MI3UQ0MM_,)ST?KT*[3SC-H^]DK7]GP/[?Y-LN?3#8IF_1"^2OZA+]9,
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MA+YF3XG3  "PUB;:W(J30 !@-=1GU-N  (LF\M*<+J0 /*[[5^/?21Z?^=H
M   &Q3-^B%\E?U"7ZR8           *"JOH   %$5H   .OSH_GV*MAPP  P
M"5SV?Q>A GG6>B\WN?\ =M0##*ZS,Z;,  1A+YF3XG3  "PUB;:W(J30 !@-
M=1GU-N  (JG<G*L'K  /*[[5^/?21Z?^=H    &Q3-^B%\E?U"7ZR9HJ!H:J
M:@        H*J^@   416@   LK'5+0 !$4[D9=@]<!44R5%;@!AE=9F=-F
M (PE\S)\3I@ !8:Q-M;D5)H  P&NHSZFW  $43N0E>#UX 'E=]J_'OI(]/\
MSM     V*9OT0ODK^H3'9F?H3]TYR3M=3,X>6,]E9V;^:;CF!R4\
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M)\3I@ !8+H6U1DE)H  C^_3R!9N  !$&RXB7];VX 'E=]J_'OI(]/_.T
M#8IF_1"^2OZA+]9,           %!57T   "B*T   %O*]4  0SLN%F;6]T!
MJH !A=VKS2W:  ",)?,R?$Z8  8_="VS)+9H  C^_3R!9N  !#^SX>8-9W
M'E=]J_'OI(]/_.T    #8IF_1"^2OZA*Y-ZTO2='>,&;%9<>3=7*N-EN"S;;
M-(PTU;IMTDJ+]IAD+7WQUL+,QAWY!AI@,ZS2F:UR(O9GYIOOI: !055]
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MF UI=K2X2G![.98/:         "-Y'.R1'Z(
M                           *.JOLODKI3]%^%.]_S/\ 0?DG#^@;E9EA
M[90\HCR,PB9LQB2(9V^KF#5;'&9.#!IL6<]+M,7D8<@CR(VV$*8-9/S>+E
M                                          X%]'X!T%>G?G7Z//)_
MTYCS==GD$>18L^/$I.&>=+LN,71:7DMH-I >ZU]-?9)&OF19L8L7;'7SGI]A
MB,FSD+I-CR_Y;H                                            /D
M^J%0
M
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MBU&^BU&^BU!AWK 4;Z+4;Z+4;Z+4;Z+4;Z+4;Z+4*BT=5R^'+C])=&%\4_\
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MWN>QV^Q3EV+.'QCMS[0'#O%.RTS!J[5GCHM5U[,U%ZK]VYJ$/7AM&J3'N#:
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M^BKW2/R1TF"H$E-CF5E/FT"=(U;>6!0C#140ZZ&K.DRG,H--4DE*H2@O698
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M5F(&WTD&)E09CX=%,Y5)Y"ND1-("45):?7 0(0%&(ZG3.#UMT&ND9,I&##1
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MW'VYNPZ(W8=$;L.B-V'1$VVY*:MV'1&[#HB37=,XW8=$;L.B-V'1%+;<=%;
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M20 LY]6&CJPT=6&CJPT=6&@>4BP?5AHF7&E&P&C8#1L!HV T5AUAT4!UB4;
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M".L 11537+ /WKB=W<>(_P#(IG=V)']W$E?66'F,_<OHP/BIW=X\AY@!TFQ
M PU  <[4IUCT=HZR7,QV?ZD/4+0$$?/3 )*AH:O&(K&@QR:^"/(VI"!B JAD
MP&0,B'"?IY@%=5-\ML)&V$C;"1MA(VPD;82-L+&V$C;"1MA(MQ=A]VG4;#9S
MF3=6N?I'[UQ.[N/$?^13.[L2/[N)*^LL/,9^Y?1@?%3N[_6-$IRF2*3I!)E"
M]>.:80F9"32 (!DD4.3K2T\2   RX?ISQ6WN$Z[R<$+R1P0O)'!"\D<$+R1P
M0O)'!"\D<&+N[?@A>2."%Y(X(7DBWF56]%P%.R65BV]F"_I'[WQ.[N/$I?X3
MDWN[$C?#Q(M54WSAYC/W+Z,#XJ=W?_I6F<:8TQIC3&F-,3$$XF:8TQIQ#=\8
MG=W'B4N[DWN[$C?#Q(GUUAYC/W+Z,#XJ=W?+1*.VI2"K5RP%-2\7IGVJ#22I
M5@I#UK ,B@2Z&8&K6I4!%E&DP:$59@RH4JA:J5PC6#VN6KI!5RP@U"T%,*:E
M2'1);HF-5+1/U>\6;AA66=S7S]66<"RGJ!!7(X)_=#H!N^,3N[CQ*7=R;W=B
M1OAXD:BJ3WP\QG[E]&!\5.[OEH@-'*44"IQ0:<T4I,.I+*5%1$4H+'8Q&B"J
M,3)CUI9:H.E/"D:%3BPTJDX.=<D<E27%22E8M*,5H$DBDMG-++U4BI0(\IZ.
M@G/1&F-:-,XTQIC3.-,XTSC3&F<:9QIG'^?3G[^^TY2G&4UYYAR#E)U'*BGI
MV4N)/0#=\8G=W'B4N[DWN[$C?#Q)'UAAYC/W+Z,#XJ=W?_I5_<G7&]]MCERM
MP@LM5HMED(N#_P#D/H!I_P#FL3N[CQ*D]5,2YZR9B0ZM</$D?6&&_.5=!OPX
M_P <C)C\<C)C\<C)C\<C)C\<C)C\<C)C\<C)C\<C)C\<C)C\<C)C\<C)@URY
M&KU8(GF"!"F6S#Z>K9B(ZMF(CJV8B.K9B(I*7ZU>J7XCJE^(ZI?B.J7XCJ=\
MXZG?*.IWRCJ=\HZG?*.SKWQV=>^.SKWQV=>^.SKWQV/?*.Q[YQV/?..Q[YQV
M/?*<NP;QQV#>..P;QQV#>..P;QQN[=^-W;OQN[=^)MV[TXFW;OZ-VKQ1NU>*
M-VKQ1NU>**VS>.JC=&]D;HWLC=&]D;HWLB31O7IW/O-&Y]YHW/O-&Y]YHX?7
M=[1W-O+&YMY8W-O+&YMY8FS+R3EN3>6-R;RQN3>6*F'>"H6MCWEJIW"O1&X5
MZ(W"O1&X5Z(I8=YI3,VZNR<"W$O#&XEX8W$O#&XEX8W$O!&XEX($8%W!: V!
M=P*B3$N_&XEWHW$N]&XEWHW$N]$V'=V< VZNN7EN%=V-PKNQN%=V*6%=F-P[
MKQN'=>&<V%=O2]4+.QOG'1_NG,'F87;%&$UTWJ9[_P NM\'I?!-)+J:?+IBJ
M75@A'$3HI!74P8,=2! /U'25%!IPD"Q N?*F JUE,H,C.). /]=)2@%3(BA4
M&B@DBRTF&PPS!883_;.:.FD2Q)O+YFD,6EL.=F=LX0;(:9-.0^SC S:*5@[I
MD!)"(Q8P9),TJ3JDA!=BFV@3.1-H 3K';@1@^"SR9<*;+JF-6T"W:,V:4JI3
MFX23#/\ MG1+3_[+_P#_V@ ( 0$  04 _P#5G.GS8\HN0:Y'F0^6A'F0^6A'
MF0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'
MF0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'
MF0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'F0^6A'
MF0^6A'F0^6A'F0^6A'F0^6A'F0^6C$_V0N6C*/,A\M"/,A\M"/,A\M"/,A\M
M"/,A\M"/,A\M"/,A\M"/,A\M")_LA<M&4O,A\M"/,A\M"/,A\M"/,A\M"/,A
M\M"/,A\M"/,A\M"/,A\M")_L@\M&4>9#Y:$>9#Y:$>9#Y:$>9#Y:$>9#Y:$>
M9#Y:$4?L>\M40+S(?+0CS(?+0CS(?+0CS(?+0CS(?+0CS(?+0CS(?+0CS(?+
M0@/]CKEJBE_,A\M"/,A\M"/,A\M"/,A\M"/,A\M"/,A\M""_['7+7-C2_9$Y
M:$Y>9#Y:$>9#Y:$>9#Y:$>9#Y:$>9#Y:$2_9"Y:,YC_L><M4L/YD/EH1YD/E
MH1YD/EH1YD/EH1YD/EH1YD/EH0+^QYRU@)>9#Y:$>9#Y:$>9#Y:$>9#Y:,>9
M#Y:$>9#Y:$9(N9OE<Y@BMA_9R_NY"EEB?9%GOG*>_F$Y3-B7X5L:]<J;^MFR
MS61^Z8+GN#:]Y6JKQ554T2>64O,>P#)S*/F/**[%LQ=FYR>]F [+=*/J4O:)
M[>@9[.=EQ'8YK6N%KM%8RE9A$ 0_ERNHB)B1EWO(NIEE;2NK,(\4S+'<]P)X
MUAKL -@>V#T*N@3&5T22N@*5:J.M6#O*WK7C9.<QA92E.<\"%5JJEI+<L]QL
M"Z++MFW++*O+=:AJYKNRX6HM=:) RA*;TRRYC;<M2S5Z0OC6FMLV7P6NK;9M
MHF6IX\NVTDKQOC+):BVUN6)D?7KDY?,S%JV]9^YL9=+4(5[+M$VU9RY&7UD9
M7LO"W8Q!Y=3&4%JSUJF=FLO+>'*8UK7MJF<JJ?U</N3A_9R_NY[85<T1,PT'
MEG817W<AG9KI,)Q5YH%=P6CO_FZ?N9-O7TNNJ7ZO=B$IJJDZ\X%AR=^4S/TB
M%'@T\QUD[86VOB^K1/$EZE+VB>WH+97&=-GKBE;L6[(V]+9\+ODWB\\R!^YC
M:1\\%PTUSVQNN%9:\C$S6W-8%M3F<6XIPQ<6_1%\@#UT!!@*::9H#5$P6N2N
MDS+@&BIF*5=*K$+JR4;F3%"&2Z5 A49H5TD4OVFF]7J, 4T;<'14>)4Q,8&F
MJFJFNDOW6+G.=9!DO[.E;FY#[=S_ %A]4^E)_P ';!-O,<LO)0N/G<0"AY[9
ME #S00,]S36W>G9FFW>>Z5V<QJT1 T3,6\9=X'<['$GYM&.K*J/>\!-0;,9R
MB3B-LF\R]=:Y9F^;=KBW#%N'<9^NE>SO6W24VW.;B[C]:3,S!76M[=FK,L<8
MUNO%-;>V"JJJ:ZJ_JXRJXG8?V<O[N3GHI.-BTK-RZ4Y>K%,*[EM67;Y1;*M9
M.T-P!,U3/M0R7AC&KHHHOAEM<SFOD2L!E,6+NLG+A9QOVB8V7BR;B!6<L=-[
M)M^S>6]1S-VW1V<]LJ .F8732]N4JW+4O!F@6,J=C#B03R?V7<6:-_V0[-;Q
M+*?EZ3KYV^L)9>YMIBF77+@-:#-79P*P5THRK!6J'S,VB>>1=T-OJ&7.3,6$
MS*@DK8;8R#&7@13LC965BR&3M6MPRVQD0056U"/DA!1[8JS':N;XK=BV90@)
M>RQRFNMFX3M*(JE<S*3<MY)M]VH\[2//,Y9-W..\CY#N!<&N_N7I&8'&S+"\
M;RTO(^82&$FVA"O96X\IR\T\QKN81A63TO)JDM6_S5!;-WP.ZV-8JU9\ZT\O
M.7%],EI6)M2MBYF\K+8+%YY=LG[HOLO6/;BI9-+^9L[>-N6PMO5GV6UXRIYL
MK'*3 9F<BRZ1= 968J;<K,Q<%GW<S#%_\F;:7<3K8H+>S\702B@V<.VXR?;3
M.C;)E/\ <#@LFZ[J9@[E-V[ES8L#>0"P5T&AG@O.UK2O'/,$O4$<X-H!7G>3
M,^T[LV):M]6,SLM$?JY2_P#V5A_9]4NH9U]Y!('>2J:(E'VX$\8%RF"P2Q<!
MS..<W,/5+>,2-XQ(WC$C>,2-XQ(4'68*DFI^N7RX%]K2_6VY;4IR_6QY;-)>
M?ZVG+:G,O^MORWR9CRV'+7UC7ZW'+@/#3_6TY;4YE?UQ.780K\MKRV8\MKRV
M8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV8\MKRV
M8\MKRV8\MKRV8\MKRV8\MKRV8+?KA<N"H2O];CEP"5J'ZZ/+\6!ROZY?+T(D
M /UNN7"4E+];SEQTU&/UPN74<-T_K:\MN5'EM>6S$OUN.6R).?ZVO+9G'EM.
M6SI\MGRV-/EM.6S*/+:<MG1Y;3ELSB?ZVG+9G$_UM.6Q5 7ZW?+:%GY;7EM1
MY;7EM1Y;7EM1Y;7EM1Y;7EM1Y;7EM0H_KK\N,@Y?+:\MF)_K9\MB<>6SY:^C
MRV?+7G/RVG+9CRV?+8CRVG+8T2_6SY;%,+/Z\/+I27=5^M'RR:JZ_P!:SEHB
M#C_K3\LPU5+]:#ECTU3_ %I^6;,&K]:3EE5FGU^O!RZ64VO+:\MF/+:\MJ/+
M:\MF/+:\MJ/+:\MJ/+:\MJ#'ZWW+;) -+]='ER.=K>6UY;,>6UY;,>6UY;,>
M6UY;4>6UY;4>6UY;,-3]>#ETND;RVO+:CRVO+9CRVO+9CRVO+9CRVO+9CRVO
M+9C(]RW,M/+YN/A_:+_NST:SW5;;[=7"?S2M4PSW-SMVV&$L\V3*^F(2OS$5
MAM46;YBEIKX/I/YHUHE1^M7F'#70#RT\PZS.<%^^H$/;T 7Q.@*?$Q.#[B]
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MM"MGPR/C/7Q_Y%H\?^1:/'_D6B>?_(K*,V?-?9['S)T\P'(K.?C_ ,BT>/\
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MV.$M_8M0*^T!B]MN^.VW?$EEY3GVN\X[7><=KO.,C0:\:N+AY[?]FNC,_P"
M&S76*VYSE*-:4;2G1K2E&M+3IE.-:4_4B==5570%:JJJ^@(UUUSQ#F!9WWZ!
M4KKI>^*\%55+$Q..<Y-YH3G-IXF'.<P\2-+7O!AY[?\ 9J%RW#V;;$7+ W>;
M( -F;DCT-G+U<YTM<M8&YAANJN5&\J,J$,J][CIM13CZ.H^@S\NUOICG'/)[
ML+ELO"[@92;"SD9I)9K;;WUO_1E-NFB-I^9. ',AM'F?<G2XSB<-[?42/O\
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MZ6[G>O2]SF5R[+IOI8'T\ZN7_P#=K1.-$XT3C1.-$XT3C35JZ)QHG&B<61S
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M_P"[4^OBFF"GP2[>_P"'T]N&58[<*=H$24/A[^ Q2W+4I4Q*33O5[WI;,9B
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M&CR*ZN?CBMAQWL@D_#9Y;8QQQ7,L ACM(6@MX@VF5G5$9B2QJ[DL<Z4NKL\
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M*7,SO'%":D O(\;A0":Z2:TSP_%+?ADC6"O,I?FJ-5O$)IQ1B"3%$0[  T!
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MOOY-2J2"5#:JA20"0#0D#+ G%_/OA*9=6MM6\.V2M:ZSROTO3PUUQ"\EGN2
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MX@O([2XTI,PAN92R1+70-Y&TB/&TL>I4902"KH6M8^!2F]M9.)^9-(D,](I
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ME=ETFHUN:(XH?NB2JG97FTRH<;^6>7>02$:BV<<C9L*UYKM2K=^GIT-J84N
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M226PMP4(EU FFE6+5J6!4D5;OD@\A.6<TRQ,BN[-1BI(J2:57F\O)XL7P_\
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M+&I=Z_=#^BOJX]YL^K/ML!=U::1L&[-!7;0:J"O+W\5"6H/WC;.\>?6GI;,
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MDUE=2Z#0 ZJKE0D-=QV3,+1],CF."6%'=!S'69]+TU4TLK,KE**6=2;&?A?
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MM9+BZB,53(V@1O"L#!4U!$(B4(I5.05V+1IOSW&SF0O1I 0'/W5"IS!S##G
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M_!)[$?8V?9S'<;,9C[&S&S&S&S&S&S&S&SNU;?)I-:&HST]*G@IGWN7&IKA
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M- *[N,P+K04J^AG;EHPU@:F"#"&:^C$E;8(-*G?"18RSKGJ(8NZKHHJZ*G4
M0+UQ<A;I896"D1:8V4D:6SW@9 !5G&Z)-:J,L2.)11;=F8<QM.94/6-0K:2
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M.0!CS"%W5484K3F$+0$"BU%*KAVD@6-BQ- :U],Y#G'EV_?'NI3# B:W+-I
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M2*E"3 Y.AG&H'LKV@[5\2X=PV\O'D10-W;B8Q,$WNZ0*JLQJ)'"K%J&JJ:M
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M7Q2=O!4)EZG=W'ZOC_+2]UP;YK_7D]$;P8L_@D]B,--,U(Q3D)S)  H*DU)
M%!A5K)O3JYN[DU\S3JJNG4 -:YD9ZE(J",>;;X[RI YK:2P745#4TE@,RM:B
MAJ*@T;3,:@*0"K L&;0K**596;F@J"":=\84!WUG55=#ZAH(#:ETZE )%2P
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MM0,RDG/8KJQV$&I H#7+;A7@D1].\IO-Y7W3=FI='#,5T:5KEH;32JAL+!O
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M'6V51JI4#2!J84@99O<VC#\V+4&!EF0$L6!C!6-:9$U+$@'+$\"SH(5L9+@
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M'%C\"GL1BXLIV(CD7:-H((((\! -#D:4.6$>_N4(634 @=0.8ZFAUEEU%]1
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M-7.K_ W>$)O *\X$CT^BRG9LSV]_'"YY%AK.(JJJOJYVDN1SS0(I8DD4( %
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ML1_"2"*@XMU\W0+$H"4%-(6E *<@H*#9D.\,/)!;(CL34@ ;34[-E3F:;3Z
MUWYLOG!)-<]I !(%:!J"FH"M*YYFIMHK55ARR%<M(55H:U% B@4I2@Q$;FW5
M]!J*^$',;"*@&AJ*@&F0Q=:[52)B-8-2#0ZN_D"<V H'.;5.!%$"$J3F2VTU
M.;$G:=E<N3+N+?B?9CL-QCB/#AP>V3>VUE<W$>I7G)77#$ZZA456M145&8Q^
MZGM)^S+[^[X_=3VD_9E]_=\?NI[2?LR^_N^/W4]I/V9??W?'[J>TG[,OO[OC
M]U/:3]F7W]WQYK_^,.T/G6C7H_-U[KT5TZM.XU:=66JE*Y5KC]U/:3]F7W]W
MQ^ZGM)^S+[^[X_=3VD_9E]_=\1<(/8R^X39I)JEN>(036D2(=(JN^17E;+H1
M)(VPD!=3+!>P6:<3[8:1KO;B,$JPSK;1$NMO]^&>8@E3*4.@?9X</]Q/[*'N
MY?G-K_:H>[OR/^I?V)Q8? )[$=WQ#YY/[,]WVY4L2!;\/IZ7-N=G==BOU$G]
MJN_1(_#BQ^!3V(_C(1:SNOS%6G)7SJE?#3T'A_S>?V4'=R_.;7^U0]W?_ /[
M$XL/@$]B.[XA\\G]F>[[=?-^'^QN.Z[%?J)/[5=^B1^'%C\"GL1@ECD!@3-9
MNJ-$94J5JT:@%C0$T8*58*U"0>^&"OYV-W((=X%+)SJE@%!+"K$+6@R%0"<7
M>J,TBJ*:D+DA@O0U5"@L*N: #,Y8N;MX6K$X4@%6!)TTTL#0CG"IJ*'4"*C.
M*UN('CG+,&J5(4*A?54'-2HR-*@Y,!M*7"PL':70 Y$>>EG!+,=-&0!E()KJ
M VUI'!;VY+M&C<YD2NO50*"27Z.9&68H2,\0R/;:=<C(-3H!5-0>K$T%"I"[
M=61RSP]L(:!1F=:5!H#7375I->:U*,*$<T@FZ:6U(6)E4G4M-3E0N=<EHX)8
MT H=N(DAM#(VD,VET(4%F44.H:B=+&@V:2":T!,D57F"R$Q@H7&[#&A7545T
MY5I0D!M.(O-XY)'DT:0 !FQD!K4C3N]T^\J*K2E"W-P\,D;HR1N[UTT7=L%8
M$@GO@@BH(SVY86>2UE$3Q;R.@#%UJHZ(-0W/4A6I4';S7TLTUNRN%E8@%6]Z
M3614';R9TH02>:*F"W%O69\QI="" 0"%8L%9P3F@.H"A-*K6G\(/8WM%V>XO
M<\1%O'-KMUMC'ID!( ,MQ$U13/FTKL)Q:<)O['B_"XIFTBXN8H#"K'(;S<7$
MTB@G+4(V VM1:L+7B?"KV*YX;.@>.6)UDCD1LU9'0E64C802#W/_ /8/_F_0
M>'_-Y_90=W+\YM?[5#W=_P# /[$XL/@$]B.[XA\\G]F>[[;R$<QH+ #PA+BO
MKCNNQ7ZB3^U7?HD?AQ8_ I[$8YPRP\;22LFY:-06KH1]H7*HRH 34T4"M-LA
MD#'5;B+DR U&HJ#SN<<_2'>Q=1:Y-U,Q9A4;2P8FNG5F5V5TTRIBZLQK6WE<
M-I!H%.1.G^B"PU4&6HL:9G!:6:9I"7)8L*\]=-*@  !:@   5)VDG W :-0P
M:BTIJHZUHP85(<CO9+ED,">!Y =* BH((353I*2"2S5*D5](8@0,X,<CN#4$
MUD+%JA@01SS2HRR[V$NWFD>122H8K0%ETFE%!I0G*ND$U"@TI=:R^J5XV-",
MC&5*D5!'W(J#4'.NW"2)<2HX4*2I4:E#%@" M,B2!0 T)%<\+;HK!0LBU!%2
M)596J:5V,:=[(\F)ID:6-W=&YK$ ,FKG*-@+:B'R(<=($U)699IMYH96.H'4
M'<.VH,I!J138*+D*##1,\ICW9C7GGW-"0:)2A%-*T))8:5&J@Q*LDDC:PU22
M*\^/=G8 .CG6FW,UP$FN)6BI0KS ISK6@04/)J%&I]UC+T#9CHG'1.-F-F-F
M-F.CCHXV8Z..CC9C9]EOU3:^L^,\1<#_ ,J[27B/9]I%-S;W&HV$:N:-*[LR
MBW<@,0\;I)(4"4GTB%K5N(0QQWYC4R+&Q=%D*C6J.RHSJ&J%8HA84)52:#[)
MFU9C@86GANB:^IZ#P_YO/[*#NY?G-K_:H>[O_@']B<6'P">Q'=\0^>3^S/=]
ML?@K+V$W==BOU$G]JN_1(_#BQ^!3V(_BL]M?_P @+PZMI%#N39&XINZC5O!=
MP;:UIHR_I'DM+SM5_F)-Q#@\;:GMX;/S5I*$$*9FNKC2AV/2/45)TLC4<6O9
M[LGP6"PX-".;%$M!7*K.35I)&ISY)&:1SFS$Y]RWZE7^TGT'AZ\OF\Y_].#R
M]W+\YM?[5#W?$6[T$GL#CAS=^"/V [OB66R]G'BD/=]L?@K+V$W=<*[1<7[4
MW5B]I8K;+''$C@A99I=>HLIJ=]I(S%%!%"6K^\'B'T>/XW'[P>(?1X_C<?O!
MXA]'C^-Q^\'B'T>/XW'[P>(?1X_C<?O!XA]'C^-Q^\'B'T>/XW'[P>(?1X_C
M<?O!XA]'C^-Q^\'B'T>/XW'[P>(?1X_C<3_F_P#S%O%OM)W9>V1D#<FH+,#0
M[#0U%:T-*&.).+=C-** /^$XGL H/_?C_+C+C78L#YEQ,^KY^/6Q^F^Q?T+B
M?^(8_3?8OZ%Q/_$,?IOL7]"XG_B&/TWV+^A<3_Q#"Z^/]D-=,Z</XB17TO\
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M[%F_Q?'[T>$_L-_\7Q^]#A/[#?\ Q?'[T.$_L-_\7P*?YG\)_8;_ .+X-/\
M-#A-?U&_^+X_>KPO]AG_ !7'[U>%_L,_XKC]ZO"_V&?\5Q^]7A?[#/\ BN&5
M?\U^%JQ&1_,9R]//BE/'C]\O#?V"O^)X_?+PW]@K_B>/WR\._8*_XEC]\O#?
MV"O^)XYW^<O#]/I<!0'[1/$6'C!Q^^>T_8</]]Q^^>T_8</]]Q^^>T_8</\
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M^O['9-X!#CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S
M7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'C
MWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S
M 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'
MCWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[
MS 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV
M'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV#@.<Q
MOWKB@</_ $ O/@-SY?\ R/#WN/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>/?
MC?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8> 'W8W[O
M^#_T O/Q^7_W''OQOWF O/L/'OQOWF O/L/'OQOWF O/L/'OQOWF O/L/'OQ
MOWF O/L/'OQOWF O/L/'OQOWF O/L/'OQOWF O/L/ <YC?N^',/_ $ O/@YB
M'_W'R./?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8
M>/?C?O,!>?8>'"Y)7?S)-1;@X/\ B O'),7:ATFX" H]H?&J)B <@'ER[_+C
MWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S 7GV'CWXW[S
M 7GV'CWXW[S 7GV'CWXW[S 7GV'AXZ)+[[XICY'Y1SP&\ 8/+ECH(=@OB>9^
M:A!Y\O '?X]^-^\P%Y]AX]^-^\P%Y]AX]^-^\P%Y]AX]^-^\P%Y]AX]^-^\P
M%Y]AX]^-^\P%Y]AX*W;RN_J+'*J8I P&[AS*@BHX5'F9$"@!$4C&[X^IWN_R
M#@!"8W[D(<P_^G^\AWA_30Y\>_&_>8"\^P\>_&_>8"\^P\>_&_>8"\^P\>_&
M_>8"\^P\>_&_>8"\^P\  2^_B(B!0 .G^\\Q$P@ !\P]41X6;+RV_D6;JG16
M)^(&\")%4S"4Y!$J(E$2F#EWA$./?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>
M/?C?O,!>?8>/?C?O,!>?8>/?C?O,!>?8>&XJRN_D!TV3>(<\ O ^,;*G4(FJ
M')$>0'.B8.0\A[W@\''OQOWF O/L/'OQOWF O/L/'OQOWF O/L/'OQOWF O/
ML/'OQOWF O/L/'OQOWF O/L/&CPO3N^T-V^RME6I"V%O.>3U&33;6Q:70B!C
ME)DA D3G/"+^,!/YF %Y^'NNG;^RN]_K;L?'Z7?_ %/5X0L[6TYC-SQ^GNN=
M5SK)HFSR?XU6O3U940>?C#;P\A76-;FOM3C# ^GXUE*K249']I?Q*Q2' NL4
MQY;,[G+9A="T/2-4B(-U<T48*MY@M5&MH)"S=CI<!"7*3.[N;-)FE&+N$UQ*
MJ85"%(43FZASK5E7/D*W*71ZR;S1U;HPI4#K@8;/VUS7!9% T' Z.X9MWJB:
MZAFS21:N3E!-00+)7?1K5GU4:Q3P(1]7R.;G:+.RMI<HI^TO*5*LZC3)N-@+
M'$TB_P 25X#]VV;-Y)PHU%7M(+&+:*2UT#")"WT*\9UF&A0GV_RT.2E:1LE:
ME;%CU2DYZPU*)K#Y73'L.I!1SQF]<,R6%9NV<*(HK>4EI\=H+!*LVVW4]I>7
M.=2"BS?0\\A99\\:UQAK%97;I*T.VV5@R&3:PZZAWZ44LW7<IH"NFF/=<S#R
M 1*4.0"(B<Y@(0H ',1$YS  ?)'AXRL^6/TWT1H=1R.S1\%9Z);Y.E:C?Y1O
M!T2C7V*J5IFI.CR]PG':3%@K*(M62KTY4!7*J($$()+,59N3):[K0'Z-3N6>
MW%* T#.*O9[M>:+:G-8MDJA5+57ZC29I^+61,U%VE%.B-1752,GQ1Y;.Z!.7
M"+TJQ6ZJ4:1BE(I%C-SF?5B-NU^3</921CVE<B:53IAK)R<I*G8Q;1HL4QW'
M:YEXCHRW,HMJO,Q"4_"NH.V5"ZP\O"+.G#$K]E.4F>L43ZQ\S51.@JLDZ3.F
M/:2 HE,;_ @_3X3_ -D3]<WQ&KT"A5V3MUWN<NC 52K0Q$#RD[,.056(T:^5
M+M6B146K=5PNLLJD@W;(J*JG(F0Q@L>@_;!FETH52E:S!3]QR[0H:_P3:;N#
M:SO(.*;+QA$'+UYY/3I 7792!-#Q:8@91-=(YJ.$K16J371KQ-YG4YEM9H1[
M +7^O9U%:X_JTU+-US)UR1<YS,HR+ SPJ:,B*;A!N<Z[98A%9NTDH='A!2K0
M0LQ>=$KU:CKO+VW-*_L<-3L]6=**&M=W)FELC))ZQ(5%&/,^1;+N".3E2-C,
MS'5)O[E]0<9H<QDKM]/P[+W<8Y7$2UAN SC=1R9U3W2M<@G4E#HR)$5)R.(5
MRS!1(X&XB,_S>7SQG;K$S</JS':1>66=MK2#.)D+ ^CJ](RC-VU?34?7XET_
M7;'%$2-&YS@83<B#&2%1G,:O@SE;5O,%#4?6X:<LLWF;>]-,U>Z_&P:S".65
MR>-N;])NXECG3520,+CR84BF$+-<E*RW^UFG;NWZ:;))$FXLYV&P.YE6LMX]
M-B"_ESVEFM:18@UD23-$)RJZ#0ZI5UDR#JE,>,HQG8,4BM"F=)1<S3-..B6V
M6SC:LV]I%RP=IG/S!K$]19Q;1N(JRRZA00Y^HG_LP_TC]W. /A,I \N]X>R\
M>"(#\1L <N?;/7P$?5#LOW9@[WJ\Q#EQ8-KEL_ER934:=D.AVVYLEH^48U:B
M;XC-K8_;9]DP=KRL?!W(:Z[2\>9 4X]<J:;T6XKH]N+@'5+@F5OL=ILU(IE!
M?:)1&%\T*X4V*K<U9Z[GU<?3K96UR<5'W"+Y)H* 9RN]3;MP6<#XK@P"15,Y
M#G352715;N$%DCF36;N6S@B;ALZ;JD,15)0I5$U"B4P 8! /T4C<N?9:RO>^
M/SB7H?X^.H/7-!?VD:7T[4_-9N2JM#6A65MMLUKFAI9M5'+J;L+&6BZEF--D
MNV\M$J+-TY1269MVY2*.?&%RO::/*79DQUG7-GH<15=,>5->6CX/,H?*WD8\
M))5EG&,YF3EI*^/ ,HDB1$S)%H8$R*F6YTG.Z%I-TL$X^Z@MHH]SHS^+@R7Y
M_P!/&0Z)4Z#8=JR<C1@2-M%LSA2T)/;A G!9=M#+EE6B0M63TG#7>+M8-(LU
M-4S7I DU*K4WE/KTLAH_5'!:G:I&2L-NF8>;BZ]D=9@\N58P9P9K2,S8GR;=
M18B22G:U+?:A&Z@,L1#6;]T[T^:B*ZLVM^*]/'DBNS/-1?QODCIGID@B_<IT
M]K"HBPG%JI-F O8! "S.5U2SN[.QBZ)C%P(]F%(LLV=73\9H&GR::S6*!-N2
M.CI.Y*-F9P(!CLTTC*"*AC"*'^W0_A2<=35_M<1:[DQP+.F>CM<JH\B>%G]$
M=V/3X'/5'LQ86D9-3=;RO-&T\::M4A&-%I%!J#8I#(IJ++$AMZJ='T.E35@Z
M@M+S,]/M[Z4LC.MU&GXIG.C1'-R[K=>DWBKJ:MCI=*1=HI*.HA1N!@,)164S
M_'L\G]#->IWJ;OM.<9K9)5FK+:KTXYS9,8A=$7R6PC'LU4^H'+H?0WL\ZBE$
M5BSM<3568IB\C3HKNMA^US1=5C(G%^E^XK9?%VUW >43_4+HN^U:6U"WW. K
MLO9:UC=>C<?81<0G'-3 [M,L1-VZ30.4BFJZA T+38?1ITVH6?IAH\]8*8S7
M;TS &))G1*QI-.G%JQI5UT#75PDX&A*1,,1HJYK#UVMVO&@D$;5:<2QJU:3Q
MGIXT=O(6(RSQ9S+Z[B=*TJ?\GDA9,FZD8::LB_D"(%$R+,")B)Q*)AXA:99B
M6I["0.&:EJ[NI4$S<FAZBICU M>@-LDSY=RQE"L[9?UHD&Q7";1VX:L$W2[=
M!1PFF4>J+<ZSC\[C3C(H'I65HL2WUJ\:51GLGKF]3.;WV;93M[@XV:L<>O7&
M2;(C9==RE&2R1U4E"',+<D)HNAW"R98-@Z1,PU$VKNG[Z;HU$V+3.L[0NG.#
MN5ZK*1$E/Q&(0=>BVL^BT,HZB45'4NV!15(R0U3*;R-NRW5'=1_NTT;Y+HV^
M.MC&O:%U.3/4HEN;*IM#%4J-E5T5GC\-&YX07!XY"0DVRR0K$>&3XH5$S7I\
MO'3U68AQ?+-M3BPZK;=%58YAE$8G9;PPGIC18&I,J'LK9!)"MN&K9RDR1GYY
MD(,VX% #]8-U=5ZZ5ZN5/*ND3=NF!I9;5$RDU4JAU&;D7-[QG>N/:N^G*S<M
M"RATUDZK( F].+:0CT7ZG)5T"0%,4>93 !BF#P&*(<P$!]4!#CK6^]+#/U>4
MEI/[/==.W]E=[_6W8^!#XX"'R^]Q'-(/&X>#UMKTEUSHJ<[(ZT2RV!B&+Q,0
MK7;'(0>0N(=C6H;1[U6ESL%I961>)Q:2JJC1N"J@')JNB6'$+/(-]PS;5LNT
M:D2G5#H<Y6X^!UE2DNI%QD1I2FK&R=6"?49N=!!!)\@Y06,BJ  F0W&&KP&/
M5J2SC$H/?Z.ZR6Z6^;M$1KV6]15P+=[;G.DV,T3'O%&,3--FIF[UJT(LL9DB
M<Z93%'GH68:/#7>US>C[!L.XSFCT_<+;DCR3NVUUJ*K]F:72G5R#E(&^U6,7
MBBNF3!RHW3*FJHTYE1Y"%^JNCP[5:#L.I4_6,T8M['-+-,*DX.BQ^=7"JU%H
MJFFC9J7H\!$,ESM)0!- R;0KJ.,0RK@%=:W.<AVE>G-?O$C?)F"824A-,HJ1
MDFC!FJS;3$L 2LHFFE'DY+. \:(=X>\4.[)V1*!B+-U0[7/LCXA=-82B( (A
MVP)RY^H(\=0/4%EU$W9Q;>J71\WE]&B-&=YC#5[/<IJ>X9;N-RK%!4I3V5E[
MOI%IE<J91\7)S!X^.A$557)4CN3@) N#G)31Q&O5MU [:]K>;M*+FD7JN/=1
ME#TO-Y&)V+W"B0+8.IG$Z]HC@:9:SE=11TW;UH^0[*A71XWIQI-.VZX=/E@S
MOJ8SC9K-?I'-ZOO,ZPZFHC+X!U)9?'U!2:SBNK9C'8Y#+MVTHY=(6)TX?INA
M:MSH=C(87)*A8X?\7=-LE>O>@7.HY=1+AL4W,6U6:K<Q.UC(!5JS=//JH","
MU=N%W,H_23%9RH)A#_ P_3X3_P!D3]<WQ&D:M2#Q1+=0I=>8@RST6G.0#L7L
M7)UZ9B9^%5503E82>K<V]8.D?&)'%!R82'(H!3!>\B9].%=;9??'U*FSUIIM
M.N(2]<LU"CKC$P<U'W-9=Y,2D?[G75='W*<I@U33:H !C&\8<\%;D*UGQT(R
MO7FL3M->LYA_3[RPNU4IU9:2$^Q6?E<Q]GSA_1F<Y5Y1BHD[BY=1<>T=NLJB
MHTJ&F9E3[?!0+2MA1"M;%=*A*T.:@,:HF(/IAO,5V12<VF*MM=S6&E'\*_#R
M-*>;"X;J)I'.B9:;D,ZRR=K:#NH+53/R1CBK,,^8T?*++A4'#U.Y5Q-M=3M3
M8_;W\&NJ_<.U54SIK\P52*/%+V++J##P)<_/)'J^>S]JL]UA$/=>AV#/Y LG
M:Y0S2TR@*,+*X>$$PD%)R4A YI (#1,=:-H:=S'/:O48.&J,LO)M6CFST'9$
M=QINGNGL4JUDT+7%6I,[%TQ26]Q):(7.B]:K'*B=)=N-/S=&GNX*[13RAC">
M6,5YK1=>=;_;KZA;71#7:.M[[:#,IY(47@,FR\4V231*EVP'9C5[)X;,93J#
MN\->=<D8S0KI>DI]Y"W6>TI"*@F5Q1$U.AU[_-D?J(M%C%.FQ;H&[12]KCQJ
MIRII)(&454.8")I)IB<QU%#F$"D(0H"(B/>  X,HWD6*Y"*MT3G1=MU2E6=F
M K1(QDU# 51T8>28#WSCX.?#DB<BQ4.S355=D([;F,V20.*:ZK@"J"**:*@"
M4YC<@*;O#R'@782D<+4JQ&QG(/6PMRN%">,30,MXWQ95E$_7%*(]H2]\ Y<
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M5-6\4FFT":+K."4FT6.\8WG3R1NU85@-2FM*M4]EL/<E:KC^8RDDXKE=G+#
MN'\PR612E%&X"F=,RIYN)Q&'RW_MQ?+3+ZISR=EZQ(3J["\N"N:C5YE5]]L-
MFCH8_-I&J%9?:C)4!))^*OE:IA#1K3)GZ<@J<*;J-0Q6I9A6\^N*%MHI<MD7
MW3K=69IBW(W"XZ8PE64<UE8>_I1I5+N^>*)'$B?B@T)S:=$S&JT_5:YE618^
M]K]&MT\XJ*[_ "^-FM)ZN7M)H"TA$]--_>:W(Q$4M!2BSV'@&32SE3*OVTE
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MCGDG&O9%DM&2DA&VFWQ\G+1;DH)N(J8DF<Z@^EXI=(H$.V<J*H'3*4HD[)0
M$$&K!LS0:F349-V3^:9MV#A$A4T7L>@VDDDH^1123*0CE$I'!"$*4#@4I0 !
ML\E-6LP-@9@:VVZY6D_D13"HFR[=@GY(PLTE3"H1+GXLBAC'*4#&$1(!XUDJ
M"294406=2RP-VZ?/Q35L"K\X-F:/,>PBGV4B"8>R4.8\_>F,_P!Y(^W>/>F,
M_P!Y(^W>/>F,_P!Y(^W>/>F,_P!Y(^W>/>F,_P!Y(^W>'3A*)B@411,H3MFD
M3EYE[_?+Y<':#Y'%:G737J&3<S5?AI9R1+=K"5(CB2CFSQ8J909%*4A5%A
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M)>7^=/KCS_\ V.ZZ</[+3[^MFR\++$(50Z:9C)IG5*@F=3EZPJBYP$B"9C"
M&.;O$+S$>\'&B=-\?H6UGTKIVO6(0&Z65:!HY:7=JYH.G9YEFGKXY F(WL%,
MLE%F](:JU8EC>R#:WMFRAC>1G52)Q)665UJ>E\R:7_8+-6-/I-;CG,;K72/C
M_3G9=_=W[.X>=69&0W&5?5AQ59&!D'!6M8FV[PCX@E:@9;0NIN1>]1[?#Z7>
M<TQQIGT?/8R[UI_J]\K-YOLP^>Z(I DH3/-ZU1*&LJRYPH2LI,NRM#>);HJ.
M!>2E^U"],8U2W;G&J;:O:<:H.>9A3*+D.9:YD=AO^175534[]9KPUU%C&SL)
M57:KEB_ 4F7CCF3 V+MI6Q:_1T=*T/HASQ&W2EQQ*YQVA67JFKU1M.D4NH9O
M5&Q=&R.V9559]_,Q:]O 6,G'Q"A5 %15/BV8=FEET"BW.M5LFD-):6NN6=3]
M1E,UIEQ?06RIR4GT\1#8U;TY"LJLWM*@G ":P39#PJQT5W[!3B\;=7K_ 'F#
M@23$,;/XZREK[VT)UN_I5EUE#:<:0B"4>_M;AE;V'VW]E$L=#.O*D@79IM@<
MK246\,U.\B9*1B'BC%<'3!1Y%/EX]VJP=@  [8*.&QC(*AWE4A*;U?T7_P [
M*?K<4'[RJM]8V/&G8G?VSQY1==H-OS6XMXYX,?(J5F[0#^N37N<_*14S&1+'
MR*@H+ 4PI+ 4X /+EQ,57=.MS0]0G87%$.G3#[6KDM K'XJ\ME;YF-LTB2FX
M6$? CHVNZ? 9-$P,C8E%XQL@P*H=K&HJ++"IUA62DZ7>\QCNJF6P?1*Y 5%G
M!J-NG3=,$TR4VB%U')RSJ$M%I,+7K;I&P3%>79!&N7YGHAR(^,5'*=9GNMUX
M?JWQ.P:47/MSC>G7/XRCH95K==J,%=L:LF((60S6S5QX_I3&;;R*T\28:S28
M'3< S#R+C&]'Z?.M:P4'3\XJ/4%%W>^:9A%#VF1UN]]4VNU_:MPTR5CE+!1(
MFJ3%EMM;:(,VL<B5O&Q2!&J8F(!A/5*4GU'7AWT:T/J-'JPJ'2:K2JB!&&O%
MOKO7V<+);()E+7-XQ$;+(N+,SK:K(KDKLR3=:179(E;#@%_4W>2MN2]*%YV"
M\]..6S.2T)"_4)+96%R1F<[FNH%FH%QN.4UN5OD@^BHE9DW<)KIL_*G;H&:/
M+2J>RN"]Y=Z?U#[KU#ST\YKL=650G=QT"4O#R'"/C'+I!=&NI/TF*3DQP4<)
MMRG,4G,"%_P!]],%_P#12^(N?]J7^ 2[@RJOC3<B*'*BW14<NEO%E[9RMVB!
M5'#E0"]_LD*8W+U.++8*Y78-0:^%M9)HV*<7;>62U;M$9!-#@6%CY3Q<1*L5
M7;@QS&*Y;J)HIF1'QAS)A5+-G4HP;O7M[5B[A7)1A9::T@JM*0C&N$MT@N2$
ME("YWAI,&<MXM!F^0;E:+%.[$P$[?[/Z#_Y]'Z&;=W0A$ $0C;MR$?"'-"!
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M'P_K=T_#GS_Z@L/[I) W+]01X83A-!HYH659V&0C)<ML@31<BPJ)'"EL?,)
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M+#\YG*OL-OFK0>(F9)A4+&[A;RBUK4*$/,+JQZ?C4Q\:;/TI$O0R_P =N/\
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MY@K#QEEO3Z;KQ8(HR5CI#V,?FY]EV<'$]7M#@]0T(>I#=L24Z#(RIUQG<&%
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M:->)VKG<9UJW5B7"\UU+&[?D;N6:M&\OT[,(>R*3-D?L0730>2J4*!_*HYZ
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ML3!\KI"Q[MDEC:4*,]THU"N1CNE).4W!B.2+#4(6KU+2&O4NE;[0I>+/*6"
M7H[^IKPU:2BT6<<WK+20]S%WZ4@$8S!^9Y'.!65>*N$ED4T^G&EVVW*5'/:1
M5>FJ/ZOJ\C3[2XCNL28HG3JWIF;/IRSP,<E<(^J=(&O,46-BHA/$Q%AA'CJP
MQKAW)%42*^ZHV.(YL]D\TZHJAB55HT(YMMXQ[7W-R1S#:+WK\97+#(4FSG8=
M-=*K%MBZ]"JLD89ZXLT4W<G=$:E*M>HN"B<!@YC60_O!+23=*W3]N@*OG&C6
MFUKON@D"5Q(B@56H-ZB].XGV[*!?^1V'M)*D(T333'JAC\:E\[JS#1:'U1Y
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M2!0(5!P91(I   +R[W'N?5Z?5JVP!-VCY# 5^)AV?B7ZH+ODO)HYHW1\6]7
M#JE[/)0X<S<Q[_"=O;4JI-K8BT)'HVA"MPR-B28)M$X\C%.;39%DB-",$2(
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M!W<Y])Y/Z"7XI28B B2I5L@B'@$2PS(!$.?J"/=W\1$!\9I=J4#ES[P<H\@
M//U?6]W(_P!'L+_.2?[KIP_LM/OZV;+\4?\ SLI^MQ0?O*JWUC8\3VG:5,JP
M-+K7N665DF\1-3[LJ\Y,QU=A63&#KD=+3LM(R\]+M6C=NU;++*KKD*4H\^(R
M+CYC1)JURDS;Z_\ B\@L-VV:TZ'EJ$PJDI;6]IS>-SYS=*DE$Q=[A70+R3)J
MW=-95JLW4626(<7.0-]#1"Z-)^;IZBCBOVMI2E+S6*ZXMMISYIISF"2S9[H-
M7K3-=Y(PB,L>39I-G *HE,V<E2LECBM&DW<?6XND3WB0S?44)FUUO2;@TSV@
M6G-*\ZIB$]JE5M]ZD&\4QDZZVDV*KIPC^^@19(YXE=I;;5)OY1U<&CNKPV2:
M]-WNI?B^G8VL7E]H= B:(]N6=0]5L4TS9NWTTQ8LRK.DNRH8IRF'4<UEM*@&
M5\Q7,X#8]1JQPD592GYE:5[&W@+8_308*)NFK]:J/0\2U,NZ2["8J)D!PW%7
M/-;K>D1DSGFKS#RO9_8X^.GG*5DG8^O6BUNXIJQ3BADF[I*O4J4<_OZ*13%:
M"!1$QTBGH6ES.X4YO1-/QBZ=1-"LK<\G(L+'AV<UNO6Z]Z<U+'1[IRWJM3KM
MKC7+Y=<B0H^6)D$OC!$@1^4V#2H)IH4K'9I,,*NW+(RCU:(V.\/LVRZ446BF
M+UDT87B[Q;I@P565(14[94_,$DSG*\R<-4@$=&8M]7='J3M&78R;Q/# J!]<
M3A@>1J"$\[HJ%]B%GB#(ZZPMW@*I%4336,G5:6QTH'DM<D<W-$/VU1O:U29O
M=BB6$[D]?M5Y3K TVD6W1HB5:KQ$1,/F,D\*\:E*CVW;4JVCS+F[S?VLY2VL
MJUONK;--2?4$7%-LK&F6J'JU[94M>I7RQ0=MDD(U6.A'D@^.^.9%-(ZB2Q4V
MU4GKC)4:Y/,ST396E'TBD7S.;NZR_)Y-E$Z!<VM2NE:A)YS&5]W)(&,4B!EU
MVZI7"":B'[YPXI^=OKE;'3,C/RZQQF7Z8&=Q[J0IM=T!E%/]-<U)O0&<XXJ-
MMC78,5)$'0>5D2%,%@.F5]GJ-FN45;(NZU;.96/M&/Z]4FT9>;T]9,J16'\Q
M9:-%PK>4N R3=:.*+CLNFBQ7!!\2/;X-1Y&8MLW>"V>>IXTRAY;J&C6D)VKT
MZE7^P)#!T6GV!^6/BJ?H\$]5>B3R+LR:) 5%41( X_"VR7-=E+;<J!&EDJ'H
M$)5I^^YW&NIB^4>M7V9K#&C6*W5&,8.5WL>SD5G2:31R8"&!LX%*LZE7M!<7
M>G772[5CU07SREWV_P [9=+I#VXLK74HFHU"L3%K</H4:!+KJ*^1 V.S9^4I
MJ';JH**-)*M:Y#S)9"[9]G,;&-8FSELDI=-31=.*)"QM5<P:%D>^[2<7(]MR
MFU%HR-"RQ7:J Q,D#7P<OD=R_P#5'R]0 #GRYB*+< [_ .GQ<;M"9WILI58*
M^(Y/5EHU;-GEIO.N/-(1R>&RT<\)H);UG-SLMN6\;'(VUA!-SPY#OW*S5(AR
M@XR^^YU><?O47DMEV>P1]V7ISZ(A:55[F2F.GY['3K398QXG(+G\L:F2,(&9
M$.97Q2I12X86N-QG4Z-GEJJL7><WOMX)26L9?:G-*%&'D&\+"7&;ME8>R\8L
MC)-F<PP8N#1[A,ZA4EP5;I]RY_VI?X!+C3GZA>GBK].D#TNW+I@RMIL4/:M)
MFYQ[U%M(N1WW<ZE&T:ST]?,KW66M8@Z[7UWRKUR4K-X[1\G(YY*8MM?5KT5X
MQU_7D^'XAB4H%\WBFL&G2]IF%Z'9T;SU"Y\TN]$>PDC!=3\,>#NSA:';%N$1
M+QP0KDBK4"+H]=&(J]'6/7W>-IH/6.C _P!YF]V2EHZ+N2>YV]W:<YSBXUJ:
MK!M+IBJ%;>,*W)LSOAK$(W@$E8U1=-<$4IBT2?2ED&N3LM_>"=-W5S"?W@UE
MV:/@M6I.!YWH.13,ITZL,[)&.+*J^S*H4V0@XR'1=$HTK$F)('(2:'LFU=EM
M.)97;IUIT4=:^?8&I*WB-E0J'4=M'6SU.;UEMA@UP9"C5IYK4KS57[:T)E%Y
M7W_CDVQDE"+&4O<[G=/K&&Y1IG0;T[9[<W6=3$<[<RW5]1[%J9+SI\Q6I!J]
M:V:Z-:O9HP#V>0(NK.&2 KSR@Q#".:9@.$77JIG\YJB=QSK<VO457^GVPT[J
MDK4.:M4;6;3 0YJM#H242K(KS[69BXZ;+"R('\C@Q."0\9C7=5M#.\:A 9Y3
M(32+K'LPCX^X7V)K<:PN%I8,"H-2L65AL+=P[21!)/Q::P%[!>7(.I^C4_8]
M;J[*4T/&JQ7X6#UW0*K6(Q_:<SS*+;&)&P]D8Q<6Q-*28+.3II%[PG4$!,(\
MY^IH=9MYE&]+DNH> O$XTOG64V?PEFZ7X2N6/3H:MYQ)0K/2-58R$+:&RM?E
MZO'R<5+G(JD59-0I"GK,1']9-M9W74WVI-.G?,K=M74W1=%Z@D,;!XVNCR"K
MME2:?BL5D+%$2,)765T5A7UBFHQRW;I$*":BC)JSZN[*?4 H6-:W;L)7ZB]\
M::5F^1;Q8J17:-?K>Z=.4J0=2()I4!*62$8R;F9K\-*HN5T3"59-*3KT)U<Z
M#:&-9DM[A+K,QVA]8<?8("<Z:PJ0Z;'5C'Y>&:Z[L:3@MYC3P+RH14NRF$CK
MJ%523:K&+U&:53NJR\6NE]-BZ2,K)L>HG<HE[KH-&:,[=PQ.OVB0@K'9)+(:
M.N6QVV.?-(Y_#PX'4,D<Y.R-HL\5K_4K)UFCDKBETGV.SZTO%U8EPF#5ZJ&F
M%RV_FB%AG2"T;=@I_P!]#U_8+Z[ASNT#UL:,^>LM"KN+M<=8WGJQG-;EMBOL
M18[#0LTK@0B;^LR[R\0]1<*I/4'PQ[=8447)R*#ZV[.)9WUC1S?.$Z^I=W:^
MMZ>=A#!;&II"KIL)%O?%F%Q=6*.(9RR0@5)1==N0RA2=DIA">AB176ZM+5=B
MQD+"Q;Z=JCE2,0DV=@>QK<R[>^*LWTT_2J4L1*,:J+R9G44[:^3^5-U42Y^R
M7L'4\>!T*E9!I*%[KFW:K>:E3Z'N1RA0)>\K5&XR4E#33TH*=J#(@K++K(F0
M:).5N1>!U*?M?5K'Y.>4"+8Z<[UC7653D/*['.U. D %W<DI:,86^<K3]&(,
M];-_= S1;Q/;\2J)?R_[_P"?+5_POX_+]O\ Y\M7_"_C\OV_^?+5_P +^/R_
M;_Y\M7_"_A-4V];T95(%"I*FV[5#*I%5 H*E24&VB=,%0(': HAVN0<^?(./
MR_;_ .?+5_POX_+]O_GRU?\ "_@JQ-_W\JI ,4BH;EJW;(4X<C@4WVW=X#!X
M?C\>D1U"^?35OPNX](CJ%\^FK?A=QZ1'4+Y]-6_"[AJL3J*ZA2+M'C.09K?C
MQU!4[60C7*3^-?(D<6E=#RF/?MDUTA.0P%53*/(>7%3Z8^N6PPU1W)TK'5O-
M-T=%9P-%V]ZL*3*-KMO GD\71=?D%C%*@0H)Q-@5$2M1;NQ(S6[F;^E$E]!+
M<4[[U:]]9V?=WK^D:T_Z3'NY,G^47.X,X_I&LMA ._\ ID'NNG#^RT^_K9LO
MQ1_\[*?K<4'[RJM]8V/%LQMO8$ZN-JEL_>+S*B$BN*#"H:/4;O)-$30\K"2K
M-W*Q];5:(.FSM!=FLN5=,W:3 !KUAS:]9;:&]0U#<[G -]X9;;/69W!;:SR=
MTDVN>D4?6ZS=[Y:LOD<X6AH%]+N7B(4Y=E'+(F6C479ZQCDY8:E<NB.?VW:=
MKLL1#-G%1WN@W#5X+5)Y2&4MCJ1<UJX9*UT#19-5)1HQ96M%5U'(JJ.V2$@H
MM4H3;=MI%D8X[ 9AE^.%H%"LV=N%,TIFMXWHMSLV@R\=?5[ IJVBP.,QL.F:
M!=Q,/ J>->M$3*K%30KM0H>G46"<0.H['8(/>WT7K[?JOHU*UR=;6(7D!M5>
MV",?7C2*\JHHR<GMS>:@K&C&1"LFS6%HNBZ@MHL6YS%TT.<TO5[#MU4G(U)7
M$M"SG9(:)J%GH<53 $;)$C$56B5(\8#V7D8IO)PBRQ6)"/5")Y54<T=5W*8K
M,-&E[ZT91-<(6/4]U<IUC/3-(]G%NXI.-=IRFDDD17]?V@:&3[(&4!0C&IT^
MY1#=VIC-HQU\QL=5"8H-5J-MRBITFPYODU0:R$=]I>+6N_PLC;YF!7</U7\K
M,*D%R5NBU10>6?'=)2AIZ,2I4_3)#281U=72%FR'>&FOXIG]E>1<O6G3_ \Q
MIK4U'B(AN*$K'PRHNBOE7XJK+VBT7G;V,1K5SJ^R6,FC9G2U(5_DG47J%QI-
MBK>D8Z2=GIAY&U7.H"F$A%8M^X<*VA@[>)R2WDSQ9J$=E1MESY? ;?8>G_3=
MMA$<SF&6BR&G83!XW'O&F661&[&A:KGNFRF)13AVWDF,G)0J"KM!@Z#QK91E
M;L7C.H"HM<-B\FU'.,EK+VM:.5_+M[Y=&%XJ4=N\1$:='4&V-LI=(N&4?.0L
M5#V=VV5*H9Z@N"QW#XEUT^FYG>VN$Z+F&<67#Z];W2F0Z'9-$G;E6=:I\SJ]
MNN-L=",1/N8NQ0;MX>/G&#A9H(I-%/$EFM#5G<;L-!L$9#%=N6D/K$/I\>]B
ML8R_,?<B-;CH[W*3USW4SGRI-1>$/)$9N"HBN99,RZFO.YVZ1IZGK74)TO;)
M)UH\/+HKI5SI_BJ1'3M//+QEAC7I']Q4J'C&\@V,W%B*I0,FMV1[;&>Q"7R!
MI$Q>R:=ID51=59[=)0L:RTG)L0H#@J5EI&MURYN[$PF\D<ONTY=K1JC>9,B#
M5,S=!4MQO5#W%*MZ->KYU/3+Z5F8RZ6.K4R#ZF6RT:I;<OI:]^0KU%WC*HE=
M=G$6=BW0]T&,B_;/T52.SF+5(B,V2^S.'P>@9QJKNH62;EXC0VUTSO![GTZI
M$J>E96^S=_7J_.YZ^K0NT@14=*O*Z<ZJZI7ZQ28+KF?U>DU*$P?#];QFO0#2
MMF7G2M=+M.?V9M)-;2N^.Z*>*6K<SX\[DCIZZ7L+U7R@AG3SRGN7Y3=\/+SC
MRYB'@1;^'ER'EQ<-+O&E:U9KS.,XMC3[@BYSNI6K,S5Z[UC1JI-1,Y2\]@'-
M\LU*ME/8##/[@6Q*L(])1D &;NWY7=3T^0ZDMCF[U'4:9S'0)6?@<4E(S6\Y
ML%X9WF2IEHK9LM;PU?B"N6ZK!N,"E%N$8]RH3QIE1*L4M<AM>UBY9U U^-I^
M99O>7]1D(#+J=$& 8JOPDK$U*'M]E]R6I2,6KR?DI5\C&((H"J<Q3JJ=RY_V
MI?X!+]#(H3%GEJ95V06M8Z;]J+UM"RLK (OJ4#ROQMJ?$!A3[7*4Q:>/!2*Z
M[1).502(#ANJHDLF16O7EHM[JS$'"P\3=K569"4S>F0"&N2U8L\].QL4X;:!
M>7@/JY 7-JHDNQD@3;R3%4ZS5\$A%U:HH:A&QXR,0ZNS2S;9 275#*MQF$EK
M3%4;5$'"N>0T<[1$#M%E7C)<B*:R216A%44TY!W:+]:7UH9KQU@E0I-_K4-G
MVB6V)G'Y*-7JQ%)/JK9LOR].CN&S*\*IK \D)=$[YE'O0#]]K*^A?;)]M)Y*
M[@X"W%<!8 B"7VSDJX/U'C*.>.BEJQ68(+KMT5W#8$U5"%.<P!P/Z7'4IJF8
M]*^_Z16&VBX]:*M9ZOC-ZME)L+RGYSFCT$D9:)AUX^6C4YJ',U=E15$>9%$^
M93!WIRXWWH,WS4).;<]43%(UKQ_J:92E8S;J_>0DUK.*4VX5R9B[I5\UA;37
MF\K5"-'R3^N.E'*;=?R=PHEQ'/+E_=D]0DLGGT/NP=-5W@\3W&9V7I3M&U5Z
M7[<AGUQT1>>:ZA 0VAR:TZ@VO*<V]BG,E(+QCMNX42$D((?W>VGKZ.VIF-Y;
M<]M4Z6]G5TW4\<P>QTFSY_E%W<+J'K!HAPMG$'&STRQC&E@L,)%-V;QT)2J'
M5K]HV/\ N^M]V"9J-^VJ[TZ:M>2]4L+<:1%;K9FEXG\VH^CT:R5G0*K2Z-=&
MRS^IF;R'EL(G(/695#LW'BB15Q_[--@8$"ZZ/?="IL?T=W#[3-MF]7@V%$NJ
M6GMY2NRMA<-Y#((=C3/'QTBQ?J0K0%5W"[Y9=RIIN,97TZ=:U%R[7@BD[O4H
M;$M3!%PVB'0JI-HQ^I"BZ8^ZT<!(R75'QBLM%)$;KCR 3#7H#*^CCJ(@I6M]
M0><]454G)#ILT:5G8W0LBJ-IH4&S2CW426,D:0[@+\\2DVJB J*'52["R0@'
M-".F/[O+8E6M1T>H;'@JDC@O4?99/IGU6F147",K;EDM9)J1>2S*0CX9KXV$
ML'NG!MEFZ:C9JB/C 5@=">= ^SA)US>,ZZDXV%/T_P#4)(UQKJF=!J#@B\:Q
MFY*35@*K:YS8)B2?13!1NW;.0;@T\4!#BID%>9?W?6P ZQVY=+5U:6@.FS:6
M\S?WG1>ZN)NGF+T%DV\5!/&%7AKR\C'JK)LS<R39)!50X.4Q5-KV3Z%_=S]1
M9](T0_37&L=EJ73[JD3,2M.Z<[CH5@K-5T^/?MGT;+)5RN7H(>#<1#-@X.FT
M(K)G<J%*<?0LZL?,#I7V X]"SJQ\P.E?8#CT+.K'S Z5]@./0LZL?,#I7V X
M0:J=&O52FZ=%7,U;'P;1B.')&Q2&<G;HF@046(V*J45!* ]@#!S\/'H6=6/F
M!TK[ <>A9U8^8'2OL!P1$W1AU7@LH43)IC@.E]HY2_MA+_Y>[/>_3X]"SJQ\
MP.E?8#CT+.K'S Z5]@./0LZL?,#I7V X9I'Z,NJA$[Y_'1307>&WV.;JR4P^
M;Q44S._DHAG'-#/Y-ZD@11=5)$IU $YREYB%>ZB.K:/K6E]4!FZ$C5J67R6P
MYKT^&73(<J4**Z9V-TU)L4>RZL)B&;,50%***4I1>.>0<_U1YC\ON9OZ427T
M$MQ3OO5KWUG9]W>OZ1K3_I,>[EOZ-Z]_.>S]UTX?V6GW];-E^*/_ )V4_6XH
M/WE5;ZQL?\)?_/ZG\ W^(O>T//LNQ*'R"@W;B ?J"/Z'(0YAWAY?I=\/_?W;
MT!,(@1V)2@(B(%+Y.W-V2@/@+VC"/(/5'NZ^@"AP1-4+8J9(#"!#*DF*>0IS
M%Y\C&*4X@'/P<_B-"3*H<J:L7=O&IE.8"*=A*O&)XPH"!3]@W?#GSY#W<B8A
MS$-[O44O:*82CV5+Y62'+S 0'LG(80$/5 >7=S?THDOH);BG?>K7OK.S[N]?
MTC6G_28]W+?T;U[^<]G[KIP_LM/OZV;+\4?_ #LI^MQ0?O*JWUC8_P"$O_G]
M3^ ;_$7_ ,^C]#-OB+K*^H7J3S[*M#5BHZV$JEF/,DDQKLSX]I%RH>0Q+UN+
M5ZO%+E)^^=KFF/, X]-O'O\ ?V3\'^/3;Q[_ ']D_!_CTV\>_P!_9/P?X]-O
M'O\ ?V3\'^("HU_K5Q5U/V>69P<(U=S$E#MG<I(*E09-5)29BH^)8BY7,!"G
M<+I)B<P%[7,0 0,00,4P 8I@'F4Q3!S*8I@[QBB'@$.\/%=^\RW?7JF?$<^^
ME=YY_(_>:]X>[=^K_P"8J%X>^'W?5GU![N<^D\E]!+<4[[U:]]9V?=WKO"'/
M1K3RYARY^N9!S#XX=[NYH1_R<WJX!_\ KV>W]K]/GXL.ZZ</[+3[^MFR_%'_
M ,[*?K<4'[RJM]8V/&O:A!5Y>WSF;9A?[]#5)L9V5>TRM.J<O88ZN(F8-7SX
M%)MW'D;!XE!9;FKZQ,YN11U+[5.K3#M'DZMT=R?6XEIF?9+!R]?I;B&(X;-\
M,L<(%T?12M"TA1UY77IA>0;65)& DP6\H*)#)=8=2=.4MAFNG^C]-TW7]F:4
M2C56LUQ]KT>L^L+_ %&J?C)8/%&B2(D7;(Q*#KQ+4 ]>JIS#C8;1#Z@J/_U?
MK].%&K,)DV+6QQ"PA.JV1QI,^?0C/7U=(O&A!4HHI%"6F-@HTSU=99(%2IHI
MJ16H6">I<5<;/U/!TYH;%;:>:N(8_3)/6#9J;4NHK'BSK9KG>H4IPBM'RE7<
M2C5DTL!V97JK5NHNDE1J VMF6]3-5I.YZ_2=;NE'KJ<#9]8R"D=/6?:[/3V4
MPE:LEDA7>TX19K^5K.04>5=K8(Z/71; SEC T2IT\?J#Q^DP%>RS)=<9P\71
MH-Z]ZOHS7;9H(Q[?/7-ONL&M5J^>&J#"O1*D<5Q(#8GJZCXI1(BQ$-83VS#+
MW(ZQTJZMU%IT&&IK)LIT@3^<!1I%M3[R^1NBLE9X%N[N2]0G%; C$22-J9)G
M2(W*9TQ;[F.9[QB.65'IKP:J;?!0UVAXJZAU73D^[TDLI18:P%M\*ZKD!#2&
M>,Z\)Z\A*31)N?(=1/UC1F^\C1W&K8W/:3L&I=,V9X2YQ6)TA]DFGUFJSDSG
MCWJ)FQT*"N\7/7M*OK3R2<>P/!*U]1% BQ%E4Y!30-0E+'3^G]W:K!+4')H*
MKPL/K#O.Y/&KC/9UJ]QLDZ_E$H"\FOVA5J63AF!46B<77D&"BXC)+NT6_2W/
M:'HM;TQ:U5"D]3/5"^C,.LL>A4,$U8S7/*K2J"IGSJS04#+P%C/+7EW,61XF
M"M7K3@G("N"K(;NZ2DVEXJM/6ZY7E+SRPY/&TRD6.M=,1'Y*Q^*#8X.\R]JU
MN_Q<@E%KVB'-$(J>X3J7>-2$"*2,Y@LFKG5%#:CH,[KV<IOM0I6+X7%5]QE^
MA8EL-[A5,@=6C>T,FM4--6W+U"E=S4VRE6#!!=/Q+U0Z*QM(@ZAO^470M/Z0
M83J3JU"UFC9WF\!-S]JF[A0V59N>M5NZ2,17J_'R=?2D$GS8YVB[XXH'? R'
MQ@7^.N-\L5XT+,=(D*3=B6S,ZCF=@K#Y: K]GBH!ZAF]UT/,;8B:"GV[QO,0
M$NZ9N&[LB9^RLBIS^(/_ )_4_@&_Z$7!K9+NV@&E(I65"5RO,I*[PC $G8M/
M<^4DF3E%-E*J"'C"(& 3&1]=SY<<B],W6(<.7[8,#F"@ _&Y*2A#<_U.7'HR
M=8OF%E/LOQWNF#K%$/4'\1+T.?R>1IT#!^J #QWNE_K&,/J &%N@$1^-S-/E
M*'ZH@''HL]9'F0__ ,GX[).E?K',;P\C8J@B'(/"/;<6Q%/]3GS'XW#@W_:K
MUBCXUP*G?QV++R_>DD^11^W8>T7][Y\^]X>.:?2AUA' .\(CD]?1Y#\;LN;\
M@8W>]4 $/D\>B;U@^:ZK?")P!B])75Z)1[X";.J.F(A\<2*:>10OZ1@ >.]T
ME=78B(@ !^+VAAS$1Y!WS:D!2AS]41  ]7CT1.KC^1F7_#!PO /<%W?,T4(I
M:3"Q:77J9%5UPHBY;-PBF[FO7ZT/S2JY7(JD(9L5(4TCB*@" %-P/Z0\&_LV
MY)]?]#[ER@NDDNBLT<)JHK)D5153.3D=-5)0#$43. \A*(" AQGO29"T+0.M
M7)K N1E7\<AU#2^R95"$%-!W/Y]=)AP1@VSBMH%\<[C+,\;Q#1!(P-'[$1\4
MI6@.D9$QJ);%S)J"454C#.4HHHG\68Z?:)VN^)3&#F'>$0[_ ,1H7TIN_P#!
MUSNW?WQ4+^?U9[N<^D\G]!+\4X?5&K5X1'XX^Y+/N[Q\C1;1R_=M.[G/Z.*K
M_.:Y=UTX?V6GW];-E^*/_G93];B@_>55OK&QX[_/O" ]X>7?#BS0E5S#/*S"
MW5PZ=W*'K]*K4-%6UV^2.@]=6>/CHQLUGG#Q!0Q%3NB*F4(80,(@(\3B;RI5
MIXG9T8]M92.H&*<$L+>))XJ);SI5FARRR$6EZQL1P"A4"=X@%#B5N<;DV:1]
MPG9!&7F[8QHE6:6:8E6\@G+H2<K/MXI.6D)%&71([(NLL=4KDH*@8#@ \6:
M5IU65@;JXEG=RA%*_$*0]N=3R -IUS:(P[,S*?<3;<H)NU'9%3N2 !5!,  '
M%<C*G0:75HVG)RB50CZY5H.#951*<4,K-IUIK&,&J$$294.)G8-2I Y$1%3M
M<5!V_P CS%\[SYRL\H+EY0:HY<4=VY?HRKES3UEHDZE9<.)1N1RH=D*!CN"
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M(Y[--6SM5--TJF9<B:IRE, &, JPJM"IBL,M56U%5B5:M!*1BE'9%5*SIBC
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M2'GWQ7ZBG1RB'QB@ACIC ;G\?O<.!+TY99Z]P)C<NH65#UWBD0'F)L=. CR
M.^ %#Y'/F(^CEEOYPTG\#7'HY9;^<-)_ UQZ.66_G#2?P-<>CEEOYPTG\#7'
MHY9;^<-)_ UQZ.66_G#2?P-<1$@/3QEP.4*I86I4 Z@)42G0=3%9455,Y_%$
M!"&159D*"8)&$X*";MAV>0^CEEOYPTG\#7'HY9;^<-)_ UQZ.66_G#2?P-<<
MPZ>,H('J%-U 3"AOT^T3'2EY#\;PAQZ/63>?V;^!_CT>LF\_LW\#_'H]9-Y_
M9OX'^/1ZR;S^S?P/\5>1/@&3%79L;0@W1'>)XWC"N$H8ZY_'%R4A$13*@4
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MA^+*>57"><N/_6NW)=AT<S45R%[>3N/&IEYAR.'BP-_\!?5_(7BWGQM?P/\
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MMI0D0*$:T5:*'%ZHD7C0L9M-3KL9)4BDPM_4F:A<5[@VAF-DMTK6ZO3-#*M
M0J%<T6UP$9]L[%FV.X2&#4$3\C%*HI^BTI*[T8I.Z7:GU9:63;%>+1I)M&+C
MS/D6RAR)N56H+=HJ9C%(80Y"(!W^)/RUSI#!S&4R7N!L^?-<L9Z6X8,-#C*%
M$3A)-S;"YLE3;@1\N^CG"C])W_T]= R8G HC7H ;),,]!OE%O.ET2NN8>#<0
M*=:IIK4HS@KE864L84[99V5(DSE<QB:\1'*)IE544*KVRR.9-;O))7JE.\Q_
M&:12ML?M;91>CR=;BWIZ*_"1,_DI6DNK='E5"22;MI<5%#-#%*GR-$P4E/6:
M"EI>HV*T1^96+\6D7KDVM#6LE;AV-<=KVU+,7J%UC 7FHTRDB1PHP8.$P1,L
M!1XTZ[$1LC12@SEA:1%=F*;(1TE.UN@*1/XTIZ?4(5XPJ<C24[ S(5@HX4.]
M<%<E1,<B7:XL&A1=9<O*;6%VK:8FB%)XE)1RHX2.=N7]LY0C#-A%Z<.0-BG3
M$>UV^]'VUE+7)&V2FAM\L;Q,BSJK2D(VM>H*W,)Q_-(K.K"TIR,<D9 _)JH_
M!;UP$$G!$W:5#:%6DWL>S<N;S$-VTFTB:W'72<M4:9=(JJU(KU.E4)*0DSD3
M(U;F$!(*H>+&/F8!3/)N,FEU"UUW'7R(4):(X'#YBTL=9*X1;C,5F7EXU=@S
M<D$%5GI.P*)"?OG$]/JM*\B6L5:-NT[ +32:=N85B3BXJ<\N4@CLP)Y5$PTZ
MS<2#07!7;,BX=I,P@(!\S)^Y#]CCYF3]R'[''S,G[D/V./F9/W(?L<?,R?N0
M_8X^9D_<AZG@]3U.?'S,G[D/V./F9/W(?L<?,R?N0_8X^9D_<A^QQ\S)^Y#]
MCCYF3]R'['',"$ 0Y_Y(>J @/J>J \?,R?N0_8X^9D_<A^QQ\S)^Y#]CCYF3
M]R'[''S,G[D/V./F9/W(?L<?,R?N0_8X^9D_<A^QQ\S)^Y#]CCYF3]R'[''S
M,G[D/V./F9/W(?L<?,R?N0_8X^9D_<A^QQ!%*'(H25BY '@#_JBG>#XP=WLW
MW@9-]>].[KI^EZ?#,Y*/C>FAU&O%G$]"1)TGBVI69TFD"$H^:K*%,@',#E*)
M>?,.?,./N5B_Y9U+[+\?<K%_RSJ7V7X^Y6+_ )9U+[+\?<K%_P LZE]E^/N5
MB_Y9U+[+\?<K%_RSJ7V7X^Y6+_EG4OLOQ]RL7_+.I?9?C[E8O^6=2^R_'W*Q
M?\LZE]E^/N5B_P"6=2^R_$DDE4HQ10[%V4A"W*HB8QA;J<BE#W7[YA'P!ZH\
M4.,=Q.R)O8G/J##R"1.GG<5R(R4/3H2,D4"+HT(Z#@B#YJH0%$S&34 O:*(E
M$!X525B-C517250715Z<MT417073,DN@LD?/Q(J@NB<Q#D, E.0PE$! 1#A&
M/F\QN,RP;14; M6,ITDZN_:-(*%>&D8.$:-W.8J)-H>"D3F<,6Q *BR7.8Z)
M2&,81I:<IF.C-'F:S%:G<WGZ]TP;%7[3G\C3YL;#7RT^Q,<Q\OAHIK)*K>,C
MR"+)9%VX(*0"L)PFK8?,K=]M-DC7L-8K*7I&U4)Z=AY1HG'RL3+S)LP-)R4;
M+QJ)&KQ%=50KQHF1%?QB92E K>Q9'>K*T!C%1J1)GH_UJ91+&0(N0@&#<SS+
MW'BV5?*\7(P3((%9)K*D1 A%#E-,5EMGFIM:Q8B()V&KM>DO96U:GTFK1DP9
MH3=?0S-.(E4&3&-;(()KHJ$01;I$(!2ID '3"7J.TS$>^ I7\?+=+^Z23!^4
MBR;DA7S)[G:[9X4CE$BH H4P J0I_P!L4!!O$C2-?&)9RONZSBAZ5]N&,93O
MEBTC[N,V'XN/)&LT$DX4= Z3(5<'*IU>UXPQC#",TJ/KR;*L@N6M,B=*NV%9
M5PCIDM&.DX!H&;^3PZ3J+<JM%2MRIE4:JG1, IG,46S*JY)?ZJT93(6-DVK/
M1YK< BRL9&:D<C8&A(G+F@-IMM&*G:HNB<ET&IS(IF*D82"Q;3N-W6<:Q<S(
MV*,:3'1EJ<FTC;!,N2/9N;8-7N5+H-)2>?)E</UDRE.^<%!5<5%  P-+O*Y9
MHTG=H\B";&Z2/2#KSZVLR-"K$9>3V1SEZLPD:.3<*$:F!;M-2*&*D)"F$!3D
M:9BVF59XFZ&0:R-4Z.-C@EV[TR"S47S!U%9@U4:N#M7"B(JI"0QDE#$Y]DP@
M,1+GPC1 EJ^830$FGT6ZV@_@A-(N9D0AG2&6)K19?=EZN\[* D+Y6NJMR\8H
M<QG#J0S?;9!T\AW=<>.G_2=N3UR\K<@MY1(5IVNYS=55S7)!S^^N&!Q,U64]
M<=,QN_P+.R8YJMB:^01\2#>=Z.]EED21,0\]T8:*3(_S%<$XV&D?^)9H%Y)-
M7'[XD!#^NX>5UOB^HH5^1CV$5)02?1QLA8>1BXA<[J&CG\=^+#R5XRA72IU6
M2:A3%9JG,=$"&$1XAH.9R_9)B#K;<S2MPDKTC;9(0U<9G:(L%&5?BW>:+,85
MFJQ;)(F2;$23,DD0@@)2% &BTE0MXDEH^21F8Y:1Z5]X?+1TTV(NFVFH]1SG
M:IV4RV3=*E3=)"5<A53@4P <W,1&G]0?JB(_]L&__IC_ /Z^X*8E,WTQ3% P
M"/33O!1Y&#F',IJ%S >7'W%;[^;7NWX!<?<5OOYM>[?@%Q]Q>^_FU;M^ 7"W
M*F;X(^4G. EZ;-U'ES(D(<^5#'LF^0/?XBTY/#-9?E@[Y;M2A#N>F+?SN(;2
M- BI*"OEUBG84PCR/G+C"S+IK("DJ1!=%;EXL!(F)'57_P"W_;E(EY+P$\LX
M=8CU:/[4C,U*.=0U3?1N@OV#K08<*U#/W+-DW9RC=JBU=+I>*$BRH&2GD\$V
MH9$M9BJ4Y*XP;JH=P\S486!DJK%0%KK3R'<URYLF%;F7;,AYAJ^7%)<PF4,<
M"G*\A,]R/J K<5(NVS]\V4P[J<LRKIRR8)1<>89&XPMADTFS"+03;H()K$02
M2* %)SYB/W"[]^;=N'X#\?<+OWYMVX?@/Q]PN_?FW;A^ _'W"[]^;=N'X#\*
M*HTK?TEDW8+(JI=..X HDH0B)DU"F+1^::A#AS#U0Y /$PS>8=U!NH>787F,
M0K*^*]3*E1J3?4'(/-,5SNKGKRD-G[^_.1.:27C$D%# JJ1$44U52'NULD<1
MW1*X:1(9K,6ZU0O3_P!0]>LLA:,>2>-<MNL?,0M59.H2^4QK(*H-Y=J*3MRW
M,"+HZZ0=CB0HTQAF\V2$EXR1AYE_:^GC=K)=I1C+283D@5YHDI5%[P"BL\0C
MY/Q+])-J[2340(GXL@!%F>85U(23B/D)&4E7TMCO4I)2.B.Y>Y1VCRP;"]<P
M9EM89R.BP[.=4;S8ND DFJ9BE*F!DS7.>K% ZM4WNAV>?O%S9S64=1=CA)B[
M6EZB]G;:,3,U=T@A/._)TVZ:Q1_X5@F1HW!)L0J8?DXZA/S<-I_ SC\G'4)^
M;AM/X&<?DXZA/S<-J_ SAUH%&S/>VSF-FH>:K<TG@^KHNV,K$-F8MWA6KRF*
M%(NT=H<P*J0Q1Y!S 0'A.O1>:[:I""VFXXD%)].%UGHM5E9+(TN4S%G83F=O
MVBD<\MK%.130. IMW8&.B"?;/VK#55L4W"8K-@KETK:<4ZP30&"]81O9DUYI
MU2YN,I:$U5VJCU+QJL6U6)%.2**HG0!-4_.!:)47J.(G6G=7?QC@F"71.3.Z
MH_:^TKW7ETZ(65LC6I=H?<]"17=)(<B^M$2$$L9%L\?V]:+AFDRPBXN8Z;;-
M8HYDPG[ 6V2;%%G8,^DT0:*6<!?I$Y?\,N<_B1(0YR&83KBK]5B\G')RB21C
M9/J9(YV6<-+'G#S,"G5TX"?<2YIQWY0J^:N%#E5[/,"II@1[!M,7Z@VT-)J1
M2LC&)8KJ ,GRL$=PI"J.4C5<QE#Q:CM44A[0<A4'GSXAX:LY[U!P4A"V0^GP
M3!GBF@@\9V-"'/2W%J027J2JRO:@9,\<L4X';'1<"4Y!,;GQ SKJA]1AI:KN
MGCR <I8'=4$8T\C L*K(MDH]"BI1B\9(5B+;QZS-9%1H=JD!!3[XB+**<9=U
M +M8^=0L<.U9].]I9+0DHSDF\VU"M.FM"9N:_&H3#--WY"T609"L4PBD('4*
M>YP[K,^IIS&:&]L<A=&R^$6M8TVZN'D(6HPNCU$7D8C8"Q;4'*+-1NB8K5(H
M% I #CT?>H?S(Z']@^/1]ZA_,CH?V$X]'WJ'\R.A_83CT?>H?S(Z']A./1]Z
MA_,CH?V$X1:J8+U D=.2+*-FQ\5T$%G";;Q7E)TDQA.T<J'CR=H0\';#GX>.
MRGT]=1*AQ\!$\1T#MCR\(AVX9,G( \/?#CT<NH_S)7G[&\>CCU'^9*\_8WCT
M<>H_S)7G[&\>CCU'^9*\_8WCT<>H_P R5Y^QO!GDCT^]0[%H51NB9PYQ>[I(
ME6=N$F;5(3GC@*"CEVN1(@?Y1S@ =\>/1QZC_,E>?L;QR+TW=22H\N8@GB=S
M 0#P<Q%=F@3ES^,(C\CCT9^ICS*VK_5X]&?J8\RMJ_U>/1GZF/,K:O\ 5X]&
M?J8\RMJ_U>#JJ]-74LDDF0RBJA\6M)2)ID 3'4./8[Q2% 1'Y <)KH=-G4HN
M@LF19!9+%[2=)9%4H'253,!>1B*$, A\@>/1GZF/,K:O]7@.STQ]32GQP+B]
MB)V?DB+A1 ! ?D"(\>B_U.>9R9]N<>B_U.>9R9]N<>B_U.>9R9]N<>B_U.>9
MR9]N<1\))=._50$E'R<Z5ZDSP.T/4FZJL@=0$!<). 3.J0@AV@+S ![W/CT=
M^K/\WFV>V>/1WZL_S>;9[9X[W3IU8B'QQZ?K,3]3LJ/2#\KGQZ.O5AY@+'[?
MX]'7JP\P%C]O\>CKU8>8"Q^W^-EEI>A:/0D#T_+8YLSTVGO*1,OE6TMI*RSJ
M/BGZZ[AW%E!8" Y#DF*H&('?*/=9!_02G_6!;/BBHAWA O,!#P@(" @(?&$!
MXKZBAS***0D2=10YA.<YSL&YCG.<PB8QC&'F(CWQ'@.?/OCR[P"/R?4_2XY=
M_GRY\N0\^0=[XW'/F/(? /9'OC\8.]X>]P'A[_>#O#WQY<^7@^,''+D;]R;E
M\OERX]7]4I@_7#@/D^#O#W^]S_6_P)[VC&-V'JA"]H1'LE!% 0*7F/>* B/>
M#O=_XB] QC& CL2E 1$>R7R=N;LEY^ O,PCR^./Q%[VS&-V'RQ"]HPF[) (D
M(%+S$>10Y^ .]W<2U[7[P7)+$X G?Y>--<JPD)O#R_:$ /!S^(U$H&,!3PUO
M[90,(%/V5*T)>T #R-V1[X<_!W;HQ3"4P6*A<C%$0$/_ #]6? (=\.[GA 1
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M#:6=.DFQR"N[0X7ZOKU2NHJL=(O5;';-B.,L[25JTQ2L4&E461O_ $=:O6Z
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M>'>+B;Q+9!+NG_SZ;Z&;<7UG+:-G26 7?JXJG5\\C(ZI3Y]=6L='C,Q<5S/
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MZD9+NG_SZ;Z&;<:):9C.<J<8)6.IZT=*44K&6BW?C=;W!I'1[6HWB3B74/\
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M+?[];_7X^:+?[];_ %^/FBW^_6_U^/FBW^_6_P!?CYHM_OUO]?CYHM_OUO\
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MN@\@^,',1'],>ZR#^@E/^L"V?%%?\P?\7%<^D,1];V_^$O\ Y_4_@&_Q%_\
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MY &-^GPXB] Z<9W)H)*)7>H6B3TS-;@W=22;EJBC#%BJA,/Y5)5PW645!<Y
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MB]D6R*ZZ1U0X IM0SHIC60::4IKO62B:X@)0&I% 9/F-E 3AS8_QKOAZSO\
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..Z'Z?A^3ZGZP?_F7?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>reqorsatarceva_850v1.jpg
<TEXT>
begin 644 reqorsatarceva_850v1.jpg
M_]C_X14517AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    /  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(T+C(@*$UA8VEN=&]S:"D ,C R,SHP,SHQ-R Q-3HT-#HU-@
M  22A@ '    $@   -Z@ 0 #     ?__  "@ @ $     0   U*@ P $
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MNL24V%E]9ZIE8%N.S'I%K;0YUKC,-:QU->Y[F_S-7ZQNMR/TGH5_I/1L9O\
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M B<F@M!$_H'21(W:_:=N[;_(7S"DDI^JDE\JI)*?J>YMKJGMI>*[""&/<W<
M?WMFYF[_ #E7;7U/U0YU]/IAVK!4Z2S^OZWML_L+Y@224_522^54DE/U'DLR
MW@?9K64G7<7L+_ZO#ZOHJ#*^I"QILR*75@^YK:7!Q_MG(=M_[;7R^DDI^JDE
M\JI)*?J7(9D/8!18*G R7%NX$?N[9:H8[,YKIR;JK6[>*ZG5G=XRZZ[V?R5\
MNI)*?JI)?*J22GZG8VT.L+WAS7.FL!L;6[6C8X[G>I^D#W[_ .6IKY5224__
MV?_M'8Y0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (
M   X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))300Z      #]
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    - $, 80!N &\ ;@ @ $T 0@ U #$
M,@ P       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! !+     $  0$L     0 !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$
M @  .$))300"       "   X0DE-!#        $! #A"24T$+0      !@ !
M     CA"24T$"       &@    $   )    "0     (    ( 0    $ .$))
M301$       B     @   D    )      @    @! $K__P    $  $K__SA"
M24T$'@      !      X0DE-!!H      WL    &              '.   #
M4@   ", 4P!C '( 90!E &X <P!H &\ =  @ #( ,  R #, +0 P #, +0 Q
M #< ( !A '0 (  S "X -  Q "X ,0 Q "  4 !-     0
M           !              -2   !S@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !S@    !29VAT;&]N9P   U(    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   <X     4F=H=&QO;F<   -2     W5R;%1%6%0    !
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M   3OP 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M/0]6K(]15C]:NH,QJ;;:*6/NQV9(DO#7&QANKZ;7[=_VZ_\ FZ/;_I?T&_\
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M%2US:\( /B9?4> YL?SS?WU-W1OK*YKFNP60X.:8-(@.U<UGZ;V>[W)?JO\
M5_\ ,7#[S_Y4>7ZU:WK_ -8ZF!SLVIP)B&-K<=9,[=GT/;]-95WUN^MKLVVC
M&R386D[6,HK<8 #C_@]RO?\ -GKPXPB/^N5?^E5G9/U0^M;LNVVG!> \Z.;=
M2TD0W_A_Y*='V>OM_P#,78_O5FQFKQ]S_NF1^M7UV$[K;&P0#.-6(+CL9/Z/
M\]YVM2_YT_7?GU;=#']&9S(;_HOWG-0W?57ZZO:6OQ;7-/(.1408U$_I_P U
M./JM]=@ !C7 "8'VFKOI_P!R$?U/^J_YK+^O_P!=_P Y5OUP^N-+6NMR75M>
M)87X];0=-WMW5^Y"J^NOUMMS'5?;+'5-<\$48]+WZ-L>QK&NK_.]+_MOU$]G
MU.^M]A+K,)[W$DDNOI)D@ NUO_D,2H^J'UIJMR#9TJZRNYP/Z++II, ND$MO
MVNW;_P ^M$^Q7^2O_ 78QGXM?< _K<3:M^M/UF&]E6?F/O<T^A4["H!<X%HV
MO_1_0][/H?I-]G\U^>MK_%[]8.M=8R.I5]4O]?[,*?3&QC-I<<AMO\RUN[^:
M8L-_U9^LA>;!T?++]=N[J%<:_2<_;D>K[_T7T;?^TU*W/\7W0.K=(R>IOS\0
MX=60*1CM-E=AAAR);NILM^@VVOW/^FH<OM>U*N#BTJN#B^;^JVH#)QBS+AUN
M^+]K_]'U"[(;4X-+29$Z0JV1;1D!HL;8-AD%CBP\?O5N:Y%R:++7 LC@B252
M_9.;M(&;<'3(<2PP0'-^B:OH>[Z'\A.%+"96:0LOZ)ZC;&Y3W.!#V#[4\Z#]
M(&^GZWN;MK=^CV_S?J)JW]$9M97DOVB&MK^V.CD;6[?7W?NLV(PZ/E ?TEWG
M#:AV@_X!)_2,HOW-R7,!,EH;6?\ ->ZK>SW>[_SUZ:6B+DVJ+J<>L5,%C@"3
M-CS8Z2=WT[7O>B?;6?NN_#^]5#TS,+R[[58!,[!LB/W=:BY'^R7?R?O_ -B6
MBKG_ "#*W(IN8:WL<6NY ,<>[EKE7?1C/L]5WVF0[>(NL:!Y!K;&MV?R?_,%
M.S LM8ZNP-<QPAPDB>_YJ&.CL%@M#!Z@=O#C8_0_?MV_R4J"KG_(-O[:S]QW
MX?WJ%]U%]9JM8XL,$@':9!#V^YCFN^DU1^R7_P G[_\ 8E]DN_D_?_L2H*N?
M9 W%PY) R2XS)]>PS+37J/5VN]KD_P!EQ/2LK<W(<RQNUV^ZQT#GVN?:=G"E
M=TSUP&W,:\"8&YPY^E]#:H,Z-6RP6-K >W5I]1Y@_P!5SMB5!5S_ )!)2,6B
M]U[&V[WC:[<\N$:=GO=^ZK'VUG&QWX?WH7V2_P#D_?\ [$G8=K@6D-+7"")/
M!&T]DJ"KGV7R'TY+&MLKL+6D.!:=NH[[F.4,=M&.[?6V\DMV_I+7V _ROTUC
M_?\ RT(=%J:[<VH!P(<"'OY!W?O?O)'HM)+G.I8XNT=+WD$<QM)V[?:E05<_
M'[&Y]M9^X[\/[TCFL_<=^']Z!7T]]3!76UK6#@23S\5,XET_F_?_ +$J"KG_
M ""[,BFMUCVL=-KMSY,ZAK:]/=[?;6U'IO;:2 "-L<^:JMP;&ES@&@O.YQDZ
MF S_ *EB/C4OK+B^-8B#X2D:3$RO79__TO3LVR^K'+Z-@>"W6S=M@D!W\W[U
MENZW<VNK<_$!LWL=O?96=[21M;595ZG^B_E_\8M/(O?4\!H!!$ZH)R['#5K3
M&NH)U&OBC2TS -.30_$<[8VRH^PAC?MN200&.8&N#QL]/8[_ -&)G9%%3*[1
M>QI</4#7YF4QA =^A?6Y_L?6][=EE>ST_P#C/45]O7J7?1))B8]*P=B^-6[=
MVUJ7[;QWD-)DD@!IJM^E(V_F?O)4KC'BQ?UJQC6!UN('EH<\&QXC=JR/T6[Z
M'[RT\=[[**[+-NY[0X["2W7]TN#7*O\ ;+O!OX_WI?;+?!OX_P!Z7"4>Y%LW
M^OZ+_L^SUH]GJ3MG^7L]R '=4-HFN@4[H/O<7;)^F/T>W=_(0[.H/KK=8\#:
MP2Z&N<8'@ULN<ACK-9L](.!>7;/H61N_=W[=B5%/&/%TTE2^V7>#?Q_O2^V6
M^#?Q_O2X2CW(ILHY@:TXC:W.GWMM+FB(_-<QK_=N0L=_5G/8<BJBNL_3#'N<
MYHV_\6UCW>I_*57]O4Q)ENDD&FV1_6;L4AUJLO\ 3!]\EL>G9$CGW[=G]K<E
M2>,>+J*+]^QVR-\';NXGMNA4:NI.N;O8!''N:YIU =P[^2Y3.;:))#0!J29_
MO2X2CW NUW5]PWLQRV1)#W@Q.IV^F_W;?Y23CU<N<&MQVMCV.+GDS(]SJ]K?
MS=WM]15[>KN8P/J%=S3,D6,;$<:V/V^Y,SK%IL#+*F4M<"0]UE9$CAL-L_.:
ME13QAT:/7],?:-GJ=]D[?^DB*BW/>X;F%CAXM,C[VN3G,MGAOX_WI<)1[D6U
M7ZVZSU W;N_1;9G;M;_.3^?ZGJ?1_,4U1;GV.<]H FL[72"-2 _3][VO1\:]
M]I<' #;$1YRE21,$T__3]1LHKL(+Q)&@U(4#BT 3M/WG^]0R[;&/:&NV@B>R
M!]HN_P!(?P_N3@"QF4;-A@W,K? ^QY@)$^YCA!VNLV_3_D;/^,3C+I+@PXF6
M"2&ZL= D[9+MVW;[D%N=U4_2H#=-3ZK#K!/&WZ._:Q.,[J<@&B!(!<+JXC]Z
M-FY*CW5Q0_=_)TOLE'@?O/\ >E]DH\#]Y_O57[1=_I#]P_N2^T71],_A_<E1
M[JXH?NI[J:::G6BM]A8"=C"2XQ^:P;A[E7&10;14,;)@OV;]KM@/[Q.[Z'\M
M,_)R0QQK=O>![6$AH)\"_:[:AC-Z@;-OI17N@O-C)C_2;-ON_JI4>ZN*'[KH
M?9*/ _>?[TOLE'@?O*J?:+O](?P_N3_:+O\ 2'\/[DJ/=7%#]U']LK#9.%F
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M7%#]U.RBE[K&['M]-VV7$@.]K7[J]?<SW[?ZZ+7377)8(GG4GA46Y.02[<Z
M###H9$#W<>WW[FJSB6O>7[G;HB./- @IC*-B@__4]53'CP7RLDDI^G&T=7
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #,    ! #A"24T$!@
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M(%A96B 'YP # !$ #  - "AA8W-P05!03     !!4%!,
M        ]M8  0    #3+6%P<&Q$-29A"/-BC-90;SEM!7"5
M                              ID97-C    _    "YC<')T   !+
M %!W='!T   !?    !1R6%E:   !D    !1G6%E:   !I    !1B6%E:   !
MN    !1R5%)#   !S    !!C:&%D   !W    "QB5%)#   !S    !!G5%)#
M   !S    !!M;'5C          $    ,96Y54P   !(    < $P 1P @ $@
M1 !2 "  - !+  !M;'5C          $    ,96Y54P   #0    < $, ;P!P
M 'D <@!I &< : !T "  00!P '  ; !E "  20!N &, +@ L "  ,@ P #(
M,UA96B        #VU@ !     -,M6%E:(        'G7   X40   %Q865H@
M        5-D  +I0   +FUA96B         H)@  #6   ,<U<&%R80
M      'V!'-F,S(       $,<@  !?C___,=   'N@  _7+___N=___]I
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M   $!08! @,'"!,4"1$2%2 6%PH0,$ Q,S0U-C(W4' A.#E@@) B&4$C&!$
M  <  0$#!0D*!@L-!@(+ 0(#! 4&!P@ $1(3,],4E DATI,T%365U38@,=$B
MU!:6UC>7$#!!(W470%%QL;)S)'2TM;9A,E)R0[,E=G>W&'@*4&!P8D0F0F,G
M&:-D949'F%4H.!(  @$" P,(!08*!P4%!0<% 0(# !$A$@0QD05!T3*2$S,T
M!E%Q(M*3(&&!H10U$+'!0G(CL].4!S! \%*R<Q5B@D,D=.'QPG464("04[1P
M8\-$5-0E-H1%%S?_V@ , P$! A$#$0   /?P
M
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M9&Z+H?0!Y#W7FD]Q\RDMHMQ++GMIL Y#H-9'=\GZ#?'/10
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M[J<R:R?1LE,H09&,9T;*^OE
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MBG&>"F'9/T[!" SB9D(CD@S84
M
M                 >:?W[\_H==1Y4           !PULQ%T4_$NTY\
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MW><MOK\C]&\47U3\U]?)%&ZSRGT[^C]\2_4  'F2^@OSVAGU7DX
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MH=#LK&D4U>^B>=Y,@R8']CQ^ZSRGT[^C]\2_4  'F<^@/SYAMU/E0
M    '#7'B#HI^(]KSX        R]JNBP?N>6J6/.        !D77]1HK]([>
MKV5         R3KM] _H]C^@!0%0 !NB\L]*_HT_%7TN
M                                          (;EN%U';,1F4S&!)H@
MR2%.,N@Z!5RK$DP     4(@L9R+/*T8>+R)BE4   !C<U_F>#'!V3.)W#&AE
M LPN8QX1Y)UD RK&UT    &*C6238*:=(O(E       44@8;#0       #7&
M8'*01<+,+T.P3Z-=!\E4*\9!+-*8>C8      @Z<QJ0/LK!9QZ'C(8   ,'F
MIHL0ZAQ%MF;B-9DLM@V,F5S403&(C'R>D(    $4C7<<)CDR"8V/0D
M6R:=3=@         #KGZ<X !TCN@        %$*V
M              "/NVXVTY&N            ^2HVYNA=A        %0LSTN^
M/R*@        5*S/2;X_(J        !W;<O1NQ?H    !>$?9Y^U/8  0YZ+
MS/'DS2@  8 P3KHNLZ2WOJY7OCQ4P;#)V2-D*['V:V\BG*KSW6   ?*E9QRJ
M1DC        "LXY=!R0^54        "MXY=OY87+2X        "J62:7?&
M   &2H6]E_SWI( $.>B\SQY,TH  $#X&^B1CDPGA[J8<G66M9FFA(U<5L,[
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MLP3Z%3+<%;*]6V3DK42)S1?E2LXY5(R1@  !;=M]R76    5G'+H.2'RJ@
M      5O'+M_+"Y:7         52R32[XP     R5"WLO^>])  AKT?F..IF
ME   ^J5^:T   _12OY6@   ^%*WCE4?)&        %9QRZ#DA<JX
M"N8Y=O987+2X        "JV2:5?&     &3(6]F'SOI8 '0OQ<2T
M    ?2ORH        /I7Y4         'VK\*         #Z/D     '-2[O6
MY0
M!J*+"(-$LSLE^$>ROE8+T+>-[(
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M1CHM<RD6P2"+U   !&@R$0T,\G:.\2/      !:1'0UQFQPNPN@IIG8
MBJ9#,4F:S%YFTLL^RRC*!VBR#)!>     (\DA@     #2V6 :?3?$:S#,)&(
MR 9B(J&<#:,:,#>$:;B5A#<R:;*#7T95(M&2#U%G<
M                      *2?A:Q=191JG-LY9Y63LEPG3/HN$L@P^1T)EEV
M%H%;.8N$N@^@
M                                             1?WG V5)U8
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M'(S%FA_=*X\QR;\R1N0'V<=:<E+NH 52R12[XX     R+$W4P.=]*
M                                &&2]2L%'+Q,1&70
M   1K,H%+.P90(:&<3+0        !BLRH#'Q=Q4P     0N)HF/RGF4 8X,C
M@$;SF,B&1@    #SEEND6B_#-Q'\WEFP8     %/(S$J0        #36:_#7
MR3O*43L(2$9RZ"]"]CU<       'EO-@1 $LLH)*(]'@    !YT2/Y&LE 7
M701O,8%_&:C:,0D)E&UP     UF&3"8I]&&S+999ET     %G&C ]
M                 !&0DV         #'9D0  QX9#    !@HT]'=,OFM S8
M08)[GI!            *??AXJV@           #Z5^5        !]*_"GZ
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M&SIGA  "MXY=OY87+2X  88PRX5QMGFZ_!25W7I=<5V*9,O4@  52R32[XP
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M4XU0   *UBE4#+#Y5P   Y5.)4    5S%+M_-"Y*7         56R12KXX
M   R9"WLP^=]+  IM^#AK8           !^'VK\J        #Z5^%/T
M    ^E?A3]         /U7\4     '-2^I69P     (GE^E-.^9I(4F6S-AS
MGT<YW       ".)(4XC$AD,J94P      1$)5F&#-)Q'<.N=\      %#-99
MM".$_#G.\      "-Y)          U'$%B Q.$LXGL0P(\%7+L+C/4Z
M  >:XFX:XBKEBDJ3T&       \R9WC&97BSB\S*)Z.0      0>->)@XQR7H
M6F>IX      QF:3#?^                       8),[
M
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MJDGK:E]GT[__ );O3R&?]X_XDQ^AD'_OST+<TTJ+G%9RWCWN-ELWFZF,7&!
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MU-.ME@:[6 H>M(_6]+@H+YINX:XPW[QA)^FT/]]]-VJU*2X.XH#<4!N* W%
M;B@-Q0&XH#<4!N* W% ;B@-Q0&XH#<4!N* W% ;B@-Q0&XH#<4!N* W% ;B@
M-Q0&XH"<Q0['#7H07]Q0&XH#<4!N* W% ;B@-Q0&XH"8Y)/)N* W% ;B@-Q0
M&XH#<4!N* W% ;B@&W7H1<- Q0T-Q0&XH#<4!N* W% ;B@-Q0&XH"4]"2EN*
M W% ;B@-Q0&XH#<4!N* W% ;B@-Q0#9KT8K] Q0T=Q0&XH#<4!N* W% ;B@-
MQ0&XH#<4!N* W% ;B@-Q0&XH#<4!N* W% ;B@-Q0"17H1K;B@-Q0&XH#<4!N
M* W% ;B@-Q0&XH#<4!N* W% 6?K4IW_Z3",CFZWMUOCVZWQ[=;X]NM\>W6^/
M;K?'MUOCVZWQ[=;X]NM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^/;K?'MUOCVZ
MWQ[=;X]NM\>W6^/;K?'MUOCVZWQ.@(52?VZWQ[=;X]NM\>W6^/;K?'MUOCVZ
MWQ[=;X]NM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^/;K?'MUOB1 0J4\&XWH0]
MNM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^/;K
M?'MUOCVZWQ[=;X]NM\4T%#I3P;C>A#VZWQ[=;X]NM\>W6^/;K?'MUOCVZWQ[
M=;X]NM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^/;K?'MUOCVZWQ*@(4D?;K?'M
MUOCVZWQ[=;X]NM\>W6^/;K?'MUOCVZWQ[=;X]NM\>W6^"R.D$ZWWN2^95J,7
M%&WN2-G;EK>0F35L\;[-7UR)M[C];6523IE'(#D&L3CC=RW64=HKQDRKG;9]
M).+J&G)YQ:1DX[*HI\RA]_DSEE8G$)HG#A1.*%U---E+[7\M[CU:1"=Z"X$R
M@M(QI3^^2<Y,=%K&J*LE04+$Y$V]R$9Q=333ALJMHQZ$YHM3D+JJ6;/??.=S
MMMDMK_\ 7O&BK: BIIJG LN(AU**KJ(=KTE--KG_ +ZWV6EA;JY!?@^3Q$89
M]69S4RV95]#6*F3;XLE5L2YG@O8_XF7N0N1B_P ^[A8V\JR/A3?Q#1U['K*A
MWXQ.&P]W6YCJ6L'>6WZYB]B/>=L<B'W_ "MX;\B%TGUR0VX?KT1KZ6735&_"
MC8]5)V0NYB3>1PYYX,VL<]I.0K[ZU+5R,EQ#2\&7,4,,C&'*ACW*.8 7HMS9
MA:QJ<+TFL)A9E4A9(8+X1N+'@[]]R5XZ/K+7 O,O(&ZF</'7G!@C<)J."SV$
M9]]MQBX *=L57&+&R]:+=_[V\Y&[*G:/CDQ1S7Q<S*_X>V<9;$-"^_\ RO\
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M !RUYZUS*/M"2)&#RA7EE9QZF,:7]5<5XCK)"VIFU#LQ/I+'#Y@!8 ;   +
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M53(J-'G.8K=K*\8)]AE8G+8$7%SQ3C'F'612<=U0&6-#TB@)CA2]BWMMFFD
M"J+#'+=O-6JF;--)"CL?2S3%B?I-S4_&N&26U$6IDNIZ,B%R'C<<JL,#R@V9
M;,H(\T>8>#(H75\-G,MNF)4@*E);?GQJ MSTD"L"5RG_ -C1:C33-'J$8,K*
M2K*P-P586((.((-P:6?BG$)]3.JY0TLC2,%N3E!<D@7)-MER3RU)+POB4^FE
M<68Q2/&2+WL2A!(OC8\M:O5Z7C>KBU4YO*Z32*TAN3=V# N;DF[$FY/I-?\
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MLVG?3K+VBHQ53/*3F4R,I'ZL$*,<!7DW5:7B4/"X>(-J4GDE1)%B> #V1VA
MREP0MV!LZW)(L96D\QP<3O* )8HXXU3 70B)F!.(:Y-[$"UJEXQPOC&GT/"C
M-(D$9TZSM(L;9>TF=B"N=@?9C!RC8,!F$GFET?@^HAS1R01FT6H1+R::QNS+
M+8G3O)[6P,;!RO!N'R"&'CO%9))$#)=-#I8US$.!8S3%2"<^ ;V2 :\P:[5<
M9@U?8Z4O"_V=8I%D#J+.BEHGCRDV)]K-;"U:_B,%OM<>@:9<+CM!#G'L[",W
MYNRV%<.GF\]:/62O!VK:*.'3I*[=D9# KHY<,I]FX7-@;@8UI]?I?-?#SJF-
MY-"8%4QKFLT>;-]HSJH)S92I/+:YHY;Y;X7VVY+_ ".*_P"5_P"-:E_2/X_E
M<2XIH].)=3"JV!!*C,P4R,%Q*Q@YF VVQL+T\VB\ZZ#7:1XVNZ:>,/"Y'L.B
M(WM /8,DX7V;_G6MQ3@I\W1!=+IX)<_V&'V^V_-RY_9R^FYOZ!0300J_"=!'
M%+Q#865-1(J1JF!(9$/;&UKJ<3937$N,\)X['%I=-IP_9'3QR]H00,PE8W4.
M&! RD"V&VO+TFJXY'JCKN(Z6(_\ +1Q9(I4=I%&5FN6]D!\"N6XZ1%>4]!"P
M^S:S43I*+ LPCBSH%)Z)S<HVW%\*.KTGF;A\'$NT<'ATD"WC"N5".Y8:@N5%
M\R*<<,#>QR[/E:C].']O%4WZ1_'^#CG"8'59]5I)(E+7"AG4@%K FWIL"?F-
M<,ACT6F35Q:>*.1XXT4NR(JN<X4.0S G$W(./+7F3A?%%@.KUFOU.HAF1;O
M965X&#D*X>-UNP4V*DJ"0:T>N\R:B"16X%+H-2(BV:1Y7N9$)0"S)[1)L5D)
M 4BQK_TFW&.&_P"A]C]G.JRS?:SIK9<G9=UVN3]7GSVR\N;VJT7$NPT\G M/
MP5="D,B]HP*2YU8AE*E>S&4F^8DG"QKB?"SJ$DX$-0TFC%V[2&.3VG@<$6RH
M^,9#,2"U[8 >4.*12H(.':B>20&^9A+%V:A+ @D'$YB,-A.RIO,K/$=&W"ET
MH0XOVBSF4M8C+DRFU[WS<EL:\VS:740(G$.&0::,-F&5XGS,SY5("$8 C,?F
M%JGX=Q73<$31OI)8<\#Z@RAFA:-#9T"Y<Q&?E"WM<@5Y73A3::#S?PI82DX!
M5)"@R312,JAVAF0D&ZW)&(LS5QGC?F+53'B.IFM&-+J9H4BTT8"PQ$IDS,+%
MGPRYC==IOPS@\4\$GE_1<<360I*69AIBK]KIV4H0S"1KH22&#,78'"C#H])%
M#"3?+&B("?20@ )]=>:]9/*C1:_7+/&%)NJB(1V>X%FN-@N+<O)^'A?_ )AI
MOVGX?,'%^!^:--IX>(2I(T<FE,I4I&L8]KM5!V7Z/+ARW\Y-J>,Q_:>,:32P
MLPB(6-].F5GRYS<2&[*H(*# EMM<+#:GL.):1TR3!;YD4J7B=01F1BH=<;HX
M!&!8'CO$>!>:M-IX-=.)2DFE,I4Y$3I=JH."#D]7+=IM!YSA198D62.32!D6
M0(%>2 K(KH)#=^S=GRL3[5JT_"(IVGRM([NRJO:/*Q>0Y%]E%))"H, MA<FY
M.HX'P#SA]F\M2%\L;:<23P)(27BAF+CV3F;(S*72]P21>O*.JX;/V6@X3IIX
M5B(NT@F55S%[@!@5SO[/M,3:U7)N?P<4_P ^#]H/E<,_2E_:-_6A7!_^G3\7
MR,1=>4>D<H^D84_!N"Z?1:G0HSG332RM&\*N2P66/*>T,;$E2ALWJ]D>2-/&
M8]1H.'-J6G,@![1YTZ2QL"&!DO8'%%"DXT!IM/'&F:^5%5%)])"@"_)?;:M1
MPO@VCT6KX299'@:69H7A$A+&.10#VBJQN"I!..(O8:31*T+<074Z:60BZ1GL
MGS2%,UR!_<4XG97"^-\(DC'%M%)(564L(YHI<)(G*XH2,5;8"3?D-<>T&MT6
MBTPGTACB1)6E8REP2TDM@BQY!8*!?-8FM?PG6<'T<$<F@DA61-5VASF$QI=<
M@LK-;,;^R"3C:QX=I)O+7"X!# L9U"2H\@98\HDRK&K-F8 NH<$@L,W+6FCX
MAP3A>EURRQLVNAE)F&1@S&) @DS/:UI&( /(;$,P%@3\CBO^5_XUJ7](_C^5
M(>$]A_J (RB;-V;"_M*Q7V@66X!V [1:N&\<U'!M!PU=.)>T^SR9WU)D7*%?
M(J($7I$L"QM;$VMQOB\JJVBU&ET\: -[1:+I!A^:#L#;.6M=/Q[C.O37ZZ61
M]5'IM0%@8,2JIE[,APL1RXFUCE& O6L\MZEXGXD(&@B?.,KQJZF)G/YC=F,I
M!O;*N..'#8M',B<4T4NGGB+W[,RP+E*/;'(UR,P^8[":X5Q3C.DTVDTNA$S1
MQQ2F=I)95R9G;* L:+8A1[1])O<?8]?P3A,>M+)_SZ2-VB!7#%XX\HFS$#!2
M]OQ@8DX 7.TV%KGYSM/SD_*U'Z</[>*IOTC^/^J<+_\ ,--^T_!J&X?'&^N"
M'LUD8JA;D#LH+!?20":XCP).!\(&KTD<,DA.HGRE9LV7(>R))&4YK@ 86O>N
M//)I5B^Q\5U&D&4ELRPE;2&^QCFQ P%JX:G#N#Z0Z_4\5U&C4222*@[#M#G8
MJK,"0F( /S"AJN*<&X:=9-K-/IX%BFF9"9F96,A:-67*0F7*&N"UQ@+\(\O^
M9^$:2.3B"S&"733/(N:!.T=)%DC1A=,0PN+V%L3;AWEX:+M-"3$FJU )MII=
M5G&D1A_]ZR>T6L%5U-^0Z'RUY?X;HY=1+HGU#-J))(U 201E1V:/C<BV'*<1
M:IX>.<%BA@T.ICAU[Q2/((!J$#Z;4H2H#0-?+*K6EC.-C>U:[1<(TZ2<"T:Y
M9M22?:U!%^PA %F[-;&5F/LDY; V)KBG^?!^T'RN&?I2_M&_K0K@_P#TZ?B_
MJ?%?\K_QK4OZ1_'_ %34?IP_MXJF_2/X_P"J<+_\PTW[3\/FKB,VF==!-I-$
ML<A'LNT?:9PIY2MQ?T5YKUOFG@#G62\;U31L[RQYM.S*T;J(Y%!4DL0Q%SCR
M6K@6CUOE/6ZCA>FXYJY'@B!,GV=NT$17]8C6-ULQ<7 VGE'#?+GD;BO#X_\
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MV\FW8=IV;3$GYEP2<.3$8'T&WT7I%A R?]A'JMLH=I&+96Y>4E2,18WPV_\
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M/S@<E6?!E#%A:_1-MN_Z,?FHDJ=MO3^*_P ]OF!H$*Q;'#EPO?<18^C;LM=
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M A!N6"C'#$WK2CBG!]%'VV;)[,V.6UQBX_O#?6G77\#TB:-ND0LV8"Q( NQ
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MRN5 25%4J"ZL,T;9O:)]JPV4O%=>P6/LU8@<I(O87/K))("J"S$*I(;4^6>
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MPN2;>DD\OX/+"Q1LS7FP )VF$#9\^'KJ$G9D'XJU<L>I>#AVG4A) N895ME
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MC,P%:;0^8.UT^OA0(2RW#Y;I<$=(^S[3 9"<;BY5=#I.$PRQ<)T]V[1A:]V
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M==_$S_O*^^==_$S_ +ROOG7?Q,_[ROOG7?Q,_P"\K[YUW\3/^\K[YUW\3/\
MO*^^==_$S_O*^^==_$S_ +ROOG7?Q,_[ROOG7?Q,_P"\K[YUW\3/^\K[YUW\
M3/\ O*^^==_$S_O*^^==_$S_ +ROOG7?Q,_[ROOG7?Q,_P"\K[YUW\3/^\K[
MYUW\3/\ O*^^==_$S_O*\O*_%M8R&:2X.HF(/ZB;:#(0?I%+(W$9\S"YM(P%
MSB; $ #T   ; +5]XZCXK^]7WCJ/BO[U?>.H^*_O5]XZCXK^]7WCJ/BO[U?>
M.H^*_O5]XZCXK^]7WCJ/BO[U?>.H^*_O5]XZCXK^]7WCJ/BO[U?>.H^*_O5]
MXZCXK^]7WCJ/BO[U?>.H^*_O5]XZCXK^]7WCJ/BO[U?>.H^*_O5]XZCXK^]3
M'[?,<NGF89G9A=8S:X8D$8XJ05.%P;"O&-]7-7C&^KFKQC?5S4_V$3RY;7RK
M>U[VY/F-?8<LYU?]T+<X"YOA@0,;'&E?7+/$IV9E O\ 5]=?8F>4:O#V"!<9
MK6OAA>XM?TBD77=M$S; R@'=:^/)Z>2GU$\&H2!1<L5  ^FU>,;ZN:O&-]7-
M7C&^KFJ&+4:@LGM'D_\ E2\H%[8XB]B0"1=1;Y/F7_+TO_TZ?UI_57F/_K'_
M "?*SHX*>D&XPVX_-RTH6126%Q8@W'I'I'S[*8-(H*BYN1@/2?0/G.%7OA:_
MT>FD9YT"L+@E@+CTC'$>JNV[9.Q_O7%M^RFR3HUA<V8&P&TG' #TT$BG1F]
M8$_4?E>7?^H/[.2M/_EK^(?@+NP"#:3@!ZS62*=&?T!@3N!KL3,G:WZ-Q?=>
M]%)9T5_06 .XFES:F,7%Q=AB/2,=GST&1@5.PC$4P5@2IL?F/H/H/S4^:51E
MM>Y M?9?T7Y+[>2AG8"YL+X8G8/6>058ZJ._Z2\]=L9%$7]ZXMOV4&ED55/I
M('XZ.74QFPOTEV>G;6>2153TD@#>:[;M5[+^]<6]&W9MK,[ +AB388[-OIY/
MP^7/\Z3]A-47Z(_$/ZI+_P!+/^S/R./D\4?2#,GZQ2X(]F?88U=A;I&RG!3L
M.(X/H=%QV6:73:>?M)RK^WFBERLSO:4M 0Q (4,96,:JH51KM7)Q.?B>EFU8
MRAS(PC*2JY7]8%*V1749$"D&4N2B!5\_<6X=I,_&8ET:PFS%F$D>F28  AKH
MA #H59!,QS"]<=EXQ-+,T'9M%)*ID92THB)6^)SJ94)'LKV>8 .CL>*ZM/,.
MIE33("^D!DR 8.556"PMFC5@PS-93(X 9/9G=--V(S6R?W2,"/7<&]\;[<?P
MP_HM^SD^5YE_R]+_ /3I_6G]5>8_^L?\GR=00;'(WXC6NUGEC1]EQW@J\/;B
M.F50%U&DEC@D37P1H-L+,T&J4+;(%D>P"E_YL&'10QM%YPT<:%452B'2J2BD
M $*3B5&!-\,37\HC-I(G>7SCJHY"R*Q=!!<(Q()90=BFX!Y*'FKLG_\ ]4E!
MQ('(ULQU/V<<*M;+VW^H_JNRS6['V;Y<:_GQ-P/7<%X=KM/YCTJ13:]8%T\<
M3 YXE,L4B*T@P50N+;"#C7\L-1K$X1J..ZGA7%FGUVECB_TO4-'&WV<$JHB>
M?2V+3MV*9%8"S#H_RXTOF7S1Y8XKH)>.Z'-'PT:5WN)%NTHAT\3&!E+*5)*.
MS*"IPMY[U/\ ,'_T_)_+73G5Q*($TK:J.9I"N@BB.EC$L.IS9%/;,+8AO:QJ
M(3=[E&;UVQ^OY/EW_J#^SDK3_P"6OXA^#R5I]5 LNG?5N&1E#*P^SSD9E(((
M! .(P(!V@5Y?\M\?\Z>6=7PK7\8TVG=.%_93JT5INF##IXG5552KMFL&(N",
M#Q_RMY0\O>65\N:/5R:2+AVKCTT7;*AEB6SR6U4\[=DTLC1R71K CE/D:7@'
M'O+W#=6^MXE'J'XF-,&G[+4,J")IH)2_9$,&L192NT6 ?6>6]9P!_,DWF?61
M3SR#0B#4 1($71M/'D9"X4HL*BXN<MBU<.TO8:./S+#H(DXJ-(ACT_V\$ELB
MV5<_9%#*T:A&)4C&]OY>2>6M$9?.^DX/I))H$7VM5I=;/)IXY1EQ=]/J442N
M5)2*5G9K6M_);@7#=/%JH]+J..:;4RO$I&JU6GTA,[D,#VD:ZDNL0<'*$ 7
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M@J@>5==P:<Z'B/">$#AZ2QG,9(LSLSLK+E4OG'LV8*RJZL& MY'T_"HDAU?
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M?5R9Q)$&]GM([*<A./M 7(%_,7E[RKQ+7<2XAQ=M,D\^HTRZ1(=-II.V[.)
M[%YI7N&<_JU!! &4 GB?!_-7F2;A622_!YH5[&5GC*B.:;M#I3&&.+K#F(Q
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M6)  P)MM] 8X7L%). O3390VG!(S!E*FS9<""<;D&VVQ##V<:BTXLLCJ2,V
ML%+?B!IM*;+* QQ.'L*6-B+@X#"V%[4LF4Y#R_0#^(U+J$=1&K6Q(&-@>4BP
MQ47V7._4+,N26,@%3MQOB-MP+7OLL0=E"-D(<VP]>S\=&-5)?'#U;:=U6ZK:
M_P U]E!RIRD\Q_*/Z UJOTS_ %/2_I?D-+ZOZI!_O?X&I?5_5)_\F3_#_2Q?
MY;_D^5JOT4_P_P!!,!.BPFP8-M-PP!&S9<WL0UKJ" Q-20PZ\IH4U).6S7[-
MFCRVN.3*SWZ7S>T;0IJ-8IEC5@&;VB"1';'*+D6;&V(Q.)-11MQ!9"!,0;$$
M(T++&IP(.1@V.8]+-<YFM(1/')9%&4YK,WL!VM=;%F!8$*=IN078">)]8(G6
M<ORWME2Q! PZ)QQ((V&AIX''L2PA&8%<Q$93,P&-@5#$7]I3E(VT+:Z[M&,&
M+$*;@#*;LN"A[XDL9#F<J25U$WVW).B_FDJ&!0 E[,Q.4!0&&-R6 )4,.*F7
M4_\ +&63+:ZEAA8'*0P5AE4!1<#:P!M4I$Z2#*HR^U[1]@.<2I!+!B" <"22
M"[#^@-:K],_+DULCB/2J;7(8W-K[%!L!AB;#';2QPQL\AV  DGZ!2QMIW$A-
M@,IN3>U@+8FX(]8K3AH76&214SE3E!8VV^ODJ1ET[E%-B0IM\W)R@@CTW%KW
M%),\#B!MC6.4X7P.SY>E_2_(:7U?+DT9=#*JLQ.-K*I8VPO>PPHR_9)<F&.4
M\NP;-IY*!2)Y(\B,65389E5K'YQF%_6#L-*\VG=4.PE2+^FWJY:+2:.55 N;
MJ<!MN<,!MW'T&L=._1S=$]''VMFS X_,?0:5YM.ZH38$@@$VO:_I^;Y<'^]_
M@:E]7X; 8U&-1K(HIG (5LQ(!Q%\H(!(((4D&QQM0S*7A(!#@'+CR?,?FY1C
ML-(QTLEF%Q[)Q&RXPQQ(WCTBK?9)+VOT3L]/J^?9331P.T2WN0"0+8X^BHM/
M%TW( O>POA<VO87VGDIH8%,K@_F F_SVM??15-)(7')E-_1;9MN#N/H-'4M"
M1 &L2>0_.!CZ-XY#>AHHV&<RY 3<"^;*"00"/GN+CT4C0S1M$3;-[0 Q &!%
MS<DVL+>R<;@BEE@D2:.]B5N,N!-V# $#V7QM;V2+DX5'%*ZLS)F]DW Q(M?8
M2"#>UQZ"?D3_ .3)_A^4JY@ 3M. 'KI-2)4> G*2MQ9L<!F )&! (PNK#D^5
M%_EO^3Y6J_13_#^%];!J<X2V892/[H:QY2&==H%Q>V:UZ$IU"*?9)%B;*V7$
M_/B2 ,& NK$$&M5(^H4B*V%B"U\N(Y,+V-BUB/00:D9)@N7DM<G9Z2HY?3R>
MJFCTZ=I#8$,-F4A6%[VL0KK<&W+:],(]*UPQ!O@00+D6/HPO:]KB]J#+I'L=
ME["]KWL"<2""+#&]A:Y%"#[.>T*WY+6V7O>UK^S>]LV&VI3]G.5+XW%C:][8
MX^K;B"18WI(TAD+%;G,H4 X7%\Q!V@7^<>D4Z#2M==M\!RB]S:PN"+G#"AIM
M1(8FS6N1L.S&Y6PORWHP0:M99@N8BP6PNH%[L;$YL V6X&%\+N3I'"K>Y-@/
M9N#M(Y01\]L*#G2M8V]%\1?9>^'+AZ>0$UV+1!'RDC,; VQ('SV%\; "UR"0
M#/I3(H>-9"3B0>S!)MLVVP)MMQ')3#31%B!<^@;-IV#;4LITY54O?-9>B+D6
M.T@$7 N1?&U :>%V3(K%B,HQ"DB]R,,P(N02,;<E%5TC@@VQP](.WT6(/S@C
M:*9)%*NIL0=H(V@_./P&M5^F?EPP:ALK1MB,I?.F%U M:[6*D-@ 00>E;6QN
MW8]JEE<7.6S!@IL+Y3;;C8VN+7IM7+,9(X6*QD')GSC*0+@6*JN>,](N&.TF
M_#]:^M8Y&BS(025RY Q!L<P]DO?-<EMF;-F6)=1FF6-U]H."2ROLZ0(]L1B^
M7!2;@%<H]K_FK)T <<JL/:S*,JK<* N8D %F8V/R]+^E^0TOJ^4+[*FX@L[B
M9HBN0"^+JR->X46&92+->RD$7;V"4U#*#IF%@,1(8R ,VVP8X8Y0?:VXUIU>
M=D:,)T UW(C16SX6-C=00>@&Y" TLNHG8QKJTD0!=J()#@, &)8=+E-S@*C@
MFU#SWNI>Q%@WLN2+!B3&QP.<^RN)_-U,!F<7&1 HM:-<8P38DD%;'8<LC#DO
M7%D:<E'DO'[.U;DBYM? $@!NB"0+ V^7!_O?X&I?5^'$7&ZH-6^L$<I S*58
MVL1LL""+YCM&!49002VM0Z@C2-'&$]DVN'B+7 Q."&Q/(+#;6FD24B'[0DC#
MVLP +,;KERX%M@8WQMA:T U&I8N)[M=0?U8$87DZ0RFQ'M B][G'32KJY(UB
M*D@*+N%Q( RW]K!,6464$AA@-7.P G*,$%FP+8'VAL&0L,1?-E((J676,_;V
MP)OE-F1L2 6#8''EV';:I3I=0Q8O$,5P*JKAQ8Y@5NPP)-]N)%Z>**=@UP>C
M;-=B3M4XC GHDWP; @_:3"O8_:^T[3VL^3/>]KVV8VM>]1O-)DT0 &55%L,H
MN0 ">B+;2H 6YQ)FTFCE,AE(O<&P /I(7&V7\W:#B0;+I&60LRPY6)O?-G<G
M;MP(-_G^1/\ Y,G^'Y48E:T187/H%\3L.P?,?54$6@G A0GV &%[@>T;J+GV
M1>[,=G*&9ODQ?Y;_ )/E:K]%/\/X!F-EJ"'2NZLK*S7CN7(.S,'6P%S@,=EB
M"7+%1&8];F!NH.46?-8$OLY=FWV0 +&M1FC9D*#+[(&..9<6-E>XM_=2ZXVN
M=5DC/;N?9P%@"RDX[ 0 <IRD!@+@BXJ5V[1'DRDD(N!4.+"]\/;87VY0H()9
MS0D34NSRS/>3(+)F-KNN?*MLI:]FRW5AM]K2SYW>)$(< @!RS2'-;HD@/<7P
MS8;*5VUDATV4;8UN#=25O?$&V!:^4Y<"RAQKRZ2=A(6LF-V#*HN7+$BY!NH&
M MF+Y0 8(SJ8H3EL5-BF1<H  ;E!:YOM"7!%Q4GV-YTE+0V)-C:)&C/M*=K*
M5)'I+#$ $G51YNRN-NW#;A>M9JU617>,!6M<@A1<%<P%B0OIZ/)FN$T\.="S
MXEK*,MVN,U\/98CT$$KL-#52K9(94-F0 R.K$YT:]S=F<W %E:1[,;+4974S
M'2F-E9>S0&[J$O<$7L #;&V15!L;B>5Y)#IV65<ULS^V" QQ%SC<XX[:ETPE
M<QO8Y^S4&X5Q8JQ86(:Q/H&6UB36M75,TCL7M9%7-GY6L=A(!918$>RV<90!
MGEG1_P!2;J /:BA[.QLP)1B6N 0;6 Q8E5B@61'# 8G:@#KB0=K*WM#8;L-A
MQU6IC![.1RPOML?3\_X#6J_3/]"D9D8QK>PN;"^VPV#^BTOZ7Y#2^K^J0?[W
M^!J7U?U2?_)D_P /]+%_EO\ D^5J@6%\J?X172&^ND-]=(;ZZ0WUTAOKI#?7
M2&^L)/K_ .VND-]=(;ZZ0WUTAOKI#?72&^ND-]=(;ZQDO]-ZZ0WUTAOKI#?7
M2&^ND-]=(;ZZ0WUTAOH^V-]:KVATSRUTAOKI#?72&^ND-]=(;ZZ0WUTAOKI#
M?72&^ND-]=(;ZZ0WUTAOKI#?72&^ND-]=(;ZZ0WUI?:'2_(:7VQL]-=(;ZZ0
MWUTAOKI#?72&^ND-]=(;ZZ0WUTAOKI#?72&^ND-]=(;ZZ0WUTAOKI#?72&^N
MD-]=(;Z@]H?G<O\ L-2^V-GIKI#?72&^ND-]=(;ZZ0WUTAOKI#?72&^ND-]=
M(;ZZ0WUTAOKI#?72&^ND-]=(;ZZ0WUTAOKI#?4_M#N9.7_9KI#?72&^ND-]=
M(;ZZ0WUTAOKI#?72&^ND-]=(;ZZ0WUTAOJ$!A?LW_)\HL\*%CRD FO#IU1S5
MX=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#
MIU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.
MJ.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:B3 E_T1S5X=.J.:O#I
MU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J
M.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S4"($O^B.:O#IU
M1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.
M:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5
MX=.J.:@1 E_T1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:
MO#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X
M=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#I
MU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:O#IU1S5X=.J.:@R0J&]( !_^
M*]J88-6RP@+8 +A=03M!.VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E
M]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E
M]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E
M]VO'ON7W:/\ S[[E]VM0B:U@@8@"R^[7CWW+[M>/?<ONUX]]R^[7CWW+[M>/
M?<ONUX]]R^[7CWW+[M>/?<ONUX]]R^[7CWW+[M>/?<ONUX]]R^[7CWW+[M>/
M?<ONUX]]R^[7CWW+[M>/?<ONUX]]R^[6GC?7,4+8BR^@_P"S2WU[WMZ%]VO'
MON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'
MON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'
MON7W:A1]:Q0YL++R*Q_N^G&E_P"??9Z%]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W
M:\>^Y?=KQ[[E]VO'ON7W:PU[[E]VO'/N7W:\>VY?=KQ[;E]VKC7/;U+[M>/?
M<ONUX]]R^[7CWW+[M>/?<ONUX]]R^[7CWW+[M>/?<ONU+FUS6$3G8NT# ]'D
MKQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=KQ[[E]VO'ON7W:\>^Y?=
MKQ[[E]VO'ON7W:\>^Y?=J&'4:MFB*.2"%Y!AL /RM7ZD_P (_H, :P-95!+5
M91<V)W8G\.S^D-:K],_T2JHNQ-A_0Z7]+\AI?5\K 5AC\O 58[?DP?[W^!J7
MU?+FU#64*XNP7,;9K<C(=I Z6PGT5PS4W=]7/*EF(  (F N!R6L1>^/LX8G+
M'VFDU#/J''M9<$)<K<F]PIL6!_.1D&&T\,CATKQNR.2_+@-0+,UO98Y;V ]H
M7&&1:GT;0RM*8WDOF&R,,Q%R"1FL%P'*3?  ZI)H))D/V4V #$%H&Q(-O96^
MW"W2O=14NGCS=F I&;;9E#6/I(O8GT@X#9\N?_)D_P /RQ\K3_H/^(?*U?J3
M_"/Z#40$NC2V"R+@5:Q %[K[)OF(S*+H+YA[)>%M.'U'VEE,G+BT7*6'*Y7E
M/+E6[%8M3$H5E$A 1C[2D*!?,20Q5S@, ;?2NLATSI(_VE3C@V6%F+J 6 #%
MB,&(LN&T@ ,CQS]D'!)8L"<ARV(4$+G(Y#[(-\) )&T:7E^U>KDB !-UP-['
M'86.%LP+3W65GA$J@Y5QC-P!@N;.'523E5@5)R@TKMI_U/99@5+Y#[048DMM
M#9KW6V0D>S=@)XHP\;!?9+/8%D+$#*<UQE;*&&8@68!K9M7IT [57E S,S,
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MV)1L+E5:[93:S #:"&0CELPP%C_0&M5^F?ER:B62T8#6 .)*B^.& N1<WN,
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M,?BT+8TR"EKU @YJ(<P<6>0+$FT%S71LEZJ>DYK&RBI$I9_69<'L.CVKG8K
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ME:-CH%6076$14/Z/6JHS1$W;VB!.WK*.-NI3;M[QK]IQAN ZEEEG?-TFK4-
MTJI1[G*IIPV;>E$C9T+6^D,\FT$Q3*LNM7W:@^$9,1Y$99G<ZY8<7O91\<]_
MT:]69LEWV,QJ5'@W7Y^(1QET4VCBR6B^P32CPP*&4(BV@Y]XEVD./;SI6,!2
MF66Y:JF*7M[H&4>0IQ O;[O= 1]SMZ<8?4O9]<@>444XUW0[R.GY@M8$ZN#Z
MU&AU'%5[(S,+BU&6@/0R%<AZ9W@\4HBF3[P\5(OET%)X,4+*IZKP=4R^\DN(
M7J\KET.'O3?+36">JU8*GIFN3\ Q8LUG[>)AV;!HLFQ].E'":"_L^_Z'U_\
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MJD,)3D,41 >4GLG-QL;1&-T6Q.7F7R4AX4*SL6FTJN-IRGV:%BUWYVT4WWS
M7#9Z5L0RY@DJ\5H0QE.WO=7KDTAFDS?.%O(Z7NB*4K&D191<K1-5LX:)-9BA
M:I,RD)5]EQ_06*KR&;2:[5"QP ^"FNFHNL9JM::07;=&NBS$%(K-S9P[H3GY
M35('@,;%=+HYCZ5"-"*CW5G*#N0$ [1137'NE-&6)MF4CA^^7F.BM@SG/KFA
M-1$.EJ>4VQ^M#1K.4LL= OI&@:A#,7#6+FU4$$#LIA%Z)>X02"WX!^T&I>I8
MW;>.DI.5:HSIZ+-3<W"5EQ+/)I+.]5H\:5S<:_9:8[DU6D?)M&;R(EXDK8Y%
M2*)F.XR+V>OLX<VO-\@GN@Q5XLUBL,$XKSRXV.$368UA])0RQC/L\P_-EY=2
M<G9V>!FH]<-FR35 / [7?'7C/"2R4A&XWJW'FE+SZX%8A9+$V@KV\M5C!NJJ
M?T8]FLSEZ_\  [YQ2!<2]IN[V]>S_D<5_-YKRAPOCSQNN.*3<Q.*UJ,GH:;R
MS/FE]H<C;&;=\I"-)J-9MI:.>E15,TG85@H4R1!54#G^PUGY <\EMNX_[_HV
M^SL+-*V&,8K,L\MD=1J,PL[MM'JSL;3:\J===XHB0SJ;E))QWCE6*;KG.X(Z
M;&;IGY9E47*ND**8@Z@^T#J@;N%$.\';VC_+TZPOD3?KI#:"KMVH7Q-C5\VM
METB25RVKPZT,L2:KS-['^D+E9J&51[Q543B(&+_*/#_(O9[97>;EIM-?RL"&
MAR%5-6+A91M-HILNP05C4SK3U;RC'QK;FQ/9Z=,R:LW"ZHMB)]BJKGV>:<E(
MMO2"5_6P6<N%$&?I"B5YPXJSD$C'*5,IS@)A /Q2]O9UP2](<MV_B7K=A)XZ
MR:7? M!I_>$GB&+W@+W@[>S[W:'3KCGKK=1&*LE2K,O4+C'()*V3,M%AH9-6
MFZ34E5#I>%.5I\N(BGXA$G[)9PR7$S9TL0W!;BQR7>/D;U@'*_':)3V+V1<.
MJNIFDE>Y:SU::R%61[B_]5-T?S;R5CFI.P&#UX[:*)HN45TBY1[.3'+@U;9M
MQU0ME.NEO8HH6*-J5L^26MFY'Z&YACKLVTD]S^,80M+9M7*B:9[ LZ;"H4BQ
M^B-D?:\<L$6B21&Z+-*'M231%JF0$DFB31+>"-4VJ2)0(5,I"IE('= H%]SJ
M2X4ZS?"3&*<I*M1:/"Z'*LB5&*N#BS!(26!:2:!*^6CF$JPTI.P4&1,155!-
MS($,!^YW.SGDHJH1),G%S7A.HH<I"$#\TI#W3',(%*']WK:C-ET7!2<O[\0Y
MD%2*E(?^J['#]PPIF,!3=PX#V#[O8(#_ "]<&_273=MXEEY*=SQUTD>_W*'0
M@,)?$,7O 43AV]GWNT/[?6"6K%Z_(7;9N-M8KU[KM!A1\::TG/;;G$77=1I5
M5;@JBFYN2\:@QE8E/O"9VYB09I@*KH@A2\AYQ+:!G6[XQ78_.K!98;.[-;H'
M1$J:S1@HZ=?1< U?6FB:"\:L"EG(>68-"(R15%&Z@HJ%31Q+CKQ-H%S@>,6,
MN)-*S7^T1:"9ZS$79ZQ;:;M&B^@++Q].54I,%\BTVLKO%9E^^<*KJIHD<'(U
MX/4Z%(VAJ[5;WHM8KS%5R4I&D-7\+>1<8S34<'[ZH-&+9,G:(B/N=H_?ZKW'
M/9XP[VIW;(,[7BIZ-\$EEH=QBZM$O:CHE*DE"'&,M53EBD<ME0[4UR>(V7*J
MU7714X8\1N1LF\/.X1RZPV'S+TE=4E.F<ONNYLK3$W;(DG9A]%H6C3KMU)*,
M$3F"+G5'S)0B3E%8@_\ L6;J5O@(6U56RQ3^"L=9LD6QG*_/PDHV49R</-0T
MF@ZCI6+D6:QTEVZZ:B2R9A*<HE$0Z>5;%<HS;(*S(RJT[(5W,*/6:%!OIMPU
M:,G$P]BJK&13%U*K,F"")W"B9EC)()D$W=(4 B8;;<@R_88>!D3S$'%:C0:K
M?XZ&EE6BS!63BF5KBI9M'R"K!RH@=9$I%#(J&((B4P@-#HUVXWX1<:5E;!6*
MS&HVK)*%8:UG46NU9L5HRBP<O /(VI1RK&.;H&08)MTA1;I$[O=3( ?_ /%'
M$S_^W7(?U0Z5I^-9CGN35)>5>SJ]7S2F5RBUY>;DBH$D)E:&K$=%QRLJ_(U2
M*LX,F*RI4B 8P@4O8S<[SQZQ?8GD<D#>/D=)S2H7&4CVP"<WHS&4G8A[(,VP
MF4$1335*01'M$.WKCKS5]DED.@OJU?K0SJUIX\XW'6*8K32\LE/E>6H5BKT0
MJ"$?@>\5!BZ(Y*].6)J]AC0?(K,SKLP2K$_-UJ2IDS.5Z%F)>GS+F,>S%4DY
M.-;/7]:E7D*\D(9W)03I<[5=5HX7;**I&,DH<@E,+1[O'';%-@D&!"),931\
MSI]OEV2! $"MVDM-Q#R2;-O=]U,BI4Q_E#W Z<P>%8QEN.Q+T2&?L,SH=8I*
M$B=,3"FI)!78R/-(JIB<>Z=<5#!V^X/2=.V7,<]UJHHRC.<1J^ETRNWJNI34
M<1PG'S"4+9XZ4CDY1BFZ5*BX!,%4BJ' I@ P]L'2Z-6:_3*=6(UK#5NJ52&C
MJ[6Z_$,DP19Q4)!Q#9G&14<T2*!4D$$DTDRAV%* =1>C:?Q[Q'1-"@TX=&%O
MEXRNC6JZ0Z5=DSS=>)%VF<@WT['E@)E4[MCX*Y/1')S*I=PYA,):SL>6YWJ]
M=)XXIP>CTNN7:*1,Y*F5=1NQLD=)-FZJH(D[3D*4W:0H]O:4.QO;\FXG<=L[
MMC-<CEC:*CCU"A+%'N$U2KD6CIIE!)24>J18@& 452"!@ ?Y Z@I3;L&QO8I
M*KMWC2M/]2S*EZ [KS60<LWD@VA'%LA996*0D'4<W47(@*95CH)B<#"0O8!2
M@!2E  *4     #L   /<  #J<HFC5"KWZD69D,=9*==("*M%6GX\RB:PL9J
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M3*IH5&LC=)I8:;=Z]$VNJSK5!T@]0;S%?G6C^)DD4'K5)8A5DC@15,AP[#%
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MVS=--<R $%4A"E/V@4 !)!!)-!!!,B***)"II(I)E B:229 *1--,A0 I0
M  [ ZI^K7G&<JN>H9[X'Y@Z/:\]J5AO=)]$>JR30:E;9:(=S]=%I(K'<)>B.
M$?"7.90O8<PB-AT;,<&QO.]"MI)5*UWRD9E2ZK<[,G.S!;%.$L%H@X5C.3(3
M5@(5\[])74])>%*LIWE  P=0%JV'!<:U6T51 C:KV31LQI=UGZVW2DD)E)&
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MEAJ#(GF%95K3Y,_I<:#R/;@S."RZ8]T#1Q3<YJD!I59N@P ,LWXWCJNW*31
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M:8R!MD,VDRMEBMEW#)-!PHW6(F<QT52DP#*=HU"'H%]Y27:0SC!H.883RI-
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M3.Q<1<WSH'+-\]G?6&3=1H>4U/F[/)X+KT'18XS<\6D>IVIXL\14*JDB@2!
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M%8^/^S:'H-W<Z G:9=*%AWL':ZQ"QJ5;=0BTDJY<D5%9-=! I2"!S"'/.R9
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MLN]/WS=92%?/&KF(]H!:(MQ@^-UJR.7;9LJZF#2M.?SJ[0@=TD=+.TA6(X*
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M 4 8^T<4?Z%_7_'X&MQR;QH6=J&:?F"M/K6,[HU4&&%[^<@OUS%])!^"0I@
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M)JA2LHL,7)>C^E 197W4SJ <B21UE'!DTRIBNMW?&6[@ 7Q5A( %%4X!VF$
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M&*QA_ 24[8G+*6G3Y+-S]9D=%%XDX1='67*^2CTVA3$\$43&ZPG_ +*N0_\
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M<R>][]L\5M:?M+(:8Y"9%HND4_*:>IH%ITBU9C.Y_IF>;5'Y9#M[G1UHZ9B
M;P39<S.2>J@HTS&+VF>K5JV.-SVEL-8L]+C',+3K'I;.MQK>]3U4AWG8[B:U
M+VA-TX8ME?YQ!JH0AO=*/\3R#SBBHQ;B[Z!A^L4FG(3CA-I"KVJUT.?@J\C,
M.E6D@DVBU)=^B5PH9!<I$A,(IG .Z.@X52(^/H_+S7^'&4X)=-CT'0]0VUM\
MI9Q&UNQ#D2UCO4_8YV%XWV:^0BC*<@ZXA&L'T0Z44!B=8B!2[1RDWGAW5*Y*
MNN/7'SCIGO%;+^8P5W2)JU9/R'=\@T.4,1R@JU&I\?G-RP2TR*2N6-FY$)(%
MR2J[UU&!)D:)Y9"[]=Z7,75GQ*]JUQU"ZW>VL;+>\\KW+",R*L\3X+59^B4R
ML06SWJGU.F+HW6S0T?$)O'38JB:3Q98[M6L)\DL_IV(,)+V2%WX/6%*%U%KI
MUASSD96-TRF\8OK52DHJ B&D[#1+W-6]PC'2AF[R/D&C9NY;"J8XER?>;PK'
MO^<!.:EUYH\B\NQW?)G&F%G?6?CY:.(E5I6(\B25:8DZ7*8[B)X):"&19'8/
M!;R,8NY;E?C()\J,"H^-VNC[EI49NFX#D=GWMSR4N=ZV"9TJ0VI]&36L/8FN
MQDM:-VL,3WGC=LD6-9R$XHGXRA047->.3]'S76]ZXG>T<Q/C E>,T:<L;9PC
MM&7QE AI:%E*9NN9R%'G7.@5!6!MQI5)NV6;6*!L:,LR,S$CI%V3D-R@DJWB
M=._\6=8W;AG8:E5WWRA><*X]V[,@RNA<X*[>':,1&V?E;:3U2,_/.)12; [H
MA8&$2DE'5:%61)GFA8;@>#R?&KV4O+7V?V5#GNP?G-7>2VA[UE&>Y=7GS1NW
MS^#=X]QIKY,?92K6,F"O)I)]+H$,T2+$F6?X/M_YNT:)S'./9I.N*<LK"23=
MO,1^BIZWD=NB:[$0#6%:I+T:/K]/D!0<@X23;*]U--L +&,'#'>X)K!*9MB6
M3<Q*AH+MY,G:3[6<VC_P[#0DX2$!@N289N?ZMI7TU47" M.XCV%5\4>Y4M&T
MC)<X@M+-H/(EUS-]H+!;0YD9_GSQ^UB/N+:N84ZX\QM:C%J+XC]_2G)A</63
M:D!02)0SJ2*Z[Q^2V\\'\;HEZY/V)::=\<*GH>BZC4Z'3HJ=H&74=6@VZ=D[
MG=?SB@TK!27ED<OU&B,FX]--'(+-4RHKIV<EQX^0T1RYI?*;CWS[>[OKO)VH
MWU[S<Y$8_;XY[-4"ZFSC,V3?CUFC3,(!.GT5A'-)"&IL3\FI$:N 9O5'L>;5
M,C85+D'[1OVE7#C2@R[/K#(:?!\8.+O 5'*[Y9;]H6R,:O"4Y.[/8?&G1@%/
MP6BDU<XJ%8*/54U7!_XKD#Q?6M*E'=;'G,Q5X*ZDCB3):A;DQ0EZ7:'4*HNU
M).1\!;8QD[<L161],;I'1\1,3]\O*_B9KG$;$\HT.]<>I>F0FFU/E&WN>1ZI
MIZDU 1[IC7:R^S2+T"D9S:X8C]^52?(H]8(^&P62=G.=R&]S>5,LZA*Y;.(_
M#>CT5W*V^5ICR;T_B;SFF^5".:R;NKUJ4EZ+5+%6"HQT=9FI)!6 D) SE*/6
M! Z3C(]/M& 6"B:*C[1O'N3.W.>07,4_+.\VZGXYQ5TG&*IH[6R?F>RK\=:Z
MQ)62'B(N,;?Y4>/BTGRSI-5))N0S9A2<J9/W?MR7GM Y!9G/-&IW6*N;TO+*
M79PX0K!%'&JN*T":"C W\Z<G\P9Z) 'MX5\4KE0,GKV$\"^7FB<I8OF%7=+&
M0O.\PLJ]W66J%4BL8)46D[0M,T-QO:J.F2<C-+Q;CY/DSL32 3"7H7\;:)&B
M0,5:KJPK\P]J58G9Y6JPMCLC5@X7A8*5LZ$/85JY'R\B1-NJ^*P>BT(H*O@+
M=SPS:;R4+Q<S[@3EFC8\[K.M8I3MO3W.<Y';V[NL'9*UM5I=0\)&U&H,LCK*
M4[#1:R"IY6;+9W'I;=HBR:D4_L1RQ?-F[UB];K-'C-VBFY:NVKE,R+ALY;K%
M.BNW71.)#D. E,41 0$!Z;,F39!FR9H(M6C1JBFW:M6K=,J+=LV;HE(D@@@D
M0"D(4 *4H    !]TVEE6#)249-G3)G)*-4#R#1F^4;*OFC9X9,7"#9XJR1,J
MF4P$4,B03 (E+V?V&S:6: A+$TCY6.G6#6=BF,NW8S<.Y*\B)AFC((.$VTK%
MNR%5;." 59!0 ,0Q3!V_^X\C"QR,.=FU1CU$C.VKI1P)G+0BZO?.F]1(( <W
MN=A0[ Z^+U_U)[]8]?%Z_P"I/?K'KXO7_4GOUCU\7K_J3WZQZ^+U_P!2>_6/
M7Q>O^I/?K'KXO7_4GOUCU\7K_J3WZQZ^+U_U)[]8]?%Z_P"I/?K'KXO7_4GO
MUCU\7K_J3WZQZ^+U_P!2>_6/7Q>O^I/?K'KXO7_4GOUCU\7K_J3WZQZ^+U_U
M)[]8]?%Z_P"I/?K'KXO7_4GOUCU\7K_J3WZQZ^+U_P!2>_6/7Q>O^I/?K'KX
MO7_4GOUCU\7K_J3WZQZ^+U_U)[]8]&$&]?\ <*(_$GO\@=O_ /D>I!FBA!"B
MU=J(I"HS>&/W"@40[YBR!0$WN_?[ Z^+U_U)[]8]?%Z_ZD]^L>OB]?\ 4GOU
MCU\7K_J3WZQZ^+U_U)[]8]?%Z_ZD]^L>OB]?]2>_6/7Q>O\ J3WZQZ^+U_U)
M[]8]?%Z_ZD]^L>OB]?\ 4GOUCU\7K_J3WZQZ^+U_U)[]8]?%Z_ZD]^L>OB]?
M]2>_6/7Q>O\ J3WZQZ^+U_U)[]8]?%Z_ZD]^L>H]DNA!@BZ<"DJ*;-X50" B
MJI^(8S\Y0'O$#[X#TF<6]?[3$(8>QB][.TQ0$>S_ *2^]VCU\7K_ *D]^L>O
MB]?]2>_6/7Q>O^I/?K'KXO7_ %)[]8]?%Z_ZD]^L>OB]?]2>_6/7Q>O^I/?K
M'KXO7_4GOUCU\7K_ *D]^L>OB]?]2>_6/7Q>O^I/?K'KXO7_ %)[]8]?%Z_Z
MD]^L>OB]?]2>_6/7Q>O^I/?K'KXO7_4GOUCU\7K_ *D]^L>OB]?]2>_6/7Q>
MO^I/?K'IFS70@P17]*[XILWA5/YE@[<D[IC/S@'\ZB7M]P?<[?[O29A;U_M,
M0AA[&+WL[1* CV?])?>[1Z^+U_U)[]8]?%Z_ZD]^L>OB]?\ 4GOUCU\7K_J3
MWZQZ^+U_U)[]8]?%Z_ZD]^L>OB]?]2>_6/7Q>O\ J3WZQZ^+U_U)[]8]?%Z_
MZD]^L>OB]?\ 4GOUCU\7K_J3WZQZ^+U_U)[]8]?%Z_ZD]^L>OB]?]2>_6/7Q
M>O\ J3WZQZ^+U_U)[]8]?%Z_ZD]^L>OB]?\ 4GOUCT[*JA! ",7)O"=QF\ ?
M&:-C+(@;MD#=J??#\8/<$0_E#KXO >I/?K'KXO7_ %)[]8]?%Z_ZD]^L>OB]
M?]2>_6/7Q>O^I/?K'KXO7_4GOUCU\7K_ *D]^L>OB]?]2>_6/7Q>O^I/?K'K
MXO7_ %)[]8]?%Z_ZD]^L>OB]?]2>_6/36&DD8@C-9D_<',T:N4E_$;%2%("G
M5>+$ HB<>T.[[OW4U_FT1_J]+^(HM:FJGM&IZ-IJ%LDZ)D/'C*9C8M3FZO0$
MHD]]O;BNQSR(CJ_0J@O88UHZE)%^U35D9)JS;%7<K%3ZA*/&V@D)J$[FU5UP
MN+7MFM1]J@:+=',DPK[JVYE/"A8*[/K2,*]0<1*A3R#46JAU$P1[JIKIN$PZ
M5OE,H%@J=5L3;*9*N7>;2LEQT*H9FP@BI1TR:.;3,;8+NR6?,W*Z+I%F50X)
MB8"D,MI]@=*7&HHZ=G^1"\S5["6KQ+AHVI0&/1J1'*$H2.(A7K=9$#3")UBO
M6+8BG>1%4 3&2K)Y2&6L<.R)*R5?;S$:K86<(L\58-+$[KA77R^SKCYVD)$'
MZS8C58W8!5!$0#IEBTOGO)O3=#6RMIM\M$\=^/-MW-*I92_N$U0V-KM0U-V2
M1:"[M%;?H)LFC5Z^43;"H1(P#V=8O8L>E9#6,^W^GW"\9QK-"BE93,?D>E#%
MI2,=<)QZM&3%-MDC(R*S!G$.H[T[Y2BY!J[(T5:F TA8HBXTF8K40C(.)FTP
M]TJLM5(1")$0E%IRT1LPZK\(G&B'^4"[<H@AVAW^[VATVF)NRU:"@WH1@Q\_
M/6FNP==DPF_#^1!BK#+2;.%E F@5*+/T==7THI@%+O@/;U%1D].5ZORL\X>M
M*]$6&PPD!,61U&@49!M6HF8?LI*QN&0G*"I&*3@Z8F #  B "ZABR<0>=8QC
M.;D*ZG+QBEFCH.16,WCYV2K1'9IZ.@WZY.X@\7;IM5C]@$.81#M^[/\ \4W]
MX>IG_/U?[Q/[#A_\\'_1G'2/^*3_ , /[$C?[K__ %3(=(_XI/\ P _L20_H
M&<_T$_\ &L/Z+E_^;;_=37^;1'^KTOXC*Y:6RKG[+Z?4&M^D\9Y"^SLJJDWK
MN(3,NVB&%BIT_)A.MX8]:U%!BR45@;/#3-0E_DXBCOT99N0XH\A]:X5U?9N:
M^K^RWH-5;Z)6:30/ZK(WG1E"F]K6ZB;'J59?HN,.E]3SFU5B$</HUT2%EE7+
MN%92*;=NWZYR1=!XDZS'0.[\0^(5/B<O8\8<DX$L-6U;,^7:UJU#/ZQC&?WN
M0;13VL8^_59M;9:9$9MW#BH4LDZ8LD')^4]TX]\)]1X\\?[_ *5[+9O <=Y?
M.JWD=AT+3N/?+Z.OW(GD/#8G%V-:-JU9JV!+Q=?DK (-%K7\AK.$R.R,D7"R
M5ZUZ&Y(L]-A>;_(??F&^4#B_D$ID.KY1H,CJ/YB5_3.=*%D5U-7"I/'+/#UN
M3SJ2;>+"S4(P9M([T:/9/3*[FPXR<I=TSJV<"L\Q>(L'&_.X.]IL-4J?*+1]
M,D*C99&;NM.CZ6[/5Y>/<(/WRI(\I7??.L44Q*;.1W?)] 6C=/SOVV>F\D:3
MQ@LL1:[+A;[GM;LDNU(XZY)?6[N!C9[8GD-'NFS!]'D)$R=D92)2J>CG(*Z%
M4B.,<C7L@R[FGDVD3B=0X0XEAN_\PL/@<0O,*O<-@]GL[F8_)-7M''#9IFO>
M$U,2+9W:*C%)1A!@[B&R#O$,*@N-6T[#@UDLO,'1DW6O^SZPK2=JQ#5--N$2
MA3L H'%2Z6QICW#OB]=X66G9*%LKDKXL4Q2+%@2%04[P\!+F'$K3=JY1U+C?
MP,RC=L[Y X%3=KXP,XO(Y5LQLK^K\NK%8SVOA[R"X_PDE,RTM,1RCN)N$C&Q
M17$;)+*I/$6%QU:%Y)M-/J_+KDKM([[6>+&-KY/MN8Z%)ZD6F,-0YTQUD=:C
M+9%;<BL\%$O<_E6H.X*Q0C&/;1Z;:+9/3?=G_P"*;^\/4S_GZO\ >)]VGQ_R
MG#]8Y(:_&4NL:?I<'FKJC5:HXEF%TL,C7:?9-.TG2+# 5IO:[JK 2KR!J4<#
M^P2T7$NGA4D6Y2'4G;[I>@TG/,\K(('G- OMEB:73XU-ZZ*RC1=S5C=L&B+J
M7='*FT:]XSMTJ;PTDSG[0ZL.G5?:,FL>8T^,3F[EI$'H=5DZ)381:";6EO,6
MRU-9-2'KL6ZJ[U&227=JI$58K$5*(E, ];D=70<\O6P81@]XY"SG&JNZ93FN
MUS5)HU-->G()UAP\=R5<^48 R+@%WK4/16KE)RLD"!RG',<ZG]7R^KZYL-/@
MKMGF-S^AU)AJ-JBIV'3F$R5VFN)5&>G3H]BZ"1D&_:_49K^BD4\)0"6?':EM
M&36O7Z0W<.[IE-9T.JSNB5-JS401?N)VI1DFYEV2<6NZ23>_S8BP55(1R")S
M% ?NH?\ SP?]&<=(_P"*3_P ^Z9L$3$(J]=(-$CJ=[PR*.%2I$,IW0$W<*8_
M:/8';V=9GS!:U?0$\VU:R9I5:[6%FD)^?L?):KN+7C_7EIEJG)FA2,X^XNRO
M'HHN5#EC $R93K=B?3'"4N0.'*[))3$[!,,O;ZG2UM">2M6<JM;/'-J4$R6P
MJ2\"9!4Z[ 4"OA324,1(Q4SF*C;)R1@LE>26Q<E<=K%1O5VK@6&XN>+5PM-:
MT.W5ENFHR6E(%""J3FP/0114^0HP?\M5*(=XUHK&3;5C^J62CHQCJ[06;Z;2
M[K)U!A-H"YAY6QMZ],OQBX21;E$Q'R@@S*)3$.J10IB!\J9SR$PS08O\^XO+
M DJ1J](M#$VH3Q71ZYG1',--.TSW*T$8KC$L@$5)4J)Q:>,!1'J26-I.?^%"
MZ&CC\TH6XP"@0^Q./0Q;Y!* F^.9CJ2Y9%N)(!0"R8E7(/@]A@'J<I&8;KC&
MF7:L0S&R6*G9YI],N=GA:U*'13C[$^A:],/WQ(1PHY2*9P4ADT#+)E6%,RA
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MI%RU23C%R&XV97E.&$WO3^3MRU6IU*OO]8BL:K]>;Y!ECG6+'-3MLDZ?>3+
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MN($AI%,QF9#K%SA1]N\&'];5?KEOHK=C2-=F7SFI6^S+TJI6JUQD+G4A)9?
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M,DA-P\4Q8HF.X;>"T*Z!MUQX2M&#0LK%N?9Q;OPPN;RKWO-7[KCSI,GR%O\
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M?A2>^Z\NC\*3WW7ET?A2>^Z*<KE(IR&*<ARK%*<AR& Q#D,4P&*<A@ 0$/=
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M 96;E%D^-0?)+8+S;+/65K)<<Z8W"3:Q<,K-U>HO!&/-,N@.HX<HYA1]NFM
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MS9'.NGN-5YC5V?/%TV^P!,!U/0H_"*?L6G9]/5"-DK&36,QX[7V_YM4)RCZ
M61C8YXR6CR3D'Z$Y,R37*NJM_%U_FQR9K$%K?M (_E#J4EM5[O-JL3W0L!Y"
M8WO-[K-9PNOP;JR=[(*QC\5%1\9#U1JW9Q[^-*@^6;O!?BY<>SMLC37*Y=..
MO(O7^;>3(\5H_(Z_'O:E%TV*YH<@J+;*;K<<^&ZS^J2=BQ)*-EVCUNO"OT[
ML#-FU79I+.==YNV(&$IE%W]F]LG+BFW&S9_QV@,UPSD3"5> O>-9CC3;,]UT
M+5MBQ*?C;!(PU@<7>*:V.+?P#=PX<,5'ZT6VY4YTCSKSV46X]\ X?VC$5<1X
MH9^SE[!8W+[<(1[QTD8<T^[A&?'PSO$1=)R"91OI2RQT1FQ]&(JIS6Y&YQR
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M9TO6<_DW<=).JG>X"/L,0$M#NB/H::9H/T51CIV%?)E79/FXI.V:Y0414(<
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M@ *I^VH8!9>+.&2.+9[-3-CSW-2YS6V-4S^=L4G,S%@E:)&QS%H2FO9U_8Y
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MG  , #UGB@X!B8GR,$RY0<<JHHGS$J+\DJB&>&^0>VE@E)IE<E^3?1NZN4%
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MBLJZ-'-72JJ+07*OAE#OCVVJ?QK"L?R&>O8E&[3.99Y6:3(VLB;Y>53:S#B
MCV0JQJ<LY5=E9I@FS*[5.N"7BF$X\DRRU3976D\M+=6]#VO'-"CH*Z8W*Z+
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MLPP/A7?HT:?MU@M;&OTO.)JW4"*07=P]<?S"2L2[3:R3194JS>L'C)SEW_\
MK6%O:BR,+HU4>O\ :E,:1]FN'(&<-(M6L#( 7CDEP^2X7BQDX6331^6C:;X
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M9J-7ZK==I<3SQRSG+9.Q<&E'P3MLU%>46;HB/$.Z8G;)^UU;CAE6RWSD)D<
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M7J&LT?<8UXU8-IVNQ!Y8C-5=N MQ244^ZA_\\'_1G'2/^*3_ , /NZ]QAO\
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M\LE\(3WW7EDOA">^ZA@!9(1%X(  *$$1_P F<?>#MZ1_GT?))_\ *$_X ?\
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*%)4O_P +_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802634000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001595248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Genprex, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-0772347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3300 Bee Cave Road #650-227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">774-4679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GNPX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,974,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Daszkal Bolton LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boca Raton, FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802642224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 20,954,069<span></span>
</td>
<td class="nump">$ 38,628,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">34,852<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">484,224<span></span>
</td>
<td class="nump">511,348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">21,473,145<span></span>
</td>
<td class="nump">39,140,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,032<span></span>
</td>
<td class="nump">48,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposits</a></td>
<td class="nump">21,818<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ResearchAndDevelopmentAssetsNoncurrent', window );">Supplies</a></td>
<td class="nump">2,864,937<span></span>
</td>
<td class="nump">3,022,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intellectual property, net</a></td>
<td class="nump">702,095<span></span>
</td>
<td class="nump">642,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">3,588,850<span></span>
</td>
<td class="nump">3,673,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,085,027<span></span>
</td>
<td class="nump">42,862,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payables</a></td>
<td class="nump">442,925<span></span>
</td>
<td class="nump">973,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,367,362<span></span>
</td>
<td class="nump">612,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,810,287<span></span>
</td>
<td class="nump">1,585,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value: 200,000,000 shares authorized; 48,105,962 and 47,874,708 shares issued and outstanding, respectively</a></td>
<td class="nump">48,106<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">125,054,453<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(102,827,819)<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">22,274,740<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 25,085,027<span></span>
</td>
<td class="nump">$ 42,862,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ResearchAndDevelopmentAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development assets classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ResearchAndDevelopmentAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149801403456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">48,105,962<span></span>
</td>
<td class="nump">47,874,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">48,105,962<span></span>
</td>
<td class="nump">47,874,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802454064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="nump">25,575<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,157,731<span></span>
</td>
<td class="nump">2,926,927<span></span>
</td>
<td class="nump">2,040,226<span></span>
</td>
<td class="nump">4,967,153<span></span>
</td>
<td class="nump">8,124,884<span></span>
</td>
<td class="nump">11,510,074<span></span>
</td>
<td class="nump">8,970,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,006,484<span></span>
</td>
<td class="nump">2,836,916<span></span>
</td>
<td class="nump">3,263,741<span></span>
</td>
<td class="nump">6,100,657<span></span>
</td>
<td class="nump">9,107,141<span></span>
</td>
<td class="nump">12,295,070<span></span>
</td>
<td class="nump">11,676,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,170,439<span></span>
</td>
<td class="nump">5,770,386<span></span>
</td>
<td class="nump">5,310,696<span></span>
</td>
<td class="nump">11,081,083<span></span>
</td>
<td class="nump">17,251,522<span></span>
</td>
<td class="nump">23,830,719<span></span>
</td>
<td class="nump">20,670,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,170,439)<span></span>
</td>
<td class="num">(5,770,386)<span></span>
</td>
<td class="num">(5,310,696)<span></span>
</td>
<td class="num">(11,081,083)<span></span>
</td>
<td class="num">(17,251,522)<span></span>
</td>
<td class="num">(23,830,719)<span></span>
</td>
<td class="num">(20,670,102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="nump">5,744<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="nump">90,098<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,142,562)<span></span>
</td>
<td class="num">$ (5,764,642)<span></span>
</td>
<td class="num">$ (5,309,817)<span></span>
</td>
<td class="num">$ (11,074,460)<span></span>
</td>
<td class="num">$ (17,217,022)<span></span>
</td>
<td class="num">$ (23,740,621)<span></span>
</td>
<td class="num">$ (20,664,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8212; basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares &#8212; basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,952,100<span></span>
</td>
<td class="nump">47,097,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149806805328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">43,117,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 43,118<span></span>
</td>
<td class="nump">$ 89,295,601<span></span>
</td>
<td class="num">$ (58,422,229)<span></span>
</td>
<td class="nump">$ 30,916,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash (in shares)</a></td>
<td class="nump">4,670,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash</a></td>
<td class="nump">$ 4,670<span></span>
</td>
<td class="nump">25,673,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,677,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of stock for services (in shares)</a></td>
<td class="nump">86,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of stock for services</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">155,959<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,191,514<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,191,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,664,969)<span></span>
</td>
<td class="num">(20,664,969)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">47,874,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 47,874<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,074,460)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">47,874,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 47,874<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,217,022)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,488,515<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">47,874,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 47,874<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash (in shares)</a></td>
<td class="nump">120,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of stock for services (in shares)</a></td>
<td class="nump">110,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of stock for services</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">163,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">163,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,568,712<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,568,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,740,621)<span></span>
</td>
<td class="num">(23,740,621)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">48,105,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 48,106<span></span>
</td>
<td class="nump">$ 125,054,453<span></span>
</td>
<td class="num">$ (102,827,819)<span></span>
</td>
<td class="nump">22,274,740<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,024,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,764,642)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,142,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,488,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802515536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,740,621)<span></span>
</td>
<td class="num">$ (20,664,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">25,575<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">4,731,944<span></span>
</td>
<td class="nump">5,347,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(34,852)<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">27,125<span></span>
</td>
<td class="num">(126,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="num">(13,127)<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="num">(530,269)<span></span>
</td>
<td class="nump">780,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1,755,262<span></span>
</td>
<td class="nump">354,344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,778,964)<span></span>
</td>
<td class="num">(14,284,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intellectual property</a></td>
<td class="num">(59,735)<span></span>
</td>
<td class="num">(40,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies', window );">Reductions (additions) to research and development supplies</a></td>
<td class="nump">157,465<span></span>
</td>
<td class="num">(11,361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">97,731<span></span>
</td>
<td class="num">(83,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">6,426<span></span>
</td>
<td class="nump">25,677,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,426<span></span>
</td>
<td class="nump">25,677,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(17,674,807)<span></span>
</td>
<td class="nump">11,309,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of year</a></td>
<td class="nump">38,628,876<span></span>
</td>
<td class="nump">27,319,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of year</a></td>
<td class="nump">$ 20,954,069<span></span>
</td>
<td class="nump">$ 38,628,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for research and development supplies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808583984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">1</em> &#8211; Description of Business and Basis of Presentation</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <div style="font-size:10pt">
    <div style="font-family:&quot;Times New Roman&quot;">
     <div style="font-variant: normal; text-align: justify;">
       We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.&#160;Our oncology platform utilizes our non-viral ONCOPREX&#174; Nanoparticle Delivery System.&#160;Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type
      <em style="font: inherit;">1</em> diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. In Type
      <em style="font: inherit;">2</em> diabetes, our&#160;technology is believed to work by replenishing and rejuvenating the beta cells&#160;that make insulin.
     </div>
     <div style="font-variant: normal; text-align: justify;">
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Oncology Platform</span></i></p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Our lead oncology drug candidate, REQORSA&#174; Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-<em style="font: inherit;">001,</em> is initially being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (&#8220;NSCLC&#8221;) and Small Cell Lung Cancer (&#8220;SCLC&#8221;).&#160;The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named <em style="font: inherit;">TUSC2.</em> REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#160;We believe REQORSA&#8217;s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, and that it can improve on current therapies.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#8211; <em style="font: inherit;">1:</em> We currently are enrolling and treating patients in the Phase <em style="font: inherit;">1</em> dose escalation portion of our Phase&#160;<em style="font: inherit;">1/2</em>&#160;Acclaim-<em style="font: inherit;">1</em>&#160;clinical trial.&#160;The Acclaim-<em style="font: inherit;">1</em>&#160;trial uses a combination of REQORSA and AstraZeneca PLC&#8217;s Tagrisso&#174; in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#8220;EGFR&#8221;) mutations and progression after treatment with Tagrisso. In&#160;<em style="font: inherit;"> August 2022,&#160;</em>the Acclaim-<em style="font: inherit;">1</em>&#160;Safety Review Committee (&#8220;Acclaim-<em style="font: inherit;">1</em> SRC&#8221;) approved escalating the dose from&#160;<em style="font: inherit;">0.06</em>&#160;mg/kg in the&#160;<em style="font: inherit;">first</em>&#160;cohort of patients to&#160;<em style="font: inherit;">0.09</em>&#160;mg/kg in the&#160;<em style="font: inherit;">second</em>&#160;cohort of patients and in <em style="font: inherit;"> December 2022,&#160;</em>the SRC approved escalating the dose from <em style="font: inherit;">0.09</em> mg/kg in the <em style="font: inherit;">second</em> cohort to <em style="font: inherit;">0.12</em> mg/kg in the <em style="font: inherit;">third</em> and final cohort. We are thus enrolling and treating patients at the <em style="font: inherit;">0.12</em> mg/kg dose&#160;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle <em style="font: inherit;">one</em> of treatment for the remaining untreated patients, the Acclaim-<em style="font: inherit;">1</em> SRC will meet and establish the maximum tolerated dose ("MTD") or recommended Phase <em style="font: inherit;">2</em> dose (<em style="font: inherit;">"RP2D"</em>). We will then proceed into the dose expansion portion of the study. The Food and Drug Administration (&#8220;FDA&#8221;) has granted Fast Track Designation for the Acclaim-<em style="font: inherit;">1</em>&#160;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#8211; <em style="font: inherit;">2:</em> We&#160;currently are enrolling and treating patients in the Phase <em style="font: inherit;">1</em> dose escalation portion of our Phase&#160;<em style="font: inherit;">1/2</em>&#160;Acclaim-<em style="font: inherit;">2</em>&#160;clinical trial.&#160;The Acclaim-<em style="font: inherit;">2</em>&#160;trial uses a combination of REQORSA and Merck &amp; Co.&#8217;s Keytruda&#174; in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are currently being treated at the <em style="font: inherit;">0.06</em> mg/kg dose level in the <em style="font: inherit;">first</em> cohort of patients and, subject to the Acclaim-<em style="font: inherit;">2</em> Safety Review Committee approval, will be treated at successive dose levels of <em style="font: inherit;">0.09</em> mg/kg and <em style="font: inherit;">0.12</em> mg/kg. In <em style="font: inherit;"> March 2023, </em>we amended the Acclaim-<em style="font: inherit;">2</em> protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the dose escalation portion of&#160;the study to be completed by the end of <em style="font: inherit;">2023.</em> We will then evaluate patients in the dose expansion portion of the study at the MTD or <em style="font: inherit;">RP2D.</em> The FDA has granted Fast Track Designation for the Acclaim-<em style="font: inherit;">2</em>&#160;treatment combination of REQORSA and Keytruda in NSCLC patients who have progressed after Keytruda treatment.&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;">The dose expansion portion of Acclaim-<em style="font: inherit;">2</em> is a Phase <em style="font: inherit;">2</em> study and the dose expansion portion of Acclaim-<em style="font: inherit;">1</em> will be considered a Phase <em style="font: inherit;">2</em> study upon the filing with the FDA of an upcoming protocol amendment.&#160;The dose expansion provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the MTD or <em style="font: inherit;">RP2D</em> in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase <em style="font: inherit;">2</em> trial which will follow the dose expansion portions of each study.</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Acclaim &#8211; <em style="font: inherit;">3:</em> In <em style="font: inherit;"> November 2022, </em>we filed with the FDA our protocol for our Phase <em style="font: inherit;">1/2</em> Acclaim-<em style="font: inherit;">3</em> clinical trial using a combination of REQORSA and Genentech, Inc.&#8217;s Tecentriq&#174; as maintenance therapy in patients with extensive stage small cell lung cancer (&#8220;ES-SCLC&#8221;) who did <em style="font: inherit;">not</em> develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. We expect to dose the <em style="font: inherit;">first</em> patient in Acclaim-<em style="font: inherit;">3</em> by the end of&#160;the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2023.</em> Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">TUSC2</em> gene is <em style="font: inherit;">one</em> of a series of genes on the short arm of Chromosome <em style="font: inherit;">3</em> whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").&#160;We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates. In <em style="font: inherit;"> August 2022, </em>we entered into a sponsored research agreement with MD Anderson to support further pre-clinical studies of <em style="font: inherit;">TUSC2</em> and other tumor suppressor genes.</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"><i><span style="text-decoration: underline; ">Diabetes Gene Therapy</span></i></p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#8220;University of Pittsburgh&#8221;) multiple technologies relating to the development of a gene therapy product for each of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> diabetes.&#160;The same general novel approach is used in each of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> whereby an adeno-associated virus (&#8220;AAV&#8221;) vector containing the <em style="font: inherit;">Pdx1</em> and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-<em style="font: inherit;">002</em> is being developed for the treatment of Type <em style="font: inherit;">1</em> diabetes and GPX-<em style="font: inherit;">003</em> is being developed for the treatment of Type <em style="font: inherit;">2</em> diabetes. GPX-<em style="font: inherit;">002</em> is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. GPX-<em style="font: inherit;">003</em> is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of <em style="font: inherit;">2023</em> to obtain their guidance on the toxicology studies that we plan to conduct. In <em style="font: inherit;"> August 2022, </em>we entered into a <em style="font: inherit;">one</em>-year sponsored research agreement with the University of Pittsburgh for the use of GPX-<em style="font: inherit;">003</em> in a non-human primate (&#8220;NHP&#8221;) model in Type <em style="font: inherit;">2</em> diabetes and we expect data from this study to be reported by the end of <em style="font: inherit;">2023.</em> In <em style="font: inherit;"> February 2023, </em>the Company&#8217;s research collaborators at the&#160;University of Pittsburgh&#160;presented preclinical data in a NHP model of Type <em style="font: inherit;">1</em> diabetes highlighting the therapeutic potential of GPX-<em style="font: inherit;">002</em> at the <em style="font: inherit;">16th</em> International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD <em style="font: inherit;">2023</em>) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.</p>
     </div>
     <div style="font-variant:normal">
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
     </div>
    </div>
   </div>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Capital Requirements, Liquidity and Going Concern Considerations</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP") applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have <em style="font: inherit;">no</em> current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our patents.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property.&#160; To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, <em style="font: inherit;">no</em> assurances can be given that we will be successful in raising additional capital.&#160; If we are <em style="font: inherit;">not</em> able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations will continue to be materially affected. These financial statements do <em style="font: inherit;">not</em> include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808820400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">2</em> &#8211; Summary of Significant Accounting Policies</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our financial statements have been prepared in accordance with GAAP.&#160; Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion the financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the financial statements <em style="font: inherit;">not</em> misleading. The results of operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of results to be expected for the full year. A summary of our significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Correction of Immaterial Error</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Subsequent to the issuance of the Company's <em style="font: inherit;">2021</em> financial statements on <em style="font: inherit;"> March 30, 2022, </em>management discovered that it did <em style="font: inherit;">not</em> recognize share-based compensation expense over the service periods for awards with cliff-vesting provisions. The following table summarizes the impacts of this error correction on the Company's financial statements for <em style="font: inherit;">2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In accordance with Staff Accounting Bulletin (&#8220;SAB&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#8220;Materiality,&#8221; and SAB <em style="font: inherit;">No.</em> <em style="font: inherit;">108,</em> &#8220;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,&#8221; the Company evaluated the error and determined that the related impact did <em style="font: inherit;">not</em> materially misstate previously issued financial statements. Although the Company concluded that the misstatement was <em style="font: inherit;">not</em> material to its previously issued financial statements, the Company has determined it is appropriate to adjust its previously issued financial statements to correct for the error in the context of comparative financial statements. The following are the relevant line items from the Company&#8217;s financial statements which illustrate the effect of the corrections to the period presented:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional paid-in capital</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">119,246,970</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">120,316,315</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accumulated deficit</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224243">(78,017,853)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224244">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224245">(79,087,198)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">For the Year ended December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statement of Operations</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,607,751</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">363,114</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,970,865</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,970,472</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">706,231</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,676,703</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total costs and expenses</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,600,757</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,670,102</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Operating loss</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224270">(19,600,757)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224271">(1,069,345)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224272">(20,670,102)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net Loss</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224276">(19,595,624)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224277">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224278">(20,664,969)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Loss per share</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224279">(0.42)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224280">(0.02)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224281">(0.44)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Weighted average common shares outstanding</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Cash</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We consider all highly liquid short-term investments with an initial maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have no cash equivalents, and had $20,679,538 and $38,392,885&#160;in excess of FDIC insured limits of <em style="font: inherit;">$250,000</em> at <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>&#160;respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"/>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Fair Value of Financial Instruments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting Standards Codification ("ASC") <em style="font: inherit;">820,</em> Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC <em style="font: inherit;">820&#8217;s</em> valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC <em style="font: inherit;">820</em> classifies these inputs into the following hierarchy:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for identical instruments in active markets.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Instruments with primarily unobservable value drivers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Property and Equipment</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96224189">three</span> to <span style="-sec-ix-hidden:c96224190">five</span> years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Research and Development Materials Costs</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase <em style="font: inherit;">1/2</em>&#160;clinical trials and are expensed as incurred. Materials produced&#160;to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or&#160;clinical activities, or have spoiled.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development supplies purchased and capitalized for future use were&#160;$2,864,937 and $3,022,403 at <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"/>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Intellectual Property</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Intellectual property consists of&#160;legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Accounting for Stock-Based Compensation</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&#160;&#160;We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Long-Lived Assets</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows.&#160;During the years ended <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>, there were no deemed impairments of our long-lived assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Recent Accounting Developments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting pronouncements issued but <em style="font: inherit;">not</em> effective until after <em style="font: inherit;"> December 31, 2022</em>&#160;are <em style="font: inherit;">not</em> expected to have a significant effect on our financial condition, results of operations, or cash flows.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808709008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Intellectual Property<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">3</em> &#8211; Intellectual Property</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We own or have exclusive license agreements on <em style="font: inherit;">15</em>&#160;granted patents and <em style="font: inherit;">24</em>&#160;pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson,&#160;the University of Texas Southwestern Medical Center, and the University of Pittsburgh.&#160;These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>University of Pittsburgh</i></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 11, 2020, </em>we entered into an exclusive&#160;license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of Type <em style="font: inherit;">1</em> and Type <em style="font: inherit;">2</em> diabetes. This license was <em style="font: inherit;">first</em> amended on <em style="font: inherit;"> August 17, 2022, </em>to extend the&#160;milestone related to the filing of a new investigational drug ("IND") application. This license was amended again on <em style="font: inherit;"> November 3, 2022, </em>to include a new licensed glucagon promoter technology&#160;related to Type <em style="font: inherit;">1</em> diabetes and set FDA and clinical milestones related to the glucagon technology.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> November 22, 2022, </em>we entered into an&#160;exclusive&#160;license agreement with the University of Pittsburgh relating to the transformation of macrophages enabling them to reduce autoimmunity activity in Type <em style="font: inherit;">1</em> diabetes.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> December 29, 2022, </em>we entered into an&#160;exclusive&#160;license agreement with the University of Pittsburgh&#160;relating to the use of an insulin promoter in combination with our existing gene therapy, including the <em style="font: inherit;">Pdx1</em> and MafA transcription factors, as a potential treatment for Type <em style="font: inherit;">2</em> diabetes.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>The University of Texas MD Anderson Cancer Center</i></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> May 4, 2020, </em>we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating&#160;to a portfolio of patent applications and related technology for the treatment of cancer using our&#160;lead drug candidate and immunotherapies.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808077216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">4</em>&#160;&#8211; Equity</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Registered Direct Offerings</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 10, 2021, </em>we completed a registered direct offering&#160;in which we sold to investors an aggregate of 4,000,000 shares of our common stock at $6.25 per share.&#160;We received net proceeds of approximately $23.2 million after commissions and expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">See &#8220;Note <em style="font: inherit;">10</em>&#160;&#8211; Subsequent Events &#8211; <em style="font: inherit;"> March 2023 </em>Registered Direct Offering&#8221; for a description of the Company&#8217;s registered direct offering of shares and warrants in <em style="font: inherit;"> March 2023 </em>resulting in net proceeds of approximately $3.6 million.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b>At-The Market Offering</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> November 18, 2022, </em>we&#160;entered into an Equity Distribution Agreement with JMP Securities LLC&#160;("JMP Securities") pursuant to which we&#160;<em style="font: inherit;"> may </em>sell from time to time, at our option, shares of our common stock through JMP Securities, as sales agent (the <em style="font: inherit;">"2022</em> ATM Facility"), up to an aggregate offering price of&#160;$50 million. Sales of the shares were, and if any future sales, will be made&#160;under the our previously filed and currently effective Registration Statement on Form S-<em style="font: inherit;">3</em> (Reg. <em style="font: inherit;">No.</em> <em style="font: inherit;">333</em>-<em style="font: inherit;">239134</em>), by means of ordinary brokers&#8217; transactions on the NASDAQ Global Market or otherwise. Additionally, under the terms of the Sales Agreement, the shares <em style="font: inherit;"> may </em>be sold at market prices, at negotiated prices or at prices related to the prevailing market price. We&#160;will pay JMP Securities&#160;a commission of&#160;3.0%&#160;of the gross proceeds from the sale of the shares. During the year ended <em style="font: inherit;"> December 31, 2022</em>, we sold 3,886&#160;shares for aggregate net proceeds of&#160;$4,532 under the <em style="font: inherit;">2022</em> ATM Facility.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Stock Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2022</em>, we&#160;issued (i) 20,000 shares of common stock for services provided to us&#160;valued at $42,400&#160;to the Chairman of our Scientific Advisory Board, (ii)&#160;13,643 shares of common stock upon the exercise of warrants on a cashless basis, (iii) 116,973 shares of common stock upon the exercise of options by an executive, and (iv)&#160;76,752 shares of common stock for services provided to us, valued at $99,010, to consultants.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2021</em>, we issued (i) 670,889 shares of common stock from the exercise of options for cash proceeds of $677,912, and (ii) 86,138 shares of common stock for services provided to us,&#160;valued at $154,648, to consultants.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Preferred Stock</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are&#160;authorized to issue 10,000,000 shares of preferred stock at a par value of $0.001 per share, <span style="-sec-ix-hidden:c96224328">none</span> of which are outstanding as of <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Common Stock</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We are&#160;authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share, all of which is voting common stock. There were 48,105,962&#160;shares of common stock outstanding at <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><span style="text-decoration: underline; "><i>Common Stock Purchase Warrants</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Common stock purchase warrant activity for the years ended&#160;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> respectively are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Warrants</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,154,747</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.37</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.29</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146,326</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.79</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,643</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,147,778</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.32</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,901,945</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">4.59</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2022</em>, we&#160;issued (i) a warrant&#160;to purchase up to 50,000&#160;shares of common stock to a service provider&#160;at an exercise price of $1.38&#160;per share, the fair market value of a share of common stock on the date of issuance, (ii) a warrant&#160;to purchase up to 50,000&#160;shares of common stock to a service provider&#160;at an exercise price of $1.49&#160;per share, the fair market value of a share of common stock on the date of issuance, (iii)&#160;a warrant, previously accounted&#160;as a warrant issuable to a consultant in consideration of services provided at our IPO, to purchase up to 3,000 shares of common stock at an exercise price of $5.00 per share, the fair market value of a share of common stock at our IPO, and (iv) we issued 13,643 shares of common stock to a&#160;placement agent&#160;associated with a&#160;registered direct offering in <em style="font: inherit;"> November 2019&#160;</em>upon the&#160;exercise of&#160;warrants on a cashless basis. During the year ended&#160;<em style="font: inherit;"> December 31, 2022</em>, we recorded share-based compensation of $55,612 associated with the vesting of warrants.&#160;We&#160;expect&#160;to record $90,689&#160;of share-based compensation for time-based vesting over the next year&#160;and another $300,000 of share-based compensation based on performance-based vesting.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#160;<em style="font: inherit;"> December 31, 2021</em>, we&#160;issued (i) a warrant&#160;to purchase up to 25,000 shares of common stock to a service provider&#160;at an exercise price of $7.22 per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant&#160;to purchase up to 25,000 shares of common stock to a service provider&#160;at an exercise price of $3.36&#160;per share, the fair market value of a share of common stock on the date of issuance. During the year ended&#160;<em style="font: inherit;"> December 31, 2021</em>, we recorded share-based compensation of $200,282 associated with the vesting of warrants.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Equity Incentive Plan</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our board of directors and stockholders have&#160;approved and adopted the Company&#8217;s <em style="font: inherit;">2018</em> Equity Incentive Plan (<em style="font: inherit;">&#8220;2018</em> Plan&#8221;), which became effective on the completion of the IPO on <em style="font: inherit;"> April 3, 2018.&#160;</em>The <em style="font: inherit;">2018</em> Plan provides for the grant of incentive stock options that are intended to qualify under Section <em style="font: inherit;">422</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended (&#8220;ISOs&#8221;), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs <em style="font: inherit;"> may </em>be granted only to employees. All other awards <em style="font: inherit;"> may </em>be granted to employees, including officers, and to non-employee directors and consultants.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan automatically increase on <em style="font: inherit;"> January 1 </em>of each year, beginning <em style="font: inherit;"> January 1, 2019 </em>by 5% of the total number of shares of the Company&#8217;s common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the <em style="font: inherit;">2018</em> Plan. On <em style="font: inherit;"> January 1, 2021&#160;</em>and <em style="font: inherit;">2022,</em> the number of shares of common stock reserved for issuance under the <em style="font: inherit;">2018</em> Plan was increased by an aggregate of 2,155,884 and 2,393,735 shares, respectively.&#160;As of <em style="font: inherit;"> December 31, 2022</em>, a total of 481,772 shares of common stock remain available for&#160;issuance for future awards under the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i><em style="font: inherit;">2018</em> Employee Stock Purchase Plan</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Our board of directors and stockholders approved and adopted the Company&#8217;s <em style="font: inherit;">2018</em> Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on <em style="font: inherit;"> April 3, 2018.&#160;</em>The ESPP has <em style="font: inherit;">not</em> yet been utilized as a benefit available to our employees.&#160;The ESPP authorizes the issuance of 208,050 shares of our common stock pursuant to purchase rights that <em style="font: inherit;"> may </em>be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on <em style="font: inherit;"> January 1 </em>of each calendar year, beginning on <em style="font: inherit;"> January 1, 2019, </em>by 2% of the total number of shares of our&#160;common stock outstanding on <em style="font: inherit;"> December 31 </em>of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined <em style="font: inherit;">not</em> to increase the number of shares reserved for issuance under the ESPP on&#160;<em style="font: inherit;"> January 1, 2022.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Stock Options</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022</em>,&#160;we had&#160;outstanding stock options to purchase 11,374,327&#160;shares of common stock that have been granted to various executives, employees, directors, and independent contractors, including outstanding stock options to purchase 950,000 shares of common stock issued as inducement grants, outside of the <em style="font: inherit;">2018</em> plan, associated with the hiring of new executives in <em style="font: inherit;">2021.</em>&#160;These options vest immediately or over periods ranging from 12&#160;to 48&#160;months, are exercisable for a period of up to <span style="-sec-ix-hidden:c96224383">ten</span> years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $0.298&#160;to&#160;$9.80 per share. The per-share fair values of these options range from $0.24&#160;to $7.93, based on Black-Scholes-Merton pricing models with the following assumptions:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expected term (in years):</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c96224456">10</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Risk-free rate:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0.07% &#8211; 4.77%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Volatility:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">75.98% &#8211; 88.38%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Dividend yield:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">In the year ended&#160;<em style="font: inherit;"> December 31, 2022</em>, we (i) granted stock options to purchase an aggregate of&#160;2,983,666 shares of our&#160;common stock with exercise prices ranging from $1.27&#160;to $3.50&#160;per share to executives and&#160;employees,&#160;(ii) cancelled options to purchase 66,667 shares of common stock at exercise prices ranging from $2.00 to $3.66 per share&#160;in connection with the termination of certain employees, and (iii) issued 116,973&#160;shares of our common stock upon the exercise of options held by an executive with an exercise price of $0.02&#160;per share.</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#160;<em style="font: inherit;"> December 31, 2021</em>,&#160;we (i) granted stock options to purchase an aggregate of&#160;2,519,628 shares of our common stock with exercise prices ranging from $2.72&#160;to $7.22 per share to executives, employees, board members,&#160;and consultants, (ii) cancelled options to purchase 118,507 shares of common stock with&#160;exercise prices ranging from $1.45&#160;to&#160;$7.22 per share due&#160;to the termination&#160;of former employees, and (iii) issued 670,889&#160;shares of our&#160;common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from&#160;$0.015&#160;to $2.15 per share.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The weighted average remaining contractual term for the outstanding options at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> is 7.08&#160;and 7.24&#160;years, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Stock option activity for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, is as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Shares</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,844,069</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.81</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,519,628</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">670,889</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.01</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,507</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.00</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574,301</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.35</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,983,666</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,973</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.02</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,667</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.55</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,374,327</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.08</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,718,035</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3.23</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><i>Share-Based Compensation</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended&#160;<em style="font: inherit;"> December 31, 2022</em>,&#160;our total share-based compensation was approximately $4.7&#160;million, of which approximately $4.6&#160;million&#160;represents the vesting of options and warrants issued to service providers, executives, employees, and board members. As of&#160;<em style="font: inherit;"> December 31, 2022</em>, our&#160;total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board&#160;members, and service providers and <em style="font: inherit;">not</em> yet recognized was approximately $6.5&#160;million. We&#160;expect&#160;to record this stock-based compensation expense over the next <em style="font: inherit;">three</em>&#160;years using a graded vesting method. As of <em style="font: inherit;"> December 31, 2022</em>,&#160;the weighted average term over which these expenses are expected to be recognized is 1.76 years.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022</em>,&#160;there are&#160;no&#160;performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider.&#160;Our total compensation cost related to the non-vested performance-based warrant&#160;<em style="font: inherit;">not</em> yet recognized was approximately $300,000.&#160;The entirety of this warrant <em style="font: inherit;"> may </em>be recognized and recorded upon the achievement of certain milestones.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In the year ended <em style="font: inherit;"> December 31, 2021</em>, the Company's total share-based compensation was approximately $5.4&#160;million with approximately $5.2&#160;million representing the vesting of options issued to service providers, employees, and board members.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149811144864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - 401(k) Savings Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan [Text Block]</a></td>
<td class="text">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">5</em>&#160;- <em style="font: inherit;">401</em>(k) Savings&#160;</span></b><b><span style="text-decoration: underline; ">Transactions</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2022,</em> we established a defined-contribution savings plan under Section&#160;<em style="font: inherit;">401</em>(k) of the Internal Revenue Code (<em style="font: inherit;">"401</em>(k) Plan") and established an employer matching program for participants in the <em style="font: inherit;">401</em>(k) Plan. The <em style="font: inherit;">401</em>(k) Plan covers all&#160;employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a&#160;pre-tax basis. We&#160;incurred&#160;$74,281 of expense for matching contributions to the <em style="font: inherit;">401</em>(k) Plan during the year&#160;ended <em style="font: inherit;"> December 31, 2022</em>.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808605776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">6</em>&#160;- Related Party Transactions</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Introgen Research Institute</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Introgen Research Institute (&#8220;IRI&#8221;) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board and IRI's sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In <em style="font: inherit;"> April 2009, </em>prior to Mr. Varner becoming an officer and director of our Company in <em style="font: inherit;"> August 2012, </em>we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in <em style="font: inherit;">2011</em> to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson (See Note <em style="font: inherit;">7</em> &#8211; Commitments and Contingences &#8211; Commitments &#8211; MD Anderson Cancer Center).</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808532576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">7</em>&#160;- Commitments and Contingencies</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Leases</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> April 16, 2018, </em>we executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On <em style="font: inherit;"> March 23, 2021, </em>we were&#160;informed&#160;by Dell Medical School that the University of Texas desired to use the space and&#160;<em style="font: inherit;">not</em> renew&#160;the space utilization agreement.&#160;The lease terminated&#160;on <em style="font: inherit;"> April 30, 2021, </em>and all our employees are currently working virtually while we evaluate future space needs post the COVID-<em style="font: inherit;">19</em> pandemic.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Commitments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"><span style="text-decoration: underline; "><i>MD Anderson</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <em style="font: inherit;"> July 2018, </em>we entered into a <em style="font: inherit;">two</em>-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy&#160;with a projected total cost of approximately $2 million. This agreement&#160;was extended beyond the original expiration date. This agreement expired in <em style="font: inherit;"> May 2022. </em>In <em style="font: inherit;"> August 2022, </em>we entered into a&#160;<em style="font: inherit;">three</em>-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on REQORSA and other potential product candidates in oncology&#160;to resensitize NSCLC and SCLC to targeted therapies and immunotherapies&#160;with a projected total cost of approximately $2.9&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In <em style="font: inherit;">2011,</em> we agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies&#160;and intellectual property originally licensed to another party under the <em style="font: inherit;">1994</em> License Agreement with MD Anderson (&#8220;Original MD Anderson License Agreement&#8221;). These technologies and intellectual property were later sublicensed to IRI (the &#8220;IRI Sublicense&#8221;). We&#160;also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the&#160;IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000&#160;payable to the National Institutes of Health.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 3, 2021, </em>we entered into an amendment (the &#8220;MD License Amendment&#8221;) to the Patent and Technology License Agreement dated <em style="font: inherit;"> May 4, 2020, </em>with MD Anderson. The MD License&#160;Amendment grants us with&#160;a worldwide, exclusive, sublicensable license to an additional portfolio of <em style="font: inherit;">six</em> patents and <em style="font: inherit;">one</em> patent application and related technology for methods for treating&#160;cancer by administration of a <em style="font: inherit;">TUSC2</em> therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to <em style="font: inherit;">TUSC2</em> therapy. Pursuant to the MD License&#160;Amendment, we&#160;agreed to (i) pay annual maintenance fees ranging from the mid <em style="font: inherit;">five</em> figures to the low <em style="font: inherit;">six</em> figures, (ii) total milestone payments of $6,150,000, (iii) a <em style="font: inherit;">one</em>-time fee in the mid <em style="font: inherit;">five</em>&#160;figures and (iv) certain patent related expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"><span style="text-decoration: underline; "><i>National Institutes of Health</i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We have a royalty obligation to the National Institutes of Health ("NIH") to be paid upon our receipt of FDA approval using NIH technology.&#160;The $240,000 contingent obligation which increases annually by $20,000 and is $340,000 as of <em style="font: inherit;"> December 31, 2022</em>, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify; text-indent: -9pt;"><i><span style="text-decoration: underline; ">University of Pittsburgh</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an exclusive license agreement dated <em style="font: inherit;"> February 11, 2020 </em>by and between us and the University of Pittsburgh, amended on <em style="font: inherit;"> August 17, 2022, </em>and amended again on&#160;<em style="font: inherit;"> November 3, 2022, </em>we agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $40,000 for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of a glucagon promoter and&#160;gene therapy technologies to potentially treat Type <em style="font: inherit;">1</em> diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#160;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an&#160;exclusive license agreement dated <em style="font: inherit;"> November 22, 2022&#160;</em>by and between us and the University of Pittsburgh, we&#160;agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $40,000 for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of a macrophage technology&#160;and&#160;gene therapy technologies to potentially treat Type <em style="font: inherit;">1</em> diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#160;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to an&#160;exclusive license agreement dated <em style="font: inherit;"> December 29, 2022&#160;</em>by and between us&#160;and the University of Pittsburgh, we&#160;agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> years and $40,000 for each subsequent year following the <em style="font: inherit;">first</em> anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the <em style="font: inherit;">first</em> commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of an insulin&#160;promoter and&#160;gene therapy technologies to potentially treat Type <em style="font: inherit;">2</em>&#160;diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) <em style="font: inherit;">20</em> years after&#160;the <em style="font: inherit;">first</em> commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><span style="text-decoration: underline; ">Contract Development and Manufacturing Organization</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We entered into a <em style="font: inherit;">three</em>-year&#160;development services agreement in <em style="font: inherit;"> July 2022&#160;</em>with a contract development and manufacturing organization to manufacture&#160;GMP grade materials for use in our clinical trials with a projected total cost of approximately $2.5&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Contingencies</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">From time to time, we <em style="font: inherit;"> may </em>become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is <em style="font: inherit;">not</em> aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.</p>
   <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808455280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Significant Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_EffectOfCovid19PandemicTextBlock', window );">Effect of Covid 19 Pandemic [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">8</em>&#160;- Significant Events</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="color:#000000;">The COVID-<em style="font: inherit;">19</em>&#160;pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines <em style="font: inherit;"> may </em>result in continued impact from this pandemic in the future, which could adversely impact our operations.&#160;Through <em style="font: inherit;"> March 31, 2021,&#160;</em>we had&#160;<em style="font: inherit;">not</em> experienced any material impact on its financial results or operations&#160;as a result of the COVID-<em style="font: inherit;">19</em> pandemic. Beginning in <em style="font: inherit;"> June 2021, </em>we experienced&#160;delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. We also have&#160;experienced disruptions in our supply chain regarding our manufacturing and testing operations.&#160;We continue&#160;to closely monitor the impact of the COVID-<em style="font: inherit;">19</em> pandemic on its business and workforce.</span></p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_EffectOfCovid19PandemicTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for effects of COVID-19 pandemic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_EffectOfCovid19PandemicTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808575888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">9</em>&#160;&#8211; Income Taxes </span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.&#160; The sources and tax effects of the differences are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax provision at the federal statutory rate</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effect of operating losses</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <em style="font: inherit;"> December 31, 2022</em>, we&#160;have&#160;a net operating loss carryforward of approximately $68.9<span style="font-size: 10pt;">&#160;million</span>&#160;for Federal and state purposes.&#160;This loss will be available to offset future taxable income.&#160;If <em style="font: inherit;">not</em> used, this carryforward will begin to expire in <em style="font: inherit;">2030.</em> The deferred tax asset relating to the operating loss carryforward has been fully reserved at&#160;<em style="font: inherit;"> December 31, 2022</em>&#160;and&#160;<em style="font: inherit;"> December 31, 2021</em>.&#160;The principal differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense.</p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802617216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">10</em>&#160;&#8211; Subsequent Events </span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><i><b>Reserves of <em style="font: inherit;">2018</em> Equity Incentive Plan and <em style="font: inherit;">2018</em> Employee Stock Purchase Plan</b></i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 1, 2023, </em>the total shares of common stock reserved under the <em style="font: inherit;">2018</em> Equity Incentive Plan increased by 2,405,298 shares. On <em style="font: inherit;"> February 16, 2023,&#160;</em>the our Board of Directors determined that <em style="font: inherit;">no</em> additional shares would be reserved during the <em style="font: inherit;">2023</em>&#160;fiscal year for the <em style="font: inherit;">2018</em> Employee Stock Purchase Plan given that <em style="font: inherit;">no</em> shares have yet been issued under the plan.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Share Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 1, 2023, </em>we issued 5,000 shares of common stock to&#160;the Chairman of our Scientific Advisory Board&#160;in consideration for services. During <em style="font: inherit;"> January 2023, </em>we issued 53,592 shares of common stock for aggregate net proceeds of&#160;$78,355&#160;under the&#160;<em style="font: inherit;">2022</em> ATM Facility.&#160;&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Option&#160;Issuances</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> January 17, 2023, </em><em style="font: inherit;"> January 23, 2023, </em>and <em style="font: inherit;"> January 30, 2023,&#160;</em>we&#160;issued grants of stock options&#160;under the <em style="font: inherit;">2018</em> Equity Incentive Plan&#160;to purchase a total of 82,500 shares of common stock to new employees&#160;at the fair market value of the common stock on the date of issuance.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; "><b><i>Warrant Issuance</i></b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 16, 2023, </em>we issued a warrant to purchase up to 30,000 shares of its common stock at an exercise price of $1.65&#160;per share to a consultant for services.&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Restricted Stock Units</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 18,&#160;</em><em style="font: inherit;">2023,</em> our Board of Directors approved the recommendations of the Company's Compensation Committee&#160;for the grant of restricted stock units (&#8220;RSUs&#8221;)&#160;pursuant to the <em style="font: inherit;">2018</em> Equity Incentive Plan&#160;in the aggregate of 353,195 RSUs to non-executive employees.&#160;Each of these RSU grants vest in installments of 50% on the <span style="-sec-ix-hidden:c96224648">first</span> anniversary of the date of grant and the remaining 50% on the <span style="-sec-ix-hidden:c96224650">second</span> anniversary of the date of grant. Vested RSUs will be settled&#160;in shares of common stock on a <em style="font: inherit;">one</em>-to-<em style="font: inherit;">one</em> basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Executive Compensation</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> February 18, 2023, </em>our Board of Directors approved the recommendations of the Company's Compensation Committee for (i) annual incentive awards of an aggregate of $972,720 and (ii) the grant of RSUs&#160;pursuant to the <em style="font: inherit;">2018</em> Equity Incentive Plan in the aggregate of 1,560,000&#160;RSUs to our executive officers.&#160;Each of these RSU grants vest in installments of 50% on the <span style="-sec-ix-hidden:c96224657">first</span> anniversary of the date of grant and the remaining 50% on the <span style="-sec-ix-hidden:c96224659">second</span> anniversary of the date of grant. Vested RSUs will be settled in shares of common stock on a <em style="font: inherit;">one</em>-to-<em style="font: inherit;">one</em> basis.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><i><span style="text-decoration: underline; "><em style="font: inherit;"> March 2023 </em>Registered Direct Offering</span></i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <em style="font: inherit;"> March 1, 2023, </em>we&#160;completed a registered direct offering, in which we&#160;sold to an accredited healthcare-focused institutional investor an aggregate of 3,809,524 shares of our common stock and warrants to purchase up to 3,809,524 shares of our common stock, at a combined offering price of $1.05 per share of common stock and accompanying warrant. The warrants are exercisable immediately upon issuance, expire 5 years from the date of issuance and have an exercise price of $1.10 per share. We&#160;received net proceeds of approximately $3.6 million after commissions and estimated expenses, excluding any proceeds that <em style="font: inherit;"> may </em>be received in the future from any exercise of the warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808573888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Restatement of Previously Issued Consolidated Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Error Correction [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; ">Note <em style="font: inherit;">11</em>&#160;&#8211; Quarterly Data - Unaudited</span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Revised Interim Financial Information</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The following tables represent amounts previously reported and revised as a result of the immaterial error associated with the accounting for share-based compensation. See Note <em style="font: inherit;">2</em> for additional information.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,409,431</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,409,431</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,384,817</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,384,817</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,717,072</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">656,678</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121,373,750</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(83,740,337</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(656,678</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(84,397,015</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,024,614</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,024,614</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,565,123</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,565,123</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,153,838</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,153,838</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,898</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,898</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121,273,050</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,251,995</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122,525,045</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(88,909,663</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,251,995</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(90,161,658</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,411,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,411,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,945,826</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,945,826</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,457,311</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,457,311</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,020</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,020</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122,432,935</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,311,780</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,744,715</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(94,992,440</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,311,780</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(96,304,220</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,488,515</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,488,515</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>



    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,730</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,730</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,860,837</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">179,389</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,040,226</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,855,796</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(592,055</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,263,741</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,723,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(412,667</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,310,696</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating (loss) gain</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(5,723,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">412,667</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(5,310,696</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224825">(5,722,484</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224826">412,667</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224827">(5,309,817</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224831">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224832">0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224833">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,879,597</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,879,597</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Six Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,543</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,543</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">13,273</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">13,273</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,737,028</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">189,899</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,926,927</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,597,865</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">369,288</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,967,153</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,431,499</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">405,417</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,836,916</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,287,295</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,638</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,100,657</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,175,070</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">595,316</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,770,386</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,898,433</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">182,650</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,081,083</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224885">(5,175,070</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224886">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224887">(5,770,386</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224888">(10,898,433</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224889">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224890">(11,081,083</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,744</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,744</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,623</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,623</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224897">(5,169,326</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224898">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224899">(5,764,642</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224900">(10,891,810</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224901">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224902">(11,074,460</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224903">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224904">(0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224905">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224906">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224907">(0.00</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224908">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,893,404</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,893,404</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,892,919</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,892,919</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Nine Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">19,497</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">19,497</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,593,309</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(435,578</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,157,731</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,191,174</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(66,290</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,124,884</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,511,121</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">495,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,006,484</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,798,416</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">308,725</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,107,141</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,110,654</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,785</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,170,439</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,009,087</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">242,435</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,251,522</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224957">(6,110,654</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224958">(59,785</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224959">(6,170,439</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224960">(17,009,087</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224961">(242,435</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224962">(17,251,522</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,877</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,877</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,500</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,500</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,082,777</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59,785</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,142,562</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,974,587</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(242,435</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,217,022</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.13</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.00</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.13</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.35</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.01</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.36</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,984,724</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,984,724</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,919,626</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,919,626</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149801256656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_CorrectionOfErrorPolicyTextBlock', window );">Correction of Error [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Correction of Immaterial Error</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Subsequent to the issuance of the Company's <em style="font: inherit;">2021</em> financial statements on <em style="font: inherit;"> March 30, 2022, </em>management discovered that it did <em style="font: inherit;">not</em> recognize share-based compensation expense over the service periods for awards with cliff-vesting provisions. The following table summarizes the impacts of this error correction on the Company's financial statements for <em style="font: inherit;">2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In accordance with Staff Accounting Bulletin (&#8220;SAB&#8221;) <em style="font: inherit;">No.</em> <em style="font: inherit;">99,</em> &#8220;Materiality,&#8221; and SAB <em style="font: inherit;">No.</em> <em style="font: inherit;">108,</em> &#8220;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,&#8221; the Company evaluated the error and determined that the related impact did <em style="font: inherit;">not</em> materially misstate previously issued financial statements. Although the Company concluded that the misstatement was <em style="font: inherit;">not</em> material to its previously issued financial statements, the Company has determined it is appropriate to adjust its previously issued financial statements to correct for the error in the context of comparative financial statements. The following are the relevant line items from the Company&#8217;s financial statements which illustrate the effect of the corrections to the period presented:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional paid-in capital</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">119,246,970</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">120,316,315</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accumulated deficit</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224243">(78,017,853)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224244">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224245">(79,087,198)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">For the Year ended December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statement of Operations</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,607,751</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">363,114</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,970,865</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,970,472</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">706,231</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,676,703</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total costs and expenses</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,600,757</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,670,102</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Operating loss</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224270">(19,600,757)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224271">(1,069,345)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224272">(20,670,102)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net Loss</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224276">(19,595,624)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224277">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224278">(20,664,969)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Loss per share</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224279">(0.42)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224280">(0.02)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224281">(0.44)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Weighted average common shares outstanding</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td></tr>
</tbody></table>

   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Use of Estimates</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b style="font-size: 10pt; text-align: justify;"><span style="text-decoration: underline; "><i>Cash</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We consider all highly liquid short-term investments with an initial maturity of <em style="font: inherit;">three</em> months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have no cash equivalents, and had $20,679,538 and $38,392,885&#160;in excess of FDIC insured limits of <em style="font: inherit;">$250,000</em> at <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>&#160;respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Fair Value of Financial Instruments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting Standards Codification ("ASC") <em style="font: inherit;">820,</em> Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC <em style="font: inherit;">820&#8217;s</em> valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC <em style="font: inherit;">820</em> classifies these inputs into the following hierarchy:</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">1:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for identical instruments in active markets.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">2:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 36pt; text-align: justify;">&#160;</td><td style="width: 72pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Level <em style="font: inherit;">3:</em></p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Instruments with primarily unobservable value drivers.</p> </td></tr>
</tbody></table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Property and Equipment</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:c96224189">three</span> to <span style="-sec-ix-hidden:c96224190">five</span> years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Research and Development Materials Costs</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase <em style="font: inherit;">1/2</em>&#160;clinical trials and are expensed as incurred. Materials produced&#160;to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or&#160;clinical activities, or have spoiled.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Research and development supplies purchased and capitalized for future use were&#160;$2,864,937 and $3,022,403 at <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>, respectively.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Intellectual Property</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Intellectual property consists of&#160;legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Accounting for Stock-Based Compensation</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&#160;&#160;We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Long-Lived Assets</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows.&#160;During the years ended <em style="font: inherit;"> December 31, 2022</em>&#160;and <em style="font: inherit;"> December 31, 2021</em>, there were no deemed impairments of our long-lived assets.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><span style="text-decoration: underline; "><i>Recent Accounting Developments</i></span></b></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Accounting pronouncements issued but <em style="font: inherit;">not</em> effective until after <em style="font: inherit;"> December 31, 2022</em>&#160;are <em style="font: inherit;">not</em> expected to have a significant effect on our financial condition, results of operations, or cash flows.</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_CorrectionOfErrorPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for correction of errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_CorrectionOfErrorPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808572656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_CorrectionOfErrorsTableTextBlock', window );">Correction of Errors [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">42,862,286</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,585,295</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">47,874</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional paid-in capital</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">119,246,970</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">120,316,315</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accumulated deficit</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224243">(78,017,853)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224244">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224245">(79,087,198)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">41,276,991</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td colspan="5" style="vertical-align: bottom; width: 26%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">For the Year ended December 31, 2021</em></em></em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statement of Operations</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: middle; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;">&#160;</td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">22,534</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,607,751</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">363,114</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,970,865</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10,970,472</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">706,231</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,676,703</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total costs and expenses</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">19,600,757</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,069,345</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,670,102</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Operating loss</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224270">(19,600,757)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224271">(1,069,345)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224272">(20,670,102)</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,133</p> </td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net Loss</p> </td><td style="vertical-align: middle; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224276">(19,595,624)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224277">(1,069,345)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c96224278">(20,664,969)</span></p> </td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Loss per share</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224279">(0.42)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224280">(0.02)</span></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"><span style="-sec-ix-hidden:c96224281">(0.44)</span></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0">Weighted average common shares outstanding</td><td style="vertical-align: middle; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0">&#160;</td><td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;">47,097,251</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_CorrectionOfErrorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of correction of errors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_CorrectionOfErrorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149804852688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Warrants</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,154,747</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.37</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.29</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,204,747</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.39</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Issued</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.54</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Cancelled or expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146,326</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.79</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,643</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.50</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,147,778</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.32</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,901,945</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">4.59</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Expected term (in years):</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c96224456">10</span></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Risk-free rate:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0.07% &#8211; 4.77%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Volatility:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">75.98% &#8211; 88.38%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Dividend yield:</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">0%</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Number of Shares</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><em style="font: inherit;">Weighted Avg. Exercise Price</em></b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at January 1, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,844,069</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.81</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,519,628</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">670,889</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.01</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118,507</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3.00</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574,301</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.35</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,983,666</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.16</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,973</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.02</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,667</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.55</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Outstanding at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,374,327</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.08</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 74%"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable at December 31, 2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,718,035</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3.23</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149809363712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Income tax provision at the federal statutory rate</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Effect of operating losses</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 87%;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
       <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808592256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,409,431</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,409,431</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,384,817</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,384,817</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,717,072</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">656,678</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121,373,750</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(83,740,337</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(656,678</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(84,397,015</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,024,614</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,024,614</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,565,123</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,565,123</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,153,838</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,153,838</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,898</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">47,898</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121,273,050</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,251,995</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122,525,045</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(88,909,663</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,251,995</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(90,161,658</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,411,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,411,285</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Balance Sheet</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,945,826</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,945,826</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,457,311</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,457,311</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,020</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,020</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122,432,935</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,311,780</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,744,715</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(94,992,440</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,311,780</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(96,304,220</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders' equity</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,488,515</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,488,515</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended March 31, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,730</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,730</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,860,837</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">179,389</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,040,226</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,855,796</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(592,055</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,263,741</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,723,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(412,667</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,310,696</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating (loss) gain</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(5,723,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">412,667</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(5,310,696</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224825">(5,722,484</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224826">412,667</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224827">(5,309,817</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224831">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224832">0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224833">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,879,597</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,879,597</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Six Months Ended June 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,543</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,543</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">13,273</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">13,273</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,737,028</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">189,899</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,926,927</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,597,865</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">369,288</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,967,153</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,431,499</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">405,417</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,836,916</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,287,295</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,638</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,100,657</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,175,070</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">595,316</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,770,386</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,898,433</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">182,650</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,081,083</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224885">(5,175,070</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224886">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224887">(5,770,386</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224888">(10,898,433</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224889">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224890">(11,081,083</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,744</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,744</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,623</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,623</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224897">(5,169,326</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224898">(595,316</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224899">(5,764,642</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224900">(10,891,810</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224901">(182,650</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c96224902">(11,074,460</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224903">(0.11</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224904">(0.01</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224905">(0.12</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224906">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224907">(0.00</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224908">(0.23</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,893,404</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,893,404</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,892,919</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,892,919</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Three Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">As of and For the Nine Months Ended September 30, 2022</em></em></em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Condensed Statement of Operations</p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Previously Reported</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">As Revised</em></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Revenues</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Depreciation</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,224</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">19,497</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">19,497</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,593,309</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(435,578</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,157,731</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,191,174</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(66,290</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,124,884</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,511,121</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">495,363</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,006,484</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,798,416</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">308,725</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,107,141</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total costs and expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,110,654</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59,785</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,170,439</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,009,087</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">242,435</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,251,522</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Operating loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224957">(6,110,654</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224958">(59,785</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224959">(6,170,439</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224960">(17,009,087</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224961">(242,435</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><span style="-sec-ix-hidden:c96224962">(17,251,522</span></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,877</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,877</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,500</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,500</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,082,777</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59,785</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,142,562</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,974,587</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(242,435</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,217,022</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      </tr>

      <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Loss per share</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.13</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.00</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.13</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.35</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.01</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(0.36</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      </tr>

      <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
       <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Weighted average common shares outstanding</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,984,724</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,984,724</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,919,626</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
       <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">47,919,626</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149806708896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">20,679,538<span></span>
</td>
<td class="nump">38,392,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ResearchAndDevelopmentAssetsCurrent', window );">Research and Development Assets, Current</a></td>
<td class="nump">2,864,937<span></span>
</td>
<td class="nump">3,022,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment, Long-Lived Asset, Held-for-Use, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ResearchAndDevelopmentAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development assets classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ResearchAndDevelopmentAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149806184992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 25,085,027<span></span>
</td>
<td class="nump">$ 42,862,286<span></span>
</td>
<td class="nump">$ 39,409,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,457,311<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="nump">2,457,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,295<span></span>
</td>
<td class="nump">2,384,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">48,106<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
<td class="nump">47,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">123,744,715<span></span>
</td>
<td class="nump">122,525,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,525,045<span></span>
</td>
<td class="nump">123,744,715<span></span>
</td>
<td class="nump">125,054,453<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
<td class="nump">121,373,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(96,304,220)<span></span>
</td>
<td class="num">(90,161,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,161,658)<span></span>
</td>
<td class="num">(96,304,220)<span></span>
</td>
<td class="num">(102,827,819)<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
<td class="num">(84,397,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">22,274,740<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
<td class="nump">37,024,614<span></span>
</td>
<td class="nump">$ 30,916,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="nump">25,575<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,157,731<span></span>
</td>
<td class="nump">2,926,927<span></span>
</td>
<td class="nump">2,040,226<span></span>
</td>
<td class="nump">4,967,153<span></span>
</td>
<td class="nump">8,124,884<span></span>
</td>
<td class="nump">11,510,074<span></span>
</td>
<td class="nump">8,970,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,006,484<span></span>
</td>
<td class="nump">2,836,916<span></span>
</td>
<td class="nump">3,263,741<span></span>
</td>
<td class="nump">6,100,657<span></span>
</td>
<td class="nump">9,107,141<span></span>
</td>
<td class="nump">12,295,070<span></span>
</td>
<td class="nump">11,676,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,170,439<span></span>
</td>
<td class="nump">5,770,386<span></span>
</td>
<td class="nump">5,310,696<span></span>
</td>
<td class="nump">11,081,083<span></span>
</td>
<td class="nump">17,251,522<span></span>
</td>
<td class="nump">23,830,719<span></span>
</td>
<td class="nump">20,670,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,170,439)<span></span>
</td>
<td class="num">(5,770,386)<span></span>
</td>
<td class="num">(5,310,696)<span></span>
</td>
<td class="num">(11,081,083)<span></span>
</td>
<td class="num">(17,251,522)<span></span>
</td>
<td class="num">(23,830,719)<span></span>
</td>
<td class="num">(20,670,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="nump">5,744<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="nump">90,098<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,142,562)<span></span>
</td>
<td class="num">$ (5,764,642)<span></span>
</td>
<td class="num">$ (5,309,817)<span></span>
</td>
<td class="num">$ (11,074,460)<span></span>
</td>
<td class="num">$ (17,217,022)<span></span>
</td>
<td class="num">$ (23,740,621)<span></span>
</td>
<td class="num">$ (20,664,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,952,100<span></span>
</td>
<td class="nump">47,097,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,862,286<span></span>
</td>
<td class="nump">39,409,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,457,311<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="nump">2,457,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,295<span></span>
</td>
<td class="nump">2,384,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="nump">48,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
<td class="nump">47,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">122,432,935<span></span>
</td>
<td class="nump">121,273,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,273,050<span></span>
</td>
<td class="nump">122,432,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,246,970<span></span>
</td>
<td class="nump">120,717,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(94,992,440)<span></span>
</td>
<td class="num">(88,909,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,909,663)<span></span>
</td>
<td class="num">(94,992,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,017,853)<span></span>
</td>
<td class="num">(83,740,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="nump">27,488,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
<td class="nump">$ 37,024,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,593,309<span></span>
</td>
<td class="nump">2,737,028<span></span>
</td>
<td class="nump">1,860,837<span></span>
</td>
<td class="nump">4,597,865<span></span>
</td>
<td class="nump">8,191,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,607,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,511,121<span></span>
</td>
<td class="nump">2,431,499<span></span>
</td>
<td class="nump">3,855,796<span></span>
</td>
<td class="nump">6,287,295<span></span>
</td>
<td class="nump">8,798,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,970,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,110,654<span></span>
</td>
<td class="nump">5,175,070<span></span>
</td>
<td class="nump">5,723,363<span></span>
</td>
<td class="nump">10,898,433<span></span>
</td>
<td class="nump">17,009,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,110,654)<span></span>
</td>
<td class="num">(5,175,070)<span></span>
</td>
<td class="num">(5,723,363)<span></span>
</td>
<td class="num">(10,898,433)<span></span>
</td>
<td class="num">(17,009,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,600,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="nump">5,744<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,082,777)<span></span>
</td>
<td class="num">$ (5,169,326)<span></span>
</td>
<td class="num">$ (5,722,484)<span></span>
</td>
<td class="num">$ (10,891,810)<span></span>
</td>
<td class="num">$ (16,974,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,595,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,097,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,069,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,069,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,069,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,069,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,069,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149728945520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Nov. 18, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,426<span></span>
</td>
<td class="nump">$ 25,677,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,232<span></span>
</td>
<td class="nump">$ 156,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants', window );">Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,973<span></span>
</td>
<td class="nump">670,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 677,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_StockIssuedDuringPeriodSharesWarrantsIssued', window );">Stock Issued During Period, Shares, Warrants Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,105,962<span></span>
</td>
<td class="nump">47,874,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,374,327<span></span>
</td>
<td class="nump">8,574,301<span></span>
</td>
<td class="nump">6,844,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,983,666<span></span>
</td>
<td class="nump">2,519,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="nump">118,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,778<span></span>
</td>
<td class="nump">2,204,747<span></span>
</td>
<td class="nump">2,154,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear', window );">Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gnpx_The2018EmployeeStockPurchasePlanMember', window );">The 2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear', window );">Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gnpx_ExcludingThe2018EquityIncentivePlanMember', window );">Excluding the 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gnpx_TimeBasedOptionsMember', window );">Time Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_SharebasedPaymentArrangementExpenseFutureMilestone', window );">Share-based Payment Arrangement, Expense, Future Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_SharebasedPaymentArrangementExpenseFutureMilestone', window );">Share-based Payment Arrangement, Expense, Future Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProviderMember', window );">Warrant For Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProvider2Member', window );">Warrant For Service Provider 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServicesProvidedAtIpoMember', window );">Warrant for Services Provided at IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_VestingOfWarrantsForServiceProviderMember', window );">Vesting of Warrants For Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantOneMember', window );">Bear Creek Capital Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantTwoMember', window );">Bear Creek Capital Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantsMember', window );">Bear Creek Capital Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_PerformancebasedWarrantMember', window );">Performance-based Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount', window );">Warrant, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember', window );">Scientific Advisory Board Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=gnpx_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,010<span></span>
</td>
<td class="nump">$ 154,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="nump">7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="nump">2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,405,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scientific Advisory Board Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">3,809,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember', window );">The 2022 ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_BrokerageCommissionsPercentageOfGrossProceeds', window );">Brokerage Commissions, Percentage of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember', window );">The 2022 ATM Facility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_CommonStockSharesAuthorizedValue', window );">Common Stock, Shares Authorized, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember', window );">The 2022 ATM Facility [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_BrokerageCommissionsPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the commissions for brokerage services as a percentage of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_BrokerageCommissionsPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_CommonStockSharesAuthorizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggerate value for the shares authorized of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_CommonStockSharesAuthorizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage applied on outstanding shares of common stock for automatically increase on each year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_SharebasedPaymentArrangementExpenseFutureMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the share-based compensation expense based on future milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_SharebasedPaymentArrangementExpenseFutureMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in shares for exercise of cashless warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_StockIssuedDuringPeriodSharesWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_StockIssuedDuringPeriodSharesWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gnpx_The2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gnpx_The2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gnpx_ExcludingThe2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gnpx_ExcludingThe2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gnpx_TimeBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gnpx_TimeBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProvider2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServiceProvider2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServicesProvidedAtIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantForServicesProvidedAtIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_VestingOfWarrantsForServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_VestingOfWarrantsForServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_BearCreekCapitalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_PerformancebasedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_PerformancebasedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gnpx_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gnpx_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gnpx_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gnpx_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149728934336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, number of warrants (in shares)</a></td>
<td class="nump">2,204,747<span></span>
</td>
<td class="nump">2,154,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightIssuedInPeriod', window );">Issued, number of warrants (in shares)</a></td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice', window );">Issued, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightCancelledDuringPeriod', window );">Cancelled or expired, number of warrants (in shares)</a></td>
<td class="nump">146,326<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice', window );">Cancelled or expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercised, number of warrants (in shares)</a></td>
<td class="nump">13,643<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, number of warrants (in shares)</a></td>
<td class="nump">2,147,778<span></span>
</td>
<td class="nump">2,204,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightExercisable', window );">Exercisable, number of warrants (in shares)</a></td>
<td class="nump">1,901,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ClassOfWarrantOrRightExercisableExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightCancelledDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightCancelledDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightExercisableExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightExercisableExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802553936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years): (Year)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield:</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate:</a></td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility:</a></td>
<td class="nump">75.98%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate:</a></td>
<td class="nump">4.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility:</a></td>
<td class="nump">88.38%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149802530352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of shares (in shares)</a></td>
<td class="nump">8,574,301<span></span>
</td>
<td class="nump">6,844,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, number of shares (in shares)</a></td>
<td class="nump">2,983,666<span></span>
</td>
<td class="nump">2,519,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, number of shares (in shares)</a></td>
<td class="nump">116,973<span></span>
</td>
<td class="nump">670,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired or cancelled, number of shares (in shares)</a></td>
<td class="nump">66,667<span></span>
</td>
<td class="nump">118,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of shares (in shares)</a></td>
<td class="nump">11,374,327<span></span>
</td>
<td class="nump">8,574,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, number of shares (in shares)</a></td>
<td class="nump">6,718,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808818272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - 401(k) Savings Transactions (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 74,281<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149806263216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 29, 2022</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Feb. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_LicenseAgreementMilestonePayment', window );">License Agreement Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gnpx_NationalInstituteOfHealthMember', window );">National Institute of Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_RoyaltyOnSalesPercentage', window );">Royalty on Sales, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_RoyaltyTerms', window );">Royalty Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_RoyaltyPaymentAnnualMinimum', window );">Royalty Payment, Annual Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment for Contingent Consideration Liability, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ContingentPaymentsAnnualIncrease', window );">Contingent Payments Annual Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_ResearchAgreementMember', window );">Research Agreement [Member] | MD Anderson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_LongTermContractEstimatedCost', window );">Long Term Contract, Estimated Cost</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_LicensingFeeAmount', window );">Licensing Fee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount', window );">Annual Maintenance Fee, First Three Years, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_AnnualMaintenanceFeeAfterYearThreeAmount', window );">Annual Maintenance Fee, After Year Three, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_AnnualRoyaltyPaymentPerYearMinimum', window );">Annual Royalty Payment Per Year, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_ShareOfNonroyaltySublicenseIncomePercent', window );">Share of Non-Royalty Sublicense Income, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent', window );">Royalty Percent, Licensed Technology Covered by Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember', window );">License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent', window );">Royalty Percent, Licensed Technology Covered by Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember', window );">Development and Manufacturing of GMP Grade Materials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost', window );">Development Services Agreement, Expected Total Project Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_AnnualMaintenanceFeeAfterYearThreeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The annual maintenance fee after the third year of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_AnnualMaintenanceFeeAfterYearThreeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual maintenance fees for the first three years of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_AnnualRoyaltyPaymentPerYearMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of royalty payment to be received each year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_AnnualRoyaltyPaymentPerYearMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ContingentPaymentsAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in contingent payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ContingentPaymentsAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected total project cost under development services agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of milestone payments made for License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_LicensingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the agreed upon licensing fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_LicensingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_LongTermContractEstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated total cost of of long term contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_LongTermContractEstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a payment to be received upon achievement of an agreed upon milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_RoyaltyOnSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_RoyaltyOnSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_RoyaltyPaymentAnnualMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum of annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_RoyaltyPaymentAnnualMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales of licensed technology covered by patents to be earned as royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_RoyaltyTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terms of the royalty agreement, as a percentage of net sales of licensed technologies .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_RoyaltyTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_ShareOfNonroyaltySublicenseIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_ShareOfNonroyaltySublicenseIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gnpx_NationalInstituteOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gnpx_NationalInstituteOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gnpx_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gnpx_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gnpx_MdAndersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gnpx_MdAndersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gnpx_UniversityOfPittsburghMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gnpx_UniversityOfPittsburghMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808817472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 68.9<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149808829248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Income Tax Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effect of operating losses</a></td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent, Total</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149803510608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 18, 2023</div></th>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Nov. 18, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,426<span></span>
</td>
<td class="nump">$ 25,677,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,983,666<span></span>
</td>
<td class="nump">2,519,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember', window );">The 2022 ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember', window );">Scientific Advisory Board Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,735<span></span>
</td>
<td class="nump">2,155,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrants Issued with Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">3,809,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2022 ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">3,809,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_EquityOfferingCombinedPurchasePrice', window );">Equity Offering, Combined Purchase Price (in dollars per share)</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scientific Advisory Board Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,405,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Non-executive Employees [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gnpx_AnnualIncentiveAwards', window );">Annual Incentive Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 972,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_AnnualIncentiveAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual incentive awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_AnnualIncentiveAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gnpx_EquityOfferingCombinedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The combined purchase price of the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gnpx_EquityOfferingCombinedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gnpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gnpx_The2022AtmFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gnpx_ScientificAdvisoryBoardChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gnpx_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_ConsultantWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_ConsultantWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gnpx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gnpx_NonexecutiveEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gnpx_NonexecutiveEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140149807238192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 25,085,027<span></span>
</td>
<td class="nump">$ 42,862,286<span></span>
</td>
<td class="nump">$ 39,409,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,457,311<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="nump">2,457,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,295<span></span>
</td>
<td class="nump">2,384,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">48,106<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
<td class="nump">47,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">123,744,715<span></span>
</td>
<td class="nump">122,525,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,525,045<span></span>
</td>
<td class="nump">123,744,715<span></span>
</td>
<td class="nump">125,054,453<span></span>
</td>
<td class="nump">120,316,315<span></span>
</td>
<td class="nump">121,373,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(96,304,220)<span></span>
</td>
<td class="num">(90,161,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,161,658)<span></span>
</td>
<td class="num">(96,304,220)<span></span>
</td>
<td class="num">(102,827,819)<span></span>
</td>
<td class="num">(79,087,198)<span></span>
</td>
<td class="num">(84,397,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">22,274,740<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
<td class="nump">37,024,614<span></span>
</td>
<td class="nump">$ 30,916,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="nump">25,575<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,157,731<span></span>
</td>
<td class="nump">2,926,927<span></span>
</td>
<td class="nump">2,040,226<span></span>
</td>
<td class="nump">4,967,153<span></span>
</td>
<td class="nump">8,124,884<span></span>
</td>
<td class="nump">11,510,074<span></span>
</td>
<td class="nump">8,970,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,006,484<span></span>
</td>
<td class="nump">2,836,916<span></span>
</td>
<td class="nump">3,263,741<span></span>
</td>
<td class="nump">6,100,657<span></span>
</td>
<td class="nump">9,107,141<span></span>
</td>
<td class="nump">12,295,070<span></span>
</td>
<td class="nump">11,676,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,170,439<span></span>
</td>
<td class="nump">5,770,386<span></span>
</td>
<td class="nump">5,310,696<span></span>
</td>
<td class="nump">11,081,083<span></span>
</td>
<td class="nump">17,251,522<span></span>
</td>
<td class="nump">23,830,719<span></span>
</td>
<td class="nump">20,670,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) gain</a></td>
<td class="num">(6,170,439)<span></span>
</td>
<td class="num">(5,770,386)<span></span>
</td>
<td class="num">(5,310,696)<span></span>
</td>
<td class="num">(11,081,083)<span></span>
</td>
<td class="num">(17,251,522)<span></span>
</td>
<td class="num">(23,830,719)<span></span>
</td>
<td class="num">(20,670,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="nump">5,744<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="nump">90,098<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,142,562)<span></span>
</td>
<td class="num">$ (5,764,642)<span></span>
</td>
<td class="num">$ (5,309,817)<span></span>
</td>
<td class="num">$ (11,074,460)<span></span>
</td>
<td class="num">$ (17,217,022)<span></span>
</td>
<td class="num">$ (23,740,621)<span></span>
</td>
<td class="num">$ (20,664,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">47,984,724<span></span>
</td>
<td class="nump">47,893,404<span></span>
</td>
<td class="nump">47,879,597<span></span>
</td>
<td class="nump">47,892,919<span></span>
</td>
<td class="nump">47,919,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,565,123<span></span>
</td>
<td class="nump">$ 29,945,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,862,286<span></span>
</td>
<td class="nump">39,409,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,457,311<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153,838<span></span>
</td>
<td class="nump">2,457,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,295<span></span>
</td>
<td class="nump">2,384,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">48,020<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
<td class="nump">48,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,874<span></span>
</td>
<td class="nump">47,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">122,432,935<span></span>
</td>
<td class="nump">121,273,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,273,050<span></span>
</td>
<td class="nump">122,432,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,246,970<span></span>
</td>
<td class="nump">120,717,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(94,992,440)<span></span>
</td>
<td class="num">(88,909,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,909,663)<span></span>
</td>
<td class="num">(94,992,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,017,853)<span></span>
</td>
<td class="num">(83,740,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,488,515<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,411,285<span></span>
</td>
<td class="nump">27,488,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,276,991<span></span>
</td>
<td class="nump">37,024,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">6,543<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">13,273<span></span>
</td>
<td class="nump">19,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,593,309<span></span>
</td>
<td class="nump">2,737,028<span></span>
</td>
<td class="nump">1,860,837<span></span>
</td>
<td class="nump">4,597,865<span></span>
</td>
<td class="nump">8,191,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,607,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,511,121<span></span>
</td>
<td class="nump">2,431,499<span></span>
</td>
<td class="nump">3,855,796<span></span>
</td>
<td class="nump">6,287,295<span></span>
</td>
<td class="nump">8,798,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,970,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">6,110,654<span></span>
</td>
<td class="nump">5,175,070<span></span>
</td>
<td class="nump">5,723,363<span></span>
</td>
<td class="nump">10,898,433<span></span>
</td>
<td class="nump">17,009,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) gain</a></td>
<td class="num">(6,110,654)<span></span>
</td>
<td class="num">(5,175,070)<span></span>
</td>
<td class="num">(5,723,363)<span></span>
</td>
<td class="num">(10,898,433)<span></span>
</td>
<td class="num">(17,009,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,600,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27,877<span></span>
</td>
<td class="nump">5,744<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,082,777)<span></span>
</td>
<td class="num">$ (5,169,326)<span></span>
</td>
<td class="num">$ (5,722,484)<span></span>
</td>
<td class="num">$ (10,891,810)<span></span>
</td>
<td class="num">$ (16,974,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,595,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">47,984,724<span></span>
</td>
<td class="nump">47,893,404<span></span>
</td>
<td class="nump">47,879,597<span></span>
</td>
<td class="nump">47,892,919<span></span>
</td>
<td class="nump">47,919,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,311,780<span></span>
</td>
<td class="nump">1,251,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,995<span></span>
</td>
<td class="nump">1,311,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,311,780)<span></span>
</td>
<td class="num">(1,251,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,251,995)<span></span>
</td>
<td class="num">(1,311,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(656,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(435,578)<span></span>
</td>
<td class="nump">189,899<span></span>
</td>
<td class="nump">179,389<span></span>
</td>
<td class="nump">369,288<span></span>
</td>
<td class="num">(66,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">495,363<span></span>
</td>
<td class="nump">405,417<span></span>
</td>
<td class="num">(592,055)<span></span>
</td>
<td class="num">(186,638)<span></span>
</td>
<td class="nump">308,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">59,785<span></span>
</td>
<td class="nump">595,316<span></span>
</td>
<td class="num">(412,667)<span></span>
</td>
<td class="nump">182,650<span></span>
</td>
<td class="nump">242,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) gain</a></td>
<td class="num">(59,785)<span></span>
</td>
<td class="num">(595,316)<span></span>
</td>
<td class="nump">412,667<span></span>
</td>
<td class="num">(182,650)<span></span>
</td>
<td class="num">(242,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (59,785)<span></span>
</td>
<td class="num">$ (595,316)<span></span>
</td>
<td class="nump">$ 412,667<span></span>
</td>
<td class="num">$ (182,650)<span></span>
</td>
<td class="num">$ (242,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in dollars per share)</a></td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>gnpx20221231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:gnpx="http://www.genprex.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gnpx-20221231.xsd" xlink:type="simple"/>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2023-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="i_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="d_2023-03-01_2023-03-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-11-18_2022-11-18_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-18</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <context id="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-18</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-04-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2018-04-03</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServiceProvider2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantForServicesProvidedAtIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:VestingOfWarrantsForServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-TimeBasedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gnpx:TimeBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:BearCreekCapitalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-03</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-01-01_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-01_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-03</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-ExcludingThe2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:ExcludingThe2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:PerformancebasedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:MdAndersonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-12-31</instant>
        </period>
    </context>
    <context id="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-01-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-03</instant>
        </period>
    </context>
    <context id="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:NationalInstituteOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-29</instant>
        </period>
    </context>
    <context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-29</instant>
        </period>
    </context>
    <context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-29</instant>
        </period>
    </context>
    <context id="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gnpx:UniversityOfPittsburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gnpx:UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-29</instant>
        </period>
    </context>
    <context id="i_2022-07-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gnpx:DevelopmentAndManufacturingOfGMPGradeMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-01-01_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-01-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:ScientificAdvisoryBoardChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:The2022AtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-17_2023-01-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:ConsultantWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gnpx:NonexecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gnpx:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-18</startDate>
            <endDate>2023-02-18</endDate>
        </period>
    </context>
    <context id="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gnpx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gnpx:WarrantsIssuedWithRegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-07-01_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityCentralIndexKey">0001595248</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityRegistrantName">Genprex, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2022-01-01_2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2022-01-01_2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2022-01-01_2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2022-01-01_2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223893"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223894"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223895"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223896"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223897"
      unitRef="Share">48105962</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223899"
      unitRef="Share">48105962</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223898"
      unitRef="Share">47874708</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223900"
      unitRef="Share">47874708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224243"
      unitRef="USD">-78017853</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224244"
      unitRef="USD">-1069345</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224245"
      unitRef="USD">-79087198</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224270"
      unitRef="USD">-19600757</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224271"
      unitRef="USD">-1069345</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224272"
      unitRef="USD">-20670102</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224276"
      unitRef="USD">-19595624</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224277"
      unitRef="USD">-1069345</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224278"
      unitRef="USD">-20664969</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224279"
      unitRef="USDPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224280"
      unitRef="USDPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224281"
      unitRef="USDPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96224203"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      id="c96224189">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      id="c96224190">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96224205"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96224328"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2022-01-01_2022-12-31" id="c96224383">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2022-01-01_2022-12-31" id="c96224456">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c96224648">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c96224650">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c96224657">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      id="c96224659">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224825"
      unitRef="USD">-5722484</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224826"
      unitRef="USD">412667</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224827"
      unitRef="USD">-5309817</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224831"
      unitRef="USDPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224832"
      unitRef="USDPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224833"
      unitRef="USDPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224885"
      unitRef="USD">-5175070</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224886"
      unitRef="USD">-595316</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224887"
      unitRef="USD">-5770386</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224888"
      unitRef="USD">-10898433</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224889"
      unitRef="USD">-182650</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224890"
      unitRef="USD">-11081083</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224897"
      unitRef="USD">-5169326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224898"
      unitRef="USD">-595316</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224899"
      unitRef="USD">-5764642</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224900"
      unitRef="USD">-10891810</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224901"
      unitRef="USD">-182650</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224902"
      unitRef="USD">-11074460</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224903"
      unitRef="USDPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224904"
      unitRef="USDPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224905"
      unitRef="USDPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224906"
      unitRef="USDPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="c96224907"
      unitRef="USDPerShare">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224908"
      unitRef="USDPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224957"
      unitRef="USD">-6110654</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224958"
      unitRef="USD">-59785</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224959"
      unitRef="USD">-6170439</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224960"
      unitRef="USD">-17009087</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224961"
      unitRef="USD">-242435</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224962"
      unitRef="USD">-17251522</us-gaap:OperatingIncomeLoss>
    <dei:DocumentType contextRef="d_2022-01-01_2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2022-01-01_2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2022-01-01_2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2022-01-01_2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2022-01-01_2022-12-31">001-38244</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2022-01-01_2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2022-01-01_2022-12-31">90-0772347</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2022-01-01_2022-12-31">3300 Bee Cave Road #650-227</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2022-01-01_2022-12-31">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2022-01-01_2022-12-31">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2022-01-01_2022-12-31">78746</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2022-01-01_2022-12-31">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2022-01-01_2022-12-31">774-4679</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2022-01-01_2022-12-31">GNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2022-01-01_2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2022-01-01_2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2022-01-01_2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2022-01-01_2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2022-01-01_2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2022-01-01_2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2022-01-01_2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2022-01-01_2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d_2022-01-01_2022-12-31">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2022-01-01_2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2022-01-01_2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2022-06-30" decimals="0" unitRef="USD">66000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2023-03-15" decimals="INF" unitRef="Share">51974078</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2022-01-01_2022-12-31">229</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2022-01-01_2022-12-31">Daszkal Bolton LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2022-01-01_2022-12-31">Boca Raton, FL</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223861"
      unitRef="USD">20954069</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223862"
      unitRef="USD">38628876</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223863"
      unitRef="USD">34852</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223864"
      unitRef="USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223865"
      unitRef="USD">484224</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223866"
      unitRef="USD">511348</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223867"
      unitRef="USD">21473145</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223868"
      unitRef="USD">39140224</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223869"
      unitRef="USD">23032</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223870"
      unitRef="USD">48608</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223872"
      unitRef="USD">21818</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223873"
      unitRef="USD">8691</us-gaap:DepositsAssetsNoncurrent>
    <gnpx:ResearchAndDevelopmentAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223874"
      unitRef="USD">2864937</gnpx:ResearchAndDevelopmentAssetsNoncurrent>
    <gnpx:ResearchAndDevelopmentAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223875"
      unitRef="USD">3022403</gnpx:ResearchAndDevelopmentAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223876"
      unitRef="USD">702095</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223877"
      unitRef="USD">642360</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223878"
      unitRef="USD">3588850</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223879"
      unitRef="USD">3673454</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223880"
      unitRef="USD">25085027</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223881"
      unitRef="USD">42862286</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223884"
      unitRef="USD">442925</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223885"
      unitRef="USD">973195</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223886"
      unitRef="USD">2367362</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223887"
      unitRef="USD">612100</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223888"
      unitRef="USD">2810287</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223889"
      unitRef="USD">1585295</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223891"
      unitRef="USD">48106</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223892"
      unitRef="USD">47874</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223901"
      unitRef="USD">125054453</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223902"
      unitRef="USD">120316315</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223903"
      unitRef="USD">-102827819</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223904"
      unitRef="USD">-79087198</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223905"
      unitRef="USD">22274740</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223906"
      unitRef="USD">41276991</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96223907"
      unitRef="USD">25085027</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223908"
      unitRef="USD">42862286</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223915"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223916"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223918"
      unitRef="USD">25575</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223919"
      unitRef="USD">22534</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223920"
      unitRef="USD">11510074</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223921"
      unitRef="USD">8970865</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223922"
      unitRef="USD">12295070</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223923"
      unitRef="USD">11676703</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223924"
      unitRef="USD">23830719</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223925"
      unitRef="USD">20670102</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223926"
      unitRef="USD">-23830719</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223927"
      unitRef="USD">-20670102</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223928"
      unitRef="USD">90098</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223929"
      unitRef="USD">5133</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223930"
      unitRef="USD">-23740621</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223931"
      unitRef="USD">-20664969</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223932"
      unitRef="USDPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223933"
      unitRef="USDPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223934"
      unitRef="Share">47952100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223935"
      unitRef="Share">47097251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223946"
      unitRef="Share">43117681</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223947"
      unitRef="USD">43118</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223948"
      unitRef="USD">89295601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223949"
      unitRef="USD">-58422229</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96223950"
      unitRef="USD">30916490</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223951"
      unitRef="Share">4670889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223952"
      unitRef="USD">4670</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223953"
      unitRef="USD">25673241</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223954"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223955"
      unitRef="USD">25677911</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223956"
      unitRef="Share">86138</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223957"
      unitRef="USD">86</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223958"
      unitRef="USD">155959</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223959"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223960"
      unitRef="USD">156045</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223962"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223963"
      unitRef="USD">5191514</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223964"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223965"
      unitRef="USD">5191514</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223967"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223968"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223969"
      unitRef="USD">-20664969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96223970"
      unitRef="USD">-20664969</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223971"
      unitRef="Share">47874708</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223972"
      unitRef="USD">47874</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223973"
      unitRef="USD">120316315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223974"
      unitRef="USD">-79087198</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96223975"
      unitRef="USD">41276991</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223976"
      unitRef="Share">120859</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223977"
      unitRef="USD">121</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223978"
      unitRef="USD">6305</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223979"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223980"
      unitRef="USD">6426</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223981"
      unitRef="Share">110395</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223982"
      unitRef="USD">111</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223983"
      unitRef="USD">163121</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223984"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223985"
      unitRef="USD">163232</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223987"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223988"
      unitRef="USD">4568712</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223989"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223990"
      unitRef="USD">4568712</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223992"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223993"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223994"
      unitRef="USD">-23740621</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96223995"
      unitRef="USD">-23740621</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223996"
      unitRef="Share">48105962</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96223997"
      unitRef="USD">48106</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c96223998"
      unitRef="USD">125054453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c96223999"
      unitRef="USD">-102827819</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224000"
      unitRef="USD">22274740</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224008"
      unitRef="USD">-23740621</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224009"
      unitRef="USD">-20664969</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224011"
      unitRef="USD">25575</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224012"
      unitRef="USD">22534</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224013"
      unitRef="USD">4731944</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224014"
      unitRef="USD">5347559</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224016"
      unitRef="USD">34852</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224017"
      unitRef="USD">-127</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224018"
      unitRef="USD">-27125</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224019"
      unitRef="USD">126795</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224020"
      unitRef="USD">13127</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224021"
      unitRef="USD">-2050</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224022"
      unitRef="USD">-530269</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224023"
      unitRef="USD">780226</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224024"
      unitRef="USD">1755262</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224025"
      unitRef="USD">354344</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224026"
      unitRef="USD">-17778964</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224027"
      unitRef="USD">-14284924</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224029"
      unitRef="USD">-0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224030"
      unitRef="USD">31700</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224031"
      unitRef="USD">59735</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224032"
      unitRef="USD">40735</us-gaap:PaymentsToAcquireIntangibleAssets>
    <gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224033"
      unitRef="USD">-157465</gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies>
    <gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224034"
      unitRef="USD">11361</gnpx:PaymentsForProceedsFromResearchAndDevelopmentSupplies>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224035"
      unitRef="USD">97731</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224036"
      unitRef="USD">-83796</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224038"
      unitRef="USD">6426</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224039"
      unitRef="USD">25677911</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224040"
      unitRef="USD">6426</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224041"
      unitRef="USD">25677911</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224042"
      unitRef="USD">-17674807</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224043"
      unitRef="USD">11309191</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224044"
      unitRef="USD">38628876</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96224045"
      unitRef="USD">27319685</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224046"
      unitRef="USD">20954069</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224047"
      unitRef="USD">38628876</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343482">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; Description of Business and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;div style="font-size:10pt"&gt;
    &lt;div style="font-family:&amp;quot;Times New Roman&amp;quot;"&gt;
     &lt;div style="font-variant: normal; text-align: justify;"&gt;
       We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.&#160;Our oncology platform utilizes our non-viral ONCOPREX&#xae; Nanoparticle Delivery System.&#160;Using this system, plasmids containing tumor suppressor genes, which are deleted early in the development of cancer, are encapsulated within lipid nanoparticles and administered intravenously to the patient to re-express the deleted tumor suppressor genes. Our diabetes technology is designed to work in Type
      &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. In Type
      &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes, our&#160;technology is believed to work by replenishing and rejuvenating the beta cells&#160;that make insulin.
     &lt;/div&gt;
     &lt;div style="font-variant: normal; text-align: justify;"&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Oncology Platform&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our lead oncology drug candidate, REQORSA&#xae; Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-&lt;em style="font: inherit;"&gt;001,&lt;/em&gt; is initially being developed in combination with top selling cancer drugs to treat Non-Small Cell Lung Cancer (&#x201c;NSCLC&#x201d;) and Small Cell Lung Cancer (&#x201c;SCLC&#x201d;).&#160;The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named &lt;em style="font: inherit;"&gt;TUSC2.&lt;/em&gt; REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies.&#160;We believe REQORSA&#x2019;s unique attributes position REQORSA to provide treatment for patients with NSCLC, SCLC, and possibly other cancers, and that it can improve on current therapies.&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;1:&lt;/em&gt; We currently are enrolling and treating patients in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion of our Phase&#160;&lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;clinical trial.&#160;The Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;trial uses a combination of REQORSA and AstraZeneca PLC&#x2019;s Tagrisso&#xae; in patients with late-stage NSCLC that has activating epidermal growth factor receptor (&#x201c;EGFR&#x201d;) mutations and progression after treatment with Tagrisso. In&#160;&lt;em style="font: inherit;"&gt; August 2022,&#160;&lt;/em&gt;the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;Safety Review Committee (&#x201c;Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; SRC&#x201d;) approved escalating the dose from&#160;&lt;em style="font: inherit;"&gt;0.06&lt;/em&gt;&#160;mg/kg in the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;cohort of patients to&#160;&lt;em style="font: inherit;"&gt;0.09&lt;/em&gt;&#160;mg/kg in the&#160;&lt;em style="font: inherit;"&gt;second&lt;/em&gt;&#160;cohort of patients and in &lt;em style="font: inherit;"&gt; December 2022,&#160;&lt;/em&gt;the SRC approved escalating the dose from &lt;em style="font: inherit;"&gt;0.09&lt;/em&gt; mg/kg in the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; cohort to &lt;em style="font: inherit;"&gt;0.12&lt;/em&gt; mg/kg in the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; and final cohort. We are thus enrolling and treating patients at the &lt;em style="font: inherit;"&gt;0.12&lt;/em&gt; mg/kg dose&#160;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of treatment for the remaining untreated patients, the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; SRC will meet and establish the maximum tolerated dose ("MTD") or recommended Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; dose (&lt;em style="font: inherit;"&gt;"RP2D"&lt;/em&gt;). We will then proceed into the dose expansion portion of the study. The Food and Drug Administration (&#x201c;FDA&#x201d;) has granted Fast Track Designation for the Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;&#160;treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;2:&lt;/em&gt; We&#160;currently are enrolling and treating patients in the Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dose escalation portion of our Phase&#160;&lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;clinical trial.&#160;The Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;trial uses a combination of REQORSA and Merck &amp;amp; Co.&#x2019;s Keytruda&#xae; in patients with late-stage NSCLC whose disease has progressed after treatment with Keytruda. Patients are currently being treated at the &lt;em style="font: inherit;"&gt;0.06&lt;/em&gt; mg/kg dose level in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; cohort of patients and, subject to the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Safety Review Committee approval, will be treated at successive dose levels of &lt;em style="font: inherit;"&gt;0.09&lt;/em&gt; mg/kg and &lt;em style="font: inherit;"&gt;0.12&lt;/em&gt; mg/kg. In &lt;em style="font: inherit;"&gt; March 2023, &lt;/em&gt;we amended the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; protocol to include additional treatments in the control group with the goal of accelerating enrollment in the study by making the trial more attractive to a wider variety of investigators. We expect enrollment in the dose escalation portion of&#160;the study to be completed by the end of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; We will then evaluate patients in the dose expansion portion of the study at the MTD or &lt;em style="font: inherit;"&gt;RP2D.&lt;/em&gt; The FDA has granted Fast Track Designation for the Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;treatment combination of REQORSA and Keytruda in NSCLC patients who have progressed after Keytruda treatment.&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;"&gt;The dose expansion portion of Acclaim-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; is a Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study and the dose expansion portion of Acclaim-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; will be considered a Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study upon the filing with the FDA of an upcoming protocol amendment.&#160;The dose expansion provides us the advantage of early insight into drug effectiveness in defined and distinct patient populations at the MTD or &lt;em style="font: inherit;"&gt;RP2D&lt;/em&gt; in order to better evaluate efficacy and increase the likelihood of a successful randomized Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; trial which will follow the dose expansion portions of each study.&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Acclaim &#x2013; &lt;em style="font: inherit;"&gt;3:&lt;/em&gt; In &lt;em style="font: inherit;"&gt; November 2022, &lt;/em&gt;we filed with the FDA our protocol for our Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; clinical trial using a combination of REQORSA and Genentech, Inc.&#x2019;s Tecentriq&#xae; as maintenance therapy in patients with extensive stage small cell lung cancer (&#x201c;ES-SCLC&#x201d;) who did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. We expect to dose the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; patient in Acclaim-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; by the end of&#160;the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; gene is &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of a series of genes on the short arm of Chromosome &lt;em style="font: inherit;"&gt;3&lt;/em&gt; whose therapeutic use is covered by our exclusive worldwide licenses from The University of Texas MD Anderson Cancer Center ("MD Anderson").&#160;We believe that our ONCOPREX Nanoparticle Delivery System allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer and are in early stages of discovery programs to identify early-stage candidates. In &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;we entered into a sponsored research agreement with MD Anderson to support further pre-clinical studies of &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; and other tumor suppressor genes.&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Diabetes Gene Therapy&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;"&gt;In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (&#x201c;University of Pittsburgh&#x201d;) multiple technologies relating to the development of a gene therapy product for each of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes.&#160;The same general novel approach is used in each of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; whereby an adeno-associated virus (&#x201c;AAV&#x201d;) vector containing the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. Our diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh. GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; is being developed for the treatment of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and GPX-&lt;em style="font: inherit;"&gt;003&lt;/em&gt; is being developed for the treatment of Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes. GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#x2019;s immune system. GPX-&lt;em style="font: inherit;"&gt;003&lt;/em&gt; is believed to work by replenishing and rejuvenating the beta cells that make insulin. We expect to finalize our constructs and meet with the FDA before the end of &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; to obtain their guidance on the toxicology studies that we plan to conduct. In &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;we entered into a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year sponsored research agreement with the University of Pittsburgh for the use of GPX-&lt;em style="font: inherit;"&gt;003&lt;/em&gt; in a non-human primate (&#x201c;NHP&#x201d;) model in Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes and we expect data from this study to be reported by the end of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; February 2023, &lt;/em&gt;the Company&#x2019;s research collaborators at the&#160;University of Pittsburgh&#160;presented preclinical data in a NHP model of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes highlighting the therapeutic potential of GPX-&lt;em style="font: inherit;"&gt;002&lt;/em&gt; at the &lt;em style="font: inherit;"&gt;16th&lt;/em&gt; International Conference on Advanced Technologies &amp;amp; Treatments for Diabetes (ATTD &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;) in Berlin, Germany. The statistically significant study results showed the treated animals had decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance compared to baseline.&lt;/p&gt;
     &lt;/div&gt;
     &lt;div style="font-variant:normal"&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
     &lt;/div&gt;
    &lt;/div&gt;
   &lt;/div&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Capital Requirements, Liquidity and Going Concern Considerations&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Our financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP") applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; current source of revenue. In addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our patents.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property.&#160; To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances can be given that we will be successful in raising additional capital.&#160; If we are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations will continue to be materially affected. These financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343483">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Our financial statements have been prepared in accordance with GAAP.&#160; Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion the financial statements include all adjustments (consisting of normal recurring accruals) necessary to make the financial statements &lt;em style="font: inherit;"&gt;not&lt;/em&gt; misleading. The results of operations for any interim periods are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of results to be expected for the full year. A summary of our significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Correction of Immaterial Error&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Subsequent to the issuance of the Company's &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; financial statements on &lt;em style="font: inherit;"&gt; March 30, 2022, &lt;/em&gt;management discovered that it did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize share-based compensation expense over the service periods for awards with cliff-vesting provisions. The following table summarizes the impacts of this error correction on the Company's financial statements for &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In accordance with Staff Accounting Bulletin (&#x201c;SAB&#x201d;) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99,&lt;/em&gt; &#x201c;Materiality,&#x201d; and SAB &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;108,&lt;/em&gt; &#x201c;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,&#x201d; the Company evaluated the error and determined that the related impact did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; materially misstate previously issued financial statements. Although the Company concluded that the misstatement was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to its previously issued financial statements, the Company has determined it is appropriate to adjust its previously issued financial statements to correct for the error in the context of comparative financial statements. The following are the relevant line items from the Company&#x2019;s financial statements which illustrate the effect of the corrections to the period presented:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance Sheet&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;119,246,970&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;120,316,315&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224243"&gt;(78,017,853)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224244"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224245"&gt;(79,087,198)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;For the Year ended December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Statement of Operations&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,607,751&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;363,114&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,970,865&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;10,970,472&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;706,231&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;11,676,703&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;19,600,757&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;20,670,102&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Operating loss&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224270"&gt;(19,600,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224271"&gt;(1,069,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224272"&gt;(20,670,102)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224276"&gt;(19,595,624)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224277"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224278"&gt;(20,664,969)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Loss per share&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224279"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224280"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224281"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Weighted average common shares outstanding&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We consider all highly liquid short-term investments with an initial maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have no cash equivalents, and had $20,679,538 and $38,392,885&#160;in excess of FDIC insured limits of &lt;em style="font: inherit;"&gt;$250,000&lt;/em&gt; at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&#160;respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"/&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC &lt;em style="font: inherit;"&gt;820&#x2019;s&lt;/em&gt; valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; classifies these inputs into the following hierarchy:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Quoted prices for identical instruments in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Instruments with primarily unobservable value drivers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c96224189"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c96224190"&gt;five&lt;/span&gt; years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Research and Development Materials Costs&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;clinical trials and are expensed as incurred. Materials produced&#160;to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or&#160;clinical activities, or have spoiled.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Research and development supplies purchased and capitalized for future use were&#160;$2,864,937 and $3,022,403 at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"/&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Intellectual property consists of&#160;legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Accounting for Stock-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&#160;&#160;We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows.&#160;During the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, there were no deemed impairments of our long-lived assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Recent Accounting Developments&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; effective until after &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant effect on our financial condition, results of operations, or cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"/&gt;


  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <gnpx:CorrectionOfErrorPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96228147">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Correction of Immaterial Error&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Subsequent to the issuance of the Company's &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; financial statements on &lt;em style="font: inherit;"&gt; March 30, 2022, &lt;/em&gt;management discovered that it did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize share-based compensation expense over the service periods for awards with cliff-vesting provisions. The following table summarizes the impacts of this error correction on the Company's financial statements for &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In accordance with Staff Accounting Bulletin (&#x201c;SAB&#x201d;) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99,&lt;/em&gt; &#x201c;Materiality,&#x201d; and SAB &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;108,&lt;/em&gt; &#x201c;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,&#x201d; the Company evaluated the error and determined that the related impact did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; materially misstate previously issued financial statements. Although the Company concluded that the misstatement was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to its previously issued financial statements, the Company has determined it is appropriate to adjust its previously issued financial statements to correct for the error in the context of comparative financial statements. The following are the relevant line items from the Company&#x2019;s financial statements which illustrate the effect of the corrections to the period presented:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance Sheet&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;119,246,970&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;120,316,315&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224243"&gt;(78,017,853)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224244"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224245"&gt;(79,087,198)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;For the Year ended December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Statement of Operations&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,607,751&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;363,114&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,970,865&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;10,970,472&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;706,231&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;11,676,703&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;19,600,757&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;20,670,102&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Operating loss&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224270"&gt;(19,600,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224271"&gt;(1,069,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224272"&gt;(20,670,102)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224276"&gt;(19,595,624)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224277"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224278"&gt;(20,664,969)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Loss per share&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224279"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224280"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224281"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Weighted average common shares outstanding&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</gnpx:CorrectionOfErrorPolicyTextBlock>
    <gnpx:CorrectionOfErrorsTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343484">
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance Sheet&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;42,862,286&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,585,295&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;47,874&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;119,246,970&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;120,316,315&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224243"&gt;(78,017,853)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224244"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224245"&gt;(79,087,198)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;41,276,991&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="vertical-align: bottom; width: 26%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;For the Year ended December 31, 2021&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Statement of Operations&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: middle; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;22,534&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,607,751&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;363,114&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;8,970,865&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;10,970,472&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;706,231&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;11,676,703&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;19,600,757&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;1,069,345&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;20,670,102&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Operating loss&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224270"&gt;(19,600,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224271"&gt;(1,069,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224272"&gt;(20,670,102)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;em style="font: inherit;"&gt; &lt;/em&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;-&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;5,133&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224276"&gt;(19,595,624)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224277"&gt;(1,069,345)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c96224278"&gt;(20,664,969)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Loss per share&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224279"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224280"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c96224281"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="vertical-align: bottom; width: 61%; padding: 0; margin: 0"&gt;Weighted average common shares outstanding&lt;/td&gt;&lt;td style="vertical-align: middle; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 1%; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; width: 12%; padding: 0px; margin: 0px; text-align: right;"&gt;47,097,251&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </gnpx:CorrectionOfErrorsTableTextBlock>
    <us-gaap:Assets
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224231"
      unitRef="USD">42862286</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224233"
      unitRef="USD">42862286</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224234"
      unitRef="USD">1585295</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224236"
      unitRef="USD">1585295</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224237"
      unitRef="USD">47874</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224239"
      unitRef="USD">47874</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224240"
      unitRef="USD">119246970</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224241"
      unitRef="USD">1069345</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224242"
      unitRef="USD">120316315</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224246"
      unitRef="USD">41276991</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224248"
      unitRef="USD">41276991</us-gaap:StockholdersEquity>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224258"
      unitRef="USD">22534</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224260"
      unitRef="USD">22534</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224261"
      unitRef="USD">8607751</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224262"
      unitRef="USD">363114</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224263"
      unitRef="USD">8970865</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224264"
      unitRef="USD">10970472</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224265"
      unitRef="USD">706231</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224266"
      unitRef="USD">11676703</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224267"
      unitRef="USD">19600757</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-RestatementAdjustmentMember"
      decimals="INF"
      id="c96224268"
      unitRef="USD">1069345</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224269"
      unitRef="USD">20670102</us-gaap:CostsAndExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224273"
      unitRef="USD">5133</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224275"
      unitRef="USD">5133</us-gaap:InvestmentIncomeInterest>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224282"
      unitRef="Share">47097251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224284"
      unitRef="Share">47097251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:UseOfEstimates contextRef="d_2022-01-01_2022-12-31" id="c96228148">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96228149">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We consider all highly liquid short-term investments with an initial maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have no cash equivalents, and had $20,679,538 and $38,392,885&#160;in excess of FDIC insured limits of &lt;em style="font: inherit;"&gt;$250,000&lt;/em&gt; at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;&#160;respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96224172"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224174"
      unitRef="USD">20679538</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224175"
      unitRef="USD">38392885</us-gaap:CashUninsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2022-01-01_2022-12-31" id="c96228150">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; Fair Value Measurements and Disclosures, defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure requirements. ASC &lt;em style="font: inherit;"&gt;820&#x2019;s&lt;/em&gt; valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; classifies these inputs into the following hierarchy:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;1:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Quoted prices for identical instruments in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;2:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt; text-align: justify;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 72pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Level &lt;em style="font: inherit;"&gt;3:&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Instruments with primarily unobservable value drivers.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96228151">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from &lt;span style="-sec-ix-hidden:c96224189"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c96224190"&gt;five&lt;/span&gt; years. Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2022-01-01_2022-12-31" id="c96228152">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Research and Development Materials Costs&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies&#160;for current and future programs. These costs include payments to collaborative research partners, manufacturing partners and consultants, and clinical strategy partners,&#160;wages and associated employee benefits, facilities, and overhead costs. These expenditures relate to our preclinical and Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt;&#160;clinical trials and are expensed as incurred. Materials produced&#160;to be used in clinical research are capitalized and included in research and development supplies and are expensed as they are used for testing or&#160;clinical activities, or have spoiled.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Research and development supplies purchased and capitalized for future use were&#160;$2,864,937 and $3,022,403 at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <gnpx:ResearchAndDevelopmentAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224193"
      unitRef="USD">2864937</gnpx:ResearchAndDevelopmentAssetsCurrent>
    <gnpx:ResearchAndDevelopmentAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224194"
      unitRef="USD">3022403</gnpx:ResearchAndDevelopmentAssetsCurrent>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2022-01-01_2022-12-31" id="c96228153">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Intellectual property consists of&#160;legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2022-01-01_2022-12-31" id="c96228154">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Accounting for Stock-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&#160;&#160;We measure options granted at fair value determined as of the grant date, and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96228155">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. In evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows.&#160;During the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, there were no deemed impairments of our long-lived assets.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96224197"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96228156">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Recent Accounting Developments&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Accounting pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; effective until after &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant effect on our financial condition, results of operations, or cash flows.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343485">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; Intellectual Property&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We own or have exclusive license agreements on &lt;em style="font: inherit;"&gt;15&lt;/em&gt;&#160;granted patents and &lt;em style="font: inherit;"&gt;24&lt;/em&gt;&#160;pending patent applications worldwide for technologies developed in-house or by researchers at the National Cancer Institute, MD Anderson,&#160;the University of Texas Southwestern Medical Center, and the University of Pittsburgh.&#160;These patents comprise various therapeutic, diagnostic, technical and processing claims. These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;University of Pittsburgh&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 11, 2020, &lt;/em&gt;we entered into an exclusive&#160;license agreement with the University of Pittsburgh for patented gene therapy technologies relating to the potential treatment of Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; and Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes. This license was &lt;em style="font: inherit;"&gt;first&lt;/em&gt; amended on &lt;em style="font: inherit;"&gt; August 17, 2022, &lt;/em&gt;to extend the&#160;milestone related to the filing of a new investigational drug ("IND") application. This license was amended again on &lt;em style="font: inherit;"&gt; November 3, 2022, &lt;/em&gt;to include a new licensed glucagon promoter technology&#160;related to Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes and set FDA and clinical milestones related to the glucagon technology.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2022, &lt;/em&gt;we entered into an&#160;exclusive&#160;license agreement with the University of Pittsburgh relating to the transformation of macrophages enabling them to reduce autoimmunity activity in Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; December 29, 2022, &lt;/em&gt;we entered into an&#160;exclusive&#160;license agreement with the University of Pittsburgh&#160;relating to the use of an insulin promoter in combination with our existing gene therapy, including the &lt;em style="font: inherit;"&gt;Pdx1&lt;/em&gt; and MafA transcription factors, as a potential treatment for Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt; diabetes.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;i&gt;The University of Texas MD Anderson Cancer Center&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; May 4, 2020, &lt;/em&gt;we entered into an exclusive worldwide license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson relating&#160;to a portfolio of patent applications and related technology for the treatment of cancer using our&#160;lead drug candidate and immunotherapies.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343486">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&#160;&#x2013; Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Registered Direct Offerings&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 10, 2021, &lt;/em&gt;we completed a registered direct offering&#160;in which we sold to investors an aggregate of 4,000,000 shares of our common stock at $6.25 per share.&#160;We received net proceeds of approximately $23.2 million after commissions and expenses.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;See &#x201c;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt;&#160;&#x2013; Subsequent Events &#x2013; &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Registered Direct Offering&#x201d; for a description of the Company&#x2019;s registered direct offering of shares and warrants in &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;resulting in net proceeds of approximately $3.6 million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;At-The Market Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 18, 2022, &lt;/em&gt;we&#160;entered into an Equity Distribution Agreement with JMP Securities LLC&#160;("JMP Securities") pursuant to which we&#160;&lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time, at our option, shares of our common stock through JMP Securities, as sales agent (the &lt;em style="font: inherit;"&gt;"2022&lt;/em&gt; ATM Facility"), up to an aggregate offering price of&#160;$50 million. Sales of the shares were, and if any future sales, will be made&#160;under the our previously filed and currently effective Registration Statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; (Reg. &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;333&lt;/em&gt;-&lt;em style="font: inherit;"&gt;239134&lt;/em&gt;), by means of ordinary brokers&#x2019; transactions on the NASDAQ Global Market or otherwise. Additionally, under the terms of the Sales Agreement, the shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be sold at market prices, at negotiated prices or at prices related to the prevailing market price. We&#160;will pay JMP Securities&#160;a commission of&#160;3.0%&#160;of the gross proceeds from the sale of the shares. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we sold 3,886&#160;shares for aggregate net proceeds of&#160;$4,532 under the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; ATM Facility.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Stock Issuances&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we&#160;issued (i) 20,000 shares of common stock for services provided to us&#160;valued at $42,400&#160;to the Chairman of our Scientific Advisory Board, (ii)&#160;13,643 shares of common stock upon the exercise of warrants on a cashless basis, (iii) 116,973 shares of common stock upon the exercise of options by an executive, and (iv)&#160;76,752 shares of common stock for services provided to us, valued at $99,010, to consultants.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, we issued (i) 670,889 shares of common stock from the exercise of options for cash proceeds of $677,912, and (ii) 86,138 shares of common stock for services provided to us,&#160;valued at $154,648, to consultants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We are&#160;authorized to issue 10,000,000 shares of preferred stock at a par value of $0.001 per share, &lt;span style="-sec-ix-hidden:c96224328"&gt;none&lt;/span&gt; of which are outstanding as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We are&#160;authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share, all of which is voting common stock. There were 48,105,962&#160;shares of common stock outstanding at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Common Stock Purchase Warrants&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Common stock purchase warrant activity for the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; respectively are as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Warrants&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Avg. Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,154,747&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.37&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.29&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Cancelled or expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,204,747&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.39&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;103,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.54&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Cancelled or expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,326&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.79&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,643&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.50&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,147,778&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.32&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;1,901,945&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;4.59&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we&#160;issued (i) a warrant&#160;to purchase up to 50,000&#160;shares of common stock to a service provider&#160;at an exercise price of $1.38&#160;per share, the fair market value of a share of common stock on the date of issuance, (ii) a warrant&#160;to purchase up to 50,000&#160;shares of common stock to a service provider&#160;at an exercise price of $1.49&#160;per share, the fair market value of a share of common stock on the date of issuance, (iii)&#160;a warrant, previously accounted&#160;as a warrant issuable to a consultant in consideration of services provided at our IPO, to purchase up to 3,000 shares of common stock at an exercise price of $5.00 per share, the fair market value of a share of common stock at our IPO, and (iv) we issued 13,643 shares of common stock to a&#160;placement agent&#160;associated with a&#160;registered direct offering in &lt;em style="font: inherit;"&gt; November 2019&#160;&lt;/em&gt;upon the&#160;exercise of&#160;warrants on a cashless basis. During the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we recorded share-based compensation of $55,612 associated with the vesting of warrants.&#160;We&#160;expect&#160;to record $90,689&#160;of share-based compensation for time-based vesting over the next year&#160;and another $300,000 of share-based compensation based on performance-based vesting.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, we&#160;issued (i) a warrant&#160;to purchase up to 25,000 shares of common stock to a service provider&#160;at an exercise price of $7.22 per share, the fair market value of a share of common stock on the date of issuance and (ii) a warrant&#160;to purchase up to 25,000 shares of common stock to a service provider&#160;at an exercise price of $3.36&#160;per share, the fair market value of a share of common stock on the date of issuance. During the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, we recorded share-based compensation of $200,282 associated with the vesting of warrants.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Our board of directors and stockholders have&#160;approved and adopted the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan (&lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Plan&#x201d;), which became effective on the completion of the IPO on &lt;em style="font: inherit;"&gt; April 3, 2018.&#160;&lt;/em&gt;The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan provides for the grant of incentive stock options that are intended to qualify under Section &lt;em style="font: inherit;"&gt;422&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended (&#x201c;ISOs&#x201d;), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based cash awards. ISOs &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted only to employees. All other awards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted to employees, including officers, and to non-employee directors and consultants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The number of shares of common stock reserved for issuance under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan automatically increase on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each year, beginning &lt;em style="font: inherit;"&gt; January 1, 2019 &lt;/em&gt;by 5% of the total number of shares of the Company&#x2019;s common stock outstanding on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the preceding calendar year, or a lesser number of shares determined by our Board or a committee appointed to administer the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan. On &lt;em style="font: inherit;"&gt; January 1, 2021&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the number of shares of common stock reserved for issuance under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan was increased by an aggregate of 2,155,884 and 2,393,735 shares, respectively.&#160;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, a total of 481,772 shares of common stock remain available for&#160;issuance for future awards under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Our board of directors and stockholders approved and adopted the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on &lt;em style="font: inherit;"&gt; April 3, 2018.&#160;&lt;/em&gt;The ESPP has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been utilized as a benefit available to our employees.&#160;The ESPP authorizes the issuance of 208,050 shares of our common stock pursuant to purchase rights that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted to our eligible employees. The number of shares of common stock reserved for issuance under the ESPP is automatically increased on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each calendar year, beginning on &lt;em style="font: inherit;"&gt; January 1, 2019, &lt;/em&gt;by 2% of the total number of shares of our&#160;common stock outstanding on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the preceding calendar year, or a lesser number of shares determined by the administrator of the ESPP. The administrator of the ESPP determined &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to increase the number of shares reserved for issuance under the ESPP on&#160;&lt;em style="font: inherit;"&gt; January 1, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;,&#160;we had&#160;outstanding stock options to purchase 11,374,327&#160;shares of common stock that have been granted to various executives, employees, directors, and independent contractors, including outstanding stock options to purchase 950,000 shares of common stock issued as inducement grants, outside of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; plan, associated with the hiring of new executives in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160;These options vest immediately or over periods ranging from 12&#160;to 48&#160;months, are exercisable for a period of up to &lt;span style="-sec-ix-hidden:c96224383"&gt;ten&lt;/span&gt; years, and enable the holders to purchase shares of our common stock at exercise prices ranging from $0.298&#160;to&#160;$9.80 per share. The per-share fair values of these options range from $0.24&#160;to $7.93, based on Black-Scholes-Merton pricing models with the following assumptions:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c96224456"&gt;10&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0.07% &#x2013; 4.77%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;75.98% &#x2013; 88.38%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Dividend yield:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: justify;"&gt;In the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we (i) granted stock options to purchase an aggregate of&#160;2,983,666 shares of our&#160;common stock with exercise prices ranging from $1.27&#160;to $3.50&#160;per share to executives and&#160;employees,&#160;(ii) cancelled options to purchase 66,667 shares of common stock at exercise prices ranging from $2.00 to $3.66 per share&#160;in connection with the termination of certain employees, and (iii) issued 116,973&#160;shares of our common stock upon the exercise of options held by an executive with an exercise price of $0.02&#160;per share.&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;,&#160;we (i) granted stock options to purchase an aggregate of&#160;2,519,628 shares of our common stock with exercise prices ranging from $2.72&#160;to $7.22 per share to executives, employees, board members,&#160;and consultants, (ii) cancelled options to purchase 118,507 shares of common stock with&#160;exercise prices ranging from $1.45&#160;to&#160;$7.22 per share due&#160;to the termination&#160;of former employees, and (iii) issued 670,889&#160;shares of our&#160;common stock upon the exercise of options held by consultants, a former board member, and a former executive, with exercise prices ranging from&#160;$0.015&#160;to $2.15 per share.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The weighted average remaining contractual term for the outstanding options at &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; is 7.08&#160;and 7.24&#160;years, respectively.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Stock option activity for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively, is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Shares&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Avg. Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,844,069&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.81&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,519,628&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.26&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;670,889&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.01&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118,507&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3.00&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,574,301&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.35&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,983,666&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116,973&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.02&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;66,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.55&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,374,327&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.08&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;6,718,035&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;3.23&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;,&#160;our total share-based compensation was approximately $4.7&#160;million, of which approximately $4.6&#160;million&#160;represents the vesting of options and warrants issued to service providers, executives, employees, and board members. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, our&#160;total compensation cost related to non-vested time-based stock option awards and warrants granted to executives, employees, board&#160;members, and service providers and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet recognized was approximately $6.5&#160;million. We&#160;expect&#160;to record this stock-based compensation expense over the next &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;years using a graded vesting method. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;,&#160;the weighted average term over which these expenses are expected to be recognized is 1.76 years.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;,&#160;there are&#160;no&#160;performance-based stock option awards outstanding and one performance-based warrant outstanding issued to a service provider.&#160;Our total compensation cost related to the non-vested performance-based warrant&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet recognized was approximately $300,000.&#160;The entirety of this warrant &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be recognized and recorded upon the achievement of certain milestones.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In the year ended &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, the Company's total share-based compensation was approximately $5.4&#160;million with approximately $5.2&#160;million representing the vesting of options issued to service providers, employees, and board members.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c96224298"
      unitRef="Share">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c96224299"
      unitRef="USDPerShare">6.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-10_2021-02-10_CounterpartyNameAxis-InvestorsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c96224300"
      unitRef="USD">23200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-03-01_2023-03-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c96224302"
      unitRef="USD">3600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gnpx:CommonStockSharesAuthorizedValue
      contextRef="d_2022-11-18_2022-11-18_RangeAxis-MaximumMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="-7"
      id="c96224304"
      unitRef="USD">50000000</gnpx:CommonStockSharesAuthorizedValue>
    <gnpx:BrokerageCommissionsPercentageOfGrossProceeds
      contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="2"
      id="c96224309"
      unitRef="Pure">0.030</gnpx:BrokerageCommissionsPercentageOfGrossProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="INF"
      id="c96224310"
      unitRef="Share">3886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-11-18_2022-11-18_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="INF"
      id="c96224311"
      unitRef="USD">4532</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c96224313"
      unitRef="Share">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c96224314"
      unitRef="USD">42400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224315"
      unitRef="Share">13643</gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224316"
      unitRef="Share">116973</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96224317"
      unitRef="Share">76752</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96224318"
      unitRef="USD">99010</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224319"
      unitRef="Share">670889</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224320"
      unitRef="USD">677912</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <gnpx:StockIssuedDuringPeriodSharesWarrantsIssued
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224321"
      unitRef="Share">86138</gnpx:StockIssuedDuringPeriodSharesWarrantsIssued>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_TitleOfIndividualAxis-ConsultantMember"
      decimals="INF"
      id="c96224323"
      unitRef="USD">154648</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2018-04-03"
      decimals="INF"
      id="c96224325"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2018-04-03"
      decimals="INF"
      id="c96224327"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2018-04-03"
      decimals="INF"
      id="c96224329"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2018-04-03"
      decimals="INF"
      id="c96224331"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224332"
      unitRef="Share">48105962</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343487">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Warrants&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Avg. Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,154,747&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.37&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.29&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Cancelled or expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,204,747&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.39&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;103,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.54&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Cancelled or expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;146,326&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.79&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,643&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.50&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,147,778&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.32&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;1,901,945&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;4.59&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96224435"
      unitRef="Share">2154747</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96224436"
      unitRef="USDPerShare">4.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224437"
      unitRef="Share">50000</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224438"
      unitRef="USDPerShare">5.29</gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224439"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightCancelledDuringPeriod>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224440"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224441"
      unitRef="Share">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224442"
      unitRef="USDPerShare">0</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224443"
      unitRef="Share">2204747</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224444"
      unitRef="USDPerShare">4.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224445"
      unitRef="Share">103000</gnpx:ClassOfWarrantOrRightIssuedInPeriod>
    <gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224446"
      unitRef="USDPerShare">1.54</gnpx:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224447"
      unitRef="Share">146326</gnpx:ClassOfWarrantOrRightCancelledDuringPeriod>
    <gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224448"
      unitRef="USDPerShare">3.79</gnpx:ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224449"
      unitRef="Share">13643</gnpx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224450"
      unitRef="USDPerShare">0.50</gnpx:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224451"
      unitRef="Share">2147778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224452"
      unitRef="USDPerShare">4.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:ClassOfWarrantOrRightExercisable
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224453"
      unitRef="Share">1901945</gnpx:ClassOfWarrantOrRightExercisable>
    <gnpx:ClassOfWarrantOrRightExercisableExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224454"
      unitRef="USDPerShare">4.59</gnpx:ClassOfWarrantOrRightExercisableExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember"
      decimals="INF"
      id="c96224334"
      unitRef="Share">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProviderMember"
      decimals="INF"
      id="c96224335"
      unitRef="USDPerShare">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member"
      decimals="INF"
      id="c96224337"
      unitRef="Share">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServiceProvider2Member"
      decimals="INF"
      id="c96224338"
      unitRef="USDPerShare">1.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember"
      decimals="INF"
      id="c96224339"
      unitRef="Share">3000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-WarrantForServicesProvidedAtIpoMember"
      decimals="INF"
      id="c96224341"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224342"
      unitRef="Share">13643</gnpx:StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_ClassOfWarrantOrRightAxis-VestingOfWarrantsForServiceProviderMember"
      decimals="INF"
      id="c96224343"
      unitRef="USD">55612</us-gaap:AllocatedShareBasedCompensationExpense>
    <gnpx:SharebasedPaymentArrangementExpenseFutureMilestone
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-TimeBasedOptionsMember"
      decimals="INF"
      id="c96224345"
      unitRef="USD">90689</gnpx:SharebasedPaymentArrangementExpenseFutureMilestone>
    <gnpx:SharebasedPaymentArrangementExpenseFutureMilestone
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c96224346"
      unitRef="USD">300000</gnpx:SharebasedPaymentArrangementExpenseFutureMilestone>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember"
      decimals="INF"
      id="c96224347"
      unitRef="Share">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantOneMember"
      decimals="INF"
      id="c96224348"
      unitRef="USDPerShare">7.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember"
      decimals="INF"
      id="c96224349"
      unitRef="Share">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantTwoMember"
      decimals="INF"
      id="c96224350"
      unitRef="USDPerShare">3.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-BearCreekCapitalWarrantsMember"
      decimals="INF"
      id="c96224352"
      unitRef="USD">200282</us-gaap:AllocatedShareBasedCompensationExpense>
    <gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear
      contextRef="i_2018-04-03_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="2"
      id="c96224362"
      unitRef="Pure">0.05</gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-01-01_2021-01-01_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c96224366"
      unitRef="Share">2155884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2022-01-01_2022-01-01_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c96224367"
      unitRef="Share">2393735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-12-31_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c96224368"
      unitRef="Share">481772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c96224373"
      unitRef="Share">208050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear
      contextRef="i_2018-04-03_PlanNameAxis-The2018EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c96224374"
      unitRef="Pure">0.02</gnpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224377"
      unitRef="Share">11374327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31_PlanNameAxis-ExcludingThe2018EquityIncentivePlanMember"
      decimals="INF"
      id="c96224378"
      unitRef="Share">950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      id="c96224381">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      id="c96224382">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224384"
      unitRef="USDPerShare">0.298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224386"
      unitRef="USDPerShare">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224387"
      unitRef="USDPerShare">0.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224388"
      unitRef="USDPerShare">7.93</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343488">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Expected term (in years):&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c96224456"&gt;10&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Risk-free rate:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0.07% &#x2013; 4.77%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Volatility:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;75.98% &#x2013; 88.38%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Dividend yield:&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;0%&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c96224458"
      unitRef="Pure">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c96224460"
      unitRef="Pure">0.0477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c96224461"
      unitRef="Pure">0.7598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c96224463"
      unitRef="Pure">0.8838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96224465"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224389"
      unitRef="Share">2983666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224391"
      unitRef="USDPerShare">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224392"
      unitRef="USDPerShare">3.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224393"
      unitRef="Share">66667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224395"
      unitRef="USDPerShare">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224396"
      unitRef="USDPerShare">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224397"
      unitRef="Share">116973</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224399"
      unitRef="USDPerShare">0.02</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224400"
      unitRef="Share">2519628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224401"
      unitRef="USDPerShare">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224403"
      unitRef="USDPerShare">7.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224404"
      unitRef="Share">118507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224405"
      unitRef="USDPerShare">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224406"
      unitRef="USDPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224408"
      unitRef="Share">670889</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c96224409"
      unitRef="USDPerShare">0.015</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c96224411"
      unitRef="USDPerShare">2.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2022-01-01_2022-12-31" id="c96224413">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c96224415">P7Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343489">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Shares&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Avg. Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,844,069&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.81&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,519,628&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.26&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;670,889&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.01&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;118,507&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3.00&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,574,301&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.35&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,983,666&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116,973&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.02&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;"&gt;Options expired&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;66,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.55&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,374,327&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.08&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 74%"&gt; &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;6,718,035&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;$&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;3.23&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96224469"
      unitRef="Share">6844069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c96224470"
      unitRef="USDPerShare">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224471"
      unitRef="Share">2519628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224472"
      unitRef="USDPerShare">4.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224473"
      unitRef="Share">670889</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224474"
      unitRef="USDPerShare">1.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224475"
      unitRef="Share">118507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96224476"
      unitRef="USDPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224477"
      unitRef="Share">8574301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96224478"
      unitRef="USDPerShare">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224479"
      unitRef="Share">2983666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224480"
      unitRef="USDPerShare">2.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224481"
      unitRef="Share">116973</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224482"
      unitRef="USDPerShare">0.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224483"
      unitRef="Share">66667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224484"
      unitRef="USDPerShare">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224485"
      unitRef="Share">11374327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224486"
      unitRef="USDPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224487"
      unitRef="Share">6718035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224488"
      unitRef="USDPerShare">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96224418"
      unitRef="USD">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96224419"
      unitRef="USD">4600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96224421"
      unitRef="USD">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c96224423">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="-3"
      id="c96224424"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember"
      decimals="INF"
      id="c96224425"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <gnpx:WarrantNonvestedAwardCostNotYetRecognizedAmount
      contextRef="i_2022-12-31_ClassOfWarrantOrRightAxis-PerformancebasedWarrantMember"
      decimals="INF"
      id="c96224427"
      unitRef="USD">300000</gnpx:WarrantNonvestedAwardCostNotYetRecognizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96224428"
      unitRef="USD">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c96224429"
      unitRef="USD">5200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343490">
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;&#160;- &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Savings&#160;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; we established a defined-contribution savings plan under Section&#160;&lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) of the Internal Revenue Code (&lt;em style="font: inherit;"&gt;"401&lt;/em&gt;(k) Plan") and established an employer matching program for participants in the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan. The &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan covers all&#160;employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a&#160;pre-tax basis. We&#160;incurred&#160;$74,281 of expense for matching contributions to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan during the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&#160;&lt;/p&gt;
  </us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96224496"
      unitRef="USD">74281</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343491">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&#160;- Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Introgen Research Institute&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;Introgen Research Institute (&#x201c;IRI&#x201d;) is a Texas-based technology company formed by Rodney Varner, our President, Chief Executive Officer and Chairman of the Board and IRI's sole officer. IRI is owned by trusts of which Mr. Varner's descendants are the sole beneficiaries. In &lt;em style="font: inherit;"&gt; April 2009, &lt;/em&gt;prior to Mr. Varner becoming an officer and director of our Company in &lt;em style="font: inherit;"&gt; August 2012, &lt;/em&gt;we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This agreement was amended in &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; to include additional sublicensing of additional intellectual property made available to IRI from MD Anderson (See Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Commitments and Contingences &#x2013; Commitments &#x2013; MD Anderson Cancer Center).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343492">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;&#160;- Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; April 16, 2018, &lt;/em&gt;we executed a space utilization agreement with the Board of Regents of the University of Texas System to establish and lease offices at the Dell Medical School in Austin, Texas. On &lt;em style="font: inherit;"&gt; March 23, 2021, &lt;/em&gt;we were&#160;informed&#160;by Dell Medical School that the University of Texas desired to use the space and&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; renew&#160;the space utilization agreement.&#160;The lease terminated&#160;on &lt;em style="font: inherit;"&gt; April 30, 2021, &lt;/em&gt;and all our employees are currently working virtually while we evaluate future space needs post the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Commitments&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;MD Anderson&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; July 2018, &lt;/em&gt;we entered into a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on the combination of REQORSA with an immunotherapy&#160;with a projected total cost of approximately $2 million. This agreement&#160;was extended beyond the original expiration date. This agreement expired in &lt;em style="font: inherit;"&gt; May 2022. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;we entered into a&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year sponsored research agreement with MD Anderson to sponsor preclinical studies focused on REQORSA and other potential product candidates in oncology&#160;to resensitize NSCLC and SCLC to targeted therapies and immunotherapies&#160;with a projected total cost of approximately $2.9&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt;2011,&lt;/em&gt; we agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated with certain technologies&#160;and intellectual property originally licensed to another party under the &lt;em style="font: inherit;"&gt;1994&lt;/em&gt; License Agreement with MD Anderson (&#x201c;Original MD Anderson License Agreement&#x201d;). These technologies and intellectual property were later sublicensed to IRI (the &#x201c;IRI Sublicense&#x201d;). We&#160;also agreed to pay royalties of 1% on sales of certain licensed products for a period of 21 years following the termination of the later of the Original MD Anderson License Agreement and the&#160;IRI Sublicense. The Company assumed patent prosecution costs and an annual minimum royalty of $20,000&#160;payable to the National Institutes of Health.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 3, 2021, &lt;/em&gt;we entered into an amendment (the &#x201c;MD License Amendment&#x201d;) to the Patent and Technology License Agreement dated &lt;em style="font: inherit;"&gt; May 4, 2020, &lt;/em&gt;with MD Anderson. The MD License&#160;Amendment grants us with&#160;a worldwide, exclusive, sublicensable license to an additional portfolio of &lt;em style="font: inherit;"&gt;six&lt;/em&gt; patents and &lt;em style="font: inherit;"&gt;one&lt;/em&gt; patent application and related technology for methods for treating&#160;cancer by administration of a &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; therapy in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to &lt;em style="font: inherit;"&gt;TUSC2&lt;/em&gt; therapy. Pursuant to the MD License&#160;Amendment, we&#160;agreed to (i) pay annual maintenance fees ranging from the mid &lt;em style="font: inherit;"&gt;five&lt;/em&gt; figures to the low &lt;em style="font: inherit;"&gt;six&lt;/em&gt; figures, (ii) total milestone payments of $6,150,000, (iii) a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time fee in the mid &lt;em style="font: inherit;"&gt;five&lt;/em&gt;&#160;figures and (iv) certain patent related expenses.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: -9pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;National Institutes of Health&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;We have a royalty obligation to the National Institutes of Health ("NIH") to be paid upon our receipt of FDA approval using NIH technology.&#160;The $240,000 contingent obligation which increases annually by $20,000 and is $340,000 as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, will be recognized when we obtain regulatory approval (the event that triggers the payment obligation).&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify; text-indent: -9pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;University of Pittsburgh&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Pursuant to an exclusive license agreement dated &lt;em style="font: inherit;"&gt; February 11, 2020 &lt;/em&gt;by and between us and the University of Pittsburgh, amended on &lt;em style="font: inherit;"&gt; August 17, 2022, &lt;/em&gt;and amended again on&#160;&lt;em style="font: inherit;"&gt; November 3, 2022, &lt;/em&gt;we agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years and $40,000 for each subsequent year following the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of a glucagon promoter and&#160;gene therapy technologies to potentially treat Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) &lt;em style="font: inherit;"&gt;20&lt;/em&gt; years after&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Pursuant to an&#160;exclusive license agreement dated &lt;em style="font: inherit;"&gt; November 22, 2022&#160;&lt;/em&gt;by and between us and the University of Pittsburgh, we&#160;agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years and $40,000 for each subsequent year following the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of a macrophage technology&#160;and&#160;gene therapy technologies to potentially treat Type &lt;em style="font: inherit;"&gt;1&lt;/em&gt; diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) &lt;em style="font: inherit;"&gt;20&lt;/em&gt; years after&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;Pursuant to an&#160;exclusive license agreement dated &lt;em style="font: inherit;"&gt; December 29, 2022&#160;&lt;/em&gt;by and between us&#160;and the University of Pittsburgh, we&#160;agreed to pay (i) an initial licensing fee of $25,000, (ii) annual maintenance fees of $25,000 for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years and $40,000 for each subsequent year following the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of the agreement, (iii) royalties ranging from 1.5% to 3%&#160;of net sales of licensed technologies, (iv) an annual minimal royalty payment of $250,000 per year beginning in the year of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of licensed technology, (v) a share of non-royalty sublicense income of 20%, and (vi) an aggregate of $3,975,000 in milestone payments related to the usage of an insulin&#160;promoter and&#160;gene therapy technologies to potentially treat Type &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;diabetes. Unless earlier terminated pursuant to its terms, the agreement expires upon the later of (i) &lt;em style="font: inherit;"&gt;20&lt;/em&gt; years after&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of the licensed technology thereunder and (ii) expiration of the last valid claim under the patent rights.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Contract Development and Manufacturing Organization&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;We entered into a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year&#160;development services agreement in &lt;em style="font: inherit;"&gt; July 2022&#160;&lt;/em&gt;with a contract development and manufacturing organization to manufacture&#160;GMP grade materials for use in our clinical trials with a projected total cost of approximately $2.5&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contingencies&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our financial condition, results of operations or liquidity.&lt;/p&gt;
   &lt;p style="text-align: justify; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2018-07-01_2018-07-31_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-6"
      id="c96224508"
      unitRef="USD">2000000</gnpx:LongTermContractEstimatedCost>
    <gnpx:LongTermContractEstimatedCost
      contextRef="d_2022-09-30_2022-09-30_CounterpartyNameAxis-MdAndersonMember_TypeOfArrangementAxis-ResearchAgreementMember"
      decimals="-5"
      id="c96224511"
      unitRef="USD">2900000</gnpx:LongTermContractEstimatedCost>
    <gnpx:RoyaltyOnSalesPercentage
      contextRef="i_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="2"
      id="c96224515"
      unitRef="Pure">0.01</gnpx:RoyaltyOnSalesPercentage>
    <gnpx:RoyaltyTerms
      contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      id="c96224516">P21Y</gnpx:RoyaltyTerms>
    <gnpx:RoyaltyPaymentAnnualMinimum
      contextRef="d_2009-01-01_2009-12-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c96224517"
      unitRef="USD">20000</gnpx:RoyaltyPaymentAnnualMinimum>
    <gnpx:LicenseAgreementMilestonePayment
      contextRef="i_2021-03-03_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-LicenseAgreementTermsMember"
      decimals="INF"
      id="c96224526"
      unitRef="USD">6150000</gnpx:LicenseAgreementMilestonePayment>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c96224531"
      unitRef="USD">240000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <gnpx:ContingentPaymentsAnnualIncrease
      contextRef="d_2017-01-01_2017-03-31_CounterpartyNameAxis-NationalInstituteOfHealthMember"
      decimals="INF"
      id="c96224532"
      unitRef="USD">20000</gnpx:ContingentPaymentsAnnualIncrease>
    <us-gaap:OtherCommitment
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96224533"
      unitRef="USD">340000</us-gaap:OtherCommitment>
    <gnpx:LicensingFeeAmount
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224536"
      unitRef="USD">25000</gnpx:LicensingFeeAmount>
    <gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224537"
      unitRef="USD">25000</gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount>
    <gnpx:AnnualMaintenanceFeeAfterYearThreeAmount
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224541"
      unitRef="USD">40000</gnpx:AnnualMaintenanceFeeAfterYearThreeAmount>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="3"
      id="c96224544"
      unitRef="Pure">0.015</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c96224545"
      unitRef="Pure">0.03</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:AnnualRoyaltyPaymentPerYearMinimum
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224547"
      unitRef="USD">250000</gnpx:AnnualRoyaltyPaymentPerYearMinimum>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c96224549"
      unitRef="Pure">0.20</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:MilestonePayment
      contextRef="i_2020-02-11_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224550"
      unitRef="USD">3975000</gnpx:MilestonePayment>
    <gnpx:LicensingFeeAmount
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224554"
      unitRef="USD">25000</gnpx:LicensingFeeAmount>
    <gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224555"
      unitRef="USD">25000</gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount>
    <gnpx:AnnualMaintenanceFeeAfterYearThreeAmount
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224558"
      unitRef="USD">40000</gnpx:AnnualMaintenanceFeeAfterYearThreeAmount>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="3"
      id="c96224560"
      unitRef="Pure">0.015</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c96224561"
      unitRef="Pure">0.03</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:AnnualRoyaltyPaymentPerYearMinimum
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224562"
      unitRef="USD">250000</gnpx:AnnualRoyaltyPaymentPerYearMinimum>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c96224564"
      unitRef="Pure">0.20</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:MilestonePayment
      contextRef="i_2022-11-22_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224565"
      unitRef="USD">3975000</gnpx:MilestonePayment>
    <gnpx:LicensingFeeAmount
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224570"
      unitRef="USD">25000</gnpx:LicensingFeeAmount>
    <gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224571"
      unitRef="USD">25000</gnpx:AnnualMaintenanceFeeFirstThreeYearsAmount>
    <gnpx:AnnualMaintenanceFeeAfterYearThreeAmount
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224575"
      unitRef="USD">40000</gnpx:AnnualMaintenanceFeeAfterYearThreeAmount>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="3"
      id="c96224578"
      unitRef="Pure">0.015</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="2"
      id="c96224579"
      unitRef="Pure">0.03</gnpx:RoyaltyPercentLicensedTechnologyCoveredByPatent>
    <gnpx:AnnualRoyaltyPaymentPerYearMinimum
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224581"
      unitRef="USD">250000</gnpx:AnnualRoyaltyPaymentPerYearMinimum>
    <gnpx:ShareOfNonroyaltySublicenseIncomePercent
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="1"
      id="c96224583"
      unitRef="Pure">0.20</gnpx:ShareOfNonroyaltySublicenseIncomePercent>
    <gnpx:MilestonePayment
      contextRef="i_2022-12-29_CounterpartyNameAxis-UniversityOfPittsburghMember_StatementScenarioAxis-UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember_TypeOfArrangementAxis-LicenseAgreementMember"
      decimals="INF"
      id="c96224585"
      unitRef="USD">3975000</gnpx:MilestonePayment>
    <gnpx:DevelopmentServicesAgreementExpectedTotalProjectCost
      contextRef="i_2022-07-31_TypeOfArrangementAxis-DevelopmentAndManufacturingOfGMPGradeMaterialsMember"
      decimals="-5"
      id="c96224591"
      unitRef="USD">2500000</gnpx:DevelopmentServicesAgreementExpectedTotalProjectCost>
    <gnpx:EffectOfCovid19PandemicTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343493">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt;&#160;- Significant Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="color:#000000;"&gt;The COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt;&#160;pandemic continues to have a major impact in the U.S. and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in continued impact from this pandemic in the future, which could adversely impact our operations.&#160;Through &lt;em style="font: inherit;"&gt; March 31, 2021,&#160;&lt;/em&gt;we had&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any material impact on its financial results or operations&#160;as a result of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic. Beginning in &lt;em style="font: inherit;"&gt; June 2021, &lt;/em&gt;we experienced&#160;delays in engaging clinical sites as a result of a backlog of clinical trial protocols requiring review created by an accumulation of clinical trial protocols. We also have&#160;experienced disruptions in our supply chain regarding our manufacturing and testing operations.&#160;We continue&#160;to closely monitor the impact of the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic on its business and workforce.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </gnpx:EffectOfCovid19PandemicTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343494">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;&#x2013; Income Taxes &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.&#160; The sources and tax effects of the differences are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Income tax provision at the federal statutory rate&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Effect of operating losses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(21&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, we&#160;have&#160;a net operating loss carryforward of approximately $68.9&lt;span style="font-size: 10pt;"&gt;&#160;million&lt;/span&gt;&#160;for Federal and state purposes.&#160;This loss will be available to offset future taxable income.&#160;If &lt;em style="font: inherit;"&gt;not&lt;/em&gt; used, this carryforward will begin to expire in &lt;em style="font: inherit;"&gt;2030.&lt;/em&gt; The deferred tax asset relating to the operating loss carryforward has been fully reserved at&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;.&#160;The principal differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense.&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343495">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Income tax provision at the federal statutory rate&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Effect of operating losses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(21&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 87%;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96224624"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96224625"
      unitRef="Pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96224626"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96224620"
      unitRef="USD">68900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343496">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt;&#160;&#x2013; Subsequent Events &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;&lt;b&gt;Reserves of &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 1, 2023, &lt;/em&gt;the total shares of common stock reserved under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan increased by 2,405,298 shares. On &lt;em style="font: inherit;"&gt; February 16, 2023,&#160;&lt;/em&gt;the our Board of Directors determined that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional shares would be reserved during the &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;fiscal year for the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Employee Stock Purchase Plan given that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; shares have yet been issued under the plan.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Share Issuances&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 1, 2023, &lt;/em&gt;we issued 5,000 shares of common stock to&#160;the Chairman of our Scientific Advisory Board&#160;in consideration for services. During &lt;em style="font: inherit;"&gt; January 2023, &lt;/em&gt;we issued 53,592 shares of common stock for aggregate net proceeds of&#160;$78,355&#160;under the&#160;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; ATM Facility.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Option&#160;Issuances&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 17, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt; January 23, 2023, &lt;/em&gt;and &lt;em style="font: inherit;"&gt; January 30, 2023,&#160;&lt;/em&gt;we&#160;issued grants of stock options&#160;under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan&#160;to purchase a total of 82,500 shares of common stock to new employees&#160;at the fair market value of the common stock on the date of issuance.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;&lt;i&gt;Warrant Issuance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 16, 2023, &lt;/em&gt;we issued a warrant to purchase up to 30,000 shares of its common stock at an exercise price of $1.65&#160;per share to a consultant for services.&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Restricted Stock Units&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 18,&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; our Board of Directors approved the recommendations of the Company's Compensation Committee&#160;for the grant of restricted stock units (&#x201c;RSUs&#x201d;)&#160;pursuant to the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan&#160;in the aggregate of 353,195 RSUs to non-executive employees.&#160;Each of these RSU grants vest in installments of 50% on the &lt;span style="-sec-ix-hidden:c96224648"&gt;first&lt;/span&gt; anniversary of the date of grant and the remaining 50% on the &lt;span style="-sec-ix-hidden:c96224650"&gt;second&lt;/span&gt; anniversary of the date of grant. Vested RSUs will be settled&#160;in shares of common stock on a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-to-&lt;em style="font: inherit;"&gt;one&lt;/em&gt; basis.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b style="font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Executive Compensation&lt;/i&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; February 18, 2023, &lt;/em&gt;our Board of Directors approved the recommendations of the Company's Compensation Committee for (i) annual incentive awards of an aggregate of $972,720 and (ii) the grant of RSUs&#160;pursuant to the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan in the aggregate of 1,560,000&#160;RSUs to our executive officers.&#160;Each of these RSU grants vest in installments of 50% on the &lt;span style="-sec-ix-hidden:c96224657"&gt;first&lt;/span&gt; anniversary of the date of grant and the remaining 50% on the &lt;span style="-sec-ix-hidden:c96224659"&gt;second&lt;/span&gt; anniversary of the date of grant. Vested RSUs will be settled in shares of common stock on a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-to-&lt;em style="font: inherit;"&gt;one&lt;/em&gt; basis.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Registered Direct Offering&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; March 1, 2023, &lt;/em&gt;we&#160;completed a registered direct offering, in which we&#160;sold to an accredited healthcare-focused institutional investor an aggregate of 3,809,524 shares of our common stock and warrants to purchase up to 3,809,524 shares of our common stock, at a combined offering price of $1.05 per share of common stock and accompanying warrant. The warrants are exercisable immediately upon issuance, expire 5 years from the date of issuance and have an exercise price of $1.10 per share. We&#160;received net proceeds of approximately $3.6 million after commissions and estimated expenses, excluding any proceeds that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be received in the future from any exercise of the warrants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2023-01-01_2023-01-01_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224631"
      unitRef="Share">2405298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2023-01-01_2023-01-01_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ScientificAdvisoryBoardChairmanMember"
      decimals="INF"
      id="c96224636"
      unitRef="Share">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="INF"
      id="c96224637"
      unitRef="Share">53592</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-01-01_2023-01-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-The2022AtmFacilityMember"
      decimals="INF"
      id="c96224638"
      unitRef="USD">78355</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-17_2023-01-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224641"
      unitRef="Share">82500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224642"
      unitRef="Share">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224643"
      unitRef="USDPerShare">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember"
      decimals="INF"
      id="c96224646"
      unitRef="Share">353195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="1"
      id="c96224647"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-NonexecutiveEmployeesMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="1"
      id="c96224649"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <gnpx:AnnualIncentiveAwards
      contextRef="d_2023-02-18_2023-02-18_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c96224653"
      unitRef="USD">972720</gnpx:AnnualIncentiveAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c96224655"
      unitRef="Share">1560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="1"
      id="c96224656"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2023-02-18_2023-02-18_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-The2018EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveOfficerMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember"
      decimals="1"
      id="c96224658"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c96224662"
      unitRef="Share">3809524</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224663"
      unitRef="Share">3809524</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <gnpx:EquityOfferingCombinedPurchasePrice
      contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c96224664"
      unitRef="USDPerShare">1.05</gnpx:EquityOfferingCombinedPurchasePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c96224665">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-01_ClassOfWarrantOrRightAxis-WarrantsIssuedWithRegisteredDirectOfferingMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c96224666"
      unitRef="USDPerShare">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2023-03-01_2023-03-01_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c96224667"
      unitRef="USD">3600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ErrorCorrectionTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2343497">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;&#160;&#x2013; Quarterly Data - Unaudited&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Revised Interim Financial Information&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following tables represent amounts previously reported and revised as a result of the immaterial error associated with the accounting for share-based compensation. See Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; for additional information.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended March 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,409,431&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,409,431&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,384,817&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,384,817&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;120,717,072&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;656,678&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121,373,750&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(83,740,337&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(656,678&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(84,397,015&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37,024,614&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37,024,614&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;34,565,123&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;34,565,123&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,153,838&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,153,838&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,898&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,898&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121,273,050&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,251,995&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;122,525,045&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(88,909,663&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,251,995&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(90,161,658&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;32,411,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;32,411,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;29,945,826&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;29,945,826&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,457,311&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,457,311&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,020&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,020&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;122,432,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,311,780&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;123,744,715&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(94,992,440&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,311,780&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(96,304,220&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,488,515&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,488,515&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;



    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended March 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,730&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,730&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,860,837&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;179,389&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,040,226&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,855,796&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(592,055&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,263,741&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,723,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(412,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,310,696&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating (loss) gain&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(5,723,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;412,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(5,310,696&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224825"&gt;(5,722,484&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224826"&gt;412,667&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224827"&gt;(5,309,817&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224831"&gt;(0.12&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224832"&gt;0.01&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224833"&gt;(0.11&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,879,597&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,879,597&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Six Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,543&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,543&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;13,273&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;13,273&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,737,028&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;189,899&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,926,927&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,597,865&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;369,288&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,967,153&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,431,499&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;405,417&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,836,916&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,287,295&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,638&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,100,657&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,175,070&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;595,316&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,770,386&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10,898,433&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;182,650&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,081,083&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224885"&gt;(5,175,070&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224886"&gt;(595,316&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224887"&gt;(5,770,386&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224888"&gt;(10,898,433&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224889"&gt;(182,650&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224890"&gt;(11,081,083&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,744&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,744&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,623&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,623&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224897"&gt;(5,169,326&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224898"&gt;(595,316&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224899"&gt;(5,764,642&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224900"&gt;(10,891,810&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224901"&gt;(182,650&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224902"&gt;(11,074,460&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224903"&gt;(0.11&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224904"&gt;(0.01&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224905"&gt;(0.12&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224906"&gt;(0.23&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224907"&gt;(0.00&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224908"&gt;(0.23&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,893,404&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,893,404&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,892,919&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,892,919&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Nine Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;19,497&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;19,497&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,593,309&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(435,578&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,157,731&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,191,174&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(66,290&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,124,884&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,511,121&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;495,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,006,484&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,798,416&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;308,725&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,107,141&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,110,654&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;59,785&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,170,439&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,009,087&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;242,435&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,251,522&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224957"&gt;(6,110,654&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224958"&gt;(59,785&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224959"&gt;(6,170,439&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224960"&gt;(17,009,087&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224961"&gt;(242,435&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224962"&gt;(17,251,522&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,877&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,877&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;34,500&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;34,500&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,082,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(59,785&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,142,562&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,974,587&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(242,435&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17,217,022&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.13&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.00&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.13&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.35&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.01&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.36&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,984,724&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,984,724&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,919,626&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,919,626&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

  </us-gaap:ErrorCorrectionTextBlock>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c3F47E9C7-B553-47EA-B8DF-84A466C866B8">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended March 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,409,431&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,409,431&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,384,817&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,384,817&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;120,717,072&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;656,678&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121,373,750&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(83,740,337&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(656,678&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(84,397,015&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37,024,614&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;37,024,614&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;34,565,123&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;34,565,123&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,153,838&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,153,838&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,898&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;47,898&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121,273,050&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,251,995&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;122,525,045&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(88,909,663&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,251,995&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(90,161,658&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;32,411,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;32,411,285&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Balance Sheet&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;29,945,826&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;29,945,826&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total liabilities&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,457,311&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,457,311&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,020&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,020&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additional paid-in capital&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;122,432,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,311,780&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;123,744,715&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated deficit&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(94,992,440&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,311,780&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(96,304,220&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stockholders' equity&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,488,515&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,488,515&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended March 31, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,730&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,730&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,860,837&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;179,389&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,040,226&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,855,796&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(592,055&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,263,741&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,723,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(412,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,310,696&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating (loss) gain&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(5,723,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;412,667&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(5,310,696&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224825"&gt;(5,722,484&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224826"&gt;412,667&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224827"&gt;(5,309,817&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224831"&gt;(0.12&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224832"&gt;0.01&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224833"&gt;(0.11&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,879,597&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,879,597&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Six Months Ended June 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,543&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,543&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;13,273&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;13,273&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,737,028&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;189,899&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,926,927&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,597,865&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;369,288&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,967,153&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,431,499&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;405,417&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,836,916&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,287,295&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,638&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,100,657&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,175,070&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;595,316&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,770,386&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10,898,433&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;182,650&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,081,083&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224885"&gt;(5,175,070&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224886"&gt;(595,316&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224887"&gt;(5,770,386&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224888"&gt;(10,898,433&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224889"&gt;(182,650&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224890"&gt;(11,081,083&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,744&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,744&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,623&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,623&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224897"&gt;(5,169,326&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224898"&gt;(595,316&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224899"&gt;(5,764,642&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224900"&gt;(10,891,810&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224901"&gt;(182,650&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c96224902"&gt;(11,074,460&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224903"&gt;(0.11&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224904"&gt;(0.01&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224905"&gt;(0.12&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224906"&gt;(0.23&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224907"&gt;(0.00&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224908"&gt;(0.23&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,893,404&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,893,404&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,892,919&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,892,919&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Three Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;As of and For the Nine Months Ended September 30, 2022&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Condensed Statement of Operations&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Previously Reported&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Adjusted&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;As Revised&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Revenues&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;6,224&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;19,497&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;19,497&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,593,309&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(435,578&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,157,731&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,191,174&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(66,290&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,124,884&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,511,121&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;495,363&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,006,484&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,798,416&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;308,725&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,107,141&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total costs and expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,110,654&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;59,785&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,170,439&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,009,087&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;242,435&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,251,522&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Operating loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224957"&gt;(6,110,654&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224958"&gt;(59,785&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224959"&gt;(6,170,439&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224960"&gt;(17,009,087&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224961"&gt;(242,435&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;span style="-sec-ix-hidden:c96224962"&gt;(17,251,522&lt;/span&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest income&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,877&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,877&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;34,500&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;34,500&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,082,777&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(59,785&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,142,562&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,974,587&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(242,435&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(17,217,022&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Loss per share&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.13&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.00&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.13&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.35&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.01&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(0.36&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,984,724&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,984,724&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,919,626&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;47,919,626&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:Assets
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224694"
      unitRef="USD">39409431</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224695"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224697"
      unitRef="USD">39409431</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224703"
      unitRef="USD">2384817</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224705"
      unitRef="USD">0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224707"
      unitRef="USD">2384817</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224711"
      unitRef="USD">47879</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224712"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224713"
      unitRef="USD">47879</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224714"
      unitRef="USD">120717072</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224715"
      unitRef="USD">656678</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224716"
      unitRef="USD">121373750</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224717"
      unitRef="USD">-83740337</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224718"
      unitRef="USD">-656678</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224719"
      unitRef="USD">-84397015</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224720"
      unitRef="USD">37024614</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224721"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c96224722"
      unitRef="USD">37024614</us-gaap:StockholdersEquity>
    <us-gaap:Assets
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224729"
      unitRef="USD">34565123</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224730"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224731"
      unitRef="USD">34565123</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224732"
      unitRef="USD">2153838</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224733"
      unitRef="USD">0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224734"
      unitRef="USD">2153838</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224735"
      unitRef="USD">47898</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224736"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224737"
      unitRef="USD">47898</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224738"
      unitRef="USD">121273050</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224739"
      unitRef="USD">1251995</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224740"
      unitRef="USD">122525045</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224741"
      unitRef="USD">-88909663</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224742"
      unitRef="USD">-1251995</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224743"
      unitRef="USD">-90161658</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224744"
      unitRef="USD">32411285</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224745"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-06-30"
      decimals="INF"
      id="c96224746"
      unitRef="USD">32411285</us-gaap:StockholdersEquity>
    <us-gaap:Assets
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224753"
      unitRef="USD">29945826</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224754"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224755"
      unitRef="USD">29945826</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224756"
      unitRef="USD">2457311</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224757"
      unitRef="USD">0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224758"
      unitRef="USD">2457311</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224759"
      unitRef="USD">48020</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224760"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224761"
      unitRef="USD">48020</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224762"
      unitRef="USD">122432935</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224763"
      unitRef="USD">1311780</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224764"
      unitRef="USD">123744715</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224765"
      unitRef="USD">-94992440</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224766"
      unitRef="USD">-1311780</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224767"
      unitRef="USD">-96304220</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224768"
      unitRef="USD">27488515</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224769"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c96224770"
      unitRef="USD">27488515</us-gaap:StockholdersEquity>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224783"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224784"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224785"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224789"
      unitRef="USD">6730</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224790"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224791"
      unitRef="USD">6730</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224795"
      unitRef="USD">1860837</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224796"
      unitRef="USD">179389</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224797"
      unitRef="USD">2040226</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224801"
      unitRef="USD">3855796</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224802"
      unitRef="USD">-592055</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224803"
      unitRef="USD">3263741</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224807"
      unitRef="USD">5723363</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224808"
      unitRef="USD">-412667</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224809"
      unitRef="USD">5310696</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224813"
      unitRef="USD">-5723363</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224814"
      unitRef="USD">412667</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224815"
      unitRef="USD">-5310696</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224819"
      unitRef="USD">879</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224820"
      unitRef="USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224821"
      unitRef="USD">879</us-gaap:InvestmentIncomeInterest>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2021-01-01_2021-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224837"
      unitRef="Share">47879597</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c96224839"
      unitRef="Share">47879597</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:Revenues
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224855"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224856"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224857"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224858"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224859"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224860"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Depreciation
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224861"
      unitRef="USD">6543</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224862"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224863"
      unitRef="USD">6543</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224864"
      unitRef="USD">13273</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224865"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224866"
      unitRef="USD">13273</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224867"
      unitRef="USD">2737028</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224868"
      unitRef="USD">189899</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224869"
      unitRef="USD">2926927</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224870"
      unitRef="USD">4597865</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224871"
      unitRef="USD">369288</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224872"
      unitRef="USD">4967153</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224873"
      unitRef="USD">2431499</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224874"
      unitRef="USD">405417</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224875"
      unitRef="USD">2836916</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224876"
      unitRef="USD">6287295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224877"
      unitRef="USD">-186638</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224878"
      unitRef="USD">6100657</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224879"
      unitRef="USD">5175070</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224880"
      unitRef="USD">595316</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224881"
      unitRef="USD">5770386</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224882"
      unitRef="USD">10898433</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224883"
      unitRef="USD">182650</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224884"
      unitRef="USD">11081083</us-gaap:CostsAndExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224891"
      unitRef="USD">5744</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224892"
      unitRef="USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224893"
      unitRef="USD">5744</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224894"
      unitRef="USD">6623</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224895"
      unitRef="USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224896"
      unitRef="USD">6623</us-gaap:InvestmentIncomeInterest>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-04-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224909"
      unitRef="Share">47893404</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-04-01_2022-06-30"
      decimals="INF"
      id="c96224911"
      unitRef="Share">47893404</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-01-01_2022-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224912"
      unitRef="Share">47892919</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-01-01_2022-06-30"
      decimals="INF"
      id="c96224914"
      unitRef="Share">47892919</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:Revenues
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224927"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224928"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224929"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224930"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224931"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224932"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Depreciation
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224933"
      unitRef="USD">6224</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224934"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224935"
      unitRef="USD">6224</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224936"
      unitRef="USD">19497</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224937"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224938"
      unitRef="USD">19497</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224939"
      unitRef="USD">3593309</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224940"
      unitRef="USD">-435578</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224941"
      unitRef="USD">3157731</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224942"
      unitRef="USD">8191174</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224943"
      unitRef="USD">-66290</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224944"
      unitRef="USD">8124884</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224945"
      unitRef="USD">2511121</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224946"
      unitRef="USD">495363</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224947"
      unitRef="USD">3006484</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224948"
      unitRef="USD">8798416</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224949"
      unitRef="USD">308725</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224950"
      unitRef="USD">9107141</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224951"
      unitRef="USD">6110654</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224952"
      unitRef="USD">59785</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224953"
      unitRef="USD">6170439</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224954"
      unitRef="USD">17009087</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224955"
      unitRef="USD">242435</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224956"
      unitRef="USD">17251522</us-gaap:CostsAndExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224963"
      unitRef="USD">27877</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224964"
      unitRef="USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224965"
      unitRef="USD">27877</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224966"
      unitRef="USD">34500</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224967"
      unitRef="USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224968"
      unitRef="USD">34500</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224969"
      unitRef="USD">-6082777</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224970"
      unitRef="USD">-59785</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224971"
      unitRef="USD">-6142562</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224972"
      unitRef="USD">-16974587</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224973"
      unitRef="USD">-242435</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224974"
      unitRef="USD">-17217022</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224975"
      unitRef="USDPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="c96224976"
      unitRef="USDPerShare">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224977"
      unitRef="USDPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224978"
      unitRef="USDPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="INF"
      id="c96224979"
      unitRef="USDPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224980"
      unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-07-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224981"
      unitRef="Share">47984724</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-07-01_2022-09-30"
      decimals="INF"
      id="c96224983"
      unitRef="Share">47984724</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-01-01_2022-09-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c96224984"
      unitRef="Share">47919626</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="d_2022-01-01_2022-09-30"
      decimals="INF"
      id="c96224986"
      unitRef="Share">47919626</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MSB<:JZM[/E'(O5,=,;"\*3%#8A5BO2VQ'MC2D1JJ?C9<IR%9ZDC!]?<D%#K
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MN@/ [W=*V><;]\*E?\&V_0]02P,$%     @ YX)_5I1$%0=( @  508  !@
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M0ZQAB?JJL'Y0?&=OVU9<*5[:Y19H#L((Z-_7G*N7!_.!]L)V^3]02P,$%
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MOW^7"!L_"N+&FR9<Q*?&XUH?EB4&&UDFP/G,X+K4;5C!^LML_!]02P,$%
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M"4<24C)I[9YL[IS3>PO8(*^L6C(/C3.@@BUN&W$U:3=D2M_+5:$&D[7<TTR
M2I;91@TR5]:U-=_896)->MZSGBN5R<;U,=5EJ7+-0;9#ISUV#+AH$'W]8-W)
ML++=4@Y)FSM4A9P;"DZ-%Z/+V^O1D5@@:^D_*G;)_)6CL7A/S":2E^(?C2%_
MU%9G4)X\@,A";O;XP- &,*.AO;Q3I$*0D1Z2X72I"U#ZLQ)>B:_/'/ZTE'9[
MFYE(+"K409GQRT<88-A!.G9H8+2IS(H:(0Y>"$MNH9"%,3<6%R0+QU-0WP#+
M@?7?-A:0I>QE>N[GZ5C.QIPRE@C\Y'%5T<@H661M(6U<EX=4&(@4CZE?$Z5"
MDN7"0 =^VR4;[5#KACJ!>^4ZT 3*B,1NJU&@K 21=)E**;0FWSZJ7Z\']>M#
MVWT12JC</%GH&,DY&^U"JCL?N,NQ_[/&4E\(YL3+O $MVE94U,E!*=_ /,7L
M4_8'4X#7C84IB*UO<O2-@\-%!I=PZ+EXJHUN,<$'DL^Q=MUP,)!B&RM+Q.TS
M)TFO6]'DBO(SQ)]U+ JY,FTU[C3%$NM1L^',4E;-&L ,5-G-\V%D/+@1_;D+
MFGZOX7X@9X?ZUE</0S @5BCKPNP5I7^%7HKDX*R6ZX-,BOT6U_!@0V?0HR!8
M12@B:ZC6$<@Z/4C S1:W69&<ID^'U#5U79 [ZP:O)75$;$YH"O5_\1QBP\XE
MFMJA40 GH[M!N1_/>?G/XXCZ[@GZ%OEC9WR(IZGA*.CB3H6FS[!'LW4WVR*-
MP5ZH36M<,#WO6J0'SX;4QK KAH9A1>*L5IZNP%YEV\H49A.2VE+:N<XO*B="
MYT8 (]RXB+USL0(FX0GZ#.+QQS/<)Q#7["B.\.,]ET!O]:H)89%T[HII1>&-
M*77611RO=^!FA"![K"]S(>/@!Q"'! OM2]7>H-A>LR*EN*!!0J<D/>N#/L7
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M>U/RD&JDLK0 []<&Q-8^T ']Q^^+_P%02P,$%     @ YX)_5KEF0O&S @
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M+?FP!O&F&#YA9#6BZ:LGN*<0BLET0/ZQWCW= ^7#)$47+;SW!9.9049F25$
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M2[,!Y L!9^GNCW'07])G_P-02P,$%     @ YX)_5K0Q398] @  _00  !D
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M\>@(LC3+!O#&O>YQQ!L/Z/9 %JZ5D:904L.2)"'7&[THN(6;O P76N?<-[+
MF>#>\.@>4.1OWXQ.T\\#9"<]V<D0.HM?\TH)EWRG3JUVL9X76AKX=8^/!'-M
MB^WOEU@/XW;)Y]0_RS?<F'C-1W%'A.'PXU1@O4(WF([DH"1K=)O8>!X*NS/4
M5F>_VO?V15O2_]W;A^%6NHUB5AK7')H>GYT(<&VSM0;9)A;XRA*W2YQ6_#ZA
M"PZ\O[:LLS/" ?V+E_\#4$L#!!0    ( .>"?U;TOOJ,Z (  #<&   9
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MM1N2%\ULV+HW$_9.V+G4#A06')KT/O%,LLW4:C9DJC I9H9X[H3E@@<]6N_
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MB$ '_)%JQ($T\3A!;!2!WX T+T0D-0@ )(T8(K(1I(A$7 O#%0PX&!$5<X/
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M'4!)3ZDIQ6(Z#%X&J0*&J2JA%B:(5DH@356$/_B6W H06Z:C%(DRP4H:Q50
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MHV'2MZOPI>:F[?NV#L.ER] ,T@:\OVWQ$W6<T '3I[OS7P%02P,$%     @
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ME7E!F?'3 PQP_$ Z9F@$6UV9%2&(G1?<DELH9(<Y9M'%QF(P-JXM#LK6WR,
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MPKP]L>T1$G(%FFV5:S@\2)S5RDM[+[S*MI4IS"90K"42=*U_R0 RXPH?+1B
M>"87*\06/$J7HQY_W,,' $I>=X1'X.&6BT-O]:H.\)*T[HKSE,(;4^JL12Y>
MWR'9 TK9H;Z<7!G//P1C((IP+JF:"QW>KUF14EPA04*K)#WKHS9%PX?Y45!
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M"SINP3'TR2VI+:USA&H.MZ::/2ZK/$6E?]UMC"7OPKU42I9&0Z6@$9"&/YN
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M],!#90UH?E[1Y;/MV 6Z)^/D;U!+ P04    " #G@G]6R:GN2UP"   =!0
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MTPFXXUU[YR9GWW\G(_'7 [Z9T3=SR/K9%:A:K"M'N/W0MDT+K-JVSWO/LKH
MFB5F+QT>!3LO_H/$ZB'[5XB(?70/';NHFOS3O_<%=W#[_<&=>_*&]@9[6+?
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MZ'&P%Q%C8Z[#'3'*CQ!)D&R"$ G"841@ ^>1:N! EGB< !M%R6] FF<020T
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M$A.XRNT.Z!)7\T0'4P=>-)Z.PLD+C:\#PTDX#2:34;?442MUU"OU#A42&6=
M> (KW)E3J3!GC-FV2J%=ZF4I)7:+'[T6/XF&TW#\0OOKN-#LJZ$7=DN/6NE1
MK_2/>4&HM&('<"/X]OS&'&=)+7P 'Y EY^:0/K]7?;LC>G-W]$4<Z1ZWNL>]
MNF\IIWF9PU^WF#^@_+M+5B^#O9@N54%BG#OFYE$H=^@L?OG)C[Q?N_[6'T1V
M9';2FIWTFEU+<U]*_32 -;.GH=UF]E<NZKR9Y*0E@QN:(IS]:79BY_G7/T4(
M3P:HNISW O^C\VGK?-J?9O+X9II[&;XWS3^([,BL[WV[!;W_/]%OS#$ZG>E^
MY/>Z=P_*@1SEMJJ2%%07>7V-MJ-M)795U1\OQJ]MA5:5&=]HZO+NELBMN1^
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M2H/:TB D$&:WWP! %O) 3UZF- !&%NB5&S6E80,#/8R!+TUIV,"($DE-Q@0
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M)4&-, 7\CI3SG)"#I3]<SX,5X5!$?7J>N=/S+Y7],+N^%:C[@5!VX0^S\]U
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M^D%--$-^HX 0:=;*K5#]9EAL0_WT263F3B*_7)+$[,3FJQ'9 ,@1W4!(6#@
M<DPY$'1$.JA)8M#QB'90RZ.QV(:?K>TSR=R=29Y0M<2!]"90M03 @*HE &57
M+0$@H&H)0$%52^X.F*L3J)5V<1.JSPR+;2B1/FW,W6EC5W'3R718W$1")FUY
M $B?!A$W3W\6(%+J_9A9;+V$D-W$0D-J9O9 :!!)X5L3B[L[9@L&<ASYD1^8
M&\P5JN,,BVVHFCZ/S-UYY-]=_W3B?:G^:01&33'!,&8J"8394PX(LW+#[JZ9
MK2#0J5D3N$)UFF&Q#=7S[#L?W*ECO#HIMZ.Y!26H; M4MB4J6XS*EJ"RI=Q.
M7X_44J'ZS;#8AA=%GPOG[ESX1_54-*=O,;JMBZKV;I7^L?G!>[?YWV/3=@DK
M9W&5FW_VM8#)MD!E6Z*RQ:AL"2I;BLJV0F7+L-B&UTN?]N?NM/^\HVPWV>R+
M Y-M@<JV1&6+4=D25+:4VX<QW6>FN/DM&BM4MQD6VU#W_6$&=Q]F3#QW=[/,
M%CPFVP*5;8G*%J.R):AL*;</8%Z-*![U! :+;:CX_@2&NT]@YAS?N:EFRQ[U
M@Q.H;$M4MAB5+4%E2SEP A9P:M8AK%"]9EAL0]'WQT;<?6PT[]C1339;]J@?
MK$!E6Z*RQ:AL"2I;RNWS+DD"9E:KKU"]9EAL0]GWIUU\RD<FIIV6NJEFBQZ3
M;8'*MD1EBU'9$E2VE /?AP2O<%#/Z;#8AM]]VI_3"?<YW<MGO&Z"N5I'95N@
MLBU1V6)4M@25+17V:>/(<A[5;X;%-A1[?^(H?O^)H]MTMLPQV1:H;$M4MAB5
M+4%E2P5XC@O*'/6(%(MM*//^B%1\HR-2-^_L:P"3;8'*MD1EBU'9$E2V5("G
MO-97)J$ZS;#8CA? Y;,'>^Q4?7]XD$SC'1[)<?R^__.[YX?5O#L\HL5X_SU]
MLZ# ^PE]DQX?1=/3'Y^,\R&O[XNR\;;J3KLBKZ6>2^KCPV:.+]IJ?WBLR.>J
M;:O=X=<'E6]4W0'TW^^JJOWZHG-P?N3/]?\!4$L#!!0    ( .>"?U8?LMH]
MP1L  %JP 0 9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;-7=?W.;2)['
M\:="^:ZN9JN\MD"_YS*I2@P-S8\9UR0[4U=7]P>Q<:P:27A <I*K?? '$C)J
MA%LB><>WLW_L) J\&L7I+]WPH7GU*<W^R.^39&5\7LR7^4]G]ZO5PX^7E_G-
M?;*(\XOT(5D6?W*79HMX5?PV^WB9/V1)?+O9:3&_M'J]T>4BGBW/7K_:?':=
MO7Z5KE?SV3*YSHQ\O5C$V9>WR3S]]-.9>;;[X-?9Q_M5^<'EZU</\<?D7;+Z
MQ\-U5OSN\DFYG2V293Y+ET:6W/UT]L;\,3)[HW*/S2:_S9)/^=ZOC?*[?$C3
M/\K?R-N?SGKE(27SY&95&G'QG\?D*IG/2ZHXD#\K]>RIT7+'_5_O=+'Y]L6W
M^1#GR54Z_WUVN[K_Z6QR9MPF=_%ZOOHU_>0EU3<:EMY-.L\W_V]\JK;MG1DW
MZWR5+JJ=BR-8S);;_\:?J[^)O1W,P3,[6-4.UJD[]*L=^J?N,*AV&)RZP[#:
M87CJ#J-JA]&I.XRK'<;-'8;/[#"I=IB<VL*TVF':V,'J/_>#Z^U^<KWF+L\=
ME/GTPS[YIVWN?MSFR3]O<_<#-S<_\<OMO\7-/V0[7L6O7V7I)R,KMR^\\A>;
MWK#9O_CW.UN6/??=*BO^=%;LMWK]<[I*C('Q=\/Y<SU;?3%^L)-5/)OGQOOD
M\VH=S_]6_-$_WMG&#__^MU>7JZ+!<K?+FPKWMKCU#&X:4;I<W>>&L[Q-;EOV
M]X_L;VF R^*;/GU=:_=UWUI:,8JS"Z-GGAM6S^JW'-"5?G<_7FIWM_6[_YP^
M7ACF9+.[U;*[<WKK;;L+_>XB^5"TWMOL;K;L[I[>>MONW@E_\_WG_^KD":UK
M=O?UN]O)S=/N;7]UP>F[MWWW\/3=>RV[1_K=WSR4_VC[Y>[F1-,)^D]]OK_Q
M!L]X[^[C+,D-F>?KY/;<N,YF-XEQG63&Y@^,'V9+XS:=S^,L-QZ*3_/RT[;>
M_U;;3#GF^#%_B&^2G\Z*046>9(_)V>O_^#=SU/O/MIY'8C:).20F2,PE,8_$
M)(GY6VRRP<JAZ./KWD6OZ,:/^SV8;#$DL0C"E+X^>.KK VU?O\[2FR2YS8V[
M+%ULNGR\+'I[>F=<I8M%,7)^MTIO_FCKW%JW:^<F,9O$'!(3).:2F$=BDL3\
M+3;<Z]RC@35J=.[#C:SA:#R>FJ:Z84@>6@1A2L<=/G7<H?XD7?;+ZAQMV.ML
MMOQ8GJ-G:7'&_BV>KY/SW1\6TW?C7=%Z<1;/VSJRMIVN'9G$;!)S2$R0F$MB
M'HE)$O.'!WW4'/6M?O,\W;+9<-0;#!L=F3RT",*4CCQZZLBCK^[(VY'XN>%\
M3K*;6;X]+\?Y_3S)<^/W.,OBY2K?#,@W@_"\=12N;;YK_R8QF\0<$A,DYI*8
M1V*2Q/PM-MKON/W1H-_HWF23(8E%$*84@?%3$1@?GW+__6V<%S6@&'@_),L\
MWERX?E/V\8_)(EFNC ]?C/WMKN,OFX_??(JSHE;\\E#NL%<L<J.H"]M*<JQ$
M: ^N:XD@,9O$'!(3).:2F$=BDL3\\6&),$?3<;-&'&XV&O<FDVEC"$ >6@1A
M2N^?//7^R;>.Y;>;5'W\J8NW73-_JVVK:V<F,9O$'!(3).:2F$=BDL1\$@LF
MA[/\<OK>F!R$9)L1A"E=?OK4Y:??/.I_&N!7FQTYB6L;[-KO2<PF,8?$!(FY
M).:1F"0QG\2"Z<&I?C(R^Y-&MR>;C"!,Z?9FK[Z?WCMRP3VY2[*LZ,Z;$K#K
M[<:;]>H^S6;_>[R?ZQOHVM%1S48U!]4$JKFHYJ&:1#4?U0)4"U$MJC1E?M+;
M_N^I(*G=?B]&8W;K]M=Q9I07YE?QJOAP,\K_JGOL^G8[5P-2LU'-036!:BZJ
M>:@F4<U'M0#50E2+*FVLQ@IZYC.EP*I+@?55(X!?UJM\%2]OBZG >1EH*Z<$
M;^/YYG[\L2&!ML7.18#4;%1S4$V@FHMJ'JI)5/,K;?]$V6M<PT,;#%$MHC2U
M -3Q.E.?K]M/UGS-^!^-U:&:C6H.J@E4<U'-0S6):GZE[7=VJ]<<%E>=_N1-
M0_08HY,:5KMKG9 S]1$YM;MBXW8T/X=J-JHYJ"90S44U#]4DJOF5]OQHMNK!
M)VT6HL<6'6U4[;EU1,[49^3:3K3GWS3.1K-RJ&:CFH-J M5<5/-03:*:7VG[
MI[7!Q.P-IZ-F:JYMR_%D/!CWFM?2T2.,*$WMX75VSM2'YZ[F<9Z7J;CJ7EEY
M:MX\7;J7F=L^OU)ODS]ME'<Y7Z,Q.E2S4<U!-8%J+JIYJ"91S:^T_8=:!A<'
M8=GVK9I!F?:MQNI6$77\:E>N$W#FRT7@E%/\S^O%AR3K?*I',W&H9J.:@VH"
MU5Q4\U!-HIIOMF7C^N-!WQHW^_SAEI-AL>'A(+TE1S<9#'JC:;/G?X_PFUFG
MW\PC\;=-C_YP8L__T-;SG<\/LVR[TR[Q^E])G+7W;#0@AVHVJCFH)E#-134/
MU22J^4?^]9L]XTOQ3[7MT:P /9 0U2)*4XM&G9\SCP3HOM=PX??-6B[%UF\>
MDRS^F#0F$JWCB!.G$&A"#]5L5'-03:":BVH>JDE4\RMM?]C?OVA>#PA:M^HW
M'[=KV<JZF)C-@<3WR-99=;;.TF?KR)K@;B\5/#U"4WZ2YD<?MM,?8=<^CFHV
MJCFH)E#-134/U22J^=9A9,V:3OJC4?,)^;8-A^9T9#6O#Z+'%U&:6A'JV)VE
MC]V=4A'RKR\)1\8*'<8&^N_1N6Z@,3Y4<U!-H)J+:AZJ253S*TT]GYL'1>-P
MJ\%%<_&-$#VRB-+4BE&G\RQ].H\<0X@TNTMFJW69[RFF%WM7*90J\CY=Q?.C
M PLTXH=J-JHYJ"90S44U#]4DJOG68<2O&%2,FA<C6S8SS<FP-V[6"#3 1VEJ
MC:@#?-8)"^2];(T 1QIH?!#5;%1S4$V@FHMJ'JI)5/.MP]7YK(OAL%E'MEOM
M/P#<;Y80-#%(:6H)J4.%ECY4^'*7+W]-R@6ZRRN65^ERE<4WY;*]QOLD6VCN
MD>B/OG.10-.)J.:@FD U%]4\5).HYA_I+>/M+1+#FAJW\9?66R6G"L9BNV*T
M-7J."M&O%E&:6FCJ#*1U) /Y?$)JKVX<G7V@P4=4LU'-036!:BZJ>:@F4<VW
M#N.,ECD8C\?-NQ=M&UJ]P7AP, %I$X>'&T;4%U'[:YUHM/2)QO?WR68=[]V"
M^W)Y4YSS9X_%0'\>+XW_CI(RS?0_K9T4C2BBFHUJ#JH)5'-1S4,UB6H^J@6H
M%J):1&EJ3:BCD=8)T4CCR&3A;359,%HG"]=)5M:1<D+PYN%A/BNV*/;?'P%4
MSR$V5OXNKT^4SR:FBZ+%FW@^WU2D+(G+Q4B7AA/?W!OE+**U'J$12E2S4<U!
M-8%J+JIYJ"91S4>U -5"5(LJ;;HWF.E=](;MSTM9=1#3.B6(^4T7);9AZ[**
MO+F]G94[Q_/NCSCKC[-SY4 CFJCF5)HR+.U/^^-F $>@S;IMS9K#X60R4)OU
MT&8EJOFH%J!:B&H1I:EUH<Y:6M\]:UG7A5TQ>(QG\_C#/-F\GV 3K3A:%=#\
M)*K9J.:@FD U%]4\5).HYEN'BQ,.)N9XW'P("VTU1+6(TM07B=6)S+X^D5E?
MS5@\S-,O25+-*J[7V<U].8<X>E%#WT#73H]J-JHYJ"90S44U#]4DJOFH%J!:
MB&H1I:FEH8YF]D^(9O[U+FKHOU7G>H0&-5'-036!:BZJ>:@F4<U'M0#50E2+
M*JUQ4<-JOZC1KP.=_>\>Z#R<O)Q\)4-_<)W+!1K;1#4'U02JN:CFH9I$-1_5
M E0+42WJ'R9/K=ZD-WQFO;?^WMN/]>E.Y_/-?+T9/:R^_EZLOHW._9Y]^3'[
M]F/V]<?L^X_9%R"S;T!F7X%,:@&JA:@649I:'>K@9E\?)/L76Z9&?[2=ZPRI
MV:CFH)I -1?5/%23J.97VOY9=SIL60D6;35$M8C2U I2)S+[^D3F^]EB=SUC
M]SXW[4@"C5ZBFHUJ#JH)5'-1S4,UB6H^J@6H%J):1&EJ':B3GOTC+WYN6\ZJ
M'D1L%K4J1A?)N2'6Y?-A1C2;)_DJ72:M90(-?Z*:C6H.J@E4<U'-0S6):GZE
M[3^P->V-FN]H#=!&0U2+*$WM_W6JLZ]/=5XGV5V:+3:C_.JZHG8<@*8I4<U&
M-0?5!*JYJ.:AFD0U']4"5 M1+:(TM0[4J<O^Z<M? N, -#J):C:J.:@F4,U%
M-0_5)*KY_<,W-_?;7@V#MAJB6D1I:@&HXY7]_Z>E++_RDB(:LT0U&]4<5!.H
MYJ*:AVH2U?S^8<SRH'B@"4M4BRA-*1Z#.F$Y.'W-R];1P[8T:*<6^B:Z]GA4
MLU'-036!:BZJ>:@F4<U'M0#50E2+*$TM#G7&<G#Z\I>ZJ45K44"#CJAFHYJ#
M:@+57%3S4$VBFE]I^Q.)P;AM)M&RX7#0]HI)]/@B2E.[<AUC'+S<NI2_)7FY
M0M3>\G(BGF7;EUFVE@(TQ(AJ-JHYJ"90S44U#]4DJOF#PVC?8-1:"JS#4F"U
ME@(T>DAI:BFH XJ#TY>?;#VK_YPN'[==O.KY5VF^*CY=&5^2E?%K<I-^7);A
MY7/CS2)=EWMLEJ!M[?IHCA'5;%1S4$V@FHMJ'JI)5/,'A^M CH:M71^-**):
M1&EJ?:@CB@-M@(FL#]7+M,I'M*N/-V..YQ>.U!]:YWI!:C:J.:@F4,U%-0_5
M)*KY1[J"N5GVT9CN5GWL/[M^)'I8(:I%E*;6DSJP.- '%G<K1Y9/3;XK]'*]
MZ>LL?9S=)IG^NB(:740U&]4<5!.HYJ*:AVH2U7Q4"U M1+6(TM2*4$<7!U_]
MVNV]9R63FW56C!>2W+B*Y_-BM/'ARW/OX-;<CM0?2N<B@@8;4<U!-8%J+JIY
MJ"91S:^T_8L/;0\XH(V&J!91FEH=ZF#C0!]LU%2'QELKZFV:!>&T=UGH#Z1S
M;4 SD:CFH)I -1?5/%23J.97VOZ[+,R+?G--:K3-$-4B2E-+0YUU'.BSCMJI
MA*6?3*#!1E2S4<U!-8%J+JIYJ"91S4>U -5"5(LH3:T)=?QQH(\_ONAD LTV
MHIJ-:@ZJ"51S4<U#-8EJ_N PV]@ZF4#SC:@649I2'89UOG&HSS>^W&1"?R!=
M:P.JV:CFH)I -1?5/%23J.97FCJ9&#0?H$3;#%$MHC2U--3IQJ$^W;BK"'?U
M9"+?S29NC7AER.M?M%,*O=^YQZ,11U1S4$V@FHMJ'JI)5/-1+4"U$-4B2E,K
M0QV6'.K#DB\YI= ?2N<B@H8C4<U!-8%J+JIYJ"91S1\>AB/[AS,*M,T0U2)*
M4XM#'9\<ZN.3+SBC0,.3J&:CFH-J M5<5/-03:*:/SP,3S;?LXTV&*):1&EJ
M7:ACDT-]5JQ\*J)\3'J_UW>./.G;Z-SE2<U&-0?5!*JYJ.:AFD0U']4"5 M1
M+:(TM3K4(<BA/@3Y+8]2ZNG.10'-0:*:@VH"U5Q4\U!-HII?:<HX8#@RF^^M
M0AL-42VB-+6WUP''H3[@^+9,C5]E2?*'<14_S%;Q_&FV\,LRT8\ T+PBJMFH
MYJ":0#47U3Q4DZCFHUJ :B&J192FUH0ZUCC\ZE@C?U$1#3:BFHUJ#JH)5'-1
MS4,UB6H^J@65IKR:97CX4#;::$1I:G6HDXU#?;+Q!:\JHD%(5+-1S4$U@6HN
MJGFH)E'-1[6@TO93#^,+RVJ6!C3@2&EJ::@#CD-]P%$SF7C_*=5/)M"\(JK9
MJ.:@FD U%]4\5).HYJ-:@&HAJD64IM2$41UK''UUK!&?3.@/I6L1034;U1Q4
M$ZCFHIJ':A+5?%0+*NW89 )M-*(TM3K4R<:1/MGX<I,)_8%TK@UH!!+5'%03
MJ.:BFH=J$M5\5 LJ;7\RT;_HCYJE 8TV4II:&NIHXT@?;7Q^,J%_?8R>[=S1
MT9@BJCFH)E#-134/U22J^:@6H%J(:A&EJ06ACC..OG$U2$TP04]W+@IH0!'5
M'%03J.:BFH=J$M5\5 M&AW%'J]>S)LV+B6BK$:6IW;U.*8ZT.:?]M\95[XS:
MS1&T9W\RBG6%:C:J.:@F4,U%-0_5)*KYJ!:@6HAJ$:6IY:".)8[TL43-E8*]
M5T$=O4*(!A11S48U!]4$JKFHYJ&:1#6_TO:OZ9F-<"+:8(AJ$:6I?;X.)X[T
MX<2JJW=?Y[VUZZ-Q152S4<U!-8%J+JIYJ"91S1\=OC>Z]7V1:*LAJD64IO;_
M.H@XT@<1W]W,BHG][&YV8[RY?9SE:?;%>)L6!<"XNH]GY=Q /Q= LX6H9J.:
M@VH"U5Q4\U!-HIJ/:@&JA:@649I:%^H(XNC(BZ17Z<T?ALSS=3$BL-=9.?#?
MO>!I^X+Y\]V?*DNF')L<H'E#5+-1S4$U@6HNJGFH)E'-KS3EAG_;  %=41'5
M(DI3"T$=.!P=>:&TIA!L7O+66@=:^SZ:/T0U&]4<5!.HYJ*:AVH2U?Q*4UX"
M:0T.^SX:+$2UB-*4OC^N@X7C(\'"=)FOYZMC-P3T2M>.C6HVJCFH)E#-134/
MU22J^:@6H%J(:A&EJ?V_C@Z.C[SR^?M, O2M=JX7:$X0U1Q4$ZCFHIJ':A+5
M_$K;GP2,1^-A<PD#M-$0U2)*4PM!'10<'WEA-#8)T#?4N>^CT4%4<U!-H)J+
M:AZJ253SQX=O=9Y.>V9S$M"RF3D<C :-U[&$Z,%%E*;VZCKM-]:G_:+X\VRQ
M7NC']FBJ#]5L5'-03:":BVH>JDE4\U$M0+40U2)*4SM_G?T;:\-$VZAO7IVV
MSZLG@(IS^G9@W^&I'WT[G2L$J=FHYJ":0#47U3Q4DZCFHUI0:?M/_5@7YK!Y
MVB?;C"A-[?EUS&]\RNJ#V[SO5;HH _WQYDWL>TG_\N'@_>V>'@;89H,V_S%V
MBYQ6+W;_(2K?B]U>(]!,(*K9J.:@FD U%]4\5).HYA_I 8-)]0[WUHJ A@51
M+:(TM7+48<&Q/BRX_WC0\<KQMJUR_/)0[I KB>)SX_>DC!F7V</')(L_)HTG
MD\\-9QL]?AO/RX<5NHQ.T$@BJMFHYJ":0#47U3Q4DZCF5]K^>&)Z,>GM_Z^9
M3D8/($2UB-+4@E.G$\='THG?/E1Y*CB_;=+-+;7&W3SK8,>KQ!#Q+-M>T.Q2
M8M ,)*K9J.:@FD U%]4\5).HYE>:V=N_GW$Q[3?+"AIN1+6(TM2R4H<;QT?"
MC2>,8_)3!S+N=KV$HESL[H@<&<UT*2UH7!+5;%1S4$V@FHMJ'JI)5/,K32DM
M_8OF>U_:MFI9=Q$]M(C2U))1QR#'1V*0X-1'I-E=,ENMR^NOQ0RH7%1AEFVT
M[U5&T.0EJMFHYJ":0#47U3Q4DZCF5YJZE-)HU"PCT]/*")JHI#2EC$SJ1.5$
MGZB,9LNCMUSU1-?>BFHVJCFH)E#-134/U22J^:@6H%J(:A&EJ9V_CE-.CL0I
MJ5NN^G8Z5P@T0(EJ#JH)5'-1S4,UB6H^J@659II[Y_W>1>_@IBO::D1I:M^O
M$Y23(PG*E[_IJC^BSE4"C5JBFH-J M5<5/-03:*:?Z0'F);FIBMZ)"&J192F
M5HXZI3DY?4W&O\A-5_TWZEQYT- HJCFH)E#-134/U22J^94V5@84UK01W@[0
M1D-4BRA-+3)U&G2BS9S]-6ZTZK]#Y[)":C:J.:@F4,U%-0_5)*KYE:9<H"SJ
MRJ!95LA&0U2+*$TM*W74='+ZBZ[_I6^TZK]'Y]*"!E11S4$U@6HNJGFH)E'-
MKS2EM)@7UKA96EHVLR[&S5LDZ+%%E*;6C#ID.GFYD.F+WVG5?[?.=02-FZ*:
M@VH"U5Q4\U!-HIH_.5P!L_E8^^0PD6I># XNMJ*Q44I32T@=&YT<B8VN/^3)
MG^NR(CB/R=[J-<8_C??WB6'US(GA_+F>K;X8<GE3+H#Y6/3U^9'%+O6M=N[<
M:- 3U1Q4$ZCFHIJ':A+5?%0+4"U$M8C2U'I1YT$GWYX'/3+DJ%^T^>;V=E;N
M',^K-7*,-^O5?9J5BV<?6QE'?YR=*TS+XH>#WO#@PIB--NN@FD U%]4\5).H
MYJ-:@&HAJD64IA:/.ADZ.9(,U0PVOG%U;7W+G<L!FMM$-0?5!*JYJ.:AFD0U
M']4"5 M1+:(TI69,ZQCH5!\#_4X+Z^E;[5HOIH<O2SY\5[*-MNF@FD U%]4\
M5).HYJ-:@&HAJD64IM:!.A$ZU2="?TT^SO)5DI558)8E-ROCE[N[9%,.]D<1
MSXTP6FL F@U%-1O5'%03J.:BFH=J$M5\5 M0+42UB-+46E$G2*=?OP;G;LSP
M<_)IN\7QH8)U<'+O3WK38?/N]I7^J#I7 #3WB6H"U5Q4\U!-HIJ/:@&JA:@6
M49I: >HDZ%2?!+W.TILDN<V-NRQ=;/KY)I=93A#B>5)>>]S>TS@WWJ>K>-[:
M[0]?<]P?M;PR[4I_*)V[/1JZ1#6!:BZJ>:?^N"3:K(]J :J%J!91FMJCZ]CE
M5)N_.G'\+S=OYDRS7#_P)X-C5ZAFHYJ#:@+57%3S4$VBFH]J :J%J!91FEHD
MZA#E]$B(DAWXHTE'5+-1S4$U,3U\S?2@UW(J=M%F/523J.:C6H!J(:I%E*96
M@#H2.3TA$DD\.*YOIW/G1^.)J.:@FI@>9NA&%]:PV?/1V"&J253S42U M1#5
M(DI3>WZ=9)SJDXS/3?GORIS2(ET:F\%!:U='PXJH9J.:@VJBTI1$;=]J/=&C
M0414DZCFHUJ :B&J192F=O<ZB#C5!Q&WX63+,MZ\CPP1W\SF9419.^M'$X.H
M9J.:@VH"U5Q4\U!-HIJ/:@&JA:@649I:"NI8X?3KW[O]%;-^-$F(:G:EJ;<B
M)XW5 AVT38%J+JIYJ"91S4>U -5"5(LH3>G^9J^."):__CY#_R-RU][.<O:.
M4][+/NPW'EMSV%8%R[DLY[&<9#F?Y0*6"UDNPKA&QS?W.KX^%/@V2__8/H9<
M=O19GF^?92Y._N63BN7G10UPLS3/C5V-:*\":!*0Y>P=-]VK KV+7O^@"J A
M/Y9S6<YC.<ER/LL%+!>R7(1QC2I@[54!?=Q/?RG ^*=QRMM[CS32O0:@84"6
M<UA.L)S+<A[+29;S62Y@N9#E(HQKU(K^7JW0!P/W)P3GAT\=GV]76FLO$.A2
MC2QG[[C]J<*PUW;7W6%;%BSGLIS'<I+E?)8+6"YDN0CC&IU_L-?YM?&CXP.%
M3H\/'6FM>T$@.9OE')83+.>RG,=RDN5\E@M8+F2Y".,:16.X5S1>,E-XI+7N
M10--%;*<PW*"Y5R6\UA.[CCEF?+^<-JX^.NSS08L%[)<A'&-:C#:JP;Z?.&W
MW&I $X4L9[.<PW*"Y5R6\UA.[KC]J=QXTA\.#WH^&BUDN9#E(HS;]OS+_#Y)
M5G:\BE^_6B39Q^0JF<]SXR9=+PN^O)SP]*F1)7=E8?CQC75V>?"Y9_XHS9;/
M??/'8//Y9<V_?O40?TRB./LX6^;&/+DKFNI=C(N?<U8NJKK[S2I]*&K2F?$A
M7:W2Q>:7]TE\FV3E!L6?WZ7I:O>;LH%/:?;'YNN\_C]02P,$%     @ YX)_
M5M;L</:5 P  P@T  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULQ5=M
M;]LV$/XKA#8,+=!:HE[MS#:0.!G6#UV#!EL_T]+9)B*)*DG9Z;\?22FR+,F:
M9V38%YND[AX^SYVH.\X/C#^+'8!$+UF:BX6UD[*XL6T1[R C8L(*R-63#>,9
MD6K*M[8H.)#$.&6I[3I.:&>$YM9R;M8>^7+.2IG2'!XY$F66$?[C#E)V6%C8
M>EWX2K<[J1?LY;P@6W@"^6?QR-7,;E 2FD$N*,L1A\W"NL4W*^QK!V/Q%X6#
M:(V1EK)F[%E//B4+R]&,((58:@BB_O:P@C352(K']QK4:O;4CNWQ*_IO1KP2
MLR8"5BS]1A.Y6UA3"R6P(64JO[+#[U +"C1>S%)A?M&AMG4L%)="LJQV5@PR
MFE?_Y*4.1,L!AV<<W-K![3KX9QR\VL$S0BMF1M8]D60YY^R N+96:'I@8F.\
ME1J:ZS0^2:Z>4N4GEW\P"<A'']'#]Y+*'VJP8EFFXOLD6?R,'DL>[U24T#?"
M.<DENM5AUX;O[D$2FHKWRN5G9".Q(QS$W):*E(:VXYK 747 /4, N^@SR^5.
MH(<\@>04P%9J&DGNJZ0[=Q3Q'N()\O 'Y#JN.T!H=;D['J'C-1'V#)Y_!N]+
M*84D>4+S[0>4E]D:.&(;=*@"*M [FM?!>S\4O0H\-.#Z3.Z7KNOXD1_-[7U;
MU( =#D[L3MC[#7O_<O8'<R@@060/7!UR!"_ 8ZI>CX+3&(R4A*4IX0(52J:1
M-:BJVG3:8NM/O%E'TJ#1&3U!HR<8U?-)B!*2:Q(1] *,'<]QG [IOEG@M*U.
M6(<-Z_ BUF^7@+ 76SP)_(Z6OE$P<6?#4J)&2C0J947R6'VTE0;&%?V"\NO2
M$?73X8>>&W8D],W.I&+:\)]>P?_M$C/MQ=R;1-V341D%_ZQJUJB:C:IZJ.E>
ME8I9/Q5>Z'L=SGVK,YRQ<ZQ=SJ6LWRX!]9[M##B3H".F-KH@ [A5B?%_62AJ
M]-,*X$=1-.UR'S#LE)13!>Y1@?M_%(MZUTXA<+NR!JW.?*WPL7KC\?)=OV-D
MG<)56>G793QS\,SOO5&C-'0W?R,*$L/"4NVZ +X':_G+3SAT?AWI4?"QS./Q
M.G\B\PU3-U3#@^[G;)S;O]5NM[KA#/C67!($BEF9RZJ+;%:;B\BM:;\[ZW?Z
M@F*Z["-,=;OY3/B6Y@*EL%&0SB12'P)>71BJB62%Z;G73*H.W@QWZI(%7!NH
MYQNF^NYZHC=HKFW+OP%02P,$%     @ YX)_5I:JX=&G @  I@<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&ULI57;;IM $/V5%96J1&K"@N\N1HKC
M5.F#JRA14U55']8P-JOLA>PNOOQ]=X$0-\)4:EY@]C+GG)F!F6@GU9/.  S:
M<R;TS,N,R:>^KY,,.-&7,@=A3]92<6+L4FU\G2L@:>G$F1]B//0YH<*+HW+O
M3L61+ RC NX4T@7G1!WFP.1NY@7>R\8]W63&;?AQE),-/(#YGM\IN_(;E)1R
M$)I*@12L9]Y5,)T'V#F4-QXI[/21C5PH*RF?W.)K.O.P4P0,$N,@B'UMX1H8
M<TA6QW,-ZC6<SO'8?D'_4@9O@UD1#=>2_:"IR6;>V$,IK$G!S+W<W4(=T,#A
M)9+I\HEVU=T^]E!2:"-Y[6P5<"JJ-]G7B3AR"(8G',+:(2QU5T2ER@4Q)(Z4
MW"'E;ELT9Y2AEMY6'!6N*@]&V5-J_4S\31I ?72!;IX+:@[6N-*V0KE+F49G
M"S"$,GT>^<:2.1<_J8'G%7!X C@(T5(*DVET(U)(_P;PK<I&:O@B=1YV(BX@
MN42]X!,*<1AVX/6:T'LE7O\$WLT^MY\&I,B XNB,"G0 HO3Y%)W]M$9KS-V(
M :X@.L3U&W']3J@%W=(41(H.%%@Z;=-2 4Q* /?S;6,<^=L6SD'#.>CD7%)!
M><'1KR7P%:C?;:2="*Z%3'5.$IAYMD=H4%OPXH\?@B'^W)&38:-OV*GOGNJG
MB[4"0(H8:,U)!1"$QTFYQ!B/VC,S:IA'G<R/DA%#F?U!6EE';:RCP63<SCIN
M6,?=]2#[?]:C$^$_ZS%I]$W>6X]):SWZHQ/U"/!KV\+OJ4CM_89X/.Z]+8E_
MU#HYJ$TY(#1*9"%,U46;W68(756M]_5Z-<&61&VH;9H,UM;5?0 >4M50J!9&
MYF4C7DECVWII9G:0@G(7[/E:VF9<+QQ!,YKC/U!+ P04    " #G@G]6(P7L
MC)D#  #<#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6S%5]MNXS80
M_15"+8I=8&N)U-6I;2"W1?NPW6"#ML^T-+:)2**6I.WLWY>D%%F69",.4M0/
M%DG-Y9P9D3.<[;EXDAL A9Z+O)1S9Z-4=>6Z,MU 0>6$5U#J-RLN"JKT5*Q=
M60F@F54J<I=X7N06E)7.8F;7'L1BQK<J9R4\""2W14'%CQO(^7[N8.=EX1M;
M;Y19<!>SBJ[A$=1?U8/0,[>UDK$"2LEXB02LYLXUOKK%@5&P$G\SV,O.&!DJ
M2\Z?S.2/;.YX!A'DD"IC@NK'#FXASXTEC>-[8]1I?1K%[OC%^F=+7I-94@FW
M//^'96HS=Q('9;"BVUQ]X_O?H2$4&GLISZ7]1_M:-@X<E&ZEXD6CK!$4K*R?
M]+D)1$<!1R<42*- ^@JG//B-@F^)UL@LK3NJZ&(F^!X)(ZVMF8&-C=76;%AI
MTOBHA'[+M)Y:_,D5H #]BNZ_;YGZH0>/BJ=/Z&MEHWQMHFS6/]R!HBR7'[7$
MS\A%<D,%R)FK- 9CR4T;?S>U/W+"'R;H"R_51J+[,H/LV("KP;<,R N#&W+6
MXAVD$^3C3XAXA(P NGV].CX#QV\#ZEM[P0E[7[=**EIFK%Q_0N6V6() ?-7$
M"WU@93/\.!:[VG1D39L-N%LD81SXG@:VZU(:RD5)$'C1M)4[PAZTV(/78]_;
M'0 9HCL0>D<C> :1,@FH$BP%2R7C>4Z%1)4F:6F-LJJ=)AVT_L0/>Y2&0F22
MX'$^8<LG/,_'?L02K04M-9/+\Q$.XDRFB1]%40_\B%R(IQ%)QO%'+?[H,OSO
MEY-H)-RX3VLH%$Q(-,XI;CG%K^+T@OP-68D'T<8XFL9^#_U0+(J])#FQ1Y(6
M?W(I_O?+2C((N#?Q2(_74 A/O!,[9=JRFKZ25<6$9L(%2FF9ZNKZE@1-AY'7
MO[C'8RB%<1)Z\3@3[!TJFG<)E_?,3^/Y>-N$_:.LD0J[!]X)4ITRC?^[LM+8
M/@ZUKPL+Z>=D1+)?@8X)D ,!\G_4EL;K<7'QDCZM,:E."3KF="CU^'RMOZ]1
MTV4.;TC*2!&/<>(-*N-Y$*;/OY(536'NZ$9>@MB!L_CE)QQYOYUI9_"A)\#G
MFX(CDN^8N+&N@/3/\//8+N7N=OKD L3:7A\D2OFV5'7#V:ZV5Y1KVYCWUF_,
MU<7VWP<S];WG"Q5KI@^?'%;:I#>)]2D@ZJM$/5&\LMWXDBO=V]OA1E^_0!@!
M_7[%=4?>3(R#]D*W^!=02P,$%     @ YX)_5JC@.IT$ @  $ 0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL?511;YLP$/XK%MI#(G4!G&2M*H+4
M))NVATY1LV[/#AQ@Q=C,-B'[]ST;PC)IZ0OVG>_[[CO?F:13^F@J $O.M9!F
M%536-H]A:+(*:F9FJ@&))X72-;-HZC(TC0:6>U M0AI%G\*:<1FDB??M=)JH
MU@HN8:>):>N:Z3]K$*I;!7%P<;SPLK+.$:9)PTK8@WUM=AJM<&3)>0W2<"6)
MAF(5/,6/Z[F+]P$_.73F:D]<)0>ECL[XEJ^"R D" 9EU# R7$VQ "$>$,GX/
MG,&8T@&O]Q?V+[YVK.7 #&R4^,5S6ZV"AX#D4+!6V!?5?86AGJ7CRY0P_DNZ
M/G:Y#$C6&JOJ 8P*:B[[E9V'>[@"4'H#0 < ];K[1%[EEEF6)EIU1+MH9',;
M7ZI'HS@N75/V5N,I1YQ-ORL+9$D^DD443XY3LF<G+DM#?F@F#?,W9\AD"Y9Q
M@5XXVY:):1):S.T8PFS(L^[ST!MY8DJ>E;25(9]E#OF_!"&*'I73B_(U?9=Q
M"]F,S.,[0B-*R>M^2R8?IN_PSL<;F7O>Q4W> CTYV:!<S0^M'YZ=8/(.7<;^
MK_2><.D)W2LXI?<+^A GX>E:1WC5I1ITZ6?1D$RUTO8-&[WCN#_U7?X;WK^5
M9Z9+CHT14" TFMUC;MW/7V]8U?B>'Y3%"?+;"I\L:!> YX7"O@^&2S#^!-(W
M4$L#!!0    ( .>"?U89_&=IJ D  .UH   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;+6=;6^C.AJ&_XJ57:WF2#T-D*9M9MM*;7EG.J>:=G:U6NT'
MA[@)>WC) :<OTO[XM0D-H2$.J/>9#YU _%RV*7<?8]_ Q4N6_UXL&./D-8G3
MXG*PX'SY=3@LP@5+:'&<+5DJOGG*\H1RL9G/A\4R9W16!B7QT-"TTV%"HW1P
M=5'NN\^O+K(5CZ.4W>>D6"4)S=]N6)R]7 [TP?N.']%\P>6.X=7%DL[9 ^,_
ME_>YV!IN*+,H86D192G)V=/EX%K_&HS*@++$/R+V4FQ])K(KTRS[76YXL\N!
M)EO$8A9RB:#BOV=VR^)8DD0[_JB@@TV=,G#[\SO=+CLO.C.E!;O-XG]&,[ZX
M')P/R(P]T57,?V0O+JLZ-):\,(N+\B=YJ<IJ Q*N"IXE5;!H01*EZ__I:W4@
MM@+TDST!1A5@? P8[PD850&CK@$G5<#)QX#3/0'C*F#<M0^G5<!IUX"S*N"L
M:\!Y%7#>-6!2!4RZ!NC:^V].ZQRR^66O3[KU65*>8B;E].HBSUY(+LL+GOQ0
MGJ=EO#BSHE1*ZH'GXMM(Q/&K[QEGY(S\2FZS)(FX$ LO"$UG8COE43IG:1BQ
M@GPQ&:=17)!']LI7-/Y%1/Q\,,F7O_YR,>2B'9(V#*LZ;]=U&GOJU,F=@"\*
M8J4S-FN)-]7QHT/QUH'Z#05@* [@YB@:[T?QQE 2']CRF(RT(V)HAM%V0-3A
M_BH6X;H,U\_;CH<Z_([FF_"SML.A#C=9^!ZN35K"[<[AK7UW.H0;D[WAKCK\
M>_8LPHV]X5[G(]\:[G<X\MJH#-=;P@-UN,VFQT1?UZXI3L/11LRCDG>RA_<;
M7[!\2\E'Y#'C-&YIV(T2)//XUV))0W8Y$(FZ8/DS&US][2_ZJ?;WMK,;"3.1
M, L)L]>P<0F30Y7GJ]&))OY=#)^WSW=DG2X2YB%A/A(6@& -U9QL5'.B5,VW
M*!1#1$:NYSEC4C8BR>5)0?Y]QY(IR__3)A\EL:]\D# 3";.0,!L)<Y P%PGS
MD# ?"0M L(;(QAN1C7N*["Z*F1C@IHS<TS>YITUG2FA?G2%A)A)F(6$V$N8@
M82X2YB%A_G@GM9_JX]W<'H J;4CH=".A4Z6$OE,Y"4%CXJ4%C_A*7+AE3\1E
M-.8+9;)28ON*" DSD3 +";.1, <)<Y$P#PGSD;  !&LH[6RCM#.ETGYD;T)4
M;R1+R0,56>J(W+-<Y"].YZQ-8$I:7X$A82829JUADZT_DMJQIC?_0MK(&ATD
MS$7"/"3,1\("$*PAG/.-<,X["4=>0)$O_V(T;YL>O%%"^NH%"3.1,$M]K R=
MO(D#5+1E'V0S'"3,1<(\),Q'P@(0K"&BR49$DTXBJBZ+CLAUFJ[$L.\N2J-D
ME;0)2@GL*R@DS$3"K,G.*-W8':/;R"H=),Q%PCPDS$?" A"L(1Y=JQ>T-*5\
M*MF0IRRO%[&X_%A$,Y:7%U'D6T2G41SQMR/RV[+<F<[)M5S>C7C$VOXFWZBK
M[2LR*,VL: UEM$Q-6]!:;2C-@=)<*,V#TGPH+4#1FG+;6C_6E7+;DEBEO.(]
M87EIF#-:M%XRJ:F]U82DF17M0)ZQH)7:4)H#I;E0F@>E^5!:@*(UQ6348C+4
M0S_!I'FXV)HF?Y_8(_\C=Z90EDAAA4A@JOD^=26]M86DF5":!:794)H#I;E0
MF@>E^5!:@*(U)5A;*'2UA^);)D:"Y?R%S&PY#<4%F%7P**&<25=4T;I.I>]Z
M XR)MILT;ML*:BT%374S>PL%:H2 TAPHS872/"C-A]("%*TIE-HUH?>U36RE
MJI]I]"P2520GT9_(?<1Y,5WE<_4ZE;K"WGD+:JN TBPHS8;2'"C-A=(\*,V'
MT@(4K2G'VE^A=S%8R&D,F[$C<IUDJW9+A9K36V504P649D%I-I3FZ+N. V.\
M,PIPNQ7SH&WSH;3@8!>:)WSMAM#5=HCW67$:I9RE- W9^LRWH[S@Y'$ALA*1
M*U"%4@Q0;P249D)I%I1F0VE.13L])(9.Q3QHVWPH+3C8A:88:L."KG8L[!/#
M]1-G>2F#M2*46H#:&* T$TJSH#0;2G,JVO89TC*3[W8KYD';YD-IP<$N-+50
M>Q!T]<)ZI84/RZC2PE,*X4BUD*I&]]8 U)L I5E0F@VE.15M9\BP(X)NY3QH
MZWPH+3C<AZ8,:A>!KK81/"QH7CI$OV?IK^]B>%A-X^JZW4O#+&$;:UNK&J"^
M BC-A-(L*,V&TIR*UO3=&1^ET*&0!VV7#Z4%!SK0O"VS-@,8:C/ YR:I1!DS
M*Z^IQ??KZPIWE=!4Y!0>25B4$DKN%U3*B=R*RJ-09)['/!(_53-=ZE;W%1:4
M9D)I%I1F0VD.E.9":1Z4YD-I 8K6U'3M.##4CH-.-PZI&;T5!O470&D6E&9#
M:0Z4YD)I'I3F0VF!L>M &4W.]D\4&+7#P% [##Z=$'\6=%X.*REQXE5(YYE(
MAWF69'*B03XXPF%"F8\+EM.E-(*'BS2+L[E\B 3/R+THEG*1'F/Q7<XH)X]O
M2T9T8D9TRCA3WW6K[EMO44.-#5":!:794)H#I;E0F@>E^5!:@*(UE5\;&PRU
ML:%;VH0^%P)*,Z$T"TJSH30'2G.-EN=6?$@FE7B@9@<H+4#1FN*IS0[&GVEV
M^+/2IM$Q;4)]%5":":594)H-I3E0F@NE>5":#Z4%*%I3^;6OPE#[*KJE3:BG
M DHSH30+2K.A-,?8=1JT)CH76JT'I?E06H"B-<53>S0,M4?CTVFS6JI3IS>H
MAP-*,Z$T"TJSH30'2G.A- ]*\Z&T $5K*K0VCAC='G51K0(>D4JRLWH,^D9N
M,R%4L6LJ5]/YOAP(M8] :2:49D%I-I3F5#3=:*RC:?KX8PKL5LZ#MLZ'TH+#
M?6B*HG:0&&H'R>?3%GT]G+:@5A,HS832+"C-AM(<*,V%TCPHS8?2 A2MJ=#:
MW&)T?$;&Y],6U.,"I9E0F@6EV5":8[2Y/[31QZ35I90';9D/I06'>M!\['-M
M<QFI;2XF>V9QMBQ3E9Q,O*/IZHF&?)57YA7G[IXX.9TQ\15GTI^BGC)4U]=7
M%5":":594)H-I3E0F@NE>5":#Z4%*%I3C;5!9:0VJ&RK\4'016HJZK'D$;%>
MERR4=Q.73V>7RP#_%=M[[RU6U]9;BU K"Y1F06DVE.9 :2Z4YHU:'E@R;KFI
MW(=6&Z!H:YD-MUYBDK!\7KYGIR"AO%UE_3Z3S=[-NWRNRS?8#.OBZQ<!W=%\
M'J4%B=F3"-6.S\21R=?OUEEO\&Q9OA)EFG&>)>7'!1/9,9<%Q/=/F5R76V_(
M"C9O.+KZ/U!+ P04    " #G@G]6LQAMON !  ", P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6QU4]MNVS ,_15"Z$,+;)&C-KW!,; D&%9@W8*F
MW9X5FXF%ZN))2IS^?279#5Q@\8-%2CR'AZ24M\:^NAK1PT%)[::D]KZYI]25
M-2KN1J9!'4XVQBKN@VNWU#46>95 2E*69==4<:%)D:>]I2URL_-2:%Q:<#NE
MN'V;H33ME(S)Q\:3V-8^;M B;_@65^A?FJ4-'CVR5$*A=L)HL+B9DF_C^QF+
M\2G@C\#6#6R(E:R->8W.0S4E612$$DL?&7A8]CA'*2-1D/&OYR3'E!$XM#_8
MOZ?:0RUK[G!NY%]1^7I*;@E4N.$[Z9],^P/[>B:1KS32I3^T7>SDBD"Y<]ZH
M'AP4**&[E1_Z/@P C)T L!Z0&D&[1$GE@GM>Y-:T8&-T8(M&*C6A@SBAXU!6
MWH93$7"^^&4\PAU\A0==&H7PS _HX'R!G@OIX!D/?L?E!9R!T/ HI RM=#GU
M(74DH&6?9M:E82?2++ <P>7X"[",,7A9+>#\[.(S#0W*C_+943Y+O%<G>'\W
M:+D7>@L_C7,PY]:^A9O:<EO]5V7'-KY,=/'"[HOKV]%=-OC&.=T/%=%!<^,]
M?>1V*[0#B9O D8UN)@1L-_O.\:9)_5X;'Z:7S#H\%[0Q()QO3.AY[\01'A]@
M\0Y02P,$%     @ YX)_5D5" ?5- @  4P4  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULC51M3]LP$/XKITB30&+-"Y0-E$:BP+1]8*J ;9]-<FDL
M'%]F7UOX][.=D!56JGV)??;=\SQWN7.^(?-H&T2&IU9I.XL:YNX\CFW98"OL
MA#K4[J8FTPIVIEG&MC,HJA#4JCA+DM.X%5)'11[.%J;(:<5*:EP8L*NV%>9Y
MCHHVLRB-7@YNY;)A?Q 7>2>6>(?\HUL89\4C2B5;U%:2!H/U++I(S^=3[Q\<
M?DK<V*T]^$P>B!Z]\:V:18D7A I+]@C"+6N\1*4\D)/Q>\",1DH?N+U_0?\2
M<G>Y/ B+EZ1^R8J;6?0Y@@IKL5)\2YNO..03!):D;/C"IO<]32(H5Y:I'8*=
M@E;J?A5/0QVV M+3=P*R(2 +NGNBH/)*L"AR0QLPWMNA^4U(-40[<5+[GW+'
MQMU*%\?%=V*$,_@(WW1)+<*]>$+[RH1;+$F74DD1ZGAPA2RDLH=YS$Z AXG+
M@6S>DV7OD*49W)#FQL*UKK!Z#1 [Y:/\[$7^/-N+>(7E!([3(\B2+-N#=SR6
MXSC@G;R#-Z3-+NW.T%J&WA,,W"#46*$1"BP+7C&99S""<5<5>HZSP.&G8ETD
MDRS-X_4.92>CLI.]RJ[KVC4R4 UN(!VQU$M09"W:70KV8QUDZ21)/ASN*=AT
ME#7]#UENL%YUC*O+F[8Y@@6:$C4?P3VQ4+M$3_\MVYN:Q5N-WJ)9AG&V4-)*
M<]_SX^GX8EST@_+7O7]N;H192FU!8>U"D\DGQV[Z$>X-IBZ,S0.Q&\*P;=RK
MA\8[N/N:W.@,AB<8W]'B#U!+ P04    " #G@G]6#B:< JP.  !EWP  &0
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M=MZN2PC&)'>W<N'!G#OS6&S#J7]F"M*1]W-CROWJ-BIWW97]P6SJN\[3 V5
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MRCOYV>5 ,*F8.^\ 4FHEE&#NW$-(>P[VO/9K"&F7 RLGY9XN0:AF=N7REP,
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M76Y0?7$LMJ%X>E^<A7WQ>95AS*^D99+:78-GY0! P:G=?KKR\8$\EE)[-1X
M4+%8>RY("@#C[B:16Y26A4=FMGS\L)384Y-P3T,Y:MP"BVWX8=3>..93C.-I
MU6,<J!:FE-@+D:,> "BI]DOV%A!0,\[=P] U *0DMJIP:S12"*D)Z3[8X>@G
M/#)S]0/%310AVBU]S%'C%EAL0_WT#C(/.\B3*\RX;VZ>GU /@#PA'P@)ZP=
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MW'127F/?O?I'\_KPIOCPEOO==U!+ P04    " #G@G]6C-]?K6X!  #=%
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M<' N>&UL4$L! A0#%     @ YX)_5E5Y)Z'N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ YX)_5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #G@G]6$,(:XXP'  #O,0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ YX)_5I_81<+W
M!   ;!,  !@              ("!SP\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( .>"?U:41!4'2 (  %4&   8              "
M@?P4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #G@G]6
MXR'Y/&,%  "N&   &               @(%Z%P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ YX)_5HE+)B:#!@  %"L  !@
M     ("!$QT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M .>"?U:;P]0P<P4  +P5   8              " @<PC  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #G@G]6(C*R1'@&  "E#0  &
M            @(%U*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ YX)_5B$+DO3M"0  "!<  !@              ("!(S   'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .>"?U:Y9D+QLP(  -D%
M   8              " @48Z  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #G@G]6^E3HBM$%  "P#P  &0              @($O/0
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .>"?U:T,4V6
M/0(  /T$   9              " @3=#  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ YX)_5O2^^HSH @  -P8  !D
M ("!JT4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #G
M@G]60P_E8-4#  #'"   &0              @('*2   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .>"?U;LJ $*0@(   (%   9
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M970Q."YX;6Q02P$"% ,4    " #G@G]61MC2X/P#   \"   &0
M    @(&59P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M .>"?U85;4X$#00  #X*   9              " @<AK  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ YX)_5LFI[DM< @  '04  !D
M             ("!#'   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #G@G]6 ",NX>0&   -$P  &0              @(&?<@  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .>"?U:LK5+$8P,
M ,,*   9              " @;IY  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ YX)_5A9N@.SG#   _F<  !D              ("!
M5'T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #G@G]6
M'[+:/<$;  !:L $ &0              @(%RB@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( .>"?U;6['#VE0,  ,(-   9
M      " @6JF  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ YX)_5I:JX=&G @  I@<  !D              ("!-JH  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #G@G]6(P7LC)D#  #<#0
M&0              @($4K0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( .>"?U:HX#J=! (  ! $   9              " @>2P  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ YX)_5AG\9VFH
M"0  [6@  !D              ("!'[,  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #G@G]6LQAMON !  ", P  &0
M@('^O   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .>"
M?U9%0@'U30(  %,%   9              " @16_  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ YX)_5@XFG *L#@  9=\  !D
M         ("!F<$  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #G@G]6G9]P@L4.   <=@  &0              @(%\T   >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .>"?U8H@5LA2P,  ,X4
M   -              "  7C?  !X;"]S='EL97,N>&UL4$L! A0#%     @
MYX)_5I>*NQS     $P(   L              ( ![N(  %]R96QS+RYR96QS
M4$L! A0#%     @ YX)_5D64]KR0 P  :1<   \              ( !U^,
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .>"?U:,WU^M;@$  -T4   :
M              "  93G  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( .>"?U8&5T)WCP$  ' 5   3              "  3KI  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     J "H 70L  /KJ      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>199</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-balance-sheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-statements-of-operations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-statements-of-cash-flows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation</Role>
      <ShortName>Note 1 - Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Intellectual Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-3-intellectual-property</Role>
      <ShortName>Note 3 - Intellectual Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity</Role>
      <ShortName>Note 4 - Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - 401(k) Savings Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions</Role>
      <ShortName>Note 5 - 401(k) Savings Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions</Role>
      <ShortName>Note 6 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies</Role>
      <ShortName>Note 7 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Significant Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-8-significant-events-</Role>
      <ShortName>Note 8 - Significant Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-10-subsequent-events</Role>
      <ShortName>Note 10 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements</Role>
      <ShortName>Note 11 - Restatement of Previously Issued Consolidated Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 4 - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity-tables</Role>
      <ShortName>Note 4 - Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-4-equity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-9-income-taxes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables</Role>
      <ShortName>Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 4 - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual</Role>
      <ShortName>Note 4 - Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-4-equity-tables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details</Role>
      <ShortName>Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 4 - Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details</Role>
      <ShortName>Note 4 - Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 4 - Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details</Role>
      <ShortName>Note 4 - Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 5 - 401(k) Savings Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual</Role>
      <ShortName>Note 5 - 401(k) Savings Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 7 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 9 - Income Taxes - Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details</Role>
      <ShortName>Note 9 - Income Taxes - Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 10 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual</Role>
      <ShortName>Note 10 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-10-subsequent-events</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gnpx20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details</Role>
      <ShortName>Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 63 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, us-gaap:CashEquivalentsAtCarryingValue, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareBasic, us-gaap:ImpairmentOfLongLivedAssetsHeldForUse, us-gaap:NetIncomeLoss, us-gaap:OperatingIncomeLoss, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RetainedEarningsAccumulatedDeficit, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 -  gnpx20221231_10k.htm 8, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="gnpx20221231_10k.htm">gnpx20221231_10k.htm</File>
    <File>ex_451285.htm</File>
    <File>ex_451286.htm</File>
    <File>ex_451287.htm</File>
    <File>ex_451288.htm</File>
    <File>ex_451289.htm</File>
    <File>gnpx-20221231.xsd</File>
    <File>gnpx-20221231_cal.xml</File>
    <File>gnpx-20221231_def.xml</File>
    <File>gnpx-20221231_lab.xml</File>
    <File>gnpx-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a1new.jpg</File>
    <File>a2new.jpg</File>
    <File>acclaim3_850.jpg</File>
    <File>attd_graphs.jpg</File>
    <File>diabetes3_850.jpg</File>
    <File>diabetes4_850.jpg</File>
    <File>diabetes5_850.jpg</File>
    <File>figure1.jpg</File>
    <File>figure2.jpg</File>
    <File>gpx002new.jpg</File>
    <File>gylze0pdymuz000002.jpg</File>
    <File>gylze0pdymuz000003.jpg</File>
    <File>gylze0pdymuz000004.jpg</File>
    <File>gylze0pdymuz000006.jpg</File>
    <File>oncoprexlnp_850.jpg</File>
    <File>pipelinev20_850.jpg</File>
    <File>reqorsatarceva_850v1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="549">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gnpx20221231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 549,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "gnpx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gnpx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gnpx20221231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gnpx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gnpx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gnpx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 312,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 61,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 67
   },
   "keyCustom": 37,
   "keyStandard": 162,
   "memberCustom": 29,
   "memberStandard": 17,
   "nsprefix": "gnpx",
   "nsuri": "http://www.genprex.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.genprex.com/20221231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Equity",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity",
     "shortName": "Note 4 - Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - 401(k) Savings Transactions",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
     "shortName": "Note 5 - 401(k) Savings Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Related Party Transactions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
     "shortName": "Note 6 - Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
     "shortName": "Note 7 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:EffectOfCovid19PandemicTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Significant Events",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
     "shortName": "Note 8 - Significant Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:EffectOfCovid19PandemicTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.genprex.com/20221231/role/statement-note-9-income-taxes",
     "shortName": "Note 9 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 10 - Subsequent Events",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
     "shortName": "Note 10 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
     "shortName": "Note 11 - Restatement of Previously Issued Consolidated Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:CorrectionOfErrorPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:CorrectionOfErrorPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "gnpx:CorrectionOfErrorPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:CorrectionOfErrorsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "gnpx:CorrectionOfErrorPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gnpx:CorrectionOfErrorsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.genprex.com/20221231/role/statement-balance-sheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 4 - Equity (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
     "shortName": "Note 4 - Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 9 - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables",
     "shortName": "Note 9 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
     "shortName": "Note 11 - Restatement of Previously Issued Consolidated Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "gnpx:CorrectionOfErrorsTableTextBlock",
       "gnpx:CorrectionOfErrorPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_RestatementAxis-ScenarioPreviouslyReportedMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 4 - Equity (Details Textual)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
     "shortName": "Note 4 - Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
     "shortName": "Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "gnpx:ClassOfWarrantOrRightIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 4 - Equity - Assumptions (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
     "shortName": "Note 4 - Equity - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 4 - Equity - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details",
     "shortName": "Note 4 - Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 5 - 401(k) Savings Transactions (Details Textual)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual",
     "shortName": "Note 5 - 401(k) Savings Transactions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
     "shortName": "Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual",
     "shortName": "Note 7 - Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 9 - Income Taxes (Details Textual)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual",
     "shortName": "Note 9 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 9 - Income Taxes - Income Tax Reconciliation (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details",
     "shortName": "Note 9 - Income Taxes - Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 10 - Subsequent Events (Details Textual)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
     "shortName": "Note 10 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2023-02-16_ClassOfWarrantOrRightAxis-ConsultantWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
     "shortName": "Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-07-01_2022-09-30",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-07-01_2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.genprex.com/20221231/role/statement-statements-of-operations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Description of Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
     "shortName": "Note 1 - Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Intellectual Property",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
     "shortName": "Note 3 - Intellectual Property",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gnpx20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information",
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables",
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information",
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables",
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gnpx_AnnualIncentiveAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of annual incentive awards.",
        "label": "gnpx_AnnualIncentiveAwards",
        "terseLabel": "Annual Incentive Awards"
       }
      }
     },
     "localname": "AnnualIncentiveAwards",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_AnnualMaintenanceFeeAfterYearThreeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual maintenance fee after the third year of an agreement.",
        "label": "gnpx_AnnualMaintenanceFeeAfterYearThreeAmount",
        "terseLabel": "Annual Maintenance Fee, After Year Three, Amount"
       }
      }
     },
     "localname": "AnnualMaintenanceFeeAfterYearThreeAmount",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual maintenance fees for the first three years of an agreement.",
        "label": "gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount",
        "terseLabel": "Annual Maintenance Fee, First Three Years, Amount"
       }
      }
     },
     "localname": "AnnualMaintenanceFeeFirstThreeYearsAmount",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_AnnualRoyaltyPaymentPerYearMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of royalty payment to be received each year.",
        "label": "gnpx_AnnualRoyaltyPaymentPerYearMinimum",
        "terseLabel": "Annual Royalty Payment Per Year, Minimum"
       }
      }
     },
     "localname": "AnnualRoyaltyPaymentPerYearMinimum",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_BearCreekCapitalWarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Bear Creek Capital warrant one.",
        "label": "Bear Creek Capital Warrant One [Member]"
       }
      }
     },
     "localname": "BearCreekCapitalWarrantOneMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_BearCreekCapitalWarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Bear Creek Capital warrant two.",
        "label": "Bear Creek Capital Warrant Two [Member]"
       }
      }
     },
     "localname": "BearCreekCapitalWarrantTwoMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_BearCreekCapitalWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Bear Creek Capital warrants.",
        "label": "Bear Creek Capital Warrants [Member]"
       }
      }
     },
     "localname": "BearCreekCapitalWarrantsMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_BrokerageCommissionsPercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the commissions for brokerage services as a percentage of gross proceeds.",
        "label": "gnpx_BrokerageCommissionsPercentageOfGrossProceeds",
        "terseLabel": "Brokerage Commissions, Percentage of Gross Proceeds"
       }
      }
     },
     "localname": "BrokerageCommissionsPercentageOfGrossProceeds",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "gnpx_ClassOfWarrantOrRightCancelledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights cancelled during period.",
        "label": "Cancelled or expired, number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledDuringPeriod",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights cancelled during period.",
        "label": "Cancelled or expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gnpx_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercisable.",
        "label": "Exercisable, number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_ClassOfWarrantOrRightExercisableExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercisable.",
        "label": "gnpx_ClassOfWarrantOrRightExercisableExercisePrice",
        "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableExercisePrice",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gnpx_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "Exercised, number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during period.",
        "label": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gnpx_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights issued during period.",
        "label": "Issued, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "gnpx_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "Issued, number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_CommonStockSharesAuthorizedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggerate value for the shares authorized of common stock.",
        "label": "gnpx_CommonStockSharesAuthorizedValue",
        "terseLabel": "Common Stock, Shares Authorized, Value"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedValue",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to consultant.",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_ConsultantWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to consultant warrants.",
        "label": "Consultant Warrants [Member]"
       }
      }
     },
     "localname": "ConsultantWarrantsMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_ContingentPaymentsAnnualIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in contingent payment.",
        "label": "gnpx_ContingentPaymentsAnnualIncrease",
        "terseLabel": "Contingent Payments Annual Increase"
       }
      }
     },
     "localname": "ContingentPaymentsAnnualIncrease",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_CorrectionOfErrorPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for correction of errors.",
        "label": "Correction of Error [Policy Text Block]"
       }
      }
     },
     "localname": "CorrectionOfErrorPolicyTextBlock",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gnpx_CorrectionOfErrorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of correction of errors.",
        "label": "Correction of Errors [Table Text Block]"
       }
      }
     },
     "localname": "CorrectionOfErrorsTableTextBlock",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to development and manufacturing of GMP grade materials.",
        "label": "Development and Manufacturing of GMP Grade Materials [Member]"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingOfGMPGradeMaterialsMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected total project cost under development services agreement.",
        "label": "gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost",
        "terseLabel": "Development Services Agreement, Expected Total Project Cost"
       }
      }
     },
     "localname": "DevelopmentServicesAgreementExpectedTotalProjectCost",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario of a dosing of first human patient in a Phase I clinical trial.",
        "label": "Dosing of First Human Patient in a Phase I Clinical Trial [Member]"
       }
      }
     },
     "localname": "DosingOfFirstHumanPatientInAPhaseIClinicalTrialMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_EffectOfCovid19PandemicTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for effects of COVID-19 pandemic.",
        "label": "Effect of Covid 19 Pandemic [Text Block]"
       }
      }
     },
     "localname": "EffectOfCovid19PandemicTextBlock",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gnpx_EquityOfferingCombinedPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The combined purchase price of the equity offering.",
        "label": "gnpx_EquityOfferingCombinedPurchasePrice",
        "terseLabel": "Equity Offering, Combined Purchase Price (in dollars per share)"
       }
      }
     },
     "localname": "EquityOfferingCombinedPurchasePrice",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "gnpx_ExcludingThe2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents information excluding the 2018 equity incentive plan.",
        "label": "Excluding the 2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "ExcludingThe2018EquityIncentivePlanMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the investors of the company.",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement where another party is permitted the right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_LicenseAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of milestone payments made for License Agreements.",
        "label": "gnpx_LicenseAgreementMilestonePayment",
        "terseLabel": "License Agreement Milestone Payment"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayment",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_LicensingFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the agreed upon licensing fee.",
        "label": "gnpx_LicensingFeeAmount",
        "terseLabel": "Licensing Fee, Amount"
       }
      }
     },
     "localname": "LicensingFeeAmount",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_LongTermContractEstimatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated total cost of of long term contract.",
        "label": "gnpx_LongTermContractEstimatedCost",
        "terseLabel": "Long Term Contract, Estimated Cost"
       }
      }
     },
     "localname": "LongTermContractEstimatedCost",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_MdAndersonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents MD Anderson.",
        "label": "MD Anderson [Member]"
       }
      }
     },
     "localname": "MdAndersonMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a payment to be received upon achievement of an agreed upon milestone.",
        "label": "gnpx_MilestonePayment",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_NationalInstituteOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the national institute of health (NIH).",
        "label": "National Institute of Health [Member]"
       }
      }
     },
     "localname": "NationalInstituteOfHealthMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_NonexecutiveEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-executive employees.",
        "label": "Non-executive Employees [Member]"
       }
      }
     },
     "localname": "NonexecutiveEmployeesMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies": {
     "auth_ref": [],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for research and development supplies.",
        "label": "gnpx_PaymentsForProceedsFromResearchAndDevelopmentSupplies",
        "negatedLabel": "Reductions (additions) to research and development supplies"
       }
      }
     },
     "localname": "PaymentsForProceedsFromResearchAndDevelopmentSupplies",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_PerformancebasedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to performance-based warrant.",
        "label": "Performance-based Warrant [Member]"
       }
      }
     },
     "localname": "PerformancebasedWarrantMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Registered Direct Offering.",
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_ResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the research agreement.",
        "label": "Research Agreement [Member]"
       }
      }
     },
     "localname": "ResearchAgreementMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_ResearchAndDevelopmentAssetsCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development assets classified as current.",
        "label": "gnpx_ResearchAndDevelopmentAssetsCurrent",
        "terseLabel": "Research and Development Assets, Current"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetsCurrent",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_ResearchAndDevelopmentAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development assets classified as noncurrent.",
        "label": "Supplies"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetsNoncurrent",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_RoyaltyOnSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sales of royalty.",
        "label": "gnpx_RoyaltyOnSalesPercentage",
        "terseLabel": "Royalty on Sales, Percentage"
       }
      }
     },
     "localname": "RoyaltyOnSalesPercentage",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "gnpx_RoyaltyPaymentAnnualMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum of annual royalty payment.",
        "label": "gnpx_RoyaltyPaymentAnnualMinimum",
        "terseLabel": "Royalty Payment, Annual Minimum"
       }
      }
     },
     "localname": "RoyaltyPaymentAnnualMinimum",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of net sales of licensed technology covered by patents to be earned as royalty.",
        "label": "gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent",
        "terseLabel": "Royalty Percent, Licensed Technology Covered by Patent"
       }
      }
     },
     "localname": "RoyaltyPercentLicensedTechnologyCoveredByPatent",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "gnpx_RoyaltyTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement, as a percentage of net sales of licensed technologies .",
        "label": "gnpx_RoyaltyTerms",
        "terseLabel": "Royalty Term (Year)"
       }
      }
     },
     "localname": "RoyaltyTerms",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "gnpx_ScientificAdvisoryBoardChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "related to the Chairman of the Scientific Advisory Board",
        "label": "Scientific Advisory Board Chairman [Member]"
       }
      }
     },
     "localname": "ScientificAdvisoryBoardChairmanMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award percentage applied on outstanding shares of common stock for automatically increase on each year.",
        "label": "gnpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAppliedOnOutstandingSharesOfCommonStockForAutomaticallyIncreaseOnEachYear",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "gnpx_ShareOfNonroyaltySublicenseIncomePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement.",
        "label": "gnpx_ShareOfNonroyaltySublicenseIncomePercent",
        "terseLabel": "Share of Non-Royalty Sublicense Income, Percent"
       }
      }
     },
     "localname": "ShareOfNonroyaltySublicenseIncomePercent",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "gnpx_SharebasedPaymentArrangementExpenseFutureMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the share-based compensation expense based on future milestone.",
        "label": "gnpx_SharebasedPaymentArrangementExpenseFutureMilestone",
        "terseLabel": "Share-based Payment Arrangement, Expense, Future Milestone"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementExpenseFutureMilestone",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in shares for exercise of cashless warrants.",
        "label": "gnpx_StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants",
        "terseLabel": "Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_StockIssuedDuringPeriodSharesWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued as a result of the exercise of warrants.",
        "label": "gnpx_StockIssuedDuringPeriodSharesWarrantsIssued",
        "terseLabel": "Stock Issued During Period, Shares, Warrants Issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsIssued",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "gnpx_The2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to the 2018 employee stock purchase plan.",
        "label": "The 2018 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "The2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_The2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to the 2018 equity incentive plan.",
        "label": "The 2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "The2018EquityIncentivePlanMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_The2022AtmFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2022 ATM facility.",
        "label": "The 2022 ATM Facility [Member]"
       }
      }
     },
     "localname": "The2022AtmFacilityMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_TimeBasedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents time based options.",
        "label": "Time Based Options [Member]"
       }
      }
     },
     "localname": "TimeBasedOptionsMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_UniversityOfPittsburghMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the University of Pittsburgh.",
        "label": "University of Pittsburgh [Member]"
       }
      }
     },
     "localname": "UniversityOfPittsburghMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes.",
        "label": "Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member]"
       }
      }
     },
     "localname": "UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1DiabetesMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes.",
        "label": "Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member]"
       }
      }
     },
     "localname": "UsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType2DiabetesMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_VestingOfWarrantsForServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "related to the share-based compensation associated with the vesting of warrants",
        "label": "Vesting of Warrants For Service Provider [Member]"
       }
      }
     },
     "localname": "VestingOfWarrantsForServiceProviderMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_WarrantForServiceProvider2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "related to the 2nd warrant for service provider.",
        "label": "Warrant For Service Provider 2 [Member]"
       }
      }
     },
     "localname": "WarrantForServiceProvider2Member",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_WarrantForServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the warrants for service providers",
        "label": "Warrant For Service Provider [Member]"
       }
      }
     },
     "localname": "WarrantForServiceProviderMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_WarrantForServicesProvidedAtIpoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrant for service provided at IPO.",
        "label": "Warrant for Services Provided at IPO [Member]"
       }
      }
     },
     "localname": "WarrantForServicesProvidedAtIpoMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested warrant.",
        "label": "gnpx_WarrantNonvestedAwardCostNotYetRecognizedAmount",
        "terseLabel": "Warrant, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "WarrantNonvestedAwardCostNotYetRecognizedAmount",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gnpx_WarrantsIssuedWithRegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued in connection with Registered Direct Offering",
        "label": "Warrants Issued with Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedWithRegisteredDirectOfferingMember",
     "nsuri": "http://www.genprex.com/20221231",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Restatement of Previously Issued Consolidated Financial Statements - Restatement (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Restatement of Previously Issued Consolidated Financial Statements"
       }
      }
     },
     "localname": "statement-statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Correction of Immaterial Error (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-4-equity-assumptions-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Assumptions (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-equity-assumptions-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Common Stock Purchase Warrant Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-equity-common-stock-purchase-warrant-activity-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-4-equity-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-equity-stock-option-activity-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-4-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity"
       }
      }
     },
     "localname": "statement-statement-note-4-equity-tables",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-9-income-taxes-income-tax-reconciliation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Income Tax Reconciliation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-income-tax-reconciliation-details",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-note-9-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-tables",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gnpx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.genprex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r101",
      "r102",
      "r168",
      "r171",
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r188",
      "r270",
      "r280",
      "r296",
      "r297",
      "r305",
      "r306",
      "r311",
      "r351",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r188",
      "r270",
      "r280",
      "r296",
      "r297",
      "r305",
      "r306",
      "r311",
      "r351",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r185",
      "r188",
      "r218",
      "r219",
      "r220",
      "r269",
      "r270",
      "r280",
      "r296",
      "r297",
      "r305",
      "r306",
      "r311",
      "r347",
      "r351",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r185",
      "r188",
      "r218",
      "r219",
      "r220",
      "r269",
      "r270",
      "r280",
      "r296",
      "r297",
      "r305",
      "r306",
      "r311",
      "r347",
      "r351",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r168",
      "r171",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r113",
      "r114",
      "r125",
      "r247",
      "r248",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r81",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r125",
      "r150",
      "r151",
      "r234",
      "r246",
      "r247",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r81",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r125",
      "r150",
      "r151",
      "r234",
      "r246",
      "r247",
      "r248",
      "r249",
      "r258",
      "r259",
      "r260",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r81",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r117",
      "r125",
      "r234",
      "r246",
      "r247",
      "r248",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r345",
      "r346",
      "r382",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r118",
      "r189",
      "r322",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r118",
      "r189",
      "r322",
      "r323",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r343",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payables"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r310"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r329",
      "r330",
      "r331",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r60",
      "r61",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r74",
      "r87",
      "r99",
      "r134",
      "r137",
      "r141",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r241",
      "r243",
      "r250",
      "r310",
      "r349",
      "r350",
      "r388"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r84",
      "r88",
      "r99",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r241",
      "r243",
      "r250",
      "r310",
      "r349",
      "r350",
      "r388"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r291",
      "r292",
      "r310",
      "r324"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r25",
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, end of year",
        "periodStartLabel": "Cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r20",
      "r70"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "us-gaap_CashEquivalentsAtCarryingValue",
        "terseLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "us-gaap_CashUninsuredAmount",
        "terseLabel": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r50",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "periodEndLabel": "Outstanding, number of warrants (in shares)",
        "periodStartLabel": "Outstanding, number of warrants (in shares)",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r47",
      "r153",
      "r154",
      "r293",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r310"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock $0.001 par value: 200,000,000 shares authorized; 48,105,962 and 47,874,708 shares issued and outstanding, respectively",
        "terseLabel": "Common stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "terseLabel": "Total costs and expenses",
        "totalLabel": "Total costs and expenses",
        "verboseLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanCostRecognized",
        "terseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Security deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r23",
      "r43"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r95",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r248",
      "r249",
      "r276",
      "r279",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share \u2014 basic and diluted (in dollars per share)",
        "terseLabel": "Loss per share (in dollars per share)",
        "verboseLabel": "Loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r100",
      "r229",
      "r236"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Income tax provision at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effect of operating losses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r48",
      "r80",
      "r91",
      "r92",
      "r93",
      "r103",
      "r104",
      "r105",
      "r107",
      "r114",
      "r117",
      "r126",
      "r149",
      "r184",
      "r224",
      "r225",
      "r226",
      "r233",
      "r234",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r260",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting error correction.",
        "label": "Error Correction [Text Block]"
       }
      }
     },
     "localname": "ErrorCorrectionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r23",
      "r42",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse",
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r230",
      "r231",
      "r232",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "us-gaap_IncreaseDecreaseInDepositOtherAssets",
        "negatedLabel": "Deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r40",
      "r271",
      "r272",
      "r273",
      "r275",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intellectual property, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r16",
      "r133"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r99",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r242",
      "r243",
      "r244",
      "r250",
      "r303",
      "r349",
      "r388",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "terseLabel": "Total liabilities",
        "verboseLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r72",
      "r76",
      "r310",
      "r328",
      "r344",
      "r384"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r85",
      "r99",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r242",
      "r243",
      "r244",
      "r250",
      "r310",
      "r349",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r20",
      "r21",
      "r24"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r13",
      "r24",
      "r73",
      "r78",
      "r83",
      "r89",
      "r90",
      "r93",
      "r99",
      "r106",
      "r108",
      "r109",
      "r111",
      "r112",
      "r116",
      "r117",
      "r121",
      "r134",
      "r136",
      "r140",
      "r142",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r249",
      "r250",
      "r304",
      "r349"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r136",
      "r140",
      "r142",
      "r304"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "terseLabel": "Operating (loss) gain",
        "totalLabel": "Operating loss",
        "verboseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "us-gaap_OtherAssetsNoncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "us-gaap_OtherCommitment",
        "terseLabel": "Other Commitment, Total"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r310"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities",
        "terseLabel": "Payment for Contingent Consideration Liability, Operating Activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "us-gaap_PaymentsToAcquireIntangibleAssets",
        "negatedLabel": "Additions to intellectual property"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "us-gaap_PreferredStockParOrStatedValuePerShare",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "us-gaap_PreferredStockSharesAuthorized",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "us-gaap_PreferredStockSharesOutstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuances of common stock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r44",
      "r77",
      "r278",
      "r310"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r62",
      "r79",
      "r396"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r49",
      "r75",
      "r285",
      "r290",
      "r310"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r80",
      "r103",
      "r104",
      "r105",
      "r107",
      "r114",
      "r117",
      "r149",
      "r224",
      "r225",
      "r226",
      "r233",
      "r234",
      "r247",
      "r281",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r94",
      "r99",
      "r131",
      "r132",
      "r135",
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r148",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r250",
      "r277",
      "r349"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r53",
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r50",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free rate:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable, number of shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Options expired or cancelled, number of shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Options expired, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options granted, number of shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding, number of shares (in shares)",
        "periodStartLabel": "Outstanding, number of shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Options exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Options granted, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r196",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (in years): (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r28",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r12",
      "r48",
      "r80",
      "r91",
      "r92",
      "r93",
      "r103",
      "r104",
      "r105",
      "r107",
      "r114",
      "r117",
      "r126",
      "r149",
      "r184",
      "r224",
      "r225",
      "r226",
      "r233",
      "r234",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r260",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables",
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r126",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-balance-sheets-parentheticals",
      "http://www.genprex.com/20221231/role/statement-note-1-description-of-business-and-basis-of-presentation",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.genprex.com/20221231/role/statement-note-3-intellectual-property",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-assumptions-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-common-stock-purchase-warrant-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions",
      "http://www.genprex.com/20221231/role/statement-note-5-401k-savings-transactions-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-6-related-party-transactions",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-8-significant-events-",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-income-tax-reconciliation-details",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables",
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies",
      "http://www.genprex.com/20221231/role/statement-statements-of-cash-flows",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Issuance of stock for services (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of stock for cash (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r48",
      "r49",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Options exercised, number of shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Issuance of stock for services",
        "terseLabel": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r48",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r48",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised",
        "terseLabel": "Stock Issued During Period, Value, Stock Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r37",
      "r310",
      "r328",
      "r344",
      "r384"
     ],
     "calculation": {
      "http://www.genprex.com/20221231/role/statement-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "verboseLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets",
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r51",
      "r98",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-4-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r257",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r257",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r257",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual",
      "http://www.genprex.com/20221231/role/statement-note-4-equity",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-tables",
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.genprex.com/20221231/role/statement-note-4-equity-tables",
      "http://www.genprex.com/20221231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies",
      "http://www.genprex.com/20221231/role/statement-note-7-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events",
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-10-subsequent-events-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "us-gaap_WeightedAverageNumberOfSharesIssuedBasic",
        "terseLabel": "Weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-11-restatement-of-previously-issued-consolidated-financial-statements-restatement-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of common shares \u2014 basic and diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.genprex.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-correction-of-immaterial-error-details",
      "http://www.genprex.com/20221231/role/statement-statements-of-operations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r313": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r314": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r315": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r316": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r317": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r318": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r319": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r321": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001437749-23-008847-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-008847-xbrl.zip
M4$L#!!0    ( .>"?U;\)WC?CN<! #<6 @ )    83%N97<N:G!GW+IW6)/-
MUC=ZA]![KU*D*H@HO0=$FHCTWD1 2BC2(P)1%*2CH"!=I(N ]-X#J(AT$) 6
M!.DD("&2$$Y\VM[O?M_O7-\YU_G^.2.3^\>:F=7NF35K!<^^GBT#C#=T]'4
M$ @$W";^ \Y6@%O:,,^[ &!H"(@# $ )D()) )(_$ "HFS "(.(3]/O#A D@
M_8T!@%W$A/E?F/@$KGL&WO-VO@^<(1DI];6TG(Q-C73T;VK_L9 !ZWSOGC<)
M(P#X^ 8%F.I>$["VL16@^$%<#0*H@*L J;-+X#U-8^.;OSG]_?RO#3/]AQ[
MA.1O7O]]_/^V,;NZ!;H0E;4GXCNN@2X^1-P- *0Y+O<"@@" _#==*#3HWF_\
MD(A9 X@*$O&+W]C]3USV&]_Y$[?_,<?<5(N(1XF.HG5V#G ' /IO1+I B(L[
MD0\]GHBO^+IZ^A+MO_3;DRX>SJY$_%OW2SX^?K_Q*R*^0)Q_CXB)^@"*=_Z-
MI_M_X7_G'_[.SN[_X#_M^J-1_OT&_K]N/M[!?\L0)79:CP ]T]_V$WWX%>IG
M\!O3$O&.[YU;1K]]3<183]<__0X )-0>P7H6?\XG.><2J$7T'\!.Q%=<G:\;
M$/$Y(M;Q];YU\R_ZG;N>.OI$3-PM)##/('US(N8DXEBW0&VSO^:\#O S_4L6
M2>/= "W-O^@?G /^D/M;UF(PU$+S+_X''F[Z?_$'TX=YF%L1,341"X=X6MXB
M8GHBOAP(-3/X:XYJF(?6K;_G! 2;_M9?F(A-W7QUK_W)'QQR-T#']*_Y\3Z!
M?]L+?NWAJ7_K+UP;Y&&N]Z=_P @7YS_T)]H"'G7SU;3XFX];H/7-OVUQ=;NN
M_:?MX TW7PNSO_A@[P5=,_US+2GU/6_CO^:3"KIYZ_ZF"Q*Q;&"(V5]K22V#
MB)OS3_ZD=^\%&9O_J2=IF)?S#>,_]2%]!MP$M(#K@  03.QW #_ "_#\LM.T
M0_SMSQ$=P!D( -P!-T#R+\K?*ZS^&/$E?IH!8< N$;D!@?^LN_;'J!L00J2?
M_D/]\U,2N/O':,@?*Z# .A'[  : -_'WX#]6^?XCS1+X3J1X_C?ISL3N0M37
MF]A_C__/]+^I_Z)H$BDW_Z($_RU1@.'OF>3:Y-?)]<AUR"^2<I.JDZJ0WB1^
M:A"[-*DBJ=+?=OQK/MDZV1@9DFR*;)ELULDS*N _M#0$EHG\=?[RQ9U_]P6I
M*)&G'.DU4C4B=R)G4G92;D"25)8H1Y,40I0L1Z1J_:7W;Z\(_ ?O_V+!O[V-
MO^917:$BH>*@TJ"Z\)\KZ<7IY?[A\MO7_^Z?/W6]\X^_M?X9^4_Y6O_F?5?B
MT^ _9X)CP77@07 /^".X'=P$"("[P,W@S^".W_B?W?7]C]WUMS33/_2!$OEX
M_C=YSG_)_.W)P"L55S:OX/\<"W*#!?T^>%I^]^X'>+I[! EH$F\'-P%]7Y?+
MEP2DKTC+ ,#ON^;/\'7(_N==QO[I7[2HGP"@YGIV=M;^+]I-XEFOCR8>__5_
MT<0ZB6&" P ^)+@$!X3\2?M] 0)DQ"C!0#QI7  ?( 1<(-HC#<@#*H &H W<
M (P <\ &<"1ZV8.XSP. 4" <> 3$  G ,^ ED 7D X5 &5 )U )-0#O0 PP
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MJ@FJ.:L5J"VK"ZC?5G^MO@PY#W&&O($@-80T7#5*-'YH7M3TTGRGN7?MRK6
M:PW7CK64M2*TNJ^#K^M>C[_^19M9VT([2WM11U#'7:="!Z4KI_M MUN/3,]
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M="0%WGZR746T0_Z16&SJX@?/454%23_9SX8#9X DEW4J:PZX1]7*#*5+H+9
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MS/79R,\?I^]N?<G&A-4\O86E66[V68E?9!O=B=4;%4_L?H)2_)X*YT9#YLX
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MXE7';'\)$(EAOG&Y-R31O0S(VJBL'X)*9,<5-$5Q5;U2W7L>[?D* -U1N@.
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M")*M:7E4*>+A59)?,RT7;Z"MQ)]&YYZM]A/C&%#X"]W[YC3<*G*X<3M76;'
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M8B%5U1COG9FE:[3R""8@!S\5+SNNL@_CQR::-S]TYW:4]+?Y*Q0#^FURRYM
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MIK3F/;69M)I)J!!)B4PV\@@%Q#37;A;D8],0O^0_)BP9@/Y'#]Z4OJ&$*5>
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MP/7#+/0Q9Q&O>G <[HSF=\OH@4*?*;H&<7[A%8ZCLJ#I^9CA&/:!H;(&#[X
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MYB^T0,#I.1O9N6)]]<_:1A2H^KD,+^3'D 9:+I.KC&;2CQ4-PI]PMBK5_BB
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MLVM\-3^^&?,1KI.M=<+I=8O"5<$?.GG[_0.W>.A\HD>VL"RA03]/4UVWJ6*
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M\@+5HW/*0W;3U'P!*\ZPH"E#[U,YTN!AA@F6L>?WKSXV[ZM5#A[635_2XX(
M%K<$,C*^ K>+VP\J\2 KF@9% J,T:LI#4Z+H//GSD14*5":KKS:WZ!Z"O*=G
M74_>T!]3;+]0:E)A2<^<Y>18C?-<QD-'=K"2 46R#9-_5FLCS>)YTBQLD\GN
ME+ZS+1%:ZFS/^84^;_1=S#R#BT$OY'4</]%\T, P7RCTI!RKH*6X3^A_M'6
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MXI$OYIVN6 V7T7W^Y=ML*X?/PAVVG0_='8+Z4)G9@!&_O69LE<TK#\.\2HM
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M!400B8IT,0)*AZA("1&B(!(@)HK2FX#"*P@1J4J)U% "$4(1$9$N/0D"2DU
M8 ,I-W[GWC&^[SUGG/'].>/\N.^/_6>-S+777'NN.9]G9:TYN<LF >*#Y5_T
M4&"$M"&?]2_D& ZI1DQ;#J//Y8VZ5CKIY60H.9Z6B:J*\M2YH!HHX\M?;R^V
M9P=&T9;TQ8HD;N(+QFWFX5L$0Z.!27B_2^^<Z^>^3R5S;ZO,FZZ.N.4=NOX\
MR/5AIEX.SF<S/-S5U[];<BTO]H:^:.J]_3HY08NPOZ>%L-Z"]C/SG:N1["/
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MIJF/7]V@1E[.<.BR@+ZZ0)S<]9+B5&.9%S</&.SER61^&,'(F]"S-G.!BK>
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M'@"9W"Q'8,R3L_"'$9FRF!/U T?KZM,73?HROU]%EJ?<5E)3,E.TZ3_W8>R
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M[@Q]GG8FGH%H"</&H,\5NRYD&K\[G#Y%D_C\847HWD?ZQ1^'+Y8U,.&L*%*
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M^D/*^F0<U+8$T6R6'B(GO'2P/C)LKUT@8D3P>NT%;'%';"9D'8#1.MT@UE/
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MH_OQ3[J?K6),6#;@6V8$M_7)!$V<RS)]V^YE\@5B>"@&=L6J):*R&"E4$<
MW?Z!Q OYGPME88!K4/Z1P%*@.XTZ-)DG=V6"PFAQ^D+/E:GD!=O:J)7&)B[A
MRU=N:6:?3&UR85-)O,00PD_:C_F!=!Y\X[^,&QG&(8^^@9= G<^BB:<  @/1
M7K!#)G*A%AD&\?<1S;F0[,*?^T,]5ZM#DSLB=/?J/6ZL$B"6(*3$>=SBP'=2
MIWZGI*'4('.(@)::1GAX[8/NGR#IEVH& WV+A)AEG&.*-DJ%4VI3=;7Z&(M?
MC[D/816\!X]]:1Q-/JN[E7="1IV?_!0'[)32U$$JF&Z\D79J>"TX>YR5]WB1
MXUVN!RL!0HEP),[@!/:7KI8N4^C;E*7B"TY>])@B'4NVOI\%O:(3^4DW;HFB
M#L]S$^U)TF1&/+A[.)S+X18QH62# "[0XYSL=RJ(1'?K?4-7UCK*"WL?^\7_
M=8(.**A?!!-%+*-7B9\R#WLB7N#]6OZ,1%>.Z8X^>%)E=+<YEF36(]6^WY,K
MKL"H5RBZ7-@ 4E@(4?B!\+X]Q'FQM;MBA7LJ7T]O-,Q]WI*02/"RV9I;\8VU
M19F7[J_U)$SG=0@RJ'(*E'XC6^'2X^'"3?$S) 5]34)<97;O40+@[=V$)<Y9
MMU, SG *EQ<N6ZFYY-()9X#<;YD28I]V"WZW[UV7F_ML]FOP?BQ6E2-7HBK!
MAP0<Q",Q2<2S4SV7#4\!C/;IA/S \&4//Z]5E@N,Q\V#.8'=[B@RYXM-,<)?
MO"6A. .Y/9GW?%]]=[HYM7N8$+ [I+):[Z+);)2"E[ZHI]AUJ\](N6@&#$U#
M#'_[FO'R3[;]I3+.-<,^CE+Q\6)#,_=[L69"5[*OPC/JLA!UBBAT)$$/+[-=
M7+ZQ56%<O(D61?!D&4S6KNW?WDT!Z-(3K<ZR*)V[]EXK()?E%/ ^P&Z&+#]*
M-L?S]<QS$4'/X;="Y6=,!]+3&1[<B/:V;SAWS?>!D")<8^*2"Y51"8>DLB<<
MPG!9-,!SH6FHD&V0>_*;V?V:OGVUNF6$'PQGK5D"ZW"PH93#""Z$\TB"!6SB
M."1O8'IF][ 'B7"SI8OX:F15S"7B*G=U/GNCQ:;F35V6P^::*/W'&D_HS;0G
MY1)^IG">B:>&@T]]#)+N-9NFW_,=*>S;;@J"8;5(?,08PO-1V19?>TU]O'&8
M?]LI@!T;H!]*&)-G.O=\:/(ZN]+UQ<6_; X92S)$T;J$12E)S;PN05Y5'DQY
MPF4KG1);VP6;9N^1[_2Q];_.+<L58IQNT!Z".!%%<@+2D"[L$^S9,6I^_^MP
M>AYF;NWU*<"])80P3 S%P7I.(MM(H"B!.WC6<(0!G-EVQBHT>ES/?029QF1P
M0WMZ__*]P!ZY%E7DI66)'^\G[R29).OYR6>V3'E)!]7GWAYTLDB[6.@FQHO8
M&'I=*M[GGGWC5J_&:,U1I;KYB[%C2!Y^C<"-![=)!;1_LIG;<+@W!O&_-^.J
M'!\G2@07>3JJ"C;J7O^05$ W?*&)HD-E+"XD:II\T,#K= ]'4OGQJ>U"L!?Z
M!@S6$1K-X5/T"Z[#GK&6()(/V;R>DDCVP*5C%L(AP!"/?+)XKEJ 8=-X(0?,
M.\D*4@C\('7+.^S^*P"='$1S*6^ZF+!+?$?Y6FZXA(K(5<,_^M%VN]G.:G;V
MD]#C['OL4//>Z=S[@X^_*]ZRR!%.SG3S[3.2! >)%2[(1Q/&[ W=\*R7+7YB
M?M2D3#!J>XT7ZG.*8A6V9S%!OEUC1X6_LDP:?Q^#EL4ZF';?+;#[)S!M3O&&
MSA%BKL>[5;S<_Y(L<8T3?&3U@NU3H-PFZ-HIX)G@5<AY2DZS"I[#K!&9.V5S
MAZF) >.<I;>?_AKJY,*<>V7QTOTS]@EM8*+8:B%MF9Z_&(GI;I"UJ4O'^%UM
M*IGK+M#Q?WD'?^%<4I$..MS7)^)O],F8 5$$K[G,U86*S01V,E]%SV!0G7PR
MU6ZW&U/NUV5.+CLWOY=S-/M.P?1H/\VTNA8U&6<4[&N(Y#Y<<=_9\RC$\ATC
M?[?>Q+,K2GPVC^P<2W%B,"^;^[:I8717/]NV,3DFU4#*Y&D">FHOZ2VCZ@7P
ML_LV#O=PT*^XHZZ3JG?E&L\F9&T;;E=]BD_2[C)>]$G<U@KU. 6<ZR+>P("(
M]JUL>$F(+@ZQBO IGJ_-Y90?FOJ4ADS4=82:/(&LQ;]O5F6Y$)BM\:4VH*:E
M=G)&OHJ<5KQN][#3"@*7RG427DVQ^Y:4;%)KE_8CML$4V7E@;QPO.8ERR9MN
MZC@%\*DJE8 \@%=4Q1:5*JK"F]\T(D_Z4]%\ Z ,J%V2^I=)4 _J Y2/:%'G
MYRK(#E%8GI:I>FF-&5U,DO].]PGDHW0NJ3F <Q7) !<<^$+1<N$NX_2RD;#8
M"%4GHL8W4O5>6LFIGG<S647;99:KA:(3M^K*!P4= O>IC. "LDQC+1+/U<-*
MYUH#FJ&4H55^73)4M?[I?\'(4JTK4&%[C:3FGE>+[)X!GG=%7NX0Z7^\MZ#,
M%3'/4)/Q\=HGZ),+0=*2"[#%'S[ED"=$MU334\"5UZ&HC7++YZ0+T,'<NR-
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M_?>_$_Q?VSX0G%_]_VQIQB G&0QK$X0M(O/848MIP-JSFX.AY8$=F/D689_
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M"=S&>;_#NU-)W0D$'F^N)VZWG>XZZ)U]/V93."8 > 8P>=@E%MO*84.V4YY
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MK*ZEB!DC4QV61D==*+-O]JGKVG[[MQ/>92]OPCZ@$(0$_$PWLI$E';/P43Y
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MMNOUYQ:PT!LUE$85$%0R;WTK&2B%GP)^73RBU@.I[SV..<:!?\6#3@&@>Z>
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MDO4FK#J^IDI6V1S^\0#(_H>/V4"OZ7,/\Z^_DG_I]L]+MRBQZ!3ZY]$!O7.
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M#_,@-,+UOR4_:+9\R)LSI3)V%==4_07Q6%T5R.]MJ*I@)76J&5WKITQ"(U>
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M+[M@,PK=D;0(W,I#A'>G\=Z.8<9.YKDU,C@_3XT9<.0L%$KD3?KK%$TQH^1
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MAYSZMZ_E0D<-V._,G=Y2.XPD"!M=/;1YR1JK[2J6Z)1B^; ^46,M@/]#RN,
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M91H,L+A'\6(YS7(O33V>W-[#_:WOTI19,CC2";[SI6D%M@(9[6:>]"7WVC4
M"L7PO2 OU%Y"BU=,$CS)=$#S E%RQ0<MX/K<6O^<57B;:A?;^*IEK(/_5+R3
MYA>5GP@<F&P,9HEH3L0AUUHP#AUMP=0&_!^/Y;7GD)%MT),?AUZFN):*Q?F$
MV'2)X)XH<*>(G[CZO(+L<F@.S?&G:X*M \A\K9EJ%,XV9"CB0#WE$THM*EB-
MB.$&TFF0AWCED1\?;?[ZI'0FZM258RFL)Y!IFG5&$E/I+)(FI;9AC\!-H,!=
M)L]O.RW@90[G:;@I<0U#N@ C)9P>*5/"B:G23KD-7%3Z*_%.W/ES)_8.41U9
M+B:4?IR,68ES('I%H\]4*D1-'1^HOQ;BRMGBQ16L](IVOV\]5Z\^K+^2!:,A
M%5Q=E#O\KZ_?%M+V%"9ZC7=0[8$8VATZ+Z.@WGE& >P"X6KD<E%7J<HC+W6T
M1BQJWBIT(<NJ)L * [(EY>8WLEUY'TQ\>ZKTVN70!L%DP%/9XS;IYYJ 7&G)
M$Q>G"!UIBGJBP$.1&X=/Z]RR9<.A(]7 O(W2\'2<Q7T=F"_)PWS9/(V_<=9(
MLU=&FG9PEM/>A@'BH5;3N4R9)R]0#C&/0VC76^63>':B$<+ IR7)8%VBV#."
M9^>)\K'X*+^/Q#O$CN\3CS"X87-3-XO7X^.M<CA<:R0I6EEV0_'JB8_/]"1
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MBUW@64M;;\<> <Q;VM=-*:CPK65;$R65MSN"N8H=?J%%[;@O2UH6*IVP3#Y
M@@@]Y\J\.C@->'^"C5$VBWUCWGL04^\[V3:ZW_MQZ*MI@F+ ^6W,?'$1EWF&
M(*7-I&#)W+6P0*J*E-_+UM-OD"]U:?8#;T+^A(-KBZ]4UX>9;G;27%?RKH><
M>I%R4M^F9P(:(<3LQYZI)+R '@3?[]?4=>:H86G]?AHN<6FXG]V3K^:-E424
M47K5==7732%3;IQAV@J4]AKR>(>=?.-@HU@/(QT<%==8/"53I6YS>[+T#(\U
MYW;3IZ$3WB^ZA/)"]$@EK!'00C@,(#IL]D%ANJV-PGUKI&]]]HV9,C!K6&0G
M?(K]Q]$YV8=<'YQ5NI>A)[0/T14'\=:#%5B4^I'>2-&,_HTE>$E[=E(A-X\L
MT=;69DWT?,0.!I./LPQY./C@*8?V\#/ON=!DO'+N3/%P5:))M3(/%@43.5?F
M?N^<UB>)]$0IC:YAO[O[( Z\(;XB@RFZT,!-K6*YJ1XV(F>X9QPU%>.B3HWA
M3%#Q-7FS5+5C&./T59NE>-SB?B0>&.@^OUV4MH-#\T":H#QT!Q8LO2FUA'??
MH/CL>6#"AI<4\R[J%)QTV>HH'Z^935%(1_C/A7(<^1/]V9_8F##= UH>2PV5
MI6LG6?=D-\RM<(V]/]_\<OKQB -_>_]QG,4P@HNN !5Y""S?_Q7,WWB^\5N4
M^W;A3*2>[]-6KK//_.ISGQ9?Z?A:/(-[[_;6F8%>&4CRBQ45AP1T_0_:WC.J
MR2!:&XV*"B(@("!=!4&Z2*]1D28"4J07E1IBB/0@)0H(T@4$I @JO4L+/:$C
M(D0ZA)K0I"> (4 2;CQKW;7..=_Y[G?OC_MC\F_>O'MFSWZ>9]Z9O7TI*_FN
M,['U<\J]LH\L(+,U=F9&0.M5?P-KA8&"/"F!2C%[AY^&#871@89%7?$FIP :
M)R7IV.*XNI=_GP*PG(X<O.<J4WCF>'&1;(KP8L:]H]#/FX/J<B=&Y,=C<)?$
M,[.S($WA=WXLW-/3QDOL9;9WY]LQ+3HO9,^M;CM3)NC_:$C0J"/I85T/(9IP
MD1A213R<!M8.4M$'B;6["\L[5%H(SA*H3PS!3W8@^4AP@72_/'=_3:[?JSR9
MMH,\?6[/A;VY(\CX N>!'0T6A97GL 'Z\=LOOO\LB\UK=GQN;@9.[=TQ,JE)
MEW>4:<W2VZY(LCC\S%/)L/^7ZL;%.T]\A 8KA BL_0(RM.HO&;/#PG$B;7XA
M!#;<Y,-)=7THN)B%P[8PT2-M_E6DT#-X<,>=+\_\  <<Z2?\P2#"7?)]O,1F
M\V%BN6]3*Z-2C/KC^3OCSYOJ)IZQWK#]K&(IV2(\.\3 :_)&XH?"SCPSWKA=
M\%JP7A!-"'7A)RT(KOFC<[7KAZ_0@=[.%NSZ]7QIL^4S":JRE0AH.,W/D,+N
MG*]MW36Y)@X6&/,Q"O6M'BFZ!27WDC'DHF7>LV4Z04XWVX+A'"L;"J_^XKWC
M/+2E0,6-TM:]ZRIU"W*&0"][G]LEVH[A+,FXK'>/_$:](&3#$C!7F;["M_&@
MH:'!NH.C6"*$4E>?RTW:[QXHW\1\_!"L,ZS [].%". TLZV*%$587[8P:?E6
MEB'UP#A5:K]LS+'6^%VH=+ ?'AB^(QEL3+#MPH2V8:,:)Q0H4(N&QC P\2%8
MI?RFW0^N0;IF!$?>+;TAB?634P ;68Y4P$7T/6X(\_N+#^*MJJTX8(<[!;H/
M9]RI^-3YU47TS9GKXU51*%:JP SL(89DV1UZA=J%;RN-3#0:>PX.D9[3/8^H
M9NV]Z//6VJGQ6[;8>(YC>I#*0#+YMVD<FUF<3=V+RJ7;UH^D5'0S]O7GY@5%
MLPO.Q_3X:/L$WZT-\/(\;I,N"-)@KZG1M!W3E"4;$>!;V"7CN,R&][SW6_':
MLZI&N5_^'%X\T5RUY?V#0S9FLV8P=4&?:G6*7#3+/)[I%! :5Z#X=,LN6*\K
M(A0MO?H*ZPL.,:(YG-%V61'M>\Z7]1B&[EUL>P6_&LR+1]GC4U%= U578- N
MSM?$@@L(S-/Z \Z]S8O;C-Y=3GRI.?<8[ZS4]MELRH<$M6MRD5++0:]#\[ :
MP)YC2N?\AL6=^8?IAZ-TEZJ$@QKDZ #,<F\D>M#54R_]>0^O65X<-'WRB.GV
M".5G0DG93%K!\M'?%&1-\\'=60T[#<=YBU6+F!3OMK7=AJ+/2RZ%L36UF\7E
M#TE9V(Q@]WE>1S9W*9P";\)'&9Q27MPIH'2NI4BYU\O6#U]_>ZP("N*LK*RL
M\"6"FT/0W^+U?I(KU$!%H1T6\O$BFPYCV-K:=SO2E;POO8I7$DE!Q#S]$<_Z
M[4>\:LH.N TLHH\GP>H4$(7R.+9=7.N8@49FNF4I#L3;8.%P1>7[E.X# <KF
M3B/CF^I@@]CE=TL/9!9RH3M]K;FS#2'L-%#:2'-\M&O=EKY!1FE\".8C:4#P
MZ,?[SC->97;2HMG,5_RF4%N)8Y/&_V77*K01B.'J:T9UH0#V'CR>;S!_O\>/
M$)QR!Y*G+RW]8JS;.=?(]W80#ED^TF27Z.@Z]S8L7EGBUA'BN*$%:H'^46U5
MVIA96>\6*+>8&"FX9T)6.@4\5X-2>.J/W1S3J1P30*P 022]6-)U:4O)Q$[2
M(_!C6>0ES<:^)<=\().Z?AFLI=/B.*$V#_YLSIYITWGT:.1A5.'^VTC@W/;?
M*AV1ITS'_U\+58D6PW^8[E.1+J> X7B'54,BU;%D7UW[%"!-A7_E,."@]#1#
M$C9V.*A;/LTRR\SBXA*SFLZ;FA?M!GP(N^V&\J./N[J;GUVPYOY!TQ"Q32*H
MBDM4@U Z>'\@7I 2AW&CIFD[3J3"5(;P1]2HL5>[7<#TC:LF=NCNJF@+ZIE1
M5&3(@U?![^4F*87_Z%%5^J]:2<US3)(.TH_NQ+1 ]^QGIF^5N8T_Q_^5,#<O
MD4 (LB%OV9(N&E&Y_S)T[%U'4]7_@SSMYW8[1C?#(Z]#?'ILQG,^,XW_LBC<
MV3/A<P79"9N$P7@_O3/9 %N:CTLKM.F !_HS@S*&[-%[ F_\.?8GR5>KL'&Y
MW"A7/?*=M->IRZI]T77NTN\B7NYWG&FY+]SE_F,J'[$3SEVU:K<9O=9]5"^I
M>=,HAS=#.&U=R4UT^.?"K9J-A063]E. Z[,UB^35XI30JH9DFFMJ5%D1"I.P
MNVSK/%+$ C=0V>:NY&O(QYKSF4??[/?H)\L@#L9?*LV,*7E4;M))7WKHN7I"
MT3L_Z)4?M^IR=1/^"J<YA0E'\7._$;X;IK<6<^0Z20PDM070P$Z><#%AAV?)
M;O3&1+!@_CQHR[6NOCKQ<>KSL347G$IED;-3MM,SCFBL#/,<+)WH2=+"NQF0
MP+AX%EQ4>+!NP:S'ZXACH?MN>0H%DQD!)2$H7F'K#XJ*U6[[K[2ODG3/YG%6
M\VWGSWY9&F#\6>H3,-ZIGF0T$9"V.6>Z5)+[PG.TX&?E5O[G%1=&7<.KN7(-
MR3-!(2X%#L%"O\DL^:1O/QWI;4D!V"QTP7ISW&.4&WYFV7;@DN"1\_3-NZK[
M"7_-EI2Z9<)"Z4EO)1V XZT7G^.,V4&@@EG=LG[!7/@SNQKM.R\310-O!2PZ
MX\$X1_[0P84KK8(G=\CW)EN%OFTJ(5!7U"U+K$FU7:8=HME.]HXA.15@3KDF
MIS-\9Z+B4U%1"MN:PLAZ$@?!C/BFEE#4E<M.ZEW#1:S[86<J@/="3/D]ALLM
MZ$9_Q="__?91\>G/8J9&GJV2+F78F)\8SNWI/.AVO]A)38%?Q3;(R">H1$?<
M87MY"<TW7Q8E6=PKR @I7"K]G/-YS(ECN@7\+019N5"3WL[X.:!3:0%?UJJ@
M^)6/L0PT"JCPN2:A+DXQN*UF?T_Y#W@XUXAD</+0'FR3<A\+Y#2\D"B0568'
M8:M9'SWCPR<G(,<.N 4X=FT5F5Q4>D]F7T1/[6I/RD>.U5==VF04?"]B *^K
MR(Q7]#L+NA-J?LMIMH_;9-M"2I.>1-/3E'R@^\ N,ZG% L^9$B#U/O):*_#\
MK.H?>SF0K'H>R<B)LN"S:4>*8Q8(*.%[>;3$)1UHV(@HTTF(D?6Q&WYD$*)B
MYF\I7Q!3)NB'7?J)L2L5D\_F^]MBH+-%G"".3VTB;Y(2B5;&U_X@I0CJIP!&
M6]NQBAOC==LZ&PH@&:G)E<C%9R^T>>^4MR]!ZPUQ]D%$>[Q2[_OZ;0?HNV;+
M!.$]/X76)O.$)=\- 8F4I#JYDLO"UP5\,H_ V,ATG''$,:K+=F @D1_&J4#2
M+0*EV$W!F%H?K&)E1/T1R:+Q$8]+M7PO?I!H),WAJW !\<'0DP=@ 497>Z Y
M?N+=ZK0CR46XD6"(FN+V9!M>N1:&=9(^>_Z9L(OIF;-M&:\H/'ZI#$OBXL$5
M8JK))@UU$2K0K5ESB$1==EK.X<WQ5^4C^27-25T] QEJMPNIW#3&S18P,@F"
M%LEIYI+B\5F+S61#_"D@-OCI%Q([E:WM]3&OO: 9,E(&:-8RTWR#6]W@NDFJ
M,/N;.Z\M^KH7,"E8=$<5NW0B;I<7%M357/>AXD<]JFEO>>_3!V$A/K'K>[#%
MR3XX.VW:1HG?6QJJ\8+A*P*,)#>LFL;%CD.'V\@LO;;J\4QE-]4(]V%VR0_O
M<1$I=6Z_ /OV7.&M&@1>8CXE7YJLZ^&(G>MMP?=V&4XZ3Y#%B <G-G/&_(.M
M#TQ+*RO2+Z[^K,E^T1K]:E[ _*NZOUB]D4R&BD3GMK).O_E'*.>N@/TM3L38
MCG6/BXHNXWU1,0DUD-31YP5Q_R"UC<_DQ"IYEMAY#H(=9NPU]/T!>!6_#%(L
M69Z38*3/ 2H(?SA@K8/?@3??V[0D<R]IB.)$W[WT&V1\TC!>%V)Z0Z-@I<4S
M<E6NW5=C;"E\'OF0\I4&<5*"7:S!]'CDFQS1+(,TW$)[CF13C;_%A"]=_-K>
M;LQE>O*?=J;>\:0/?'R6TYR<G,>&[]H*/K<J(M*J)>_<OT27<&T,4%RJ? D
M.+/N*)&U>.?J;;.R\!*Q$X-ZW]2/M@DMFR)9!D96TVH-14UO>EZ4CF7+7C%9
M00RV(*J*DFTT=VOF/=JP**9Y6(M50F^OQCY0LF^GNVTZL6@_KRN4MY7@7\T?
M'Q>T&FJ=.!<=5"MHO.9PM @]9TUBT>6<Z I.W#>48\ET_:LY'UX?E,W:P;'_
MDSI20",4\^D!Y.K]G>/7T]RN1ZUW7JTDU 9)ST./Q]29%FV!9T&,T)<M*]!,
MT%3POE()\8"_S".F *=23R^O5B+?"*E4H(NK8[5325"YYFO:SB8WJERU\5*
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MY^0^[&(7D<I"N'7X]F"!%=20EK+>7'ZEIWSP;-O8GB-_QU(D4,SD27SEUJ\
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M^!* +%T."188_RT_+2E0_;'3WOE.EG8F9 N=N80528[K,<=DL/81+[Y>3W[
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M']9^ .?_ZX0;UAN9__</4/_+?#^;^P]02P,$%     @ YX)_5B]2&8,R?@$
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M[?_+PN3D'. (B7H=PC>= AR](-P. "1/'7W] P& [!==,"30]Q>^ V$6?TA
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M+/FI]+/OP.)@]3#DB/SHR?'IXR:" 6'NQ.ODQ-?!W^%W* "#*K$+E%EO%P,
MK14 ,$-Y&Y7-GUSP=R'ZD[\"?W+M_QO\)U_\710 H )Z_0KCM=H!X#541>Y
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M&\)M>"IVR24#"LU@7Q=HH=2X-LG"<&17U=9+NCW9QB5YSLBOSI&IIFJ^0;R
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M>+T11X.NTT@IFD=&<+:$AA8:OIQ90SB94Y)<J>+ISVO+6([TR]4.BT;2)YP
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MV9]E^XCJA/IF^AIOU/"Y^_/-W,B^,+PD-X%2 G/,O#3?<+\ 7]PMO1&NV-<
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M>!7=,KV57K5F+9HH.!Y$JV! S5E9Y#$K%!TQE,3#5$)L'N1\=4#1;RV/%N&
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M(MX^%J5=-*6['RI?<E5R(4_]U3E]SLA0EB=Y[RT2T//.9/4:;-"I"ZN%QY\
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M2<A?[,-,^;=.5R3\@5M?Z:9(#4L!=I0E5/ZCX/YU"3>+=4ZYZ!]P:3/1,K&
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MU_@V0D(AW#['SC66!^18<MVQCV!_:*9[@^,[H0NY$$%_]N$@H_,D^D8[S:>
MGAQ&=;Q!*Z@YH-<4P2S+4(FGTNY(#DU\"L^8 _U*%YGY:Y9X!#%"*3WX8*3
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M1V+9:# Z FBAP "EEJW9THV\YQ=<-B"\NS\?=6"^H,LI<Y>B?D%+S*PTWYO
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MU#>#C]2RE:_Z1=P)XU Y4>)Z_+,EWA-@Z?)Q)0!*RR4/])(D_#'* 0;RU+2
M8AI?G>'S+\3^.I?DW!S!(9YQSL\FKU7F]*T>V.JRFJ'K3J<H/LK H1J>XVY
MC1R(V=0ZL+.&N%.G^\IKWB[<$\J'<ZEM49U7ML1 W4DXW1<Z[^PO0Y09#D <
MB0?K,T;L6>8K(N.DK&DN%+_D=GOE&*UD*-C=M8^B'^EK1P\[ZZ;@^_5*L==:
MPZ=.QRREY;,7?A&:D<E&PD NV3>+S(II;0,X,.,FU=%M(JV T@'N:6E1+X);
ME^OWJ%UUL>+M!2/5QC]).,NOB<]59:078WVAQ)8>:)-?W&[R*/L";'Q7D_>>
M>NG&8Z6."J."RA^S5[2>FQN AWXE6:S>/E:E&L7U76:F8$4=<F>Z=')SUTUG
M?4\\9L?%Y&'F]8RL)]^.?+)#?3YW&:*-^0AK-D_L/(4VHM:FTZZ0[+/ZW-6F
MFQ9@/!L"@/NV57R?I,VKC6_WLA9:,RJ:>FU2ZJX-MZ^^[OI('5O@,X1VP:@.
MFMQ E.86.,EYK>@M"M,/97<E;MQNP0BGCQ)#U%5^\=QI!UGXM<8M>R2'RGI\
M,OD;G]1Y$=#O,N*G*1$J424F#>,,"-O7C3!K5$K>+?^R%Z-1USR./@B_N"Q9
MM4Q*UP/W@H4/HLW@!2:V"$F9A^J!QQTG:D]F6LIS9L6M.>P,GU]&W+8O? ""
MGC620FO"-5.A+%E-;0\J1N5\[[,/(/!K&;(Y3Y^<\KZC3::DZYHE/?P@H&HF
MW>][5"GEH05WBNV</GD[41O'#=0Q'&C8/@P;+>80Q*,=H9FHHR,K1I-'1:G;
M&(M'WJ:XY.;,;ZLK_;X.\W+X[94=X_':C8#/PZ;\B72Y&F_7--VX4*.SG)VT
MKEJ*4I"7BWT0^LKCCV%J,$;KH+3]"'7;_(NV#+S?2&;RSR%(Y-Z9TI]B=B3S
MU76QZ]+5-]\K6G9#T;P5"C<XA@E4TP*[10,N&IOI)$/5SZ_LQ^.:ZE"F^D1<
M#7O&RA5Z5R%*O4DIH.9;PI,LE0MF;O6U Q?W/>NWT(@2&"K)^I2,BU7^[3CM
M/"N%5K/W5STXO<3UHYX9<XC+S93]_YY[_]='^/:6R[Y) +0^?O/G"C@A;U)S
M#JU:/AC^+2LZ^+1XDL"O'6%CYBY6B]! ZD:*8KO,"(A(S<N%.P$&EC15U[Q#
MT)TIG7]QGW5\\]979'H#VD"T[B1F&A8Q-I?>36@9Z(9CCP&3=C3MM*>\C,<I
M&?ZS5?Y_[<RD/#_U23T\NM!,^WW<L.KS(>@N"9#_W@T!E ]!O:.V?4M<,"'W
MC;SL>#JRH'J=.XQ^QRH>>9IS-L"SDNO[R<N[>"N.I(HKSW%$O]07'O<H<&/H
M4R1IC)&>.<:0K%D>8;EN3UHN\P3B#)0B@F3'CGO]]TY==?=ATO"^B0"#E$&@
MVPC]@XHQ_5:AO21 &V_QI5,&WK(D 510$"Z]MT.%;,OG%G_FC/>$/WCC?+'@
M^:\;FT=7'WV&LTR*(G@K!+JIO_\(<.QUSK+V*EJ_@.-#Y4F<[W1H_"SP<J#Z
MPC$L(A4VZ896I;4Q>2D'.(P^PY&FFZ*M1.O/QU+:?H9P#R,N.%I%7,VS\3[7
M[ZEOHG,G9=?+[2*Z)^]\G/RMSVJW[58N3G4KY+&L-_GS,)/[),OM[64Q3PCL
MGY&"@ ]P3"$\UTA(.N^@?&S:3_I6SA3!U"GKR2*;BM!';<!A7YXYAQ.&+K\\
M!#7R%56B,&>T:GS'/^=3-/G@_*TF*(&TN^_3X\SM,VO;4UX)<G'L(0 'ZAXX
MAL2K!>$FDNXY%^#C-^].+K=.^0JY64M;"%Q/ WU=N#SX<<R91EA09G*%4&'T
M]9!VVFRL_3Y&2Z"O]F=FOKJU\"-[E4-0]<TY"W&^N6KJB[G)Y+*;[DISC.80
M[ZIQ=(-YCYXN0\;A-2N"GZ]YPY"@@6:RSXX3-QYH5[6\";V\''DK[S<NFD!]
M2$IEF.][_1 KO#"NQ4J@&J])\X[.9@5"KHOS+]VNAI5[Z@[]F&/7OE'&[2':
MA;__GF79G3!BG1UK?;0+%)['R A[D1++0Q 633C(Z7QU\(RPG HY0O!2?TAR
M8>7_V-59],U[828UJ"ALRZ)+2_7EI]+FB_P"&R[7RMG/H>O:,(2W,:?7@C._
M9UH^QN1G0Y?QA'>:# ,K.LO^&<-#:!5QWR1GXWR?;UI^FS-9N !I;3 +7?WC
M$4/EQ0A@AF!-A#XPH(3= D=6^O./%F_0^1Z-\0-A=Y[F2/6:#491C"2<;*ZU
M+J>L"G*-[9Z$0?_[0_>Z9C2TQ7T!)XNZK3M[-\64[T/YT/W=B\\>P;0Q>VG#
M<AZ&JM*R>EJ4GPZ.R7H7>)H=?*O&0_,8MK&/- &]*N-#4(R/RRW@ N5(C0IH
M,*#FXTSMXJ?0R^M&E=;A^.[__OJ/'Y#\NQ5-WC+I(XIF%:'E6[&;PUL0VY1%
M=Y=$IRON$@F+"AFO?+5NE%G]!^F#MO\=TD$\UVO@)8U=1K>CRM1_!TLBJ6%_
M:/\9V$QD\1$&<.U+;303U^+)X6AC2L0521F_W@L'G6N+A [!9_(I^Y7LLDV-
ME1Z>.+5 )O;MV(E+KU:?KV:ZX\J_LXC9U=^2L0ZE6G5<H8C^/HF#32BDUJ4.
M^7Z"9J/]_L^Y^2#PH 'KA>=B+L*.:1A!@!F$KPS?VL[2OP6K5M%966_-CK/?
M[G@9FEW":Q_$8I<S_UMPK!#+'S(F"/!M]$VNR\I-SEYOE6PN;;F9D&,L1RS6
M[@F4>8BJ#O LDE9[TT%BL!4WLU?3ZGI5'^(!Y136X761WK%7[3MA/C_V2VV'
M5 R^10V32ZP?W']M/7GO\:,GX32Y]<^QHJ;N^ZY\%B+__KOZ$6 %AG34;R;7
M NW4M@LUPGD]3Z-1U!!NW.GKXG95Z4JG^:CP8";;TU>"U9P4PIL3P#"=P/J(
M((/CH!;M%$:QU!JU[3)2)@0K3A^"XI5<O-N#I[\]S2[V-9P[[365Y1 ]<$7K
M(-4']7)- F$YO=<O030?=C_%*E3EHV:J%]:+(3F=VVLMP=G2^A5V-_' ZE1X
MRH=-$=L.C!MFDM (2\/>UTPBMO02I+]:O;DG64KY9"VLI"\EE_Q!74XZEK-"
M_^&=7VH/;>!T"+F%(?F7&M;S>,@5E=M?:$ASJ$:V;4;=49-_%NKH/QDN^]YG
MK"F2:]\$VR7!Y&!^.01QHL66+1LC;;N-Q*@RO7^=?7+C?N5\TLHZ59I^QCM8
MGK]DS>M]8>FLJ8&[8 KA46$; 0C.:6:#),1OES;.8WL@9[!=59"=J\RSV+D^
M5O5+FW9:&-+YK(2G!-L79FGO@80AIA?31:+:8$'8+GV#"Q1UY8^ZLO+OFVB&
MJV&S\8Z=+A6"YI"<-DY3H@[]>][R(0@!!EC8=$,6VE;,&<J%.FVT4CT2':T7
MN*AYRPJ.53GU#6,BA29=&APK\[*5L/8L\&-YD"<A#L,;5FS2>BWGL6OZ3$ZW
M0]#I<H#57A[[^ /U]_@N''"F@H'[/H#<EVZ"'DC"]YP/<@B^)##F$^P(6I_Z
MO;O^GAV [3G;KH-\8Z/\066GO2(B]H;-=\-X<?QSI@Z+5^W8(Q@CAA/-,65W
M^!"4D%@%]-CA;G6ZN"%.Q?IDMYPUW;&9'C/.2CK[?NC1QN?29NR:^&9GC:NA
MWHVF%?C!C%$OP-("!9?_^RP.LP&\>J@HJQYG3/8];YU6G\;09R^E@H53KVC8
M!C^Y5&M.+SPHT (39Y<U$XVD@6+K:YI@H'(1@9?M#CK^R31#04HZ[D28W"9J
M-/S/6HF#]58$4[G*.3];PCAP$O84L&8UY_=#T- -+=B^Z"[LX*@>,Q:^JCGW
MG<F)HX;1I8%O"!I'5VZA3KY[4WUAEYC]M!V%-/P"],]8\!6CA,/ <;:I$RH@
M.7V)W)1V'<]M8"A[+7_I.WF (7/F$*2,I4XR>W]B_S1?VS=A\K(&^W/?@$,0
M_?PZ84_+L9+5_52+[5@<]08A(4\SD1$>0OFAK<YA@]"8"]#+)/9ZGG]I\^U<
MLTNP[,.+^&L'*5 O+!>F&W:LB J.\ITI_T+N*#QPN=4JIBOK/?J!^:#R7,;'
M 9&:Z[<48U,56\^5/*V2?E3']Q7/Y/@G^]_RKGD1_V,)US480V26R4WPVM==
M@D-X,/R6[#4TONF\R=LS!0;#4%Z"6:HP3?O+G_T$#-UVR(AE8*(>H/4/\I#H
M!T:JK-:3,H#B49D[W_?-H#R+3:,+E@]<C#!EFCE7\857Y9Y+!RI+F?_DZ-<$
M='.7-?L/0<D8)5IY0R2-SQ#6E_=JKV:=N&$IS:U5[=1\)F;+M9#=.IA X\%O
MLFI@#$XD 4;IAZ 4QP8K@;A8(XOF_,6:L8*:Z/ZIFBVE$H5FZS;-W."Y&L)R
MTR&H/C6[_4$/+:N;VG,BYJI51/:M&V=!1]5 '/=^=@IBNQRQ?NEIAR!!+1PG
MRIR2$UV+RG+-+GKW+DKUJ>)PC)^<: J?R)T=\VO_2,R3V0>O#D$_3M)8\9MC
M_!!$2]IB]0 @A^L"SWNM5,0Q3Z)\]P<FX$MB[R/RM3MG!.&AOJDK^E^N<O/6
M1J0%N=:G"8YE#QV"Y%L%1R[E:GD%MFU&_H?WD?7_:0DZU/=-. U&(?6E@U'=
MV&0<KQI&@O337;E]LE$U G%7^V35SZ"M'4VGK!B_8=Z*_=?+?B*;CVX<<1=;
MQLV5W*!">S=@_,K]^%3GFB2WIMVU^$IXZ-_'(7]BZDZ8N/S+N*J+K4P<YW0X
M]B#XU_,;'+WNYX$+-'F;+]! )>K8TRUMA'U_ZOU.P7<SZAF-V_RGJ;ME#:=*
M^-.>SEC0ZQS4VBQ!63 5M/;!,X.0Y:;IIO2CP(65EN1V^>7\=#:@;*"W+0B2
M' +OD+JY:)1=\=)5*Z=N/O?E26BK2WJ.KM?)@4U3X2,[I$V.8E1Z/[:18V [
M^7%+#,-RN0!,N5U3:OSZ9^')QGW1M]J=!16*C;G!+JN-IRRM8AQ[GB?>>2)^
M H RN6:IM1N]AR#P(<BOP)Z,[[(5"H *&)RD$ 10\;T8P[Q1M3];$5;*MVWK
M"DR"=*W"M'*"JA4@RL-J#L<\<//7OF.$&(I4TD="_!XV%BU?2OR!D9U@C-7?
M6?@^'#V248;VSAIN:W&O]F?; 7>1ZOWZP.FZ4 'E5D S@KR1+L7@H"EE5/],
M7I:"<?]8Z6T8##"LB<+L+AVLO/0]MW3=0B'04>H%W\**YF;;RG_KF7"B@P]!
M)QK(R!0#[O)U'&>[>FEYADZL;*KA2#/FY/L/TW_^-(=:C/QVWOYW)_;%M2/W
MC>";>&()_1>MI0M+E-WX:,0!V,-I1Q%B71P#SDV]S#/)9OXUQZ>:F;=4%33J
MK?;+D04K[I?5]&;%R&! /;?['^;4("2Y217&#I@[4"'Q!F%%[DLF0>JK,ZW%
MKNVIP=(W6Q?Z0$ER$VW'V$UR/HZ"T"2R[=RU[P,D+KFZ)BJAM\"^9TD%F";S
M>KE3E^J6+Z*ERG_2;R<)_HJ(-!(E-O]*AA#%00H^!CIW"I#IL'>_ 0C%-DD#
M@>%PA>-X#%1II,LTGYRG9:A0J3G8M:R>0<2;42^?%"U?VK-AZ7OGQQL0BO!M
MS01<BVTW-A8BV CC J+[1?,"FRAL_FIASE\-2^.V&&UNLU82+>F?L=FZG]H&
M07ZG\LFD!0)9,]E(9<.(>Y+A!0^J!=!+O.8'@F0UA/,D]-[M=O^^YA\/KB8I
M*IYX=EENF6V5,+>R?+#=C05.-ZTN@0$8Y5*[%,5J$>DPT[0M"<@:7KA-?3Y!
MN9HV<&>Q<V\B_$Y_\XAXCV2MM,I]_/B)G4/0_ )]'+B[?\?UW@T&E!:2FQ"H
M]:+H_8=8CSSBS6,+[?FQEAF2%@K$!:7+XYV3<1=K_3X2FLMF624/W.9'B^63
M61KW1]5-JN<AG%ZH,%66=CJ$H+(N%2Y*//*21\7/]?HW$_ZN6T_?/XEH$OD]
MM@7=]T"MD/VV),B0."@8(_FSTXC&D=@.?0-DFA%HYW\\6W"9'X5SF7H=6U@-
M;77E 1U]E3<&( ]!QRV \$JTP)2!XPHYDDJX_=]=/6M4FQ;RXDWKM2*?FMXJ
M>>?+S<4F89VBEB4HD>C>+BK( V244]P.[<51[6RCC$2!8#)6U!6U;]OZA>&?
M*_BC_B<]5R]F=C#PRM=W49Q+#OQUW&<>'=4Y"0N@X%%XY@DV:O!'UL!LQ'*N
M+QE,W&\WKAWP4V]J&SAG$4ON>UUX(T[?]Q5-\O.GSQ8G^$Q!$2(BO[>W2O:]
M@7AZ()!*'>MB"E'=LU; _&@KG%T::=^^%UXT/Z^8W3HF;S#*T_8R^UVEV)NJ
MU'T,2IG\;3:6H4^3OS7!.$?CAC6VM.*N3+A_=T_JM54UY38<$=VW.R-CX:1X
M9SKAOE_ :W!H<7O<&/TW8/46#9ME<,%75%W&A%#.^HG:*/4:#=]H6QT:EU^:
MU?.4C_4#$CSCX84>S%\HO#XMGB$"^;CW*YT<@8MKC4U/49I"8UD%9-_0:;GA
M%C K>=VYM$QPM4<K0.D$N_^@6R;BHE?T9<C-F^Z0&FR7.8;WA[LZS3;^.RVJ
MMF-Y7\;D9F>='H)HJ7:;31?KYYN@.&R:\<'#S^?3ISX/!C]+)9^CE.D)#0"\
M!O7PMVT#=2R]T=#*.<<Z-.!1QY6N^\M-+^E=:L8^J:*KX9F)1Y6$WSZP 1FE
M%;<K?_SOYIBG4*'V,Y2:8#,@H_AK@#O7!*&E*7$M*>(FO)Q!^CFDF'J]N0+N
MB>HQ"_I;"0%CNVY@V%!574RUV6JC4P$- 1B.^FB[&1^=,(L9>C AEW?";)PC
MC^.!@T^B&Q<'[V79?Z;AR"V)_>LF^] -''?U@GFN(T3(P M!/KUJ]93SW07G
M15?N*$[]C_LZBR7'MC^C:F$4988PN(O%1(PNXPJ5E*;41,V-PT@#<#.:;!$E
M8N.=.F@*KW&?$OM,XU:BW,TV!:'3XN*CH(AID>^0AK];0=0->OFD=A7^")"W
MX ;C<U6OK>*87VMJG5SU%I3+X<I0O/PC3%6D)^U6AKL/M8)Y8I1J1:GH1HJB
MYM%6(45 1!=QM?7XYE[MR^![ON_%[)Q[Y>QE?Q(#3B$R>B5M+JM4)('V[))6
M,,>87PIY#LK1[ ;6RVZ8L5X]7:)/?>8=AY5,(D6^V4(IR=3I5#;?^4R5=Y\^
MK3K&H#29)QX267D$ZH]PN0,XK2!Y>ZBBX]J0S7V"^BZ2W\7P58OE*1<E=!3E
ME(A,,L+'E[O@-=MZGNH:;BZ:#DP1[J4G8$Y2:S^0#:5,IAHCN:_3%'0[(30U
M]U,3%4V$"YSDB!<K*>:/"BW5!8X)/PI1O.-HI<D0QBW?ATBZD#=Q EJ/:/<?
MSS+D,^<;[1.V=J'D^DRLYF!:Z*=YJ?=^GXA2IYX8]B?1%L86MLFR.%JP/55Q
M('DEOL_Y>MA#:R\E7&AG0%/,6)#T>?'V#]_2Y-Q*8@NZHT)IKK:;NZQ2&5#-
MMQS*&!HS:"GM=CU(KZ6V^*I;2/G$+O?MIH;]F_S=-,3[;H\VM:<"-F'GCONS
M_4Q2[6)<8GU0'^"F$'A05<X-P,LB&>6N4.[*];_!"C,T8\^)<"M4W%68WMPG
MG7\T9#JTSY70"P74(!_3V1@B-%B:.MHAB,(+[6JY+9J778@K=XMLU>E\87I_
M@R>C2NN\3)\OJ+]+"B[4!XHT-D7AXZ'+12R7A7:CR9M3T_(IO\,I,@\NJV_)
M3R )CWX/K/4(;Z]N-F>O]"1\]XXLE7DO;S3]_W*!WW]5^Z?^.ZG.E$=[ XGD
M-@F&*;6G?P*52>J=E23%:QGJ4'@=R:O.2")S."A<&7=*ZX+EL1NX<YY>BMWW
M/_&H()] J0XD23BISK>,=@4IB1*C^"5K_+'FO6^@7(&ZO6\<;S6C#7^ACE@I
MW EPM3YJ?='Q7&UH?Z^LV66HY6E\ E.).8\5@R[C9%58R2MV_BU*DZ(<QS E
M1X:Y-+11/Z?K)(>4K^LY9'1F?BIM&*GOTCIS.LVUJJI?]ZBX@)?)0<DAR!_V
M=)(A2\/V68W%[7V/86K B<CX$'4.XXE:=0T&)/CMF7TIDQ"%7YKREBE!5IT7
M!TD=#XXX@_;MDACD@Y?0Y;<$(2,5]*,OCRZ&$.*@_,AV8SP*9S6%YBZ:LX7C
M47H+UID'ZGB-0)X)\]5!Q9I&&Y\T@X[-""ZYFL>:FR8L&K#-H)'4")9IY\><
M09M25;'=4N29&8;#<A64]^N/5E+/?L)*@%_3>Y>71,L24_-4GW.O,[(>UMD=
M!T4VF*('#D''/APTM9ONWV4HSN8.Y&"D)C"G4+;V=YH0T*MM8CKOB.Y7<HF/
MGD;KCB"44Z7]$HM>>'B)C %>S!,/<O(<8QOSD5S  B4^!8W 4HK*G'Y(6C<E
MN$2*V>MD):;\/76Q.S[589CY)R76KNLRQ^QSQ[C_EJ0S-N!&[$O]@$JI+]-$
MB\ACPN;>>48OD7?;[DQI_%IS0:G9'?T86501)&'79<QCA3A>Q=$'H][(QW-A
MNW6+1ZEA%)_OO4@!)](]$C7.B=<HTJS'IB%#/F<GP'1LOO?^1'_=F^?M*>0K
MJ]*@R).FZ/ 5"*"NW+/(?37?>1P-H4'Z.B4F&)"[*XMPQXD_GS!CQ?Y_D0:>
M3K<M,\WR=)I?&'"FR@E\ %'>0?T)@$KSVV)6S]PN>HU2[5_BI\5'-9&X+$-*
M[NVY=8S^JBG9D"P-I0W"I8/U))12 ^4Y1_#"T6ML$J_![]_@<QXA@=,%+6D8
M=<"Q&U$*I']T5T[NJT=%]!I)SS3.:6@\08ANV+?X%$H0%9,LBI8:3F:I2YDY
MV%CDTN$L;2H'D/3GLVAY)'P9DB@K_0Y(+7*',_D(,VJ(XO3>#&?.T=Z@8ILQ
MX2?74J(\HDP5GR_?X)C2<NR#\D.7ZX)^,-EH6D2Q;H+PNNP%:B&!/*JRW]-P
M[['7Q>89)&84^5 Y:NU.6* E?Z^KGN6[BPZ*\3=9ZA&"5EXA"/T0<Y>E.289
MN.DFU;3KO@;TKT_6%$W)%S2Z1-I0=-]'I)]<B;LDL5KP4L"24U>F[(E1;7&G
M$XYYHH:\Z#[YD=XI 4305/O<U6@K&SDS3.FF^N:6SHG /P&>R3>;.P(J+%ZC
M"AUNA-5_4&TL&+(-0.YC41K[])M4;+]+A"V_Y3))#!;0+-?T.FWC&GQAJHXW
M6 *9X?G^F4*,Z$*4V?)IMJ]O\!FLT0FHCO6,PGID+R;WT(#4)CPW,'R#>C1]
M<RH_9*L9%_SX+VU@#5_@64?\"CE[]JN'STJTNQN-Q=N!E61L%$3<F[H=O<NI
M!(10&\QH-16IOE%S\XNN,"?+AV75Z)D,DW\^=N<(:XX\EXEWV/XH)=%@\[GT
MT>:#UP;AM2@3.RHRI9V-,LIA53<K94/C;>=2_(4+];$(]#H[?.H 4#1/36H]
MOYQFBN+H1@(JS+H*U *]:!)S*N"Q6S6,*T3FRG:7;[>N.4TT'_G@/CIG6&<C
MME.@]]JR4(@8VUO0?GD2@PEHLKJ[XA 4HTF_095MH$4;[_OU;MF;S1@84R(U
M>]01"$3Q7 #Q.=W^\_%O0^$IDJ>J>! *]5H/15Q/[/X[!"U7RQY!B@ 3^F[@
MOME",!!<Y *D]Q:>M;*8-7O7T#HI=+-QSME8:V=4.*'X8HGO;9_%)\9R+"<%
M$V;XL-A7= _&9>!&S8+1<'%H$VKR1^:ISAG/Z6H#:P1<HZ+*5#27GGSR?L[O
M:\-:N3P9"="9QGA?XBZ2I=/T.II8%P10SDW": 2X0](OTV3SBY2JV#,HH5<S
MNPJ>B7^W6.T92>A-D(^<L"C6UG]Q@^.+L.,HEGJ=1/Q[ZZ 2ZK>HZTZSP9,7
M-K8P^_:YW7]SGF%]QRBI@D3RW70[O8AAA>81I^;VZ[U%"VT!B!*.'I@41A<S
M Y/J5#"ASCI3(4\-.*CXWBVRY@7G+]^G=\%"L"YAP:5S\T$GB M%+\QBD*'>
MH1?=BI\8U1=W6M.@#)%38X[P?4U. -*7>W-#+ZZ"K'D<*&=RWJ7^332P@LMT
MER5@=3];K+YOR5$L6+E34/) ZE?6.'.0T*+^=P"9\#C^"=) M=(-OG0<N6DK
MCHJ:L+)XU(:X)RX?\6)B^A<O9:$]I5O"63WS2(_ ;WYPR0]\'/,":PQ>9[B5
M8):,SA^\0D/@Y(CT!&)) %L7@6570YM%,^<M@]^LBU6+<]WFQ[6V)%1GMDB?
M#A<K!;)8M,@$PJCQ%*4&<L2H;N_2R:R>QZ\Z1=]/:_4VS&/Q??<"I6SCIFN/
M#_J>N&'U+?R4G3RIT)]M\X3J*H3HQSRQ6,S0 ,+YWK+R2=?>W]ZJ#3P8%=9W
MK3F=MZ-45'*F1"0;EZ^6IC.J]%/""W0(JAJ4\T[%B[ VMGN$Y4!54/ARPZDD
MBLYVS&.>QX>@U-H9;I. UZ6MV(7BEM\&AR#2Y\'L>4Z/BF//2@6/["J*_#X$
M]>. TW^?8M@6UV]LY!@I9C22V.=1(^K9S]YG_I(:)M^%!PC&#;M9/?R4]$K#
MU>?)9X-9LBY#V+P_[Q#41TK/V"#P,1Q\X-0E,$]9>FQMVDL_+%S]CZZF 3[T
M[Y7I97U/_9$YM]ISKY) ^RI)_V8VZ <-M.\,H88^DHP!Q^MUYU=$ON2J1=,2
MMW^J!F'-[/[E<69.//<3U32LS.7938=$/W$,,GE8O^]:""F6=+1=K]. NMV+
M2W37@W&9KFR+8[U_M"(^4,NS=:CIITPOIEU>NKXM?%,KJSVHSH?G[&4C2G&[
MV/(A:.O?:^87:*-1U3+T. #KR]M-C]_:K-V%B2B<[2LB#D14]&']ZLV?65ZP
M$GZ[,R!QVF*QD1\^O(U=+BE4HD(9PD(4V^Y#D) _T9KP=$6TU3$J!(@^@T#]
MV'AK6;[TK?E7H9+?T[C%I:N)PR*OP?5O\&,*K"Y-9=C0W)NHOC+V?3@PAN\'
MRP88<!2CDF;=9QF70B++@"JG-G5ZC8KJTR#AV[XB B).,J7/OFI\C3W5@>S&
M_A]MP_)UW_]K&S0;M:6/EWQJ[W.\4<T;5"%]Z:)"AU<S1:2IQ5XW5T)J\:5$
MFO";U^#J-_CGC\: TX%%RZ2YK!6_OFUA?_I>-%J#IISXJ,T0:CNB?"/=MC-G
M9D+'5[UI556RX<_QQ'YVU7&L+Y0/_;AIRM$!:**,Q3^.K:VH2/3^TF[XVM6Y
M0'0K":>NL?H^.$BP]IO:N/PY4 K?:3:B?W$2Z/3_Q6/UUQ];$6A?/OQ'DY4/
MM75A*^=+^JMF*8/[@XI)_/O]1^NW].OUADZ_!C]G0EG%U=&"$*OH]/0!''^C
MM6YOX9$F(!(21YY<G0J\&Z 95Z;>\^]+[U#69<\0*6^UTE7$]@V&\4%LR"B,
M MTZ^<9_IE.B?@*CC%:;9'"3WXC]O3+A$A%I(R^=\#9AJZLM_LC#LU+?Q"5&
M#YH/08'IB=ACAZ  -Y,N#%<\F;<VESP6G[JR>.UW_U[9Z)-6[G#M#\UQ=W8R
M&'5^$7&@=RLB X ND]O6*X F=J.5%A;#</$C2Z7'R4H Z2+-Z>2% KN_/:'$
MF+"'[L-O!OF)S[I/)1<4)0CRE[(] 1L"BRP+1SPHZ3P=< /0L7:QGD*KPCFB
M#T%UY5A)][F?G;+QUUS8.YL1&J=#W5VM#!MW%'L_WU)[H_/V,MB'!F%RS=),
M*+.]AZ"D0L@7Q":&GZ$)9)<"^;8TZ=N%JOE.[VC:,R5"9<UE?'G4XI]_K]P6
MLAG_= QW_MFWEO0R(S4,:8D+T,:C0@UAUK3&0BF:W.2(D7H#]:!O(%X=0U(Q
M"?CN_F:NT#O3[(,$]]I)1-'3RDXQ%G%3T$8T9 KZKA<"3OG!T%]VTKZHC1,;
M*QJ%Q-4H35JI_S'[PV@C>V?87#Y6<EP]"?0;"2@=@C8#*."GLH:M-'!J.QNR
M"*@<Z*87"MOR@Q,E<Y,(C5N4K!'_UU&_M/<5WST+3WBI5C;T1\+H0Q@5[)K/
M/"%5P;CII 8E2S0#(<%D/Y,S^X[$U:F:7\]C^@T(&DJ#BZ^6O3H@#<I;I&4L
ML:JWA:@1CZ34B+DV3*KOSC5N"_S(^JGK')?[8.39/=&?I]FMPKQ]>"[9G>VR
ME%@V4F1.$<2-CC.GH6 MB+ _CE>S78!FU=< >)G7C6\C%6B*U6?@00];4XI-
M^=LM6"3IO'KS&]>S;:\N4-@62V4IW]*WBI8A220>M#I94]S\-6!^ASJ]E=9
M$1L?.>_V=6Y4>F@8J;-[=+Y'X\B_.-7!1I; QO=KQC!5J(1^_\!VH15<BBC3
M8*8]@&(+3G[9."JY9FAKG7Q=M%E74SHM/0")#!1T\CK8WOY[; E$AQ$KZ&E
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M#WS/G,S(A<EO!#S%J'ZX*ON7ZQ&=Z=4)#YU\/M>[?J&._):CB^O3(PS7AZ3
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M\R.OMZ4-$BKV?3123<HQXG=AEVZ+ (7=Q3P%O0A)V 4IAM<G%<!Q+;KAQ;+
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M4EJX8/N]O77/IY;;"Z42X:;[G!5H86W*H.]$B?]I7'< !7;BY<0QB/XBV2X
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M_*J66_<^/C:.ZL@5X5L,22 UVZ1:J@.*M%4>XM=!Y6DS6)5E2CW#]GX;=\B
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M8*=QBSIK#HNVF[L@0:"03!*C]!3DIQJT&%Y:TWHV<[8)\<.D[/+->"%T29F
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M49=C/W$CYTJ:8\&'L)/_90VI-O:?JWZ2!;>X5FT("O>!\>),%VW!NL\37>5
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M*W=RR!T)<0CI%<F'G5_'H3MTC-,]X8NQUJ"8/FNT/<^R@O\VJJ&JV?X[)9I
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M3%)BW56GZ&%^FU%.8%3D_CPV^S\C]L>IS ]LUDYR_9/1!H.1A^Y8YA5L!M$
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M+K77DR>UH[]#U;+\_L$PXJ0=LZ"U^B3SS9[W/#8WOQR3R4MKPF[[D:XTE8$
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M-30J$/RGA86BJ&$3%BO?14HE,!IG4-\">M"!+ D U#\[ECJ=6**4I%T ILG
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M83M&#HU;X5/S)*_^'^R]9U23S]<V&BLJ39 B-4A'FC3I1.4'B A([T0%I$1
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MFFH47$ #/,RF 8;3)K_0T<,=^/)S SJ\<8 O'RYA<"8TP+'L=!PEFLX#]0W
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M"HS>DSQ_2^R=P(/DR*4>R$:AN>*(#-'3+"\HW1/^[L1T$9@:DB\Y$@0_[X$
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MX>-Y,]3G]*X051WIG[HOWWJ2GGCL2P6>P050(XB(OT=3_YT!68"QP(?@5VB
M!;H=Z$D]=+]) WP(H]_*Z#09'&?/1QKJ01MH -;G1'4:0/OO\:?1<?]RU^)
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M&CW[F"@I2GV*7BC1N3F&XH6WN\"$0S,,P$HVN-WDIW6:'+_!4%ROM[#<<-^
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M\2T4%S'9\;UOUXERCEY/DUQ!N'AP0T/&BI'E[].K3;[W$?.\Y'-$8](M+[
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MHD-&YL#92(LWSN]^W94%3ZFJSSGB4G(25#2H%:2A$8BDF6E&54[8U!0N=DN
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M&Q*T>F3[J@<MY?4++R\*A4T6N:=L3Z7ZNP3O#Q(+>JDOTCJCI.RSKR+3<:_
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M+FB'/!=$<>/T\+KI/9JGVQXE8NB:[$#,WYC)84KT<\*\\2N#O*5NQ>C?A$.
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M.&V^M5F2\6@D=R@ *H1I#3[QH;%^2,0BO*Q4]L[>.K&)VDXIM43FA6/QP3J
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M_FRU_-EJ^;^PU7*R<G$._6UN#*#/V0+ &> R8 ?  5L "C CO_L=D;@G\O)
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M\$%^\AU/$IH@Y[K6NGHZRFJ:2N@O6$)532<8'$P" *XP3P1J\FMB:L:,TPF
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M:;X_WY78;=TSWIO;]SG .7ATR'58<Z1Q-'KL>GQ\O J<^W$85PXU?\  2##
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MIZN%@(IO]Y*(.;MIU6\YLFJ:4*X_PJ\P(F/^?BXB;CJ#W542U:7=B+4!' X
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MBY9ID.U&^<^J?S?W.^#*^FXNZFMQ_TSG^PF/>O?2S'[_3UH@/JA"FV3-:36
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M)L-L]RNK]F>\O330&CO7Y-$*3Z#)\3B"V$)!-=^WEZ9&"KG)89&)S>9$<AY
MIF.J5YNT82OL^<I ZSUW.\.G(MOYU\$O;E><];U2IEV3Q5 SH?: V:MM>A&9
MC9MEOH^T5R=?1*6]K>;E&ZGYF]:5WTNG1O+8+PG*M8OSC8CS-OJD4!V)=,B]
MDPMCOIK78(_+5D@36FK_T(B[6&G(,O/>E<#!.MYV%E>\S*BI<HF\!HJQ>J5D
M[Z7X83[<<GON>EADY2U3 I5K[EJ(%.\<>@=Z!X;<UFONEQ>T#,T:E?:D]>]_
MFO32OM+R?$H"^6/@GB?11W_MOJ@*+=(RDOB3$."%10W#(],/Y$R>57#D+7,4
MRF1Q;Q$G,K!]%<P5U"XZGK%^X>8 -HWF9%^WG )&U477CX9)D:G8MWW >&==
M\.VHB^Y@7?L*+5;4K]>=LE&18Q\W(,?K4.D!?X_EPR'/GM1]A;M.01/!"-X-
MW= PYL,37^U[A/>L8??18[B50".7'MN$Y?D!>)36W9*KV./^PF5N\A*OY#;R
M^T%)Q.)4M'T+R5:%@\5ON)]T]$]<;2K"JW.ULYQ*V]&5'_&Y;7 UF8I3:S$\
M.BGCJLBRYEEWD3#>1EB83@N6R]W\B?:H-Y@"V9X[SG+Y5)Q^"/^9)3(BX0;/
MC$JMRUU81/A2]BR+#(X?NQ*3>L2>E%1Q*F$KLZR,Z&._N.JW(:7YAI:HUOXI
M-J+13N[)N84Z.SZ<E#,/S)LTG2B%24NS),X?+KJ8E+(+*D%NF#_IZ%'*R6A.
MZ&?K<'WZI(AF5'BI9(ILBDO=(\X[1Q)YK^K42V^0Z JGZ;0.U ZT]4B9*C<F
MOLCB,47O()$RAZHY3M2C-6K&F.;KU"5QO/8UW"GZ:Q&&!NH>$=KNDEW1-.MQ
M<YS(6I1L+S<P7(L.(?[TO=/C"Q\9LCIIVB0ZW5N"DKK&AE.0]8V@)1389SRB
M=Y#4]HCHDVRE:<]<C=!&1'0&2NM_X>J\PM4'#C.A91I'6ELQ;(V:NJ>73ENE
MGHLTXC$ED7)X $&V-62V<2:X]*+>\CAG/$:^%R@P_C_4O'507%&S+SJXD^ 2
MW)TPV*"!X#;!W=W=W=T9W#TX@TN0X,'="2&X!H('>^2[W[GW.Z?.N:=NU;NO
MZM7^8\_J7Z_NWKV[>_5:4S/,BL/1\QP_F]$]__\ZP*V<5U/[&'F3Z9EX(RCM
M0T8CE(!--ASUQF0@ OI3;/F"\N3_=0!;.6_4]3.F37D>B90@*-[3B>3J)YVG
M"VA?RFDR?CN7]/IC8HMDIJ>$$!G6)ZE0E>GR3ZGI^-?S2IY8:?>4@LX?/7="
MSZ&(N$1U$ER3%:NMS,Y_DJ./BA@KU53Z:^A? #J'VOXQ2XH&Z8=ZSU!LR+Z
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M#%%HU>&1F+FQ;&$HM$=3)/#BT0')%]PT$JK*[?!O28UC)63@B^H539P/B0A
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MN7N@^[P@S6,8V.\$SH,Q1J=/B;SMJW@+/04BK8BZC>8;,0&F4L\>52HO &#
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MD@2OZ?2$^T02.O@ &H/U=?=SETAJ:6 W>H,Y<5%.F(-DP@?5VQW:=[%^0'(
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M8=AK4A!;S *9$'&C&;M%@*)+Y&J@5:0DQ9MF*EQD#J:Z_5=M7XZ<Z^%3AU1
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M(UTO)^]OEJ.N<-!/HC62E'XM5Q=3XY->I>?;&86%D@QCU?+4*<ZM<"-DO69
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MUK54BV/B&;3P'J*'$2V,6T?"J_2L;KAW7M;G$=MK6%!?LI;"YCCUOL13_*Z
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MT4I \_<_+;\G;+D@7_YMYO^ J/^]X-E7P27_A/^#7BLR]_>S@O]^]C]AKG_
M?\WZ-[W0_RE<ZM];_:_"J?]E-BRG!\:I(CV0@\)LDW<YA,P!BBBX:8SNU3-
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M_.2(PA0"@,7LUH?U.-5N-=<;9ZD>J4>O,UF[.3+N3Z4*7IF3]L%5 S;\J6Q
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M/'^4CGG[C(R2%Y'%IPFO9S7#M8&4MG.+3I1HA)H)/#6U#W]S"C.D8!-8<S;
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M>#ZB\X(DJI0Q$ .0LD'I$%]RG_O.;D%-I'VE2HU_OU9WU:1E]T3^GL>S,EN
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ML4:,)9DPO7G'[;[:XW/U>&<VL[^^GMB'BO!YZ&HK8NQ>%9P?CROK7MB_-J-
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M\W@,"]@O6')Z5% V5+SBBI]Q_-O3MBF]/FY=<\G'ZZ^YWV!PIU"@0#"S&U9
MW"H#<9?S@BL7HLI\;)ZK+-W/31%F)FM1Q0 4^0>!+V6X=14HQH2?1>-4D4.E
M5M(+)F0>5+U*RZ\)G^>I*Z"/@Y)-(_9& 3P$ISS_AXG](Y;\+[[\7N-PW,9O
M4'BY_#MJC!C5WDVQJE(?U5W+,.R<?/?%9_<A3JJN9.$J4>H'P-^/EIP>DBX
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M"VF48.LPAPC AL$T$QYO)DR&33<28UUP(_IJWRU3+#D^.ZMV"8V<IJZH[CA
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M$5^>!EX$7+$??H7]<;]@N#Y!N[A=U=R9)ED[J*OMR1)J_!_ N'NF6B]NW#\
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MA=71ONI/1I9ITT3*I\LD]2Y=B9P.UGA(^&168O\O_!99#D*TC2P*7S'Z(CX
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M3*74(62LEKMUJF(^OUFLUZ&:*OY>=L$[+.&D7#P\6Q0.LX<N%4T4$B&.<P%
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M2N@  !':GW=.G_SV:-\0=P]_;U%.XO3^D7J0#W>W_-\< _!U'X?;[>T6'_\
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M)++8O/=#N<#(S][KT+18>[!&5ZN7"R:S294'QV]ESB8CYHAQGS&1*Y59.!4
M"H@<S*R2]HI,/19I-A\G3TC-P3"I2R5C\*L7[E*.72,._3GO>BF;^ YP<^8
MD\7B[Y+1(C$;UO54G)AC69*F<8<B;[19K!YSM^Q7=.JA6/"26A8-ZT62>K'$
MY&B@B4P 81#M,:#DV:[MDF&56L1<]7]1W/%)?!LCM59<O)>,,ZSJP6=1C%3$
M=!KPBH.S)E12:D,F;KX%"B,SH;AY0Z="3GR=+6&\++UZO14Q[ZHFA$R<S9CG
M9M'_ +TH_(1NLNN?S!6 "&'QAUCUR*T%O>[[$+JQ2P*5Y*VW2!B6S99VI'J
M)9FQQ,8R52.H*8K((I&()NA1#L6 AG5"BKC+1KV6"%BUZ\QLDE#QT@=G)201
MS0R4H\C6,H4R2ZW@,DFX 2&$#=0[6.WX)?,AL=7:6ZY0=JG,\E:R$:2WT>P6
M>M7!.:7BC(D.]C9FH2I3N5?$1PBS472440Z*CK*ZL8_@*3G<A7OE'3;@RAXK
M*=&AYZ@5>\-[OG]U-)N86Y4N-BYQ*/=29A22;R3%PW^V! #BN]CE8J5;2#=J
M1RZ9G:/D7S1PS3>LBKN$153<MUX^1*JD!A$AD5RF+]H<!%Q(,)6B3DOF[YY$
M.GK1]7Y22H,G(-TVS^+<.$E5W-6>OF8%360,9NHJET*8HAT[6*)9R57N3"-D
MI"IVZ,;/(FPLV$PT*D$M6;$R24>H-9)JFL0'#)R4JI .'C('4.SOBE3D7$]=
MH;C[%\D4KI7V]>E,S/4)#3;1B!X&,M,9+N5SW:(L5,<HO&9&I4VS0$RBL)NJ
M1-1OUF5@D'E$SC2-_GJ76AKA='MD'GU1E;!:YRO5E=]%O;#-.(:O*MRKF,4B
MAR%357(4!$M3TVBK,UF6@9_GUZD*W)GAAN5;B]&IL9<ZU!:%"QS^2&%G0K\X
MGYC1=0Y2]3>68Z?0PL;'%2%+LB]9EI:LQL\P=P<NM7IU8Z47.5]C*MU'"D3*
MJG3(V=-$U$UA$I4U"=P%"K6*,M6<24W=6DO7:3/,IRL/)2W,H-XHZGH.K2C=
MVH[G6L._:G4>-6AU2-UDQ,H4IBCT8QKYU3TM%F8%<L:P=.(0EUE*O&O??')6
M+58X3CV!82(^:<$RF;I+?;#T/W]J)=JU/0FPR]KY9TW@4[L&3MJW:I[/-:N=
MQL-1-$7R1<2,;(P%*KMFK;\LBNF==,!1.=!)?H805OT;:JBK1CM7D\XNK&=A
MSU,[%H"A)"97L:#L8A1JV!J<%W)EA*3RQ\1@\(]&\LD^SRHTA!L-K:R:;FMU
M^JHLWZC=/[I&[TIV<0FV>*2R1??"F J@N2!XQ%0/%H&=H2U4:7>XT]0+I'0K
MV 2OZ]:?1JU:CYZ69$\R969LFS[R&;EVDH@03 0H]!\(YSQZS^ZPDPSP#%,@
MS=[/V"=J3C0G]&SRD1U,H-FTI]#MXDJSB0@(4IDG:C9LU5^W%N4I/M0AG#]M
M"K6-FWEE:\N[18J3K5HH1DVG5(958HR"+=0BS=-V* @40.F53N$H=CL(Z A6
M#%51ZLJS91;%HU46DW(/))91N@@FB=20=E!5<PE$5E0 Q^HAU[+BHT;*&=(>
MZN3*()*&<M0\P ;N#'((K( "QOM#=2_;#W=X]8J5<1$6O*02;Q*$D5H]HJ_A
MT9%%-N_1BGATC.(Y-\W1(FL5$Q 5(4 , @ =%C((I(F<*^<N*292"LL)")BL
ML)0#S%133*43#U'PE /8 =N1FWQ;J;G+;R2TJI:E84;&,2^CJ58:EB&?8&DA
MGODQ+60@V$S3<Y9J/_-<.%EW:RX^85$Q$4U#(H)(F65%98R29$Q66$I""LJ)
M +YBIB)E 3#U'H ![ [4*A/)2S9)(9#L]$Y$8[=,E"MP\KGFSYO(R$K5+<C6
M[!7K)GUM9$<R[HKZ*G8>2C7Q'!SG1!P5%=+;=8=WF_;9O7)*P46Q[;M>IC3V
M]CM:^84X*'G$)#U;.JE1,ZI57I%:5=(L&L7$(+F%\X4=+N53^,(N7D(2*?R\
M(+D8:5>QS-U)1 O"%3=_);]=%1U'^\ID JGDG)XRE !Z]I\6M6KC4;6J9>TB
MW@XQ'[I5CIG1,K8!3:E^653(J&()G'F#X#"'L'M&QL+!Q$1'0J9T8=A%QK-@
MRBD5"G*HE&M6B*2#%,Y5# 8J12 ("/7N$>TLJQAHEFK/.#.YU5I',VRLTZ,B
M#8SF6411(:2<&;E!,3K"<PD  Z].[LBH1JW(HV1%NW4*BF4Z#<WEB9NB8"@9
M)$11)U(7H4?"'=W!T_+ZSQ;J<N1QG7$J*4=V\6SA,["4WC08EH\EB+G14,DL
M?/,^79L@ X=6[R7?IB "4W;^7ZU1)V>F<P91EI:GOC=1"0B,<A4747C<&=-P
MF"J2<K$N7=C$"F$AQG@ >\@=MFXWWQ,!K&PT">ISIWX#*+0LB];"M7;.R*!T
MQ&2JED;-))KW@ .&I!^#M2M,LT>\CK_Q8V*=HNW59J )J3=5C9)W0]JK**9@
M\"K:;JYG3Z+$2F RR;%<OL(/:NW.J2K2=JUM@HBSUJ:8'%5A,0$]'MY6&EF2
M@E**C20CG:2R9NGVQ#@/=VYHS\^*BB>=6J"RROL_,,=)E5<VSZ ]S:MB] \D
MCV8E'[TX  =5GAQZCU$1XP46I,V1']IR^J:YH$VW;I(N[;I>KP$7<[=8I18A
M?->N/>9(C%L=03&1C639N7HFBF4O8._O_0^SVY7/IDZYV68&H&3UMB9915)A
M7:;G<%/JIM"J_:MPDK+;))X<I0 HJ.![Q[NW&*!K4=')SFF9M6-TTB?:(%3>
M6[0=<A(ZXRLM*..@*.E(Z/D&D6U\?^ CX]!$H 5, ^I\'Z?P]_7MP=_T%WW^
M',I[;7_6SO'_ &;Y5VY\6V;6.]>UO:K%28TKI3S 0@<IK4+3*_')F* "1H1I
M!"H4@!]J*QN_Q"(CQDRBD1Z#1!IDU.M=HD4RMC/+1H%YA&=LO=JE7C<@!(OY
MNRR[A0%3&/X4/+2*;RTDP#_;_/T[;(SHL:SA:]KU2H6].81@3RVC"XWLLY$7
MQT@B ^% +)9ZDM+K%* %,[D%C@ >+NXE_P#B&I?]MFB]O45_K%ZE_P"01W:+
M_JS,?^RQ+MPPQ^VM4G]4TS?\/J-ICW "+:3KCVW0SF<B')0[U&LQ&LU&JI>G
M04UA 0$.H=B)))E333*4A$R% I$R%*!2D(4O0I"E*   !W=.W%.XJH-QEJYR
M1DH-BY,AU=DC;;E=Q4E6B+D!ZHMG#JNLUE2=!!0[=,>X2!VYF:8]CTW%MJ6>
M9!1*](*$*=2+K]TGKM8+.@T,;J9$TT_I\6*XAT\8,T^H]P]NG;FY&135NV92
M]MJ-M=((( DB:5N./T66G5CI@(E,L_E%EG"QP#]D45,8>\1[<(WCY=1RZ5XK
MX2"KA8PJ**>3FU=13$YSB)S"":90ZCWCT^I;^.V"7\<5I610U%7?2$55ZO,V
MN_6:VUMK;%)23D+?#SK=E4X]E*I,VC-J@G[TLBNJLJ</+22J>NZC$QS#08RU
M7/.+;)PK,T9!VZ5HLJ$;]V,3%B=4L42<:G3,Z;)G.@B_(N1+PI@0A>U^PO::
MFSN^7Z; .*U<:P^7>LTY&.742<)J-I"-<,Y**DHY\W2=,WC59)TS=(IK(G(H
MF0P1]%HW$CCO"UB-;%:(,%,CI,NNNF!O&)Y26FX:1F)ITHI]L==XNNLH;O,<
M1[:?R!X?9M!8KNV=UJ>ODEGM):I0^5;9 P+%U+66JR-'1(:!K5T>Q*"IH>3C
M46I%'A2MGJ2R"XJ(:GPDO$](V>(QZKU[6L#E)9PL[D83*;#*#7[)G(N72IW)
MX&F61=BYATC>,S-I+&: 8$&S=,GY2<4R@HH4AA3(8W@ YP ?"05/";P 8>[K
MT'IVKVOZ3P1DL>D+IQU]1:C\NL^J_"O.N/N.I:!J50BI.A9B^TMA=[C9N=C2
MT:%5OE-&V3RCJ"6F13?QPLUGZK-#TG[[)\%F\+)OO27J_'6?O5-XXU*V27'?
MG\Z=<=[:SU#=T(*%6EZ#*0YXBP^]79;S5$'Q7B"KDIW/57D]2)/,.6L'R[@?
M2WYQ8??X1#A9EV3YOR+VK3,ZC8F45M7,JE6BRS7-NZV76V'W29W,OG#F9\Q\
M^<NS1J[UZS'D5QZXL83&4>Q6+A?LD3$YOGM>C&ELO>RV'CQ)59NZGW9S).[U
MK%LF6;-H\F)ATZDI1X0AG;I0W4_;TMB4'C;/QV#9O@-M)R=RS.>&.6\T[87E
MQHF9X/"Q>S;UQGN\JU)M5M-7ZC;*X\N0H6&P5MW("0@)LY%RY0X3V7E'Q!Y@
M>HIQ.IWIP53 ,6AM:P.#WW7L(WU/9K+<[A);+QD6>SL-F]HNN.N:;7X^U%][
M6@V5--%.WC8%SG<OKANK3EG!Z$T]2G2.3^?[GCO$+.+=1KQ@TXK;F^7Y[H//
M]:>7T"I8(CA3YM2K%FK]-N2/<,DD6#-9(&C\_$_):-ENAYPEZ@_#RI^GGZ@<
M<I"UF.L/&NH9ER$L5LC=RMI%%'JTM*2_$73-,HB(&7Z@]?UT?.$42(FJ-8V/
MBA(3G&9CZTW,/9Y" M=-A'>5+X1'>F?6\WP2WR,%[PO&.<JD=1K3"&CFBS<6
M;I\Q30<-A2#PFRGC4TXP?=P:A\R_6(N.9\1['QCC^5F:9UP,V"T5F-S3D;4^
M)$)I.:-TZC':2X0@L_>IRL7&Q3.S3+)-H4CG_F_$FM\99^<M&-4/)8O+Z_.V
MNCCFUS>V#*W\EF^DA?**:/C#UK06FF5:80GVQDU#!,).3"NY$PN%?28HM@R'
M46\1QVT2;L?+GCLTP;/N2&D(P\E7]KKV;625XMZ%9(RE[K$YMI-JA9EY BX?
MOVB!TYIBP>O(I)$/3MN&N\0N5?-#A3E,IZ@3^W\<+MQ2@H^Y95KF\7RIRN&W
M%3T\XR6EH'^1"@UJ+O5?I,21@_6H\=;6BR;9F@)/=+3<+7FG++-*;K&J\([_
M ,0K[A/!')=5L/'W&,OIN&(U7(8[D%)VA6W\#5<BT6J6%&XUM%I'P#V$EGJZ
M0R9I1\W)6-RK_%*78<I'G_WB>Z;E8-<C*\T3UQKQ*N/,^]QUCM 78[Q&QMN.
M5BXXR_EO81-<(=Y$/55E&!UW"BIN,_$.>X!VNL%R#UK[+H'+([7%X2EY-M'&
MZ5N7/R^8[=0O$,G'1.Z836:9?JC#/F2PN$HM!\G".F96YSMS;C,R7"6]:UPP
MI7JJ\8]?N?'#*L]A).$UKC#2_2[HN$4:0H6+,Y2&B=5SCC_RI3AY>1IK1BZ2
M<?(2BR;!R9AY8^JQ(<?N/\AG\G'>HWRRM&'\8+^]9YTXA)5Y@^"62AYM/LTU
M).*QV)M<VZ16)%I^)O6(^330!%(K<6Z?-RV0?".\Y-,[=Z-'([+;G0<]X74C
MAMG8<O+AH>,V&&Q"@5&%NMAN_(26IR3FR_(E^L9W:KM$[HS!^M[V[(GS,SKT
MXN/SG$J3KWHY53/$SY1\E971M=WBB<D95VZSB:LS9ZS*[Y W# )6;@6]HE@-
M("TFR&>R?@(4R6J[IQZX#:OP7XM63@+C^8(U[0\'A..[2P;=3]NOTS/D99M$
M/G Q4E%T2;BFKA\HB@$RHV.LF+A)%-VX]4JGZCP2U_4><^[VOGWH/%SG.PQ:
M+U6J*XKHG'FZPW&[-:OR8D ,^Q-U5J"@EG"=(\UB098_C327;RRKL^(U'AGQ
MT<X%M>I^@MR?X\:S>JFPB\ZEWG*V4K/$%YD<#N-^82$>*NL$FF%W;15@D'*S
MR-=NWRH.R(@<0Y&4RF<?N449%:3?/2VH6E<=KQP*S3@7G;V@9CSBIMTT.SP%
M<QZRRT3K&J4O* F(VXW*.?J(K5--HF62?%;-C)>LM:,#X-(1UT;Z]P&N' )W
ME^=U>N/*N]IE6X]V;5K3Q+;12L0SRJ31TIG./;8\@"PRTY(-UC2!GO@* <P*
M2IP[U.^<_=F]1#(]TX5>I#$T*O2N<8;Q;A;+B,E6R/\ DJ\?)S6,Q''_ #RE
MW"!F,]*B5Q:5W E:LY)*PJ+%O/&5CP'N%9*V]?:B;/M\G'8M4ZOF>U\';ERQ
MV35<UL$/H$$HWBM4RC,LSL+5";AA4]ZJ2+U6.49I$4\*O)S/\,XY6^H<0J;Z
MJ6#\C2XUCG'[.M9H]PQ9_P"GC4J=;K)E_$NS3M6SK:JO5.8KII8+%5"H* M*
M1Z\LS8NY&/315]-)MJV(;-L_&?-V?JIZ5)4_E9QSJF)4?([SKVC\<'V8T=YQ
M6:.)*F4;)R.V%JD<YK$BV<HQ*0 X;M6AFC(&^#;C.</)K'+EG_/;6G6P6[-^
M%N>YU3F_'!/+.0^59_=++SV^[:3UGE,ML=>DJ>_E8EDQ:UV.7.5L_8,%X2/.
MY],#/*KP(TC/EF^>\IHWGWRQFZP2HYSR&XK;WC.[9M-9X?:HRPL9WD<YV31;
M]4I^ CC@^7HPUL%_*C?<44SZWR%Y+)!)W_A)GL?Z-><6\L[/3+73W/$R\S"W
M)_DTQ4DU#,E3<C=#:U9LY, &>LWM)7:N#^,ABE_->V\E[>5-TPRJCR4W$PQU
M!(I:+BZ,E$46GMO <B@NK9<9!E'D$OVQ?>/%W 4>UIEI&&N&O:SJ4[;] N[.
MJURP72R6:>LLB[L-XF2PE=8R<RXC$GLHH*B@)"FV;F3(8Q0 @=H^'AM.]0Z*
MAXEBTC(J*C\3N#9C&QL>@FT8L&2!<=\*+1HU1(FF4/UI"@';^=[U&OF9N7XG
M>TML7)RL[>:[Z#),VTWI>R9K:J4[NLW$036.CVRTI-52LPLK,LJS"(I%21)[
MP+1J!A P$,;M.<6K9+ XT3B'*M*_ D>.2G?S&$W)20D\S>)%56%TZ1I[QK(U
MPXE*)$&\:S\0]5B@-ZT)2'.GG'+6O1&KU*4!$PL'=PK\'"T;6JTHX%,B1IB/
M>QL?+*(@)C>ZS29NH^$_3+N(VP7V$H_);"*I&YU"1MQF&4.CM.=UA-"(HEHH
M<A(J-FDO88VN%:1TQ$)J*2"+IH=T5,6JY#%>S=AEXR"A8Q [J1EYE^UBXN/:
MIAU4<O9!ZJ@T:()A^N.H<I0^$>VN5_CEL]/UN0PZUL:=I U%VJ^8Q4M)QQ9&
M.=1LH9!*.LM>?^6Y;HRD:HZCEGC%T@18RC=4I9;8_DHR>;\LJ;!7&ORJ**WR
M>;1L\@8FC:76G*Z@ F,P$4PAI?RRB(J-Y XE_P &H!<TX7[-?82A<AL.A$J#
M1D;C+MH=CM690R@H4F4IDK)J-F;^WUJ$40BI6&!4S[Q,RO$BJ-UQ\AY,3<DP
MAXB.;G=R$K*O6L?',6J0>)1R\?.UD6S9NF7O,<YBE /:/;8:-QXVFFZQ8L(G
M8BO:4C47JDA'Q;V;9K.H]U$3)4BQ%JA%E&CEJ,A%K/&)7K1=N*OG(G('!W_0
M;?0_1^6\J_4[;7W_ /\ =I>/^SC*NW(U&4CG!:ER$^2-_I;XZ/D-9J,N\.W@
MKVV;*$$Q3+0N@04DFYZ#Y@%<HJ& OFEZY7QRT&\P%7Y68?3H7-9BDS[YE#2&
MI52FL6L!4=+SY-RH@C9T)BOM&Q99JU$[R-EDG!542H';K+3VI;?HU2RV@5MD
MX?RUIN,PUB8]%-LB9<6S0BQP=2THX(3PMV;1-=XZ5$J:*9U#%*.Q\E8^,D8*
MEV)>$IN4PDPB+699970F(Q%6>SS RK@(R?M+A5W-/&H** S4D?=Q,841$>)?
M_B&I?]MFB]O45_K%ZE_Y!'=HO^K,R_[+$NWIV?UI,._AM#ZG'/IW_P#UJ8GV
M?]56F]N=W_FSCQ_;/K73]/ZG,?\ _*Y3_P!A]#_5[<'_ .JQAW_9W ?4@;UN
M&=R+B]P$>WA$;M2[98Z)996MMW#AVC6;"_K;YD6=AD'+I0Z)7)%%FPJ&!!1(
M#G U4R7)*?$4/.J1&$B*O58-)4C"+8E64<J?LBZKAX]>O':ZCARY<**NG3E4
MZRRBBIS''M9VU-M]8MCBDVA_2;FC6YZ+G%:E<XILQ>R=2LJ<8Z<G@K+'LY-L
MLLQ= DY32<)F,0"G*(]MRV_091FS2AZ-/P5-A'"J R%YTFS13Z(HE&@&*JA5
M965L$\NF4R213BBS(NY4 J""QR\D-;.U.>JYUQ^JF3/Y9(!38KWF_7*-MA(Q
M Q_"*ZK*OT,SE4A0'RDWJ!C=!.GXORI5PJ;PI(IJ+*FZ&-X$TRB<YNA0,8?"
M0H]P (CVYE<D9VG[MFF7\+K.UKEM3T_+I&CZ#I*,_2Z9=,ZF\VS">=L[J5GL
M3>_1+:J-I]M!R,DI(M3K-VJ2Y3=M>Q[1< U?BOR%P^/SJT7G%]=?9_8'[C.]
MA:V1UF&CTV\99;;O0KE6IUQ39B+>@S?F=0\[#O&+I(O@06<<S>6RM&T7[B.$
ME^Y99]H=<!M6@MEKDN(-FLM7O;^DHFL7R0O&V9U6%E8<7SMDH=%0GO!&YO$!
M<4F(O*M#VG3.2NA0.3X-B] <4R&LEWOT[1[3I)V,G:] M%3H%,@X"CTF5D)&
M0D)(A$TF8D0(X6.DB>'N.C8E>^/%T=NYEA.Y1HDWGEEL5?=0\N\BRN2V'+;?
M>:3-PTVBU*]8.6D@<RK1<@JIHJ^)(E*P;0.0V*TC;='6CV]"R6V:93X+1;:X
MEW)V,(W@J?)S+:>D5Y]\D=O'D30$S]P0R3<%%"&*&(8AI5\I..\A.0,/IMBS
MO'Y?3<YO#F4A\^VI3$8LJ%XSJRV2A/K#H]A#S8.)0?J2;@S:0:&1*\C'R*.L
M42I\C,/LESP=I(O]KJT+J5)D9W)H^%.NC-R&B1K6;4=5&/@7+95%^N^*BDR7
M2.DN*:A#%")T=E*8ORH+E;J;I;/1\;UQT>P4\E@2CW]@H,K><9ND+9&T!846
MK-XY@GSL8]\4B#DS=0 24[5+*LDI-9SG-J)#-:]3J/38=C 5FN0S,#>2PBHF
M/10:-4O&<QSB!?$JJ<RAQ,<QC#^2TQ_FE+B:>[V33IK9M/7B@<@>Y:C8H2N5
MN;NDM[RX7#Y7D8.HQK904@32%-F3H0!ZB/Y8EQ.J.>L:IQ[;462S5EG%9EK'
M7F<;2Y9%X@_A8F<AYAG:(D52/UA*Y;/DGB1S^--4I@ 0I>)X=0:WF.4YY#E@
MZ;1ZFP)'0<(P%RX?.122 3K.G\G)/%WCYXX.L\?OG"SERJJNJHH;\UX9Q=XR
M\7MPU;)X5RIMFN7:B5UH^J\S<6BC^NYG0RO'4E'+.'%73-(S3],OC2*NM&#^
MO(/AW#D_R7RVRY7L5\<H8[G-(N[)NQM-8RJNKLY^T6!TT;NGJ+;^4>Z>[E3_
M &0%#,H%NH( 54.OU-FPAJV:C?S1"=]QB3<E(/R/L=#\R<HZI5554TVK:==)
M*0SU0PB 1TFX 0'KT[8UM4QP4Y01.:6M7^2/>&8T]@JFGEV@NX]%S./$&<ZH
ML\-F]K:QLX'@(8PMF+DI ZJCUEL.VAB]:^6]+8\]T& !LE<\LO;-JX;1=PJK
MIRFH@=0B+E1N]8KE.SDF*RK=8HE.!BOVB.*27)[-VSQ5Q7]2X_1BMK4=,VP>
M>@_LF7&64T&E339%4/.*@A),DU@4\A\H0/%V9TEMQQYMW\JI.C"I3F<;Y*PO
MDH 0@"2/N+)*LM&R!1*'B5%--,.@]0 .ZN<K]?L;+B]38^K2E7F,1;NHBZW[
M:*I,I)JMZEH+&(?.:A0*W#2R3>4;*E=R$TW?LRID1:IK+&-/8'MT:\"-=N4)
M^FW.".W;7+,[W&H.$H.\TZ17163;2T<5VJDJBH0[5\R76:N"'06.49)M%X^]
MY69BB\44@=,P:*^Z&4<M&X^:V=VO)%'2MWJ,XU0.45O<DY9@14#"B[$H= 94
M=KQTYNWA-8#)L*=+YOR!DH0Q&I>ADB15KCTZTV0;I]W[)Y:9 ^'IVH_++4Y]
MIQ.I]<AI"#E\D]YAKGI&T4B<;D%Q0+M!PL@[J%$J24BU;2!%%W3Z8:/F2!F[
M=J;QJ]N($EQUX]:EML?3J?M+.V/,\A6LLVKKN;E\W6AVTJ=S(L/=U9)&+<&2
M /'XBHF^+OUNF<@\?OF+6^7Y,6^SQ5;T"+;Q4M(UQ[0LV8LYQHBV>/B*1Z[Z
M-<H%.)@$5$#ATZ  C'U:0ED<_P!NS5Q)SV&ZX$<,D%9F)-N@C-56TQR2C=S-
MYU=4F3=*3:IJIKHK-V[QN;SVI"'7A--XGZK/-HJ1(6(T7&:U,[!0)1P8QRL)
M.N66ALG\[#K.TR =)*091C]#KX3IE,4>L+"5KC=R)G4V[P6S6[\AONWH^?4\
MZ'073IS9MC4268@S1^V,E$M'CQ3H!$D3F$ [4?.L5Q7:>5#13&Z=:-+U?/ZA
M'AGZ>OS<O:$K72Z*B[E6<HG5ZM&1T<#<[X/?W(KF66*F*A4T^-.8[)0+/E^D
M59EHZ5DH]R9)1]B@S2.MWR7CPD6B#AVFE[_%/T$ %4#JO\I=%!ZHK%$>@]0#
MG1>LYX5\@;O2K[NNC3U*M==JL>\A;3!R+-BE'R\,X4FTE'3)Z9(13-Y91'H/
M< ]W:/JJD-()VA/C\TKZE?,B4)0D\3.$XTT,9#S/ #\L@ H"7Q>'S.[K\/;@
MS== X4<A*;3:'R*QZQ76TSU4CFL/5Z]$3*"DO-3#@DVLHVCXQ !.L?P&$I"C
MT*(] ^IA-4X]8U?MKM$#R-C;+-P&?13>4DHJO(YOH$:K-/4G#UB1-@21D4$?
M%XQ'S%B]WPAS)<<B^/NGX@WND?AI*BMH<*UB4[*>"-IGRT2),UD)#SS102;8
M5@'P@7W@G3KU'IVY4:5D/$#=M+SNUK9O]S-WJ59CWU>G@B\?I4-('C':TRU4
M7(RE6:S93J0H@JB8.\.\>(5%OM<EJ==J?QQQ^N6VJ3S<C:;KEAAZ-"L9:%E6
MZ:JZ:$A'/43I*D YP*<H@ C[?R$E&$?2$6:08.V)9.*63;2L<+MLHV!_&.%D
M7**$@S%3S$3F3.4BA0$2C[.UTW+@!I^F;Q5;5.OK#,6ZBR\-*ZW<1DI5W,';
M<A\1NIU:SL5@!^[5.O-QR;URZ$XJE08F5,D5W59SBBZ4LK %H]Y8)'@UOZ<X
MW?%$Y#*+QL5-)U91XB<X#T(AY B4/M1ZCUKUQY6(W;.:E%.% C[MR-CF>;T;
M.(R43ZR3K)^.5=%E/R4U(,6OE JJR8G<B"1'4H5$W7M6>/V.(/WC%@Z=V*ZW
M>>!L:V:9H$PFW+8;S:5FB238'\B#1%!NV2*5O'Q[9NT1 $D"_E ATZ_H]/[?
M:45]0>(X^0NYAI=Y3AVG&I[;WU!-EI7Z(T9=\K<SGDPLIB&<E5\ ^ S$K4ZI
M4W1G"9%D1451\Y)1+S43^6LEYA!+YB2@=? J3KU*/P&#M7],S*3Y&1+F!?R=
MB/1YSEKR7O656*]RT8_AGNDV_-[YJ5EJ]FO:L7*N$Q=ND%$A4.5P*0N44%DO
M6>J<$PK5<G.4VZ<8=LXMRUAGX]W!7>5XW8AQ/?149:THMP[E*=$3>MX*Y@'"
MCQ$%D6B@O"(JH>6"G(_G)R+X_/\ BHTM_'WCOQ9R;&+)IN>:;?Y&(R6V;/JN
MA:5>'N3RUJH$,SD[MM'R+7V[:9?/'$?"JO7233WM% /4<]/.@\6XK1JCSPW_
M )77;.^87\LN9U/(,NS3FW;I&T71UKU E[$?<3WK#/NPDT4&-?KLPRLONC,R
M3EL"SKW6[X#J/IC7CE]B]'TK)Z]15:MNN&5&[W2!C\J0M1N1F<.K'IN467*+
M1EFF%-52^ZST/:/,54DHXQV)S@.,X[R3S:Y:#"W*Z\G+$IH5TWBCZ)HO$?$X
MJP14GQ;Q+<K>XEGM@Y-ZG.U^8=QSVS0*C]NQ/& 5XZ=%\MZX3W#B?Q\U6G/-
M6T?B>7E+K<Y?>,UGX>\A,8RQXR86FPWS+KI/R')"@<B<4S]PZBZ-+4R/8 ]D
MTF8OA<QP.3)<%+98N/:]A80>9>HUQLU-6EWK'7UHX_$Y.\_Z_P C<:W.76GK
M/#L[K5&6?UQ1:0:UU=].QCUZ!",U1,LGVB<4Y4<8.76V+\<.(/+KCS"(Q?+W
MBG"\5-Y@]U81E?NU6QMG6HW+>0$))<E1B&UD2/H0,4Z=8VQ5W4FJ[(G(N-Y9
M\G8JZLLW/=**AQD?\@GN&S/,B0HD9FT%&W!MR0M'&M1QD5L2@KFW595*1!9:
MR.85(33)C+BD8W]F/]H.G3_V>WZG=U_0ZC]7[ B/L_/\?;O_ $_T?@Z_D>[V
M_8_[O;O_ #_J?4^S[>W0/8'Y=^H'7V]O[G]S\KZ]>X/:/P!T]OZ7:U3]/Y0X
M'HJ%,:6YS.1N9:Y0=$L*;BBU2>O%IAF5>J%@EYB0L434ZQ(/U(]%$[L&K-93
MR_ F<P:Q;<KM_IU2MVE,:KVI89Q2C-?T*6U_+&]_<1KNAON6>A5UO9HL&;>"
MD!+8FE3J:HPEA(>']\6<)'4[<P^,W):M8VOI7$>;Q)M(ZQQU^[MOCUR#<*#)
M7U"BEA-#7EY^M:AF,='-UIQG\JR"2D;8(AV -A=&;D-BS9';XYNGR1MG#=SM
M<]AN@0?'=IRQJ=K?TQ3CZML$E&(5T]]L$['BA$G2!6(D'"Z#5-[[ZLFV-HN.
M7+)^4M8O-3I^WVW-D;1@%OK,'R>5X\5US;=0K'&6>G/<FFGV:-KS8SYDB -$
MI:/*9ZP4<M$E5R<0MDML8\XKY7O7&CD7R/NM0Y%9Q>XZYI4?#LXPC2YG2:+I
M\2]0S9AC5,@=955>3,RT(>S-3H+1B;;W9V0VO:GHKC<<4AL8J>5:?/5O9< T
MVCZ-:L1W+2(_),FW7-\Y=0;FWWO,;E?I (TJS%J>3CG)?*D&+151!-6WVZ$X
M[\O+-I>=<AN,F!:%QPDL+L=*W>HEY675*K9-ICZFS_<YHMY1:ODJVLBL<9NQ
M(H09A9O'!C(16 TS(N5-BM":M,A]/L\9Q[N;K.N/=\O>=P>JP^8[W<4R"RH-
MY94>T1CJ23 CN/C5)!%!R[37$R9?[&IL3NVI'JR9U469G"172J2?Z]1-N)P6
M.F3IWB " =DV*TDP2>K"4$6:KQNFZ5$X") 3;G4!4XF !$.@#UZ=ODCW]E\J
M^Y?*7R9[TA\H?)WG^[>_^Y>9[S[E[S^Q^;X?!X_M>O7N[,63N08M7DF=9*-:
M.';=!S(*-T_-738H*J%5=G02'Q'!,#"4O>/0.R+)1VV(\<%.=!H==(KE<B8"
M90Z*!C@JJ5,H=3"4!  ]O9&,4?LDY)R@JZ;QYW2!7R[9$0*LX1:&."ZJ"1C
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M.G.,Z4M)DM*<B9XVCS&,R5342$B12^ /42F_4J4X^7CE'4>8OW)8I!<C[C6
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M<0+;+SE%V'D1R%N7&*H\<X'CI3M1FY_?RV'2HR%3IO\ G6*EW+F15;RBYTB
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M)H[MKC5^KUH:D.B7!JMZ(&&IA)/%(;JF(GP4#!"![<Z]#T@4+W4_AP+ (2]
MS-:;>7&U,\_*Z*5^I/\,#DQJD"5[ENR>;^!K10D)L3N6'%%B!&/1,KB@R*RC
M9YE#HRML?YCC0^XEVASKK0B1B3"_RQ+_ '4*:Y@EX0>XBS6E) A-_7J&C020
M2_-R?S41G984 JO2@& (6_AZ"?^( S#)8I_[(J=9G@7Y[HX@#^UM;D\;FY9W
M2$:R*]^BJR[:5O&+ULN^L-FG2V$IS3/J5[98)$I]G_XFD9$KP\]J0),NR>9'
M+)@_X%#1+&5W.^G =-01OWB&JGV SVL[1B3ZM8/+-630_#J)T<!!\JHZ1:';
MIJTH_.2562S26G/6HOCK4J.I=@Q(MMB6%_X39!JS$X\7-^:K3T:MHY8 ?<JG
MO2Z_J.K\ 7\S,7 ?8ZS6&,NK%-9V>://G]!5FUK4Q/BANDA[Q >]1MNIBO+X
MC@J'S+OGWFHN2%<Z0V5[TDD4#VPI>\2"WG"S?LY$9FNACL[9#):O:=RS(E_&
MUX3OW;+S.HO8"<6R77:N))2PJFLFCJCA\\[94'.\0<,/;_+RLY=&*H+8X2\!
M7L\HDSG.LW%J^B;/1?G73!6#EEK]![8V4EAJ2GF?\_L:$G2L<:Z;_.0^Q>4?
M\UNR;-4KS.Q86[N%]'!],^B6+8W>'GOF+0!>,@+'DF?N3,!Z_KB:H9I]AX;#
M#;%BLM?YA6W5X@D$^=-VFL9[$[<PR:_+IMU#DR2'.H-8WZ[3>5NI0R^W*_).
MES4]D6LVZ>O3H6_Z]WNP'#T2FA3YZ;'LMU:DPQ\IAQ&8V!M5<DN%7[?UP:)K
M#!H\A/EJ?JXA',=2CI2<'GA1-O')!O+$P=,UYY24"Z'F-/'#5)?BF&;:A!0U
M!'DKK$*2Z]]\=6^;>]U(/;T&>?&QMHG#V0PSF@3RA^LU7;E4+M.9KSC-UU('
M<''AAOJ1TN9AY2G"E2XZ<ZE+Z#(J*S%MYT_FDBU2> 6A"H2C*DS5#6-'M5QI
M\2H+$\PS-*]YY>4O8D+X)5&B->W-\4GG'Y-(+I_:FQ:X$1N2US)OJ/X$$^-[
M\O)B#W\[@1&>@T*I.KWF+N/_$:VK77FL2P22H$5SO00!EVEIIE%E$/(K.LA6
MSTO?5HGYE?UK/OD.,.10@QYA*AXA>A&H]9R$3X;P'6:-43:_<Z_YM,3HE("7
M'6J?$$B07,)PR53!>"7XG$C\ZS>>L6HR2,9[0(7SM!B+TFFK+;S93)N2D=??
MT@V\.W>QC%Y3=#^O&U/3,>BM'I+Z@B.\+$IH#;U,K]"Q^CS9"T_;W@&%[P!J
MIK6E7*&&<W90M1Q$PX]R:\50)]&6#83)>'R@&Q2ML];(J+!OM:#+@NF*TX^)
MD-,6REEPH;"R2!YM6"NL>/*,4,T^Z.>\P#K\)J4A*)&+.;L.S&OUNMHIL4DW
M$!:0$DCY3*]!FN#34TY.C@=<8FIU)U:J (76S[3T_/96INE4-.:J_'7G\:1M
MVI&6OYG?DA<_O5#16;]ZFN(G<*4NLF"^94*A+2PF6>RL*TL5*R!TIE ?.=A&
MV.M2I7 K<M.B-CHFH"QT@,2+.^I%Y_I$ 8KR3<'9&'O33?$9)\M?E;5A8YV)
MUVA-T$D+:@ ;M%7J.7"D(QK,)C"8L6<AV*Q/9MRYCHY9@FR_:EE$)5&AC_%M
MDI"G[GH5MS-TC(94W+5I2_,\8E7^B2%-Y71;M^101(L=7.UBK[/<*,79X'5S
M5YGPC+698USCB SQ%LE8=ZMJDY,M0:%]T5FAW[-C+(]CJ?^<9JF8R70+[V;$
MM,J_=B]$O4GN;"-=]0XH3?(P;(J/':8W':JD<D@;6CDG@# ?W]SN,S(UR&89
MBM4GZ.GQW.K0M*:5;FUE,-0E^[*W.( 5I!.=!=X!:_;3$/_\>S;FY.CG$$EO
M3W&:_GSPMRHTTY#+#LG:[6J33)+/(G7^FLWBX5F>(+3JABAEX]9?MK0N'J!1
M6[:UB):SA2]4CGJ9"=4*>E^TJI?(;F1A-N9-2FNO/\6&1]H-A^-+QY&E1A"7
M_["N@=3A;X 6<29:N9,O4J+9!/3W,"TE#;D@"O[$'2[J6AW"0S@J)VU4<6G3
MV%&399L,I5M1Z#MT=<#,=,E@?X9O]KWMF[RMG;U\_L5<\:CS3');H&.S+O%A
M!3$M!OM^A=!/C<,F!#XS;GIF67A8WV8QYM,440/_F&*H.GK]Q'*P1_>LEJY6
M<+HJ.%R'<^!JCC8>1HQH'M5AIN-5IKL9"V?3M7\!\9GEP_.%&].XRO4&AW9R
MV2E[29JJG(&/UCN3;\G[:Y3*".5TR33[E7?5G\<6@@;8;!15?,Q-&%';(-&K
M1U3E),ZBQ_43"H$!2,[,#@82E_0QWHP9L_A:]4XE;"WO *;&-Q#Y#_/,R.?Z
M=8:7J,T=EQ:709>8\90^=9O'>9>U 52>5-G1RGR81+<O:BEZX"\.:T/]G!E:
MN"W#)ZACNFOJX7:F21=A>YF2L[6=JLF$[%H#F8*-CHG9@I.G-71*7Q5Y*GMO
M=Y.^+H_VZ43^Z*QEOX(11$W!P'&I6,"UEQQ8C;O6LYA8LF;3G_8C$$J;;CCC
MM'HL'EJ(P2'=#\^<H&D8:92?5T4C2VC:6BMR,QVB+Z%Z=,2.\L*]O#)%7BY.
MO:)'DI?9%</V,Q&.7!Q-9>3$-S8=L>+K4]2A&.<\U^*2T.%<QY[TGUOCWA6F
MNUIG68O>92X4AEE7X])+@K54E9W04Z_ %W=0Z-&G*M#V[3EXTD.<\8*[JM.D
M, 5L&".MLWB>"PD6MFT<..VX&QI6]1>_93PW>N#QY@UCMU;N8)AA+9FUO('1
M:Y+&KL(;J:O!,HS.]X=EV%Q\[4.-(^:D:F[?]<_VZ76)R6)'$8,6)IF,!_A=
MV-M[S([7?!,W'E0UIU'&K!@MU,J5C<%>A/G[WB@E6&=XDI$EVX<'LA%BB_/"
M"1SE-?0'C]:V!YLTKGU47QF>M*[V)V?W2H3IU-.;37\_=7[7R01ZL2T.VMR<
M/,TD-8</CW3[F)-E$8Z,1<@T.*G3[Z8;YIP*B@GBV*5E K-#AJ@2D_4#JUR8
MU>/VDD/CYIH_07?-UVLKE.GR,J&-UII^N%=97RG2T%(2%=UVHR8E/VB8P&_(
MO#5P9OH1&>RJ+EN\\,CI>$L^2\76[OX.$-R&.:%>. %Y"O"IR9XY6J?IG'X6
M;_4"A5.2//%NVM\5C/5[AHPR$IX7@JCE;LH6Z7"5672ZY^\D'NZK:S?/Y2T3
MJ6H2QCPI_6<+Z6.K4=-I>\W[K<96^3!3DV5;MGXB\[Q=&\1V:/"D_+2+BZQ?
MUIEG>2*X,9!)\<U1+/US$+%!S9[9VB=FS ACP*X#2UNM88#["7 K\; 5:,V1
M+0:+0>C5ZS*/,W)"MTA[H;\O'@Y[LY_2/;/T"]C(7]E5(;,M%-+5JF,UY(TQ
M<TJA]<W"C,Z:EQ[ZZC0C^28&R']3T>LK+JC*+HNG_NW+W:IZ19]43;+L!3Q]
MHR]I8O6B\XX/H+.3HW0H'PUXEPRS%:_CCZ  (V1P^<A@:ZO6 ZI^R@,/LWU)
MQH,8;AQT&:UY8EKNC/G."!WO"^T^W9J(]OL.II'].9:E:T7< D:4C?DKE2L@
M&3>P;RFY'S65;F1;.NJYL%.-O@.*7OD3]/W%+/"U*Y>S-?7'].FX4M!G4&L;
M<MM@=6 ,V14M(')YU'>,NM/E*X(B+@+@S$4F3:<%])B.B>!YS]\"6=X21@(3
MS/HEZ<VK#S^.?RZX\]T4R[-+!UK 2Q 6*H@[81HT$*NO+>(/V&E&N>K?5)8?
M.NE4RT9<)W /5PD,YAZG+&M-W_1>[7MIJ2][?E8*<L0*;JQ "</'*ZNWNB+U
ML*)1B73.L.8FXKPH%H_E_4PLWVE Q/B4;'W5DIPM_]9UXM]H.D_ =9FY5-^E
M+'YB%N+5X$N&IS,? P]W5QELHA)OU<V_Y."I1<U!K,K=L;2CT(VZ5][HH+Q:
M?^V$UEYX2;NK/I+?&+:X!HH87&X*;NWHD!"^'.)N*H=XE&5-FQ*@U_0\_ARA
M<:$2@U7/W/^(DDLTS1I% H/<L#0L306<W%!U*E%Q,.Q<5V=6QMNT;.FV!*<>
M]:0(JUY\"P:4)7H_48G=*(2<7 2 4&B5!$6$M<7A8$4>?M> P2(2KWSNQX+B
M-0O/#EFPX >A'+,]U+?#.Z)MV/ZY=:^WGZ!#,K'0@4\LL7<!_/XAS&\G8)<B
MXFENAW< @_#=.Z"<L#U"W#<$0?CY+*N[)]7_3VK!ZV\0,:H&TCO@ZT.PW] -
M,K*'0[Z@T%"HP]:'9ZC5K5=2Y+,WFQ0K180H#Q5.%X.2C.35CY8HC4V(MQR0
MF</@@ I";=X=_<3ZSQ_PX#/*B2S5\ L8Q?14)TP:>#EP6V.F*1QNDS6T(#F9
MZ+%.(VO[BC2P,D(\-Q+#+:Q U&=55 B^5?MFF=O*7/O2X5(&9OD\K.'WQ+@4
M6<E\'.G1T6YKHL?3?%H<2+RB.*%)HD0 "=3JUT*M#9Z2=38B";M,%\T"K[C*
M/EWF9@*.6M@V??;C9^N#JV8$/+.Z?-J.JP2-$-H0LWAD9!T$*#UWX_$K.L*F
M"+7X#3]*6S=WW^,_\X4G3RM*XVP3A*MY5[-N^922DD)SQ:B'A)6J-_*O9">D
M*DF:2$LC1;:!]0*5BMQ\P\S(QO;())??9"4P)?;X/2AEU5*+/S"K$*T0PUN!
M="JXUA,LZ_FPOEL]-6ZNP3C#1<*(=;*KJ(LZS>.=9CUA]E^16DXK)+D48!@F
M;""FYYI%2H[27.(#];G:SD*==KCB2LW1$PFZDX "1:L<CG<,2,,,M5WUTCTL
M<;94:K)L84YON#T4N(5;.>$FG=IW-&1%A!P+8)*\HIT>+BSJ\EK)Q,^S:8,A
ME;-%>[IQ5"5HU7F9A3 T$<$GA6HW5<7R^*65,CSR54\)C2V_SS@*AF5^#TLT
MVY?T*HDJ3NW:2?*#=MD<,GC<IO\4I]YH0SN_<(4I/&..GD#H6[E89=1 0@B"
M*Z7-&%]MW!,FAEX*;!OEXL@KC3$-Y89;V:JQ^$9I\HOWI)AH1H"4+0EN@U;@
M5<Y.*YZ(Q)N-U=19=SQK&S6+5.#OPK&1LQ%.$5 DIS(=602%!G2H8$2H8?<,
MM2,G0.)NQ8ZS_)/2HA8L(!7,&=/6_W1UD=M")TK=2982ADC(=XLT=0-[3U>!
MO_>==W<.AG;]!V55FP,9A_)5<*6DO67XV/! [57T 5,$'45*L(\8(;^K+<N.
M/;G\%(.JQ[[D7BP;A^](3IFL'E=ZDU@6M4'_B+Q##7\'O<*0Z^N71C?1]$5M
M56-":G*">>,X\DOU>#3,;TD5/,H$S%@^,WKQ'HRP>,;I^DP:]&[]>$^)#&:@
M:%J?J@52NPL'%%-.XXC0Z!Q%<IYHU=^.C$"6IZ88K%6W+]?"NZ DF=J#HT4+
MVSS]'4V6ZBUKX&Y".[0SD+.X^"<E BAW"Y8IQHCC,%_(T8'GI*]66F7I*H-W
M\L8N/R]/<=%V4:=XA9()Z1)?UQ:)'0F>V3HJ/$>D!F^0[@)=JR9X@"2QERXD
MO7,O_A<F.IU.Z>8'1BD73?-*^)XA#(:/$+&B,_%W  \F].<_E\A*LPZ3O A2
MP"2"/#,W:RY*6T-@ =95S'2FOM95OH8]#H0:(<E90>9[H<HO:!:X1^5*)X5Y
MG+K,J_71P6858[FM=M'4"X8_/QX9"/EE29UGAZ\Q:7T,% !L9[3)*_V=</#+
M>!U7M^&'93=Y#%/["O'SP^YD6?P4;J<Z"S0\5K5QO1^=H'YVBM?X^W]S>Q8F
M%GEY!^0M^4T:33_\;@I"7C:AH&9OE^C$ IFPT8$,FQ\]";;? 5JS-A$E[-"0
MJ (7=O!L*E,>7)Y<FW4:I8!LJ4F8^[&PT?4SW[.7#]1JC=([P-*P&_;H'O07
M]QX VU[C.'D*V?@PY0^^\VL!W7F\^4=N01[? >*U;H '(:0L_J=[OY2_/=%R
M\64' CE])9XY/S\67.?W 'A[A3T+M]ZV^X7%>BR^G1L3Q[:?P+F?3(EOW<4>
MW1U_V)PM,0HM 9<LG1**;R%7D\XN;RZ"&UYK@K:(NB;6A=O? 76K'4)$W5]]
ML\1/0.</3Z_^LY#3LU<CQX,';P]8Y;K'*'5FX)JW0.$@1';Q#:AL+#0(/@&A
M"^CO*\"6*R:\1D,'[5S 1HZQ^K&[HYZ2:?SN+D6.A+0E^B$%W3[[EB$8/5 "
MWOZ W@&.)7O^=BK<RP#BL[MC"@!1%E^B!&S)(;+CTAQ:[/.?2Q]!WUS2"] 9
M#<[?+DYLY?,5:G/.&PX'NE,P5U!$_#3@;X,_><QA",MW3AK'3F#F=1MUWJ]"
MXN<?MO,^N_^NQNM=MIDY56C+C3UTX%VA/=)0BD] Y6F>3 ER#]8AZV<!#G%K
M<4Y>OS%<8<O]:O8S/_.:F/%MGQ6/2K;7BDV1J.^X0N;DQOM&RFD5-51/D&.2
M21F[QZ\[/8$>GJ#S%,EB(_M;)B'@'LG/"V37T3'$_@9KM>;PO6>[(8*;UJ*E
M9\B<U]RSO2T]O8\A8:)<U9FO&E&W3\"\GN L782U$HM\8(3WV-"2"2S+1$%D
ME%CMZ\66+;KSY!W1I'HV^HIKFYFS73ZCQ;!P81FAI-7@NNT$,B.H(R\N8^J;
M(6E71SA&2)@$/\$RP>?6[M6P@U66V RI+V\9[G5&FD 94W.V"TR^_<NK#I'3
M50^"^TSENAP9S;$D$-0ZQ;1FAQDR/E'!(*Z:2XO%C$NOUM3=2UZI\R$'FGT!
MV7V%TP[R40&1/WIL.NT)><-#'5VY0? 8;F#6BXHAN3$A295$)_IN"'#9=DX6
MLX&G6^&U@,LZMQM#+;=IJ5(@;0!RD5C&B=<FT(O6X)1T@+S QHBHSF'EC DC
M]C-H0(_WX7:$3N'ED^=P2XP7Z7#$/&LH^H6W11Z%/9SM1E*I9E5#4CDAT=X0
M18($>9FYVB<M85%L=, "L,$L=BC*FRXRI^S2,8$33UG0 O3#U2(@N/2Z))JG
MJCOV6XQ-3P/E!#V]:5?3^ WN[\H(2J^5;+= <4+)"4,F5RCG'O?4X?'8^,RE
MW4G.AQW%WRZ&YJM7]NPF5;NICIB&U /V9;-M?@UJ(TZ5SFMXCNKD:4^]H#BG
M(!:Z>H2\ 1EY3/R<]!+,[F?N-&>7"$L!R9U!ZD>M&(/=)DC,P;>(QEV/"O1F
M 0/PZ,$]0J*O[I:2WGBHH[(Q,<EE6H$.KDZ,Q"$N5>>($*TEO@?,,CKI+,D)
MFT=DT1M_"$XUQ^A<XA6KY@S78E,7NU&^5EA6Q9 T;U08+!HHC"UJS9LS2+/8
M;$USWOC;4J>WLS]]N\M)%.Z$ZO#8PKE@79].ZIZ[DI;H\CYSQ\JP>WC*]6RA
M!\>X1]-^'*K8F9?(&8I=+.>UY@OWE)N#FPM]M@[7<V^WVF&Y+^:"_V"VX"(5
MB\?<9=*N]_)-HX"L'[MF0X:&:;FX)HSNE"4T.=85W%(6C;+ZYZ*@V'F? ?FO
M!UVA_.+U)9(EO;*;%^ '1X*I:'="ZD^+FX93A1S:JVA]5G_Z2?<$+WNF831Y
M)W]8<2/!$<OOW%D>AQR35U[YAS_^H$Z>,'!_J7X'Y+NH$0>OO .N1,QS2>]&
M+-"VG['>J*"/!;R1OU!D' X@^"2G4_11?_W66CAUA>O+O @KVU\K#J.*RT3U
M-3-C>^5V@L=T(;W#/5KNSI*VV/I30GQ,F0339;2!+2K9'+NCNTJX_N%:R,WI
M_*-IR17L3.AW'_<_3>EH:9D&TB%Z73H#:7Q(H6D;CES/9G*9$O'E5VQ>0E?[
M)UC@UDX20HVLZK<O[>(V2T[BY?<"$253G;K6'9&3Z)$5+,U/;3LOYN,/X\!\
M "'-_,M),CB9OD2.4//M[#3^QWT"15LAZ@$CTV0*M>1^:.DK?G;[0'BB_$23
M+-\=9-3J\RKB.:._:9).@R:<BI5%V9SD:K^,U)%$X!P:1K[:58E[UC8SZ;?-
M1 NA .\<["('_>@R3:MSPS.TMC-\$^^,?E'6AB6*^0A[= V-0^4/GS%>WFRB
M@;SX'TNFP3[<06W()8.8.]^4)78V M,VK3$) A4+$ECP1D_LOO32"^>/*_49
MS@RP2[.A1!PJ =F:H;01YBM"HU,1PM\!)C# 1%HX%634*&'D7Q_>#G]?POJ;
M4JSVK7\X-F)?:@MY%KZ49/$AKGYZ;>_,\@??OA&/^2*JL"#_^OH!&7)WK,IF
M^G:32TG\($E<M]0+<XU O(DA(GTC#V%V>-MZ: O=1RX"XPKYU7?W=FW*.[#Y
MO)K[A_AV):^9/3Z-O ,0GGT96X:O;Y/>,.^>])P3#D[H7^@A-\T[U),+6@]:
MJT?V \HYE347->"9U:@<81VC+2/'_Q2>X\#?4?N6_:_N?O_J[J_W/T=O>P?\
M-75[> >D_"N5S?]JW/V_1J75].F>]"'-?^R&1AK87L7F[S:Z&%(O*GCA/6<6
M0:LWK0))OH -0S")=?*X R#I7D8!^-L^W2;=()W]07ZE>VC_'P8%_M\4J<W_
MWSZ-W@'[W57_:/&O;B>@)[W+_SWIU_W_AL[GO_COH@K]W43> <PZ1O[O@/G_
M9'K_HZ9![X"J;ES^UYR73G/?5\%.X9O_KP/.VW^B'OZ;!O_'Y1>LME>"DZ25
M^Z#.]9ST$UI\B[?K.+17Y,&[+=:1T\' .>#W8I[L2]>>GZ[H8@LZ];JR"%(.
M\DGH%M%?".:_"]]?#,&_E(T>W_ZA[/V7<O?U:](;QC^4_0^>Z5]H_W+ZNT].
MWFD]J*\>V?:_ W+6:BY*_K**? <(MQIM*?^EA?WF_Y=6]K]@$K^\[?DC-[P#
MMG-"_\UJ^=^MF _N__^(]O\@GOXWQ.7_B/@_9OG\W[%\^OT.&,BI^3>TM9K3
M=\!ER;_H^A]B6(+]Y_7OJEGR+S]==9F-_"5\%MFU9\YM%"7!*/@.*%@$K[BL
M1HY@_WD'[#TST 8( 0ZY8MZRNI+UO_XEX/\WL0PMOZ]?$_W^)E;'.?3@F>:?
MS-7O($_>J?Z3.?,!XIS3@G\R-QHE++PL_4_F4G#\_.MC_\D<$\L_ 1'_4RGZ
MQG_QA/]/\-9D8C<6_!OO7OO"7B&6S\K_;QZLR\^)'YY=5BU/G*LL&)Q:LRCY
M&1(1Q>_IZHQI&=9;X1B6!+T"IV7%D<4)?B"]!:U*FN9>ILCG=0SFTB=W6C<-
MLGL;J7.7K15JAI:L5$G%6X3C:D+4&><M>HZE=-K.U/C,>=+8 8"7:-2_A\)C
M:XJ_D:7RDA]19YM/).KB]B-OCN%9EG='3E"-0PZYA#M2EOCN@N^Z;\XE,;+U
M*SOQ=G)3V?ZM:9?<;Y^\/;1DND:7RR\]<^T217C2C^K,QADX2) .3X/J.=C\
M8-JNQ;KU;":4:)G4ZH*@6@N-!)$03*3\[S2PR? _H17G .(EHN>G)UH=%Q6@
M<O,HTJE:&:OXEK6R<M7Y>VN*=NM'6IX[YH]<\)HGQ25=E1*K/T.A"/:0WG[E
M2HC#*RBSE'QB$,A3D/N(\.&E!E"T18P=6:.4]1H(SY?OS(2TCFW=G%*533E3
MF?6SO,$O08>*44M3\-C(+NA[HJI^CEU:%.%KVTLDZM]3:6W?;S+V!;FA]AV0
MEO<<5/H.R$CS@#7,DKXCME0YO7>2IOVICAW3V3Q:Z"ZFI>/;QSZ3+<F992MF
MJ"W>AV6^14QRB@(]F$__L_?K92*T_U@=X<;FM2O36=;.XAW168!@L)]4&."0
MC(K#E84$ *N*BBH!^#R[!<G:.'V([@7++>G+L ]"V-/FHNPTJ\\81Z645P_$
MCEEB(.7-WB3?1<_":3YGN?6@J@^HXNV<B5SZ*_9IZRMMX27&9*6U5PQJ$S8Z
M:#GL:,OPV8 "6:;S H$XE6;924(E&"*YQLQG#-*#SYF3RZ<G;[ [1)LM=81_
M)^.9Y>7-.R#NX=G]$8N\9/#*E2FG9/>NP=K9LZ"582.!V[!RW;&RPGZA;,ZN
M^1V O9;D]YL)WA-UYLZ9-#""ZI@^S,,-@IVQ\\C07)2O3$ZQCQ N65' ;Y-J
MC]AO+1N*.FT_"Z-/CHFS+(V$2"@ 3T5%=):5N\,+,_CE,[*OI>1JQ B>G\MQ
M>70TSJ5,S0#\<_&/Z$1-X4F2Z@AY7+<()]8P&!2BGC>+T&=C%.:_Q?DMM!'J
MCN@2:5U(,NQDMD8Y(<W]:+'$Z$)HHG/]7PJVNWUWWP@6_$;]![*X:^670SP\
M]N1CN$F^<UI^1I:G(HH14S]*UY.F+HLA1T=7-CB,"CVKD$]%',9W9ZRYX!*.
MN#))KQW0/B"B=S)F:DX\RVC=HEMG9;<FL)V-Y4ME^]F=[R&*E@ 1AE6!L'W+
M!.ITD/VUY.3./&L'YW2C(7>(-2[!6#IW'K56EZC_=W'Z+)JB*8I".<T$+668
M)8([@ 2'[UF\$5J8I.42U$=9I6!&45[GY4[*]WN5PHT/HCLJ'"K:@WQ>54 @
MPTT>!*O,,/H3F@^_@T^L#UGEF'A_WV#K,O14<&M]Z=^K2NB\X1G9^H0)JE]1
MSZ8*F(UH'_$[?6^2H78Z/M@AHXFT2\5F*GK78L:F#JF RF1OQIS71S8@,Y>9
M?)>>T;30=+TM-CXZ_KN2D!R;9&10DS\A-<%M/C)Y(?DZA5N*J-M0/<+//EZ1
M7Z2KN;U]L$:6VOM& '?BAYS(YFB'HKW8*J" 5]O(9I7VENVI@<3^/"]WC+;4
M4M6$XAZBC]Y]E)8B>6(YCB3Z:RG&#Y37_K^MS/K"(_9%NG_EB%QN;&.UP%4W
MH1-*QM^PFCO.6C2WSB6!&JQG,IP/$U[% ?H33G/X*@=$^K"YN0)2C\TTG.&&
M:VL,LLH02#;/21X;:6>X3:/0Z1]C"E2GYY[0I@$.I=ZGD7]HNR&:;52D9D^:
MJ %:!A*;%QG2G@ AP/L226I:<%)PRM?YDZ\NRR9T<2]D\4>9)0H#) %W\,2M
M;-"JF9$?QU[',TE^2(_"0F&@FPSNYJ72.U]+EF2= U)6'_V(WM:GZJ#NR-.0
M?\^^2>] 9G>M8KHV<J@:3IX,I6UB1JT'[)*B_$7C/;_D'(/PQ&KG].8JO3VJ
M-^I+)KJMOG,A>UCC[8D":PE;P]9%Z7Y<Q,H:R"MN24'$QG)-PUF%<[4OCS[-
M:^.8^W1#CZUE:%;WTN%\4 O?8-)8I5 'E+K<GA8W=L.#H=F";6"G%F:21L9T
M=76.50K,U*X*I]YZ=<OH YC[ET(#\&#3GC9^#[6\49TBM[QI-UEV)VNF88S,
M02VBL 7K3D25D</\3L^GEMG@U8@3<)939:GZ\X';%OJ F =<>H8"Y!R:&.5/
MV6=F9(E#0^ D[Y4LHYLN:1%,9^=$ +=RJGKXZ03TYJQB5^7I4T=X%7=EX3G-
M>P^I7'.C1<Q H&GG!&WFYD$0PA[EPCAHI>E>ZQ;EW,!?^83\NI=\RFAWG[D&
MQ1RDP6MMW!0IE!,1_<82>%TM T/2]4K-_8\I)!PZ,^&%SP-$9W2AAN.URR]<
M.T:KF]IYQPRLPQVOIUR)3[,F?+1:)#ASA=I<\=_N?,[4[U$5BB5G+*"*\Q*.
M'1;HW+MB./5"Q$!J=?;EVB2H4;7 TRE'+&-.HZPHIT#]0?F^(3(W+8FM;=K1
MBU#14[/O9 1 4CG78D3<;R/B88%()IZ&9(G;4%/2+5X@I=<?SE"&2X<V<K)B
MU&X3#:)U6ABI(4;K5";A%&N%I-E]K<BT/0#87[GP$EZA2C.>7?T)\N9>#/16
M@PD<\O/F</0*ZK+%YG$_W-X837 E5))C5+!%>H7K*4@<_A!EM?E$H\]YW2 G
MI-V>W=U["L,JK?M)A1\2_GYSL%P3WO;&S 0J4!D1E&?Q/,B-)*C)4ZVS,^Q)
MF)HL\_O4X9&(JJJCLM*9D<;XA7Q J52QTA!;.^>V+G8O-Y?K1NG972_^34;-
MX,/ [OI1MNWG-PKN9%65O#4R*@#2 EYT>6:2RZ):5EKY2H7+Q3B>@A;#[3(W
MRP(</.B'PL81/3S3L&:U&BHQHUF445"-;<&*D!&MFW6&NAF'/>:X2;E.\*'G
MG-@A5VJ7;N=T_8^(<HE6ES2"#IYOJ)<?HN\Z)9CX*(@LWDSY)XB .QSRI_;6
MV)QT'%GK*V.TJLWA\?E?\C?UC,C,4BG(3)F^WGV0@/;;JF?(EU9LBZ+8RSA3
MRS(RI>;A'/FM)E"OY)T7B/:2 S<MEM7S8B '2_-!@0Q VRK&A2IU0@&,UZ_4
M^2A'8O(PTD+C)B)01RUZ3#X%!6X?T1A&.503G6Q5T)P+\SVK5J<;)_).S,"*
MZ1S>_@2#HM6S5YD:F, :U T^XU ^=Q5>\7;#L?J)>H94-_8.L(8\1Z-O_EU?
MN=D? OQW_4A/2:\XE%60\HFIV8\_7,:>"O:L+Y-AX=$, C5^2@02C"DTA,R1
M@PX3\@T4ZD]*U5"@2L.C/LR6!H!^IJ?=O.ZZ*0B(PZK5S]1<SD\9XV/UM\5L
M#@GH;Y"(5E"590&A_77%PF[.CI;WB!7'<BS!5@LJ]6K SR'V<+88;KXQE%D_
MVFYW;8812KFR G\ZW)8%^YO;M2+/Y@7EQ@Y-$P*\X%ZR)UM\LV#OB+;^\D:%
M'#UG3ZY>^@?>W8.._M)6O8/]._-BWP%Y_TS ['\FX#\1SNYJQW0_MN9 !+N=
MM_V]T_VF5^^QZ.\[<R"$W<XFW=[+;_]W'XA3GAIE[>"/E-E_;4W88-%D6MQ_
MSCAQ.1VNXU&!L)^8/5M>UB68"0</\*ZVT.1MDR1*BMT>S(V[QCJ#"1)^=*#O
M%.NDF'6,3Q=QTTLM%$PH3JY]U'-MU,J>W:]F;5HN7*T<0> <QB-9[FZ/",]M
M(5,2:2MS'HS 1@P^<5*]N:/GE'2N4=I->GUF"\A>@?!F\",]Q\^Z(,K$;K8
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MU-'B7D!,".W &]4?@O$].VJB5S;"V8>C(?XX*KJJ*T4/3K^#G\]V E\2Y"K
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MCZ($$Y_/%PX(RA<&A!GV%*Q*J#\4"_)] #K(PE0K'D"&P<O[KY-3O\]6BSX
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M8(]WH#8X5J_ S$"CA-HF9;U_6:[%'?>TT3U> ]VA/(7\6OWPA&?+/6=XZ81
M GG<W?N':>UVM:J[0FV'7%:)4J;FMEFT:Z:J)45LJ#Z&*/RWG4@XIX:A,\I[
M=4FW>1V<>0A.@G9 I4UQ@40D5:$5D&ZD $9$1+P@4A"&7\,K:YQ!9W$Z!1)C
MA;)A5Q?M#J8O=VG\+R^-52$'44;V(CB&QY)(EQD]?9L?-6A-_C4SB $$[;ZA
MHV, @: _I%%GKE;/]><?@+.LJX6>N_:(]Y]B#]ROV/Y_Z-ZE_W.JP_%S&]^C
M!% \3D61[.&>)<#S[A&)>'^]'#ZS-4R\U@D-_?XA.?!"(4];L ?-:'SDGBTL
MAB1$+]\'@H&&&+://25<3'G]GW^0PA\9_N^[B*VAI@N,1+P11-,+\#8-+B[(
M\9_LX2+\NZ[CGV ]:,I@HHDCQ!0,3ZN9ZT+G-6US<!';9(;)0WQW+G^=$5D,
M1W\"'7QBYCSBTO,GN&OW:$\Z\YU\CF((D]R\NC>'>)W</Q<MHQ;I"M*))AI7
MRMR?%'1H76Z0)QYJ,//,^Q&7/!&B?%>NY)**\[CG3^K!I0[F>3Y<4E7,IKJ,
M_)Y U!%MO,1$O(JN<*Q/E#;$L\FF2[^-4;3ZQFG<-'G-\-9@>NWI/W+)E*.<
MO%9:HRD[F@4]K.;"M50*.R>[5CW#9BJU!2,2@C9B_2VCDS&E9L.FP?!6Y5#S
M*$N[@PJ[(+U;8?KZHD;KBV"LZXUO%-MKDYD$BGEV(6I1,EV2QLA#F80+W+G'
MU(_A.1!6EP%[I+E#F$=@#*/MXB?>P%+YU=/9^:HJQBPW=44=FFY=)&(1K/2
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M?C84[=A =EYXD&[>'^50Y5I9ETD*_);BPL<8 7U25G_:]]6&1WM8UBP;137
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M)L\17M;P^*RD. A?ME,3U=$S1A?E /=$B/FD%Z$W_H/HH]Y#OAZ6\8"26?>
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MKQ36\.W[9RQ1L.R)]1HSD?+:3'Q63,8-(SHZ4+?PD&FD25F:2:E]!B$8$ B
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M)'VN:Z\UNXL^C.AD:G:@X,PTH"_'R)9/QEK  E_&'+6=$<A'/:_?VT>= "+
MGJ( -)JZ3W'Q3*O $SDA* %W^KU[5;=!S[;(A*)RRL-.34AH<DD7I+[ML:*
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M"98>*1\-_K;YO8X+QU/@GQZ+';><&)W,$^ $0J!SD/-?J0 )U(D]H"IZOP0
MZ&X  #-4MU';_:D%_VI$?^K7OQ#P?X;_U(M_-44 J()>IVF\=A< O(&Z\!V(
M]R4 .$WA+2\!Q')R_^I_MV /N0M_>-%"E1 92"#\Y 4 BA8 . XB$'"Y!,)Q
M$23L# !TW?I3@YXV<JAF>''I%$URN-T!_J/]J4__BX[_^09.)9 '_O--F(,R
M-&(BHM.?OQL)&<EI(R<E)2&C((=".=0IJ6BH*"FI*2DHJ.FHJ6EHH49!1<]
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M.)T=?>_&Y6J6 E6+]//<<\]@]R)Q-B.H6I%M$9P/<@FI 18'+)LF\9%]]NN
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MW[U! ":9;#HTG_;DSJ  R2,K N"I.1>)EMD.4'S)T(N"(<+[I[FNTX63/2$
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MG"QZ*CB;AJ8IO5VLDZJH[ GQ\)]Z?&1>^:C6*4A$V&_VOGYJ2"1.Z"=%3!E
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MKH]<,$S543RG<OSIT?T??Y[^+$,8:("P7_ 0B;T/1G];.$>83$ P##O+D3<
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M[_),66.O#K'Y&,D(":PA)X<KOS2K!@;BJ631#FK"J4DZ?7%Q)LVF-'?BJDF
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MPQ5V!\XR0; \F$H0I/A-XF,+HU:U436Y^_TXA;+A<WM$6YZ+7G@A'[B$O+%
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MR_F ]VY$3B@S_1@I[;DKRG;CY2:PXMH"G9<W'5<<(_896#4F=9GPCQ$I[7C
M'K;3F=N)$P%G"IP7%54 <I+N9KG1F/#]BAM3Y\/O9T[=<>P<B[92&ED7VN]
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MLR7BQ1..3Z.B:@OVCCO M\;T;_%\MSF"\*5<_!)8 /1PA52+V&+$E*LC)G9
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MQL"9O3%_4[VIB6+:^C?28:V5,]8/7HN&F0XN_7ER4X/GYKWF#<^[@NTTT&G
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M1KQZQO!99-+<VX44U8/.GG/1>:.2P9?6.-?.UL;#4H[.<I-8;']!0I]-(7P
M2M[5=6?(2>_ 7YM=.WKI"WX*T]=6WR>PO0LZB_KJB$H,\]'8'&TQ_$0G#:BP
MR^O%0H&CV16OK",M5,/^X\/U5AJHEBD2^S !R48^ 31GS]YODVOZE%Z65\+D
MX[?,0R[VHO+EM]2[O]<H+_T#O:"B<-YC[(#*]T.!C6(H)$2NM!Y6-WK<*EFP
M14@KHA-23E)ZLE+F[-95O:QCDWWXDDW+OC0@KMGL#EX=L%H7E+$Z.;GXEC^E
MYHO_BYR,.S)M7X/E1APS:Y MD(NJ%:9D?0+C2/+G'1O= &QOHBK(ZK"_YK;U
MVU*_0!CQ*NI#@>G$7#,-I++UW,QDYYGZ*_.#C7;"7-LQM$J% ;>>%[/$JRLX
M70&QJ10F%,4^#C,X*!R+QCJUZ/3 ', 96=7>>RY;+OL.\-.U#J^B!F<F?U6P
M=AL;"847+)<4A_,8<@=$[90ZD 0 K7E60[ZI_A..[%86Q$MA5WBA>:ROT'_G
MJ#LC%+"(9_5+L=BXQMN(XBK6<^V^8Q?HPFQM2!>3ZZ#)FM@WZ1?U89@:I+X^
MI=W@/[5X1[MB4IQ,#P#(70-K)CQTW%<?\)TWJY9B6E!H7S)+AMB.5G\:W4S\
M4WMF[G>M+.HM_**W_XU%&BATL-19]YK:0Y.4TYE++8'(XEC3^(Y/+RL9D-,+
M5\8R+SFK'YEIZ, ,.G*H(Y!93)]@LSIBW14G/9GX,&J]!X@DQ%O>$9UQ1TCY
MOO0<OZWN%=\F94Y8B8,Z6;&W/JY?>1/,M3Y9P1X^1-;RM#D50IEX]@J\8-$3
M[H9ZP*$1@*KMP5 0^H<)Y9 ^3K0)N2SHA+I?639Q93XSE"R8/!G>G#JC\^2W
M8.M#[*;;F0.P]$?PJJFU"*71)_Z$DW%MQF6 BQCWFR^,F09Z/EQ:_> TLK%F
MM^%9D(22RJWXHDWU^WJD*N<GKAB1?-\=\SW^\@L6<UO(Q2"PNA^8K)*/+ZW>
M3Z^F8.)EOZ BSD@W0@KO%\#L;<Z/DHEF-%"U&)E#$[>]@2(DFQ'EB^<#535V
M=:MW-_<L'-I)7S???,BZR9^@H?5')M#XHQ]4I=@Z@S?C8G:ZIF.99K';I)/K
MT4:HI-V9]KX^,_?"/1^.PVT:Z%0WO6UI(#\3*C,'<1(6[IMQ=D0%C)JQT/+)
M3<98C+NWV7A'F%[YZ(&Y^>LR;I<.(YZP,\OD.W%T@5-0;_0RUWZX/E!V?M)%
MHRHPK_8ACEAUZRFE3-!R<(NN21$3(_]99A0.(/K8GLXZ"BK@>20@CFUS9R9S
MT%$?@M 9W=B34FX3%*LGFL0X#,I6I1Q9))M4U&C OW1#/Z^U^]Z8*8Q/):UA
M_L[++E<[!\@10ZC,L)P)YTPP5<%OJCW *C]\#\P)A+1:RR6V'BF\D_3166",
M(YQPLDW2=+CU%?0F)VT%!/%!-HNASP(A=/[_L-DH/0]]+\@("/O;%<VHJ/$1
M\@HFT^,3EDPM93=T9,O:*^L23J*^"WK]*WL+"JU,%J=\1;.3)8 K&&:$7!"1
MN?_)R V$"?&B$U8[9N(0^N>FY$/.'SX?T<-I61>93L5N U<0@@Q#2%M5&TV"
MX)<%RFDH*]!O-NC3)]QAWN!<GY=<9/%8*$-8F;U>II"O@/\%S/(ORANYAPG>
MH53*K;O N(*[YLZBI9$M7/.Z%K ![%.@458A7$?"?=%:25/%+^$5OZS>.<W%
MN-0"A@UI0,RZ\OB^,TF0K@1#]Q? []0D,^ZXAL7,G6__J6-[G>KX8S?R,'*B
M5B#$9&CTD&X63@E14D0H:7OP2(,NNM[E(B&IHS^^/^<*HU[&1)N8CR>R#G&F
MP(5[9MZ<GIE]KJC8%_Q6GS'(Q+1RH"1E^6AM]O?,(U;)G8A!+9QM.4-**5>,
M[)<JAY'$I\.9L)C-P-P?#YC3%AAWJU[=79]%B]!['(E\HHY2BCZ%D (LW!?
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MOX\43&@@W5_49.C?Z5;Q_]-T*W_I#58:2/06P8':YLI% ST20IFC_A0@KM%
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MT]Z;3QX37G]P\77R7#AW9KGZBV262>Q SR>[9_=.V5Y0#W GJQZ3Z&2<_0]
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M<CM0@V)8("\DF9 "/3FX6P)5Z$T,PY#;66V17CB::;[7"'60P4]G%T:$)\2
MHAN;WI[7(X0]B]]Q/:4=11,CFSY.2<?;=5 P)(6D7O,3IXRDM<(U!1JQSX%R
MF^@VB2KDY0OFDXM?FX>,DX^\ )M7-";[[?B=\^%EC%072&C]?_+3RX\^G86V
M-YE:^D[$83.^RVG?H-,N^,(HIV6J[@''7WZ+Y&]7"2V=C@Q)%;["!,M#>,<
M&296,SC:.Q4_I3$P.S3H.'CI()U>9A=F2BY]=W1BEX/LT2OJZ:VX'GKZE"W
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M$\-TR+:VXF+<Q*VQ(49S3FE^2JT^1^WY6W\O8__&DU\_;CG'.*\-ZHM;0.]
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M9Y[;/$]Y5G@Y> UYS_,6\;[C(^:3YW/E2^)KY=OD%^ _Q7^5OX;_HP"3@+Y
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MJM6IG][/O(1]MQO; ^JM7SSN@V\+F/=OVDB0S^7>.CV,L0=10DKU<G?*XK9
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MV@-RF4WM+$4(>/C<Y;\]PFLCWQ++D2P0FG\V_^PV3.WCA0$&6<M$46]:#AK
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MHS7F)TEW_1?W@)QC-=1A(SSDS\1;W/']IPIK=6SOGABJZI:P-!6-2]6VG5>
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MRZ$[RB+/_+8FJ.@L*4E5R4Q*WL.,4YA1Y%;DNWZ-Y7ZC\WDOCQL9BKQR.D/
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M"V\C[?(O!UT=4_QL$!G?NJT]QASM7/.&<#3W/#K&;0_8*17JB6"O7M;EVAB
M&5:U(ILV2X^\],EK>B#=] 6D.%/M2N^2I.3RQI*)SN^U)T7@E]L(.-R4HNZ,
MF8_1J)+OXJ0]ON&23Z0(Y726V+N1)$(7MX_!7[T9^JPV;W0K&BV3NZ&0KOGU
MHFN9F@T>_LDF9BKM._<250JF9ZI("A0F;!,NVVK;FJ2+%"=]9O06[>J4</9<
MT'Y8O%;C]]XJ0?(2;WKCL;:D F9%'O];W#X29Y=>.74:9**KBZS4I<;4P^G-
MR_%;60JS>JC779-K<],)LT_[4L7Y-Y0//N*^ECTK)\5CG_SZF?Z\D%VP:<V1
M ;?E\D<0KC:['DNJRU=REU"/)N<X[L6$O,TRF&-U#R YI@BG)+A\5%"\/+)8
M</BROL^E!HN'+XXV4J[7%B#ZL@D&@Y[V\8+[+]D_"T@6H5E(>*JWF'5D\%R(
M6[^M=5KL2IX3;^_$V! /JW>4"/.$:JS^_'6FZTX,XID]WI52=-3$L? ([R99
MA:$/-]+FU18:VR^"S9V38_@HM!FU:696TK^0;&UQ%C+&!N9Q%LN LZ>1!441
MRN-/=$[&W\]:()5D67P''QY)'2R>FI6[3:91RAJ<5MANE.A+FG])I@J_H'26
MH?CVN\]NYVYWOGYF2U)57%]_+C+9^"2SS;8'.:W'6?;7@T0W?9ML]<]2"Z8N
ME^=3\#^'R(#>YG7)I:CW^RE(^Y?!0R\L/*JBN"()-_02 N0T!IG:A.+445[J
M-H"I2*J6 MV=&O+ZI06S4 3YN)WCQ9(F--<L$Z48LG"](^7M/41>M??_P[P[
M!E<"1/^"-YIH@HEMV[9O;&-BVYQ))IG8MFU[XMS8YB0WMHV=MP_[WON_16W5
M5NV7[@_=?>KTX:_/J?8NAG5XTZ!X'F_'#Q64*AG&#GUWH:KZU7(X<7@@B*S>
M?S0.#-K%#O)PR) =@7<B73N4VLFE[^6E>)CSA2R23+FXG.7'*./NXC[#F6+Z
MYK.H(V6??DLYGLF L(CUEWZNW$XRF\$<L/ZCP<EI+=.F+F.1HF(Z$X+8 EUS
M*9@"NF1P0@^= VK5L<2<(9Y+O?PFCMZLKJ6M@C!=34]ERH+>/EF2*,/?9MRK
M.*F7J_([3%&\<G-T#Y;9DW58$SG "95$Q0R]0$/#@%T<O:72S0+C00F7FY*\
M@],@6TL79K$YT4HC@2"SDK3]-ZX[-O2B$6==S*OJ%U=;#4\7@JX&2Z&?';P>
MNB[B9_L/.D!H7%M[M@WY^&@$%Z;CV7!#2=#'=J?1<G.0>:9N8*!8IH69F!HO
MMVYQ)TY:ITU+F8M9716# H^Z9FO.O-PT+ZDS5ZZMK0[V3.<5N@*D3%O('&AI
M>4M'F1#2T^&F\%(#;:'<JIVMS56:8;@UB@899<Y&Q"D#J1/JU_Z,/!)RIL@!
M'B37&87JG*KRZ"<@O><_MZLAOP@#/@'YG,L@JML%^D70\G%>PQ/DA2E[4O1,
M7_&*U%P\>**J2</!KJ#8BEY%N\@K@]L<NE*U0J9<K2BY[(2#0JLL_M .F=XP
M8FI*;H6Q,$5=G&.R .<7BQI%K7@!!:QZM'@Q! ='*19_1L #E\8==LJPKPQ#
M0XZ*JR?:QJC5I2-<B)Q5#F[RKR02<7* .J27KX!V*FE $63*^!H,]2? FE&"
M]?9TF2S^B(BKJG^J']:V7-Z)ORMJ4'=*&\CWLSZA(^C!>0PS(H4! J9^F:4[
MQQFKUIX3:KZLRPPM<4C9FD)^?+%2CE! E^LAE)1JO?"ATN0*Y*+X^^R5*X>7
M#*IISD@5KR2OR>:;;6L+[)OL<RT5:!-()26'CF+Z(SKHM5'FW$0+;7"9%50U
M,G(2LX;1$,+[U8PK0;?D9[]FO)[:2!E'DB8&7B GYKXB]HX*H*N\UKRLF'XL
MH]=FOG;^Y+:&=GF(?E9 -<\J#544$_J;&)Q &'D\;&WLCBMLCU/ZNL!;)P*8
MU-X[MG5H0U<4YF%G<M3V6W..+_^?Q?FF%,L89T2&>.CKJ.K^:?\W)8['!D&T
M==K@$6V]/.9=CT*L59F,7YE=T6R!*N*RF;;^J5M?AL:A1.)T#LZJS0 +3W5F
M,;QO7_+5XV3**A'VN9G..YZX^6T=4K&=QT/;.\,H4N%M\?7V&8O]W$%;>Q'>
M,NUAXG9FEISAB>'7!KN>HU],\(%P32WKJ)R3(]'B#.Q?LT=;&T"CN^5F@3=H
MPW_(AVVDL;PV.^O^KK_BB(6]_M2-GNU@S.$9RXP9OEI=A:*/P],W;RZZ8C2#
M&"G[Y>PIW>Z)Y?GT<YW? 4>'Z;I@[E(X>&!M &:4BB%Z3VMU7,>X?;37$M70
MX/OF7S9]I1B)E!MIT-J*]D-<A.RP=UIF6%!"/68$9SE>.46UB$@^25A]9L*"
MCAEAT/#]HCWO :PI)P#Y7]8RI0%Z_RP0!6,,ELA.Z'5W3L&WNO0RE 4*7P*(
M,9^[85D?.#A>L..G(_(2=_9X[Y%_3/:OZ&XW;F&IE#:DH>J=N6NR8&L@(2KC
MN;^+W)WVYAW>"_@0N-C\>R%+%S2V]L[OK%)*ME0!><Y7?_ZND_GJBCQ3NY6%
MD7B&@TGAW/D0,GQ:WWYQ"T72K[U.P$7':U_-JM[,LF[09Y<X@)$:I^293Q1A
MZ:7^H&[$]0FPT7M4:G(\O[0/Z=YX3%F>TS>02'7>*IBXWC,6+? RIIL!H6.$
M?XM$\FG@Q;E^>(C?4+R!(_E:UT\8"9>OY4T@2>B6YTT8]!-W92&UHWUYI9J^
MF$A\XB=-?27K@?<,'K)EJA K;W>CKV_,9MI95&J=8KT"=-Q8:BP'>E$L7DV=
MO$/7.#'<GM? 8[QWZ.3:]\9&)2S#>:2D4/POZ/SVQIY)9RE3^OX'71[.9SF'
M:,<<0!N8!U;3.##8^Z+J2MMWY6$O M8XKC.6G-%G7?_4VB*FN+W@F8>&AI,5
MKZVEN=<,,Q]GE0/D7J."]S"+]&VLBG)^L=B,#1HR0H0#CGI]1NDHC4GDPRR#
MYQ/P'+KXM_@!D1) :/>=+>^?7#9+,'9]-[C.N9;CK2#95ZFJ5<GJS=HB=4B!
MQ7!05;\4H;7P6Q!#%_PL4[ " A D,)2]!(S4<SA <9:<I>%?+]_63#GONHEA
M\3-\PTME<!G=4EK;H!* AFU=AC^.(0S=JNG['WC7Q4"]YI*.S28X_LZ]7AML
M/B1!PEG>#9,PE0IT$<&J^6DO@$ZZ7Q^-$,?7SCA]&WU?504<;CCP).+C<$6
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M/] P@2TK7=A]=U%9]69X9%?0+DKJ2(<C=>N2A2,X60L-BKPC@_F3LW$"J\Z
M^>Q%-]8?VD][_W3C:Y>\L=0G5J% XO03S<\(4T'!>R%'?7=W9>QXC9RIB,-]
M 6ZA-!M'L\+*RLJKKA],3F]JCR,!FYYW((>'T(BF$PVCG:C(?.-5G-F:+0NX
M+">-+K*.4F:$M<2-C\0L/YRN*0)ST^.BT]IBQ$-62R;PTJHG*9]J&%?#2*5>
MMU\G;J9<M8UO#G^;JD4%H**5R](+FQ,UOE>3W"?JG47QRD='I7Y'3&K.;8@!
MR\Q]K2SNLA>BM1ICU0U24+!G;7MUCQB&ZR=#+M; @,H&WHU2)$XD  44TIM'
M]EC;K9,U=>Q*63CZ>)EMFMQ<"N-,,LI%#<72)W2?Y6,38B4G;L;F],<XDO&*
M?=[#*&@ -.5\-DI8#_5:#>&8, H*&  Z/ZI?Z6 ZAJ^Y8&;SCD0UF]>S0>SY
M$6M#L<B_=TIB-M[72H7KN6U>N5-LA,B3[_ 9[P;"\^!?T\\^!EATY 3U>ZU4
MEQGV8OGF3?W:13+XO>KZ!U1T LS?J,^P\S<$I_=K- 6X[AJPOC76JX<RXH=?
MM5)%#*J^JTY)[9<L/1R4!%^[&_L[7&WUD4M3.!0;$.)4%I;G:VK"Z,A HXH>
MWN-$J%^/5QX]'%X04=]&A8HW_A"SZ-%2NOL$"-7@%UR(FU%>VCI&KV$]*C;E
MRV4M#@T;BD@7[BUK M4FPA;>8W)^\_Z-3S#[/C8F8_[=!HX\C>06VA4V#0S_
MIJ[4S<XBWGXQ5+Q?W$(U)TJT^WN^>=S&-25*$G-PK/4(EU\JDAQ70C KHD?%
M"E;HET/ SNX/GA$W?NX[*MM[MT^ ,H"Z[\C=C8>Q-=I AR!DCVL610JXIQWG
M[^$,\DY-B2O0[DM.F$+]76%_W>?\, &WYZZW-NCM@IFW!RO9YMMY:<0>V=QG
MP4V8(K;D=9M6VMX_C^W5@Q3ELT?O:EM^?N[R()^C_S"$-R?,T!R-=VE[H>>F
M-S+':YI"C;:^J2<?)&<[#EP>;&OJ"$FQ]9X?2N""C2\C5H$[XOJ?)'4/B'AY
M1X9UV;//D-?<;.F>5)"=_4(UY7ND4S[U^P2''.!JX:XRV>9M$=<U ;00&$>?
M2/"CR+&</SI[3;I48L1,0FW,[LG(*'9Z9&ODU]ZJ^WH(Y<^.E1.8B>UV2.Y0
M3/2Q=<G<Y.E I4<X9,P:X6564O0= IHM!4CN3D^A.CR-,<LFA][E4!60O]!Z
MYQ00^Q_%"%>K)?XFZHC1^<WP#]L (AQ9QSJ]7^,&S-UD#-LY_!5]+CPA$W6'
MP67"[^4N.S\RPM:4MGC3&.VE$L'.Q.P1C68//J?'N98LMS.&0_/AB033!FV!
M SY?@<6L&U$!=')I#G:)(8H([0W8?QS1'?6RU9'\E%Y@%Y^QG]X04#K$10ZU
M^ B>#*C)/295D[T#I1WY=H* &#Z/3,>C>Y$08 ^<-L;KEOQP(A;V#;.P_ +E
M&+O)TN)^>X*]%.EN\R )X,4Y@T/A1DJ*UWIQ(VA+\+YI5V R7D8+VV,:@_NJ
M8-5()E%O38ZY/_O,?GV<82&LOE+N>PKK2/T"LUE='TQ74-:KS( M$5<)A@"%
M"JFU]D\ )D6."( W08D$U@C;4VN=FQZI";%"*V%N!XOS$R K9=4K>;<2> _X
M!6+^#TXI%Y] 34_61PKM'H0:)UV"PCH\-6+X"4#64Y4;O=9,D)DT"TG?@EM-
M2U0%F@ I$I38;$&3C=8!XL3$7)/%SU_]_-:Y4O=8KWI_(&7*I96^]Y._+1+$
MEM#X"UG&9EK,O?T6$K+/E+O!>7INL6<>,04?K#;UD,;&G+5<NN.CX[=>I>KI
M7%#]'L/\S6MY<TR.UE%+MLNI#MM;F)\OT %/%3?'H0I:@"R-.?5@T+SI?T)*
MC8BPVD[)[ IVS.RX]DGNU,^7ODJ)'>;$(&3,N;N$HL_0L7O+1UL;'E[;4R"<
MS!YJ9)=S_F%#9K7V?8V?5CS/N!Q(0"#M+GAX<.'A^!V[OJ<UW'XUR_\>'YMQ
M6'8D3R!Y78V%JJ*9I-(QY\!Y-( #NKM/@0KKA*VD1,6AX!3G!ED^W^[[=0@G
MPH*G =P'U:,B]S=/(>>OO&$WV HNOW?G];5<3&N8"N/14Z(U[YP&FYR7L@27
M8/]41WLB*28GDC,)J0I@QE+;FJG/1-R2X$5+_)+Z [*;#K:75C.]9'"A#+'6
MT,.O##4^H=V?N*F%-!BJ8_=ZZL;/Q"^##1U@D!6 ?8[-/]#Y?H6S6LN.S5Q
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M-BB$'^!MYXN-["YM>LJN<;WUM;4!-&#N$ 6S>40.D*I3/:M_WMO@/'(<08Y
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MLZR N&^&S->XMKC5+BV- NSB=!PN PSRJC+%T;UN"=RJ,5%0])!5$-!.G9\
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M&9[[,<FQ^[%B&7T] .>L\3\Q4VA!RM3E:/A"Z^ID.YR?YFN/]/2G7@<V/7I
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M3RAA=O>&(W5>%?S^\N+,A@DXH[6>QD*7J%"Q<,&Z3#-;@X!RZ*Z#S!(!"?[
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MQ77W9;/9NH$AFYERT'_7##$$7SI9AM1C9KF!+UM%Z5%J+[U!9"0 B ,R81$
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MN@2*;-&__RS;*E14$&0B>B OZ-+UG0B$-LK[[Z"B.D"S) GMK#]:LMEKMQB
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M^K!*A6D-">ZO(MS5FLZ%#!K\>2"YK&\!?>=0<8H(]NI>H.@<*YF4)&RAB%/
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M=K*=5F=TJJPH%!==YT!TJ!NS?O5N6SS QB(Q#],ZW-6$[6)(Y[2V-QM=*Y0
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M'FYJBWMS'_/R<^7O$?[*E-W&9<&X66VQ,>27^U*\AWW3*,2;_M"/5?GP'P'
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M,'3$ZRA>XEFI8<_6K1NT)W0&\/=$%_9A1K1NG7-A_]S0$!O$[X C3K%%XT?
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MQM QTC2O*XW[U4=[\+C\M(55'(R39T<6J^4#0QA$53-QX%2MT7>W::'>++.
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MMEH>/;@=66"#DA;MUG9.^1QWXS5**39D:!+K%Y/S;*P)K>3>G+XCO-RU$[O
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M)ZO=G\9L,4?)BPZ)_NK-).XM9@")*X/U3IY^0Q369UA2\_CSE\X5RN)6>:6
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MCVO;QK;OKTD!@,P+B5E6&_J@O7S0F"IV@0L8H= F]@B$.XY"QQ.-61G[>!S
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M5%$!9P 'S%;/'K/MPV[@]K9]B/T-(/;XB?Z_H3C:(A[L[?'W]I=$ #$(>XH
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M]!W,!^F[A\/E$@% "E !]  SP YP P( !! 'I $%0 70 ,X"AH I8 78 C#
M&?  D( ?< FX#%P';@/W@5@@ 4@!TH 70"Y0!)0!E<!;H [X"+0"'4 ?, R,
M ]/ /+ *;() ("(0!8@.Q SB /&"3H+$0;(@)9 &2 ]D#+("700Y@3Q!/J!+
MH*N@VZ H4 +H*2@35 @J![T%-8*^@'I (Z ?H$70!AX8CQR/'H\-CP]/!$\6
M[PR>+IXIG@V>$YXW7B#>-;Q[> _Q4O%R\$KQWN)]Q.O &\:;QEL! V R\#'P
M"3 $+ M6 QN"K<&.8"0X!'P+' =.!>>!*\#UX*_@8? ,>!V?$)\.GQ,?@J^
MKXUOA@_#]\8/P;^#GX#_ K\4_P/^5_P1_'G\'0(*@N,$)PGD"70(+ F<"/P(
MKA/$$:03E!#4$G00C!.L$A(2'B/D)Y0AU":T(G0E#"*\0YA$F$_XAO +X2CA
M"A$1$3/122)%(D,B*!&:Z#K1(Z(<HAJB-J)QHE_$9,0<Q.+$FL36Q)[$5XCC
MB+.(JXG;B">)-TFH27A)Y$D,21Q( D@B29Z15)!\)ADGV22E(>4G520U)74E
MO4SZD#2/M):TGW2)C(R,BTR.[!R9"UD8V4.R K(&LA&R=7):<B%R-?(+Y#[D
M]\@SR-^0]Y O45!0\%&H4%A3H"GN4612O*<8I/A%24<I3*E#Z4 92IE(64K9
M1CE+14+%2W6&RI8JD"J.JICJ,]4,-0DU'[4:-90ZA#J1NIRZBWJ%AHY&C,:0
MQH/F#DT632/-=UHB6CY:#5H'VFNT:;3O:4?IP'3<=&IT,+JK=,_H:NG&Z0GI
M^>EUZ%WI;]/GTK?0SS/0,D@RF#/X,R0R5#$,'P,?XSNF<\S]6.2QHF.=QS88
MV1C/,,(9(QCS&-L8UYA8F528X$RWF/*9.I@VF#F9-9C=F!\PES$/L."S"+&<
M8_%C26:I99EAI6=58(6QWF(M8NT]CG=<Z+CQ\:#C:<<_'5]A8V?38O-B>\3V
MGFV&_1B["KLK>PQ[-?L/#CH.)0X7CAB.&HXI3@;.,YSNG \Y/W#.GSA^0ON$
MSXFG)UI.;'+Q<YEQ7>'*YQK@)N66Y7;DCN%^QSW/P\&CSW.))YNGEY>$5Y;7
MF3>>MYYWC8^?SX+O!E\9WW=^)GX=_D#^;/Y^ 0H!90%O@52!=D%"05E!-\$D
MP58A/"$I(6>A1*'/)_%.2I]T.9ET\LLI@E-RISQ/I9[J@I!#SD!\(=F0$>%C
MPGK"5X3+A&=%>$2L11Z(U(OLB$J)NHL^$^T3HQ4[*W9%K$)L45Q('":>*-XN
M02&A*1$J\4IB0?*D)%PR6;);BDY*7^J&U#NI;6D9::1TGO0/&1Z9BS*/9;ID
MZ66-9._(-L@1R*G*A<I5RJW+2\NCY8ODYQ0@"FX*60K?3_.?AI]^=GI4D4L1
MJOA4<5B)4^FBTA.E8>43RE#E5.5O*MPJ#BKI*I-G!,^XGLDY,ZLJJHI4+5%=
M4Y-7"U9[HPY6UU*_I=ZB0:MAII&@,:C)I>FDF:TYKR6E%:3U1IM 6U?[@7:7
M#IL.3"=39_ZLS-G@LQ]TR75-=!-TO^D)Z2'U*O3Q],_J1^OW&_ :>!J4&0*&
M.H;1A@-&_$;>1J_/$9XS.I=X;L)8S/B2<;T)G8F=29;)JJFJ::1IGYF F8_9
M.W,J\POFF>9K%NH641;#EB*6P98?K5BL7*Q>61-9FUNG6Z^<US@?>W[\@M2%
MZQ<Z;?AM_&T:;5ELW6VK[*CLH';%%PDN6ES,NK@%-82F0E?L=>P?V\_#U&#Q
ML&D'%8<8AQ]P17@4?-)1T3'*\;N3HE.TTP]G9><XYQD7-9<$EP57;=<4US4W
M0[<,MUUW"_=\#V*/BQ[EGK2>;IX?$.P(?\07KY->U[V&O>6]8[WGD;K(=!0(
M98-ZA:;'+(P^^0CXA/N,^"KY)OK^\C/W*_:G\??T_Q0@%! 1,!FH&?@\"#\(
M%O3NTHE+ER^-!)\)?AH""K$/>1?*'7HM=#Q,*^S%9=++;I>;KXA>B;JR?-7B
M:L4UMFMAUT;#M<*SKU->1U[ONJ%P(^4F_DV7FRT1$A&/(G9N.=QJNBUZ.^[V
MUAW8G::[8G<?WMV]YWBO)5(Z,OD^X7W/^YT/E!^\B**)"HP:C=:/+HWAC+D5
MLQQK%]L8)QF7$D\:[Q,__%#OX:M'/(_N/]I*<$[H2%1-S']\_''$X[4DAZ2V
M9)7DO!2VE-LI&T]<GG0_U7I:FLJ7&I=&F.:;-O',_%G]<]GGF>DLZ;?3MS,\
M,X9?&+_XD"F3F9EU/"LR&R_;)_M'SH6<UESUW%=YD+RG^<?R;Q< !3X%4X47
M"SN+=(O>%<L6Y[WD??FXA*[D5BFH-*!TOLRY;/B5U:LOY6?+WU4H5)2\%GZ=
M47FB,K&*H2JRFK3Z6O5N36#-RANO-S-OG=Z.OK-[U_?>\GW[AW,?6FIU:QOJ
M-.O>UY^IKVE0;*ALE&\L;Y)M*OLH_;'TD]2GDF:IYI(6Z9;2SS*?7[7*M59\
M.?VENDVY[>U7]:]U[3KM'SL,.KYTFG5V=UWH&NYVZ/[>X]ZST.O;N]D7UD_0
M?VN >B!N\/A@ZI#@4/ZP]'#5B/K(IV\FW_I&8:/38ZBQK?%K$Q03<9,<DYG?
MQ;]7_M#\T3IU?FI\VFMZ<^;Z3YJ?CV<%9E_.J<Q]FK><'U] +NPNWEEB7LI8
MEEQ^MV*T,KCJL;JY=NL7\Z\7Z[+K]1L6&Y.;?EM$6P^W!;<K=G1W^G<]=G>Q
MI\VXI0#V@VT\1T< 6,S [!FL ("N%0!(S^^MIW$%=/2-+P#\)WAOS8TKT@"0
MU@4 ID$ H-<, (\2,,M9#'^J"P!@1(7!*P!X$A*'U\':%[=.QQ9VS#[!CP@
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MJPTG3HED0%>??C%;>.(SY%+Q%L97_'-]LWK17'1::61YJL>*(\T[."*0D?U
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M!OLJ@LC\X]=UBZBUW,"7+B6MT2M"HSGC#A_F'.I#INB"'& UZ58375?@HKM
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MW@%8WK96O,],6W5P&->T;39D<'F2Z;9,BL[-JU)XEXW[GW@9U+=!^EEF$VG
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M\<?X1,73I'QC/'CTZ<//4HK??QE\OO:@;" $_QID\2-(=3:<4O&5+EZ'_Y;
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M?4.<N8*"WOP_^S@;$<V9>%N(\..6UWN:AO2_>-2(#SV1?&\6DBT5HJD)$YR
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M8I +=_!L+&_ _$7R'X\F&Y^=T)[IG<X[!BGSPQK/(5I.K/#AKORE;1O%P(K
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M'!TO\JOCI].^&;1!1U*743NV-?'YX]/K@5@@SX'B4M$5,$:)2_=^B-WRU+T
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M7Q>[QJ^=5?O#T;SE=7?*YN%WULIY,'N^KU;2^9&C!GD::_?/5[Z?_]IQSYR
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M+Q$H?VAYVIJ7A2IJ^]%;1'#@1&!TO(1%!=D1@Q"GXRCAZW9US*%W!WG'$93
MH JE/PR>U6.$Z,$;J#1A1Y6Q)6J9Q].FL3'8,5K3">7-5_V/B1$G$'Z,^(=
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MK8EM_.:.3-!EXLYZD8'+$-LTX5^(W[@\M6(UQVQNK\_3^Q@-$O,T_P\Y:O2
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M6R 3Q]S07G<PHYN1!YR;@9<#!.1RJU_8VKY]BD'-M)9H6%=LR"#4Y%CT>UL
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MI"90[>B[4]?,5AI2/P$;@Q*.!$B)J["8A%TUK5RVN]5<Q+ZR1#_4VBY1@F1
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M'UPG,I7M;%H';BUB>4P@UXQ$<#V,,%H NU]/5R^18%)SQ74+3[QD/JYKM^6
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M",/5@4+X%NY;5/(RQT0%&E9'PQ5KRWR;OO:]/9UK8]T#7X"TG6L<M",$DR_
MA,4GKL$1@NG?6/@GKM@7(,0K/OSW)Z[@]?8'^Z?BL8S?-.&S'<YM.',>Y!?
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M2_0GQ^AS=-G)-U,%C5Y$RR;/W<F)YHXP)T. ]QCN=]!^ 7KOB2<^>X;=U+\
MP2>"&9O^L1>57P#H&7^V]B,BDYP[4:YF0_L-A^4*]K$)&_[C0WS(7WXI3+BP
M* ,U5M4S;&&W2*IR?)+4T%$]_I)Z'B6K+QUI_:M6'@;2NO5BW!'=A!-R%X10
M8(P&+,M)JMID[48?%1'4D, _",H7Y,O/5V,]?WVA[WAK)7D:YL,^9W]<__GV
M*(B7![Y=>[.>@FP?+2 Y(W!=>BO86GC^8%_FJ)N@UO5K7BS8!-3\9QE?L3$A
MK':4G]T:-U0U)RQ2WDVVARD92FKX;[H0XOIO=W OR1[_:%[D(4'="U_1C WO
M_463U#=LJ'L#KYC29/2V+P#J#4T,#W*\*SZG[8\EM@O5Q+5<ZH9AR^/%<5O/
M D&FKGS9"36=HD;:_</(V:"8A-%?!FBS-JR9&O-U^@Q5M/2-8Q<QQ^Y+5]Z(
M77AVKKAT0'R1DF%%?6Q;?*RH80-1TT@S#6WGBO*/?WL)C[-L,.+J#4#A4*N"
M2)*,%(U#YQ03Y3*4(B4?:&JMHW78?[S-"'%>9[H6H;R23[=)(SF=&0,C2Z=+
M+/.G@:/_-QEE5_9&<AXU;^@(\6A!PS+!S[S]Y7-K]G,,5_4?!J[X"DNX>G;P
MDU,]$6Y+W5OEUC7EM^ 2#FRP$[)PC\85:IK:B080"&"USM V)?M$0]U>\C(Y
MI?TKN;S9/EM#TK*138/YHZ@0R>BIR*L4'&S!*1KQ=DZ>AVA4_C!/\U@8R1#R
M\?O%M 6B8""N0]#X<S%W6(CD#?3L]CGRC0_;CXH8QD$M@I]_IZ([.^?7QM/?
MG$N;M>@2G9H7\DK-BG2'L/ F1N30J!L<C\J,P4P.T[T.)>:1LG!A&2)GK?)
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M=/>C(Z7%-K%OY3/4]#!9[K7))<J7;"IW"@5R&>^^EWCJL:9;-63*Z)Q2B*>
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MV!39C]5*Q';PCHD?*U/*@0CKP?'TGH@*_8MF%ML5&#0^NX,&&N.&922:#59
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MIN%9_=ULE9T!3J0+65YAN?@:K[GG1\_H@ K=L I8B@&^^.28XXTM0CX^NUQ
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M(VUSF"8T'^)4B@"8&6+QB+"F=VR>!8N>;&G#!H1;HK#!:S+9O::3QC(KFK\
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M8?EBY!$D$5:Q+ GIG9<N>N\A"\!)OTTDGS"_M1JIX7*63"]<WJ^*LQI$S$F
M1=6UQZKKIL>+W=JK\UO!CCV+\0;R#7\R2<^6XWM?"-M$SZ>6;^3NP1M/C#XY
M;9Y]@>W2K/,;G&L)6*67_9DG9U'!VUD91, (=V&>_M+Y_DN6H5E>\IYR8%UR
MFF&4U&AL5@6!861W'"T1S4IXB_4!HPK C4=$&0@$7.R22\?:5U'=#OAUKYZJ
M2IM_K?@\0T>QHF[V\YU!@7*SW#(HL_R2%46Q+\-HK"LLQJ5U0;2M/(TZQA 7
MAB3A%5]HJ396'"*7^NG]N%K5+V"RUT;XGGX3+%;YG'I<([YJJ@^<K@C$?P]4
M< G+D\!4">-<FLY6QEO88V*<V_M<L/!C\IOA5VB/H#I\;LN,BG^MHW[Z!&LB
M$K\E8XX:>'/[P)(U;]7 /VI"0Y-8/6]@;*T4 LOTZRA<"#<RTFXTD9JK4U1S
M.%!BBW9=X P%<@1+G:9X#2818=@6GXG4');9>M9!3B\O)"NUJ$QV#A%YY_67
M#P].KAD'IX3 7.LP>7\!M=$ 17N<#WSYUXCQZ3'F0.42Y?KS;=/,,1.&52&[
MA-5UWD//<S?;.#-6(A;JV=&W%!V!<TR= DZ,S@^'4(AOWS4@.2N,XNV(N6 7
M'?'0-H8=;V)RS&EH:?6($P2EE$>D@[2N7-HKYP!U_]=7>DNE:-2]HZ?6.]OB
MDW4[9YVIQG*_>9+L3^9E/<FCSM/)6I()T7>T9^ 9)IZ(2J<!$].$T'B##J<Y
MFPSF-CE/)'K)H^LGUL%.X=BX5)_B^/9)M9(;2\YQZ6H*25P5M0CU;WHJPB05
MC^V<-(3QB79BL$.E'EIR9\&#)=]AGQ*>I=\D?P$2N>JA@I.?O'2=^XO&%P]H
MJV+W#!C.]7EGJ;27"6)CDZD:DFV)N.@W1 X\OF&WRO@W06]\=E=A)XV3&23+
MM4]B$%(!AOD*S&)#+6CY]=<"NHHYEJ+R)J@F5+,L;%7:T\)32B&+2PE+%2C?
M+AC?O!K-X=IA18P26B#?5'NBU511K)FM5?VH'B(XQ(G++SMOD>%C7'8:E<9A
M$VC);;6),E(8+C3Q%R!6MMW<*OCTONLLO83TS[#Q#&CC:CBV37$WI"PYR&Z*
M818B[<TT3!?3K9G1WU@S,<515624@#:@]3#Z0';H.B9C:L-HL9HL4&'X"S@Z
MTH#A7*X^;#9QX;8WT<=$4I\RCY0P9HRV:-0J0QW'?\ O&SYB\J.!7^'>IZMY
MXG=&,M<PYKW!7-_O["M]\IDJ]F7O&/=0,#$&MVZFR4"T'KZ_</8W(<XE%!1^
MAO:!U&9.QMN"_:9&D]F*T\\"?JXF6O@[QH<J_NT:A=:J& /=_*S20PJ\)US(
MR"%<"#0BQ;@9S8:[S,'D5)Z.L3(.083VX3^PZ\[NC/>J!I/3YP7CNP3,"_:\
MF+4>!S:)XD&97YM%*_(Y\=_;H7F.HY^ZTJE[<ZU.ZC6BZCDZM?''^#HV5;\E
M7.+29JD]%]0AD1MG/HT.F3_0JC/;E)+-',V-1T+3RWU@L+)DX'$*WMO*&1)?
MHEZ.B9NB<]ITVQ%IVUB%,G[=S4PP$MV/<1A\DP;NK:F#]#'FEJ2BT%0GI2;C
M9Q[PVS:3E^_&I!VY,+ZCS7NO#H=>$"29G/URM8*+77%G&&> %,RV\$>"(PDM
M!A13O=+D[1H%U??A]5Y^W9EZG&=:O[ CB?BC[47@8VI'D) $ 7>3V&1%5JBR
M34MA+G4-7I^XVSGO@H*Q^OYWH/E0RPC))W&5_@9-QJ:4/,< S53ZD@?N>"$^
MF09.F$G;[8U)^MAP0U166 I_54%V ^<XOOQ? -6D ?'BI\RF1,B4!9<;(S\T
MR2Y))M!0JT*D 7I]F0U? V%QH)QDF:JI#<HC'7$$2WBM<+T0L/HM/7GLRO J
ME,QM3[.&H/0'9T\7:%'GO\K$@&'U'Y'FUF 54E]G_<#(\0D@4_F3A\"F#N*F
MOX 14N5D%IT]6RJ1?=-#C#.3R98GC4R6I.\096?MDKDX1U(Z YO9\X:&-J=D
MAA2."\QK47L->41X7TK!J;:?+1!F=5M9#&A93,C A"W>)9B2SNENYOUT>8=;
M[QA>.IF:8%.PS0Z)DZ&(."W.BY?K!XLMCTU9Q!2I3'%UB/6.C&3Q\ 5O<OE@
MV^:8&G4:I=M&4)&;:L87EU 2SOR:*J#<+<F%6($U1_)K-TB]6"&9RZMJOS>F
MLC2G2Y,L9G6,*]363*B(#_00_-N@_?&F[]")@UQ"P%@E >Q7A/T;4I7?L<(G
M8_PH]39Q-TU<>$N\EA2EZMIX*/)(Q;3O:MLE#('$LD\D:,R1J>@EJHH*.#M!
M(@J?*#8_(U0B\NRST33X5&%DX$L7F#PAA](EYID[SB:PFBPDE=5.UVYLZ=QY
M-MOC"V9&9:S2J<@QNFX026&0&KL.=W(NMCNIDC=<19AM6XU]J7D*>0-"#MG=
MP4QRU$4QJ\P_>+1ULKN%5D<6QW%:<]V&<8ZT0U+S=^QY&?#M1,U^/85<%AD/
MP>=]PN<LB9"F08U2J4G)G88!AA66[YSI?XZ5OA7@7U.:AZ--5LB@X2>;J(#2
M>F0CS48*-]M=$D61<.3#08$,..]E\%3D,202I$/>P(H ;_S=L((!$OD4%"A8
M?31 ;!%_-#1W[+HWI)8+[CKQAUC3478L3=>7'GK+>8<$\D^6*?L2<B.ZLNLE
M\NJU$6[55JWR[![4DC+6['P6Z=*%\1&!#-0R%T)=95WVCU'94,G>W 8_J2U#
MMA0,UG<970G)92:N?/2,T;PYB2>*<BQ4H%<P'_I#*_:;:^R--&J?[AO^"UA9
MWFD:'VLM33AW9-C&\C2754G(GD8.@XI==/H7O6YFT/(8?D1$UJS2_L7*ID-[
MPO2#\AB9K/;].%UCG][LQU$RL(Z]&MK0,W(_7]\31W18\< [(\I]M;G4<[%D
M)'U2EZ1X\67M('-D^8&\O/Q%CP#C*MZYSL3:#UIWEEK+^2S.23^MLA#.X<AF
M(72&L^?,A*N.#RM)F84O9U+2:S.ZW$6V!"X3=6WQ=YB2&4HE8#-74OYN!MDD
M>'WZ%$NR'&3HC6I,.KY(.TJL5WQ]CZ2&DDM(A!993/V]Y4BS.G)*12[CK\>Q
MJZ0OEG.=N2V-L8FM.H//=U"47RGIWRBKUMFX?M/U?C .-]0=YWWH;;Z(E#=9
MY3YK2O#G($ ]TM2^'4R_I8J%#KRP)<;CLXJ;.3H=A16L<75]MB=I;37VF%2L
MYBNPP^-]'!I6VAM ,IVR7S"^M!I?8<8LD,''ZAGT:6:E@QY\Y21\/A+9NQGR
MV_O8(J+,LP8)B&TX8]WKSV;4I3RX95*8O&AWFQP[*9U6A)0J3YBJ)QBTHW(,
M65PI@HZ;#_YL0X9OS1/IG6A9:8N$O/?-:*KH1ILU?2/#ZW2T'%O,!<9^\VK9
MK6N8_4P:D:MS6G8[XV/Q# ;.\G=<3M[(^6SY;T<+SPJ+&T$7QX:N9*!'K8G'
M@NOV</4BLQ2^C0FFM+)ZO@H>J#*^##G&*@VFZ7N^T!<J8S*K$)T)*A038^@[
M/VHMJ>CP#Y7G;P9K&JZU,,\\>:@]#V!=#5(8^%]Q2'JHE6"/M8KIBT?HF8U_
M$K)X\'%P%S]0!N2BJ\,!=S'L?I\H_@("J4^]Q%HUJT6^-(QFVTT]$A!P,QS$
MF(J]L9*;YC-:12[:GTH3R=_IA:F)"'BTNZSS3%HIK*H8V:T5'58@LE)G64OZ
MUJW#4ZPG:*CG9)@;[0HO[39!ZK.5$^_6.)U8<-\T,>"R*/VT=.4QS\L,+2!=
M="/M+0M52*,:\<I+,G.LRHS"900P/\<CR2*]6@!<C7SPK#R$FCLC$IH$,2;8
M*K6H#6(V-7GNZ,B*CA2$OBOG2UI4Q$,D#Z4#4V&RI 7FB],G&%/]BK+0?%I8
MN4BV%N,H;QHPHV9HE,B_PYB//<*4JL22I(H$+Q>#I =A,;TL;5B:V]Y]P>4B
M^XR#A_[0:=AN[O8LJFCKIT6-?,=?0*K/Q3Z\-'<E)R*1_G RG4*%QR[^[5]
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M%@2A!>V-X1PCVVL&*>.L) 3ARR\'(0 (3$!(1$Q"2D8.^CL1%R'((9$& !&
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M*)XF!@@#DCBJ,'ZAX\"M90; T53^2_D#M]_:P:'(?\!P5'XO7 #*Q]W]P$F
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MD+>==PV6 9<8O?$YY7/=YX.ODF^:[W<_"[_R2[274)?>^ OX1_K/7=:\G!M
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M^%1@_S-QL),3 'S-Q^T9K " OAL R&P.\FE\ ?W^LA@ _B/X(.?&%VD R!X
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MA) 9L;5"^FOEQRU?O[[=\V4M\I#Y=+FEH/^&>5OH+ L;:'1#^Q&O'>V7GCU
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M^Y2'_6EX<?54O#O@PB)%-4DCZA-?<5JALS"/Z3&1= B?F,K6+7U.@&]UK9P
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MV#&INKB";B**H*]O1=.='VD@XHTCXD@U.2BZZ5-=2&+>K2H3S89/H)W5A\"
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M@TS-Y#FX7V;%YT&+R\B _7M$B[1\2YP)3V_[VGO"QOB!<WWZRE +P5 W<OO
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MGB]<S&5.TLEJ$+Y?E[K84NEWWILI[!SS#]W^$A2=\.E[,;F\YL^_9-^U_:#
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MU:/$TL1F5Z_().R$$$#1H#-0[N@YJKSP!HB+09>@K^G8R_HQ*"1/ZCYRL7U
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MQN.?O%F*5XAH;"B3:,@39%&;\611T7 4BR&*@N  Q>DB['F](JQH_2SL\YX
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M>7 X J*W0FOKVJFAN)/D=726-UX)NO3KZ9-/1+ 'P5QHP M2 ,"'C6PKW#>
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M;T#1T9N:B&J]DP!>9:6\BO5LU3 PN'O_C)D\G6(>-<9$#O=63U1I:P77Q(^
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M\?U7L\W=J_W'.*O/F];;O&OYF5CC#Z#WJ\Z.7F5A\1[[G+I\Y,)*G$YG^.F
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M&YK[8R0+E$\#N"B\KRT(K9;VH$VK+P87H2KP>;QC%9Y [P\4L,%ISPC2W+S
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M8IFR:Y&3;T"T?'(B,3./%O"FK'E#,9'&.M7]\8F.;;I#3"<G.QEJ@<PL/Z>
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M<&*2_:+4CJ0@6G59E_3*Q.MW57UP'3HE^7N<I GRZO2>L;Q')\O)=3.7Q+\
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M#RJ[9$5GI5>7)KF&SBF% MQ<S<FK'RI29&:4803J_#Y*7Y0C<N;"$CO'-,8
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M1T9E/*G^_13S3&.R?_I_F/S(2ZFO56'NZC>)15I &^+QC[3)>'(-2>GA':W
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MJ@?*>T>I!88OQ5..N-4+FWJ'1[B4WX M&3:O&SULPJE^"<EJUL3[\G25+F9
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M0OR'H3?/<[#S17LT +8#%#W]"8ATEA/%/.!\7>LE!D48,4O6@ZEH'E ?$!"
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MFU+#&T/W-N=X@&>I9?O%&DW(48D5ROGE#_:=8?PA%U*WM*38,!GI"5*UR')
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M\0O_1FJ<"&M2FHLR4R*EC^J57NGN_Q'X#@?QM9..>%8ASJX1:KR7K#W3<ZY
M*77B[5-1:S6JRZT;DSN03;5^@SR40]E4WP 11BW57 ID4E!"^:WEV6<"^1?"
M0./EVO6V+<G-CGH:$T&';,#2\-4:!'5RH6VC7R/O,(EZ3$KE\E]H2"[=!$#>
M<IAX?6GB;L%"XB:'=O@55S1)=W:<?;;776--LG(6LS"F<15.DYVIFB31LO)-
M3)R N2J$08BCZ8^<0Z/ ;UMV>\A.1:7,CA^]J.B1.7#B]!<R;KEWDCC-(.QT
MZ&G[.Y:Q,1(@BE)NVSGWEPV$YR%*< ZXSASDO?!RB\<N-G(JE<GUZ9Q8AMNL
M>B:[H&4!+O,PK\Q9-8/&Q])J<)9':;Y^HR16=OO3!OW(03?<PS.>1NAZGA26
MC<M<5@L$Y+Y2C%$>\=>4<6XF+3B>C6:;GO5@:S7EYN$6BCNGZ*S)961(T5%'
MWDJR?"C$^=.F<8N?>:\C=3MV<8#K$!B$9DG+S%='A,RM%C1TQW2HZ6GZ1,4-
M[4HAU'VB<@BQKB*5D4O-W;+@W5X&?7[]OA^<X3=@.;L?OI_&<1 1$?K$[]A#
MN'S=^JY\,3@I94:QR?V>H_C?R%WM)<JD7P=XH/WH0L_J3OR+%%?;]%4.I$4&
M)3\CH71U9-11HW:IN3<1OA.<<*ZM7Z9RNWO-,!=M8I09*R2F35J05W7E7I]S
MET 25GIZVT&B2:,Z_<#_ '8\GRE$")J !-OB,;X:L^97'_@YQGM/"BSP2^Y4
M?#J_ [?RWK\%8=R+#+V^-D6EE6A,(90U:<D;D+]G+2#I,WUA+VE_AIEA95G\
M3&.VT?@X56D.;E'+S8*S]9)8*KII[H04F:U7BN'KH')K00@,_M-IZP^4I@+U
MQ5:Z]Q,1X><9>5W&O-OAVUQBCN](V6,DM\XT15GMO&^7FG5)C(MK#25FS5>;
MJS3WE,5WSKT  P>00Z^*]P_SMN5OH^WV2H\F?AIU9JF5DXLNC<^+*3&;A4:N
MD)P*NCCO)9!Q9722?8J$1)"8?*!>P\5>(?&;AI-<K*MEV.0T/?M+A]YR+*$B
MZ6,@1Y?99W#Z4[CIJ>?W>T2LE8%'*"?I@9P*1A!3L'7QK/\ <48<-'T<?:>)
MRNG)\K)+:&4DTL:W&.$4B6U._BF;.VRL8@S,JF[.]\IC+IE%$!3-WZ^'I2>5
M=WINRZYS_P#C+6W7^4DM0:Y(U;-TIC3>+.BY2RH6;0TV]D)A*DTZC,6S5LM(
M*&?O' G76\3>4*)Q L\BI*N_A%<#_B!W3E8V>BJNT6Y"<;:+=^(G&2/ES"4P
M'EY:/;RUR1$X%*HW$ITQ 2]NN&(F[B)N)W'0XB)O,(B.0T\1[F_MA[C[?G^^
M>-7)N[3%[?6SB@CJ#C):2C84$LL2M6L5HM.F] LM0/%K*SUX@:L=RQA7HNT@
MC4I!T)$Q.KYBZ#<[Y8-<I%@U/'J+BU^>9)<V%.+9H+)]BB=VQ^TR2#JNSB*^
M@Y+H<:JM RA@$6S61=ME$U4E2E3'/M[Y:<V^1>225RI%QN>0;)K5*F,^T0N?
MSI+/"5"Z1U:RRJ2,C07UA;-74G$IND6\F+)%)?S(E.F>R\Q:>]MU,T_1,SAL
MMV" K4PW8YKLT33ECFS:S:/35(YPG*Z%E\>Y<QL'-MUVKQ&)=JLEQ7;E0(B
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ML?)1(VF[I19!(:<56 >A&Y:R@VV YVF="F>GQFTP,S"5+^Z/3]ST9O4Y U6
M Y=R[&N-\-XFAK7AO)O#>132Q:,HI5M-MH'^F=Q=X)+<2.+4[ J5EDUX0R>U
M!+9U"@LOV.BVK=7=%K/[L6QSS!!!()NP,O5DVN>W6QX3>E6$RH)$#,:'UDS[
M2Y\@P/Q TKO. 0-ZN0;!YW,%UIJ4/B8HNG"3$FI(QDA;+=!D82F\V3DI@<<W
MA@D&+YVH>6!XLO>PXV-(T;O-XEKI<X@A-G?=K*PO^SJVF&MXUJPI7*>@YZM9
M]L\A,?^\B63_+E.4 Y^^GN'K6.1ZQV;#>5DT6)+UCE$C10R>7PPB.3KI0-[
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MSYI4"#%U^ -?EPG40F_M_']02P,$%     @ YX)_5H6/P&#K @  Z0D   T
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M(GI;-D08VA7M&4KB9[!J<;FZ5_/ Q$0PHBTZPH'.W9=U/X?W^51:4+L;??U
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M^L4]SS8[F"?.7CN'AT3*"903*"?05Q/H\5#TNX9<CUPS)S'8RT J7DN&<6V
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M"-?G5S>72VG80G]+LN&!*"KZVQ(D:_R)R_]02P,$%     @ YX)_5AW3/.!
MG@  Q*H   L   !F:6=U<F4Q+FIP9^R[>3S47_\__+8E5!)2Q%0*A90L$:82
MDH^]K#&59(M)R&#,A)!UREIDR9(0DSW;C%T1L@X&8T;990:-8;9[/I_KNU[7
M=?^^U^_WN.\_[L?C/N8\',?K?=YG>;Y>K^?KG#/L<?8L</"FH;$AP,4% &F<
M'X!-!)X9P#P> H"I*7 6 ("] "^7),#'*7%$ #TNJ?\H&W(I #Q_E;D!(-H#
MX/VW>C/@;RGMW_[^VV^>7*Y_D^;4Y7+_NS175R[/?Y2O_?D8>PVX9.$.]8?Z
MN4,?'[]X[CQPZ9JQ*2_OWQK]JWSZK^+!$>GX"110R;OT3.#U*NT:@MT"B.SE
MNL;5Q<-U$N 6X>(1X6)W "!.PWQ<?Z5_ZQC Q<W#R[>'?Z^ H!!'H.8@P,W%
MP\/-R\/']^=KN$(Y_P=X1?@.G;AP=8^HY3W^D[YBJF&OWNV5O5;1*FXU2#YU
M\?Z3< '!PQ)'CDJ>EI-7.'-635U#\Y*6MOYU T.C&\8WK6_=MK&ULW=P>>#Z
MT,W=P]///^!I("PH..)Y9%3TBYC8I.24U+3TUV\R\O(+"M\7?2@NJ:RJKJFM
M^US?T-;>T=G5_>5KS]#PR.@8;GQBDDB:^_%S?F%Q:9FRL;GUF[I-V]G]<UR<
M^>3Z]_1/QR7"&1<W+R\/+_^?X^+B#OQ30(27[\2%/8>N6O+?\Q4]J1JV5^S:
MJW<5K0*R%ZW(XO>?# H>/J5&/$WY<VA_C>Q?&UCX_]'(_F-@_SDN/* /</^5
M>#@?/AX>'KX]?)RT9^^>/]->P;U_)<%_2_O^2@?^3,+_D?YLA(O3 B\O+S_G
M<U!(0.C@_W9B3W-@*<V>!/;Q<  NPB,"@ $F8\4 $01'L('P9S0HT2VV'',,
M#B8GELX-B$U>B(5]?(<\.>G<9H2/H$GNE(/Q^=3QJC?JWI#9$+GX[L<6]@\?
MK#T+SNA/L.L[8T0,#9:PRHQ"(:;-)R45B9").>H*&=I%."3?S@8.PKQNDXWB
M[DBG::?LX\7OL>NB7VG91C>4YA6>,>Q;I6Y>2+B.=[(TLI8,&_YEF.0B@7$,
MDKNS@WBHYS2^<'0EEG&7_#2!<MF T]'7'FR 7*.^6#-M&'KHE[O-E'CXS,EZ
MNSG^M\+!S#)TM@KR(8&7 $=6,?,*&QIE3E96>HF]N*'W[;YO^$T7]-R=K=FY
M%Y'./29#Y"33H&GTJ_?RA#:;=V/&CJ,W52"*\IM@$?77+K1H\N9<^AJ(5+")
M.$[3[*AH+5B6CU$B19F62@I?T_6JKWJ+& 5+Z$"%N_ &H_?)@1&'UDUB6BVA
MCUT.^$@4?3/72]TU);&!<46B>1S<[0/M]7)&>6;ABJWES+*#\D>BVLH$:7&C
MNRX'X15"PJ[:DN=(T!<G*.I1Q<4T0_JJOFF#M\P]H+'*F==ZGW1O6&R/6LZG
M'P[.&B8[IU?KM7"9Z<WOFP.U5VSB.AI*O6K90%/6C;ZK.PI%,I-XKYPDD##<
MEP2:5.P  RQ!AA,;B,$]+_?^59 ]<^7:=#5?FNH"YON>"\Y%],MP81J88LY9
M("FU@1?9AZHI_ S%>G4AY0/SLQ="3!QA67F1@B\O'/WAIKYK,J<RCB7:QL!/
M$\WW+3Z9@3DLM+KXO/FPE+07>F+?^;D@_LN5?HX($$UB=N!9#C?\'A&Y=P>W
M/Z#(4U,S,%T9,[\<6!<Z=)/AFA#\JDPF.&EQ))V6^?;!>\:0*7RU6N>-E4^J
M0H"9"N/,F2+Q'SMITS43($5$#Z1"<[5X#CF!;T$H46S;0R]:C=;HJI^N_YQR
MP]E>Z+S2^..+W86A FS@ (.9 %Y,60)M?\,RG/PA%4:,C*)V<SIO-QMX5Q-J
M?"?:DCR33S_$:IW480.NHTT\1/R93P>^SE_0$-:/2I$<8 -1ESGP@K.![YE$
M*$,0PM*]HP3F0TC W9@U+)6K%/TK<1T7EAS,PJBW/P=IM&,.3]?<3MFWC49R
MGI1BIH 7WW*0N3U"8#QYIK/".K+.$MAD ]>@D5CR&23M-XC<C22;Y^R*PI79
M0)@)&^@N->_&5A)6P>3N=DW$>0HN0BU+UKC":6C@XC> RO/MJUY[1B_M'EV+
MU<H&CNI<!,6QCL'TC<?\ZX^@WTB9"7Y:[7FPKVCY#.3=G<2IL>\0F@N6)C_
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M-I\?J@'-\_',^&W:..V/^[)@6IWDO$FSM?U5?YGJ83"M5PM^=Y.(44!^5:-
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MUQ2I87$M#@=>(]W[3/X@SS>6H33Z9[Z;GM6Y[IM<@_%Y['46,G&Y/7B@544
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MC1E%\'NEZ:F-K'%"A( /^$S%4+DOW7YB!OU#'0^2\HO1[UD"B/XDF' ;V4N
MM!9B5S^B%A"]&IPUF+8WV\[HNNS/LV;\A0_!:X/D< .\7 3IH4RTP>O8QTP.
M5,+"WM'><B(:"X_2#(&SM\^@:W"]Z6DSB,:,OGJS0RS'I8401K-P$D(2?H4-
M1)X@6W="J@@)6_LM8)AEK\4UJ\E^X[(%NG5%_$[O1MB .LX+(KC*4*<?@TFU
M@(_J' TJGVSYMEWIL<!4O'GNYQBL9>=-5+#@+N>%/J (57"F?#3\Q@!S+N^F
M^8(U>&V8TS^%7>&8-^8N>=^,?MI:?2P2\%LY\\1I:UO%6]L'[T&MB5NH<;5T
M3\ZL<QP(A3<H!D_MH*@ZE91MAC(3>H7<7UI*RR1*V;WXUL#8+][AEZU3L G<
MS[7]2 .U[B>B\+W.R0:#ISY][XXN2]*R.EG[L_6GOK]<,[<*/GWV!_!1!D11
MNDMU.GR/4<R!\C1HK^9.SKB>'&&%&:>!U)ZYE&DF"GEX3L]GJ;3N9ZA.8H"I
MPNWH3?R@?>=BTT[ ;[VQ/(S2WR,8_-_UL=Y4N'H1'?=WM2B:S\!SY!8/!<P2
M>)_[+T@4_4^G93T,;_HCQKDQQE'TXIBD<,S,/!LP;ZB+,4.=_Y;4\25?M](T
M1'@5^MXS&+S:25XW'5,^7=$4;1)OS-MC=>/KPTNN.A$10\_TWN3%*@#_-:,S
ML%Y0B24]89HXR:M/OQ-$CIGJ\S[IX%3,I&2"SG8UV\?,Q:ZPM.!/R?RKG DH
M11VE;="N'N%3+L/-9RS?U[.;,RM(#EN#</13D,7#,&*6PX-<Z-=90SU4&<FZ
MY+[O<*4GLHDGOCWI;Y[ZK94K"I: \Y#U.]F -$O.@PWL&3;V@HBOB-0PMK<C
MO)CIZU+1_,F?C\TU(^VP @QQ7_(*<2":(1(02)WP][I1EO'(^X#+G0=<D %H
M'-)36;\%0K9 'V1 *LAO_?1SEZK<XQZF"QWS25N6/:2X]54H"_-[5Q4)-9>!
M_Y$V;,#,9DEX:J]-,ROK\-!;>/OVR\)O NOV':1D_QZ([AV35D.7-Q#0Q5M'
MV8 H[MM/L]LCMJ=NV2K=\C<I2VK\-5.TA%<M27-YIG5JBQMSG_:5[LP0H"GF
M3T%@F9V'DYRZRF5KZUX]3/F2'^EZ[>D/2A^\V9NNC<!!CCVL&=6[#+\.%?+8
M.6DJKR]C_4@WX[8.KAE^F?F<#;BI1(^E'V0#;9HRS;[^?LI=Q:Q415&<TLZ*
MTUG<R,XF!3<KO%9#Z8'&L$Z1%]J]%<U'& 84-^MDZYI#GR9X9C\(LP' PA>2
MEX:MZ.X&QUN;(NDWX69-(=+7S@\M25Z4LCN8,WLJ@+L&^0 9D2/D/Q!/D*S1
M!;<?UMA&'*,XMA?=?/G!RXX1N7,?W*:E(^S E"NCW+ZGM6F=D.XU%>OK8=^8
MHPU78J9@^!C'PX=9(J!]CLIK>7P2R<?3B,P)_*F,W2..+0<-92WBOM^]BQ!7
M%N^WI_"OGN3X#L&5+B4Q'C8@D-B@RL_41-=E_LHIA!O1]W*@?HF2SDS47F>A
MT'52G%K@7SQ03.%BCS%C.<$,!4*$M+(!'G"LGLI93-2&TBFUD_ J?RE3'[CR
M,&>9LR6'FWS)ZT;5515CN8XO7&-Y8S(T?XB&.9O071D"Z=1(F@IR]E+-C>K'
M_57JWUJ\#<R,OR[]1G>C]L*%*'(H'?"!IA-T*X>.[R YH5N-.U<71;1^K]G/
M+FMJITQNE]=[CVF,K83V5:B1WIEY++GU(1)W$?Q;4(.@P%:4( S5"M[O#]Y'
MJ[+5II:Z<!?@XI\\A*Z[-0<G^-N$Q[^UQK[I-?2QM/)L=?:@H(C3Z$Y4%(<Z
M! ;)I\K4NYW&,-Q<+LVR]C2?B_W989%@I^TWD:7FV?-V9*YAA'&#K+FJ3XGY
MC05HSMOM5!F18;CXJ=[ \O&!S#(;GI>E9U&6L9\(%>;=#\GCS+<._8--W' 3
M9F4 ]C)3]LMT4_?/X(5F!&[0R;)DA)D_.K/>5WQ&<==8+JER8Z2U>\>_LI*U
M7)V676+J-+TVX4A9[\ZIU.PB\,.B2;;1B$-+M1G=49@SDZU0W;YO,W<R@JZ(
MO%:A,/+5MZ.C,$?UR7Y4AQSBQXNA^72A]KJ7:M&TUXY?[%@/,2GE4J1H1K+Y
M80Y3/_FWG=GW*5-G0D[_:%J3^H V"-R=DN?]45A3OC;TZRO6M@<E]D]NA?_M
M8@?'9-Q]S;&0&G_RK1-)DS,VTTHW%D931'='D/<JV4 .C VLA['$/6.!4JJ4
MRLXVBD4#$8W&'V$79L#T662D0]ZSL\RH7E;H'!O \-,L_U/(YD.N(/:_M"$6
M^I]BMTL4N-'_V0CH_[NO$G>]?8O/ I &"O_K[O>'^5?W8N9]7A2BON_[SO\%
MQ/%4WL@HD%"3E_PSAFG^2I$E7=\!_UIM.TFQ^+:^>%CK#OD K(P-Q!)JHML'
M(D$"2@B%E5=31N>J#F5=OIEV4?IW![JM^P=SU@\WA#V-]$3BD784:)?314M:
M:,$U)3U1PL#CJ!^12:3%=PG;!WHD+J$+L?<'HAVBUXR+B]9\*?,N'R$Q#R*N
M#_VXXV#7E77JELYAW<3+MKK'G+234H[_FL.^6GNHHQO?=F_Q?H78U+W;FOS3
M\F[0-^.,0\P<'6^Z$:R?0'W-+%&./?81(T,>7O@R3.RW,K8@/Y ]VA>J2W>$
M^Y$)+9"(C+*IJI2QFALRW495=6P %5/^WNK5S@VMMJ0#1C=_@Q) $HP39'GB
M3!&%OW/SXV$'?[<'+NLF<GHWO@<JP4B8/<PW>@=IP]0H&B<PV>]'OX9_U21.
M[H\Y_TW#!MMZ1K^+>FSA:/GS 3$&FF9 /\&PI253,* (D*AZ]?<:][5\RK&$
MGP*%+N!U[AMF6N"._4ASA BY,_IYD];[Q<,6G9+CCMT'[L<?OQ_+]>C &QW<
M?'P9M(C#T&^=2#U]HW,[$O^M-UXS788?,;K[?N_=O5I[&BHN3=9\7/[:>"IU
M]W3EUL6BF^>Q9S_5]-*&.VVR]Y)K"TF-=*^XWE!56<5VCZ,9@4#8\ZN],L&V
MEG?0"=7H@U[98B/5.8++$0:CY??/0&$NAUZ 9.?'8=#")QF@+'!E>I>)+R63
MY)3VCJART*.8PM^1$%ID'E#4]'A'YH94H<NVEC5N$FNAN!E"]4ZG)E+<.E%'
M/5BJM+@#[_(9.F-XDXP))=D$M,5U*5_?GF-UT)O,$W_=I@S63 Q8%YCRP!ZH
M^<*X7-;X+G'#SJ M+V)S?W3$J\[ T1:&R7<=5Q*$(Z+'30'(_16R[Q*WVN3'
M2YZTNSP./*# ,P^>0%/]:5_)FG;UT7=HD<(O=+0^.#E[2F@@[]MEH54.S/L>
MUP(T+Z%K'3G.!A'"ZI9$K_%1!.=N4= =$)!1Z9*D1G'QXEI1]\-7067N+(<_
M'AR+((CO'B3X,Q5XY@;^R99"-_(?SQARA=DX^@!+T 7<H8B<R+P%Y:I>C'+O
MRO.NFH_3;4=,^4%>S:A5_/FMK*MT';G\6?-:^8Y\+]#$C$;RVGUZ?!IDNW1;
MG]I!^UW$&D#N66^Z%Y*_'V&2[FBG+!UH<"KI&)<\79VVE/N5,OK[ ^+4(JA*
M.L+)Z3[I##?W<\WCD?V*<?O-,P)RLY)3H*<I!A_*1+=P7[-&BWHE+WK=*G1O
M+D W.IN;FPI/@,8Q4)D[B+YL@4R2ULL5Y0>1\?6;&BX_"-F!+F6AQL[V9$<G
M"BI&[^BBPP"JVI7,JO?ESLP4HW^JVS8::C9K;NHITCCYI*9\5T;.\8##P81U
MUQ'%9 HAMJQ)>';:K7,[KD'ZY)ACFDR>>O^E\LK/A!>F9>CP@'3R3-:>LN*R
MJM?*YY"C9K./4:M>7[J,2ZQ\GSX-GJ1NUEF/M!6NR7XK+Z_&4\"Z8#<H/KH;
M*QU0:I]I\MV_^<2/-T5AZZ><#"_#C/DZ3)\9\UPJ468#? *XL3F6Z#KM^BQ(
M,*J>&<U\_Q!:L]-8NY-M:UJ//DR1:"?$8*MS.I#17_,8FCE$T^UH9[>Q]:'3
ML0+\BI5R=R1LMM$7D!/T.1.&)JC2FG9SZQO<GED0,)V_*O<-L[&STCC9N.AE
M<Z;\J^*2RHR!<1T^:<U[=-EOI+)Y)G&MT0OTQ/M4 \95;'OZ7-$D@6,W?="B
M'JPS%'^0D(Z*-TGX %PW7"K!9\,C0_-6.O_!#\07UAF+&#4$GG! #1QYWC-0
M4J\XL B&:]^6.(Q+&YLW@7TC-SP*E#XB4T,AQ+,$X?8T_8^,>^0],<3+ZZ*3
M<*O*N@@S;+7%_? KI5)!K&<!Z$$0+_RX.2=2J.3EL);;T/W,^4AB;W7RMRO+
MIS9.N<3OBEH_MX0YNS6_0SL_+.POFU16#/[UI?Q'2>=_NU'Y?>)/ISN".:KI
M-DBZMW6_ ZG]U_<+.(C_TQ4+F\I=X%A(]5!C^PP^,<LK_W(6GP.+@-W!$5B!
MWS>JH2\0\K6#*G+Q?Q3K$5/D@1_<6K)C#00 ;DPV[Y06;]*?U;72=30WEA15
MNQ>^?N>0WEWA8."7>]X')\\&US0$/F@_9@;S(/8SXTNNL!PE9TV4;$2<:92/
M@D/GA*2E;D7>SA"*/CM[J8?:+5L8+!S!<",B08L6L)S6R7B'\O0G=D:^ J>/
M%+=V7=&19$@RJ[%>2"ZX/06N)TYS(9;NOSG7)MG<_/-7T=,7IAUI^WRY-2F&
MT_M#D.%@#T(BH4;O-9R'+@_S)+1,FKV5=3*R2]7HYBW[]JHEUUMK84_]$JFX
MIZ#8@#XX_;1^E41#2D6W677;%(R>K?N9;OQD<6T1D0)W9>:S#L$%AQPM*?-U
M8A)\)OIN1S?/N;5V'5+_*J]._CG0D3/92_T\"JYDB2\E,2[0@B[@SY4&/X?<
MP7_1<G^Y=0G]F*9)%V!HD65*,!JTZ  PJNGNG2_0WQJJ'Q\Q/B5J](1EO[6=
M>GR5[^,9J+=DI]C=LR7Q /]=/G^9"PP,PYNF2!2.0$KXJ_ 6[!J6*8QF2QLN
M_Z+>SMC<>TKNM]%>@4LD;*XY%XS0*L/%S-E"2Z\8F9*ID6Y%91W8^] M-4'M
MZQW<$]W27]%O.6&C$$.OEM9+!M\>W>K3NQ!$DJI7%WB8>/Y!C+>Y:O((S\I,
MD^"NKB.52ON@(S#[TUMQ5B*L2&1:S>2G0<F=Z[#$X^?WW445WGR?[*W<MWR_
MQ.Q"T1F-_,JU4'\-Q#&:8R>X#M=Y Z/&,*[.-*49$(MO?%<+>K(G_ZS,N8?6
MH\$'%7_73D[.],]<=K0;4[AG\2'V?$GN74"7[R$MI'T7'.GO"!9V/USL5C1N
M6*$OYB+X(A\ %!VN'S(<S$[<RUB.%WZAOCY^F1I(,4KT@8? 5,P:GVY4)QM\
MN%&)V$KJ*="X;1A\0'%-6?Z/VD'_1MV3WRK">\2B=%?M:[O>&1K_>'O %"'A
M!>:%^TJL4>3;D'OA9F-J<5[-VJ%W;U0>U2EZ";T0Z9* 2:5GYD_>\0A6STKX
M/=B8,<:;:$R(D#WYK'_F1WP&,%(.Z<P^GM/NX#Y"J@[I,.0V,"O)PI/1XK1>
MNBU#@G9" -6I/16HG0^X#*\)9_G)A8KX[>+Z941H%?0_6$,9C"J88[OWK J7
M?G3B/./^\J[&G$_[X VTYJ6L&T3/FPD[24\K&[$F\OF7*[^TDHZ7X--VIR<<
M^[)P;6O(5L(^AAN%'R*9_A8>B$:ZD^[+WA#/OR4K7W[!>:<8,8CEWO)37<Z^
M-+0V.46Z,HQ*H<^I4PQ3R?(M$!D=<Y*YT+*B[A92.""Y:,9PHYK;?M^]B91W
MO(DP=$ 5\QD;<,4;)ND33[]YW\4&-#Q 3W6?>/W4 7?._WX\'#1RQW-35RFI
MSD1MF@T0FR'8SA'5Y8#<2AS,,:21T*>;V&W-K,0^=%*=-(G101;]X7)T0K2J
M?A>H(=EBZW+:LP([@Q&9Y)EY)^\'_/T)]UTM=)\8A)XF$B:29\&1L1JO9INU
MCHK>5>&N[V;LE5Q$M:*C#N_68&J@N1/_%VOO&=94M[4+QP<140%1D$Y40)"J
M=&FQ 0("TJ5&1:1$C$@+$(B"]*;2%(4H14!*1)JT1+ITJ9$62 +2(:&$!2E\
M//L]WW6=O=_]GFN?[_I^S/4S:V7,,<<8]YSWN.=8KW?SVYQ;37H F]J6CF%D
MFUVS<3:W4Y58R3H,ANVCK>)=?W9>YKOX@(\J2QE=PN,R3(*W= 1H_@F>F- <
MQ'69RBE%LD7=\%KNHPM&4@W>Z\]#'F%[_R;,4O9!*Q&BV9J4^1BD/0;WKL@3
M*S,J3WRM9T%#7)@0OO?T*O\.V]]$7*7P;R4M'"_]?+6P@_DLN1K_(8.T1K7U
M4+,UZ9Y+B,PEA##R5?5H%1H#702+_YL.#ZPV,^(@'D^J3M.Y$>A]D'E&%4TJ
M],6F^_XO>CSK6&*A5SKT6U_I&?1A2T-_G<NF\M][CMX-HX8V;6'Z((<8NL /
MPM%!$2/FYQ7Y5:YO@C,:X*4F<&!*MI;=TOSJ)E&)%QB:D:+%$E%<&G&8A^^.
M5E@E)$.1=ILCI/4(W)DP,/!DOA5[ 5#3R\JW5W1[6[&2$/R*QYC89#V;Y:^@
M)%._#YHH"GX22"K:O!ZMI*^@Z[:S!2E<?Y[N@,VBH%M&@^=C3K<)E$\4IE@D
MK#E&,&=@OV%SZ[_[2-JX,<R/G3OCQ_DRF]7OIM6P<Q"PGS!PY8C$H+8M]\CT
M7N.7#\/C9,HDOLM@%-Z3#5M,4#%4I&2*4S3K5&V.2FG,E91NL?Y\GWT091CW
M5T<RBNB :K;@H.UDT5!R6=F!.SH]WE.KF1?I:[):!-IF=1(A^2JZOK<WOQ0E
MMX19JM(+_^\0M6&G8[IRN@D2Y7(ANEE<F2JIKI779)X63F?[</'9Q\C.[;((
M4D9\@QRX!<+[KBI>$SN10V@X;_2_R+&<AR,F^ P)R5H3L)>5&7+3OKVX_[%Y
M+V3Q(+4NF$(M[QS2Y_L/1I![NUQ_K$-@>)D:3V3R?7',XV9#;Q.]JR\.*8<2
M?!>A"F'M*!&(!SPY$TG0H6Y'I;@2(<I_1GF^/=F<RYZBP87(]YL^\F!E,)(
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M7^_2#S*#*!PK(Q0R$==FSL^X1]FR3 QL!QT?7*W5O+)K^"1M]:M7G=A(3WH
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MJ,QP U[[?T'@H<,D((2D_O5K36V#>^3'C6NM7\)VY(/QBTP0_P^&"54@GJ%
MU$YT_4$ ZTF/Y/K=7;&]QNOO&J6=#);Y4[\TBW0C]Q]%0H:XR\EBMERR^ ^J
M:P(^8AFZIB!D%?T*:PAR2D\;9O?7)K&U[L@+-Y] -Q^45!<N(] CH#*$0UJA
M';9ZX>^NB0-,2S&'BR&L6L,.4?V34HKTU6:S+XXJ8ON_!S5S?IX225V.$HV
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M4=?1 :683!P77)VE<,1@RAZ3Q1\F"<+OZ6WR$ _CSW 3^ORV+!/3,\>DW(!
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M+;5F\%U0(98:T@EPH]\")*Y3>)JNN7O.A/2Z3-R(.CSN?U><]_0M]:2 C],
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MFJ%1XA>HT1%ST'#;,*G1[)"/\%42_$*G&S0UVO_L?'(7=HR2P3A=0#:/K5*
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M;Z">?L%+7*P>.$?M;^TL(+@4^O'^M3'^4V_E@]]9_!PZ!O40S@FH7$?%LA0
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MA1"VW=8C"@$Q\VEZ3_EFW0^[<XS6L"0=FSPI-6WJHP,E%OJY4-DO">Q_35%
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M3 6@//^*=]X5066654O"'?%YM?%GS?^T_"B.@3>'5U00U'@_90VXZ:ACR N
M>QY0"<LV[?K;M5NC.N3D5;_1U\7O$T^?'#_0,J KOEF;B'X .@5TL30'B3Z2
MU>.(D+ZSWQ9#Q0G] \<&Y,N%?1#+K"M .M-X)BP*R[3!Y;MP3($@!4^KAMK$
MC)X[#_A4?Y1?#3L\'[_UU5&BNCRM9=G< []C/^S##,310YY^;QGV3Q0 )YK
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M& [U3L\X;"?1;;CU;A**!%16V<!E_]LNA4356E0 '"WBBIT%2_!&C"774&K
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MBTX^HY@,9-AX''@IS31%IQDTZZ22JJ(^)AJ^G/7DJ;:]$/I3E4KEM!']NJ(
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MI;[Q5A] 7=1RON"NYU4PNWD2GA2>BBI</5==/>[6VS!T/U)8C1+P0IU\E>&
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M,AX9VN"4[;H^(Q]?-1JU@6[4HGMTC/9@:[Z7OLG[Z%2G:%B.%A<0<Z]#SN=
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MN 08ZL V7JAY.5Q91>RMN:QX=$3*$.-.)@W0'MHU,K!UEK/:*%I^&LGWE=_
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MK/4?+XO8&YR^R7I!860N0DD7<V%W/S?4BH'ES*MW=U9WO@0W]][ZP:]PE8&
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M1Q;B2;R V4WB2#*^4-\6;\4J>NYFQ3.C7V6M<Z^Q'@WSE^8*B@,V6L A4R<
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M#$-=M@ON6F"+*?FI]S7R L62W5QBI>*[L"_D.NDSCYZ1EU-WQ6.P]K/Q$=M
MULQNLH=,)5[(B0<N[8[L$CD>BC1"?5GT?!6O;&\M%@5Q7;?J\-<HSR'S$=;G
MOQ<JA*ZH:/5?QF#79EZ)_$K8--*4LS<C_>BA?D<=DZ6*]P02^? /S>@JE0?U
MO@34J&553MRD;W]2N/<^\?SF%1;&#N>?;.R["$I&)?J%94/J"S5'NN%ZU>.U
M?)89X]TT'?QZ033SV"'(1*$PAL^V9C:*XE197EU5%3XEVG+]4V%2XI$8-N2K
M*I\RBY8S8;Q7AT$\VJ#"9R5T6CR+8,Y&2?AYG&*X]X8 C))X3/7N^1M2@\*D
M\];E]A^;\$&JI/07Q3B_/$_^,Z*OWX(8C:#W8:]1 A GU,F50]#)5!W #^\Z
M2FB:/);-EN&N,?[Z5"&TX!O2(LA=Y%J?H DT'EPQA^)0D-#@!"X:NV:OFHZ4
MRZ Y/#TO6G.4S1@DZM0_3]#8LQX= H,PCN.PH\X)J\*BI=75PU-0-?,61(^>
M7G:RW[HOHFNQY'3J588A^G1*<B.S2R-_OTR][NR+[DEXN'9-ED$R=],C-A];
M/_@YY;QXYY=L5V"NG9PWLPWMZ(+4/W9? JE__'=1(KF BD15H,.H O 2&/-*
M"A_7Q/7(LT[$BHC3&[ [9J^!U)E#4.LAB,]ET!5Y9M#^2WV"B:7V]UNV(4$:
M?JAQO:;GCJ2+&_'>:/0S5B,A#^W/(V>N)]BV)%W,S+9Y2K>'EO 8F\6=/24,
MCMA!PX8>GQF2LAM:-]0Y6B?E^6'I4PX(>8^.B(G34"7?(WBTP;CA%O7J^= \
M>,"-=-LM\C[#H-59AWOC,8Q2];OMID \R6@5><)8. GG5:1_"#K^([^NK/WL
M!/^*2<Q'$*<)O?O5N>#V0-$BLB2AY M>']K.GX'.\BU<=M2I9>ETQ?)*&0O/
MQRO,5T$^Q[>J"FEL]E+'O40G3EH6;5K7IDV=<)SF]E0R,7'WO,,N3>A;-\;#
M!)V1 H/U N_-8?#J-CG;]>>3<E@MUI='QWY^\/:J 3U_:*:%]\ RXLV>5VX<
M6S[ A+PSK]=2:,AK\YQB<N?UFQ-?8##TU3DI,!EW=:^D>W37"+"_G]M<L#PP
M:6G3[*VP,MVN*CJ=\>2+P[?0MY<Z="K-JRBI9$8'? -?AZ(O'W%Z27'5];%^
MC]S^_>JJ&XZB7?OQQII@[7;.]<42EW:Y2]>#_@K4XO(=3]Y6WPZ:'%]C;_"I
MOI$0NBU/U[W2*#VT;;5;7J/M"!*,]_]^" J+S-WF@"CTVR[[\VQGN=;??  (
M]+!P+;$J("3>59\;<PXN%ESU?I34>0B2YKY$=IV#"2,\@&*:"T351804DR'Y
MULN*EEK?:U)9/<]]&TE9K_AH>$E$C( N.U\=)SXBWO%#$R0<9$971+Y,:*S%
M%Q##<]P683WY>KF-T*]N%]R^YP9D;M-MC4;2(E&Q\;6*N$#55L=[:1[,.GB1
M$ D(_/LOKF[!I\>\5CS;GVIP4HH1U_ ;)Y:=<YQ\S) 71W;L\[!6)R)N<>?:
M>M63AG5/FWS%:D-==H7.[YH!CKD6*[P!'C)AE/<_)7N?K.WN#E1MQ_%^-S&I
M/96/17:C6-SDT[\<GZWE\_6-_"!P"%(.PTYT9%K6?54^92!.'T4\!'7V1<'8
M$;(YK@>C(>L,6] YVY;J[+U;#AQ2/MGW*F*:?C73TQ=;$-G7_6;4+Y-=WSOI
MBO:]4!/(#ZR=218ZG[!;YK1G'QOV!#IO8[*W5DR@DJ@<FZ/^45VX@D0K,R6#
M;PYOJNOCW_YZ$'!@EN^*84+PX%75GPX9#IUCQTN:E#=F@#A[F(]P\](KS_4S
M]E 9*.5K[L^*;Q@"D?>%/FGN)F#[\OEJPE>L:NJG)4Z$B<Z"?JW;+&23[,DB
M0[_6W>I[QK.J;CA?E%<LZM; ,@6;[S[":JMK^9O%(.D!^HY,#AKQ?#"/#I"6
MF$T9*R9R)^ARKID=#9B-:H640UIU4I2G1FZ(N-GAJC.M]!DTH4.>?<5GU*KV
M=H<(-JE1S[YJ='G*AGM+BZQ<V#]G+\)2#7;T?@,),ZE+6Q_?+0+<>_VEP];[
MQA3H\PJ2W:W6^5PR[778]ZH*O@4>-<)0XAI/3J>S$JQS?3AT0;%B#KKW4[R>
M#'QEG#(^^UWR0P,E#2DPY>3Q7L=#X;V0D<T#9;M7N:63W[*%$B+.\)QJOZ2N
MUY2IU$\]!_?I:V\\54,R>(,HLG^@6/KP05&NS\5K#&;.UK[!]5S9"'7"9.KS
M^BL>NS9*4*.R_*>Z#RQ>9\XEZBK\' 3]EV[Y/V_TOU<#^>?_Z43(\WK(K#KS
M1JNM^.?XNT.R+SOEN<0?.FAT[H]FD>6 $X1.''>JKS#C8%A>^Q*3U/=UJ7P%
MTH?376=U[*ZB'[X/.LD"4I=P>A_$3)-5S&'99D;Q6\=F0K_KY.EK@72X=3F?
M:QZ) ]&#F!/__$:ZQ#,)/IG)FP5ML+%032)?>SPKV8GPO,P)>6'@%_>4\@M=
MUO4R7-L+^);GWL,5R965Z^]VN$'M,3+'/_[^ HF\'_YOS7I18*K".*#4E"E5
M16#+]D#-VO#WK)]KN< YH77:3MCXY-R:D97P,%TU,70WG&#6G'&]]3:16\DW
M-970Y3LWUO((7GSVK$--TJ"\R,/1;N&+_4@Q9#^$VZ-1&-C0YL,<]3;'NK+>
MNA[]3#3E*+S[JFH"]]O".-V9P6N%<)F-5@TPH?$-WIXHT)[%_7B'56/(Q%<G
M"QJ"G_[F>4[VV\M(QC/!H>V!NB1EQ$6B;\LT?7,^L =+@HU>B#J:46?5<B9&
M.T$SXY4XV+CWD@HJ>)I-MI$'<640"7;A3Z.EWY_-N/"9FV>E01Z3QTQF2JV/
MJ?<IK'X*AG//@);;I<_\,<S_;5-F%X3SM8(YZI4"<+)\8S+9>=/Y8^=0[C<D
M5DY#S\1=*Q'#131AZ!'BF9NT#-CCZ85"1G)7^R8UM"V<HL[=GTCD"&#>M12G
M^_2I0>(O-.;IK2N;6U0PNS,HW\LO<79P/:=2]Z&SS0/#X(S]1V=\Q3X67_RK
MHI\?(OD"*_%*Y=*9$+GCZM=X?B^XHT-+LV.MK:@3&A=7J>J$>X<@^R$UG2/%
M'6_F0Q*^G\H@*"_(/]X,C=F"Z;2["5KYL-B7+AO/<+WUTM,\>EY00N-5S HF
MH,&O+[[Q_)(&>UEMN=)+772/L]J(2L MAE%93E[FPM'$RYHG9C>B&H\!#J[.
M?K.!EM(RJF-J-=4AW]J\S][CJO1*]&?;V2<2XPU':"$:'%V-8D5<R;.&!U@2
MBI2N. N+'HW-F'C:$CL',G.6.]8*QITZ,S*2BI]F)^L1,B,*X:T6U414C)J;
MT&YJGM4-_NR!^2_5]^6?MN^%Y(!.OW[(?S"T&PB@9C%' +9.*)#P2>O3ZG5Q
MPQ>&4HJ%+*Z<G7Q>+2%M._)-#80<7'A8-L#54H>LQ*5+0^X-/!X\RQ^L-#8'
M#NA)"'\"55@GOHMQ8Y2GV5?OUI$_%KP6?P?:+N$_!.&A017I8_+K9FW^@1G?
MQ#BU%+XYG\ORECI>LH!)ZQ->@90C(-5*'<\H^;UK6)4*V-BRBX-;-?C"VHNO
M36-I(&KDLW@A^(TV,WT'W*1[CU$&7X".A\IMG%?,RURBC<4#+D]T#\WAHH9V
MY7^H.>-9[7==0P[48=#R*-6.+UO7]Z_48KEOW1*3 ,R6B0RMP5WG@M3LVZ:%
MZQEQ[,(69(W11YE3!_LYL1<VS<>9'(RZ!/3V?"\9:7[4X"-[$1S;?PSG$P+N
M[&(?ABME.I%KWB1W"\5 U3ZBA8!8 @J/B=50=[*]Y">_BF9P<BH^&H-['NW3
M;5)BY<'6S792.#F+,+IK._QL4J=##CX5$.!VI>WEM4<I_,H!3M>MO@X&OIN9
MNTTJ_;E^A[TR)\%!(,=N=84-E:P+DT)V^:#SX5Q6 Z9XU_3 *[;#Q=E*G/(E
M93HR/'J*NDWHC\O_6)/ICXVN!QC1B6[A7RLK,]776 X6/'E3/S2-ZD<^3X3B
M"\*00@@9P'56VF!W9;3M8+ZQ_+W+_>G%JD<)[E+SR-R<F2#H#=A Y7J%;\H@
M]GO(K7QM'>.!Y'":^O=+[FS."D_UUX[.MH8_'5A#*(NE%]P<B+&"J!446(+(
M 92T>M?9:0Z@'&>3U1E1-U3/>-ZV$]<5UNKG>Y!KK,SJ,_;]UB'(-)>&_B,1
MOT;?0 DHW.1H1$7?">@[*\74'(-JTR=N='9OK)X\VU96QC>HB/ZLZ9 (%OV]
MZME?;O1?FZO*NQY/_2U[]:4CMR7GP-@L$R TVPHN9D)(^8QU3YLZ4UK=&"[_
M+95)/MTGE<K=>1?&1)-U8AT",([5U?OH%5;1U>G.XB:.J&53PHH$"Z=.YU?+
M(YWG/RR\!E?>,VN&L6DH X5-AR"ZDGI?O(W,7CN_:4( ,AHN9&0Z]"[IL5$5
MF?>KFO#.;E^$@M/..F^G=;712Y>3.D^"Z\*2;X "]W./S?^UCO%1;K,62!7C
M.M>L[//1.MGGC:>@]H<@)I[VRH5R>'51]K$W=N_J2O :?DPM%''Z7RN2LS;0
MW09"91K<18C^QK":\0?7.C65X=+E_\?8>T<U%7Y=@T&D*"!([ZB J'2EMZ!(
MER)(+U$Z1)IT"$1 0+J @"*"]$YHH09"K])[+Z'7A!I("./O^[YYYWMG9JV9
M/\Y=Z_YSU[KWGN><O<_:S[.SS.=-U<.$9G$S5BID<D;??'^=]V"\4AHPC.W.
M]P*IM=!YYV'.8._M*FG">,*[W(2DBURJG@ME6:(K?65(@"/N/028IAD CI9M
M B_#G22FW>K9#I@T7YUH/2"L,L_O)9AQ$4.=AHDA'ABJK7 Q6<W?"E=+H\)K
M=%52&6,J<U5/7WFGG^GWYI)-FM#;&*W;1]T 7*G9L4:6V+95>;TI-C#R'DB
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M %9RH,Q""OQF5$X#J_M/7?.,%ZG0*A3/7.]GR.N@0!ZFA-Y,\AI@7".P^P9
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M^FK*C"PJ,1P(T85B3:K%4C!;N/0&EP-J/ H&# %:2:\@:Z&,C@3MHA*=TJK
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M(Y?)\/8K%C+373*GS'%'MXSX^/ZZFE[?1:<>L.2!+1]5H>%3">RL@9U+NIE
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M+"5O  E!*#3!Z^0Z\%\"7C(= JFW0,!)S_\Q@%H@<$%[2:![.48^YGP=1Y>
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M;H? CB7RU;EW)XBF1%_CV;[QYKG=/+#YI<^:1,X:*'JY>BBK?$_IFK_#Z.W
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MB?U]7:F36\>)=Y.]1O&&H[MN 6#4T7>LDDS!@UG)-J."#WIIQKG[.AHS>Q<
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M0<6E[Y-LDU/*+ECPVPUL5I,?; S]T4SBN7DPUQNAXELOG/O5,A/TKTN&/@-
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M;+ASGDW(3(M^%^68K@'@?W4D+-011;"-),IMK/,S3!^XO2UX_%>.A^262=\
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MOVOP18]>E(ZRNTR>)Q7%6\-IO@&]<7Q=G4\S:8_)X=:G/ZMDQ^Q#S(=B$?B
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M]'FL^S**&8B@X@D:>@YBKA^1]R5.:)F3-HQ8-:CZ3!6DN&H:\J0DLL=F_39
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M&NK3]EZ"T!D!\WRA.FOU%D"+V<_T)A6X6BR=^[99CMGGDGZ.I"UJ&N0F;;'
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M6EW[9:<7+O.$&^E/U-3+Q])6O3#P]?3GM]7G<+=GTSS_8$*^;<,TF5,E4-\
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MN"3Y]KF;OGW_4*N?E_G<%/0-B'FJHJMB= *NKX_AY;\ >-J(E$D<1B3*G*N
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MQ'B4.!W[&//B66662[0/>IT_@:2IPZS'&.HI>^ /_J5__B[<0QMQ';%3,J;
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MSV.*G76A@O9"(6."*<08A<Z; 2#'$^_JN=+I'K^U'BSJHU><]]93XJ48)Z]
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M@I-]1O1UEG\EJ4/I1X90A+8"-%"7SP&;PFF;\$C?P)WP[W0FSGU>UR9UJ/&
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MW._>X09^VSPIK-\*TG3N&I_+Y:SL]X\Y\L5YI\4M-#*"F7V6JAU1+@_@KTC
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M[;LD%W##R&V/XO0-!&^2.+NX ;]&RD5SX(AS<P.%]M*;6.4F!ZHY\IW9XW/
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M*7W6,";"6N2W>L)\"NY!LDG5&"_>DF:E*I2EO+TE^Z7&$_JQ8^JMH8/B8JB
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MXR3WU)?+Q(.ZZ^6X+C<;I-(/3]@O&,I^>6^)#7*_+[KSXP@>MUVX;!B/E:(
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M*VL$AVE=ELFQ:VC5(S+ND&]/K#;;OEO@$&ZJ;\E^4+*>/=U[J_T+:^CIW8K
M*W_J=[J U7)97_WC^J?RT<,>3,I-XOM N1[;Z2<1L%V-N-60!?V@C0XP/8%.
MA[PP%4P?G%D?F%N_70J\M,!QUS12A0]VH'B0C04SPOKMA$=;P3_\?>KBU#U@
M&1G<W2]J,V[.MW47/TTZJ:PT :4?:W6!KT((\#X^U<F%&5?O8>/M&3%[FRM2
MLYTW&ZE#&8]+>+OQJAA5?CV4-[%-VK0N<?]/,.V=+/5"QK?^LN"H8-HE"N"Z
MH2 J2@9J^] R3;2N58_S-2]5K[39L2FZQF_+EF/+9I(L!Z5/2@*[2C(4,&W:
M7:]1Z6- NDD3R^T3P5R'1&A<D"&;M7,]]H?U;>X.,INJZ"C8+01B@=UXWZJ,
M4;W#9K@[_V;!<C*1*NKCW(7H:@XRKH#QA)'=<D;N1_*<RZA85:EKR/BXZC\A
M^7"DTL<IN$U"QTWW6ZP>XZF6G>A(NPH!KD/((\H14@W:!C[7!JS\H^V7?](/
M+'[Z8279#:3;+@WR\O.V)P]K6G*I1UP/)',@\F&@8/_:*1#-(D%^^6E<:7\%
M!5!8UJMY$EW/<R$U%BI" 73(M2OZO_77A$>BA\<L(%MG&6P?EU\Q](&C9<\+
MEP?+!L/A99R9@YK\_%^,%I!I].#G.,DN^,T (_ZMAN^A#^P3!E$5(7'8+OP^
M(6M9-&,\^,G7(ZTTP !X"G#U(6,@X&*[$??FPW-"-F9/HY6JEVI#Z@013K[B
MPDY6OB@AZ>&D3;(D9Y]IU":B@0O<RJ\$A/ \E^:U$:EP*"0NL&>C*^GRO+^D
M438OL+M,=ER?<WIF18HGD <U <<^U1MF H:?'V<(0FR"3N43^QXF)WU,">B]
M1[V?]QASC:0[)=IA\M>757SM6XQ*?UXA530YO=?2-:<'E3WWXU"']G"69Q7H
M<N SN!/$+?+&GC@;:J1\E(B,$/7A EE=_#@NK9.<.>A]:/G('2WZ)N3'0\V%
M$K[)>?+@N6#4!^3KI"N6:K<#A'Y:SK2]RA%/FFH&,\[-2$;(EM&_!-=9VG;)
M&$=NW$D+1^U F&%#!>QU\.N;YTF=!]%&=&[*.MGPW=)L#87P@'L)(Y<9TOU>
M.F[)1B#1M0IK;;,\U657^YY>/Q17-K;E-FH..[@J$J/=L<\8N$X!+ ?[Z^TJ
M!3J_XYX-,3;[\&D:*)X9.5*B>W3 $FQ&""HA-(_KI!!":F>''SYAT$F\DP*K
MXW<G%N0C;X+89ES ]>NIRVZT3VYNRS]S85[YNJ<\EU0I>JIN&+8P#DGL9 $]
M"X_DI:5F)1VX@(%C'NC\/LS0O=&9:=MORA;V"8UG',G'ZT@_;P\@P<M\TO4D
MB-< +$2><4RZ'/SKW73QR:U=U  >"@V,A:Q3M0%H4L_,UTM(+,A'!3U NB64
MS"&KC&CC>C*\/84>602+$(Z128!WF2L5Y\$2W&X=CMRV?[^139JC ,)B@TVQ
M:XC.' C WXT\^]WE7?@[ARNMC>.Y]4K&?B_>(;$Z<-;'\&4Y;&O24<#/N=N@
M^&_ -4@%.KTUP<OK/D_\3=5&1!>2()CFI**QTA!KQ'JNYEI5QL.4];*;<0#I
M1!+\/N@5 !?$;[QZ5IX7>-HC%'KDP>E<GW%HU7!-<)HUR=C0!B:;@[7NS$Y,
MQL&[LR>J6&O;Q[^8PLTLE6"F<(S/KG1]P67U]7K7_5/Q>,9@\W)_!C):7]=6
MY0'QB>_O(>D_8_Y"/Y9@]N39[-_C[?*V:BU7CHEFU+/0ZQ>\!-GE,@LRC[_P
ML\@ I*<]3XY>"F=QO*/BKO)UTC^V$Y8 %3:X^'+C3E7>_0ER4-E)RU)2= ?!
M?HF.L7H(-%/T2_[G$@>&1GBFQ7P?=GN-/!+QT&5P3X3LN,XCG$[D.9+JABO'
M''B^I5>-7+N;=>NW,$<I%%MX?+0!9_M/ 0O)&5-*@E9L'?&^Q&ADK<<N8RZV
M2S* UQ_1.'(>5XY@/***6@B&&,8;6\-51>.OZF,^K2:E.@GD-R),$2J$4O%N
M"$.KCFQMF(A#=7IZS"_;LMSU2$0C#R2LK@7,0+#6Q.*#9_8J"A-^KWQX1 M,
M\.,*6>O:>F<#S.*--@Y<.D<-V]%-UOY3\(27DDR;[)X#?V>CU^XO1WOS)(K.
M.N! ><7^LAXG61$-F1QFG']T#C3J&F6]E@\2%ZGX"?,8'1_)&PO%R1CBDT.F
MI8W!Q@BJ 6T:KW'9LRYL =X(13(B/M;#>O745'R8NI>9N6#B3G]UM_F2<H/N
M17H5SCQ"QM;<"'?C],Z5MMS4")Z6VZM5=DA=@A]> />"D$!\2GI*B CD=#]X
M*]952K/;D:@ ZLHFYK)'9Q5=MPA\6UIQ=8ZW+F$R&PEU;?96R+".PE>7;U4Z
M"Q1D6T/^7HA68?]$8?<'9KM@3..8ZOKZ1\E:7!&_C=[G^@A/H%))$"Q?YLK_
MF*:K;A[#MXV_^B"3.YL[C%8+\IA!%'UEN+>DTE!L@ Z]]PLOV^N/]].J0VIW
MSO$'#Q\O73]SE7.++HJQ:-0G/AEO.VGVF]O-?9XI.DWV@-WW#^KCTHK+[^NU
M<L4WI_RLM=V$!S[;U:1IWY\D\A,%R(,+G%C'SD\D<QR_9N1.=V9-:QG^V]S?
MQR776/CROY;"T"@[UBHL3=3)R,T^IFTI%]^'OX8 '_?2]4(#DQL4$55 \VI4
MJV+1=C;KP-S6:7)O%_05:Z\2:FJ]-22VPIK=G(Y8%.WYSLAW2K4UQT_Q08 /
M%\NR0:[IY_+6&-EHXYMC@,NB-_EYI1+#D$H4@,N>B"PR0FD!"1C!!]U9F<QA
M/;^#@?8TC I?T?KTW4PJO_4M="DI'MM6T(&\J>/OY>0NUCJ4O_ N Q&>47DX
ML;?CM>4Q7;*,+UD"AN8#)V1]#MW=,T?NS=VLYDD::]^++YL]VR'I9>,*KD-F
M7>PNC69/CN\6O$EZB7@L%\\XT/(O@IA!'/79SI=O-Z4]?$*[%N5J7'<BU*-O
MY!WBI]$^AF /J3OVN)S?T<&)&!J9B5HR*\..8R#QQ^(VD=5C[NMR8PYKR<+*
M*_R;]+#L_J(.MQ\%JA]\6Z3ZEW\JDLI6>94QQ>'?@U_B/,*/9QN'Y]QC^*YU
ML1CFT#1QLO0&V86KJ'=+NE23N@]+QJ?:#$U;R(,_Z]+>"X^\3^Q2R3[;>3II
M;3AA!ZUFTQYAT"IQ:<!(QH,8V#(=GR%OTDMQKH]0:9EH?;Q3P*1"5;Q _@NF
M;;^W-6N&$7$O7_^U5N@?)[DZ@^A#SC+-0/!+4WKNMJAS1]'3J('<I, +$':C
M)P&,D4\BLVDL/_20.9/8=Q?(,Z3ETGR\SUL-!:XP[@I_#S8@+ ;@ A>[;Z%K
M46SCW^CY='/>MC(?U"-ML%YQ;[- X%L0;@F+@?BE;(B+CC5.R-]_V$J;N--Y
MWIO]LN:O?8! <^0 9YQNB:<6Q^741?XB/^HBSW/3]BKZ[1#DP(.B6ITFFJ'7
MD+:18B7S%Z*'HO/UUFH:+,_XUR#H/T33>JQO!/3%J5D]*KO<:'[!H@,?U^+D
MJRA^'?_FMD00M4W?;E$(#$66'#6SU7HVYBI03>3%5[CA@_I9"]UP\H#J7JV!
M$/K C3X/1NCY0OI7",':M&'<QY;N62*9I34DXQ1D55UKS)/X8 9_MS28&[O8
MS>WFT-TN38@+<#F/BA:HOX6V5 P*\M_[^/UV?OE9?S'-W^=&&K=!KR\RD:M6
M_TN?FA5)6UG:+'R?>Q&SVE?9(PPL"MXA2L)_UV%&B)P^D L>Z*9^$/E1=M)%
MD!X%\)D+0+J+ B_5-EB!ZKX[ [$(,\,J&[VK![4K?AD]7N/MHEWMLO_I*N5(
M0"Y-MPJ0::RI>"_2#SX)SU, ?*EB+9Y)F-E8TD?<""FQ^9]8@L_#-Z<JK4+!
MP2@R'?1M[ \0KR2 D7!V3!+=04RCR-<EP7L0'&AG>9:@[ZWFX2"XD2MT)+WV
M46YE4994:KX31;I50S;P,/FGJP7[R)%I5!=/>J_9.1_'G6J(_Q]+9/[;GDV@
M,<HB136F01\TI<IX1-XJ7#YWK(!Y.('I3T9NP,9\\\$3PK5U5;BKQ;:%X<^.
M5 :S7G9<NLEX:@B;/)>NG)VWW9(WRS"HLM%G_N;>=;]\X)% H/FO=IZ+'/(=
M_Z">^NR%G.+-!RYLTF=;(>N&_,48-4]F*:IH89:_P*\RIM[26J[YSHRWGW&\
M#S50E,5E=L/1_+T01I"0"QI652+>$%%QQZ<J*]7+;J[/U=&IB['YW37.XV\T
MT^@24K@$!; 37W!.B\A"OCPXDX?0PY%!%$"1,4H$2P'@TQN16-^V[\'/8I5U
M7#'U*?+56EE/_;"<#L;LPN\2Z;W!5;P3YL@:CPCWS^N*"2N5F@Q<V\8/E9_1
M3#W_[_9@T& H!9"27D8!M"+/Z0-, Q&](V<B5GW$P7] B#VLA'ZV'['"&X;"
M#TUJ#T[_H\>AO64S,"H*H-]@'#F720&H%8F'7G"J:HC?V1:! NPU_ ^Z(;&!
MF:$G=$&BX.LNH-N6?YM2^JGOOUB!.K;Y[Z<2K7C?'1C_'&L'[F2R*ZE0 &]:
MU&X.&>_-UQ*78B^'Q&AXP9A0)3BY]\X5<]/ZQ3K>+0EUO[JKB ].*E-"'_J,
MG%V>AZ/DR*9'M[<@!M""P^O_,%;I1BI;EQHK!2SKZ&D\4"U<[B.%_6.=E05C
M;7RM*__/4]29>>'$S^OWOGZ\PF+T"$@9O9A#-24^4.RHA.1-]P0L]AW$-"-#
M7V&+$S[W -IQ!E_P+$TMRFX5G;UC[!^)$;].$07[8&B0),.\M;/510K$YE$R
M';&,D]KZ6P/H1:@FHP3WH'(TL0ZEZ:S9*\LZ@Y=@+'9^&R*ZU$'TG-WFLCV>
M G$VUK2$S11%_]EVD+!GOU7:=SH.UCWW^R?A>J+)]PF^*V;6<N/[QV?D02_:
M%]N"Z(IT^X[+7//Z4K)S)S9<&7>.XHFCZ_T[YZ:JZB8ATH8M$]8;U@JO/I6N
MW&&IER:87OOIE=HCX\AZUK>T."N,84]JE:_8R3;+L[>7S;LH+G#PN/-0=NZT
MFC7AJM+-1@'4>#X;(7UEJ]4/LT?7+84>+O0W-+#<%VXPYK!->_A),W!/;62J
M!O_5"!0F 'M>R*N-&+:UQL_CIM*]X"7Z7ZUR2KVY5?7TGQD(-#>_\1!I^Z!K
MC2U5T2)Z^(^H-;7^)/<T9"S[B%Y[P:D0I!@6\F6$J#O$"JN=?P(R.2Y<.RZ6
MKPMF+B1/M8,F2<(8R5O3_K"%0WW0F/ACCK&G 6QC-FTM8A3 WF?]Z5-$*8D:
MQT3L@=W&@:,\OEB\^2M8CQX<Q31'O#8.Z=4N_B94J]JE#A9;-+*]MV6S'CNT
M(^7P-W:S3Q>#P-6X! &E89- JDJX4T&4\Q*';-]?&K1#8\#?5]4ES\^Y2(0H
M,JW.VME#>&=G\FK4OF*26!M!$6'YC]&6$F9[%JX2P/^9XG3>UIOD)5=1K2.>
MVSL4)J2LPUL#R8+70'J0\5840/0R>0SG7NCEXHJ6?_AGB$TG\_KBLX#R0?"S
M.H]I[N<3K=1N2VNXN8]S46"7EN==!I]^F0S['X.QNEENOCG@Z!IKCKX!(ZFD
M*:0D3##X#6%ON8!)[[/^BJT1%^<WFXHN^TS/#KYN<Q%G'''%:S-%F;!H*KG>
M.(+F_@RV ES$XB1)S/_.BI[2$HF:E<GTVNG6-$]WZL83ASF4 GPI%=]( 21O
M)A%?BAY)+Q?T+":VB^)>-=,CXT^<\ZU#0T.^)([VZH?X$,V#U0AQG[?P[.T\
M.+,BJ&I;&"VI*>MY<RA=B/]GQAI)"F I+WF[X-HQ,I)]0>J(6[,]91N]VOLP
M>0#D5+65#RV[R(?;[T'Q<)P-&I^TXN7GZ)LC(?[4W_Q8-3"6#*]%HAE7<JLM
MV7"]Y1TK[^!CUKE2)</$QR1/ID<T"2?/0&-:I. &?MY[+^ 6S?#W$F(>$NX1
MYS!2[@OOD:>3"F2^;2\-3[:2<O$N78.1-/I0U$I4%P7 $:Q3L SZPH? J.HC
M?&0""C\-S18.Z3([GX=!CS9ZD#SMBELPL<E:!$&_SHD\2 >@[[IT/7GX ;@(
M$KU(':R!\;@L'!$LB'G]MU)E5""3BCKCV3MS5FP/BL2T3SX_=-/<P#PYU'_;
ML_KR0_#0.\]AF IXCPK7$Y%),N>JM+0&;TF.#$ W/6;",9F]29S^Q;-[9,F)
M??'C+3/,BR-I$8V1WXM68C3;?9T4P#3;QG(W5UTCKM"N#^[>?ZG9\_(P!2!N
MKGH!':(A,;.;4P ?8OMZ)'%W+25WBXZH6P,$O3+41]0A -AX 0=(?(L+CRC?
M_+<8L0KWRID4F:QT!Y/X*WA$GLD_@MY[YN:Q"E*8?/>YF@+XUL!C3'VJ;/P/
MP[[^L-->:4*[N*]@AK6A@.;?4C4YJ?67W]&P#A"X?N+XP@H<RY!4M'^S]V-$
M@BGY<(_F"Z)[&@8BN2NY[JNX_<BX?8O\<09XKRR?FK",Z[+ .8V/),@Z?W7Z
M^Y.=P;-/Y1G-,;OD;MN*#U:98#;8=Y>[M$CB]!*?5&XH>W'(SN]=^(L1MKZR
M/"T+PH?F'\W5K2:SI69S4B-C[<]Q?0F@>]O@FOJ"4F>^NQ,O)XZ#ZIT%$M\<
M<0G%<;Q3Y$=.(16#V7&G*R&+\<=0ZR1N%P1/<\\WUXJWW1Q#GQ^ ^MH L)5@
MKG]K#(2"KY*%)+OU&7N+NEL^X+_R5C6#E>$,DZ?DB&5Z0SUD6UMCJZ7&6 25
M^>67+16J6>7B68DZ";3@T+*TT+,#$X)BN4LCM,U&NJ@O^YK!)<?]R9$H"H#6
M!WDM6!U%@I;N1#UKF!3'-(2AWHQ>ZGUG$)1JA]-W78F]FK0!)E^/$8LAZO7>
M3$[@&S\1AS11 %0P>-C"55^@/%ZU8)E8A/B'4H+(?(T.4;M'2,%-:(BQT@KI
M0;[ZNYX"N!+,].KVE3'7/F'@X5 @ZK@@5I9YJ?R]Q+C*G 25285QR1%?=YO(
M9'J)RY15G(V6X[VT67"FD+(<%5FS3LL >O;S^'$K$9,4>=#J@#WH;F<>YS7>
M,?^9CQ9RB#!/OQX&9[8+M]/#C3Q'CH(8_&<MQC:@T$%QH7V+UP:<O'<%+8+"
M'P%S(%<H@)=)2<C+QLH7S#VW%EH[VD=?C-UR[8E4/NKQY0-<Y,)=]*5MF\)[
MT</Y)<NS9PN:H4-#V#*F1\:![R%)Y$L7W\%.;A#K[(&=OL#<Z'9+ZF'\%L2)
MY$=(QY'[EI%1)+=E),L"^LSW3^9[@8Z!]W4CR K3T!-(-+"*?4^CPG_'!"<<
MH6+DYN#V-O@[^Q_[>JK3YXGIFXM7X&\8T<AEWPHWA,V.E?C<1P6&]W+] O!N
MNE EU$I%TIXY44O'\Q6P#QUS)/ "'C0M+M1 -(>-_M2YW[>RI_F 2[5P>"-U
MF"V(ZD+!VA^.8=J1-VFK^*'A>?-B,U5\_=;OOL^JHBF-6,8>R]V7B;@*B0UV
M[ACQB%L;9[&DM8M4LBC)'D=/SO'"%##/+5K9],H'C/1:-JH0S?L*:I/Z&-&2
MRP7=\%UN".^VU*R>B/?LG>LW\PLB]'BSSMMP<+P1(0OGT>U1L8.28S?#>P8H
MA=1^.'N[NI87];BO.$0T"^NWNT?4)P [,_FX_CJ.?S95KHC*'^'1S_WX^=AD
M"Q+W%C994!NW)?U;):24W>P%8]:T.13;AX^_*&RUQ3$-=A5@\[?%>6>BO22I
M;[L7_TV:HS=<*NG3?TD78K:^_]?%J--HF:G@7G^\XU8V3M4!KWU1"+I-8#;"
M@N-E0Y3&]S)%'P[3L1DQ'2=D(MJAF82.E<5X+LE(5S=O#R8;@;^=G3I&Y#>B
M-U>)JV^0@GU[MD3M][Y(;(&+]=CN/8@\(8C,\@#L$ZQ(%"9Y8?LZZ1!14W8@
MPSWY+#OT[E6@8XSG(:-1CY,3I :R1TM?F8&F )(JUI&C;X[NYKT4&(KZH5.P
M ?D0F+1G2=3ZEOH!A__VN2NMNZ O&>)+_KW(UJ[B/]YE51(CF_1_\?7=44T]
M[;I14)0J(" U""(" M([L='%" A(C8J(@(CT%A)0Z4U 0$%!!02D1*37(*$(
M2"^!4)-(;PDE!-(NO^^<<\]WSEWK_K&SUNS9.WO6S+SO/,\S\\[P.\VS06:_
M]E^&>35GK_["+1M^+;F+=AH_V'D(>V-&4"&EC5/]YRX261(W%D>2JFM+W,ZY
M<I?EG_JUA:I$I%#=& !F"GD>"^)QS^YN-P]1E!90GC7W\U.RX_Z8\BX/Q[<#
MWP02!TE)!/]*B'UP%[V7[</=89&/T/)=KF]R[8]HW^'/BFI:?/#])E7(1[MZ
M+!<JW'6:$FF6Y$\4#?IDJP3Q<D89V<VBKEH]TYUCR(YX?I>SO&JN"B9!_PVI
MCDG6![HW!O89!Y1(>6]R5&&E#"XXA]/D=L&_D-7H32""W&<PG-Z=G9#0XW*3
M_:-(9#;M-'F=*(S/R'K]_/$0U,K'/<CU1%":QN%'A%/WBLQ.I>,JW!4QV8T_
M:(<GB8D24Q*D(E5%%?MW'\<O_#A\&_EF=0)YK]D,#^%=L2\8LB/#G$QG34\L
M<@:FIDVM;L93S]*2D>Z*2<X:M*_-PI^#$[H$T$?AL[LH'^^K'VPP1:_TY [8
M.B'<-9^D'<<_"UC>\'J\:.T2\^<W4X2>B5ZXS(DA,KB;KC81L+)'<VOW<P^T
MRDM[ZC5M.+,8XVUZH-?>:@N."_U[)([^/*8@-"MM+,7A&6WCTR0>=+*,'(0S
M+,&!^?NP<GJ6 1DL?2KVCR^+NT:#"_F95G%KVJ/K \W28>4]9>NAZE7^=6[@
M8&C=_:F.DOI7>DFA5PI8!I U7*^@<GC%-Z%_6^6J<DFB/!B'%<L)FVBK2Q[!
M[!\7DKEJ@K<WK$HF9]R=I4;EO?@%R_Y6N64*]RAZ_;7[>O5[!4V4A9,E],@*
MQP!TL(&CYX3!W!X3I0&%A[G6DU=//)@"7P3/+1?O(61H65 ?Z:0]#MM[-83-
MW*@"VF>UDBIK@ZP0G;HKW7].:^E7MQU5O]4>O1U[]\3W[#?;WIY7ARL.;@>R
MK=U_PM75:D VH=Q>TRYSOL0 1"$ PVKRIS5?+/Y(YG=_7%N?FB:-UWGM4B.N
MO3T51C= \,,G^[XS "MXR(WU^1WF,?@Z!D(#H/\P #\O5[HBR, .^Z[LSDUO
MW5O?301=94VK&P194B%W_NW9(19"%#[O4#2  3AB (Z9T'"Y8TV OM8QY!N%
M,  ("H(F--YW[P2D D@P'#S4Z@?3V[* 1T*V?\-A]?!?PJ"_2_L@RDE'^(K[
M=>"8/6W8S!CI;SGT7P=__<<54I2B?^49DJM"U2'<>0[G4N%4_O'RF3^13DVM
MVERA>\\*>1(C$^\Q5_\OZFTQ]N)1577:UF(MZF1U,MCU1AH<(+>+P@([\CB"
MBTB)XP$(+O+H@PF)B;1+":9AOC]^"86\,;DH>5*RZ<"M!#&DR--2Y@P<*VA-
MZ:\U<__S7;OZL4H]5S$.*8ET:P*Q/P/Q-0-Q%-#/;J[X)?4AC(,'6&W\^U>E
M.CN<+A];:@KV&.4]%N$5._^TV>4!67!!\1RY"RSL&<@5$B;Q8^=O:C9@$/C.
M\3;L'H539=5Y0MO/0%S7[U?>,10CU*&ROV5A'8 *;)TAKKOO>SN^G\N7SSW_
M,O\'0HN6<!U8A8A^E<AQ@#RRE@]7^P[__=^[ .60CI%X>@ !3?E7+B#<PH O
MM6*]T2BZNJ?F4^"6CK#P2_9TT\"OKUXJPZI/( R"*5 H6;M AAB=?7;U0[?:
M.-D%)_T*ZJX[,7=^HKS&3K[-W>8LTSN6+\=0?_/9UW@ =8(\"<(M>C  VXKT
MU\Y6SN5$!)#P<Q]^\ \71\A61,:E._<1N.BF@9_H?X\Y??!LF'0;Z% &$T1)
M^V?N^STP7[JX\%ON^%_D>9@2V1NK[;Z-N[#H4YS%?>BB.96XO%L&V.\]3%@P
MHKX#)P))2O#-,^M<=&%);*[6JW4Z&2%$=J48!LNUZU\EDFI*#+1>=S3637O5
M5ABG]-X_;-FYPGVD9P!-80 X4@E]]& G^#S?_N74[[?*5B<:"W]("-=/6 \Z
M:O[^S(P&_>4[[K>.TX>V?UP*P[4JX+]EU^D-=3N(]]VFU4Q1(A9F<V_%!@EX
M^@T_./H6M71X?4!?!/Y; 7*T L\(U;M\W#LM 5_CKS Q1FA-Y"@LF(.,-#.7
M[CCRM\_X\I)R250P])K>C2/;'. ;"%OBA"T+RN:5N;:BQ,EST-2%1)=699_<
M#XCGZ&N6:M(B:*W%$A#4UNL"I>Y:2;YN?^LYJ,*SW-EF-<_%WY&"@01KJUXF
MPEW]C#&R6SN,G_ T4]6;;;5RE?0HX="'_61WB?ZW1K"\CN9GPY:_?(VWOS3A
MZ<OK%G>?<U3C#HVF$KV7MD"*F?>W!FMEX?*@5MG,_"(.,W#3J(VWXN;+GG,O
MM2!*ILN$?G:W;O4\ 0; 50]T-Q>/(ID$N&$I*Q5287*6Z]Z^!9TB;XI);6H;
MSJSD3X2$KF/L&ZNK@PVT&;MDU##&=/&&<L:4) ^,-/1R+@,[QT1+:?[G] >C
M<"$N?KW.EB6$"QR:]L[ZT]7DQ0B\B,H.7'8OCPMZ9FAO,)8N1^RL13 -ED_.
M3AEYOSCYGG\[ZRE@GZ55[F-^3S5$@-XC=#I=OGS%X5!7J1 %16LH\>=L*&RS
M2X&)+CX6FTYB)41>DEG<ED*-F8ZW>M?1(#A\**W/)Z36&$ ZO)\^S;=$ E66
MU\4^'*U)X2''Z["MJ/8Y:9,PRN7"MYY5)-0O;U6=FSG@:\$!)TM1H?2" .$4
M/EF9[+-/$KTP(QW#[Z3S6FI84PZ*C>U%%[,Z%:=2S$::S=53G^8]:?S@,L;#
M%@AR9]_0*&9:2O&M-5XXYSD!.S]#U1^K:#;"<9UR$EZMT7E?V!2XAFR$2-V'
MO[RLCHZTI_>@[9\FA7]=T5=.OO#>P"U=Z%.VOXKNYHN_OH*8FX*-N)8FK#1J
M>ON,YYS\N+<8<XQUYH3.LTURHH'[F<1K3%O+(]]E9L N*[3SKZ1DZ__:&FO;
M:GTMME#G]#5PJ$3O.9GNA(/ K:^6<--Q+LD&;K?H0RP2#:74YQ.YW8O=5+XJ
ML';6KSRVZ?Q#+]H/+9+2-35BT<8!P=-J%,;O0*[XK6H;Y'M"F/O3[WP Q79F
MGG"_^A4X"G;>X9N$XJ;/6^V\V=I3T"!"7:>8-CGCLWVP0+N&RHJ089S0:U6?
MQ:VG>M>ER=<1ME=[K3VL*ZW7NC)8Y;(+370,Y3Q;#T+MQ 1XB H"LNW--C)-
MS]-LT[T*TASJ$#<5_XD3OCJG3 !1KW*HS<E[WTJBDE-,\)3IF'Q6ZM^L=EM[
M):?3.RPF?X6IM91NN#A=[2B_@JI*KL'F>/;L>0NN"5?DNTC53'*=7S0,I#Q%
MZNJ&5<S^PD\&V+[K>UG+7?:[]+4(-?H>UQTQN= /, >(@ET%^+U5Q_#2X@N!
M9E>W?/,0,="9X*BL9<L2,[8_WZWJ5*4$!.4V-HZ ;G147E44WJP,:CB.:[_1
MJ&G=</FFEMI^U'P;!PBG.:&JR+MA,^;U-%D<W,\FLND]T PBN9/;<L7(1@KI
MQ6NI]AY2F+]=FTF]L^>#Y#OOP)\=XQ?M=[F7B0,Y^GGNLBH8TQ,24%_NB!7[
MIIW6D_W$['NHGLT72?.>SNC#YRF%7<L/[NC9^_OPN0B"L>8%LTV2.RF=0,X:
M2$RKY!A5JPRC:ZNMBF"JU;=Z_8N%5E&#@?*0I>#$4AQG#C;!T.$9>X+J3IU!
M(G=>5^L;VG=]V6 67$669WFP6NZ\[9AN2< 9,;URL5^)_-N.7!O[1!5;PJ4Z
M&QBP2B,TBKX>_,>3\OM@+UT_8H0!L*@R7CK7)V?QLE3*OW!K==Y)6]2ZLMI]
M)".DYTIAX%:YM]6^=Q>$O5J/)\Q<TJ1AY_G&EWCQ3]#9"*:\<E@H?9H! #2K
M++38HW#2T4^>.KE?;WSC6TP627%Q'BX+5L2UOG8[W?(E.&WY_IC2DIEW4*^F
M2T,MQ3:1:D54C-^D2JI_PI?*O/!6=(IM3S^IH.DJ_64SGG0M5\SL6KN1:.KC
M+_&OO<)2[N-AKFZ8[K:7RPE:_.Y6D]AU3)!GIO,ZS(,&O+40)_'*^)=,$S"(
MC\)- =('LO2%R#IP?);345[L]6=XW1"?B)=*1]G4]T,*\AL5"TU-L=JW33"A
M3_RE5SP/Y+ QL;K^NL+88O\50?\/S\=S78$RE_Q).*1V&LA8/X@\3M&>)Z-_
M'?T(LE.[<G)04%3Y]19^#BDG-2)LFNEU>8>)?5@I:6S_]T(\[8#(]:H97-YY
M*5>T1;T]D%FECOTZ<PD)T3V/T;E>3YCOE"MVUON&M7Z?'-7-;H2_+J;WR-/M
MY-47;[X<!B\+;H7[0+Z#JAB C<&"8#!V<SME;LP\K-3PB_-#%1%SVLR!VN$N
M(3M<@\Y#4^^V2W+NI=\XGQ/MD_Z+NGYP$V?H[N]]:DJ9%JT:V_CET'3S0K^X
M[C)V/R7JA<'\JTOOS#T#SMI9=UUXP>RS#DD54R4[^1%*\37)\:DAC9[KU_2:
MW],%/ABSK$(:A;A>0T_J>A>[SWLGCW8,WY3B3PQ4']RN@)'\,$@EI$?3E"H#
MD.PL-%P0HQA2;*]<]VCQCPHY>ZY6K%#?UE+>Z7)%N?_1T0F:H/O\#E<M U!A
M\H_HWW!_;YM,^.^DXP*?R ?)DP5?(_0OT#XC'R-9J5#B//7RT425C\M+^?PZ
M[H[/Q=QI-Y:1:MN-02C//M")!V1.+XO<Z;O&$J]NFR?SG$A^&7*Y1M<3!Q)<
MP7PP9S&F#]=QRUSG9-/RSI&N/:U?TSU%IN#*^_>>@L^&\"=C?0>SF%XRYSU_
M@D8D#5;6?U2[*AI:<7]U/D,O/WS#(3.FA"S0'MC*.91N6)=:P5KIED&G)H;E
M+3I]NO'")$5^H@@A'H$0(=.YZ6>#-X7?^H>U&=%^>I#XPPO8 Q! \KIXR@(Z
M:=$BK=%\:AFC8E*9?SA/RZ2SKKXV'Z/Z(.3.YQS8](CC0?.@N^,'W2G5R%-3
M4-D)_WG^&3EWX!.7B^#6[]>9@)M"Y#%/!H"[>C#:O8)L:2PQ]#CM"BYJ=.E]
MW=QSTG*AF]D"(JE5)KO[-E%.9^5HL7UV1M8W-6HEM^W(=EM$9J'\CF5A?/=C
M]_8$C_6<N6$_S>G&I.K6#>HR$%=[ZR:?(U&I622CMBF^R:QA]VX- 7]W>.\W
MU/JS&:E?_*-DW5$'^\NFJ(?N8L)U1,XJ5Y&)-/"+GT79+C>WZ[3$3\PD9ZS-
M<U>7&V&7$P*V8RSZ&[MPFHM)7!?Y&MH07^%//,/UIU%S4A/[Y:_ZS /2;&79
M /&A0%@&&2'\U YF9"40AQ#0/N_@(;,N%68H<Y Q/!^+2S24E$/A?4/U,85!
M=U7Q-;.&:=LSVWM<"3MD]XWGFZU"'OPD_M+%4J,D"N_6.3VPI=P@W!TD$FR$
MVX_*PT!YBU>%W@3?;\Y5BA+MX\:T#A$$8J&B1*!1/5IUM?]M9>#N(_E,I>0W
M;@W?@V2P$'X[#R9C($;]+1-'^V^DKD%D5WC+^B+9;/566T.TQII=KH6NBKV6
M7T^GQE>D6=/JT.%=G6,T] &E2M0LFY9YG1_C?O^EUY0IYLBS%,2EYB6XQ[;^
M22*\<.'Y$_^'(<SA!N$7*<I.[LXGB"IDM 6A$QVGP,_RP$9*^*++<'+H1YCU
M+CKN3MXTYJ=9VL0!UX7!AXG7@1&("0;@5?;='"SR#<8F7U:J)0TCWS_>=Z+'
MISXB++>]=0#)]W*9LW%RAJ;];G3QE3FE?V[:,TR>DP["ZPZRW&)A3V==?ZS$
M:_%&8Q;B (V?$R4O+[1X6U?G=+>*M@XM9.*],0J2\@ ;_%+WC>0: G"3@S#X
M2U^8.(&HH"J->]5X<\S>>7J#[>0C9=^>Y&:QC"-/+%B JD&N\(;J?+L\-7KY
MRO(ONW$C\Z(&1"K(??!-MEY,#$M"LXJ+:,0/*46)E,7?NDPI+HY0%AR$Q2=0
MFC<RW_ ;&]^%.E8_#XN,=$^G+9)T+#DGENR@C7JBZQIQ7]:V[A)>KMLYF>;]
M[1/XK;YP, ^7R)JMDG/OPZHJ@R!9Y8[*MI-(+WUF*(!P$*G/:;]Z9+Y6.O<;
MK5*5]_&T("MX!,G:K(+P.%)=%8WZ52L4^:!0LI&)NKZU'0WBINM"[]:'"['-
M;YA+@F.[1F()UX+OZ3GP[7^4;WN?.,@6V]55)C/\Y46(^93<_+;^:)QF$=.[
M1ZX)W6,6KVRIM4[.11,@ ?U3Y" <"/7)&_6C/HU^TJTR->NRQHTTE95Q<HE?
MX<PJ[^"C,(%W!!5#E,@+J]?Q-#5T#BF6H)\1D$]VL'5Z.F]E&8V[3=MS;5R@
MR6%3XN:YJ$8+>KPFS43)C#&U$.E,X_=_BZU0L,NM1<)8UZOZ8%O-X#4_^S U
M#L=MM(,#4=\SIOG![RH3BZ)7'3*F^>Y&;E^]9D,E&VG9>Z>JB*IB2CFWTA]D
M=M371+TL6>);3Y]K[8/'8S[U4W^01['C,^III:Y8B>>OKMT0RX@DG,0;$<!M
M\J!N[1GN^I.V-SZJCBJU?]9_OPZQ"O;=O44$H_Z2,UY[>UQTJZ]+JCLS&QJ9
M3??%P0N\69]<2-DX7/3MZ%)_L[9;C_2<4+*M_83Q6!;Q/79/2O4ARUJ&K#SM
M8?!'G&$E)N5:Z9"G1Z%Y[_-^SGTJ6 76%KT!_1B/2AHHV^;'1EO+SDMR=MAN
MHA.WCUOEJ+R>^#H8MN H><9>C\BGU<<O'@$V)7.AYCGV]$"D-#*8*(D2-J\H
M+>52>2A\-G@R^L+VQ]>0'Z$I*(?PN\=PI>&=@[DH]:N-W1?.ML@(E56(.T2I
M3^EC?7-N_J>S!?AP_)SR;D*CVQ1AR=-!(,:W8]C_>[OE&ZP\7K/)))RB__W/
M[F:H\;:_R9>$SA^1JC)^SU,[E&&#?RJ4#JJ2,_JHNN08+(1M=@Y<3HZ ?,@(
ME&CW$USO003$M&6I$R]=:_EZU=A"Z87R]_E@IDFA/B#KU6BXG^L@32=^60\'
M/^$9"H^%&N'T('=\2;MJ%2.&7-SXPM#9EZWG"4%4297YF:O%7?OY.MR!$F?0
MSP"V =?%'(@N6$ATJP(9!N((+I3R?%#(R\1[_F$;-WJ&1\[J%P/ U:RX<(](
M?MSQH& 8)?P]O3K6UJ-6^T6WU5S3VI63-6,R/FPWQ'N-67^0)$\WH]J0+,T<
M!/J!Y5BU,+]&:&MG?3;VSXBJ3YJE;NO=SDMOM6W++*X#E6!]/@6P"T1+PR_6
M4+/O"R<B0%#/E?!_7ZYQN$UR9@!2/3OS2,IKR"--]%#V 352#7A$RF( KJN>
MH%X,7J8;F</IR"WDGJ>MO!,X&?[7'\T K-/7&0##&M^QR5/_J08MJ_VG&@1)
MW3_",@#,SQF ])QQT,99'P;@2Z$XJ+B&\C4S%;92\/2,\K,3@L/ZA]TP3T5S
MXNFXLF;BJL;0G%K5^T5N3=]D[5(73;4E9TWR/&&PK;&.Q)*@!JF<NX!Z3ZV#
M9[2,<4.TH7+D/,H5ZM5TQYQ?0I2L"05,V C.#IPW@/U]&+KWF:MII<R+"3)"
M!1=@UK-56\,S-AX;YS&_L!I:V'50!=CRX3?-.H^,HA4#N)C<?=:U_YA^8[-[
MLI-V*_<&;,;/R6M\C/^>WOCH\<CE^B'Y9.1,]E)W,E4(OJ3FS@# ;2+T98F*
MW7 ,^"81&*.K5 Z5'<T]Z+ R%\TZ"GXHQKQ[(<T(*!\N<$RQ0$(!FS=W0'%S
MW#6$V3*?U\R9!Y!GROHAS"[)<G]:KP7GH[+R!%NYG# >]\Q.%9*^CFK_9NT2
M&HMX0.K!M69"1(-5?6@U__KF>U'[C\6J:[]' S:%'\SXY_RN:!=1BD,]S'.T
M:1%GO8+0(R<10>T@5BJ( 3BKD5C1VOW0-?D<65KQ(B:?:2P;L"<KUZ<*2LQE
M)@HD*="!J[9S3^M<O?G&WF:(QQ8*9_P,>X@NX31\]L_V,8 2J+CZSX2R$!UA
MV'93%5 ]O!)R,EBQ,Z]J?WZ3V^4K5'54?E_NPZ9(%\DFXI;G51YNM>Z\1/BY
M.YS[!UV%BVR"?U:7;DN&K],6,;X@;LC[7"X0YS\3TZ)@+"1*#<SIP>W4[^6O
MV^EPN2I+_HK2J] ?S"XMUT"6+#?,#,Y'?/G_:6+A*O\K5_Y_*F9W[8RL[!IK
MTPO6)WA6[?NK;6O]%G0MBY\\]_NMYSD(T_ 0BDXAQ'2%UF;I.#AAW#5\41*$
M'HG;G0^ ]PS@0!78%+QZK7=-_^+:>W:CH^U0 /TS3!&J2/9V/[9>^4)$S%7)
MZ/5[+786CZY7G&H0O\;T4<QS[=ATR7*_YLYGVE$U"C"K/^^>_#UD6/R ,P)?
M#N<_-J*:H$V.[Y ''J$QR6J"6]5U[O(%[K[#*DEEMJ.2\<>&%/V'5A0*;T>-
M@[;W 7#/7Y&"+*HUAP+']I-"1A!Y<74HN) 'Z-S^]*? I4'+:$WGQ;KSM\2,
M6=8A%2Z1UX'9#( P"]6QQ86V^,\"F]YZA#5YB@&0DK-E $+@>T([WU==>%JR
M%H#4=YLZM)[C.\16%>>>?T0^V'^(?&:37,/1FY"3]!D0<1-[$X3TH6:V'KT8
M)RAN=C( 8G/GC]%\%JC'$P "&9E>.R6^HF)J?I*5UD=@H<8U"M!"4,=MP4I5
M!6$A#3# L2]1N<D (#3A>ZR N7^7Z1)&6G/^9[H$L';E:'C5F.L9^=A#B#<@
MU[_0K5?&ET&<H+\"BC1_4&^+4/1_"W6CM&ETI,P%)EVTUF)/=Z_/7D6"\Z5+
M#B;,V<MWTI:WL[>_$"Y8ST 4P%MYO>E]\./?%'7(=MY ^I\LRE+-N58'!L"?
M;IU7=B/D<DJQT>.R%_:81_RC-<WM,2^X7+*'=J7HA]_K#G96C\+GO@K[5$?;
M79=^76FRO/,EDHS^1A] 5M?F?3$K7ILX. @*RHZO_14XJEV2%/NX($+@#\RA
M5@42!M4E.^#D>3N=58GC_3E3'HJ%W46K1.^G1FDZX=L:TIDAR2J;$*%NRA-J
M0,-PP81NCN?]\-LWSNU :#9=[Q)K3^"?[>\ARF% Z$NB31T1V!&JD!_&^:7P
MP3.W^U$/$_,[5<VRHJH&8,@HWV_Q^DK ,W2MX*\7P['/%.>-B!HQ9:KK)7?^
ME*5U/,D, GR,WKTO<S2QG*!_&C9TD!WU1]N@9LT.XF$?^'E#&B0W=6A1+$(;
M85/AI'C:WJ>5TU5656;= WTPU8W)D2XAWPY??HHK=N+/&*_\9<&3UV&-Y(.A
M@4+59NLMR@,7GJ;NZX$VEGN?L_'O3/P%DA+J6<.>?D)9JI*5*'?!"W#^E5!=
MOP=.,VUO(;IH=J!%KM9B:F'=P[NS*Q9^JYWA/A3=:7*[J%'GQ)QD'"Z9911_
MQDQ9JA?SN?X,V*+>;QLBN0:O6>[2A*H%%4^KU6$*LZ?:#XUH;-!=0])@KL:;
M1'5P>7@A00/WM '?4$/1<W7A<<?U^@=G/71MBGQR,>8@<M#>Y\7?EI2O4@G6
MX;SW$PPSY!%S_.=Z)#(-PHN8(\=8J9.T1!#V8A.Y.TA^-6FSS,O[2]@["Y$L
MWYS$K(P@_DLB4;\7;%?GWO\JKVANAZWVB'Q\C%2'NZ1[%D$A8WMDW;K:YH1[
MV2,0&0/4UYFW]! 6WX]['&,V:O3+GN#'# "5C\\2'*W/:V)RGSYI:2Q:*X)^
MYXYY6O*(L#.'QB9.D(02NL^=OGGZ\96SJ-#TB98\.JM;B*LK8?=7FH=2R,1V
MN:PR1?6)[5E"#,FQE1CSYGF-(A=Y8*T=W3L3)Q%WL^IA(B]5W"<>C\L5R.\0
M9/_I[@*KH)4]W6;1-+\TDICF/J47!N3-7? S%9QPRG/U7QW/%>RA:->]?&%R
M:7/6/_RL:D[*.?O@B\?T7L2#>VY=PC7=5]WZ?.!EI"1,979RCFI#Y"-EEY)N
MR4;))/(@@U.ZD%ZC).57GK9@H>#6 WN0.OFS_FUHKOZV+BN52JNAGWD&YU %
M<7C">*HH>FG5M5DLI0(#UA\/+C<$<Z'*2J-\R^YRL25GA(X7">K<2LO^N9+3
MT/FZIPJ*BO?1M?OX_?Z:=8Q$D8G^_71PT.HDBGR"@+H^L3=*Y+)(G/ESP"D>
ME7,E!]QK2N%\U3*/FRC"RD'.U.0E"2JI*$X-5S:)[S.-_&QEA?T1NXH^'M;H
M,H2ZA,61)*I2/U_^99>^*S,.:X8&?D">5A[JPR']B^YB4L1O*:=_9#^'K/SX
M7CWD;')PYPE78X>O"F0TY+2#D3K.4>/<XZIOXT+NAJ^:>=+B;6Q';<=#6[B6
M8:H$3\U.(A<I61M)T=#Q,*F[8DC?\%HZ^*G+A&]-(6!T."Z#F<W.I]\MZC^#
MDD[<I?,E4*39KNA?'D _+VT=._28/,QY^5MP.YYVDNBV8;V %%!+B6_6<Y6.
MJ0FQ%"RHXGC/5WMRY3P%W9/'@GP*YSNN>+IJ]4BAIY[5K[H2DJ\OOV6#M^(*
M*M+9#;BDI1^2W-ZE65)XY>XG$QT_@Z9IZWS[*1-_D%=,]&2VB&+L;WQL@)24
M@IU9^%;ZSDHX'I\BL()3J3#-<_DQLIF\8Z@,6&IU(,*[4J+GI A>?\_QP@,"
MV(Q.-78Y9=[:>072WMOF#0;A(1V#G$61SYLOJKUV5':8<;QK[1*OW-;D1HZQ
MIWC?(DL2=E%'K'8/@@-[=58VT[2DC WM\([\S'L]2\C+!)=7.UMGL8T/[LSQ
M9,K8?,253)C;R1GTEY:::!2EDI%L9-ZX@<H:OT225:%MKORE=R_>66^D!]H.
M!QGMR@=XR?X*>#$5APZ]IF>D&T_K)< JB?H4DB&!%M.NI^GD63<Q9!_]G)O=
M:Z>Y0:\-T8-,H@N^1L'YJ5:?5Q=^AI<G>FXK:E+[8138GU;V5D+1KSP.=Z%D
M&QR;YH<(_*GH362YWX+?E:$N([Z-L;+#!M?OX<^I*1O![3VW%_>=9"%1# #+
M7@)8U-.X;J*6V!D0>'?<?7+'"*EV&$5Q#3ZY\2V=R-/NVEP9P/WAWA:[\-LI
MOJ-5(@4[#;4^MMKS01(8W%1^[F6Y%O94-U;\T#(?<3FY5<!#VV@#*_T::CS<
M7VQ_=8O=Y4I.G*O%WJ;S-Q6N-Z41P>/VX[-&P7;V YMJ4_)-DEG3$T?=52\/
MY&&>^VOE1WE))(TJ^V:!>R)FO'*(*J9.V!1]8,2SL24C)5;MJ]G,F3K>@1E6
MZG-RR.?:%EP+\.;+!X/^E3^Z75]X'HF0W;$7_&DG,;VG6"LWVD1+%ZW6 D6"
M.@>G',S(**+ '7*40-QVM;SEW(4OG27MASY_"4:^H>CVO-HL5.7"=AR('9$9
MU'!N[9R#ZHA(=>(3JX:X+4_2@?FK6=;)"_&] J<H>XA^;_*5Z ]N7BP116]?
M^[9>_#FU_EJ\/VPJAM?%)]A>4]? K#VKO:S:J2)C_@_71(L._09I?K\']+8T
M WS,]]Z&U]%\P31FZU["OXZ /:1TZRN,[PV>FVNO&\'8VX=X,%\1UDKYHS5H
MHP>HD#8DIY>LAX9OCE?D%Q=,**D.I#E\?Q4_'?Q8.[<^'_>G0M>HQ  89Q3S
M),2+^O.WB"G=?D'D=6+H$:^384*Q$QN;C**N@ZN?E[)>%5^<49[NZX,'>LIZ
M,I$H9-?I!*L?HZ=+ONO,1?9B7O&&>3D2UYT7SQ+%8G"?) :V;<-O3M\SJ<O_
M?.'*YU=G$*PC^V%@-C+);)";7"&SN<#YT_Y"=^^D^&YRA]LTWSHI5XTPG]C\
MZ#,RIJ)SJ)9BG,[T1:9[YS-7$@/@E9<@ID?(B]MS H(S&0"C89N)I6=%E?7&
M!4TMK.SBK\XJ=<'(V]E'#EU"N47EL-[0;U7E]5GW6@A-?2_7V]R=YZ_">2$:
ML-E&I_'N!%VV[RC52'GYFE//RC]9+D1/WOD@.]]T3_^%GMPJ0O"2$<EFG._)
MO'"P>VOXKYUOG$TQ+&NR]FQYQ\7@A(H2!;KFV3;I@BNA]WV9  WQ)+>.&S=F
M6$2V^L/,T?'-[@2\48V8-J$0=^O)*YD7F\2K#VXD4?U9RH/FJ\Q,O@@[Z:M)
M@^M_6/#F?GFUO(^H^)MRFRAL@#4W55GT4#(1B45%VUH6[:D=U8!X+CJ?_U%/
MO2IMJFSY<\ERJ>9C Z(E<Z*2G'6.!B0'*;_!V_#<M7JW5; =(@_N!&-RS$9J
M1(U0$%[_DK-.OJ=C4ZP33UL=WF< JMB]<%XJW?HG*. I7NN:.%PJ<KSL^ZRP
MV-=*F/Z :M[IJ6"%12'A%';/+)O8E(.T:\86>]/VQ^\!(^ERY'@Z#H_MO<'W
M":\:I*&2,MLEN=KMZ^<L'0>[,/JG,F#'(SAV.,EXU]!W2FK;H'5S!V%C&S69
MN"N-/8),I5IV8F5KP'G>LV,'PCL6^A5D*X*^-Y.C(P>XXR5?JWF:@:".SWJ>
M_5[>6:C.2/,IW*QM!_=ZG_ZG8L->TG=?D=1?:D.KD)_@1#5S-<4:4*S*C=*F
MR-A'0#<+^NI?BNTG\@&V:).#4 ?.>5!=5TT,S"DJ-=&*,W4\,]HZMRQ"A/P)
MT(\-4+EZJ^A6;(FIWXC)Z$LP57YUV*Y)91^F<W237/G^D9)IJP"7U71WID_*
MBXE0C268&=2"L$&"GZ?>^OK0$"V4RATY=+5;CKJ^G[V.)67A@&]:CRM?K QC
MY>XC<5=XJ]<Z-'T.*4T-QW/C$'&V^LH/A!2K!YE;;5]:B83[RNTQ  N(-ZW7
MZ,,36?J*!%(A2XR_G"U_)>VK<K]J,5)=+W(!O?'1>X$#R@"<TK;V(:+,6"R<
M?1U[>@?D#. ZSV#>6420X)/)/_G7?E]!35M].QPW*'!]5AJBM^%&U2+S%5 U
MB5 Q^;']FE8SD>ISO][:,0 8_8PE>,U!TD(+0:T_.5U73IZZ\A,E?+)=]V]Z
M/$4*Y H1FME.Z,Y54?04?O3U1TK?+N#8P_OD >%/4Z*TC=K+@^X/J1K$W*^M
M";)+3-Q@35S.LS]4X"6HB/<0\S -WUQUG665/'**Q$Q] @-;-N;*#LBC2GAG
MG7["AVY!FT*^&/>N3YIS)+3M>@DYM)AC-M8&\]7Z.45F>0^!]F8CH['O8!=J
MM0U+O)ZGMB==NR3'SZH,+D'T(9A6 NE2Q)28:K:>J&;[I)G /PS + ^T +T7
M@@5-W5I(07F?>6!W"[ONV1?[\#I:@ZUE\6VRXS)Z! EIAS_"^8K<M<UI3,'T
MA%7/9J2MS7_8S94CFXE=218U.[<:=IEDV[+9>/@,RI\G1!7^-H>Q=TQX5]NB
M\[@A^,/#QZ%\+K_ZH7Z41QX']ED=>CIW,XRK:ZLX>%UB>$0[XFFUY \$>#L,
M1 X/PNHY=^D$"W'4SME'73..4?KI\HU3CI"/CXG%$=53"L)+;JZ+B>3B39LU
M%S/Y)XN(79ZK+QOTK1UB9)O3$DO*]-[ERV@IV*"OCH8[97M^.41RDN6CL2\N
MM>%_)%M?5-,TZ=OHZ38J,GK:ZC;$ )S0E?]&-24+N&*3/ XW'@][+RF=/U67
M__"M4?$FQ"4XL*^-?H'@-(CJ5_U3>^#QJ^ Q&Q257C?7*DQ[1Q>"/B0G>*O'
M8<MO/X.)UH2/.OW<FAOL.T,S/4"TN-+BH%Q%JW6A R6X<C>*/=]515WJ:9?1
MLZ,$1(<F?@6!JO_X?'WI\ ]V,\1#]CX69J*:X[O:6CL;" IA )R:[]R'_WRI
MV7O_I?_395,%W?ZF705ON:J!9NG\2;)<-_"LKN0WQYH-R0Z87X_X+\>N3FNC
M0EA76_VEUY!D9P[R#>E7=#4H:,)U0C'@FY>YM?GH2<E37.*<2T@7O*5@7$5B
MW9N76F)B@H%,O+)$V_2/^;TS!=.AX=T-F;C=Q/NE+E5';W,OE\U\6R@73;-Q
MCLV-OU*!'_WW YK^G[@LL99CRFQN1&\I_&<?,^CA_XK)TOL?,5GT<U0_!D"R
M LD 0 X@1VJEF15%W: =[74&8)\!.&;D^?8-'@"Y?13]S!0#(*U5P@!,\N 9
M@%NFU!0$FHLLZ4;].%?$ #PT2Z%Q7&$ZBH<TV:$;*SX]MO:ND'P--]\X#?M0
MSGW@B??&)"TF'[^W,U.TM;CB,V-MX,A5N/6-($6="R=6-F1].V1^,?^A!_$>
MZ>:@>/KV/'=7B=<3)G*=U;/F2;Q@;,8OQY2FU62Y16]]^.$& W P_*TLK3M/
MOO>%EJ9FS[X:[ _7^#.U>79,1R:I+G/8L-[ZOBNK'N!DH^:D]FD6\0/$[]_2
M>9O77LOA0QD [GV^H_Z"98K"*&BW![3';75EDE, +T!-V^9-'7O01RTE:CW-
M\3[J8@!:DV"3U&/FEN: @Q\1LPYM<:8T3,0EA8U;_)>28Z3C@[.]#U?F#X:+
MHTY&@&XR (]M@D:;#9T2'C]K_$A"-*\O("<3Z#?^V16P8A@N2QF).+<L8MMW
M7 )]=2IW_-9NN[-N7?8!1?V>:])&0>;%2] M%G<6L9J-QNU$_'  2V68W^4A
MSAO[%1HVQ.B\[^X'F>"BXK#B@I00ZTL"E@VKV^8G_F)8-KDH6G-K0^0BU'#O
M 29>JG&N\Y'"JB2+1P6AN5B-)*+PLR-->O;AF2.AP]=8JU4&@(,.7&D]FS:E
M*&P2V[G\W *Y))^;N[\>"D_YVMH<W2,?_^'!%:T%BX=Z$O$>HR4G;EDM=05@
M@+Z:F&[ 7[&S&QRP4*HH69[(A (*[X-$/.;.CFRJ)AD&9Y^]V!+BW'$[L<SB
M["]EGK-\1V<KW-]ZVIO/I?C;/6J)P_K&>)YZZR4%=AD\C91IY5XE!+.1WHKQ
MO>X(I>=_ZRR;L3.L"\*B',_444D,0%@O4\2LS&>00XRI#(NI_?5[XZ"_@D$,
M@..3XVYM#NVG",![&LF>-,H\33:S-?M_YO;]C]P(/6E2Q'$C7L0/4D[.,0 K
MF0CL5SP-FK<-7(;,(#=/, "7;G7GD4X=6\ZP/ 1ET'UT")H##41<_$=>.C)@
M %Y=9@!Z9(G;M*A'QX]84[PA<4#"[?E#*6<]!N!'&>A(%NFUPK3K@(=0WY5#
M_E-P*QV'J<-[3,=W_RM=\-!S2O_?@]P00@A7,@L#(*5S#'1](;33A1LL*ZA
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M9XLAVBDU#@WLPDLB?(XG<A?0,_;E[T(S/_D4_7E@Y"?<T7GW@MRK@M?K_<%
M% ,PA6QC +@N.]#4MEZH\35IW-PRZF@NAES%EP6+<L'<(_>>?8T<:1[%<VPA
MOU&5B ;'=5\GZLRAOKAYD[TN^]RFK)Z1Q_6@["\L9DWBRP?*\)7+K4]I"<B_
MLU U.FV;GF'FK$31)*?CG+://\;3C54"Q>%XIZ6:UM)^7@LICVP\,?GDS;O4
MY/%QZ/FA8Y[PCZER5@^>0$;MK4^,8GR?"@1S+)N.^'=[318]U(^F?0;]C0W>
MI;?5(8^D2LG/ZAD B#2E^Q!-\B:>!&-4NNBGT50Q7:FBZ4\>76$W9)I^WU+F
M&U":5B/_P[F-4C#6LWF;C9 _)@R 8]@(TXYI/$V!J$'EP>,/HIIML2EGYAT?
MF 3@/DC'SZ;=M& _VU+WT2=UI.FXZ,Q!M$(C:NLJ_(!\7 6 \+KC6^8,0)HU
M?I[">IS_M90TA[S$ #Q6G$*1WM)2H=((LH>YI#D:5%LQ\M>X3D?]N7G]*N3%
M/S"=8@@?^E!T[.+<& #["'W7_[4\;#]%F*I *]!UPH4-GE.,J9X\-<SRJ''@
MFI)S"([K#:3:*,9?SPC2,E1-JAN57VQX*]5SU?*\0AN7(Z<<[(F*;$OZORTM
MVY7GPK)L<B-6)K07<Z.*K@J]X9XQ%%MFYS=@/R%6K[8J=H+L1C$F2W?RSTGH
MBXZ^8&9M^]S8%<1NF7X39.10 V6C^,"[ZZ) \PUT,^?C8IYUVQ1,.>1590"H
M[ S NFT$U8_ L@DDOM*[K$G5*GIP/+)4OUE:UVG^$Q9F(PX5T[84(@V278$8
M,#VR\2$#4)='KWD)XR)+$0^ZLI%QJDD:1I7QWFSSZGDOGWR,"K&^Q?/1MU[/
M?9+S^G$MPQ;)3/3;_6STYF-+'9+;@=,%S4CO&(#/3S\P )$@F@>EZOH$_%D+
MK\&/$1"6:[2 (B+#[5T;<$4I]UW$D9DC _#6&DWS\UZ$*"N:HEN(TIL"09[R
ME83 7-U.N;Q:_T&L\U-5$$:%'N6DP0"<7)WAG%\U"B66^]F0]S^38VX2QN??
M;&3C.[B4K_?X95BQ;NL,:.(+ U"W:/F@%>M1)$$A0C_OWY6Z\1WO&#4@1N5F
M=9@W^=;>\LST3T70T?CP?S5ZSG\U>C3+\)ZM\$+?(-_\RM ,N:M=3\/B*@4;
M#58"#/8&A<5OE/S'=M+CM#FT=;9FF^AZSLZEW[A&^3":(]Q^2>7U1W0X5T37
M%XUTQ0-WZ >E P^ENHG7R5TUXND]Z92:6]8_FQM&$.7E62KFWLJ&9]L4?M_\
MF_QQ/*][OT2"LK"L-1@*H,:GD.3(OUP7*&_ ,C5]TWLZ7QL>+=X<3I6LW;D%
MW;C+HM<9?H,POV#;N7T:>H\(BM^??2KJ/&]#6"9!-9CD)&:^9L3=3(_@30Y#
M8^P<EX^&CSWAY9_W31L.!04VFHC>G4.=I>[J[8/F:']A40FZ3*%2'SUI2?5-
MR?+EA\A[GF&=R)^@+CV7>Y\VV'WLG>8?K/%R@5@&JI2^7F,  C3RBOF.2MYU
M<3 ]&VP!/9;+>Y==M)%![/4ZB9L;[4W&FS?6L:8.@'#/*LU5HY=N3IVHE$@$
M;J$GYZN6HZ@0[":XDQB<JBZ3UB6%.9-L@OT_Y5S74Q/JMPU%*:)P)/02E"((
M6"@B2$!$"%(,B+10HE0I(3] .B2 1Y100D=!B"(EU,BAA(Y2#T6!T(0@4N0
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MX6>^[J^*6PF6\?-IIZ. "T FGA!*3EI-&_IJ96&*$2<A<9\"=;*^ZSG,]W$
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M[-\/[: R24HVH$%<.;BL&(WG-?3"H= ].SMKJ]J6@81@9.(+?$/9X@I/D>^
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M5Q^P*S;A7R*6IAR+;*&DM S)]^W^MC2J#C2LWG"L7J3@"K!@^U!EV_>IT^G
MYOPJE)7\[+NV<:W$&K<KL1_;&5EK:O@<VT/WD_K.#(R0.:38Q)AVONI\68#S
M.</2"-%J0$^0H[8A?(ZQX-OCFFE'%XQ=P.XA$@+?EX$8XT&).<(6=+?I(0BZ
MQ!P+ D9J0S';K"Y0>QM!-=Z-4F)_.%R4XR]NTJDIEQ$E90> "UO4A>UI!MOX
MFQMT:@QC@4=0 PBL.7)GL$,@+E10Z_N<.C9FW,1_^;!&Z0*Z1(HN\-]O!'\0
M*&$0%RI62OS;N%9:'#TBQ KQN3EUZ).V89YH41?2'S8C#0*-&RGP<$&%#2TV
MNZ:-N<6()P5(*"8^)R[F7(6_T)E$ 9148WO0MY:HRRE^E($VX99#N<\P_/@*
M&ADRA+M:Z23]XS+4R0"=8/4'G63I**'3@?M-S^3^8H'84F+%R<PE4XB%Y*[)
M4CESXLY,CSK$@EWEC@Y32Y0N3_DIUU-47!@H(_WA8:6,T8^5,4:A,@?N(J>P
MF OL.-@2/G+,,,NP0\2PL55=P/^<"[P,&F\3<F$J".0>.,;O=PX#T\WH0O$L
M%T49_1UZ**?Z^X/YOM/];G+T"/,5-P5#+D?6CCNWTI8U@=OMY((K SZ0_>[[
M#\9#(-T8)Z0?..(_F@P[ZHS#0S!MZ81\8].Z,._F8B[CN?M N#&2PH^0KW#Y
MR03H%D0$NRP97%M4!2C8U1"5E;6N"_A>+O R/!NLY*LP?9"4?^#8_YP*E/&C
M FE'Q//;U(7S:2[.,AI+1MG72NJ!@WL&(3"@A4V!GG<>QYG&=,'Y/A?.,Q5&
M2W'&6(H[<""['=C:3CC$OC@>4;MF5_*:U 7JA_ST24?MBB.AQS&J<.A"5+0J
M"Q):CX3ZW%F:A',?JP634X?8*G8",Q"L7+"E7:5&=_4%+3KH<IZ"W%M7A7"Q
MO##-%FIIW"HMY=(>:VG<1%HF<KJ'ZVTE"3$-2;C*$G1YREKNK23/9KR+O@[X
M)+9VJA06_(GSHLG92*(N/\E/U=7+T1KOQDJI0_><* .GQRNRK>E"O"RM=T0S
M+ZC7@VE^FYJ0[>7G]++[A2.^&B,[/6ZA515=WI2?+=04:QZ=<(NEW\8"$0>
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ME:.0]30)HG9T>JE(\%-$*A"1N(]7BUKPVJ;JWP(#5B* #%73V'\% CB64'G
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M6-F24UG12/X@UO?Y'_9:"F*SE7Q,?*#%DA5Q]I&SU5)R!"V2.K$U28T548:
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MVJI\T6V/%H1HI\%DIT"W&5Q/@+W"&-U=XGI*3'8>=&= 7YL";J)$Y]KJ>DI
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MN]#W9Q<*F0'PH/.>&4"\?ZE4@4QG5YPR_E3:.HN+HDJ44EV,D!P6'<8)^0^
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M=8+[?145E0OLCR>VC/\#J:+,+N;'4]K&F9HP;!GGHRDMX_P96Y:/PPGMX0M
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MP/@FI[L2+BM?E]E#<*=PF=V'GVN-83!/%A0H8D'ZW\!E]N BN[K,'E\Y5QO
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M*5Z"VD;?T(932[UDE@$F-)/^2Z ;8/_543$"Y;'S_3C:157--MV!B=SLK#T
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M&,JSO2*34KP;)/*=NU6 7SGJ*'1BOR-I('Z6.*AF=KVH+A%-61%8&V$36]1
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M:__B$R7>!-[!A *>YTE;>W5+>5P.WOX9S&1U9QF$&#AQ:S*7@B:+-6KA-5;
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M)I;I 81L& :(H8 :'&:HQ0)-@2B8S[6C@=^ H)@]ETAM"OV_C)%<,9+C&L,
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MI(>K?;Z)C%7>=H&KQ0+SU]=O<JJZ^"%ZN:,[U@6A2.9;*K[UE1G)95>W^A,
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MI<7PIL\?*>R\Q&VQ' LW#I_U%+X :NK S,Y+L@7H7=DHCR.KAD,<B: *IPF
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M[!+PD?Y$?]G\BO[/(U5V^IO_!U!+ P04    " #G@G]6ZN-_YLDZ  #^Z@0
M%0   &=N<'@M,C R,C$R,S%?<')E+GAM;.U]77/C.)+M^XW8_U"W[K.ZRN[N
MF:Z)Z=U0^:/&L54EA^WJWMF7"9J$+$Q3A 8@5=;\^@N0DB7+!) @"9"$\;"S
M718 'AQ\928R$W_]K\=E^F:-*,,D^_7MR0_OW[Y!64P2G#W\^O;;[61Z>W9U
M]?8-RZ,LB5*2H5_?9N3M?_WG?_R?O_[?R>03RA"-<I2\N=^\N5L468+H.5FB
M-__S\>;SF\F;]S__Y?3]]9<WW^[.WIR^/_UQ\O['R8\GD\E__C7%V1]_$?]S
M'S'TAH/(6/G/7]\N\GSUEW?OOG___L/C/4U_(/3AW>G[]S^^VY5^NRTN?DWR
MIPJ'A7]^5_WX5/1%T]]_+,N>?/CPX5WYZU-1ANL*\D9/WOW/E\^W\0(MHPG.
M!".QP,+P7UCYQ\\DCO*21FT7WDA+B']-=L4FXD^3DU/.V0^/+'G+67_SIJ*.
MDA3=H/D;\?^_W5P]^^8#RE84/?X0DR5O]/3TY/3'DW>BX#L..D=+E.63C.1H
M<G(RH6C_-S*?\'IK3 J6;B:8L0(EDYADC*0X$:,\F>.,]QI'Z>2I%N,4E(@6
M%,U_??N0K1XGNX\*T/_/YC?SS8I/2(:7JQ2]?7= #V^3\8+E>'SF?]B6%R0,
M@*H*-GK,$5\PVV'=(4])_(Q0 9;MIC=#\0\/9/TN0;B$*_ZC9+MDFO_C'Q=9
MCO,-7X,1SG:?2Z-[E/[Z5O9SA285LY?0+8L=H?F,'J*T^N;T$;,:0)(2)IA>
M3CGQEW]\Y</&[LCE;AQNGX9A>L]R&L7Y$1S#6HUIFT?LOESP!9L\1-&JX@ZE
M.=O]94_B]@__.,<L3@DK*+KCT^8C;_\/22\,:HRW!Y/37OIP02FA9X12%(N-
MY0F6I .ZXDZQ/TUDOAVB*_Z?QZM17[ ?O'?1?8IT6)\54N$\/!BF-'Y#*!=9
M?GW+Q1[^RQSQL4H^5]^0'M'E\5 "X1\LQ8R_B'F*DE_?YK1X0A'1^,5Q\[RA
M;8EWJXB*,R5>X#39U9Y3LC3?D@B,&OYA2[3D7))$GYUP YBOI-%F8H\=-Y-&
M=:P2G1@P]LYKIC\!2!U@"D[&2@%TJ_=E,D!D(6)Z;N_)^>N[6IVC:VWMEPG#
M#QF>XSCB?T)K<0),#+4O91ONM"D C* =6=6.+N9S/KMG\S.RQLG)A^N(<[W$
ML4RD-:H3E+>@O U/>0L*T A/\*  !04H*$!! 0H*D L%J(&4YUP+^M.$HK2\
M8>'=SC<3WHF,1:6B9GH5!6G*G4X$1Q-4HW!Q%'2/,>D>-]7*OA8+^^Y@7=<@
ME?2I00M!NPK:5="N@G85M*N@707MJG_MJO51[ES7^G&"LQRE*=<'BRB=K"A9
M(0[:4,W2M.).PP(!"<I54*Z"<C4FY>J*[Q'9 ^:'T)0QE!LH508U@S(5E*F@
M3 5E*BA309D*RM1PE"GC(]RY$G4R21"+*5Z)#XC H?N"\2%D;!)ER>0^8IAM
MPXF>8!@J6"V^X#" JBW(H)@%Q2PH9F-2S&;T(<KPO\NU?/84&RE.HRRY/ECG
MLWG-_(%K<;8^$U2^H/(%E2^H?$'E"RI?4/F&H_+9/>]=ZH<)B8OR/X0*A,KY
M/L'9G-"EH1H(;,B)MF>$Q8I2-^6?3P2$RS1ZJ%&B:G^WJ-9-BP3S1B\Q75XE
M=7CJ?K>/Y_,V7XT<T7$)^YB^1LMC85+RJT4L9^+<H2@Z(TD=F+J?;:(IJ-A
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MP4(<4^'4>"7&0OSFX-1X)<8J?#;AC'@BOU[H_-W@C'@BQEY _;;AS'@BT5Z
M',7A%Z>>2+90?SPX,9Z(N1<:-U\X(5X)N5)W<3@?7@FV\(@H.$&>2+F*# QP
M+CP1:Z6Y%N!,>"+%*K-@[-FPGR?F/DJC+$83MD H9Y.JAPN4XSA*#1Z] S7C
M)$>, 9*0]M."KW^3C'\'Q\=U1&>TO+A)?HO2 G'QM#Q1CI WJ-E7CZH#<5KD
M"T+QO]%Q^*9!C7Y[4-KQP.B?E^X7N3RFVZ1*R-D)P7N0&>V:5!JF)KFL2=60
MA[3WE(*04>H]&6F(]7$_,5Y?E$](M]DL(Z^QT.;=1('2HY8$X=9K+VFI$S'A
MA@0O*0&8W1P]37(Z8<5R&=&->'F#X8>L]&H5J5OC6/C]<H23%4EQC)&!F:%Q
MT^X>(VF.+I@CNC%'C/85$D;S [V$_VM/'O_'/[Y$CWA9++^@F@0)TM_MH\*9
M&E7=[]91W0B?K)HI5ON;&S12AFI^'>][,./O04\OVMSNCXKITTEQO3TH=._4
MF%4.EJQ@]5&+H>'UF?#Z3#"'F72^7K @FA-^[+W66\ 4 M?8K3K*(5>(O6,W
MVZC[+5="QC[>+BW> QWZ8/%N^<!4$T'=N>WNIPGZ5\'GKZ%=[KB:.YM;_9>#
M/<VJ/>TCBN@91>B/LVB%\RC]/:(B(]DLJ[=T&-6Q!^_N.S&&]Z*./7C,&!SK
M')IX^*Y(<]ZV'(RL3 >?OWB,TT+<8-PMT.G[DU\NRJ5]E<5\N>,UNDZC3([+
MN'('@*^R-6*\MF+L)$4\LVI+(%XC6CK$\D&XC_AAO)VX<K9 %3H 5J511%RP
M.,<4Q?ELSL4,/G?DR& U.H!VR^6!*A/,-%EC1NCF(XEH<K:(L"!&CM"H8@=
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MU3JO]:1YO0YW-V=&J-?A(=>[)O Z?.NZDG=?AYO=$&P K\-!KZ>+J=?AVC?
MNZA7ZB-H_4;AE3H5]F0'?R5NB(Z\62RZ+GK.9I-]U[[#X]-_L0F9<[Y$OT2B
MQ<J"N" I'TRVM2K"/1Z;M.K$Y;$YL 8^CTV,Y=,DP:*C47H=X>0J.XM6.(_2
MVE<&C>HX-?E/DW\6+"]YOB,2>/7O+MP([AG.T2VB:[XR*IE%I)9[R,I6ROSJ
M4B+<?-9M1H0RSKQ4]Y2S0%K.;;KB<ND(:DG&QZ'6G1=4UBGJKRBO4N]]ECLR
MU99QBO)&7-]D*+F(:,:%(*:<#NK"[J^NF3Z)QXMR?;J+-,+;<Y:1HP7%:CS7
MC>J$ZW<(WMG\]D!XJ/B<WK.<1G&NZP*D;G J,'4JJ/Y^2>CV-)?/I":-#*>?
M7]'W\J=&_7M1>0C]*L6LEL.G;F,PO6PX>/5UW??JV9:EZL*S@GV=Z"T0@\[T
MD?N$@(ZA5^(MU,!;1"]#>4>*LLL$K)5ZYUH$Y<7 9N.=JP:4(X@*ZYWC!90<
M@/'$N\45_/8:W5^H3"JOU^].*YMZM^_J^3#4%;W;?)LPI%+(@K\:U)SRRGS5
MFELN7I>KF=L;O=?E:::XT'K-GE^J"YW7ZKFEM8KUZ+(2L<5DGI+O!@FY="WT
MX8HB 1%2;5E-M;5UV1)>L]>4Q @E[)(OD!L^S'Q*+Z99<H[6*"4K4>JV6*U2
M_,)@W[RA2?9+_^XYNV<;T;/SX(Z<\1G)N[+&?/9]W'QC(CGT]B'"[&%:A93R
M/FAN.FU^RJT;#L<H_D_L?^LH%1WB@YM3'.=<\. _\"%^_H>#DKRS:2$.E'/,
M5H1%Z2=*BI68%)C%U3./*-&^WNX20E_/O[PREGMZ,JA-%RM!FG>4(BYSGZ/J
M_S]U_.*Q\JH4+YA6[YK:X-D8Q/'#J8Z8/D=<#HBK%W$E/-05<8KQ)8O3.":%
M8#G:"(LK'PC^%RZ!)I]Q=(_3<C.6]*9=8P/I-S^G$)]I<@<82-6^#O>7V/@,
M(UP3GN4+1*LWF,'=>EEU.-UZDA"V=@"-)&+>0-_]$Z2?%926ZIGYPI/4;_8"
MJ87^75.TBG"R>R#\XE'8;L3^T&2B0AKK:^IR:;=.PKW$6<2EX4,)5])=> ,]
M'7-P@)I%VKRA(?3W*EMS@:7%B-8T,*P1K0'8;$0!#0VAOS5:J%D_:QH8UHB:
MJ_3-&PHQ'2]0[NQ&=V0:<_6&\J,LYYH+%I*RZ@34UNOKL'L!C,\3/C/RS74:
M9;D(2>=_+:U@T)Y)&^BMBP<&/G%;)UYSFLT//-UD/8/6&T!B24D7Z@M/3OI!
M/MZ($;&!7@IK/SQ01%K%A_B0D7O#JD;GE;A-AR2+2D_%D&1Q ,Z: _7":"5-
M^\)6"QXZ]FD9RP)33BO[]ZZ^3#RK3!V,B/R>Q][,7"-Z3UR_!^B*4)@N\KJ\
MN)M><EA8S!\JEC(N].3(L5M; QJ4) )N]RPL8I\8;'0_8V'M^L0IX'+6EP@-
M6PL:[I1@+Y2CAR=[NZ83>-5L+\@C)QSSF#AL?EWDRY)NI1Z#KP\]$VQ:T'%
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MSUMCP-R86SWL15@,F":]"0!,B_&C&0.F177S 2;$^*6+ 1-B9!$%,V3\!,:
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M#,D9WY^$@T$8W":A\_W:CJZBVP3YT+]L/Q79+3A*N*>1IX$@';AAX@K'&]C
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M-H2PACSPY=;F(%N;RN6V*M*?L\7R$KO>SKN]%0]\5AZX-H2PACSPY=:F6?'
MM1+_S[R]%0]<5SUPM82PACQPM6OS\9WW^#X2<9A&CHAAJ?#OOK!=&JWKW1];
M?[.LC_@!_FM9__U?CW;C WV7__7CT(J3D0\KTX5'UV/O+_'>:C:&R0=K8$<]
M+WAOT1_T:]<>>/[HO74'Q!I;E^+!N@D'=O!AZYB?__'=$)[\L1^I9_8%)LR]
MMW:&CQ\L)_3#Z+WU7PWZWP>K8SO?>U&8!FZ]^-.#YR9]'$?C'W!=&,&TWEM!
M&(AL5#O#Q&IL6>_*7]A<_@L;\'_F2_,+IY;FO_],P^1#88'XRQJO6\V*84^[
M<DGE@N^.+3AN<]WVO1Y\@5GH(H)E_M@Y_G9Y<7=V:MW>M>_.;F$W.\=RU4O'
M\S^%D?Q/81#9&&@(<@0X ./]YNMOSTZ^W5S<7<"[VY>GUMF_3_[9OOQ\9IU<
M??UZ<7M[<76YS#$UYAK3;W;<]X)>$@8UZW3[9-MJ-?9VC\QQ9 12LJP_2C.'
M$TEFW[+3))3_^3"-;IZV3SN3U^3\ZN:K]1&8 HSH,AW 0QPKL)$#NL)[?QHZ
M*7)]3!_=LB13N1'=,@;;;%' I=FH_TI<)GO@\2M=XJ.)5.>+;L+K^^:K'7UG
MKG<5B+?&0B1VQQ=J #P!8BOT&"] J?*^\>$'#@1LF/#]>&@[0/2_;#7X[Z'M
MNNIO7BK\>/PQZ80NB*P$Y$+BJF'=BRC!KI]R6DDX_, CW=V&I=Z"C5W=R55K
M.(LVVT&0VCYKM5O +*.!G?RRY<%S0'"_[X2AW[%]/X3Y/<Y)PK!=K?UFZT.1
MC&GC/KY+W+F6Z&AON_5<:]0Y;E]>?FM_L6[.KJ]N[JSK;S>WW]J7=];=E06<
M^ [8+=-@<\>ZNK&:>V_<M];5N77WSS/+X-2:2[=/[N!G><O1SJXF6Y[].Z 2
M4"4DR;PC2EZVJ-LO2KJ"\K"RLYOCCF%D)7UA=;T8MM@:"3NR0/,2[FR6R5KW
M&:MI.;I\[Z+&#B/IN_8('RF".0GS5#AL!>PT:Q;^,$ZATT7J)N_%U<T+S:YB
MU,MAU%BY%WMH>RZ?63<V@%FCO>UU1TS-=S?MR]L+9,RKY]G/(7] CZ21&?.Z
M/KNYN#JUSF^NOO*H7NK?N*(O]>YUD)SE-N)L#O[$]Q_-;:.>A(.!%Z.KRCKW
M@,?"V07I)@<VB9V<D7,%K^?+Y^03#42K/FSM[DZ1F6MOFXQY5,QU;XU[8R8M
M_&<1#"/Q6+,N F=[B8;X?)+\S=FC[2065M1;8=?B4DBLC[3LV+H="@>]::[E
M!=9%$ELG?3N"6]^NJQ%9HAY(_Y"I(,!^/!:\8S]\NNK(?N5.RV\BGOI<6H6A
M2BSY]&]-D;D6"EVUUGNX3$M[Z01)MW(V-H-5P1D+(U!XR.U.G=2HAULT.@E=
M,:X$D4-_&(7W^)P%3 /??@!38B)WFZ$*_7S;<F<_7DC7/4=$%A(G1XUZX^"@
MM;-[,&/%6>)71^S']O(-G1L+S/$0[/'(^B.-O-CU'-PWE"&>><;HLJAG!]Y?
M]/?;G_@0O+G8OMF^W;8D(FMDY6E>JES%%7I=1*LTW9?:>_/]DPR 2HM8%VI9
M4W'5=MU(Q+'\SQ<O$,TY1=7.3J-A?1+".K'O!0S;=JW_VM]KU%NM6;+KIUE^
MPQ9^C0QPO4GZ!!L61W?AP[RZ;AL=:4&1=FN3??*YUY$F<15=@X8-6L/2%/ [
M\6C'U7E:<.^O0UAM__]Z0[:%YEKI@\.#W?U*ZWX.Y5'N$FK8PPA.BS>T?4NC
M_,/7" 48_]3Z-="NA<1;KD+/Z>E]DH=M?[*'+7.I87BDT3SZ$,,,?#'LAX&P
M M+Y:V@T^2GJ<98="1L.GPM3?S/QX"*?;L.%"QS5PX,Q%>/M9#;])012N<8A
M+F2*'QSLUG?W#XZ>*1@Z/VW<PCF)O,2#QT<:[LT:IE&<HK,S"2VX@JRP9NM-
MYRV>,@PVMYWD_<RQ3W,$/R4 L,H@Y]%*8IR=,$G"P0>^K<Y_O8]#WW/1\ZO=
MNC+ M[.WE/"><?R:DX\?P:CB=@K;Z5N4=SLOBY2SDCOPC&,N#5<M:_$;S[GX
MD8TTM;3PYWQOO1T-.J'_9GY9^#HW^CE/F8H?T2$3CTX?&P-;P$T?^AY\D['<
M";KA7(D!SSBC26)1BI%1L]4AQC*G6,3@*BP&8=;6K*$=6?>VGPKK[XWM1J-I
M#3'9O5\:,5A7XAVSTN<;WS-RGTE;*'D2,XDY]^_SY?6_7__>/-OQN@/-:N81
M.Y-<!%G+N&, ><Q"/H%+.W;M/\>RH4_LH0=6KX6IP2)9V&9@)6\GI^3E53Q*
MRWFB;54F(Q8?@<IU6LT@QH/X4:_SIK6W5[/4O][.*$59E48/FGPOI\E;V!=O
M;5=RV?;0/A:^Z!5448N=YO9><5FS;#CL-N!@=*\SLIR^<+[CT[Y;'J]AE&6'
M>+%E6P]@-M2_!^%# &.Q8UA<%WZ(4S1H[=AR1=<+.'GD)O4%SWRWL:>VQ-A!
MV)UM_OT_(M8Y6Y1,.%<*TF\PDE]Q(+=R'(3N/:_5>AD6^8(YA-;*$[-6O5-!
MF, W?Z8>GA X&%U,\(HH\3,NLX%UKF,8R5S'[!#]T#;]*_33(+$C2AF+XI]O
M>Q[Z@F+F^3WBZ;QION4/?3@[N$6N9?N^WB=S SM"7@!/G[5GQBE3(A7W$7_&
MU%3+31'KGBX=1L(1Y(1JMOAYE!H?6V_@H2"!K3@%93[N8\UR9'&9(]QH)T6:
M>[#C<8*CF^5LW@*#"%SK3<N8<@>$.5S4^0,FA#?1]7 GCD<^#%.78QH)#=>.
M$^NHP4]P[5&\/1<1GJ11!,_AQ&?4!!,[2>>E1:#[,1U"T2&__3+,'XR-ITX+
M-P?V9> E"6RG\&%_HC! -=(?U2P!.N7(ND#!;#ODBCZU$YN32 LTFSW$9#IC
MLN%&]%+?SHCZMGYGO<&/!Q]:.ZUM+4& LP$]#RDA\3FHF(>OZ5+$;^<C.&-M
M<&DD_54$-Y'@2+GPX77"LAT'""ZRD6APS5&S"$J_Q?S0>ND/\0 H%=X2J1,/
M*S\8VL$(>24\#=@*SJQG@1[[D/35K]O .@4-C109JI:@\ O[\9T/DT;(O[L?
M](5S7#)QC/I*Y)?JZ@DCUM=*C0L.0*?>4H+ Y/[;3]2 ?\R:F>7E_N$LF_%@
MU--<W8L>G<6"D]+J5L&WG:/MG07";\L)N"U@=,G"DB]([;R#!CWS%T34[^<*
M.Q8FW]R F<_O3RG.;G][=S/FEPF.:O^,V>WN;Q]LP 3;1?E2[>383FX$CRTY
MB4_-GOD91-(<=6G1"9R*7AB-2ES(=!&=%T=>-+\WN4S7+.KIE4#<:('8*A2/
M5GNYD<+QEBTKGJ<VK_A/:3=5>[N9XG(&_Z>=_Y3&7B#B^-G@:"J!O0J"?-W'
M;6/$8K5[FRL(SZ33D"?*GL-*#+Y^,:CV_3/M^ GO]3.+PY?.HUD9P$H)[.HB
M89'NE/@#%@7,&>/'"!W%Y< 4Q6!_$EIIS+$+>"^CI"4:\DG%O# 6AN_R1_CR
M!P]>C4&1 "8?8B3BWHO)M WLP/%L'R,="): %V,30->.W-C"XBS/+<^E5S'I
M-_;;TB!$SKZ:0<2/&605P[D] P6ODE2>)VPKTPAD6 D3<C&,9"<)854C+<!N
M>4D,#PKL'L77LRH5.XY!<<;OU.Z);E=0'#.0E4AXJX?AS0#H Q<\"GTK!*YJ
MD$T6TDIAEI$NM-AM[!J5%K=VU+'AL?6K1U^,*$/A37//^K9]B^BP!ZU]+,MX
MBS//IBDSOCH^$(Q!G%TO&G! =PCOMO$BH&=*3')IQ';J>HD<U_;D3,0+IQNU
M\=(P:F<K=N[;O6> 2]MLVJ,(;MP7OJ]CK6\F983E@I2P[V^+*4:SS#Q\S0K$
MVOC&E,7;5Y)^]./;A2FV=J\'6X)[-J#L5IET+E?Z/J3#@OP (^?R3X<SU3'K
M(1E9L+*48T2A]2[FXL#38O6$* <6!5_^;QH(:Z=1X_7!%>5/F$AA#T%2/'JP
M-\(?67^7>WI.>1'PPN*F7M.I/O=#.]FR$/ 3?MW? @[B\=Y]NSW= G)RX(%^
M3(%<$]4S2 =NF,B?\YMNMBS?.M[7Q:MJ)'*38?=\#\&ID7S3A%.M(M$%EA,X
M KDFKH#CAS&NVA"H0XPO2\9*Y;+&6 " 7%BME)4MTAN\U\>4IHYT65BN/1I_
MZ/\ LPYC9%^8#0MK22)<X!"!WL/ 50BI?Z82K L>\??F]LX1OT<7&U".9B0[
M4.#TD&8X3;J0%EV>+?#2)-XFFH,1.GVKN4=+N5/#Q8J$]8#_FD5C7)5!11FW
MN"#Q59J08@-;JHFN81 =7662W<7E^6*$MX.=1)M[6\=[S=K1P6ZM<7 X@0!I
MBTJ.VB2:RH:^^MV:FI=]>G7R[>O9Y=VM=7%Y<G5S?7731O#[3_^Q;L[.SV[.
M+D_.5I3]/ ])T3>E.>OV&SB.\O_?:K Z3&;/OBPGQ&M4;V1NT*3-4BE$]YB?
M%CZ.+-TK))?/24IX(6L3.;16FS.8QAHJ-;=G)S7,2XN!8<MG4<(2,GT\"%@L
M;J;:Z<PZJ[G;1C$,%!I(?4R_NVS\2+LR^8,POB67%(*D!KR&R+ ?^J#AP>8
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M<E3C%?RAE ?3BKK6W;?;D]:V?E"?H  &A'$0NL L!\"7;. Z ]7S!=<&(R/
MD3P&,8JB=(@F-,X&.;=-ZP6BH8\VE'0MD1\!61A(6NVI 78+YKKL"I1)*L67
M4:3$Z/8$IB?B[(DHV&V0Y4D8>W%-M@-!S .<$ W#A;WIUVA/<T_$E\*\2/PI
M1PJQ9UB8(6@%N+38%2S)W9=?GHX0P!KZV*@'R* C9(DF"EMT*C#AH-J!XH_)
M!5]++PJU=B(W]3>A>+UQ%J3D2 /OSU10PJD'@@A70(*OZ_'  -"I[*'D07HD
MB8_+(P6S5'.( FL6_]M IE&P$SQ9N3[<]8Q6 -U,Z+-&QY*J/,MFL+9\9\W9
M8MMAIR3O],X'J_G> CJ0"XS>4=+3X&SX2M33YLI3Y67]UX1UC87^J!BAWTW$
MH,7R64+?F3Q3J%W09;*UWKL6?Y##J#?YSWQML<%S"M?1S]@.#1E%P76HR!*'
MW,:4RO\+C,:QK6O%S9"L[^Q>Y $;DDR?,S,,8L6S66=+@.B6"9(8$W(_7@="
M2,%-4)W$I <T$N@R#@U6>O;Y_"9COH-4]J13_*>'+)'SP<B=JT\1C46-%?4V
MN6II#S;2PD!8+8-V*:S1K=U%C^,-UW&>A(.!ER1"9(/2UUNW-Z9H4"$BM9/*
MVL'=19V3']_8;NSSIT'OW?>>I 7^INM%<2)W-.R3"[J;+7 2ZB<<37I"C*@P
M[L1'$"\+P*QQQ* #*U98"9C/[&E8^'[+?+7%;[7D"X&O-;:;K?PE#+-'E:]>
M0/CS??(02SLRZ:?QS&/#<7WSX3@H'C[U-J/'<5<^^3"5/Z1G4'[,:!))ZHYR
M4B')NE(%P Q@FF +(AH'RS'?#Q_4ZG0]&O>$6$B;R%,^5+[2&!]!!8S0W@P#
MCD7DQ &UYQ(#:56F ?TJ7+TN-2M'Q;2+V+ 0Q+_@AVM!3%<.[$=OD Y@JCY*
M;Q1TN#)OMK[>G6Z]M?@@(C(QL$-7,JF6NN;FN@47T4+3.^"!9'DY@LW,T%CJ
M1U"EXTDK38WTK/,P9*HX1>6R+6U6J5/H$W=^VL[.&3*3'C7G<ZUS&X[S780(
M;:=D>/*-:M7&N)]:UBFL3W$-W'EF81F'ZX?P]GNA68]P)>?1-^E75 )V60*V
MA0)6<K07DK*M.:5L:S$I^U5$0+C_;0^&'T#.;&=2]E<Q2J+4M>>6L@\4NG.]
MF)*=\82,D6A!.*I7;%O7FKU&IA[#)I;B-9KU-O8-ULL=)77G/I1>5KG4J6$+
MWC\HC!IFRV5-E+5;QC4W)UMO-99"C=E.1YA#D^!*:%UEPZ(HM2&K<,4ST4'.
MG*^$N09"<(>#TI+EF:RC19"O(9C .'+5@=  C]3KJ@E.58QB"&DH30J$;0L9
M"0)ST(CQDBHT)J58#'6PI/R[DBY,4& '"E7!AE-% QFC2["Y>/8$-XGP@GML
MMMA#-(KX20*1B7BJ5)3A6('9MUU:P()$$+!5*4;6BZ=Q#LF@B W$$0HCE#A2
M6)RVG\+]6PMP?W4L%N+^^J:,^Z\YDUWSX=U-)93L:)+G1"DHDG8"=P:=98J2
MXB1P8&,\1KBAA<>EPS P%3Q]FI$6*6D,+@%ZDJ4HS"B(CQAD8)7-ARW_&,0$
M/<]V[V'AD*-36@C' V(,4K-61<XWW0B*$D2 1%W1I;P'SF&7;NZR@,GXD<+;
M*3[.AQO;1V6G%EX$@LX928-!%M'@$]#U[GM]5-MP^HKU=E,?^SZ[L!)_&4HC
M,RYVT=-JL]8\8X<H*X:5Q+4ET34_06-:U,Y[%'B78-EEAA_*/*!K&4O*R)HS
M()F659JTU*+>M?3YV2D@FED8..[)LHQI//8SD&^ (1-N3F\X%P3&\R/O3ZGW
M *LG\'5!3<UT5'%,':(4*9+^K!/%Y* E7Z*?9M[?S*MP6\][=9&UNQA%"S6^
M@_2[CCL9T$GAW>-YU\-E ZXO!J$:HJV=U3BDP+4CUQ .AE#&DQW*H\7ZDSJ]
M,,MLI7/R-K/7V:A&OSJ.3$OBZVQU\JH2K5;.V-%3 +/2\[4&:4X[Q#Y4,G$>
M\\N3\-%S,+'0HP[A C0/;#E7B;P?%GGDSF?_/JRM] 78E$3 *<H4?K6D1(I)
MS[8C<NZ?]*-P$&*JJ+4CK0&F1>KWA[8(/M+!8DI6W_!,BT?09NG</(21[Z(J
M*2NF,0"/KAX<U;< 0^"QQ^KEG7@$XOYZ:K4QCA;#6&3XXX2+LM]L&;]MO1WW
ME)-#$-^NXNY3(^Z8[QH^<-3 53_1J@0I,3(==ZAW45CBN91A=MNG%8Q*@T.F
MZSSSBM=DU\4.AEXQC#)$>A\->?7EU11<CS L*^4T,1VZ E-60QJBPG$FHP%W
M'W:9+Y=V6U:O2I:(Z9E$MDR+J3PJ0 (8WPCQ"XT4;<,!%9D]9^Z(A)]"\NBF
M$<UT&(FZD:F1NI*BF.2R*KH)$?^U/39K<*JG910M%(P^5?D1GXT@ZMP!Z9][
M$Z8-#XY7EJ[Q(-B(T[S/'RF>YZHTZ"+/N_:2).ZD4:^O[%3T5(3! P.^2TX%
M/_T36! <HC,W=0H>S$D/-(,;BM^H9!(\HI%0+OBP+#G(SN=;J6)XY):D1.,)
MY^0;DO;YW!7#@16#R4*/0O=V$*)3AQPN^ P/;13VA$]^IHHJVYC\+H*P;@/W
M<#S2.A@T/PN?M/^5S?I>4.3'S)I"EYW[R$__:G?;4NJAK6>F-+D>:&()F4DZ
MGXD,%91WN K$5_LI4!EYR%'\P>@Z:'@$$F_7MJ(0Y&- FE4(O)O7$+29-!*%
M-*<2H($RAYDRH=@F"X>)QQ81*JTPX"(+EG;9)/+8EOD/+<XKRB<]*#]'YMC(
MMD8/FQ1N>L;.8L\PZ,0<Q%A^U\8F<^56Y<<RMJSQ9*V\CD\Q+T_V>$1W0Q*E
MJB4%16ER!EA'8#50T<-F])OCXHA>ZC%VM%0(23'G5!U%7C0N8'E#WPX,<.IY
M5 XX)/41J!ISZ!Y3.::B,%1!X1>]Z@'J<&%0IQ,*V\UM.;*\FW]>&[PQ=-G-
M7*!,[H:M%QI.I:UX..9F&J[+B")Q$SR7L!CGHA.EF '"SF#)XS%Y-:,?/?T,
M90BKK_@(R\S0R6P>?D6=2I#GTF0%-&I:#IBSG.KX0>8G]$' ^$K/90LP4_*S
MTD:]SBW%8)K[L$\7N,.L!<-%)V'0%9$",VVC_PD[A]^9XH=C$W>9BQMW4^LI
M;]IW=Z>T8F]Q I](E:F!^@+2.I !/BS3P2/K4-X6\@X/74M .KP]JBP)<W*D
MZUT[]@.@"3A<?1NXO6 ?E*L9@JPJDT5JRD<%=GA]")8JF3(4!:C)!!X9U>[Y
MJ4/6$04_<?*4I"P3SC +&=6QEU5XUR$K_&GZ;N?XACP*8,9I/26VZM:Y:JT5
M+[WL\^=9W(6,B792A[-4_\JX!U=8\(<\XYKMTG6Q*M9[,Z:FQQK.U.9A;9(8
M#:PS8%,@#DXQK0$S =$L:&OY^089GO9+3KO4\%:BS/W?K]?6K0#MT\.^E=87
M3 Z,L7@%M948!;[#;^!T4RU7\_>IAZIB4ZVC]\;?B%F64IU!+9_I2^)JA(J^
MI-_#>H.*CG[:W=?L642E*B3 $!UT-[%IS->M21$.FTI6#_Y7NHQB8-KD9(D$
ME]?&?>#<65,=LLJ 4$+G>PW-/%;=8 E@$7M<YZO'Z<D:WB&^Y.][C>V&!33E
M,U(0-^.A(&)/>6S);"3-AT3%T!YE%W"<?^"QQU1@)2M;;'"U-101\<0W._]X
MJPS(7A3&L<0>D-DS&H1 3@HFZXX/1:X?_CV57%CL@?C,@I88;W*-)]&N.D#1
M<&@BM*-<,6#IK'-\*92MGLW=3;>M-HU4YY#M-)GZM6E- ]^I'1[*/+?)F\3)
MP'IW J DO1A8[(W_3C@CF<S11U(208_X^VYM;Z=5N:6>0Y+<B)ZRN4_)YM;2
MI)(B2Y BG(/"9VA'YF(^F+D6-@(?YKT>FH]1EKSFI<PQF#T[P"-=#^_/&@G6
MNZ$C73DP@"25A@!GC% KPQRKQ#/<.*KMM7:G\%DVP0A4E<$%ABG,!V-(S%GG
M>48-^;L*&0JWA$O_O;G=V$-&RD\A;WQQ$-A,B2PVBM/SB-@&T<-CO %@QUY,
MH2P/BPX\9BD4Z0<&GJ)14$.3$I;:VK/0!HXSSZ""BU!7TJM9- 3JV2(W\&8C
M&S@)$HX@PCQS_ Z9?Y['[6SO:Y%DJPQ2*6-BE==)5[L2S@X=G.38=%GRC0QV
MRAZ*$1O#<@ J<4OVO\4YXDUZ&E)8J?7;%*NHPE>8@*_0JO 57C6^0NZVI16K
M3ZZ6Q[P0;T@>D^>OF%]S/:Q8IEI6.'MEU@Y[,J)@>MBSB(=*S2B$N<TB,H1"
M-_SX0\[\FJ.0W@AL:\\JIL1DL0T2<+XW((5B[!VZBD/&%:@20I6/CL5-S/JW
MCL@'=?+U=QD: "D9^%NA$(]FQWF:5)D)'V@P:+=X02J]LD971M/QJOVY&#-X
M'/KH<^^'#WI\4EK./<#BV##!CH+JH)=YLIA>NB,?>+W4"'#!\,VYK(3"1F-0
M1 1]=OACAE88)5UX<,AY5P50@WQ84!8WLU][KKR+;8M!#FP)%H6[G7NF3L90
M" AR2F1Q%N@@EWR@*2P+I-4R;W46K6+5S:BR(8TM3@=PU#2*0UE3GJ'D2"^9
MD#3/X2]16B:+?*6*> .,L"6_;*E9WK<:OQ_N-;;_&/9 1D;.A%_>'1M2:M:K
M)@-E59K5!,UJI]*L7K5FM=JW@BYU@34CR,O0VM-9NYQ;-X=J]3(+\7*0(Q^]
MXY-,:\&$*8R ?E4%PML6.J7D%2K$2/9M3UXZR"[5=[&13%H+J@SR^1'&KE,*
M7\H +MG-#P@J_0?FKO@$[:CS,]\38L88UH\$M">C6Z5 Q)@^WT=_/4,O<":%
MH@*N:H,OG,@C1>L#?S455@AD_8CR6GR1M<\@" P\CWG,!LIRX)X:5.IEO&H;
MZVJRH7A<I$#>A)@ ?&2F1E\,2*I3079_%'-R"TV&M5EZ*E5U9<YLB<MP9[YP
MXBLXQ2*+PI]>MH&F_TPI<$TYK4./E67*O[B!GP<P>2?ULT6ADB14H-3>8GJ[
MP(0F!MJ@"5\4\29P.&HKC=ISBEC JC[TA<\^H<!.4E2Z\CLCJSP< O*H<82%
M(L^3KU(J)P*$$F(J.N4Z,44@SK.T&5  Y!;&EIM2E"0;'FJ=BO[HI:7D0F_B
M@Z&\0':'CR3M);R,J]BP.D!6Z0^Q%4($KW#Z-M:@ 6/!P'Z6&DLJ6RST&3/'
MV;4=A*-%_9]H?D!''O, Y-,[(Z.K2]EQT @B8^>BQN7C7M#W.A[=+V<B'YWA
MFJ@*/0HS,2(LHK:J; JUD8H(R2>GH4HPKTA=F<LERJ6(,!*)YA\R_0"M#_;)
M]3S>&T]3IZ1\U-!UO03:<AT?JVSND3)4BI'L*IO#-UE;'KWF(@3-BT%(%:OD
M22ZC6H/AFY4D,OU[0K*TU'$NP\Q0Y(H4Q9<DL P'RW3]%*40BL!(SE-P-N40
M0+DCSS8P_$0F\)JO_)H/K\U&O"8(]!UX\F FL$%&:BM78Q<H(]L8])^/HA !
M-:WO7F#'F$QY5_A&UK+_-1JHA#V6X03@ T8^\D@ESLOXHADB'H1N%L#%$FR6
M<R1.N0^$]68(4@C^B4;L WHK<]/H6V3/5+:LJTQ@-P($$$<'AAPX5TD0)+\2
MV?02Q0:U>K-M_8:"%Y,@/I_?6(CS#;RP \L=JWQF_*%&RA1=PMJ"&'3@O]F#
M:84Z-$LXK3ZG;\'!PDT*,XYNZ1OC- )Y(Q0DDF#\0[P&E)VHN">6&V*9&;M8
M[#0)S162#Y'H-7CM V9O"GM@"G>N"]=JUF0@K4P%H0NE@!J#T]JFY9 C<H#O
M>W HJ-B$RT& [DBMP>R^%$6R2K6@ZFU.Z<"'ZJ^[7?W] R%V%+>;B-"C)05"
M8=4C 84*W@_CETHR?*V(%D?&82\4Y6K'R>,3O(/7R3'6"#Q,24TU;G+\Q4GJ
M?%<2N63\&B\+5\Q(@?=#ELRJS!X_9FM9B<.E6%2XT!>LX[!#$.VI;57K162)
MCKX8)!*0,Y'4>,*U4J>DLI19/20_I8YK'AZ-\IZI-_C% !2@>V2=UZ?U)FG2
MUQEDW"FBQ=49(-#.(*04A)ZKR^68)R@DO'NBYKM\XCF."SVB*O Y-7\<!O.E
MR6^5G V=T3C$3*^;-@K#ZR[]OM(LPA?#YD@\(7H@D#Z_+L.P&Z(J09-03<H)
M9\ZP7!68*#-ELWWJ] 1YI<3R>G->%O.?S+*29;Y8 &&3C2#O!8/0^3X,/=*9
M2!T/(WEQ1S".(+QWI/#IA!R'U-<+ ZAQ(<NCC:D02!R@$3L:%$/NG0Q;)XF=
M_93'_P/##O.1,Z \O7/IL"X-8.%N6[=I!XMU*8-:QP;T@@]%A!IZ%C47 X%'
MJF=U/>%3-CD' .H:,)-:+7!%H%3Y*,DB\6#9=7:^[$B',Y,#,Q=<T3-.(\F7
M*N#-N07!W7HGYX;>3#MG-QF$IAZ>;1;ZB:0GPADE(5426'=U?S0 00'?"+.>
M1QG/NW043^Z^M.N[-5:%>):2)$II019W4+.,_$&G?03IDN'$Z=-I2 !*/<2]
M5F<T=RJU.L#VZ)JSW#4?'DH$B1MY9Y8'77*8C3QL9M&[M&/'"]YU#0@YS&1Q
M1!Y=I48E\T3AW&$IR,-;Z@NWK4^2C_#57$0" H*!,20= /7JM]<LT*FHMK6/
MQ),99;K"30'"9DBQM4(Y/\JZ[QY2*6=3C23-<O)/G"M'YF%C"EWL11RTPN@L
M8W=4YOJ3K3)$D(I%,DX[L&=1-)*H15SRW0D3KM54AH6VR6I%@&'Q"#RC><28
MYUD7(OC0:M(K5::<4A+(S<@56!S2M6)$GU"03&S'%"P,@_^]V:(K[GZ]B!%'
M[U9B"H(R#JM#@D,[5#M>]J>DU;RQH9]48UV\X#] '8',09\-!Q8RF?9#M^-Q
MR]7!C[;U<Q4"KBQ&,[TE)3%P525JV,/*%Z)FJ1]L1,ZI3R-FD:/(0-C!R&&0
M9SW/K/N53D$(:QIS#S]%#N@T->L"E2V;0P*>'X)*U*W.VU//6RX9L7GPCY*#
MA]]0C[+V '&^;3X\9REVW[4#:C.F\"WSN8T[C7\@0>XU)CRU'7O&_6QG9GI!
M_D2CQ@R"8 !OE"K5=%$#)CS1TO2G:I@'I%2NQS1!::T LV3AR.?,;7PLE?PB
MP&E6)XQ'3!_5#5-*JHC_A(C_;A7Q_WDB_B]W'/\9/J#L).7#%QD;8;F) EF#
MPN6!L11:(7L02YE<"8_+.D/:<9[AL3ON7M0TQR-#'F\WJGH130,C9[E!A23\
M?<6'35@Z'@#O@<2?@$<@'YTP+; R0X0"F#RK#6.PZS:\7/M*--,M&_2]G@Q>
MY^@+]SY'&ZRUPC9VP3@C>[Z@\(UJ(#C)CXWT0$Z 5#;T<!"[*L*X*$4\R-1W
M+>IEP3I#$%H^#(03.H:(-ZZT[=SS.:@M@[WJ#67 9MO6>>9=JE'Y2&3ZF<^_
MM+_=M+E,O6:@('1&)CP^IPE0&4F0U2R.8<=1%JX1)\J4G<! G(X+:E+S$(YX
MD/25TG#.:$X(!%LKH.^I<"*WMF#'$I;3Y,P$F>X;!A3TIER"G)WKAD!N>/@T
MY&.<1O=PROR)$ZCTZR5[5Y!'DK-=F4[(,PG-PNXQ6U9&$'UC5( 9GD^"C\,.
M(0'!R)$#0OK+T(:4D/,,AY,#![0M#-: H(EL+(SB^"(3![DYR>5'5G,><O'-
MV>U;G<_ (,DQG7'VAF3>FUL/\W;4I%3%F<1NYD/*1^H>P7U-+5X?&8G?E!\
M^Z3N)ON?).ACYE[BPJX'NPC2G3L1,C\^ZH1#2I-B[T 2(L=S*6<#%$'"[H]S
MP/WDS\H/0#(O-U4=<TQ,[LRFYP6CJFT>'9Y'LV,-\U<G0R!'!S<%QNPXZU'
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M<\Q0\\^$2O8JQ7&^#:R7M8%5BO2\;6"+\*)OO+=9B](5="A]X\$+.(Y)EV.
MOZ3E*%P&UR%WIT2A7*% (6$I+G0@S7J/LJU;LCB>]-9XRF&#\2*!C\]*BO3%
MQ2KC3/]-S%RF6,)Z9]4M^<('C0REW#S24 1MH\ZN*V4G4LV0]M=RA3C8AL:;
M*-](2N[.*,.@1)]>&,:ZM*+8JE6GJ55J\(^=NYP)G>2[""@"P/,B^POG6L@#
M560EX[D6\CSW >8)LNI$7>9U^A_CN\U52?Y6.9:TDYAR=2*2H5A)U!.Y8^(%
MV"9LK&<])<7E\AGHX,:%7+\3,Z.,'46^X&P'D-V@BOC8#=F$_!Q/Z+$YD13=
MR#5IKW&L%RMO:,#NY"?D4DGEC+/[2-OGS_#4%";HYR9OLC]982\1>K+\:F-_
M"[F>,D:$< 4#[R]Y\KP(6 -F<J/C6N99)HA>!,M^1X>]XX7#.,,,EE )W%G-
M;"N ;B%B5C5F)X1ME^M!*5^D^PKH&AFYN&1K:_B'K"&=+>FMV2#(J!T)V^ -
M)&>2SR5RI0G(W2ZVE3!6,M$-571&6(Z5LB^-4E:,#!A/(88K1Z5\8@UT/\*I
M-A+3C,>1_E@$*,_1+UD)VKT>2 Q!E&X]4G$-$'-:T/^A0D?%WK_JMV:1,B.%
M1D+A2LRPQPS"W$CKC,0 V^>I;'F5-JM!061S;5T]8C2!P[B/IB])VN1;BX07
M=&763W[XLEDW#EN77!(J,&5]4NE(S)C'9?-=6Y:[YL,C,M']>W-)7800'2MM
MAYQ9TM&?\73T,JAO%:O-JN)D=2C:'-240#*IB%UML@[(4+>(82LSKJ![<;$M
MYJR3(V1R@W958;+^+>U+F]A;;W3YJ"RS6GI3>XGPN;3.]FM+W&M^]FYDY-KA
M /#X0I?'7'2W,5G$IY(:F/RH%#5 ^= 9#>TX([E"[)H",E2L@14"F.6)J@8I
M@Q=?L5&;\>YBU<,$&9I5A1B'CT:''(#]691.JLL@"D,LMPE ,'(AM&08'5V6
M@N^F)H=1MI)R=2JJ?.KPKAA]2:<*$"$6&@^@-RL95Z >D(ME+<)9GI,S*LO,
MF=IB:U+Q<\9K>/&NQWLAE T)7T[,+C>",E P57*/N?ZHI-:)K,;&ES.DQR)$
M"LN 1A2GO1Y&S<T!R5.G04N-MF+&2,:6C(8E\=BT8:V5K5)7WLM@TE1YH//E
M@>Y5>:!5'NB27=1D/;, ;S/;8,1V8!XY;^MLM_78,LWCZL_\^NLOX6BII&X=
M*U/!:#$E366)JH!7@ *#@26)J""9K0G'PYG\VL^@,9(P9?!7,=(]$Q.O+N_6
M1DEL6"6J5SSC#^05.]WL34+U@($E"^MK\GJ%[I"'H"$?;J'N/3-Q6.QU?3!#
M;,[?-*P+H\MZOF22VE,1LD+!9[U$J\*Z&H.!G*)\E"@35-!E)#]/P@-EP(0^
MJ;,*]XNBJ%W[/N1J/(JGJM_DM?)I,@-)#81 5YPQJ<YJ3TVK1+(@#-TDO *9
MM!^/7!957,RC?: 28"H>P9<\(/1V+EJ)-?"5#OS$X5WR4>93JS@#I?00FHL^
MFNSPI,INRE!&XSO)I4=HC%&=42%9@=%Z2WI8*&7#]XW>L*JP-,OT0X<TM<=R
MLBC^G7;@JRIK+V:CR40#(RTRE_(@P_P4=XZ5_HOB6Z64LL^E)*)?RX%JC 6.
M-!,HHM[DD_X?P)@5.M%?^WWHK)&>/!Z1BF6[;=FXJZ+O)P[O5OKMR3V?IQT#
M<0,EWW<07MSP(-19.^VAW6W691L$X&=>$CK],'"IH[N6/!I$@" #G2AEF#5&
MC(XD:!LB!W"8R>''ZG$0:(V#+8<<*50)A\</#=^;4<X!;.^C=TQP1TE:PWPN
M[4O(?!?T?N6/T&776"5+@\93Q7R8P!/RIY_@A^2<C4D6G'/:*6.B*1#M\^QT
M&+40$C4Z1Q>0GDC,J0M-U)IB46_-:O]Z)YN!8((KUB;7P2Z@K@T2-*AK4^M4
MC7CR9NOZ%&[=>ENSG/JOGO3!._5VQZ_.UM.+8<R(4TVYK1B6RH3TI'S2BYU?
MW\'&O1O<7=WH(S,9S4L?!"V5:,<T3%5D8\8U"AJ9I)8=Q!J]K(:'FFBK)KOW
M$OTAX@SEFF>^?1DB<AGKP YB.GN"R S>J@\/'5?U2!G3R>-OT@FW,ZRM!\Z5
M(L]B#CC+S0%GN5FWX;B [,5RN(NVJ\*$[PCJ.()Q7^TVT? M*LE2-WSU9;M[
M+S)1;I2>G#MF.0]_33(P"7#N21V?$]9S\'JXV-8;%&^9!'O+8C9!AZI$!).3
M)9AW%7CCXYR5YQ?E* 7)$%G&T!(JA^>3A:$"2JN9QY3(^,:.WWUM7_^:'2$-
MTV1/ QR5->7R%Q%K>%OC>%A!ZO@BC>5IR$7/F,@S);,KX^&:)EV08=KP+%!C
M30'Z:NDYQCRRY",8$"YCF&*U$*7)<]:29XJ7,!Z0<.0K:H2GZ]H#*B4J&I#4
MZXVM/]4JR.M19E('5.&'FI%O(E>[II5A[/I<+\)?U#AH8,A(G$:])$IGX.Q)
MJS43=&0'Y@?T-@<21,M+=2)90% C*JNH!&,0>48Z\3A"LAG$K,[D$X?WC3H6
M2HK48)H&B\R<((HHF;7WPBPNIM4FUT3G+8VZUB1>3X!TBXJO4O"(G#TX-EB^
MF61R.T;'/]EAD\A:JX"Q=>_9^I1EJF8)!:O9@;)( &Y9!F%YK!@?S'3N4\41
M28-XR$ZA$GS07&JRX@K97*MXP7K&"_:K>$$5+WA:QZMBGY:L&TQOY/\E&D-W
M-$C_HEUL&0UA)OWX[KGZ=<VW6+-VJ!"X,((4QN)D:],YO@8%Y%=60"XD-#PW
M/6#6_H3@R0^-Z-G68&I?Q 5:#(W1S<XTHMHI:33TFE;5I*Q;*<IE3*6MU8!;
MK08\-YGE&O/QHJBE,=Y?2>4)4OF@DLJ55'Z>?*Q<,M9P>O(3QWNS6"@P&R,!
MH/&!/$@&"B2&(S5VBU'/HQWEF1]-)BQ%&E*I!/_.N)J&([U8XU ]XS \U)%%
M/ [M0/=,R2!2<RA"$@ Y'^_4P=0J)?Q':^55ND(.U/U&87Q3=,7 ?**R!$9:
MJ&?FK0:%1AJB1TT".!UI6JNIF!\WK2Q/;L[*P*Q3)'_:?O-0J*J40BU*7Y6,
ML'?*-M/<QV+GQ2.4K0@=$8ER3K#</#L.E9%-C=XZ7<QBA)[,"KDX[9B@9D8S
M"%BV[QYUYU(5@UAD*#!8<_GKELP)-S+![ZP,<ILCMAD6%X]"QV.UOSP7?9(0
MXA/1YCE[7,(CF'5.QGO-LK%$XHIGWC=;%>=C/0SCRL)O82\ "C8AB&AE;(;X
M\;DBAK[B/D9]>>BQXBF)PI&.#^3GC$G]JG525DEDA.S4UJ@Z1MS&'I6F^)('
MNJJ)CVVTB@+J1B\HA3 5@3(U\%LT?4H/$3^"5S*4@!^2D&G=P\IE__3\C%^S
M6@@C2&;V8? "2H+/Y2W)F(J!=BR1CXQD+ ;@QWU.O;A?*/5C[L#I&EGKA5B8
M#["Q^ZRE1HC/XR)A&1X&2N:VQP)]>2Z6-47H%Y21 9!B2:XW3*Z"0^/@4 YU
M5^5VJ=YVY-\<Z"YI%'_(6H3)"C<5[E*W&T<OU^>AT+HB5R7IAE8<:N^C$6"7
M_F]R?9++$=ZB^Q'DYE5:VJ#\G[J)!+&FZI@\%8^Y$(G1?FQR:K#?>I*(R!>O
M&PYFVEM?I""DZLT]JDZ]^$*?<C"*>:(@NL0"=>-@4$T5]M.CMY"&($_6N-QY
M <_9<_2*?[KILL(VT6-NFMUI/IS=I3:+?AY?S-<LO57[7"0[+.BZ>!(DY_LQ
MO(\?<WY6/I@)/IC#R@=3^6 6$:13Q\'<04%49/42%GP[%;#B*1[;]:VJ>)K0
MN4HCU4]%]K+"+$14/W-P(V8-!*>Z&*8C)I9(U!$*^R<VU<GE,$<85B2'/*)P
M+XH("EE= MCX/LR;->#\!D_?6%2),_B3(E@*PHR/ 784QL9-MSS6JLI@0<9J
MNPDH@1CCN(8N<QNRYD4B<-$$YUH/NZ3=-BM;$@LCYGYE:"J0+1.F"8'2ZJ0D
MN$^ Z>-WI24_X.K#>Q'C;#C9/#\_!&M/(U49PKE(A4QO!0<3QB'291]H(8PD
M)HN&TZ J!U<MO\(X2A1@?!*EW&B/WYIMBG(YF-Z<H3WR0YNSY6C\8//8 Y@?
M9A 3_3BAG?R 7?&"^N22M2&M]N&QA8/XZ ?#WP_W&H;.5_K+K$CP*PC970T-
M6 >3<>18!@^MP#=>4EG<)&)^@6'=]3,^8N'C""F=ZLU1;/2HMQL[<33L4&@Y
M$5:[)%3TUK&CR,, AS2KL0*;^TUQD;;QF/O0(UC6-(O]8C1'V!%5<JD',*IK
M//3!!*])8#DW$%Q1;G'% ["U-TK8O%6 4)(P"Q*GQ(RVVM9U'RWXIG0@YSH!
MD)L@@R'5(C1; 5GRKN6.A-<:4F<T#=60=?C*()P*?@&4_PJN5'K]RZ0*86B!
MS-?P=YY3XUW!YT1B*!+9/LU@^VX8JQ(3!+3QR--$J.^(!-ZW_6X=$S4ULIUT
M/F#6ZMJ1Z1J?GKDPW+)&BZRV:<FN'(J$/(1:E$3N,J"IN L!W]?!0J_BW:KE
MK0S:R%/ -\3Z]43-\&6J.J;'%$FAFKTA8A1%LG]CP;FJ;M$MBVTJ"C*@==']
MFHR&0A?4<EH_U3, G_!DS6BBAI7&,LQ*SU%-=E%73G272=)AU/EAK4UJP%3X
M)WMID\J\;5UTN;2C;P]A)MC++^>GEA 2G*/MZNH'&8;P_8!R82-50VBV<I61
MM2L#R8S6DOIZIT.&[;)-YE(;TXK-)L84HBI6)X+N1G6UY!TF99"V(<+9PE[K
M4EA=>Z5.;/;6DIICC827=0^?CU2?!SE/%=W!7 :>(W(\=YE(>-8L$#R6,'$V
M',;E*[2\D\.S&3<X2Q'PR@HSU5!YKG0^7$PXSHU90=U%9L^E'-PI5<9I6TZA
M\)%HP9SO(1PNKD>:B*FW]HR\<N5-<.4=5:Z\RI6W9%>>XBU7<&X\%).G64&^
M=6,SWH<L8KJE H_>J/+E2804ZF6AFM&3H%)U-2;DE.YZ[U"SL\1+!^SO,5-O
M2 E@-'MX5BS#SW?B$=YP&Z9)_T$@ FI@?95 ^2?L_D+4C)Y$#(';+^6.J9#,
M1<"=EG,@"&K$8(T(>Z!2:V#\_XL=X-N@-X18[_/UM&:=MT]NL6VW[2'.*"5J
MI)%UZZ  I%J\MGOOQ9B@]"FTHV>!&UA*P&_=AH<IC+T0L<\IST$Z8VFQ ]@J
M/P^SJ]W&B !+9IS,'LHP4HS6"5C+R]!H$I763*N*4_1&4C\4)$E7W#-Z!IJB
MK 57>_K$X6E(.]Q% NR%O<(RV*R+,>9[>-(S@""3 M<]2[XA? D#!277^8R4
M4:4BGBR0_CH-:B\# U+FSEA#<'H%]P2O*>JC8M]1@)B5<881(1,8*"E-@@RR
M-4H>'23)R,3!'^\IG6N'J0(#UINLPCA04Z,&'J8SG)J=/@X9]#P)K?+^F1);
M"9&'WFZKME.\80Q1"!I^/(Z8&(FZ[$[_5[%79V[L)4F].GXA6\-F_3?-$=9,
M5"8<G:J?SW4P"<< 8S@UF-;7L/RS9\D4JM(&@#A@LXDWW67@A^@D9J/5 7N.
MV)"*13=EL]GL5YI[O>JS,O^FZ_ZXY#Q\H QFLJ.,KF7PE*P/N'4]%9@3$<E
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M*_+1HFC:,&TT)<%D;2-A[0%(W8;FOF(XA!=R73/"V1@942MYMTR-,SC.E"3
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M3KNW-PE6N,I36-RJEN;L&8H,/"?+8ED7B$J%M<4#@^R%N#;L1TXRXDBJ7/V
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MR-G"FW.W"F+.RL0UHYCHX<$$$_]4 %=::1D^AWRHI%1C(T.@=()$7\2$U6!
M"5LY1GO\FOK=_B#Z5YHC%?/$F4-T>,ET#'_+=JV?)1&@7(^J,P/[XM6;GZ)%
M-F)-TZ5M,H,>V-O)T^F"T :F/())^6-R=]T+AL89Y@U9&]D^-.0M_,5.'B[
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M_* .GP(GH9G29NS12WQ//&4Y4=PNV$]V 4-P%?A9M0[#,^HH1HY+$8+0]%V
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M;7RQ/='L'U;%O*E3(72FD)K\=-!V<-#:$6:=!RKF/&M=_( \.VG'9=CLC$X
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M:*4/!_?1$'].T_Z?J8*,I?!&K6TR%-<SB3+JL V$\]!M1#QCA7VNEV*!3ZO
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M3&D\J$D/]7Y7-A4=J:99O>U CUV'TX;OX95(K%+,%1U!5%^YQ-&D'0E;)L3
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M!@D<#FJ+196R1,@Y;T9(;+,H<CQWA(:27I4XA 0.)_>]""N[].SJK3%Y)@:
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MFPJK'A=$FM!V&<%JOR8 "OZ;0I/=\^!T&N&7I< A/&9J"R48(M2PU=H]Y/=
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MW(RT++5%'JN2,[UOH$C.+ETQ)2NDE>UMUJM03$8>WH@'[;OY63 '_#HK$;2
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M$&Q+"=-CEU0 2;!BGFD+'"Q,?;@#;,G>E.:Y:(_P*U%60O<_<E++Y^N&.A'
M1?>]S;%89M?$B'7G8R$M14A>6O:SENMB<M%[/DO?;KEG4I]43>\JU4,.3(&]
M[>^(L.XOASVU>UC2)HU8\HYAK_D7/MCB ^ Q[9?)3.;AA<;ZT )*3L=!1:U=
MWAI&<<^3."2/H!9^]XQ:/P[1.HCICV4QSU#:>X?:4:0BJD,I%O!)!&+$\3D3
M)2&*=(Z+4D:R_]UW&^Z>P[L,SF]+,L44D:II6"U8+>^MA]TKG%!TF34"[VFD
MJ!O,WF1!*M1ERC 4)W5,%Q37 C-H<6:C1ARH4E/4M_HQ_2=:;1IP!V*KI@.$
MHJGMS'1F!\W2(SH4XJ;=.P2D5 GZ/?7#(//4I0-M .Q D?C]R'?1]U/Z]RWD
MP'*R&;^(L] L<?*.'D6K-"FK$)M-*>YF@3^;H 5#/V$)0Z3WZ;MD(:T0*WEW
M@>*!WF__&$YNR8T1!4N2DW'$Y(QP#9ULN%.>9%)!M0X+LK4'9<O/\;D4/LQ=
MPL=.<D"=;4E:85^-LM0SI_I&0RTZ:RKQ5 MW/N]80[3Z ?8X[JO^#&"! VVP
M0*V7F?$04U\&I=<'GN[P2FW E0VB?Y;X6<[(78E)R5/T0F3[7M9L]73N$'N2
MGCJ(JN$YYQ ]*U)NOHB2B<5>JX % 0'B)4C?7D$>BMQD #\<G'ZFN+]E/\)W
M,-%E$2%-IL;:6>XTTRFV*4J"-C0$.L 1ALD2@HSA:(R;PD3D"9F1V,BN<OU"
M2ND$[0T&XF$-7A$ND#+\ZU2ZJ,RSRM!%.@@@@M7,!$;#LAC-7#^2/O!\TK-R
MBMP&P0;#!_&;E!8G7IM;C1$XN4 .6 ]_LW:] E:=U9&.*0#JV-M[1D;9AKR@
M2&A F;:RZS])A+^V8UUMF$!YL8H0]+>\FZ$%$-VJ /D 4)0PE$5\C]C9A[A=
MUSGM"N'F_# C@,)N-3)0?&<)RZ)W18J'<(>,CG2:,K8#9\PBGG*L4)"5->)F
M6"3E6"B/D?)WO!$!B78ERE!J'DA(B9:B4]?<<P$Y)[!,!>Y(&3VQ;5H 1L'J
MX&$:1&^8&7M.437"=V'.1X=9,'8=M69(-]XW?F;-\OBZK$^XO0<HLV; F46Z
M&FX*G/%)2X"M2PM@[2 UKF\G/\WN5F& 251R-.^FOW< IL\&8#K> 9AV *9/
M;W>>%;EOIT92HN,1^LYYFNA7I6)=NC8E+XI]5+2N+YK_J57@8"PU(M:IL"2A
M3O,8QH3IQG"M-QNQTV+.TG!B:J=,\2;V Z"6:\+ G2H RQ;CM>Y%(5!MUX;V
M!#+T2+N<MHS^Z65880#Z$;$5\R5\2JU_%;GL57AM>.XG9##0_<G@G'H'L0D;
M;GBY+L%\;#(18[$-"'=X04:RJM7'L<#P+;5ZVN15$$^!?F=2,]<^W 64AM@)
M6!2852DULD/.?:GR:[45%6)S5\B!_3_G]'07<,=]Q _$*Y3=:)C4U/EW4W9H
M?45/8+ZY;CC"QT3Y86=-IYM(EGP9NF=;TB%-,J--P;-QVY6,!=/?PK4?\HY+
M*O%C#V.2K%VMW?GT6'1+8#H)%BWR6+/=_92-R8KE#..T"*T>LINS0DO$V*['
M>O\*MNN$;-I;5/TM6>L^16\DD H@K_LC_1_FFJTDVHX.!Z\];\RI6GZ7*D5V
M?0U^/'7N2\CEUG8];@EQ.Q(!)D8DYK9TF3C&SKX0 ,],V+U6F17U/#&"CRHX
MJ&;6B/2P>U?0::0EC1S!=6^;!!:([J&^^8H+;O2TBHE-."#NH:Z/%7HGNK:5
MLVIE$%SOS:+*>EX@]J7AFD(W3:%*D%+7'"(P?N75S#)"C#O=;$QLJ;<%3SJ9
M:#>TFO*V J++A4Q/N_/6SM6F8J-)-F=MB?-)LI]<YFQ"WV Q\DQ\1#<@+5*:
MPCUQ5:B &L>!@$!N0^L=UZT]1UM^S']U];N7L+%'9;:D?4:MNWX%"SAZGE+?
M*TZ^+C@F[QAO+L]_?>X;6TF%FSVF:%"Q,<DE1$&\JZFH=5GJX_/)&$?.Q@[=
MV_VFDD[$$K^F]1_(;TS1?:4_H AELM!+!9IJ7Y%ZE=G(@^DQAB]]DU"+9O3$
MR=@3+HZRU:-7:VY'63EJ%CT(AT3NI&<WH.E/4P=WFV1E58??XLF0:5M@#'?8
M5!@9@P&^*LS,T)BXXHE.B2M$<';@.,5YI\! @F^TI"0W3X!A9+ /EV[JPE6;
M<+Z;+_1IF-VQN^?PA'3J.^'+<)UW(D\L;$$]7"6GXI,L2 F32LUP5EEI;3TV
M0V%!R8,5;2OP=EJ%SI+-7>>V22]W:LM%3 ,DT%%>TXBH$J^FGN[H2+FG$U"B
M]O3=_"IT=D1#<$AP8EY\MZD^I&TE882YXZJU7H9LN*BUY3OD]2XW;PU[05<T
M5!9S0E*!@]H3S@,)+Z/9?KC3_-[[)1?WV5!I(RQ0K0'MG@6O7/'M#\;@[,P"
MVFQYB"%XE/ 0JS52#['C5TNF9<J6IFTV,2T$]B8W>W+X#6&:RFQ*'B*QPF"
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M-6F:8PX142#TN<._!'<5Q0V>+!Q&B5S-*3+B3*Z@D'=3F7HK-%EQ/>SS!,3
M59F,WL*F8)P*B8RG<.%;N+QHIC/\.;'/!;\X'8W2N72DM"!.G"0^M)>:QI3M
M92[?F0D?LBW]FBG2*@OWC=M^OIFO\LEH!ME'Q3ELD'-VF<,M"FMQ]U2<5+#;
M[D:+4)1^Z_&^H(", V&WFSW=LNTI6<Z-9OJ>,%BSH]ER35V?!69R[>WIH3Z<
M,X&\.4%/9SLF,_E=AI>.P^I'FB ]Y%39K=%LB_A1U4P);L&)L77>OHKX5\*E
MY^&:ZC[#$M-7S=PQK'[-LW]S5YN^6X>&@V8@S,Y!7AR7O^"8FN$K<(X.HR:*
M.7EO3$!E>_NX\A;K&YD.2+&B%G1F/2;!,<^Y#1J&%^B3UA@#%\;E/A"=PI%\
MRO-ONDJ"!MV(HAL,<B@YN$!L-I2,GRI4\Y4/\GDX(6%,NB_!^,0J;.!MQO3!
M72'^W%+UU'I>ZG/=J@.[<A*9ER2VRD%1)V.8[,F$73E)*3!0%$HH.>\A4A4N
MXLA6/;F=4A>)_-*MFG&8P-;!V.@V>#EH+[.\N*9$:N;J?9AH*:)#W0TA(RF
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M=[%$/J_X^8QH+RVXC/O5J[HZDSR!#<V8&2;RSJULJZFJ(!,Y 3H_+N/O6'W
MD,ZH^$&_7V>$@KWH^YFB]&#0M2>D%K5W)MBNV<ZH7U90$1OG/=M-Y#\JY,[6
M:]V';8P9^6:'!E9>)=PR9N^T0!&#[P-V N3A\@S2L9M)BB;TGLL-(ZV>BC (
MG2D=*4'>">"*E?>KT-MM4S@1^PL;8-]8L5YM9&T=MAC8ON0P*TP-F*JLK=R'
MP4N]O?,Q@2!.@2"^G$ 0$PCBUP].(H\[@Z1?!4]LROC\Y=DX[VS7V Y*[,]6
M7\>X5H8=Q_MS&!18=%*J),.4E'?[#?9V[LM,5"T#$MUDD[H]><C:2 +0+CYV
M23L-'][/B8)>B([XA\(_B&NN"B0D/O[H\OGKCS[)^#6(NFDA:5P]2<@LGCBX
M_>K:_IU/7EST[QWZ1O2*[/X7%6<\Z.L,L,>WGC%+D?_ W[@/(CMU_7_@#?DO
M??S1DQ?_\..3Q)+B#_DK%WM_J<H=F5PD/63]UZ39IS?%,9O>GL^^)?>&2$8R
M9MA-9 TKVU_[J>VMY8 HI$5&^YGAKI_YX[UCGIA\WC$?26]V7]?4F?C:!P*-
M1+*9--26K421+?$P2=/RYMBBF1&@SB-KF?C!M&!&KQ9'^\&FN +RD1Y#KSZ\
MO[S*9Y6R!KV$!HQ 7T50 A(O^BOR43_Z^[.7%Q?T8KS];SD(DKI&N&!T_WYP
MBTT%YXY=T:?> ZFW AP-&6?YGE[_AZ>7?U>D._/L,,Z67R@_)@6^<013=/+N
MVUQ_KP&KR+JF[KFXA&3CHMDW.417715-38N* _.]BY0OF_S?_F/8]B2(I5TB
M[F*T12P6W4[7UNN8<HDFP2;]2EC?$*) =#BOQ+Y?.>E5OS" ZQ_JG[V-O0YW
MQ;>(=>:"R5\"217V<[\ZBR#'T#J3MJ:'Y6V#/NF7,0I<U;+430(E693EL*1T
MCX^9"C"_N"W_B\*%?%FHD&Z<$A:L*Z2P=<A;I--54W9)TKZX>;USG/AIB7 I
M_97IH*>45HC'9*F;]S1C63DDR"TQNG_YX^_KX*)L7%GDVL>US+?Y6O+^<6<%
M)S0F\U;]\[\C'V)0._M6U@,>GYR#V;=AO[^8DZ&\-+OP#W:C_LZ;U>1A)5/(
M&TW_R.2MGE.8L7^2:/(%=)6V(K)JW-LT[OJ FU*3^!R:[DN8NZC'<.Z@KW0<
M6OW>ND58,B@)L)C2#=Y9>%,LWB"\"HR9DKX@1^"2'0'=X+1R1W.V/+%'\_>]
M939O8&_#+XY]8^A-6$_">+3Q .#D%&FK()<CM&WB4@D-89A"XSACC^T:R0[Y
M#6Q3[(0>8.$-J-XJH:?W=&IN+E[595D?IEZO7Y*'U/=] 9O[I]K<:[:Y0(K3
MP[[#LUZ3_<;3@K5-A3&3H)>H,!*-')]B?HVB:$ >.DEIH;)\9*>B)H(-^G<B
M6LL*J=NN<MJSSSGS\JAL^OQ31LR1\NN%_#MCG5S*#C)E3^/V72-]Z!V ;$S_
M(VQYS"JYW3)Q $:RE'%B?3=^*9!J6. 5Y2LX_KXSWPYR9W0%3<=*@I(",!^B
M;:D*Q9&2_VJQG7=-BVV+NH\/F[K442,6RB0/J"%<%N*W+*HSRKLLC\*-ZQ<V
MWY3NJ0&*".?*MA*;K0)6B6OFL=1"3RZE,NWFVR69ZQY-H(@P;VC;)K(A84(B
MVA*9-H4#(#! U>,8](L5NT /Y2.[$LU>C$EL6 (DGU7==LY3&S.H[F>(986*
MF6$,H)*6'_$<&X>ZI*"K"XGO[18>:MR-R(#])Q$KQ=QQ[P[)98E/FR3K*C]C
M]4$Y:W>@1J&(5!+AK-MLK7H6B%*I.ZYTHI,[=XGPCIBRSB:O()G-5M:-,<!
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MDVD,TZK/@L1V TB#Z8J6)"PH+;&7;EQ)SE/_7N0_%=LMM:4 "8J%Z*T)!5#
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M<61&#-K[-YAZG[^&A6B@C[K,1]O\YV+;;>'2<X+'?22E,0TO(T,<(N0S^'0
M37@WV)T)<3!GAJD.A$"4+2"OI'26CD?20JTD6&V&94=9(WX__L> 8"A"ZJ"!
MPM$J;UG<+:\HTR<ETV<$;>C\CN.XO?N VY&8RUZ\V+3UFLCN,N,!96.09/]O
MRHI<N3;4LUR5L]Q0M>S[.@+JI7C\C].C/]C\GR;DU).ZP43[/=%^OV?:[]E/
M.&?+PEVYI!A%'932E&*:LUBY*/9-IW9E6G+R?4B7+.T%J'Y)5Z%MM2S>.&X:
M>;M.&!KW(J\0>0O4+ /6S!%6": S]F(TU:/]0CV3DGWUUCT)OZ-M9K"YDC?R
MK12U+^NFZ79[[S H_:E?<=,V2[[SS1.5L2,@F1#C/D<V*& %FET=NJZJ9;**
MN<N]6N>4ZS,BM*;A+- Z<LL._2OX[-Q#&TN2@:7O4#=OY)IYQ7(KM(;S7;X@
MQ@7V: I0).6E.$@9LSZKNP1/31T\)86)2HE'<@]C)['H/0[Q$N'NB3"ZW[!6
M*RF,993\$=<6B2XJ ,3?Q8(;/X[P8K[=U$05RUM/TIVUSSN^?)3U*I2%HA-A
M2:&?_I@61D6$GG9H:N]C,B4CFI=<":1*<R*L9E/%SPM>ISA*Z3(6=/'C/V=_
ME8]?,(BS_SNS;-=$;9X9&O1 C$JE57RI59MG<\IL[X_TK=,WK0QA(%S!B!?4
MFQHOQZS!X8(08%5.A'2@&5&H$/N7'+)46F1T:;($%!R0#Q#U4O7XI[__TM]6
MPFGJ;S=^@XQLC:* S(9;&I+893H'O)2.\NZ/P)?ZE5K61^<,#P%_=DA,8DC-
M$A;0:Q>Y>3*B(-A;P*1<[7SV7:'UK^[$G)+$*G68<Q4T)X7<BF&)WC!EHZ!N
MK5B4BLUE%BP%9^0*NYS:I^6,F/+4=R5/_7#*4T]YZE_D3?\M.C0Q3S%[T>V1
M?PMJ?+:^/'G7_22&31J/5>0IIM7L6"*"C?$XAC3T+L+G3(IQ8^>33^2Q+&</
M(<9IQF,?T]!J(H'I<D8:&LYGRED14PO0F*2$"+(*AQ#>#I+N757\JW.]I(!_
MB#=<NBXHJ=&C5. 39QDPCX&1)V%,*2KSD0B.NK-&<L=M^"?I=:JY6295GTHU
MI]0PF T#NI/RT83?1[\C7J MG:<2HQI@14 DR4O'1D*(BRR<!FI]LZXM.TZ/
M)I;&5%NPY?GL,JBOZ.WJ:W8WS=^H[ZX-(FEVGA@*0(-D9._3<5JG?X:O^9E1
M0$4U>_;]D^L?>D,*I[U'CXA>1=#YH<-M7UE-T>%() 26 ,1_]O*'BXQ?9,+.
MJ]TJXOO&?J$^GC<2!?(>DQ Y>K,J%FW@O <U(]''%&^"AGO(FSY[]=?,D':6
MWL]]H<!D/TCR.K4OC)(*X$@P";SA4%.FO+[M$)QK[R.*:=OX!8FEA,)"FC%H
MD80#2FQ:F%P':S@+"]8O$1^AL,:0=EH,X3-71'"#747#,L*#TS\9.@=46]ZJ
M>MW@)&2RC'D8T[@Y_>WR96:3PF8+2\U*S9=,G<%QU:(@FI%8]14TM \_BDK=
M@B?.>ZI-R)3_W97^V=\4DS6^JR.VPI&D@$M+AF)>HYXW)U_G.,?3F(LE)$MM
MUX)43;=3W!":7%R6&<&,&8-O')PIBA2*?W=,KQ6+\9+ )]2Z<7U2 M@H%S9V
MW@W?53*+MWUQ-T4TOUW,,O_+TY"0H<H='967.3$D_OG3^7T/3B[(=7Z>-_[0
M??AY!D3%8[+Q3;Z</?J*1[^O4><*F2TT<)<BR+X*%0$PK'5E>49P3/[K3UPF
MH#9@SG1K^@P 2D&RSOT0<T;O4N90E,]'*G2A^71=U\O8(<=+&"%)&*'<_X7]
M'0T%L L$)V]0"5@*!RD1=&SJDO.LRNNY=!A-*[5BRH<!%NV73<7=  2ZL!VK
M&#/2LL2()L,FFKZ0 HZ#&4"KT3;)&56&RE"Z+X99LUVQ\]-1G4RGG4P(O<6R
M3=?.';?<OH%@LMIN0:X%^Y<4/]BFL:I/WY;OB71.G @AHM5WS)@4,15C6WC-
M\%Z!Z4W;X6,SB"72I,NH-)4?R>(-2M.RLCA06)5TCFR"@=IK>7]:MGYNG%[Z
M*2* 34R_U]18TE6B$\GYZE5HAC5&&OG4>0 VBRNSD?%?J$[GY >9')XG@FOM
M*4)Q:8'OL*F)+)!C(,>3UPH2/V=/3#OA$S!>32<I@$&9T.ZJ$P126S]\#77H
M+0-/Y-;%PF\$FKH(G0GMOEZ\P6+V*XXJ=?R^Z.TQWP7/CVN(8):X5S=%6;?U
M;G,$8QI(<I'ZR*G52>!N,@VH M02W21S+G_WGP=2$+M:777*!DQ#\I\G8U@W
M>264/0:Q3\!YNU<A4FI<;%[:>J/<ZY,2(X9A:^2&2BZ\NN31IGZB7\@$@V!4
MS4XV%S#]U;4!82XA3==*LQ$^N7<*=.1F <2V*@]$KP_K,CTCH^A;V%&XZI>"
M8U8^/":.3 F#&9P*I51CC\=X::Y5QP$"Q.@-3;"?VHBK9]"J7G145".D'PT
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M&%IQ36'I/[X4;N5FH$4AUQ)2\1_/7Y^;8NYDYI.9?Y@S*B7I\I:^UPS_M4N
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M<>FOM2J0N%KE5_[9L'*(P!^\:1V)E ?R*6U<Z^CXM()@=: 8B"L<'T$M4-S
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M??_BNS;R] U;E;_XZOSKI N9?X!OK#>++S;HVQM\>J^I^?SQR-6DZ8E:+6M
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M/K+X.<Q1MN/JBN'R_@\80T33<6"K]%)XBB6"OQN?)#Z%;E[)VV+%)WDO;9S
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M/6P:8=8F,[FO9K*K44\<8SF_M1R6X,'[+I3?CB:KNJ=69=7"DF*PK?ZM7;5
MMH7S[)((-YV@8W1(N!(GP2<2S'$0*^-(I&/8DJ\Y(5\+9$Q9D.\>XV@C'':
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M^$;LO5.=@TVWL!KE?%;BY&?:X0F??/C;_Q/B2=H(7WSV^9^B=_JZ73,CQ'.
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M73.U(_<M+MB:,\'2HUXSYH93HEG ]=P56[="*=MPKS;5WI/R ]=$!5DO?W_
MY$OG;J)CW43_?>XF.G<3_?+=1(3:=C:C;J\)$'QI90IJF"2NB.L$@]&4-X*B
M2#N P".R29IDB M <*4B*LZ]/<,^7*L23!E=R;HYVNJ2Z[!R8([2C-ZMN6=F
M76D7*C?[H(65DN$'UW%=7G37K-Y6MXQ(R9I'4@ZB8WAT!5 -Q&]2 D^4M),
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MJ81:G7QK11YO<'!8(E5-#6]78> +-[@LZ2?00@E>C3Z1 FH@05=MI;G:((K
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M^";-;S[8;?7 =[VR]23]RL P<+ P@]%09:I2DB@!U*3E<0/-Y#669V$E>*2
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MBAUJ#,X<F?S%&]/1X!(+D+8S$@?M1T&]V5Z.FU)VEGU(0HOPVH7;U[9.TNK
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M14R?^EMS' &=+%8!KV+L4J+L_KUJ<V?+P=>IW0/&QA[GEJQO6:?@V]:U6N
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M()ZQC%]2/<?H=?L6S5K%US=AM?:'2'5%//P;=FF']\$018R/F"N/[)!U5JP
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MW><?++'/P8[<MF- ^J89D#;6LZOA3'F$H@Y%*+L#;!0%6 =#0?T[@BQC!$J
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M,@MD7&7MK!+P$O>BP'2#7L%$:'982.2%Q(J(B?5_T7>5\T%[D' %:4 :07>
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MMC1U,J'8_LDIGX6T#*JHR##30E.:IN1LFDD,.ZE;K.;L*93((1\-R6(BIR0
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M+ OTFW%2E%QN&N6 X0COQ6QPE9LK'*VZ0@D@BO'*2S"PHE.B]79"/\_%CQ'
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M%'4Y6HDD&G4KE2&83\JN!ZX6FG4F9![K.:9B]W:V=P+],E/W\ "9QAVPYIC
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M35_$2FZ)RZ)+70+':;G7H9@,G_?W]O2[X?]Y\4/01'L:YE65S]KPGFY*:"^
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M,GF&YFQ,HSH;30WG3Y)A;Z73+4U^NV%8V(CP\\$)YT.T+NU (9UU66]=!"*
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M=%>.,Y?8]3?3)VU52.AE$5Y;!S1:[DKU^J603=]N%&7<=0>G>1(CC)F)].(
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M,%0"/)47$M^G\%D(O/4; O>=9]6Q&2;1PJE5S<SY<Q]JQ+AW_*:S1:!2Y0)
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M=4,D4TO6O$5G+/.!EAZ2& 7/)^5^V1Q^I<[X/7!L2L2$,JY0*'D1W8?<;**
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MT'/;5NL]^$?;J^LV#;GCD9X2]2/4SVKQLD;F^8;)?ABUT%2MMY^&&IN@OK1
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M]5.0J<[P<LE3B<?,K)K^];+]EL6!SW0?\U;Q/]AKY@FD/&!>[O#U?E48\[I
M6V]4.T!$#F1?V,1O-&J7IC4KNFTK(] B[2FP/4 >4(A'P)AJ./L7.';D(1=C
MR0'V%FBDR/N !P$W T8.#"Y'A0]&'F-B,#%\- *&Z"DV\XG5/\!&X(JH-YO
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M_I-^=I;_*.V6$NZPL;"&[LY6G!:N3JLW^A]\?FI<@P,K8,;( 9L.#^$A:?B
MUNBC>X [>HH1/G12;UC.),1EK^??@FT-;?2Y>4PW 1G@*8$.!\%OF'J@<Q>5
M!8>?8'M+.)+OAIZ!X 43S699R\3/1)<AX,</%J1=?44.S\],<ABPA/F"QL3S
M+0=L/G+9N;;M/N--C2SF89WO]'W%*(X")]%&9M0@^KU%0.71)C!X0-T X6#
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M1\J3<!:)2N3*X+OD_*7;"&,,HZ%[Y=H[M_R)Z^OV]?"KZSR2G< -A]S =/M
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MWE%"X&)8"RP3VP06P43VF0@'8KY4' 6$Y]9&+O5,\##6%^6Z46XA-^Z_T^,
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M1"P"?I=A$'KLFP58&;C.AN#LU]5.QB!.#A$4T<MPD:8AP*G$9S&HGQB?DN
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M&Z<*;C\7 \;ZE(_L?!"W1IX9>XKWP0"CW"EC\)P!#NLE[Y98>]UGIA^G(EH
M?^;ZS1 4:,_G003X%D"X%GUSCG*3<)LO!X_#)I!(G7CTX1)+#-X#,PQN &DS
MMG\YB05K4;D.6 ^J+J;' G[ %7H,S>05+"8>SL91 K;'=&!C:&ZHP,S@C [B
M0:%'$)_J"]R:YIGFG8R$ZV@R]N]XFN] Z=QU/6+X$>?7,;O&KRS8"S?A?!0J
MTTA(N5H_3Y.O1(Y8I!\P-7$A_9$-)A/;8N:UDRJ&$'.HAZG1U)>N-TB#_TI
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MA_ :Z<838B^FA#O!UT0*M1X%F8 (C++QVA_QQ'J$FWZ:PA?Y<6N86$H%R"-
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M&0@9<*L^\5'JHP _X 5>+6=*DZ'AJ@B;9]^;*5\_*Q<H2 +8H7</A"B;Q/F
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M6I] +MDH:H+0CT1AKFW^^,?#I<$#T\PNYMK0_RY<)I4H&:Z^7-_CKYPG)_1
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MY?@DZB ZUJ[XI&PZ=OJ.+7:/YF2;1I:W!/*MXK\=>KLNM0@OJ[OKT6[P-6W
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M?K1L_-/L"3&_?A5C?Y((RU'W<AP[A=B<>2YV'Z3D$R#8D9@"/4*IIP^%$U&
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M%K3W'U/(=PP7F#U3U4?KTE)![%#=TW,[T6)C+91+R"OL.LQ #$<5_$;8-Z]
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M[*LF: 9&8WX8V?=&]KUIG'W+B+7W<V+M+>U[8PS4[G"H]NHQ:V1&R3&@?)O
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M%Y<36_]7^_R1U>5?]M;[5\M_SJ_W7ZSO!KY-_K,G^0/R&O(^\@[R ?(6\@9
MB+R-O)'\(_F'$_PO[_KZEW?],YOY7_+X@GR\_]M\SG_/>6+)D+/E9[^?)?YI
M"W5'A)YL/+V P,A@;T^O4"%=\'9P%S+V=Y63$5(\JZ@$ "=WS9_CZR?7G[N,
M:_#?M+N_ $#+[?CXN.7?M,O@7J^]#V[_U7_3)%K!8X(; /H37<."P__03BY
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MY.C4]:DOT_;32U_<OGR;N3F#1X>C#V=OSU'.)<RSS&<M\"^\6)1<K%Y27?J
MN8CYB+7 SBZ[+O_X&O*5N')OE7$U:PVZ5O9-\5O+=X/OG]?MUE=^!/XXW(C;
M9-U\MG5FJW9;9_LCSAJW@@_&'^\D_3SUL^27\J_.W:N["WM^>X?["813A-+?
MYW[W'5@=K!U&$*F)3XXDCYI()J2Y8[_CXT#G8.>_0@%RL))Y@%GT3@D ,-H
M #N8M]'9_<D%_RJ0/_GK7PCX?\)_\L6_BBH 5(&ODS!>KQT WH!5_#;(6P<
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M8SA4ZORUH)E>/]%FX]"&M,\(N"YA]AB@5#DJ#47=;4KMT?+%]J8ZO_Z]K]Z
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MT\BU+7J0PDY7PVQ(2).Y ;:4 *T;?GGH3!I4+WF@4IW(2K2>^O7AUK)I2WX
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MQ%.KRMO0#G[@O68VDD.O[:)O/]U(\"31S./@G3&:G\/*[9Q.#?ABH.RI/(B
M"P4]5F/?8G@GB&M/5VO>*4::4:<;B@5:,;534B1\;X6"+JX2(TC@6Y:M3I&K
M@SX0E)^HS6[-T*_!PQ.VP_+4=-1>?P_9,_&>3]?"]^-W^'S.7V\_]YSY$<H5
M.CN]5TV806'R7.09?BS(C9/$$1+FT\+QEH1HB;A?4%J? N=#QVP&WM1GO3MC
MGL+S.9<5--P8GF<*SH-+7W'T"AF$C^]>$/VL?8:H/RVO+?S=]OK+U<HE* N!
M#$;OX\B7-I.Y=M=H/GVO9XXCQ0NMNQ-R6C;AE_P]%,X$%K=([MD2VV7;UT//
MS#3P:N&[JB!XHMU;MO!CU[V[>6E0IO+RK%\_ _)="WAER>S=L#(]5"9UY-,?
M/=$,*$.4P"=:@K C7.LYH;;*.6N)+<9A53XL7RZN7JQ-,/[R._ AS_OK0 W_
M6PD.R,Z)NY+H3)=39\  +E]ENI6+J#-1]TD-8]J;ZX>%,M@BU7R/F*8BQ>-'
MZB=4>M,N*K8H%4EU_=1_O, 7+E70)S]+OI<.+NNF#5ZIJXVE1>0% K[GB[\^
MF9^-*6N1%!A'Y*#1@\,["/^MRX78P>'^5!I+BI4&@#(:BB\AT>SCK$"'T'0H
M1R2,]S(Z+P]]"XN.ZMJ+.=-:^WE7RX SV;4M??@\A0?FH@*2T*%0)I26\TLK
M8(^3$(*%QA5PM8B$O5Q0?8AO.E@SP[M=.+CN.U,EBZU_7.2I0,[!FB0."*4-
M*$/:02\P:?/+B]J[>A1?B%^[%UI=CRCJX4U)+O3"?\A=IW?7+@GAH%>X<XHW
MA.71FP>*OY->OS]5G;E[#,S^W'M.L#M41U[R+=>R];,PQJO=4UZD0C3W"0+:
M?*0OO/4O!?(V*_8DY:8.M9<ZC1*R;'1@BE])<4CWHUQ-[D,=(GTK(6"9D4O+
MMY,WN3@\Q&9 NHCR0=G#,?W38Q?=#&TX8Z7/W- ]5:WT&;SI%H"WA,A2@J?M
MM+8X8J'+?$JYTF\%#T\*V(UZ(#$NQX7]>/&GT66O=.&LZ[U$Y&$I^2HLI:TA
MH _Z!?2.Y>S[FF;8$4;PO&A16\JC[W'DF)(+I1BU'%Z[-@4UVI$KO#,X$,"Q
M8-]QA_F-8@U[7)72LEIW0$+!FX!-/%9>$&F,STK&QUXEH [5$*G=Z)M[!VQ>
M(2;*MGD/H[Q=$@R=1/M%I(6Z*.7X@OA2%V'<,.>V.)0 T1D[[]NS(. 0O-PG
MR)[:H?[1BILM.O_'9>.51J,],K+&+"MG84S'[%W5I" 43=M2)HPVAHTP?A7/
MGX9HZ[VU!X:UJ90+"X2V[H:<C6Q;F8])4XQ[\>X[!NU G\'-=.L< %_ 2$0>
M%;5Y'@-),#JB!G:1%R&!G5SKJV;PM;+5>B8(Y15U%)B6J1U%<1C+!+_/Z=2Y
MK/_R"/LHN7E52K.FHP!G@4J$4J(\8 D+POCMI&H5>!*)$[>7IT14P7O>MNB2
MZ-K?;\!]J=Q0.SLXA'HI^O/.JL'6I;Z?1A5?H/9(=O FN$:4(+!6?BK]WH;+
M]9E^]$U-D'MT95K3"E76=K_V?3N;K7>E3/%,(5ULJ)OQ/=UF.DJ)NVU+CQ=I
M6V"O"*\7NZ67H0_-$4-=?9VV]T>2B2:1U?9RCYP^JBIH#E\V>PH$6S Y7$]D
M>WZ;68+0L0Q#R^^%36ES$V6;")\PBQR('\L-#Q=-:_'71^[*;E2V0+T]2TRC
M$*?K4EP:S =6*.Y=_F*?/HMW#,![DN@H\=M+:_%(/UP?B2V5RA?*CF3&>W8*
MTL;V6O%R9SB_]FXZZ!,-MK<IOF.^RIF6V7V%L[X0$L'J=!D\P"GR"9Y!N"HX
M[7K.= ^,12_@M:VONFI9.6+9K&62*!_FDRS0DA,V:[**?FS@_IMYF"=^CC&R
M>A-<%HJTSV';,[E=;4PMU$7KO'6M;_$6>OCXY%T!IV[V@0K?P*[@Y(@(E5_I
MD3M7W@K?0R^5ZM-0*>@(^AU>0'7H:ZN0VL.=^)'LV.00?<);;!O]-Q+/E":T
MN@/SUE-*(.!Z])FN2/< \1D&ML(L!;[3F49ZL3^MZL ]K4R"$6\2[N#U^A8X
M"7DO">.6N.$,3]=2!*I74!BG1A3F5GLWZ&Y2SE7'](UD9C0O>IGM7>;-S#DP
MC0!'RY)8O)R82,*($*NQW6U^0[SSZ?B>6]D)N[,?7*]-OKCM@E9M>OJQ]%'8
M P.KH8 GR$65<&B-Q :JD#0D6ZZ=C44]%#R3:VGMXHVTPP[-1U:Z/#B;<B[F
M\X:(6>.:U]R<OP39;6UYT'GNHCHN$8-P>MACX$&++FZDKZGD(5()M]^= XLG
MZF*&4'&;0<]M1E0F:[G#&V[]-&J6NS 7;T8C+'XFI<)Z B6 \DU%&V^T^3I!
M$4Y8Z#VD!L9IIL A7TNZZR?!7*,/KZQZX/Z2B'.8JRW$FHNY&=Z3OMO]]K0.
M["+1%)Q=B\A-> ]FA#X'GQJ2<OIZ<K[&G)EH@05@RP^CZ?R<><5YL[^DZW*C
MC>,4[7A$W9)^.B:^)G45,.U6DQ$=<2N]V0BT59]T;F(;MX'\2\8HT;TTFWZS
MFB<U# I)XF<-;F7H0 5(X\= +77O"'K$Y*A4%DF_+$]/H 9S"6HD.P/\Q>(W
M^C)C;'GN)OGA)52MO?*#O<_%%L5F3PQ,I)O9J+HV"VBUU;Q1-2-$UEA,:D(=
M,Y<M@5?#*2X?VE SN17Z7B7@W;RIJQ]CH\FY_O1U@\Q12X[3>4\@4TW,R3"<
M<368[ BTP*/+UJ=:Y<;;&I3/::IA^;3XNJ?1[@4)&T))/13J25?[RT-6BC@M
M W*]T<:.TJV$AX<<2"W"RT,I:^*IR5_- YK,+ZVMO?=8=:-EN',0;W>2BS_/
MB=":>^7PS+@Q-BJ2CRA#?F^7@BYC%J-)E"5 #TVM!UX[^"Z<)3@Y8[3L.M$%
M24@&3:7P1?1!_(Q8W'J'Z.E"/EI#/BA3^\ICWH.BO4#"2SRH'9$##&F71KI'
M!+T6V6J/0C"_\<,%I;.(8"TN/V'$+F=-SD>98,4A"%N1"&R;:HRG/L0N1XW(
M)K^T4( 9$?BR:$MH[E9#L;\86\9?*:]$Y.P= ^93*;E!>XFJZ9&B,@S^P&_5
MY.=R"HZC:AO' .;I,>"5B$HP]881Q2U;!3(Z1^>C"XEO;^Q+!@^LK/EOJZIH
MO'W&X,D!09OI<P#_QU7W'.?/@LW8PRL(U-ZMN(T%[9<E"X@\[8& $-_0U_[A
MALV?DN^(\2I><+M-&W/D1?Y->4K6;;+XK<VR;_\+FWR6&'<#42J1SX\,,9:^
M:Z@9Z%Y-XO)7JYSL+Z[CQ5='4 SIN8E9U^C2(G4A@[B>AUM=IU8_V!X#6)6%
MYBB!ZOBE^("9L57LUF]'Y7JK@6L[;_C?7[W"!/",V"9DBE!^$B[BEG +FU8+
MLKDP9BH:V-N2'4Y7A%?YU- K0'5CT;4IXYJ[1OC,A?&OARQG4>I@PG4G< &,
MUTH>U,%9UVWCBH[R?P@4^THF\ 7V-%KWD:^05\$_W H[!CI'Z-'>X_;VWF=?
MVY8;C;_/^*A#9>)/'0&_M..:&V7]\ZIMY.](D5L<SN="ZC]]CY'I ES%4ZMU
MBHI,R QX;A&'&5U]4;55#U^8K SX(<=8,Y,O7]X*2:*TDH&_X1RP1U2WQ[#C
M)B+4'>)R7RLH0/B#:NK[A+ADEG"O(U@BV\NT11%KAC4X2S"WH#G:"#\HSHT9
MDGW9F.I+1NNP\?Q&TEHKHZ?,<(GT+>D8P9++@3X_#$F>^N[X1)NIF:^DH0S#
M^E[7%%_)+;EBP>9K4M7CX@4A>)^=H0"T+:G#>LDDI'!@Y4BQ*A!^<YKQ.3("
MK_K64S"_R:\E7ZA1?)6_\SM#UE(2AEE"0(WJQUV?@AZXX(\8L?<-N,MHJ2_K
M@D*";CP>EN8E@>[!@332 YN[%;!:'Q6O@885;I*ERL$SBTF;6]6$D,8V?'AE
MF7U<_7N\RN_Y]Y9]<!-KBR]/SP=T3]-7(:^G_^S[\6+!?C$R(7Y3<?Z'*6-=
MT9U],;LPNLK-QO&Z]TAWS =XUYYMYFYO@>M>>(.D>WB#&CM_T.. IT_V@P.I
M;4LBEAS$H[7Y-/J=Z^RZ9W<46B;61'_^A-1Z3G(< Q_LQWLGS*=,&\:)Z<VJ
M*8+\#>\:4 1UQBFB_PT$ZIWP79QRW+S_3>=.S9*MBN!/3<:!5YSXKD$F,APK
M<>K#!I.[Y?U9YS:*=PK=DR!\<Z^V56[SN[E?2YLH^U612DUDS+VJ,!!"T:1?
MX?-6VE@^M]2$%T>U92GF/"'_Z5>UY7CH;#1O)Y^=M6M#0\/5M-Y8NN=61;<[
MIO86K2M?7!H(FPX_!O37%[/%I5GA,X=2M_917^'Z'%:-D87_N[]:G.2IE%I'
ME:M'#]M<"DXAMN&LJLT!=-9>0\);\/JYLRGB(HV7LT5:/T94HZKC8$O8U/BF
M^%0PTM06RH6G&%MU-7V(JPYG<:ML,G(-/Y#/X3EDF'Z9859B!S7(#+@_(+&_
M^?-<B'I-R;TR\X+N%YO[T"RGMWU=3F@]S#&06D08*"2-',3W5%IU7PJ39HSH
MOJ6)3I(53;)>Z'G(H5PY,ZMA.-]G>W!H#]Y#=\#C4T?3K&CN.[IDH^O5NFWT
MA@=?HETU_=PGQDY!.G65#H:21I7"0PE41P^*BD1&&CH&F(E\6&9&PH]#URYU
MSJKL\*EPR\V;.WH\%UP]GII(HIF,!'P_P[!G4F\[_9(C&AP#[7Q.))C3<P^V
MC[Y6P?F.)7[L$3-^?BB195Q0AWEQ$;]K\JZOZ<(1\S",P;>-KVTI!UK'E8IO
M,"-85"#%1[?KS"BG'M>GVWFKU8_\A+LD;*UYZVR!"=,@75H"*5E3 :OAQ(/P
MA4]6N/V\&6;BM2V["(TYSZ%>T,WJ%(_"6<L39)B[3KY I-Z8+T10MPM"\6[J
M;_$,W*],KXR=F6Q/,4H3D13)"H^\YDJ><%1,@&#HJ^/;($3VYPMKFSF"L:[.
M01G/C#E;O!9?Y^ ;:] 375>[7<H.U:MS9%%AMK/SNT2X27QTGOJD%V9M!#X?
M\3.B+6W:3)\3US=%:3599^='?:FIM25?VD[C7$[D:EI]L4*IS,>^-P ;O,ZZ
MF@I<@@RB#'Z_;V1&R8X0@=NU%##!<GYJB%?Q,]GT]D?+I89(O2H*;TX=_N&[
M^OK%2J)1(S\OL(Q:>H+"F0V-S&+[^N@K"=8(-?-1^<*)7](&CVK62:=:K:*E
M+33>4X6F.+0'OE18:#GL7,19.G$1;0CQAQ<0 1TDZK$M_Q;V(A_UAL[9W.:'
MVB-X"F]SE5>OWCM:#;6:T=U<KZI ? I"<<*6<L"'\^(#=5C*,> 1;=);P*92
M/D+EA-1L&V]QQ7XI=A ?'UPLGIMMZ2#K\PRE]<J6&9"F//7)%%--$'%L/N1J
M:(?Q("7 G)N9GU".$:]DS"]\08CM?GW@,)Q6RBQM=RAC+E4A]Q'[W6#+EJ4E
M_0PYFJ@/[AX94%JUHR=UL'AUAY0/Y3%CMI6/WM4UI75^S[&N]?UT9:5^QQ8M
M*AE[9U4]UO&GZZ$^0AO,M5(^X#!A[O&]@GRCE42]:%=E.(L)[8+U<J,-#T7H
M(D-"C_6FD'^O08P6:'?DR9<01+]#]9BY!=5II'D](ZX!LV&;GXL+I]GBLI'U
M4RG?WI2]^([\R4=SBGK3=H^S07TJ;:!HWD=)K9+(@&FD-';[KG G\RD?7LN7
MN,7N\3F'RNI,S >;J_#PEP\699^ER8P^__TPO%W\ML8B*SC;C1@R@F]'#!^>
M'%%DW39&-"L:P&IXCB//ERYJ5:7QCY#[1$@R,$Q-Q;B<9?_(R2,I9421DK@L
M0>1H./E.4)Z#$*77.KTK&V*-5WW*]-[3$Y/'MN^8&3KS1-1J+/%<\4YE7@J7
M86<]DU)LZJ-CP-N)(&Z8H,U.&D-GO5]*)2,<8B6ZX&Q(S5$B0Y-\+$D$O#=/
M1Q7)/>7'&5*LC_5P3A9__JAHPI6<2;H 55E 2A\5M$JB.F!M7AHCK,CS!"F2
M.@Z>TD*/<6*J2O7#SAJ%0<GMO5E,_&5%\S<?.]@^61O)Y>-:Y$/>.ZL,64?1
MH):J4 PQXHB:9:V4E\P/B-!B(ON$7&58<H3=Z+:L<F\<FD?0)FGGPMO>V5?H
M-S6151R*90S2GAV@IT+OD!1P\&25;8)QG2G3(H:4GD-J\*OZQGU@NEO_]'1W
MQ ^_(#H3L1J6("EI.82HH/1J6[+3F^Q>9J@7K"Z@BX^9%IVLALU.W(P1(\![
M0GRFCH$9JP8N\&F>++BS&(%VE1>+[1VC06M5\6G>6"--+;Z+[ZLFG'%SXM"T
M*4-*-A"\0>^@#H/%VW+=B<;Z2O\887'RX<YJ8#<6_:P0IV&M7VJ]W^CI;9/P
M?.EV="&N:V^;$(*/70I(U!;SBD!_7:#&A5IQJ]VJ[(V-\N6<;V'YO6./EDF3
M=M!;^5KQ*,ZJ VUJ/=KF#[_?>IK0O 0ELR&\GEKN@;*W*)/D<9/I7?+$R[5U
MUP-JJ6?K@JMH+$\_L!02J$PYO(SS*VYCDB5J17F26ZOF-(7N/6<^T[-"@]9D
M4MWL7ZZ+,?J&PAD5H$TPVQLCU8@,_=2+C81=7)?-.]QTYZML\P>B^6QOX]9[
ME2,;-A^,!)3.7>KO%IC"DT':GS-7M9X&?<Q5DW.IF@)I0$A^N6Z+2M(61"BU
M9Y%D:MZ,_?JD&S8T'74X)*^0V/<UT3!KUJ6?RLJW&9EK/(@W)'))&^*J-V&X
MA=Z#H>[P?(!P!XS>S*8KE?%+F^8!;/;K6?M3N <O:JV1>P\N_#P?(.U+R<07
MX*2-GR:R!?1QY4,()4M.=.CO05ZW"C8P14AYW.[&OE=BV.N9@9@QF03M4"NE
MWMX+9R_'5S'>V@:C:)PG%MX-G?7$H'JV>9 :N>WAK5""11D!=O5MZV3%=E6%
M"O7$S6*=Y "1\CX9RYVS8=\ !HYG5ZG'80!)&V&R5T P+$+\:&_J5M^_O_L-
M;:+1OXS8]PM/'DWK;/%/J4A**<Q\?!?"N59  ULJ@M&1U)"^3O$'JB^Q]$YL
M\WIA0:_ZR@D!5\=N3(O4!6;+NZM\5.@+%G91B[QI1"%HE;/2=F-D9A%+O;%Y
M*$@8[U*[^KU)/JF.F0-18S5J:VR^CF:-+ENP_S)X2,L7/L2N&,9_5ZD'V79X
M*J8/5JNUN!E_""/\Q$;$$0/ \(@I]"B<^91O_AE"(E-3TZNB*)?3;-_KS[9E
M^'FY6R0_Y-L,-;]]V@6R9[6I!YY-G 2K0R%"<BV*9SUGW"<+K9DOW%HW^HMO
MWL54VL3PS/3TA2E)S<1 3#;R"46YZ[ES.P7@%=1Q[9=&:K(3^ZY?A%F\*4$6
M P<(3KWJ_B]5T\(H2?.64?V)0^SR3]^VE*K*9]$PP(5BG33!4?J:,&Q TB+.
M'/Z "\58F\KA8^L8BZM?[$)QC%_ >V1CRK:=FW-\<S4BQ29<TRZ[?)F/V9LS
MZ/>4<N>'V';M79V&+3V'U<CW5/,0Q3X+G43[) 4D#RXF>8G/U'&7%=LX)B<O
MJJKD)W?=<,N5'=G?T25]=N Y\^@(#VF,1$M X761 I6^4P<>30L"+7A7P\"*
M1STOT<;\$=SRDH*V4LIE>1^9F()NFT86=,$)4K!.:"**6=,,.\_ULU<)X=D9
M?G5=R4>1H&89)V" ]I3DJ+>K[&BQ<K[SE7I8]YMN]5-M%=)@FR!LZ06*1].[
MC%"$^0BC:H%AY>_<VN_*E6C#<[XJBQ2LC [S/9NN7^=!-KNOH6OIX<YD9#I8
M4D'(*R=-+G*UN9Y#2KP@BD]I<Q *.FN^7?7QU,?G9^\5L'\?-6(WKQ_=TA4>
M_6CTZKPGJRI/*7KN,W7C=RCN6L'=@X).9G;$< "K3XYI0>RNE[* T^6)7WP_
M9/W'S1IG]GSA&[^%N66526X>8D8C3_BD'S$I_H(1I!O:CYPZ!)6GMU1&6+VR
M4,R[&G[,MK%6N-8BUTBFDD"=^"LI"T87:^9;5X1Y,A>92GC.5X_ 4V$UL.[J
M>R0J0J9J.0;.Z@5CT3Y/-,5=6Z3U4Y$7$*^KFO7AM6<4K1DIN[*CQ]FI&Q X
M^.[I:<I)#N.QYFHRHC;>JKOZE&\.*@Y)C]583(61DR2_M7&U.!<CBGIR/)XC
M@[-MPR;O!?5$>_+:VHYPOLO@8.:X%,<A\5#M,_5<%KB7K\O?*5J"/=06621T
MFM)WQ=!/"HTB#9I:,R.<49C#@07E!.EF8Q<;C)Q[TMV!NSPL1JM-3C/9>QN$
MD$,[1&(WK_R],$87K:A.?$=0Z7?UJ?C((J>>@*#F_O?6<B^2%VC#56<X.#6,
M^C6M>A>Y8,YM205U!GGX\KY;;;=O:HI4(*_CX5UX9PQ]I<_4.G;6!$<J$>C>
MCP@QZ%T<3A-T$3$,9N-PZ$FAGN1U:H>RVZ(ZKJE4)\BZTQ%4#S'NV7$BS=RT
MJUI$V\K)(0/782+-2[V6I&"#D!S@(P$,.RF#"<PX":Q3@J8$5I[3)W"=1)5/
M@[SBIZE5ZFA+</=,.2^<OX=P]JK$N*<%B;QQ;"&6"# GP9:*H31$@4,=[V.
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MPI<;;FS^%'Y+TP,D&.@)5L1+N(!.^9G%GBQ>_P;LB"""VPS/U;9\)-(5HQ#
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MHE0Q->]I^7#!H3ZK^AC0+'ZT'+&D:-C(^=,Q\S":D&&(DX^O_5+DFV=RY8G
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M9'5"@77C1-"V^%LSV[X<M==L3R)%LH9$,@TOU.#L5!Q!!1>5H,5$8K4@Z*?
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M(BWW*D?!UAHK-@65"-S5(:ZB'T//*N7_@!V%TU4QX,Y$G)&9>]IM68.[(HR
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M+P$J9&_\#/>Z]=?.,;V311F-Z4TK=WU,FMAWY>N-3RXTRY<*6]EB%\V./88
M?CUT,""5[\+93]\A"Q18C:^,8:SBMQ[DG(Q19?>HWB-DM<:47+46IN/EK7\U
MH35Q]LF/."JVFV_WCV("02I0O_YSB% =".T/6.34$ISWFO&N]I3B7Y!^II[B
M+A0Y79PMU*&VLJQQU3^@/W0V1S!8XM6X]?M@YRJUAF"A:YBRT7I7VFV<$K$P
ME*BI-E]CF7@.>(A,;68^1!O]HB*;W#N9OE(:$%#UX^=('?B-S;\HCU .T\;1
MUU*]3R-"*]:F]F#BK[>L$'E&#Q=LDE=?AR;\7BGVF*T,6F\CQ/(>G;I6PM)6
M@7)KZ:"33;%Y,TTJ,4RWO$UJ4/E.5];:KGON"*4=J+USFP %J2$"<RJQ;?"A
M*;^"'2)Q25\@KH.-YE[PSSNME.C'GI1KL=93/D?VZL!;]:7T;O<X$]]7AFH:
M +A&'V5L._[,Q8/,)E-]:KP,&6,>9=ARRX@/FMYI1/R)&^T*$13$.^5B'X^X
MN+%TIL8H9^5DO ^ZG&ZBV>SX6U8 ;5+CC2O]GF6:[8TP&?XYX]<VFCA2J?>I
M7-<1[KU[04>3G.:Z$8V'_\OBG[,290S9$I(8>8V"T:(A&1;.D?06*>RUU[?V
M(VKARXIH9QUOX@ON!67&%0-[2*G%#5:[D\>=N3CD3EP)^3%I]RM9+Z5?2QF/
M2%*4N;O)?Z1Y_Z[0I/1(G\,',<.;[]0^"@LH?V97& &\"D.0.8NQ^6E+1LY7
MAY3;IZVG[=)6JT3S[>RAC5X!FX$/JC^'0D,D;UZZ)X1@+Q9MC:*)ZK4D@Y:=
M4_(X98JWU4 Q2MLT;V3A,IJ%R.8I>[L($7VUA.=&4:J,H6W" =>7IN5VF2Z>
M,1"_F$ZY#JY#]6G=G*G9/\9**^=%-E<:!11M3B/X:M2^K-:PW6!A'%'4_QO=
M(4J1!]B]+, _M.^*(MXG.,<&U[/9+I FT()<7?B(.%R2\,21@)K]<H@/9_BE
M(9&<.FW#N9>IWTJ6.:DV\EC)7&+8@J3Z8]$F!.$M1C#6):!R.^QDH_XLN]"^
M?ST[_&-S-GMI)U1PZF7A_=?[#H<M47A;UCBU^KA"9,,X.:+*BWU+8;-<KW%,
M:ZH"/6;#HEOR//U^C(+GZ:^YDTLE=/S>%;$4AES\'MT+UPZ"97=*!?C97%_>
M6IQ/%6\0D@TSA]$LD0N^RI^GFZS'GS%S]_%<<G+;TBA)S",&(EQ&>KW@:-%O
M-TB^61MQ]D5F]X\DX=9\PN];.BLH7O\;&S;<\X?<HM&J^_11O:80(,'K%!4
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M=V%??M/E?ZB5_!]E(:FRY@:#N8>$#:\>6SE O^?0"[>DBKQH_+I1=?NR6C)
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M%WG;QEN>_)I HZ702FC)7@(RS2X^@*APIK9LXY@JCG5HG RSW;SODO\))\9
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M5X$=Q+M_@@[_V&C$7AM<SYH0_.*]8?K&F2MWP$Y:^>_E'-_'FKMML>)#:=!
MNAL7SW :Z^3$P5M59PO1UXM '=^6#_8LV_3T*)V:'ATNBIHX>BA>U ']^+^O
M?%U_YZR.;$YP[3T'T-;)13*!K?L6[A"^S]]_M]E]8_*3:1.8*?+X1Q4#<_4W
M@0WJB8KZ8>???A0F.$$=!^W3]%[6'Y2[1+Y+\C@%D?R>M.'7RG$"*E8=DTI,
M$8_5$WV6H3N]#+=AF='/-^C$ !S.]QTO@!@:Y5Z(+Z=P.(+Z\V_.=&JJ).Z1
M93P"BDD6%DBU[-T:*47*_7XJ.?8!;.?"U?2WO^A^3UI_ITA>3/0IRH@6\UD!
MF9I@9$;*]N")IH@Z.MALV%5=N/.F/_?2QU&2TF[8C-?RNQE/<OJB#:\-X?^2
M>5X170AR.U/U$.M8'.<8R1YE]\-) )D<<8%0$QD]LP%^%_>QT%V1Y+HGDE?O
MJPA[/Z7>WI(Z6*8P!IP#Z*Z1G)?J=SRQ?M<@K.T)9@3KM$X[B)S?A<LPC5<R
M A^YT++L--OS+F?GRQ"H>%5=A22!GER;D9P7K3TB<YP5= M"0+\HJA>I_&P0
M7?M*#SX57%UP!>QA"36:6&Y_.3?L#^4P?,ZG I4(@ \$6FIS4OU=Y3H8W34]
M!UPN//L<Y0KBT?E*.L4QVT4V1A1BP"FF</C$GM\GJ^;V#RCJ.5[SMS]^,&#>
MOBL.Z#MTJ.^'DN[R$RU(0@2Q)_C<I&YA!\_VM=@:%@ZKMQO6>WF/5H18-5(8
M#'"B]XKNO\[D]5A]"8@HU(6DX*LI3-6G,F2W+L*1G1SZU%D.VY(AEJB4DM*E
MO#=--U'LGQ;R\N#!Y1_VLYR\"-^%CD!>CH5(=!3>0NYM =XL=T:8Y%'E/3,!
M?BWE_>DW',2ZZ/E(J/7*TVRM,78&]GNIVO?!UY:3 7^WI%:=4POP=J#9?6+4
M6;$HR1FWS^UUHI)8<\SD(WJPY7?%B]JPL:-5%^R2<SITJM9<+4$7N1 J3"?H
MAJTG244LHLX!<Q/$;CP2?9H&U"?IGZIMY G6^T5YE)O*G-Q:N628VG'M!U(!
M4"A,PVH'.%U()D4>4I@:\>K+'BB_E!PD+>25*TXN4>L27K1\F47YYZE11TO+
M9'$+//1! ZR2MS7-\5X O\>U'8;K^V1V)(5I$5] _(TOZ"NX_-\VMI=  0W/
M0J;A>>49@\[F"8\N78]\S$(H)WK\9MU#Z50]^J$;T50GEW4AU247.']Q82Z[
M[(G%*4O_".ZUKKC36E]G%GO-<T!",).F\OZ3I):NSR&9?0V=A:T 988;EP(5
M-@M:0G87\?44AC/\S[G^ JY.<]8$Q:[[A*!3^ND%^XZ1AZMO;O+>B+,SY =D
MP?WI1)(!QUM2*\YL4;V!2/=S #.$&>\,W8,XUK3D$AAQ!W.HDR MODFWZ6"Q
MYL!<76DK#JUOM@8>XE==*^NH<2%D+FRGXZE'Y  &V,=BWT>1)!F=ZBMWSIQ4
MVWV?N?S2!U759R04-^WX??LF]V4#(6- Q*%NY,O(@0*\T_Z5_E.11? ^\>U4
M35"$]V-2=AU8#A7F%W^D/CQ<ZR0EFO(B'0-4U@^VI?W+ZV1=> /8(!/U<I&)
M;'$6#X>F=5--OWR.QY!>F<THSALY-'3"X="=L1]&?U"K*7%I(DFQ<<8K$AB&
M@7N:^<G_<@>B\):+;T&7=X]8Q 8$1?.V!\)RXUY";+4^8I&L6V'-76\WT N#
MG+<UBB;E#7/]&5DZ&@SHQCL#3IU(4GT%3:*EA [327[T DTS?IN4A]DWB#=J
MF?2AT?+BS5%R5X^GF_\7:/24.IK5K*B;81JTU)(OD(L&-4<E%C9/*SH#R$X3
M\(]*1D;[S%N/MT&^B,;F5CB\*>X9N\.>=X(C0?>F 8]DSR7OA0D*HP_>RF]V
M:Q 7I"6;N8Q2*ZM;$(#%"T@>&-NM6UH_]U$-(O!@TC!-=V__L^]Y;,"H<$_P
MKZY_0?/?79DE) :*S21U]/+U3,$L6_-_!A(/YAQL_O3TNR/R&2S=XE_\=BG.
ML$RX'B@UU,WT7S;_;]<KAFZPFQ__-P[BIW0\F"J:,Z'3]4D7"9M0"F^-56SQ
M=S)BG!L*?&/S06?_GT'OC63 R>-D_*X"A5$.7V!Q5E1(LC^#U]B2J@[-6\=V
M\DY1)W'YGRH6YPHSO8W"9UWL/<N>6/DD"8E(# 0X#+Y%+M47 #0""$ C_,#'
M9:GAE%I7>S_FN44!.C/H0[Z&C&7*:/CT6_O2"?G;-A]1*L/03GFJHWXN+.&B
ML0\H' N4<0ZR1./TL;%S_[1*@C&2,O*KOEYQ5W;GOKORC,I8W_2O'\+\R1K1
MZ52]-ZSEEI D:;J=4P(3]K]:?(XEX(5P)#W)";,0OAOT(G>[7"/KNU#Z-$.J
MD*_LCQ*Q6:R<^#/."@TSN@E.ZSB2*X41A,_MOV!0LO%RM::?C9ISK%^6T8RT
M")Y8* @O=5(UE5UPO(LBPC/(W[Y#I=:8Z;\-U8 OE$^U,\TZR9DU^2:!%G&[
M=6857Q,F$LDW:8^FLTR6T[*7V^FEPZ KK]QZ^JPG-?XGO2+5D1O7NIWU+E<1
M6>?L8[W6+;#3SF"),C2DTLZTUG/F]4V.2T-9 7XBWO[)M=?^=% _O4Z=4<";
M16%<Q>=BZV,Z^5G3.A_G+B@3Z&*.%OE,RTFF*$Q=5;.-XP.;Q5Y.?XV^7_*J
M\S>84Q"1#(#H"%M=2,>%!;_\DN2T"%M'126HJ9%2T+_(9O@*@CNT_@5&:958
M< N6A6)!CG!**[=EIQ@8&+Q^=K\TNNX-:*D22+U"VCT',.Z AY (4,MHO.XB
MT7*=J#HUZ*CHI64]JS63KU&@\GH_E[_U*^O7BO_=0L[_$DV=SG5::667$9@9
MQ",AA,79,EE_5L_PQ(SN#L$/]SZ2>T+V0:!BP%S&]2:]J%"1\I([)\JJ[A2V
M_8GU\']*IFQ>1I4&^]<;6C.YH$)"-U9<3[*&]AWU!YM%!$7&:Y?]8)X-]HUQ
M4RCIOS19HCA0ZN?PI9F5@A20YP4B3@;3X?57Y\&CCF-P1[63Y\G?^6.YNJ+3
MOMET%K3? U"_>^6HJL_Z3.'[E(1Y7G)9UO0)HF7A4WZ+"YHDR]%KUH^34,NJ
M6YC^^ZPV.&3&T=KQDQ7(O!M$"CL'/,'K-5:"O=Q@K02]+VJV(U^*OI,'=(1
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MX^2GVYZ<H>HE 0=[MSK\ =L6.DS1Z0:-8VC*"?')$;S>VSX"WCVO(FI;)J:
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M@VCU%/&@49811:N3/IG^X7L'A@RN\)L':QF)(IQO9HV8^;:[-2B+2-9(6HC
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MXNG0SCO[\7EGU8F4"=^46ZGI;_)_=_A$O#W0!.\[?\B_>_:^6PB,&&P?R W
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MS+ &0B@)D_^=N**A'/]MP=,^YE7+K:N3_MY]\I;GO.Q>1V>&GRH/LMP?H@O
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M+ ]\_]PRW$:8K<N&X3@*7]YX8NM D^L._GQ)IA+O;7]'MV)]8F.OC?FR=+!
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M("'.-JAYI-KQQH@BS?2EE,H5*4R[T#C_023L^)&.8J'.(05)JUC_4YO-$(&
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MG6.*R>Z)X5H#7 EO] 4+-S#SNNC\%6V:.$4J]]4KK9SZ_-%LGM:8\^G<ER'
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MJI_\FEX1PO?.IV0^Z;H+A%(:[I(%DZJ;6&&J0_?RWW<T</W.']*YO?>HH/-
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MI^C.]M;1U6:?XG<>Q%AXW0=_K[O^([3$IU=E6&#IS:TSM@^/9< J"\3_.P
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M!\Q?0>9,/*I&3D !I#$&5#!/%1$99ZDO 8/E!XP"YB6[8<K%(;N.[L8N)YT
M<6W;#KZ(<,3IVY&C9_00LB./OPO'6X93S)D<F12)7:)L4M=YI"F,_-19M1D8
M@%.@?=;X4CQ7])19(:[XA^UBO0R0E/9OY7&26>T_=_95_DF4"7",9H0\!)'
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MB8YTO9G_5G_-^,,+_V#CV\(/$KJ<..;.TKG55?9*Z \4B,)&V&&>=_4G4T4
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M4_<(*9&W?6PH0>!#3'V4$/V^HLX:;(;C?933\"@#[MJ$;G+]L-^V83-3Z"Z
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M8SAW_)P4?!!/Q+6#>9&08;^>%ALM@FG] G@D\DK@:\^HLD/= 14^KOZZU)S
MMAT;W21UER*D$M&T@B#MNJ[&Q*=9D67<^OWE@]G93CY]D8\^4=IVO86A4A0Q
MXDX[# PT'K!\)^YT);KU@%E;A%WKO)'WZ[)ZN (.#Y52$4'[<*>F.I>L3;.;
MUHV]@N.Q&5)Q=+9WX@\,ZDBR6Q6DW/;6*MVN1K2;^>@99"7*68Q1Q>FWQ>/
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M;:^/.8N.S0.R].,_=H^5CZL>1^ER_9R%F_C]^3HOW?1+4'CI)__SK!>W-Q7
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M7="/_%T=-I!@-ZW^9D6*_IRFR%_PP:V3%#."(6Z3KP@X!>&W)DOR 3-=(#8
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M9?.OTRA3#.5\OHP_1U/X,_^(;[ELI'+>ER.@RED2;"", =Y(577%-S*O(]\
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MI(/"#8X1!#N%2*UQ1]\ W;+E;X#)GV6^&XN^#RV"6Y_FW@"'"G."%Z>"S[H
MIUEUMC< ,F?5&^!+2.D;P-?@#;!]^ 8(^J'^UY&)J+P!.JO? )=.,#.*.A//
M5,N=+RA$Q2\O?WUP9/XKMO6WUV!TY=?7GC= WR2BK%3$?N>_'Y_\=Z+E&^"&
MUC+G_H[\E<F/YXO?#)K(=//%@Q34]PF'0_[/'\PW +[BQ+:WKO4>L#LCT_@C
M[VC<EMO)_9$FQND17_R1JDT5X^DBD'2:+*S=*OS!=V?B_4.&/$CQ]^K4+V0X
MA=B]Z)H---]X#I_G,;QBEJ2LOMAO<G,?ILRM9%*4[M,ACA7U[^BLW-)NQ.U;
MK\HF(!OB#BBL3[B5^*IU;6VSMYIQ'T6LB:K2,;8?UN**^8C"+YR-G-2 +O$X
MQLM3YRO!CY([3_.XQ+ZHYB<!11W4CI,_+QF^G]R-J'(?'O.HU:LUX$^R5QMA
M/DN[(SZI9UHP.E+_>,D='*U]#Z'H,ABH%F@7<_'!E5*1<[^2)/6V+!EVK<\:
M[)TN^#E&2N@C2WS^J(SULKTZBVGDE<#W0TT(AI"&.MAF2E>=&ZPX/(K&@LFY
M%C_TJ'%/+GWX_:,&PY2ZZR@7Z9I[.;R(,^!%C!$?.SH@@O:?,F: ?X;RG#-!
M?1;]B4+.BVZ;R<H&#HRI9EX &]4T@SE/'0E*=_ME9:"A9,+O&E*OIJ70?7CW
MQF?J\$I>W0W=G^\2XFVZ<V]@*]IS6[4I3,)04[&J44=-0M1/XAPU>"#/-'QE
MLGU-/C1&>0^=79-B=S*H@Q"%5H&!+X&.)(F) UK'6]F@L!0-*BF@C<C'08Y-
MK@[2!NBL]>G%!5]D>0A!.!!-X4/P6@+/# .?L/UFNY)$=:=GI,:W[Y/<R^2(
M[V 2'^?HLT:/%OZ>P<]8-XRXVG(=H4HSD*I<<,0V1[Q D&G%?+'^OQ']KT/I
M/:%T]3NRW.DI(22  JP?X!!>M7T&<C'SX?,H#_,Q_1H.S.C8EKN#UX]@8+5]
MQ,AT_=*M.74&8K02.!MA+?-<.?!!W:B$NC?#NUM+9D\G;2+I89R8Q/ZVBN]!
MV+7J&(^GXJFE@(5Z-[Z -FVTM0Y(/@!0N0*J:EF5SJ^X&7)0K(Y^>TDFP&W&
M4>PAB*%""<R%S1%C3U@,EQJQRXN@2\!1% /\K\#-JCRR@IBKMUAQ3M2+*G#]
M//7EF<KS$Y"?<XJ6Z/'X63N;:UX@/CBQ%F=6PM\%&;$E.0XXUBQ4R>!*IH[!
MVS*D=UN)M0$=6LN+ST#+;>N.U116^XXH#\A%EIM.<@([<)J26L1<;3!_]X%_
M/5\K;#^]WUF\;(;^2>_HO6>IJ-.<V.\#?6BU<:Q^BIIQ>@$I7\8TW#UY-S/R
M!>]Z><7#NE,M5!X*HCT3NF*NZ$=<[;, !QJVC:+*<?G07''7CYYT8Q*_,YXR
M4C:&^:)9Q;X!=*DQMA7./R46#Q0<X65XZ0S88O=C5L+KY$5,3OY]; +^.Z"'
MSMW@I6%SC7K0'EN.V7-=?6W)[%=RM1W@#[4,'RK\":'M_VOX[?;E8T3G&KCJ
M<RL9X[J65D*B:I/T;'@?\0EI2I\6""N%[4M/[-!3KBI<$HS.L%(57#_+B:.;
M,17[XN#%23 <XRIQB<?RD:&:$>XL4%:7T@D&UU6^+^B@\K#NC# P1;5'EK]+
MVE7;99.P?Y] @Q'Z$W>/A[0MSMQE^'3LH^ZXCGZ"Q\%ZZS>4Q_P)/:],C([Z
MPW'K9:W$L'QI9N60; D9,1QUJ>[_?>O_&2JWVC\B^>F/C^=A^'[W&VN$]S\[
MQI;FHOG"^0XV^9Z<[[P!Q*%.R0>^R%Y2-&'L5NTIG^$K\+%]KD1&6L&&@!M
MQ(WT?TNO_ZK?Z-=4A%P8.S7AJ06(7IZ?W "(*\1F-H=>(]-SEZC0K&#U6_^5
MMLR[L 3V[UVQ:,7OG$ZM*F?AIV8J!7J'&[^P&C*P<AE%Q4I?3P0153:6+QXG
M6JI=:FL/N%)6F!<STGWOI*D^>IAU^&LBYL>,S\P.Z*,]I'.(MY 'QNV&8,-@
MV-Q3>BWZ)*7%<#FEU;_K,?X_OWFH?0[WDK#>:N<Z8XLS<:PEN+[_\4S'9>+R
M:5K==$ZY:<[ICW)DY(K;1/X@O/OL4W9Q*:64NP,;/2'0WQ@)Y0_&&R#:V))(
M(X%TFWN(GJ34OM7BT%Z3IW)!LM_9;&3LG8=MZ,_)FQ&@6?Z$C2%K6Z&2D(\I
MF*/Q&_>W0_4&3(8@@A3P5Z&++E-2ER?_$^U7LODVU8*5R#2;^>,I.):&ID3J
M9)^[U2L6617=KZ7;/UPROWL&XR9OG?F,]+:(>D1'GD=WJ.D=]I1PE&ME^8OA
M*,#\*R08+K^P 8,KEF[]!X,%-V5EQ6JIN0<<M?(2M@DZGB,ZE76>4QO9O(^(
MR0(C_ +7R^.=39DZC6TZJBQ#8=([ LH[6@D$&9A\BG'C([Y "PS@Z-1+)V=L
MWV--;UQ;&EP28SZZD-_/F=2J?$^N+<;H9VK7V^]\IBIN_WN_=Y2>;&N\ 2+6
M0J?* :5%6*JG%AU!WI:UQ\Z*#P%C'?=IG8KJE+.,G_XD%O.']]GCH.T7;NU,
M-NV8-DKX( $I F5TV+E2WY.O#9_<<)1:;R-/;IMH(I9LSK/^I*Z903,F>R)E
MQ)5>48&V_-+D[+S7#E2WPLM8/8Y*2I[\ZZ%#_N7L?Z1 2_2C#\JHA[G[0F3Z
M!C K/E!P"RXB<L/:_?@=3):\9U5V_+X!8IG*BMB4/K]4ZTB@2EQSY.>H.2S+
MYF$7J!Y_K'Q\S^)XYZQX[JA9?3RA'Q6G)4S$FTY  61PISFV\@OLQ:^5*EX=
MO%?2%D9C&7U1C*1=UYZ-"E3H7H[*\%JP;^_^;C$R? \?6,( 4)T@;>=1XZ"F
M^=T0DR:>#)4H&MC^F2G[7>A6#1+)*#W_[+/]M?JX.%#O,_7>&^#.L^U\I,24
MG(EB]V-4_+CG03-D U/&R<01V#2+IR/M][NX8>IE5:F8)WQ9*UB:7<>6%%,M
M+Y[KN^Z&)\F+A57%=??__D6@;64'P]^S[)!SH<%\^B4XO2#:XXS".+8(-&U^
MS&R.6'HM%AOQ/7@L>NZVK19:#[LL^05$5<9#_B,9N#)=)(^CS1@HLK<JE=9=
MP?I^Z ,LQIY-?K&\Q^V9ZU9HR.U2AJ/-G2N:P_1RP]K JE.EN*W_Q#YYW4-P
MBD"WC)W\0<987WI37>)<FV$&I&=U=<6]3@3L*<_LE<<VSP57<J&:>\E1H:@3
M;T7;U"P1O1GD<RZ[X5H%BK5IJAR0?."U\LK;:A._QUM9PDP$*"=S ZF> I=;
MU^"V[D/;>"DGK"SVUSY+'?"F>?-B_E)2<&W%![8OB6R9A5;Q\6]1I([4>J9_
MW1<X1 + 7?2YW"AJ9?RS_2MA ZA^PP/>^;'* 2K*VW5@E39R[B9NRCQ2"FQ(
M^K H/RZ\E!6T@\QGID]W2_4N4H!KZ^*KHQK9^\G*[%/SA6I]7W^P1I"]1]$-
M2&+.K2YM8:^M065DPP4YRO9A><1-=K?]-0LCG&"K(E8V>[I:9135Z61B:JWX
M1'_YD8(E-6EE%U5'K$'AAFBHP#"GXBA)$ 66E@M/[WPO57."H$]>R5G!BB)(
MQF%S#]')1>V>15>4*KP6\YNBT@*QM2MC4M>.H.+B@J:5(^DJ*H-9X*P'T7XF
M6%X\VD11\UQ6#$?-=.NO X!E+2]5 Y1N!FJXZA$TQ$>N-"9)C4\WX[:*?4HD
MLO[N@+D5V0NO\&OH*--7.D80<UVR@"9.!1MC87#"X_CB7&^\VS-MRV*9B@FH
M'+!X +?>)!_L0QO8RYF1Y))25\&R)@62H?TU4O-1Z!8.(E\G7M8V58<?;&*(
M=B7:]'HX9JUA?M> IHOO5%P1/5]/6Y07CUU*9_/7*A5A_IV/^C<@<FW:/N)C
MOGBO^A[.5R8T=_Z[^RGI7]]?:J9U3OJ-6'2/!2<WD$\F8@R]]/X)4IOJGRM'
M.OX ]KY$8:FBCY9S_OPIX\I!SZ&"KJ#SK4)B6"1=7@A4:.E^C,XF6Q2.A$E)
MQ\]JK[0+DV 5F2I'U)>DSH4V0L/49!1E]DP_2I29,(";V,1(A)<^^S)+]EH/
M(?PVN)"<7QQSM:ZI1;LO'B\N'3A8VJB.PD@T?#RAW*B&+2DCS39)EE/HK'RL
M=G=WPL;=$U5R;NE.>8?H$[Q$$X.[!BR#6<UP<AA@,-AQ=N(GE!.NM-[FJ6]4
MU*VD)%9@<G]WY7@1 ;$%'992)S'5@JHEC4A=R0XFE14C782<KHXY[;[&C=B%
M S-I:4K+-7'[-X[LU_H<]EQ7OWP1WWPY@&/4SO#)A125CV]*$:!L/LW46@G=
M<&@FBVOX\1]3)="E.ME4PG31.VHHKW+FNU1?,8Y^W0V,B@G\/6:VTMM!E**F
M*1%W+,,D);!X7USXZ!$Q(&OO;&W)QC=$<'1-E!@""$ "!H"2FFM>Y[K7Z# H
M6>,PUQCOX<W-\5DEBB.M$L,_DKX!6L46OFAQQ@ .(OQM(+MIW8E 203IP#'C
M;\>Q]F0C;/'[#"9_C-\ 6OG.A3T6+ARH[GAT(OHI_/;KV6,2Y;@Q&1;;_JC#
M6RH.4B60\[.+C]?6>YH?N(<S#@HSCP=E8(U2%-'T[U^OE9U*W@"USN M<L:"
M4;ZV[+>_\[&OE'(V3S6/F9N[%J%.?2!/D!,(A1JMZXH865"/[@4I1M6H,OA^
M''/4HHFM']-Z\J7D#0I9"[T@XJ2.K09L>EN!5XRDD3?2R:;$'//[E\FFT@_&
M!0^FO[U^2GW]8(WZZKGJNTG5^2SKF!T_.:5S__QI&?_YOND-\$O*]R%#<(MS
MLO.@?> 55N8-T#N)**(XPJ? =*1#>U\A=NF3;/?597KT&I<:%[*K(#];"8J=
M=QXYD3D3,-'?VC?B-LC,59+C9U&D<\B8*2IT65H?J5BA^*7N]0:H&SC1("-_
M'?S=!^F#)E>4DMQCVKT(7).\JH[H/-2>;:B9N?4B ;4%4W\:JM/,&JMR+12V
M:5-KIR>E[6%#V\@,+-[[SR "#@2CC90<_Z =!Q.IW7>RS5G?CJ"&H'Q:'*B+
M4@NCB J,UZ-H&<]E6I[?9ON &\;>*J#1:%;5_&L'ZD$38FNF'5O;RM;? ^2/
MYE$U72L(@X0&A/(1SDV)X4[:_V=?94G:&X,NOBM)5K1)^=K"25\A!2DR*XUJ
M1"5/*"O[=@M6^$XNE?ANA/D^1!R6Y&*XOF*]&+V&C(F\/HO\U9[B&P#IM>8-
M(&+Z\PW@\_$-L W*R_,#;SQ(W,8^$7-@_KG\&]MC23P#GP9>T#-"7QY"WP!A
ME1$1@+WS-MX*CH)A/GE?%F.#O31]F(=#'[G;/C??+J*#8"6VTI-:G?Y'RCD$
M(WGK@9P1W!.HLF(]?D,T^66,RI^9R+I/EI<U7<>H#G=[UBJ$/%&9*/M3-C];
M4T>AS0E2E$N=%H^.\ZWXXM'#W!_]NQ B-G[(D"S4UH239NU=Y:81:SLIY#'[
M& H6*L_62^TDF]0,1G+'XU]8GR.65.:EPN$\KE6@N##/6Y4^]\:,RZ_3YZYS
M!L.6RAKYVO)A,OY8=7= 0"9\E#P;<P:<<3#[>DA5AE&SH:QO*+6*BY OY;NC
MQ5S<APL$5*R;LTB9U"[=Z<#T1@\976C)L@+IVR(J#E"0NVP+R1S<0_A/VM"2
M)[C+]KW1FG-$\-8^5VPU!BU+@41E\ 8?T^['3#<T+&$^N3-JWZ=]-#@0R%W0
M[0B)HTPQ1<DU3K"#QY?);<^7$(3[MLJ7+98HLD]9=.2&57)VH;8WF9\P%3C4
ML1M#;3 P0Y9<0L(:@H82'R?AP:6\?\KDT@ NYZZJ8%Q'#:-.,;7SZB,.F9J$
MDVNIG64RMHJEH&1YC..:B#AL5+(IR) [PESN"*4S('V60I,J;JEG&D7-1#!Z
M%H?J3P?:>!Y\X/5%^E/^!EB X!M]W:^/F.Q7);UA7I!JKIG5VV>8P$(TA$68
MF>&^+9(W\_;&88;64DH\*W'I><,[@;?C,D)FUG"*/[:_QQ2."!F0@;[.8Z^L
MB">.?AD\;%IE6R_\U$*.>72:WIIL)]D-]WQ,=1I-V]5HY$8+!\"@_76#4Z\.
M/@SW/_RGJ@(LKA(2Q7LWCE'+;)R8;;$4>'74K)*#(G$,03A=,9R,KY:RW]TG
MGH%%4SL&Q:QI 67OFP&T%+YL4F0I:F>5P-HXN27X #+'J#? QT?U_"G%TZG:
MR@61P-CN:[WTMA&%<FY4NL3H7TZOSG-'6J(\QKYTGS\2,'CSPYM/J1)0B1X/
M:_\U+A73_SB8^S]A>NRAM8[)RL?PRW=#=73H0\]'*9QRC-P%>]7SBJU6V=HJ
M_C1G7&DUMLS/-?W[J1R%KGDZ(BF1]Z5G\[5+FA@$[[W1S3/,^/+F=V+9_39G
M7)7V2X8:8M@&U!*.B29"()MI/>"F^#P[#^ZOL3T<<:]43=;R&G,&L* 3:SH\
MC44SX[ROS'T>\'W!D+6]PMFI\XRIR.Z5L&7)KJ<YQ]PC:V]WM_DPT_8H,3LI
M[GB)DB.9Y%7+/.G1X7DO&>?"C65XI-\-Z8RSX3&:LVB.BXX*?P.$D:V1AH[.
MV@P01$"*KUXVIMC&1TYN:X*CRGHKBW+>*9O7<)I*%HE5<N**2W7W)N\SFOGO
M@K*&@G!#YJQI-FN1.76:/7)I%^/K/I)3K=>\.&$#@R2\#"]6;,:H#B/67;C
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MO7QSY^[>F;N[,[/W5O^>?]ZWNMXC=9XZIZJ@2] MP$<9"6D)  P,#,#H[0>
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M#CFF,?5E>MB::5 Z0J3>71P7/,[V^QC&80=FY4B"^0$TJ@G.3K/8(^]5T%@
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MCBZH6*_/B<(V+((KRH_-FGS3]%<74'K0:IGZC1V&F\2Q-<)8WJP-T/B4" 4
M/W6]R?,FT[2LSI6>F'U;<0;/XOP2S.,BY\_E;^Y"E N<]/(:&UXW-!*L2#V7
M%RPB!&?.WW 6AE3%L958?D5^!OR#2O8=T',DZUO6^>6-_R2IW=T&?16 KQA4
M!(=/7V9CGVSK8>;75ONH4#NI[,J<XF>JVWD+19F_7Z>\3Y&H"S^;=+I$F_\]
M*AHD1_Q<5"?P9B;*E%@HP. M3?CS+E ;U8_2S?72DD@SJTO)KZQB85%9$CAF
MBX\5W9> 7C+@ZJK:W*(L*QL@9E%L2M_%0 36_Q4I_AY;6>1_!WP#3"@@[HWF
M%M_HZ9&UW+VZ_8TRR2VA@*I_O&JJ<2HN'$BTTQ4KK(&M+*X=\(_!W"OYMQV>
M$T_0'T^<H(#\G#;2?^_3W^^%">]'Y9D-:GXS[K%(N^+D.+;0$40&"#,UA DO
M[4D79NR.KP+II=1JC("6:VQ><!2538/^"$T0I:!CVHFB8IO77ULH,6@BQFL6
M[8UW/3G",X6D>HH>F+YE=LLD4C!AZ_;>_"@8&[5)3&?C^T1MM;(O'Q8.$,^V
MF@V9M($?W.,ON2&Y<I89NGZJ2A>N6/I:)ZATNFOX.=/S[4T]P"A(;JJ *YR+
M]H_M<U*]X9&7]))8%AR*H+*M -9%@!$:OTGK!/-V2D?Y@VG_78VX1:5>'V:^
MS#)5?#MZ$J:BBTK>PN#'OD$FB(8@[NH GXVGQFH_7A/&LO8$YK".Q>",CT^&
M+@C/T_M@@W=WP?:+U,]4W^-BA#FL^/N%*&^_+&]O+<9ZB>F/$A3F[]T#HXQF
MM^L:FT(H0C<^[XA_""\!*/$!!.E=*D9:(;%A#&"SYDR=VLM= KM$>)Y'-'DE
MB&84V#46Z5.-,8<'DO,),>:@&)."US- .-HU%9<KU9$##_?W&'(4&]\[\ W)
MB;#AQ6ELN"N!:^;WRVTC@3I\P&#?3S(916-!Y8,4ONRJ<&""97.*%VR! Y#"
MKK!N9&I=.7*P_?=?>YI&UDVZAWN8>#' H3U><,]#V^[/DYFRXR[D9^V"A]\Z
MXK=/7&Y^"^,P)NQ!:E?QB;."UIW9O^XW7EU0&Y*WN$[WWFIZ=:D/CLO'$GB)
MB=W7%5X,+@K?+>W-:V;ND0<U&_TI&J:9[,U:&UKB>LLIJ/J[B3\J\NSB5WVK
MXKK@[I-VU9=V UMO6W;II?T22XZ.U:!I.>C W-DADO5B8J*6^AEE[T52728H
M#3;*T,F<_1%E._*MPN%>5H ?"A"=$'Y;Y/&>OT$!W^OZNJZ)W^+P@@(T6%)G
M$3GX[Y\=&_#-,+S*6G+/FE(8D9<\-BD>BD_0SF1K._?H9PMZI0X:HEKS#4:;
M>A5P])X1I6V[18=OQ.Q:\9PTW,8?)5CWW3?U$\;<->%F^-6^T]%4V8.YV;TN
MZACX6Q/:!A&\<'94!WXTC5[G>GP'@E4YB(DP*D:PJD]?U+&:^2:$J4M/Q:VZ
MJOOQYR:\Y: T38[68:ZW9;#.?CM!_DOEVNHXHRDJ!B\=H'NJD\4F5+O2(CV_
M"8+62*+&R_ 7@/#S(94D6NUU'6(+DRF[*'Y<LD;9VJ2DY1TZQ)G1+]IF*UPJ
M#284#(J$G/+O"DZT'VSJSF@Z$_.O-BX8WB-! 8378(3^%<4(QO93ME-S^KM=
M 3X_<5N7N7P>Z^FJ-SXSP_XWYZO_;QA[RKZ*3$$!AJIOS/1&P[T7J<^!N:^=
MQ6_\&=ID3?N,N(GS[/58_:M%'6(VO3[F0)V;AKD]7:CY <,7"J#U%%1PRATL
M>4NQK/PY?FCGC #;/'_&)U73;7?S(@@S0]PF><I9^"/I8S,'[G)7R,PC1W"E
M#J3L,?:&Y<Y'-,A\ CK"O)T@7:E6Q(,]^YJTF+7#>>V%ZN&KST#4N4>?2,!)
MFR;)1=.K]$W8BUOSFTA3^DSIOF[(&/QB>\T)4CF"JXVUO&)33LF5-O^&QP+X
M">GI'#X>-=[6K<D*]8>:PK[C9>*'V:BN;#=W-66V,HL@NVCOSWJ%?;;6VPFA
M&?U[QT]'/\KL3WZ?J9![UZA1D38YB\5,EFWU-OEPP/944C<^>+5H_MIQJ8I#
M4;$+":6XQL3RO/RVWHS8PX4QG@E:V0;<1,E)>QC'M#>6(LI2"C T#1;2.ZA"
MC!AN5E3TUKNT\5?<U:3UF5+NONWKJ#+[SV1E.L>:0N2Z)GL#I<U^PYH()E$N
MF\%:BYTL"Y6V*V>#ZW:GP]3X0QTULP*01TT:A!_/FH76[.*HK3*S?!.41"+<
M=5OP_"*\ FH^XC[$L_V#J)]RUWSLC._[7L49)5];8@_HZ7L-!!LA*(.]QQ16
MI4P@CZSRW<K9%WK-0;)+6FOAFW$0JT:&#Y&$C,R?U96N=;)D(LVG_,O"7^F2
M\;Z2D/Y\72'"V;U+TUB'E0,%@@B")73C(/8'3:*"-POEJ#HTY-E'&L(*;]EP
M[W!@'75]O'%B,;^RN-HU?9;I(X_=O]<@"<UTJ?)KE?6K>4E8K]3J="&'0X$]
MF; L2Y[218^\Y4@(FQJ_/H55GCVK;^&@M?^B)P'&\ET;1H? KET]+(IR%J2Z
MG^*L=Z>ZY#NF*>$$#K)Y7PO<59'E]K06L')$,#!-K_X();H]W:5V]JX^"E3I
M[629G0XR9!MLM^?^-M(67XTIM=GSX U1V7;)7"G_XP,3*#_07]$?D:]&_P?^
M_)6NA(Q>JA'3P)"N!Q-.:?=;]\V-L.)H^^O>_0Q_41-?1JOK%:[GM,OE<T&6
M<:?;UM6$J=X? XJV_D7S3%B7]CO9IY\!_KY-8W$2[%%S3XQNS*NW)C;>X 8H
M(/R\:E[;;A]&%38Q -[I/!)L5V:XE#1?_Y SO^U($:^ _W@XIW8GA#EW>I"!
MR\JJN93;H2<\52>0 [\EH5AHL;&J9^4U6YE64=-T3DGUL84 7V@KN >L\XG3
M;Y$T;'8# '&^'^I3WF@MT^_?4!]E%NEKO@5F'-N,^,,NK8GG'7O44F@QT:B'
MY^ZLH$D]*PA_N"DK<!K1_O,6Z6Q?(C_GO?M? ,UB46+Q^CJ!2%!FPMC*0!S=
M7IHH+:?EKO1U9"?V\8,6:.LM$R+<_)6_7.#:KK;:)GLFR?H277EF\:21F,)+
M\U=?X72C:^/P9(+SFL1"JM^!*V88FURC>GB%#ZWCO>L4A_++ X;7$,-[) 9G
M3,RO)GPA1M_V]#<WF"MD:Y_BQZK"&EPC3+0YU*.=&MX'=/<,[PI&T!Q;@;;)
M%@1FF3/SO4*^X#T!)J>C4 [SNG>7U#MT!QX-8L9IK@K4[2HOBK;"-J$ L$ZC
M=W+V2Q:W^R+&"%P?:Z=3:^F,E?Y:^"YVIO)^ZZ7$%RW/%&IZTOQBR@2MD 9@
M@K.BP5ZBWF& T8+YA5O^46ICM0[!IV7BWRE&O@N3"CY9&=<RNYVX4,"(4#44
M4-E$]LA[[(7G<9=Z$^%NZ"P !0SR:;1]ROQ4:'_.4M>5I1>.'8"T>G5ZO7M1
ML<H<C@2?:(D]QG'U)=- L!GM:]L0?TV4D=_:TV*G[HJHS<$#QO<K,S8AX8A8
M52V^X@ !Y@K^$9>"WMHN1BJ"B(@;:J<,F>SX%(JR9!+Q.8BVKY@=9^%\_L8Q
M0UWEU]JOX.ISC6[]C>#$W-[R8\*^8UP-/HMLQO6U/+O+%9CFQM\LS30Q?#!G
M+@:MN8CM5#%$?Q?E@[,X9W<?%N4+/1TD?O>\3LS:G2Y%X:D]Q#XC7LDN9[V.
M"$[Z]*Z@AU]W(5FY&ZZPZLICVYK'2+7W%M08L>=T!^IT&4&X7^!/01<?0=&N
MV.J7P$K.?1RSU+6NX<.<OOY5(K[YRK<)(A3\;#/BJP_66UJ^=UXE:,*5D"/]
MJQ\H'(=S_M7,Z*Z2?H@4I@F"&XC:$538L1_W:;$VSOOGK?#/$M?9#PT=A30*
MTO8Y$4POL?RS[9;1N/B9\EZ4$7(6>ML$LF:Q;7$@0FH(N-<^OOY/C@6,=G<W
M:\IZ?93'F$O.C>A9;&A]VK6?^^#MC+JT*6@MB\4EJ_QL!02\P5[RM2I6+!ER
M(2DXV#5N^BCA ?]EJ_3P/C4[G_AC9U*6 @W1V;C7C4=C>\Q.[Z>F#-J^H2OS
M5(3 V8NJG[Y: ^TDOOU&::) ",X!*?R]C9\'6++<QG$$-8F).I1VD"H]<)BA
M(\P9U3LV2GA/90YTDO9J4IGEI:SV<[C"7ED<QZ*8?A?T[NB58W:>1DC\FOPE
MYTA"Y@ECW:^\NP&$>M_6[2)W*4K9NZ3J]@$)Z(C/<DCLG!\<DWPC"/QL3M>-
M(_!14D>#CNW; T:[=JGTA^XF'[6@JDY.7KB/+D,&BK,-TL*1#4A5C2^_A"E2
MDUDDZTD5_MIU^_M?'.8T7+N77^SVZO18MDS;S4B<4,&..E2-11Z8WV-MN_O]
M7CO&,+H0&#!^!#.IJFNV"I@(8Q[''S/2MGZID/O>+M5=@SR)..C\(W@5!]N?
M9A[KU/ALOGT][R$^/^Q#FX0H'"GKXJR@S<KFEGT(^<IC] /I*L)UN;LAW#/P
MVVJA[%B55=$_QTHBA19J9;V/I+@YC(N6[:&>E=I53O6U7\(\)@WQ!X6NL&8[
M/(2([PUWT/&LQ30@O#[\EJOM;' 91@# >]C]+3?.TPS%4%=Y)*?"(_?&XK8"
M4Z?')M6'!;!ZE-[H+1?7BGD4EX9C!=?O$JE=Y=[(&G'LX?_P>NP;>'YN9\MH
M[Z><\4L/K$WKR81X12RXV9HEMMUYZ44Y!F@4_=B>JC:4]J*-UE-T-HWAF?--
MD-(R#Z.)<EII)?P,._PL?C'6STVX/K>B4(A4VQI?0"L0540Y1.6()B%=>?CU
MPC^WV--^2KHK=%.9ZREM1( B],!D7(1WB.:Z,B:R12TI0?ZO):'2]ZQ?#9:,
MI2LT(79$:K,TEXR_@),U*6)[PX)8-!A=12Q(6S$NVIM(5:?VODCF<*KY<D56
MA"S^9AKI%U*G&2><V4RH#N+M,V<2QJTAOQQL8[J4%UJ80TC14GM><3P=/C*^
MC)]2;723E FE$4 !@6J$).O_KE1$2<$OCAKBL*(D+3M&Y S9ID?F]Z,M")U!
M7%O7"QK!1WCG 1NO_][TWO15I/BU\PQT[9L$4Z/ESP(%Q,LJO[&AZ4/D6H4P
M/FBX\"WS6V1]'@#8_U--_G^!FB8WQHJNM!.[70SGVF!AI>'0YC^)OWET&T[_
M2/OAO<OF*D_>!^Z5TYL_IBA%*UAWZD)W.Z#>EM(&?9/1W?$PI9:;AZSJYUCL
M\WI1)UZNQ4B([D##M+E6$XL;4>U+N,-,?HH-HEV*J6>3G(8<>3;O@U;I(!LO
M_A"8G%EK;?V^7$VKLEVLW"J55$M-EA;#-)& :JNT#Q1B_Y;9(OM! 6)-$<+G
MSZ!G<2>N*XX-^IF$83H+*2+$Y1X*69>'Q7I5$:>NBZ!-T._3'<4G*( ,"L"0
M?"9OZKKF]TQ\?8L%**!?TUQ)_K.H=!LJ?=8/ST\0[_O5_MR[5^%7RE\.B/I5
MSY,;5%! %P0*@. T>91\G^),9"KYZV^XT$)GLHMG6IF#JS)7!04@9F^^H'4"
M_[4G]LU%R"IH_'1'^%^_*?<ZZ[OK?3C+*:"37_I03AVC+V^ =(WCB^6Y>?4_
M)%%'1>[AKCT*"8L2$,5[_'K2R!N'1NV4VS*W2[.V*(9;]4&R5?L+<RFG9A]A
M2')(5DILR9@;;8:T!Q\W3%H< ME>HKXCF( ^*S'_<QL&Z-]:Q\PSO^=.PY^X
M/<.0P&:F1/2II3C6QIE'F-&]]H0(SWF5UV @AAZA7Q/7GV*ZDB-;9KBA?FF]
M5D$"D3Q&L*Q0 ^,^B,<[81FQ$Z'=#:63!T)$2P"G)R%*=C? _&;-S?^'-37F
M0UN*A^.[N_X\B:A+; 'X #8F9>Q1R3O#V;RB*S)#1&^V8KQ[0?OO5L7^=Y*Z
MJZE__)_Z;//?^$P<\'_626^C_M)3L9^/$M1K4[K&;HU!O=YQVFOWL;9F36)Z
M:&RQ6.?&^DHQPA^Y%N)>E;?F5P3GR02G:32<E^ER1?H2_L:?W@$M?Q;N,/17
MQ9U@SR/5T:)C\BY19>5^C&'0#32-P2(WY6$_ C[_BOP/00_;_]BQD8[:NO1U
M9G)\II7!?"0"7O<H0=UEU<UA6H08YR[206-!^Z_#S(YD:PHS!0Y2)$5VI3 U
M&3<92WG&1KE;D:?.L;P)YO2$TQY-1IF6Q"BO8RZ3ASTLZ?I)=?<U#LYZ8<-+
M14J3HZ0 )HJ ,Y-Z6',AU8H5&M/D8:"6EKYU1O) 41SJ2IG#X!>2%F)GK\,'
MC232CQ"2OB1"@=+@$?</PCK7^HJB,_6,;.O78_AV>M:XE2BF*9_4#3K\3UB>
M;2I*B_'P"]:'>&EECK3V?*FW2JYIGNQV*Q;[C=UC4\B]=^>>%O7%<<S"U^F!
M2IG6.3;ZG:?&Q]]D&HS#[23%O)%XK9T>&_/I/E:7).R(A4]GPA[;8!JB6[=&
M0 'R;:E.=ITJG?,(L["/,_<_S1M]?'Z'Y(?OB/"[+)2)[ZYZFGOES*_B*3H1
MYL/,O<P^NNCA>_946MG[Q$ B]Z33"6-#+&MAOJ/TA -*1D9XR-)+P%L0H5P^
M<.Z* OPV$<FPA--F3+N?]:SG 2?+V*U&BAMK;G:J]:EM%A>W,T_/EB5'!BCR
M^@>/;T%#5AG-Z*28^24BM3,,+%G$X4JK%^4=6[:V[C9WO?PWFX^LR0)M)3'+
MIH*=.?/UHZ?& NY3^^-_1L%_I+86L;8'$F3+P5]#M?:W9=W\G>7MI>[8KN A
M,5L[U85CA#'TIL1B]6JM&9A]3M05N19-7 FT8J2+!%,4,0ADKCG>N=UJ*:V^
M&DU-S-@8_6!".K:2*8*IKN*%EH>;"4E%MZM%7R^B&!B>RF(Y"'/PN;G67GM;
MH\MOO8!R*, /)G:RM46M-<>5]=K!YMCR:"'QJY*T/4:_L5FJNQSX9,C@.<>K
M2G9Z-X.1"3N7OUN -,\RTBTEU_@#0^/T8'=41?IZKJ/UJ8U"1H!&Y3%5*_FO
M2'K5?]E_K8C%LJGQ=!!IF:?6[R5_5W67EH5^J',CJSD#YNR@VU7HD+^]JEP
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MNY0.[(H*$VQE<9;_3)W^'^*+([NL7.J+]EM-V!K^'<>@86*L5)[K-H$K%C4
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M'5F&!MH\Y&2M9"UVC6@-8A3X 8UD%RPSTB@YW2UN7>NF&&"SM;S;T^C O!/
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M94A\[*F3"_S"MFF8(]) >QT57N3OG?^)L_NY6TD[<:*#EBF ))<95^$TI^I
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M:+]3(-42XH/YJ25%AA87\DLGIM\O&6'S9KQJJ>)4+:?+7#><MP^TF1;H-?R
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M> \C.R/9>J;"_>O<=3U'RCS34AHQ$0I%!Y5#K760XG6?KR6<Z[U'\?P>:U>
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M3=)'TYZ];MRL:N#\5^9\^'>QG6J'?NV=%TSMW\S^WTTLX?_7S/Z/B?V?\QH
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M\_.:M,HP::!$]P2&JA\^5Z3FWW KF)(;D9@=DF\;^HIHCL5B["YYZC4"*^U
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MC^O ^30_T=P-:^\)((-AY)5@OKA24NB_^RLQ@BJ3J]?X!V"U.V=9ICNHFU4
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MC!0.F@X7R*>MB7AN80W8][P*4Q#= 8')<:W#$OS6G<X:FUIIH-F/,R27VRW
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M@_[Q8+L4<1HK(8C"AO7</ M_PA>-(&,'5Z2O.!.Z>0V]7["SQ:0$[O<]-/^
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MJCTCV?\2FV:DO%C'1..&J+S>L5,+NIG8& %0'T<'!TS#LK!+@M^B+.8HES.
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M7IGTW<5.Z&F7H02)D ,NQ/@@UN!\XLZE:_5U/YV:^'YSVEY:&]R]E6\W==0
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M@ %@"E@!$, !< '< 2_@)G '" 2"@0@@"H@#DH%4X#60#10 I4 5\ YH!%J
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MQDL7VW_9BGN'5Z_B_;Y%#AF$A<?FE,Z35T_27WUJ=$F?S;A6ZAH(FQ2SN@0
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M]=8;/.?D?-^OK=0!@)*T@M_KQ-V&9P]N<M$@[[U-Y;^4$KF97>RVQ>P7ZR?
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MF=3"YHZ']&T__P 1YR$.H=&#?PCQ\X92SE5I_&.I%,%$GHI/FKA)5XFLU5=
MX8G=&=-%72CINJ[=._\ O';\YW+V5%,R<BP1;!9%FDP5_&O8Q3^C>P#Q^4"+
M._S!Z7Y%=/&)G\A.HK*1DFFW8Q<@@T02<BNDT#\U!]S(,CJ\(F4A/-E<X2N:
M+"?LX*7[ 1S<MY\WOY:U!NJW4=F=5V#R;T;3_P#Q'G"KJM(]V>2725*$DBT4
M_=MVS45(^%AINTBQS,AG,MDM%KQB5/.5#6.BT")<(9\RE7$O3[I7BMOV@HHM
MQ1<IE/(NGKA51_*,Y"P/9*.7BW?]$7> B<K] 0<K_74$H&!\@!3.4!XI%_\
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M(A'?\3'5.XS]+DW2Q'#K\" "(P4423D48L(2=^*<R_014+)$239R2HB21/\
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M";]RG&)KMV_/UY4JFG9E+/-P<FGK5OD&M4;@45?X]RT'Z+Z;1EG$@L\_!?\
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M! !$3(G*!$/<%4@(  (B8AR\'P_X>>U3[6J5F-K4(H3JQ"L[+/\   1X!1$
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MY)0J#7\Y@N'+\RJ13)<Q"$3+ZK$WY^"@^R9 ]B>/Z"(^_!Y_Q#WX ?EXM?\
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M*214@\9 WLGZ*#LQ1(J4_F$0#GU"<^9.?(O#JD(#EU]3^Q6J@E. @8/ Q2F
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M"YJS6S6&*H-%@D*ED644$8B%AJ^Q]?MQUS:7.&DHV3A9,!$!V"O_ .4Y#Z%
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M*I#3,38HGTK'>J?4BZEW4I%,3U?L!<M/DK7AZ478*IM#9.7F]OSN).7M!M#
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M;.V+SQ*<Q>"HH8165$/-$12DP\ZSY:XRK+?[;EHF+GHS?.FP22%ISJS50A1
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M;K:@&6,@*T8/ MK*BC<5-:$9BHSQ8[%>;!.N\7*ZHHE =W6I%0$+9#2U2:4
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M20H%&FB &-U#"IK6F/EYTUT;',.C+W<)9IYIY%DGM[B-*7"2%52*)([93-$
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M"!I6I)%*DMD"=(''$5U:S.1K"$/3,D$U% .[,8S'\S@J<\%6D\?=CEN. !Y
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M6>04J"K,!0G+"7LJ1_ 1@N OA8J?\0H23F,P*Y*>';_,Q(&9\D^[W$\5ATQ
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M8F=)G,;V4DR:S&2--"C!4S12#FK5KQXUQL2R;C+JD$C'V5!/+1J 4H!Q &9
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ML?ECF)GYP77S:J'AB"6%2DJQ:@6'LD.I56IV@U##NJ1CF5T!472>-&#Z^'<
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M>-.ZM37'#+#(>S",> .,A2,9_HJ?(R!BM12JY$?V>XCL[L%[* -)H6-5)HH
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M,,^P]H_IW86-AX3V]E!Q_P#)])@CZ7(R- :>>AR/H.'N+R8&$ 9R,*NPSJ_
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MEBH'-**[*&<N)]\ZAOGN=VNWHTA% *"JQHHHL<:BHCC4 9=^*R6Y"R]B^*I
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MUML8<V4*RO'GS&4D@Z!3-D )930T%!4Y8V_<[4"5+J\-M'&M3(TH4-PX:2&
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M:JAH2K#A)-2JAEXQ0 G2U))B"%0&I))[\R3VDGB23F3QKGA+2^?CDKG[E?\
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M[A!R!#R-X8R"A=0ENE>7&"2L8.9S.;.W&25JO(U232@'DBM+.$R7+FBJ.W]
M'$DY <<4LRD^[CVI^*1GM6 '(L.V4@C]0=N'D=BTC&I)-23WDG,GT^0-V^;!
M']>"SY #RM);2:2PHPI57'<Z'PL/2/01A[C9X>5?J"SV]:JX'%X"<S3BT1JR
M_AU#&8QS;27(@!@<U8#@'6HK09*P(=1D"1EB.VNP+>[8@ DUC9CP 8@%6/8K
M@5X*6/TY8$;PZA",^Q-,LQ'I<PQM_9(\LN]'*\F+16_>H ]],/. >6A[&8GL
MP .&(+6UA,EW*ZHB#BSNP5%'G9B!Z\6/0UUO+[0L>W-=WER%)%U<M$9;J245
M4L((]=M!'5@IC9* R@F$1/)%TA8EEL+9F)"J?;N9*^U<7!&MV/L*5C0*JTP:
M'&9QD<12QRLDR,&5E)5D93565A0JRG,$&H.8PECNT*-U7M=Q')>/$@6XNX"0
M(KP%5J98Y!HN"* .R3'VCA.M=EM#!M.[S2+-%0#D7\8#2B@R N$99E%%\7,R
M&$EA?3,C!E/<RFH/V\>_"WMNFFUO(Q,H'!6;*11_9<-EV"GDOMIE:O\ BIZ:
MA9!ZSI:G>S'^8+;9GW!TL)'"D5R )S'H\U:5XC&VF&\G :X"4D?72JM65->2
MO&![7LJ#4 $#"V]@X"JM2ZT?2&-!3,\R>5LD!J2U9'\*X%Q,@:] TH":A&:N
ME$KVUJTLGM/1V)"T $A4"W( 5R:<QCQ*KV(?P$G4PS IQ(KF/N]/<?J"3P K
M]F(W@>KN R95#@4)0'AK9*E1Q/9GEB._M+AFB!$@RU:01[<8XE2N4L7XEJ5H
MZC"H:QWD=&!4ZM(84$D;<)(7&1J*,*HX##%U&;]H;5I)(UC11H%#I8LK5(#-
M5A$" @/A/#$NTSW :)#H) &I@AH 6XD9#SF@K7R]+=%KE<Q(U[=C.HN;M4,<
M; \&AM5A!'X7DD'&OUDUS,VF&-"S'N514GU 8:*7*1FYTH[I'4<N/T00:4'[
M;2'B?*D<2%I6(  S))R 'G)Q+MD# [BXI<R \.^W0]BKPE(]IO#P!Q0</)XQ
MEWX\*Y'''"H/2?H))&Y612"&!H01P(/81A]]MT"W2,%N444%6]B=0,@LAJ''
MX7!["/)44\]>!'<1VC_RC/#[3>2EKJ%=4;,:LT=:$,>UHS12>+*48YU/TK?7
M_N=9\[3222.?^R/]4>0(HJS$ >DY#$>WQGW-I$L([B0-4C>EG+5]'DZ6MTM5
MG-FL]Z(V.D.]M$S1+JSH>:4(-,F KEBZMDDNO^I]QOQM]RTC9*@47-R%0U8/
M-I19@SL8W4@'3(IP1CS^6F.D=WCFY<+W(MI3V<JZ]RU:Y'2S+(*Y54''5VS[
MEM\J=16A7<.:Y!YGPT@B<@',*8Y&\0+AV+584 %1C9Y3QCN)H_4VF0?82?)M
MDQ-(VDT-W4D&C/T,5/J_F&!=YGYD01@@D8E=7X0:FE/,<B: XA2TBU-R6+1P
MKK DJ K*J^$/HU!FRHI["<.I1Q$ATLK J8T[00?\2X(IE71"I%?$<6]M;$!D
MD'BID)--:@=O(C)<]@9HU[\0VEK#J!4G37Q.[,%34Q[6;4SL?PJ3V 89;F0&
M9$5FT@T)8Z0$&9)+9*O$\3@L[!0.-2!2O8?/7+T\,'RE&<!PNHCN6M-1\U>W
M%V$A9VB"&BT\8==0T^>G][LXXN#;7-)5FJAIX2A :-7'ZC D,,B*'.JX?;IX
MR  :#MTALP#_ +R!_"3Q%$<9-@07<E%9CD 2=69$L2J"2DE#S4 ]W+4Y*V+Y
M%H]O$JE(ZLH!?.5M%58'6 "F04^*F=<;A9[5?R+:,V8#:J,5&H:C4U'#4#7*
MA)(Q4\?)+U-O,(?9[%@1&W"YN*5BMQWJ2 \Y%=,*L,F=*WFYW\QDO;B5I'8_
MB=R68^;,\!D. R^LBM96 29_'_RH@99?4530?[>)KF;]]*[.WI8EC]E:#S>6
M??G'^8U&*WKV2$>.7_NU/A[-;#NQ3Z&7L]V"P.7Y,,Q[?HHL^=I,#%*.^.3P
MG^Z:.#V%<75E+[<4C*?/0TKZ^(\WDL;X$Z$D&KSHW@D']TU]*@]F*CAB./6J
MZF JQH!4TJ3V =I[L*F_[--!&U-$E-4+U%08YEU1O5:,-+$Z2#2A'EA5N(AT
MGTQR2(?R#R;1&WLFYC_[0Q>.>)FD/^VV!C?;7;-7\4EZ>O!$%]HG5$65<UJ6
M34-(92X\(8$UQT,MC8S6YAW"ZCN5D;4?B1#&1W!*14'*TJT5-#:F!8_1VA(_
MWC7D 'I,J ??CYJIU%;SC?6V6\EB8L&CY=$5A6E3531) %6J\G0C59AWTQM$
M9XR7,S^I0B?EKY!(IHRYCTC,?>!BUN",Y(U;^\H/Y_YAN#=(>5*@&I14K0UX
M95![17N[L7]QMCK#;K%&A=UUL=)-"$J%J<Q5B=*BG$XNTW2ZC62(+1SX599B
M79Z$D\QF%' X*JA<L&_1@RT9JC.C-X(TKWI$"3VAI,\S@S9&-=17SB/W2M_?
M:1AZ*XF4CW"N&([VB147^Z[D^D#NP8'<F*.5I/6%0*OH5F)IWXY,K56%I6'9
M4'0$!IQTAF_+QPT<S:GA60 GM!=".%,]! /F&)8)&+:49%)S+!7U@-7B=#BO
M>!GB6V!I$2$7]F@,D(]:%T'G0##R.ZI;LPK4@*8Y#G2N58936G$QR'L&(5VV
M2,R,O/+'Q(E#R]0*GQ<X>!T!STJQ((P#O(5:VP5)$U%?;))"GQ+J]EN)!4<5
M.#<V1.@(%U4TEB*U;O[:9YD#/R  9X6;<Y#%;\=(H96\RJ?9K^LU .X\,6\*
MQB+;X%*Q1+[* YDU.;.YSDD/B<]P"J/K)U'X;15'HGG57^U8Z>ORY<<66UI[
M%I JG_F.!)*?6S ?ZOT'6U@+Z15CD H.0U,Q"BIX5-3V8>"X71,IH02,CZB0
M?43BFJA.6 "14X(J*CC@T/E8>; N.V>WAD/I* '[QY #PX>HY'[L;7<L?><H
M(W]I/ U?25KZ\*D:EG)H !4GT 8VSJFW%U97%HR6-W%/&.1>VY4FSF:WG7E3
MM&BM:RGEN51+=M0+,<$;[LDFR[FW_M%@.9;%CVR6,KU11V_#3J,SIA[,7&\;
M'=VV[[%$NMYK1B[1)^M<6[!+FW %-1DB$:DTUG*L1''G7(]6J-ORD^2RNO\
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M+$"XB'9'(PE091RG),2.1S+=#0NH-%/=(K /"W>LBCS,W'%1P^B!VGABHMV
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M.^J)Z3'0X>L<RI7R-\_5E_Z:R0L#SJ^VP-9=&>O<)-DJ^6913!KA=_;Y+C/
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MBIBN4UM#TL\0^BDQF%9E\&C5^CK,Z+^#FCX;D)-T"%EY07@6N8OZJTHAJJ"
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M=P<&"\$D?"M?75!6'08F;S.M]; >-83H=^^D[*P6Z5+5)*5#*9,]+<<I#5P
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M 9%8 /9_ "M U+\6DFTON&XVXFM+1KN%+ZXBU.B<J"0*"[M&ZQQ\P,]*("2
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M]$I"W,4#:+BVG# 07UI/'&+B%WCF60QJ1-=73UNI6+R4H 7;-CI4*@S)II4
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M.@+THJY@F;IK>WBDN5BBE66$L8GCF!,;58 HS:6&AZ-495&>"8W# &F1KG]
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M P(81I77-(3E&@(8+6I;2QI2E1)'(68@4JNE6U+J4 ZV*EU!,8D5.92@H<L
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M@04B!TH ':A9_P *@TSH,0[O='3NS:H;B)0:21,I5)82:@,@.ET-*E003J-
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M&ZG7=MMW7;KB9HI)K20R1S21:7M-G"LD<L,<TB_';F\D:![2WCM5YBR,#?\
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M*K-I%7X5KQ7B..$ACCB=GC=T*2*RR"/-UC(R:11F8\FIP!Q-N@518I((]3$
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M5F'BFMI)O_3W$T]?7S*_R *HJ3C76OG'YNY?R\>&*  #R\<%CQ)\N>"RY/\
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MTP&4U4\/+I857'NGR[C^8\<>*$^K/'[M_LQE$_V4QD@4><_HQ[URWFX#[,4
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M8T<2.<B>Y[D3ROJWH^"8S1=ZN:84=UA;54JOQW/H!;!Y8U4$FSU+X@K&39V
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M9[$C^7A&H$5'JC_75L7R7X]8^SX7POY :3XW=6Z#J>]5^9[%2:['UT29H=K
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MPCA_QS#\@.@]6YYV3ISQ6O8J'CE'F\UQVPYG3S0DMKG+:TEM<:&WZC"#%",
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M7P<O4W=W%B9"JLZ>-3HE;/D7,&>:0VQ1Q22P"1WO\>YO]E\J%7\6ZGE(T_\
M?&\BS1$3_P"?,Y?/]_\ 86'#KCFKR\HVVALN.NTGZT9NBDS+F=(QRV4NC;!0
M$>CL;0JQ_8R0LL B(=47VN$G2<Y@#=IU/1Y&;W'-86?T5=B(-O29V8:7F>E,
MYL^LES:[JG5J6EBD-60I/Z>*XB".R,GYM[&^F4<^0^WY[I%SNUIM1@VNC29
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M-(1/RYO'\ G>?<QS#(GT^GE')_L].="TD=QO8KF-)'*P3U\>6HA&N)]'?O\
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M.O<+;6,6OF0<FS.0[J<YK()\3:Z$-OS^ULGE>U1%XYU>:!!%7VL!0Z22U_\
M"!53J.&Z3"MJ*II+&OJ=/&-'=^K8V/TF9_RUWWNB$:CD2DM(-+;N&WZ%?5N(
M/W.>U5TF"U=S7W-)=] CYBIB5$P1061;/,Z.)H[3/DE?:.W/WD:/%+",\;!_
MG$$Q_L<14]?IJA_4WS[NY?<P"M?%:>CFY=: 8_S#4>@I9Y1_S"(SW?;<!$7Z
M+ZT=<&N6V2SC7%?K12'OA#>#3NK:6OE5YQH5S3U X097N]OA2^1_@JKZ!A8,
M:RM!V^(VZZF4@1UZ@Z1K[C.FIS11F4CK&EQ^>R,:*1[%:Z:2851^WV?6YYY"
MN03[.PR%?>6%K6CD3*Z?M]3L<[9W^4B'8%BM_E/ T$2 :1[?M2IOWQL]WM;Y
MU>7.,(=H(-1&VP7E8I\S:=CD"?,S$AK7>(]]4<JQ4>+8HBJL4]L02JCFO1(.
ML,KHNEM9\W5YR(YR-DIJ=KG;#'<RL)(%:J_D\SS?]?T[0%1%4MC!>B(KVJNB
MUEW3UUQDM=F[J-KLUH(CYV:F\BQU@RMBPWP/NA8?<])Z\6)39TZJA80(-C,
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M0SM1FZF*-4_^FKZT$VH[)RJV!C,C)W^WC974Q]K=9K(1(\>5(.E=GFG@76E
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M66@ N*>UC:N7*NC-DR3G5QQG/Y=*5RJB>K?B3.3EWQ\=\ML=OQW]1HZNKO\
MY)\B!:2[F=LM)H;.ZCSXO2ZNI,VEL33#@,1XAECHUGGQNLA\<_BOJ?CYK.GW
MU1FI6IZ9TC/]&S63S=K L*W2=-FQ":[3'EGR.>.6-#JV-\6,^4-Q&*P;G>KS
MX^81JW7#:B;G.Q_'OI&A?7+,P?4<WH*F_P!%R_K-? _+VEO0;2ZJG3*^UCQS
MNABF/"_Z!&GHKZZDT%#/U\#LV:Z;9="E5EWBL9F^P[EFPG6W$),#46KI.OKZ
MG[M%*_(U\")?!>*5-^PX*M<T<=CA1Q,&".-[_NO'' QH0#>7PBD>P+&HKO\
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MWK*?Y.\_M:'1TNNTG*_S&GZOCUO(K$B:#<<1U+A=2I[FKD1!B.Q8E@P,8I7
M,YXQ-]6O0H71JJGU)*^!FM?J=&*8/:85E/75E586^%YK?C!M_P"=+^:!AXIS
M(I"UK%B _+M^Z5-<EY1L'E*"VK:?49:5.=8WMER?4P0U$?5VD\\:5)_6,IJ(
M#Y1Y8B^*]LL,.(UK$&K[DVVK,Y/U<"+K;>]O[*GI+RNQW*LF=[/UN#!N81ZT
M.NZ<"$Z5 0HR>^OD@C*@RF<GJ*"ERE=107R(6;I:K-THI-]PS7UH(IRVDVNH
M*U+G0<VV-><$=J'<<L@I9+D<AX;$=$!*M(M!=T^.H\=DK*EM834N.A:VQC:3
M<[.DF?F"O(N2@#,(=O#082GBB85J.*C%M]_8<S)EJ^-5$9H.L:S2Y_D/QMM9
MXCGL*O:;*WW:0(M=8T]V\%F0.7_,&DS(C7!^Q]U[4@CYQ6YWY?\ 5,]7K5T=
MXF2N.=_"WG9"3&V<Z949B66-T;Y$V4FX*:25TA]7GI!U_P 3QHC%B[OO5U;=
M7Z&2!33OTBWE0JTT[ JL6W?@^-92J'"SE!!'GC/D5^?IQQ$-]OPU#R47W-SV
MNJZF3FPRRVE!MQ4S+.PKLKL(3VU>E00_LNWG,]1G9#0WU#(]R&$DC\J^/81F
M>DVG+Y!ZT>?DP(=G0-*+53,C'VD0K*02%+'- ZSP3J=7[Q4UNX) 6$=75UF(
M4\3O=PVR9QK :>ZV]#O;2)!Z5'OM;DN8YZBUB9N1SCG, UC47U?5-MH);-L*
MPG3%S*3?RL%6 5GMYO\ *_4\K@5>]OJRLOIT=;6ZFTLG0YXRT\"^-6R)3(-_
M(:ZG&6%+E!(8@OM/(KWM1_ITR0U6F.B(,2__ %-'\^6!_P#ICO\ $1?VN^GX
M(G_3-^UJ*KG8G5(B-\JY56BGHB-1%1555_#QZZ*K_=Y=I/<SWK[G?EWU58Z&
MBK^U$A*-$_9[?'CZ?T;W:1BN!/YYQ?JNMHI#51'1=;8U=;SK*RV+^/W(TC>2
M"-_:CVHO[/08XD]HHX1@$WRJ^T8F-&QOE?*KX:U$_I<)Z(K7HJ*GI93 ,]ZJ
MKO\ "B?7SY_;Z1A0#<U$\(BIY3]G]W]WJVK\Y?W^=B7;&MMHM%=VE,*>Y@71
MF&-^FRHSFRTBD4/WV*TWV7*/W^Q5;ZS=K=[>^N*&HNH,S1T46%FX@-C3N/ C
MZ*-JX0:4-;N+"VS\/\JI;D<LJHB>T@R/<5=-JM$;0?*;4)V* '/5N.B:+):?
M Y6ZI[&2TUB^%E"68*35,%%J:K/A"2BI+2M17G1CF")J,O!M&W4;.7<NHCVS
M%CN_-LC(-SV&=">2&Z=7F(Z)+4+E"LN.51_P>WUY]8U7_P#M =OZS&C(OU]M
M;(Y[SJ;+]O\ X&/MF,543Z.?]5^J?T<YGN>QD2VN5RL]2/5@FP]3&)4_<(OE
M$3[5FZ&]JK]$5OU^B_VC.&==PVEZ,$X*K2Z(>;:*,;$"*0ZTUU#GNLJNP?HA
MA&4X0PG*10?1Z^TJ,>+GV>YGF(7$Z1T'<XZ10@Z1)KM:/85<:PK>IIUQ9M3K
M(VNMJ$PX9T;):* P+HZ"<U&N6/%VV?B1")[15NHUPB]AKJQOX,%:W<1,KU@5
M6]WAKR@G6I0M_C4;T14]7\)69X*!M"_Y6/M'W.0]JC&L<N;M'F.^QJGQ7,4)
MB.<;VK[2>'-5K;2T,QY 5%3:W,@0O;]XL:HKI-G($#WJC/OE!%<UGN5&^]4\
MJB>I?RBSS;ZZP-6V,"]ST44 >WSUZ:ZK**5EKJO+*2%#NZZ1;@.]%+]H\1R%
M"Y[7)ZQ=AT%]LX.ZU4;,5K*.(R<>KC?9CR+S97HWD&L+&9&-, 2RE_5!-,WQ
MY7URG,]%G'J!=@UEGB\[JD6,N5IKN!#B2HA-//(9A(-1>FGACQI0VD$PI&N)
M[1K[DWO-](^5G)/,^2UW:MEJ[AT:-DZO%S[>PIRH22A7S&V5::L(0S5']MPU
M:@U<]R)ZQ4_1<M[?S3G73;:NHN:]CZ+D(--S_5VM\JIEH\]L:WF:#$!UWA/T
MPUO% .4KV)Y:KD]=@SU3P3O.\@<&T<C,]0UN&J,I:U%%,AT@-+./'JY>CK]!
M9#AT1G27""!Q58)_A/*(GKBNILKB?<YKODZN3#75!!63&AYBP!7E)T/3A.X)
MZC%5$BXAQ9IU171Y4E!JGEKO6"P(N<=!Z=M.D,V!L[G.=LSY9K8^%C19FBDS
M":"UJ(B CQ9;7M5A%5S47Z+]/6E=0\"[[>[/ WZT/4>61Z/+0-SS,9LX[55&
MFOTL=*&DL\EH:8;W0IE?)D>]XW-<QOCZR^X3N(]OSW*DK,O:Y[874/(,K=P#
M7:R#CZX&6_*:"1))(CS9OYDR21 :D4)%:JO]K5MN68WF?5.Y]!R]177VZH>2
MT]1*BX"INFN)2?S1H-);TM,&]N@,4L:J"0LUXO#W-8BIZQ?.HF>W%/?;GD5E
MVBN;K*%,U)IL[4Z%N8FT&GHYLAUO3ZQEFY7(!6O$H41_O\.;Y3D><XYUGKFR
M'@H/29\?FX,N2-59:PNI.?CR)[]#>4[D*MI&5BHSW)_&W^_Q4W5IEM#A[&RB
M?F9F.UK8#-/G#?=(-:V\952Y]:V<C1H3P$Q6>PC?KY\HC2Z4^IC47Y::*Q+B
MSUT?1_:-&(/[45]NJ5SX9T<K)0R?^U KFHB^?'J.6WC3I6A?%A3(>:UBU'2[
MFFC20#E1"7.3Q<F@YA5V)8A&$##M[:>037,4L9J^6>HG IF)VVYS_0[VI)5^
M_9YVJZ32:FD;(-4Z?)5%;3U'*<=1T%,Z9^IPFPR D5ZO>:0JB1KM1R+C70['
M8[>UGR;VZO-%#DPS;5M&)(#B9:4VNKZ.QI\_&7PUD/W>6E>=%(QSB)ZZC_\
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M/-;1)%%8:C*\P=U;?4;+>:^- 4>_[3::Q8<B58L>K?R]6SVF;[U1/'GTW?\
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M^&?+,5V;([FRG1^)TPHTG2[_ !<?-VT-]+'VFK>TXI4E229;:T)F^&_1?AE
MZ/ [#@M%R*O[YS'K'5,*8>=M7_R[1U-'BMU4Z>9#LX@\[U^I@@>%SHY%DE:4
M;O8Y%7U\E<AO:C47?1)&IT4XO<]":79$^1^5M,=.A\WOHU@9WY2%=Y&M<E)-
MJ(K 1XTEJ$8Q$,J^N<<O%@M27IE9FN2Q;'G[*QRZN#)J.J0;:V!*JU>CQ%K:
MICI)D5W\ 45WKY'W\_DO4.I\W^0>TRO4,OK^.9V+MK;/ZFLR0,C<<]V><6SK
M;.M$KHC)%;8I[X;QD<CU8J+ZY=W&YX'W29167Q=T^/O<_C\O7[W38C977016
MD+,ZHE1;AJ6V#*F$ARN <K!H5K?JJ+XI.L7_ "SYF56"T7QMH:*O_P"35/=Y
M;H5+L8N_NI<K+]&BT5N.1 8&H:DE(A"E8CBA)^+OIC?R$'H-;!91@##@=:26
MG4(P GD#:W>NGGDSB:)ZM5Q'F(][QN8JKZ:OCRC7L<K?*I[VM<BN'[D_B9]Q
MJ*WW)]6^?*?5/4>^O,I S?YLAV5N6C](WN_MR.CF<.1,L,U25F<6CK2G17 6
MSMQK+3ZM8K?XEC6>>R]Y9YP89M;<YC].P'+\N?/W%?*I[]\*-FX&CUEC=K3S
MC?E73[I!I)]CR>[QX]9#63NQM?H(U#(M^<<;UU;5XOJ==$O:HT.*;=T:W]A)
M+;5]!*>HH\8(4D,(DE[&M1!IZZC_ /9"=S_^.#;_ -C<<\K+T.>MR65+?TTZ
M:(TBI):4$\<^+"NH\94D$JY;F*UZC\O$[VD:URL1J[NQ[FP?2)_0>E<T;7XG
M%6]EGJ%]GF$NBYX%QK2PV746*=TN4:Q/$CB.6/'##&J_<<[T@^'\MLZ#1UNI
MRO(M?SS.6-QM RL=)_F+H]!*Q=G:_8F5%;;Z@!9>L=8/<^22%%>4Z1V-:K,]
MI:D^=MMAG#0@#,2!+;I]IT<[/^8!X-E5RY\"9%Y/R6AB4B2 &>)L^\D#3^-S
MU]::[ K0Z"^H;'3LFM<GYJEBZVW?QGGGY54\?;E3(A-/9A>G\3&*U?I^/JZU
M31!CV-;;;G7X=Z#8OZ;:-H\UQ.%>PQ+_  BDUECJYJ!=X_\ :1VN;]6(J3>@
M"K(<;19%.G0LG8LCC_._F+V)@LK!M3F<USY?\K3]',6.I/=]HAO*?5/5KO(%
M/"C7=5FNBX<QV"]YII+S1X2!7WW@JD:V?GLWI)4)A6HU481JK_$GGUJ-555,
M.%>LRLO'7ZQF*U;*'5=,R,Z1:N8Y7+^9DY2^C GO;X:1L<:JB?7S=VL2#7CT
M-;30:ZZ8","/^IUG'M3"MPV!!A8UA[6/@=ZU9)%12R6UZ/<JJUR^A9YH&R-9
M52I^;SIU"KI<^[YW43=]B:%Q$^I'W?,K#0TT8I/P?61Q^5\-1&\E&"1:F=,=
M2BKZ^*2;;!R&MGK<X[?4,( R3)\OD/6RM=/&-/MAS>BE*3_*:OMZ&?M^,U>:
MS7*0TNX'0F@?INEMM5OY9^8'QV7+< ?2V^#ZQ2)*@WSW_=BA9#BS!^)0V+Z^
M06$X3 T?/MW.%S&;.QN_U ==36M-E[NVMH-= W4>I@VZ4FG,P@9D6;&>T$Z(
M J^\+E\= L^H2*RIG;FQIR0,/268K@$)*2+,C%MIDJ.,<$EO;)):QWV/<QD>
M.)"/<[^%@(H41KC$^W&CL_B&!B)Y><BI_B^T-/<YWC^Y/'GT*,+S[!-1/<O^
M)[OQ>1Z_M<]RJJ_[?ZNCI,'VCE&WNL=&F3==38_HF0TUMEXE=*?!GRM#6TEQ
M.FTH(4T3@E?)8-HRM5CE1R>/5!L\;?5&IR6JIZ[09K2T$^-:TE]16\44ZKMZ
MBSAD-$GUUA#.PH3">YA!N1S55%_IS^/L]/GJ[6ZV'>V&5RTZZK8FCTT#+MK7
M::=GZ21)'9W,/.MNH:SRQA$9$26'[JL^ZSW5/.Y>HH8V\OL]=:VEQQK2&/2V
MN7S<^EJM!H:^F>5)\NGI;+1P 2I#&*()I@6/5'$:B^LQD;G59NIU>V_6OY,S
M%G>5D#0Z[^6X0[/1?RQ2RI0K*^_0*TS)$W\J(OY4#D(7VM5%]9?"VNHHJ[9[
M:#I+/'Y6;:0XU_IZ['-J7ZN=1512MF6<7.,OH2S7A8]L9)8O>K?N-\_V\J;)
M?]N-#CFE2"?C[ 1QN*5_C_U1L5?3AC>PA*[$8>%.5B^6CL)E8;2'C_7SX='#
MH1L<GE?#D5/Z*3+S2H&NZ'6[/D]H5RHC60NF8R[S\3RJ_1JNTZ5GM7_QHW]O
MH0IPU#."W\O."Y%:X$Z/Y#, ]J_5KPR1O:J+]45/']EDN=Y_W)=;S25&3KRM
M_&&ZXE,CS+5_GZ("CK5/.,J_1H8SU7Z)ZOK;/,4>4;)AYW"@5/"1>>8FMAX[
M#"'_ /0)E%2LGHG_ (YSU_%5_HY_!8%A8E7> T5G]QJN%^G9IOZU)81414;[
MY@(8T1?\3C(G]IM.H0>COWD7-Z)>P7? \6"GM>L+8@MAZ:16_=)HA'AY!MN-
M)4R4L(TZ+!>YK6/_ (">K;1SZJ4EEH+.PN9\:L[/>KFT-:2C32@@4%U07L.-
M &IU:,:*YK6(B-\)]/5O6H_18M[4%.2KJ(6-UN+T5S#>DBO@7=S79?+;.BG2
M'HK@F^])B,<BJ42M^OK]W]WX_P!'N\KY_'SY7SY_?Y_'TGE57PGA//[$_<G]
MWK&TFQ#NK&[Z!^MMR-'@<+=;VWM$S88\JZ\UU)[I,=D($IA/*M5%;[E^B-7U
MT?I\+2W#,YQZ,Z7U.DM,G>T?0\(SV"((=]SZYCP;Z.::$R$C*UK@R!HY6$7V
MJGK5Z:PSG<LWF<1A[7HM]>[#BNNS-0W*TX8LB46IFV?LCVMO*CS!DB0AJA93
M/*L7PU?5QV+4S+&-S_/Y&OW%G/A54BRM0YFT%6GAR 487-E2)CQVP%?':J/8
MKG(O^%?6YRV<E69=)S>SSE3K:>TJI%7,C/U]!&T^5LJMDASOUG/WM-*:Z/-#
M_E.*UXO\3%]?DF&Z)I9!>D:_D=:'$<XOM<[0[OGU9%M]K79D=8]2WM9FHTQK
M)$T+?LMDL()/J-R^LK>VV?[;7_SOL+?"Y',2N,:T6[O-'1TP]!8I!QC_ &VQ
M*E*HGO%,:CA&<-[4^K%]6=[8VVVS4;.:W)XS;Q=?SO2Y>[YO8[PCH^-ONB5%
MJ$,S-8#1RV_EP7ZH:O:=481[//GU0\:-*LI72-#F++:LI*:L/9QJ#&5ATANU
M&TMXSTA9:EMIR_8K"'5761?H!KV_Q>O".<G^Q53_ -UZ7^-WU7RO\2_5?WK]
M?Q]>5555?Q5?JOI4\JGG]J?BG]Z?W^@R=]1XVL+6D%5#9GS=-77Z%8\=A'V]
MI0YRTCYP"&]Z-?./*C??,UR(!$^OJJLL]C'SA4]I66C*B)RS 02W25DX$_\
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M-\N^GK7Q\[I&7-SSS5GQ.V8!\ULW+;*%#!.D9^P+*$%WZA&A2QD50N(-&O\
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M)Y7Z)]$\_P"S\/7^)?\ W7_GY]+_ !?]W^SZ?]WISW/\(SW.5?Q_A:BJJ_\
M<GJ.:8+[=O=^RTL4=_C"A6)^2@K^'C\G%5$5/V$<_P#?_7_TNGLC2BA8WYM_
M?D"B2#1HWNX=G4'^;EC$^/#^\[^$?W7L^X[Z-\K]/7^L?P'M6KC8'M/7^O=Z
MZ#QOF%E76I]CV_)]]^.7.,3RBQXO30X!Y'5Y>KVU+,I'0Z-)LN!;Q"QI8P.1
MJNQO6>2?(3F>*^;M!\+?B#S[Y$_Z?/4*<>XG?*NSY5S\^?Y'@>;LRA&=6P78
M32M/?T5/:9Y+[.3)YXJVM404<LE/]0:K^86QH>%=I[AW;*=NPVYZ]!3+#Z]\
M;9G#.29;EV3P6_G"?4[0?#=35Z'-3LW7S#2*>W_,RTBH.W')ET?PQO>R<BY)
MS?A?R(X;T'Y)7NVF1<_M>I=VR&CQG4N(<"XQ6V->&1:S4V%=FK+9:Z.160(:
M1:&$0LV?,)4_#9FIU-N3D>PV79LYM>25?;]9\;8>[U$;F;=1SG9:GL>)8MY7
M9CF$S.S_ /W#JX<>RMKJ!)52&KP1C_$+ENS^:^ O>(3/@I>:_$?+36_*WY%<
MOY+TGYD_\Q;E_0=W5_(;FY+6ZWG2>5YF+72*&@UDR+&D-E6$B/5$D E1Z_YN
M6O5?D;W/9[+XR?Z9OQ+ZMSC7<8Z-TGDG-K#Y,2.(?(K4:CY'\]RN,ET8K&[U
M6EQ5=(#5V#)]8.(@PR*YZD7WZ1NU^4W/OC'OO^1WPIV?PUW79NI=LXI2ML=Q
MSG,W76]MS?D7.ZAG*/DE9:GL]Q/SVFS^A=.G1Z\$:N6+!@R R)-1QFRWV0@]
M=OLE+W-)SF5>U\/87^1K)WZ7;:6ASLF0RSMZ6IL? I9H["MB.(/[RL^X-7>@
MNOY4F5:S 'E5V;IPCFWUA%BJU)DYL<AXT6OJ82.3[\Z::+!"JHCS-<YK7%CY
MB)G@"\.9[*N/-VLX2M54:9E^27F,<9Q%3PHX[YS1_7_,=]//N_5- \2.1?#L
MMSUKU8BJJI]MDCPURI]/_:K]/V^?363:BH,B*JN-9YN>&2J?3PU?Y?TTZ/\
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MTBW\_A_^JK#\?/C\5C>/Q]1*^!7/86:1HHS7#/839)%7Q]B#14P["]G357_
M% #0BIX5[$_B2MW&^@OBGKY$6VH\]8K&+=3;B-[GUVBUK89I4"L'3N(I:JE
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M(]%!7W;V_2%:,:THS*C)/W@/>C:#34L\\O'Z>O'/2.SWQ)$T3W.%(J;7V/\
MO1G0Y(B1YD=KD7[HWC<OA%10Q8H QHL80P1XT<; @C@"Q!B"$(VM&(0AM1K6
MM1$:B>$]:7N423)9=:G!4V*LJI5<Z!]ZILGRG7X6N(K!6=A7 A0CN:Q%("O
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M2K-E8_-;18H+68)"PXC"JZ2K K]SU;<CZ+CZJFOIP)7/;,CIG\JLTMG MED
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M+!L6[KGQI;7!>I0-8AF.8BJK5\?T5,>0G@K<@.G.GT1$FY37Z^@DM^GT]R
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M+SZE&Z*"9&B"-+=4=NXY!8)9)$2*+0Y@:>Y3$\.TT[N%)M(U/16TG@M-E:<
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MO26-+6<_N^1QLAS2! JG0] FQZ+/%S+&OFJ5H'.@LS\ZYL!D#%B*T8SL.UY
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M3Z^O;]PH_P#UA.]CO^_POI'V("VBM5%:RRDR)D=/'[/RA2+$<G^UB^F  (8
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MCZW^6,<HP46QCSX90/1IPCTU)#F2P,(YK_#4L89GI]/*?<7TDG0TC-.9%_\
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M/Z?R[F5[;:''L@5Q[.$EA5RX5O$6#>9O0U_N&MIE-- _X>?%]S7.:C#"<.0
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M@_'\7V*GIF=J)QU1/:-EC[G>//G^JBI]%145%3\45/JBI_>B^OO_ 'S??_\
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M8GAR>4M[^%L;%I/#E3WM(UWX?7RB+Z'/U]U>[*:%Z$ ?77$_0,BD3ZM) KK
MQ*:J(U?P6'&C^/V>/7ESE<J_M<JJO_>OU_J1Z\,61,%]V,Z9'BC<:1)'(EBA
MQ*J()O\ $:ST-@8<"&)O\9#G\HBHQZIE<G,^RMO%@K.T!(_L41-!:E)8VZ"(
MSPA@1I<EP!/^GN")GT3\/_(23;H!PQ5.MB2Q(B-]BT/2,U$8ZR?[4_A:[;8.
M3&\K^+RL3\53S_14Z#.VA*'3YZ82QSUX*,&;^0EFBF@38T^MD?\ "W>=O:N2
M6#:UI_,>Q@'(%Z?5KFV^NXWGW1)%=$/=;_@=863::'!Q6>7V&RY$(B.LND\.
M,15(T<9IKK*^[\K- Z.P9T:8!1F$_P ^P@GM>QWM56N1'-5456N145/Q14\+
M]?ZL>,QI#2IAV184..$LJ;.E$5$%$@PHS"RYTLJKX8(3'D>OT1JKZCV'=&6U
M5*4(9U=PG.6(('5]" J>^+(Z'<HR9!X-BI2>%(><TNEEB\LA0&/5"MJS3PT\
M"-053L_DLOF()*G$<^S+S?F29G"TI2G+!@RI*?>L)TDAK6YE?\1-,1WM8/\
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M9!3F+@8Q[/WN<,YW[KD_[MNS9E9W575U575U=5CK&<Q;S#B%C+*?DST VMJ
M"P! ! AA5  7RL&@#X Q 'QL'@ ;&.//O#/L] \:'.A'8.\7G("^*)@@-D\#
M?6-O.@&\'_1YT+</P)N? 7"*XN"N8(NTL6/1=42BD5Z.2 \606%>09;3VM8(
M)_<]""<0Y!<4DN2'+G$6 6%)?@%) 7&(#VXZ;+]M# : =)R#-G#UTW$/\K!0
ML)\(8+@_Y"3X71<8ZR]=8%R_ZX(#^\E#$.<G;W+<'_S4?NB#O6/>8I8 "58+
M2T5M@(/Y!,BP)6 ;@L6_ ]< "1$1T2$BDD.'2"@/$Q^FI"4G(2&GI:>FIJ6F
MIJ<DP:8?M[].,-+#ATG)2"G(R"AHR,C(:/9^R&CVJU#^-PPPSP E$=  Z;@P
M5H!#"<.EA&%&(,6(,2]A<I"4^#!L^J$@+H#AX.$3$!(=(CX,^T<D9"'< R0%
M@.'!<''P</ )"8CP<4F$("0E+MX)*@%\!3UK:E;/RX($--$/2LZ<9*/5;[01
M$D9=Z58D9(\Q^#*^C/ 2H<LHO<JA%&MHJ_P\$RUZI,=HPNYKV;47O=Z3*RJG
MXK*NE\>_[)M:S:YHZO^X=L[>YT9"3F7SP/2ZF*JQ@^_-Q-RJEL&9#4J @P-)
MBX>5B9  7P0KP@D!*CQ( D]6:GS!R]$T>Q(TZG=_$6*S&4==B5$TH$5X"2^S
M$^P)0,@A\KP'$B+SB*VRD2C:;N*G"/]:@E._1, , Q)<;)N40 Y\#BH/M)(S
M_L+508\!SJ+FPZ)'MCUKBH-VOL&W9=,^%:$QX':=4N?93!T,<&7  .,U(Y?O
M#IV+/+HCAU[G$0U:)/KQDKX=41[O*./8$)Y5?-AZHKNXILBF+!RDXI6/;7<<
M%;S;'B)W=2!X\J'#KF'43B@&C-F:8D"SV[J85X"%V\")K<NY5=-UQ[<T.U>X
M&HX5W^LBK'S>PD_-F'[8=/"B<:'9FD%.O_U[YK0;[9IVC<W-=9Z]L_U+0Q4\
MU9F115&T:S*T46RYWHCKC1C0HC,2W,;D&'Q^KXV&Y=XJ#.!2W7V) 9]+QPKF
MBW5J/AU]2Q^9%4KJ5#*#_K014&<:%I03:,"TVA&\8F@<5<9^MNXU!DSF(G\*
M"C$I^\5D3F[:H5]6SAZ! <FI@3K;A6;7(^;*!3H$F? H5&<(-8RC-C3R T<=
M,."8IMS77 RPE]L8TFE83O.^0:B!0-1]K8QJ6'R5B^Q/*W@C^%ZCK5?7XMWL
M+JHX>@TYGT"_YM:87VS4F/U,TGR2=V,[>&.JZ'BMD<'.S&$,8'JU=KR,BW(R
M >^[W#E=2%/%DU6J;'[A;0S^._'N1CVR>2/6=GZ%7LDD<XZWAI<:5JM8WEW?
MY7M8L6JZR+54V%1<. @4&S=NBO5M!]??&9=2BF?F&R4SWI78DMO2FILB-^_P
MPP!E;0R(C," +9W@I14,>%)PMAL#CIP8WZW$N\SXU*=U5^>SD1:D>_B'D<9-
MFR+E^X^,Y52W1G:C'GZ/>-?]X%O,]W/+E$]:/GP,GDSSS9T/>F6KY?9-=PP#
MW'92?/KR,>#HQO!2Q)QDHUS/H0]GIR=JG/J--VL+ZUP:<@>ZM$222!T'6TTS
MO@<O(Q')ED@=?QR8]R(;[(7"FO[X\1J^)M%@/V%WB(EOS\B;.3=6^=X3$_:!
M+_I?%&_HR2TWM>.<U<1M'7'<+=Y)?_?)N&3[[&;]Z\>]MSI("BH3B0M**B4)
M9US=(GTK+F! 4H,1!GRM3*O&@ #"$"05E7B4[@>]74$4G_WZ:OK FQ[MSQYW
M[SL]KW!$'R^J7',O>I-D#UK&-#^MX6<OS]54)(^8+2_OO$LM%IM']CNAT>UX
M]!1$B^1A)=?7O!ZL+B9\M+8V4E&B"X@@]!F\F#H:+.6,]R)=EVK>$M,U%]SL
M=_]Z&/EQ]X+.%=[=_/%CBDR6M)5$@LKH5KE6Y#OSNN+E3 P(_1[\7<)R]^)3
M_\B!3?P'[>$O1>9-S5^&M**?XEPJ6'[#7H@PO:!X536# :1EO9-QJ"E^]_WZ
MDH3;<['C9GA3<E8[+'G2E)]VF*%NU'\B.C:=MF.P=>3)NPLN:<*C[4/E8-"X
MNO.S^]I1")WR>JZQ^'/P^W7+]A2J;9'#DI?X[R<C1JI62==W-]9\V9I7OXR7
MY=3DD!Q7R%RQR,( SOHFAYYYBI,<-8.>J[>/CT3U<M!Z'TVT.V=&8!-#TOAY
MX?B;X7S+J$F.=AZ5\</#3L^$Y2Q[DDU;NW:#O\:_DQ>II@L(N4(:<+%\FWG3
MH6Y+S<@H>?"J]^)%D83*I[G?/^N_=+A)=Z>WXJ6\+_\E _7^T_Q#9C#:B<!8
M!59NZLZJ5;+@+OT.[Z6L;1'1N9[FFJ;[K5*5BT4S,AC0.IRKR8M@79 Q/MM#
M^B[+S_E!?.3"PMMWEIK)OB(= GEI+AC@G]:F=L^PKRE(KZ0[W$*WTZ&^C=6L
M(K>_.;M!]9NK>8MN('S^J.*NZXCOW*.4X<4[S+['>X4-(NR"<W>]5L\&S#^<
MJRQY(VIGNEY3%Y22=93 ;-=YQLME'B'%(5LVV27CD- U4Y)3F>AN1^[Z:8=:
M)LS<R.'"O1D,\&B)F0V>E=O0<8'G23X?RQ>K:%$]-G32;ZEX*'!L6+]Z,C"B
M"0.,W&OJ\TZ1,"52[92L1U1.5CZ]GU:&ZL[,#'1NM:J->F0S;UF(+"ST0DM9
MTHD4N>RTG]VN67N;5+QP%(&833;="2XDU4]2V;7.72LMH=<P>M"U?*GZ/>E;
MN>_C4\$I#KMW-'W(,4#<__CT$ 9DT<U"E:<P8$$3 TJ7C /D5+9[0_M<ZO+6
M.BLG*HK&(F9%ZD(I.GN"[%LN8L L&TH)Q^_RE\F.Z$-0K B/."4_>X_AB:ED
MH<RQIWPB:[%S;[O<"CS@7KZ:E4CD=XOZM)5'Q6/Z8WK!7;[/'G*51D>7;<Z_
M 8P"2-Y-: 44_;'A^(=8?]^63;Q[KX+DGJ7G8KKGY)JCOE^.PH";W!C0Z5LL
M>"%W5U @+;9KMC"2]"0\,E'+\56#M__;V2'"<(8@:$)J+20[YTF?=S^[8T9P
M,M(T+D28Z9UWX8O68LOV-]Z5VM5&ML<R1UW(>@U*72N*+E@ZJ#8@+E>$-$Y)
M?4O,L3=<O.AC<2_T]H>!USY/=&J1&Q4-ZD+)=Z)O'FI(:5@S\6=Z?#>-Y'(1
M(P:D9L;U?MI),>%EJUMU3?HT$Y3$5U'Q!F]U. ?@];T&% ,8(//]7O[Y31-_
ML_K7B5%.CY;*[!\'>[] EM"CW0M8W;,BMU5WON17JEIN:_<;#7@!-[=FVI),
MQX20+M [^WY*L7\%G'*SC7QV+&CC056FM_Q<8(5$0RW!V+89TZT '5='9\*2
M]Y,8D-%[MELMI>_SXT0YAASJAWR.;% L0\0$Z]6DTTT:64\P/"-:V6&_;>"@
M.J^XU=*# :1U*1@0&'!V[IC2Y;GZA*-]U37#ET1+X'P9"07YMH3BMP/R3\K[
M?)4V*VT)[CE_]-Z1](_3%K&QO=REWQYY+97UU]2EGJWYQN@S\&E78]:L>SN$
M=W3;_-!Z\_2SE?4&U.79G7-:)N;JEY]$G'J' 4[O;T6'KL8>_Y2L=TLJ?,5K
MV]U"Y@B]S>I[ CW%U MF%V9B)AG3$".(^S.[R#G:AJU721C@V3!;AP%LV=^.
M%WRZZA:P_'D) QZW1:DLE")8[TCAJ,MM3;%HITC&//CP>+OMKMR2V,Z1X*D8
MJ$N28LB'*HZW^>ZJG^BN_>P:%GQ\ARUQT;V.)3 C::ES-T93F7L797\<.92!
MOE?T>2?;<>U2)W'#:]]=;2,9QJ+&U# $-"BS8G9"!X-[NR&'G&.+&SIF)F3!
M/;C%BP%MF>/>)+=O)_1;V;_U>II^]>3$3-#7@K-J\R>B7>8O-@I^4*/<:OC0
M_X@W+3HJYAT/SSLRYA[UV&7$)2H#3,]B_5,J26TV1Q5-%@RPZ6]B2HU1%SNO
M'KIQ#!&Y4+&] >EK@ $W3#! SWG<*%7N5/],$)Q5(E,I2LO(:\Q^YOS$AI*[
M)]NL]&#^^_>Q#K/%195+W9'VDY+?-@+BBSF#N^7PYTV\^Q;8-^6<V1]?8-3K
M:EW% )WMD1&2=RWS0YN<#9?2YH-'*IW'YJHN7AUCGA&6/_52U!(##',>EF[T
MR4@^=G,Y*J482#$:+%)?-<-9Q_5![1O[2QREJX:7O&L45%\L^9AQ\9'QG,AU
MN;5>RT%^^T1O8()TQ=MU0W!G)D'A*_.]! G*)9=ATW&XQQ5R/!I1_?[#9N?I
MJF6V7R6/I"]\JTN#FDJ>'OT@<Z2R"N<0KY/?R0TKV0J&IR0^Q,[6B*,O3%LH
MBQIJ,_V:GXA4G9NIR))(+]D6=ZJ;W<H<_$83DS#:]=EDZ7&,IJ:I">Z&=V X
M+CS---)BS&%>/+[[Z6@\,N*UZS=H =DE-;*3715Q0<0L2=G^Z=33T4%P]O83
MWH#ZV#5D@;?K?*2L?%O^<^3%*N)7H1NN%P_?'9MOZ-6),)$K*7Q]B)+H95\6
M^E',BX"@5=JY'8^T+0/B8&BE]V3!(5.L0.Q8R\,I@YBOG[MK+V?YOL> [HJQ
M]<Z=:HA@VEA^A#EV,VV&J;S64N79G-9%_KOGX2Q/$H]0J79OJ[[FI(_.W6$P
MN4IW_LU'[Z*MW,1=VXSWR.!0M1W1[^1?=$8Q@.HN-JOE]A #%,9PLC(P(/WS
M97UU'E5L8(RMCPTZ]95MU&)Y%W8JD./2V2EU<DSOZO='TN;M329&@MN-[QF^
M,.'>2'DZ-F 4;(4^^^VJZD[EV"?30ZSBM68T.REK7SR#S6Y 0K\]1H$!P\1R
M2Y48@-(),O-ZE&7S=//U(YG$<#7>2TLBKEXID]]>*; IKWUW0\ZOKB]X-BU]
M"X96#/E]*;9196940#;]P\:N[XK!D6&Y)?9F:1ZDK(&7T<N8;W(S@@'!B8<O
MY'SF)<]IK_QB_L5A?.[MZMDS#1^#4S]_CV%5H]F^1+E-BP'<WV>" RY<#PJ>
MD?K63:5I%+ 'WH+&[^?/FMT.S)]7[F% C)(ZW&CNB_)Z0,U \".H>G#9X/?B
MGYC9/4Q#_*Y7PU?UP/O%^RUPJ3L7JZ[I064Y+.'9]0 ,P-*HA;+G/V4FJN\T
M3MMZ XUD3M$$X4_4LK9IVQDY,:9Y'JNYF"',$GWJKPV\$"\_$#^CKHV'A]TN
MDC/!3 $N([LJT][&&@)@<>Q8',7KSNW O);Z0_@>/D7%^"]TL#A)+&YG#_]C
MHPW 80^4DSOZK#?:PQL-%?=V[4#7"VU@@T2Z8BG4W=%V=N[>;@?YO;NB*VJO
M3(ZM:^#DMT=QQ@F]5^<73SN4CK6;G:'R>4,(1 H4@35P!TCHRP*TP1D@ @2
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M*1 HI(>QHQW4N5!_.;D['%B,; ^A#\ET!HE&(]U<D>X./ZJ0'&#V1/@-3GH
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MA$N(VD)2VTF(VMC;"]O;V@D<<-L_I[5V_9WKGE2V$$<;&WX$PM9&#"X@8HV
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M[<4F0CQ\ A@NT2%BG,.P@W<9?B+Q8#BX^Z\R4$ %/!P" F(<&,0=#Q?LO4\
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M/^&7<1L$&]V$P=476597,C(GE6Q?LBL?\0@QO&9T/9N#:/\E!QCV)0< -KZ
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MP&[-)EN#F-31EI"1Z8S"F]S7N>4NIR2^CQMU6JYC 4#7R%*)VE1%Q)&4/-;
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M8CKH2MI=N0<B ^H3A.GSJ-/^1?2"7:U1ZJB CPXOCC$Q!=@S39J<I+[G]HY
MN^!1I7U637H\S6?$P&058XKM5KMV?+F^/*XF\DIM'N.1=VN:'W>#M+_"GY'R
M%!^3DG&;%]5\[_)E))+SB%Z"4F\[;FA,B4-"X5&>5M?:G$03%\V/59YGE.\V
M/?LQUF@-&X=4ZG>@Z$/WJF)#R@< "1/N>XL(B_Z0?W!!EXX=?#G^X#.H\S$A
M/RK#'A=M0_GA;%\7:*:QJ2AZ!ACHS+==1DE;H3X:=/DDN@C >5O'K_3?,.!Z
M"*S*_*@13T'6G5]M&?&E+KJ8#?RCN__'MO0*:@%H69DM)6'L@E9X10,C;D,
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M-Z+\+$-O70I>%X=FT$25(TUR*Z,E<B89I@JSG#E)UT-E]?,&N&3&@SA.+&/
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M@:2"5V0O^TCNJL'SA?O-B)*#?!2_6ODDS0"OFE!@A6Q(WIY(!/7PATY^.<B
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MY?!9G=(:'6L-#$RDPK;9@4;'JL<$[I\$(UCR[>'?2=S9#U/Y5)AI@6K\?[^
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MT3WMM2T:;M2&NFG+O#5XH:[K60L:]C*S\+QXNP2O3K(^[!BZ]6/+N:R6>#\
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MW5^Y__RB24Q,?A?P!_#)P^;T=F2KSTVS^-F<_>NF=OJF@/^?P3\HMM[>Y_]
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M+10%]IMK(139ER@$;)]AM/NB@Y"T3A,2..]9NN+0Q>+VUCE?CB$9RZ-YX2Z
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MB4H+(:BZK'/8S"WXK;)B7E=GZ0?EPPX0;C>=E2R_L!BP !N:947E/O2LLK2
M^HL=,Q7]-2O!PU*?!FE]=L6Q3#7I%[)<GK:B'O'-+G6U>=V=@:><':A>PD.U
M(9Z'71:H%IAE7(T@"IP*#).;>F\4Z,I4!TB.R^+)QH>4.D9"^=O.36/ZLSXU
MN6T<Z"05%8NFAXAFLF:"V8Z(Y7GD1T_\C1>&@8*LY,Y:[&";/X#JFA<F59&1
M7Y-/_7)GA1'7=+SS65C3^ QU"NZI>%9@8Z3**>X BLL/!#MD*EWRRL4HZH&K
MN@TL\N  6:#O8!(IG>&L6"BQC;<F :\7Z6NY\K&Y-:O$U+)5 6#N]5?T6;7X
ME_-9GR*NR=HP%H=2A-@2*WDL*TY$&SK$"5I"21%$ 94U(C;8S5^&W].\[JGV
M^#^+V+\E+'LH$,2J X!K<F.7,SM)Q:7E#G;.UJG*4"NZ3DQA\50>M%Q+:,88
M">L:;-&AS#$:<HLNN&#BD*J2:G4.Z&FR@),K%286U^=29-;'J"9-M^0"<EUM
MYTVSB:/,3H#4V\;8@JX3/5J(30RX1#U!75,PU9<CW)[]L?$LHP0'+8."%*5H
M=@F))-!/1BGQ2K5LI;L2"!@=)J=B<N.Q,Y.W$DP)-D@<61#7+=QBM] OYB-F
MRV>/29L&LC0ECHXN(&Q5@!XX-WH2*ZD[U_<>?6F'GZ(N)CFAG\T<VVV9>IQ@
MJ>*BE9@,L+CAW)OMV%][S\?N?$AS"- .Z$O_*K#5GV6$+QJE#[FI'MSX\/R[
ML@=_..>IVH*948XJ"#E)&"!UR*1#]K%2]),GDQRE,AMMW_3K3OTE/#W]T$[V
MS#NTGPKPZ1F/W\-S\ZO0[^%'CI_>7@?@^SZ\.MRMC%Q]NC"N_Z7A#Z \/>?<
MX0] C[J[,>CNWR0"J'V#RYLS@ARBLM(R0[QC'@]5_UK_^&!48[C.'GXF?N&=
M,?+).[6#Q_O<N^/5]OB.:MN8"\D?@%OG3SW+_T\0RH3_ ?28?=@I<*H>E";\
M 20L;J LTC?%UTEAVMOG[V0- I<J#?6-U);/_YI?7M0?P%KCQN7'+Q>!L;+:
M9]YYYS<,\$-1[=<\&I.!?-N$ZZ,.4CP]+N!K^G^@F?X?^+?R?Z;=\S]>O9'X
M'^ 1^ ?^5F:YV^DV?.G:^RCO;P-=H_B?T9E]%B)H&UGP\5F4HO:]6'NS3>2%
M=VJJANV[A=+C,:)ZQ1MGJZSUJI$;38:4;X.TZ@-3:8?0&B89(R'>_QWB^;<[
M?N,"U+V[\ W#A-7,K/]),.6QVO-@?<)GI8+=2S[;_PX[#.I;"WPUE5JGQ&U5
M6S'%)S\:YI\TW<BZIY,Q)!MY,7>2+J7\.%O48'(?NFL"MMF*J8V!LDF"IZ/?
M*K<V;?^,3-B";FJIB:<:B;.O,A_/ ^L-:D7%CEMT^.4FAOKX8$@)N^$GX=F?
M?7@;RS7;HWU%B]^D$6\).?T8&&D^2![ ^9[A?E@-OXC>&.'WSGI/).09FJZ<
MZ@/(K\S)2?7*>BE&@V;E#>C9*.SQZ&CQUI>3EYO-Q7[4E+P)I>,!NJ?C:"6T
MNJ.)MK[FY.T:N+['N=?\?&>')'C?A!Q"A;ZXDE\]$GR/;+S-;OGS?NL*>Z^Q
M)HTZPRO/^)MXBTJW^#):[)3$&%"Z:;D&;L40,"Z2S!,;N*#+9CTI5ZV_<\?W
MA1*.6!]*8)FF94O\#= @?0KH_O'I4^&\7Z_XA^>G=S[]B@U#;G-V?[7ZK-?3
M\I7LM^/)(\%/"2'K#"O"'\7C;4]'<V\\N>'YK?\[#ZK#*-!/./P=)CSLH **
ME@0:=9O+,%.H$_NW-_F'+R;Z"N@EZSDY]S\_E=()E//"=7]@ 29W5Z76I%X=
M2O9H</OOCHF@[&+%;4:(*=?%!IB\"5S/8;J/5[4@W;73@P&\H>K2Y,YT/1&=
ML#V,%7H'<=.Z.F/3%3HMN3 IMY![&T]4S;6EB;Q=.#CB/B_<F3K6[B>D*_QZ
M;U15_S"K,[8H34!@P5@J?/177^]G--0%)/1\<L5*%T&=4J6ZO5SCF1FYZ69(
M9+W'V;1]FUVF=]3XHL3=*. #RZ*-))9::5<CD Z8X($7SM&<?\UI#E^($BK/
MG#]0H;_O<9=R]'SX;K/R]J;C!+:WK5A$/SG-Y&4(=I^-N#S;/5&Z\Y;KNX[X
MAMZ#[=L?.PO<D]WBQ(4W2^,/(DP%>'-+D)3$Q9B8+PG# 3?I[/+RB]I\?<Y<
MK+G%DW,4H>1'0#JLF%$E:%,/-?CF$U]N#S2L_>#8,G.&!+HPVT'FE4J:&J]C
MRZV>?/Q^-_E- &$"^%,IPB<U8#1(DICS5! AM4-791FBXP%LJNN2#*J4;I@#
MQ(6V1]Z01W\)_WEHJ$4\1!\S.Q_-HL]=X&6IZ%K'ZSMW!1H?52Z2T0N1FY,^
M<QB&6)H\>#PCZLPLT>E"N5K)83,:/[5.:;H^1E@SE_7UZ761\0+/8*W3]?'5
MR+^=GC"R@K9S(M-' (\G*]+JLP2-8\EK9EE G@AT\H"\K+WY:04E<3X:V%XP
M&D/E8;3W )@69IB<(GC0;"#SL-[9FIK1L16K(%2>.^][Y]M3W.'M?M9/&SWW
M^IXZ;:V'0Z2?,/4%;:T_HOX#N!7ZBO*Q\U9H[*?$G\E.C$$C)\KJCD>\M;IV
M4+N,IUM5.-GSVC 48WRM5Y!R%_H\7AO8LE'/S*P:(.RMHZ!RZ!OXO"!3;"@F
M\9D-'1-T%BBO#[3,TO$-.S Z)(A1OG;##X@M9@XJL3?9S0!-M,'!*\HDE*[4
M1N*<H=2LGMB5:B;;F:%=I0EIXAAK)(=M_.M5N*K'ROI2,7 ABLP\451&3SIO
M+XFV1>$ULRX-2/2['N\UO('\(:A+@M&)Z<W8RJ4>)UNH^P+=;=O)0%Y=S1Y/
MJ:I\[E0OK.+<*WA08]1'O@3:&I \78D,,!PL^L+O1&^;L^^KYV>]K]!KIB1@
MP?O0LQ^=NN!5:?0 ]U)\0PZ0/CLE;Y_#BH-I*.XE_'MT8#$(4.T\\<PXU+HI
MYNQ,$6.5RCGHLU,?!S\H\-:NS5%@56\=?>OQM>^ZQG5$F/>-=$/]F;Z>Z(6"
M%7L:[P5ZX33=7#HZNY@LNA_]_N=4L7.6M+UZ^\H#%UY]Q)E4>891IRF&BF20
M,\>F*MT#?0 #IG$&2%3TR$]_,?Z(RJE % 35A7;'LTM[RK+7QC$J\0K:;8O4
ML</G<_SME=#=T2"%EZJ?LRIP$BTT8</A9*>CI4"*="H^*AZPFRE(1==+]M.]
MI,?<3U/&E^^(7"-_W[IA_C5WH?IK[V.SG?N0%SN7_\)F$3^I9JYQORM:F'G[
M!^?WZI'^M+NCN\<OF+\K_ %P9-0^,CA<_.EXI^;R5OF]R_"=W13K29^1"6+6
M'.[;IN2U.0\9F]VZ$R>UF2:CC5\'"+5B[_C(D@8R!L/3+WD"_D45AU>DQ$@;
M\XL?K9MQ?P!-_]KW_Z7;TO?U):-"_P8R8?/VX_]CEA> DQ?,C3/5G_,PZP<<
MZ3M*H(F!.@D2+2XC2H$]34!LUM"_7H<G_WX=7.3&"R@;U&05JVD+G'W(3H:$
M!OKZEII4)6EI #[[62MNTWDU0LSFE0(G)PLJVZ<C4M*].U2<K8''?NK/(@1,
M4SVI0A,92ZR":XCS> U:^UY$]EA_+9XRHE7($?5H:T/1O'GG49'UC+=D9*27
M0=R)/LVZLW6'\5LUPQ.^'JT%W,A+P=X>M+)@YJLN>TW2+,!4/62=&+-%&YJ1
MU$'I&C1VXEM6()+=N]!^^NIV@A:[XN8876]#^FA%MIJ[)=_+5E]&T3Z,Q%VE
M+6U>$[ERXNM4>=(>[5Z;MW &0((Q&+N3ZSW@]J*E+LSIE/:AUARKY1<QG0 O
MBTR[37737B"1:$'4*/A.A,]:RJ&RT1P#"F@1CV2-.=C>(]2J,.X+3387V&7&
ME/K<JG=''2@+6ZXB>7FW'<"&Z6/O8K\8M=)%6D<G_A3F>$7[>V(7=6$M"CWH
MRH'+>X':]@6U9:]C8D;VB&XRSRJW\,A20Q76'=1'U-$Z(7;U'M"A5I^YA\+B
M#I(&2$J!'7_8V/J:K^6\-Z&M9[Z4KCJLW]U9>M>RB6G)N,2,W]USG<:F O5N
M,*CTIL](J2@ZBO*3O80O,(V;<7V?"%!>KOAI^%*75XE3.+-_9[O"1/H+#+/F
M(C_,G>=&T#\JU4RM"0!9H0),(A^P'U\%,G:M)-IIV4\H+$CM9:I#]Y:?W^9^
M"+Q,I_LV1A&IIM?IZ: C)T!:&T6UXIVI\C!B-_6BQD]*2,E>:WUZPCYO#WT&
MS^PU9,6DW.M1RU30U1J0I?;KS-G,W*CGX/#/]A#5^FQY'J!!'*,05:;X\ AI
M&[5@G=)_USN -$L;23>L0T-E: ;SCRO+*<][M%618[[LHC9H 5.8<K[+T^HH
M]M$8LQ#T(>A@/V?-SCAO!0(Q>+Q-[FDJ5I8:?H_AYQ'G3BX'HRXPLN;U@*>F
MD"0Z<1IB 2';MI0C5V651YF,G)W>LMAN19-EB23;15Q/UX]9Q%C0+VAK]CD7
MU-5%F9E)%MD>7#<Q3T0!65K=QH-$FG!CT<Q-B/PAECJ8;91MWCO3"\+\J,8J
M$PNG"^,LY[=N><.*;&&X^WQT"!=G,MQ%K?#(\4VAJ]+AQB8LH,*>QOE,G+^9
MAL\V01XZ?5PR_KYMQZ1/"OVNZLR"IT9D2\PFG_2>C$OE.\N5<NN9\A"*A,T
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MCCEV \YS?VG]_.M^_ %@[Z?]%W'^;T^7;HWM:FG\0MR;'!< GF1^I(W<_P.
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M;X24&8<?-)[GDGP*,+T1UXEAV/B^\JEG,5R_UPTI,?2UO%YUS<\V6?3'>E:
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M=([NQH6:+ZHA>+ 5(?!2E9?>=B:HPC*%I(-X+_S]?'V42)P4YF!N+I57)?]
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M$<'9',EM\AR[(+).ODALF[-8>G;G?<3*6",BM)99/![F4GQ <?PSA5\(+1%
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M_87>=ZG#K77O[TW']>S!'GAO[B8=VV8N@M3XVT%=3/1%<E-W^.>*LB8 ]3&
M_V0ZM:QM?EA+YE9?TH/0I0.G=1_UILT#[P_TT7P?W1:>^:2&-QU.MPYW+WUV
M6W'ZA]&&#RH/K+^\ ?6[&3Y:>.:;&)[_H'(6?F&P#-;Z^5"CYI$L -_\P9<K
M9_K^HV/^\81TB1O4;_Z1?GJ\&>E2IO*G2IEY[_*LNWU)YB%3P]>3AI_M/T.M
M+FW^H7R#=_'&4_Z4]_SCJ</!J3O#6YW#YUMG:T[?_/]?@7Y:/ZY=I.X,/EA^
M1?U#8R6$S^XW0)9U;4^:@F1=VZ;#;>O#%EB1HC8@/?;!;P"#RF0S__V')@7=
M.7R_T@D7!B,77X['[W#&Y^&)/TIW'VA^_-2UFO.GU9_YE&LY_VC=Y>6_VAQ:
M^M/FAMOU/X5TNW\*$Q8]?PI_\U/,_],]*>N_^B/\5QWP0^-O0-BEC4_^?W;[
M'R;^.;Y>8>Y#3<L;2;X7MWT7_CF<?ZA;6BQ\M3S?H#<W?W?[GTJ]4]Z_ >NO
MGK+6+'PU.-]2E/\-:'DDJZ%XIUK0&KG/[.R9 '*3_N8N%64X;GYYUH QNOWX
MD:RB]=VAGJHQC\NS>HA(19_VU)=53RG9NLNS]UMU7+N\)V>RM;":)&BH_#49
MZ-"-.T\R_I=)L(E]ZR'?KI15K8OG\IG*5] F2Z%2RE_S<2%12N]PO'GS?U$/
MB;<QTM_,B#Q)'FMH6#HHLCD8^U]F>+!O60IM!"):)P:Y/!"P=#.I?DOXX+9Z
MZIOW&V!W4]^74OJ21BMN<'"-V"E3DER8]WC6 I4, ,V0NI-H;9C*BG2]:V/;
MEUD.FX@5$(WWJ$RKJ=4MSBJ\;219[RB!T4PW4&HM&9-*.RM_H>O!!8H35[\H
M(T;5X$0=QM*6'1/LR$*Z3:%"JC31MV* M@N/A[3$.8.9-Z+ Q</T">(NS#:^
MD70L'$7T&B/;),D\;*11);BH$ <G'O7W'\,[V#:WP/*<IF. E<E9S5GMY,6:
M%O/">'S#QFOS-[+U(GHTELZ4Q2QC(($TA$H$7<%$2MC:Z;DS!&P;J=O0 #C)
M-[K:/2U'8I.J7O)LT/;95ZEG/Y[K'#U97[LTU3[9VF-[M;QQ<J)-_\(I9?K^
MT-MS^-J7TL\UZWVRQ\._ :2OLNZ\C[[_^ONY8WGSIYB;B<RG#O<>['W!]HD]
MH.U*QVQ*A;,QHW3KPZ''B2,@4CPT/)9[277U?'D4U"C<SU6/790*EPU@,%\K
M%!+O4;-R]E% E#I\[7@HI&J6+<ZL[9 S*?HYFGTMABDF)G*>)L05AP+>9E>P
M/8//F4E7816'N6(8;TVRM5L;)PO3]+K/@2U-L]9;R/P\\KSPX>7U!AHC=B^#
MZI^BDA&:^C2@L(FR%FIJ 7;,FM^*QTEM18*\N,]QR[Y[;[HSG4Q45EI:#+N'
M;X!2>/%SQL[8$_NX;7%9;*!5W78LA/H8:OM+K3*7PH)286# $RTP0W3V2.=D
M6K_ATLW1]!7T19@]FYW\1#1^R].GM-)<KY"> 1K[A#W$QJA902/GPDPUG@Q"
M"[\*:Q')7;>(TS_WQ%2*0?R'=MHZP[*/^GHDGW=HRLZ19A&*TW-'YJOJ-E1M
M236\XG\83@X+*MS9913"P?4=TGJXC1*@U-([6;EQ2CBVC-,[,XE>(PN?-58,
M9-NREN'X.2[E*\*LE1.SX.=JB7K4FW4:-UC&I4-Z68/47Y[2;\XT8ZJ,O2O,
M0$T-TSSJF]HBU;'6W;7DHN*?#5[0<?B^."7('E5GT9 V(^2#$N6Q\(IPZ[@R
MZP.;*H\T3B#)" #'WZ\KFIY3Z<@*">#*F;6XZQR9<J7O:QMK!^G[29L<0?IR
MJ40/40=K._5Q[K@T -V=6N%XRI@KWSY$?ZGC=$G1D!>I'?#U#9FW&5:<\D%P
MEA;-398PO1@?I^W(5J@'W+J).]4S'K#DO["+7KH1W?6%*3247[7E\C55:.BI
MSY&I*M4$[B?VXD'9+Z\;#:E=CW*N[=SJW'BK?-F=0U!2?9PB(YFS'=/B@5D$
MWM%/0M<)XV9$I-FB80!S1CV7P;T4<?RZ>%U?KV69"<;:0D:2Z6F^KMPN;1\&
M]HF%2=_)CZ-=(YWOZ$ D3E!2F8L1KLJTOC:JW#ER_@F^-UYQJXD$.64&=Q,K
M45Q!9ZG6X+(C*\M@"[ZEDV](\9Z)09V<8$]2&L$<I;.5M5&&"G0@"YS6TP1C
MQ.&4M-/M:9D9I>."%%V_/=(F>Q*0S!C[5&RVC*4XPU)3M- ^HJ?.:H*W>?JE
M2NJ5^PZVF\%Z]5D"_"3"-^K7Z:Q_,M]C^@EMT+.?!_G35-C7K+2'$I+ +!2?
M.&TM41Y7 V&5E&-SZ[=R600#V8[B^A/JJCK3"8S]D@K$*'?P9ELKFX*FRIGQ
MN!3%:I-^W;!RAK6M$6Z&K.K/'-.'\F;(-3]04$NA<3 (XAFV?F8TCU)J;)+*
M+,D.%AUZR-Y3D1$W*!]C#/DL46].EQ1\LPI+0\)%N6"1+$S'6NO3O0PS*Q$2
M0J%<K#K*,JMY#0KS RKI3'B5C7P>];@T;U9R&9[9&4@SU(]R3?+DEZ/2LZV6
MN"19+.%LX!U%Y:'-BR2,GK)4.;P46OPFJ(OLT.D]_Y7OQOR<J37W;QS(W7?5
M;CC]#<#WGN5\'^Z_S* :^K_K5?6KAX^,O7@VGJG&1A0ND*CO2^D9'A>7_Z<>
M^Q\][;?D#+-^?RKZC\\N;;Z$QOBS/FMJM9\<TC=N%(P]3(?6XA1]91Q?!Q&H
MF4=%.K,!JG(VD&5MOAG#A/V^72Z%>KJ:"CN'2'*FYG_9X[?Z^FC._NM$B&/8
MUYT,W?C@RI@!$4ND0879:QT,EZ4/O?SGU">_1*\D#2]J\W_*T5;\E\(#IW>_
M ?#HK?^[_NJ@[[ T_NF43$I6>TPRVR&;$WA[UH)-:X/FS?^C*=^XO2A4&*\.
M&@FL%\)%25(+RT'UO0=?][8UJ&[P*T2?&ZU]>?JYYG)(^_C2_K^<M@-LF7J8
ML_7EICNSM6-RH3DL+!NAGY?0X2$(>VTUQV9BLT#?+7.-)6';('QW;B5N&^+0
M25LNPB1.BG"0H1:%J#M!E5QEXJ7#KKNCES>]Q!\K=(,U/=NNFYMXV^K;JUV[
MZH6(%]+1I3P5C'*7C5F8?5F=L]J'E6MK8#8\.^G)EG!-0)KE";WO7C2_V\_#
M'7.-Q628JKL5RVDGW"5@7!2&-'P:J)29#0KB$C)(AL#,EU9ZA]@TP&+6CY^#
ML%*L26:W0V**!9V<292EA[:Q>D_NW5+] :=XQ9XM569-=W=9PNY> %^9#O)4
MNCX635!(R,)TCCL%+AO!OV;5'LW)2P^,E"PO"0,Z$]*[@I;=^P5Z6QRG=L>^
M.2?OY!)$I$F;%JAU23#1A"C*#^M$%I13[*GC]$;&FZ2;P4+8]$HE;A/M-V<9
M.LT[4<D 2[J>#)!#>+&560N"*#>.%P_ 50HLC^X6?_)5F"?XC'4VO\ZO*I2N
M- TA;[0:Z20JV6=19#;6W3_QX%K(1RG5FL[T0!A;G304(Y1%N*$),0&]G"EG
M076XFZJ,0&71N%X19AE4^1R%H>S]/3(%-AP]WG'QH'8MM%$2,2_TJ;@68JDY
MI<^5X)+HP2;FLXV$@<M0CL@)A@>2R2P454LI/K>8](#-D5A1HKJZ:["^LM*!
M18L$HJ0\"]#K)BFGH$'0S'L: @;QM/@",-NP^9;LAIN\!>7,!)N=B=?&<0M(
M"ZX74OC027!GP<KU_*&4WA8Q#1U)&&(Y"LN0+0 D-:&@B<%H!\:68WEUD #D
MF =Z&O8ABH8RHK831UY5L.8UE02CQF0+/0;.^X13^ ?SM"95,A3Z5+HKIU><
MM"*(!<TS&S4"ZEYSW)C]NJAM=AF\LT11\/9.;RNC'->8Q3R>W6SW-3I*RJ",
MP<")+&[GEENU21=B$-W!_!PMX&[?@MYY0^$7S]N4NUT>(:Y'#['-BI1$4:O'
M*95CI;I-]$-EMYU)5%.D[MG/YY U$K%Y1<J6DI(8+0;G74]7X%A+L+VPD7)D
M&8(NR>CQ9*$AH1RWVH_LS\\V,3-Z0 3><6L/P^)C*(R;7<?P'DE82N=MZN6K
M4[J^!T58P]=S=0]-OZVLV=J>*6/#M^]&=V<!,.(6<UC)&9(V$Q/3*JP7&630
M-;DT'FU@QL4IG)K/=_H8D#/S&*V$,\OVIO]58X-$O7M-(W22B4L.)2PWBQL_
MT;"5FB-)65P(O[87+]Q<F(4'.LIW)0LH4D(IXLDT\^TRJO,B#,+:LG)E[_ K
MJ%M">#,$)$RD\$&5A::JU F6PD]Z07 [U--0S+;*G>RBCIV.AQJ#=7?N[,0X
M*HP+&\D^AJ0HOQ9TG>?Q)"28L+*BP  ZER8>X1CC 3V_+V<9;;"T*BS5P\S3
M&4M7BH$FH]WR^;M.,L#&PB.F6$7VU?V:NB2R[-=D,72<G&T2X?*;@3K* Q;)
M=$+B]_=CPH,CK.=FO_504$33P[ YQZJ!;PW#2I3HY>7J8TJ+O,)6@D64GL:M
M2N) G#VR2J0)7^)6(5F@%NM0:4>T"-YJ7TS:H>10-#)147^VY&6STW![_56*
MEFP(2AZ@V_MAR+4R18%,<'2$B(TPC:+KMI4A>3=BP5;U:Q%'+X4DP5R_6^H#
MIQEX5^0P0'? 1$Y/LA0G6E435)6L3['O]OSV=7;+^5&/W;.!<U*^+F**L(:2
M@0G/G:P"5UH*^Q;)=^C%C5[>@Q!*=+96WX%ALVO$R)R4%(/]G5 Y4CWDK,S/
MF4G)+E8%LW1SA*B)I*ZG/6EM:%:P[9J)?."]_A^V(85)UIG&K;-]HHU73*0-
M92N/G9%\G)\E,)$29@;#[KXW/615#[]@%YRRSYU)$4PMI)'+Z*N@<:;@$ $E
M<9P[J*7M6^@E\C<@MP#]3F;NJ0),PL,^;MF6HVF"0U>MDU&TX\&@5%F.]9+-
M6WAX,(N#W28*@G7E=G8!$_)2!LP@+*RB^$]4B;PDF\/@L(89/NF@_R4S<%_%
M:KOS70 ,D,35^%2IQGF;Q@E),S>0YFZE/JY],*-)?N!0%H-N=AB!N!L(#@.^
M9?)C[3XTOZIU^R)_X?M1Y&=UJ WW[JO7&21>;6R+<F?WK&4U-SG* 2\<%>4@
M=]W)"9YD>,5 ;&1T=(I(Z![,L26!W;XG5M0R'8PA5>OJS+"MU<E1;5#)&-3,
M&/7.(Y%$G6S CXF' /E@-T"EYE>\'=@D>4 3+8$^?">4 D&OR6/WEZO9[&EL
M#:=@]!/%2C+&>KQM3#%E6!7YH7&A)H4[A=@8R1KA7%N+N@K!4H3K//?JJ6K8
MXRO*W5*@FA8776//?6"4U="T@=]U!Q2>Z,1U^A,J>\WSIZR6H[72^ DF4'=D
M-A:_4;4210:7<-\':N?S70D?JMUZ69@%K$]#&J27FB$SQ2=JRS);<60XY["E
M]D*B#0K4UNK!CJR>43*#@/+B$93F(B22NU@4.'GL3'4WC\G'QU-L/?E>!VN4
M O54'C:XSMGC(+ JB2Q,WNT4?@05:4U+YZZEIZ=G6#UU32;='9#-%"^+BBW)
MDBI*,T4MF-OYU\C0E=F_Y>13,,T6@8U_5Q*S2Y]PW6.J>BS-#)>"$I@\M[,0
M[P[L,%F(P2I# 'ZN)9M%NE[[8[X9WI=:VH(Q*,T+G\!*7(91YMP:B/NV[_E!
M"JT!??:B>%[G0H ![ \<8\A,MT',*R_=-IKK!?/"61RY531*J1T?X1EGF(SW
M39WH"$D)5FU*<RFVSD0M+<,K]]S+Z.5$,VYIY^I4<\EE%GLFY]Z9D1%GH:N,
MI Z_'@0&>U*NI>D(D.3BZ"#*A+D%3L>PI6=ZN0RS9MUU?Q[2B@+#RJI*T0A2
M*"@EJ$K).S;3)B<:(PZ0$V#L(;-Y;W/6;8X6((4A33.IU9:#Z3*]!2R\)S:_
M0!<Q@9S>YQ?:R50"2GNAIV(6I50+AA*8?8D\.<GPBDR?Z2L*[+=B0T1Z]\R(
M$F /1"8@\D*:I58I22"*"#(<6PZIE"*0ZA!&Y#]K]&6_!C">"4M&N#<_8!V?
MFY%8/\FU0L'*A:'-MN()B<9Q*,%,4D42PRB*  V5 B'E^MU8ULI*HN>"<B7Y
MKHYHA:9VM><AZ-C3HMZQ!QW9 B0BHI$,;J3BYL;V&:T=&4BX&A8NUA4%3=>5
M/)*J=I+@9*:@ID)HP'2II>*H"AA'!1R#4L)0?E70'M:"=,- K9$%!2;!("Y^
M!'?+VF**8A+VBO$B?I=EKI0Z5<!3@2N3/.UQ?9V])RAMVC +)PFK$XY<58P:
MF&O>D_<$8MVE=,SKZ?.U)WCN18TS:^H F9=ASH!83I[WMRE(ZH(8^[]-426H
M)GGR]@,>%TOI-L];S3;/1<;B2 9_ QBPFW.W).;,R@H)L2AE>0IQ8:[] 0:/
M8C0:'>Q%JS.(6[W5J4"Z/3/@11_ NH:@?F\+ '2ZR_LR^].&I(BWN7-F156Z
MW 4@=BKUS%T"6::9C+L]KH_5*/O"Q6YIO*RJY;X%VXEG%<QAUE$-4ESQ<*6#
MGN[VH[.76H);M$0=QOR]'/J_-H)KAA"5\@CCNSH@ $U=,4(EN8/._]ZMIRW8
MS4-A5N-D'/2TAHY5F5Q7")& 4J,(D>'RG?9ORJ6=Q9-3W0C6K9 +I%/KV:MF
M&^?G2ET=5P[-E)WBN"I(:ZGD2MX"I],1;?\-D/MA-N0K@+T]V2:2,V:DE"$8
M#W4JF)JC0/TH%X1(I5!1.79=]^K[RAK5/"JR@<J(:QHY<3*3$PO20=2PB<<!
MC2>6GG]+7BJ:"['\*,:RN6@7NGO.!DNJ'RN;$!GWU?NP'30S1T\K2*=[-:7P
M^;MGHNHAKV+OYS34A[:^7:4!?CR_D"NK?OI#-^=@^9+SW*G"ZZO;Z+\#_ZTX
M.CS@RX^TL[J;XZ!$KG.Z%M7*;5;-OP#\WQOF6WXJ;@^;OCZ=SN#5N-VO;0R8
MNT51%W3_<M$*?J)DXU_::AB(?!7(H;6S^U1 $97,(F]C:W$I\2+^OSSWV__P
MW%R5&,>Y+V^C;XD,7=*("ELIG'!CBM7C:6LH?4!L,Q&L%F3LE3>H4VYQQS'Q
M<A 75=*J2:G))*@%HA3H,UQEZ5_@185=TX0*]0530 EJ\P7 :>:2_31BE V!
M)&Z8NN4>Z+J*+[>4Q8$3[V@'5_:K(*OJ@WG4RA1@*V+ZGAO+4QOM#2-N[')S
MJ7"-:3#J-;*+$J2JH":#[#2/YP;E-JE;U0/AM>@8KU_,_$C6Y99B'A^1QNA+
MM2TW,BO:3CVNF=AJ+XPO9XLB4VV\(WP#<>MT/.PX[/Z9<2+4$:."7GLJ;2,F
M!SPD@HN=(,()2T;]6Z*;UMNC.<"I="F@1;* ;C$<N<$.. @QO^_2]GAE0@1_
M_U#8N-@V\[!R!(5*E [V 7;FU6X,/NL5:^ ?6%FI7!2/$X3O>/)*4LY7QB8<
MD>^EJ/5G3UFCUZ=.8+N*5>_MTW,DXVKP \OC% $BBU2*$&NQHY$7"0<G(J^]
M5.+9J$F'VX6.@SYLI[<-Z;3'05D!UPCI^YHLCSJ>7;YO]](6<6$=+'81 4&"
M1#@4L#5 ; V9A'!>CUPQ8"O2+T5LP.E)W)E:D935<DO65G*97S,YO3A^(8XB
M04!DC;7VCEM+\@ENH2N@"J/EF%P<5W5HDP]GY>1*;5JZ&=7]1>[;O:[4 LQO
M@%=TUTMA]YA?\<-NETY4VQE=Q\J/+FO]WQNLC?[;?4&=]XD8:7=1L?WIRTZB
M5.B[T5=8]RB-T5+S."%ZGO+R$K<'.V8T:*J"!M=X^[6<"+_X@6/-SWZ+$]C1
MYO=^Y:J+:L))/PYJ@VGFE%\6:2!4,WD4WMY/&KB'KW1][Y>^6-+5ST-HL;I=
M:,E,$4>[]R2\W]7#U5F)'3T@@R[+^BPE'F.(<Y+I^XA1'7<\FO1RKU;P6UMR
M\5DQ\J<?KP?:$9)&DK8[9YGS1X9*PDK'#OX0U'$E^9&3N6%RNOV&?6 G_E%0
M2I:H@14G1&1NU*-/U4LD\^".$'7=V"3(+ -?",EID$8PK[C+][KR^03O5IVM
M&E0A10)2A3Y6D1ZJ-[<.FK$YURL8!'OU;735OIAH2-O)?<,=;'&7L6NPIC2O
M7 '8F6WRA[>$Q/MJMGJ SJ0\F8QW4O(0+#7W.H %O6FU[*9I?^_:?%%Y4##L
MW\29VM#$+?\OT6CQ.?=0+B9,WS0L KJM[PR5MX-;RHSHFRNY0R)S/S4MQ3[8
MW.<V@5""=\,5!+Y2J\JP1&8WC[S6_F+S@GB*L876KT ?EY)9;WN8%2D%*(GF
MH#*L?23/9Q)J48MCASU6E8^3C8VQ-9$V2D$N"&M,'/4#:+Y4YNOX!VZ,X0)S
M#1J^:5I$FBD?"V$C.4<F2GM&'=44%3;D,H/([C*[#1;'''>!#<PR=W"8W'V:
MQ(L:OI(]-K:H2L40^Z[W:@-H7"%G$[B!)<V86IBRKZFCGBM@CQ]W\,1JM<,C
MTP4@.5FNN3GRM$REL/TK'86W6M2XI_BIN#W:L9II/3(NW)5XM(OU3!9RQN5Y
MN#A3',%:F;%\Z0[>LH.Z<PG"FA=M1I9V%4DET/O.SR^S**X6.7%%E50!I49,
MOPGCVM.!'!&=YSJ4\K6T76_[<IY2JUB^Y7:UZ7P@O\5[EL W!<',Y:U7]"A9
M_*I1UE!CA7A-WZ]L[9ZH'+<M:!]O.OV<>NS_^2%#PXLZ&=\;.U^]6 (8\H\"
MLI3G=4P$W.R>BEHI'_WD?-3MZY7TE9SL<K:;?_;#SKOAA?V[PU^*ZGK'$XOX
MA]I3KZ3&]WT'1=J%BR7-,'(I/2XX%-<12/KB%J\1?'F[.;O@2D.(1* ;06'D
M0M<9:^V4'"EDP%1=E19LX/P$6J)LQ:?LK?J(35[VFPA\ "Y:% 9'\6+D>F;?
MUR?LF2?*7NL+LVT9IFL'G\&>"UCJ-42$+1 \TLO^$*<B[>>]B]?_U&VZ1?;Q
M+8D@KJ<6?1(0[0PH3S5M&5[XJC[TI?W[*RJK]=?\EAOON9>W#G_R.MVS>7 [
MNL;7*[7Z-#CYV.^+@I\JRCA=*S3EP:%%=B%3&T3E_+_#(2Y#-<R+- SI0@TN
M:*5Y B,UTI.6(7[>3->P>J@W+2%*A3'<8.G55_8O8KS/OB7Q8TW_6E+JM)Q/
M=KYA+U$_ZN@_WGX_FL"%N#B5E3T2P;H7 Y+-<ME49RVDH+7=E*K[9=9Z>$\X
M"4N!F;<SQ(4<;45LEW@!H/2;"E+O0-!*=C916)+WE \@8>L0!_\[GG&@Q>^/
MAW.Z*O74U,.3: CE5QBSE[NU7)E\F;:P6@>V.GK0J9J@0ER:(ODA&K RVN=B
M;3%2!F>A!*7 E9D'+82,.$,"JHH'8:5FOM=JK<#.0!"1UV@?"E!O(M-WENR9
MRYPQ4;"Z>([SWE.QZ7#+>C3_E';:GBHL?:M\.2"4(!'A%()4'$E_)G%:9)[T
M)N.M: 7]/Q<#CJ[.R+XQ'"(OH)ZGPU*S.LO#AGK9GL5(8&Z(')L@5%X+'J)Q
M%6&%&!NGA)ORT.C9T,8C=, <)5+[#J9^U\IL% /%B;1(_##H/O1Z2"1O1^GJ
M6EE\D,LD27]GU2B:0M(J87;9*V;NN8!D+76.N[!HTD?X:!PL+L2<P_!I<;;J
M,V-38_^F:QVY[)G:0S)P%G%'G51E5M#I7H>ST9-"5%^AS1Q'%ET/JI&@Q$>/
M7QGOAL6WNE9*HE9QSBX:2@#/;08/^XZ9=_B<&KGD$>  &]])I11OIJ%*IB=B
MYJ5N#D,2J/4B1(FTJWV"MI9"\COG2G:2<F1E%)U@WG=Y$9\H>LG0/DA24]W=
M.,>3ZI*$3LE@ /B%?P#;@4-65#I;SA*<ZY;6AC, 57 G7KDJJ4$X'L*VEOM$
MOGG70LL)48N/L/84QV>8QQ\[9\$0N92)PIU081.Z0B%,9X1  KW2<Q94)UW:
MN'<5'MJRWDE*BT#B9DV@KN7- V?=\7SY49TTB0@SWZN1M>\Y10KR&$T8+$C;
MTZ;5PQ.,5%U]@&5.G-)!ZLN(0,%&\4:%(Y;6."JCU@[#:@'+M9&ZH#DP8Z-Z
M\]U.:48N[)O&QO9"9H_>!Q&--9#0Q+2YP6B#0@:LLT":,&#>+;!((&4#']^5
MJ7ZH)8;CHC&'N$P.*@0C2V(:6#Y">(XJA>X5<_?5"0.:R&>LLAP$@9(Q@8YX
MY;7V6!7+/#6 TX1@* K*4JOV6(:$--',L(X7'^GD.###]7I>C<%_9^5BN#.S
MGU2T37H9S)5S[&2"/\_(+5^US@WSOA;,8<8JA'8NYM)5>18X5>9N$6AUSF-G
M&A8D%6 83Q-!Y>B^939O*=C#F8W'R=XTOL:8$8-[%0K@'<LUDH%-D X 8C(7
M,VV:<'W4M>D.?NGB3)\6XF>JBCV198TXL@(3%F+MA"#,A0Q!ILQ-\4"RH(,^
MW"M29+( J9V'2K>::RF#J5FJ>]>%64!(  "2-( WP$$U9CO&Y^F3J0YFFG 9
M$1B1E2*S.:F*!U@LV"$_X&PJ60GJ>U/IEB>V*_(FRW:1[V&\"*D<"M'C*%56
M,B/[X8XL]GU3/6:IN%&BN"2=CP04P0KL@S)'S38]]9@5F0.EE8P'#J)/-FS6
M1AHIL*+Q(DU%3!R.D6G34@/D,"X-DR6L(EJULST_08\BLP'3$';1L$K&G.6R
M*# KB)R3,$#!,_R@,0RH=J _#>2GF725L8Z#5_;DMWWE5QV9477DSBNEE.KC
MCHNJWB=4W-8@XL0A6#>.W9'!)WA6A]B!'4;.1RRMV[E'J4HO'NC"[F\,NC=4
MJZ2I9<]1&"0QBB0IS;[/D+_NGA]CW9[P::@F?53HY:F7ZUIS [,P]\"<196O
MO8^QL(/(0)$/F8F&+?,[46#22!\5U\V.8K]D\!,=,>2L^SV#*W39JES;TUR,
MC=GRZN2I(;6H&3TU(5V1U]VLI4.6'W\#2-JCIE-.JZFRKI7&9X%6E:8[VN/'
M%8<<8)6ZQ@RFL?X$OK$OT2WWC9[XK8P/I[/0K[7G#/1>[\(#JR8\07[5;,55
ME=7@8[$KQX_9QGM_*%6=6O?%,1\[9Z>/:U91?E<I,9$Q\M63]D0+YK"0@ $
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M%R;/<"6T2P 8_E*?KD=MET29=RNG3^JTNJ^ZGCL /)9+;\'I\E34BJ+=YTR
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MAX"@ 4MD6@@;.G?A^^''.DJ93IQS5G$ZJF%U1'5. \[Y=8EE*B_J8AYA"\$
M+!A:YSB>]<. VQH"%*([U36%#4*A3QB$ZVIG]O[N"%R9^E$ADD6+&I1!$UX,
MWYH3G%1T@&PI8!V(VU<C6YR,/*X%*7#AK%&N9/F![1X:8MJI,4B.60:5_4S
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M7QD>MU8?C\WO']\ #\I8<<,7EZ\#WQXF MX 6*?_0_IO=S%=+%_VTP'I=DJ
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M6T._WT0?E3\ D0E&E)7YQH17EZ;[5Q^ M_G=R,]3/X&4,QFB;YZ-GD]>_!^
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MN!"^ITB@D?^9T<)_-?JJ)V:Z8Q]N#9TK_R?$]Q]$]YCP#H/6,FLS2904!^W
M8PA[E*0C>N(WA\DV?>AN4*1OS&:V&$J1WX\A&$RAE\$+UZ.2_69DM"3/':!2
MLKH<*]UWQS%Y  S*7[C_TZCWGX2U5[IQ+!S7JVV\$Q']I_PX:EB2+>[[BA8&
MF\H(\RX5UH&K1P(9V2>3/:+_A>/_'\/M<$*!BHWU<0&P;&D9DOT6D-2%]J\J
MP72I'(36)6V5G(T@4V#=[:)A8YS,^X-QP^LZ'WFOY_]FOQI ]P$XM!#5CT'=
MTM0_)21AR79_=ZBUC<Y;9-+.*8L^)J*;@ZU2C_(6-LET294T$-3$6TE'K#&E
MRH[)11@-9P\#.&J_<99/ES=I(?O8=KF[I@[]/@7AJ!-NT18P&C"7^1!ZY<$:
MTA&3X$/&\=?!M7%_;^@XTNVK4O9W^^ \HP;=".OL_HV3'U?C%ZX/MH6@'(LB
MK[^/\9=QYW&(35CD.N=Y_W+90#Y= [CU:SPI$9I;)R+Z-_E$%8B;U<*Y9Z6A
MWBZ[SIB AYL?\*Y-/+Q&O8354XDZ?H[2(&F2C!.,S#4AW>Q45HX'GK.90S\N
M[CRE7N]M[JRE5(MLN7 65JJY)]G_C&F<,>+@3[E^?/LE0V!Q)\)]O7TB3'CZ
M()1FFP2#B=BKF2DG^>LQ7:DO#K_CTNZGC!,B 87HDV,^Q-YM-4,)DO$R?(82
MKO[UQS&]E!\)R>#HC4]PYPX*_%*9 E=^N?%+0]%N>0N6/].T<^W8W,Y]?I3S
MP^@N.SP>T^BO[+B"-P<T@^8L&&^T]&Y&X6WN3#"B4G(5H]!-"\'**H2:QTLX
MYX6:^GN0*5&9101B8ESIT8HZ(Z:[7)J_U6,J[G,GT+68;CNV+:M-)TO)CL9N
M:8XE$6.U[X"7XY /P%'9%:[HN<+K)V/TP)NC-^3UKAF1#*,?H<&/"6);)#?^
MN 6^?1\ R5B4#\#PY8.+J,I1X,S)B"?U3>A,T<*N$!04U(L,V#.,'[5;45CL
MXHXUM4;GR:_@6<E-\#?I#^*UR,,7/0;J_7>WY]V9#\#*1>?W]PF5G[4YK$A,
MXM@2Y5EQV58:E33N_#[]E1V]LB&6;$%X!Y=HW8.^?</1\WX!X9 "^>.UNZBO
MCNF:A=;[99O5V2AY^1;9/H]["%%;?8I-0,O;"/!BM)DOV=K6:E,$;W*>1O1@
M6KJV7G[&9+;Q/1*WF4KITF[N\*DAY>X;_ZKG@^?9!8F[I;2$<YJ_CK-F<G#2
M=RU(=.LE_&.(5J%%"TOYGM$=R6_4LBU71>=R?U+AN*ZE@I.'\:F#%[:GBZA2
M!#K%&Y]%C(BFFH[^L)K2B:86WFC'F 28O;(7U1[V>+7-CN&JUGJ;X4K^ Q/%
MXCW^]([D%:<G[$5-;L&[[+_+0#-"001-C^ITUEXUB]T$\]Z5+AM]G)\R,O*_
MGLEGT-OD#9P9<SW"+4ZR>X MQUB=$4X:]H:$E*T6FKH/-^QVZ[TZ8R.#=)H
M#4T1YDP/&XM?=&T"B_;9$G(V=G6Z"V_2ZMSE!L9B]E5C<K=7:"N+/?R(XS5;
M<X6Y@.P^'HG^&C?M@#YE5D)WGW_9=&@PU2![\^,IO=VE \+2Y;&6H<67"@)Q
M,I#OBWZ$UCVIPQM(@1CY=#P%9K5\A:B6&N?OE/(UC;PT^4Z<-IPBEC?6D]>#
M;8,' ' >DD"(-\I O*^&D;/XAOL!$*1_WE -N ;_UEFYJC#UO)\A ;JO??G)
MW=Z6X,5^S:#E^ OU--7H4)0>FQ,?8V2TDHX)AJVT >O/YXD,3&S#^=HI5-6\
M\"&TXWE42'7*+T;2F.Y6K:?,=:YH^G8=F=Z$^+KCO_A<BLCQT5*[A&2]8.(:
M6P:FAJHE[)34LJT;O NP18,_1@<4T JVQ#&/5Q%3$;1&[DZ4VURI(%7:OUS;
M*=W';F28)-T18%5,%/4X)$._9-6YZ150>R4("S)X<8T_7A:-*RE*LW-?B\->
M)V@RA==%7IHR\'H'#3MTQ\P/9MIQ91+S B:%8N.<9(YO:NU@X%2F&83%I#8O
MLRW1)=;,W;M^:ZR=!]IN<(WI[#-AR6:7#J6OZUN'\C2.IG7;JT';9F8&F0BK
M@0J RY'^!+^>XTEJ&(AIJN4K@_'LAGYT+:_VC]F'6#"[>@U*3U#L3$ZW5E-T
M,#93;=I@KU)H#009+VSNU7:PRN/FA=S,)^ASIOQ*^JF:LJICD)PU?= 9;%EH
MX,BOY*CU1/;,0&VIM$'3:?]:M5YHF<C,D#_^IV=_JV!!Y'1!Z/8F^\S=0C5O
MPPU!86#T>V*<RS',;%WI&PT]/WN?#$(;_:2:ZR?<5ZB'>9@/P*S"#DO@6L8C
M=%<H0WT\+P6=2_$F-E&G_E!&JTN;=;#&]_VOK(%-XID;/<I,K8C['E_$ZL,A
M*=8K%;@.^RF+79+FF!+!)F;[0@:2U=B&[>R3IAV.Q=;EYC+#1&/A:E-Y\FR.
M=^?G.EWA+L#P].PYQ%IZ^.%V!;>0O3!04,<6@2+^A%<+_@^Q#CTF]2Y,*,'
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M*!'9#A4BYAX;=I0_.Y >TYH#*I=TK5CTJ8O8,13KF->JEPDQ<6!)=6G:'&7
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MM1-R$);Y"AVBSXQ$H [WJJ>!XF/9<J7?U$Z;.X_DHD^(. %<?'TB:4V[1DX
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M5JV^Z]D)YB\IUOM(DNC5[MQDU/9+\^KBP]SW9$:%\WFH3I-;E*IZ^(SQ\9F
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MT>Q[**[T]/I(=B YX[@^"9!RUCBYX]NH]^LW,@_0<O_/WT']QE91E1XAU-0
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M?P!^^3+:^[SY#^2+1C]!;3'F,U1R"9.E_/'=8@>XCTPKLSM#COK"J;5 _=8
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M:/8XU/4R1+(+"TN61EY=33&V%F.JR1S;1D/O9[FPN!XYC!3UZ)#02B@IXXH
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M'7$S^J,BX.GT!A?D)^1X_XO297=GWX_*SP!27Q/[O[XF_+6N0N\&&0<K(T)
MZ_3M*P;_7YF 7@+H/TJ0[2?E<_*\XLFS$/RN9_@TU! 8U/6]KW^E>A<;FR/_
MA&*([$[*J!Z4EJRKE&P^J7EW294$0B82YPIQNGR;V$6(P?4;5O]1'M'D](2D
M_9J'/S&V+69SYNE#0>"$5E_YZR+G7]0038YD;^(U[K+$Q 8N,N.B$AF1$0X)
MD?&PF^#</7 (&BGN[OW]O$H[I1R(P?+R^GM^IHFZAY2O89P1_V)FX.]F_L5+
MSK]Z<?Q7+_^U&O%W6J8N-4U[-O,$&.""VA0Y#A76\?)IA$AU)S]V$Y]_G\9
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MQ;$<WFEH-]>?%-LR64Y[*=0OU6'P:CZ\_95EWWR^+V&<P;6P9B5*CX^2 <\
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MYO'L<+L9$]V,E9\S":@T%2\B3)Z,%=>KXQO2^N\=+*Q5(S"B"SC<_#Y?B<B
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M6@XB-,*.L@88176NQ!@4R 1]\;U4.RGO3#K38H%Q/'39,R8\4:JT(2BE5;-
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M#:3&BI,N/X*V4^E;>4 >5\%J[SLJB?YV&\K<@K911 X24IWN 8:!@.-AEEU
M,"Q4052@=2<$>N>\MQ7A?@$4TMVOKX%A[Y\U3^Y*((=$((R$1+] ($]X0P5D
M@/6[VP2KH[T[[1EW!*/@_5SO@<F, /\""/IKW6-BO@S8!K"^GP@470B$SP/3
MH@&R/O_%,X#\U_3](!#H<(/Q!>"/GY_Y0?PVM)O@-/6#OU*98 V?SR!-H'FL
M^G;LT?/!7_-S#K]^BF#C8.7%Y(W7NX\VP"*XA)I@! -;2;A\$[^?TF< VN31
MZ_8R2H72Y<\M_+\_F>"C2*!^>\7_L4Y 0O4?U;2:/JZG/^Q=1C2N[1'.3?2O
MMCX(=?F[<+K7_!..\D5TW_[SD0^'#A>7:(J+,7N0D;X,=,-M2#385[?'K0D$
M-$2[_\XX)E $"^\"[66TEJ-9XW7?6Q9GM/+Q-\)\4AMQ&7^60=OT8@\R=[?F
M&P@C7\!@G^QCILL=9W(ME"ZRU^85@F&-.X+>PVP1<AW6KR*F8I]A87B2?Y'U
M/7L/)5./?+>].+C0Z$16\I%FD1R,-IE@E9W"G$2P\$RGM^S,-*+,Q *^Y7H0
MQ"\=FB$P9*UMUCPQ>UG)^Z=*L;9EK4W2JHA;8,YDD;M6!J$I,6?SGYTP-G)Z
M1.GOLVA-FEGO"+:-;=JI6V&38*]MLA<C&/)[\,"?W,1C(\/#7J(,=9&TU241
M7\H+18VRUHSN)%L1V*%//DSR#W'(I]:ID!@RO?C]@+_W,67=O+E;CG:CASJ3
M[+05=!Z4BTZ;0Q1$!D>075V:K7%KK>.1':6T_C%D-W>C:KTH1Y4FQ]UJTZ97
MMXIJU=BJ1T ?&9]?5Y%=NBW%FA\OBTP20IO$NHD&0\UDVZ[;Q[A$1,2JETXX
M?:%.RJ:^YL'VG 5N;S]\;"!!A%Q4U][%1%6+>Y1<=J5#W20-F9;NWF4$S[+Z
MRE]?9IJRTH*WAE*INI(UICRO.$]*J_'"0T7=.BHY9WZ=*4;NEN9"MR5GND3L
MSRCE,VK#=5!F;6YO2NR@@G ON]S\\.+YNP,+]1!M"LY80MHG1VLY3XX21L;R
MH>@X\IMKX OQ>)W?<OINCL69K".-O(EDF\+D!1:8]L)%-V\K6YZCF_GN7),-
MB+H'AJ?EJ[JVS(2.:$G6"">UZ=M#59E1N+0U"HE*V5XK%#5Z8Y+< HNU?X1=
M\VJE?7']F996OU4R"]-RIY23!21UB#F<8#6U!DR;F*4,FEQ+V/X:G>:9\.(;
M8:56\X:<><-66=;1YH!)?/.R_Y:R"PR%C7H:TXV9HVDRQ"V<BK,KX(2)2MXY
MYO.M8M;:T<ODO:L:.X?.VWB,I[1W;7-R^4*L4:H)]E$'3P(I5_T,N2#QEWP@
M.[5--Y,BUB3M!_U6YOKOSN-ZCY7$UEK0RS@'$N".(=5:UW3TYGM-@3QD>Q-K
M5DRBH5C&N'"'G"*S351V(LR/L)#S>^K6+0JW5D-@IC1=DX]S>3F+5%AL8&B=
M>FW=[K+KQI'KYOXEX3'LNEA+0:;8$@_5M\V9]99W>W_D$0.+CN[4BA76GF21
M)])G\P (_SPCXZ;52Z#P"AE^*<>A\*:B-NV$^61=I_3<2 >_4MZ0><.C35E3
MS$6I&W2]HJ9I+K<S>J^KE52R4=[OZUHGU%X)Z1COGU<EU E7J6DQIL*4AR@8
M<)'U DE$NR]@4W]QN-?\?HY_J2PF\=M\#RECC,&53GG(T H#SD)9OFBPZACU
MXL*2LIE51=EX"?X>MT!\$#JP> /DHS(BWYN^S[#NG&O:-.N'?.GHFD&@BTZD
MYC&5$N_\JNU=,^QZA=&AQ3?+*LMX$IIUA1;GD0WJ.R=U[OLM5E.B<L-#;.FA
MR09'_4T$DI*,JFZ.6G4*WW+98\IW_Y,OP(#3IY^O>/53J],K=^$_2$?ZM;_%
MN4L>=9^/8X .]I/[WBGHKX?YG=TN(P2=*W1=17R_&^36]JCNW7)"19[_/(@-
MA<O/VU\6#ZM97Q:W2'9;R.F2F^JR.P(#35?$7.7)F&1!55!%OW$A(+M%N/>&
MKVF34Q7<7^<*;=V#9%E$'&*[^EA&F^E0:&R;SVUT:./3\R5;4966E6PTQ-BN
M4(#;JR$K_QX=7'07HIF35<PEDZHX%HHN9^K4!>4HN]!?R^6)TO.TZ9PHY&=>
ME(I,52G;%J.WQ(CE#SV^J>6??>AL2]/1P[JH11IV5&#)*E! >\.!/ G[ 809
MMY!]=\%0OBI6%_.@RFU(% ;5X4=#/#Z2G&ZK!6R&;'Y0.^5P<^TLC,1U>J0E
M3D*V\!RGHK.\HMFV8<3 1I=1I/N^*)<H=RGQ4ZQU[;)WRU7]_-Q^O"R0U#?)
MUKV\K/,:-U5F9);?IT%J1&++N%B08&*Z(-:2(%S@PJA&!=\JS<&B\FVAQW2.
MW*1J#S6^PW@H7DWN4K+2T%V%GT73@R[WK\V2=.E>RA #FI?9N]-A!JD0QRPH
M-C[93K[5#'1(]XK4S@V,2R_4,JZ19]Z=]^3H5+:SU[R:+R ^*GV&D1;_"DH*
ME_SINB3%JBP9%6X !>6\5 7O]$%ANESI\F?1]313U5:G^>T][*&F&><2_T0]
M,YR[2S1(LZC'*L54F&1=)<N8O/@JS:8NT;_#G+RY-J>E;7RY=[R4IW,-O4HK
M-4J_7;9.:U=<(-SS=\60I!1?D&%S<\T"$#H1K+B9SX_#+S1EV\&S+-$R-20;
MB('XV/.M%7$N5VU=?NW$,*N)Z%0VYJ-X-7Z+'TD17E[B$)'[F_Y(AT8][7GK
MF=_FE$9^B7I\_?(9^D2TFS",5&#87.92G'9W-6HTN8,1B1'I! 9AMPH7%\)N
M^7%D2^O8H'*A!R9D)^=$&FS-M8EW</TVC<;P<7E2V.T$&V)\=P^K5^S41+H<
M.#QT)N%)\9GCG*LT>G3IYNT,LO"*2&='F'Y[^6'CZCAE+7$A]%%.JC'UG$O-
M#H'X%F0U!E*;>SA#>HN6(G-X9/M:2VP9];BDW7?X-_+:N$)^N]*R:J^0>5:4
M<SH[5ZYC%9@-LNK+383.RA&D'$&P[V;VVY&)7-BI<2.-NU51Y@@W-6=]]HN'
MZ7:1YG/E-*O,0J;*B+5$%(2'!V2G">06K!_+.7>FAAD%$@5 89&]*,=.6_1H
M])S-[<U+#P_C"N&-<M1V<Z9,XD4&E(KY\]1T%"0TR9+IC<W$<CV/<.XYV0N)
M!)+<,^S5.=<B^DKQ*17W$ZJ0\ ["F%MT=*KQ0J6)ZO*:B=%N065QXQ9+JFLR
MQ8G<FP_+]!^$)+=@"1X*_[J458B#!1YZCEVL<5/5IV\?6&<MV5&ZY'9X!$R
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M ?;F_EX%LUNHGRO*IMD<\+RON48R]>#EI/:V%?*ZOM;=!AE![PTW+:#8=)8
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MWT^"&D-^ 5(4^9>=(2,F0.#Y:"D#LE$8PO\A(&R<#8;C,XE0.GQFF$R=QP#
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M;3"NLYM[EOCRJ,>_2O%:7;23F#2*M--(Q1&3/[HO(I,Y1721[:B7;*!B@)@
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M3=,P.N0,$E5 0** 9)8D07+.24! 6);,+BP+"$A0,2(B(" @H 21+%E 0$5
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M(/Q53QSYGWKBJ/VJ)R[.49MZN$=]T=8!^TGC0%=LCAI +0/D6 UME771^ I
MB<4 AU!L^3 0!I 3$Q.3$).3D)!3DY&24=-3D9-3T9^@I:6GI3U!38Y-!]E?
M)QP*,C(*2HICE)3'Z"@I*>DP/Y1T^U6H_YL&4*\!:F+ ''B"A\,.X%+CX%'C
MH$;1BI&BWN$HH*4DP,&F P7Q !Q<? )"(F(24C*<?RQ$6PCOL/ 8@(./@X>+
MCTM 1$A,@$<NABZDQL,_32-"H&AH1\ON=564D"[J:9$2!R>]T1M[,7'XM4YE
M(JYHXR^?OX*]00QIQ=>Y56),'%3?IB,DCG>93D"^E835=_M,KJGQ/,RX41K[
MKF=J/;.LH7=ZP\S1]V;<L_+&OIE-275S)[];\5D53?VS6]0 +BY:6GRL3$2$
M!""L"*=%:/#1$GBQTQ*(7HVBPTCPQJCSBQBG_6?XM6AE8WJPM_A7+D*, $3<
MH+==:"'2CSNHFDH@(!-'(OQK"7A^BH : LCQL'U2 PK ADFTZ9I[:T'"V^R*
MD8L=3.!-<?'4P)'=0K^RU*IW#P<L@IQR()>L[K<&J.:72O>]; 7E^8!6 I-V
MVFSSH!4<ZRDW0C+6W1U1@![#!DLMXZ2M5CS %K"1X#<O5[*$ JKV4,".R-[=
MU-+HD=IRO-KV:\-D%SLD!_@)GL5;V;D'U*GS.(KYA<P^"U@586-BWSFFR*&L
M9R5?[L!@M"4:M3!@]:**>1:6$_?)L&Q3<GD;NE'N$)2  I3J2LQM\V/N-BW:
M7,ZK>=D[6#'NV/;.=+EL\](T*RPS/F+>?+-:85G.#UGG@ *T@P:#7(=&6JJT
MSYY>8J^P?-O%N-P>/ O=Y0IT+4YUV@O8H-WK1-:7V$2/&Y<Z"%?,U260^ZV-
MQ>]=WXO_L=H;\_WS=NK=L9/!6Y^Z0OI:7!F(.H93S923O)VIBLHFBX.N1%J=
M2J ?00[.;RN8!V\'\2\VH0"28F_W$AX.RKN/AUVSX\RCP/I/)G8_Y[D-!6W+
M*73QK;8M1H#UES9K9A%%Y15;_-Y<JX/S>[&;1>,?48 ("B!/74YVAJ( GENZ
ML$ %K4XJW!*U<WOQW7Y#C-M)2 6(PGR(2O>9Y'1;T]<LST:*-DK.V/6[%?E=
MV%&P;L@OZ8:JECU^I8-GY]@V%NX[6MMHL3!^9[X;V327TIY_,K8W,-44-!BI
MVR>12Y:X/6K\C=?O27M:N_)27K!I<.9>:N'.LD^ Q4D9'H4"BKJI-USWN=)F
M3KR0:12IWJU+*_&0@ WNC$9N\$-BD68@Z=V MYU.>G1$H.(UL"WEZ>W=>WX=
M(T/#*,!Z0^$-CU?]E@*=9^J8J\5&C&#Y2]*3@8_>>+L7>C_:M&12HV7:M'LT
M7FK;<W''R=RZDHFWL9I_;5Z5]<+9%XB)$ZU>CU@7F;;$R5R#$!;=V50>@KZ0
M. N_IPM!"B4*ZPPAUTHV/[X\6:COMK2!1WP<E&X'9ETLK?:=*>[V$"J<WYN=
M0P$:#UH6+RD$T\I?];XXC+,5[!&<DE37KGQ7H?I[3J0?7V%^LN+&:B$ >=EG
M8Z&<#!JXP-S*OU4R["NAG!"1ZCC>6Q, ]R@H[.//3-JHD$JZ+N)6U!M/*"Y=
M;R"Z*=JDFI*:O:EE7;LPM^D0R%M556.:(Q:PFOERO0]YLZM=OQ\:N^R6],"V
M M:]P>]CJRM6(K,-L)8,[#:92W0NLZ  %W!M:F5913 *^#*6]9WS,L;)7D*V
MQZ^;IEI *[@>+3>!5H-*!\'#=G3#->MVDAQ@.:%N"^5!V"+KYR(Y*K.\2$,S
M!<NJZR+9Y4.\X)4F1XWH+_U,)Z"%S_J7QS<744!2^O!>_#H3"CA?IN9D>59H
M&T^MC+#'';I\T2)Z5F%N*3M_W!RI9H$"+ T<_?IH'-;[".,&V]HH1_J(C%]*
M]@RUAJ, U?74^9+U<C8NJI$=T[<A_L$)?4)MK26,(V#U9_VO:/-*K1WE5 N0
MY\J[D:XHX/&S\>^L:HL^9H8?%QNSI&M :8VW4C7[)4?3]S[V68X_7?6P=1YK
M[PQ(3=OH'DSHMYR<7]^\0,(5XV:1\:#/8F>FJ;RN2WIIPV*/;(]:_('>M>A3
M*K$VJ<$>&W*#+\<A+^29;&9JK2@\?6=8Q[QS_384.I?*6S2X4!W+M2\V9'=D
MJ]P:*[K!BX*>0_V:E'AKUUIWZ_H45LZC)U3J#_JLC?!GL]/3W8X"W'VBQ?W'
M9B1(/!4^LS3$;Y/EA8P8[P6%( TMFI:_D'VN8SG._VB[J4:>RN_FKJSLE7.(
MS]K;MHOXC5OMMS(&44"V3D"[#1 ##L75!$FP<P??O3-_ZLIM\0&GU*[^@15T
MN-EN9HGJ?\_6;4>D1%'V[G*(3#*R;B&DS>)*$Q(=#;U@P[O@O2FJM9,H($KQ
M [*I;]&-3/1\M-.ZNRPA"N ZOGG\ @IXF;6#9EY/(S3O7:D$7SAY6X=6(2/W
M)6R'#Q&4VW]]S[5[JTJA/60RCP_9M'&SGZ%"HKPRS6XI/V-MN<!J-3A5E;[&
M:?$D_EYG8ZB/0KJ"PDQ'0D=P4;]Q#O38$ K(%,QLLBY9S]]32ET*R:N^?I_L
MHG(%B8^Z@5_DMN'*T.<]VCT!J6UKN;H?MR/'W&Q?V>Z:DB#;^]]P+'L(:T19
M.SC[;NOUJ 79(]] KMYK 6M"YX-\KJ;[58\6*;7GCE_P"-ZR4PP5+WXBEPY#
M.GQ$EO7?"\[0BV#]:/H>;X]>J <%Y** 1Q5(6^1:(;)G=3'UPB-EZQZ1^CNW
MV8L885LK3A4H@#M^N3V/[<T"G88PHG!;X=/N=FUJR0[C*3F\17H!;[>W@#RW
MK>$GZ:*=M9 @W5&F1?[$F6J"!Y]F'HG?INQM<YJO25F%V^:@ '/T\'MNM^^9
M^ >7N06@@#Z91\Q+0X]);H/=O/ITE@?7Y>IT(=8;U8MN)1[I3)P#EGI]HG='
M+@&3>U3P&A0@$?!EDC@2.6V+-'5RV#5 ]BU5>V01?)*=FQG5UCPV_CUD*DM]
M<'$9!;1:1ZZ:N3L6LGKOS4<A>S<&]!;=W8^13YJQO5QRV(M<&_,M$_K1O3&>
M:C9*'J+F),JT%[[UN$<RR!2YL!E7Q] O_HU25>5$C_X\"@!)(?,W!@!"T&N2
MJYN)U6@*G'I7'UGX(Z^N$!U748"TV:XG<E+;<A%N;67#=>/[1NDIR4 _\Q6E
MW,7"OF'O4^;#9WUTO=_0@;NVYH99&HL*"M=JA+9A/?I./:OYFS2+PBE;-)J"
MM=$.H61E=3_(M2)S6"U=*]@&NPJ*JQ]3S17/9[P6?* -&UI&AW'Y4OTBVZG"
M'8*!QF"!H-<*^>^&*A;U^^QJ8IUFY+?$D?3G2$,O?K*4J%L/41YK?XK4W0P!
M_5ATV['9O;1H#>;(-N\5VMAKY5UO;!1S\7KO4==:5EV7:%\?TIN:=V/F3>>W
MEHWAZN?FC+L\"E#UW-7=XYT5>]U&%0H-6^<71CEXLNL4CGWN?<![8EG"W.XF
M\QWH@GO%G,30;CO2E;FVOXSOTT17[O7PF;U<5SR>$R6"IZ#?Z]Q0G1MDQ4S&
MU[4UHV24\J,\3N*D-0Y(G"2X?U8V> /J%@5W+N['??_I#I?1;DQ2Z=4D3\1[
MK[/"Y[V#[^3.!=;>^D9[XRRWF0N9T%Q*NCO4>.23\H!\S]J37398UF)@4GE%
M<"1L+3C-=;SS9%GL5)WSS?*Z<AEI)JN*_M'MO(%[,O(&K%W6LQ3/?:_OX?"L
MWTO;;6OVQA&U9$+'6=!*;J#<V.K.QGQFFJ!NCF 62Y$QP7T@1D)V8)['K[ML
M-8!GV&*[8$>AQD1.3/A5];(9CM@+]]N[HZZ"ZMM<X\W;*& @[FXE"F#[,'(7
M:I>_Y.56"32QK%A.6Z^#Y=M-QUT>+$\(%CWQ)RQOK'#Z%K)&<$[X;-G]@M?]
M(F^9.>^L_G@.3G]Q08"<Y8GOETGPND+P:%VSUK6"D/<2>T/M(WZ?=Q>.CZIN
M).:#P\EI<(8<CFUN/YJIG@>I+\6C'T1648"]K4/U#X60;9HGN:D.% WUT>>;
M!<5X^E^TEO8_W_"M'II" 9!WZWGY;>^]ST+[855-YV>'9H=\/3/]=#9>>[2Z
MO7[$]%@:::OL>ET&Y/[BPM#K0!^7#99+*,#TXT LP444\$!3HR%MRZ9QN&;2
MK4+VI5IRRE;P0M%FGU?1^*VMIT'1*&!J%P4L:0[XOF1XT-5/S*Z/[R$7C98&
M\HU53YMQF/]%68840W+5_>U'T^2^G?>7-\J_:?ON1?</4'VKTP6CZ[8HG6)X
M5NWMBO/Z%B[+GN+H]OBKJ+G2Z%F9.*EJ=>TQ1>;&+M_ES4Q%<P76HLK-ON#)
M.JI5C9F2K5/?0P((@N0VA,VM+/LH\6/:&W0FK!62ME! $1\I9D2J17GS^^3R
M$$/+[3$R-\MKY,;&/3S4GVT.:0 11>V).2-,C!<_,9)]G#TI\X@<?0^QEP<)
MY;VL!=V^_IF744>GT#H5U;6^-"R4RUP;<?53A96DQ[7S?FO!&W$K%=YNN=Y?
M<4H"3]5LFOF51I6569AG[X7_"/D:KL^^U?.%$0=?[SF/8!.%93?C DF/VT2$
M@!C0':/\E7DYHCA]Z73$-E03GU#Z:@$5DYS<?130>2<Y2E6GH#.0\:+<^?X9
MB$@84?"-C<J]IKZM"DCLTCH*F)13#:H)B ^BT;P3J?5FH!8$'1VVC%]^Y?>@
MRR$:<,D9S^2 S01_,RD0F6C8=6T$7>V;((J[)<O$PN&;%]D)1;*^*OTZMGVF
MH$5B)5#Y_EMMG]VN3_U\*,"]^DU=Y%;F9LL5IN\H(. B%\N4E21R+WROO:0O
MTBG[G-./0+GW.*,&0]Q5!.>>;(]8%P<_VF49'7^O7/)<OFH4_'KHC>#-RD:B
MZU:"\!.+H"0YMD\VUB5S%DQU?L&C=PSU3WQ%=)G4#OI=#V%=U5Z.^R[Y=6_]
MI9;<^V<?I*_F2T7D?TP-]!!TOKW3+U*X!55J"C'S'H#SI56U=Y,'/IZ)J/OJ
M 1Y=".$UW:W1T8R;YV3TB-IU7#(ZY5J, G18K\0U93EHS(Y7.&U6<&E.L@BF
MA6\M^;X?)X*N\)3/F;@NZ%56#^![K;@E^N",G/LA:"Q=?H=3'">;.Z1&D";2
M4[#?)Z@^4*3%09/JLHA,<FW2[G#(PYA(<T%/-Z^A@4VIRJG62._<H?&VT>4-
M^L" ZD>OD3?\Q%NCP$S4C>4*L$HQF89GKUOX( *>G')]9BKWF2A*UA)CZ;[>
M4HNT[69U'ESP&SP7,L_.)] >>'.&0>IRZ?OMH:E9T<'/&(._-5Q1+;/-KVHW
MD(2N=GHD#)?5?=2?1:9D=>XT@%0K-Z7;G7'=SEFS16A0=6_5%*HWUFS&$P$2
M[]0?9VK2XG>CNC>8SA2\)7L7]:3G!E[X>=K2W=GM'M'EHDAGM_)K/,5$0X+H
M1^T0JA4]H"A!K>TF16O^%_FF1R2T*^"P4P4EL.X]M?;O[R8%HS_5WXDC.5U5
MU,&Y'+T\[+O]P"JY5[_KB:2N?DY]'FWC>'J=&^V]E2PV1C8-@K<+$PH!$E"M
M2!\OY:T0'NVEAY=97Z&=QM8A_36Z^U[;4NN]![OUV]';JIWK[9]WFPU7"LX$
M+P1F/TM,=L[?9,#U%8Z>9$U\\S(PUBM*L=1$I/A2G>-NP0#5*FWU7(B V#>X
M,K.;[];59;O33U)Q=PN&;HH%7"V!9=*O7%L#<RMTN0^O[.68!.;>9:V:"XJ.
MQ-M*7=V7(2?5N7KW](Y"I<*AVOLR&NX6OQB4L@B]RE6MR:$YO%34YEWW_)DH
MKP32UO'#L8G1Z8+!K-F5T74ZP996L&)&0&-0FZ ;,76+=N),I5+>2MJW<:,8
MXU/-$B(-:3PCC15;-7>P&JU.C:15P1S73&-91XL5>XB"U^K\CWV>?'ELYKW,
M,<UK.;MIJ^NWONQ-S;+/[WGNL8[$LBQ,W%I):T\G#>>G:&HJ;KHF,:(M+8 4
ML:[3:V*;&.PNK'UE;AYFJ3CT886A2G%S*;<+'/*F+@0I=[>ATL+N22^#C ^E
M #3E7'DL*;R$7.)#@X!S7/W =P5UQSZ1ZJ!L0W.ZP&#=F4L3+SP*7C2VU@>E
MZ7,S9FYJR5*-F>ICQ@0MP^,I:X6/K.BQ21^]:+#;LY067]6X%!@DZ1%/@U>3
M'[RPL24V7H&<*^NVAE]@]^])H6>8FJ)9_AA*+CSG<'[+:WEKQ;7DCMN8;>5P
M&D>D.#'OO73[ZZB>#9.F2()OQ9J\2*]2'T_ UYIGF/ ,6TQ9_17D"G35&+QW
M[4%N+BX/][4.E;VK72H10[M9T.6Z][;"&=&I.=&V?.@L>\6C('LY<Z*:^'2D
MMQ\0$N@X@W['EC;W"-+OI?191]H-O3"9/[M7E[]<LDTV@Q]MO&&D/6V"SEBT
M1<>(!O,A/-8-2T)[A52Y<\]%:S/.NI2PQYM15>9GOFG:=CH]'+)<]@V)EB^;
MZUL..HL_G4!UB>X"GZ?H1:N7U-O5D)P32Q_=LK@7\J%C_-F]R6.BBP6;(5Q7
MJJ*U@G,TK^2@LRRP!^6+FL]MWL]>,#%9E:6#[\\&I&90H=\1I[,+8XTT]5&#
MJ.53]W\N3(H)"@-22IJZ^/C8I2XJ9AQ+ (^)2YT9LRB()F#+N+!EQ]K:D4'/
MFVI)"#Q]"PH)ZO6P93+8LEU,^<$B(0"0><)=H A]'X2G#P*-8E8< 0-OA+$]
M#.:.Y="$(B 0J(_'(8S)E=WA&)P*6]?8Y3*&0\D%@:GSLTT(7,_. V*B>L$$
M3:( E $[  K T!<;H LH 2! !! %A/=5P58P@,-@CL80A(^GOKTK&$TF!PP
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M1+, 'D -D ,4P!D[L+>GHH&!#N9U_S#_/6WV[1^YZA; M*4"XK8C7K._UV<
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M$C^YE-8E2NW[L.N9/;@V*$$JZ3S>%\Q_O"!J7J=,&)1_O<^L0-6!E4_+WP@
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M)<O\S )UCMN4 2:SUP#<;(=$ZZ^A>'/;4J' ^XXM;ZKD]1? K5/'$R8'$PT
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M7=GFCQ6BJK0?B'H6LW+Y,MK%N_5%3"%&JG7?XQTZA,[9NAMXW*4H4BP_(]%
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M6V^-RL[Q1&?T\'>*F(G%IAK9;SS%G9K-- J+,<[<--H5>KD<1QO4AAUW&<Q
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M5;SVFR/D_%+%2V99IQT5!OED>C0L&A?9 O- >D_G9I0$!D#RJ5."-"N/*O$
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M2'M^8E-'ZF=\,S6.@Q'%-4T8:YDYB_[:^D/5C9IW2A/PC.T5*,\"@-COM,E
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M["M#>A[>B%13,W&]2DOFDD=Q8&\C>!10/\O8,<%U8]#;.9[ABHB/1["Y_MI
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M/Q;?<%9HWA)#5&'R>TODL8)DQ*I:'LHF\CDE5OYJ&0D'C)03\>J,L1^H@_R
MX"IZR2>:<::2QZU8M35"[Y^3HKEV!OVU]:N)D5U_0CFF*,R@/)YD2WMG<*Y
M-2)WWJ4AJTL%D.,R2L&YGY@\.165&O^8J";[@.#PU&=^^OG-I_($=Y:!"M[R
M14\4#@8C %AL20MK4GG7B 9#+X]%<=FU@/*LB6MK$/C%K!])F"?NYON!O_.
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MHN!U9>D(1/N;C?L+FOAG6DCM> #->!5>&7)#*0S<B4]G% _N4TOOOY[->WG
M>B_QK$FS'/BUW&#A\C2SNJT:-(+2X\'EB#9K,)B72V,1"Y#RZ<XK$=X53X])
M@DXA59Y1WDB^Y4]G$4%E1PVZ=0\(K:VW%P5?0P/WQ6J9\'#G+%\M6RC[B#&
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MB01]F@@4EZ:#,*MC6#79\ATIS4G(*SV*FC3]E7 $E'R(\DVZ3Y%<K3OJ]/1
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MR)^Z#76C0PP#U$=;7V?\_##_Y203(+;\SLU&OE]*?\3-Y<"SK5R=;%&>7(9
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MPOP, ,$R333IWZ85C+P8X363H@K!RH:8JRS8&Q&YTC;;"R6A&;^S:"XF.-1
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M,!$S4J+$0K6DEKDT'<]OK?PIC!PV#>8%AI6-8>S, J"(*MU3\P+$\7US'K^
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M%K=@DH!G-&:+=9J,>YB4907KI-;P1UEAQ_NL<@A!;LC4M46SH&%.YX4EMB(
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M,&92*L7;.HO3;IU"K]>2G@&,_Y*T[KKPL!<O1KKS5:W@?XB9)IH8=.$D$\O
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M/P V%UU+E&W=E8\3\^):IL_0@3P%]3Q%$7-#XE[3';O8!N-GZ>KK@1 ]ZL]
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M<[V:VO3FU_&L@_KF+U=VS:KO+"*#;B6Y7]NO8+"&OO$-@C?)/  T.:_<3!\
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M.A%"G5H'!BK8 *)/HIS"A/5>F53'_-!A%G$Q2FP+]W:S?^N#GC@<U7N962$
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M(W7G\J0*Y:4C)5E\,G.%Z\NA7(>S)>4^?BT"V:Q.>L=<1H9?^0#VY;+I!>$
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M86^-V1;@GLN<?5]WSGSG<*^; 5)>$TD+A7:J_![=6:A*2:BV1^>E243H(4B
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M[[UO24M^^1W95<SV=J&)+RQ2LS[9A,!^0K])<3/\V8P/SEM+59?.]L%T];V
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M&9PA$F]SI7J,[="-F"347]E_M,_6$GZG!M:-B 'OHVDK<@3Y3[S:.IWI"40
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MO DE%2'54H-4.>"R9MFF7I@?>87+S^ Q7S VGIBOS>N<Q*8DUUZ%2LL,J=W
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MY38<V$B8*[YCK>"B1A=3M(ND#O>3DC)&0'LOIDBV$2FUNU2OMZNZB&NZ)QJ
MH4EQ1O];6"E@74:ZWI&;HE.N@%7S@UJ;L@<UT(!:V!6!G$9V55 NGQK%* MC
M_SNS&,J=[OW&A]=%;CK!1NV6K1+"$1,7+0!LXXQ6@@3U 4;)ER1U=9"<W4O
M%5U:E;WX #%/39>!L3*\V*#4)175RWY%]?JM6E-+LBUO)I@I?(T(._8ZUCE%
M5X"Z6##S<DD'?_=E1.*:SU9VU CEUY,8ZX<C?4EWQ;[ ;]H4A;J&BNH*[''Q
MN$RO?*K@MU?F M;CK;@(D&,$V$S0>8VI%%%O-$42U^6^2T02Q8B-QBC[5V&)
M*N=\5N&L5T*XQR-:7R_&%Z5K3:_NC<%'!-F>)R7V!7&A@F9>>X9U6AF2PFD"
M-*R&Z@R0\+\9;=BWGZ\LCQ_>%E0Y=$ZK*_UN/17</IHW;1O)0YY1D<Z.G(-]
MRF+F4V,H&N'-\D!L,92&@Q&1-RC3^32="M.-1CCXHS=91H_FA<*'YJUB;Q=X
M8[3GV2F[LLYN-*&0A'0-X% BJ>*8K[TF;=$[2YJ")81#7LXIV#5;I/I+=@&*
M5YOY1UP_?_XY3@)_2DAB9 O1]_*/0XH S=HIG:OSY]XK<O89?'#N^JN=UZ+B
M!A_%;-"LDC5)O.[GF;9>9J6:'$"J(AV3-GS/?-* ^KKZF9%R>_RS,,_X=%?2
MQT<HSP(+%EEBM8U%32N:%ZXCI?*<BKC<BA^AU]JV_W6!F.H9=QX)(Y3H^W%]
M >6%N670FUVS<2YJJR5N\=VW4^.(S=[HG#6W^S/-W8*JZV60*X4#&NJ<+DIA
M.0I"JPI"G25,Q?T[.G_#GQ/D[KH%O@,A<LVMU."-EJ7NXN.\NU9IX07>N*=+
M:^"E?L45-("48.K$@)E8="L<P>"C]GUF8$LI6D6NMA)+4H#(=&J=J>AWM8&5
MRK(=/G9@(V8OD&Z9XE@,2^&I[*B:PU4H20D]K55?B"(09R'>N4Y10T3M*V5"
M@]%KXTX^<+*9^(@6U(7?U4[(5!BJSUJ&Z^HX"]V[,',T+Y,OLZZR<@6IS@QI
MC_/Z$9+F2R@&ZUO6PT@\CWLKP:,J:NP18V#[!?F]EJ+%;"\#:3NA;#>,-]7-
M!1[ZR6[+KVW*&WA2_5A,YJOVR9E25SR,;W4@=;*&P>76XEIZL6(*&:N46EQH
M^:#L0ZM&T;9MI@J/Y:]@KCDW07[#.*S@$.!9I3UUFG(S<ZIIKUM5:R43)ZE<
MW<&/%X)?IW=%'E@3>4#-+ZV6!3L:!3W5W\E'AZ<M<PA3N(CGD:KM"SMG9(CY
M?CI2(J(UQ%0P;\%7A#2AB&Y\C@K3V]8(*+XTPO ::]\XO.)GLU*N+%H<X3:E
MH#2ZQN:0T._%1M+>_3MS*#VZ;UB()<V.T8]Y)G98==BI5EWXGBV8<]?3?6.2
M*C]STXUR[LZ-ZD6> 1'*7(<D^A#K;_*_!J[]C]A-66W0@UG./YWP0EPP*?3$
MW><6#:"-RIJ+,G\ G/YY2"*-Q@:*^YM6"WL+0G9)_EO?76C&9C:VNE=,_8C=
M4LQ-Y@LVTCOI@O!^1J&89/.F6!A8L5']\D^',N5'*!]PL*,Y--Z]UHF=_GK&
ME64GG5B28R/-#0K0R,C*W^""PX7C\J:G,>[0W5O+,3O%"=PC%LA SDS_!S5?
M$12' D0YN!/<70=W#\%ED,%=0G!WMP!!!Q]\\,$'"^Z$$%R#.PGN$"! " 3V
M[WEK#WO8JMU35W5UOZZ^O-?OTO#H3<]$T?Y!(9,]?]170*:4P=N[Q&]Q)*%L
M/'"^XA\%H-8Z\:A<U[7:Z!GNLL*W&>?B_J*$=#.ECV89)]_%^M]IZ5;\!O;Q
M8DF(P)<11M!TW8%KQZ5<9BL;1D"Y0BN]BKA]9J*86Y9K,ZIG7@8V/<-GKOPP
M'(8%ZTU-G4M-ZZI2@H)D)^ +Z?Q!0LOPH-9G0:)T=T)!=QB\A)+QV7+F*RV;
M3>(&C\.'Y#%?IX)B)1\+C_^$,:>3B:7LN*5*FI2@-3.XAA/#B6VL@:D<4R^O
M-BLBCN@'_U9']F=]-R.!?![O!YWWPAOVFT:5FI34@G@TXX8^H&H5I!O;'C\E
M?1I$/-*0U-9N 4Z>M\$HY_',GU= O5-ITI(HIG%^16PB?76>D+A:7LF4G"&+
M>H8:YU2L)WIK-FV7:02W'79ZO(_4#PE0W<!^EY!)O-HUCV[2$?L;=AD;R8KH
MZ,8!?;@K68AP;Y3FLGER69ZD,56'R5>(/J&!/-@[W[V+![;3!MER7[/O-#Y]
M0.YIE-^@'QR6YQ#0L0'<'X_?S/N3)2\Y.EZI.R/@!AD:JN'G^$:PVPSVCZ&M
MXZ4XYE&M GWV7\7XCP?S@9UK%IQE.C%^C$R=R#PZ7.DZ$X><(*1%"6Q1G!B$
M21*:90T6CUTS>+S!<.[S9P(-&C4-=54)F5TQ&UJ:):4L\:=HC2CFAVZ]K%S\
M+IQR*Z!(9X]?B;+26AG4JBB\;/_B!&3$_G/7;2Z5,4I""7=K*-BE+J(2H:C#
M"I689OM12"HDR$@@L?1.;XP$7]9G[6?D1B.T<C^./]4J4Q4=^!0+H/>I> Q+
M=OF<_2(F ND'OUW*3&PQM%I3.,2O-'EO^T.@0UYV5M#.S++W=D3',)HC0U9?
M YR;.5)_@Y-D:J[<DK9!J]$4W3$D4!#/-'LVWU!J7_9#WF2WY-QSGO"&>T:A
MY"[?3[%P"5M'4W'&(22.K=4PS]UXY*M9K51[_Z?65;-2:?<,,%WOP%SK'RG<
M[TG1D&&M(?1!J$7? :Y\1"Y+H.6"12,&^YX0<"O9-6'#I//D*&@(\9(R/XS_
MHLQ1'_ZQ4R:E1YF/YIUSW&TM$\RBZE0HUKU5V?'&TH')KU?9[AN6@]!1D!07
M51N[Z.XJ%J9SE"/K!\6+?R0W:*$?@ 75V%;LIV9N^X<=6B."QPY)-K1FO'PS
M:SUY04(%3=_3FJ8)@X2LBT(QJWUS1]M]+Q33=60U5&&Q/%&%HPW:2SPYL&%G
M[P,.^8)&RY:S\5._D<&_SE_Q]+X[+R5,"KN&!@:K528KK65X/.] T!Z"&V_$
MDM>%:&7(VN@&,_%VHD5@6"T'SCZ"(D_8-H2NT1%-(KJ"UJR#&)Q3"\24 D0/
M$%;^^<=TL?%541J7[[_SDF+SJSGDES-M),ID\>)9:X&RC'*&FUO^97IIYQ:.
MOV%<QWL[""O)L/O 69HNK^+W?DZBNF]VJM_ &TEPI"-[];R"F$BK^SAKM"S'
M#O)1%SU]*5!BOC9SUF_^FM,?VA+_>VML%?MEI""A\KI#3].\*R^8%WS/G\%3
M/V.78"Z,.HB1I ])-#[RH">I E("" $G4,=;2'O-OD&*7!XH[89EL+D9(:84
MJ=#"^*Q%J0**2.A!>O=C]/+^C9T=G9DW55DFV,*T.PQ<"9P9=OMBLMKBB;N<
M%@^?VZG+;MO])QR*W",D+R(5E<=4S4DRC/T*8"CT$4TR1XR&O>=QDURNJAZ?
M4')T.TLTT])K6]AU;+ST'2?ENLCR3*@H6^OPQJ*IKB[]UK-$+X&X!3<*^<YS
MWP6[<6+UVW57]EYDGPC.?#%) DT6=*'SX''P_F.1,\*&0RQ>_E8Q8MN@]A-W
MWJP7FR_6XG^W\:L;6!:6QKA%6HC6,:^_:EZ[D)_#T?:%NF-R,3P.<G5<84#D
M_4PVO'J60G0G&M+4C$^-@IE_GW_.%B\''Y N)E@*S>-?+#@D+;NV6/&5PR^(
M2^!VQK$,S%U>5: /E7:GL\:G$VL$<<W+)!]L:]Z2D:F" KG*>;Q'WS 2';4,
M,5?&/V1(D+ ',:<=ZKGO@2NP$';Q:_6^=PV$&H>[%*76Y6-THA-?_9<=.T$L
M2%'[*%DV)9CBKG!W0LEX("QVR/?O+#.3'9 F?1\46!:SG@$_=1P^R9^ EG]2
MSK*0@@AR)CH0'?WV/21G(G &(J,%,B!+FSL9OG,QV'6C_!<[JM\QU#7Y$&E*
M%5XA>(_\E0XQ;@<1\75\=+S3O2;0T3= CER06!  2X2E<N\_TW83.^SKFFM.
M[5-]]VO',I5 [_/O<U&75)* H'I?SZ2BN*2:T_=R!3:L,!17!%9(X(![;U1
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M_//AJZ7,S54*17%+#NCG[7!0*0JF!:MTF<8!GA_+UFBI_DBK\Y9HK59!I5
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M'1A!!;(\\6ERT?B5!-.9;IRW(L:./WO25"^NK//FL;059J8H@>98,M-TOTE
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M0(U:<:?SEX_%M+HSK.28"&)4(A\TU)KC**QK/0VZ4X),, S22F+TU=H,OZK
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MFSK]K6_;H@Y<KPL<9[]D-99K>!PP&5W2&6_L.M^N?/<PG-=2"!2=GKI7ZCD
M+Q81]H!6D:(61$37W:Q71M!UIO@M?C!_WV])?A!U'R$219OP#.96L"/5X:C4
MODBY)L?+D;W49MIG<LZLPD/Q@:N[;6@Q_CY]DHSI2.LM6F;S+PP*MF'G><^N
MG=RL+F:US83D,&6&Z")P5=I,U,=N1A"BJFE\+%X0)-]_H%&A[]S5/SXD$TV^
M;3MYB/.>M3<'&VKAMAS=QAC:O4?S_<&4+EOS,"]>*8>7L4Y@])>T)>V)U\UX
MC#S M[DEK]K^L<UFOR)!;_QL;)#?L(Q2@A4_XX1 *L?>\_<9IPY#ISG);@"0
ME]?#(*PV-@<'KY:U\\B?+"L'*G!_KU%6OXBSDQ6783I;N)8GP G>B[A(X4!T
M$9L(_M<VW0<G2OV-?&5BR2@=86@#,S$MRZ]1:9K4TAB3R*REHC1JJ'N79>V)
MZJTRSK[):?$[A8/@:[S/I;_\2_9.A%U'76PJ+;6MX\I;'X/OB;PF2ZX&9=]X
M[]4L9+*S24@U;[ RU7(+1= $,1T+(FJV@\R&:3$<S!;$WCS3W5!-QBZW.QG@
M=Q5-.QH$+NM^GR>Z&=A_@;7HKZ,,Z^OX0<JRLDW4O[1(IJHVV14XS>6)L4XM
M4DM.M]:2G+CZ;>AGS;L_V3K9ATEY%&?5"G.M:$&]%5HTZHDU16O@$)4=PR.S
MK.9]3,.:[_R"F&HLL[)5$P[G>2V5VPC#.>ONM(YJP68DKOD2VTTVQ,4F4ZT*
M3H<>4;%-Z<T"WI*G.<Z[/58MS[U1EH8NRPJQI$-<:?Q2W6Z9) R#A"&8N,ED
M6S:8H_F2]JWQD7BF'F>P^;:DA> =PO6&T.-N^BIDCDUDND<!DV4%3/3N:U ^
M$P:WHDYA'=S-5,PY?5E?7Y]$G&#X%;"'CUB6W/!,LB^P].40@'286._-$<_M
MXI:F?: 'KL'0]7?9Q-,BV/D3XEH551H[@C%.[D;/^ONWCNFK5N@;_CX%E(07
MFX?WG%UL1_X-\_I[]?]K2?8KX&H:8YSC%7![-_J"^0IX]JC/0U\G2UOJ-A6)
MCF]W@6]MB,CQF[P;RF^7#Q*F+K?\X1G-H48_AK1RP:[U[^"'C''PO_*35T!O
MS]'9F_>MA3(/.:'_/IS=9U2]W%P5UTF'S_N^ K8M;N_B&M?!Q4^3_>&?[YY
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M%?XGF&YZ(SE1[L]$HVES;A:&@!1/$"G8BP/G,O[>'^!WS,Q*]Z;G9TXISO+
MU1!];W$9=K]8J,*C5%\?9<^X\7)B)K8-P\F3\AD)OK8 ZCAW#0F0HFR=MO0R
M#H2]0*@:-4[J&VI"YO1GC$8#U8+W[_ UH7BF+"YM!2'2.5U\-W9E-R=&D$BZ
MA %(_CX^(+X4=4C</^X'$ETVIUIY33Z"9Y-4!-.'H4L6UY8,.1ZB3E*)1)3_
M>0#EH=MKK]<Q%8Z,[K?;I22CQ%6*W$9.>YLS@,%&-_2T57C]"@C9F$,;K&'
MYL[W';;#3 /N?"  H0[+\879*4IARUX(Q%UAR.N!OY$,$W) G)096/G?6$5&
M&%T@(1W35U_44.1&:S>"=XA:!9TI,/,F]D=142$T(=C2EU_I/2694HM$;&&Q
M1&QEHYCM3''(#]'1DD>,8$_@_3U&S]K<LT1US%OA&43A.)O*KWD-*7#-4VVJ
MER#&#_ZGR.<^TF^C;C Q_C3LGO\NJX08^8<Q- .]= 'BG*TW 5MO^KY_P4A&
MBR#1X(N<8)K"QD =&CS[\A-)3@$I)&2KL&SMX>^U.7>&;\])U6Y#*:'6D/&
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MD$!3BO>JX_C^(^QNZ1=J-G7>B<^8+4KY3&AP/ZX,0IZ:5M- !ZMWA.-EIDQ
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M(1,G\*^URPA+)5R *XD1"]HH3Q]F\A?ER+_P=J^JG:,-L)K>T?W0N[L*^ "
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M7+T7[4W\:3K5?%$EDI:F_V'&NNNN2;4'Y0+]HW7:1,K(_69?PF@ND^39OYG
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M!&ETTB[UY!@5!]X<S\HP+(_LHUOQ59?0R&Z7I@N$CX<M5'V;,S&;'K[(MQ'
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M#]+B3=*LEF2/BV_S.?V[(GHE1$5F^O,9,:.!2<>:MVV[LN-)@)<H4=S%#%2
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MH/I@E RUVW4Q&/$4,Y=G5^M"DI0Q1+%NY4V:VGPMMT'<H49E.GL@O?/=I/<
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M>SE+L]4Q>UZK""6S6R6YL(8JQ&*5206K7^298>2/-WU1^OX?.W#6(1%=_CM
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MB3*KBH. !"1MIFF=QLVDL]HLW0:B(S0AZE&EJ?AZX8K'KCQ-<"@Z4>93"8Z
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MJHIDA>75@?/;+ W@P1'>%&0NV2,W/B-7H#WNW>8,=*#74W:IS(,Z+H=L1LP
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MLQ;/QY./[LEY O39"8>AL?0)P</'P2=DD PW-J&3$]'"$=#.W8/2,SDT=*)
M*@DNZE?P^B\;=+L3[6JGCUW913VYL:1N8%=C5#RD]%M1:;O#;3(AEZ^Q5=L4
M1C1VI<5;QXV8?[GVJ>EI:N,,:.!5OTEU?J#+IN&?%? ]PZLEKU)&.Q^4BHCY
M9N]."-W;]2[3 MMK]XZ;E=8M/!&N)1OP%S8,DQLDK9AVHG@JRHJ?4[S=AB^
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M8 17I?/ R(E62G.P+8E45PW7=">G\_BQ\Z9+BX'3\-LWSE7"QYI^2_W,J7K
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M[)K;HC8+L0R_RL&E:P09Z>9S#;TWR5(SIWZ,*#:G!HQW5L35;I"F\SX GC\
M'I;^!E!+ 0(4 Q0    ( .>"?U;\)WC?CN<! #<6 @ )              "
M 0    !A,6YE=RYJ<&=02P$"% ,4    " #G@G]6+U(9@S)^ 0"/K@$ "0
M            @ &UYP$ 83)N97<N:G!G4$L! A0#%     @ YX)_5F !O>.0
M'0( !5T" !               ( !#F8# &%C8VQA:6TS7S@U,"YJ<&=02P$"
M% ,4    " #G@G]6_,4HT&CB  "V]0  #P              @ ',@P4 871T
M9%]G<F%P:',N:G!G4$L! A0#%     @ YX)_5MXOV6 [Z@  :Q8! !$
M         ( !868& &1I86)E=&5S,U\X-3 N:G!G4$L! A0#%     @ YX)_
M5C&NPI6*^P  VR4! !$              ( !RU ' &1I86)E=&5S-%\X-3 N
M:G!G4$L! A0#%     @ YX)_5KBO\5!/%0$ ZST! !$              ( !
MA$P( &1I86)E=&5S-5\X-3 N:G!G4$L! A0#%     @ YX)_5LA[:H,)%0
MO',   T              ( ! F() &5X7S0U,3(X-2YH=&U02P$"% ,4
M" #G@G]6A8_ 8.L"  #I"0  #0              @ $V=PD 97A?-#4Q,C@V
M+FAT;5!+ 0(4 Q0    ( .>"?U9J-V#X/ @  )PY   -              "
M 4QZ"0!E>%\T-3$R.#<N:'1M4$L! A0#%     @ YX)_5J(R:'98"   ?3P
M  T              ( !LX() &5X7S0U,3(X."YH=&U02P$"% ,4    " #G
M@G]674A*60\&  #I,@  #0              @ $VBPD 97A?-#4Q,C@Y+FAT
M;5!+ 0(4 Q0    ( .>"?U8=TSS@0)X  ,2J   +              "  7"1
M"0!F:6=U<F4Q+FIP9U!+ 0(4 Q0    ( .>"?U:,"<>HP1@" .@M @ +
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M>#(P,C(Q,C,Q7S$P:RYH=&U02P$"% ,4    " #G@G]63>Q7[;L] 0 T2@$
M#0              @ $P)Q  9W!X,# R;F5W+FIP9U!+ 0(4 Q0    ( .>"
M?U893U=7>S<  /@Z   6              "  19E$0!G>6QZ93!P9'EM=7HP
M,# P,#(N:G!G4$L! A0#%     @ YX)_5C3]MVO2/0  VD$  !8
M     ( !Q9P1 &=Y;'IE,'!D>6UU>C P,# P,RYJ<&=02P$"% ,4    " #G
M@G]6Y8M[1O<:  !T'0  %@              @ '+VA$ 9WEL>F4P<&1Y;75Z
M,# P,# T+FIP9U!+ 0(4 Q0    ( .>"?U9L>JYP>'8  "%[   6
M      "  ?;U$0!G>6QZ93!P9'EM=7HP,# P,#8N:G!G4$L! A0#%     @
MYX)_5E_'K?UE-P, P%X# !,              ( !HFP2 &]N8V]P<F5X;&YP
M7S@U,"YJ<&=02P$"% ,4    " #G@G]6[75][/!4 @ #GP( $P
M    @ $XI!4 <&EP96QI;F5V,C!?.#4P+FIP9U!+ 0(4 Q0    ( .>"?U8P
M$Q%,7%\" //7 @ 8              "  5GY%P!R97%O<G-A=&%R8V5V85\X
>-3!V,2YJ<&=02P4&     !P ' #?!@  ZU@:

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
